PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mapelli, M; Panjikar, S; Tucker, PA				Mapelli, M; Panjikar, S; Tucker, PA			The crystal structure of the herpes simplex virus 1 ssDNA-binding protein suggests the structural basis for flexible, cooperative single-stranded DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; DENSITY-MODIFICATION; ICP8; REPLICATION; ASSOCIATION; DOMAIN; IDENTIFICATION; DIFFRACTION; LOCATION; PROGRAM	All organisms including animal viruses use specific proteins to bind single-stranded DNA rapidly in a non-sequence-specific, flexible, and cooperative manner during the DNA replication process. The crystal structure of a 60-residue C-terminal deletion construct of ICP8, the major single-stranded DNA-binding protein from herpes simplex virus-1, was determined at 3.0 Angstrom resolution. The structure reveals a novel fold, consisting of a large N-terminal domain (residues 9-1038) and a small C-terminal domain (residues 1049-1129). On the basis of the structure and the nearest neighbor interactions in the crystal, we have presented a model describing the site of single-stranded DNA binding and explaining the basis for cooperative binding. This model agrees with the beaded morphology observed in electron micrographs.	DESY, Hamburg OUtstn, European Mol Biol Lab, D-22603 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tucker, PA (corresponding author), DESY, Hamburg OUtstn, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	tucker@embl-hamburg.de	Panjikar, Santosh/D-2709-2012; Mapelli, Marina/AAC-7346-2022	Panjikar, Santosh/0000-0001-7429-3879; Mapelli, Marina/0000-0001-8502-0649				Agrawal V, 2003, CURR PROTEIN PEPT SC, V4, P195, DOI 10.2174/1389203033487207; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; Chen YM, 1996, VIROLOGY, V221, P281, DOI 10.1006/viro.1996.0377; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DeLano WL, 2002, PYMOL USER MANUAL; Dudas KC, 1998, J VIROL, V72, P257, DOI 10.1128/JVI.72.1.257-265.1998; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; Falkenberg M, 1998, J BIOL CHEM, V273, P32154, DOI 10.1074/jbc.273.48.32154; GAO M, 1988, VIROLOGY, V163, P319, DOI 10.1016/0042-6822(88)90272-3; GAO M, 1992, MOL CELL BIOL, V12, P1330, DOI 10.1128/MCB.12.3.1330; GAO M, 1989, J VIROL, V63, P5258, DOI 10.1128/JVI.63.12.5258-5267.1989; GODOWSKI PJ, 1986, P NATL ACAD SCI USA, V83, P256, DOI 10.1073/pnas.83.2.256; GUPTE SS, 1991, J BIOL CHEM, V266, P11413; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE CK, 1985, J VIROL, V54, P731, DOI 10.1128/JVI.54.3.731-738.1985; LEINBACH SS, 1989, BIOCHIM BIOPHYS ACTA, V1008, P281, DOI 10.1016/0167-4781(89)90017-1; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Lukonis CJ, 1997, J VIROL, V71, P4771, DOI 10.1128/JVI.71.6.4771-4781.1997; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Mapelli M, 1999, J STRUCT BIOL, V128, P219, DOI 10.1006/jsbi.1999.4192; Mapelli M, 2000, J VIROL, V74, P8812, DOI 10.1128/JVI.74.19.8812-8822.2000; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nimonkar AV, 2003, J BIOL CHEM, V278, P9678, DOI 10.1074/jbc.M212555200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Reuven NB, 2003, J VIROL, V77, P7425, DOI 10.1128/JVI.77.13.7425-7433.2003; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990; White EJ, 1999, BIOCHEM BIOPH RES CO, V264, P493, DOI 10.1006/bbrc.1999.1566; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	47	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2990	2997		10.1074/jbc.M406780200	http://dx.doi.org/10.1074/jbc.M406780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15507432	hybrid			2022-12-25	WOS:000226449100075
J	Qin, L; Li, X; Ko, JK; Partridge, NC				Qin, L; Li, X; Ko, JK; Partridge, NC			Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G(1) to S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-REGULATED KINASES; MARROW STROMAL CELLS; MAP KINASE; GENE-EXPRESSION; GROWTH-FACTOR; OSTEOSARCOMA CELLS; DNA-SYNTHESIS; MUSCLE-CELLS; BONE-CELLS	Parathyroid hormone (PTH) plays a major role in bone remodeling and has the ability to increase bone mass if administered daily. In vitro, PTH inhibits the growth of osteoblastic cell lines, arresting them in G, phase. Here, we demonstrate that PTH regulates the expression of at least three genes to achieve the following inducing expression of MAPK phosphatase 1 (MKP-1) and P21(Cip1) and decreasing expression of cyclin D1 at both mRNA and protein levels. The induction of MKP-1 causes the dephosphorylation of extracellular signal-regulated kinase and therefore the decrease in cyclin D1. Overexpression of MKP-1 arrests UMR cells in G(1) phase. The mechanisms involved in PTH regulation of these genes were studied. Most importantly, PTH administration produces similar effects on expression of these genes in rat femoral metaphyseal primary spongiosa. Analyses of p21(Cip1) expression levels in bone indicate that repeated daily PTH injections make the osteoblast more sensitive to successive PTH treatments, and this might be an important feature for the anabolic functions of PTH. In summary, our data suggest that one mechanism for PTH to exert its anabolic effect is to arrest the cell cycle progression of the osteoblast and hence increase its differentiation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [DK48109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545; Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CIVITELLI R, 1988, AM J PHYSIOL, V255, P660; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607; Drissi H, 1999, CANCER RES, V59, P3705; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002-220769; FINKELMAN RD, 1992, BONE MINER, V16, P89, DOI 10.1016/0169-6009(92)90879-I; GUO K, 1995, MOL CELL BIOL, V15, P3823; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; MACDONALD BR, 1986, ENDOCRINOLOGY, V118, P2445, DOI 10.1210/endo-118-6-2445; Nasu M, 2000, J ENDOCRINOL, V167, P305, DOI 10.1677/joe.0.1670305; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Onishi T, 1997, J BONE MINER RES, V12, P1596, DOI 10.1359/jbmr.1997.12.10.1596; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1985, CALCIFIED TISSUE INT, V37, P519, DOI 10.1007/BF02557835; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006; SCUTT A, 1994, CALCIFIED TISSUE INT, V55, P208, DOI 10.1007/BF00425877; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Tam VK, 1998, ENDOCRINOLOGY, V139, P3072, DOI 10.1210/en.139.7.3072; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; von Stechow D, 2004, J CELL BIOCHEM, V93, P476, DOI 10.1002/jcb.20174; WADAYAMA B, 1994, CANCER RES, V54, P3042; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528	46	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					3104	3111		10.1074/jbc.M409846200	http://dx.doi.org/10.1074/jbc.M409846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15513917	hybrid			2022-12-25	WOS:000226449100087
J	Yamauchi, A; Marchal, CC; Molitoris, J; Pech, N; Knaus, U; Towe, J; Atkinson, SJ; Dinauer, MC				Yamauchi, A; Marchal, CC; Molitoris, J; Pech, N; Knaus, U; Towe, J; Atkinson, SJ; Dinauer, MC			Rac GTPase isoform-specific regulation of NADPH oxidase and chemotaxis in murine neutrophils in vivo - Role of the C-terminal polybasic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RHO-FAMILY; NUCLEAR-LOCALIZATION; HOST-DEFENSE; GENE; ACTIVATION; PROTEIN; CELLS; EXPRESSION; GP91(PHOX)	The Rho family GTPase Rac acts as a molecular switch for signal transduction to regulate various cellular functions. Mice deficient in the hematopoietic-specific Rac2 isoform exhibit agonist-specific defects in neutrophil chemotaxis and superoxide production, despite expression of the highly homologous Rac1 isoform. To examine whether functional defects in rac2(-/-) neutrophils reflect effects of an overall decrease in total cellular Rac or an isoform-specific role for Rac2, retroviral vectors were used to express exogenous Rac1 or Rac2 at levels similar to endogenous. In rac2(-/-) neutrophils differentiated from transduced myeloid progenitors in vitro, increasing cellular Rac levels by expression of either exogenous Rac1 or Rac2 increased formylmethionylleucylphenylalanine- or phorbol ester-stimulated NADPH oxidase activity. Of note, placement of an epitope tag on the N terminus of Rac1 or Rac2 blunted reconstitution of responses in rac2(-/-) neutrophils. In rac2(-/-) neutrophils isolated from mice transplanted with Rac-transduced bone marrow cells, superoxide production and chemotaxis were fully reconstituted by expression of exogenous Rac2, but not Rac1. A chimeric Rac1 protein in which the Rac1 C-terminal polybasic domain, which contains six lysines or arginines, was replaced with that of the human Rac2 polybasic domain containing only three basic residues, also reconstituted superoxide production and chemotaxis, whereas expression of a Rac2 derivative in which the polybasic domain was replaced with that of Rac1 did not and resulted in disoriented cell motility. Thus, the composition of the polybasic domain is sufficient for determining Rac isoform specificity in the production of superoxide and chemotaxis in murine neutrophils in vivo.	Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Med Nephrol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Scripps Research Institute	Dinauer, MC (corresponding author), Canc Res Inst, 1044 W Walnut St,R4 402C, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu	Yamauchi, Akira/F-2202-2010	Yamauchi, Akira/0000-0001-9205-6922	NHLBI NIH HHS [R01HL45635, P01HL69974] Funding Source: Medline; NIAID NIH HHS [R01AI 35947] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, P01HL069974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DINAUER M, 2003, NATHAN OSKIS HEMATOL, V1, P923; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HAWLEY RG, 1994, GENE THER, V1, P136; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kim C, 2003, J IMMUNOL, V171, P4425, DOI 10.4049/jimmunol.171.8.4425; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Li SJ, 2002, J IMMUNOL, V169, P5043, DOI 10.4049/jimmunol.169.9.5043; Mardia K.V., 1999, DIRECTIONAL STAT, P93, DOI [10.1002/9780470316979.ch6, DOI 10.1002/9780470316979.CH6]; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; Pop M, 2004, J BIOL CHEM, V279, P35840, DOI 10.1074/jbc.M404346200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sadat MA, 2003, HUM GENE THER, V14, P651, DOI 10.1089/104303403321618164; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Williams DA, 2000, BLOOD, V96, P1646; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832; Zicha D, 1997, Methods Mol Biol, V75, P449	43	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					953	964		10.1074/jbc.M408820200	http://dx.doi.org/10.1074/jbc.M408820200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15504745	hybrid			2022-12-25	WOS:000226195200014
J	Ho, M; Kreitman, RJ; Onda, M; Pastan, I				Ho, M; Kreitman, RJ; Onda, M; Pastan, I			In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIMICKING SOMATIC HYPERMUTATION; B-CELL LEUKEMIAS; PHAGE DISPLAY; RECOMBINANT IMMUNOTOXIN; AFFINITY MATURATION; CYTOTOXIC ACTIVITY; PSEUDOMONAS EXOTOXIN; DIRECTED EVOLUTION; BINDING-AFFINITY; FV FRAGMENT	Recombinant immunotoxin BL22, containing the Fv portion of an anti-CD22 antibody, produced complete remissions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias with low CD22 expression. Complementarity-determining region (CDR) mutagenesis is used to increase antibody affinity but can be difficult to perform successfully. We previously showed that antibodies with increased affinity and immunotoxins with increased activity could be obtained by directing mutations at specific DNA residues called hot spots. Because hot spots can arise either by somatic mutation or be present in the germline, we examined which type of hot spot is preferred for increasing antibody affinity. Initially, a second generation antibody phage-display library targeting a germline hot spot (Ser(30)-Asn(31)) within CDR1 of the antibody light chain was mutated. Substitution of serine 30 or asparagine 31 with arginine produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold over BL22 (5.8 nM) and 3-fold over the first generation mutant HA22 (2.3 nM). More importantly, a 10-fold increase in activity over BL22 and a 2-3-fold increase over HA22 were observed in various B lymphoma cell lines including WSU-CLL that contains only 5500 CD22 sites per cell. For comparison, two phage-display libraries targeting non-germline hot spots in heavy chain CDR1 and CDR3 were generated but did not produce Fv with increased affinity. Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation.	NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Rm 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	Ho, Mitchell/F-5059-2015; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ho, Mitchell/0000-0002-9152-5405	NATIONAL CANCER INSTITUTE [ZIABC008753, Z01BC008753] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Beers R, 2000, CLIN CANCER RES, V6, P2835; Benedict CA, 1997, J IMMUNOL METHODS, V201, P223, DOI 10.1016/S0022-1759(96)00227-X; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; CAMPANA D, 1985, J IMMUNOL, V134, P1524; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; Frankel AE, 2000, CLIN CANCER RES, V6, P326; Ghetie V, 2001, MOL BIOTECHNOL, V18, P251, DOI 10.1385/MB:18:3:251; Graff CP, 2004, PROTEIN ENG DES SEL, V17, P293, DOI 10.1093/protein/gzh038; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; Kabat E. A., 1991, NIH PUBLICATION; Krauss J, 2003, PROTEIN ENG, V16, P753, DOI 10.1093/protein/gzg096; Kreitman RJ, 1999, INT J CANCER, V81, P148; Kreitman RJ, 2000, CLIN CANCER RES, V6, P1476; KREITMAN RJ, 1995, SEMIN CANCER BIOL, V6, P297, DOI 10.1006/scbi.1995.0038; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Lavoie TB, 1999, MOL IMMUNOL, V36, P1189, DOI 10.1016/S0161-5890(99)00130-3; Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Mansfield E, 1997, BLOOD, V90, P2020, DOI 10.1182/blood.V90.5.2020; Mohammad RM, 1996, LEUKEMIA, V10, P130; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Neuberger MS, 2002, BIOCHEM SOC T, V30, P341, DOI 10.1042/bst0300341; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; NEWMAN MA, 1992, J IMMUNOL, V149, P3260; Pastan I, 2003, CANCER IMMUNOL IMMUN, V52, P338, DOI 10.1007/s00262-002-0353-8; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rossmann E D, 2001, Hematol J, V2, P300, DOI 10.1038/sj.thj.6200119; Salvatore G, 2002, CLIN CANCER RES, V8, P995; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEN GL, 1988, INT J CANCER, V42, P792, DOI 10.1002/ijc.2910420527; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Wang CL, 2004, P NATL ACAD SCI USA, V101, P7352, DOI 10.1073/pnas.0402009101; Whitelegg NRJ, 2000, PROTEIN ENG, V13, P819, DOI 10.1093/protein/13.12.819; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	44	80	100	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					607	617		10.1074/jbc.M409783200	http://dx.doi.org/10.1074/jbc.M409783200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15491997	hybrid			2022-12-25	WOS:000226025100072
J	Matlhagela, K; Borsick, M; Rajkhowa, T; Taub, M				Matlhagela, K; Borsick, M; Rajkhowa, T; Taub, M			Identification of a prostaglandin-responsive element in the Na,K-ATPase beta(1) promoter that is regulated by cAMP and Ca2+ - Evidence for an interactive role of cAMP regulatory element-binding protein and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE BETA-1 GENE; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; MDCK-CELLS; KINASE-II; SUBUNIT GENE; CREB; EXPRESSION; ACTIVATION; RAT	The Na,K-ATPase is a transmembrane protein responsible for maintaining electrochemical gradients across the plasma membrane in all mammalian cells, a process that is subject to regulation at the transcriptional as well as post-transcriptional level. Included among physiologic regulators in the kidney are prostaglandins. Previously, we demonstrated that prostaglandin E-1 (PGE(1)) increases the activity and expression of the Na,K-ATPase in Madin-Darby canine kidney cells (Taub, M., Borsick, M., Geisel, J., Matlhagela, K., Rajkhowa, T., and Allen, C. ( 2004) Exp. Cell Res. 299, 1-14; Taub, M. L., Wang, Y., Yang, I. S., Fiorella, P., and Lee, S. M. ( 1992) J. Cell. Physiol. 151, 337-346). In this work, we present evidence that transcription of the Na, K-ATPase beta(1) subunit is stimulated by PGE1, an effect that may be mediated through the cAMP and Ca2+ pathways. Transient transfection studies using 5'-deletion mutants of the human beta(1) subunit promoter indicated that region -100 to -92 containing the sequence AGTCCCTGC (a prostaglandin-responsive element (PGRE)) is required to elicit the stimulatory effects of PGE1, 8-bromo-cAMP, phorbol 12-myristate 13-acetate, and okadaic acid. Electrophoretic mobility shift assays indicated that both the cAMP regulatory element-binding protein ( CREB) and Sp1 bind to the PGRE present within this region of the beta(1) subunit promoter. The involvement of the PGRE and Sp1 sites in regulation by PGE1 was further confirmed by the increased PGE1 stimulation that was observed following insertion of the PGRE into a promoter/luciferase construct containing a portion of a heterologous promoter and the fibronectin promoter with four GC boxes. Further evidence suggesting an interaction between Sp1 and CREB was obtained from experiments conducted with pLuc-MCS-beta72-167, which contains region -167 to -72 in the human beta(1) subunit promoter. The PGE1 stimulation observed in Madin-Darby canine kidney cells transiently transfected with pLuc-MCS-beta72-167 was reduced when the two GC boxes immediately upstream from the PGRE were translocated farther upstream. Also consistent with an interaction between CREB and Sp1 are the results of our immunoprecipitation studies indicating that CREB co-immunoprecipitated with Sp1 when an antibody against CREB, Sp1, or the CREB-binding protein was used.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Taub, M (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	biochtau@buffalo.edu		Herman, Maryann/0000-0002-9652-8517; Taub, Mary/0000-0003-1382-3885	NHLBI NIH HHS [1R01HL6976-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABOOLIAN A, 1989, AM J PHYSIOL, V256, pF1135, DOI 10.1152/ajprenal.1989.256.6.F1135; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; BONVENTRE JV, 1991, KIDNEY INT, V39, P438, DOI 10.1038/ki.1991.55; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breyer MD, 1998, KIDNEY INT, V54, pS88, DOI 10.1046/j.1523-1755.1998.06718.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CARER EP, 1997, AM J PHYSIOL, V272, pL542; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; Derfoul A, 1998, J BIOL CHEM, V273, P20702, DOI 10.1074/jbc.273.33.20702; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FENG JI, 1993, NUCLEIC ACIDS RES, V21, P2619, DOI 10.1093/nar/21.11.2619; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GICK GG, 1988, J BIOL CHEM, V263, P16610; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; Kim E, 2004, J BIOL CHEM, V279, P11188, DOI 10.1074/jbc.M313291200; KIM KS, 1994, J NEUROCHEM, V63, P834; KITAGAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P339, DOI 10.1016/0167-4781(91)90174-K; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; KURSTJENS NP, 1990, BIOCHEM BIOPH RES CO, V167, P1162, DOI 10.1016/0006-291X(90)90645-4; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MAMIYA N, 1993, BIOCHEM BIOPH RES CO, V195, P608, DOI 10.1006/bbrc.1993.2089; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAIER MH, 1986, MINER ELECTROL METAB, V12, P42; SCHERZER P, 1992, CLIN SCI, V83, P307, DOI 10.1042/cs0830307; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Shell SA, 2002, BIOL REPROD, V66, P659, DOI 10.1095/biolreprod66.3.659; Skou JC, 1998, BIOSCIENCE REP, V18, P155, DOI 10.1023/A:1020196612909; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; Taub M, 2004, EXP CELL RES, V299, P1, DOI 10.1016/j.yexcr.2004.04.046; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; TAUB ML, 1992, J CELL PHYSIOL, V151, P337, DOI 10.1002/jcp.1041510215; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; Uchida C, 2002, J BIOL CHEM, V277, P39082, DOI 10.1074/jbc.M201380200; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wendt CH, 2000, J BIOL CHEM, V275, P41396, DOI 10.1074/jbc.M004759200; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200; Zhuang Y, 2000, J BIOL CHEM, V275, P24173, DOI 10.1074/jbc.M002953200	57	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					334	346		10.1074/jbc.M411415200	http://dx.doi.org/10.1074/jbc.M411415200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485816	hybrid			2022-12-25	WOS:000226025100041
J	Altroff, H; Schlinkert, R; van der Walle, CF; Bernini, A; Campbell, ID; Werner, JM; Mardon, HJ				Altroff, H; Schlinkert, R; van der Walle, CF; Bernini, A; Campbell, ID; Werner, JM; Mardon, HJ			Interdomain tilt angle determines integrin-dependent function of the ninth and tenth FIII domains of human fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; DIPOLAR COUPLINGS; CRYSTAL-STRUCTURE; POLYACRYLAMIDE GELS; HETERONUCLEAR NMR; PROTEINS; ALIGNMENT; COMPLEX; SEGMENT; SITE	Integrins are an important family of signaling receptors that mediate diverse cellular processes. The binding of the abundant extracellular matrix ligand fibronectin to integrins alpha(5)beta(1) and alpha(v)beta(3) is known to depend upon the Arg-Gly-Asp (RGD) motif on the tenth fibronectin FIII domain. The adjacent ninth FIII domain provides a synergistic effect on RGD-mediated integrin alpha(5)beta(1) binding and downstream function. The precise molecular basis of this synergy remains elusive. Here we have dissected further the function of FIII9 in integrin binding by analyzing the biological activity of the FIII9-10 interdomain interface variants and by determining their structural and dynamic properties in solution. We demonstrate that the contribution of FIII9 to both alpha(5)beta(1) and alpha(v)beta(3) binding and downstream function critically depends upon the interdomain tilt between the FIII9 and FIII10 domains. Our data suggest that modulation of integrin binding by FIII9 may arise in part from its steric properties that determine accessibility of the RGD motif. These findings have wider implications for mechanisms of integrin-ligand binding in the physiological context.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Mardon, HJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.	helen.mardon@obs-gyn.ox.ac.uk	Bernini, Andrea/H-9412-2012; Werner, Joern/E-1148-2013; Altroff, Harri/B-3544-2011; van der Walle, Chris/AAB-9641-2022	Bernini, Andrea/0000-0002-7528-2749; van der Walle, Christopher/0000-0002-1561-1213; Werner, Jorn/0000-0002-4712-1833	Wellcome Trust [073028] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Altroff H, 2003, J BIOL CHEM, V278, P491, DOI 10.1074/jbc.M209992200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Copie V, 1998, J MOL BIOL, V277, P663; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Ishii Y, 2001, J BIOMOL NMR, V21, P141, DOI 10.1023/A:1012417721455; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Kauf ACW, 2001, BIOCHEMISTRY-US, V40, P9159, DOI 10.1021/bi010503x; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OBARA M, 1995, EXP CELL RES, V216, P273, DOI 10.1006/excr.1995.1033; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Sass HJ, 2000, J BIOMOL NMR, V18, P303, DOI 10.1023/A:1026703605147; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; van der Walle CF, 2002, PROTEIN ENG, V15, P1021, DOI 10.1093/protein/15.12.1021; Werner Jorn M, 2002, Methods Mol Biol, V173, P285; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	44	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55995	56003		10.1074/jbc.M406976200	http://dx.doi.org/10.1074/jbc.M406976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485890	hybrid, Green Accepted			2022-12-25	WOS:000225960800123
J	Galigniana, MD; Morishima, Y; Gallay, PA; Pratt, WB				Galigniana, MD; Morishima, Y; Gallay, PA; Pratt, WB			Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; GLUCOCORTICOID-RECEPTOR; HSP90-BINDING IMMUNOPHILINS; MAMMALIAN PROTEIN; BINDING-PROTEIN; HIV-1 VIRIONS; CYCLOSPORIN-A; IN-VIVO; FKBP52; RAPAMYCIN	Although cyclophilin A (CyP-A) is a relatively abundant small immunophilin present in the cytoplasm of all mammalian cells, its general function(s) in the absence of the immunosuppressant drug cyclosporin A is not known. In contrast, the high molecular weight hsp90-binding immunophilins appear to play a role in protein trafficking in that they have been shown to link glucocorticoid receptor-hsp90 and p53.hsp90 complexes to the dynein motor protein for retrograde movement along microtubules. These immunophilins link to cytoplasmic dynein indirectly through the association of the immunophilin peptidylprolyl isomerase (PPIase) domain with dynamitin, a component of the dynein-associated dynactin complex (Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004) J. Biol. Chem. 279, 22483-22489). Here, we show that CyP-A exists in native heterocomplexes containing cytoplasmic dynein that can be formed in cell-free systems. Prolyl isomerase activity is not required for forming the dynein complex, but the PPIase domain fragment of FKBP52 blocks complex formation and CyP-A binds to dynamitin in a PPIase domain-dependent manner. CyP-A heterocomplexes containing tubulin and dynein can be formed in cytosol prepared under microtubule-stabilizing conditions, and CyP-A colocalizes in mouse fibroblasts with microtubules. Colocalization with microtubules is disrupted by overexpression of the PPIase domain fragment. Thus, we conclude that CyP-A associates in vitro and in vivo with the dynein/dynactin motor protein complex and we suggest that CyP-A may perform a general function related to the binding of cargo for retrograde movement along microtubules.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol,Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Tecn Argentina, Buenos Aires C1428EGA, DF, Argentina	University of Michigan System; University of Michigan; Scripps Research Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	mgali@umich.edu		GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28010] Funding Source: Medline; NIAID NIH HHS [AI 054196] Funding Source: Medline; NIDDK NIH HHS [P60 DK 20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051	31	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55754	55759		10.1074/jbc.M406259200	http://dx.doi.org/10.1074/jbc.M406259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496417	hybrid, Green Published			2022-12-25	WOS:000225960800097
J	Huber, IG; Wappl-Kornherr, E; Sinnegger-Brauns, MJ; Hoda, JC; Walter-Bastl, D; Striessnig, J				Huber, IG; Wappl-Kornherr, E; Sinnegger-Brauns, MJ; Hoda, JC; Walter-Bastl, D; Striessnig, J			Opposite effects of a single IIIS5 mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; SKELETAL-MUSCLE; MOLECULAR DETERMINANTS; DRUG-BINDING; MESSENGER-RNAS; SMOOTH-MUSCLE; RECEPTOR-SITE; BETA-SUBUNIT; DILTIAZEM; BLOCK	Replacement of L-type Ca2+ channel alpha(1) subunit residue Thr-1066 in segment IIIS5 by a tyrosine residue conserved in the corresponding positions of non-L-type Ca2+ channels eliminates high dihydropyridine sensitivity through a steric mechanism. To determine the effects of this mutation on phenylalkylamine interaction, we exploited the availability of Ca(v)1.2DHP(-/-) mice containing the T1066Y mutation. In contrast to dihydropyridines, increased protein-dependent binding of the phenylalkylamine (-)-[H-3] devapamil occurred to Ca(v)1.2DHP(-/-) mouse brain microsomes. This effect could be attributed to an at least 2-fold increase in affinity as determined by saturation analysis and binding inhibition experiments. The latter also revealed a higher affinity for (-)- verapamil but not for (-)- gallopamil. The mutation caused a pronounced slowing of (-)-[H-3] devapamil dissociation, indicating a stabilization of the drug-channel complex. The increased affinity of mutant channels was also evident in functional studies after heterologous expression of wild type and T1066Y channels in Xenopus laevis oocytes. 100 muM (-)verapamil inhibited a significantly larger fraction of Ba2+ inward current through mutant than through WT channels. Our results provide evidence that phenylalkylamines also interact with the IIIS5 helix and that the geometry of the IIIS5 helix affects the access and/or binding of different chemical classes of Ca2+ channel blockers to their overlapping binding domains. Mutation of Thr-1066 to a non-L-type tyrosine residue can be exploited to differentially affect phenylalkylamine and dihydropyridine binding to L-type Ca2+ channels.	Univ Innsbruck, Inst Pharm, Abt Pharmakol & Toxikol, A-6020 Innsbruck, Austria; Med Univ Innsbruck, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria	University of Innsbruck; Medical University of Innsbruck	Striessnig, J (corresponding author), Univ Innsbruck, Inst Pharm, Abt Pharmakol & Toxikol, Peter Mayrstr 1-I, A-6020 Innsbruck, Austria.	joerg.striessnig@uibk.ac.at	Striessnig, Joerg/S-9334-2017; Tuluc, Petronel/C-2527-2011	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731	Austrian Science Fund FWF [P 17109] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Brauns T, 1997, BIOCHEMISTRY-US, V36, P3625, DOI 10.1021/bi9613584; Clark NC, 2003, NEUROSCIENCE, V120, P435, DOI 10.1016/S0306-4522(03)00329-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dobrev D, 1999, BRIT J PHARMACOL, V127, P576, DOI 10.1038/sj.bjp.0702574; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FERRY DR, 1984, N-S ARCH PHARMACOL, V327, P183, DOI 10.1007/BF00500915; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Huber I, 2000, BIOCHEM J, V347, P829, DOI 10.1042/0264-6021:3470829; ISHIBASHI H, 1995, BRAIN RES, V695, P88, DOI 10.1016/0006-8993(95)00815-8; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KWAN YW, 1995, J MOL CELL CARDIOL, V27, P253, DOI 10.1016/S0022-2828(08)80024-7; Liu XR, 2001, GASTROENTEROLOGY, V120, P480, DOI 10.1053/gast.2001.21167; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; OEKEN HJ, 1986, EUR J BIOCHEM, V156, P661, DOI 10.1111/j.1432-1033.1986.tb09629.x; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sinnegger-Brauns MJ, 2004, J CLIN INVEST, V113, P1430, DOI 10.1172/JCI200420208; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; Wang MC, 2004, J BIOL CHEM, V279, P7159, DOI 10.1074/jbc.M308057200; Wappl E, 2001, J BIOL CHEM, V276, P12730, DOI 10.1074/jbc.M010164200; Zhorov BS, 2001, ARCH BIOCHEM BIOPHYS, V393, P22, DOI 10.1006/abbi.2001.2484	34	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55211	55217		10.1074/jbc.M409008200	http://dx.doi.org/10.1074/jbc.M409008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504730	hybrid			2022-12-25	WOS:000225960800029
J	Jastrzebska, B; Maeda, T; Zhu, L; Fotiadis, D; Filipek, S; Engel, A; Stenkamp, RE; Palczewski, K				Jastrzebska, B; Maeda, T; Zhu, L; Fotiadis, D; Filipek, S; Engel, A; Stenkamp, RE; Palczewski, K			Functional characterization of rhodopsin monomers and dimers in detergents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BLUE NATIVE ELECTROPHORESIS; CYTOCHROME-C-OXIDASE; TRANSMEMBRANE HELICES; 3-DIMENSIONAL STRUCTURE; TRANSDUCIN ACTIVATION; LATERAL DIFFUSION; MEMBRANE-PROTEIN; LIGHT; DIMERIZATION	Rhodopsin (Rho) is a G protein-coupled receptor that initiates phototransduction in rod photoreceptors. High expression levels of Rho in the disc membranes of rod outer segments and the propensity of Rho to form higher oligomeric structures are evident from atomic force microscopy, transmission electron microscopy, and chemical cross-linking experiments. To explore the structural and functional properties of Rho in n-dodecyl-beta-maltoside, frequently used to purify heterologously expressed Rho and its mutants, we used gel filtration techniques, blue native gel electrophoresis, and functional assays. Here, we show that in micelles containing n-dodecyl-beta-maltoside at concentrations greater than 3 mM, Rho is present as a single monomer per detergent micelle. In contrast, in 12 mM 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS), micelles contain mostly dimeric Rho. The cognate G protein transducin (Gt) appears to have a preference for binding to the Rho dimer, and the complexes fall apart in the presence of guanosine 5'-3-O-(thio)triphosphate. Cross-linked Rho dimers release the chromophore at a slower rate than monomers and are much more resistant to heat denaturation. Both Rho* monomers and dimers are capable of activating Gt, and both of them are phosphorylated by Rho kinase. Rho expressed in HEK293 cells is also readily cross-linked by a bifunctional reagent. These studies provide an explanation of how detergent influences the oligomer-dimer-monomer equilibrium of Rho and describe the functional characterization of Rho monomers and dimers in detergent.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Basel; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, P30EY001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; APPLEBURY ML, 1974, BIOCHEMISTRY-US, V13, P3448, DOI 10.1021/bi00714a005; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; Dupuy C, 1997, LANGMUIR, V13, P3965, DOI 10.1021/la9604285; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P485, DOI 10.1016/0003-2697(83)90621-8; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; KUSUMI A, 1982, BIOCHEMISTRY-US, V21, P5978, DOI 10.1021/bi00266a039; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; PREININGER AM, 2004, SCI STKE; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Sakmar TP, 2002, CURR OPIN CELL BIOL, V14, P189, DOI 10.1016/S0955-0674(02)00306-X; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Vogel R, 2004, J MOL BIOL, V338, P597, DOI 10.1016/j.jmb.2004.03.006	66	119	124	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54663	54675		10.1074/jbc.M408691200	http://dx.doi.org/10.1074/jbc.M408691200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489507	hybrid, Green Accepted			2022-12-25	WOS:000225793600093
J	Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD				Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD			Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase	ONCOGENE			English	Article						palmitoylation; protein; palmitoyl acyltransferase; RAS; intracellular signaling	ACYL TRANSFERASE-ACTIVITY; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; H-RAS; SACCHAROMYCES-CEREVISIAE; N-RAS; LOCALIZATION; PURIFICATION; CANCER; CELLS	Protein palmitoyltransferases (PATs) represent an exciting new target for anticancer drug design due to their pivotal roles in the subcellular localization of a number of oncogenes. We show that the Huntingtin interacting protein 14 (HIP14) is a PAT with a preference for the farnesyl-dependent palmitoylation motif found in H- and N-RAS. Characterization of HIP14 in mouse cells has revealed that it has the ability to induce colony formation in cell culture, anchorage-independent growth, and tumors in mice. Activity of the enzyme and its ability to transform cells is dependent on critical residues in the active site of the enzyme.	Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Smith, CD (corresponding author), Penn State Univ, Dept Pharmacol, Coll Med, H078,500 Univ Dr, Hershey, PA 17033 USA.	cdsmith@psu.edu			NCI NIH HHS [R01 CA75248, R01 CA075248-09, R01 CA075248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Danesi R, 1996, MOL PHARMACOL, V49, P972; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Eummer JT, 1999, BIOORGAN MED CHEM, V7, P241, DOI 10.1016/S0968-0896(98)00202-8; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hiol A, 2003, BBA-MOL CELL BIOL L, V1635, P10, DOI 10.1016/j.bbalip.2003.10.001; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Ueno K, 1997, J BIOL CHEM, V272, P13519, DOI 10.1074/jbc.272.21.13519; Varner AS, 2003, BIOCHEM J, V373, P91, DOI 10.1042/BJ20021598; Varner AS, 2002, ANAL BIOCHEM, V308, P160, DOI 10.1016/S0003-2697(02)00212-9; Waddick KG, 1998, BIOCHEM PHARMACOL, V56, P1411, DOI 10.1016/S0006-2952(98)00211-1	39	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9230	9237		10.1038/sj.onc.1208171	http://dx.doi.org/10.1038/sj.onc.1208171			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489887	Green Accepted			2022-12-25	WOS:000225638000008
J	Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM				Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM			PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways	ONCOGENE			English	Article						PKC; glioblastoma; mTOR; Akt; proliferation	PROTEIN-KINASE-C; GROWTH-FACTOR; MESSENGER-RNAS; PHAS-I; EXPRESSION; ALPHA; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; TRANSLATION	We previously demonstrated that protein kinase C-eta (PKC-eta) mediates a phorbol 12-myristate-13-acetate (PMA)-induced proliferative response in human glioblastoma (GBM) cells. In this report, we show that PMA-stimulated activation of PKC-eta in U-251 GBM cells resulted in activation of both Akt and the mammalian target of rapamycin (mTOR) signaling pathways and an increase in cell proliferation. Expression of a kinase dead PKC-eta (PKC-etaKR) construct reduced the basal and PMA-evoked proliferation of PKC-eta-expressing U-251 GBM cells, as well as abrogated the PMA-induced activation of Akt, mTOR, and the mTOR targets 4E-BP1 and STAT-3. Treatment of cells with the PI-3 kinase inhibitor LY294002 (10 muM) or the mTOR inhibitor rapamycin (10 nM) also reduced PMA-induced proliferation and cell-cycle progression. Expression of a constitutively active PKC-eta (PKC-etaDeltaNPS) construct in a GBM cell line with no endogenous PKC-eta (U-1242) also provided evidence that PKC-eta targets the Akt and mTOR signaling pathways. Moreover, activation of 4E-BP1 and STAT-3 in both PMA-treated U-251 and PKC-etaDeltaNPS-expressing U-1242 GBM cells was inhibited by rapamycin. However, activation of Akt, but not mTOR was inhibited by the PI-3 kinase inhibitor LY294002. This study identifies Akt and mTOR as downstream targets of PKC-eta that are involved in GBM cell proliferation.	Univ Virginia, Dept Pathol & Neurol, Charlottesville, VA 22908 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Virginia; Columbia University	Aeder, SE (corresponding author), Univ Virginia, Dept Pathol, 415 Lane Rd,POB 800904, Charlottesville, VA 22908 USA.	sea4s@virginia.edu			NCI NIH HHS [CA90851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BENZIL DL, 1992, CANCER RES, V52, P2951; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Choe Y, 2003, J NEUROENDOCRINOL, V15, P508, DOI 10.1046/j.1365-2826.2003.01023.x; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fadden P, 1997, J BIOL CHEM, V272, P10240; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guizzetti M, 1998, EUR J PHARMACOL, V359, P223, DOI 10.1016/S0014-2999(98)00620-7; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hesselager G, 2003, CANCER RES, V63, P4305; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; Konopka G, 2003, CURR MOL MED, V3, P73, DOI 10.2174/1566524033361609; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krasagakis K, 2004, J CELL PHYSIOL, V199, P381, DOI 10.1002/jcp.10434; Livneh E, 1996, ONCOGENE, V12, P1545; MAYER M, 1994, DEVELOPMENT, V120, P143; MAYER M, 1993, GLIA, V8, P12, DOI 10.1002/glia.440080103; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NAVE BT, 1999, BIOCHEM J, V1, P427; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Okada Y, 2000, VERH DEUT G, V84, P33; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Rajan P, 1998, J NEUROSCI, V18, P3620; Resnick MS, 1997, CANCER RES, V57, P2209; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Rooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9; Sano T, 1999, CANCER RES, V59, P1820; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; TODO T, 1991, NEUROSURGERY, V108, P11; WANG X, 1998, BIOCHEM J, V183, P261; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weis J, 1999, J NEURO-ONCOL, V44, P243, DOI 10.1023/A:1006303221064; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yamamoto M, 2002, ANTICANCER RES, V22, P4265; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	66	80	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9062	9069		10.1038/sj.onc.1208093	http://dx.doi.org/10.1038/sj.onc.1208093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489897				2022-12-25	WOS:000225492800007
J	Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M				Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M			Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma	ONCOGENE			English	Article						array CGH; diffuse large B-cell lymphoma; Fragile Histidine Triad; 3p14.2	COMPARATIVE GENOMIC HYBRIDIZATION; FHIT GENE; CHROMOSOMAL IMBALANCES; EXPRESSION; CLASSIFICATION; TRANSCRIPTS; PROTEIN; ACID; SITE	Deletions of the 3p arm have been detected in various solid tumors, but no study to date has investigated this deletion in diffuse large B-cell lymphoma (DLBCL). Recently, we demonstrated that 3p14.2 was deleted in approximately 30% of DLBCL cases by use of a genome-wide array-comparative genomic hybridization (CGH). For a more detailed examination of the genomic losses at 3p14.2, here we made use of contig BAC array for 3p14.2, and found that 12 DLBCL samples displayed losses. All of the deleted regions were located within the fragile histidine triad (FHIT) gene, and the most frequent region of loss was mapped to 0.4 Mbp of the region encompassing the introns 4 and 5 and exon 5 of the FHIT gene. Concomitant analysis of transcripts showed that the FHIT gene was aberrantly transcribed in 31% of the DLBCL samples examined and that the lost exons of the aberrant transcripts were correlated with genomic deletions. These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts.	Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 514, Japan; Aichi Canc Ctr, Dept Hematol & Chemotherapy, Aichi, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Med, Aichi, Japan	Mie University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp	Nakamura, Shigeo/I-1571-2012; Ota, Akinobu/CAC-5999-2022; Ota, Akinobu/AAI-9396-2020; Ota, Akinobu/H-4510-2019	Ota, Akinobu/0000-0002-6296-2921; Suzuki, Ritsuro/0000-0002-5974-7614; Yamaguchi, Motoko/0000-0002-7094-6489; Tsuzuki, Shinobu/0000-0002-3209-3550				Albitar M, 2001, LEUKEMIA RES, V25, P859, DOI 10.1016/S0145-2126(01)00042-X; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Berglund M, 2002, MODERN PATHOL, V15, P807, DOI 10.1097/01.MP.0000024375.04135.2B; Chen PM, 2004, ONCOL REP, V11, P349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Dave BJ, 2002, CANCER GENET CYTOGEN, V132, P125, DOI 10.1016/S0165-4608(01)00548-9; Druck T, 1997, CANCER RES, V57, P504; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gemma A, 1997, CANCER RES, V57, P1435; Hallas C, 1999, CLIN CANCER RES, V5, P2409; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HARRIS NL, 1994, BLOOD, V84, P1361; Hendricks DT, 1997, CANCER RES, V57, P2112; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Iwai T, 1998, CANCER RES, V58, P5182; Karnan S, 2004, GENE CHROMOSOME CANC, V39, P77, DOI 10.1002/gcc.10298; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297	33	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9148	9154		10.1038/sj.onc.1208136	http://dx.doi.org/10.1038/sj.onc.1208136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480422				2022-12-25	WOS:000225492800017
J	Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H				Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H			Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors	ONCOGENE			English	Article						flat-type colorectal tumor; RASSF1A; 3p LOH; K-ras; tumor suppressor gene; methylation	K-RAS MUTATIONS; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; CPG ISLAND; CANCER; METHYLATION; CARCINOMA; LUNG; 3P21.3	Flat colorectal tumors, characterized by high-grade dysplasia from early small. at mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48. at colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias). RASSF1A hypermethylation was detected in 39 of 48 (81.3%) tumors and RASSF1A methylation was also detected in 19 of 39 (49%) normal colonic mucosal tissues. 3p21.3 LOH was detected in 20 of 42 (47.6%) cases, but RASSF1 methylation was detected in cases with LOH (14 cases) and retention of 3p21.3 ( 20 cases). K-ras mutations were detected in seven of 48 (14.6%) tumors and the concordant occurrence of K-ras mutation and RASSF1A methylation was detected in three of 48 cases (6.3%). Overall, there was a statistically significant mutually exclusive relationship between K-ras mutations and RASSF1A methylation. In conclusion, promoter hypermethylation of RASSF1A is a frequent event and may start early in the background normal mucosa in this tumor type. An alternative cascade of abnormalities in RAS transduction pathways may be responsible for the. at morphology and aggressive nature of. at colorectal neoplasms.	Juntendo Univ, Sch Med, Dept Pathol 2, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Course Mol & Cellular Med, Dept Mol Genet,Div Mol & Cellular Med, Niigata 9518514, Japan; Tokyo Rinkai Hosp, Div Pathol, Tokyo, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Pathol, Tokyo 104, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Clin Lab, Tokyo 104, Japan	Juntendo University; Juntendo University; Niigata University; Japanese Foundation for Cancer Research; National Cancer Center - Japan; National Cancer Center - Japan	Fujii, H (corresponding author), Juntendo Univ, Sch Med, Dept Pathol 2, 2-1-1 Hongo, Tokyo 1138421, Japan.	hfujii@med.juntendo.ac.jp						Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chiang JM, 1998, CANCER RES, V58, P3289; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; Fujii H, 2002, J PATHOL, V197, P298, DOI 10.1002/path.1122; FUJIMORI T, 1994, INT J CANCER, V57, P51, DOI 10.1002/ijc.2910570110; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2001, CANCER RES, V61, P3573; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kuroki T, 2003, CANCER RES, V63, P3724; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; MINAMOTO T, 1994, CANCER RES, V54, P2841; Morrissey C, 2001, CANCER RES, V61, P7277; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; Mueller JD, 1998, AM J PATHOL, V153, P1977, DOI 10.1016/S0002-9440(10)65711-2; Olschwang S, 1998, INT J CANCER, V77, P366, DOI 10.1002/(SICI)1097-0215(19980729)77:3<366::AID-IJC10>3.0.CO;2-6; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rubio CA, 1996, DIS COLON RECTUM, V39, P143, DOI 10.1007/BF02068067; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Sparks AB, 1998, CANCER RES, V58, P1130; Spugnardi M, 2003, CANCER RES, V63, P1639; TADA S, 1994, CANCER, V74, P2430, DOI 10.1002/1097-0142(19941101)74:9<2430::AID-CNCR2820740907>3.0.CO;2-C; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Yashiro M, 2001, CANCER RES, V61, P2676; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; YUKAWA M, 1994, GUT, V35, P1258, DOI 10.1136/gut.35.9.1258	44	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8900	8907		10.1038/sj.onc.1207993	http://dx.doi.org/10.1038/sj.onc.1207993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480433				2022-12-25	WOS:000225354600005
J	Le Floch, N; Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Dale, T; Gespach, C				Le Floch, N; Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Dale, T; Gespach, C			The proinvasive activity of Wnt-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3 beta and c-Jun/AP-1 signaling	FASEB JOURNAL			English	Article						axin; Dvl-2; sFRP-3; trefoil peptides; HGF; Rho GTPases; Rho-kinase; PI3-kinase; GSK-3 beta silencing RNAs; matrilysin	EPIDERMAL-GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; CARCINOMA-ASSOCIATED ANTIGEN; PROMOTES CELLULAR INVASION; MAMMARY EPITHELIAL-CELLS; F9 TERATOCARCINOMA CELLS; G-ALPHA-O; BETA-CATENIN; FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION	Inappropriate activation of the Wnt/APC/beta-catenin signaling pathways plays a critical role at early stages in a variety of human cancers. However, their respective implication in tumor cell invasion is still hypothetical. Here, we show that two activators of the canonical Wnt/beta-catenin transcription pathway, namely Dvl-2, the Axin 501-560 fragment binding glycogen synthase kinase -3beta (GSK-3beta), and the negative Wnt regulator wt-Axin did not alter cell invasion into type I collagen. In addition, both Dvl-2 and Axin 501-560 exerted a permissive action on the proinvasive activity of HGF and intestinal trefoil factor. Upstream activation of Wnt signaling by the Wnt-2 and Wnt-3a ligands, stable overexpression of Wnt-2, as well as GSK-3beta inhibition by lithium, SB216763, and GSK-3beta dominant negative forms (K85R and R96E) conferred the invasive phenotype through several proinvasive pathways. Induction of the matrix metalloprotease MMP-7 (matrilysin) gene and protein by Wnt-2 was abolished by inactivation of the AP-1 binding site in the promoter. Accordingly, invasion induced by Wnt-2 was prevented by soluble FRP-3 and FRP-1, sequestration of Gbetagamma subunits, depletion of the GSK-3beta protein by RNA interference, the c-Jun dominant negative mutant TAM67 and was not reversed by wt-Axin. Thus, the proinvasive activity of Wnt-2 is mediated by a noncanonical Wnt pathway using GSK-3beta and the AP-1 oncogene. Our data provide a potential clue for our understanding of the action and crosstalk between Wnt activators and other proinvasive pathways, in relation with matrix substrates and proteases in human cancers.	Hop St Antoine, INSERM, U Signal Transduct & Cellular Funct Diab & Digest, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Cardiff University	Gespach, C (corresponding author), Hop St Antoine, INSERM, U Signal Transduct & Cellular Funct Diab & Digest, 184 Rue Faubourt St Antoine, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013; Dale, Trevor C/D-3749-2009; LE FLOCH, Nathalie/I-3415-2015	de wever, olivier/0000-0002-5453-760X; Dale, Trevor C/0000-0002-4880-9963; LE FLOCH, Nathalie/0000-0002-6411-7975				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; BARBIER M, 2000, NATURE, V406, P897; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahmen RP, 2001, CANCER RES, V61, P7039; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DEGROOT RP, 1993, ONCOGENE, V8, P841; DEWEVER O, 2004, IN PRESS FASEB J; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; EMAMI S, 2004, IN PRESS PEPTIDES; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hao L, 2004, CIRC RES, V94, P68, DOI 10.1161/01.RES.0000109413.57726.91; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Howe LR, 1999, CANCER RES, V59, P1572; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu D, 1997, LAB INVEST, V77, P557; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Monga SPS, 2002, CANCER RES, V62, P2064; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Polakis P, 2000, GENE DEV, V14, P1837; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 1996, ONCOGENE, V12, P153; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	79	62	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					144	+		10.1096/fj.04-2373fje	http://dx.doi.org/10.1096/fj.04-2373fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507471				2022-12-25	WOS:000224849900006
J	Fan, CY; Ren, HY; Lee, P; Caplan, AJ; Cyr, DM				Fan, CY; Ren, HY; Lee, P; Caplan, AJ; Cyr, DM			The type I Hsp40 zinc finger-like region is required for Hsp70 to capture non-native polypeptides from Ydj1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE YDJ1; SACCHAROMYCES-CEREVISIAE; DNAJ PROTEIN; SUBSTRATE-BINDING; ATPASE ACTIVITY; YEAST HOMOLOG; DOMAIN; SIS1; SPECIFICITY; MECHANISM	The cytosolic yeast Hsp40 Ydj1 contains a conserved zinc finger-like region (ZFLR), which has two zinc-binding domains (ZBD), that helps regulate and specify Hsp70 function. To investigate the mechanism for Ydj1 ZFLR action, ZBDI and ZBDII mutants were constructed and characterized. ZBDII mutants exhibited temperature-sensitive growth defects, but yeast tolerated mutation of ZBDI. However, ZBDI and ZBDII mutants were defective at facilitating androgen receptor (AR) folding. Defective AR folding was associated with the accumulation of complexes between AR and Ydj1 ZFLR mutants and a reduction in Hsp70.AR complex formation. Purified Ydj1 ZBDI and ZBDII mutants could bind non-native polypeptides but could not deliver luciferase to Hsp70 and were defective at luciferase refolding. Interestingly, the ability of Ydj1 to synergize with Hsp70 to suppress thermally induced protein aggregation was blocked by mutation of ZBDII, but not ZBDI. Hence, ZBDII is required for yeast to survive heat stress because it is essential for Ydj1 to cooperate with Hsp70 to suppress protein aggregation. On the other hand, protein folding is dependent upon the action of both ZBDI and ZBDII because each is required for Hsp70 to capture non-native polypeptides from Ydj1.	Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cyr, DM (corresponding author), Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	DMCYR@med.unc.edu	Caplan, Avrom/GPT-0824-2022	Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060598] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60598] Funding Source: Medline; NIGMS NIH HHS [R01 GM056981, R01 GM067785] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Fan CY, 2004, MOL BIOL CELL, V15, P761, DOI 10.1091/mbc.E03-03-0146; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; WALL D, 1994, J BIOL CHEM, V269, P5446; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679	34	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					695	702		10.1074/jbc.M410645200	http://dx.doi.org/10.1074/jbc.M410645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15496404	Green Published, hybrid			2022-12-25	WOS:000226025100082
J	Lee, HJ; Barry, CH; Borisova, SN; Seto, NOL; Zheng, RXB; Blancher, A; Evans, SV; Palcic, MM				Lee, HJ; Barry, CH; Borisova, SN; Seto, NOL; Zheng, RXB; Blancher, A; Evans, SV; Palcic, MM			Structural basis for the inactivity of human blood group O-2 glycosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOR SUBSTRATE-SPECIFICITY; GROUP-B TRISACCHARIDE; GROUP-A; O-ALLELE; RECOMBINANT; ABO; SYSTEM; GENE; TRANSFERASES; RECOGNITION	The human ABO( H) blood group antigens are carbohydrate structures generated by glycosyltransferase enzymes. Glycosyltransferase A (GTA) uses UDP-GalNAc as a donor to transfer a monosaccharide residue to Fucalpha1-2Galbeta-R (H)-terminating acceptors. Similarly, glycosyltransferase B (GTB) catalyzes the transfer of a monosaccharide residue from UDP-Gal to the same acceptors. These are highly homologous enzymes differing in only four of 354 amino acids, Arg/Gly-176, Gly/Ser-235, Leu/Met-266, and Gly/Ala-268. Blood group O usually stems from the expression of truncated inactive forms of GTA or GTB. Recently, an O-2 enzyme was discovered that was a full-length form of GTA with three mutations, P74S, R176G, and G268R. We showed previously that the R176G mutation increased catalytic activity with minor effects on substrate binding. Enzyme kinetics and high resolution structural studies of mutant enzymes based on the O2 blood group transferase reveal that whereas the P74S mutation in the stem region of the protein does not appear to play a role in enzyme inactivation, the G268R mutation completely blocks the donor GalNAc-binding site leaving the acceptor binding site unaffected.	Univ Victoria, Dept Biochem & Mol Biol, Victoria, BC V8W 3P6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Toulouse 3, Hop Rangeuil, Immunogenet Mol Lab, F-31059 Toulouse 9, France	University of Victoria; University of Alberta; National Research Council Canada; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Mol Biol, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca; monica.palcic@ualberta.ca		Evans, Stephen/0000-0002-0366-4027				Amado M, 2000, VOX SANG, V79, P219, DOI 10.1046/j.1423-0410.2000.7940219.x; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Nguyen HP, 2003, J BIOL CHEM, V278, P49191, DOI 10.1074/jbc.M308770200; Palcic MM, 2001, TRANSFUSION MED, V11, P315, DOI 10.1046/j.1365-3148.2001.00314.x; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; SETO NOL, 1995, EUR J BIOCHEM, V234, P323, DOI 10.1111/j.1432-1033.1995.323_c.x; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x	25	48	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					525	529		10.1074/jbc.M410245200	http://dx.doi.org/10.1074/jbc.M410245200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15475562	hybrid			2022-12-25	WOS:000226025100062
J	Bhattacharyya, M; Ray, S; Bhattacharya, S; Chakrabarti, A				Bhattacharyya, M; Ray, S; Bhattacharya, S; Chakrabarti, A			Chaperone activity and prodan binding at the self-associating domain of erythroid spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MEMBRANE SKELETON; ALPHA-CRYSTALLIN; IN-VITRO; FLUORESCENCE; SURFACE; HEMOGLOBIN; ORGANIZATION; EVOLUTION; SYNUCLEIN	Spectrin, the major constituent protein of the erythrocyte membrane skeleton, exhibits chaperone activity by preventing the irreversible aggregation of insulin at 25degreesC and that of alcohol dehydrogenase at 50degreesC. The dimeric spectrin and the two subunits, alpha-spectrin and beta-spectrin prevent such aggregation appreciably better, 70% in presence of dimeric spectrin at an insulin: spectrin ratio of 1:1, than that in presence of the tetramer of 25%. Our results also show that spectrin binds to denatured enzymes alpha-glucosidase and alkaline phosphatase during refolding and the reactivation yields are increased in the presence of the spectrin derivatives when compared with those refolded in their absence. The unique hydrophobic binding site on spectrin for the fluorescence probe, 6-propionyl-2-(dimethylamino)naphthalene (Prodan) has been established to localize at the self-associating domain with the binding stoichiometry of one Prodan/both dimeric and tetrameric spectrin. The other fluorescence probe, 1-anilinonaphthalene-8-sulfonic acid, does not show such specificity for spectrin, and the binding stoichiometry is between 3 and 5 1-anilinonaphthalene-8-sulfonic acid/dimeric and tetrameric spectrin, respectively. Regions in alpha- and beta-spectrins have been found to have sequence homology with known chaperone proteins. More than 50% similarities in alpha-spectrin near the N terminus with human Hsp90 and in beta-spectrin near the C terminus with human Hsp90 and Escherichia coli DnaJ have been found, indicating a potential chaperone-like sequence to be present near the self-associating domain that is formed by portions of alpha-spectrin near the N terminus and the beta-spectrin near the C terminus. There are other patches of sequences also in both the spectrin polypeptides, at the other termini as well as in the middle of the rod domain having significant homology with well known chaperone proteins.	Saha Inst Nucl Phys, Div Biophys, Kolkata 700064, India	Saha Institute of Nuclear Physics	Chakrabarti, A (corresponding author), Saha Inst Nucl Phys, Div Biophys, 1-AF Bidhannagar, Kolkata 700064, India.	abhijitc@petal.saha.ernet.in	Ray, Sibnath/C-7369-2008	Ray, Sibnath/0000-0002-6313-3930				[Anonymous], METHODS ENZYMOL B; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BEAVEN GH, 1978, ACTA HAEMATOL-BASEL, V60, P321, DOI 10.1159/000207731; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; Beissinger M, 1998, BIOL CHEM, V379, P245; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BERGLUND A, 1986, FEBS LETT, V201, P306, DOI 10.1016/0014-5793(86)80629-9; Bhattacharyya J, 1999, J BIOL CHEM, V274, P15505, DOI 10.1074/jbc.274.22.15505; BHOWN AS, 1989, BIOCHEM BIOPH RES CO, V164, P894, DOI 10.1016/0006-291X(89)91543-X; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHAIMANEE P, 1977, FEBS LETT, V78, P119, DOI 10.1016/0014-5793(77)80287-1; Chakrabarti A, 2001, BIOCHEM BIOPH RES CO, V282, P1189, DOI 10.1006/bbrc.2001.4715; Chakrabarti A, 1996, BIOCHEM BIOPH RES CO, V226, P495, DOI 10.1006/bbrc.1996.1383; Chattopadhyay A, 2003, PROTEIN SCI, V12, P2389, DOI 10.1110/ps.03302003; COHEN AM, 1986, BLOOD, V68, P920; COLE N, 1993, INT J BIOCHEM, V25, P1555, DOI 10.1016/0020-711X(93)90511-C; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Datta P, 2003, BLOOD CELL MOL DIS, V30, P248, DOI 10.1016/S1079-9796(03)00019-6; DE M, 2000, J CELL SCI, V113, P2331; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DIAKOWSKI W, 1995, BIOCHEMISTRY-US, V34, P13252, DOI 10.1021/bi00040a041; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gallagher PG, 1997, J CLIN INVEST, V99, P267, DOI 10.1172/JCI119155; GRATZER WB, 1982, METHOD ENZYMOL, V85, P475; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; GUAGLIARDI A, 1995, J BIOL CHEM, V270, P28126; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; Haque ME, 2000, J FLUORESC, V10, P1, DOI 10.1023/A:1009402126863; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; HAUGHLAND RP, 1996, HDB FLUORESCENT PROB, P320; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL ZD, 1986, J CHEM EDUC, V63, P162, DOI 10.1021/ed063p162; Hinton A, 2003, J BIOL CHEM, V278, P34110, DOI 10.1074/jbc.M305353200; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KAHANA E, 1992, BIOCHEM J, V282, P75, DOI 10.1042/bj2820075; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majee S, 1999, EUR J BIOCHEM, V260, P619, DOI 10.1046/j.1432-1327.1999.00159.x; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; MARIK T, 1984, CELL BIOCHEM FUNCT, V2, P21, DOI 10.1002/cbf.290020107; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mondal M, 2002, FEBS LETT, V532, P396, DOI 10.1016/S0014-5793(02)03721-3; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Nardai G, 2000, ARCH BIOCHEM BIOPHYS, V384, P59, DOI 10.1006/abbi.2000.2075; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Ray S, 2004, MOL MEMBR BIOL, V21, P93, DOI 10.1080/09687680310001625800; Ray S, 2003, CELL MOTIL CYTOSKEL, V54, P16, DOI 10.1002/cm.10082; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAMBROOK J, 1997, GUIDEBOOK MOL CHAPER; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; SUBBARAO NK, 1994, CELL MOTIL CYTOSKEL, V29, P72, DOI 10.1002/cm.970290107; WALLIS CJ, 1992, J BIOL CHEM, V267, P4333; WANG JL, 1971, J BIOL CHEM, V246, P1185; Wichterle H, 1996, J CLIN INVEST, V98, P2300, DOI 10.1172/JCI119041; WILLIAMSON P, 1982, CELL, V30, P725, DOI 10.1016/0092-8674(82)90277-X; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YOSHINO H, 1984, J BIOL CHEM, V259, P4496	78	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55080	55088		10.1074/jbc.M406418200	http://dx.doi.org/10.1074/jbc.M406418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492010	hybrid			2022-12-25	WOS:000225960800013
J	Leiros, HKS; Kozielski-Stuhrmann, S; Kapp, U; Terradot, L; Leonard, GA; McSweeney, SM				Leiros, HKS; Kozielski-Stuhrmann, S; Kapp, U; Terradot, L; Leonard, GA; McSweeney, SM			Structural basis of 5-nitroimidazole antibiotic resistance - The crystal structure of NimA from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METRONIDAZOLE-RESISTANCE; NITROIMIDAZOLE RESISTANCE; HELICOBACTER-PYLORI; FERREDOXIN GENE; BACTEROIDES; PROTEIN; RDXA; STRAINS; OXIDOREDUCTASE; MECHANISMS	5-Nitroimidazole-based antibiotics are compounds extensively used for treating infections in humans and animals caused by several important pathogens. They are administered as prodrugs, and their activation depends upon an anaerobic 1-electron reduction of the nitro group by a reduction pathway in the cells. Bacterial resistance toward these drugs is thought to be caused by decreased drug uptake and/or an altered reduction efficiency. One class of resistant strains, identified in Bacteroides, has been shown to carry Nim genes (NimA, -B, -C, -D, and -E), which encode for reductases that convert the nitro group on the antibiotic into a non-bactericidal amine. In this paper, we have described the crystal structure of NimA from Deinococcus radiodurans (drNimA) at 1.6 Angstrom resolution. We have shown that drNimA is a homodimer in which each monomer adopts a beta-barrel fold. We have identified the catalytically important His-71 along with the cofactor pyruvate and antibiotic binding sites, all of which are found at the monomer-monomer interface. We have reported three additional crystal structures of drNimA, one in which the antibiotic metronidazole is bound to the protein, one with pyruvate covalently bound to His-71, and one with lactate covalently bound to His-71. Based on these structures, a reaction mechanism has been proposed in which the 2-electron reduction of the antibiotic prevents accumulation of the toxic nitro radical. This mechanism suggests that Nim proteins form a new class of reductases, conferring resistance against 5-nitroimidazole-based antibiotics.	European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble 09, France	European Synchrotron Radiation Facility (ESRF)	McSweeney, SM (corresponding author), European Synchrotron Radiat Facil, Macromol Crystallog Grp, BP 220,6 Rue Jules Horowitz, F-38043 Grenoble 09, France.	mcsweeney@esrf.fr	Leonard, Gordon/D-2160-2019; Leiros, Hanna-Kirsti S/E-4000-2016	Leonard, Gordon/0000-0001-5030-0122; Leiros, Hanna-Kirsti S/0000-0002-2726-6322; McSweeney, Sean/0000-0002-3758-3161				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BREUIL J, 1989, PLASMID, V21, P151, DOI 10.1016/0147-619X(89)90060-7; Carlier JP, 1997, ANTIMICROB AGENTS CH, V41, P1495, DOI 10.1128/AAC.41.7.1495; Chiu HJ, 2001, STRUCTURE, V9, P311, DOI 10.1016/S0969-2126(01)00589-5; DECLERCK PJ, 1986, BIOCHEM PHARMACOL, V35, P59, DOI 10.1016/0006-2952(86)90555-1; DECLERCK PJ, 1983, FEBS LETT, V164, P145, DOI 10.1016/0014-5793(83)80038-6; Diniz CG, 2003, MICROBES INFECT, V5, P19, DOI 10.1016/S1286-4579(02)00052-7; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P201, DOI 10.1093/jac/31.2.201; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P9, DOI 10.1093/jac/31.1.9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fang H, 2002, INT J ANTIMICROB AG, V19, P361, DOI 10.1016/S0924-8579(02)00019-5; Goodwin A, 1998, MOL MICROBIOL, V28, P383, DOI 10.1046/j.1365-2958.1998.00806.x; HAGGOUD A, 1992, FEMS MICROBIOL LETT, V95, P1; HAGGOUD A, 1994, ANTIMICROB AGENTS CH, V38, P1047, DOI 10.1128/AAC.38.5.1047; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; Jamal WY, 2004, MED PRIN PRACT, V13, P147, DOI 10.1159/000076954; Jenks PJ, 1999, J ANTIMICROB CHEMOTH, V43, P753, DOI 10.1093/jac/43.6.753; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kulda J, 1999, INT J PARASITOL, V29, P199, DOI 10.1016/S0020-7519(98)00155-6; Kwon DH, 2000, ANTIMICROB AGENTS CH, V44, P2133, DOI 10.1128/AAC.44.8.2133-2142.2000; Land KM, 2004, MOL MICROBIOL, V51, P115, DOI 10.1046/j.1365-2958.2003.03791.x; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P975, DOI 10.1038/nsb1297-975; Liepinsh E, 1998, NAT STRUCT BIOL, V5, P102, DOI 10.1038/nsb0298-102; LOCKERBY DL, 1985, ANTIMICROB AGENTS CH, V27, P863, DOI 10.1128/AAC.27.5.863; Marais A, 2003, RES MICROBIOL, V154, P137, DOI 10.1016/S0923-2508(03)00030-5; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Musayev FN, 2003, PROTEIN SCI, V12, P1455, DOI 10.1110/ps.0356203; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; QUON DVK, 1992, P NATL ACAD SCI USA, V89, P4402, DOI 10.1073/pnas.89.10.4402; Rafii F, 2003, FEMS MICROBIOL LETT, V225, P195, DOI 10.1016/S0378-1097(03)00513-5; Ragsdale SW, 2003, CHEM REV, V103, P2333, DOI 10.1021/cr020423e; Stubbs SLJ, 2000, J CLIN MICROBIOL, V38, P3209, DOI 10.1128/JCM.38.9.3209-3213.2000; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P1688, DOI 10.1107/S0907444903015142; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRINH S, 1995, MICROBIOL-UK, V141, P927, DOI 10.1099/13500872-141-4-927; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	42	55	56	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55840	55849		10.1074/jbc.M408044200	http://dx.doi.org/10.1074/jbc.M408044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492014	hybrid			2022-12-25	WOS:000225960800107
J	Lloyd, LJ; Jones, SE; Jovanovic, G; Gyaneshwar, P; Rolfe, MD; Thompson, A; Hinton, JC; Buck, M				Lloyd, LJ; Jones, SE; Jovanovic, G; Gyaneshwar, P; Rolfe, MD; Thompson, A; Hinton, JC; Buck, M			Identification of a new member of the phage shock protein response in Escherichia coli, the phage shock protein g (PspG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; COMPLETE GENOME SEQUENCE; INTEGRATION HOST FACTOR; GENE-EXPRESSION; YERSINIA-ENTEROCOLITICA; SALMONELLA-ENTERICA; PROTONMOTIVE FORCE; STRESS PROTEIN; ROTARY MOTOR; OPERON	The phage shock protein operon (pspABCDE) of Escherichia coli is strongly up-regulated in response to overexpression of the filamentous phage secretin protein IV (pIV) and by many other stress conditions including defects in protein export. PspA has an established role in maintenance of the proton-motive force of the cell under stress conditions. Here we present evidence for a new member of the phage shock response in E. coli. Using transcriptional profiling, we show that the synthesis of pIV in E. coli leads to a highly restricted response limited to the up-regulation of the psp operon genes and yjbO. The psp operon and yjbO are also up-regulated in response to pIV in Salmonella enterica serovar Typhimurium. yjbO is a highly conserved gene found exclusively in bacteria that contain a psp operon but is physically unlinked to the psp operon. yjbO encodes a putative inner membrane protein that is co-controlled with the psp operon genes and is predicted to be an effector of the psp response in E. coli. We present evidence that yjbO expression is driven by sigma(54)-RNA polymerase, activated by PspF and integration host factor, and negatively regulated by PspA. PspF specifically regulates only members of the PspF regulon: pspABCDE and yjbO. We found that increased expression of YjbO results in decreased motility of bacteria. Because yjbO is co-conserved and co-regulated with the psp operon and is a member of the phage shock protein F regulon, we propose that yjbO be renamed pspG.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Inst Food Res, Inst Food Res, Mol Microbiol Grp, Norwich NR4 7UA, Norfolk, England	Imperial College London; University of California System; University of California Berkeley; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	m.buck@imperial.ac.uk	Hinton, Jay C. D./B-2142-2008	Hinton, Jay C. D./0000-0003-2671-6026; Jovanovic, Goran/0000-0001-6587-7645; Jones, Susan/0000-0002-7801-9786	NIGMS NIH HHS [GM 38361] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038361, R01GM038361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams H, 2002, FEBS LETT, V518, P173, DOI 10.1016/S0014-5793(02)02695-9; Anjum MF, 2003, INFECT IMMUN, V71, P4674, DOI 10.1128/IAI.71.8.4674-4683.2003; Arends SJR, 2004, J BACTERIOL, V186, P880, DOI 10.1128/JB.186.3.880-884.2004; Beloin C, 2004, MOL MICROBIOL, V51, P659, DOI 10.1046/j.1365-2958.2003.03865.x; Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRISSETTE JL, 1991, J MOL BIOL, V220, P35, DOI 10.1016/0022-2836(91)90379-K; BRISSETTE JL, 1990, P NATL ACAD SCI USA, V87, P862, DOI 10.1073/pnas.87.3.862; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; Darwin AJ, 1999, MOL MICROBIOL, V32, P51, DOI 10.1046/j.1365-2958.1999.01324.x; Darwin AJ, 2001, MOL MICROBIOL, V39, P429, DOI 10.1046/j.1365-2958.2001.02235.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; Dworkin J, 1997, J MOL BIOL, V273, P377, DOI 10.1006/jmbi.1997.1317; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; FUNG DC, 1995, NATURE, V375, P809, DOI 10.1038/375809a0; Gabel CV, 2003, P NATL ACAD SCI USA, V100, P8748, DOI 10.1073/pnas.1533395100; Green RC, 2004, J BACTERIOL, V186, P4910, DOI 10.1128/JB.186.15.4910-4920.2004; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; Jones SE, 2003, J BACTERIOL, V185, P6707, DOI 10.1128/JB.185.22.6707-6711.2003; Jovanovic G, 1997, J BACTERIOL, V179, P5232, DOI 10.1128/jb.179.16.5232-5237.1997; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; Jovanovic G, 1997, MOL MICROBIOL, V25, P473, DOI 10.1046/j.1365-2958.1997.4791844.x; Kao KC, 2004, P NATL ACAD SCI USA, V101, P641, DOI 10.1073/pnas.0305287101; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; KLEEREBEZEM M, 1993, MOL MICROBIOL, V7, P947, DOI 10.1111/j.1365-2958.1993.tb01186.x; Kleerebezem M, 1996, EMBO J, V15, P162, DOI 10.1002/j.1460-2075.1996.tb00344.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSTU S, 1979, P NATL ACAD SCI USA, V76, P4576, DOI 10.1073/pnas.76.9.4576; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Martinez-Antonio A, 2003, CURR OPIN MICROBIOL, V6, P482, DOI 10.1016/j.mib.2003.09.002; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Model P, 1997, MOL MICROBIOL, V24, P255, DOI 10.1046/j.1365-2958.1997.3481712.x; MONOD J, 1952, ADV ENZYMOL REL S BI, V13, P67; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; POSSOT O, 1992, MOL MICROBIOL, V6, P95, DOI 10.1111/j.1365-2958.1992.tb00841.x; RUSSEL M, 1993, J BACTERIOL, V175, P3998, DOI 10.1128/JB.175.13.3998-4007.1993; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Thompson A, 2001, TRENDS MICROBIOL, V9, P154, DOI 10.1016/S0966-842X(01)01977-1; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Wang QF, 2004, MOL MICROBIOL, V52, P169, DOI 10.1111/j.1365-2958.2003.03977.x; WEINER L, 1991, GENE DEV, V5, P1912, DOI 10.1101/gad.5.10.1912; WEINER L, 1995, NUCLEIC ACIDS RES, V23, P2030, DOI 10.1093/nar/23.11.2030; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	56	71	75	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55707	55714		10.1074/jbc.M408994200	http://dx.doi.org/10.1074/jbc.M408994200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485810	hybrid			2022-12-25	WOS:000225960800091
J	Nagata, K; Asano, T; Nozawa, Y; Inagaki, M				Nagata, K; Asano, T; Nozawa, Y; Inagaki, M			Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; DIVISION CYCLE; OVARIAN-TUMORS; GENE; CYTOSKELETAL; MLL; FILAMENTS; PROTEIN; MSF; CYTOKINESIS	Septins are members of a conserved family of cytoskeletal GTPases present in organisms as diverse as yeast and mammals. Unlike lower eukaryotic cells, the physiological significance of mammalian septin complexes is largely unknown. Using specific antibodies, we found at least five septins, Sept2, Sept7, Sept8, Sept9b, and Sept11, in septin complexes affinity-purified with anti-Sept7 antibody-conjugated column from rat embryonic fibroblast REF52 cells. Immunofluorescence studies revealed co-localization of Sept7, Sept9b, and Sept11 along stress fibers in REF52 cells. Biochemical and immunoprecipitation analyses revealed that the three septins directly bind with each other through their N- or C-terminal divergent regions. These septins per se formed distinct and characteristic filament structures when transiently expressed in COS7 cells. When two of the three septins were coexpressed in COS7 cells, combination-dependent filament elongation, bundling, or disruption was observed. Taken together, our results suggest that septin filament structures may be affected by interactions with other septins included in the complex.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Aichi 4800392, Japan; Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Int Inst Biotechnol, Gifu 5040838, Japan	Aichi Cancer Center	Nagata, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya Cho, Aichi 4800392, Japan.	knagata@inst-hsc.jp	Inagaki, Masaki/B-9920-2016					Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; Dent J, 2002, P NATL ACAD SCI USA, V99, P3064, DOI 10.1073/pnas.052715199; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Ihara M, 2003, J BIOL CHEM, V278, P24095, DOI 10.1074/jbc.M301352200; Joberty G, 2001, NAT CELL BIOL, V3, P861, DOI 10.1038/ncb1001-861; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kinoshita N, 2004, GENES CELLS, V9, P1, DOI 10.1111/j.1356-9597.2004.00696.x; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Russell SEH, 2000, CANCER RES, V60, P4729; Sheffield PJ, 2003, J BIOL CHEM, V278, P3483, DOI 10.1074/jbc.M209701200; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	33	116	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55895	55904		10.1074/jbc.M406153200	http://dx.doi.org/10.1074/jbc.M406153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485874	hybrid			2022-12-25	WOS:000225960800113
J	O'Neil, CH; Boffa, MB; Hancock, MA; Pickering, JG				O'Neil, CH; Boffa, MB; Hancock, MA; Pickering, JG			Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN ACTIVATION; ENDOTHELIAL-CELLS; COLLAGEN-SYNTHESIS; RECOMBINANT FORM; GLU-PLASMINOGEN; LYS-PLASMINOGEN; LIPOPROTEIN(A); EXPRESSION; SURFACE; ATHEROSCLEROSIS	Elevated plasma concentrations of lipoprotein(a) are a risk factor for the development of a variety of atherosclerotic disorders. Despite intensive study, the mechanisms by which lipoprotein(a) promotes these disorders remain to be unequivocally defined. It has been demonstrated that lipoprotein(a), through its unique constituent apolipoprotein(a) ( apo(a)), stimulates vascular smooth muscle cell (SMC) migration and proliferation. These effects arise from the ability of apo(a) to inhibit the formation of active transforming growth factor beta (TGF-beta) from its latent precursor, which in turn is caused by the ability of apo(a) to decrease the formation of plasmin from its precursor plasminogen. We utilized a battery of recombinant apo(a) variants that represent systematic deletions of the various domains in the molecule to further probe the mechanism underlying the effect of apo(a) on SMC responses. All recombinant apo(a) variants that contained kringle IV type 9 were able to stimulate SMC proliferation and migration and to decrease the formation of active TGF-beta; conversely all recombinant apo( a) variants lacking kringle IV type 9 had no effect on these parameters. The kringle IV type 9-dependent effects of apo(a) on SMC proliferation required the presence of plasminogen, suggesting for the first time that this kringle mediates the ability of apo(a) to inhibit pericellular plasmin formation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada	Queens University - Canada; Western University (University of Western Ontario)	Hancock, MA (corresponding author), Queens Univ, Dept Biochem, Rm A208,Botterell Hall, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Pickering, J. Geoffrey/G-3341-2011; Boffa, Michael/N-6539-2019	Pickering, J. Geoffrey/0000-0001-6474-3274; Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; Caplice NM, 2001, BLOOD, V98, P2980, DOI 10.1182/blood.V98.10.2980; Ford CM, 1999, ARTERIOSCL THROM VAS, V19, P1843, DOI 10.1161/01.ATV.19.8.1843; GABEL BR, 1995, BIOCHEMISTRY-US, V34, P15777, DOI 10.1021/bi00048a023; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gazzaruso C, 2003, INT J CARDIOL, V87, P91, DOI 10.1016/S0167-5273(02)00202-4; Gong Y, 2001, J BIOL CHEM, V276, P19078, DOI 10.1074/jbc.M101387200; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grainger DJ, 2004, ARTERIOSCL THROM VAS, V24, P399, DOI 10.1161/01.ATV.0000114567.76772.33; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hancock MA, 2003, J BIOL CHEM, V278, P23260, DOI 10.1074/jbc.M302780200; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Keesler GA, 1996, J BIOL CHEM, V271, P32096, DOI 10.1074/jbc.271.50.32096; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; Koschinsky ML, 2004, CURR OPIN LIPIDOL, V15, P167, DOI 10.1097/00041433-200404000-00009; Kraft HG, 1996, ATHEROSCLEROSIS, V125, P53, DOI 10.1016/0021-9150(96)05844-3; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Mallat Z, 2002, CURR OPIN LIPIDOL, V13, P523, DOI 10.1097/00041433-200210000-00008; Marcovina SM, 1996, CLIN CHEM, V42, P436; Marcovina SM, 2003, CLIN CHEM, V49, P1785, DOI 10.1373/clinchem.2003.023689; Marcovina SM, 2003, CURR OPIN LIPIDOL, V14, P361, DOI 10.1097/00041433-200308000-00004; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Morishita R, 1998, HYPERTENSION, V32, P215, DOI 10.1161/01.HYP.32.2.215; Pellegrino M, 2004, J BIOL CHEM, V279, P6526, DOI 10.1074/jbc.M309705200; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Rahman M, 1998, PROTEIN ENG, V11, P1249, DOI 10.1093/protein/11.12.1249; Rand ML, 1998, ARTERIOSCL THROM VAS, V18, P1393, DOI 10.1161/01.ATV.18.9.1393; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Scanu A M, 2001, Curr Cardiol Rep, V3, P385; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Yu H, 2003, CHINESE MED J-PEKING, V116, P721	43	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55187	55195		10.1074/jbc.M409860200	http://dx.doi.org/10.1074/jbc.M409860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498766	hybrid			2022-12-25	WOS:000225960800026
J	Six, EM; Ndiaye, D; Sauer, G; Laabi, Y; Athman, R; Cumano, A; Brou, C; Israel, A; Logeat, F				Six, EM; Ndiaye, D; Sauer, G; Laabi, Y; Athman, R; Cumano, A; Brou, C; Israel, A; Logeat, F			The Notch ligand Delta1 recruits Dlg1 at cell-cell contacts and regulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE; DROSOPHILA MASTERMIND; INTRACELLULAR DOMAIN; HUMAN HOMOLOG; MAGUK FAMILY; PDZ DOMAINS; PROTEIN; CLEAVAGE; SERRATE; RECEPTOR	Delta1 acts as a membrane-bound ligand that interacts with the Notch receptor and plays a critical role in cell fate specification. By using peptide affinity chromatography followed by mass spectrometry, we have identified Dlg1 as a partner of the Delta1 C-terminal region. Dlg1 is a human homolog of the Drosophila Discs large tumor suppressor, a member of the membrane-associated guanylate kinase family of molecular scaffolds. We confirmed this interaction by co-immunoprecipitation experiments between endogenous Dlg1 and transduced Delta1 in a 3T3 cell line stably expressing Delta1. Moreover, we showed that deletion of a canonical C-terminal PDZ-binding motif (ATEV) in Delta1 abrogated this interaction. Delta4 also interacted with Dlg1, whereas Jagged1, another Notch ligand, did not. In HeLa cells, transfected Delta1 triggered the accumulation of endogenous Dlg1 at sites of cell-cell contact. Expression of Delta1 also reduced the motility of 3T3 cells. Finally, deletion of the ATEV motif totally abolished these effects but did not interfere with the ability of Delta1 to induce Notch signaling and T cell differentiation in co-culture experiments. These results point to a new, probably cell-autonomous function of Delta1, which is independent of its activity as a Notch ligand.	Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1961, Unite Dev Lymphocytes, F-75724 Paris 15, France; Max Planck Inst Biochem, Abt Zellbiol, D-82152 Martinsried, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society	Israel, A (corresponding author), Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, 25 Rue Dr Roux, F-75724 Paris 15, France.	aisrael@pasteur.fr	Six, Emmanuelle/H-7891-2017	Six, Emmanuelle/0000-0001-7806-0968; Cumano, Ana/0000-0002-4578-959X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bilder D, 2001, TRENDS GENET, V17, P511, DOI 10.1016/S0168-9525(01)02407-6; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Brenner M, 2000, NAT MED, V6, P1210, DOI 10.1038/81297; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; De Bellard ME, 2002, DEV BIOL, V249, P121, DOI 10.1006/dbio.2002.0756; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Harris BZ, 2001, J CELL SCI, V114, P3219; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hukriede NA, 1997, GENETICS, V145, P359; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; Klueg KM, 1999, J CELL SCI, V112, P3289; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lendahl U, 1998, BIOESSAYS, V20, P103, DOI 10.1002/(SICI)1521-1878(199802)20:2<103::AID-BIES1>3.0.CO;2-U; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Lowell S, 2001, MECH DEVELOP, V107, P133, DOI 10.1016/S0925-4773(01)00459-2; Mantovani F, 2001, J CELL SCI, V114, P4285; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Pfister S, 2003, J MOL BIOL, V333, P229, DOI 10.1016/j.jmb.2003.08.043; Pourquie O, 2000, CURR BIOL, V10, pR425, DOI 10.1016/S0960-9822(00)00510-8; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Reuver SM, 1998, J CELL SCI, V111, P1071; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Sun X, 1996, DEVELOPMENT, V122, P2465; Szafranski P, 2004, DEVELOPMENT, V131, P2023, DOI 10.1242/dev.01097; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Zeng CY, 1998, GENE DEV, V12, P1086, DOI 10.1101/gad.12.8.1086; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	54	49	50	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55818	55826		10.1074/jbc.M408022200	http://dx.doi.org/10.1074/jbc.M408022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485825	hybrid			2022-12-25	WOS:000225960800104
J	Zhang, XM; Azhar, G; Zhong, Y; Wei, JY				Zhang, XM; Azhar, G; Zhong, Y; Wei, JY			Identification of a novel serum response factor cofactor in cardiac gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; NATRIURETIC-FACTOR GENE; TRANSCRIPTION FACTOR; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; EXPRESSION; SRF; ELEMENT; MYOCARDIN; HEART	The transcription factor serum response factor (SRF) plays an important role in the regulation of a variety of cardiac genes during development and during adult aging. A novel SRF cofactor, herein called p49/STRAP, for SRF-dependent transcription regulation-associated protein, was recently identified in our laboratory. This protein interacted mainly with the transcriptional activation domain of the SRF protein and was found to bind to SRF or to the complex of SRF and another cofactor, such as myocardin or Nkx2.5. The expression of p49/STRAP affected the promoter activity of SRF target genes in a non-uniform manner. For example, p49 activated MLC2v and cardiac actin promoters when it was co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was strongly induced by myocardin. The p49/STRAP mRNA was observed to be highly expressed in fetal, adult, and senescent human hearts, and also in hearts of young adult and old mice, suggesting that p49/STRAP may be an important SRF cofactor in the transcriptional regulation of mammalian cardiac muscle genes throughout the life span.	Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Zhang, XM (corresponding author), Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, 4301 W Markham 748, Little Rock, AR 72205 USA.	zhangxiaomin@uams.edu; jwei@uams.edu			NIA NIH HHS [AG 18388, AG 19946] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG019946, R01AG018388] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bodyak N, 2002, NUCLEIC ACIDS RES, V30, P3788, DOI 10.1093/nar/gkf497; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Groisman R, 1996, J BIOL CHEM, V271, P5258; Helfand SL, 2002, NAT REV GENET, V3, P149, DOI 10.1038/nrg726; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Li X, 2004, NATURE, V427, P687, DOI 10.1038/427687a; Lu XG, 1998, J GERONTOL A-BIOL, V53, pB3, DOI 10.1093/gerona/53A.1.B3; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Muller JG, 2002, J MOL CELL CARDIOL, V34, P807, DOI 10.1006/jmcc.2002.2019; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Pardee AB, 2003, GENE, V321, P17, DOI 10.1016/S0378-1119(03)00839-4; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Schratt G, 2004, EMBO J, V23, P1834, DOI 10.1038/sj.emboj.7600188; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsou H, 1996, EXP CELL RES, V229, P432, DOI 10.1006/excr.1996.0388; Vaitkevicius PV, 2001, P NATL ACAD SCI USA, V98, P1171, DOI 10.1073/pnas.98.3.1171; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang XM, 2003, AM J PHYSIOL-REG I, V285, pR552, DOI 10.1152/ajpregu.00631.2002; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhang XM, 2001, J BIOL CHEM, V276, P40033, DOI 10.1074/jbc.M104934200; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	42	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55626	55632		10.1074/jbc.M405945200	http://dx.doi.org/10.1074/jbc.M405945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492011	hybrid			2022-12-25	WOS:000225960800081
J	Zhang, YY; Lin, YS; Bowles, C; Wang, F				Zhang, YY; Lin, YS; Bowles, C; Wang, F			Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; INTRAEPITHELIAL NEOPLASIA; SACCHAROMYCES-CEREVISIAE; NEUROTROPHIC RECEPTORS; TYROSINE KINASE; POINT MUTATION; TUMOR-CELLS; PC12 CELLS; PROSTATE	Fibroblast growth factors (FGFs) are upstream activators of the mitogen-activated protein kinase pathway and mitogens in a wide variety of cells. However, whether the mitogen-activated protein kinase pathway solely accounts for the induction of cell cycle or antiapoptotic activity of the FGF receptor (FGFR) tyrosine kinase is not clear. Here we report that cell cycle inducer Cks1, which triggers ubiquitination and degradation of p27(Kip1), associates with the unphosphorylated form of FGFR substrate 2 (FRS2), an adaptor protein that is phosphorylated by FGFR kinases and recruits downstream signaling molecules. FGF-dependent activation of FGFR tyrosine kinases induces FRS2 phosphorylation, causes release of Cks1 from FRS2, and promotes degradation of p27(Kip1) in 3T3 cells. Since degradation of p27(Kip1) is a key regulatory step in activation of the cyclin E/A-Cdk complex during the G(1)/S transition of the cell cycle, the results suggest a novel mitogenic pathway whereby FGF and other growth factors that activate FRS2 directly activate cyclin-dependent kinases.	Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wang, F (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	fwang@ibt.tmc.edu		zhang, yongyou/0000-0003-2413-9106	NATIONAL CANCER INSTITUTE [R01CA096824, R56CA096824] Funding Source: NIH RePORTER; NCI NIH HHS [CA 96824] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Feng SJ, 1997, CANCER RES, V57, P5369; Fernandez PL, 2002, PATHOBIOLOGY, V70, P1, DOI 10.1159/000065998; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HEPLER PK, 1994, P NATL ACAD SCI USA, V91, P2176, DOI 10.1073/pnas.91.6.2176; Jin CL, 2003, CANCER RES, V63, P8784; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lopez ME, 2000, J BIOL CHEM, V275, P15933, DOI 10.1074/jbc.M909299199; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Ribisi S, 2000, DEV BIOL, V227, P183, DOI 10.1006/dbio.2000.9889; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2003, SCIENCE, V300, P647, DOI 10.1126/science.1084149; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; Wang F, 2002, IN VITRO CELL DEV-AN, V38, P178; Wang F, 2002, CANCER RES, V62, P1898; Wang F, 2003, HDB CELL SIGNALING, VI, P265; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A; Yan KS, 2002, J BIOL CHEM, V277, P17088, DOI 10.1074/jbc.M107963200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	42	27	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55348	55354		10.1074/jbc.M409230200	http://dx.doi.org/10.1074/jbc.M409230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15513912	hybrid			2022-12-25	WOS:000225960800047
J	Clausen, JD; Andersen, JP				Clausen, JD; Andersen, JP			Functional consequences of alterations to Thr(247), Pro(248), Glu(340), Asp(813), Arg(819), and Arg(822) at the interfaces between domain P, M3, and L6-7 of sarcoplasmic reticulum Ca2+-ATPase - Roles in Ca2+ interaction and phosphoenzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; INTRAMOLECULAR COMMUNICATION; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; SEGMENT M3; A-DOMAIN; BINDING; LOOP	Point mutants with alterations to amino acid residues Thr(247), Pro(248), Glu(340), Asp(813), Arg(819), and Arg(822) of sarcoplasmic reticulum Ca2+-ATPase were analyzed by transient kinetic measurements. In the Ca2+-ATPase crystal structures, most of these residues participate in a hydrogen-bonding network between the phosphorylation domain (domain P), the third transmembrane helix (M3), and the cytoplasmic loop connecting the sixth and the seventh transmembrane helices (L6-7). In several of the mutants, a pronounced phosphorylation "overshoot" was observed upon reaction of the Ca2+-bound enzyme with ATP, because of accumulation of dephosphoenzyme at steady state. Mutations of Glu(340) and its partners, Thr(247) and Arg(822), in the bonding network markedly slowed the Ca2+ binding transition (E2-->E1-->Ca(2)E1) as well as Ca2+ dissociation from Ca2+ site II back toward the cytosol but did not affect the apparent affinity for vanadate. These mutations may have caused a slowing, in both directions, of the conformational change associated directly with Ca2+ interaction at Ca2+ site II. Because mutation of Asp(813) inhibited the Ca2+ binding transition, but not Ca2+ dissociation, and increased the apparent affinity for vanadate, the effect on the Ca2+ binding transition seems in this case to be exerted by slowing the E2-->E1 conformational change. Because the rate was not significantly enhanced by a 10-fold increase of the Ca2+ concentration, the slowing is not the consequence of reduced affinity of any pre-binding site for Ca2+. Furthermore, the mutations interfered in specific ways with the phosphoenzyme processing steps of the transport cycle; the transition from ADP-sensitive phosphoenzyme to ADP-insensitive phosphoenzyme (Ca(2)E1P-->E2P) was accelerated by mutations perturbing the interactions mediated by Glu(340) and Asp(813) and inhibited by mutation of Pro(248), and mutations of Thr(247) induced charge-specific changes of the rate of dephosphorylation of E2P.	Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Inst Physiol & Biophys, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2003, ANN NY ACAD SCI, V986, P72, DOI 10.1111/j.1749-6632.2003.tb07141.x; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lenoir G, 2004, J BIOL CHEM, V279, P32125, DOI 10.1074/jbc.M402934200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	47	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54426	54437		10.1074/jbc.M410204200	http://dx.doi.org/10.1074/jbc.M410204200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485864	hybrid			2022-12-25	WOS:000225793600065
J	Collier, J; Bohn, C; Bouloc, P				Collier, J; Bohn, C; Bouloc, P			SsrA tagging of Escherichia coli SecM at its translation arrest sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANS-TRANSLATION; STOP CODONS; PROTEIN SECRETION; NASCENT-PEPTIDE; FIMBRIAL OPERON; QUALITY-CONTROL; 10SA RNA; GENE; RIBOSOME	SecM is expressed from the secM-secA operon and activates the expression of secA in response to secretion defects. The 3'-end of secM encodes an "arrest sequence," which can interact with the ribosomal exit tunnel, preventing complete secM translation under secretion-defective conditions. In a cis-acting manner, ribosome stalling enhances secA translation. Pro(166) is the last residue incorporated when SecM elongation is arrested. We report that secretion deficiencies lead to SsrA tagging of SecM after Pro(166), Gly(165), and likely Arg(163). Northern blot analysis revealed the presence of a truncated secM transcript, likely issued from a secM-secA cleavage. The level of secM transcripts was decreased either when secM translation was totally prevented or when Pro(166) was mutated. However, the accumulation of a truncated secM transcript required secM translation and was prevented when the SecM arrest sequence was inactivated by a point mutation changing Pro(166) to Ala. We suggest that ribosome pausing at the site encoding the arrest sequence is required for formation of the truncated secM mRNA. SsrA tagging affected neither the presence of the secM mRNA nor secA expression, even under translocation-defective conditions. It is therefore likely that SsrA tagging of SecM occurs only after cleavage of secM-secA mRNA within the secM open reading frame encoding the SecM arrest sequence. Accumulation of transcripts expressing arrested SecM generated growth inhibition that was alleviated by the SsrA tagging system. Therefore, SsrA tagging of SecM would rescue ribosomes to avoid excessive jamming of the translation apparatus on stop-less secM mRNA.	Univ Paris 11, Inst Genet & Microbiol, Lab Res Regulat & Biogenese Enveloppe Bacterienne, CNRS,UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Collier, J (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	justinec@stanford.edu	Bouloc, Philippe/ABA-5732-2021	Bouloc, Philippe/0000-0003-4601-3387; Bohn, Chantal/0000-0003-1569-9072; Collier, Justine/0000-0003-4213-9687				Abo T, 2002, GENES CELLS, V7, P629, DOI 10.1046/j.1365-2443.2002.00549.x; Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Bohn C, 2002, MOL GENET GENOMICS, V266, P827, DOI 10.1007/s00438-001-0601-1; Bollag D.M., 1991, PROTEIN METHODS; Butkus ME, 2003, J BACTERIOL, V185, P6719, DOI 10.1128/JB.185.22.6719-6722.2003; CHITTUM HS, 1994, J BACTERIOL, V176, P6192, DOI 10.1128/jb.176.20.6192-6198.1994; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Collier J, 2002, MOL MICROBIOL, V45, P745, DOI 10.1046/j.1365-2958.2002.03045.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; FORTIN Y, 1990, J BACTERIOL, V172, P6607, DOI 10.1128/jb.172.11.6607-6610.1990; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; ITO K, 1981, CELL, V25, P143, DOI 10.1016/0092-8674(81)90238-5; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Koo JT, 2004, MOL MICROBIOL, V52, P1813, DOI 10.1111/j.1365-2958.2004.04099.x; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Loomis WP, 2001, MOL MICROBIOL, V39, P693, DOI 10.1046/j.1365-2958.2001.02241.x; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Murakami A, 2004, P NATL ACAD SCI USA, V101, P12330, DOI 10.1073/pnas.0404907101; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nakatogawa H, 2004, CURR OPIN MICROBIOL, V7, P145, DOI 10.1016/j.mib.2004.01.001; Nakatogawa H, 2004, CHEMBIOCHEM, V5, P48, DOI 10.1002/cbic.200300751; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; RAJAPANDI T, 1994, J BACTERIOL, V176, P4444, DOI 10.1128/jb.176.14.4444-4447.1994; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RIGGS PD, 1988, GENETICS, V118, P571; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Salavati R, 1997, J MOL BIOL, V265, P142, DOI 10.1006/jmbi.1996.0724; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarker S, 2000, J BACTERIOL, V182, P5592, DOI 10.1128/JB.182.19.5592-5595.2000; Sarker S, 2002, J BACTERIOL, V184, P2360, DOI 10.1128/JB.184.9.2360-2369.2002; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sunohara T, 2004, J BIOL CHEM, V279, P15368, DOI 10.1074/jbc.M312805200; Sunohara T, 2004, RNA, V10, P378, DOI 10.1261/rna.5169404; Sunohara T, 2002, RNA, V8, P1416, DOI 10.1017/S1355838202020198; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Ueda K, 2002, GENES CELLS, V7, P509, DOI 10.1046/j.1365-2443.2002.00537.x; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	62	26	27	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54193	54201		10.1074/jbc.M314012200	http://dx.doi.org/10.1074/jbc.M314012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494397	hybrid			2022-12-25	WOS:000225793600038
J	Henderson, NC; Collis, EA; Mackinnon, AC; Simpson, KJ; Haslett, C; Zent, R; Ginsberg, M; Sethi, T				Henderson, NC; Collis, EA; Mackinnon, AC; Simpson, KJ; Haslett, C; Zent, R; Ginsberg, M; Sethi, T			CD98hc (SLC3A2) interaction with beta(1) Integrins is required for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; AMINO-ACID-TRANSPORT; LYMPHOCYTE-ACTIVATION; SURFACE-ANTIGEN; CELL CARCINOMA; HEAVY-CHAIN; EXPRESSION; 4F2; ASSOCIATION; SUBUNIT	CD98hc (SLC3A2) constitutively and specifically associates with beta(1) integrins and is highly expressed on the surface of human tumor cells irrespective of the tissue of origin. We have found here that expression of CD98hc promotes both anchorage- and serum-independent growth. This oncogenic activity is dependent on beta(1) integrin-mediated phosphoinositol 3-hydroxykinase stimulation and the level of surface expression of CD98hc. Using chimeras of CD98hc and the type II membrane protein CD69, we show that the transmembrane domain of CD98hc is necessary and sufficient for integrin association in cells. Furthermore, CD98hc/beta(1) integrin association is required for focal adhesion kinase-dependent phosphoinositol 3-hydroxykinase activation and cellular transformation. Amino acids 82-87 in the putative cytoplasmic/transmembrane region appear to be critical for the oncogenic potential of CD98hc and provide a novel mechanism for tumor promotion by integrins. These results explain how high expression of CD98hc in human cancers contributes to transformation; furthermore, the transmembrane association of CD98hc and beta(1) integrins may provide a new target for cancer therapy.	Univ Edinburgh, Sch Med, MRC,Ctr Inflammat Res, Lung Inflammat Grp, Edinburgh EH8 9XD, Midlothian, Scotland; Vanderbilt Univ, Med Ctr, Vet Affairs Med Ctr, Div Nephrol, Nashville, TN 37232 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Edinburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; University of California System; University of California San Diego	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, MRC,Ctr Inflammat Res, Lung Inflammat Grp, Hugh Robson Bldg,Rm 219,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	t.sethi@ed.ac.uk						AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; BELLONE G, 1989, EUR J IMMUNOL, V19, P1, DOI 10.1002/eji.1830190102; Bouck N, 1979, Methods Enzymol, V58, P296; CARNEY DN, 1980, CANCER RES, V40, P1820; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; ESTEBAN F, 1990, CANCER, V66, P1493, DOI 10.1002/1097-0142(19901001)66:7<1493::AID-CNCR2820660710>3.0.CO;2-0; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kolesnikova TV, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-10; Liu SC, 2000, J CELL SCI, V113, P3563; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Miyamoto YJ, 2003, MOL IMMUNOL, V39, P739, DOI 10.1016/S0161-5890(02)00255-9; Moore SM, 1998, CANCER RES, V58, P5239; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; SUOMALAINEN HA, 1986, J IMMUNOL, V137, P422; VANDERKAAY J, 1999, PHOSPHOLIPID SIGNALI, P109; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Yoon JH, 2003, ANTICANCER RES, V23, P3877; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	45	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54731	54741		10.1074/jbc.M408700200	http://dx.doi.org/10.1074/jbc.M408700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485886	hybrid			2022-12-25	WOS:000225793600101
J	Liu, W; Xu, DR; Yang, HM; Xu, H; Shi, ZQ; Cao, XM; Takeshita, S; Liu, JZ; Teale, M; Feng, X				Liu, W; Xu, DR; Yang, HM; Xu, H; Shi, ZQ; Cao, XM; Takeshita, S; Liu, JZ; Teale, M; Feng, X			Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; OSTEOPROTEGERIN-LIGAND; TERMINAL KINASE; DENDRITIC-CELL; TRAF FAMILY; SIGNAL-TRANSDUCTION; MATURE OSTEOCLASTS; BONE-RESORPTION; T-CELLS	Receptor activator of NF-kappaB ligand (RANKL) and its receptor activator of NF-kappaB (RANK) play pivotal roles in osteoclast differentiation and function. However, the structural determinants of the RANK that mediate osteoclast formation and function have not been definitively identified. To address this issue, we developed a chimeric receptor approach that permits a structure/function study of the RANK cytoplasmic domain in osteoclasts. Using this approach, we examined the role of six RANK putative tumor necrosis factor receptor-associated factor-binding motifs (PTM) (PTM1, ILLMT-REE286-293; PTM2, PSQPS(349-353); PTM3, PFQEP(369-373); PTM4, VYVSQTSQE(537-545); PTM5, PVQEET(559-564); and PTM6, PVQEQG(604-609)) in osteoclast formation and function. Our data revealed that the RANK cytoplasmic domain possesses three functional motifs (PFQEP(369-373), PVQEET(559-564), and PVQEQG(604-609)) capable of mediating osteoclast formation and function. Moreover, we demonstrated that these motifs play distinct roles in activating intracellular signaling. PFQEP(369-373) initiates NF-kappaB, c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38 signaling pathways and PVQEET(559-564) activates NF-kappaB and p38 pathways in osteoclasts, whereas PVQEQG(604-609) is only capable of activating NF-kappaB pathway. Significantly, the revelation of these functional RANK cytoplasmic motifs has not only laid a foundation for further delineating RANK signaling pathways in osteoclasts, but, more importantly, these RANK motifs themselves represent potential therapeutic targets for bone disorders such as osteoporosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Guangdong Prov, Peoples R China; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Sun Yat Sen University; Washington University (WUSTL)	Feng, X (corresponding author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,VH G046B, Birmingham, AL 35294 USA.	xfeng@path.uab.edu	Xu, Hui/A-8167-2009		NIAMS NIH HHS [P30AR46031, AR 47830] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R01AR047830] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; GREENFIELD EM, 1992, CALCIFIED TISSUE INT, V51, P317, DOI 10.1007/BF00334494; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Jimi E, 1999, J IMMUNOL, V163, P434; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peschon JJ, 1998, J IMMUNOL, V160, P943; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	41	43	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54759	54769		10.1074/jbc.M404687200	http://dx.doi.org/10.1074/jbc.M404687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485878	hybrid			2022-12-25	WOS:000225793600104
J	Cui, NG; Kang, YH; He, Y; Leung, YM; Xie, HL; Pasyk, EA; Gao, XD; Sheu, L; Hansen, JB; Wahl, P; Tsushima, RG; Gaisano, HY				Cui, NG; Kang, YH; He, Y; Leung, YM; Xie, HL; Pasyk, EA; Gao, XD; Sheu, L; Hansen, JB; Wahl, P; Tsushima, RG; Gaisano, HY			H3 domain of syntaxin 1A inhibits K-ATP channels by its actions on the sulfonylurea receptor 1 nucleotide-binding folds-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; BETA-CELL; 3-DIMENSIONAL STRUCTURE; MOLECULAR DETERMINANTS; EXOCYTOSIS; MODULATION; DIAZOXIDE; TERMINUS; SUBUNIT; COMPLEX	The ATP-sensitive potassium (K-ATP) channel in pancreatic islet beta cells consists of four pore-forming (Kir6.2) subunits and four regulatory sulfonylurea receptor (SUR1) subunits. In beta cells, the KATP channel links intracellular metabolism to the dynamic regulation of the cell membrane potential that triggers insulin secretion. Syntaxin 1A (Syn-1A) is a SNARE protein that not only plays a direct role in exocytosis, but also binds and modulates voltage-gated K+ and Ca2+ channels to fine tune exocytosis. We recently reported that wild type Syn-1A inhibits rat islet beta cell KATP channels and binds both nucleotide-binding folds (NBF-1 and NBF-2) of SUR1. However, wild type Syn-1A inhibition of rat islet beta cell KATP channels seems to be mediated primarily via NBF-1. During exocytosis, Syn-1A undergoes a conformational change from a closed form to an open form, which would fully expose its active domain, the C-terminal H3 domain. Here, we show that the constitutively open form Syn-1A mutant ( L165A/E166A) has a similar affinity to NBF-1 and NBF-2 as wild type Syn-1A and was equally effective in inhibiting the KATP channels of rat pancreatic beta cells and a cell line (BA8) stably expressing SUR1/Kir6.2. Although dialysis of NBF-1 into BA8 and islet beta cells effectively blocked wild type and open form Syn-1A inhibition of the KATP current, NBF-2 was also effective in blocking the open form Syn-1A inhibition. This prompted us to examine the specific domains within Syn-1A that would mediate its action on the KATP channels. The C-terminal H3 domain of Syn-1A (Syn-1A-H3), but not the N-terminal H-ABC domain (Syn-1A-H-ABC), binds the SUR1 protein of BA8 cells, causing an inhibition of KATP currents, and this inhibition was mediated via both NBF-1 and NBF-2. It therefore appears that the H3 domain of Syn-1A is the putative domain, which binds SUR1, but its distinct actions on the NBFs may depend on the conformation of Syn-1A occurring during exocytosis.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; NovoNordisk, DK-2760 Malov, Denmark	University of Toronto; University of Toronto	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Rm 7226 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	Herbert.gaisano@utoronto.ca						Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Dabrowski M, 2001, DIABETOLOGIA, V44, P747, DOI 10.1007/s001250051684; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fox JEM, 2003, METABOLISM, V52, P1313, DOI 10.1016/S0026-0495(03)00199-9; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jarvis SE, 2002, J BIOL CHEM, V277, P44399, DOI 10.1074/jbc.M206902200; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Matsuo M, 2002, EMBO J, V21, P4250, DOI 10.1093/emboj/cdf419; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	29	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53259	53265		10.1074/jbc.M410171200	http://dx.doi.org/10.1074/jbc.M410171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485808	hybrid			2022-12-25	WOS:000225680600056
J	Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ				Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ			Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation	ONCOGENE			English	Article						Rho GTPase; Rho GDI; Tiam1; cyclin D1; NF-kappa B	RHO-FAMILY GTPASES; CRYSTAL-STRUCTURE; NIH3T3 CELLS; INDEPENDENT PATHWAYS; RAS TRANSFORMATION; DEPENDENT PATHWAY; GENE-EXPRESSION; ACTIVATION; PROTEINS; TIAM1	A novel splice variant of Rac1, designated Rac1b, is expressed in human breast and colon carcinoma cells. Rac1b contains an additional 19 amino-acid insert immediately behind the switch II domain, a region important for Rac1 interaction with regulators and effectors. Recent studies showed that Rac1b exhibited the biochemical properties of a constitutively activated GTPase, yet it showed impaired interaction with downstream effectors, suggesting that Rac1b may be defective in biological activity. Whether Rac1b is a biologically active protein was not addressed. Therefore, we evaluated the biochemical, signaling and growth-promoting properties of authentic Rac1b. Similar to previous observations, we found that Rac1b showed enhanced intrinsic guanine nucleotide exchange activity, impaired intrinsic GTPase activity, and failed to interact with RhoGDI. Surprisingly, we found that Rac1b, like the constitutively-activated and transforming Rac1(Q61L) mutant, promoted growth transformation of NIH3T3 cells. Rac1b-expressing cells also showed a loss of density-dependent and anchorage-dependent growth. Surprisingly, unlike activated Rac1(61L), Rac1b did not show enhanced activation of the nuclear factor kappaB (NF-kappaB) transcription factor or stimulate cyclin D1 expression, the signaling activities that best correlate with Rac1 transforming activity. However, Rac1b did promote activation of the AKTserine/threonine kinase. Therefore, we suggest that Rac1b selectively activates a subset of Rac1 downstream signaling pathways to facilitate cellular transformation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Chicago, Dept Obstet & Gynecol, Div Gynecol Oncol, Chicago, IL 60637 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Lengyel, Ernst/D-9220-2014; Singh, Anurag/C-7347-2014	Lengyel, Ernst/0000-0001-8624-1507; Singh, Anurag/0000-0003-4705-8683; Der, Channing/0000-0002-7751-2747; Sondek, John/0000-0002-1127-8310	NCI NIH HHS [CA63071] Funding Source: Medline; NIGMS NIH HHS [GM62299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h	46	138	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9369	9380		10.1038/sj.onc.1208182	http://dx.doi.org/10.1038/sj.onc.1208182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516977				2022-12-25	WOS:000225764100008
J	Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY				Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY			Dickkopf-3/REIC functions as a suppressor gene of tumor growth	ONCOGENE			English	Article						hepatoma; hepatocellular carcinoma; dickkopf; dkk-3; REIC; tumor suppressor gene	BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; DOWN-REGULATION; CELL CARCINOMA; C-MYC; REIC/DKK-3; MUTATIONS; IDENTIFICATION; ANTAGONIST; EXPRESSION	To identify putative tumor suppressor genes in hepatocarcinogenesis, we combined the representational difference analysis and reverse northern blot identifying downregulated genes in human hepatoma tissues. One of them was Dkk-3/REIC. Dkk-3/REIC was downregulated in 11 out of the 20 human hepatoma tissues as compared to their counterparts of noncancerous liver tissues by northern blot analysis. It was also downregulated in 29 out of 48 human cancer samples including the kidney, urinary bladder, prostate, pancreas and lung cancers. Its gene product, Dkk-3/REIC, was found to be N-glycosylated and have two isoforms, the 55 kDa in the cytosol and 50 kDa secreted in the medium. Ectopic expression of Dkk-3/REIC in HeLa, Hep3B and Huh 7 cells led to suppression of cell growth, which was primarily attributable to induction of cell apoptosis. The suppression phenomenon was found to be cell-type related ( most prominent in HeLa and least in Hep3B cells) and cell-density dependent ( attenuated as the cell density increased). Transduction of Dkk-3/REIC into HeLa and Hep3B cells caused suppression on colony formation in vitro and reduced tumor growth rate in inoculated athymic nude mice. In conclusion, these data indicate that Dkk-3/REIC functions as a suppressor for human tumor growth.	Chang Gung Mem Hosp, Liver Res Ctr, Tao Yuan 333, Taiwan; Chang Gung Univ, Sch Med, Dept Microbiol & Immunol, Tao Yuan 333, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, No 5 Fu Hsin Rd, Tao Yuan 333, Taiwan.	siming@adm.cgmh.org.tw						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; CARDIGAN KM, 1997, GENE DEV, V11, P3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gao S, 2004, INT J CANCER, V109, P230, DOI 10.1002/ijc.11592; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lin CH, 2001, CANCER RES, V61, P4238; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Micsenyi A, 2004, GASTROENTEROLOGY, V126, P1134, DOI 10.1053/j.gastro.2003.12.047; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sasaki T, 2003, CANCER RES, V63, P801; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD	30	144	163	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9183	9189		10.1038/sj.onc.1208138	http://dx.doi.org/10.1038/sj.onc.1208138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516983				2022-12-25	WOS:000225638000003
J	Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M				Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M			Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays	ONCOGENE			English	Article						mucinous cystic neoplasm; oligonucleotide microarray; 'ovarian-type' stroma	MULTIPLE GENES; FLUID ANALYSIS; DIFFERENTIAL-DIAGNOSIS; CELL-DIFFERENTIATION; ABERRANT METHYLATION; SERIAL ANALYSIS; TUMOR-MARKERS; CPG ISLANDS; K-RAS; NOTCH	Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon neoplasms usually located in the body or tail of the pancreas and usually in females (>90% of cases). Clinically, they are often misdiagnosed as non-neoplastic pseudocysts leading to failed opportunities for curative resection. To better understand the biology of MCNs and to identify markers of the disease, we performed global gene expression profiling of MCNs using oligonucleotide microarrays. Using laser capture microdissection applied to frozen sections, RNA was extracted from the neoplastic epithelium of MCNs, from the adjacent 'ovarian-type' stroma of MCNs, from histologically normal pancreatic ductal epithelium, from pancreatic acinar tissue and from fibrous stroma in pancreata affected by chronic pancreatitis. Each RNA sample was subjected to two rounds of linear amplification followed by hybridization with U133A gene chips (Affymetrix). The expression patterns of selected genes were confirmed by quantitative RT-PCR and by immunohistochemistry using tissue microarrays containing 19 resected MCNs. A total of 114 known genes were overexpressed in the neoplastic epithelium compared to normal pancreatic ductal epithelium (>3-fold) including S100P, PSCA, c-myc, STK6/STKI5, cathepsin E and pepsinogen C. Activation of the Notch pathway in the epithelial component of MCNs was evident by the demonstration of overexpression of Jagged1 and the downstream Notch pathway member Hes1. In the 'ovarian-type' stroma, several genes involved in estrogen metabolism were overexpressed including STAR and ESR1 genes. Some of the genes identified as overexpressed in these neoplasms may be useful as markers that can distinguish MCNs from non-neoplastic pancreatic cystic lesions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol Med & Oncol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P573; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Deichmann M, 2003, J CUTAN PATHOL, V30, P363, DOI 10.1034/j.1600-0560.2003.00073.x; Demos TC, 2002, AM J ROENTGENOL, V179, P1375, DOI 10.2214/ajr.179.6.1791375; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Fukushima N, 1997, PATHOL INT, V47, P806, DOI 10.1111/j.1440-1827.1997.tb04462.x; Fukushima N, 1999, ADV ANAT PATHOL, V6, P65, DOI 10.1097/00125480-199903000-00001; HAMMEL P, 1995, GASTROENTEROLOGY, V108, P1230, DOI 10.1016/0016-5085(95)90224-4; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Hruban RH, 2001, CANCER J, V7, P251; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Izumo A, 2003, ONCOL REP, V10, P515; Jabara S, 2003, J CLIN ENDOCR METAB, V88, P484, DOI 10.1210/jc.2002-021274; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Klein AP, 2001, CANCER J, V7, P266; KOWITZ A, 1992, EUR J IMMUNOL, V22, P1199, DOI 10.1002/eji.1830220514; Li DH, 2003, CLIN CANCER RES, V9, P991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logsdon CD, 2003, CANCER RES, V63, P2649; Luttges J, 2002, AM J SURG PATHOL, V26, P466, DOI 10.1097/00000478-200204000-00008; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Miao XP, 2004, CANCER RES, V64, P2680, DOI 10.1158/0008-5472.CAN-04-0651; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohhashi K., 1982, PROG DIG ENDOSC, V203, P348; RUBIN D, 1994, SURGERY, V115, P52; Ryu B, 2002, CANCER RES, V62, P819; Ryu B, 2001, CANCER RES, V61, P1833; Sand JA, 1996, SURGERY, V119, P275, DOI 10.1016/S0039-6060(96)80113-9; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Sato N, 2003, CANCER RES, V63, P3735; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; SESSA F, 1994, VIRCHOWS ARCH, V425, P357; Seth P, 2002, CANCER RES, V62, P4540; SOLCIA E, 1997, TUMORS PANCREAS, P220; Sorianello E, 2002, EUR J ENDOCRINOL, V147, P387, DOI 10.1530/eje.0.1470387; Sperti C, 1997, AM J GASTROENTEROL, V92, P672; Sperti C, 1996, CANCER, V78, P237, DOI 10.1002/(SICI)1097-0142(19960715)78:2<237::AID-CNCR8>3.0.CO;2-I; Su GH, 2001, P NATL ACAD SCI USA, V98, P3254, DOI 10.1073/pnas.051484398; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Thompson LDR, 1999, AM J SURG PATHOL, V23, P1, DOI 10.1097/00000478-199901000-00001; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; van der Heijden MS, 2003, CANCER RES, V63, P2585; WARSHAW AL, 1990, ANN SURG, V212, P432, DOI 10.1097/00000658-199010000-00006; Yoshizawa K, 2002, VIRCHOWS ARCH, V441, P437, DOI 10.1007/s00428-002-0645-6; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005; Zamboni G.K.G., 2000, WHO CLASSIFICATION T, P234	69	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9042	9051		10.1038/sj.onc.1208117	http://dx.doi.org/10.1038/sj.onc.1208117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489895				2022-12-25	WOS:000225492800005
J	Louis, K; Guerineau, N; Fromigue, O; Defamie, V; Collazos, A; Anglard, P; Shipp, MA; Auberger, P; Joubert, D; Mari, B				Louis, K; Guerineau, N; Fromigue, O; Defamie, V; Collazos, A; Anglard, P; Shipp, MA; Auberger, P; Joubert, D; Mari, B			Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; GENE-EXPRESSION; RETINOIC ACID; STRUCTURAL DETERMINANTS; PROTEOLYTIC ACTIVATION; N-CADHERIN; PKC-ALPHA; T-CELLS; IN-VIVO; CANCER	Stromelysin-3 (ST3, MMP-11) has been shown to be strongly overexpressed in stromal fibroblasts of most invasive human carcinomas. However, the molecular mechanisms leading to ST3 expression in nonmalignant fibroblasts remain unknown. The aim of the present study was to analyze the signaling pathways activated in normal pulmonary fibroblasts after their interaction with non-small cell lung cancer (NSCLC) cells and leading to ST3 expression. The use of selective signaling pathway inhibitors showed that conventional and novel protein kinase Cs (PKC) were required for ST3 induction, whereas Src kinases exerted a negative control. We observed by both conventional and real time confocal microscopy that green fluorescent protein-tagged PKCalpha and PKCepsilon, but not PKCdelta, transfected in fibroblasts, accumulate selectively at the cell-cell contacts between fibroblasts and tumor cells. In agreement, RNAi-mediated depletion of PKCalpha and PKCepsilon, but not PKCdelta significantly decreased co-culture-dependent ST3 production. Finally, a tetracycline-inducible expression model allowed us to confirm the central role of these PKC isoforms and the negative regulatory function of c-Src in the control of ST3 expression. Altogether, our data emphasize signaling changes occurring in the tumor microenvironment that may define new stromal targets for therapeutic intervention.	Fac Med Pasteur, INSERM, U526, IFR50, F-06107 Nice, France; CNRS, INSERM, U469, CCIPE, F-34094 Montpellier, France; Univ Strasbourg, INSERM, U575, F-67084 Strasbourg, France; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Mari, B (corresponding author), Fac Med Pasteur, INSERM, U526, IFR50, F-06107 Nice, France.	bernard.mari@unice.fr	Anglard, Patrick/M-6618-2019; Mari, Bernard/Q-5832-2019; Fromigue, Olivia/B-8225-2013; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard P/D-7445-2015; AUBERGER, Patrick/G-1491-2013	Anglard, Patrick/0000-0001-5701-441X; Mari, Bernard/0000-0002-0422-9182; Fromigue, Olivia/0000-0002-3050-6155; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Guerineau, Nathalie/0000-0003-2517-4210; Defamie, Virginie/0000-0002-6405-0539				Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Andarawewa KL, 2003, CANCER RES, V63, P5844; ANDERSON IC, 1995, CANCER RES, V55, P4120; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Boulay A, 2001, CANCER RES, V61, P2189; Boyd RS, 1999, BRIT J CANCER, V80, P315, DOI 10.1038/sj.bjc.6690357; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Delany AM, 2001, ENDOCRINOLOGY, V142, P1561, DOI 10.1210/en.142.4.1561; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENGEL G, 1994, INT J CANCER, V58, P830, DOI 10.1002/ijc.2910580614; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Fromigue O, 2003, ONCOGENE, V22, P8487, DOI 10.1038/sj.onc.1206918; Fromigue O, 2003, INT J CANCER, V106, P355, DOI 10.1002/ijc.11232; Guerin E, 1997, J BIOL CHEM, V272, P11088; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Leverrier S, 2002, BIOCHEM J, V368, P905, DOI 10.1042/BJ20021253; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Ludwig MG, 2000, J BIOL CHEM, V275, P39981, DOI 10.1074/jbc.M007529200; Luo DC, 1999, J BIOL CHEM, V274, P37177, DOI 10.1074/jbc.274.52.37177; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Matrisian LM, 2001, CANCER RES, V61, P3844; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Nozu F, 1999, AM J PHYSIOL-GASTR L, V276, pG915, DOI 10.1152/ajpgi.1999.276.4.G915; Ohmori T, 1999, THROMB RES, V93, P291, DOI 10.1016/S0049-3848(98)00188-1; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Porte H, 1998, CLIN CANCER RES, V4, P1375; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; Quittau-Prevostel C, 2004, J CELL SCI, V117, P63, DOI 10.1242/jcs.00832; ROUYER N, 1994, INVAS METAST, V14, P269; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Toole BP, 2003, CURR TOP DEV BIOL, V54, P371, DOI 10.1016/S0070-2153(03)54015-7; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Vallentin A, 2001, MOL CELL BIOL, V21, P3351, DOI 10.1128/MCB.21.10.3351-3363.2001; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; Wang CS, 2002, INT J CANCER, V99, P792, DOI 10.1002/ijc.10430; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Yoshiji H, 1999, CANCER RES, V59, P4413; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	69	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1272	1283		10.1074/jbc.M405482200	http://dx.doi.org/10.1074/jbc.M405482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509588	Green Published, hybrid			2022-12-25	WOS:000226195200052
J	Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R				Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R			Predisposition to mouse thymic lymphomas in response to ionizing radiation depends on variant alleles encoding metal-responsive transcription factor-1 (Mtf-1)	ONCOGENE			English	Article						cancer susceptibility; lymphoma; positional cloning; gamma-radiation; radical scavenger	PLACENTAL GROWTH-FACTOR; TUMOR-SUSCEPTIBILITY; HOMOZYGOUS DELETIONS; GENETIC DISSECTION; POINT MUTATIONS; COMPLEX TRAITS; CANDIDATE; LOCUS; MICE; MODIFIER	Genetic predisposition to cancers is significant to public health because a high proportion of cancers probably arise in a susceptible human subpopulation. Using a mouse model of gamma-ray-induced thymic lymphomas, we performed linkage analysis and haplotype mapping that suggested Mtf-1, metal-responsive transcription factor-1 (Mtf-1), as a candidate lymphoma susceptibility gene. Sequence analysis revealed a polymorphism of Mtf-1 that alters the corresponding amino acid at position 424 in the proline-rich domain from a serine in susceptibility strains to proline in resistant strains. The transcriptional activity of Mtf-1 encoding serine and proline was compared by transfecting the DNA to Mtf-1-null cells, and the change to proline conferred a higher metal responsiveness in transfections. Furthermore, the resistant congenic strains possessing the Mtf-1 allele of proline type exhibited higher radiation inducibility of target genes than susceptible background strains having the Mtf-1 allele of serine type. Since products of the targets such as metallothionein are able to suppress cellular stresses generated by irradiation, these results suggest that highly inducible strains having Mtf-1 of proline type are refractory to radiation effects and hence are resistant to lymphoma development.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Niigata 9518122, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Niigata University; Niigata University; Kyoto University; University of Zurich	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Asahimachi 1-757, Niigata 9518122, Japan.	rykomina@med.niigata-u.ac.jp		Maruyama, Masaki/0000-0002-9534-4652				Adini A, 2002, CANCER RES, V62, P2749; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Hellsten E, 2001, DEV BIOL, V240, P641, DOI 10.1006/dbio.2001.0476; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sato H, 2003, CANCER SCI, V94, P668, DOI 10.1111/j.1349-7006.2003.tb01500.x; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Wang Y, 2004, FASEB J, V18, P1071, DOI 10.1096/fj.03-1282com; Wright AF, 2001, GENOME BIOL, V2; Zhang H, 2003, CURR BIOL, V13, P1625, DOI 10.1016/j.cub.2003.08.054	42	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					399	406		10.1038/sj.onc.1208197	http://dx.doi.org/10.1038/sj.onc.1208197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516976				2022-12-25	WOS:000226279700011
J	Bobard, A; Hainault, I; Ferre, P; Foufelle, F; Bossard, P				Bobard, A; Hainault, I; Ferre, P; Foufelle, F; Bossard, P			Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; LIPOGENIC GENE-EXPRESSION; LXR-ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; OXYSTEROL RECEPTORS; GLUCOKINASE GENE; MESSENGER-RNA; METABOLISM; CHOLESTEROL; SREBP-1C	Sterol regulatory element-binding proteins (SREBPs) are transcription factors involved in the synthesis of cholesterol and fatty acids. In adults, the isoform SREBP-1c is the predominant transcript in the liver of fed animals, and it activates triglyceride production from glucose when diet is enriched in carbohydrates. Studies have shown that SREBP-1c expression is dependent on insulin but also on the availability of oxysterols, ligands of the nuclear liver X receptor (LXR). The aim of this study was to investigate the regulation of the hepatic SREBP-1c expression in vivo in situations where drastic nutritional and hormonal changes occur, from the gestation to the weaning period. In this paper, we report the discovery of LXR-independent SREBP-1c transcriptional activity during late gestation. In utero insulin injection prior to the natural rise in insulin in late gestation triggers SREBP-1c mRNA elevation, nuclear SREBP-1c binding activity, and expression of its target genes independently of LXR transactivation. On the other hand, during suckling, we observed strong SREBP-1c mRNA expression despite very low plasma insulin, an expression that may be due to LXR transactivation. In contrast to insulin, LXR is not sufficient to trigger nuclear SREBP- 1c binding activity and target gene induction. This could be due to the concomitant induction of INSIG-2a by LXR and subsequent retention of SREBP- 1c in the endoplasmic reticulum.	INSERM, U465, F-75006 Paris, France; Univ Paris 06, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bossard, P (corresponding author), INSERM, U465, 15 Rue Ecole Med, F-75270 Paris 06, France.	pbossard@bhdc.jussieu.fr	Ferré, Pascal/K-1250-2013; Bossard, Pascale/O-6680-2017	Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X				BATTAGLIA FC, 1978, PHYSIOL REV, V58, P499, DOI 10.1152/physrev.1978.58.2.499; Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; BOSSARD P, 1993, EUR J BIOCHEM, V215, P883, DOI 10.1111/j.1432-1033.1993.tb18106.x; Botolin D, 2003, J BIOL CHEM, V278, P6959, DOI 10.1074/jbc.M212846200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAGEN LM, 2004, IN PRESS BIOCH J; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; DILS R R, 1980, Biochemical Society Transactions, V8, P292; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GIRARD J, 1991, BIOCHIMIE, V73, P71, DOI 10.1016/0300-9084(91)90077-E; Girard J., 1977, GLUCAGON ITS ROLE PH, P563, DOI DOI 10.1007/978-1-4612-6366-1-36; GIRARD J, 1982, BIOCH DEV FETUS NEON, P517; GIRARD J R, 1981, Biochemical Society Transactions, V9, P369; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Janowski BA, 2001, J BIOL CHEM, V276, P45408, DOI 10.1074/jbc.M108348200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PERDEREAU D, 1990, ADV ENZYME REGUL, V30, P91; *PERKINELMER LIF S, 1999, REL QUANT GEN EXPR B, V2; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	42	26	32	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					199	206		10.1074/jbc.M406522200	http://dx.doi.org/10.1074/jbc.M406522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509573	hybrid			2022-12-25	WOS:000226025100025
J	Higashimoto, Y; Sakamoto, H; Hayashi, S; Sugishima, M; Fukuyama, K; Palmer, G; Noguchi, M				Higashimoto, Y; Sakamoto, H; Hayashi, S; Sugishima, M; Fukuyama, K; Palmer, G; Noguchi, M			Involvement of NADP(H) in the interaction between heme oxygenase-1 and cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMN-BINDING DOMAIN; CRYSTAL-STRUCTURE; P450 REDUCTASE; RAT HEME; ELECTROSTATIC INTERACTIONS; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; CORYNEBACTERIUM-DIPHTHERIAE; SOLUBLE FORM; COMPLEX	Heme oxygenase-1 (HO-1) catalyzes the physiological degradation of heme at the expense of molecular oxygen using electrons donated by NADPH-cytochrome P450 reductase (CPR). In this study, we investigated the effect of NADP( H) on the interaction of HO-1 with CPR by surface plasmon resonance. We found that HO-1 associated with CPR more tightly in the presence of NADP(+) (K-D = 0.5 muM) than in its absence (K-D = 2.4 muM). The HO-1 mutants, K149A, K149A/K153A, and R185A, showed almost no heme degradation activity with NADPH-CPR, whereas they exhibited activity comparable to that of the wild type when sodium ascorbate was used. R185A showed a 100-fold decreased affinity for CPR compared with wild type, even in the presence of NADP(+) (K-D = 36.3 muM). The affinities of K149A and K149A/K153A for CPR were decreased 7- and 9-fold (K-D = 16.8 and 21.8 muM), respectively. In contrast to R185A, the affinities of K149A and K149A/K153A were improved by the addition of NADP(+) (K-D = 5.2 and 9.6 muM, respectively), as was the case with wild type. Computer modeling of the HO-1/CPR complex showed that the guanidino group of Arg(185) is located within the hydrogen bonding distance of 2'-phosphate of NADPH, suggesting that Arg185 contributes to the binding to CPR through an electrostatic interaction with the phosphate group. On the other hand, Lys(149) is close to a cluster of acidic amino acids near the FMN binding site of CPR. Thus, Lys(149) and Lys(153) appear to interact with CPR in such a way as to orient the redox partners for optimal electron transfer from FMN of CPR to heme of HO-1.	Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan; Osaka Univ, Dept Biol, Grad Sch Sci, Osaka 5600043, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Kurume University; Osaka University; Rice University	Noguchi, M (corresponding author), Kurume Univ, Sch Med, Dept Med Biochem, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan.	mnoguchi@med.kurume-u.ac.jp	Sugishima, Masakazu/M-2773-2019; Sugishima, Masakazu/B-1049-2010; Sakamoto, Hiroshi/A-3181-2011	Sugishima, Masakazu/0000-0002-0840-4929; Sugishima, Masakazu/0000-0002-0840-4929; Higashimoto, Yuichiro/0000-0003-1382-8598	NIGMS NIH HHS [GM55807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auclair K., 2003, PORPHYRIN HDB, V12, P183; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Davydov DR, 2000, BIOCHEMISTRY-US, V39, P6489, DOI 10.1021/bi992936u; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Dong Z, 2000, AM J PATHOL, V156, P1485, DOI 10.1016/S0002-9440(10)65019-5; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Gilep AA, 2001, BIOCHEM BIOPH RES CO, V284, P937, DOI 10.1006/bbrc.2001.5075; Gilep AA, 2001, ARCH BIOCHEM BIOPHYS, V390, P222, DOI 10.1006/abbi.2001.2371; Gilep AA, 2001, ARCH BIOCHEM BIOPHYS, V390, P215, DOI 10.1006/abbi.2001.2372; Gutierrez A, 2003, EUR J BIOCHEM, V270, P2612, DOI 10.1046/j.1432-1033.2003.03633.x; Hayashi S, 2003, PROTEIN EXPRES PURIF, V29, P1, DOI 10.1016/S1046-5928(03)00023-8; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; ILAN Z, 1981, J BIOL CHEM, V256, P66; Ivanov YD, 1999, ARCH BIOCHEM BIOPHYS, V362, P87, DOI 10.1006/abbi.1998.0981; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Luft FC, 2002, J MOL MED-JMM, V80, P615, DOI 10.1007/s00109-002-0372-0; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NISIMOTO Y, 1986, J BIOL CHEM, V261, P14232; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; Paine MJI, 2001, BIOCHEMISTRY-US, V40, P13439, DOI 10.1021/bi011147l; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sakamoto H, 1999, J BIOL CHEM, V274, P18196, DOI 10.1074/jbc.274.26.18196; Sakamoto H, 2002, EUR J BIOCHEM, V269, P5231, DOI 10.1046/j.1432-1033.2002.03230.x; Sakamoto H, 2000, J INORG BIOCHEM, V82, P113, DOI 10.1016/S0162-0134(00)00149-5; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11539, DOI 10.1021/bi00094a010; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; Strobel Henry W., 1995, P225; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2003, BIOCHEMISTRY-US, V42, P9898, DOI 10.1021/bi027268i; Sugishima M, 2003, J BIOL CHEM, V278, P32352, DOI 10.1074/jbc.M303682200; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; Wang JL, 2003, J BIOL CHEM, V278, P20069, DOI 10.1074/jbc.M300989200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; Zhao Q, 1999, PROTEIN SCI, V8, P298; Zhou Hong, 2000, Yamagata Medical Journal, V18, P25	68	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					729	737		10.1074/jbc.M406203200	http://dx.doi.org/10.1074/jbc.M406203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516695	hybrid			2022-12-25	WOS:000226025100086
J	Sakthivel, S; Finley, NL; Rosevear, PR; Lorenz, JN; Gulick, J; Kim, S; VanBuren, P; Martin, LA; Robbins, J				Sakthivel, S; Finley, NL; Rosevear, PR; Lorenz, JN; Gulick, J; Kim, S; VanBuren, P; Martin, LA; Robbins, J			In vivo and in vitro analysis of cardiac troponin I phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ESSENTIAL LIGHT-CHAIN; FAILING HUMAN HEARTS; TRANSGENIC MICE; HYPERTROPHIC CARDIOMYOPATHY; RECONSTITUTED ACTOMYOSIN; CA2+-STIMULATED MGATPASE; CONFORMATIONAL EXCHANGE; REGULATORY DOMAIN; A PHOSPHORYLATION	Adrenergic stimulation induces positive changes in cardiac contractility and relaxation. Cardiac troponin I is phosphorylated at different sites by protein kinase A and protein kinase C, but the effects of these post-translational modifications on the rate and extent of contractility and relaxation during beta-adrenergic stimulation in the intact animal remain obscure. To investigate the effect(s) of complete and chronic cTnI phosphorylation on cardiac function, we generated transgenic animals in which the five possible phosphorylation sites were replaced with aspartic acid, mimicking a constant state of complete phosphorylation (cTnI-AllP). We hypothesized that chronic and complete phosphorylation of cTnI might result in increased morbidity or mortality, but complete replacement with the transgenic protein was benign with no detectable pathology. To differentiate the effects of the different phosphorylation sites, we generated another mouse model, cTnI-PP, in which only the protein kinase A phosphorylation sites (Ser(23)/Ser(24)) were mutated to aspartic acid. In contrast to the cTnI-AllP, the cTnI-PP mice showed enhanced diastolic function under basal conditions. The cTnI-PP animals also showed augmented relaxation and contraction at higher heart rates compared with the nontransgenic controls. Nuclear magnetic resonance amide proton/nitrogen chemical shift analysis of cardiac troponin C showed that, in the presence of cTnI-AllP and cTnI-PP, the N terminus exhibits a more closed conformation, respectively. The data show that protein kinase C phosphorylation of cTnI plays a dominant role in depressing contractility and exerts an antithetic role on the ability of protein kinase A to increase relaxation.	Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Div Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Vermont, Coll Med, Dept Med, Cardiol Unit, Burlington, VT 05405 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Vermont	Robbins, J (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, MLC 7020,3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.robbins@cchmc.org		Sadayappan, Sakthivel/0000-0003-2006-7678	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056370, R01HL060546, P50HL052318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69799, HL52318, HL60546, HL56370] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2000, FEBS LETT, V469, P168, DOI 10.1016/S0014-5793(00)01271-0; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Finley NL, 2004, J BIOL CHEM, V279, P54833, DOI 10.1074/jbc.M408304200; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HABER HL, 1993, CIRCULATION, V88, P1610, DOI 10.1161/01.CIR.88.4.1610; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; James J, 2002, J MOL CELL CARDIOL, V34, P873, DOI 10.1006/jmcc.2002.2025; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Knott A, 2002, J MOL CELL CARDIOL, V34, P469, DOI 10.1006/jmcc.2002.1528; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MacGowan GA, 2001, AM J PHYSIOL-HEART C, V280, pH835, DOI 10.1152/ajpheart.2001.280.2.H835; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; NOLAND TA, 1993, J MOL CELL CARDIOL, V25, P53, DOI 10.1006/jmcc.1993.1007; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Noland TA, 1996, BIOCHEMISTRY-US, V35, P14923, DOI 10.1021/bi9616357; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Palmer S, 1998, CIRC RES, V83, P179, DOI 10.1161/01.RES.83.2.179; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; Pi YQ, 2002, CIRC RES, V90, P649, DOI 10.1161/01.RES.0000014080.82861.5F; Pyle WG, 2002, AM J PHYSIOL-HEART C, V283, pH1215, DOI 10.1152/ajpheart.00128.2002; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Takimoto E, 2004, CIRC RES, V94, P496, DOI 10.1161/01.RES.0000117307.57798.F5; van der Velden J, 2003, CARDIOVASC RES, V57, P505, DOI 10.1016/S0008-6363(02)00662-4; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; Ward DG, 2004, BIOCHEMISTRY-US, V43, P5772, DOI 10.1021/bi036310m; Ward DG, 2004, BIOCHEMISTRY-US, V43, P4020, DOI 10.1021/bi036128l; WATTANAPERMPOOL J, 1995, J MOL CELL CARDIOL, V27, P1383, DOI 10.1006/jmcc.1995.0131; Wolska BM, 2002, CIRC RES, V90, P882, DOI 10.1161/01.RES.0000016962.36404.04; Yang QL, 2001, CARDIOVASC RES, V51, P80, DOI 10.1016/S0008-6363(01)00273-5	46	79	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					703	714		10.1074/jbc.M409513200	http://dx.doi.org/10.1074/jbc.M409513200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507454	hybrid			2022-12-25	WOS:000226025100083
J	Lesage, B; Beullens, M; Nuytten, M; Van Eynde, A; Keppens, S; Himpen, B; Bollen, M				Lesage, B; Beullens, M; Nuytten, M; Van Eynde, A; Keppens, S; Himpen, B; Bollen, M			Interactor-mediated nuclear translocation and retention of protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; TARGETING SUBUNIT; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; SUBCELLULAR-LOCALIZATION; BINDING; NIPP1; IDENTIFICATION; INHIBITOR; TRANSPORT	Protein Ser/Thr phosphatase-1 (PP1) is a ubiquitous eukaryotic enzyme that controls numerous cellular processes by the dephosphorylation of key regulatory proteins. PP1 is expressed in various cellular compartments but is most abundant in the nucleus. We have examined the determinants for the nuclear localization of enhanced green fluorescent protein-tagged PP1 in COS1 cells. Our studies show that PP1gamma(1) does not contain a functional nuclear localization signal and that its nuclear accumulation does not require Sds22, which has previously been implicated in the nuclear accumulation of PP1 in yeast (Peggie, M. W., MacKelvie, S. H., Bloecher, A., Knatko, E. V., Tatchell, K., and Stark, M.J.R. (2002) J. Cell Sci. 115, 195-206). However, the nuclear targeting of PP1 isoforms was alleviated by the mutation of their binding sites for proteins that interact via an RVXF motif. Moreover, one of the mutants with a cytoplasmic accumulation and decreased affinity for RVXF motifs (PP1gamma(1)-F257A) could be re-targeted to the nucleus by the overexpression of nuclear interactors (NIPP1 ((n) under bar uclear (i) under bar nhibitor of (PP1) under bar) and PNUTS ((P) under bar P1 (nu) under bar clear (t) under bar argeting (s) under bar ubunit)) with a functional RVXF motif. Also, the addition of a synthetic RVXF-containing peptide to permeabilized cells resulted in the loss of nuclear enhanced green fluorescent protein-PP1gamma1. Finally, NIPP1(-/-) mouse embryos showed a nuclear hyperphosphorylation on threonine, consistent with a role for NIPP1 in the nuclear targeting and/or retention of PP1. Our data suggest that both the nuclear translocation and the nuclear retention of PP1 depend on its binding to interactors with an RVXF motif.	Katholieke Univ Leuven, Fac Geneeskunde, Div Biochem, Afdeling Biochem, B-3000 Leuven, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Div Biochem, Afdeling Biochem, Campus Gasthuisberg KULeuven,Herestr 49, B-3000 Leuven, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Cohen PTW, 2002, J CELL SCI, V115, P241; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Jagiello I, 2000, J CELL SCI, V113, P3761; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kim YM, 2003, J BIOL CHEM, V278, P13819, DOI 10.1074/jbc.M209621200; Llorian M, 2004, BIOCHEM J, V378, P229, DOI 10.1042/BJ20030950; Mizuno T, 1996, J CELL SCI, V109, P2627; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Okano K, 1997, GENOMICS, V45, P211, DOI 10.1006/geno.1997.4907; Peggie MW, 2002, J CELL SCI, V115, P195; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Van Eynde A, 2004, MOL CELL BIOL, V24, P5863, DOI 10.1128/MCB.24.13.5863-5874.2004; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	34	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55978	55984		10.1074/jbc.M411911200	http://dx.doi.org/10.1074/jbc.M411911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15501817	hybrid			2022-12-25	WOS:000225960800121
J	Llano, M; Delgado, S; Vanegas, M; Poeschla, EM				Llano, M; Delgado, S; Vanegas, M; Poeschla, EM			Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SUBCELLULAR-LOCALIZATION; TRANSCRIPTIONAL ACTIVATION; ORNITHINE-DECARBOXYLASE; KARYOPHILIC PROPERTIES; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; HUMAN GENOME; HUMAN-CELLS; RAT-LIVER	The transcriptional coactivator lens epithelium-derived growth factor (LEDGF)/p75 acts as a chromatin tethering factor for human immunodeficiency virus type 1 (HIV-1) integrase protein, determining its nuclear localization and its tight association with nuclear DNA. Here we identify a second function for the LEDGF/p75-integrase interaction. We observed that stable introduction of HIV-1 integrase ( IN) transcription units into cells made stringently LEDGF/p75-deficient by RNAi resulted in much lower steady state levels of IN protein than introduction into LEDGF/p75 wild type cells. The same LEDGF/p75-dependent disparity was observed for feline immunodeficiency virus IN. However, IN mRNA levels were equivalent in the presence and absence of LEDGF/p75. A post-translational mechanism was confirmed when the half-life of HIV-1 IN protein was found to be much shorter in LEDGF/p75-deficient cells. Proteasome inhibition fully countered this extreme instability, increasing IN protein levels to those seen in LEDGF/p75 wild type cells and implicating proteasomal destruction as the main cause of IN instability. Consistent with these data, increased ubiquitinated HIV-1 IN was found in the LEDGF/p75 knock-down cells. Moreover, restoration of LEDGF/p75 to knocked down clones rescued HIV-1 IN stability. Subcellular fractionation showed that HIV-1 IN is exclusively cytoplasmic in LEDGF/p75-deficient cells, but mainly nuclear in LEDGF/p75 wild type cells, and that cytoplasmic HIV-1 IN has a shorter half-life than nuclear HIV-1 IN. However, using LEDGF proteins defective for nuclear localization and IN interaction, we further determined that protection of HIV-1 IN from the proteasome requires neither chromatin tethering nor nuclear residence. Protection requires only interaction with LEDGF/p75, and it is independent of the subcellular localization of the IN-LEDGF complex.	Mayo Clin, Coll Med, Program Mol Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Poeschla, EM (corresponding author), Mayo Clin, Coll Med, Program Mol Med, Guggenheim 18,200 1st St SW, Rochester, MN 55905 USA.	emp@mayo.edu						Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004; Hautbergue G, 2001, J BIOL CHEM, V276, P8005, DOI 10.1074/jbc.M010162200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirai I, 2004, ONCOGENE, V23, P5124, DOI 10.1038/sj.onc.1207658; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nguyen KL, 2004, VIROLOGY, V319, P163, DOI 10.1016/j.virol.2003.11.021; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Sharma P, 2000, BIOCHEM BIOPH RES CO, V276, P1320, DOI 10.1006/bbrc.2000.3606; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	48	131	138	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55570	55577		10.1074/jbc.M408508200	http://dx.doi.org/10.1074/jbc.M408508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475359	hybrid			2022-12-25	WOS:000225960800074
J	Luo, Q; Kang, Q; Si, WK; Jiang, W; Park, JK; Peng, Y; Li, XM; Luu, HH; Luo, J; Montag, AG; Haydon, RC; He, TC				Luo, Q; Kang, Q; Si, WK; Jiang, W; Park, JK; Peng, Y; Li, XM; Luu, HH; Luo, J; Montag, AG; Haydon, RC; He, TC			Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; RECEPTOR-RELATED PROTEIN-5; BETA-CATENIN; TGF-BETA; BOYDEN CHAMBER; CCN FAMILY; CYCLIN D1; GENE; EXPRESSION; BMP	Osteoblast lineage-specific differentiation of mesenchymal stem cells is a well regulated but poorly understood process. Both bone morphogenetic proteins (BMPs) and Wnt signaling are implicated in regulating osteoblast differentiation and bone formation. Here we analyzed the expression profiles of mesenchymal stem cells stimulated with Wnt3A and osteogenic BMPs, and we identified connective tissue growth factor (CTGF) as a potential target of Wnt and BMP signaling. We confirmed the microarray results, and we demonstrated that CTGF was up-regulated at the early stage of BMP-9 and Wnt3A stimulations and that Wnt3A-regulated CTGF expression was beta-catenin-dependent. RNA interference-mediated knockdown of CTGF expression significantly diminished BMP-9-induced, but not Wnt3A-induced, osteogenic differentiation, suggesting that Wnt3A may also regulate osteoblast differentiation in a CTGF-independent fashion. However, constitutive expression of CTGF was shown to inhibit both BMP-9- and Wnt3A-induced osteogenic differentiation. Exogenous expression of CTGF was shown to promote cell migration and recruitment of mesenchymal stem cells. Our findings demonstrate that CTGF is up-regulated by Wnt3A and BMP-9 at the early stage of osteogenic differentiation, which may regulate the proliferation and recruitment of osteoprogenitor cells; however, CTGF is down-regulated as the differentiation potential of committed pre-osteoblasts increases, strongly suggesting that tight regulation of CTGF expression may be essential for normal osteoblast differentiation of mesenchymal stem cells.	Univ Chicago, Med Ctr, Dept Surg, Oncol Mol Lab, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China; Third Mil Med Univ, Dept Clin Biochem, Chongqing 400038, Peoples R China; Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Surg, Seoul, South Korea; Univ Chicago Hosp, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Funct Genom Facil, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Army Medical University; Catholic University of Korea; University of Chicago; University of Illinois System; University of Chicago; University of Chicago	He, TC (corresponding author), Univ Chicago, Med Ctr, Dept Surg, Oncol Mol Lab, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	tche@surgery.bsd.uchicago.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR050142] Funding Source: NIH RePORTER; NCCIH NIH HHS [F05 AT 002014-01] Funding Source: Medline; NIAMS NIH HHS [1K08 AR 50142-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Bergwitz C, 2001, BBA-MOL CELL RES, V1538, P129, DOI 10.1016/S0167-4889(00)00123-3; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Bloomfield KL, 2001, BIOTECHNIQUES, V31, P1242, DOI 10.2144/01316bm02; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capdevila J, 2001, ANNU REV CELL DEV BI, V17, P87, DOI 10.1146/annurev.cellbio.17.1.87; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Christian JL, 2000, CURR OPIN CELL BIOL, V12, P244, DOI 10.1016/S0955-0674(99)00082-4; Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Haider AS, 2003, CYTOM PART A, V53A, P1, DOI 10.1002/cyto.a.10032; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kingsley D M, 2001, Novartis Found Symp, V232, P213; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lam S, 2003, DIABETES, V52, P2975, DOI 10.2337/diabetes.52.12.2975; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V234, P206, DOI 10.1006/bbrc.1997.6528; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; URIST MR, 1987, CLIN ORTHOP RELAT R, P295; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu LF, 2000, GENE DEV, V14, P585; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	74	259	273	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55958	55968		10.1074/jbc.M407810200	http://dx.doi.org/10.1074/jbc.M407810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496414	hybrid			2022-12-25	WOS:000225960800119
J	Gomez, E; Powell, ML; Greenman, IC; Herbert, TP				Gomez, E; Powell, ML; Greenman, IC; Herbert, TP			Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP center dot Met-tRNAi) and the dephosphorylation of eIF2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; INSULIN-BIOSYNTHESIS; MESSENGER-RNA; PHAS-I; PROINSULIN BIOSYNTHESIS; MAMMALIAN TRANSLATION; REGULATED KINASE; GENE-EXPRESSION; AMINO-ACIDS; INITIATION	In pancreatic beta-cells, glucose causes a rapid increase in the rate of protein synthesis. However, the mechanism by which this occurs is poorly understood. In this report, we demonstrate, in the pancreatic beta-cell line MIN6, that glucose stimulates the recruitment of ribosomes onto the mRNA, indicative of an increase in the rate of the initiation step of protein synthesis. This increase in the rate of initiation is not mediated through an increase in the availability of the initiation complex eIF4F, because glucose is unable to stimulate eIF4F assembly or, in the absence of amino acids, modulate the phosphorylation status of 4E-BP1. Moreover, in MIN6 cells and isolated islets of Langerhans, rapamycin, an inhibitor of the mammalian target of rapamycin, only partially inhibited glucose-stimulated protein synthesis. However, we show that glucose stimulates the dephosphorylation of eIF2alpha in MIN6 cells and the assembly of the translational ternary complex, eIF2-GTP.Met-tRNAi, in both MIN6 cells and islets of Langerhans. The changes in the phosphorylation of eIF2alpha are not mediated by the PKR-like endoplasmic reticulum eIF2alpha kinase (PERK), because PERK is not phosphorylated at low glucose concentrations and overexpression of a dominant negative form of PERK has no significant effect on either glucose-stimulated protein synthesis or the phosphorylation of eIF2alpha. Taken together, these results indicate that glucose-stimulated protein synthesis in pancreatic beta-cells is regulated by a mechanism largely independent of the activity of mammalian target of rapamycin, but which is likely to be dependent on the availability of the translational ternary complex, regulated by the phosphorylation status of eIF2alpha.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Herbert, TP (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	tph4@le.ac.uk		Herbert, Terence/0000-0001-5402-0814				ALARCON C, 1993, J BIOL CHEM, V268, P4276; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHEN JJ, 1994, BIOCHIMIE, V76, P761, DOI 10.1016/0300-9084(94)90080-9; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; ITOH N, 1978, FEBS LETT, V93, P343, DOI 10.1016/0014-5793(78)81136-3; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jefferson LS, 2003, J NUTR, V133, p2046S, DOI 10.1093/jn/133.6.2046S; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; MARTIN SK, 1994, FEBS LETT, V356, P279, DOI 10.1016/0014-5793(94)01284-9; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Sood R, 2000, GENETICS, V154, P787; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Tokunaga C, 2004, BIOCHEM BIOPH RES CO, V313, P443, DOI 10.1016/j.bbrc.2003.07.019; WANG SY, 1988, ENDOCRINOLOGY, V123, P1008, DOI 10.1210/endo-123-2-1008; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH N, 1987, BIOCHEM J, V246, P245, DOI 10.1042/bj2460245; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yan LM, 2003, J BIOL CHEM, V278, P18177, DOI 10.1074/jbc.M301116200; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002	57	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53937	53946		10.1074/jbc.M408682200	http://dx.doi.org/10.1074/jbc.M408682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475356	hybrid, Green Accepted			2022-12-25	WOS:000225793600007
J	Khyrul, WAKM; LaLonde, DP; Brown, MC; Levinson, H; Turner, CE				Khyrul, WAKM; LaLonde, DP; Brown, MC; Levinson, H; Turner, CE			The integrin-linked kinase regulates cell morphology and motility in a Rho-associated kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PHOSPHATASE TARGET SUBUNIT; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; C-SRC; PAXILLIN; ILK; PHOSPHORYLATION	The integrin-linked kinase ( ILK) is a multidomain focal adhesion protein implicated in signal transmission from integrin and growth factor receptors. We have determined that ILK regulates U2OS osteosarcoma cell spreading and motility in a manner requiring both kinase activity and localization. Overexpression of wildtype (WT) ILK resulted in suppression of cell spreading, polarization, and motility to fibronectin. Cell lines over-expressing kinase-dead (S343A) or paxillin binding site mutant ILK proteins display inhibited haptotaxis to fibronectin. Conversely, spreading and motility was potentiated in cells expressing the "dominant negative," non-targeting, kinase-deficient E359K ILK protein. Suppression of cell spreading and motility of WT ILK U2OS cells could be rescued by treatment with the Rho-associated kinase ( ROCK) inhibitor Y-27632 or introduction of dominant negative ROCK or RhoA, suggesting these cells have increased RhoA signaling. Activation of focal adhesion kinase (FAK), a negative regulator of RhoA, was reduced in WT ILK cells, whereas overexpression of FAK rescued the observed defects in spreading and cell polarity. Thus, ILK-dependent effects on ROCK and/or RhoA signaling may be mediated through FAK.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA; Brookdale Univ Hosp, Dept Surg, Brooklyn, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	Turnerce@upstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kiss E, 2002, BIOCHEM J, V365, P79, DOI 10.1042/BJ20011295; Labouesse M, 2003, CURR BIOL, V13, pR528, DOI 10.1016/S0960-9822(03)00448-2; Li FG, 1999, J CELL SCI, V112, P4589; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Medley QG, 2003, J BIOL CHEM, V278, P13265, DOI 10.1074/jbc.M300277200; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 2000, J CELL SCI, V113, P3673; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 1999, J CELL SCI, V112, P1655; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200	60	50	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54131	54139		10.1074/jbc.M410051200	http://dx.doi.org/10.1074/jbc.M410051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485819				2022-12-25	WOS:000225793600032
J	Tie, JK; Jin, DY; Loiselle, DR; Pope, RM; Straight, DL; Stafford, DW				Tie, JK; Jin, DY; Loiselle, DR; Pope, RM; Straight, DL; Stafford, DW			Chemical modification of cysteine residues is a misleading indicator of their status as active site residues in the vitamin K-dependent gamma-glutamyl carboxylation reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PROPEPTIDE; PROTEINS; ENZYME; IDENTIFICATION; COAGULATION; EPOXIDATION; MEGAPRIMER; BINDING; SYSTEM	The enzymatic activity of the vitamin K-dependent proteins requires the post-translational conversion of specific glutamic acids to gamma-carboxy-glutamic acid by the integral membrane enzyme, gamma-glutamyl carboxylase. Whether or not cysteine residues are important for carboxylase activity has been the subject of a number of studies. In the present study we used carboxylase with point mutations at cysteines, chemical modification, and mass spectrometry to examine this question. Mutation of any of the free cysteine residues to alanine or serine had little effect on carboxylase activity, although C343A mutant carboxylase had only 38% activity compared with that of wild type. In contrast, treatment with either thiol-reactive reagent 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, disodium salt, or sodium tetrathionate, caused complete loss of activity. We identified the residues modified, using matrix-assisted laser desorption/ionization time of flight mass spectrometry, as Cys(323) and Cys(343). According to our results, these residues are on the cytoplasmic side of the microsomal membrane, whereas catalytic residues are expected to be on the lumenal side of the membrane. Carboxylase was partially protected from chemical modification by factor IXs propeptide. Although all mutant carboxylases bound propeptide with normal affinity, chemical modification caused a >100-fold decrease in carboxylase affinity for the consensus propeptide. We conclude that cysteine residues are not directly involved in carboxylase catalysis, but chemical modification of Cys(323) and Cys(343) may disrupt the three-dimensional structure, resulting in inactivation.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Invitrogen Corp, Res & Dev, Carlsbad, CA 92008 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Thermo Fisher Scientific	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	dws@email.unc.edu		Tie, Jian-Ke/0000-0002-8447-3408	NHLBI NIH HHS [HL78318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R13HL078318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouchard BA, 1999, BIOCHEMISTRY-US, V38, P9517, DOI 10.1021/bi9907375; Bristol JA, 1996, BLOOD, V88, P2585, DOI 10.1182/blood.V88.7.2585.bloodjournal8872585; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CANFIELD LM, 1980, ARCH BIOCHEM BIOPHYS, V202, P515, DOI 10.1016/0003-9861(80)90457-9; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; FRIEDMAN PA, 1976, BIOCHEM BIOPH RES CO, V70, P647, DOI 10.1016/0006-291X(76)91096-2; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P148; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kuster B, 1999, ANAL CHEM, V71, P1431, DOI 10.1021/ac981012u; LIU TY, 1967, J BIOL CHEM, V242, P4029; MACK DO, 1976, J BIOL CHEM, V251, P3269; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Rishavy MA, 2004, P NATL ACAD SCI USA, V101, P13732, DOI 10.1073/pnas.0404989101; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1979, BIOCHEM BIOPH RES CO, V86, P500, DOI 10.1016/0006-291X(79)91742-X; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Tie JK, 2003, J BIOL CHEM, V278, P45468, DOI 10.1074/jbc.M309164200; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WALLIN R, 1982, ARCH BIOCHEM BIOPHYS, V214, P155, DOI 10.1016/0003-9861(82)90017-0; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718	29	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54079	54087		10.1074/jbc.M408945200	http://dx.doi.org/10.1074/jbc.M408945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492002	hybrid			2022-12-25	WOS:000225793600025
J	Westmeyer, GG; Willem, M; Lichtenthaler, SF; Lurman, G; Multhaup, G; Assafalg-Machleidt, I; Reiss, K; Saftig, P; Haass, C				Westmeyer, GG; Willem, M; Lichtenthaler, SF; Lurman, G; Multhaup, G; Assafalg-Machleidt, I; Reiss, K; Saftig, P; Haass, C			Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SECRETASE CLEAVAGE; BIOCHEMICAL-PROPERTIES; PEPTIDE PRODUCTION; ASPARTYL PROTEASE; KNOCKOUT MICE; PRO-DOMAIN; BACE; EXPRESSION; RECOMBINANT	Cleavage of the beta-amyloid precursor protein (APP) by the aspartyl protease beta-site APP-cleaving enzyme ( BACE) is the first step in the generation of the amyloid beta-peptide, which is deposited in the brain of Alzheimer's disease patients. Whereas the subsequent cleavage by gamma-secretase was shown to originate from the cooperation of a multicomponent complex, it is currently unknown whether in a cellular environment BACE is enzymatically active as a monomer or in concert with other proteins. Using blue native gel electrophoresis we found that endogenous and overexpressed BACE has a molecular mass of 140 kDa instead of the expected mass of 70 kDa under denaturing conditions. This suggests that under native conditions BACE exists as a homodimer. Homodimerization was confirmed by co-immunoprecipitation of full-length BACE carrying different epitope tags. In contrast, the soluble active BACE ectodomain was exclusively present as a monomer both under native and denaturing conditions. A domain analysis revealed that the BACE ectodomain dimerized as long as it was attached to the membrane, whereas the cytoplasmic domain and the transmembrane domain were dispensable for dimerization. By adding a KKXX-endoplasmic reticulum retention signal to BACE, we demonstrate that dimerization of BACE occurs already before full maturation and pro-peptide cleavage. Furthermore, kinetic analysis of the purified native BACE dimer revealed a higher affinity and turnover rate in comparison to the monomeric soluble BACE. Dimerization of BACE might, thus, facilitate binding and cleavage of physiological substrates.	Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany	University of Munich; Free University of Berlin; University of Kiel	Willem, M (corresponding author), Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	mwillem@med.uni-muenchen.de; chaass@med.uni-muenchen.de	Saftig, Paul/A-7966-2010; Reiss, Karina/B-3175-2010; Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575; Westmeyer, Gil Gregor/0000-0001-7224-8919				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bowman MJ, 2002, BIOPOLYMERS, V66, P126, DOI 10.1002/bip.10232; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Dunn BM, 2002, CHEM REV, V102, P4431, DOI 10.1021/cr010167q; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803; Gorelick FS, 2001, MOL CELL ENDOCRINOL, V177, P13, DOI 10.1016/S0303-7207(01)00438-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong HS, 2003, BIOCHEM BIOPH RES CO, V307, P922, DOI 10.1016/S0006-291X(03)01270-1; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hong L, 2002, BIOCHEMISTRY-US, V41, P10963, DOI 10.1021/bi026232n; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Kopcho LM, 2003, ARCH BIOCHEM BIOPHYS, V410, P307, DOI 10.1016/S0003-9861(02)00690-2; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; Marcinkeviciene J, 2001, J BIOL CHEM, V276, P23790, DOI 10.1074/jbc.M101896200; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shi XP, 2003, J BIOL CHEM, V278, P21286, DOI 10.1074/jbc.M209859200; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Shultz MD, 2000, ANGEW CHEM INT EDIT, V39, P2710, DOI 10.1002/1521-3773(20000804)39:15<2710::AID-ANIE2710>3.0.CO;2-P; Sidera C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-25; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Toulokhonova L, 2003, J BIOL CHEM, V278, P4582, DOI 10.1074/jbc.M210471200; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TSUKUBA T, 1995, ADV EXP MED BIOL, V362, P331; Tsukuba T, 1996, J BIOCHEM, V119, P126; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3	67	97	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53205	53212		10.1074/jbc.M410378200	http://dx.doi.org/10.1074/jbc.M410378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485862	hybrid			2022-12-25	WOS:000225680600050
J	Zhao, GJ; Mao, GZ; Tan, JX; Dong, YZ; Cui, MZ; Kim, SH; Xu, XM				Zhao, GJ; Mao, GZ; Tan, JX; Dong, YZ; Cui, MZ; Kim, SH; Xu, XM			Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; NOTCH; APP; PEPTIDES; MUTATION	gamma-Secretase cleavage of beta-amyloid precursor protein (APP) is crucial in the pathogenesis of Alzheimer disease, because it is the decisive step in the formation of the C terminus of beta-amyloid protein (Abeta). To better understand the molecular events involved in gamma-secretase cleavage of APP, in this study we report the identification of a new intracellular long Abeta species containing residues 1 - 46 (Abeta(46)), which led to the identification of a novel zeta-cleavage site between the known gamma- and epsilon-cleavage sites within the transmembrane domain of APP. Our data clearly demonstrate that the new zeta-cleavage is a presenilin-dependent event. It is also noted that the new zeta-cleavage site at Abeta46 is the APP717 mutation site. Furthermore, we show that the new zeta-cleavage is inhibited by gamma-secretase inhibitors known as transition state analogs but less affected by inhibitors known as non-transition state gamma-secretase inhibitors. Thus, the identification of Abeta(46) establishes a system to determine the specificity or the preference of the known gamma-secretase inhibitors by examining their effects on the formation or turnover of Abeta(46).	Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Chicago	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, 2407 River Dr, Knoxville, TN 37996 USA.	xmx@utk.edu		Cui, Mei-Zhen/0000-0003-4745-6999; xu, xuemin/0000-0002-7426-272X	NINDS NIH HHS [NS42314] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Kuo YM, 2000, AM J PATHOL, V156, P797, DOI 10.1016/S0002-9440(10)64947-4; Roher AE, 2004, J BIOL CHEM, V279, P5829, DOI 10.1074/jbc.M311380200; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	20	132	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50647	50650		10.1074/jbc.C400473200	http://dx.doi.org/10.1074/jbc.C400473200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485850	hybrid			2022-12-25	WOS:000225355800003
J	Ventura, C; Maioli, M; Asara, Y; Santoni, D; Mesirca, P; Remondini, D; Bersani, F				Ventura, C; Maioli, M; Asara, Y; Santoni, D; Mesirca, P; Remondini, D; Bersani, F			Turning on stem cell cardiogenesis with extremely low frequency magnetic fields	FASEB JOURNAL			English	Article						gene expression; cardiac differentiation	PEPTIDE GENE-EXPRESSION; PROTEIN-KINASE-C; ELECTROMAGNETIC-FIELDS; TRANSCRIPTION; LYMPHOCYTES; MYOCYTES; CA2+; RAT	Modulation of stem cell differentiation is an important assignment for cellular engineering. Embryonic stem (ES) cells can differentiate into cardiomyocytes, but the efficiency is typically low. Here, we show that exposure of mouse ES cells to extremely low frequency magnetic fields triggered the expression of GATA-4 and Nkx-2.5, acting as cardiac lineage-promoting genes in different animal species, including humans. Magnetic fields also enhanced prodynorphin gene expression, and the synthesis and secretion of dynorphin B, an endorphin playing a major role in cardiogenesis. These effects occurred at the transcriptional level and ultimately ensued into a remarkable increase in the yield of ES-derived cardiomyocytes. These results demonstrate the potential use of magnetic fields for modifying the gene program of cardiac differentiation in ES cells without the aid of gene transfer technologies and may pave the way for novel approaches in tissue engineering and cell therapy.	Univ Bologna, S Orsola M Malpighi Hosp, Lab Mol Biol & Stem Cell Engn, Natl Inst Biostruct & Biosyst,Inst Cardiol, I-40138 Bologna, Italy; Univ Bologna, Dept Phys, ICEmB, I-40138 Bologna, Italy; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Sassari	Ventura, C (corresponding author), Univ Bologna, S Orsola M Malpighi Hosp, Lab Mol Biol & Stem Cell Engn, Natl Inst Biostruct & Biosyst,Inst Cardiol, Pavil 21,Via Massarenti N 9, I-40138 Bologna, Italy.	cvent@libero.it	Mesirca, Pietro/X-4999-2019; Remondini, Daniel/ABA-9971-2020	Remondini, Daniel/0000-0003-3185-7456; Mesirca, Pietro/0000-0002-9538-3096; MAIOLI, Margherita/0000-0003-0187-4968				Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; CADOSSI R, 1992, FASEB J, V6, P2667, DOI 10.1096/fasebj.6.9.1612290; COSSARIZZA A, 1989, BIOCHEM BIOPH RES CO, V160, P692, DOI 10.1016/0006-291X(89)92488-1; COSSARIZZA A, 1993, EXP CELL RES, V204, P385, DOI 10.1006/excr.1993.1048; LAI H, 1993, BIOELECTROMAGNETICS, V14, P5, DOI 10.1002/bem.2250140104; LINTS TJ, 1993, DEVELOPMENT, V119, P419; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Thomas AW, 1997, PEPTIDES, V18, P703, DOI 10.1016/S0196-9781(97)00004-1; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; Ventura C, 2000, CARDIOVASC RES, V45, P1054, DOI 10.1016/S0008-6363(99)00408-3; Ventura C, 2003, CIRC RES, V92, P623, DOI 10.1161/01.RES.0000065169.23780.0E; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; Vorobyov VV, 1998, BRAIN RES, V781, P182, DOI 10.1016/S0006-8993(97)01228-6	18	68	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					155	+		10.1096/fj.04-2695fje	http://dx.doi.org/10.1096/fj.04-2695fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507470				2022-12-25	WOS:000224849900005
J	Qian, Y; Liu, KJ; Chen, Y; Flynn, DC; Castranova, V; Shi, XL				Qian, Y; Liu, KJ; Chen, Y; Flynn, DC; Castranova, V; Shi, XL			Cdc42 regulates arsenic-induced NADPH oxidase activation and cell migration through actin filament reorganizatlion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; IN-VITRO; P47(PHOX); TRANSLOCATION; LOCALIZATION; CYTOSKELETON; MECHANISM; INTEGRITY; AFAP-110; DYNAMICS	Although arsenic is a human carcinogen, the molecular mechanisms of its action remain to be understood. The present study reports that exposure to arsenic induced actin filament reorganization, resulting in lamel-lipodia and filopodia structures through the activation of Cdc42 in SVEC4-10 endothelial cells. It was also found that arsenic induced the formation of the superoxide anion (O-2(.-)) in SVEC4-10 cells. Immunoprecipitation and Western blotting analysis demonstrated that arsenic stimulation induced serine phosphorylation of p47(phox) a key component of NADPH oxidase, indicating that arsenic induces O-2(.-) formation through NADPH oxidase activation. Inhibition of arsenic-induced actin filament reorganization by either overexpression of a dominant negative Cdc42 or pretreatment of an actin filament stabilizing regent, jasplakinolide, abrogated arsenic-induced NADPH oxidase activation, showing that the activation of NADPH oxidase was regulated by Cdc42-mediated actin filament reorganization. This study also showed that overexpression of a dominant negative Rac1 was sufficient to abolish arsenic-induced O-2(.-) production, implying that Rac1 activities area required for Cdc42-mediated NADPH oxidase activation in response to arsenic stimulation. Furthermore, arsenic stimulation induced cell migration, which can be inhibited by the inactivation of either Cdc42 or NADPH oxidase. Taken together, the results indicate that arsenic is able to activate NADPH oxidase through Cdc42-mediated actin filament reorganization, leading to the induction of an increase in cell migration in SVEC4-10 endothelial cells.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; W Virginia Univ, Sch Med, Ctr Canc, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of New Mexico; Indiana University System; Indiana University-Purdue University Indianapolis; West Virginia University; West Virginia University	Qian, Y (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA.	YAQ2@CDC.GOV	Shi, Xianglin/B-8588-2012		NCI NIH HHS [CA060731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Barchowsky A, 1999, FREE RADICAL BIO MED, V27, P1405, DOI 10.1016/S0891-5849(99)00186-0; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Brown MD, 2000, J NEUROBIOL, V43, P352, DOI 10.1002/1097-4695(20000615)43:4<352::AID-NEU4>3.0.CO;2-T; Chou I N, 1989, Biomed Environ Sci, V2, P358; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Corsini E, 1999, J INVEST DERMATOL, V113, P760, DOI 10.1046/j.1523-1747.1999.00748.x; Cramer, 1997, FRONT BIOSCI, V2, pd260, DOI DOI 10.2741/A189; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Faisal A, 2004, J BIOL CHEM, V279, P3202, DOI 10.1074/jbc.M310010200; Fenteany G, 2003, CURR TOP MED CHEM, V3, P593, DOI 10.2174/1568026033452348; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li JM, 2003, J BIOL CHEM, V278, P12094, DOI 10.1074/jbc.M209793200; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; LI WD, 1992, TOXICOL APPL PHARM, V114, P132, DOI 10.1016/0041-008X(92)90105-2; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Ochi T, 1998, ARCH TOXICOL, V72, P566, DOI 10.1007/s002040050544; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2003, J INORG BIOCHEM, V96, P271, DOI 10.1016/S0162-0134(03)00235-6; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Smith KR, 2001, AM J PHYSIOL-LUNG C, V280, pL442, DOI 10.1152/ajplung.2001.280.3.L442; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zhao QQ, 1998, TOXICOL APPL PHARM, V149, P99, DOI 10.1006/taap.1997.8352; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	44	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3875	3884		10.1074/jbc.M403788200	http://dx.doi.org/10.1074/jbc.M403788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15492012	hybrid, Green Submitted			2022-12-25	WOS:000226983900090
J	Li, GT; Yan, Q; Nita-Lazar, A; Haltiwanger, RS; Lennarz, WJ				Li, GT; Yan, Q; Nita-Lazar, A; Haltiwanger, RS; Lennarz, WJ			Studies on the N-glycosylation of the subunits of oligosaccharyl transferase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NASCENT CHAINS; COMPLEX; PROTEIN; GLYCANS; DOMAIN; BIOSYNTHESIS; OVALBUMIN; MEMBRANE; YEAST	In Saccharomyces cerevisiae, oligosaccharyl transferase (OT) consists of nine different subunits. Three of the essential gene products, Ost1p, Wbp1p, and Stt3p, are N-linked glycoproteins. To study the function of the N-glycosylation of these proteins, we prepared single or multiple N-glycosylation site mutations in each of them. We established that the four potential N-glycosylation sites in Ost1p and the two potential N-glycosylation sites in Wbp1p were occupied in the mature proteins. Interestingly, none of the N-glycosylation sites in these two proteins was conserved, and no defect in growth or OT activity was observed when the N-glycosylation sites were mutated to block N-glycosylation in either subunit. However, in the third glycosylated subunit, Stt3p, there are two adjacent potential N-glycosylation sites ((NNTWNNT)-N-535-N-539) that, in contrast to the other subunits, are highly conserved in eukaryotic organisms. Mass spectrometric analysis of a tryptic digest of Stt3p showed that the peptide containing the two adjacent N-glycosylation sites was N-glycosylated at one site. Furthermore, the glycan chain identified as Man(8)GlcNAc(2) is found linked only to Asn(539). Mutation experiments were carried out at these two sites. Four single amino acid mutations blocking either N-glycosylation site ( N535Q, T537A, N539Q, and T541A) resulted in strains that were either lethal or extremely temperature sensitive. However, other mutations in the two N-glycosylation sites (NNTWNNT)-N-535-N-539 (N536Q, T537S, N540Q, and T541S), did not exhibit growth defects. Based on these studies, we conclude that N-glycosylation of Stt3p at Asn(539) is essential for its function in the OT complex.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X	NIGMS NIH HHS [GM61126, GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185, R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chavan M, 2003, P NATL ACAD SCI USA, V100, P15381, DOI 10.1073/pnas.2536561100; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; GLABE CG, 1980, J BIOL CHEM, V255, P9236; Jitsuhara Y, 2002, J BIOCHEM, V132, P803, DOI 10.1093/oxfordjournals.jbchem.a003290; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; Li GT, 2003, BIOCHEMISTRY-US, V42, P11032, DOI 10.1021/bi034832w; Mitra N, 2003, BIOCHEMISTRY-US, V42, P12208, DOI 10.1021/bi035169e; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Nishimura I, 1998, J BIOCHEM, V123, P516; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Yan AX, 2003, J BIOL CHEM, V278, P33078, DOI 10.1074/jbc.M305337200; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Yan Q, 2002, P NATL ACAD SCI USA, V99, P15994, DOI 10.1073/pnas.212637999	20	25	25	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1864	1871		10.1074/jbc.M410969200	http://dx.doi.org/10.1074/jbc.M410969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15507441	hybrid			2022-12-25	WOS:000226341700020
J	Yaworsky, DC; Baker, BY; Bose, HS; Best, KB; Jensen, LB; Bell, JD; Baldwin, MA; Miller, WL				Yaworsky, DC; Baker, BY; Bose, HS; Best, KB; Jensen, LB; Bell, JD; Baldwin, MA; Miller, WL			pH-dependent interactions of the carboxyl-terminal helix of steroidogenic acute regulatory protein with synthetic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; CIRCULAR-DICHROISM SPECTROSCOPY; MOLTEN-GLOBULE; MITOCHONDRIAL PROTEIN; STAR; CHOLESTEROL; MECHANISM; VESICLES; BINDING; DOMAIN	Steroidogenic acute regulatory ( StAR) protein facilitates import of cholesterol into adrenal and gonadal mitochondria where cholesterol is converted to pregnenolone, initiating steroidogenesis. StAR acts exclusively on the outer mitochondrial membrane (OMM) by unknown mechanisms. To identify StAR domains involved in membrane association, we reacted N-62 StAR with small unilamellar vesicles (SUVs) composed of lipids resembling the OMM. Solvent-exposed domains were digested with trypsin, Asp-N, or pepsin at different pH levels, and StAR peptides protected from proteolysis were identified by mass spectrometry. At pH 4 SUVs completely protected residues 259-282; at pH 6.5 this region was partially digested into 254-272, 254-273, and 254-274. Computer-graphic modeling of N-62 StAR indicated these peptides correspond to the C-terminal alpha4 helix and that residues Leu(275), Thr(263), and Arg(272) in alpha4 form stabilizing interactions with Gln(128), Asp(150), and Asp(106) in adjacent loops. CD spectroscopy of a 37-mer model of alpha4 (residues 247-287) indicated a random coil in aqueous buffer, but in 40% methanol the peptide was alpha-helical and achieved maximal alpha-helicity at pH 5.0 in the presence of SUVs. Reacting the 37-mer with diethyl pyrocarbamate incorporated into SUVs increased the number of modified residues. Thus the C-terminal alpha4 helix is critically involved in the membrane association of StAR with OMM lipids. The membrane association and the alpha-helical structure of the C terminus in the presence of OMM lipids are also pH-dependent. These results further support StAR undergoing a pH-dependent change in its conformation when interacting with the acidic phospholipid head groups of a membrane.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA; Brigham Young Univ, Dept Physiol & Dev Biol, Provo, UT 84602 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Brigham Young University	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR 4,Rm 205,Box 0978, San Francisco, CA 94143 USA.	wlmlab@itsa.ucsf.edu	Miller, Walter L/J-3696-2012; Baker, Bo/C-1466-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, T32DK007161, K01DK002762] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01614] Funding Source: Medline; NIDDK NIH HHS [DK37922, KO1 DK02762, DK07161] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; Mills RL, 2003, J PLASMA PHYS, V69, P131, DOI 10.1017/S0022377803002113; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Safarian S, 2003, J PROTEIN CHEM, V22, P643, DOI 10.1023/B:JOPC.0000008729.20730.59; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUBBARAO NK, 1991, BIOCHIM BIOPHYS ACTA, V1063, P147, DOI 10.1016/0005-2736(91)90364-E; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	28	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2045	2054		10.1074/jbc.M410937200	http://dx.doi.org/10.1074/jbc.M410937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15489236	hybrid			2022-12-25	WOS:000226341700039
J	Nelsen, CJ; Kuriyama, R; Hirsch, B; Negron, VC; Lingle, WL; Goggin, MM; Stanley, MW; Albrecht, JH				Nelsen, CJ; Kuriyama, R; Hirsch, B; Negron, VC; Lingle, WL; Goggin, MM; Stanley, MW; Albrecht, JH			Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; HEPATOCYTE PROLIFERATION; LIVER-REGENERATION; BREAST-CANCER; MAMMALIAN-CELLS; EXPRESSION; PROGRESSION; INSTABILITY; GROWTH	In normal cells, cyclin D1 is induced by growth factors and promotes progression through the G(1) phase of the cell cycle. Cyclin D1 is also an oncogene that is thought to act primarily by bypassing the requirement for mitogens during the G(1) phase. Studies of clinical tumors have found that cyclin D1 overexpression is associated with chromosome abnormalities, although a causal effect has not been established in experimental systems. In this study, we found that transient expression of cyclin D1 in normal hepatocytes in vivo triggered dysplastic mitoses, accumulation of supernumerary centrosomes, abnormalities of the mitotic spindle, and marked chromosome changes within several days. This was associated with up-regulation of checkpoint genes p53 and p21 as well as hepatocyte apoptosis in the liver. Transient transfection of cyclin D1 also induced centrosome and mitotic spindle abnormalities in breast epithelial cells, suggesting that this may be a generalized effect. These results indicate that cyclin D1 can induce deregulation of the mitotic apparatus and aneuploidy, effects that could contribute to the role of this oncogene in malignancy.	Hennepin Cty Med Ctr, Div Gastroenterol G5, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Univ Minnesota Canc Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Mayo Clin, Div Expt Pathol, Tumor Biol Program, Rochester, MN 55905 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA	Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Hennepin County Medical Center	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr, Div Gastroenterol G5, 701 Pk Ave, Minneapolis, MN 55415 USA.	albre010@tc.umn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Bartek J, 2001, NATURE, V411, P1001, DOI 10.1038/35082655; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Collecchi P, 2000, CYTOMETRY, V42, P254; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Deane NG, 2001, CANCER RES, V61, P5389; Duesberg P, 2004, CELL CYCLE, V3, P823; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Grisham JW, 2004, GASTROINTESTINAL ONC, P471; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hansen LK, 1999, J CELL SCI, V112, P2971; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 2001, CURR BIOL, V11, pR698, DOI 10.1016/S0960-9822(01)00412-2; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ilan Y, 1999, SEMIN LIVER DIS, V19, P49, DOI 10.1055/s-2007-1007097; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kuriyama R, 2001, METHOD CELL BIOL, V67, P125; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Levy L, 2002, ANN NY ACAD SCI, V963, P21; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 2001, METHOD CELL BIOL, V67, P325; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Lung JCY, 2002, GENE CHROMOSOME CANC, V34, P276, DOI 10.1002/gcc.10072; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nelsen CJ, 2003, J BIOL CHEM, V278, P25853, DOI 10.1074/jbc.M302360200; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nelsen CJ, 2001, CANCER RES, V61, P8564; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohta T, 2002, J CELL BIOL, V156, P87, DOI 10.1083/jcb.200108088; Ott G, 1997, BLOOD, V89, P1421, DOI 10.1182/blood.V89.4.1421; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rennstam K, 2001, CANCER RES, V61, P1214; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sherr CJ, 2000, CANCER RES, V60, P3689; Shibata M, 1998, LANCET, V351, P1773, DOI 10.1016/S0140-6736(97)08002-1; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sutherland RL, 2002, BREAST CANCER RES, V4, P14, DOI 10.1186/bcr411; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; TARAO K, 1994, CANCER, V73, P1149, DOI 10.1002/1097-0142(19940215)73:4<1149::AID-CNCR2820730405>3.0.CO;2-9; TARAO K, 1992, GASTROENTEROLOGY, V103, P595, DOI 10.1016/0016-5085(92)90852-P; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Warner SL, 2003, MOL CANCER THER, V2, P589	53	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					768	776		10.1074/jbc.M407105200	http://dx.doi.org/10.1074/jbc.M407105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509582	hybrid			2022-12-25	WOS:000226025100090
J	Zaim, J; Speina, E; Kierzek, AM				Zaim, J; Speina, E; Kierzek, AM			Identification of new genes regulated by the Crt1 transcription factor, an effector of the DNA damage checkpoint pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; BINDING PROTEIN; YEAST; EXPRESSION; GENOME; REPLICATION; TREHALOSE; INHIBITION; REDUCTASE; REPAIR	The Crt1 (RFX1) protein in Saccharomyces cerevisiae is an effector of the DNA damage checkpoint pathway. It recognizes a 13-bp cis-regulatory element in the 5'-untranslated region (5'-UTR) of the ribonucleotide reductase genes RNR2, RNR3, and RNR4; the HUG1 gene; and itself. We calculated the weight matrix representing the Crt1p binding site motif according to analysis of the 5'-UTR sequences of the genes that are under its regulation. We subsequently searched the 5'-UTR sequences of all the genes in the yeast genome for the occurrence of this motif. The motif was found in regulatory regions of 30 genes. A statistical analysis showed that it is unlikely that a random gene cluster contains the motif conserved as well as the Crt1p binding site. Analysis of microarray data provided supporting evidence for five putative Crt1p targets: FSH3, YLR345W, UBC5, NDE2, and NTH2. We used reverse transcription-PCR to compare the expression levels of these genes in wild-type and crt1Delta strains. Our results indicated that FSH3, YLR345W, and NTH2 are indeed under the regulation of Crt1p. Sequence analysis of the FSH3p indicated that this protein may be involved in folate metabolism either by carrying serine hydrolase activity required for the novel metabolic pathway involving dihydrofolate reductase (DHFR) or by directly interacting with the DHFR enzyme. We postulate that Crt1p may influence deoxyribonucleotide synthesis not only by regulating expression of the RNR genes but also by modulating DHFR activity. FSH3p shares significant sequence similarity with the product of the human tumor suppressor gene OVCA2. YLR345Wp and NTH2p are enzymes involved in the central metabolism under stress conditions.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Kierzek, AM (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	andrzejk@ibb.waw.pl	Speina, Elzbieta/ABB-3371-2021	Elzbieta, Speina/0000-0002-0734-9390; Kierzek, Andrzej/0000-0002-2605-9057				BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Baxter SM, 2004, MOL CELL PROTEOMICS, V3, P209, DOI 10.1074/mcp.M300082-MCP200; BERTANI LE, 1994, GENE, V147, P131, DOI 10.1016/0378-1119(94)90052-3; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; DURBIN R, 1998, BIOL SEQUENCE ANAL P, P308; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jensen MR, 2004, GENE DEV, V18, P245, DOI 10.1101/gad.1184004; KITAMURA K, 1989, J BIOL CHEM, V264, P6344; Le Crom S, 2002, NUCLEIC ACIDS RES, V30, P76, DOI 10.1093/nar/30.1.76; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mercier G, 2001, MUTAT RES-DNA REPAIR, V487, P157, DOI 10.1016/S0921-8777(01)00116-1; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Schultz DC, 1996, CANCER RES, V56, P1997; Sebollela A, 2004, INT J BIOCHEM CELL B, V36, P900, DOI 10.1016/j.biocel.2003.10.006; STRYER L, 1995, BIOCHEMISTRY-US, P748; Voit EO, 2003, J THEOR BIOL, V223, P55, DOI 10.1016/S0022-5193(03)00072-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	32	41	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					28	37		10.1074/jbc.M404669200	http://dx.doi.org/10.1074/jbc.M404669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494396	hybrid			2022-12-25	WOS:000226025100005
J	Akhtar, MW; Srinivas, V; Raman, B; Ramakrishna, T; Inobe, T; Maki, K; Arai, M; Kuwajima, K; Rao, CM				Akhtar, MW; Srinivas, V; Raman, B; Ramakrishna, T; Inobe, T; Maki, K; Arai, M; Kuwajima, K; Rao, CM			Oligomeric Hsp33 with enhanced chaperone activity - Gel filtration, cross-linking, and small angle X-ray scattering (SAXS) analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; OXIDATIVE STRESS; BIOLOGICAL MACROMOLECULES; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ALPHA-CRYSTALLIN; REDOX SWITCH; ACTIVATION; RESOLUTION; MECHANISM	Hsp33, an Escherichia coli cytosolic chaperone, is inactive under normal conditions but becomes active upon oxidative stress. It was previously shown to dimerize upon activation in a concentration- and temperature-dependent manner. This dimer was thought to bind to aggregation-prone target proteins, preventing their aggregation. In the present study, we report small angle x-ray scattering (SAXS), steady state and time-resolved fluorescence, gel filtration, and glutaraldehyde cross-linking analysis of full-length Hsp33. Our circular dichroism and fluorescence results show that there are significant structural changes in oxidized Hsp33 at different temperatures. SAXS, gel filtration, and glutaraldehyde cross-linking results indicate, in addition to the dimers, the presence of oligomeric species. Oxidation in the presence of physiological salt concentration leads to significant increases in the oligomer population. Our results further show that under conditions that mimic the crowded milieu of the cytosol, oxidized Hsp33 exists predominantly as an oligomeric species. Interestingly, chaperone activity studies show that the oligomeric species is much more efficient compared with the dimers in preventing aggregation of target proteins. Taken together, these results indicate that in the cell, Hsp33 undergoes conformational and quaternary structural changes leading to the formation of oligomeric species in response to oxidative stress. Oligomeric Hsp33 thus might be physiologically relevant under oxidative stress.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Agcy, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Prot Design Res Grp, Tsukuba, Ibaraki 3058566, Japan	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.res.in	Arai, Munehito/A-1258-2012	Arai, Munehito/0000-0002-1223-2242; Tangirala, Ramakrishna/0000-0002-0738-329X; Inobe, Tomonao/0000-0002-5864-6889				AMEMIYA Y, 1983, NUCL INSTRUM METHODS, V208, P471, DOI 10.1016/0167-5087(83)91170-5; AMEMIYA Y, 1995, REV SCI INSTRUM, V66, P2290, DOI 10.1063/1.1145667; Arai M, 2002, J MOL BIOL, V321, P121, DOI 10.1016/S0022-2836(02)00566-1; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Graf PCF, 2004, J BIOL CHEM, V279, P20529, DOI 10.1074/jbc.M401764200; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lakshmikanth GS, 1999, BIOPHYS J, V77, P1100, DOI 10.1016/S0006-3495(99)76960-2; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Raman B, 2001, FEBS LETT, V489, P19, DOI 10.1016/S0014-5793(01)02074-9; Rao C. M., 2002, PINSA-A (Proceedings of the Indian National Science Academy) Part A (Physical Sciences), V68, P349; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	34	25	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55760	55769		10.1074/jbc.M406333200	http://dx.doi.org/10.1074/jbc.M406333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494414	hybrid			2022-12-25	WOS:000225960800098
J	Ikeda, K; Quertermous, T				Ikeda, K; Quertermous, T			Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCAM CD166; IN-VITRO; EXPRESSION; IDENTIFICATION; MELANOMA; CLONING; ATHEROSCLEROSIS; RECEPTORS; SELECTIN; ANTIGEN	Cell adhesion molecules regulate a variety of endothelial cell functions such as migration, response to inflammation, and angiogenesis. Recently, activated leukocyte cell adhesion molecule ( ALCAM), a member of the Ig superfamily, has been detected in the primitive subsets of hematopoietic cells and endothelial cells during embryogenesis. ALCAM supports the development of hematopoietic cells as well as enhancing capillary tube formation in vitro. Here, we isolated a novel soluble isoform of ALCAM (sALCAM) that is produced via alternative splicing. sALCAM contains the single amino-terminal Ig-like domain of ALCAM and lacks a transmembrane domain. When expressed in cultured cells, sALCAM was properly secreted into the media. Both ALCAM and sALCAM are expressed in a variety of cultured human endothelial cells. Notably, their transcripts were differentially regulated in human microvascular endothelial cells (HMVEC) upon tumor necrosis factor-alpha stimulation. ALCAM significantly enhanced tube formation of endothelial-like yolk sac cells on Matrigel, whereas it inhibited their migration in vitro. sALCAM completely abolished these effects of ALCAM. Furthermore, sALCAM enhanced migration of mock-transfected endothelial-like yolk sac cells that do not express ALCAM, indicating that sALCAM has an independent effect on cell migration in addition to modulating ALCAM function. In addition, sALCAM significantly enhanced migration of HMVEC, whereas it inhibited tube formation of HMVEC on Matrigel. sALCAM demonstrated an ability to bind ALCAM and partially inhibited ALCAM-ALCAM homophilic interactions. Taken together, these data characterize a novel soluble isoform of ALCAM that may have ALCAM-dependent and ALCAM-independent functions, providing further insights regarding the role of this adhesion molecule in the regulation of endothelial cell function.	Stanford Univ, Sch Med, Div Cardiovasc Med,Falk CVRC, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA	Stanford University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med,Falk CVRC, Donald W Reynolds Cardiovasc Clin Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.	tomq1@stanford.edu		Quertermous, Thomas/0000-0002-7645-9067; ikeda, Koji/0000-0002-9972-7255				Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Bowen MA, 1997, EUR J IMMUNOL, V27, P1469, DOI 10.1002/eji.1830270625; Bowen MA, 2000, PROTEINS, V40, P420; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x; DEBERNARDO AP, 1995, DEV BIOL, V169, P65, DOI 10.1006/dbio.1995.1127; DeBernardo AP, 1996, J CELL BIOL, V133, P657, DOI 10.1083/jcb.133.3.657; Degen WGJ, 1998, AM J PATHOL, V152, P805; Gho YS, 2001, CANCER RES, V61, P4253; Gho YS, 1999, CANCER RES, V59, P5128; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Ikeda K, 2003, J BIOL CHEM, V278, P3514, DOI 10.1074/jbc.M204563200; Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200; ISHIWATA N, 1994, J BIOL CHEM, V269, P23708; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Levesque MC, 1998, ARTHRITIS RHEUM, V41, P2221, DOI 10.1002/1529-0131(199812)41:12<2221::AID-ART18>3.0.CO;2-I; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Meager A, 1996, J IMMUNOL METHODS, V191, P97, DOI 10.1016/0022-1759(96)00005-1; Morbidelli L, 1997, LIFE SCI, V62, pPL7, DOI 10.1016/S0024-3205(97)01042-4; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; Ohneda O, 2001, BLOOD, V98, P2134, DOI 10.1182/blood.V98.7.2134; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; POURQUIE O, 1990, DEVELOPMENT, V109, P743; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHWARTZ CJ, 1985, ANN NY ACAD SCI, V454, P115, DOI 10.1111/j.1749-6632.1985.tb11849.x; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; van Kempen LCLT, 2001, J BIOL CHEM, V276, P25783, DOI 10.1074/jbc.M011272200; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7; Zimmerman AW, 2004, J CELL SCI, V117, P2841, DOI 10.1242/jcs.01139	36	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55315	55323		10.1074/jbc.M407776200	http://dx.doi.org/10.1074/jbc.M407776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496415	hybrid			2022-12-25	WOS:000225960800043
J	Kamath-Loeb, AS; Welcsh, P; Waite, M; Adman, ET; Loeb, LA				Kamath-Loeb, AS; Welcsh, P; Waite, M; Adman, ET; Loeb, LA			The enzymatic activities of the Werner syndrome protein are disabled by the amino acid polymorphism R834C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; NUCLEAR-LOCALIZATION; SYNDROME GENE; AGING PROCESS; MUTATIONS; SEQUENCE; EXONUCLEASE; PROGRAM; DENSITY; VARIANT	The Werner syndrome protein, WRN, is a member of the RecQ family of DNA helicases. It possesses both 3' -->5' DNA helicase and 3' -->5' DNA exonuclease activities. Mutations in WRN are causally associated with a rare, recessive disorder, Werner syndrome (WS), distinguished by premature aging and genomic instability; all are reported to result in loss of protein expression. In addition to WS-linked mutations, single nucleotide polymorphisms, with frequencies that exceed those of WS-associated mutations, are also present in WRN. We have initiated studies to determine if six of these polymorphisms affect the enzymatic activities of WRN. We show that two common polymorphisms, F1074L and C1367R, and two infrequent polymorphisms, Q724L and S1079L, exhibit little change in activity relative to wild-type WRN; the polymorphism, T172P, shows a small but consistent reduction of activity. However, an infrequent polymorphism, R834C, located in the helicase domain dramatically reduces WRN helicase and helicase-coupled exonuclease activity. The structure of the E. coli helicase core suggests that R834 may be involved in interactions with ATP. As predicted, substitution of Arg with Cys interferes with ATP hydrolysis that is absolutely required for unwinding DNA. R834C thus represents the first missense amino acid polymorphism in WRN that nearly abolishes enzymatic activity while leaving expression largely unaffected.	Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Box 357705,1959 NE Pacific St, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Hess, Maureen/E-9769-2013		NATIONAL CANCER INSTITUTE [P01CA077852] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77852] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Castro E, 2000, AM J MED GENET, V95, P374, DOI 10.1002/1096-8628(20001211)95:4<374::AID-AJMG14>3.3.CO;2-W; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Ogata N, 2001, J BONE MINER METAB, V19, P296, DOI 10.1007/s007740170013; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; Passarino G, 2001, GENOMICS, V71, P118, DOI 10.1006/geno.2000.6405; Rong SB, 2000, MOL MED, V6, P155, DOI 10.1007/BF03402111; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Ye L, 1997, AM J MED GENET, V68, P494, DOI 10.1002/(SICI)1096-8628(19970211)68:4<494::AID-AJMG30>3.0.CO;2-L; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55499	55505		10.1074/jbc.M407128200	http://dx.doi.org/10.1074/jbc.M407128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489508	hybrid			2022-12-25	WOS:000225960800065
J	Huang, JN; Huang, Q; Zhou, XL; Shen, MM; Yen, A; Yu, SX; Dong, GQ; Qu, KB; Huang, PY; Anderson, EM; Daniel-Issakani, S; Buller, RML; Payan, DG; Lu, HH				Huang, JN; Huang, Q; Zhou, XL; Shen, MM; Yen, A; Yu, SX; Dong, GQ; Qu, KB; Huang, PY; Anderson, EM; Daniel-Issakani, S; Buller, RML; Payan, DG; Lu, HH			The poxvirus p28 virulence factor is an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; ECTROMELIA VIRUS; CAUSATIVE AGENT; COMPLEX; PROTEASOME; SYSTEM; CHAIN; RECOGNITION; DESTRUCTION; EXPRESSION	A majority of the orthopoxviruses, including the variola virus that causes the dreaded smallpox disease, encode a highly conserved 28-kDa protein with a classic RING finger sequence motif (C3HC4) at their carboxyl-terminal domains. The RING domain of p28 has been shown to be a critical determinant of viral virulence for the ectromelia virus ( mousepox virus) in a murine infection model (Senkevich, T. G., Koonin, E. V., and Buller, R. M. (1994) Virology 198, 118-128). Here, we demonstrate that the p28 proteins encoded by the ectromelia virus and the variola virus possess E3 ubiquitin ligase activity in biochemical assays as well as in cultured mammalian cells. Point mutations disrupting the RING finger domain of p28 completely abolish its E3 ligase activity. In addition, p28 functions cooperatively with Ubc4 and UbcH5c, the E2 conjugating enzymes involved in 26 S proteasome degradation of protein targets. Moreover, p28 catalyzes the formation of Lys-63-linked polyubiquitin chains in the presence of Ubc13/Uev1A, a heterodimeric E2 conjugating enzyme, indicating that p28 may regulate the biological activity of its cognate viral and/or host cell target(s) by Lys-63-linked ubiquitin multimers. We thus conclude that the poxvirus p28 virulence factor is a new member of the RING finger E3 ubiquitin ligase family and has a unique polyubiquitylation activity. We propose that the E3 ligase activity of the p28 virulence factor may be targeted for therapeutic intervention against infections by the variola virus and other poxviruses.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA; St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University	Payan, DG (corresponding author), Rigel Pharmaceut Inc, 1180 Vet Blvd, San Francisco, CA 94080 USA.	dgpayan@rigel.com; hlu@rigel.com						Banks L, 2003, TRENDS BIOCHEM SCI, V28, P452, DOI 10.1016/S0968-0004(03)00141-5; Brick DJ, 1998, VIROLOGY, V249, P42, DOI 10.1006/viro.1998.9304; Brick DJ, 2000, J GEN VIROL, V81, P1087, DOI 10.1099/0022-1317-81-4-1087; Chen NH, 2003, VIROLOGY, V317, P165, DOI 10.1016/S0042-6822(03)00520-8; Chen NH, 2000, VIRUS RES, V66, P155, DOI 10.1016/S0168-1702(99)00135-5; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gray TA, 2000, GENOMICS, V66, P76, DOI 10.1006/geno.2000.6199; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Guerin JL, 2002, J VIROL, V76, P2912, DOI 10.1128/JVI.76.6.2912-2923.2002; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kentsis A, 2001, J MOL BIOL, V312, P609, DOI 10.1006/jmbi.2001.5003; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Moss B, 2001, FIELDS VIROLOGY, P2849; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pickart CM, 2000, NAT STRUCT BIOL, V7, P999, DOI 10.1038/81018; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; SENKEVICH TG, 1994, VIROLOGY, V198, P118, DOI 10.1006/viro.1994.1014; SENKEVICH TG, 1995, J VIROL, V69, P4103, DOI 10.1128/JVI.69.7.4103-4111.1995; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wong BR, 2003, DRUG DISCOV TODAY, V8, P746, DOI 10.1016/S1359-6446(03)02780-6; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	33	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54110	54116		10.1074/jbc.M410583200	http://dx.doi.org/10.1074/jbc.M410583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496420	hybrid			2022-12-25	WOS:000225793600029
J	Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J				Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J			Regulation of c-Met-dependent gene expression by PTEN	ONCOGENE			English	Article						receptor tyrosine kinase; tumor suppressor; hepatocyte growth factor; scatter factor; microarrays; epidermal growth factor receptor	FACTOR/HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR EXPRESSION; TUMOR-SUPPRESSOR PTEN; HUMAN GLIOBLASTOMA; PTEN/MMAC1; MUTATIONS; PATHWAYS; RECEPTOR; 3-KINASE/AKT; MULTIFORME	Receptor tyrosine kinases (RTK) and the tumor suppressor PTEN co-regulate oncogenic cell signaling pathways. How these interactions influence gene transcription is inadequately understood. We used expression microarrays to investigate the effects of PTEN on gene expression changes caused by activating c-Met in human glioblastoma cells. c-Met activation by scatter factor/hepatocyte growth factor (SF/HGF) altered the expression of 27-fold more genes in PTEN-null U-373MG cells than in PTEN homozygous primary normal human astrocytes (523 vs 19 genes). Restoring wt-PTEN in U-373MG cells dramatically altered patterns of c-Met regulated gene expression. This effect was varied depending on the specific gene in question. PTEN reduced the number of c-Met regulated transcripts from 931 to 502, decreased the relative number of genes upregulated by c-Met from 46 to 25%, and increased the relative number of downregulated genes from 54 to 75%. PTEN and c-Met co-regulated many genes involved in cell growth regulation such as oncogenes, growth factors, transcription factors, and constituents of the ubiquitin pathway. c-Met activation in PTEN-null ( but not PTEN reconstituted) cells led to upregulation of the EGFR agonist TGFalpha and subsequently to EGFR activation. Using PTEN mutants, we found that PTEN's transcriptional effects were either lipid-phosphatase dependent, protein-phosphatase dependent, or phosphatase-independent. These results show that PTEN has critical and mechanistically complex effects on RTK-regulated gene transcription. These findings expand our understanding of tumor promoter/suppressor inter-relationships and downstream transcriptional effects of PTEN loss and c-Met overexpression in malignant gliomas.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Lombardi Canc Ctr, Dept Oncol, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Abounader, R (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway,Room 400, Baltimore, MD 21205 USA.	abounader@kennedykrieger.org; laterra@kennedykrieger.org		Colantuoni, Carlo/0000-0001-6818-6380	NINDS NIH HHS [R01 NS045209, R01 NS032148, R01 NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045209, R01NS043987, R01NS032148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bowers DC, 2000, CANCER RES, V60, P4277; Cheney IW, 1998, CANCER RES, V58, P2331; Colantuoni C, 2002, BIOTECHNIQUES, V32, P1316, DOI 10.2144/02326mt02; Davies MPA, 1999, BRIT J CANCER, V79, P1542, DOI 10.1038/sj.bjc.6690246; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Sano T, 1999, CANCER RES, V59, P1820; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	29	51	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9173	9182		10.1038/sj.onc.1208146	http://dx.doi.org/10.1038/sj.onc.1208146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516982				2022-12-25	WOS:000225638000002
J	Gunawan, J; Simard, D; Gilbert, M; Lovering, AL; Wakarchuk, WW; Tanner, ME; Strynadka, NCJ				Gunawan, J; Simard, D; Gilbert, M; Lovering, AL; Wakarchuk, WW; Tanner, ME; Strynadka, NCJ			Structural and mechanistic analysis of sialic acid synthase NeuB from Neisseria meningitidis in complex with Mn2+ phosphoenolpyruvate, and N-acetylmannosaminitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; ACETYLNEURAMINIC ACID; CATALYTIC MECHANISM; KDO8P SYNTHASE; 3-DEOXY-D-MANNO-OCTULOSONATE-8-PHOSPHATE SYNTHASE; BISUBSTRATE INHIBITOR; CAMPYLOBACTER-JEJUNI; ENZYMATIC SYNTHESIS; CELL GLYCOSYLATION	In Neisseria meningitidis and related bacterial pathogens, sialic acids play critical roles in mammalian cell immunity evasion and are synthesized by a conserved enzymatic pathway that includes sialic acid synthase (NeuB, SiaC, or SynC). NeuB catalyzes the condensation of phosphoenolpyruvate (PEP) and N-acetylmannosamine, directly forming N-acetylneuraminic acid (or sialic acid). In this paper we report the development of a coupled assay to monitor NeuB reaction kinetics and an O-18-labeling study that demonstrates the synthase operates via a C-O bond cleavage mechanism. We also report the first structure of a sialic acid synthase, that of NeuB, revealing a unique domain-swapped homodimer architecture consisting of a (beta/alpha)(8) barrel (TIM barrel)type fold at the N-terminal end and a domain with high sequence identity and structural similarity to the ice binding type III antifreeze proteins at the C-terminal end of the enzyme. We have determined the structures of NeuB in the malate-bound form and with bound PEP and the substrate analog N-acetylmannosaminitol to 1.9 and 2.2 Angstrom resolution, respectively. Typical of other TIM barrel proteins, the active site of NeuB is located in a cavity at the C-terminal end of the barrel; however, the positioning of the swapped antifreeze-like domain from the adjacent monomer provides key residues for hydrogen bonding with substrates in the active site of NeuB, a structural feature that leads to distinct modes of substrate binding from other PEP-utilizing enzymes that lack an analogous antifreeze-like domain. Our observation of a direct interaction between a highly ordered manganese and the N-acetylmannosaminitol in the NeuB active site also suggests an essential role for the ion as an electrophilic catalyst that activates the N-acetylmannosamine carbortyl to the addition of PEP.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; University of British Columbia; National Research Council Canada	Tanner, ME (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	mtanner@chem.ubc.ca; natalie@byron.biochem.ubc.ca	Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Lovering, Andrew/0000-0002-1856-7975; Gilbert, Michel/0000-0002-0204-4408				ANNUNZIATO PW, 1995, J BACTERIOL, V177, P312, DOI 10.1128/jb.177.2.312-319.1995; Asojo O, 2001, BIOCHEMISTRY-US, V40, P6326, DOI 10.1021/bi010339d; Baardsnes J, 2001, TRENDS BIOCHEM SCI, V26, P468, DOI 10.1016/S0968-0004(01)01879-5; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Barbosa JARG, 2000, J MOL BIOL, V303, P405, DOI 10.1006/jmbi.2000.4138; BLACKLOW RS, 1962, J BIOL CHEM, V237, P3520; BONDINELL WE, 1971, J BIOL CHEM, V246, P6191; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; COMB DG, 1960, J BIOL CHEM, V235, P2529; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; FINNE J, 1985, TRENDS BIOCHEM SCI, V10, P129, DOI 10.1016/0968-0004(85)90274-9; Fukuda M, 1996, CANCER RES, V56, P2237; Furdui C, 2004, J BIOL CHEM, V279, P45618, DOI 10.1074/jbc.M404753200; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; Grossmann M, 1997, ENDOCRINOLOGY, V138, P92, DOI 10.1210/en.138.1.92; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Howe DL, 2003, BIOCHEMISTRY-US, V42, P4843, DOI 10.1021/bi026553z; Hwang TS, 2002, BIOCHEM BIOPH RES CO, V295, P167, DOI 10.1016/S0006-291X(02)00620-4; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Kaustov L, 2003, J AM CHEM SOC, V125, P4662, DOI 10.1021/ja028688y; Konig V, 2004, J MOL BIOL, V337, P675, DOI 10.1016/j.jmb.2004.01.055; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE ED, 1997, CRYSTALLOGR COMPUT, V7, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; MASSON L, 1983, J BACTERIOL, V154, P728, DOI 10.1128/JB.154.2.728-736.1983; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; ROSEMAN S, 1962, P NATL ACAD SCI USA, V48, P437, DOI 10.1073/pnas.48.3.437; ROSENBERG A, 1995, BIOL SIALIC ACIDAS; SEEHOLZER SH, 1991, BIOCHEMISTRY-US, V30, P727, DOI 10.1021/bi00217a022; Shulami S, 2004, J BIOL CHEM, V279, P45110, DOI 10.1074/jbc.M404561200; Shumilin IA, 2004, J MOL BIOL, V341, P455, DOI 10.1016/j.jmb.2004.05.077; Shumilin IA, 2003, BIOCHEMISTRY-US, V42, P3766, DOI 10.1021/bi027257p; Sundaram AK, 2004, BIOCHEM J, V383, P83, DOI 10.1042/BJ20040218; Suryanti V, 2003, PROTEIN EXPRES PURIF, V27, P346, DOI 10.1016/S1046-5928(02)00633-2; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vann WF, 1997, GLYCOBIOLOGY, V7, P697, DOI 10.1093/glycob/7.5.697; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VIALLETELLE V, 1992, TETRAHEDRON-ASYMMETR, V3, P673, DOI 10.1016/S0957-4166(00)80497-8; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; Wang J, 2001, BIOCHEMISTRY-US, V40, P15676, DOI 10.1021/bi015568e; WARREN L, 1962, J BIOL CHEM, V237, P3527; WARREN L, 1959, J BIOL CHEM, V234, P1971; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	58	63	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3555	3563		10.1074/jbc.M411942200	http://dx.doi.org/10.1074/jbc.M411942200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15516336	hybrid			2022-12-25	WOS:000226983900053
J	Kramer, W; Girbig, F; Corsiero, D; Pfenninger, A; Frick, W; Jahne, G; Rhein, M; Wendler, W; Lottspeich, F; Hochleitner, EO; Orso, E; Schmitz, G				Kramer, W; Girbig, F; Corsiero, D; Pfenninger, A; Frick, W; Jahne, G; Rhein, M; Wendler, W; Lottspeich, F; Hochleitner, EO; Orso, E; Schmitz, G			Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY-CHOLESTEROL; BINDING-PROTEINS; SMALL-INTESTINE; RECEPTOR; IDENTIFICATION; CORONAVIRUS; SITOSTEROL; METABOLISM; MICRODOMAINS; COMPLEX	Intestinal cholesterol absorption is an important regulator of serum cholesterol levels. Ezetimibe is a specific inhibitor of intestinal cholesterol absorption recently introduced into medical practice; its mechanism of action, however, is still unknown. Ezetimibe neither influences the release of cholesterol from mixed micelles in the gut lumen nor the transfer of cholesterol to the enterocyte brush border membrane. With membrane-impermeable Ezetimibe analogues we could demonstrate that binding of cholesterol absorption inhibitors to the brush border membrane of small intestinal enterocytes from the gut lumen is sufficient for inhibition of cholesterol absorption. A 145-kDa integral membrane protein was identified as the molecular target for cholesterol absorption inhibitors in the enterocyte brush border membrane by photoaffinity labeling with photoreactive Ezetimibe analogues (Kramer, W., Glombik, H., Petry, S., Heuer, H., Schafer, H. L., Wendler, W., Corsiero, D., Girbig, F., and Weyland, C. (2000) FEBS Lett. 487, 293-297). The 145-kDa Ezetimibe-binding protein was purified by three different methods and sequencing revealed its identity with the membrane-bound ectoenzyme aminopeptidase N (( alanyl)aminopeptidase; EC 3.4.11.2; APN; leukemia antigen CD13). The enzymatic activity of APN was not influenced by Ezetimibe ( analogues). The uptake of cholesterol delivered by mixed micelles by confluent CaCo-2 cells was partially inhibited by Ezetimibe and nonabsorbable Ezetimibe analogues. Preincubation of confluent CaCo-2 cells with Ezetimibe led to a strong decrease of fluorescent APN staining with a monoclonal antibody in the plasma membrane. Independent on its enzymatic activity, aminopeptidase N is involved in endocytotic processes like the uptake of viruses. Our findings suggest that binding of Ezetimibe to APN from the lumen of the small intestine blocks endocytosis of cholesterol-rich membrane microdomains, thereby limiting intestinal cholesterol absorption.	Aventis Pharma Deutschland GmbH, Dis Grp Metab Dis, D-65926 Frankfurt, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany	Sanofi-Aventis; Max Planck Society; University of Regensburg	Kramer, W (corresponding author), Aventis Pharma Deutschland GmbH, Dis Grp Metab Dis, Ind Pk Hochst,Bldg G 879, D-65926 Frankfurt, Germany.	Werner.Kramer@aventis.com						Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Arion WJ, 1998, ARCH BIOCHEM BIOPHYS, V351, P279, DOI 10.1006/abbi.1997.0563; Benbacer L, 1997, J VIROL, V71, P734, DOI 10.1128/JVI.71.1.734-737.1997; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BURNETT DA, 1994, J MED CHEM, V37, P1733, DOI 10.1021/jm00038a001; BYERS SO, 1953, AM J PHYSIOL, V175, P375, DOI 10.1152/ajplegacy.1953.175.3.375; Cai TQ, 2002, BBA-MOL CELL BIOL L, V1581, P100, DOI 10.1016/S1388-1981(02)00128-2; Clader JW, 1996, J MED CHEM, V39, P3684, DOI 10.1021/jm960405n; Compassi S, 1997, BIOCHEMISTRY-US, V36, P6643, DOI 10.1021/bi9620666; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; FELDMAN EB, 1969, BIOCHIM BIOPHYS ACTA, V193, P221, DOI 10.1016/0005-2736(69)90077-7; Field FJ, 1998, J LIPID RES, V39, P1938; Frick W, 2003, BIOORGAN MED CHEM, V11, P1639, DOI 10.1016/S0968-0896(03)00047-6; GLOMBIK H, 2002, Patent No. 2002050027; GRUNDY SM, 1983, ANNU REV NUTR, V3, P71, DOI 10.1146/annurev.nu.03.070183.000443; Hansen GH, 2003, GUT, V52, P1424, DOI 10.1136/gut.52.10.1424; Hansen GH, 2003, BIOCHEM J, V373, P125, DOI 10.1042/BJ20030235; Hansen GH, 1998, J VIROL, V72, P527, DOI 10.1128/JVI.72.1.527-534.1998; HARWOOD HJ, 1993, J LIPID RES, V34, P377; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Huggins KW, 2003, J BIOL CHEM, V278, P42899, DOI 10.1074/jbc.M303422200; Jardinaud F, 2004, BIOCHIMIE, V86, P105, DOI 10.1016/j.biochi.2003.12.004; Klett EL, 2004, SCIENCE, V303, P1149, DOI 10.1126/science.1095519; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Kramer W, 2003, BBA-MOL CELL BIOL L, V1633, P13, DOI 10.1016/S1388-1981(03)00068-4; Kramer W, 2000, FEBS LETT, V487, P293, DOI 10.1016/S0014-5793(00)02372-3; Kramer W, 2001, J BIOL CHEM, V276, P36020, DOI 10.1074/jbc.M104665200; KRAMER W, 2000, Patent No. 0218432; KRAMER W, 2002, BILE ACIDS GENOMICS, P147; KUNZ J, 1994, J NEUROCHEM, V62, P2375; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; MCINTYRE N, 1973, AM J CLIN NUTR, V26, P647; MOOSEKER MS, 1976, J CELL BIOL, V71, P417, DOI 10.1083/jcb.71.2.417; MULLER G, 1994, BIOCHEMISTRY-US, V33, P12149; Nomura R, 2004, J VIROL, V78, P8701, DOI 10.1128/JVI.78.16.8701-8708.2004; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Santos AN, 2000, ADV EXP MED BIOL, V477, P43; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; SODERBERG C, 1993, J VIROL, V67, P6576; Sparrow CP, 1999, J LIPID RES, V40, P1747; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tresnan DB, 1996, J VIROL, V70, P8669, DOI 10.1128/JVI.70.12.8669-8674.1996; van Heek M, 2000, BRIT J PHARMACOL, V129, P1748, DOI 10.1038/sj.bjp.0703235; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON MD, 1994, J LIPID RES, V35, P943; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465	57	93	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1306	1320		10.1074/jbc.M406309200	http://dx.doi.org/10.1074/jbc.M406309200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15494415	hybrid			2022-12-25	WOS:000226195200056
J	Rajan, RS; Kopito, RR				Rajan, RS; Kopito, RR			Suppression of wild-type rhodopsin maturation by mutants linked to autosomal dominant retinitis pigmentosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE INTRACELLULAR-TRANSPORT; RETINAL DYSTROPHIES; MONOCLONAL-ANTIBODIES; CYSTIC-FIBROSIS; MOLECULAR-BASIS; QUALITY-CONTROL; DEGRADATION; RECEPTORS; PROTEINS; MEMBRANES	Autosomal dominant retinitis pigmentosa (ADRP) has been linked to mutations in the gene encoding rhodopsin. Most RP-linked rhodopsin mutants are unable to fold correctly in the endoplasmic reticulum, are degraded by the ubiquitin proteasome system, and are highly prone to forming detergent-insoluble high molecular weight aggregates. Here we have reported that co-expression of folding-deficient, but not folding-proficient, ADRP-linked rhodopsin mutants impairs delivery of the wild-type protein to the plasma membrane. Fluorescence resonance energy transfer and co-precipitation studies revealed that mutant and wild-type rhodopsins form a high molecular weight, detergent-insoluble complex in which the two proteins are in close (< 70 angstrom) proximity. Co-expression of ARDP-linked rhodopsin folding-deficient mutants resulted in enhanced proteasome-mediated degradation and steady-state ubiquitination of the wild-type protein. These data suggested a dominant negative effect on conformational maturation that may underlie the dominant inheritance of ARDP.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	kopito@stanford.edu						ADAMUS G, 1988, Peptide Research, V1, P42; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Inglehearn CF, 1998, EYE, V12, P571, DOI 10.1038/eye.1998.147; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; LACKOWICZ J, 1999, PRINCIPLES FLUOROSEN; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Milam AH, 1998, PROG RETIN EYE RES, V17, P175; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Phelan JK, 2000, MOL VIS, V6, P116; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Saliba RS, 2002, J CELL SCI, V115, P2907; Sung CH, 2000, INT REV CYTOL, V195, P215; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; VRABEC T, 1989, ARCH OPHTHALMOL-CHIC, V107, P1061, DOI 10.1001/archopht.1989.01070020123044; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	39	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1284	1291		10.1074/jbc.M406448200	http://dx.doi.org/10.1074/jbc.M406448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509574	hybrid			2022-12-25	WOS:000226195200053
J	Akimova, OA; Bagrov, AY; Lopina, OD; Kamernitsky, AV; Tremblay, J; Hamet, P; Orlov, SN				Akimova, OA; Bagrov, AY; Lopina, OD; Kamernitsky, AV; Tremblay, J; Hamet, P; Orlov, SN			Cardiotonic steroids differentially affect intracellular Na+ and [Na+](i)/[K+](i)-independent signaling in C7-MDCK cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-GLYCOSIDES; OUABAIN; ATPASE; APOPTOSIS; PUMP; MARINOBUFAGENIN; NA+,K+-ATPASE; LIGAND; INHIBITION; ACTIVATION	Recently, we reported that ouabain kills renal epithelial and vascular endothelial cells independently of elevation of the [Na+](i)/[K+](i) ratio. These observations raised the possibility of finding cardiotonic steroids (CTS) that inhibit the Na+, K+ pump without attenuating cell survival and vice versa. To test this hypothesis, we compared CTS action on Na+, K+ pump, [Na+](i) content, and survival of Madin-Darby canine kidney cells. At a concentration of 1 muM, ouabain and other tested cardenolides, as well as bufadienolides such as bufalin, cinobufagin, cinobufotalin, and telobufotoxin, led to similar to10-fold inhibition of the Na+, K+ pump, a 2-3-fold decrease in staining with dimethylthiazol-diphenyltetrazolium (MTT), and massive death indicated by detachment of similar to80% of cells and caspase-3 activation. In contrast, Na+, K+ pump inhibition and elevation of [Na+](i) seen in the presence of 3 muM marinobufagenin (MBG) and marinobufotoxin did not affect MTT staining and cell survival. Inhibition of the Na+, Rb+ pump in K+-free medium was not accompanied by a decline of MTT staining and cell detachment but increased sensitivity to CTS. In K+-free medium, half-maximal inhibition of Rb-86 influx was observed in the presence of 0.04 muM ouabain and 0.1 muM MBG, whereas half-maximal detachment and decline of MTT staining were detected at 0.03 and 0.004 muM of ouabain versus 10 and 3 muM of MBG, respectively. Both ouabain binding and ouabain-induced [Na+](i),[K+](i)-independent signaling were suppressed in the presence of MBG. Thus, our results show that CTS exhibit distinctly different potency in Na+, K+ pump inhibition and triggering of [Na+](i)/[K+](i)-independent signaling, including cell death.	CHUM Hotel Dieu, Ctr Rech, Montreal, PQ H2W 1T7, Canada; Moscow MV Lomonosov State Univ, Fac Biol, Moscow 119899, Russia; NIA, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Russian Acad Sci, Zelinsky Inst Organ Chem, Moscow 119840, Russia	Universite de Montreal; Lomonosov Moscow State University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Russian Academy of Sciences; Zelinsky Institute of Organic Chemistry	Orlov, SN (corresponding author), CHUM Hotel Dieu, Ctr Rech, 3850 Rue St Urbain, Montreal, PQ H2W 1T7, Canada.	sergei.n.orlov@umontreal.ca	Akimova, Olga/I-2669-2014; Cossette, Suzanne/I-8008-2016; Bagrov, Alexei/AAM-6509-2020; Lopina, Olga/ABE-6918-2021; Tremblay, Johanne/E-2154-2013; ORLOV, SERGEI/I-4071-2013	Lopina, Olga/0000-0001-9608-0196; Bagrov, Alexei/0000-0002-2903-8673	NATIONAL INSTITUTE ON AGING [Z01AG000609, ZIAAG000609] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKERA T, 1985, EUR J PHARMACOL, V111, P147, DOI 10.1016/0014-2999(85)90751-4; BAGROV AY, 1995, EUR J PHARMACOL, V274, P151, DOI 10.1016/0014-2999(94)00735-P; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Chueh SC, 2001, J UROLOGY, V166, P347, DOI 10.1016/S0022-5347(05)66157-5; Contreras RG, 1999, J CELL SCI, V112, P4223; Daniel D, 2003, INT IMMUNOPHARMACOL, V3, P1791, DOI 10.1016/j.intimp.2003.08.004; Dmitrieva RI, 2003, J BIOL CHEM, V278, P28160, DOI 10.1074/jbc.M303768200; Dmitrieva RI, 2002, EXP BIOL MED, V227, P561, DOI 10.1177/153537020222700803; Fedorova OV, 2004, J HYPERTENS, V22, P389, DOI 10.1097/00004872-200402000-00025; Fedorova OV, 2003, HYPERTENSION, V41, P505, DOI 10.1161/01.HYP.0000053446.43894.9F; Fedorova OV, 2002, HYPERTENSION, V39, P298, DOI 10.1161/hy0202.104344; Fedorova OV, 2001, HYPERTENSION, V37, P462, DOI 10.1161/01.HYP.37.2.462; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Glitsch HG, 2001, PHYSIOL REV, V81, P1791, DOI 10.1152/physrev.2001.81.4.1791; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Ho CK, 2000, EUR J CELL BIOL, V79, P765, DOI 10.1078/0171-9335-00091; Huang YT, 2004, BIOCHEM PHARMACOL, V67, P727, DOI 10.1016/j.bcp.2003.10.013; Kawamura A, 1999, P NATL ACAD SCI USA, V96, P6654, DOI 10.1073/pnas.96.12.6654; Krenn L, 1998, PHYTOCHEMISTRY, V48, P1, DOI 10.1016/S0031-9422(97)00426-3; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; Liu J, 2000, J BIOL CHEM, V275, P27838; Maixent JM, 1998, CARDIOVASC DRUG THER, V12, P585, DOI 10.1023/A:1007747623749; Mohammadi K, 2003, J CARDIOVASC PHARM, V41, P609, DOI 10.1097/00005344-200304000-00014; Orlov SN, 2004, PFLUG ARCH EUR J PHY, V448, P335, DOI 10.1007/s00424-004-1262-9; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Pchejetski D, 2003, BIOCHEM BIOPH RES CO, V301, P735, DOI 10.1016/S0006-291X(02)03002-4; Saunders R, 2004, EUR J BIOCHEM, V271, P1054, DOI 10.1111/j.1432-1033.2004.04012.x; Schneider R, 1998, J BIOL CHEM, V273, P784, DOI 10.1074/jbc.273.2.784; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; Ward SC, 2002, HYPERTENSION, V39, P536, DOI 10.1161/hy0202.103048	34	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					832	839		10.1074/jbc.M411011200	http://dx.doi.org/10.1074/jbc.M411011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494417	hybrid			2022-12-25	WOS:000226025100097
J	Chahdi, A; Miller, B; Sorokin, A				Chahdi, A; Miller, B; Sorokin, A			Endothelin 1 induces beta(1)Pix translocation and Cdc42 activation via protein kinase A-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; P85 BETA-PIX; ACTIN CYTOSKELETON; SIGNALING PATHWAY; BINDING PROTEINS; MESANGIAL CELLS; RHO GTPASES; MAST-CELLS; RECEPTOR; PAK	p21-activated kinase (Pak)-interacting exchange factor (Pix), a Rho family guanine nucleotide exchange factor (GEF), has been shown to co-localize with Pak and form activated Cdc42- and Rac1-driven focal complexes. In this study we have presented evidence that treatment of human mesangial cells (HMC) with endothelin 1 (ET-1) and stimulation of adenylate cyclase with either forskolin or with the cAMP analog 8-Br-cAMP activated the GTP loading of Cdc42. Transient expression of constitutively active Galpha(s) also stimulated Cdc42. In addition, overexpression of beta(1)Pix enhanced ET-1-induced Cdc42 activation, whereas the expression of beta(1)Pix SH3m(W43K), which lacks the ability to bind Pak, and beta(1)PixDHm(L238R/L239S), which lacks GEF activity, decreased ET-1-induced Cdc42 activation. Furthermore, ET-1 stimulation induced beta(1)Pix translocation to focal complexes. Interestingly, pretreatment of HMC with protein kinase A (PKA) inhibitors blocked both Cdc42 activation and beta(1)Pix translocation induced by ET-1, indicating the involvement of the PKA pathway. Through site-directed mutagenesis studies of consensus PKA phosphorylation sites and in vitro PKA kinase assay, we have shown that beta(1)Pix is phosphorylated by PKA. Using purified recombinant beta(1)Pix(wt) and beta(1)Pix mutants, we have identified Ser-516 and Thr-526 as the major phosphorylation sites by PKA. beta(1)Pix(S516A/T526A), in which both phosphorylation sites are replaced by alanine, blocks beta(1)Pix translocation and Cdc42 activation. Our results have provided evidence that stimulation of PKA pathway by ET-1 or cAMP analog results in beta(1)Pix phosphorylation, which in turn controls beta(1)Pix translocation to focal complexes and Cdc42 activation.	Med Coll Wisconsin, Dept Med, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Med, Div Nephrol, Kidney Dis Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, Cardiovasc Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL22563] Funding Source: Medline; NIDDK NIH HHS [DK41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Chahdi A, 2004, BIOCHEM BIOPH RES CO, V317, P384, DOI 10.1016/j.bbrc.2004.03.062; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; GomezGarre D, 1996, HYPERTENSION, V27, P885, DOI 10.1161/01.HYP.27.4.885; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Koh CG, 2001, J CELL SCI, V114, P4239; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Prepens U, 1997, ADV EXP MED BIOL, V419, P349; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Song J, 1998, J CELL SCI, V111, P2257; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; YOSHIMURA A, 1995, KIDNEY INT, V48, P1290, DOI 10.1038/ki.1995.413; Zegers MMP, 2003, EMBO J, V22, P4155, DOI 10.1093/emboj/cdg398	34	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					578	584		10.1074/jbc.M411130200	http://dx.doi.org/10.1074/jbc.M411130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513924	hybrid			2022-12-25	WOS:000226025100069
J	Dakappagari, NK; Lute, KD; Rawale, S; Steele, JT; Allen, SD; Phillips, G; Reilly, RT; Kaumaya, PTP				Dakappagari, NK; Lute, KD; Rawale, S; Steele, JT; Allen, SD; Phillips, G; Reilly, RT; Kaumaya, PTP			Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOGRAPHIC IMMUNOGENIC DETERMINANTS; MAMMARY-TUMORS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; ONCOGENIC PROTEIN; NEU PROTOONCOGENE; TRANSGENIC MICE; BREAST-CANCER; EGF RECEPTOR; IN-VIVO	Cancer vaccines designed to elicit an antibody response that target antigenic sites on a tumor antigen must closely mimic the three-dimensional structure of the corresponding region on the antigen. We have designed a complex immunogen derived from the extracellular domain of human HER-2/neu-(626-649) that represents a three-dimensional epitope. We have successfully introduced two disulfide bonds into this sequence, thereby recapitulating the natural disulfide pairings observed in the native protein. To evaluate the immunogenicity of the doubly cyclized disulfide-linked peptide versus the free uncyclized peptide we examined the induction of antibody responses in both inbred and outbred mice strains, with both constructs eliciting high titered antibodies. The disulfide-paired specific antibodies exhibited enhanced cross-reactivity to HER-2/neu expressed on BT-474 cell line as determined by flow cytometry. The antitumor activities of the disulfide-paired specific antibodies did not improve the in vitro growth inhibition of human breast cancer cells overexpressing HER-2, but showed superior antitumor responses in the context of ADCC and interferon-gamma induction. Inbred mice (FVB/n) vaccinated with the disulfide-paired epitope exhibited a statistically significant reduction in the development of exogenously administered tumors in vivo compared with mice receiving either the free uncyclized or the promiscuous T-cell epitope (MVF) control peptide (p=0.001). This study demonstrates the feasibility and importance of designing conformational epitopes that mimic the tertiary structure of the native protein for eliciting biologically relevant anti-tumor antibodies. Such approaches are a prerequisite to the design of effective peptide vaccines.	Ohio State Univ, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA; Dept Obstet & Gynecol, Columbus, OH 43210 USA; Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA; Chem Biol Interface Program, Columbus, OH 43210 USA; Ohio State Biochem Program, Columbus, OH 43210 USA; Johns Hopkins, Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol,Ctr Biostat, Baltimore, MD 21231 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Johns Hopkins University; Johns Hopkins Medicine	Kaumaya, PTP (corresponding author), Ohio State Univ, Arthur G James Comprehens Canc Ctr, Suite 316 Med Res Facil,420 W 12th Ave, Columbus, OH 43210 USA.	Kaumaya.1@osu.edu	Kaumaya, Pravin T. P/E-3354-2011		NATIONAL CANCER INSTITUTE [R01CA084356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Brossart P, 2000, BLOOD, V96, P3102, DOI 10.1182/blood.V96.9.3102.h8003102_3102_3108; Bullesbach EE, 2001, J PEPT RES, V57, P77, DOI 10.1034/j.1399-3011.2001.00832.x; Cabezas E, 2000, BIOCHEMISTRY-US, V39, P14377, DOI 10.1021/bi0003691; Calvo JC, 2003, J MED CHEM, V46, P5389, DOI 10.1021/jm030210x; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dakappagari NK, 2000, CANCER RES, V60, P3782; Dakappagari NK, 2003, J IMMUNOL, V170, P4242, DOI 10.4049/jimmunol.170.8.4242; Dings RPM, 2003, BIOCHEM J, V373, P281, DOI 10.1042/BJ20030295; Disis ML, 1999, CLIN CANCER RES, V5, P1289; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; Disis ML, 1996, J IMMUNOL, V156, P3151; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; DISIS ML, 1994, CANCER RES, V54, P1071; DISIS ML, 1994, CIBA F SYMP, V187, P198; Doherty GM, 1996, J SURG RES, V64, P68, DOI 10.1006/jsre.1996.0308; Ercolini AM, 2003, J IMMUNOL, V170, P4273, DOI 10.4049/jimmunol.170.8.4273; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jasinska J, 2003, INT J CANCER, V107, P976, DOI 10.1002/ijc.11485; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; Kim JY, 2003, J NEUROSCI, V23, P5561; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; Kopreski MS, 1996, ANTICANCER RES, V16, P433; Kumagai T, 2001, P NATL ACAD SCI USA, V98, P5526, DOI 10.1073/pnas.071060598; MARTH C, 1992, INT J CANCER, V50, P64, DOI 10.1002/ijc.2910500114; PRESS MF, 1990, ONCOGENE, V5, P953; Reilly RT, 2000, CANCER RES, V60, P3569; Riemer AB, 2004, J IMMUNOL, V173, P394, DOI 10.4049/jimmunol.173.1.394; Scholl S, 2001, ANN ONCOL, V12, P81, DOI 10.1023/A:1011192622688; Shi TS, 1999, J ORG CHEM, V64, P4590, DOI 10.1021/jo981748r; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soll R, 2000, J PEPT SCI, V6, P387, DOI 10.1002/1099-1387(200008)6:8<387::AID-PSC267>3.0.CO;2-M; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stockmeyer B, 1997, CANCER RES, V57, P696; Sundaram R, 2004, J BIOL CHEM, V279, P24141, DOI 10.1074/jbc.M313210200; TANG RP, 1990, J CELL BIOCHEM, V44, P189, DOI 10.1002/jcb.240440307; Tetenbaum J, 2001, BIOCHEMISTRY-US, V40, P12215, DOI 10.1021/bi010796u; Vinter-Jensen L, 1999, APMIS Suppl, V93, P1; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yip YL, 2002, CANCER IMMUNOL IMMUN, V50, P569, DOI 10.1007/s002620100226	50	53	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					54	63		10.1074/jbc.M411020200	http://dx.doi.org/10.1074/jbc.M411020200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507452	hybrid			2022-12-25	WOS:000226025100008
J	Eastman, SW; Martin-Serrano, J; Chung, W; Zang, T; Bieniasz, PD				Eastman, SW; Martin-Serrano, J; Chung, W; Zang, T; Bieniasz, PD			Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOWN-REGULATION; IMMUNODEFICIENCY-VIRUS TYPE-1; MULTIVESICULAR-BODY; ESCRT-I; SACCHAROMYCES-CEREVISIAE; PARTICLE RELEASE; ASSEMBLY DOMAIN; GAG PROTEIN; HIV-1 P6; TSG101	Endosomal sorting complex required for transport-I (ESCRT-I) is one of three defined protein complexes in the class E vacuolar protein sorting (VPS) pathway required for the sorting of ubiquitinated transmembrane proteins into internal vesicles of multivesicular bodies. In yeast, ESCRT-I is composed of three proteins, VSP23, VPS28, and VPS37, whereas in mammals only Tsg101(VPS23) and VPS28 were originally identified as ESCRT-I components. Using yeast two-hybrid screens, we identified one of a family of human proteins (VPS37C) as a Tsg101-binding protein. VPS37C can form a ternary complex with Tsg101 and VPS28 by binding to a domain situated toward the carboxyl terminus of Tsg101 and binds to another class E VPS factor, namely Hrs. In addition, VPS37C is recruited to aberrant endosomes induced by overexpression of Tsg101, Hrs, or dominant negative form of the class E VPS ATPase, VPS4. Enveloped viruses that encode PTAP motifs to facilitate budding exploit ESCRT-I as an interface with the class E VPS pathway, and accordingly, VPS37C is recruited to the plasma membrane along with Tsg101 by human immunodeficiency virus, type 1 (HIV-1) Gag. Moreover, direct fusion of VPS37C to HIV-1 Gag obviates the requirement for a PTAP motif to induce virion release. Depletion of VPS37C from cells does not inhibit murine leukemia virus budding, which is not mediated by ESCRT-I, however, if murine leukemia virus budding is engineered to be ESCRT-I-dependent, then it is inhibited by VPS37C depletion, and this inhibition is accentuated if VPS37B is simultaneously depleted. Thus, this study identifies VPS37C as a functional component of mammalian ESCRT-I.	Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10016 USA	Rockefeller University	Bieniasz, PD (corresponding author), Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10021 USA.	pbienias@adarc.org		Martin-Serrano, Juan/0000-0002-8183-3914	NIAID NIH HHS [R01-AI052774] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052774] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; BEGLEY D, 1995, MOL GEN GENET, V248, P69, DOI 10.1007/BF02456615; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Goila-Gaur R, 2003, J VIROL, V77, P6507, DOI 10.1128/JVI.77.11.6507-6519.2003; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Stuchell MD, 2004, J BIOL CHEM, V279, P36059, DOI 10.1074/jbc.M405226200; Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000	37	67	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					628	636		10.1074/jbc.M410384200	http://dx.doi.org/10.1074/jbc.M410384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509564	hybrid			2022-12-25	WOS:000226025100074
J	Fukuyama, T; Ogita, H; Kawakatsu, T; Fukuhara, T; Yamada, T; Sato, T; Shimizu, K; Nakamura, T; Matsuda, M; Takai, Y				Fukuyama, T; Ogita, H; Kawakatsu, T; Fukuhara, T; Yamada, T; Sato, T; Shimizu, K; Nakamura, T; Matsuda, M; Takai, Y			Involvement of the c-Src-Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and formation of adherens junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; SMALL G-PROTEIN; GTP-BINDING PROTEIN; TRANS-INTERACTIONS; MOLECULE NECTIN; RAS; RAP1; CADHERIN; SRC; POLARITY	Nectins, Ca2+-independent immunoglobulin-like cell-cell adhesion molecules, induce the activation of Cdc42 and Rac small G proteins, enhancing the formation of cadherin-based adherens junctions (AJs) and claudin-based tight junctions. Nectins recruit and activate c-Src at the nectin-based cell-cell contact sites. c-Src then activates Cdc42 through FRG, a Cdc42-GDP/GTP exchange factor. We showed here that Rap1 small G protein was involved in the nectin-induced activation of Cdc42 and formation of AJs. Rap1 was recruited to the nectin-based cell-cell contact sites and locally activated through the c-Src-Crk-C3G signaling there. The activation of either c-Src or Rap1 alone was insufficient for and the activation of both molecules was essential for the activation of FRG. The activation of Rap1 was not necessary for the c-Src-mediated phosphorylation or recruitment of FRG. The inhibition of the Crk, C3G, or Rap1 signaling reduced the formation of AJs. These results indicate that Rap1 is activated by nectins through the c-Src-Crk-C3G signaling and involved in the nectin-induced, c-Src- and FRG-mediated activation of Cdc42 and formation of AJs.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Tumor Virol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@biolbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Matsuda, Michiyuki/0000-0002-5876-9969; Ogita, Hisakazu/0000-0001-6750-1668				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; IRIE K, 2004, HDB EXPT PHARM, P345; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, ONCOGENE, V3, P201; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YONEMURA S, 1995, J CELL SCI, V108, P127; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	54	119	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					815	825		10.1074/jbc.M411099200	http://dx.doi.org/10.1074/jbc.M411099200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504743	hybrid			2022-12-25	WOS:000226025100095
J	Hosoya-Matsuda, N; Motohashi, K; Yoshimura, H; Nozaki, A; Inoue, K; Ohmori, M; Hisabori, T				Hosoya-Matsuda, N; Motohashi, K; Yoshimura, H; Nozaki, A; Inoue, K; Ohmori, M; Hisabori, T			Anti-oxidative stress system in cyanobacteria - Significance of type II peroxiredoxin and the role of 1-Cys peroxiredoxin in Synechocystis sp strain PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; THIOREDOXIN SYSTEM; MOLECULAR CHARACTERIZATION; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; REDUCTASE-ACTIVITY; OXIDATIVE STRESS; THIOL MODULATION; CHINESE-CABBAGE; TARGET PROTEINS	Two antioxidant proteins, SLL1621 and SLR1198, were captured in the cyanobacteria Synechocystis sp. PCC 6803 using thioredoxin affinity chromatography, which was first applied to the survey of thioredoxin target proteins in chloroplasts (Motohashi, K., Kondoh, A., Stumpp, M. T., and Hisabori, T. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11224-11229). They are annotated as AhpC/TSA family protein ( SLL1621) and antioxidant protein ( SLR1198) in CyanoBase (Nakamura, Y., Kaneko, T., Hirosawa, M., Miyajima, N., and Tabata, S. ( 1998) Nucleic Acids Res. 26, 63 - 67). Based on sequence homology analysis SLL1621 and SLR1198 are categorized into type II peroxiredoxin and 1-Cys type peroxiredoxin, respectively. In vitro interaction between SLL1621 and thioredoxin was confirmed using the recombinant proteins expressed in Escherichia coli. Furthermore, we found that SLL1621 shows remarkable glutathione-dependent peroxidase activity. Disruption of the sll1621 gene had a dramatic effect on the viability of the cyanobacterial cells even under weak light conditions (50 mumol.m(-2).s(-1)), suggesting this peroxiredoxin is essential for this cyanobacterium. In contrast, although the peroxidase activity of SLR1198 was scarcely detected, disruption of the gene, slr1198, certainly affected the growth rate of the cells. The results indicate the physiological significance of two different peroxiredoxins as an anti-oxidative stress system in cyanobacteria.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Agcy, ATP Syst Project, Exploratory Res Adv Technol, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Dept Life Sci, Grad Sch Arts & Sci, Meguro Ku, Tokyo 1538902, Japan; Kanagawa Univ, Dept Biol Sci, Kanagawa 2591293, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); University of Tokyo; Kanagawa University	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259-R1-8, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Cheong NE, 1999, PLANT MOL BIOL, V40, P825, DOI 10.1023/A:1006271823973; Choi YO, 1999, BIOCHEM BIOPH RES CO, V258, P768, DOI 10.1006/bbrc.1999.0714; COLLIER JL, 1995, J BACTERIOL, V177, P3269, DOI 10.1128/jb.177.11.3269-3276.1995; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Gaber A, 2001, FEBS LETT, V499, P32, DOI 10.1016/S0014-5793(01)02517-0; Goyer A, 2002, EUR J BIOCHEM, V269, P272, DOI 10.1046/j.0014-2956.2001.02648.x; Haslekas C, 1998, PLANT MOL BIOL, V36, P833, DOI 10.1023/A:1005900832440; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jakopitsch C, 2001, BIOCHEM BIOPH RES CO, V287, P682, DOI 10.1006/bbrc.2001.5616; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Klughammer B, 1998, PHYSIOL PLANTARUM, V104, P699, DOI 10.1034/j.1399-3054.1998.1040426.x; Kobayashi D, 2003, PLANT CELL PHYSIOL, V44, P269, DOI 10.1093/pcp/pcg048; Kobayashi M, 2004, PLANT CELL PHYSIOL, V45, P290, DOI 10.1093/pcp/pch034; Kong W, 2000, BIOCHEM J, V351, P107, DOI 10.1042/0264-6021:3510107; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lemaire SD, 2004, P NATL ACAD SCI USA, V101, P7475, DOI 10.1073/pnas.0402221101; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Matsuda N, 2003, PLANT CELL PHYSIOL, V44, pS66; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Mowla SB, 2002, PLANTA, V215, P716, DOI 10.1007/s00425-002-0819-0; MULLER EGD, 1989, J BIOL CHEM, V264, P4008; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; Perelman A, 2003, J BACTERIOL, V185, P3654, DOI 10.1128/JB.185.12.3654-3660.2003; Rouhier N, 2004, PHYSIOL PLANTARUM, V120, P57, DOI 10.1111/j.0031-9317.2004.0203.x; Rouhier N, 2003, ANTIOXID REDOX SIGN, V5, P15, DOI 10.1089/152308603321223504; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Stacy RAP, 1996, PLANT MOL BIOL, V31, P1205, DOI 10.1007/BF00040837; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Tamoi M, 1996, ARCH BIOCHEM BIOPHYS, V334, P27, DOI 10.1006/abbi.1996.0425; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; WERNERGRUNE S, 1994, MOL GEN GENET, V244, P144; Williams JGK, 1998, METHOD ENZYMOL, V167, P766; Yamamoto H, 1999, FEBS LETT, V447, P269, DOI 10.1016/S0014-5793(99)00309-9; Yamazaki D, 2004, PLANT CELL PHYSIOL, V45, P18, DOI 10.1093/pcp/pch019; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	52	95	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					840	846		10.1074/jbc.M411493200	http://dx.doi.org/10.1074/jbc.M411493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509585	hybrid			2022-12-25	WOS:000226025100098
J	Kuo, HC; Moore, JD; Krebs, JE				Kuo, HC; Moore, JD; Krebs, JE			Histone H2A and spt10 cooperate to regulate induction and autoregulation of the CUP1 metallothionein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; SPT21 GENES; CHROMATIN; ACETYLATION; PROMOTER; CONSEQUENCES; EXPRESSION; REQUIRES; COMPLEX; PLAYS	Copper is an essential cellular cofactor that becomes toxic at high levels. Copper homeostasis is tightly regulated by opposing mechanisms that control copper import, export, and copper binding capacity within the cell. High levels of copper induce the expression of metallothioneins, small sulfhydryl-rich proteins with high metal binding capabilities that serve as neutralizers of toxic levels of metals. In yeast, the CUP1 gene encodes a copper metallothionein that is strongly induced in response to metals and other stress and is subsequently rapidly down-regulated. Activation of CUP1 is mediated by the copper-responsive transcriptional activator AceI, and also requires the histone acetylase Spt10 for full induction. We have examined the role of histone H2A in the normal regulation of the CUP1 gene. We have shown that specific H2A mutations in combination with spt10 deletions result in aberrant regulation of CUP1 expression. Certain lysine mutations in H2A alleviate the transcriptional defect in spt10Delta strains, though CUP1 activation is still delayed in these mutants; however, CUP1 shutdown is normal. In contrast, serine mutations in H2A prevent CUP1 shutdown when combined with spt10 deletions. In addition, swi/snf mutants exhibit both impaired CUP1 induction and failure to shut down CUP1 normally. Finally, different Spt10-dependent histone acetylation events correlate with induction and shutdown. Taken together, these data indicate that CUP1 transcriptional shutdown, like induction, is an active process controlled by the chromatin structure of the gene. These results provide new insights for the role of chromatin structure in metal homeostasis.	Univ Alaska Anchorage, Dept Biol Sci, Anchorage, AK 99508 USA	University of Alaska System; University of Alaska Anchorage	Krebs, JE (corresponding author), Univ Alaska Anchorage, Dept Biol Sci, Anchorage, AK 99508 USA.	afjek@uaa.alaska.edu						Czermin B, 2003, GENETICA, V117, P159, DOI 10.1023/A:1022927725945; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Daniel KG, 2004, FRONT BIOSCI-LANDMRK, V9, P2652, DOI 10.2741/1424; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fernandez-Capetillo O, 2004, J EXP MED, V199, P1671, DOI 10.1084/jem.20032247; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; Hess D, 2004, MOL CELL BIOL, V24, P135, DOI 10.1128/MCB.24.1.135-143.2004; HOTTIGER T, 1994, YEAST, V10, P283, DOI 10.1002/yea.320100302; Howlett NG, 1999, FEMS MICROBIOL LETT, V176, P379, DOI 10.1111/j.1574-6968.1999.tb13687.x; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kim MKH, 2004, CANCER-AM CANCER SOC, V101, P2106, DOI 10.1002/cncr.20626; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Lo WS, 2004, METHOD ENZYMOL, V377, P130; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Mellor J, 2004, BBA-GENE STRUCT EXPR, V1677, P100, DOI 10.1016/j.bbaexp.2003.10.014; NATSOULIS G, 1991, NEW BIOL, V3, P1249; NATSOULIS G, 1994, GENETICS, V136, P93; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Shen CH, 2002, MOL CELL BIOL, V22, P6406, DOI 10.1128/MCB.22.18.6406-6416.2002; Shen CH, 2001, J BIOL CHEM, V276, P35209, DOI 10.1074/jbc.M104733200; Shen CH, 2001, MOL CELL BIOL, V21, P534, DOI 10.1128/MCB.21.2.534-547.2001; Sumner ER, 2003, MOL MICROBIOL, V50, P857, DOI 10.1046/j.1365-2958.2003.03715.x; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Theocharis SE, 2003, INT J BIOL MARKER, V18, P162, DOI 10.1177/172460080301800302; Torok MS, 2004, ADV PROTEIN CHEM, V67, P181; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; Wang C, 2004, METH MOL B, V241, P207; Winge DR, 2002, ADV PROTEIN CHEM, V60, P51; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; WRIGHT CF, 1988, J BIOL CHEM, V263, P1570; Wyatt HR, 2003, GENETICS, V164, P47; YAMASHITA I, 1993, MOL GEN GENET, V241, P616, DOI 10.1007/BF00279904; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581	43	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					104	111		10.1074/jbc.M411437200	http://dx.doi.org/10.1074/jbc.M411437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501826	Green Submitted, hybrid			2022-12-25	WOS:000226025100014
J	Miyase, S; Tateishi, S; Watanabe, K; Tomita, K; Suzuki, K; Inoue, H; Yamaizumi, M				Miyase, S; Tateishi, S; Watanabe, K; Tomita, K; Suzuki, K; Inoue, H; Yamaizumi, M			Differential regulation of Rad18 through Rad6-dependent mono- and polyubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; DEFECTIVE POSTREPLICATION REPAIR; RING FINGER PROTEINS; DNA-DAMAGE; COMPLEX-FORMATION; UV MUTAGENESIS; YEAST RAD18; P53; MECHANISM; MDM2	Rad18 is involved in postreplication repair mainly through monoubiquitination of proliferating cell nuclear antigen ( PCNA). Here we show that Rad18 protein was detected in human cells as two major bands at 75 and 85 kDa by Western blot. The bands were identified as nonubiquitinated and monoubiquitinated forms of Rad18, respectively, by mass spectrometry. Multiple ubiquitinated bands of Rad18 were detected in vitro in the presence of E1, E2 (Rad6), and methylated ubiquitin, indicating that Rad18 was monoubiquitinated at multiple sites through autoubiquitination. Rad18 self-associates, and this interaction was abolished by replacing one of the conserved cysteine residues with phenylalanine in the zinc finger domain (C207F). In the C207F mutant Rad18, monoubiquitination of Rad18 was not observed in vivo, suggesting that self-association was critical for monoubiquitination. Monoubiquitinated Rad18 was detected mainly in the cytoplasm, whereas nonubiquitinated Rad18 was detected predominantly in the nuclei. Furthermore, Rad18 was shown to be polyubiquitinated in cells treated with proteasome inhibitors. Purified Rad18 was also polyubiquitinated in an in vitro system containing E1, E2 ( Rad6), and ubiquitin, and it was degraded by the addition of proteasomes. These results suggest that the amount of Rad18 in the nucleus is regulated differentially by mono- and polyubiquitination.	Kumamoto Univ, Inst Mol Embryol & Genet, Kumamoto 8630976, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Internal Med 3, Kumamoto 8608556, Japan; Saitama Univ, Fac Sci, Dept Regulat Biol, Urawa, Saitama 3388570, Japan	Kumamoto University; Kumamoto University; Saitama University	Yamaizumi, M (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Kuhonji 4-24-1, Kumamoto 8630976, Japan.	yamaizm@gpo.kumamoto-u.ac.jp		Suzuki, Keiichiro/0000-0001-5603-9105				ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kunz BA, 2000, MUTAT RES-FUND MOL M, V451, P169, DOI 10.1016/S0027-5107(00)00048-8; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; LAWRENCE CW, 1976, GENETICS, V82, P207; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; Shekhar MPV, 2002, CANCER RES, V62, P2115; Tateishi S, 2003, MOL CELL BIOL, V23, P474, DOI 10.1128/MCB.23.2.474-481.2003; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; TOMITA H, 1993, MOL GEN GENET, V238, P225, DOI 10.1007/BF00279551; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	31	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					515	524		10.1074/jbc.M409219200	http://dx.doi.org/10.1074/jbc.M409219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509568	hybrid			2022-12-25	WOS:000226025100061
J	Tai, SL; Boer, VM; Daran-Lapujade, P; Walsh, MC; de Winde, JH; Daran, JM; Pronk, JT				Tai, SL; Boer, VM; Daran-Lapujade, P; Walsh, MC; de Winde, JH; Daran, JM; Pronk, JT			Two-dimensional transcriptome analysis in chemostat cultures - Combinatorial effects of oxygen availability and macronutrient limitation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; HYPOXIC GENES; YEAST; GROWTH; CARBON; MICROARRAYS; GLUCOSE; FAMILY; ACID	Genome-wide analysis of transcriptional regulation is generally studied by determining sets of "signature transcripts" that are up- or down-regulated relative to a reference situation when a single culture parameter or genetic modification is changed. This approach is especially relevant for defining small subsets of transcripts for use in high throughput, cost-effective diagnostic analyses. However, this approach may overlook the simultaneous control of transcription by more than one environmental parameter. This study represents the first quantitative assessment of the impact of transcriptional cross-regulation by different environmental parameters. As a model, we compared the response of aerobic as well as anaerobic chemostat cultures of the yeast Saccharomyces cerevisiae to growth limitation by four different macronutrients ( carbon, nitrogen, phosphorus, and sulfur). The identity of the growth-limiting nutrient was shown to have a strong impact on the sets of transcripts that responded to oxygen availability and vice versa. We concluded that identification of reliable signature transcripts for specific environmental parameters can be obtained only by combining transcriptome data sets obtained under several sets of reference conditions. Furthermore, the two-dimensional approach to transcriptome analysis is a valuable new tool to study the interaction of different transcriptional regulation systems.	Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; Heineken Tech Serv, Res & Dev, NL-2380 BB Zoeterwoude, Netherlands; DSM Life Sci, Div Bakery Ingredients, Technol Cluster, NL-2600 MA Delft, Netherlands	Delft University of Technology; Heineken; DSM NV	Daran, JM (corresponding author), Delft Univ Technol, Kluyver Lab Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	j.m.daran@tnw.tudelft.nl	Tai, Siew L/E-6476-2016; de Winde, J.H./AAC-5520-2021; Daran, Jean-Marc/X-8787-2019	Tai, Siew L/0000-0002-2148-3115; de Winde, J.H./0000-0002-7999-9317; Daran, Jean-Marc/0000-0003-3136-8193; Daran-Lapujade, Pascale/0000-0002-4097-7831; Pronk, Jack/0000-0002-5617-4611				Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; ANDREASEN AA, 1954, J CELL COMPAR PHYSL, V43, P271, DOI 10.1002/jcp.1030430303; ANDREASEN AA, 1953, J CELL COMPAR PHYSL, V41, P23, DOI 10.1002/jcp.1030410103; Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Blom J, 2000, APPL ENVIRON MICROB, V66, P1970, DOI 10.1128/AEM.66.5.1970-1973.2000; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Boles E, 1997, J BACTERIOL, V179, P2987, DOI 10.1128/jb.179.9.2987-2993.1997; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cohen BD, 2001, NUCLEIC ACIDS RES, V29, P799, DOI 10.1093/nar/29.3.799; Daran-Lapujade P, 2004, J BIOL CHEM, V279, P9125, DOI 10.1074/jbc.M309578200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dwight SS, 2004, BRIEF BIOINFORM, V5, P9, DOI 10.1093/bib/5.1.9; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Flick JS, 1998, GENETICS, V148, P33; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Higgins VJ, 2003, APPL ENVIRON MICROB, V69, P7535, DOI 10.1128/AEM.69.12.7535-7540.2003; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Homma T, 2003, CRYOBIOLOGY, V46, P230, DOI 10.1016/S0011-2240(03)00028-2; Jansen MLA, 2004, APPL ENVIRON MICROB, V70, P1956, DOI 10.1128/AEM.70.4.1956-1963.2004; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; LARSSON C, 1993, J BACTERIOL, V175, P4809, DOI 10.1128/JB.175.15.4809-4816.1993; Lau WTW, 2000, P NATL ACAD SCI USA, V97, P1107, DOI 10.1073/pnas.97.3.1107; Lelandais G, 2004, NUCLEIC ACIDS RES, V32, pD323, DOI 10.1093/nar/gkh135; Lodi T, 1999, MOL GEN GENET, V262, P623, DOI 10.1007/s004380051125; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Mewes HW, 2004, NUCLEIC ACIDS RES, V32, pD41, DOI 10.1093/nar/gkh092; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Persson BL, 1998, BBA-BIOENERGETICS, V1365, P23, DOI 10.1016/S0005-2728(98)00037-1; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P3214, DOI 10.1128/AEM.55.12.3214-3220.1989; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; Regnacq M, 2001, MOL MICROBIOL, V40, P1085, DOI 10.1046/j.1365-2958.2001.02450.x; Rosenfeld E, 2003, YEAST, V20, P1115, DOI 10.1002/yea.1026; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Sandager L, 2000, BIOCHEM SOC T, V28, P700; Schmidt U, 2003, INT J BIOCHEM CELL B, V35, P119, DOI 10.1016/S1357-2725(02)00124-3; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; VENTER U, 1989, NUCLEIC ACIDS RES, V17, P1353, DOI 10.1093/nar/17.4.1353; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; VISSER W, 1990, APPL ENVIRON MICROB, V56, P3785, DOI 10.1128/AEM.56.12.3785-3792.1990; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; Wu J, 2004, P NATL ACAD SCI USA, V101, P3148, DOI 10.1073/pnas.0308321100; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	69	110	113	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					437	447		10.1074/jbc.M410573200	http://dx.doi.org/10.1074/jbc.M410573200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15496405	hybrid, Green Published			2022-12-25	WOS:000226025100053
J	Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP				Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP			Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice	ONCOGENE			English	Article						fatty acid synthase; HER2; neu; transgenic	BREAST-CANCER; PROSTATE-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; FOOD-INTAKE; OVEREXPRESSION; PROGRESSION; CARCINOMAS; HER-2/NEU; CELLS; GENE	High levels of fatty acid synthase (FAS) have been found in cancer precursor lesions of the colon, stomach, esophagus, oral cavity, prostate, and breast. Inhibition of FAS with C75 has led to a significant antitumor effect in both human breast and prostate cancer xenografts. Recently, HER2/neu, which has also been identified in preneoplastic breast lesions, has been shown to regulate FAS expression through the PI3K/Akt signal transduction pathway rendering them susceptible to FAS inhibition. Utilizing the neu-N transgenic mouse model of mammary cancer, weekly treatment of the neu-N mice with C75 (30 mg/kg) for 10 weeks significantly delayed tumor progression. Only 20% of the C75-treated transgenic mice developed mammary carcinoma by 220 days, compared to 50% in the vehicle control animals. Two C75-treated animals never developed mammary cancer. Analysis of mammary tissue following 10 weeks of C75 treatment revealed a significant delay in mammary maturation as manifested by a reduction of the number and caliber of mammary ducts and budding epithelial structures. Apoptotic changes were increased, DNA synthesis was decreased, and the expressions of FAS, neu, Akt, phospho-Akt, and p21(waf1) were all decreased when compared to vehicle controls and FVB/N mice. Importantly, these effects were restricted to the breast epithelial cells that overexpressed neu, not involving other normal duct structures in the skin, liver, or kidney. C247, an FAS inhibitor chemically distinct from C75, significantly delayed mammary maturation similar to C75. Thus, pharmacological inhibition of FAS affects the expression of key oncogenes involved in both cancer development and maintenance of the malignant phenotype. Moreover, these data identify FAS as a potential novel drug target for breast cancer chemoprevention.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; FASgen Inc, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Bldg AA,Room 154A,4940 Eastern Ave, Baltimore, MD 21224 USA.	fkuhajda@jhmi.edu		Jaffee, Elizabeth/0000-0003-3841-6549	NCI NIH HHS [1R44CA99435, 1P50CA88843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA099435, P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 2001, AM J CLIN PATHOL, V116, P129; Boggio K, 2000, CANCER RES, V60, P359; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fabian CJ, 2001, BREAST CANCER RES, V3, P99, DOI 10.1186/bcr279; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Jordan VC, 2000, J STEROID BIOCHEM, V74, P269, DOI 10.1016/S0960-0760(00)00103-5; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Lofts F J, 1992, Cancer Treat Res, V61, P161; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; McFadden JM, 2002, ORG LETT, V4, P3859, DOI 10.1021/ol026685k; MCFADDEN JM, 2004, UNPUB J MED CHEM; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Nemoto T, 2001, PATHOBIOLOGY, V69, P297, DOI 10.1159/000064636; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Reilly R T, 2001, Curr Opin Investig Drugs, V2, P133; Reilly R Todd, 2002, Methods Mol Med, V69, P233; Reilly RT, 2000, CANCER RES, V60, P3569; Reilly RT, 2001, CANCER RES, V61, P880; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Visca P, 1999, CLIN CANCER RES, V5, P4111; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG HQ, 2003, P AM ASSOC CANC RES, V44, P1100; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu RL, 2002, MODERN PATHOL, V15, P116, DOI 10.1038/modpathol.3880503; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zhou WB, 2003, CANCER RES, V63, P7330	42	131	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					39	46		10.1038/sj.onc.1208174	http://dx.doi.org/10.1038/sj.onc.1208174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15489885				2022-12-25	WOS:000226125800006
J	Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T				Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T			Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells	ONCOGENE			English	Article						E1B-55kDa; PML; p53; nucleocytoplasmic shuttling	E1B 55-KILODALTON ONCOPROTEIN; E1B-58KD TUMOR-ANTIGEN; 5 E4ORF3 PROTEIN; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; MONOCLONAL-ANTIBODIES; SUMO-1 MODIFICATION; INFECTED-CELLS; CELLULAR P53	The 55-kDa gene product from subgroup C adenovirus type 5 (Ad5) early region 1 (E1B-55kDa) plays a central role in the oncogenic transformation of primary rodent cells primarily by inactivating transcriptional and presumably other functional properties of the tumor suppressor protein p53. We have previously shown that Ad5 E1B-55kDa possesses a leucine-rich nuclear export signal (NES), which confers rapid nucleocytoplasmic shuttling via the CRM1-dependent export pathway. In this study we report that an export-deficient mutant of the viral protein (E1B-NES) substantially enhances focus formation of primary baby rat kidney cells in combination with Ad E1A. Transformed rat cells stably expressing the E1B-NES protein exhibited increased tumorigenicity and accelerated tumor growth in nude mice compared to transformants containing the wild-type E1B product. This 'gain of function' correlated with enhanced inhibition of p53 transactivation in transient reporter assays and the accumulation of the mutant protein and p53 in several dot-like subnuclear aggregates. Interestingly, these structures also contained a large fraction of cellular promyelocytic leukemia protein (PML), a known regulator of p53. These data indicate that E1B-NES promotes oncogenic transformation by combinatorial mechanisms that involve modulation of p53 in the context of PML nuclear bodies. In sum, these results extend our previous observation that inhibition of PML activities by E1B-55kDa is required for efficient focus formation and provide further support for the view that blocking p53 transcriptional functions is the principal mechanism by which the Ad protein contributes to complete cell transformation in conjunction with Ad E1A.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93047 Regensburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	University of Regensburg; Heinrich Pette Institute	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Landshuterstr 22, D-93047 Regensburg, Germany.	thomas.dobner@klinik.uni-regensburg.de						Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	59	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					55	64		10.1038/sj.onc.1208170	http://dx.doi.org/10.1038/sj.onc.1208170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15480414				2022-12-25	WOS:000226125800008
J	Aledo, JC; del Valle, AE				Aledo, JC; del Valle, AE			The ATP paradox is the expression of an economizing fuel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYSIS; OPTIMIZATION; EFFICIENCY; TRANSPORT; PATHWAYS; GLUCOSE; YEAST	The strong negative correlation between glycolytic flux and intracellular ATP concentration observed in yeast has long been an intriguing and counterintuitive phenomenon, which has been referred to as the ATP paradox. Herein, using principles of irreversible thermodynamics it was shown that if the ATP-consuming pathways are more sensitive to extracellular glucose than glycolysis, then upon glucose addition glycolysis performance can switch from an efficient working regime to a dissipative regime, and vice versa, depending on glucose availability. The efficient regime represents a good compromise between high output power and low dissipation, whereas the dissipative working regime offers a higher output power although at a high glucose cost. The physiological and evolutionary implications of this switch strategy are discussed.	Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, E-29071 Malaga, Spain	Universidad de Malaga	Aledo, JC (corresponding author), Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, E-29071 Malaga, Spain.	caledo@uma.es	Aledo, Juan C/E-6029-2011; Aledo, Juan Carlos/Z-4236-2019	Aledo, Juan Carlos/0000-0002-3497-9945				Aledo JC, 2004, BIOESSAYS, V26, P778, DOI 10.1002/bies.20063; Aledo JC, 2002, J CHEM EDUC, V79, P1336, DOI 10.1021/ed079p1336; ESSIG A, 1981, P NATL ACAD SCI-BIOL, V78, P1647, DOI 10.1073/pnas.78.3.1647; Heinrich R, 1999, BIOCHEM SOC T, V27, P294, DOI 10.1042/bst0270294; KEDEM O, 1965, T FARADAY SOC, V61, P1897, DOI 10.1039/tf9656101897; Kondepudi D, 1999, MODERN THERMODYNAMIC, P333; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; MADDOX J, 1991, NATURE, V350, P653, DOI 10.1038/350653a0; Medina MA, 2001, J NUTR, V131, p2539S, DOI 10.1093/jn/131.9.2539S; MelendezHevia E, 1997, EUR J BIOCHEM, V244, P527, DOI 10.1111/j.1432-1033.1997.t01-1-00527.x; NEWSHOLME EA, 1991, ADV ENZYME REGUL, V31, P225, DOI 10.1016/0065-2571(91)90015-E; Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Santillan M, 1997, NUOVO CIMENTO D, V19, P99; Somsen OJG, 2000, BIOCHEM J, V352, P593, DOI 10.1042/0264-6021:3520593; STUCKI JW, 1980, EUR J BIOCHEM, V109, P269, DOI 10.1111/j.1432-1033.1980.tb04792.x; THEOBALD U, 1993, ANAL BIOCHEM, V214, P31, DOI 10.1006/abio.1993.1452; van Rotterdam BJ, 2002, FEBS LETT, V510, P105, DOI 10.1016/S0014-5793(01)03210-0; VANDERMEER R, 1980, BIOCHIM BIOPHYS ACTA, V591, P488, DOI 10.1016/0005-2728(80)90179-6; Velicer GJ, 1999, ECOLOGY, V80, P1168, DOI 10.2307/177064; VIEIRA FL, 1972, J GEN PHYSIOL, V59, P77, DOI 10.1085/jgp.59.1.77; Waddell TG, 1999, BIOCHEM EDUC, V27, P12, DOI 10.1016/S0307-4412(98)00266-0; WESTERHOFF HV, 1983, P NATL ACAD SCI-BIOL, V80, P305, DOI 10.1073/pnas.80.1.305; WESTERHOFF HV, 1987, THERMODYNAMICS CONTR, P228	24	24	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55372	55375		10.1074/jbc.M410479200	http://dx.doi.org/10.1074/jbc.M410479200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509563	hybrid			2022-12-25	WOS:000225960800050
J	Andreau, K; Castedo, M; Perfettini, JL; Roumier, T; Pichart, E; Souquere, S; Vivet, S; Larochette, N; Kroemer, G				Andreau, K; Castedo, M; Perfettini, JL; Roumier, T; Pichart, E; Souquere, S; Vivet, S; Larochette, N; Kroemer, G			Preapoptotic chromatin condensation upstream of the mitochondrial checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MEMBRANE PERMEABILIZATION; DNA FRAGMENTATION; DISTINCT PATHWAYS; CYCLOPHILIN-A; HISTONE H2AX; APOPTOSIS; CASPASES; AIF; QUANTITATION	When added for a short period (2-4 h) to cells, the kinase inhibitor staurosporine (STS), can trigger double strand breaks, the formation of nuclear foci containing phosphorylated H2AX, Chk2, and p53, a decrease in transcription, and a minor degree of peripheral chromatin condensation. This "preapoptotic chromatin condensation" (PACC) occurs before mitochondrial membrane permeabilization (MMP) and caspase activation become detectable and is not inhibited by Z-VAD-fmk or Bcl-2. PACC is followed by classical apoptosis, when cells are cultured overnight, even when STS is removed from the system. After overnight incubation, STS-pretreated cells manifest mitochondrial cytochrome c release, caspase activation, phosphatidylserine exposure, and apoptotic DNA fragmentation. Caspase or MMP inhibitors did not influence the advent of PACC yet did suppress the evolution of PACC toward apoptosis. Importantly, two unrelated MMP inhibitors (viral mitochondrial inhibitor of apoptosis (vMIA) from cytomegalovirus and mitochondrion-targeted Bcl-2) had a larger range of effects than the pan-caspase inhibitor Z-VAD-fmk. Caspase inhibition simply prevented the transition from PACC to apoptosis yet did not reverse PACC and did not restore transcription. In contrast, Bcl-2 and vMIA allowed for the repair of the DNA lesions, correlating with the reestablishment of active transcription. PACC could also be induced by a gross perturbation of RNA synthesis or primary DNA damage. Again, inhibition of MMP (but not that of caspases) reversed PACC induced by these stimuli. In synthesis, our data reveal the unexpected capacity of STS to induce DNA lesions and suggest qualitative differences in the cytoprotective and DNA repair-inducing potential of different apoptosis inhibitors.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Andre Lwoff, UPR 1983, Lab Replicat ADN & Ultrastruct Noyau, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; PERFETTINI, Jean-Luc/N-4699-2017; LAROCHETTE, Nathanael/R-4298-2017	KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; LAROCHETTE, Nathanael/0000-0002-7936-678X; Andreau, Karine/0000-0002-9773-0733				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Banath JP, 2003, CANCER RES, V63, P4347; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Castedo M, 1996, J IMMUNOL, V157, P512; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harborth J, 2001, J CELL SCI, V114, P4557; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; McIlroy D, 2000, GENE DEV, V14, P549; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shinzawa K, 2003, J CELL BIOL, V163, P1219, DOI 10.1083/jcb.200306159; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Wang XD, 2001, GENE DEV, V15, P2922; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2000, METHOD ENZYMOL, V322, P208; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55937	55945		10.1074/jbc.M406411200	http://dx.doi.org/10.1074/jbc.M406411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498771	hybrid			2022-12-25	WOS:000225960800117
J	Audebert, M; Salles, B; Calsou, P				Audebert, M; Salles, B; Calsou, P			Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL-FREE-EXTRACTS; V(D)J RECOMBINATION; MAMMALIAN-CELLS; IN-VITRO; IONIZING-RADIATION; BIOCHEMICAL-CHARACTERIZATION; CHROMOSOMAL-ABERRATIONS; KU80-DEFICIENT CELLS; BACKUP PATHWAYS	The efficient repair of DNA double-strand breaks (DSBs) is critical for the maintenance of genomic integrity. In mammalian cells, the nonhomologous end-joining process that represents the predominant repair pathway relies on the DNA-dependent protein kinase (DNA-PK) and the XRCC4-DNA ligase IV complex. Nonetheless, several in vitro and in vivo results indicate that mammalian cells use more than a single end-joining mechanism. While searching for a DNA-PK-independent end-joining activity, we found that the pretreatment of DNA-PK-proficient and -deficient rodent cells with an inhibitor of the poly(ADP-ribose) polymerase-1 enzyme (PARP-1) led to increased cytotoxicity of the highly efficient DNA double-strand breaking compound calicheamicin gamma1. In addition, the repair kinetics of the DSBs induced by calicheamicin gamma1 was delayed both in PARP-1-proficient cells pretreated with the PARP-1 inhibitor and in PARP-1-deficient cells. In order to get new insights into the mechanism of an alternative route for DSBs repair, we have established a new synapsis and end-joining two-step assay in vitro, operating on DSBs with either nuclear protein extracts or recombinant proteins. We found an end-joining activity independent of the DNA-PK/XRCC4-ligase IV complex but that actually required a novel synapsis activity of PARP-1 and the ligation activity of the XRCC1-DNA ligase III complex, proteins otherwise involved in the base excision repair pathway. Taken together, these results strongly suggest that a PARP-1-dependent DSBs end-joining activity may exist in mammalian cells. We propose that this mechanism could act as an alternative route of DSBs repair that complements the DNA-PK/XRCC4/ligase IV-dependent nonhomologous end-joining.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	bernard.salles@ipbs.fr	calsou, patrick/AAB-5123-2020; AUDEBERT, Marc A/C-1153-2008; salles, bernard/B-8531-2008	AUDEBERT, Marc A/0000-0001-7898-6912; Calsou, Patrick/0000-0001-7951-9806				Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Barrows LR, 1998, MUTAT RES-DNA REPAIR, V408, P103, DOI 10.1016/S0921-8777(98)00022-6; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Boulton S, 1999, CARCINOGENESIS, V20, P199, DOI 10.1093/carcin/20.2.199; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Brown ML, 2002, P NATL ACAD SCI USA, V99, P4532, DOI 10.1073/pnas.072495299; BRYANT PE, 1993, MUTAT RES, V299, P289, DOI 10.1016/0165-1218(93)90105-M; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; Calsou P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1; Cheong N, 1999, INT J RADIAT BIOL, V75, P67, DOI 10.1080/095530099140825; CHUNG HW, 1991, RADIAT RES, V125, P107, DOI 10.2307/3577989; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Dibiase SJ, 2000, CANCER RES, V60, P1245; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; FERRO AM, 1982, J BIOL CHEM, V257, P7808; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Johnson AP, 1997, MUTAT RES-DNA REPAIR, V383, P205, DOI 10.1016/S0921-8777(97)00003-7; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nocentini S, 1999, RADIAT RES, V151, P423, DOI 10.2307/3579829; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Pion E, 2003, BIOCHEMISTRY-US, V42, P12409, DOI 10.1021/bi0344432; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rudat V, 2001, INT J RADIAT BIOL, V77, P303, DOI 10.1080/09553000010009026; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Stenerlow B, 2003, RADIAT RES, V159, P502, DOI 10.1667/0033-7587(2003)159[0502:MOPDDS]2.0.CO;2; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Taverna P, 2003, CANCER RES, V63, P838; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2002, CANCER RES, V62, P6990; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Duijn-Goedhart A, 2000, MUTAT RES-GEN TOX EN, V471, P95, DOI 10.1016/S1383-5718(00)00122-4; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Veuger SJ, 2003, CANCER RES, V63, P6008; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Virsik-Kopp P, 2003, INT J RADIAT BIOL, V79, P61, DOI 10.1080/0955300021000038644; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Zhong Q, 2002, CANCER RES, V62, P3966; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	86	515	536	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55117	55126		10.1074/jbc.M404524200	http://dx.doi.org/10.1074/jbc.M404524200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498778	hybrid			2022-12-25	WOS:000225960800018
J	Barthelmes, HU; Habermeyer, M; Christensen, MO; Mielke, C; Interthal, H; Pouliot, JJ; Boege, F; Marko, D				Barthelmes, HU; Habermeyer, M; Christensen, MO; Mielke, C; Interthal, H; Pouliot, JJ; Boege, F; Marko, D			TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; PHOSPHODIESTERASE TDP1; COVALENT COMPLEXES; SPINOCEREBELLAR ATAXIA; ENZYME; YEAST; CAMPTOTHECIN; MECHANISM; PATHWAYS; PROTEINS	Tyrosyl DNA phosphodiesterase 1 (TDP1) is a repair enzyme that removes adducts, e. g. of topoisomerase I from the 3'-phosphate of DNA breaks. When expressed in human cells as biofluorescent chimera, TDP1 appeared more mobile than topoisomerase I, less accumulated in nucleoli, and not chromosome-bound at early mitosis. Upon exposure to camptothecin both proteins were cleared from nucleoli and rendered less mobile in the nucleoplasm. However, with TDP1 this happened much more slowly reflecting most likely the redistribution of nucleolar structures upon inhibition of rDNA transcription. Thus, a steady association of TDP1 with topoisomerase I seems unlikely, whereas its integration into repair complexes assembled subsequently to the stabilization of DNA.topoisomerase I intermediates is supported. Cells expressing GFP-tagged TDP1 > 100-fold in excess of endogenous TDP1 exhibited a significant reduction of DNA damage induced by the topoisomerase I poison camptothecin and could be selected by that drug. Surprisingly, DNA damage induced by the topoisomerase II poison VP-16 was also diminished to a similar extent, whereas DNA damage independent of topoisomerase I or II was not affected. Overexpression of the inactive mutant GFP-TDP1(H263A) at similar levels did not reduce DNA damage by camptothecin or VP-16. These observations confirm a requirement of active TDP1 for the repair of topoisomerase I-mediated DNA damage. Our data also suggest a role of TDP1 in the repair of DNA damage mediated by topoisomerase II, which is less clear. Since overexpression of TDP1 did not compromise cell proliferation, it could be a pleiotropic resistance mechanism in cancer therapy.	Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany; Univ Kaiserslautern, Dept Chem, Div Food Chem & Environm Technol, D-67663 Kaiserslautern, Germany; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; NIMH, Mol Biol Lab, Bethesda, MD 20894 USA	Heinrich Heine University Dusseldorf; University of Kaiserslautern; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Boege, F (corresponding author), Univ Dusseldorf, Sch Med, Inst Clin Chem & Lab Diagnost, Moorenstr 5, D-40225 Dusseldorf, Germany.	Boege@med.uni-duesseldorf.de	Marko, Doris/B-9354-2014; Boege, Fritz/H-3261-2019	Marko, Doris/0000-0001-6568-2944; 				Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; CALDECOTT K, 1990, CANCER RES, V50, P5778; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christensen MO, 2004, J BIOL CHEM, V279, P21873, DOI 10.1074/jbc.M400498200; Christensen MO, 2002, J CELL BIOL, V157, P31, DOI 10.1083/jcb.200112023; Christensen MO, 2003, NUCLEIC ACIDS RES, V31, P7255, DOI 10.1093/nar/gkg927; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Christensen MO, 2002, J BIOL CHEM, V277, P35932, DOI 10.1074/jbc.M204738200; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; GEDIK CM, 1992, INT J RADIAT BIOL, V62, P313, DOI 10.1080/09553009214552161; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Liu CY, 2004, DNA REPAIR, V3, P593, DOI 10.1016/j.dnarep.2004.03.030; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mielke C, 2000, GENE, V254, P1, DOI 10.1016/S0378-1119(00)00294-8; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nivens MC, 2004, CANCER CHEMOTH PHARM, V53, P107, DOI 10.1007/s00280-003-0717-6; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	33	108	114	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55618	55625		10.1074/jbc.M405042200	http://dx.doi.org/10.1074/jbc.M405042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494395	hybrid			2022-12-25	WOS:000225960800080
J	Benie, AJ; Blume, A; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T				Benie, AJ; Blume, A; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T			Characterization of ligand binding to the bifunctional key enzyme in the sialic acid biosynthesis by NMR - II. Investigation of the ManNAc kinase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIRST 2 STEPS; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; STEREOCHEMICAL COURSE; PHOSPHORYL TRANSFER; RAT-LIVER; SPECTROSCOPY; EXPRESSION; CATALYZES; SUBSTRATE; RECEPTOR	N-Acetylmannosamine (ManNAc) is the physiological precursors to all sialic acids that occur in nature. As variations in the sialic acid decoration of cell surfaces can profoundly affect cell-cell, pathogen-cell, or drug-cell interactions, the enzymes that convert ManNAc into sialic acid are attractive targets for the development of drugs that specifically interrupt sialic acid biosynthesis or lead to modified sialic acids on the surface of cells. The first step in the enzymatic conversion of ManNAc into sialic acid is phosphorylation, yielding N-acetylmannosamine-6-phosphate. The enzyme that catalyzes this conversion is the N-acetylmannosamine kinase (ManNAc kinase) as part of the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Here, we employed saturation transfer difference (STD) NMR experiments to study the binding of ManNAc and related ligands to the ManNAc kinase. It is shown that the configuration of C1 and C4 of ManNAc is crucial for binding to the enzyme, whereas the C2 position not only accepts variations in the attached N-acyl side chain but also tolerates inversion of configuration. Our experiments also show that ManNAc kinase maintains its functionality, even in the absence of Mg2+. From the analysis of the STD NMR-derived binding epitopes, it is concluded that the binding mode of the N-acylmannosamines critically depends on the N-acyl side chain. In conjunction with the relative binding affinities of the ligands obtained from STD NMR titrations, it is possible to derive a structure-binding affinity relationship. This provides a cornerstone for the rational design of drugs for novel therapeutic applications by altering the sialic acid decorations of cell walls.	Charite Univ Med Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; Univ Luebeck, Inst Chem, D-23538 Lubeck, Germany; Univ Konstanz, Fachbereich Chem, Fach M 725, D-78457 Constance, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lubeck; University of Konstanz	Peters, T (corresponding author), Charite Univ Med Berlin, Inst Biochem & Mol Biol, Campus Benjamin Franklin,Arnimallee 22, D-14195 Berlin, Germany.	stephan.hinderlich@charite.de; thomas.peters@chemie.uni-luebeck.de	Peters, Thomas/AAE-1509-2022; Peters, Thomas/GQB-3622-2022	Peters, Thomas/0000-0002-7570-8260; Benie, Andrew/0000-0001-8274-0456				Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; Berger M, 2002, EUR J BIOCHEM, V269, P4212, DOI 10.1046/j.1432-1033.2002.03117.x; Blume A, 2004, J BIOL CHEM, V279, P55715, DOI 10.1074/jbc.M410238200; Blume A, 2002, FEBS LETT, V521, P127, DOI 10.1016/S0014-5793(02)02856-9; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Herrmann M, 1997, J VIROL, V71, P5922, DOI 10.1128/JVI.71.8.5922-5931.1997; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Jacobs CL, 2001, BIOCHEMISTRY-US, V40, P12864, DOI 10.1021/bi010862s; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KAYSER H, 1993, EXPERIENTIA, V49, P885, DOI 10.1007/BF01952603; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; LOWE G, 1981, BIOCHEM J, V199, P227, DOI 10.1042/bj1990227; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Oetke C, 2002, J BIOL CHEM, V277, P6688, DOI 10.1074/jbc.M109973200; POLLARDKNIGHT D, 1982, BIOCHEM J, V201, P421, DOI 10.1042/bj2010421; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319	19	20	21	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55722	55727		10.1074/jbc.M410239200	http://dx.doi.org/10.1074/jbc.M410239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498763	hybrid			2022-12-25	WOS:000225960800093
J	Kamau, E; Bauerle, KT; Grove, A				Kamau, E; Bauerle, KT; Grove, A			The Saccharomyces cerevisiae high mobility group box protein HMO1 contains two functional DNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-MODIFIED DNA; 4-WAY JUNCTION DNA; HMG-D; INTERCALATING RESIDUES; NHP6A; TRANSCRIPTION; RECOGNITION; COMPLEX; DETERMINANTS; ACTIVATION	High mobility group box ( HMGB) proteins are architectural proteins whose HMG DNA binding domains confer significant preference for distorted DNA, such as 4-way junctions. HMO1 is one of 10 Saccharomyces cerevisiae HMGB proteins, and it is required for normal growth and plasmid maintenance and for regulating the susceptibility of yeast chromatin to nuclease. Using electrophoretic mobility shift assays, we have shown here that HMO1 binds 26-bp duplex DNA with K-d = 39.6 +/- 5.0 nM and that its divergent box A domain participates in DNA interactions, albeit with low affinity. HMO1 has only modest preference for DNA with altered conformations, including DNA with nicks, gaps, overhangs, or loops, as well as for 4-way junction structures and supercoiled DNA. HMO1 binds 4-way junctions with half-maximal saturation of 19.6 +/- 2.2 nM, with only a modest increase in affinity in the absence of magnesium ions (half-maximal saturation 6.1 +/- 1.1 nM). Whereas the box A domain contributes modest structure-specific binding, the box B domain is required for high affinity binding. HMO1 bends DNA, as measured by DNA cyclization assays, facilitating cyclization of 136-, 105-, and 87-bp DNA, but not 75-bp DNA, and it has a significantly longer residence time on DNA minicircles compared with linear duplex DNA. The unique DNA binding properties of HMO1 are consistent with global roles in the maintenance of chromatin structure.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Grove, A (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	grove@lsu.edu	Grove, Anne/O-5998-2015	Grove, Anne/0000-0002-4390-0354				Alekseev SY, 2002, DNA REPAIR, V1, P287, DOI 10.1016/S1568-7864(02)00005-8; Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; Balaeff A, 1998, PROTEINS, V30, P113, DOI 10.1002/(SICI)1097-0134(19980201)30:2<113::AID-PROT2>3.0.CO;2-O; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Dolinski KJ, 1999, GENETICS, V151, P935; Gadal O, 2002, EMBO J, V21, P5498, DOI 10.1093/emboj/cdf539; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Ghosh S, 2004, J MOL BIOL, V337, P561, DOI 10.1016/j.jmb.2004.02.010; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Grove A, 1996, J MOL BIOL, V260, P120, DOI 10.1006/jmbi.1996.0386; Grove A, 2001, J MOL BIOL, V311, P491, DOI 10.1006/jmbi.2001.4763; He Q, 2000, BIOCHEMISTRY-US, V39, P14426, DOI 10.1021/bi001700j; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; Klass J, 2003, NUCLEIC ACIDS RES, V31, P2852, DOI 10.1093/nar/gkg389; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Lu J, 1996, J BIOL CHEM, V271, P33678, DOI 10.1074/jbc.271.52.33678; Masse JE, 2002, J MOL BIOL, V323, P263, DOI 10.1016/S0022-2836(02)00938-5; Moreira JMA, 2000, EMBO J, V19, P6804, DOI 10.1093/emboj/19.24.6804; Murphy FV, 1999, EMBO J, V18, P6610, DOI 10.1093/emboj/18.23.6610; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Payet D, 1999, J MOL BIOL, V294, P79, DOI 10.1006/jmbi.1999.3246; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Stros M, 2000, J BIOL CHEM, V275, P35699, DOI 10.1074/jbc.M007167200; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150; Webb M, 2001, J MOL BIOL, V309, P79, DOI 10.1006/jmbi.2001.4667; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Wong B, 2002, BIOCHEMISTRY-US, V41, P5404, DOI 10.1021/bi012077l; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	47	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55234	55240		10.1074/jbc.M409459200	http://dx.doi.org/10.1074/jbc.M409459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507436	hybrid, Green Published			2022-12-25	WOS:000225960800032
J	Navarro-Lerida, I; Corvi, MM; Barrientos, AA; Gavilanes, F; Berthiaume, LG; Rodriguez-Crespo, I				Navarro-Lerida, I; Corvi, MM; Barrientos, AA; Gavilanes, F; Berthiaume, LG; Rodriguez-Crespo, I			Palmitoylation of inducible nitric-oxide synthase at Cys-3 is required for proper intracellular traffic and nitric oxide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; ESCHERICHIA-COLI; SKELETAL-MUSCLE; TRANSPORT; CAVEOLIN; TETRAHYDROBIOPTERIN; DIMERIZATION; MACROPHAGES; CALMODULIN; EXPRESSION	A number of cell types express inducible nitric-oxide synthase (NOS2) in response to exogenous insults such as bacterial lipopolysaccharide or proinflammatory cytokines. Although it has been known for some time that the N-terminal end of NOS2 suffers a post-translational modification, its exact identification has remained elusive. Using radioactive fatty acids, we show herein that NOS2 becomes thioacylated at Cys-3 with palmitic acid. Site-directed mutagenesis of this single residue results in the absence of the radiolabel incorporation. Acylation of NOS2 is completely indispensable for intracellular sorting and .NO synthesis. In fact, a C3S mutant of NOS2 is completely inactive and accumulates to intracellular membranes that almost totally co-localize with the Golgi marker beta-cop. Likewise, low concentrations of the palmitoylation blocking agents 2-Br-palmitate or 8-Br-palmitate severely affected the .NO synthesis of both NOS2 induced in muscular myotubes and transfected NOS2. However, unlike endothelial NOS, palmitoylation of inducible NOS is not involved in its targeting to caveolae. We have created 16 NOS2-GFP chimeras to inspect the effect of the neighboring residues of Cys-3 on the degree of palmitoylation. In this regard, the hydrophobic residue Pro-4 and the basic residue Lys-6 seem to be indispensable for palmitoylation. In addition, agents that block the endoplasmic reticulum to Golgi transit such as brefeldin A and monensin drastically reduced NOS2 activity leading to its accumulation in perinuclear areas. In summary, palmitoylation of NOS2 at Cys-3 is required for both its activity and proper intracellular localization.	Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Fdn Ctr Nacl Invest Cardiovasc, Madrid 28029, Spain	Complutense University of Madrid; University of Alberta; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Rodriguez-Crespo, I (corresponding author), Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	nacho@bbm1.ucm.es	Gavilanes, Francisco/K-9903-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Rodriguez-Crespo, J. Ignacio/M-1966-2018	Gavilanes, Francisco/0000-0003-1047-2362; Navarro-Lerida, Inmaculada/0000-0001-9994-8069; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Berthiaume, Luc/0000-0003-0926-059X; Corvi, Maria/0000-0002-6192-5029; Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X				BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bredt DS, 2003, J CELL SCI, V116, P9, DOI 10.1242/jcs.00183; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; Felley-Bosco E, 2002, BIOL RES, V35, P169, DOI 10.4067/S0716-97602002000200007; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Navarro-Lerida I, 2004, J CELL SCI, V117, P1687, DOI 10.1242/jcs.01002; Navarro-Lerida I, 2002, J CELL SCI, V115, P3119; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; RINGHEIM GE, 1995, BIOCHEM BIOPH RES CO, V210, P711, DOI 10.1006/bbrc.1995.1717; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tisdale EJ, 2003, J BIOL CHEM, V278, P38015, DOI 10.1074/jbc.M305381200; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783	31	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55682	55689		10.1074/jbc.M406621200	http://dx.doi.org/10.1074/jbc.M406621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485846	hybrid			2022-12-25	WOS:000225960800088
J	Streb, JW; Kitchen, CM; Gelman, IH; Miano, JM				Streb, JW; Kitchen, CM; Gelman, IH; Miano, JM			Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PROTEIN-KINASE; SSECKS GENE; SRC; CELLS; SERUM	A Kinase Anchoring Protein 12 (AKAP12; also known as src-suppressed C kinase substrate (SSeCKS) and Gravin) is a multivalent anchoring protein with tumor suppressor activity. Although expression of AKAP12 has been examined in a number of contexts, its expression control remains to be elucidated. Herein, we characterize the genomic organization of the AKAP12 locus, its regulatory regions, and the spatial distribution of the proteins encoded by the AKAP12 gene. Using comparative genomics and various wet-lab assays, we show that the AKAP12 locus is organized as three separate transcription units that are governed by non-redundant promoters coordinating distinct tissue expression profiles. The proteins encoded by the three AKAP12 isoforms (designated alpha, beta, and gamma) share >95% amino acid sequence identity but differ at their N termini. Analysis of the targeting of each isoform reveals distinct spatial distribution profiles. An N-terminal myristoylation motif present in AKAP12alpha is shown to be necessary and sufficient for targeted expression of this AKAP12 isoform to the endoplasmic reticulum, a novel subcellular compartment for AKAP12. Our results demonstrate heretofore unrecognized complexity within the AKAP12 locus and suggest a mechanism for genetic control of signaling specificity through distinct regulation of alternately targeted anchoring protein isoforms.	Univ Rochester, Sch Med & Dent, Ctr Cardiovasc Res, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Rochester; Roswell Park Cancer Institute	Miano, JM (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Cardiovasc Res, Aab Inst Biomed Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.	j.m.miano@rochester.edu	Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207; Ramirez, Christina/0000-0002-8435-0416	NCI NIH HHS [R01 CA094108, R01 CA 94108, R55 CA094108] Funding Source: Medline; NHLBI NIH HHS [R01 HL 70077, T32 HL 07949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA094108, R01CA094108] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070077, T32HL007949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Camus A, 2001, MECH DEVELOP, V105, P79, DOI 10.1016/S0925-4773(01)00384-7; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; Chen JY, 2001, BIOCHEM BIOPH RES CO, V281, P475, DOI 10.1006/bbrc.2001.4362; Coats SR, 2002, BIOCHEM BIOPH RES CO, V297, P1112, DOI 10.1016/S0006-291X(02)02275-1; Coats SR, 2000, J MOL CELL CARDIOL, V32, P2207, DOI 10.1006/jmcc.2000.1246; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Nelson PJ, 1997, MOL CELL BIOCHEM, V175, P233, DOI 10.1023/A:1006836003758; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Scott JD, 1997, SOC GEN PHY, V52, P227; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319	31	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56014	56023		10.1074/jbc.M408828200	http://dx.doi.org/10.1074/jbc.M408828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496411	hybrid			2022-12-25	WOS:000225960800125
J	Westerheide, SD; Bosman, JD; Mbadugha, BNA; Kawahara, TLA; Matsumoto, G; Kim, SJ; Gu, WX; Devlin, JP; Silverman, RB; Morimoto, RI				Westerheide, SD; Bosman, JD; Mbadugha, BNA; Kawahara, TLA; Matsumoto, G; Kim, SJ; Gu, WX; Devlin, JP; Silverman, RB; Morimoto, RI			Celastrols as inducers of the heat shock response and cytoprotection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HSP70 GENE-TRANSCRIPTION; STRESS-INDUCED APOPTOSIS; DNA-BINDING; FACTOR-I; MOLECULAR CHAPERONES; APAF-1 APOPTOSOME; ACTIVATION; CELLS; FACTOR-1	Alterations in protein folding and the regulation of conformational states have become increasingly important to the functionality of key molecules in signaling, cell growth, and cell death. Molecular chaperones, because of their properties in protein quality control, afford conformational flexibility to proteins and serve to integrate stress-signaling events that influence aging and a range of diseases including cancer, cystic fibrosis, amyloidoses, and neurodegenerative diseases. We describe here characteristics of celastrol, a quinone methide triterpene and an active component from Chinese herbal medicine identified in a screen of bioactive small molecules that activates the human heat shock response. From a structure/function examination, the celastrol structure is remarkably specific and activates heat shock transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as determined by the induction of HSF1 DNA binding, hyperphosphorylation of HSF1, and expression of chaperone genes. Celastrol can activate heat shock gene transcription synergistically with other stresses and exhibits cytoprotection against subsequent exposures to other forms of lethal cell stress. These results suggest that celastrols exhibit promise as a new class of pharmacologically active regulators of the heat shock response.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; MicroSource Discovery Syst Inc, Gaylordsville, CT 06755 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu	Longo, Kenneth A/A-5631-2010	Matsumoto, Gen/0000-0002-9339-1682	NCI NIH HHS [T32 CA 70085] Funding Source: Medline; NIA NIH HHS [T32 AG 00260] Funding Source: Medline; NIGMS NIH HHS [T32 GM 008061-21, R37 GM038109, GM 38109] Funding Source: Medline; NINDS NIH HHS [NS 047331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061, R01GM038109, R37GM038109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047331] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abbott A, 2002, NATURE, V417, P109, DOI 10.1038/417109a; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; Allison AC, 2001, PROG NEURO-PSYCHOPH, V25, P1341, DOI 10.1016/S0278-5846(01)00192-0; Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BEERE HM, 2001, SCI STKE; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Chang FR, 2003, J NAT PROD, V66, P1416, DOI 10.1021/np030241v; Chen B, 1999, PHYTOCHEMISTRY, V51, P683, DOI 10.1016/S0031-9422(99)00079-5; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Deng JZ, 2000, BIOORGAN MED CHEM, V8, P247, DOI 10.1016/S0968-0896(99)00276-X; Elia G, 1996, CANCER RES, V56, P210; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gunatilaka A. A. L, 1996, TRITERPENOID QUINONE; Heemskerk Jill, 2002, Trends in Neurosciences, V25, P494, DOI 10.1016/S0166-2236(02)02236-1; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Jin HZ, 2002, J NAT PROD, V65, P89, DOI 10.1021/np010428r; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LI RL, 1989, INVESTIGATIONS CLIN; LIU RY, 1994, J CELL SCI, V107, P2209; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Mizushina Y, 2000, BIOCHEM J, V350, P757, DOI 10.1042/0264-6021:3500757; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NGASSAPA O, 1994, J NAT PROD, V57, P1, DOI 10.1021/np50103a001; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SOLOMON JM, 1991, NEW BIOL, V3, P1106; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; Sreedhar AS, 2004, PHARMACOL THERAPEUT, V101, P227, DOI 10.1016/j.pharmthera.2003.11.004; Suh N, 2003, CANCER RES, V63, P1371; THOMPSON DC, 1993, CHEM-BIOL INTERACT, V86, P129, DOI 10.1016/0009-2797(93)90117-H; Vigh L, 1997, NAT MED, V3, P1150, DOI 10.1038/nm1097-1150; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Wissing D, 1996, INT J HYPERTHER, V12, P125, DOI 10.3109/02656739609023695; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	60	315	337	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56053	56060		10.1074/jbc.M409267200	http://dx.doi.org/10.1074/jbc.M409267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509580	hybrid			2022-12-25	WOS:000225960800129
J	Gorbea, C; Goellner, GM; Teter, K; Holmes, RK; Rechsteiner, M				Gorbea, C; Goellner, GM; Teter, K; Holmes, RK; Rechsteiner, M			Characterization of mammalian ecm29, a 26 S proteasome-associated protein that localizes to the nucleus and membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; CHO-CELLS RESISTANT; VHS DOMAIN; INTRACELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; DENDRITIC CELLS; CHOLERA-TOXIN; UBIQUITIN; ENDOCYTOSIS; RECEPTOR	In addition to its thirty or so core subunits, a number of accessory proteins associate with the 26 S proteasome presumably to assist in substrate degradation or to localize the enzyme within cells. Among these proteins is ecm29p, a 200-kDa yeast protein that contains numerous HEAT repeats as well as a putative VHS domain. Higher eukaryotes possess a well conserved homolog of yeast ecm29p, and we produced antibodies to three peptides in the human Ecm29 sequence. The antibodies show that Ecm29 is present exclusively on 26 S proteasomes in HeLa cells and that Ecm29 levels vary markedly among mouse organs. Confocal immunofluorescence microscopy localizes Ecm29 to the centrosome and a subset of secretory compartments including endosomes, the ER and the ERGIC. Ecm29 is up-regulated 2-3-fold in toxin-resistant mutant CHO cells exhibiting increased rates of ER-associated degradation. Based on these results we propose that Ecm29 serves to couple the 26 S proteasome to secretory compartments engaged in quality control and to other sites of enhanced proteolysis.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Utah System of Higher Education; University of Utah; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rechsteiner, M (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	marty@biochem.utah.edu	Gorbea, Carlos/L-4406-2019	Teter, Ken/0000-0003-4176-9361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM039007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043022] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39007] Funding Source: Medline; NINDS NIH HHS [F32NS43022-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Benmerah A, 2004, CURR BIOL, V14, pR314, DOI 10.1016/j.cub.2004.03.053; Benmerah A, 2003, TRAFFIC, V4, P503, DOI 10.1034/j.1600-0854.2003.00102.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Ehlers MD, 2003, SCIENCE, V302, P800, DOI 10.1126/science.1092546; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glickman MH, 2004, PLOS BIOL, V2, P25, DOI 10.1371/journal.pbio.0020013; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hauri HP, 2002, BIOCHEM SOC SYMP, V69, P73; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Kajava AV, 2004, J STRUCT BIOL, V146, P425, DOI 10.1016/j.jsb.2004.01.013; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lohi O, 2002, FEBS LETT, V513, P19, DOI 10.1016/S0014-5793(01)03287-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MAKAROW M, 1985, EMBO J, V4, P1861, DOI 10.1002/j.1460-2075.1985.tb03861.x; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Moron VG, 2003, J IMMUNOL, V171, P2242, DOI 10.4049/jimmunol.171.5.2242; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Patrick GN, 2003, CURR BIOL, V13, P2073, DOI 10.1016/j.cub.2003.10.028; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; PRESCOTT DM, 1972, EXP CELL RES, V71, P480, DOI 10.1016/0014-4827(72)90322-9; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; RECHSTEINER M, 1974, J CELL PHYSIOL, V84, P409, DOI 10.1002/jcp.1040840309; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Tarlac V, 2003, J NEUROSCI RES, V74, P406, DOI 10.1002/jnr.10746; Teter K, 2003, TRAFFIC, V4, P232, DOI 10.1034/j.1600-0854.2003.00070.x; Teter K, 2002, INFECT IMMUN, V70, P6172, DOI 10.1128/IAI.70.11.6172-6179.2002; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Yang YL, 2003, FASEB J, V17, P790, DOI 10.1096/fj.02-0654rev; You JX, 2003, J BIOL CHEM, V278, P23369, DOI 10.1074/jbc.M212887200; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	76	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54849	54861		10.1074/jbc.M410444200	http://dx.doi.org/10.1074/jbc.M410444200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496406	hybrid			2022-12-25	WOS:000225793600114
J	Lee, YN; Malbon, CC; Wang, HY				Lee, YN; Malbon, CC; Wang, HY			G alpha 13 signals via p115RhoGEF cascades regulating JNK1 and primitive endoderm formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; EMBRYONAL CARCINOMA-CELLS; HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; GTPASE-ACTIVATING PROTEIN; FAMILY TYROSINE KINASE; RETINOIC ACID; RHO-GTPASES; G-ALPHA; EXCHANGE FACTORS	The heterotrimeric G-protein G(13) mediates the formation of primitive endoderm from mouse P19 embryonal carcinoma cells in response to retinoic acid, signaling to the level of activation of c-Jun N-terminal kinase. The signal linkage map from MEKK1/MEKK4 to MEK1/MKK4 to JNK is obligate in this Galpha(13)-mediated pathway, whereas that between Galpha(13) and MEKKs is not known. The overall pathway to primitive endoderm formation was shown to be inhibited by treatment with Clostridium botulinum C3 exotoxin, a specific inactivator of RhoA family members. Constitutively active Galpha(13) was found to activate RhoA as well as Cdc42 and Rac1 in these cells. Although constitutively active Cdc42, Rac1, and RhoA all can activate JNK1, only the RhoA mutant was able to promote formation of primitive endoderm, mimicking expression of the constitutively activated Galpha(13). Expression of the constitutively active mutant form of p115RhoGEF ( guanine nucleotide exchange factor) was found to activate RhoA and JNK1 activities. Expression of the dominant negative p115RhoGEF was able to inhibit activation of both RhoA and JNK1 in response to either retinoic acid or the expression of a constitutively activated mutant of Galpha(13). Expression of the dominant negative mutants of RhoA as well as those of either Cdc42 or Rac1, but not Ras, attenuated Galpha(13)-stimulated as well as retinoic acid-stimulated activation of all three of these small molecular weight GTPases, suggesting complex interrelationships among the three GTPases in this pathway. The formation of primitive endoderm in response to retinoic acid also could be blocked by expression of dominant negative mutants of RhoA, Cdc42, or Rac1. Thus, the signal propagated from Galpha(13) to JNK requires activation of p115RhoGEF cascades, including p115RhoGEF itself, RhoA, Cdc42, and Rac1. In a concerted effort, RhoA in tandem with Cdc42 and Rac1 activates the MEKK1/4, MEK1/MKK4, and JNK cascade, thereby stimulating formation of primitive endoderm.	SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA.	wangh@pharm.sunysb.edu	malbon, craig/ABF-3604-2020					Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Cadigan Ken M., 2002, Trends in Genetics, V18, P340, DOI 10.1016/S0168-9525(02)02707-5; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KANUNGO J, 2000, J BIOL CHEM; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Le Page SL, 2003, AM J PHYSIOL-CELL PH, V285, pC1197, DOI 10.1152/ajpcell.00083.2003; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; McGrew L, 2002, MOL PHARMACOL, V62, P1339, DOI 10.1124/mol.62.6.1339; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Rattan S, 2003, EXP BIOL MED, V228, P972, DOI 10.1177/153537020322800814; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sayas CL, 2002, J NEUROSCI, V22, P6863; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; van Triest Miranda, 2004, Methods Mol Biol, V250, P97; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	62	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54896	54904		10.1074/jbc.M407581200	http://dx.doi.org/10.1074/jbc.M407581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492006	hybrid			2022-12-25	WOS:000225793600119
J	Mahrus, S; Kisiel, W; Craik, CS				Mahrus, S; Kisiel, W; Craik, CS			Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDED SUBSTRATE-SPECIFICITY; SERINE-PROTEASE; MEDIATED CYTOTOXICITY; PROTEINASE-INHIBITORS; CLONING; PURIFICATION; EXPRESSION; SUPERFAMILY; LYMPHOCYTES; MET-ASE-1	Granzyme M is a trypsin-fold serine protease that is specifically found in the granules of natural killer cells. This enzyme has been implicated recently in the induction of target cell death by cytotoxic lymphocytes, but unlike granzymes A and B, the molecular mechanism of action of granzyme M is unknown. We have characterized the extended substrate specificity of human granzyme M by using purified recombinant enzyme, several positional scanning libraries of coumarin substrates, and a panel of individual p-nitroanilide and coumarin substrates. In contrast to previous studies conducted using thiobenzyl ester substrates (Smyth, M. J., O'Connor, M. D., Trapani, J. A., Kershaw, M. H., and Brinkworth, R. I. ( 1996) J. Immunol. 156, 4174-4181), a strong preference for leucine at P1 over methionine was demonstrated. The extended substrate specificity was determined to be lysine = norleucine at P4, broad at P3, proline > alanine at P2, and leucine > norleucine > methionine at P1. The enzyme activity was found to be highly dependent on the length and sequence of substrates, indicative of a regulatory function for human granzyme M. Finally, the interaction between granzyme M and the serpins alpha(1)-antichymotrypsin, alpha(1)-proteinase inhibitor, and proteinase inhibitor 9 was characterized by using a candidate-based approach to identify potential endogenous inhibitors. Proteinase inhibitor 9 was effectively hydrolyzed and inactivated by human granzyme M, raising the possibility that this orphan granzyme bypasses proteinase inhibitor 9 inhibition of granzyme B.	Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of New Mexico; University of New Mexico's Health Sciences Center; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu			NCI NIH HHS [CA 72006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Dahlen JR, 1999, BBA-MOL CELL RES, V1451, P233, DOI 10.1016/S0167-4889(99)00095-6; Dauber DS, 2002, J VIROL, V76, P1359, DOI 10.1128/JVI.76.3.1359-1368.2002; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Kelly JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/jbc.M401670200; Kelly JM, 1996, IMMUNOGENETICS, V44, P340, DOI 10.1007/BF02602778; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; POE M, 1991, J BIOL CHEM, V266, P98; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; Smyth MJ, 1996, J IMMUNOL, V156, P4174; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Volanakis JE, 1996, PROTEIN SCI, V5, P553; Wilharm E, 1999, J BIOL CHEM, V274, P27331, DOI 10.1074/jbc.274.38.27331; WOODARD SL, 1994, J IMMUNOL, V153, P5016	34	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54275	54282		10.1074/jbc.M411482200	http://dx.doi.org/10.1074/jbc.M411482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494398	hybrid			2022-12-25	WOS:000225793600048
J	Nelson, EA; Walker, SR; Alvarez, JV; Frank, DA				Nelson, EA; Walker, SR; Alvarez, JV; Frank, DA			Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1 PROMOTER; BCL-X GENE; BINDING-SITES; GENOMIC SITES; EXPRESSION; TRANSCRIPTION; PROTEINS; GROWTH; CELLS; CIS	STAT5a and STAT5b are two highly related transcription factors that control essential cellular functions. Several STAT5 targets are known, although it is likely that most remain uncharacterized. To identify a more complete set of STAT5-regulated genes, we used a modification of the chromatin immunoprecipitation procedure, which does not presuppose any information regarding these targets. Employing Ba/f3 cells in which STAT5 is activated by interleukin-3, we have identified novel STAT5 binding sites that may be regulatory regions for nearby genes. These sites are typically found far from transcription start sites, and most do not contain CpG islands, indicating that they are not in traditional promoter regions. Nonetheless, when the expression of genes near these STAT5 binding sites was examined, all were expressed in Ba/f3 cells, and most were modulated by interleukin-3. Furthermore, genes identified by this strategy show unique expression patterns in acute leukemias, tumors characterized by activated STAT5. Whereas both STAT5 isoforms bound to all promoters tested, STAT5a and STAT5b bound with different kinetics, suggesting that at least some of the differences between the functions of these two proteins are mediated by their DNA binding activity. Therefore, this method of transcription factor target identification represents an effective strategy to isolate transcription factor targets in an unbiased fashion, and it has revealed many novel STAT5-dependent regulatory regions outside of traditional promoters.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Rm M552B,44 Binney St, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA079547] Funding Source: NIH RePORTER; NCI NIH HHS [CA79547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chavany C, 1998, MOL MED TODAY, V4, P158, DOI 10.1016/S1357-4310(98)01227-1; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Euskirchen G, 2004, MOL CELL BIOL, V24, P3804, DOI 10.1128/MCB.24.9.3804-3814.2004; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Frank David A, 2003, Cancer Treat Res, V115, P267; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jolivet G, 1996, FEBS LETT, V389, P257, DOI 10.1016/0014-5793(96)00598-4; Kubota T, 1998, PATHOL INT, V48, P22, DOI 10.1111/j.1440-1827.1998.tb03823.x; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood-2003-06-1992; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Myerowitz R, 1997, HUM MUTAT, V9, P195, DOI 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.3.CO;2-J; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Pestina TI, 2003, EXP HEMATOL, V31, P1198, DOI 10.1016/j.exphem.2003.09.002; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rascle A, 2003, NUCLEIC ACIDS RES, V31, P6882, DOI 10.1093/nar/gkg907; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264	41	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54724	54730		10.1074/jbc.M408464200	http://dx.doi.org/10.1074/jbc.M408464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498775	hybrid			2022-12-25	WOS:000225793600100
J	Shepherd, EG; Zhao, Q; Welty, SE; Hansen, TN; Smith, CV; Liu, YS				Shepherd, EG; Zhao, Q; Welty, SE; Hansen, TN; Smith, CV; Liu, YS			The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; SIGNAL-TRANSDUCTION PATHWAY; B STREPTOCOCCAL DISEASE; AU-RICH ELEMENTS; LIPOTEICHOIC ACID; MAP KINASE; FACTOR-ALPHA; CYTOKINE BIOSYNTHESIS; INNATE IMMUNITY	Mitogen- activated protein (MAP) kinases play a pivotal role in the macrophages in the production of proinflammatory cytokines triggered by lipopolysaccharides. However, their function in the responses of macrophages to Gram-positive bacteria is poorly understood. Even less is known about the attenuation of MAP kinase signaling in macrophages exposed to Gram-positive bacteria. In the present study, we have investigated the regulation of MAP kinases and the role of MAP kinase phosphatase (MKP)-1 in the production of proinflammatory cytokines using murine RAW264.7 and primary peritoneal macrophages after peptidoglycan stimulation. Treatment of macrophages with peptidoglycan resulted in a transient activation of JNK, p38, and extracellular signal-regulated kinase. Most interestingly, MKP-1 expression was potently induced by peptidoglycan, and this induction was concurrent with MAP kinase dephosphorylation. Triptolide, a diterpenoid triepoxide, potently blocked the induction of MKP-1 by peptidoglycan and prolonged the activation of JNK and p38. Overexpression of MKP-1 substantially attenuated the production of tumor necrosis factor (TNF)-alpha induced by peptidoglycan, whereas knockdown of MKP-1 by small interfering RNA substantially increased the production of both TNF-alpha and interleukin-1beta. Finally, we found that in primary murine peritoneal macrophages, MKP-1 induction following peptidoglycan stimulation also coincided with inactivation of JNK and p38. Blockade of MKP-1 induction resulted in a sustained activation of both JNK and p38 in primary macrophages. Our results reveal that MKP-1 critically regulates the expression of TNF-alpha and interleukin-1beta in RAW264.7 cells and further suggest a central role for this phosphatase in controlling the inflammatory responses of primary macrophages to Gram-positive bacterial infection.	Ohio State Univ, Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Childrens Res Inst,Dept Pediat, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	Liu, YS (corresponding author), Ohio State Univ, Childrens Hosp, Ctr Dev Pharmacol & Toxicol, Childrens Res Inst,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	liuy@pediatrics.ohio-state.edu	Shepherd, Edward/E-4080-2011; Welty, Stephen/AAZ-4307-2021; Welty, Stephen/AGS-7454-2022; Liu, Yusen/E-3527-2011	Welty, Stephen/0000-0002-6321-8440; Liu, Yusen/0000-0002-0994-0109	NIAID NIH HHS [AI57798] Funding Source: Medline; NICHD NIH HHS [HD43003] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD043003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057798, R21AI057798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1995, J CARDIOVASC PHAR S2, V25, P1; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canton R, 2003, CURR OPIN INFECT DIS, V16, P315, DOI 10.1097/00001432-200308000-00003; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; Chen PL, 2002, PROTEIN EXPRES PURIF, V24, P481, DOI 10.1006/prep.2001.1599; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DINARELLO CA, 1997, CHEST S, V112, P321, DOI DOI 10.1378/CHEST.112.6_SUPPLEMENT.321S; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; FOSTER KD, 1992, AM J PHYSIOL, V262, P211; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Handel-Fernandez ME, 2000, MACROPHAGES PRACTICA, P1; Hoffman JA, 2003, PEDIATRICS, V112, P1095, DOI 10.1542/peds.112.5.1095; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Kengatharan KM, 1998, J EXP MED, V188, P305, DOI 10.1084/jem.188.2.305; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Nagahira A, 2001, BIOCHEM BIOPH RES CO, V281, P1030, DOI 10.1006/bbrc.2001.4476; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pearlman M, 2003, OBSTET GYNECOL, V102, P414, DOI 10.1016/S0029-7844(03)00583-0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Vieillard-Baron A, 2003, AM J RESP CRIT CARE, V168, P1270, DOI 10.1164/rccm.200306-816CC; Wang JE, 2004, CRIT CARE MED, V32, P546, DOI 10.1097/01.CCM.0000109775.22138.8F; Wang JE, 2000, INFECT IMMUN, V68, P3965, DOI 10.1128/IAI.68.7.3965-3970.2000; Weber SM, 2002, J IMMUNOL, V168, P5303, DOI 10.4049/jimmunol.168.10.5303	68	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54023	54031		10.1074/jbc.M408444200	http://dx.doi.org/10.1074/jbc.M408444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485842	hybrid			2022-12-25	WOS:000225793600018
J	Varela-Gomez, M; Moreno-Sanchez, R; Pardo, JP; Perez-Montfort, R				Varela-Gomez, M; Moreno-Sanchez, R; Pardo, JP; Perez-Montfort, R			Kinetic mechanism and metabolic role of pyruvate phosphate dikinase from Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORTHOPHOSPHATE DIKINASE; GIARDIA-INTESTINALIS; ESCHERICHIA-COLI; STEADY-STATE; ENZYME; EXPRESSION; CATALYSIS; KINASE; PHOTOSYNTHESIS; PATHWAY	The kinetic mechanism and the metabolic role of pyruvate phosphate dikinase from Entamoeba histolytica were investigated. The initial velocity patterns in double reciprocal plots were parallel for the phosphoenolpyruvate/AMP and phosphoenolpyruvate/pyrophosphate substrate pairs and intersecting for the AMP/pyrophosphate pair. This suggests a kinetic mechanism with two independent reactions. The rate of ATP synthesis at saturating and equimolar concentrations of phosphoenolpyruvate, AMP, and pyrophosphate was inhibited by phosphate, which is consistent with an ordered steady-state mechanism. Enzyme phosphorylation by [P-32(i)] pyrophosphate depends on the formation of a ternary complex between AMP, pyrophosphate, and pyruvate phosphate dikinase. In consequence, the reaction that involves the AMP/pyrophosphate pair follows a sequential steady-state mechanism. The product inhibition patterns of ATP and phosphate versus phosphoenolpyruvate were noncompetitive and uncompetitive, respectively, suggesting that these products were released in an ordered process (phosphate before ATP). The ordered release of phosphate and ATP and the noncompetitive inhibition patterns of pyruvate versus AMP and versus pyrophosphate also supported the sequential kinetic mechanism between AMP and pyrophosphate. Taken together, our data provide evidence for a uni uni bi bi ping-pong mechanism for recombinant pyruvate phosphate dikinase from E. histolytica. The DeltaG value for the reaction catalyzed by pyruvate phosphate dikinase (+2.7 kcal/mol) determined under near physiological conditions indicates that the synthesis of ATP is not thermodynamically favorable in trophozoites of E. histolytica.	Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; National Institute of Cardiology - Mexico	Perez-Montfort, R (corresponding author), Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Apartado Postal 70242, Mexico City 04510, DF, Mexico.	ruy@ifc.unam.mx	Moreno-Sanchez, Rafael/A-3158-2011	Moreno-Sanchez, Rafael/0000-0002-9587-7184; Perez-Montfort, Ruy/0000-0003-0810-1159				Agarie S, 1997, PLANT MOL BIOL, V34, P363, DOI 10.1023/A:1005897118660; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V6, P118; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V7, P118; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; EDWARDS GE, 1985, ANNU REV PLANT PHYS, V36, P255, DOI 10.1146/annurev.pp.36.060185.001351; Eisaki N, 1999, BBA-PROTEIN STRUCT M, V1431, P363, DOI 10.1016/S0167-4838(99)00057-6; EVANS HJ, 1968, P NATL ACAD SCI USA, V61, P1448, DOI 10.1073/pnas.61.4.1448; Ghosh SK, 1997, INFECT IMMUN, V65, P4243, DOI 10.1128/IAI.65.10.4243-4249.1997; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HATCH MD, 1968, BIOCHEM J, V106, P141, DOI 10.1042/bj1060141; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Herzberg O, 2002, BIOCHEMISTRY-US, V41, P780, DOI 10.1021/bi011799+; HRDY I, 1993, EXP PARASITOL, V76, P438, DOI 10.1006/expr.1993.1052; KUKKOKALSKE E, 1985, INT J BIOCHEM, V17, P575, DOI 10.1016/0020-711X(85)90288-5; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MCLAUGHLIN J, 1978, ARCH INVEST MED, V9, P141; MEHL A, 1994, BIOCHEMISTRY-US, V33, P1093, DOI 10.1021/bi00171a007; MILNER Y, 1976, J BIOL CHEM, V251, P7920; Moons A, 1998, PLANT J, V15, P89, DOI 10.1046/j.1365-313X.1998.00185.x; Northrop DB, 1997, ARCH BIOCHEM BIOPHYS, V342, P317, DOI 10.1006/abbi.1997.0131; Osteras M, 1997, MICROBIOL-SGM, V143, P1639, DOI 10.1099/00221287-143-5-1639; Park JH, 1997, EXP PARASITOL, V87, P153, DOI 10.1006/expr.1997.4206; REEVES RE, 1974, ARCH INVEST MED, V5, P331; REEVES RE, 1968, J BIOL CHEM, V243, P5486; REEVES RE, 1968, J BIOL CHEM, V243, P3202; Saavedra E, 2004, EXP PARASITOL, V106, P11, DOI 10.1016/j.exppara.2004.01.009; Saavedra-Lira E, 1998, BBA-PROTEIN STRUCT M, V1382, P47, DOI 10.1016/S0167-4838(97)00139-8; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Scorneaux B, 1999, J VET PHARMACOL THER, V22, P6, DOI 10.1046/j.1365-2885.1999.00185.x; Segel I. H., 1975, ENZYME KINETICS, P560; THRALL SH, 1993, BIOCHEMISTRY-US, V32, P1803, DOI 10.1021/bi00058a014; Varon R, 1997, COMPUT APPL BIOSCI, V13, P159; WANG HC, 1988, BIOCHEMISTRY-US, V27, P625, DOI 10.1021/bi00402a020; Wei M, 2000, J BIOL CHEM, V275, P41156, DOI 10.1074/jbc.M006149200; XU Y, 1995, BIOCHEMISTRY-US, V34, P2195, DOI 10.1021/bi00007a013; YI Y, 1994, MOL BIOCHEM PARASIT, V66, P165, DOI 10.1016/0166-6851(94)90050-7	36	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54124	54130		10.1074/jbc.M401697200	http://dx.doi.org/10.1074/jbc.M401697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485834	hybrid			2022-12-25	WOS:000225793600031
J	Vazquez-Prado, J; Miyazaki, H; Castellone, MD; Teramoto, H; Gutkind, JS				Vazquez-Prado, J; Miyazaki, H; Castellone, MD; Teramoto, H; Gutkind, JS			Chimeric G alpha(i2)/G alpha(13) proteins reveal the structural requirements for the binding and activation of the RGS-like (RGL)-containing Rho guanine nucleotide exchange factors (GEFs) by G alpha(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-ASSOCIATED RHO; HETEROTRIMERIC G-PROTEINS; PDZ-RHOGEF; TRANSITION-STATE; RGRGS DOMAIN; P115 RHOGEF; LARG; RECEPTOR; LOCALIZATION; MECHANISM	The alpha-subunit of G proteins of the G(12/13) family stimulate Rho by their direct binding to the RGS-like (RGL) domain of a family of Rho guanine nucleotide exchange factors (RGL-RhoGEFs) that includes PDZ-RhoGEF (PRG), p115RhoGEF, and LARG, thereby regulating cellular functions as diverse as shape and movement, gene expression, and normal and aberrant cell growth. The structural features determining the ability of Galpha(12/13) to bind RGL domains and the mechanism by which this association results in the activation of RGL-RhoGEFs are still poorly understood. Here, we explored the structural requirements for the functional interaction between Galpha(13) and RGL-RhoGEFs based on the structure of RGL domains and their similarity with the area by which RGS4 binds the switch region of Galpha(i) proteins. Using Galpha(i2), which does not bind RGL domains, as the backbone in which Galpha(13) sequences were swapped or mutated, we observed that the switch region of Galpha(13) is strictly necessary to bind PRG, and specific residues were identified that are critical for this association, likely by contributing to the binding surface. Surprisingly, the switch region of Galpha(13) was not sufficient to bind RGL domains, but instead most of its GTPase domain is required. Furthermore, membrane localization of Galpha(13) and chimeric Galpha(i2) proteins was also necessary for Rho activation. These findings revealed the structural features by which Galpha(13) interacts with RGL domains and suggest that molecular interactions occurring at the level of the plasma membrane are required for the functional activation of the RGL-containing family of RhoGEFs.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Inst Politecn Nacl, CINVESTAV, Dept Pharmacol, Mexico City 07000, DF, Mexico	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Rm 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	VAZQUEZ-PRADO, JOSE/C-1630-2017; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	FIC NIH HHS [D43 TW06664] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Barac A, 2004, J BIOL CHEM, V279, P6182, DOI 10.1074/jbc.M309579200; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	39	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54283	54290		10.1074/jbc.M410594200	http://dx.doi.org/10.1074/jbc.M410594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485891	hybrid			2022-12-25	WOS:000225793600049
J	Bannai, H; Fukatsu, K; Mizutani, A; Natsume, T; Iemura, S; Ikegami, T; Inouie, T; Mikoshiba, K				Bannai, H; Fukatsu, K; Mizutani, A; Natsume, T; Iemura, S; Ikegami, T; Inouie, T; Mikoshiba, K			An RNA-interacting protein, SYNCRIP (heterogeneous nuclear ribonuclear protein Q1/NSAP1) is a component of mRNA granule transported with inositol 1,4,5-trisphosphate receptor type 1 mRNA in neuronal dendrites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SOMATODENDRITIC DOMAIN; SYNAPTIC PLASTICITY; FLUORESCENT PROTEIN; LOCALIZATION; STAUFEN; INSULIN; IDENTIFICATION; TRANSLATION; ASSOCIATION	mRNA transport and local translation in the neuronal dendrite is implicated in the induction of synaptic plasticity. Recently, we cloned an RNA-interacting protein, SYNCRIP ( heterogeneous nuclear ribonuclear protein Q1/NSAP1), that is suggested to be important for the stabilization of mRNA. We report here that SYNCRIP is a component of mRNA granules in rat hippocampal neurons. SYNCRIP was mainly found at cell bodies, but punctate expression patterns in the proximal dendrite were also seen. Time-lapse analysis in living neurons revealed that the granules labeled with fluorescent protein-tagged SYNCRIP were transported bi-directionally within the dendrite at similar to0.05 mum/s. Treatment of neurons with nocodazole significantly inhibited the movement of green fluorescent protein-SYNCRIP-positive granules, indicating that the transport of SYNCRIP-containing granules is dependent on microtubules. The distribution of SYN-CRIP-containing granules overlapped with that of dendritic RNAs and elongation factor 1alpha. SYNCRIP was also found to be co-transported with green fluorescent protein-tagged human staufen1 and the 3'-untranslated region of inositol 1,4,5-trisphosphate receptor type 1 mRNA. These results suggest that SYNCRIP is transported within the dendrite as a component of mRNA granules and raise the possibility that mRNA turnover in mRNA granules and the regulation of local protein synthesis in neuronal dendrites may involve SYNCRIP.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Neural Signal Informat,NTT IMSUT, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan	RIKEN; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST)	Inouie, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tinoue@ims.u-tokyo.ac.jp	Bannai, Hiroko/I-7130-2014; Natsume, Tohru/M-7627-2018; Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Mizutani, Akihiro/GPS-4809-2022	Bannai, Hiroko/0000-0002-0951-488X; Natsume, Tohru/0000-0002-1510-2582; Inoue, Takafumi/0000-0002-2728-0060; Mizutani, Akihiro/0000-0003-4155-802X				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Bagni C, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0004.2000; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Duchaine TF, 2002, J CELL SCI, V115, P3285; Feng Y, 1997, J NEUROSCI, V17, P1539; Fujii S, 2000, LEARN MEMORY, V7, P312, DOI 10.1101/lm.34100; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; Higgins D., 1998, CULTURING NERVE CELL, P37; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; Hresko RC, 2002, J BIOL CHEM, V277, P25233, DOI 10.1074/jbc.M202556200; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Job C, 2001, P NATL ACAD SCI USA, V98, P13037, DOI 10.1073/pnas.231485698; Kacharmina JE, 2000, P NATL ACAD SCI USA, V97, P11545, DOI 10.1073/pnas.97.21.11545; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Kuhl D, 1998, CURR OPIN NEUROBIOL, V8, P600, DOI 10.1016/S0959-4388(98)80087-1; Lin SD, 1998, J BIOMED SCI, V5, P111, DOI 10.1159/000025320; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Racca C, 1997, J NEUROSCI, V17, P1691; Rook MS, 2000, J NEUROSCI, V20, P6385, DOI 10.1523/JNEUROSCI.20-17-06385.2000; Severt WL, 1999, J CELL SCI, V112, P3691; Shan JG, 2003, J NEUROSCI, V23, P8859; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186; Tiedge H, 1996, J NEUROSCI, V16, P7171; Tiruchinapalli DM, 2003, J NEUROSCI, V23, P3251; Torre ER, 1996, J NEUROSCI, V16, P5967; Wanner I, 1997, HISTOCHEM CELL BIOL, V108, P345, DOI 10.1007/s004180050175; WOZNIAK M, 1993, NEUROCHEM INT, V22, P1, DOI 10.1016/0197-0186(93)90062-A; Yanagida M, 2004, J BIOL CHEM, V279, P1607, DOI 10.1074/jbc.M305604200; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	56	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53427	53434		10.1074/jbc.M409732200	http://dx.doi.org/10.1074/jbc.M409732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475564	hybrid			2022-12-25	WOS:000225680600076
J	Kurz, EU; Douglas, P; Lees-Miller, SP				Kurz, EU; Douglas, P; Lees-Miller, SP			Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; CATALYTIC SUBUNIT; HISTONE H2AX; P53	The requirement for the serine/threonine protein kinase ATM in coordinating the cellular response to DNA damage induced by ionizing radiation has been studied extensively. Many of the anti-tumor chemotherapeutics in clinical use today cause DNA double strand breaks; however, few have been evaluated for their ability to modulate ATM-mediated pathways. We have investigated the requirement for ATM in the cellular response to doxorubicin, a topoisomerase II-stabilizing drug. Using several ATM-proficient and ATM-deficient cell lines, we have observed ATM-dependent nuclear accumulation of p53 and ATM-dependent phosphorylation of p53 on seven serine residues. This was accompanied by an increased binding of p53 to its cognate binding site, suggesting transcriptional competency of p53 to activate its downstream effectors. Treatment of cells with doxorubicin led to the phosphorylation of histone H2AX on serine 139 with dependence on ATM for the initial response. Doxorubicin treatment also stimulated ATM autophosphorylation on serine 1981 and the ATM-dependent phosphorylation of numerous effectors in the ATM-signaling pathway, including Nbs1 (Ser(343)), SMC1 (Ser(957)), Chk1 (Ser(317) and Ser(345)), and Chk2 (Ser(33/35) and Thr(68)). Although generally classified as a topoisomerase II-stabilizing drug that induces DNA double strand breaks, doxorubicin can intercalate DNA and generate reactive oxygen species. Pretreatment of cells with the superoxide scavenger ascorbic acid had no effect on the doxorubicin-induced phosphorylation and accumulation of p53. In contrast, preincubation of cells with the hydroxyl radical scavenger, N-acetylcysteine, significantly attenuated the doxorubicin-mediated phosphorylation and accumulation of p53, p53-DNA binding, and the phosphorylation of H2AX, Nbs1, SMC1, Chk1, and Chk2, suggesting that hydroxyl radicals contribute to the doxorubicin-induced activation of ATM-dependent pathways.	Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Kurz, EU (corresponding author), Univ Calgary, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kurz@ucalgary.ca		Lees-Miller, Susan/0000-0001-5809-2516				Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Ahn JY, 2000, CANCER RES, V60, P5934; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; Chabner B.A, 1996, GOODMAN GILMANS PHAR; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Goodarzi Aaron A, 2003, Prog Cell Cycle Res, V5, P393; Ha N, 2003, J BIOL CHEM, V278, P17885, DOI 10.1074/jbc.M210560200; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MEREDITH MJ, 1987, CANCER RES, V47, P4576; OLSON RD, 1980, J PHARMACOL EXP THER, V215, P450; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pernin D, 1999, EUR J CANCER, V35, P1130, DOI 10.1016/S0959-8049(99)00059-3; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Siu WY, 2004, MOL CANCER THER, V3, P621; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stern N, 2002, J BIOL CHEM, V277, P602, DOI 10.1074/jbc.M106798200; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Watters DJ, 2003, REDOX REP, V8, P23, DOI 10.1179/135100003125001206; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Ye RQ, 2004, DNA REPAIR, V3, P235, DOI 10.1016/j.dnarep.2003.10.014; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yih LH, 2000, CANCER RES, V60, P6346; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	56	206	209	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53272	53281		10.1074/jbc.M406879200	http://dx.doi.org/10.1074/jbc.M406879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15489221	hybrid			2022-12-25	WOS:000225680600058
J	Petrosillo, G; Ruggiero, FM; Pistolese, M; Paradies, G				Petrosillo, G; Ruggiero, FM; Pistolese, M; Paradies, G			Ca2+-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms - Role of cardiolipin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART SUBMITOCHONDRIAL PARTICLES; CELL-DEATH; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; APOPTOSIS; CALCIUM; MEMBRANE; PORE	Release of cytochrome c from mitochondria is considered a critical, early event in the induction of an apoptosis cascade that ultimately leads to programmed cell death. Mitochondrial Ca2+ loading is a trigger for the release of cytochrome c, although the molecular mechanism underlying this effect is not fully clarified. This study tested the hypothesis that distinct Ca2+ thresholds may induce cytochrome c release from rat liver mitochondria by membrane permeability transition (MPT)-dependent and independent mechanisms. The involvement of reactive oxygen species (ROS) and cardiolipin in the Ca2+-induced cytochrome c release was also investigated. Cytochrome c was quantitated by a new, very sensitive, and rapid reverse-phase high performance liquid chromatography method with a detection limit of 0.1 pmol/sample. We found that a low extramitochondrial Ca2+ level (2 muM) promoted the release of similar to13% of the total alamethicin releasable pool of cytochrome c from mitochondria. This release was not depending of MPT; it was mediated by Ca2+-induced ROS production and cardiolipin peroxidation and appears to involve the voltage-dependent anion channel. High extramitochondrial Ca2+ level (20 muM) promoted similar to45% of the total releasable pool of cytochrome c. This process was MPT-dependent and was also mediated by ROS and cardiolipin. It is suggested that distinct Ca2+ levels may determine the mode and the amount of cytochrome c release from rat liver mitochondria. The data may help to clarify the molecular mechanism underlying the Ca2+-induced release of cytochrome c from rat liver mitochondria and the role played by ROS and cardiolipin in this process.	Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Via E Orabona 4, I-70126 Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buege J A, 1978, Methods Enzymol, V52, P302; Colell A, 2004, FEBS LETT, V560, P63, DOI 10.1016/S0014-5793(04)00071-7; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crouser ED, 2003, ANAL BIOCHEM, V317, P67, DOI 10.1016/S0003-2697(03)00044-7; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Esposti MD, 2004, BIOCHEM SOC T, V32, P493; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; FLEURY C, 2003, FBIOCHIMIE PARIS, V84, P131; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kanno T, 2004, FREE RADICAL RES, V38, P27, DOI 10.1080/10715760310001626266; KAUPPINEN RA, 1984, AM J PHYSIOL, V247, pH508, DOI 10.1152/ajpheart.1984.247.4.H508; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MCMILLIN JB, 2002, BIOCHIM BIOPHYS ACTA, V158, P97; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schild L, 2001, FASEB J, V15, P565; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; THOMAS WE, 1987, BIOCHEM J, V247, P315, DOI 10.1042/bj2470315; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200	55	133	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53103	53108		10.1074/jbc.M407500200	http://dx.doi.org/10.1074/jbc.M407500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475362	hybrid			2022-12-25	WOS:000225680600038
J	Zhang, JH; Kew, RR				Zhang, JH; Kew, RR			Identification of a region in the vitamin D-binding protein that mediates its C5a chemotactic cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GC-GLOBULIN; DES ARG; STRUCTURAL BASIS; STEROL-BINDING; ACTIN-BINDING; PLASMA; NEUTROPHILS; COCHEMOTAXIN; RECEPTOR; LIGANDS	The vitamin D-binding protein (DBP), also known as group-specific component or Gc-globulin, is a multifunctional plasma protein that can significantly enhance the leukocyte chemotactic activity to C5a and C5a des-Arg. DBP is a member of the albumin gene family and has a triple domain modular structure with extensive disulfide bonding that is characteristic of this protein family. The goal of this study was to identify a region in DBP that mediates the chemotactic cofactor function for C5a. Full-length and truncated versions of DBP (Gc-2 allele) were expressed in Escherichia coli using a glutathione S-transferase fusion protein expression system. The structure of the expressed proteins was confirmed by SDS-PAGE and immunoblotting, whereas protein function was verified by quantitating the binding of [H-3] vitamin D. Dibutyryl cAMP-differentiated HL-60 cells were utilized to test purified natural DBP and recombinant expressed DBP (reDBP) for their ability to enhance chemotaxis and intracellular Ca2+ flux to C5a. Natural and full-length reDBP ( 458 amino acid residues) as well as truncated reDBPs that contained the N-terminal domain I ( domains I and II, residues 1 - 378; domain I, residues 1 - 191) significantly enhanced both cell movement and intracellular Ca2+ concentrations in response to C5a. Progressive truncation of DBP domain I localized the chemotactic enhancing region between residues 126 - 175. Overlapping peptides corresponding to this region were synthesized, and results indicate that a 20-amino- acid sequence (residues 130 - 149, 5'-EAFRKDP-KEYANQFMWEYST-3') in domain I of DBP is essential for its C5a chemotactic cofactor function.	SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kew, RR (corresponding author), SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA.	rkew@notes.cc.sunysbedu			NIGMS NIH HHS [GM 63769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063769, R56GM063769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Binder R, 1999, MOL IMMUNOL, V36, P885, DOI 10.1016/S0161-5890(99)00110-8; COOKE NE, 1986, J BIOL CHEM, V261, P3441; DiMartino SJ, 1999, J IMMUNOL, V163, P2135; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gomme PT, 2004, TRENDS BIOTECHNOL, V22, P340, DOI 10.1016/j.tibtech.2004.05.001; HADDAD JG, 1992, BIOCHEMISTRY-US, V31, P7174, DOI 10.1021/bi00146a021; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; HIRSCHFELD JAN, 1959, ACTA PATHOL ET MICROBIOL SCAND, V47, P160; Kanda S, 2002, JNCI-J NATL CANCER I, V94, P1311; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; KEW RR, 1995, J LEUKOCYTE BIOL, V58, P55, DOI 10.1002/jlb.58.1.55; KEW RR, 1995, J IMMUNOL, V155, P5369; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; METCALF JP, 1991, AM REV RESPIR DIS, V143, P844, DOI 10.1164/ajrccm/143.4_Pt_1.844; Mizwicki MT, 2003, J BONE MINER RES, V18, P795, DOI 10.1359/jbmr.2003.18.5.795; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; OSAWA M, 1994, BIOCHEM MOL BIOL INT, V34, P1003; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; PEREZ HD, 1988, J CLIN INVEST, V82, P360, DOI 10.1172/JCI113595; PETRINI M, 1991, J ENDOCRINOL INVEST, V14, P405, DOI 10.1007/BF03349090; PIQUETTE CA, 1994, J LEUKOCYTE BIOL, V55, P349, DOI 10.1002/jlb.55.3.349; SENIOR RM, 1988, J IMMUNOL, V141, P3570; Swamy N, 1997, BIOCHEMISTRY-US, V36, P7432, DOI 10.1021/bi962730i; Swamy N, 2002, ARCH BIOCHEM BIOPHYS, V402, P14, DOI 10.1016/S0003-9861(02)00033-4; Swamy N, 1997, PROTEIN EXPRES PURIF, V10, P115, DOI 10.1006/prep.1996.0720; Trujillo G, 2004, J IMMUNOL, V173, P4130, DOI 10.4049/jimmunol.173.6.4130; Verboven C, 2002, NAT STRUCT BIOL, V9, P131, DOI 10.1038/nsb754; White P, 2000, TRENDS ENDOCRIN MET, V11, P320, DOI 10.1016/S1043-2760(00)00317-9; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZWAHLEN RD, 1990, INFLAMMATION, V14, P109, DOI 10.1007/BF00914034	34	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53282	53287		10.1074/jbc.M411462200	http://dx.doi.org/10.1074/jbc.M411462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485893	hybrid			2022-12-25	WOS:000225680600059
J	Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ				Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ			LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution	ONCOGENE			English	Article						LRP6; beta-catenin; Writ signaling; proliferation; tumorigenesis	RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; ACTIVATION; MECHANISM; COMPLEX; PHOSPHORYLATION; OSTEOSARCOMA; DICKKOPF-1; MICE	The Wnt signaling pathway plays key roles in both embryogenesis and tumorigenesis. The low-density lipoprotein (LDL) receptor-related protein-6 (LRP6), a novel member of the expanding LDL receptor family, functions as an indispensable co-receptor for the Wnt signaling pathway. Although the role of LRP6 in embryonic development is now well established, its role in tumorigenesis is unclear. We report that LRP6 is readily expressed at the transcript level in several human cancer cell lines and human malignant tissues. Furthermore, using a retroviral gene transfer system, we find that stable expression of LRP6 in human fibrosarcoma HT1080 cells alters subcellular beta-catenin distribution such that the cytosolic beta-catenin level is significantly increased. This is accompanied by a significant increase in Wnt/beta-catenin signaling and cell proliferation. Finally, we demonstrate that LRP6 expression promotes tumorigenesis in vivo. These results thus indicate that LRP6 may function as a potential oncogenic protein by modulating Wnt/beta-catenin signaling.	Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol,Div Neurosci, Boston, MA 02115 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Li, YH (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	li_yo@kids.wustl.edu						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BAO B, 2002, NATURE, V417, P664; BAO B, 2001, NATURE, V411, P321; BRENNAN K, 2004, ONCOGENE; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X	32	67	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9129	9135		10.1038/sj.onc.1208123	http://dx.doi.org/10.1038/sj.onc.1208123			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15516984				2022-12-25	WOS:000225492800014
J	Lodygin, D; Diebold, J; Hermeking, H				Lodygin, D; Diebold, J; Hermeking, H			Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression	ONCOGENE			English	Article						epigenetic silencing; CpG methylation; tumor suppressor; p53; 14-3-3 sigma; prostate cancer	HISTONE DEACETYLASE INHIBITION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; CELL CARCINOMA; EXPRESSION; ADENOCARCINOMA; TUMORIGENESIS; DEMETHYLATION; INACTIVATION; RECEPTOR	In order to identify tumor suppressive genes silenced by CpG methylation in prostate carcinoma (PCa), we determined genome-wide expression changes after pharmacological reversal of CpG methylation-mediated transcriptional repression in three PCa cell lines using microarray analysis. Thereby, epigenetic silencing of the 14-3-3sigma gene was detected in the cell line LNCaP. 14-3-3sigma encodes a p53-regulated inhibitor of cell cycle progression. Laser microdissection was used to isolate different cell types present in diseased prostatic tissue. Subsequent methylation-specific PCR analysis showed CpG methylation of 14-3-3sigma in all 41 primary PCa samples analysed, which was accompanied by a decrease or loss of 14-3-3sigma protein expression. In contrast, normal prostate epithelial and benign prostate hyperplasia cells showed high levels of 14-3-3sigma expression. PCa-precursor lesions (prostatic intraepithelial neoplasia) also displayed decreased levels of 14-3-3sigma expression in luminal cells, which are known to contain shortened telomeres. RNA interference-mediated inactivation of 14-3-3sigma compromised a DNA damage-induced G(2)/M arrest in the PCa cell line PC3. The generality of CpG methylation and downregulation of 14-3-3sigma expression in PCa suggests that it significantly contributes to the formation of PCa, potentially by allowing the escape from a DNA damage-induced arrest elicited by telomere shortening.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Inst Pathol, D-80337 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Meeker AK, 2002, CANCER RES, V62, P6405; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; SAKR WA, 1994, IN VIVO, V8, P439; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Singal R, 2001, CANCER RES, V61, P4820; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	29	74	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9034	9041		10.1038/sj.onc.1208004	http://dx.doi.org/10.1038/sj.onc.1208004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489902				2022-12-25	WOS:000225492800004
J	Saleh-Gohari, N; Helleday, T				Saleh-Gohari, N; Helleday, T			Strand invasion involving short tract gene conversion is specifically suppressed in BRCA2-deficient hamster cells	ONCOGENE			English	Article						homologous recombination; BRCA2; strand invasion; sister chromatid exchange; gene conversion; DNA double-strand break	HOMOLOGY-DIRECTED REPAIR; DNA-REPAIR; CHROMOSOMAL TRANSLOCATIONS; CANCER SUSCEPTIBILITY; MAMMALIAN-CELLS; RAD51 PROTEIN; BREAK REPAIR; BRCA2 LEADS; RECOMBINATION; DEFICIENCY	The BRCA2 tumour suppressor protein is involved in maintaining genetic stability through its role in homologous recombination (HR), where it mediates RAD51-dependent strand invasion. Here, we show that BRCA2-defective cells are not completely impaired in HR by strand invasion although the spontaneous HR rate is 10-fold lower than that in wild-type cells. Furthermore, a DNA double-strand break (DSB) triggers HR repair by strand invasion also in BRCA2-defective cells, but less efficiently. Thus, either the strand invasion pathway(s) in which BRCA2 operates is still operative in the absence of a functional BRCA2, albeit at a reduced frequency, or there is a separate pathway for strand invasion still functional in BRCA2-deficient cells. Consistent with the latter hypothesis, we show that HR events occurring in BRCA2-defective cells differ from HR events in wild-type cells. These data suggest that BRCA2-defective hamster cells are impaired in short tract gene conversion but maintain proficiency in sister chromatid exchange.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Univ Stockholm, Arrhenius Lab, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	University of Sheffield; Stockholm University	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Gohari, Nasrollah Saleh/ABB-4209-2020	Gohari, Nasrollah Saleh/0000-0003-1256-0323; Helleday, Thomas/0000-0002-7384-092X				Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400	28	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9136	9141		10.1038/sj.onc.1208178	http://dx.doi.org/10.1038/sj.onc.1208178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480413				2022-12-25	WOS:000225492800015
J	Enoksson, M; Robertson, JD; Gogvadze, V; Bu, PL; Kropotov, A; Zhivotovsky, B; Orrenius, S				Enoksson, M; Robertson, JD; Gogvadze, V; Bu, PL; Kropotov, A; Zhivotovsky, B; Orrenius, S			Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; INDUCED APOPTOSIS; CARDIOLIPIN; RELEASE; BAX; ACTIVATION; PROTEIN; ETOPOSIDE; ENCODES; COMPLEX	Caspases are cysteine proteases that play a central role in the execution of apoptosis. Recent evidence indicates that caspase-2 is activated early in response to genotoxic stress and can function as an upstream modulator of the mitochondrial apoptotic pathway. In particular, we have shown previously that fully processed caspase-2 can permeabilize the outer mitochondrial membrane and cause cytochrome c and Smac/DIABLO release from these organelles. Using permeabilized cells, isolated mitochondria, and protein-free liposomes, we now report that this effect is direct and depends neither on the presence or cleavage of other proteins nor on a specific phospholipid composition of the liposomal membrane. Interestingly, caspase-2 was also shown to disrupt the interaction of cytochrome c with anionic phospholipids, notably cardiolipin, and thereby enhance the release of the hemoprotein caused by treatment of mitochondria with digitonin or the proapoptotic protein Bax. Combined, our data suggest that caspase-2 possesses an unparalleled ability to engage the mitochondrial apoptotic pathway by permeabilizing the outer mitochondrial membrane and/or by breaching the association of cytochrome c with the inner mitochondrial membrane.	Karolinska Inst, Inst Environm Med, Div Toxicol, S-17177 Stockholm, Sweden; Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA	Karolinska Institutet; University of Kansas; University of Kansas Medical Center	Orrenius, S (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.	Sten.Orrenius@imm.ki.se	Kropotov, Andrey/AAE-9324-2021; Bu, Pengli/J-3575-2019; Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014	Bu, Pengli/0000-0003-2576-0607; Zhivotovsky, Boris/0000-0002-2238-3482; Kropotov, Andrey/0000-0002-1865-4008	NIEHS NIH HHS [K22 ES11647] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011647] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALIGA BC, 2004, CELL DEATH DIFFER; Buser CA, 1998, METH MOL B, V84, P267; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	23	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49575	49578		10.1074/jbc.C400374200	http://dx.doi.org/10.1074/jbc.C400374200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15475367	hybrid			2022-12-25	WOS:000225229500006
J	Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R				Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R			An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients	ONCOGENE			English	Article						antibodies; heat-shock proteins; HSP90; ovarian cancer; phage display	HEAT-SHOCK-PROTEIN; PROGNOSTIC-FACTORS; EXPRESSION; AUTOANTIBODIES; CARCINOMA; ANTIGENS; DISPLAY; MARKERS; SURFACE; HSP90	To gain insight into the mechanisms of molecular recognition and humoral immune response in ovarian cancer, we used fingerprinting, a phage display-based combinatorial selection to isolate peptide ligands to tumor-related antibodies present in ascites from patients with advanced disease. First, we have isolated a consensus motif (sequence CVPELGHEC) in 86% of the peptides screened; this enriched motif was selected from a total of 108-109 unique random sequences present in the library. Next, we identified the heat-shock protein 90 kDa (HSP90) as the native antigen mimicked by the motif. Finally, we evaluated the expression of HSP90 and the presence of antibodies against the HSP90-mimic peptide in a large panel of ovarian cancer patients and controls. In tissue microarrays, we show that the expression of HSP90 is ubiquitous. However, the corresponding humoral immune response against HSP90 is restricted to a subset of patients with stage IV disease. Together, these results show that screening humoral response can identify tumor antigens that may serve as molecular targets in ovarian cancer. Recognition of such relevant proteins in the immunobiology of malignant tumors may lead to the development of therapies.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Mario Negri Inst Pharmacol Res, Dept Oncol, Lab Biol & Therapy Metastasis, I-24125 Bergamo, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	warap@mdanderson.org; rpasqual@mdanderson.org	Giavazzi, Raffaella/J-7424-2018; Giavazzi, Raffaella/ABB-9768-2020	Giavazzi, Raffaella/0000-0001-5249-8208	NCI NIH HHS [CA836393] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BOOKMAN MA, 2000, PRINCIPLES PRACTICE, P403; BRINTON LA, 2000, PRINCIPLES PRACTICE, P3; BUICK RN, 1985, CANCER RES, V45, P3668; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; Conroy SE, 1998, EUR J CANCER, V34, P942; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kenderov A, 2002, CLIN EXP IMMUNOL, V129, P169, DOI 10.1046/j.1365-2249.2002.01887.x; Luo LY, 2002, BRIT J CANCER, V87, P339, DOI 10.1038/sj.bjc.6600439; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; Marsden DE, 2000, SEMIN SURG ONCOL, V19, P11, DOI 10.1002/1098-2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3; Meyer T, 2000, BRIT J CANCER, V82, P1535; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SRIVASTAVA PK, 2001, PRINCIPLES PRACTICE, P1; Taylor DD, 1998, ONCOL REP, V5, P1519; Trieb K, 2000, BRIT J CANCER, V82, P85, DOI 10.1054/bjoc.1999.0881; Witkin SS, 2001, EUR J GYNAECOL ONCOL, V22, P249	24	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8859	8867		10.1038/sj.onc.1208082	http://dx.doi.org/10.1038/sj.onc.1208082			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480432				2022-12-25	WOS:000225354600001
J	Gavins, FNE; Kamal, AM; D'Amico, M; Oliani, SM; Perretti, M				Gavins, FNE; Kamal, AM; D'Amico, M; Oliani, SM; Perretti, M			Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct	FASEB JOURNAL			English	Article						FPR; ischemia/reperfusion; PMN	ISCHEMIA-REPERFUSION INJURY; ENDOTHELIAL-CELL-ADHESION; ACUTE CORONARY SYNDROMES; LIPOXIN A(4) RECEPTOR; LIPOCORTIN 1; ACTIVATES NEUTROPHILS; T-LYMPHOCYTES; IN-VITRO; LEUKOCYTE; INFLAMMATION	Recent interest in the annexin 1 field has come from the notion that specific G-protein-coupled receptors, members of the formyl-peptide receptor (FPR) family, appear to mediate the anti-inflammatory actions of this endogenous mediator. Administration of the annexin 1 N-terminal derived peptide Ac2-26 to mice after 25 min ischemia significantly attenuated the extent of acute myocardial injury as assessed 60 min postreperfusion. Evident at the dose of 1 mg/kg (similar to9 nmol per animal), peptide Ac2-26 cardioprotection was intact in FPR null mice. Similarly, peptide Ac2-26 inhibition of specific markers of heart injury (specifically myeloperoxidase activity, CXC chemokine KC contents, and endogenous annexin 1 protein expression) was virtually identical in heart samples collected from wild-type and FPR null mice. Mouse myocardium expressed the mRNA for FPR and the structurally related lipoxin A(4) receptor, termed ALX; thus, comparable equimolar doses of two ALX agonists (W peptide and a stable lipoxin A4 analog) exerted cardioprotection in wild-type and FPR null mice to an equal extent. Curiously, marked (>95%) blood neutropenia produced by an anti-mouse neutrophil serum did not modify the extent of acute heart injury, whereas it prevented the protection afforded by peptide Ac2-26. Thus, this study sheds light on the receptor mechanism(s) mediating annexin 1-induced cardioprotection and shows a pivotal role for ALX and circulating neutrophil, whereas it excludes any functional involvement of mouse FPR. These mechanistic data can help in developing novel therapeutics for acute cardioprotection.	Barts & London, Queen Mary Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Dept Expt Med, I-80138 Naples, Italy; UNESP, IBILCE, Dept Biol, Sao Paulo, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Universidade Estadual Paulista	Perretti, M (corresponding author), Barts & London, Queen Mary Sch Med & Dent, William Harvey Res Inst, Ctr Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Gavins, Felicity N. E./AAU-6010-2020; Oliani, Sonia Maria/E-3476-2012	Gavins, Felicity N. E./0000-0001-7008-5423; Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595				ABE Y, 1993, BRIT HEART J, V70, P132; Anguera I, 2002, AM HEART J, V144, P811, DOI 10.1067/mhj.2002.124831; Baxter GF, 2002, BASIC RES CARDIOL, V97, P268, DOI 10.1007/s00395-002-0366-7; Blum A, 1996, LANCET, V347, P56, DOI 10.1016/S0140-6736(96)91585-8; Bonder CS, 2004, J IMMUNOL, V172, P45, DOI 10.4049/jimmunol.172.1.45; Cerwinka WH, 2003, AM J PHYSIOL-HEART C, V284, pH535, DOI 10.1152/ajpheart.00311.2002; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Christophe T, 2001, J BIOL CHEM, V276, P21585, DOI 10.1074/jbc.M007769200; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; D'Amico M, 2000, FASEB J, V14, P1867; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; de Lemos JA, 2003, CIRCULATION, V107, P690, DOI 10.1161/01.CIR.0000049742.68848.99; Dewald O, 2003, P NATL ACAD SCI USA, V100, P2700, DOI 10.1073/pnas.0438035100; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; He R, 2000, J IMMUNOL, V165, P4598, DOI 10.4049/jimmunol.165.8.4598; JOHN C, 2001, J ENDOCRINOL, V169, pP150; John CD, 2004, TRENDS ENDOCRIN MET, V15, P103, DOI 10.1016/j.tem.2004.02.001; Jones SP, 2000, AM J PHYSIOL-HEART C, V279, pH2196; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; La M, 2001, EUR J PHARMACOL, V429, P263, DOI 10.1016/S0014-2999(01)01325-5; La M, 2001, FASEB J, V15, P2247, DOI 10.1096/fj.01-0196com; LATINI R, 1994, J CARDIOVASC PHARM, V23, P1, DOI 10.1097/00005344-199401000-00026; Le YY, 1999, J IMMUNOL, V163, P6777; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Lefer AM, 1998, CIRCULATION, V98, P1322, DOI 10.1161/01.CIR.98.13.1322; Lefer DJ, 2002, BASIC RES CARDIOL, V97, P263, DOI 10.1007/s00395-002-0363-x; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Mallat Z, 2002, HEART, V88, P467, DOI 10.1136/heart.88.5.467; MANCUSO F, 1995, J IMMUNOL, V155, P377; MAULIK N, 1993, CIRCULATION, V88, P387; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Pannitteri G, 1997, AM J CARDIOL, V80, P622, DOI 10.1016/S0002-9149(97)00434-7; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Perretti M, 2001, AM J PATHOL, V158, P1969, DOI 10.1016/S0002-9440(10)64667-6; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 2003, NEWS PHYSIOL SCI, V18, P60, DOI 10.1152/nips.01424.2002; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Ritchie RH, 2003, EUR J PHARMACOL, V461, P171, DOI 10.1016/S0014-2999(03)01314-1; Scalia R, 2001, CIRCULATION, V103, P2598; Schottelius AJ, 2002, J IMMUNOL, V169, P7063, DOI 10.4049/jimmunol.169.12.7063; Solito E, 2003, FASEB J, V17, P1544, DOI 10.1096/fj.02-0941fje; Spagnoli LG, 2002, J AM COLL CARDIOL, V40, P1579, DOI 10.1016/S0735-1097(02)02376-8; Stokes KY, 2002, MICROCIRCULATION, V9, P407, DOI 10.1038/sj.mn.7800148; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Varda-Bloom N, 2000, J MOL CELL CARDIOL, V32, P2141, DOI 10.1006/jmcc.2000.1261; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8	56	58	61	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					100	+		10.1096/fj.04-2178fje	http://dx.doi.org/10.1096/fj.04-2178fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15507472				2022-12-25	WOS:000224849900007
J	Kutcher, ME; Klagsbrun, M; Mamluk, R				Kutcher, ME; Klagsbrun, M; Mamluk, R			VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during development	FASEB JOURNAL			English	Article						endothelial cells; sensory neurons; kinase inhibitor	ENDOTHELIAL-GROWTH-FACTOR; IN-VIVO; NERVOUS-SYSTEM; RECEPTOR; EXPRESSION; ANGIOGENESIS; RAT; DIFFERENTIATION; NEUROPILIN; SURVIVAL	Vascular endothelial growth factor ( VEGF) is a potent regulator of vascular function through its control of multiple endothelial cell functions. In addition to its key role in vascularization, VEGF has recently been shown to have neurotrophic activity during hypoxic stress. In the central and peripheral motor nervous system, VEGF treatment increased neuronal vascularization and perfusion, as well as having direct trophic effects on neurons and Schwann cells. However, the role of VEGF in the sensory nervous system remains unclear. To characterize the differential effects of VEGF on endothelial cells and neurons in sensory ganglia, we used explanted mouse dorsal root ganglia (DRG), a culture system containing neurons and endothelial cells in close apposition. We show that VEGF is expressed by neurons and satellite cells, but not by endothelial cells or pericytes. On the other hand, the tyrosine kinase VEGF receptor VEGFR-2 was robustly expressed by endothelial cells throughout the extensive DRG capillary network, but not found at either the transcript or protein level in sensory neurons or other nonendothelial cells of the DRG. Both soluble receptor sequestration of VEGF and small molecule kinase inhibition of VEGFR-2 signaling rapidly disrupted the connectivity, branching, and structural integrity of the capillary network of embryonic DRG; this effect was no longer evident postnatally. However, VEGF inhibition showed no detectable effect on neuronal health at any stage analyzed. These data suggest that endogenous VEGF is a strict requirement for vascular, but not neuronal, maintenance in developing sensory ganglia.	Childrens Hosp, Vasc Biol Program, Karp Family Res Labs, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Childrens Hosp, Vasc Biol Program, Karp Family Res Labs, Room 12-210,300 Longwood Ave, Boston, MA 02115 USA.	michael.klagsbrun@childrens.harvard.edu		Kutcher, Matthew/0000-0003-4566-5359	NCI NIH HHS [CA45548, CA37392] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, R37CA037392, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; BAKER DM, 1989, J NEUROCYTOL, V18, P647, DOI 10.1007/BF01187084; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHENG L, 2004, IN PRESS J BIOL CHEM; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hogan KA, 2004, DEVELOPMENT, V131, P1503, DOI 10.1242/dev.01039; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; MATSUDA S, 1984, CELL TISSUE RES, V235, P13; Matsuda S, 1996, ANAT EMBRYOL, V193, P475; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pinter E, 2001, AM J PATHOL, V158, P1199, DOI 10.1016/S0002-9440(10)64069-2; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2001, NEUROREPORT, V12, P105, DOI 10.1097/00001756-200101220-00028; Stupack D.G., 2002, SCI STKE, P7; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073; Wood JM, 2000, CANCER RES, V60, P2178; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084	44	33	36	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1952	+		10.1096/fj.04-2320fje	http://dx.doi.org/10.1096/fj.04-2320fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15479766				2022-12-25	WOS:000224849900023
J	Vissing, K; Andersen, JL; Schjerling, P				Vissing, K; Andersen, JL; Schjerling, P			Are exercise-induced genes induced by exercise?	FASEB JOURNAL			English	Article						dietary status; repeated biopsy effect; transcription factors; metabolic genes	HUMAN SKELETAL-MUSCLE; ALPHA-B-CRYSTALLIN; METABOLIC GENES; TRANSCRIPTIONAL ACTIVATION; CONTRACTILE ACTIVITY; RESISTANCE EXERCISE; GLUT-4 GENE; EXPRESSION; INTENSITY; RAT	Numerous human in vivo studies on skeletal muscle gene expression have investigated the effects of given interventions. These have been founded on the assumption that presampling can be regarded as a representative control for postintervention sampling. However, many genes are responsive to the metabolic status, which varies during the day, so that observed differences in gene expression between the pre- and post-sample may therefore be a result of the daily variations rather than an intervention. Furthermore, the sampling itself can cause a local stress response, which may also influence the expression of some genes in later samples from the same localized area. To test this, we performed a short-term human endurance exercise study in which muscle biopsies were obtained from healthy untrained individuals (n = 14) before and in the hours after exercise to measure the expression of mRNA for previously reported exercise-related genes (e.g., PPARgamma coactivator-1alpha (PGC-1alpha), pyruvate dehydrogenase kinase 4 (PDK4), MyoD, p21, (heat shock protein 72 (HSP72), lipoprotein lipase (LPL), citrate synthase (CS), and glucose transporter 4 (GLUT4)). To test for changes unrelated to exercise, one half of the subjects did not exercise. As suspected, several presumed exercise-induced genes were induced even without the exercise. Our data demonstrate that presampling is not always a representative control for postintervention sampling, illustrating that use of presampling can cause erroneous interpretations of the underlying induction signals.	Rigshosp, Copenhagen Muscle Res Ctr, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Schjerling, P (corresponding author), Rigshosp, Copenhagen Muscle Res Ctr, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark.	viridis@biobase.dk	Andersen, Jesper L/W-6813-2019; Vissing, Kristian/GOP-0449-2022; Schjerling, Peter/F-6194-2011	Schjerling, Peter/0000-0001-7138-3211; Vissing, Kristian/0000-0001-5810-5241				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; ANDERSEN P, 1985, J APPL PHYSIOL, V59, P1647, DOI 10.1152/jappl.1985.59.5.1647; Bennett CD, 2001, EUR J COMBIN, V22, P27, DOI 10.1006/eujc.2000.0436; Bickel CS, 2003, J APPL PHYSIOL, V94, P2255, DOI 10.1152/japplphysiol.00014.2003; Brau L, 1997, BIOCHEM J, V322, P303; CAREY JO, 1994, BIOCHEM J, V298, P613, DOI 10.1042/bj2980613; Feasson L, 2002, J PHYSIOL-LONDON, V543, P297, DOI 10.1113/jphysiol.2002.018689; Febbraio MA, 2002, J PHYSIOL-LONDON, V538, P911, DOI 10.1113/jphysiol.2001.013145; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Hargreaves M, 2002, MED SCI SPORT EXER, V34, P1505, DOI 10.1097/00005768-200209000-00017; Hildebrandt AL, 2003, AM J PHYSIOL-ENDOC M, V285, pE1021, DOI 10.1152/ajpendo.00234.2003; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; Neufer PD, 1996, J BIOL CHEM, V271, P24089, DOI 10.1074/jbc.271.39.24089; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; Neufer PD, 1998, AM J PHYSIOL-CELL PH, V274, pC341, DOI 10.1152/ajpcell.1998.274.2.C341; Nordsborg N, 2003, J APPL PHYSIOL, V95, P1201, DOI 10.1152/japplphysiol.00257.2003; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Psilander N, 2003, J APPL PHYSIOL, V95, P1038, DOI 10.1152/japplphysiol.00903.2002; RANTANEN J, 1995, LAB INVEST, V72, P341; SCHJERLING P, 2001, J APPL PHYSIOL, V88, P794; Siu PM, 2003, J APPL PHYSIOL, V94, P555, DOI 10.1152/japplphysiol.00821.2002; Tunstall RJ, 2002, BIOCHEM BIOPH RES CO, V294, P301, DOI 10.1016/S0006-291X(02)00473-4	28	84	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					94	+		10.1096/fj.04-2084fje	http://dx.doi.org/10.1096/fj.04-2084fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15516373				2022-12-25	WOS:000224849900001
J	Lovering, AL; Lee, SS; Kim, YW; Withers, SG; Strynadka, NCJ				Lovering, AL; Lee, SS; Kim, YW; Withers, SG; Strynadka, NCJ			Mechanistic and structural analysis of a family 31 alpha-glycosidase and its glycosyl-enzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; CATALYTIC NUCLEOPHILE; INTESTINAL SUCRASE; ASPERGILLUS-NIGER; D-XYLOSIDASE; ACTIVE-SITE; GLUCOSIDASE; CLASSIFICATION; IDENTIFICATION	We have determined the first structure of a family 31 alpha-glycosidase, that of YicI from Escherichia coli, both free and trapped as a 5-fluoroxylopyranosyl-enzyme intermediate via reaction with 5-fluoro-alpha-D-xylopyranosyl fluoride. Our 2.2- Angstrom resolution structure shows an intimately associated hexamer with structural elements from several monomers converging at each of the six active sites. Our kinetic and mass spectrometry analyses verified several of the features observed in our structural data, including a covalent linkage from the carboxylate side chain of the identified nucleophile Asp(416) to C-1 of the sugar ring. Structure-based sequence comparison of YicI with the mammalian alpha-glucosidases lysosomal alpha-glucosidase and sucrase-isomaltase predicts a high level of structural similarity and provides a foundation for understanding the various mutations of these enzymes that elicit human disease.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca	Lee, Seung/K-8669-2018	Lee, Seung/0000-0002-8598-3303; Lovering, Andrew/0000-0002-1856-7975				Abe A, 2004, J MOL BIOL, V335, P811, DOI 10.1016/j.jmb.2003.10.078; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BERGFORS TM, 1999, PROTEIN CRYSTALLIZAT, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chaillou S, 1998, J BACTERIOL, V180, P2312, DOI 10.1128/JB.180.9.2312-2320.1998; CHAMBERS JP, 1982, BIOCHEM BIOPH RES CO, V107, P1490, DOI 10.1016/S0006-291X(82)80167-8; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; COGOLI A, 1975, J BIOL CHEM, V250, P7802; CUDNEY B, 1994, ACTA CRYSTALLOGR D, V50, P414, DOI 10.1107/S0907444994002660; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Deslongchamps P., 1983, STEREOELECTRONIC EFF, P4; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frandsen TP, 1998, PLANT MOL BIOL, V37, P1, DOI 10.1023/A:1005925819741; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANOZET G, 1981, J BIOL CHEM, V256, P3703; HAYASHI M, 1984, CHEM LETT, P1747, DOI 10.1246/cl.1984.1747; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HENRISSAT B, 1993, BIOCHEM J, V293, P309; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Hovel K, 2003, EMBO J, V22, P4922, DOI 10.1093/emboj/cdg494; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; IGAKI S, 1989, ANN M JAP AGR SOC NI, P292; IWANAMI S, 1995, BIOSCI BIOTECH BIOCH, V59, P459, DOI 10.1271/bbb.59.459; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Kano T, 1996, BIOL PHARM BULL, V19, P341, DOI 10.1248/bpb.19.341; Kashiwabara S, 2000, BIOSCI BIOTECH BIOCH, V64, P1379, DOI 10.1271/bbb.64.1379; Katsuya Y, 1998, J MOL BIOL, V281, P885, DOI 10.1006/jmbi.1998.1992; Kimura A, 1997, BIOSCI BIOTECH BIOCH, V61, P1091, DOI 10.1271/bbb.61.1091; Kobayashi M., 2003, Journal of Applied Glycoscience, V50, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, GRAFIT VERSION 4 0; Lee SS, 2003, BIOCHEMISTRY-US, V42, P13081, DOI 10.1021/bi035189g; Lee SS, 2002, J AM CHEM SOC, V124, P4948, DOI 10.1021/ja0255610; Lee SS, 2001, BIOCHEM J, V359, P381, DOI 10.1042/0264-6021:3590381; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Lunin VV, 2004, J MOL BIOL, V337, P367, DOI 10.1016/j.jmb.2003.12.071; Ly HD, 2000, CARBOHYD RES, V329, P539, DOI 10.1016/S0008-6215(00)00214-7; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Monroe JD, 2003, PLANT PHYSIOL BIOCH, V41, P877, DOI 10.1016/S0981-9428(03)00133-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano N, 2001, PROTEIN ENG, V14, P845, DOI 10.1093/protein/14.11.845; Nerinckx W, 2003, FEBS LETT, V538, P1, DOI 10.1016/S0014-5793(03)00148-0; Numao S, 2000, FEBS LETT, V484, P175, DOI 10.1016/S0014-5793(00)02148-7; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Okuyama M, 2004, PROTEIN EXPRES PURIF, V37, P170, DOI 10.1016/j.pep.2004.05.008; Okuyama M, 2001, EUR J BIOCHEM, V268, P2270, DOI 10.1046/j.1432-1327.2001.02104.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; QUARONI A, 1976, J BIOL CHEM, V251, P3250; Sampedro J, 2001, PLANT PHYSIOL, V126, P910, DOI 10.1104/pp.126.2.910; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Yang JK, 2004, J MOL BIOL, V335, P155, DOI 10.1016/j.jmb.2003.10.026; Yu SK, 1999, BBA-PROTEIN STRUCT M, V1433, P1, DOI 10.1016/S0167-4838(99)00152-1; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; ZONG N, 1989, AGR BIOL CHEM TOKYO, V53, P187, DOI 10.1080/00021369.1989.10869249	73	145	153	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2105	2115		10.1074/jbc.M410468200	http://dx.doi.org/10.1074/jbc.M410468200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15501829	hybrid			2022-12-25	WOS:000226341700045
J	Ahting, U; Waizenegger, T; Neupert, W; Rapaport, D				Ahting, U; Waizenegger, T; Neupert, W; Rapaport, D			Signal-anchored proteins follow a unique insertion pathway into the outer membrane of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOM CORE COMPLEX; YEAST MITOCHONDRIA; IMPORT RECEPTORS; TRANSLOCATION; BIOGENESIS; MACHINERY; CHANNEL; PORE; BETA	Signal-anchored proteins are a class of mitochondrial outer membrane proteins that expose a hydrophilic domain to the cytosol and are anchored to the membrane by a single transmembrane domain in the N-terminal region. Like the vast majority of mitochondrial proteins, signal-anchored proteins are synthesized on cytosolic ribosomes and are subsequently imported into the organelle. We have studied the mechanisms by which precursors of these proteins are recognized by the mitochondria and are inserted into the outer membrane. The import of signal-anchored proteins was found to be independent of the known import receptors, Tom20 and Tom70, but to require the major Tom component, Tom40. In contrast to precursors destined to internal compartments of mitochondria and those of outer membrane beta-barrel proteins, precursors of signal-anchored proteins appear not to be inserted via the general import pore. Taken together, we propose a novel pathway for insertion of these proteins into the outer membrane of mitochondria.	Univ Munich, Inst Phys Chem, D-81377 Munich, Germany	University of Munich	Rapaport, D (corresponding author), Univ Munich, Inst Phys Chem, Butenandtstr 5,Haus B, D-81377 Munich, Germany.	rapaport@bio.med.uni-muenchen.de						Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; DAUM G, 1982, J BIOL CHEM, V257, P3028; Diekert K, 2001, EMBO J, V20, P5626, DOI 10.1093/emboj/20.20.5626; Gabriel K, 2003, EMBO J, V22, P2380, DOI 10.1093/emboj/cdg229; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Johnson AE, 2004, NAT STRUCT MOL BIOL, V11, P113, DOI 10.1038/nsmb0204-113; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; SCHLOSSMANN J, 1995, J BIOL CHEM, V270, P27116, DOI 10.1074/jbc.270.45.27116; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Sherman F., 1986, METHODS YEAST GENETI; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki H, 2002, J CELL SCI, V115, P1895; Tu SL, 2004, PLANT CELL, V16, P2078, DOI 10.1105/tpc.104.023952; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; Waizenegger T, 2003, J BIOL CHEM, V278, P42064, DOI 10.1074/jbc.M305736200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; YAFFE MP, 1989, J BIOL CHEM, V264, P21091	28	65	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					48	53		10.1074/jbc.M410905200	http://dx.doi.org/10.1074/jbc.M410905200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501820	hybrid			2022-12-25	WOS:000226025100007
J	Abrams, MT; Robertson, NM; Yoon, K; Wickstrom, E				Abrams, MT; Robertson, NM; Yoon, K; Wickstrom, E			Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BH3-ONLY PROTEIN BIM; BCL-2 FAMILY-MEMBER; HEMATOPOIETIC PROGENITORS; GENE-EXPRESSION; RELATIVE BIM; CELL-LINES; RECEPTOR; SURVIVAL; ACTIVATE	Glucocorticoids (GCs) induce apoptosis in lymphocytes and are effective agents for the treatment of leukemia. The activated glucocorticoid receptor initiates a transcriptional program leading to caspase activation and cell death, but the critical signaling intermediates in GC-induced apoptosis remain largely undefined. We have observed that GC induction of the three major protein products of the Bcl-2 relative Bim (BimEL, BimS, and BimL) correlates with GC sensitivity in a panel of human precursor B-cell (pre-B) acute lymphoblastic leukemia (ALL) cell lines. To test the hypothesis that Bim facilitates GC-induced apoptosis, we reduced BIM mRNA levels and Bim protein levels by RNA interference in highly GC-sensitive pre-B ALL cells. Reducing Bim proteins by either electroporation of synthetic small interfering RNA (siRNA) duplexes or lentivirus-mediated stable expression of short hairpin RNA inhibited the activation of caspase-3 and increased cell viability following GC exposure. We also observed that the extent of GC resistance correlated with siRNA silencing potency. siRNA duplexes that reduced only BimEL or BimEL and BimL (but not BimS) exhibited less GC resistance than a potent siRNA that silenced all three major isoforms, implying that induction of all three Bim proteins contributes to cell death. Finally, the modulation of GC-induced apoptosis caused by Bim silencing was independent of Bcl-2 expression levels, negating the hypothesis that the ratio of Bim to Bcl-2 regulates apoptosis. These results offer evidence that the induction of Bim by GC is a required event for the complete apoptotic response in pre-B ALL cells.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Wickstrom, E (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 233 S 10th St,Suite 219, Philadelphia, PA 19107 USA.	eric@tesla.jci.tju.edu						Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; ALNEMRI ES, 1992, CANCER RES, V52, P491; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; FINDLEY HW, 1982, BLOOD, V60, P1305; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; KATO GJ, 1993, BLOOD, V82, P2304; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu JX, 1999, BIOORG MED CHEM LETT, V9, P3231; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Medh RD, 2003, GENOMICS, V81, P543, DOI 10.1016/S0888-7543(03)00045-4; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Planey SL, 2003, CANCER RES, V63, P172; Planey SL, 2002, J BIOL CHEM, V277, P42188, DOI 10.1074/jbc.M205085200; Planey SL, 2000, BIOCHEM BIOPH RES CO, V279, P307, DOI 10.1006/bbrc.2000.3922; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357; Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tissing WJE, 2003, LEUKEMIA, V17, P17, DOI 10.1038/sj.leu.2402733; Tome ME, 2003, BBA-MOL CELL RES, V1642, P149, DOI 10.1016/j.bbamcr.2003.08.002; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2004, P NATL ACAD SCI USA, V101, P7052, DOI 10.1073/pnas.0305757101; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; Yamaguchi T, 2003, GENE THER, V10, P375, DOI 10.1038/sj.gt.3301897; Yip KW, 2004, MOL THER, V10, P533, DOI 10.1016/j.ymthe.2004.05.026; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; ZHANG SM, 1995, RECENT PROG HORM RES, V50, P429; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	50	99	101	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55809	55817		10.1074/jbc.M411767200	http://dx.doi.org/10.1074/jbc.M411767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509554	hybrid			2022-12-25	WOS:000225960800103
J	Baev, D; Rivetta, A; Vylkova, S; Sun, JNN; Zeng, GF; Slayman, CL; Edgerton, M				Baev, D; Rivetta, A; Vylkova, S; Sun, JNN; Zeng, GF; Slayman, CL; Edgerton, M			The TRK1 potassium transporter is the critical effector for killing of Candida albicans by the cationic protein, Histatin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SALIVARY HISTATIN-5; 2 PORE DOMAINS; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; K+-UPTAKE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; FUNGICIDAL ACTIVITY; ELECTROGENIC PUMP; PROTON SYMPORT; CARRIER TRK2P	The principal feature of killing of Candida albicans and other pathogenic fungi by the catonic protein Histatin 5 (Hst 5) is loss of cytoplasmic small molecules and ions, including ATP and K+, which can be blocked by the anion channel inhibitor 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid. We constructed C. albicans strains expressing one, two, or three copies of the TRK1 gene in order to investigate possible roles of Trk1p (the organism's principal K+ transporter) in the actions of Hst 5. All measured parameters (Hst 5 killing, Hst 5-stimulated ATP efflux, normal Trk1p-mediated K+ (Rb-86(+)) influx, and Trk1p-mediated chloride conductance) were similarly reduced (5-7-fold) by removal of a single copy of the TRK1 gene from this diploid organism and were fully restored by complementation of the missing allele. A TRK1 overexpression strain of C. albicans, constructed by integrating an additional TRK1 gene into wild-type cells, demonstrated cytoplasmic sequestration of Trk1 protein, along with somewhat diminished toxicity of Hst 5. These results could be produced either by depletion of intracellular free Hst 5 due to sequestered binding, or to cooperativity in Hst 5-protein interactions at the plasma membrane. Furthermore, Trk1p-mediated chloride conductance was blocked by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid in all of the tested strains, strongly suggesting that the TRK1 protein provides the essential pathway for ATP loss and is the critical effector for Hst 5 toxicity in C. albicans.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Dent Med, Dept Restorat Dent, Buffalo, NY 14214 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Yale University	Edgerton, M (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 310 Foster Hall,Main St Campus,3435 Main St, Buffalo, NY 14214 USA.	edgerto@buffalo.edu		Slayman, Clifford/0000-0002-3029-2054	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060696] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 10641, R01 DE010641-10A1, DE 00406, R01 DE010641] Funding Source: Medline; NIGMS NIH HHS [GM 60696] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Baev D, 2002, INFECT IMMUN, V70, P4777, DOI 10.1128/IAI.70.9.4777-4784.2002; Baev D, 2003, INFECT IMMUN, V71, P3251, DOI 10.1128/IAI.71.6.3251-3260.2003; Baev D, 2001, MICROBIOL-SGM, V147, P3323, DOI 10.1099/00221287-147-12-3323; BERTL A, 1993, J MEMBRANE BIOL, V132, P183; Bertl A, 1998, PFLUG ARCH EUR J PHY, V436, P999, DOI 10.1007/s004240050735; Bihler H, 1998, FEBS LETT, V432, P59, DOI 10.1016/S0014-5793(98)00832-1; Bihler H, 2002, BBA-BIOMEMBRANES, V1558, P109, DOI 10.1016/S0005-2736(01)00414-X; Bihler H, 1999, FEBS LETT, V447, P115, DOI 10.1016/S0014-5793(99)00281-1; BLATT MR, 1983, J MEMBRANE BIOL, V72, P223, DOI 10.1007/BF01870589; BLATT MR, 1987, J MEMBRANE BIOL, V98, P169, DOI 10.1007/BF01872129; Bobek LA, 2003, ANTIMICROB AGENTS CH, V47, P643, DOI 10.1128/AAC.47.2.643-652.2003; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cognetti D, 2002, YEAST, V19, P55, DOI 10.1002/yea.804; Dong J, 2003, J DENT RES, V82, P748, DOI 10.1177/154405910308200917; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Edgerton M, 2000, Adv Dent Res, V14, P16; FONZI WA, 1993, GENETICS, V134, P717; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; Gyurko C, 2000, ANTIMICROB AGENTS CH, V44, P348, DOI 10.1128/AAC.44.2.348-354.2000; GYURKO C, 2001, A LEEUWENHOEK, V79, P279; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 2001, J BIOL CHEM, V276, P5643, DOI 10.1074/jbc.M008229200; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; Koshlukova SE, 2000, INFECT IMMUN, V68, P6848, DOI 10.1128/IAI.68.12.6848-6856.2000; Kuroda T, 2004, J MEMBRANE BIOL, V198, P177, DOI 10.1007/s00232-004-0671-1; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; Lesage F, 1996, J BIOL CHEM, V271, P4183; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Li XWS, 2003, J BIOL CHEM, V278, P28553, DOI 10.1074/jbc.M300680200; LOSBERGER C, 1989, CURR GENET, V16, P153, DOI 10.1007/BF00391471; LUBIN M, 1964, CELLULAR FUNCTIONS M, P193; Madrid R, 1998, J BIOL CHEM, V273, P14838, DOI 10.1074/jbc.273.24.14838; RAJ PA, 1990, J BIOL CHEM, V265, P3898; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Ruissen ALA, 2001, BIOCHEM J, V356, P361, DOI 10.1042/0264-6021:3560361; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; SLAYMAN CL, 1973, J MEMBRANE BIOL, V14, P305, DOI 10.1007/BF01868083; SLAYMAN CL, 1989, BIOCH CELL WALLS MEM, P295; TROXLER RF, 1990, J DENT RES, V69, P2, DOI 10.1177/00220345900690010101; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai HY, 1997, BBA-GEN SUBJECTS, V1336, P367, DOI 10.1016/S0304-4165(97)00076-7; Uhl MA, 2003, EMBO J, V22, P2668, DOI 10.1093/emboj/cdg256; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Xu YY, 1999, ANTIMICROB AGENTS CH, V43, P2256, DOI 10.1128/AAC.43.9.2256; Zeng GF, 2004, J BIOL CHEM, V279, P3003, DOI 10.1074/jbc.M309760200; [No title captured]	60	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55060	55072		10.1074/jbc.M411031200	http://dx.doi.org/10.1074/jbc.M411031200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485849	hybrid			2022-12-25	WOS:000225960800011
J	Jiang, HM; Weyrich, AS; Zimmerman, GA; McIntyre, TM				Jiang, HM; Weyrich, AS; Zimmerman, GA; McIntyre, TM			Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E-2 production that modulate motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALKYL PHOSPHOLIPIDS; ACTIVATED RECEPTOR-GAMMA; WOUND-INDUCED CA2+; PROSTACYCLIN SYNTHESIS; EXPRESSION; ANGIOGENESIS; CANCER; INFLAMMATION; MIGRATION; SYNTHASE	Endothelial cells line the vasculature and, after mechanical denudation during invasive procedures or cellular loss from natural causes, migrate to reestablish a confluent monolayer. We find confluent monolayers of human umbilical vein endothelial cells were quiescent and expressed low levels of cyclooxygenase-2, but expressed cyclooxygenase-2 at levels comparable with cytokine-stimulated cells when present in a subconfluent culture. Mechanically wounding endothelial cell monolayers stimulated rapid cyclooxygenase-2 expression that increased with the level of wounding. Cyclooxygenase-2 re-expression occurred throughout the culture, suggesting signaling from cells proximal to the wound to distal cells. Media from wounded monolayers stimulated cyclooxygenase-2 expression in confluent monolayers, which correlated with the level of wounding of the donor monolayer. Wounded monolayers and cells in subconfluent cultures secreted enhanced levels of prostaglandin (PG)E-2 that depended on cyclooxygenase-2 activity, and PGE(2) stimulated cyclooxygenase-2 expression in confluent endothelial cell monolayers. Cells from subconfluent monolayers migrated through filters more readily than those from confluent monolayers, and the cyclooxygenase-2-selective inhibitor NS-398 suppressed migration. Adding PGE(2) to NS-398-treated cells augmented migration. Endothelial cells also migrated into mechanically denuded areas of confluent monolayers, and this too was suppressed by NS-398. We conclude that endothelial cells not in contact with neighboring cells express cyclooxygenase-2 that results in enhanced release of PGE(2), and that this autocrine and paracrine loop enhances endothelial cell migration to cover denuded areas of the endothelium.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, NC-10, Cleveland, OH 44195 USA.	mcintyt@ccf.org		Weyrich, Andrew/0000-0001-9622-4647	NHLBI NIH HHS [HL 44513, HL 44525] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R37HL044525, R01HL044513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Bradbury DA, 2003, J BIOL CHEM, V278, P49954, DOI 10.1074/jbc.M307964200; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Gilroy DW, 2001, FASEB J, V15, P288; Griffioen AW, 2000, PHARMACOL REV, V52, P237; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Ibuki T, 2003, J NEUROCHEM, V86, P318, DOI 10.1046/j.1471-4159.2003.01848.x; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; Janowiak MA, 1998, ENDOCRINOLOGY, V139, P765, DOI 10.1210/en.139.2.765; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Laulederkind SJF, 2000, EXP CELL RES, V258, P409, DOI 10.1006/excr.2000.4961; Majima M, 1997, JPN J PHARMACOL, V75, P105, DOI 10.1254/jjp.75.105; Maldve RE, 2000, J LIPID RES, V41, P873; Mark KS, 2001, J PHARMACOL EXP THER, V297, P1051; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Ozaki-Okayama Y, 2004, CRIT CARE MED, V32, P795, DOI 10.1097/01.CCM.0000114576.60077.FC; PETERSON HI, 1986, ANTICANCER RES, V6, P251; POMERANTZ KB, 1984, T ASSOC AM PHYSICIAN, V97, P275; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; SHOLLEY MM, 1977, LAB INVEST, V36, P18; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239; Tran POT, 1998, CELL PROLIFERAT, V31, P155; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; Zweifel BS, 2002, CANCER RES, V62, P6706	42	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55905	55913		10.1074/jbc.M406094200	http://dx.doi.org/10.1074/jbc.M406094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485847	hybrid			2022-12-25	WOS:000225960800114
J	Shan, WS; Yagita, Y; Wang, ZH; Koch, A; Svenningsen, AF; Gruzglin, E; Pedraza, L; Colman, DR				Shan, WS; Yagita, Y; Wang, ZH; Koch, A; Svenningsen, AF; Gruzglin, E; Pedraza, L; Colman, DR			The minimal essential unit for cadherin-mediated intercellular adhesion comprises extracellular domains 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; UVOMORULIN-CATENIN COMPLEX; N-CADHERIN; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; C-CADHERIN; HOMOPHILIC ADHESION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; BINDING	N-cadherin comprises five homologous extracellular domains, a transmembrane, and a cytoplasmic domain. The extracellular domains of N-cadherin play important roles in homophilic cell adhesion, but the contribution of each domain to this phenomenon has not been fully evaluated. In particular, the following questions remain unanswered: what is the minimal domain combination that can generate cell adhesion, how is domain organization related to adhesive strength, and does the cytoplasmic domain serve to facilitate extracellular domain interaction? To address these issues, we made serial constructs of the extracellular domains of N-cadherin and produced various cell lines to examine adhesion properties. We show that the first domain of N-cadherin alone on the cell surface fails to generate adhesive activity and that the first two domains of N-cadherin form the "minimal essential unit" to mediate cell adhesion. Cell lines expressing longer extracellular domains or N-cadherin wild type cells formed larger cellular aggregates than those expressing shorter aggregates. However, adhesion strength, as measured by a shearing test, did not reveal any differences among these aggregative cell lines, suggesting that the first two domains of N-cadherin cells generate the same strength of adhesive activity as longer extracellular domain cells. Furthermore, truncations of the first two domains of N-cadherin are also sufficient to form cis-dimerization at an adhesive junction. Our findings suggest that the extracellular domains of N-cadherin have distinct roles in cell adhesion, i.e. the first two domains are responsible for homophilic adhesion activity, and the other domains promote adhesion efficiency most likely by positioning essential domains relatively far out from the cell surface.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; NYU, Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10023 USA	McGill University; Icahn School of Medicine at Mount Sinai; New York University; New York University	Shan, WS (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	weisong.shan@mcgill.ca; david.colman@mcgill.ca	Svenningsen, Åsa Fex/H-5443-2015; Yagita, Yoshiki/S-6954-2016	Svenningsen, Åsa Fex/0000-0002-5651-265X; 	NINDS NIH HHS [NS 20147] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020147] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DOYLE JP, 1995, J CELL BIOL, V131, P465, DOI 10.1083/jcb.131.2.465; He WZ, 2003, SCIENCE, V302, P109, DOI 10.1126/science.1086957; Horikawa K, 2001, J CELL BIOL, V155, P1297, DOI 10.1083/jcb.200108156; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Leckband D, 2002, STRUCTURE, V10, P739, DOI 10.1016/S0969-2126(02)00783-9; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Lustig M, 1999, DEV BIOL, V209, P340, DOI 10.1006/dbio.1999.9250; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MATSUNAMI H, 1993, J CELL SCI, V106, P401; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Sakurai T, 1998, BIOTECHNIQUES, V25, P382, DOI 10.2144/98253bm09; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yoshida M, 2001, NEUROCHEM RES, V26, P703, DOI 10.1023/A:1010999622760	49	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55914	55923		10.1074/jbc.M407827200	http://dx.doi.org/10.1074/jbc.M407827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485826	hybrid			2022-12-25	WOS:000225960800115
J	Wang, SW; Zhu, JY				Wang, SW; Zhu, JY			The hTERT gene is embedded in a nuclease-resistant chromatin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERASE-REVERSE-TRANSCRIPTASE; NORMAL HUMAN-CELLS; LARGE T-ANTIGEN; HISTONE ACETYLATION; ALPHA-GLOBIN; C-MYC; ACTIVATES TELOMERASE; TERMINAL TRANSFERASE; IMMORTAL CELLS; LIFE-SPAN	Normal human cells rarely undergo spontaneous immortalization. Given that ectopic expression of the human telomerase catalytic subunit hTERT leads to cellular immortalization, the endogenous hTERT gene is likely constitutively repressed. Hence, we have examined the chromatin structure of the native hTERT locus and the neighboring loci, CRR9 and Xtrp2, in normal human fibroblasts and a set of immortal lines. Using generalized DNase I sensitivity assays, we revealed that the entire hTERT gene was embedded in a chromatin domain that was as resistant to the nuclease as the well studied beta-globin loci in both telomerase-positive and -negative cells. This condensed domain was at least 100 kb in size and contained the intergenic region 5' to the hTERT gene and the downstream Xtrp2 locus. A transition from the nuclease-sensitive CRR9 locus to the condensed region appeared near the 3'-end of the CRR9 gene. hTERT transcription was associated with the appearance of a major DNase I-hypersensitive site positioned around the hTERT transcription start site and several minor hypersensitive sites. In telomerase-negative cells, the inhibition of histone deacetylases by trichostatin A led to the opening of this chromatin domain, accompanied by transcription from the hTERT gene but not the Xtrp2 gene. In contrast, the inhibition of protein synthesis by cycloheximide induced transcription from both the hTERT and Xtrp2 genes, indicating that histone deacetylases and labile factors coordinate to silence this chromosomal region. Taken together, our data suggest a novel mechanism of hTERT regulation at the chromatin level and have important implications for studying telomerase expression.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhu, JY (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	joz1@psu.edu	zhu, ji/HDM-1538-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071725] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 071725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Anguita E, 2001, P NATL ACAD SCI USA, V98, P12114, DOI 10.1073/pnas.201413098; Armstrong L, 2000, MECH DEVELOP, V97, P109, DOI 10.1016/S0925-4773(00)00423-8; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown KE, 2001, NAT CELL BIOL, V3, P602, DOI 10.1038/35078577; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Ducrest AL, 2001, CANCER RES, V61, P7594; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Horikawa I, 1999, CANCER RES, V59, P826; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Kyo S, 1999, CANCER RES, V59, P5917; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lopatina NG, 2003, BIOCHEM BIOPH RES CO, V306, P650, DOI 10.1016/S0006-291X(03)01033-7; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang SW, 2004, GENE, V343, P69, DOI 10.1016/j.gene.2004.09.006; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	51	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55401	55410		10.1074/jbc.M411352200	http://dx.doi.org/10.1074/jbc.M411352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15516693	hybrid			2022-12-25	WOS:000225960800054
J	Bercovich, Z; Kahana, C				Bercovich, Z; Kahana, C			Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LYSATE; INTRACELLULAR DEGRADATION; REQUIRES INTERACTION; POLYAMINES; CELLS; TARGET; GROWTH; ACCUMULATION; MUTAGENESIS; REPRESSION	Ornithine decarboxylase(ODC) is the most notable example of a protein degraded by the 26 S proteasome without ubiquitination. Instead, ODC is targeted to degradation by direct binding to a polyamine-induced protein termed antizyme (Az). Antizyme inhibitor (AzI) is an ODC-related protein that does not retain enzymatic activity yet binds Az with higher affinity than ODC. We show here that like ODC, AzI is also a short-lived protein that undergoes proteasomal degradation. However, in contrast to ODC degradation, the degradation of AzI is ubiquitin-dependent and does not require interaction with Az. Moreover, Az binding actually stabilizes AzI by inhibiting its ubiquitination. Substituting the C terminus of AzI with that of ODC, which together with Az constitutes the complete degradation signal of ODC, does not subvert AzI degradation from the ubiquitin-dependent mode to the Az-dependent mode, suggesting dominance of the ubiquitination signal. Our results suggest opposing roles of Az in regulating the degradation of AzI and ODC.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kahana, C (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	chaim.kahana@weizmann.ac.il						BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; COFFINO P, 1991, J CELL BIOCHEM, V45, P54, DOI 10.1002/jcb.240450112; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gandre S, 2002, BIOCHEM BIOPH RES CO, V293, P139, DOI 10.1016/S0006-291X(02)00194-8; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Koguchi K, 1997, BBA-GENE STRUCT EXPR, V1353, P209, DOI 10.1016/S0167-4781(97)00106-1; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	36	58	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54097	54102		10.1074/jbc.M410234200	http://dx.doi.org/10.1074/jbc.M410234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491992	hybrid			2022-12-25	WOS:000225793600027
J	Finley, NL; Rosevear, PR				Finley, NL; Rosevear, PR			Introduction of negative charge mimicking protein kinase C phosphorylation of cardiac troponin I - Effects on cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; N-TERMINAL DOMAIN; MUTATION; SITES; EXCHANGE; AFFINITY; BOVINE; RABBIT; MUSCLE; REGION	Protein kinase C phosphorylation of cardiac troponin, the Ca2+-sensing switch in muscle contraction, is capable of modulating the response of cardiac muscle to a Ca2+ ion concentration. The N-domain of cardiac troponin I contains two protein kinase C phosphorylation sites. Although the physiological consequences of phosphorylation at Ser(43)/Ser(45) are known, the molecular mechanisms responsible for these functional changes have yet to be established. In this work, NMR was used to identify conformational and dynamic changes in cardiac troponin C upon binding a phosphomimetic troponin I, having Ser(43)/Ser(45) mutated to Asp. Chemical shift perturbation mapping indicated that residues in helix G were most affected. Smaller chemical shift changes were observed in residues located in the Ca2+/Mg2+-binding loops. Amide hydrogen/deuterium exchange rates in the C-lobe of troponin C were compared in complexes containing either the wild-type or phosphomimetic N-domain of troponin I. In the presence of a phosphomimetic domain, exchange rates in helix G increased, whereas a decrease in exchange rates for residues mapping to Ca2+/Mg2+-binding loops III and IV was observed. Increased exchange rates are consistent with destabilization of the Thr(129) - Asp(132) helix capping box previously characterized in helix G. The perturbation of helix G and metal binding loops III and IV suggests that phosphorylation alters metal ion affinity and inter-subunit interactions. Our studies support a novel mechanism for protein kinase C signal transduction, emphasizing the importance of C-lobe Ca2+/Mg2+-dependent troponin interactions.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Cincinnati	Rosevear, PR (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	rosevear@proto.med.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NIAMS NIH HHS [AR44324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; Burkart EM, 2003, J MOL CELL CARDIOL, V35, P1285, DOI 10.1016/S0022-2828(03)00240-2; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Calvert MJ, 2000, J BIOL CHEM, V275, P32508, DOI 10.1074/jbc.M005764200; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Finley N, 2000, J MOL CELL CARDIOL, V32, P1439, DOI 10.1006/jmcc.2000.1174; Finley NL, 2004, BIOCHEMISTRY-US, V43, P11371, DOI 10.1021/bi049672i; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; Huang L, 2001, AM J PHYSIOL-CELL PH, V280, pC1114, DOI 10.1152/ajpcell.2001.280.5.C1114; Kapp GT, 2004, BIOCHEMISTRY-US, V43, P3814, DOI 10.1021/bi035683k; Kobayashi T, 2004, BIOCHEMISTRY-US, V43, P5996, DOI 10.1021/bi036073n; Leblanc L, 2000, ARCH BIOCHEM BIOPHYS, V384, P296, DOI 10.1006/abbi.2000.2103; Li MX, 2003, BIOCHEMISTRY-US, V42, P14460, DOI 10.1021/bi035408y; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Smart JL, 1999, BIOPOLYMERS, V49, P225, DOI 10.1002/(SICI)1097-0282(199903)49:3<225::AID-BIP4>3.0.CO;2-B; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Sumandea MP, 2004, ANN NY ACAD SCI, V1015, P39, DOI 10.1196/annals.1302.004; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TRIGOGONZALEZ G, 1993, BIOCHEMISTRY-US, V32, P9826, DOI 10.1021/bi00088a038; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Ward DG, 2004, BIOCHEMISTRY-US, V43, P5772, DOI 10.1021/bi036310m; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54833	54840		10.1074/jbc.M408304200	http://dx.doi.org/10.1074/jbc.M408304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485824	hybrid			2022-12-25	WOS:000225793600112
J	Jonas, BA; Privalsky, ML				Jonas, BA; Privalsky, ML			SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR SUPERFAMILY; THYROID-HORMONE RECEPTORS; RETINOIC-ACID; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; KAPPA-B; HISTONE ACETYLATION; SILENCING MEDIATOR; PROTEIN; PHOSPHORYLATION	N-CoR and SMRT are corepressor paralogs that partner with and mediate transcriptional repression by a wide variety of metazoan transcription factors, including nuclear hormone receptors. Although encoded by distinct genetic loci, N-CoR and SMRT share substantial sequence interrelatedness, form analogous assemblies with histone deacetylases and auxiliary factors, can interact with overlapping sets of transcription factor partners, and exert overlapping functions in cells. SMRT is subject to negative regulation by MAPK signaling pathways operating downstream of growth factor and stress signaling pathways. We report here that whereas activation of MEKK1 leads to phosphorylation of SMRT, its dissociation from its transcription factor partners in vivo and in vitro, and its redistribution from the cell nucleus to a cytoplasmic compartment, N-CoR is refractory to all these forms of regulation. In contrast to this MAPK cascade, other signal transduction pathways operating downstream of growth factor/cytokine receptors appear able to affect both corepressor paralogs. Our results indicate that SMRT and N-CoR are embedded in distinct regulatory networks and that the two corepressors interpret growth factor, cytokine, differentiation, and prosurvival signals differently.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Jonas, Brian/AAS-3639-2020	Jonas, Brian/0000-0002-4921-5809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053528-02, DK53528, R01 DK053528] Funding Source: Medline; NIGMS NIH HHS [T32 GM007377, T32 GM007377-22, T32GM07377] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Berger SL, 2001, SCIENCE, V292, P64; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Glass CK, 2000, GENE DEV, V14, P121; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guenther MG, 2000, GENE DEV, V14, P1048; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Tsuda L, 2002, CELL, V110, P625, DOI 10.1016/S0092-8674(02)00875-9; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	80	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54676	54686		10.1074/jbc.M410128200	http://dx.doi.org/10.1074/jbc.M410128200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491994	Green Accepted, hybrid			2022-12-25	WOS:000225793600094
J	Silberg, JJ; Tapley, TL; Hoff, KG; Vickery, LE				Silberg, JJ; Tapley, TL; Hoff, KG; Vickery, LE			Regulation of the HscA ATPase reaction cycle by the co-chaperone HscB and the iron-sulfur cluster assembly protein IscU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 MOLECULAR CHAPERONE; ESCHERICHIA-COLI; SUBSTRATE-BINDING; J-DOMAIN; SACCHAROMYCES-CEREVISIAE; KINETIC CHARACTERIZATION; NMR STRUCTURE; RICH REGION; DNAK; BIOGENESIS	The ATPase activity of HscA, a specialized hsp70 molecular chaperone from Escherichia coli, is regulated by the iron-sulfur cluster assembly protein IscU and the J-type co-chaperone HscB. IscU behaves as a substrate for HscA, and HscB enhances the binding of IscU to HscA. To better understand the mechanism by which HscB and IscU regulate HscA, we examined binding of HscB to the different conformational states of HscA and the effects of HscB and IscU on the kinetics of the individual steps of the HscA ATPase reaction cycle. Affinity sensor studies revealed that whereas IscU binds both ADP (R-state) and ATP (T-state) HscA complexes, HscB interacts only with an ATP-bound state. Studies of ATPase activity under single-turnover and rapid mixing conditions showed that both IscU and HscB interact with the low peptide affinity T-state of HscA (HscA(double dagger).ATP) and that both modestly accelerate (3-10-fold) the rate-determining steps in the HscA reaction cycle, k(hyd) and k(T-->R). When present together, IscU and HscB synergistically stimulate both k(hyd) (congruent to500-fold) and k(T-->R) (congruent to60-fold), leading to enhanced formation of the HscA.ADP-IscU complex (substrate capture). Following ADP/ATP exchange, IscU also stimulates k(R-->T) (congruent to50-fold) and thereby accelerates the rate at which the low peptide affinity HscA(double dagger).ATP T-state is regenerated. Because HscA nucleotide exchange is fast, the overall rate of the chaperone cycle in vivo will be determined by the availability of the IscU-HscB substrate-co-chaperone complex.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lvickery@uci.edu	Silberg, Jonathan J/A-3817-2010		NCI NIH HHS [T532CA09054] Funding Source: Medline; NIGMS NIH HHS [GM07311, F32 GM64949-01, GM54264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; CUPPVICKERY J, 2004, IN PRESS J MOL BIOL; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2001, P NATL ACAD SCI USA, V98, P14751, DOI 10.1073/pnas.011579098; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Goffin L, 1998, MOL MICROBIOL, V30, P329, DOI 10.1046/j.1365-2958.1998.01067.x; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Mally A, 2001, NAT STRUCT BIOL, V8, P254, DOI 10.1038/85002; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Tapley TL, 2004, J BIOL CHEM, V279, P28435, DOI 10.1074/jbc.M400803200; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WALL D, 1994, J BIOL CHEM, V269, P5446; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wittung-Stafshede P, 2003, BIOCHEMISTRY-US, V42, P4937, DOI 10.1021/bi027333o; Yan W, 1999, MOL CELL BIOL, V19, P7751; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	56	71	73	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53924	53931		10.1074/jbc.M410117200	http://dx.doi.org/10.1074/jbc.M410117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485839	hybrid			2022-12-25	WOS:000225793600005
J	Wang, HM; Hu, XY; Ding, X; Dou, Z; Yang, ZH; Shaw, AW; Teng, MK; Cleveland, DW; Goldberg, ML; Niu, LW; Yao, XB				Wang, HM; Hu, XY; Ding, X; Dou, Z; Yang, ZH; Shaw, AW; Teng, MK; Cleveland, DW; Goldberg, ML; Niu, LW; Yao, XB			Human Zwint-1 specifies localization of zeste white 10 to kinetochores and is essential for mitotic checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH-DEAL; CENP-E; SPINDLE MICROTUBULES; HUMAN CANCERS; ZW10; DROSOPHILA; COMPONENT; MITOSIS; CELLS; MAD2	Chromosome segregation in mitosis is orchestrated by dynamic interaction between spindle microtubules and the kinetochore, a multiprotein complex assembled onto centromeric DNA of the chromosome. Here we show that Zwint-1 is required and is sufficient for kinetochore localization of Zeste White 10 (ZW10) in HeLa cells. Zwint-1 specifies the kinetochore association of ZW10 by interacting with its N-terminal domain. Suppression of synthesis of Zwint-1 by small interfering RNA abolishes the localization of ZW10 to the kinetochore, demonstrating the requirement of Zwint-1 for ZW10 kinetochore localization. In addition, depletion of Zwint-1 affects no mitotic arrest but causes aberrant premature chromosome segregation. These Zwint-1-suppressed cells display chromosome bridge phenotype with sister chromatids inter-connected. Moreover, Zwint-1 is required for stable association of CENP-F and dynamitin but not BUB1 with the kinetochore. Finally, our studies show that Zwint-1 is a new component of the mitotic checkpoint, as cells lacking Zwint-1 fail to arrest in mitosis when exposed to microtubule inhibitors, yielding interphase cells with multinuclei. As ZW10 and Zwint-1 are absent from yeast, we reasoned that metazoans evolved an elaborate spindle checkpoint machinery to ensure faithful chromosome segregation in mitosis.	CAS Key Lab Struct Biol, Hefei 230027, Peoples R China; Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Proteom Res Lab, Beijing 100086, Peoples R China; Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Morehouse School of Medicine; Ludwig Institute for Cancer Research; Cornell University	Yao, XB (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei, Peoples R China.	yaox6@ustc.edu.cn	Cleveland, Don/AAN-9783-2021; Yao, Xuebiao/P-5771-2014; DOU, ZHEN/N-2022-2013; Hu, Xiaoyu/M-2786-2015	DOU, ZHEN/0000-0003-3303-9393; Cleveland, Don/0000-0002-1934-3682; Wang, Hongmei/0000-0002-5881-2488				Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Scaerou F, 2001, J CELL SCI, V114, P3103; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Starr DA, 2000, J CELL SCI, V113, P1939; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; WILLIAMS BC, 1994, J CELL SCI, V107, P785; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435	27	93	101	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54590	54598		10.1074/jbc.M407588200	http://dx.doi.org/10.1074/jbc.M407588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485811	hybrid			2022-12-25	WOS:000225793600085
J	del Re, E; Sidis, Y; Fabrizio, DA; Lin, HY; Schneyer, A				del Re, E; Sidis, Y; Fabrizio, DA; Lin, HY; Schneyer, A			Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; EXPRESSION CLONING; SIGNALING PATHWAY; SERINE KINASE; III RECEPTOR; BINDING; BETA; GROWTH; FOLLISTATIN; PROTEIN	Activins and inhibins compose a heterogeneous subfamily within the transforming growth factor-beta (TGF-beta) superfamily of growth and differentiation factors with critical biological activities in embryos and adults. They signal through a heteromeric complex of type II, type I, and for inhibin, type III receptors. To characterize the affinity, specificity, and activity of these receptors (alone and in combination) for the inhibin/ activin subfamily, we developed a cell-free assay system using soluble receptor-Fc fusion proteins. The soluble activin type II receptor (sActRII)-Fc fusion protein had a 7-fold higher affinity for activin A compared with sActRIIB-Fc, whereas both receptors had a marked preference for activin A over activin B. Although inhibin A and B binding was 20-fold lower compared with activin binding to either type II receptor alone, the mixture of either type II receptor with soluble TGF-beta type III receptor (TbetaRIII; betaglycan)-Fc reconstituted a soluble high affinity inhibin receptor. In contrast, mixing either soluble activin type II receptor with soluble activin type I receptors did not substantially enhance activin binding. Our results support a cooperative model of binding for the inhibin receptor (ActRII.sTbetaRIII complex) but not for activin receptors (type II + type I) and demonstrate that a complex composed of activin type II receptors and TbetaRIII is both necessary and sufficient for high affinity inhibin binding. This study also illustrates the utility of this cell-free system for investigating hypotheses of receptor complex mechanisms resulting from crystal structure analyses.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Reprod Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Schneyer, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Reprod Endocrine Unit, BHX-5,55 Fruit St, Boston, MA 02114 USA.	schneyer.alan@mgh.harvard.edu	del Re, Elisabetta C./AAW-8913-2020	del Re, Elisabetta C./0000-0002-9645-4845				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Brown CW, 2000, NAT GENET, V25, P453, DOI 10.1038/78140; Brown CW, 2003, MOL ENDOCRINOL, V17, P2404, DOI 10.1210/me.2003-0051; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; De Crescenzo G, 2004, J BIOL CHEM, V279, P26013, DOI 10.1074/jbc.M400655200; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Donaldson CJ, 1999, ENDOCRINOLOGY, V140, P1760, DOI 10.1210/en.140.4.1760; DONALDSON CJ, 1995, BIOCHEM BIOPH RES CO, V184, P310; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; HILDEN K, 1994, BLOOD, V83, P2163; Leal AMO, 2002, ENDOCRINOLOGY, V143, P964, DOI 10.1210/en.143.3.964; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; MATHEWS LS, 1993, RECEPTOR, V3, P173; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Rodbard D, 1975, RADIOIMMUNOASSAY REL, V1, P469; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; Schneyer A, 2003, ENDOCRINOLOGY, V144, P1671, DOI 10.1210/en.2002-0203; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sidis Y, 2002, ENDOCRINOLOGY, V143, P1613, DOI 10.1210/en.143.5.1613; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; Wada W, 2004, AM J PHYSIOL-ENDOC M, V287, pE247, DOI 10.1152/ajpendo.00390.2003; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196	43	26	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53126	53135		10.1074/jbc.M408090200	http://dx.doi.org/10.1074/jbc.M408090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475360	hybrid			2022-12-25	WOS:000225680600041
J	Munroe, ME; Bishop, GA				Munroe, ME; Bishop, GA			Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN BETA-RECEPTOR; JUN KINASE ACTIVATION; MONOCLONAL-ANTIBODIES; LATENT MEMBRANE-PROTEIN-1; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; NF-KAPPA-B2 P100; GENE-EXPRESSION; CELL-ACTIVATION	Members of the tumor necrosis factor receptor (TNFR) family play a variety of roles in the regulation of lymphocyte activation. An important TNFR family member for B cell activation is CD40. CD40 signals stimulate B cell TNF-alpha secretion, which subsequently signals via TNFR2 (CD120b) to enhance B cell activation. Although the function of the pro-apoptotic and pro-inflammatory receptor TNFR1 (CD120a) has been the subject of much research, less is understood about the distinct contributions of CD120b to cell activation and how it stimulates downstream events. Members of the tumor necrosis factor receptor family bind various members of the cytoplasmic adapter protein family, the tumor necrosis factor receptor-associated factors (TRAFs), during signaling. Both CD40 and CD120b bind TNF receptor-associated factor 2 (TRAF2) upon ligand stimulation. Wild type and TRAF2-deficient B cells expressing CD40 or the hybrid molecule ( human) CD40 (mouse)-CD120b were examined. CD40- and CD120b-mediated IgM secretion were partly TRAF2-dependent, but only CD40 required TRAF2 for c-Jun N-terminal kinase activation. CD40 and CD120b used primarily divergent mechanisms to activate NF-kappaB, exemplifying how TNFR family members can use diverse mechanisms to mediate similar downstream events.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, 2193B MERF, Iowa City, IA 52242 USA.	gail-bishop@uiowa.edu		Bishop, Gail/0000-0002-1291-5078; Munroe, Melissa/0000-0002-6933-9745	NATIONAL CANCER INSTITUTE [R01CA099997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028847, T32AI007260, R01AI049993, R01AI028847, R56AI028847, R56AI049993] Funding Source: NIH RePORTER; NCI NIH HHS [CA099997] Funding Source: Medline; NIAID NIH HHS [AI49993, AI07343, AI07260, AI28847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bhushan A, 2001, IMMUNOL RES, V24, P311, DOI 10.1385/IR:24:3:311; Bishop GA, 2002, J LEUKOCYTE BIOL, V72, P19; BISHOP GA, 1995, EUR J IMMUNOL, V25, P1230, DOI 10.1002/eji.1830250515; BISHOP GA, 1991, J IMMUNOL, V147, P1107; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Bishop GA, 2001, ARCH IMMUNOL THER EX, V49, P129; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Craxton A, 1998, J IMMUNOL, V161, P3225; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Feldman AM, 2000, J AM COLL CARDIOL, V35, P537, DOI 10.1016/S0735-1097(99)00600-2; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; HAMANO T, 1982, J IMMUNOL, V129, P1403; Haridas V, 1998, J IMMUNOL, V160, P3152; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hostager BS, 2002, J IMMUNOL, V168, P3318, DOI 10.4049/jimmunol.168.7.3318; Hostager BS, 1999, J IMMUNOL, V162, P6307; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hsing Y, 1997, J IMMUNOL, V159, P4898; Kaneko Y, 1996, EUR J IMMUNOL, V26, P3061, DOI 10.1002/eji.1830261236; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kollias G, 2002, CYTOKINE GROWTH F R, V13, P315, DOI 10.1016/S1359-6101(02)00019-9; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lesley R, 2004, IMMUNITY, V20, P441, DOI 10.1016/S1074-7613(04)00079-2; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; MERCOLINO TJ, 1986, J EXP MED, V163, P155, DOI 10.1084/jem.163.1.155; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Renvoize C, 1998, CELL BIOL TOXICOL, V14, P111, DOI 10.1023/A:1007429904664; Rieckmann P, 1997, METHODS, V11, P128, DOI 10.1006/meth.1996.0396; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schonbeck U, 2000, INT J BIOCHEM CELL B, V32, P687, DOI 10.1016/S1357-2725(00)00016-9; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wilkinson N, 2003, ARCH DIS CHILD, V88, P186, DOI 10.1136/adc.88.3.186; Xie P, 2004, J EXP MED, V199, P661, DOI 10.1084/jem.20031255; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; Zeggini E, 2002, ARTHRITIS RHEUM-US, V46, P3304, DOI 10.1002/art.10698	58	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53222	53231		10.1074/jbc.M410539200	http://dx.doi.org/10.1074/jbc.M410539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485859	hybrid			2022-12-25	WOS:000225680600052
J	Wei, L; Yang, Y; Zhang, X; Yu, Q				Wei, L; Yang, Y; Zhang, X; Yu, Q			Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis	ONCOGENE			English	Article						Src; anoikis; lung; cancer; tyrosine phosphorylation	TYROSINE KINASE-ACTIVITY; FOCAL ADHESION KINASE; HUMAN-COLON CARCINOMA; C-SRC; EPITHELIAL-CELLS; V-SRC; PREMALIGNANT EPITHELIA; PP60C-SRC ACTIVITY; GENE-PRODUCT; CANCER CELLS	Src plays an important role in cell proliferation, differentiation, adhesion, and migration. Altered Src activity has been strongly implicated in the development, growth, progression, and metastasis of human cancers. We have analysed the change and regulation of Src upon cell detachment in anoikis-resistant human lung adenocarcinoma cells and compared with that of relatively normal and anoikis-sensitive epithelial cells. We found that Src activity was increased in the anoikis-resistant lung tumor cells when they were detached and cultured in suspension. The detachment-induced Src activation in the tumor cells compensates for the loss of cell survival signals caused by disruption of cell-matrix interactions and contributes to anoikis resistance of the tumor cells. Pyk2, rather than PI 3K/Akt or Erk, appears to be the key downstream effecter of Src in mediating the cell survival signals. The increased Src activity is mainly due to the phosphorylation of Tyr-419, rather than the dephosphorylation of Tyr-530 of Src protein. PDGFR, not FAK or EGFR, appears to be the upstream protein tyrosine kinase responsible for the detachment-induced Src activation in the lung tumor cells. The increased Src activity upon cell detachment may contribute to the metastasis potential of malignant tumors.	Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Boston University; Boston University	Yu, Q (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	qyu@sibs.ac.cn			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059678] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59678] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BJELFMAN C, 1990, CANCER RES, V50, P6908; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hisano C, 2003, CELL BIOL INT, V27, P415, DOI 10.1016/S1065-6995(03)00032-5; JACOBS C, 1983, CANCER RES, V43, P1696; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Ogata Y, 2003, HYPERTENSION, V41, P1156, DOI 10.1161/01.HYP.0000064342.30653.24; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Wei L, 2001, CANCER RES, V61, P2439; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1	53	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9052	9061		10.1038/sj.onc.1208091	http://dx.doi.org/10.1038/sj.onc.1208091			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489898				2022-12-25	WOS:000225492800006
J	Breustedt, DA; Korndorfer, IP; Redl, B; Skerra, A				Breustedt, DA; Korndorfer, IP; Redl, B; Skerra, A			The 1.8-angstrom crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EBNERS GLAND PROTEIN; DIRECTED TRYPTOPHAN FLUORESCENCE; BINDING INHIBITOR; COMPLEX; CYSTATIN; GENE; PREALBUMIN; REFINEMENT; EXPRESSION; SEQUENCES	In contrast with earlier assumptions, which classified human tear lipocalin (Tlc) as an outlier member of the lipocalin protein family, the 1.8-Angstrom resolution crystal structure of the recombinant apoprotein confirms the typical eight-stranded antiparallel beta-barrel architecture with an alpha-helix attached to it. The fold of Tlc most closely resembles the bovine dander allergen Bos d 2, a well characterized prototypic lipocalin, but also reveals similarity with beta-lactoglobulin. However, compared with other lipocalin structures Tlc exhibits an extremely wide ligand pocket, whose entrance is formed by four partially disordered loops. The cavity deeply extends into the beta-barrel structure, where it ends in two distinct lobes. This unusual structural feature explains the known promiscuity of Tlc for various ligands, with chemical structures ranging from lipids and retinoids to the macrocyclic antibiotic rifampin and even to microbial siderophores. Notably, earlier findings of biological activity as a thiol protease inhibitor have no correspondence in the three-dimensional structure of Tlc, rather it appears that its proteolytic fragments could be responsible for this phenomenon. Hence, the present structural analysis sheds new light on the ligand binding activity of this functionally obscure but abundant human lipocalin.	Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany; Med Univ Innsbruck, Inst Mol Biol, A-6020 Innsbruck, Austria	Technical University of Munich; Medical University of Innsbruck	Skerra, A (corresponding author), Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany.	skerra@wzw.tum.de	Skerra, Arne/A-2269-2013	Skerra, Arne/0000-0002-5717-498X				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BONAVIDA B, 1969, NATURE, V221, P375, DOI 10.1038/221375a0; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Filipek R, 2003, J BIOL CHEM, V278, P40959, DOI 10.1074/jbc.M302926200; Flower DR, 1996, BIOCHEM J, V318, P1; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Fluckinger M, 2004, ANTIMICROB AGENTS CH, V48, P3367, DOI 10.1128/AAC.48.9.3367-3372.2004; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; GASSNER NC, 1998, THESIS U OREGON; Gasymov OK, 2004, BBA-MOL BASIS DIS, V1688, P102, DOI 10.1016/j.bbadis.2003.11.006; Gasymov OK, 1998, BBA-PROTEIN STRUCT M, V1386, P145, DOI 10.1016/S0167-4838(98)00092-2; Gasymov OK, 2000, PROTEIN SCI, V9, P325; Gasymov OK, 2001, BIOCHEMISTRY-US, V40, P14754, DOI 10.1021/bi0110342; Gasymov OK, 1999, BBA-PROTEIN STRUCT M, V1433, P307, DOI 10.1016/S0167-4838(99)00133-8; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GLASGOW BJ, 1995, CURR EYE RES, V14, P363, DOI 10.3109/02713689508999934; Glasgow BJ, 1998, BIOCHEMISTRY-US, V37, P2215, DOI 10.1021/bi9720888; Goetz DH, 2000, BIOCHEMISTRY-US, V39, P1935, DOI 10.1021/bi992215v; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1995, PROTEIN DATA BANK NE, V71, P6; Holzfeind P, 1996, FEBS LETT, V395, P95, DOI 10.1016/0014-5793(96)01008-3; HOLZFEIND P, 1994, GENE, V139, P177, DOI 10.1016/0378-1119(94)90752-8; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; JOSEPHSON AS, 1964, J IMMUNOL, V93, P532; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; LALMANACH G, 1993, J PROTEIN CHEM, V12, P23, DOI 10.1007/BF01024910; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REDL B, 1992, J BIOL CHEM, V267, P20282; Redl B, 2000, BBA-PROTEIN STRUCT M, V1482, P241, DOI 10.1016/S0167-4838(00)00142-4; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Sack RA, 2004, EXP EYE RES, V78, P371, DOI 10.1016/S0014-4835(03)00198-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scalfari F, 1997, COMP BIOCHEM PHYS B, V118, P819, DOI 10.1016/S0305-0491(97)00218-6; Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X; SKERRA A, 1992, NUCLEIC ACIDS RES, V20, P3551, DOI 10.1093/nar/20.14.3551; Skerra A, 2000, METHOD ENZYMOL, V326, P271; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; vantHof W, 1997, J BIOL CHEM, V272, P1837; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wojnar P, 2002, J HISTOCHEM CYTOCHEM, V50, P433, DOI 10.1177/002215540205000314; Wojnar P, 2001, BIOL CHEM, V382, P1515, DOI 10.1515/BC.2001.186; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yusifov TN, 2000, BIOCHEM J, V347, P815, DOI 10.1042/0264-6021:3470815	66	96	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					484	493		10.1074/jbc.M410466200	http://dx.doi.org/10.1074/jbc.M410466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15489503	hybrid, Green Published			2022-12-25	WOS:000226025100058
J	Nakatani, Y; Kaneto, H; Kawamori, D; Yoshiuchi, K; Hatazaki, M; Matsuoka, T; Ozawa, K; Ogawa, S; Hori, M; Yamasaki, Y; Matsuhisa, M				Nakatani, Y; Kaneto, H; Kawamori, D; Yoshiuchi, K; Hatazaki, M; Matsuoka, T; Ozawa, K; Ogawa, S; Hori, M; Yamasaki, Y; Matsuhisa, M			Involvement of endoplasmic reticulum stress in insulin resistance and diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MELLITUS; REVEALS; ORP150	Type 2 diabetes is one of the most prevalent and serious metabolic diseases in the world, and insulin resistance and pancreatic beta-cell dysfunction are the hallmarks of the disease. In this study, we have shown that endoplasmic reticulum ( ER) stress, which is provoked under diabetic conditions, plays a crucial role in the insulin resistance found in diabetes by modifying the expression of oxygen-regulated protein 150 (ORP150), a molecular chaperone that protects cells from ER stress. Sense ORP overexpression in the liver of obese diabetic mice significantly improved insulin resistance and markedly ameliorated glucose tolerance. Conversely, expression of antisense ORP150 in the liver of normal mice decreased insulin sensitivity. The phosphorylation state of IRS-1 and Akt, which are key molecules for insulin signaling, and the expression levels of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, key enzymes of gluconeogenesis, were also altered by ORP150 overexpression. This is the first report showing that ER stress plays a crucial role in the insulin resistance found in diabetes and thus could be a potential therapeutic target for diabetes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Ishikari, Hokkaido 9208640, Japan	Osaka University; Kanazawa University	Kaneto, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneto@medone.med.osaka-u.ac.jp						Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; DON D, 2002, J CLIN INVEST, V110, P1383; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154	16	367	394	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					847	851		10.1074/jbc.M411860200	http://dx.doi.org/10.1074/jbc.M411860200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509553	hybrid			2022-12-25	WOS:000226025100099
J	Redeker, V; Levilliers, N; Vinolo, E; Rossier, J; Jaillard, D; Burnette, D; Gaertig, J; Bre, MH				Redeker, V; Levilliers, N; Vinolo, E; Rossier, J; Jaillard, D; Burnette, D; Gaertig, J; Bre, MH			Mutations of tubulin glycylation sites reveal cross-talk between the C termini of alpha- and beta-tubulin and affect the ciliary matrix in Tetrahymena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; POSTTRANSLATIONAL MODIFICATIONS; INTRAFLAGELLAR TRANSPORT; GLUTAMYLATED TUBULIN; AXONEMAL TUBULIN; DIFFERENTIAL DISTRIBUTION; FLAGELLAR MICROTUBULES; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DYNEIN; MASS-SPECTROMETRY	Two types of polymeric post-translational modifications of alpha/beta-tubulin, glycylation and glutamylation, occur widely in cilia and flagella. Their respective cellular functions are poorly understood. Mass spectrometry and immunoblotting showed that two closely related species, the ciliates Tetrahymena and Paramecium, have dramatically different compositions of tubulin post-translational modifications in structurally identical axonemes. Whereas the axonemal tubulin of Paramecium is highly glycylated and has a very low glutamylation content, the axonemal tubulin of Tetrahymena is glycylated and extensively glutamylated. In addition, only the alpha-tubulin of Tetrahymena undergoes detyrosination. Mutations of the known glycylation sites in Tetrahymena tubulin affected the level of each polymeric modification type in both the mutated and nonmutated subunits, revealing cross-talk between alpha- and beta-tubulin. Ultrastructural analyses of glycylation site mutants uncovered defects in the doublet B-subfiber of axonemes and revealed an accumulation of dense material in the ciliary matrix, reminiscent of intraflagellar transport particles seen by others in Chlamydomonas. We propose that polyglycylation and/or polyglutamylation stabilize the B-subfiber of outer doublets and regulate the intraflagellar transport.	Univ Paris 11, Lab Biol Cellulaire 4, CNRS, UMR 8080, F-91405 Orsay, France; Ecole Super Phys & Chim Ind Ville Paris, Neurobiol Lab, CNRS, UMR 7637, F-75005 Paris, France; Univ Paris 11, Ctr Commun Microscopie Elect, F-91405 Orsay, France; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Universite Paris Saclay; University System of Georgia; University of Georgia	Bre, MH (corresponding author), Univ Paris 11, Lab Biol Cellulaire 4, CNRS, UMR 8080, F-91405 Orsay, France.	Marie-Helene.Bre@ibaic.u-psud.fr	Redeker, Virginie/L-8929-2018; Gaertig, Jacek/F-1553-2010	Redeker, Virginie/0000-0003-2694-8388; 	NIGMS NIH HHS [GM54017] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054017] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOUTTE A, 1991, BIOL CELL, V71, P227, DOI 10.1016/0248-4900(91)90069-Y; AREVALO MA, 1990, J MOL BIOL, V214, P105, DOI 10.1016/0022-2836(90)90150-K; Bane BC, 2002, CELL TISSUE RES, V307, P57, DOI 10.1007/s00441-001-0483-x; BAROINTOURANCHEAU, 1992, P NATL ACAD SCI USA, V89, P9764; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P337, DOI 10.1002/cm.970270406; Bre MH, 1996, J CELL SCI, V109, P727; Bre MH, 1998, MOL BIOL CELL, V9, P2655, DOI 10.1091/mbc.9.9.2655; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; CALLEN AM, 1994, BIOL CELL, V81, P95, DOI 10.1016/S0248-4900(94)80002-2; Cohen J., 1988, P363; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; DupuisWilliams P, 1996, BIOL CELL, V87, P83, DOI 10.1016/S0248-4900(97)89840-1; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FLEURY A, 1995, PROTOPLASMA, V189, P37, DOI 10.1007/BF01280290; FLEURY A, 1992, DEV GENET, V13, P247, DOI 10.1002/dvg.1020130312; Fouquet JP, 1996, MOL REPROD DEV, V43, P358, DOI 10.1002/(SICI)1098-2795(199603)43:3&lt;358::AID-MRD10&gt;3.0.CO;2-Y; Fouquet JP, 1997, TISSUE CELL, V29, P573, DOI 10.1016/S0040-8166(97)80057-2; GAERTIG J, 1992, PROTOPLASMA, V167, P74, DOI 10.1007/BF01353583; GAERTIG J, 1995, J CELL BIOL, V129, P1301, DOI 10.1083/jcb.129.5.1301; Gaertig J, 2000, J EUKARYOT MICROBIOL, V47, P185, DOI 10.1111/j.1550-7408.2000.tb00037.x; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gagnon C, 1996, J CELL SCI, V109, P1545; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; Huitorel P, 2002, MOL REPROD DEV, V62, P139, DOI 10.1002/mrd.10086; Iftode F, 2000, BIOL CELL, V92, P615, DOI 10.1016/S0248-4900(00)01107-2; Kann ML, 1998, CELL MOTIL CYTOSKEL, V41, P341; KANN ML, 1995, TISSUE CELL, V27, P323, DOI 10.1016/S0040-8166(95)80053-0; Klotz A, 1999, CELL MOTIL CYTOSKEL, V44, P263, DOI 10.1002/(SICI)1097-0169(199912)44:4<263::AID-CM4>3.0.CO;2-V; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; Lechtreck KF, 2000, CELL MOTIL CYTOSKEL, V47, P219, DOI 10.1002/1097-0169(200011)47:3<219::AID-CM5>3.0.CO;2-Q; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Marshall WF, 2001, J CELL BIOL, V155, P405, DOI 10.1083/jcb.200106141; Mary J, 1996, J BIOL CHEM, V271, P9928, DOI 10.1074/jbc.271.17.9928; MCGRATH KE, 1994, CELL MOTIL CYTOSKEL, V27, P272, DOI 10.1002/cm.970270308; Million K, 1999, J CELL SCI, V112, P4357; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; Multigner L, 1996, BIOCHEMISTRY-US, V35, P10862, DOI 10.1021/bi961057u; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; NOJIMA D, 1995, CURR BIOL, V5, P158, DOI 10.1016/S0960-9822(95)00037-6; Norrander Jan M., 1994, V13, P201; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Pechart I, 1999, BIOL CELL, V91, P685, DOI 10.1016/S0248-4900(00)88532-9; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Plessmann U, 1997, J PROTEIN CHEM, V16, P385, DOI 10.1023/A:1026332621215; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; Redeker V, 1998, BIOCHEMISTRY-US, V37, P14838, DOI 10.1021/bi981335k; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Regnard C, 1998, BIOCHEMISTRY-US, V37, P8395, DOI 10.1021/bi9804131; Rosenbaum J, 2000, CURR BIOL, V10, pR801, DOI 10.1016/S0960-9822(00)00767-3; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sackett D L, 1995, Subcell Biochem, V24, P255; Schneider A, 1997, J CELL SCI, V110, P431; Schneider A, 1998, FEBS LETT, V429, P399, DOI 10.1016/S0014-5793(98)00644-9; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Skiniotis G, 2004, EMBO J, V23, P989, DOI 10.1038/sj.emboj.7600118; Snell WJ, 2004, CELL, V117, P693, DOI 10.1016/j.cell.2004.05.019; Song L, 2001, J BIOL CHEM, V276, P29754, DOI 10.1074/jbc.M103184200; SUPRENANT KA, 1985, P NATL ACAD SCI USA, V82, P6908, DOI 10.1073/pnas.82.20.6908; Thazhath R, 2004, MOL BIOL CELL, V15, P4136, DOI 10.1091/mbc.E04-03-0247; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tucker C, 1997, J BIOL CHEM, V272, P9481; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; Weber K, 1997, FEBS LETT, V419, P87, DOI 10.1016/S0014-5793(97)01436-1; WEHLAND J, 1987, J CELL BIOL, V104, P1059, DOI 10.1083/jcb.104.4.1059; WEHLAND J, 1987, J CELL SCI, V88, P185; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; Xia L, 2000, J CELL BIOL, V149, P1097, DOI 10.1083/jcb.149.5.1097	83	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					596	606		10.1074/jbc.M408324200	http://dx.doi.org/10.1074/jbc.M408324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492004	hybrid			2022-12-25	WOS:000226025100071
J	Durchschlag, E; Reiter, W; Ammerer, G; Schuller, C				Durchschlag, E; Reiter, W; Ammerer, G; Schuller, C			Nuclear localization destabilizes the stress-regulated transcription factor Msn2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; NEGATIVE REGULATION; FACTOR GCN4; UBIQUITIN; PATHWAY; DEGRADATION; ACTIVATION; STARVATION; INHIBITORS	The transcriptional program of yeast cells undergoes dramatic changes during the shift from fermentative growth to respiratory growth. A large part of this response is mediated by the stress responsive transcription factor Msn2. During glucose exhaustion, Msn2 is activated and concentrated in the nucleus. Simultaneously, Msn2 protein levels also drop significantly under this condition. Here we show that the decrease in Msn2 concentration is due to its increased degradation. Moreover, Msn2 levels are also reduced under chronic stress or low protein kinase A (PKA) activity, both conditions that cause a predominant nuclear localization of Msn2. Similar effects were found in msn5 mutant cells that block Msn2 nuclear export. To approximate the effect of low PKA activity on Msn2, we generated a mutant form with alanine substitutions in PKA phosphorylation sites. High expression of this Msn2 mutant is detrimental for growth, suggesting that the increased degradation of nuclear Msn2 might be necessary to adapt cells to low PKA conditions after the diauxic shift or to allow growth under chronic stress conditions.	Univ & BioCtr Vienna, Inst Biochem & Mol Cell Biol, Max F Perutz Labs, A-1030 Vienna, Austria; Univ & BioCtr Vienna, Ludwig Boltzmann Forschungsstelle Biochem, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Ludwig Boltzmann Institute; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Schuller, C (corresponding author), Univ & BioCtr Vienna, Inst Biochem & Mol Cell Biol, Max F Perutz Labs, Dr Bohr Gasse 9-5, A-1030 Vienna, Austria.	Christoph.Schueller@univie.ac.at		Reiter, Wolfgang/0000-0003-1266-8975; Schuller, Christoph/0000-0002-1649-1217				Alepuz PM, 1999, GENETICS, V153, P1219; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; Cameroni E, 2004, CELL CYCLE, V3, P462; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hopper AK, 1999, CURR BIOL, V9, pR803, DOI 10.1016/S0960-9822(99)80494-1; Jones DL, 2003, PHYSIOL GENOMICS, V16, P107, DOI 10.1152/physiolgenomics.00139.2003; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; Moskvina E, 1999, MOL MICROBIOL, V32, P1263, DOI 10.1046/j.1365-2958.1999.01438.x; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schuller C, 2004, MOL BIOL CELL, V15, P706, DOI 10.1091/mbc.E03-05-0322; Shemer R, 2002, MOL CELL BIOL, V22, P5395, DOI 10.1128/MCB.22.15.5395-5404.2002; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; SPEVAK W, 1983, MOL CELL BIOL, V3, P1545, DOI 10.1128/MCB.3.9.1545; WEN W, 1994, J BIOL CHEM, V269, P32214; WILSON RB, 1993, FEBS LETT, V325, P191, DOI 10.1016/0014-5793(93)81071-7; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729	34	57	59	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55425	55432		10.1074/jbc.M407264200	http://dx.doi.org/10.1074/jbc.M407264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502160	hybrid			2022-12-25	WOS:000225960800057
J	Beischlag, TV; Taylor, RT; Rose, DW; Yoon, D; Chen, YM; Lee, WH; Rosenfeld, MG; Hankinson, O				Beischlag, TV; Taylor, RT; Rose, DW; Yoon, D; Chen, YM; Lee, WH; Rosenfeld, MG; Hankinson, O			Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR-ALPHA; HIPPEL-LINDAU PROTEIN; AH RECEPTOR; TRANSACTIVATION DOMAIN; DIRECT BINDING; HIF-ALPHA; COACTIVATOR; COMPLEX; ACTIVATION	The aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor (ARNT/HIF-1beta) mediates an organism's response to various environmental cues, including those to chemical carcinogens, such as 2,3,7,8-tetrachlorodibenzo-rho-dioxin (TCDD or dioxin), via its formation of a functional transcription factor with the ligand activated aryl hydrocarbon receptor (AHR). Similarly, tissue responses to hypoxia are largely mediated through the HIF-1 heterodimeric transcription factor, comprising hypoxia-inducible factor-1alpha (HIF-1alpha) and ARNT. The latter response is essential for a metabolic switch from oxidative phosphorylation to glycolytic anaerobic metabolism as well as for angiogenesis and has been implicated as necessary for growth in many solid tumors. In this report, we demonstrate that the thyroid hormone receptor/retinoblastoma-interacting protein 230 (TRIP230) interacts directly with ARNT and is essential for both hypoxic and TCDD-mediated transcriptional responses. We initially identified TRIP230 as an ARNT-interacting protein in a yeast two-hybrid assay screen. This interaction was confirmed in mammalian cell systems using co-immunoprecipitation and in mammalian two-hybrid assays. Furthermore, TRIP230 could be recorded at sites of activated transcription of either TCDD- or hypoxia-inducible genes in a stimulus-dependent fashion by chromatin immunoprecipitation analysis. Finally, using single-cell microinjection and RNA interference assays, we demonstrate that TRIP230 is indispensable for TCDD- and hypoxia-dependent gene transcription.	Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci,Mol Biol Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif San Diego, Dept Mol Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Hankinson, O (corresponding author), Univ Calif Los Angeles, Med Ctr, Ctr Hlth Sci,Mol Biol Inst, Dept Pathol & Lab Med, Box 951732, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NCI NIH HHS [CA28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen YM, 1999, P NATL ACAD SCI USA, V96, P4443, DOI 10.1073/pnas.96.8.4443; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Glass CK, 2000, GENE DEV, V14, P121; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Ma Q, 1997, J BIOL CHEM, V272, P8878; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200	52	59	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54620	54628		10.1074/jbc.M410456200	http://dx.doi.org/10.1074/jbc.M410456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485806	hybrid			2022-12-25	WOS:000225793600088
J	Curran, SP; Leverich, EP; Koehler, CM; Larsen, PL				Curran, SP; Leverich, EP; Koehler, CM; Larsen, PL			Defective mitochondrial protein translocation precludes normal Caenorhabditis elegans development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAFNESS DYSTONIA SYNDROME; DISTAL TIP CELLS; INTERMEMBRANE SPACE; DAUER DIAPAUSE; IMPORT; BIOGENESIS; COMPLEX; MEMBRANE; GENETICS; RECEPTOR	We demonstrate biochemically that the genes identified by sequence similarity as orthologs of the mitochondrial import machinery are functionally conserved in Caenorhabditis elegans. Specifically, tin-9.1 and tin-10 RNA interference (RNAi) treatment of nematodes impairs import of the ADP/ATP carrier into isolated mitochondria. Developmental phenotypes are associated with gene knock-down of the mitochondrial import components. RNAi of tomm-7 and ddp-1 resulted in mitochondria with an interconnected morphology in vivo, presumably due to defects in the assembly of outer membrane fission/fusion components. RNAi of the small Tim proteins TIN-9.1, TIN-9.2, and TIN-10 resulted in a small body size, reduced number of progeny produced, and partial embryonic lethality. An additional phenotype of the tin-9.2(RNAi) animals is defective formation of the somatic gonad. The biochemical demonstration that the protein import activity is reduced, under the same conditions that yield the defects in specific tissues and lethality in a later generation, suggests that the developmental abnormalities observed are a consequence of defects in mitochondrial inner membrane biogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles	Larsen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	larsenp@uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070415, R01GM061721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM070415, 1R01GM61721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Antebi A, 2000, GENE DEV, V14, P1512; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BRENNER S, 1974, GENETICS, V77, P71; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Curran SP, 2004, TOP CURR GENET, V8, P59; Curran SP, 2002, J CELL BIOL, V158, P1017, DOI 10.1083/jcb.200205124; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gerisch B, 2004, DEVELOPMENT, V131, P1765, DOI 10.1242/dev.01068; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hoogenraad NJ, 2002, BBA-MOL CELL RES, V1592, P97, DOI 10.1016/S0167-4889(02)00268-9; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Kaldi K, 1998, BIOFACTORS, V8, P221, DOI 10.1002/biof.5520080308; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nishiwaki K, 1999, GENETICS, V152, P985; OKIMOTO R, 1992, GENETICS, V130, P471; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Rospert S, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P277; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Snow MI, 2000, BBA-GENE STRUCT EXPR, V1494, P104, DOI 10.1016/S0167-4781(00)00224-4; Su MW, 2000, DEVELOPMENT, V127, P585; SULSTON JE, 1988, CELL LINEAGE, P123; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Tsang WY, 2003, BBA-MOL BASIS DIS, V1638, P91, DOI 10.1016/S0925-4439(03)00079-6; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Wiedemann N, 2003, J MOL BIOL, V327, P465, DOI 10.1016/S0022-2836(03)00118-9	62	20	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54655	54662		10.1074/jbc.M409618200	http://dx.doi.org/10.1074/jbc.M409618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485840	hybrid			2022-12-25	WOS:000225793600092
J	Dostanic, I; Schultz, JE; Lorenz, JN; Lingrel, JB				Dostanic, I; Schultz, JE; Lorenz, JN; Lingrel, JB			The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; SITE-DIRECTED MUTAGENESIS; SODIUM-PUMP ISOFORM; FAILING HUMAN HEART; DEVELOPMENTAL REGULATION; INOTROPIC RESPONSE; BETA-SUBUNIT; EXPRESSION; OUABAIN; MOUSE	The primary objective of this study was to examine the functional role of the Na,K-ATPase alpha1 isoform in the regulation of cardiac contractility. Previous studies using knock-out mice showed that the hearts of animals lacking one copy of the alpha1 or alpha2 isoform gene exhibit opposite phenotypes. Hearts from alpha2(+/-) animals are hypercontractile, whereas those of the alpha1(+/-) animals are hypocontractile. The cardiac phenotype of the alpha1(+/-) animals was unexpected as other studies suggest that inhibition of either isoform increases contraction. To help resolve this difference, we have used genetically engineered knock-in mice expressing a ouabain-sensitive alpha1 isoform and a ouabain-resistant alpha2 isoform of the Na,K-ATPase, and we analyzed cardiac contractility following selective inhibition of the alpha1 isoform by ouabain. Administration of ouabain to these animals and to isolated heart preparations selectively inhibits only the activity of the alpha1 isoform without affecting the activity of the alpha2 isoform. Low concentrations of ouabain resulted in positive cardiac inotropy in both isolated hearts and intact animals expressing the modified alpha1 and alpha2 isoforms. Pretreatment with 10 muM KB-R7943, which inhibits the reverse mode of the Na/Ca exchanger, abolished the cardiotonic effects of ouabain in isolated wild type and knock-in hearts. Immunoprecipitation analysis demonstrated co-localization of the alpha1 isoform and the Na/Ca exchanger in cardiac sarcolemma. The alpha1 isoform coimmunoprecipitated with the Na/Ca exchanger and vice versa. These results demonstrate that the alpha1 isoform regulates cardiac contractility, and that both the alpha1 and alpha2 isoforms are functionally and physically coupled with the Na/Ca exchanger in heart.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066062, R01HL028573] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66062, R01 HL28573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Dostanic I, 2003, J BIOL CHEM, V278, P53026, DOI 10.1074/jbc.M308547200; Golovina VA, 2003, AM J PHYSIOL-CELL PH, V284, pC475, DOI 10.1152/ajpcell.00383.2002; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Jewell EA, 1992, ACTA PHYSL SCAND S, V607, P161; Kang WK, 2002, J PHARMACOL EXP THER, V302, P577, DOI 10.1124/jpet.302.2.577; KENT RB, 1987, P NATL ACAD SCI USA, V84, P5369, DOI 10.1073/pnas.84.15.5369; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; McDonough AA, 1996, AM J PHYSIOL-CELL PH, V270, pC1221, DOI 10.1152/ajpcell.1996.270.4.C1221; Muller-Ehmsen J, 2001, CELL MOL BIOL, V47, P373; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Pieske B, 2003, CARDIOVASC RES, V57, P874, DOI 10.1016/S0008-6363(02)00841-6; Pieske B, 2003, CARDIOVASC RES, V57, P871, DOI 10.1016/S0008-6363(02)00849-0; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Radzyukevich TL, 2004, AM J PHYSIOL-CELL PH, V287, pC1300, DOI 10.1152/ajpcell.00231.2004; Reuter H, 2002, CIRC RES, V90, P305, DOI 10.1161/hh0302.104562; Schwartz A, 2001, CARDIOVASC RES, V51, P9, DOI 10.1016/S0008-6363(01)00336-4; Schwinger RHG, 1999, CIRCULATION, V99, P2105, DOI 10.1161/01.CIR.99.16.2105; SHAMRAJ OI, 1993, CARDIOVASC RES, V27, P2229, DOI 10.1093/cvr/27.12.2229; SHAMRAJ OI, 1991, BIOCHEM BIOPH RES CO, V179, P1434, DOI 10.1016/0006-291X(91)91733-S; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; SWEADNER KJ, 1987, P NATL ACAD SCI USA, V84, P8404, DOI 10.1073/pnas.84.23.8404; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Wang JN, 2001, AM J PHYSIOL-CELL PH, V281, pC1336, DOI 10.1152/ajpcell.2001.281.4.C1336; Zahler R, 1996, AM J PHYSIOL-CELL PH, V270, pC361, DOI 10.1152/ajpcell.1996.270.1.C361; Zahler R, 1996, BASIC RES CARDIOL, V91, P256, DOI 10.1007/BF00788912	33	123	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54053	54061		10.1074/jbc.M410737200	http://dx.doi.org/10.1074/jbc.M410737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485817	hybrid			2022-12-25	WOS:000225793600022
J	Ikari, A; Hirai, N; Shiroma, M; Harada, H; Sakai, H; Hayashi, H; Suzuki, Y; Degawa, M; Takagi, K				Ikari, A; Hirai, N; Shiroma, M; Harada, H; Sakai, H; Hayashi, H; Suzuki, Y; Degawa, M; Takagi, K			Association of paracellin-1 with ZO-1 augments the reabsorption of divalent cations in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSEPITHELIAL ELECTRICAL-RESISTANCE; TIGHT JUNCTION STRANDS; THICK ASCENDING LIMB; CANINE KIDNEY-CELLS; CALCIUM REABSORPTION; MAGNESIUM TRANSPORT; SELECTIVE CHANNELS; DIRECT BINDING; HUMAN HOMOLOG; MDCK CELLS	Paracellin-1 (PCLN-1) belongs to the claudin family of tight junction proteins and possibly plays a critical role in the reabsorption of magnesium and calcium. So far, the physiological properties of PCLN-1 have not been clarified. In the present study, we investigated whether PCLN-1 is associated with ZO-1. We also investigated whether Ca-45(2+) transport across the paracellular barrier is affected by this association. In vitro binding analysis using glutathione S-transferase fusion protein showed that the C-terminal TRV sequence, especially Thr and Val residues, of PCLN-1 interacts with ZO-1. Next, PCLN-1 was stably expressed in Madin-Darby canine kidney cells using a FLAG tagging vector. ZO-1 was co-immunoprecipitated with the wild-type PCLN-1 and the alanine substitution (TAV) mutant. However, mutants of the deletion (DeltaTRV) and the alanine substitution (ARV and TRA) inhibited the association of PCLN-1 with ZO-1. Confocal immunofluorescence demonstrated that the wild-type PCLN-1 and the TAV mutant localized in the tight junction along with ZO-1, but the DeltaTRV, ARV, and TRA mutants were widely distributed in the lateral membrane including the tight junction area. Interestingly, monolayers of cells expressing the wild-type PCLN-1 and the TAV mutant showed higher activities of Ca-45(2+) transport from apical to basal compartments, compared with those expressing the DeltaTRV, ARV, and TRA mutants and the mock cells. Ca-45(2+) transport was inhibited by increased magnesium concentration suggesting that magnesium and calcium were competitively transported by PCLN-1. It was noted that a positive electrical potential gradient enhanced Ca-45(2+) transport from apical to basal compartments without affecting the opposite direction of transport. Thus, PCLN-1 localizes to the tight junction followed by association with ZO-1, and the PCLN-1 . ZO-1 complex may play an essential role in the reabsorption of divalent cations in renal epithelial cells.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Mol Toxicol, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Pharmaceut Sci, 21st Century COE Program, Shizuoka 4228526, Japan; Univ Shizuoka, Sch Food & Nutr Sci, Physiol Lab, Shizuoka 4228526, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Pharmaceut Physiol, Toyama 9300194, Japan	University of Shizuoka; University of Shizuoka; University of Shizuoka; University of Shizuoka; University of Toyama	Ikari, A (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Environm Biochem & Toxicol, 52-1 Yada, Shizuoka 4228526, Japan.	ikari@u-shizuoka-ken.ac.jp	Hayashi, Hisayoshi/K-5883-2013; Degawa, Masakuni/F-5702-2010					Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Blanchard A, 2001, KIDNEY INT, V59, P2206, DOI 10.1046/j.1523-1755.2001.00736.x; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GIULIANO AR, 1991, AM J PHYSIOL, V260, pG207, DOI 10.1152/ajpgi.1991.260.2.G207; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982; Ikari A, 2002, J BIOL CHEM, V277, P33338, DOI 10.1074/jbc.M200310200; Ikari A, 2001, BIOCHEM BIOPH RES CO, V287, P671, DOI 10.1006/bbrc.2001.5644; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; McCarthy KM, 2000, J CELL SCI, V113, P3387; Monnens L, 2000, NEPHROL DIAL TRANSPL, V15, P568, DOI 10.1093/ndt/15.5.568; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Muller D, 2003, AM J HUM GENET, V73, P1293, DOI 10.1086/380418; Olsen O, 2003, J BIOL CHEM, V278, P6873, DOI 10.1074/jbc.M210165200; Quamme GA, 2000, FRONT BIOSCI-LANDMRK, V5, pD694, DOI 10.2741/Quamme; QUAMME GA, 1989, AM J PHYSIOL, V256, pF197, DOI 10.1152/ajprenal.1989.256.2.F197; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Weber S, 2001, J AM SOC NEPHROL, V12, P1872, DOI 10.1681/ASN.V1291872; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	29	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54826	54832		10.1074/jbc.M406331200	http://dx.doi.org/10.1074/jbc.M406331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496416	hybrid			2022-12-25	WOS:000225793600111
J	Palm-Leis, A; Singh, US; Herbelin, BS; Olsovsky, GD; Baker, KM; Pan, J				Palm-Leis, A; Singh, US; Herbelin, BS; Olsovsky, GD; Baker, KM; Pan, J			Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; MYOCARDIAL-CELL HYPERTROPHY; CONGESTIVE-HEART-FAILURE; N-TERMINAL KINASE; MAP KINASE; GENE-EXPRESSION; ANGIOTENSIN-II; X-RECEPTOR	All-trans retinoic acid ( RA) has been implicated in mediation of cardiac growth inhibition in neonatal cardiomyocytes. However, the associated signaling mechanisms remain unclear. Utilizing neonatal cardiomyocytes, we demonstrated that RA suppressed the hypertrophic features induced by cyclic stretch or angiotensin II (Ang II). Cyclic stretch- or Ang II-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAP kinase) was dose- and time-dependently inhibited by RA. Significant inhibition was observed by 5 muM RA, from 8 to 24 h of pretreatment. This inhibitory effect was not mediated at the level of mitogen-activated protein kinase kinases (MKKs), because RA had no effect on stretch- or Ang II-induced phosphorylation of MEK1/2, MKK4, and MKK3/6. However, the phosphatase inhibitor vanadate reversed the inhibitory effect of RA on MAP kinases and protein synthesis. RA up-regulated the expression level of MAP kinase phosphatase-1 (MKP-1) and MKP-2, and the time course was correlated with the inhibitory effect of RA on activation of MAP kinases. Overexpression of wild-type MKP-1 inhibited the phosphorylation of JNK and p38 in cardiomyocytes. These data indicated that MKPs were involved in the inhibitory effect of RA on MAP kinases. Using specific RAR and RXR antagonists, we demonstrated that both RARs and RXRs were involved in regulating stretch- or Ang II-induced activation of MAP kinases. Our findings provide the first evidence that the anti-hypertrophic effect of RA is mediated by up-regulation of MKPs and inhibition of MAP kinase signaling pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Div Mol Cardiol, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Dept Internal Med, Div Mol Cardiol, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Pan, J (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Div Mol Cardiol, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.	jpan@medicine.tamu.edu						Aboseif SR, 1997, PROSTATE, V31, P161; Aikawa R, 2000, MOL CELL BIOCHEM, V212, P177, DOI 10.1023/A:1007185711745; Akazawa H, 2003, CIRC RES, V92, P1079, DOI 10.1161/01.RES.0000072977.86706.23; ALESSI DR, 1993, ONCOGENE, V8, P2015; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clabby ML, 2003, J BIOL CHEM, V278, P5760, DOI 10.1074/jbc.M208173200; Clerk A, 1999, AM J CARDIOL, V83, p64H; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Davies EL, 1997, BIOCHEM SOC T, V25, pS223, DOI 10.1042/bst025223s; DE LUCA LM, 1991, FASEB J, V5, P2924; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Fischer TA, 2001, HYPERTENSION, V37, P1222, DOI 10.1161/01.HYP.37.5.1222; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fuller SJ, 1997, BIOCHEM J, V323, P313, DOI 10.1042/bj3230313; Georgiades P, 1998, CELL BIOL INT, V22, P457, DOI 10.1006/cbir.1998.0282; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Hiroi Y, 2001, HYPERTENS RES, V24, P385, DOI 10.1291/hypres.24.385; Hofken T, 2000, BIOCHEM BIOPH RES CO, V276, P680, DOI 10.1006/bbrc.2000.3530; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Kagechika H, 2002, CURR MED CHEM, V9, P591, DOI 10.2174/0929867024606975; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kim L, 1999, AM J PHYSIOL-HEART C, V277, pH1808, DOI 10.1152/ajpheart.1999.277.5.H1808; Kodama H, 1997, CIRC RES, V81, P656; Kodama H, 1998, CIRC RES, V82, P244; KOMURO I, 1990, JPN CIRC J, V54, P526, DOI 10.1253/jcj.54.526; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Kosaka C, 2001, HYPERTENS RES, V24, P579, DOI 10.1291/hypres.24.579; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Molkentin JD, 1997, CIRCULATION, V96, P3833; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Samarel AM, 2001, J MOL CELL CARDIOL, V33, P1637, DOI 10.1006/jmcc.2001.1427; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; Ueyama T, 2000, J MOL CELL CARDIOL, V32, P947, DOI 10.1006/jmcc.2000.1135; Wang HJ, 2002, J APPL PHYSIOL, V92, P2162, DOI 10.1152/japplphysiol.01192.2001; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	76	58	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54905	54917		10.1074/jbc.M407383200	http://dx.doi.org/10.1074/jbc.M407383200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494319	Green Published, hybrid			2022-12-25	WOS:000225793600120
J	Tomita, T; Mizumachi, Y; Chong, K; Ogawa, K; Konishi, N; Sugawara-Tomita, N; Dohmae, N; Hashimoto, Y; Takio, K				Tomita, T; Mizumachi, Y; Chong, K; Ogawa, K; Konishi, N; Sugawara-Tomita, N; Dohmae, N; Hashimoto, Y; Takio, K			Protein sequence analysis, cloning, and expression of flammutoxin, a pore-forming cytolysin from Flammulina velutipes - Maturation of dimeric precursor to monomeric active form by carboxyl-terminal truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; PLEUROTUS-OSTREATUS; TOXIN AEROLYSIN; MUSHROOM; ACTIVATION; PURIFICATION	Flammutoxin (FTX), a 31-kDa pore-forming cytolysin from Flammulina velutipes, is specifically expressed during the fruiting body formation. We cloned and expressed the cDNA encoding a 272-residue protein with an identical N-terminal sequence with that of FTX but failed to obtain hemolytically active protein. This, together with the presence of multiple FTX family proteins in the mushroom, prompted us to determine the complete primary structure of FTX by protein sequence analysis. The N-terminal 72 and C-terminal 107 residues were sequenced by Edman degradation of the fragments generated from the alkylated FTX by enzymatic digestions with Achromobacter protease I or Staphylococcus aureus V8 protease and by chemical cleavages with CNBr, hydroxylamine, or 1% formic acid. The central part of FTX was sequenced with a surface-adhesive 7-kDa fragment, which was generated by a tryptic digestion of FTX and recovered by rinsing the wall of a test tube with 6 M guanidine HCl. The 7-kDa peptide was cleaved with 12 M HCl, thermolysin, or S. aureus V8 protease to produce smaller peptides for sequence analysis. As a result, FTX consisted of 251 residues, and protein and nucleotide sequences were in accord except for the lack of the initial Met and the C-terminal 20 residues in protein. Recombinant FTX (rFTX) with or without the C-terminal 20 residues (rFTX271 or rFTX251, respectively) was prepared to study the maturation process of FTX. Like natural FTX, rFTX251 existed as a monomer in solution and assembled into an SDS-stable, ring-shaped pore complex on human erythrocytes, causing hemolysis. In contrast, rFTX271, existing as a dimer in solution, bound to the cells but failed to form pore complex. The dimeric rFTX271 was converted to hemolytically active monomers upon the cleavage between Lys(251) and Met(252) by trypsin.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan; Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama 3388570, Japan; RIKEN, Div Biomol Characterizat, Wako, Saitama 3510198, Japan	Tohoku University; Saitama University; RIKEN	Tomita, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan.	tomita@biochem.tohoku.ac.jp	Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Berne S, 2002, BBA-GEN SUBJECTS, V1570, P153, DOI 10.1016/S0304-4165(02)00190-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BERNHEIMER AW, 1987, TOXICON, V25, P1145, DOI 10.1016/0041-0101(87)90132-2; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Bittencourt SET, 2003, FEBS LETT, V549, P47, DOI 10.1016/S0014-5793(03)00763-4; Bornstein P, 1977, Methods Enzymol, V47, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Espinar MTF, 1997, CURR GENET, V32, P420, DOI 10.1007/s002940050297; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; FAULSTICH H, 1983, BIOCHEMISTRY-US, V22, P4574, DOI 10.1021/bi00288a035; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gros E., 1967, METHOD ENZYMOL, V11, P238; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landon, 1977, Methods Enzymol, V47, P145; LIN JY, 1974, NATURE, V252, P235, DOI 10.1038/252235a0; Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nonaka T, 1997, J BIOL CHEM, V272, P30032, DOI 10.1074/jbc.272.48.30032; Ohnishi M, 1998, J BIOL CHEM, V273, P453, DOI 10.1074/jbc.273.1.453; Parker MW, 2003, TOXICON, V42, P1, DOI 10.1016/S0041-0101(03)00106-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Sakamoto Yuichi, 2000, Mycoscience, V41, P279, DOI 10.1007/BF02489684; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; Tadjibaeva G, 2000, BBA-BIOMEMBRANES, V1467, P431, DOI 10.1016/S0005-2736(00)00240-6; TITANI K, 1964, J BIOCHEM-TOKYO, V56, P241, DOI 10.1093/oxfordjournals.jbchem.a127986; Tomita T, 2004, J BIOL CHEM, V279, P26975, DOI 10.1074/jbc.M402676200; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; Watanabe H, 1999, EUR J BIOCHEM, V262, P850, DOI 10.1046/j.1432-1327.1999.00440.x; WILMSEN HU, 1985, EUR BIOPHYS J BIOPHY, V12, P199	33	11	17	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54161	54172		10.1074/jbc.M408783200	http://dx.doi.org/10.1074/jbc.M408783200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489231	hybrid			2022-12-25	WOS:000225793600035
J	Sinenko, SA; Mathey-Prevot, B				Sinenko, SA; Mathey-Prevot, B			Increased expression of Drosophila tetraspanin, Tsp68C, suppresses the abnormal proliferation of ytr-deficient and Ras/Raf-activated hemocytes	ONCOGENE			English	Article						tetraspanin; Tsp68C; yantar; Raf; hemocyte; Drosophila	DENDRITIC CELLS; EGF RECEPTOR; SUPERFAMILY; PROTEINS; ORGANIZERS; INTEGRINS; COMPLEXES; MIGRATION; RESPONSES; PATHWAY	Tetraspanins are evolutionary conserved transmembrane proteins thought to facilitate cell proliferation, movement or fusion by acting as organizers of different signaling events. Despite their prevalence and conservation, their specific role and functions remain largely elusive, as their redundancy in various. organisms has hindered loss of function studies. Here, we take a gain of function approach to study Drosophila tetraspanin Tsp68C and its effect on larval hemocytes. We recently characterized a lethal mutation in ytr, a conserved gene that encodes a nuclear arginine-rich protein of unknown function, which is accompanied by abnormal differentiation and proliferation of the larval hematopoietic tissue in flies. A hemolectin (hml)-Gal4 construct carried by hml-Gal4 transgenic flies was sufficient by itself to abrogate the hematopoietic defects in ytr mutant larvae. This rescue correlated with the overexpression of tsp68C, a tetraspanin gene nested in the hml promoter. The suppression of abnormal proliferation by the hml-Gal4 construct was not restricted to ytr-deficient hemocytes, but was also observed in hemocytes expressing the oncogenic forms of Raf or Ras proteins. However, it had no effect on overproliferation mediated by a constitutively active form of Jak. New hml-Gal4 lines, in which the tsp68C gene was silenced or deleted from the promoter, no longer rescued the hematopoietic defect in ytr mutants nor suppressed the activated Raf-induced overproliferation. Therefore, change in tetraspanin Tsp68C expression has a strong suppressor effect on abnormal proliferation and differentiation of hemocytes in the context of specific lesions, such as overactivation of the Ras/Raf/MAPK pathway.	Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Sinenko, SA (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, 621 Charles E Young Dr S,Life Sci Bldg 2204, Los Angeles, CA 90024 USA.	sinenko@mcdb.ucla.edu	Sinenko, Sergey A./C-3703-2016	Sinenko, Sergey A./0000-0001-5517-8218	NHLBI NIH HHS [R01 HL62434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anzai N, 2002, BLOOD, V99, P4413, DOI 10.1182/blood.V99.12.4413; Asha H, 2003, GENETICS, V163, P203; Bach EA, 2003, GENETICS, V165, P1149; Berditchevski F, 2001, J CELL SCI, V114, P4143; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Boucheix C., 2001, EXPERT REV MOL MED, V2001, P1; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1993, DEVELOPMENT, V118, P401; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; Engering A, 2003, EUR J BIOCHEM, V270, P2412, DOI 10.1046/j.1432-1033.2003.03609.x; Fradkin LG, 2002, P NATL ACAD SCI USA, V99, P13663, DOI 10.1073/pnas.212511099; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hubner K, 2002, INT REV CYTOL, V214, P103; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mantegazza AR, 2004, BLOOD, V104, P1183, DOI 10.1182/blood-2004-01-0104; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Scherberich A, 2002, THROMB HAEMOSTASIS, V87, P1043, DOI 10.1055/s-0037-1613130; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Sinenko SA, 2004, DEV BIOL, V273, P48, DOI 10.1016/j.ydbio.2004.05.022; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Sorrentino RP, 2002, DEV BIOL, V243, P65, DOI 10.1006/dbio.2001.0542; Tarrant JA, 2002, MOL CELL BIOL, V22, P5006, DOI 10.1128/MCB.22.14.5006-5018.2002; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	32	98	98	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9120	9128		10.1038/sj.onc.1208156	http://dx.doi.org/10.1038/sj.onc.1208156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480416				2022-12-25	WOS:000225492800013
J	Rosenberg, MF; Callaghan, R; Modok, S; Higgins, CF; Ford, RC				Rosenberg, MF; Callaghan, R; Modok, S; Higgins, CF; Ford, RC			Three-dimensional structure of P-glycoprotein - The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ABC TRANSPORTER; CONFORMATIONAL-CHANGES; ATP-BINDING; CLOSED CONFORMATION; ELECTRON-MICROSCOPY; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DOMAINS	Multidrug resistance of cancer cells and pathogens is a serious clinical problem. A major factor contributing to drug resistance in cancer is the over-expression of P-glycoprotein, a plasma membrane ATP-binding cassette (ABC) drug efflux pump. Three-dimensional structural data with a resolution limit of similar to8 Angstrom have been obtained from two-dimensional crystals of P-glycoprotein trapped in the nucleotide-bound state. Each of the two transmembrane domains of P-glycoprotein consists of six long a-helical segments. Five of the a-helices from each transmembrane domain are related by a pseudo-2-fold symmetry, whereas the sixth breaks the symmetry. The two a-helices positioned closest to the (pseudo-) symmetry axis at the center of the molecule appear to be kinked. A large loop of density at the extracellular surface of the transporter is likely to correspond to the glycosylated first extracellular loop, whereas two globular densities at the cytoplasmic side correspond to the hydrophilic, nucleotide-binding domains. This is the first three-dimensional structure for an intact eukaryotic ABC transporter. Comparison with the structures of two prokaryotic ABC transporters suggests significant differences in the packing of the transmembrane a-helices within this protein family.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Oxford, John Radcliffe Hosp, Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England	University of Manchester; University of Oxford; Imperial College London	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	r.ford@umist.ac.uk	Callaghan, Richard/ABG-1638-2020; Callaghan, Richard/B-7032-2012	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Ford, Robert/0000-0002-0958-1505				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Gabriel MP, 2003, BIOCHEMISTRY-US, V42, P7780, DOI 10.1021/bi0341049; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GLAESER RM, 1992, ULTRAMICROSCOPY, V47, P256, DOI 10.1016/0304-3991(92)90201-T; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rothnie A, 2004, J BIOL CHEM, V279, P34913, DOI 10.1074/jbc.M405336200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897	39	149	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2857	2862		10.1074/jbc.M410296200	http://dx.doi.org/10.1074/jbc.M410296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15485807	hybrid			2022-12-25	WOS:000226449100060
J	Del Vecchio, RL; Tonks, NK				Del Vecchio, RL; Tonks, NK			The conserved immunoglobulin domain controls the subcellular localization of the homophilic adhesion receptor protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; PTP-MU; IN-VIVO; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; RPTP-MU; EXPRESSION; INHIBITION; BINDING; ALPHA	The receptor protein-tyrosine phosphatase mu (PTPmu) is a homophilic adhesion protein thought to regulate cell-cell adhesion in the vascular endothelium through dephosphorylation of cell junction proteins. In subconfluent cell cultures, PTPmu resides in an intracellular membrane pool; however, as culture density increases and cell contacts form, the phosphatase localizes to sites of cell-cell contact, and its expression level increases. These characteristics of PTPmu, which are consistent with a role in cell-cell adhesion, suggest that control of subcellular localization is an important mechanism to regulate the function of this phosphatase. To gain a better understanding of how PTPmu is regulated, we examined the importance of the conserved immunoglobulin domain, containing the homophilic binding site, in control of the localization of the enzyme. Deletion of the immunoglobulin domain impaired localization of PTPmu to the cell-cell contacts in endothelial and epithelial cells. In addition, deletion of the immunoglobulin domain affected the distribution of PTPmu in subconfluent endothelial cells when homophilic binding to another PTPmu molecule on an apposing cell was not possible, resulting in an accumulation of the mutant phosphatase at the cell surface with a concentration at the cell periphery in the region occupied by focal adhesions. This aberrant localization correlated with reduced survival and alterations in normal focal adhesion and cytoskeleton morphology. This study therefore illustrates the critical role of the immunoglobulin domain in regulation of the localization of PTPmu and the importance of such control for the maintenance of normal cell physiology.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Beltran PJ, 2003, FRONT BIOSCI, V8, pD87, DOI 10.2741/941; Bianchi C, 1999, EXP CELL RES, V248, P329, DOI 10.1006/excr.1999.4428; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Chang C, 2004, SCIENCE, V305, P103, DOI 10.1126/science.1096983; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Krueger NX, 2003, MOL CELL BIOL, V23, P6909, DOI 10.1128/MCB.23.19.6909-6921.2003; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Symons JR, 2002, BIOCHEM J, V365, P513, DOI 10.1042/BJ20020381; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Wang J, 1999, MOL CELL NEUROSCI, V14, P370, DOI 10.1006/mcne.1999.0789; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Zamir E, 2001, J CELL SCI, V114, P3583; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1603	1612		10.1074/jbc.M410181200	http://dx.doi.org/10.1074/jbc.M410181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15491993	hybrid			2022-12-25	WOS:000226195200091
J	Hart, LS; Yannone, SM; Naczki, C; Orlando, JS; Waters, SB; Akman, SA; Chen, DJ; Ornelles, D; Koumenis, C				Hart, LS; Yannone, SM; Naczki, C; Orlando, JS; Waters, SB; Akman, SA; Chen, DJ; Ornelles, D; Koumenis, C			The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE CATALYTIC SUBUNIT; IN-VIVO; HISTONE H2AX; RADIATION SENSITIVITY; GENOMIC INSTABILITY; V(D)J RECOMBINATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; RADIOTHERAPY; EXPRESSION	The adenoviral protein E4orf6 has been shown to inhibit both in vitro V(D)J recombination and adenoviral DNA concatenation, two processes that rely on cellular DNA double strand break repair (DSBR) proteins. Most of the known activities of E4orf6 during adenoviral infection require its interaction with another adenoviral protein, E1B-55K. Here we report that E4orf6, stably expressed in RKO human colorectal carcinoma cells or transiently expressed by adenoviral vector in U251 human glioblastoma cells, inhibits DSBR and induces significant radiosensitization in the absence of E1B-55K. Expression of a mutant form of E4orf6 (L245P) failed to radiosensitize RKO cells. E4orf6 reduced DSBR capacity in transfected and infected cells, as measured by sublethal DNA damage repair assay and phosphorylated H2AX (gamma-H2AX) levels, respectively. Consistent with the inhibitory effect of E4orf6 on DSBR, expression of wild-type but not mutant E4orf6 reduced recovery of a transfected, replicating reporter plasmid (pSP189) in 293 cells but did not increase the mutation frequency measured in the reporter plasmid. The kinase activity of DNA-PKcs (the DNA-dependent protein kinase catalytic subunit) toward heterologous substrates was not affected by expression of E4orf6; however, autophosphorylation of DNA-PKcs at Thr-2609 following ionizing radiation was prolonged in the presence of E4orf6 when compared with control-infected cells. Our results demonstrate for the first time that E4orf6 expression hinders the cellular DNA repair process in mammalian cells in the absence of E1B-55K or other adenoviral genes and suggest that viral-mediated delivery of E4orf6, combined with localized external beam radiation, could be a useful approach for the treatment of radioresistant solid tumors such as glioblastomas.	Wake Forest Univ, Sch Med, Sect Radiat Biol, Dept Radiat Oncol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Koumenis, C (corresponding author), Wake Forest Univ, Sch Med, Sect Radiat Biol, Dept Radiat Oncol, NRC 412,Med Ctr Blvd, Winston Salem, NC 27157 USA.	ckoumeni@wfubmc.edu	Yannone, Steven/G-1927-2011; Koumenis, Constantinos/B-2002-2008; Yannone, Steven/ABA-3524-2021	Koumenis, Costas/0000-0001-5945-4726	NCI NIH HHS [CA77342] Funding Source: Medline; NIAID NIH HHS [T32 AI07401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ader I, 2002, ONCOGENE, V21, P6471, DOI 10.1038/sj.onc.1205838; Akman SA, 1996, CARCINOGENESIS, V17, P2137, DOI 10.1093/carcin/17.10.2137; Amorino GP, 2000, RADIAT RES, V153, P384, DOI 10.1667/0033-7587(2000)153[0384:EOREIV]2.0.CO;2; Amorino GP, 1999, INT J RADIAT ONCOL, V44, P399, DOI 10.1016/S0360-3016(99)00033-4; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bernardi RJ, 2001, CLIN CANCER RES, V7, P4164; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bonner WM, 2003, P NATL ACAD SCI USA, V100, P4973, DOI 10.1073/pnas.1031538100; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Buchsbaum DJ, 1996, GENE THER, V3, P1042; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Collis SJ, 2003, INT J RADIAT BIOL, V79, P53, DOI 10.1080/0955300021000038626; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; ELKIND MM, 1988, RADIAT RES, V114, P425, DOI 10.2307/3577116; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; Halmer L, 1997, MOL CELL BIOL, V17, P2624, DOI 10.1128/MCB.17.5.2624; Hendry JH, 2001, RADIOTHER ONCOL, V59, P117, DOI 10.1016/S0167-8140(01)00285-7; HIRT B, 1969, J MOL BIOL, V40, P141, DOI 10.1016/0022-2836(69)90302-7; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Li SY, 2003, NUCLEIC ACIDS RES, V31, P5848, DOI 10.1093/nar/gkg775; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Marangoni E, 2000, CANCER GENE THER, V7, P339, DOI 10.1038/sj.cgt.7700111; Nazarov OB, 2003, RADIAT RES, V160, P309, DOI 10.1667/RR3043; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nicolas AL, 2000, VIROLOGY, V266, P211, DOI 10.1006/viro.1999.0062; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Orlando JS, 2002, J VIROL, V76, P1475, DOI 10.1128/JVI.76.3.1475-1487.2002; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sekiguchi JM, 1999, COLD SPRING HARB SYM, V64, P169, DOI 10.1101/sqb.1999.64.169; Siino JS, 2002, FEBS LETT, V527, P105, DOI 10.1016/S0014-5793(02)03176-9; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Watanabe F, 2004, BIOCHEM BIOPH RES CO, V319, P596, DOI 10.1016/j.bbrc.2004.05.031; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153	38	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1474	1481		10.1074/jbc.M409934200	http://dx.doi.org/10.1074/jbc.M409934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15507430	hybrid			2022-12-25	WOS:000226195200076
J	Shang, LJL; Dudley, SC				Shang, LJL; Dudley, SC			Tandem promoters and developmentally regulated 5 '- and 3 '-mRNA untranslated regions of the mouse Scn5a cardiac sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; BRUGADA-SYNDROME; GENE-EXPRESSION; MESSENGER-RNA; HUMAN BRAIN; TRANSLATIONAL REGULATION; FUNCTIONAL EXPRESSION; ATRIAL-FIBRILLATION; DOG-MODEL; MUTATION	The SCN5A gene encodes a voltage-sensitive sodium channel expressed in cardiac and skeletal muscle. Coding region mutations cause cardiac sudden death syndromes and conduction system failure. Polymorphisms in the 5'-sequence adjacent to the SCN5A gene have been linked to cardiac arrhythmias. We identified three alternative 5'-splice variants (1A, 1B, and 1C) of the untranslated exon 1 and two 3'-variants in the murine Scn5a mRNA. Two of the exon 1 isoforms ( 1B and 1C) were novel when compared with the published human and rat SCN5A sequences. Quantitative real time PCR results showed that the abundance of the isoforms varied during cardiac development. The 1A, 1B, and 1C mRNA splice variants increased 7.8 +/- 1.7-fold (E1A), 6.0 +/- 1.0-fold (E1B), and 20.6 +/- 3.7-fold (E1C) from fetal to adult heart, respectively. Promoter deletion and luciferase reporter gene analysis using cardiac and skeletal muscle cell lines demonstrated a pattern of distinct cardiac-specific enhancer elements associated with exons 1A and 1C. In the case of exon 1C, the enhancer element appeared to be within the exon. A 5'-repressor preceded each cardiac enhancer element. We concluded that the murine Na+ channel has both 5'- and 3'-untranslated region mRNA variants that are developmentally regulated and that the promoter region contains two distinct cardiac-specific enhancer regions. The presence of homologous human splicing suggests that that these regions may be fruitful new areas of study in understanding cardiac sodium channel regulation and the genetic susceptibility to sudden death.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Decatur, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Dudley, SC (corresponding author), Emory Univ, VAMC, Div Cardiol, 1670 Clairmont Rd 111B, Decatur, GA 30033 USA.	sdudley@emory.edu	Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021	Dudley, Samuel/0000-0001-5843-5961	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 2002, CIRC RES, V91, P1114, DOI 10.1161/01.RES.0000046046.53721.90; Baroudi G, 1999, CIRCULATION, V100, P278; Baroudi G, 2000, FEBS LETT, V467, P12, DOI 10.1016/S0014-5793(00)01099-1; Baroudi G, 2002, CIRC RES, V90, pE11, DOI 10.1161/hh0102.102977; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bezzina CR, 2001, CARDIOVASC RES, V49, P257, DOI 10.1016/S0008-6363(00)00272-8; Bremner HR, 2002, AM J PHYSIOL-LUNG C, V282, pL124, DOI 10.1152/ajplung.2002.282.1.L124; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Donahue LM, 2000, BRAIN RES, V887, P335, DOI 10.1016/S0006-8993(00)03033-X; Gaspo R, 1997, CIRC RES, V81, P1045; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Gollob MH, 2002, CURR OPIN CARDIOL, V17, P229, DOI 10.1097/00001573-200205000-00004; Hake LE, 1997, BBA-REV CANCER, V1332, pM31, DOI 10.1016/S0304-419X(96)00039-X; Herfst LJ, 2004, J MOL CELL CARDIOL, V36, P185, DOI 10.1016/j.yjmcc.2003.11.014; Herfst LJ, 2003, J MOL CELL CARDIOL, V35, P549, DOI 10.1016/S0022-2828(03)00078-6; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kang JX, 1997, P NATL ACAD SCI USA, V94, P2724, DOI 10.1073/pnas.94.6.2724; Lu CM, 1998, J MOL NEUROSCI, V11, P179, DOI 10.1385/JMN:11:3:179; Ou Y, 2002, NEUROGASTROENT MOTIL, V14, P477, DOI 10.1046/j.1365-2982.2002.00348.x; Probst V, 2000, CIRCULATION, V102, P281; Schade SD, 2000, MOL BRAIN RES, V81, P187, DOI 10.1016/S0169-328X(00)00145-5; Shang LJ, 2004, BIOPHYS J, V86, p424A; SHENG ZH, 1994, DNA CELL BIOL, V13, P9, DOI 10.1089/dna.1994.13.9; Stennard FA, 2003, DEV BIOL, V262, P206, DOI 10.1016/S0012-1606(03)00385-3; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Watson J, 2000, J MED GENET, V37, pS82; Yang P, 2004, CARDIOVASC RES, V61, P56, DOI 10.1016/j.cardiores.2003.09.030; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; Yue LX, 1999, CIRC RES, V84, P776; Zhang H, 1999, GENE EXPRESSION, V8, P85; Zogopoulos G, 1999, J MOL ENDOCRINOL, V23, P67, DOI 10.1677/jme.0.0230067	33	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					933	940		10.1074/jbc.M409977200	http://dx.doi.org/10.1074/jbc.M409977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15485820	hybrid			2022-12-25	WOS:000226195200012
J	van Lith, M; Hartigan, N; Hatch, J; Benham, AM				van Lith, M; Hartigan, N; Hatch, J; Benham, AM			PDILT, a divergent testis-specific protein disulfide isomerase with a non-classical SXXC motif that engages in disulfide-dependent interactions in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; FOLDING CATALYST; QUALITY-CONTROL; REDOX STATE; FAMILY; DOMAINS; BONDS; YEAST	Protein disulfide isomerase (PDI) is the archetypal enzyme involved in the formation and reshuffling of disulfide bonds in the endoplasmic reticulum (ER). PDI achieves its redox function through two highly conserved thioredoxin domains, and PDI can also operate as an ER chaperone. The substrate specificities and the exact functions of most other PDI family proteins remain important unsolved questions in biology. Here, we characterize a new and striking member of the PDI family, which we have named protein disulfide isomerase-like protein of the testis (PDILT). PDILT is the first eukaryotic SXXC protein to be characterized in the ER. Our experiments have unveiled a novel, glycosylated PDI-like protein whose tissue-specific expression and unusual motifs have implications for the evolution, catalytic function, and substrate selection of thioredoxin family proteins. We show that PDILT is an ER resident glycoprotein that liaises with partner proteins in disulfide-dependent complexes within the testis. PDILT interacts with the oxidoreductase Ero1alpha, demonstrating that the N-terminal cysteine of the CXXC sequence is not required for binding of PDI family proteins to ER oxidoreductases. The expression of PDILT, in addition to PDI in the testis, suggests that PDILT performs a specialized chaperone function in testicular cells. PDILT is an unusual PDI relative that highlights the adaptability of chaperone and redox function in enzymes of the endoplasmic reticulum.	Univ Durham, Dept Biol Sci, Durham DH1 3LE, England	Durham University	Benham, AM (corresponding author), Univ Durham, Dept Biol Sci, South Rd, Durham DH1 3LE, England.	Adam.benham@durham.ac.uk	Benham, Adam/AAC-6606-2019	Van Lith, Marcel/0000-0003-0225-5501; Benham, Adam/0000-0002-0919-7431				Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Clissold PM, 2003, BIOESSAYS, V25, P603, DOI 10.1002/bies.10287; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Haebel PW, 2002, EMBO J, V21, P4774, DOI 10.1093/emboj/cdf489; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; Marcus N, 1996, BBA-GENE STRUCT EXPR, V1309, P253, DOI 10.1016/S0167-4781(96)00133-9; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Miranda-Vizuete A, 2004, ANTIOXID REDOX SIGN, V6, P25, DOI 10.1089/152308604771978327; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Norgaard P, 2001, BIOCHEM J, V358, P269, DOI 10.1042/0264-6021:3580269; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WATANABE D, 1994, J BIOL CHEM, V269, P7744; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200	40	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1376	1383		10.1074/jbc.M408651200	http://dx.doi.org/10.1074/jbc.M408651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15475357	hybrid			2022-12-25	WOS:000226195200064
J	Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA				Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA			Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1	ONCOGENE			English	Article						cell cycle; Id1; breast cancer	CANCER-CELLS; C-MYC; TRANSCRIPTIONAL REPRESSION; G(1) PROGRESSION; GENE-EXPRESSION; ID-1; ESTROGEN; GROWTH; D1; DIFFERENTIATION	The helix-loop-helix protein Id1 has been implicated in regulating mammary epithelial cell proliferation and differentiation but the underlying molecular mechanisms are not well characterized. Under low serum conditions, ectopic expression of Id1, but not Id2, allowed continued proliferation of immortalized mammary epithelial cells and breast cancer cells. Conversely, downregulation of Id1 impaired proliferation. The effects of short interfering RNA (siRNA)-mediated downregulation of Id1 were the same as those following downregulation of c-Myc: decreased expression of cyclins D1 and E, reduced phosphorylation of pRb at Ser780 ( a site targeted by cyclin D1-Cdk4) and reduced cyclin E-Cdk2 activity. Decreased cyclin D1 expression was an early response to Id1 antisense oligonucleotide treatment. Inhibition of c-Myc function by siRNA, antisense oligonucleotides or a dominant repressor resulted in downregulation of Id1, while ectopic expression of c-Myc resulted in rapid induction of Id1, suggesting that Id1 may be downstream of c-Myc. These data indicate that in mammary epithelial cells, Id1 has cell cycle regulatory functions that are similar to those of c-Myc, and suggest that cyclin D1 may be involved in Id1 regulation of cell cycle progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008; Swarbrick, Alexander/E-6107-2010	Caldon, Liz/0000-0003-1392-3472; Swarbrick, Alexander/0000-0002-3051-5676				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carroll JS, 2002, CANCER RES, V62, P3126; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Desprez PY, 2003, J MAMMARY GLAND BIOL, V8, P225, DOI 10.1023/A:1025957025773; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DUBIK D, 1987, CANCER RES, V47, P6517; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guan XY, 1996, CANCER RES, V56, P3446; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARA E, 1994, J BIOL CHEM, V269, P2139; Holmes ML, 1999, MOL CELL BIOL, V19, P4182; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Itahana Y, 2003, CANCER RES, V63, P7098; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Tanner MM, 1996, CANCER RES, V56, P3441; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON PH, 1991, CANCER RES, V51, P3996; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968	51	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					381	389		10.1038/sj.onc.1208188	http://dx.doi.org/10.1038/sj.onc.1208188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15489884				2022-12-25	WOS:000226279700009
J	Hong, SS; Wiley, JW				Hong, SS; Wiley, JW			Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PRIMARY AFFERENT NEURONS; ACTIVATED ION-CHANNEL; CAPSAICIN-RECEPTOR; DORSAL-ROOT; DIRECT PHOSPHORYLATION; NOCICEPTIVE NEURONS; MODEL SYSTEM; CGRP RELEASE; MICE LACKING	Diabetes mellitus is associated with one or more kinds of stimulus-evoked pain including hyperalgesia and allodynia. The mechanisms underlying painful diabetic neuropathy remain poorly understood. Previous studies demonstrate an important role of vanilloid receptor 1 (VR1) in inflammation and injury-induced pain. Here we investigated the function and expression of VR1 in dorsal root ganglion (DRG) neurons isolated from streptozotocin-induced diabetic rats between 4 and 8 weeks after onset of diabetes. DRG neurons from diabetic rats showed significant increases in capsaicin- and proton-activated inward currents. These evoked currents were completely blocked by the capsaicin antagonist capsazepine. Capsaicin-induced desensitization of VR1 was down-regulated, whereas VR1 re-sensitization was up-regulated in DRG neurons from diabetic rats. The protein kinase C (PKC) activator phorbol 12-myristate 13-acetate blunted VR1 desensitization, and this effect was reversible in the presence of the PKC inhibitor bisindolylmaleimide I. Compared with the controls, VR1 protein was decreased in DRG whole-cell homogenates from diabetic rats, but increased levels of VR1 protein were observed on plasma membranes. Of interest, the tetrameric form of VR1 increased significantly in DRGs from diabetic rats. Increased phosphorylation levels of VR1 were also observed in DRG neurons from diabetic rats. Colocalization studies demonstrated that VR1 expression was increased in large myelinated A-fiber DRG neurons, whereas it was decreased in small unmyelinated C-fiber neurons as a result of diabetes. These results suggest that painful diabetic neuropathy is associated with altered cell-specific expression of the VR1 receptor that is coupled to increased function through PKC-mediated phosphorylation, oligomerization, and targeted expression on the cell surface membrane.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Hong, SS (corresponding author), Univ Michigan, Dept Internal Med, MSRB 2,Rm 2562,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	hongss@med.umich.edu			NIDDK NIH HHS [DK56997, R01 DK52387] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056997, R01DK052387] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Anjaneyulu M, 2003, PROG NEURO-PSYCHOPH, V27, P1001, DOI 10.1016/S0278-5846(03)00160-X; Baba H, 1999, J NEUROSCI, V19, P859; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 2003, PAIN, V105, P5, DOI 10.1016/S0304-3959(03)00259-8; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chen X, 2001, NEUROSCIENCE, V102, P185, DOI 10.1016/S0306-4522(00)00454-1; Crandall M, 2002, PAIN, V98, P109, DOI 10.1016/S0304-3959(02)00034-9; Davis J, 2000, EUR J NEUROSCI, V12, P171; Flores CM, 2001, EUR J NEUROSCI, V14, P1113, DOI 10.1046/j.0953-816x.2001.01736.x; FUNAKOSHI I, 1976, J BIOCHEM-TOKYO, V80, P1185, DOI 10.1093/oxfordjournals.jbchem.a131388; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Hall KE, 2001, J NEUROPHYSIOL, V86, P760, DOI 10.1152/jn.2001.86.2.760; Hong SS, 2004, J BIOL CHEM, V279, P29341, DOI 10.1074/jbc.M404167200; Hudson LJ, 2001, EUR J NEUROSCI, V13, P2105, DOI 10.1046/j.0953-816x.2001.01591.x; Hui SW, 1996, BIOPHYS J, V71, P1123, DOI 10.1016/S0006-3495(96)79314-1; Ichikawa H, 2002, BRAIN RES, V958, P459, DOI 10.1016/S0006-8993(02)03701-0; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung J, 1999, J NEUROSCI, V19, P529; Jung JY, 2004, J BIOL CHEM, V279, P7048, DOI 10.1074/jbc.M311448200; Kamei J, 2001, EUR J PHARMACOL, V422, P83, DOI 10.1016/S0014-2999(01)01059-7; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Khan GM, 2002, NEUROSCIENCE, V114, P291, DOI 10.1016/S0306-4522(02)00372-X; Kilo S, 1997, PAIN, V73, P201, DOI 10.1016/S0304-3959(97)00108-5; Lawson SN, 2002, EXP PHYSIOL, V87, P239, DOI 10.1113/eph8702350; Lewinter RD, 2004, J COMP NEUROL, V470, P400, DOI 10.1002/cne.20024; Ma QP, 2002, NEUROSCI LETT, V319, P87, DOI 10.1016/S0304-3940(01)02537-X; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; Marchettini P, 2004, EUR J NEUROL, V11, P12, DOI 10.1111/j.1471-0552.2004.00795.x; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Obreja O, 2002, FASEB J, V16, P1497, DOI 10.1096/fj.02-0101com; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Rashid MDH, 2003, J PHARMACOL EXP THER, V306, P709, DOI 10.1124/jpet.103.050948; Ryu SJ, 2003, J GEN PHYSIOL, V122, P45, DOI 10.1085/jgp.200308847; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Spruce MC, 2003, DIABETIC MED, V20, P88, DOI 10.1046/j.1464-5491.2003.00852.x; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; Szallasi A, 2002, AM J CLIN PATHOL, V118, P110; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497	61	179	197	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					618	627		10.1074/jbc.M408500200	http://dx.doi.org/10.1074/jbc.M408500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513920	hybrid			2022-12-25	WOS:000226025100073
J	Qiu, XB; Goldberg, AL				Qiu, XB; Goldberg, AL			The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; SERINE-PROTEASE; CYTOCHROME-C; IAP PROTEINS; CELL-DEATH; DEGRADATION; SMAC/DIABLO; ACTIVATION; FAMILY; BRUCE	Smac/DIABLO, HtrA2/Omi, and caspase-9 play key roles in the initiation of apoptosis. The inhibitor of apoptosis proteins (IAPs) are believed to bind to the N-terminal IAP binding motifs of the mature (proteolytically processed) forms of Smac, HtrA2, and caspase-9. However, we show here that BRUCE/Apollon, a 528-kDa IAP whose degradation promotes apoptosis, associates with their precursors as well as the mature forms by binding to regions in addition to the IAP binding motif. Through these associations, BRUCE promotes the degradation of Smac and inhibits the activity of caspase-9 but not the effector caspase, caspase-3. In response to apoptotic stimuli, BRUCE is degraded by proteasomes and/or cleaved by caspases and HtrA2 depending on the specific stimulus and the cell type. These results suggest that the ability of BRUCE to antagonize both the precursor and mature forms of Smac and caspase-9 is an important mechanism for the prevention of apoptosis under normal conditions.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Qiu, XB (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	xqiu@hms.harvard.edu; Alfred_Goldberg@hms.harvard.edu		Qiu, Xiao-Bo/0000-0003-2608-9376				Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson DE, 2000, CANCER RES, V60, P1818; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martin SJ, 2004, NAT CELL BIOL, V6, P804, DOI 10.1038/ncb0904-804; Palaga T, 2002, NAT CELL BIOL, V4, pE149, DOI 10.1038/ncb0602-e149; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Qiu XB, 2004, EMBO J, V23, P800, DOI 10.1038/sj.emboj.7600075; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vernooy SY, 2002, CURR BIOL, V12, P1164, DOI 10.1016/S0960-9822(02)00935-1; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	33	66	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					174	182		10.1074/jbc.M411430200	http://dx.doi.org/10.1074/jbc.M411430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507451	hybrid			2022-12-25	WOS:000226025100022
J	Yang, ZB; Vadlamudi, RK; Kumar, R				Yang, ZB; Vadlamudi, RK; Kumar, R			Dynein light chain 1 phosphorylation controls macropinocytosis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; P21-ACTIVATED KINASE PAK1; CONSTITUTIVE MACROPINOCYTOSIS; PROTEIN; ACTIN; CALMODULIN; ACTIVATION; MECHANISMS; ENDOCYTOSIS; LOCOMOTION	Recent studies have identified dynein light chain-1 (DLC1), a component of the dynein motor, as a p21-activated kinase 1 (Pak1)-interacting substrate with binding sites mapped to amino acids 61-89 of DLC1 and phosphorylation site at serine 88. Here we investigated the role of DLC1 phosphorylation by Pak1 upon the process of macropinocytosis. We found that Pak1 associates with dynein motor and that Pak1-DLC1 interaction starts at the initiation of pinosome formation and persists in early and late endosomes. Pak1 phosphorylation of DLC1 on Ser-88 controls vesicle formation and trafficking functions, as Ser-88 substitution for alanine prevents macropinocytosis. A peptide spanning the C-terminal 19-amino acid region of DLC1 efficiently blocked Ser-88 phosphorylation and macropinocytosis. These results suggest that the regulation of DLC1 by Pak1 is a novel mechanism by which a signaling kinase might influence macropinocytosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NCI NIH HHS [CA80066, CA90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080066, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Bretscher MS, 1998, CURR OPIN CELL BIOL, V10, P537, DOI 10.1016/S0955-0674(98)80070-7; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ho A, 2001, CANCER RES, V61, P474; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lian JP, 2001, J IMMUNOL, V166, P2643, DOI 10.4049/jimmunol.166.4.2643; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thompson CRL, 2002, DEVELOPMENT, V129, P4185; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	41	29	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					654	659		10.1074/jbc.M408486200	http://dx.doi.org/10.1074/jbc.M408486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504720	hybrid			2022-12-25	WOS:000226025100077
J	Zhang, QW; Southall, MD; Mezsick, SM; Johnson, C; Murphy, RC; Konger, RL; Travers, JB				Zhang, QW; Southall, MD; Mezsick, SM; Johnson, C; Murphy, RC; Konger, RL; Travers, JB			Epidermal peroxisome proliferator-activated receptor gamma as a target for ultraviolet B radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED ALKYL PHOSPHOLIPIDS; INSULIN-RESISTANCE; RADICAL FORMATION; IN-VITRO; EXPOSURE; LIGHT; SKIN; KERATINOCYTES; MECHANISMS; EXPRESSION	Ultraviolet B radiation ( UVB) is a pro-oxidative stressor with profound effects on skin in part through its ability to stimulate cytokine production. Peroxisome proliferator-activated receptor gamma (PPARgamma) has been shown to regulate inflammatory processes and cytokine release in various cell types. Since the oxidized glycerophospholipid 1-hexadecyl-2-azelaoyl glycerophosphocholine (azPC) has been shown to be a potent PPARgamma agonist, this study was designed to assess whether the PPARgamma system is a target for UVB irradiation and involved in UVB-induced inflammation in epidermal cells. The present studies demonstrated the presence of PPARgamma mRNA and functional protein in human keratinocytes and epithelial cell lines HaCaT, KB, and A431. The treatment of epidermal cells with the PPARgamma-specific agonist ciglitazone or azPC augmented cyclooxygenase-2 expression and enzyme activity induced by phorbol 12-myristate-13-acetate or interleukin-1beta. Lipid extracts from the cell homogenate of UVB-irradiated, but not control, cells contained a PPARgamma-agonistic activity identified by reporter assay, and this activity up-regulated cyclooxygenase-2 expression induced by phorbol 12-myristate-13-acetate. Subjecting purified 1-hexadecyl-2-arachidonoyl-glycerophosphocholine to UVB irradiation generated a PPARgamma-agonistic activity, among which the specific PPARgamma agonist azPC was identified by mass spectrometry. These findings suggested that UVB-generated PPARgamma-agonistic activity was due to the free radical mediated nonenzymatic cleavage of endogenous glycerophosphocholines. Treatment with the specific PPARgamma antagonist GW9662 or expression of a dominant-negative PPARgamma mutant in KB cells inhibited UVB-induced epidermal cell prostaglandin E-2 production. These findings suggested that UVB-generated PPARgamma activity is necessary for the optimal production of epidermal prostaglandins. These studies demonstrated that epithelial cells contain a functional PPARgamma system, and this system is a target for UVB through the production of novel oxidatively modified endogenous phospholipids.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus	Travers, JB (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Herman B Wells Ctr Pediat Res, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.	jtravers@iupui.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Travers, Jeffrey/0000-0001-7232-1039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62996] Funding Source: Medline; NIAMS NIH HHS [AR01993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Nghiem DX, 2002, J INVEST DERMATOL, V119, P600, DOI 10.1046/j.1523-1747.2002.01845.x; NISHI J, 1991, J INVEST DERMATOL, V97, P115, DOI 10.1111/1523-1747.ep12478534; NORINS AL, 1962, J INVEST DERMATOL, V39, P445, DOI 10.1038/jid.1962.137; OGURA R, 1991, J INVEST DERMATOL, V97, P1044, DOI 10.1111/1523-1747.ep12492553; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Schwarz T, 2002, PHOTODERMATOL PHOTO, V18, P141, DOI 10.1034/j.1600-0781.2002.180307.x; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Trautinger F, 2001, CLIN EXP DERMATOL, V26, P573, DOI 10.1046/j.1365-2230.2001.00893.x; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; ULLRICH SE, 1995, PHOTOCHEM PHOTOBIOL, V62, P389, DOI 10.1111/j.1751-1097.1995.tb02359.x; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamamoto T, 1996, BRAIN RES, V739, P104, DOI 10.1016/S0006-8993(96)00817-7; ZIMMERMAN GA, 1995, J NUTR, V125, pS1661	34	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					73	79		10.1074/jbc.M409795200	http://dx.doi.org/10.1074/jbc.M409795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516334	hybrid			2022-12-25	WOS:000226025100010
J	Zhang, ZR; Cui, GY; Liu, XH; Song, BL; Dawson, DC; McCarty, NA				Zhang, ZR; Cui, GY; Liu, XH; Song, BL; Dawson, DC; McCarty, NA			Determination of the functional unit of the cystic fibrosis transmembrane conductance regulator chloride channel - One polypeptide forms one pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; ESCHERICHIA-COLI; MOLECULAR-BASIS; ATP BINDING; CFTR; MEMBRANE; CYSTEINE; DOMAIN; IDENTIFICATION; ARCHITECTURE	The magnitudes and distributions of subconductance states were studied in chloride channels formed by the wild-type cystic fibrosis transmembrane conductance regulator ( CFTR) and in CFTRs bearing amino acid substitutions in transmembrane segment 6. Within an open burst, it was possible to distinguish three distinct conductance states referred to as the full conductance, subconductance 1, and subconductance 2 states. Amino acid substitutions in transmembrane segment 6 altered the duration and probability of occurrence of these subconductance states but did not greatly alter their relative amplitudes. Results from real time measurements indicated that covalent modification of single R334C-CFTR channels by [2-(trimethylammonium) ethyl] methanethiosulfonate resulted in the simultaneous modification of all three conductance levels in what appeared to be a single step, without changing the proportion of time spent in each state. This behavior suggests that at least a portion of the conduction path is common to all three conducting states. The time course for the modification of R334C-CFTR, measured in outside-out macropatches using a rapid perfusion system, was also consistent with a single modification step as if each pore contained only a single copy of the cysteine at position 334. These results are consistent with a model for the CFTR conduction pathway in which a single anion-conducting pore is formed by a single CFTR polypeptide.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA	University System of Georgia; Georgia Institute of Technology; Oregon Health & Science University	McCarty, NA (corresponding author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.	Nael.McCarty@biology.gatech.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045880, R56DK056481, R01DK056481, R56DK045880] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK045880, DK056481] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; Chan KM, 2000, J GEN PHYSIOL, V116, P163, DOI 10.1085/jgp.116.2.163; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; DAWSON DC, 2003, CFTR CHLORIDE CHANNE, P1; Devidas S, 1998, J BIOL CHEM, V273, P29373, DOI 10.1074/jbc.273.45.29373; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; FOX JA, 1987, J MEMBRANE BIOL, V97, P1, DOI 10.1007/BF01869609; Gallet X, 1998, J MOL GRAPH MODEL, V16, P72, DOI 10.1016/S1093-3263(98)00015-1; Gong XD, 2003, J PHYSIOL-LONDON, V549, P387, DOI 10.1113/jphysiol.2002.038232; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; Lansdell KA, 1998, J PHYSIOL-LONDON, V512, P751, DOI 10.1111/j.1469-7793.1998.751bd.x; Laver DR, 1997, PROG BIOPHYS MOL BIO, V67, P99, DOI 10.1016/S0079-6107(97)00008-4; Lin CW, 2000, J GEN PHYSIOL, V116, P535, DOI 10.1085/jgp.116.4.535; Liu XH, 2004, BIOPHYS J, V87, P3826, DOI 10.1529/biophysj.104.050534; Liu XH, 2001, J GEN PHYSIOL, V118, P433, DOI 10.1085/jgp.118.4.433; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, BIOCHEMISTRY-US, V38, P5124, DOI 10.1021/bi982525y; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; McCarty NA, 2001, AM J PHYSIOL-LUNG C, V281, pL852, DOI 10.1152/ajplung.2001.281.4.L852; McCarty NA, 2000, J EXP BIOL, V203, P1947; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramjeesingh M, 2003, BIOCHEM J, V375, P633, DOI 10.1042/BJ20030774; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 2004, J BIOL CHEM, V279, P39051, DOI 10.1074/jbc.M407434200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schillers H, 2004, CELL PHYSIOL BIOCHEM, V14, P1, DOI 10.1159/000076921; Schwalbe RA, 2002, BIOCHEMISTRY-US, V41, P12457, DOI 10.1021/bi026304a; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinreich F, 2001, J BIOL CHEM, V276, P2347, DOI 10.1074/jbc.M005733200; XIE JX, 1995, J BIOL CHEM, V270, P28084; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304; Yue HW, 2000, J BIOL CHEM, V275, P10030, DOI 10.1074/jbc.275.14.10030; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhang ZR, 2002, BIOPHYS J, V82, p240A	49	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					458	468		10.1074/jbc.M409626200	http://dx.doi.org/10.1074/jbc.M409626200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504728	hybrid			2022-12-25	WOS:000226025100055
J	Atwell, S; Adams, JM; Badger, J; Buchanan, MD; Feil, IK; Froning, KJ; Gao, X; Hendle, J; Keegan, K; Leon, BC; Muller-Dieckmann, HJ; Nienaber, VL; Noland, BW; Post, K; Rajashankar, KR; Ramos, A; Russell, M; Burley, SK; Buchanan, SG				Atwell, S; Adams, JM; Badger, J; Buchanan, MD; Feil, IK; Froning, KJ; Gao, X; Hendle, J; Keegan, K; Leon, BC; Muller-Dieckmann, HJ; Nienaber, VL; Noland, BW; Post, K; Rajashankar, KR; Ramos, A; Russell, M; Burley, SK; Buchanan, SG			A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; ACTIVATION LOOP TYROSINES; AFFINITY IGE RECEPTOR; CRYSTAL-STRUCTURE; C-ABL; PROTEIN; DOMAIN; SYK; COMPLEX; PHOSPHORYLATION	Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase required for signaling from immunoreceptors in various hematopoietic cells. Phosphorylation of two tyrosine residues in the activation loop of the Syk kinase catalytic domain is necessary for signaling, a phenomenon typical of tyrosine kinase family members. Syk in vitro enzyme activity, however, does not depend on phosphorylation (activation loop tyrosine --> phenylalanine mutants retain catalytic activity). We have determined the x-ray structure of the unphosphorylated form of the kinase catalytic domain of Syk. The enzyme adopts a conformation of the activation loop typically seen only in activated, phosphorylated tyrosine kinases, explaining why Syk does not require phosphorylation for activation. We also demonstrate that Gleevec (STI-571, Imatinib) inhibits the isolated kinase domains of both unphosphorylated Syk and phosphorylated Abl with comparable potency. Gleevec binds Syk in a novel, compact cis-conformation that differs dramatically from the binding mode observed with unphosphorylated Abl, the more Gleevec-sensitive form of Abl. This finding suggests the existence of two distinct Gleevec binding modes: an extended, trans-conformation characteristic of tight binding to the inactive conformation of a protein kinase and a second compact, cis-conformation characteristic of weaker binding to the active conformation. Finally, the Syk-bound cis-conformation of Gleevec bears a striking resemblance to the rigid structure of the nonspecific, natural product kinase inhibitor staurosporine.	Struct GenomiX Inc, San Diego, CA 92121 USA; DESY, EMBL Hamburg Outstn, D-22603 Hamburg, Germany; Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Memorial Sloan Kettering Cancer Center	Atwell, S (corresponding author), Struct GenomiX Inc, 10505 Roselle St, San Diego, CA 92121 USA.	satwell@stromix.com; sbuchanan@stromix.com		Burley, Stephen K./0000-0002-2487-9713; Post, Kai Wolfram/0000-0003-1002-3989				Badger J, 2002, ACTA CRYSTALLOGR D, V58, P284, DOI 10.1107/S0907444901020133; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Costello PS, 1996, ONCOGENE, V13, P2595; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hofmann WK, 2004, LEUKEMIA LYMPHOMA, V45, P655, DOI 10.1080/10428190310001625755; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jin L, 2004, J BIOL CHEM, V279, P42818, DOI 10.1074/jbc.M407096200; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; UNDERWOOD KW, 2003, STRUCTURE CAMB, V6, P611; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang HY, 1999, J BIOL CHEM, V274, P32159, DOI 10.1074/jbc.274.45.32159; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang J, 1998, J IMMUNOL, V161, P4366; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0; Zimmermann J, 1997, BIOORG MED CHEM LETT, V7, P187, DOI 10.1016/S0960-894X(96)00601-4	38	168	176	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55827	55832		10.1074/jbc.M409792200	http://dx.doi.org/10.1074/jbc.M409792200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507431	hybrid			2022-12-25	WOS:000225960800105
J	Lu, J; Zhao, W; Frost, LS				Lu, J; Zhao, W; Frost, LS			Mutational analysis of TraM correlates oligomerization and DNA binding with autoregulation and conjugative DNA transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; F-SEX FACTOR; ESCHERICHIA-COLI; BACTERIAL CONJUGATION; TRANSFER GENES; IN-VITRO; PLASMID; EXPRESSION; ORIGIN	F plasmid TraM, an autoregulatory homotetramer, is essential for F plasmid bacterial conjugative transfer, one of the major mechanisms for horizontal gene dissemination. TraM cooperatively binds to three sites (sbmA, - B, and - C) near the origin of transfer in the F plasmid. To examine whether or not tetramerization of TraM is required for autoregulation and F conjugation, we used a two-plasmid system to screen for autoregulation-defective traM mutants generated by random PCR mutagenesis. A total of 72 missense mutations in TraM affecting autoregulation were selected, all of which also resulted in a loss of TraM function during F conjugation. Mutational analysis of TraM defined three regions important for F conjugation, including residues 3 - 10 ( region I), 31-53 ( region II), and 80-121 (region III); in addition, residues 3 - 47 were also important for the immunoreactivity of TraM. Biochemical analysis of mutant proteins indicated that region I defined a DNA binding domain that was not involved in tetramerization, whereas regions II and III were important for both tetramerization and efficient DNA binding. Mutations in region III affected the cooperativity of binding of TraM to sbmA, - B, and - C. Our results suggest that tetramerization is important for specific DNA binding, which, in turn, is essential for traM autoregulation and F conjugation. These findings support the hypothesis that TraM functions as a "signaling" factor that triggers DNA transport during F conjugation.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Frost, LS (corresponding author), Univ Alberta, Dept Biol Sci, CW405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	laura.frost@ualberta.ca	Frost, Laura/A-2639-2014	Frost, Laura/0000-0002-8433-8230				ACHTMAN M, 1972, J BACTERIOL, V110, P831, DOI 10.1128/JB.110.3.831-842.1972; CHANDLER M, 1983, J MOL BIOL, V170, P61, DOI 10.1016/S0022-2836(83)80227-7; Csitkovits VC, 2003, J BIOL CHEM, V278, P48696, DOI 10.1074/jbc.M310025200; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; Fekete RA, 2000, J BACTERIOL, V182, P4022, DOI 10.1128/JB.182.14.4022-4027.2000; Fekete RA, 2002, J BIOL CHEM, V277, P16705, DOI 10.1074/jbc.M111682200; FINLAY BB, 1986, J BACTERIOL, V166, P368, DOI 10.1128/jb.166.2.368-374.1986; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; HAGEL L, 1998, CURRENT PROTOCOLS PR; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Ippen-Ihler K., 1993, BACTERIAL CONJUGATIO, P23; Jun L, 2002, PLASMID, V48, P24, DOI 10.1016/S0147-619X(02)00007-0; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; Lu J, 2003, MOL GENET GENOMICS, V269, P227, DOI 10.1007/s00438-003-0826-2; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; Miller DL, 2003, J BIOL CHEM, V278, P10400, DOI 10.1074/jbc.M212502200; MOORE D, 1987, J BACTERIOL, V169, P3994, DOI 10.1128/jb.169.9.3994-4002.1987; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; Penfold SS, 1996, MOL MICROBIOL, V20, P549, DOI 10.1046/j.1365-2958.1996.5361059.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHWAB M, 1993, MOL MICROBIOL, V7, P795, DOI 10.1111/j.1365-2958.1993.tb01170.x; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Verdino P, 1999, J BIOL CHEM, V274, P37421, DOI 10.1074/jbc.274.52.37421; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS NS, 1970, GENET RES, V16, P113, DOI 10.1017/S0016672300002329	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55324	55333		10.1074/jbc.M409352200	http://dx.doi.org/10.1074/jbc.M409352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509578	hybrid			2022-12-25	WOS:000225960800044
J	Shiina, T; Konno, A; Oonuma, T; Kitamura, H; Imaoka, K; Takeda, N; Todokoro, K; Morimatsu, M				Shiina, T; Konno, A; Oonuma, T; Kitamura, H; Imaoka, K; Takeda, N; Todokoro, K; Morimatsu, M			Targeted disruption of MAIL, a nuclear I kappa B protein, leads to severe atopic dermatitis-like disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NC/NGA MICE; SKIN; ALPHA; FIBROBLASTS; ACTIVATION; GAMMA	MAIL (molecule-possessing ankyrin repeats induced by lipopolysaccharide) is a nuclear IkappaB protein that is also termed interleukin-1-inducible nuclear ankyrin repeat protein or inhibitor of nuclear factor kappaB (IkappaB) zeta. In this study, we generated Mail(-/-) mice to investigate the roles of MAIL in whole organisms. Mail(-/-) mice grew normally until 4-8 weeks after birth, when they began to develop lesions in the skin of the periocular region, face, and neck. MAIL mRNA and protein were constitutively expressed in the skin of wild type controls, especially in the keratinocytes. Serum IgE was higher in Mail(-/-) mice than in normal. Histopathological analysis indicated that the Mail(-/-) skin lesions appeared to be atopic dermatitis ( AD) eczema with inflammatory cell infiltration. In addition, markedly elevated expression of some chemokines such as thymus and activation-regulated chemokine was detected in the Mail(-/-) skin lesions, similar to that observed in the skin of patients with AD. In Mail(-/-) mice, MAIL-deficient keratinocytes might be activated to produce chemokines and induce intraepidermal filtration of inflammatory cells, resulting in the onset of the AD-like disease. These findings suggest that MAIL is an essential molecule for homeostatic regulation of skin immunity. The Mail(-/-) mouse is a valuable new animal model for research on AD.	Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; Iwate Univ, Fac Agr, Dept Vet Physiol, Morioka, Iwate 0208550, Japan; Gifu Univ, Dept Vet Med, Fac Appl Biol Sci, Gifu 5011193, Japan; Hokkaido Univ, Lab Anat, Dept Biomed Sci, Grad Sch Vet Med, Sapporo, Hokkaido 0600818, Japan; Gifu Univ, United Grad Sch Vet Sci, Gifu 5011193, Japan; Inst Phys & Chem Res, Immunogenet Lab, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan; Natl Inst Infect Dis, Dept Vet Sci, Tokyo 1628640, Japan; Kumamoto Univ, Dept Morphogenesis, Kumamoto 8600811, Japan; Inst Phys & Chem Res, Cell Fate Signaling Res Unit, Discovery Res Inst, Wako, Saitama 3510198, Japan; Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Iwate University; Gifu University; Hokkaido University; Gifu University; RIKEN; National Institute of Infectious Diseases (NIID); Kumamoto University; RIKEN; Hokkaido University	Morimatsu, M (corresponding author), Hokkaido Univ, Lab Cytol & Histol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.	mmorimat@med.hokudai.ac.jp	Morimatsu, Masami/A-6698-2012	Morimatsu, Masami/0000-0003-0740-0157				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560; BURSTONE MS, 1958, J NATL CANCER I, V21, P523; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Heishi M, 2003, INT ARCH ALLERGY IMM, V132, P355, DOI 10.1159/000074903; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Ito T, 2004, GENE, V342, P137, DOI 10.1016/j.gene.2004.07.032; Kitamura H, 2003, ARCH HISTOL CYTOL, V66, P53, DOI 10.1679/aohc.66.53; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Konno A, 2003, AUTOIMMUNITY, V36, P247, DOI 10.1080/0891693031000141077; KOYAMA Y-I, 1990, Journal of Dermatology (Tokyo), V17, P211; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Noso N, 1996, J IMMUNOL, V156, P1946; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schon MP, 2003, J INVEST DERMATOL, V121, P951, DOI 10.1046/j.1523-1747.2003.12563.x; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Villagomez MT, 2004, BRIT J DERMATOL, V150, P910, DOI 10.1111/j.1365-2133.2004.05937.x; Weih F, 1997, J IMMUNOL, V158, P5211; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200	32	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55493	55498		10.1074/jbc.M409770200	http://dx.doi.org/10.1074/jbc.M409770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491998	hybrid			2022-12-25	WOS:000225960800064
J	Tran, AX; Karbarz, MJ; Wang, XY; Raetz, CRH; McGrath, SC; Cotter, RJ; Trent, MS				Tran, AX; Karbarz, MJ; Wang, XY; Raetz, CRH; McGrath, SC; Cotter, RJ; Trent, MS			Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT SALMONELLA-TYPHIMURIUM; MEMBRANE-BOUND PHOSPHATASES; ESCHERICHIA-COLI; RHIZOBIUM-LEGUMINOSARUM; STRUCTURAL-CHARACTERIZATION; OUTER-MEMBRANE; INNER MEMBRANE; IMMUNOBIOLOGICAL ACTIVITIES; POLYMYXIN RESISTANCE; EXPRESSION CLONING	Pathogenic bacteria modify the lipid A portion of their lipopolysaccharide to help evade the host innate immune response. Modification of the negatively charged phosphate groups of lipid A aids in resistance to cationic antimicrobial peptides targeting the bacterial cell surface. The lipid A of Helicobacter pylori contains a phosphoethanolamine (pEtN) unit directly linked to the 1-position of the disaccharide backbone. This is in contrast to the pEtN units found in other pathogenic Gram-negative bacteria, which are attached to the lipid A phosphate group to form a pyrophosphate linkage. This study describes two enzymes involved in the periplasmic modification of the 1-phosphate group of H. pylori lipid A. By using an in vitro assay system, we demonstrate the presence of lipid A 1-phosphatase activity in membranes of H. pylori. In an attempt to identify genes encoding possible lipid A phosphatases, we cloned four putative orthologs of Escherichia coli pgpB, the phosphatidylglycerol-phosphate phosphatase, from H. pylori 26695. One of these orthologs, Hp0021, is the structural gene for the lipid A 1-phosphatase and is required for removal of the 1-phosphate group from mature lipid A in an in vitro assay system. Heterologous expression of Hp0021 in E. coli resulted in the highly selective removal of the 1-phosphate group from E. coli lipid A, as demonstrated by mass spectrometry. We also identified the structural gene for the H. pylori lipid A pEtN transferase (Hp0022). Mass spectrometric analysis of the lipid A isolated from E. coli expressing Hp0021 and Hp0022 shows the addition of a single pEtN group at the 1-position, confirming that Hp0022 is responsible for the addition of a pEtN unit at the 1-position in H. pylori lipid A. In summary, we demonstrate that modification of the 1-phosphate group of H. pylori lipid A requires two enzymatic steps.	E Tennessee State Univ, James H Quillen Coll Med, Dept Microbiol, Johnson City, TN 37614 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	East Tennessee State University; Duke University; Johns Hopkins University	Trent, MS (corresponding author), Box 70579, Johnson City, TN 37614 USA.	trentms@mail.etsu.edu			NIAID NIH HHS [K22 AI 53645, K22 AI053645] Funding Source: Medline; NIGMS NIH HHS [R37 GM 51796, R37 GM051796, R37 GM051796-08, R01 GM 6440] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI053645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Appelmelk BJ, 2000, GUT, V47, P10, DOI 10.1136/gut.47.1.10; Appelmelk BJ, 1997, TRENDS MICROBIOL, V5, P70, DOI 10.1016/S0966-842X(96)10084-6; Appelmelk BJ, 2000, TRENDS MICROBIOL, V8, P565, DOI 10.1016/S0966-842X(00)01875-8; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hoshino K, 1999, J IMMUNOL, V162, P3749; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JOHNSON AG, 1994, CLIN MICROBIOL REV, V7, P277, DOI 10.1128/CMR.7.3.277-289.1994; JOHNSON AG, 1987, REV INFECT DIS, V9, P512; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mitaku S, 1999, BIOPHYS CHEM, V82, P165, DOI 10.1016/S0301-4622(99)00116-7; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Ogawa T, 2003, FEMS IMMUNOL MED MIC, V36, P1, DOI 10.1016/S0928-8244(03)00093-2; Ogawa T, 1997, VACCINE, V15, P1598, DOI 10.1016/S0264-410X(97)00102-3; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, CELLULAR MOL BIOL, P1035; Schmitt L, 2002, CHEMBIOCHEM, V3, P161, DOI 10.1002/1439-7633(20020301)3:2/3<161::AID-CBIC161>3.0.CO;2-F; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1998, J IMMUNOL, V161, P5464; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Suda Y, 2001, J ENDOTOXIN RES, V7, P95, DOI 10.1179/096805101101532594; Suda Y, 1997, J BIOCHEM-TOKYO, V121, P1129; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; TOMAI MA, 1987, J BIOL RESP MODIF, V6, P99; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2004, BIOCHEM CELL BIOL, V82, P71, DOI 10.1139/o03-070; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	77	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55780	55791		10.1074/jbc.M406480200	http://dx.doi.org/10.1074/jbc.M406480200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489235	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000225960800100
J	Chaisson, ML; Branstetter, DG; Derry, JM; Armstrong, AP; Tometsko, ME; Takeda, K; Akira, S; Dougall, WC				Chaisson, ML; Branstetter, DG; Derry, JM; Armstrong, AP; Tometsko, ME; Takeda, K; Akira, S; Dougall, WC			Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; IKK-ALPHA; LIVER DEGENERATION; RECEPTOR ACTIVATOR; NF-KAPPA-B2 P100; KEY REGULATOR; RANK; LIGAND; GROWTH; OSTEOPETROSIS	Signaling through the receptor activator of nuclear factor kappaB (RANK) is required for both osteoclast differentiation and mammary gland development, yet the extent to which RANK utilizes similar signaling pathways in these tissues remains unclear. Mice expressing a kinase-inactive form of the inhibitor of kappaB kinase alpha(IKKalpha) have mammary gland defects similar to those of RANK-null mice yet have apparently normal osteoclast function. Because mice that completely lack IKKalpha have severe skin and skeletal defects that are not associated with IKKalpha-kinase activity, we wished to directly examine osteoclastogenesis in IKKalpha(-/-) mice. We found that unlike RANK-null mice, which completely lack osteoclasts, IKKalpha(-/-) mice did possess normal numbers of TRAP(+) osteoclasts. However, only 32% of these cells were multinucleated compared with 57% in wild-type littermates. A more profound defect in osteoclastogenesis was observed in vitro using IKKalpha(-/-) hematopoietic cells treated with colony-stimulating factor 1 and RANK ligand ( RANKL), as the cells failed to form large, multinucleated osteoclasts. Additionally, overall RANKL-induced global gene expression was significantly blunted in IKKalpha(-/-) cells, including osteoclast-specific genes such as TRAP, MMP-9, and c-Src. IKKalpha was not required for RANKL-mediated IkappaBalpha degradation or phosphorylation of mitogen-activated protein kinases but was required for RANKL-induced p100 processing. Treatment of IKKalpha(-/-) cells with tumor necrosis factor alpha (TNFalpha) in combination with RANKL led to partial rescue of osteoclastogenesis despite a lack of p100 processing. However, the ability of TNFalpha alone or in combination with transforming growth factor beta to induce osteoclast differentiation was dependent on IKKalpha, suggesting that synergy between RANKL and TNFalpha can overcome p100 processing defects in IKKalpha(-/-) cells.	Amgen Inc, Dept Canc Biol, Seattle, WA 98119 USA; Amgen Inc, Dept Pathol, Seattle, WA 98119 USA; Amgen Inc, Dept Med Sci, Seattle, WA 98119 USA; Kyushu Univ, Fukuoka 8128582, Japan; Osaka Univ, Suita, Osaka 5650871, Japan	Amgen; Amgen; Amgen; Kyushu University; Osaka University	Chaisson, ML (corresponding author), 1201 Amgen Ct W, Seattle, WA 98119 USA.	chaissom@amgen.com	Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009	Takeda, Kiyoshi/0000-0002-1778-6332; Dougall, William/0000-0001-9487-251X				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; DAI S, 2004, J BIOL CHEM; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008; Jimi E, 1999, J IMMUNOL, V163, P434; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Menaa C, 2000, BIOCHEM BIOPH RES CO, V267, P943, DOI 10.1006/bbrc.1999.2042; Nishimura T, 2000, AM J REPROD IMMUNOL, V43, P351, DOI 10.1111/j.8755-8920.2000.430604.x; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Ohazama A, 2004, DEV CELL, V6, P219, DOI 10.1016/S1534-5807(04)00024-3; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; Rudolph D, 2000, GENE DEV, V14, P854; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	39	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54841	54848		10.1074/jbc.M406392200	http://dx.doi.org/10.1074/jbc.M406392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485831	hybrid			2022-12-25	WOS:000225793600113
J	Wower, IK; Zwieb, C; Wower, J				Wower, IK; Zwieb, C; Wower, J			Contributions of pseudoknots and protein SmpB to the structure and function of tmRNA in trans-translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TMRNA; ELONGATION-FACTOR TU; TRANSFER-RNA; 10SA RNA; STALLED RIBOSOME; MESSENGER-RNA; BINDING; SEQUENCE; L27; S1	Bacteria contain transfer-messenger RNA ( tmRNA), a molecule that during trans-translation tags incompletely translated proteins with a small peptide to signal the proteolytic destruction of defective polypeptides. TmRNA is composed of tRNA- and mRNA-like domains connected by several pseudoknots. Using truncated ribosomal protein L27 as a reporter for tagging in vitro and in vivo, we have developed exceptionally sensitive assays to study the role of Escherichia coli tmRNA in trans-translation. Site-directed mutagenesis experiments showed that pseudoknot 2 and the abutting helix 5 were particularly important for the binding of ribosomal protein S1 to tmRNA. Pseudoknot 4 not only facilitated tmRNA maturation but also promoted tagging. In addition, the three pseudoknots (pk2 to pk4) were shown to play a significant role in the proper folding of the tRNA- like domain. Protein SmpB enhanced tmRNA processing, suggesting a new role for SmpB in trans-translation. Taken together, these results provide unanticipated insights into the functions of the pseudoknots and protein SmpB during tmRNA folding, maturation, and protein synthesis.	Auburn Univ, Dept Anim Sci, Auburn, AL 36849 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Biol, Tyler, TX 75708 USA	Auburn University System; Auburn University; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Wower, J (corresponding author), Auburn Univ, Dept Anim Sci, 210 Upchurch Hall, Auburn, AL 36849 USA.	iwower@acesag.auburn.edu			NIGMS NIH HHS [GM58267] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058267] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; Chen GJ, 2000, BIOTECHNIQUES, V28, P498, DOI 10.2144/00283st08; Felden B, 1997, RNA, V3, P89; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Giedroc DP, 2000, J MOL BIOL, V298, P167, DOI 10.1006/jmbi.2000.3668; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hallier M, 2004, J BIOL CHEM, V279, P25978, DOI 10.1074/jbc.M314086200; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; Maguire BA, 2001, J BACTERIOL, V183, P6565, DOI 10.1128/JB.183.22.6565-6572.2001; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; Nameki N, 1999, NUCLEIC ACIDS RES, V27, P3667, DOI 10.1093/nar/27.18.3667; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nameki N, 1999, J MOL BIOL, V286, P733, DOI 10.1006/jmbi.1998.2487; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; Tadaki T, 1996, FEBS LETT, V399, P223, DOI 10.1016/S0014-5793(96)01330-0; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 1996, RNA, V2, P1306; WOWER I, 1992, J BACTERIOL, V174, P1213, DOI 10.1128/jb.174.4.1213-1221.1992; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063; ZWIEB C, 1999, NUCL ACIDS RES S, V41, P200	35	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54202	54209		10.1074/jbc.M410488200	http://dx.doi.org/10.1074/jbc.M410488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494393	hybrid			2022-12-25	WOS:000225793600039
J	Esau, C; Kang, XL; Peralta, E; Hanson, E; Marcusson, EG; Ravichandran, LV; Sun, YQ; Koo, S; Perera, RJ; Jain, R; Dean, NM; Freier, SM; Bennett, CF; Lollo, B; Griffey, R				Esau, C; Kang, XL; Peralta, E; Hanson, E; Marcusson, EG; Ravichandran, LV; Sun, YQ; Koo, S; Perera, RJ; Jain, R; Dean, NM; Freier, SM; Bennett, CF; Lollo, B; Griffey, R			MicroRNA-143 regulates adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; CELL-PROLIFERATION; TARGETS; RNA; DROSOPHILA; IDENTIFICATION; PREDICTION; BIOGENESIS; SEQUENCE; ENCODES	MicroRNAs (miRNAs) are endogenously expressed 20-24 nucleotide RNAs thought to repress protein translation through binding to a target mRNA (1-3). Only a few of the more than 250 predicted human miRNAs have been assigned any biological function. In an effort to uncover miRNAs important during adipocyte differentiation, antisense oligonucleotides (ASOs) targeting 86 human miRNAs were transfected into cultured human pre-adipocytes, and their ability to modulate adipocyte differentiation was evaluated. Expression of 254 miRNAs in differentiating adipocytes was also examined on a miRNA microarray. Here we report that the combination of expression data and functional assay results identified a role for miR-143 in adipocyte differentiation. miR-143 levels increased in differentiating adipocytes, and inhibition of miR-143 effectively inhibited adipocyte differentiation. In addition, protein levels of the proposed miR-143 target ERK5 (4) were higher in ASO-treated adipocytes. These results demonstrate that miR-143 is involved in adipocyte differentiation and may act through target gene ERK5.	ISIS Pharmaceut, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Esau, C (corresponding author), ISIS Pharmaceut, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	cesau@isisph.com		Marcusson, Eric/0000-0002-0504-8674				[Anonymous], 1995, HELV CHIM ACTA, DOI DOI 10.1002/HLCA.19950780219; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boutla A, 2003, NUCLEIC ACIDS RES, V31, P4973, DOI 10.1093/nar/gkg707; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Enright AJ, 2004, GENOME BIOL, V5; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Michael MZ, 2003, MOL CANCER RES, V1, P882; Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003; Nelson P, 2003, TRENDS BIOCHEM SCI, V28, P534, DOI 10.1016/j.tibs.2003.08.005; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rosner B., 2000, FUNDAMENTALS BIOSTAT; SEMPERE LF, 2004, GENOME BIOL; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	30	799	938	3	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52361	52365		10.1074/jbc.C400438200	http://dx.doi.org/10.1074/jbc.C400438200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15504739	hybrid			2022-12-25	WOS:000225493400079
J	Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C				Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C			The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RAR alpha and regulates differentiation of hematopoietic cells	ONCOGENE			English	Article						AML; balanced translocation; myeloid differentiation; MNK1; eIF4E; c-myc	ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA TRANSPORT; P14(ARF) TUMOR-SUPPRESSOR; TRANSLATION INITIATION; CYCLIN D1; MALIGNANT TRANSFORMATION; HISTONE DEACETYLASE	Microarray analyses were performed to identify target genes that are shared by the acute myeloid leukemia (AML) translocation products PML-RARalpha, PLZF-RARalpha and AML1-ETO in inducibly transfected U937 cell lines. The cytoplasmic serine and threonine kinase MNK1 was identified as one of the target genes. At the protein level, MNK1 was significantly induced by each of the three fusion proteins. Protein half-life analyses showed that PML-RARalpha enhanced MNK1 protein stability in U937 cells and ATRA exposure decreased MNK1 half-life in NB4 cells. EIF4E, the main MNK1 substrate, plays a role in the pathogenesis of a variety of cancers. Upon MNK1 overexpression, eIF4E phosphorylation increased as a sign of functional activation. Interestingly, MNK1 protein expression decreased during myeloid differentiation. Inhibition of MNK1 activity by a specific inhibitor (CGP57380) enhanced differentiation of HL60 and 32D cells, further suggesting a role for MNK1 in the myeloid differentiation. In addition, kinase dead mutants of MNK1 significantly impaired proliferation of 32D cells. Immunohistochemistry of primary AML bone marrow biopsies showed strong cytoplasmic MNK1 expression in 25 of 99 AML specimens (25%). MNK1 expression was associated with high levels of c-myc expression. Taken together, we identified MNK1 as a target gene of several leukemogenic fusion proteins in AML. MNK1 plays a role in myeloid differentiation. These data suggest a role for MNK1 in the AML fusion protein-associated differentiation block.	Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-4400 Munster, Germany; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Munster; University of Munster; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Serve, H (corresponding author), Univ Munster, Dept Med Hematol & Oncol, Domagkstr 3, D-48129 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018	Müller-Tidow, Carsten/0000-0002-7166-5232; Mlody, Barbara/0000-0001-5184-1772				Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Ferrara FF, 2001, CANCER RES, V61, P2; Flynn A, 1996, CANCER SURV, V27, P293; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2004, LEUKEMIA, V18, P720, DOI 10.1038/sj.leu.2403296; Muller-Tidow C, 2004, CLIN CANCER RES, V10, P1241, DOI 10.1158/1078-0432.CCR-0954-03; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nathan CAO, 2000, CANCER RES, V60, P3599; Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	44	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9162	9172		10.1038/sj.onc.1208164	http://dx.doi.org/10.1038/sj.onc.1208164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516979				2022-12-25	WOS:000225638000001
J	Dorovkov, MV; Ryazanov, AG				Dorovkov, MV; Ryazanov, AG			Phosphorylation of annexin I by TRPM7 channel-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-2 KINASE; HEAVY-CHAIN KINASE; PROTEIN-KINASE; ION-CHANNEL; CATALYTIC DOMAIN; TERMINAL DOMAIN; ALPHA-KINASES; BINDING; RECEPTOR; IDENTIFICATION	TRPM7 is an unusual bifunctional molecule consisting of a TRP ion channel fused to a protein kinase domain. It has been shown that TRPM7 plays a key role in the regulation of intracellular magnesium homeostasis as well as in anoxic neuronal death. TRPM7 channel has been characterized using electrophysiological techniques; however, the function of the kinase domain is not known and endogenous substrates for the kinase have not been reported previously. Here we have identified annexin 1 as a substrate for TRPM7 kinase. Phosphorylation of annexin 1 by TRPM7 kinase is stimulated by Ca2+ and is dramatically increased in extracts from cells overexpressing TRPM7. Phosphorylation of annexin 1 by TRPM7 kinase occurs at a conserved serine residue (Ser(5)) located within the N-terminal amphipathic alpha-helix of annexin 1. The N-terminal region plays a crucial role in interaction of annexin 1 with other proteins and membranes, and therefore, phosphorylation of annexin 1 at Ser(5) by TRPM7 kinase may modulate function of annexin 1.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Ryazanov, AG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	ryazanag@umdnj.edu	ryazanov, alexey/J-8081-2017		NATIONAL CANCER INSTITUTE [R01CA081102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057300] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81102] Funding Source: Medline; NIGMS NIH HHS [R01 GM57300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dempsey AC, 2003, STRUCTURE, V11, P887, DOI 10.1016/S0969-2126(03)00126-6; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rosengarth A, 2003, J MOL BIOL, V326, P1317, DOI 10.1016/S0022-2836(03)00027-5; Rosengarth A, 2001, J MOL BIOL, V306, P489, DOI 10.1006/jmbi.2000.4423; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Ryazanova L. V., 2001, Molekulyarnaya Biologiya (Moscow), V35, P321; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; WANG W, 1994, BIOCHEMISTRY-US, V33, P275, DOI 10.1021/bi00167a036; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Yoon MK, 2000, FEBS LETT, V484, P241, DOI 10.1016/S0014-5793(00)02160-8	37	159	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50643	50646		10.1074/jbc.C400441200	http://dx.doi.org/10.1074/jbc.C400441200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485879	hybrid			2022-12-25	WOS:000225355800002
J	McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J				McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J			Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones	ONCOGENE			English	Article						TGCT; microarray CGH; regions of imbalance	DIFFERENTIAL EXPRESSION; BREAST-CANCER; HYBRIDIZATION; GENES; KIT; MUTATIONS; PROTEIN; TESTIS; DNA; IDENTIFICATION	Identifying changes in DNA copy number can pinpoint genes that may be involved in tumor development. Here we have defined the smallest overlapping regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has been previously investigated. Definition of the regions was achieved through comparative genomic hybridization (CGH) analysis of a 4559 cDNA clone microarray. A total of 14 SORI were identified, which involved at least five of the 11 samples analysed. Many of these refined regions were previously reported using chromosomal or allelic imbalance studies. The SORI included gain of material from the regions 4q12, 17q21.3, 22q11.23 and Xq22, and loss from 5q33, 11q12.1, 16q22.3 and 22q11. Comparison with parallel chromosomal CGH data supported involvement of most regions. The various SORI span between one and 20 genes and highlight potential oncogenes/tumor suppressor genes to be investigated further (Supplementary material is available at http://www.crukdmf.icr.ac.uk/array/array.html).	Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, Sutton SM2 5NG, Surrey, England; Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Royal Marsden NHS Foundation Trust	Shipley, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	janet.shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; huddart, robert/0000-0003-3604-1990; McIntyre, Alan/0000-0002-4791-7292; Zafarana, Gaetano/0000-0003-1391-4488; Shipley, Janet/0000-0001-6748-8678				Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Chen JZ, 2002, BIOCHEM BIOPH RES CO, V294, P161, DOI 10.1016/S0006-291X(02)00446-1; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Lu YJ, 1999, LUNG CANCER-J IASLC, V23, P61, DOI 10.1016/S0169-5002(98)00093-2; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, CANCER-AM CANCER SOC, V32, P1186, DOI 10.1002/1097-0142(197311)32:5<1186::AID-CNCR2820320527>3.0.CO;2-8; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rapley EA, 2004, BRIT J CANCER, V90, P2397, DOI 10.1038/sj.bjc.6601880; Rapley EA, 2003, APMIS, V111, P128, DOI 10.1034/j.1600-0463.2003.11101171.x; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; SAMBROOK J, 2001, MOL CLONING LA MANUA, V3; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Skotheim RI, 2002, CANCER RES, V62, P2359; Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; WATSON JV, 1986, BRIT J CANCER, V53, P331, DOI 10.1038/bjc.1986.56; Zafarana G, 2003, ONCOGENE, V22, P7695, DOI 10.1038/sj.onc.1207011	36	35	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9142	9147		10.1038/sj.onc.1208115	http://dx.doi.org/10.1038/sj.onc.1208115			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489896				2022-12-25	WOS:000225492800016
J	Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G				Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G			The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression	ONCOGENE			English	Article						Fhit; lung cancer; apoptosis control	HISTIDINE TRIAD GENE; TUMOR-DEVELOPMENT; DEATH DOMAIN; EXPRESSION; LESIONS; TUMORIGENICITY; MITOCHONDRIA; TRANSDUCTION; CHEMOTHERAPY; INHIBITION	The expression of the tumour suppressor protein fragile histidine triad (Fhit) is often impaired in many human cancers and its restoration in Fhit-negative cancer cell lines suppresses tumorigenicity and induces apoptosis. Although the proapoptotic function of Fhit is well documented, little is known about its precise mechanism of action and further studies are needed in order to elucidate the putative therapeutic properties of this protein. To this end, we have engineered the lung cancer cell line NCI-H460 in order to express different molecules involved in the control of apoptotic pathways. Infection of these cells with an adenoviral vector transducing the Fhit gene (Ad-Fhit) revealed that complete protection from apoptosis was conferred by the inhibitor of caspases Cytokine response modifier A (CrmA) and by a dominant-negative form of the adapter protein Fas-associated death domain (FADD) and partial protection by a dominant-negative form of caspase-8, while cells over expressing mitochondrial mediators of the apoptotic response such as Bcl-2 or Bcl-x(L) that are resistant to treatment with cisplatin, remained highly susceptible to cell death triggered by Fhit gene transfer. In line to what was observed in H460 cells, Ad-Fhit efficacy was not affected by Bcl-2 overexpression also in two other lung cancer cell lines (A549 and Calu-1). Analysis of cytochrome c release also confirmed that in Bcl-2- or Bel-x(L)-expressing cells apoptosis could be detected by terminal deoxynucleotidyltransferase mediated dUTP nick-end labelling (TUNEL) assay before any evidence of mitochondrial membrane perturbation. In conclusion, our analysis indicates that the Fhit protein exerts its oncosuppressor activity through induction of an apoptotic mechanism that seems to be FADD dependent, caspase-8 mediated and independent from mitochondrial amplification.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Fondazione IRCCS Istituto Nazionale Tumori Milan; Vrije Universiteit Amsterdam	Roz, L (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	luca.roz@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Ferreira, Carlos Gil/AAD-4104-2020; Giaccone, Giuseppe/E-8297-2017; Roz, Luca/AAB-3889-2019; Andriani, Francesca/D-4898-2017; Ferreira, Carlos Gil/G-4957-2013	sozzi, gabriella/0000-0001-9360-6914; Ferreira, Carlos Gil/0000-0002-7228-7018; Giaccone, Giuseppe/0000-0002-5023-7562; Roz, Luca/0000-0001-5817-7149; Andriani, Francesca/0000-0002-6178-7789; 				Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Broker LE, 2002, CANCER RES, V62, P4081; CAVAZZONI A, 2004, ONCOGENE        0913; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ferreira CG, 2000, CANCER RES, V60, P7133; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huisman C, 2002, CLIN CANCER RES, V8, P596; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mori M, 2000, CANCER RES, V60, P1177; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sozzi G, 1998, CANCER RES, V58, P5032; van Heerden WFP, 1999, J ORAL PATHOL MED, V28, P433; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9102	9110		10.1038/sj.onc.1208142	http://dx.doi.org/10.1038/sj.onc.1208142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489891				2022-12-25	WOS:000225492800011
J	Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X				Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X			The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization	ONCOGENE			English	Article						p53; iASPP; apoptosis	P53 TUMOR-SUPPRESSOR; APOPTOTIC FUNCTION; DNA-DAMAGE; INHIBITOR; PROTEINS; ANKYRIN; FAMILY; 53BP2; CELLS; DIE	ASPP1 and ASPP2 are both proteins that interact with p53 and enhance its ability to induce apoptosis by selectively elevating the expression of proapoptotic p53-responsive genes. iASPP(RAI) is a third member of the family that is the most conserved inhibitor of p53-mediated apoptosis. Here, we have described iASPP, a longer form of iASPP(RAI), which at 828 amino acids is more than twice the size of iASPP(RAI). Using two antibodies that recognize both iASPP and iASPP(RAI), we report that this longer form of iASPP is the predominant form of the molecule expressed in cells. Like iASPP(RAI), iASPP also binds to p53 and inhibits apoptosis induced by p53 overexpression. However, whereas iASPP(RAI) is predominantly nuclear, the N-terminus of iASPP is entirely cytoplasmic, and the longer iASPP is located in both the cytoplasm and the nucleus. The effect upon subcellular localization of the longer N-terminus of iASPP means that this new, longer form of the molecule may be subject to greater regulation and provides another layer in the control of p53-induced apoptosis.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China	Imperial College London; Ludwig Institute for Cancer Research; Air Force Military Medical University	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	x.lu@imperial.ac.uk	, Susana/AAA-9282-2019	Royer, Christophe/0000-0002-9882-7676; Bergamaschi, Daniele/0000-0002-3955-1091; Llanos, Susana/0000-0002-8555-9326; Gillotin, Sebastien/0000-0002-4129-4936; Lu, Xin/0000-0002-6587-1152				Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yap DBS, 2000, J BIOL CHEM, V275, P37296, DOI 10.1074/jbc.M004359200	18	52	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9007	9016		10.1038/sj.onc.1208088	http://dx.doi.org/10.1038/sj.onc.1208088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489900				2022-12-25	WOS:000225492800001
J	Luttrell, DK; Luttrell, LM				Luttrell, DK; Luttrell, LM			Not so strange bedfellows: G-protein-coupled receptors and Src family kinases	ONCOGENE			English	Review						G-protein-coupled receptor; focal adhesion kinase; epidermal growth factor; mitogen-activated protein kinase; receptor crosstalk	GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; DEPENDENT TYROSINE KINASE; C-SRC; EGF RECEPTOR; ANGIOTENSIN-II; MAP KINASE; BETA-ARRESTIN; LYSOPHOSPHATIDIC ACID	Src family nonreceptor tyrosine kinases are an integral component of the signal transduction apparatus employed by growth factor receptor tyrosine kinases. As such, their role in cellular growth control and malignant transformation has been the subject of intensive investigation. In contrast, classical G-protein-coupled receptor ( GPCR) signaling involves activation of second messenger-regulated serine/threonine kinases or ion channels, and is primarily involved in neurotransmission and the short-term regulation of intermediary metabolism. Over the past decade, this strictly dichotomous model of transmembrane signaling has been challenged by the discovery that GPCRs also exert control over cellular growth, proliferation, and differentiation, and do so by stimulating tyrosine phosphorylation cascades. Several mechanisms, from the direct association of Src family kinases with GPCRs or receptor-associated proteins, to the transactivation of receptor tyrosine kinases and focal adhesion complexes by G-protein-mediated signals, permit GPCRs to activate Src family kinases. Conversely, Src activity plays a central role in controlling GPCR trafficking and effects on cell proliferation and cytoskeletal rearrangement. It is now clear that GPCRs and Src family kinases do not belong to separate, exclusive clubs. Rather, these strange bedfellows are intimately involved in multilayered forms of crosstalk that influence a host of cellular processes.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, R56DK055524, R01DK058283, R01DK064353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64353, DK55524, DK58283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gschwind A, 2002, CANCER RES, V62, P6329; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; LUTTRELL DK, 1992, CELL SIGNAL, V4, P531, DOI 10.1016/0898-6568(92)90022-Z; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	103	170	174	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7969	7978		10.1038/sj.onc.1208162	http://dx.doi.org/10.1038/sj.onc.1208162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489914				2022-12-25	WOS:000224558300007
J	Dransart, E; Morin, A; Cherfils, J; Olofsson, B				Dransart, E; Morin, A; Cherfils, J; Olofsson, B			Uncoupling of inhibitory and shuttling functions of Rho GDP dissociation inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; SELECTIVE ACTIVATION; STRUCTURAL BASIS; CELL-ADHESION; GTPASES; COMPLEX; CDC42; RAC; PHOSPHORYLATION; DOMAIN	Rho GDP dissociation inhibitors (rhoGDIs) are postulated to regulate the activity of small G proteins of the Rho family by a shuttling process involving the extraction of Rho from donor membranes, the formation of the inhibitory cytosolic Rho/rhoGDI complexes, and delivery of Rho to target membranes. However, the role of rhoGDIs in site-specific membrane targeting or extraction of Rho is still poorly understood. Here we investigated the molecular functions of two rhoGDIs, the specific rhoGDI-3 and the less specific but well studied rhoGDI-l, in HeLa cells using structure-based mutagenesis of the rhoGDI protein. We identified two sites in rhoGDI, which form conserved interactions with their Rho target, whose mutation results in the uncoupling of inhibitory and shuttling functions of rhoGDIs: D66(GDI-3) (equivalent to D45(GDI-1)), a conserved residue in the helix-loop-helix(GDI)/switch 1(Rho) interface, and D206(GDI-3) (equivalent to D185(GDI-1)) in the beta-sandwich(GDI)/switch 2(Rho) interface. Mutations of both sites result in the loss of rhoGDI-3 or rhoGDI-1 inhibitory activity but not of their ability to form cytosolic complexes with RhoG or Cdc42 in vivo. Remarkably, the mutants were detected at Rho-induced membrane ruffles or protrusions where they co-localized with RhoG or Cdc42, likely identifying for the first time the site of extraction of a Rho protein by a rhoGDI in vivo. We propose that these mutations act by modifying the steady-state kinetics of the shuttling process regulated by rhoGDIs, such that transient steps at the cell membranes now become detectable. They should provide valuable tools for future investigations of the dynamics of membrane extraction or delivery of Rho proteins and their regulation by cellular partners.	CNRS, UPR 9063, LEBS, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Olofsson, B (corresponding author), CNRS, UPR 9063, LEBS, Bat 34,Ave Terrasse, F-91198 Gif Sur Yvette, France.	olofsson@lebs.cnrs-gif.fr						Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Biou V, 2004, BIOCHEMISTRY-US, V43, P6833, DOI 10.1021/bi049630u; Blangy A, 2000, J CELL SCI, V113, P729; Boquet P, 2003, TRENDS CELL BIOL, V13, P238, DOI 10.1016/S0962-8924(03)00037-0; Brunet N, 2002, TRAFFIC, V3, P342, DOI 10.1034/j.1600-0854.2002.30504.x; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gandhi PN, 2004, BIOCHEM J, V378, P409, DOI 10.1042/BJ20030979; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gibson RM, 2001, BIOCHEM J, V359, P285, DOI 10.1042/0264-6021:3590285; Golovanov AP, 2001, J MOL BIOL, V305, P121, DOI 10.1006/jmbi.2000.4262; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Ikeda W, 2001, ONCOGENE, V20, P3457, DOI 10.1038/sj.onc.1204463; Jiang WG, 2003, CLIN CANCER RES, V9, P6432; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Morin A, 1996, MOL CELL ENDOCRINOL, V117, P59, DOI 10.1016/0303-7207(95)03730-6; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; Richman TJ, 2004, CURR GENET, V45, P339, DOI 10.1007/s00294-004-0505-9; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	49	25	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4674	4683		10.1074/jbc.M409741200	http://dx.doi.org/10.1074/jbc.M409741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15513926	hybrid			2022-12-25	WOS:000227096600083
J	Graceffa, P; Mazurkie, A				Graceffa, P; Mazurkie, A			Effect of caldesmon on the position and myosin-induced movement of smooth muscle tropomyosin bound to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; BRIDGES PREDICTS REGULATION; LIGHT-CHAIN KINASE; THIN-FILAMENTS; SKELETAL-MUSCLE; HEAVY-MEROMYOSIN; CROSS-BRIDGES; 3-DIMENSIONAL RECONSTRUCTION; COOPERATIVE ATTACHMENT; NH2-TERMINAL DOMAINS	It is known that the actin-binding protein caldesmon inhibits actomyosin ATPase activity and might in this way take part in the thin filament regulation of smooth muscle contraction. Although the molecular mechanism of this inhibition is unknown, it is clear that the presence of actin-bound tropomyosin is necessary for full inhibition. Recent evidence also suggests that the myosin-induced movement of tropomyosin plays a key role in regulation. In this work, fluorescence studies provide evidence to show that caldesmon interacts with and alters the position of tropomyosin in a reconstituted actin thin filament and thereby limits the ability of myosin heads to move tropomyosin. Caldesmon interacts with the Cys-190 region in the COOH-terminal half of tropomyosin, resulting in the movement of this part of tropomyosin to a new position on actin. Additionally, this constrains the myosin-induced movement of this region of tropomyosin. On the other hand, caldesmon does not appear to interact with the Cys-36 region in the NH2-terminal half of tropomyosin and neither alters the position of nor significantly constrains the myosin-induced movement of this part of tropomyosin. The ability of caldesmon to limit the myosin-induced movement of tropomyosin provides a possible molecular basis for the inhibitory function of caldesmon. The different movements of the two halves of tropomyosin indicate that actin-bound tropomyosin moves as a flexible molecule and not as a rigid rod. Interestingly, caldesmon, which inhibits tropomyosin's potentiation of actomyosin ATPase activity, moves tropomyosin in one direction, whereas myosin heads, which enhance potentiation, move tropomyosin in the opposite direction.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Graceffa, P (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	graceffa@bbri.org			NHLBI NIH HHS [HL66219] Funding Source: Medline; NIAMS NIH HHS [AR41637] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bacchiocchi C, 2004, BIOPHYS J, V86, P2295, DOI 10.1016/S0006-3495(04)74287-3; Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; Censullo R, 1992, J Fluoresc, V2, P141, DOI 10.1007/BF00866929; CHACKO S, 1990, J BIOL CHEM, V265, P2105; Chalovich J. M., 1997, CELLULAR ASPECTS SMO, P253; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; Chalovich JM, 1998, ACTA PHYSIOL SCAND, V164, P427; CHEN RF, 1965, SCIENCE, V147, P729, DOI 10.1126/science.147.3659.729; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; Dillon PF, 2004, AM J PHYSIOL-CELL PH, V287, pC590, DOI 10.1152/ajpcell.00264.2004; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; Fredricksen S, 2003, BIOCHEMISTRY-US, V42, P6136, DOI 10.1021/bi0274017; FUGLSANG A, 1993, J MUSCLE RES CELL M, V14, P666, DOI 10.1007/BF00141563; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; Gordon AM, 2001, NEWS PHYSIOL SCI, V16, P49; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Graceffa P, 1999, BIOCHEMISTRY-US, V38, P11984, DOI 10.1021/bi9825495; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; Graceffa P, 1997, BIOCHEMISTRY-US, V36, P3792, DOI 10.1021/bi961652w; Graceffa P, 2000, J BIOL CHEM, V275, P17143, DOI 10.1074/jbc.M001979200; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Guilford WH, 1998, COMP BIOCHEM PHYS B, V119, P451, DOI 10.1016/S0305-0491(98)00002-9; Guo HQ, 1999, J MUSCLE RES CELL M, V20, P725, DOI 10.1023/A:1005537132581; HAEBERLE JR, 1994, CAN J PHYSIOL PHARM, V72, P1400, DOI 10.1139/y94-202; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; HUBER PAJ, 1995, BIOCHEM J, V312, P617, DOI 10.1042/bj3120617; HVIDT S, 1983, MACROMOLECULES, V16, P740, DOI 10.1021/ma00239a007; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; Khromov A, 1995, BIOPHYS J, V69, P2611, DOI 10.1016/S0006-3495(95)80132-3; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Li YP, 2003, AM J PHYSIOL-REG I, V284, pR192, DOI 10.1152/ajpregu.00290.2002; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; Mabuchi K, 2001, J MUSCLE RES CELL M, V22, P77, DOI 10.1023/A:1010392322503; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1996, BIOCH SMOOTH MUSCLE, P77; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PHILLIPS GN, 1980, BIOPHYS J, V32, P485, DOI 10.1016/S0006-3495(80)84985-X; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; Rembold CM, 2004, AM J PHYSIOL-CELL PH, V287, pC594, DOI 10.1152/ajpcell.00082.2004; SELLERS JR, 1987, REGULATION CONTRACTI, V18, P381; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; SOBIESZEK A, 1981, EUR J BIOCHEM, V118, P533, DOI 10.1111/j.1432-1033.1981.tb05552.x; SOBIESZEK A, 1982, J MOL BIOL, V157, P275, DOI 10.1016/0022-2836(82)90234-0; SOBIESZEK A, 1977, J MOL BIOL, V112, P559, DOI 10.1016/S0022-2836(77)80164-2; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SWENSON CA, 1989, BIOPOLYMERS, V28, P955, DOI 10.1002/bip.360280504; TAO T, 1983, BIOCHEMISTRY-US, V22, P3059, DOI 10.1021/bi00282a006; TSURUDA TS, 1995, BIOCHEM J, V309, P951, DOI 10.1042/bj3090951; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1993, BIOPHYS J, V65, P892, DOI 10.1016/S0006-3495(93)81113-5; VELAZ L, 1989, J BIOL CHEM, V264, P9602; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; VIBERT PJ, 1972, J MOL BIOL, V71, P757, DOI 10.1016/S0022-2836(72)80036-6; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WATSON MH, 1990, BIOCHIM BIOPHYS ACTA, V1054, P103, DOI 10.1016/0167-4889(90)90211-U; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; WORD RA, 1993, J CLIN INVEST, V92, P29, DOI 10.1172/JCI116564	87	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4135	4143		10.1074/jbc.M410375200	http://dx.doi.org/10.1074/jbc.M410375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15504719	hybrid			2022-12-25	WOS:000227096600019
J	Ma, CL; Kotaria, R; Mayor, JA; Remani, S; Walters, DE; Kaplan, RS				Ma, CL; Kotaria, R; Mayor, JA; Remani, S; Walters, DE; Kaplan, RS			The yeast mitochondrial citrate transport protein - Characterization of transmembrane domain III residue involvement in substrate translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; FATTY-ACID SYNTHESIS; STRUCTURE/FUNCTION RELATIONSHIPS; OXALOBACTER-FORMIGENES; TRICARBOXYLATE CARRIER; REENTRANT LOOP; PATHWAY; PURIFICATION; IDENTIFICATION; PERMEATION	Previous examination of the accessibility of a panel of single-Cys mutants in transmembrane domain III (TM-DIII) of the yeast mitochondrial citrate transport protein to hydrophilic, cysteine-specific methanethiosulfonate reagents, enabled identification of the water-accessible surface of this domain and suggested its potential participation in the formation of a portion of the substrate translocation pathway. To evaluate this idea, we conducted a detailed characterization of the functional properties of 20 TMDIII single-Cys substitution mutants. Kinetic studies indicate that the A118C, S123C, and K134C mutants displayed a 3- to 7-fold increase in K-m. Moreover, the A118C mutation caused a doubling of the V-max value, whereas the S123C, E131C, and K134C mutations caused Vmax to dramatically decrease, resulting in a reduction of the catalytic efficiencies of these three mutants by > 97%. Examination of the ability of citrate to protect against the inhibition mediated by sodium (2-sulfonatoethyl) methanethiosulfonate (MTSES) indicated that citrate conferred significant protection of cysteines substituted at eight water-accessible locations (i.e. Gly-115, Leu-116, Gly-117, Leu-121, Ser-123, Val-127, Glu-131, and Thr-135), but not at other sites. Importantly, similar levels of protection were observed at both 4 degreesC and 20 degreesC. The temperature independence of the protection indicates that substrate binding and/or occupancy of the transport pathway sterically blocks the access of MTSES to these sites, thereby providing direct protection, without involvement of a major protein conformational change. The significance of these extensive functional investigations is discussed in terms of the three-dimensional CTP homology model that we previously developed and a new model of the dimer interface.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kaplan, RS (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	Ronald.Kaplan@rosalindfranklin.edu	Mayor, June/AAP-1544-2021; Walters, D. Eric/C-9626-2010	Walters, D. Eric/0000-0002-1513-3522	NIGMS NIH HHS [GM-054642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Friedman M. A., 1986, PRINCIPLES MODELS BI, p[45, 105, 154, 346]; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KOARIA R, 1999, J BIOENERG BIOMEMBR, V31, P543; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; Ma CL, 2004, J BIOL CHEM, V279, P1533, DOI 10.1074/jbc.M310866200; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; Walters DE, 2004, BIOPHYS J, V87, P907, DOI 10.1529/biophysj.104.042127; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Xu Y, 2000, J BIOL CHEM, V275, P7117, DOI 10.1074/jbc.275.10.7117; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255; Ye LW, 2002, J BIOL CHEM, V277, P20372, DOI 10.1074/jbc.M111140200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	25	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2331	2340		10.1074/jbc.M411474200	http://dx.doi.org/10.1074/jbc.M411474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15498760	hybrid			2022-12-25	WOS:000226341700070
J	Martowicz, ML; Grass, JA; Boyer, ME; Guend, H; Bresnick, EH				Martowicz, ML; Grass, JA; Boyer, ME; Guend, H; Bresnick, EH			Dynamic GATA factor interplay at a multicomponent regulatory region of the GATA-2 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; BETA-GLOBIN LOCUS; RNA-POLYMERASE-II; HYPERSENSITIVE SITES; HISTONE ACETYLATION; CHROMATIN DOMAIN; ERYTHROID-DIFFERENTIATION; MAMMALIAN-CELLS; BINDING PROTEIN; NUCLEOSOMAL DNA	Given the simplicity of the DNA sequence that mediates binding of GATA transcription factors, GATA motifs reside throughout chromosomal DNA. However, chromatin immunoprecipitation analysis has revealed that GATA-1 discriminates exquisitely among these sites. GATA-2 selectively occupies the -2.8-kilobase (kb) region of the GATA-2 locus in the active state despite there being numerous GATA motifs throughout the locus. The GATA-1-mediated displacement of GATA-2 is tightly coupled to repression of GATA-2 transcription. We have used high resolution chromatin immunoprecipitation to show that GATA-1 and GATA-2 occupy two additional regions, -3.9 and -1.8 kb of the GATA-2 locus. GATA-1 and GATA-2 had distinct preferences for occupancy at these regions, with GATA-1 and GATA-2 occupancy highest at the -3.9- and -1.8- kb regions, respectively. Activation of an estrogen receptor fusion to GATA-1 (ER-GATA-1) induced similar kinetics of ER-GATA-1 occupancy and GATA-2 displacement at the sites. In the transcriptionally active state, DNase I hypersensitive sites (HSs) were detected at the -3.9- and -1.8-kb regions, with a weak HS at the -2.8-kb region. Whereas ER-GATA-1-instigated repression abolished the -1.8-kb HS, the -3.9-kb HS persisted in the repressed state. Transient transfection analysis provided evidence that the -3.9-kb region functions distinctly from the -2.8- and -1.8-kb regions. We propose that GATA-2 transcription is regulated via the collective actions of complexes assembled at the -2.8- and -1.8-kb regions, which share similar properties, and through a qualitatively distinct activity of the -3.9-kb complex.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.	ehbresni@wisc.edu			NIDDK NIH HHS [DK67633, DK50107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R21DK067633] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender MA, 2000, BLOOD, V95, P3600, DOI 10.1182/blood.V95.11.3600.011k42_3600_3604; Bender MA, 2001, BLOOD, V98, P2022, DOI 10.1182/blood.V98.7.2022; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Im Hogune, 2004, Methods Mol Biol, V284, P129; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kiekhaefer CM, 2004, J BIOL CHEM, V279, P7456, DOI 10.1074/jbc.M309750200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Minegishi N, 2003, BLOOD, V102, P896, DOI 10.1182/blood-2002-12-3809; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; Molete JM, 2001, MOL CELL BIOL, V21, P2969, DOI 10.1128/MCB.21.9.2969-2980.2001; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Peterson KR, 1998, ANN NY ACAD SCI, V850, P28, DOI 10.1111/j.1749-6632.1998.tb10459.x; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642	51	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1724	1732		10.1074/jbc.M406038200	http://dx.doi.org/10.1074/jbc.M406038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15494394	hybrid			2022-12-25	WOS:000226341700004
J	Hara-Chikuma, M; Yang, BX; Sonawane, ND; Sasaki, S; Uchida, S; Verkman, AS				Hara-Chikuma, M; Yang, BX; Sonawane, ND; Sasaki, S; Uchida, S; Verkman, AS			ClC-3 chloride channels facilitate endosomal acidification and chloride accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; GOLGI; ENDOCYTOSIS; LEADS; CONDUCTANCE; TRANSFERRIN; EXPRESSION; VESICLES; KINETICS; MUTANT	We investigated the involvement of ClC-3 chloride channels in endosomal acidification by measurement of endosomal pH and chloride concentration [Cl-] in control versus ClC-3-deficient hepatocytes and in control versus ClC-3-transfected Chinese hamster ovary cells. Endosomes were labeled with pH or [Cl-]-sensing fluorescent transferrin (Tf), which targets to early/recycling endosomes, or alpha(2)-macroglobulin (alpha(2)M), which targets to late endosomes. In pulse label-chase experiments, [Cl-] was 19 mM just after internalization in alpha(2)M-labeled endosomes in primary cultures of hepatocytes from wildtype mice, increasing to 58 mM over 45 min, whereas pH decreased from 7.1 to 5.4. Endosomal acidification and [Cl-] accumulation were significantly impaired in hepatocytes from ClC-3 knock-out mice, with [Cl-] increasing from 16 to 43 mM and pH decreasing from 7.1 to 6.0. Acidification and Cl- accumulation were blocked by bafilomycin. In Tf-labeled endosomes, [Cl-] was 46 mM in wild-type versus 35 mM in ClC-3-deficient hepatocytes at 15 min after internalization, with corresponding pH of 6.1 versus 6.5. Approximately 4-fold increased Cl- conductance was found in alpha(2)M-labeled endosomes isolated from hepatocytes of wild-type versus ClC-3 null mice. In contrast, Golgi acidification was not impaired in ClC-3-deficient hepatocytes. In transfected Chinese hamster ovary cells expressing ClC-3A, endosomal acidification and [Cl-] accumulation were enhanced. [Cl-] in alpha(2)M-labeled endosomes was 42 mM ( control) versus 53 mM (ClC-3A) at 45 min, with corresponding pH 5.8 versus 5.2; [Cl-] in Tf-labeled endosomes at 15 min was 37 mM (control) versus 49 mM (ClC-3A) with pH 6.3 versus 5.9. Our results provide direct evidence for involvement of ClC-3 in endosomal acidification by Cl- shunting of the interior-positive membrane potential created by the vacuolar H+ pump.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Tokyo Med & Dent Univ, Grad Sch, Dept Nephrol, Tokyo 1138519, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tokyo Medical & Dental University (TMDU)	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73854] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; George AL, 1998, P NATL ACAD SCI USA, V95, P7843, DOI 10.1073/pnas.95.14.7843; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Gunther W, 2003, PFLUG ARCH EUR J PHY, V445, P456, DOI 10.1007/s00424-002-0950-6; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMADA K, 2002, AM J PHYSIOL, V279, pG268; Sonawane ND, 2003, J CELL BIOL, V160, P1129, DOI 10.1083/jcb.200211098; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Yoshikawa M, 2002, GENES CELLS, V7, P597, DOI 10.1046/j.1365-2443.2002.00539.x; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	38	149	157	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1241	1247		10.1074/jbc.M407030200	http://dx.doi.org/10.1074/jbc.M407030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15504734	hybrid			2022-12-25	WOS:000226195200048
J	Gardian, G; Browne, SE; Choi, DK; Klivenyi, P; Gregorio, J; Kubilus, JK; Ryu, H; Langley, B; Ratan, RR; Ferrante, RJ; Beal, MF				Gardian, G; Browne, SE; Choi, DK; Klivenyi, P; Gregorio, J; Kubilus, JK; Ryu, H; Langley, B; Ratan, RR; Ferrante, RJ; Beal, MF			Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; ORAL SODIUM PHENYLBUTYRATE; CREB-BINDING PROTEIN; LONG-TERM TREATMENT; EXPANDED POLYGLUTAMINE; DEPENDENT NEURODEGENERATION; TRANSCRIPTIONAL REPRESSION; MEDIATED TRANSCRIPTION; ALTERED TRANSCRIPTION	Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), however, the means by which neurodegeneration occurs remains obscure. There is evidence that mutant Htt interacts with transcription factors leading to reduced histone acetylation. We report that administration of the histone deacetylase inhibitor phenylbutyrate after onset of symptoms in a transgenic mouse model of HD significantly extends survival and attenuates both gross brain and neuronal atrophy. Administration of phenylbutyrate increased brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots. Phenylbutyrate increased mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. These results show that administration of phenylbutyrate, at doses that are well tolerated in man, exerts significant neuroprotective effects in a transgenic mouse model of HD, and therefore represents a very promising therapeutic approach for HD.	Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA; Bedford Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Cornell Univ, Coll Med, Burke Med Res Inst, White Plains, NY 10605 USA	Cornell University; NewYork-Presbyterian Hospital; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Cornell University	Beal, MF (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,Rm F610, New York, NY 10021 USA.	fbeal@med.cornell.edu	Langley, Brett C/P-7207-2017	Langley, Brett C/0000-0003-4009-2109; Klivenyi, Peter/0000-0002-5389-3266; Ryu, Hoon/0000-0001-6544-3732; Choi, Dong-Kug/0000-0001-7041-1524	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035255, P01NS045242] Funding Source: NIH RePORTER; NINDS NIH HHS [NS045242, NS32958, NS35255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406; Andreassen OA, 2001, ANN NEUROL, V50, P112, DOI 10.1002/ana.1085; AUSUBEL FM, 2000, CURRENT PROTOCOLS MO, P61; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Burlina AB, 2001, MOL GENET METAB, V72, P351, DOI 10.1006/mgme.2001.3156; Carducci MA, 2001, CLIN CANCER RES, V7, P3047; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; DOVER GJ, 1994, BLOOD, V84, P339; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hoppe C, 1999, AM J HEMATOL, V62, P221, DOI 10.1002/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; JENKINS BG, 2004, IN PRESS J NEUROCHEM; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kiechle T, 2002, NEUROMOL MED, V1, P183; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Obrietan K, 2004, J NEUROSCI, V24, P791, DOI 10.1523/JNEUROSCI.3493-03.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Perez-Severiano F, 2000, BRAIN RES, V862, P234, DOI 10.1016/S0006-8993(00)02082-5; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Schilling G, 2001, NEUROSCI LETT, V315, P149, DOI 10.1016/S0304-3940(01)02326-6; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Schilling G, 2001, NEUROBIOL DIS, V8, P405, DOI 10.1006/nbdi.2001.0385; Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Yu ZX, 2003, J NEUROSCI, V23, P2193; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	51	351	366	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					556	563		10.1074/jbc.M410210200	http://dx.doi.org/10.1074/jbc.M410210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494404	hybrid			2022-12-25	WOS:000226025100066
J	Chung, MC; Kawamoto, S				Chung, MC; Kawamoto, S			IRF-2 is involved in up-regulation of nonmuscle myosin heavy chain II-A gene expression during phorbol ester-induced promyelocytic HL-60 differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IRF-2; IN-VITRO; FACTOR-2; CELLS; ACTIVATION; IDENTIFICATION; REQUIRES; FECHTNER; MUTATION; MUSCLE	Transcription of the nonmuscle myosin heavy chain II-A (NMHC-A) gene is regulated by various factors, including cell type, proliferation and differentiation stage, and extracellular stimuli. We have identified an intronic region (designated 32kb-150), which is located 32 kb downstream of the transcription start sites in the human NMHC-A gene, as a transcriptional regulatory region. 32kb-150 contains an interferon-stimulated response element (ISRE). By using HeLa and NIH3T3 cells, in which NMHC-A is constitutively expressed, interferon regulatory factor (IRF)-2 was found to be the only major protein, among the IRF family proteins, that bound to the ISRE in 32kb-150 both in vitro and in intact cells. IRF-2, which is known to either repress or activate target gene expression, acts as a transcriptional activator in the context of the 32kb-150 reporter gene. The carboxyl-terminal basic region of IRF-2 serves as an activation domain in this context. This is in contrast to its acting as a repressor domain in the context of the synthetic core ISRE. Furthermore, after treatment of promyelocytic HL-60 cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), which triggers differentiation into macrophages, both NMHC-A expression and IRF-2 expression were found to be up-regulated with a similar time course. TPA treatment leads to recruitment of IRF-2 to 32kb-150 of the endogenous NMHC-A gene and acetylation of the core histones surrounding this region. In addition, the ISRE in the 32kb-150 reporter gene recruits IRF-2 and mediates TPA-induced activation of a reporter gene in HL-60 cells. Together, these results indicate that IRF-2 contributes to transcriptional activation of the NMHC-A gene via 32kb-150 during TPA-induced differentiation of HL-60 cells.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kawamoto, S (corresponding author), Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	kawamots@mail.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004236, Z01HL004236] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki N, 2003, J CELL SCI, V116, P247, DOI 10.1242/jcs.00235; Beohar N, 1998, J BIOL CHEM, V273, P9168, DOI 10.1074/jbc.273.15.9168; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Childs KS, 2003, NUCLEIC ACIDS RES, V31, P3016, DOI 10.1093/nar/gkg431; Chung MC, 2001, BIOCHEMISTRY-US, V40, P8887, DOI 10.1021/bi002847d; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; Madsen CS, 1998, CIRC RES, V82, P908; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Manabe I, 2001, J BIOL CHEM, V276, P39076, DOI 10.1074/jbc.M105402200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; Seri M, 2003, MEDICINE, V82, P203, DOI 10.1097/00005792-200305000-00006; Staal A, 2000, J CELL PHYSIOL, V185, P269, DOI 10.1002/1097-4652(200011)185:2<269::AID-JCP12>3.0.CO;2-L; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TOOTHAKER LE, 1991, BLOOD, V78, P1826; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; Xie RL, 2003, J BIOL CHEM, V278, P26589, DOI 10.1074/jbc.M301491200; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	49	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56042	56052		10.1074/jbc.M404791200	http://dx.doi.org/10.1074/jbc.M404791200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496418	hybrid			2022-12-25	WOS:000225960800128
J	Lin, AC; Roche, AE; Wilk, J; Svensson, EC				Lin, AC; Roche, AE; Wilk, J; Svensson, EC			The N termini of friend of GATA (FOG) proteins define a novel transcriptional repression motif and a superfamily of transcriptional repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TOWNES-BROCKS-SYNDROME; HISTONE DEACETYLASE; HEART MORPHOGENESIS; BINDING-PROTEIN; GENE-EXPRESSION; COFACTOR; DROSOPHILA; SALL1; INTERACTS	Members of the Friend of GATA (FOG) family of transcriptional co-factors are required for the development of both the cardiovascular and hematopoietic systems. FOG proteins physically interact with members of the GATA family of transcriptional activators and modulate their activity. We have previously shown that FOG-2 can bind to the N-terminal zinc finger of GATA4 and, via this interaction, repress GATA4-mediated transcriptional activation of various cardiac promoters. In this report we further characterize the domain of FOG-2 necessary for repression of GATA4 transcriptional activity. We show that FOG-2-mediated repression is not blocked by the histone deacetylase inhibitor tricostatin A, suggesting that FOG-2 repression of GATA4 occurs via a histone deacetylase independent mechanism. N-terminal deletion mutants of FOG-2 revealed that the first 12 amino acids of FOG-2 are necessary for FOG-2-mediated repression. Fusion of these 12 amino acids to the DNA binding domain of GAL4 demonstrated that this region is sufficient to mediate transcriptional repression even when recruited to a heterologous promoter. Single amino acid substitutions within this N-terminal domain of FOG-2 defined the critical amino acid sequence as RRKQxxPxxI. Interestingly, a search of the NCBI protein data base identified several other partially characterized zinc finger transcriptional repressors from various vertebrate species that contained this motif at their N terminus. Taken together, these observations define a novel transcriptional repression motif and a superfamily of zinc finger transcriptional repressors.	Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA	University of Chicago; Stanford University	Svensson, EC (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, 5841 S Maryland Ave,MC6088, Chicago, IL 60637 USA.	esvensso@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL 071063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anttonen M, 2003, BIOL REPROD, V68, P1333, DOI 10.1095/biolreprod.102.008599; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Clyde DE, 2003, NATURE, V426, P849, DOI 10.1038/nature02189; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Fossett N, 2003, P NATL ACAD SCI USA, V100, P11451, DOI 10.1073/pnas.1635050100; Fossett N, 2001, TRENDS CARDIOVAS MED, V11, P185, DOI 10.1016/S1050-1738(01)00092-5; Fossett N, 2001, P NATL ACAD SCI USA, V98, P7342, DOI 10.1073/pnas.131215798; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; Gaston K, 2003, CELL MOL LIFE SCI, V60, P721, DOI 10.1007/s00018-003-2260-3; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Huggins GS, 2001, J BIOL CHEM, V276, P28029, DOI 10.1074/jbc.M103577200; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jia Y, 2003, CARDIOVASC RES, V60, P278, DOI 10.1016/S0008-6363(03)00528-5; Katz SG, 2003, P NATL ACAD SCI USA, V100, P14030, DOI 10.1073/pnas.1936250100; Katz SG, 2002, MOL CELL BIOL, V22, P3121, DOI 10.1128/MCB.22.9.3121-3128.2002; Kiefer SM, 2003, HUM MOL GENET, V12, P2221, DOI 10.1093/hmg/ddg233; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhou MX, 2001, J EXP MED, V194, P1461, DOI 10.1084/jem.194.10.1461	46	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55017	55023		10.1074/jbc.M411240200	http://dx.doi.org/10.1074/jbc.M411240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507435	hybrid			2022-12-25	WOS:000225960800006
J	Tanaka, S; Antoniv, TT; Liu, K; Wang, L; Wells, DJ; Ramirez, F; Bou-Gharios, G				Tanaka, S; Antoniv, TT; Liu, K; Wang, L; Wells, DJ; Ramirez, F; Bou-Gharios, G			Cooperativity between far upstream enhancer and proximal promoter elements of the human alpha 2(I) collagen (COL1A2) gene instructs tissue specificity in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; 2(I) COLLAGEN GENE; INTERFERON-GAMMA; TGF-BETA; TNF-ALPHA; CBF/NF-Y; EXPRESSION; TRANSCRIPTION; SP1	Interaction between the proximal (-378) promoter and the far upstream (-20 kb) enhancer is essential for tissue-specific expression of the human alpha2(I) collagen gene (COL1A2) in transgenic mice. Previous in vitro studies have shown that three Sp1 binding sites (around -300) are part of a cytokine-responsive element and that two TC-rich boxes (around -160 and -125) and a CBF/NFY consensus sequence (around -80) confer optimal promoter activity by interacting among themselves and with the upstream Sp1 sites. Here we report that mutations of the Sp1 binding sites, TC-rich boxes or CBF/NFY consensus sequence lead to reduced transgene activity, thus underscoring the functional interdependence of the proximal promoter elements. Loss of the Sp1 binding sites was associated with loss of transgene expression in osteoblasts, whereas elimination of the CBF/NFY binding site (alone or in combination with the TC-rich boxes) was correlated with a lack of activity in the ventral fascia and head dermis and musculature. Additionally, transgene expression in skin fascia fibroblasts depended on the integrity of the Sp1 binding sites and TC-rich boxes, and on their physical configuration. Evidence is also presented suggesting cooperativity between cis-acting elements of the far upstream enhancer and proximal promoter in assembling tissue-specific protein complexes. This study thus reiterates the complex and highly combinatorial nature of the regulatory network governing COL1A2 transcription in vivo.	Hosp Special Surg, Lab Genet & Organogenesis, Div Res, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, Gene Targeting Unit, London W6 8RP, England; Imperial Coll Sch Med, Renal Med Div, London W12 ONN, England	Cornell University; Imperial College London; Imperial College London	Ramirez, F (corresponding author), Hosp Special Surg, Lab Genet & Organogenesis, Div Res, 535 E 70th St, New York, NY 10021 USA.	ramirezf@hss.edu		Wells, Dominic/0000-0002-1425-6344	NIAMS NIH HHS [AR 386481] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; Bhattacharya A, 2003, CANCER RES, V63, P8167; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; DiLeone RJ, 2000, P NATL ACAD SCI USA, V97, P1612, DOI 10.1073/pnas.97.4.1612; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Houzelstein D, 2000, DEVELOPMENT, V127, P2155; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; INAGAKI Y, 2003, CONNECT TISSUE RES, V35, P193; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Luchetti MM, 2003, J BIOL CHEM, V278, P1533, DOI 10.1074/jbc.M204392200; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NAGY A, 2003, MANIPULATING MOUSE E, P289; Ogata K, 2003, CURR OPIN STRUC BIOL, V13, P40, DOI 10.1016/S0959-440X(03)00012-5; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; VARGA J, 1995, ANN INTERN MED, V122, P60, DOI 10.7326/0003-4819-122-1-199501010-00010; Varga John, 2004, Curr Rheumatol Rep, V6, P164, DOI 10.1007/s11926-004-0062-8; Verrecchia F, 2004, CELL SIGNAL, V16, P873, DOI 10.1016/j.cellsig.2004.02.007; Verrecchia F, 2002, EMBO REP, V3, P1069, DOI 10.1093/embo-reports/kvf219; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	37	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56024	56031		10.1074/jbc.M411406200	http://dx.doi.org/10.1074/jbc.M411406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15516691	hybrid			2022-12-25	WOS:000225960800126
J	Wong, DS; Zhang, JY; Awasthi, Y; Sharma, A; Rogers, L; Matlock, EF; Van Lint, C; Karpova, T; McNally, J; Harrod, R				Wong, DS; Zhang, JY; Awasthi, Y; Sharma, A; Rogers, L; Matlock, EF; Van Lint, C; Karpova, T; McNally, J; Harrod, R			Nerve growth factor receptor signaling induces histone acetyltransferase domain-dependent nuclear translocation of p300/CREB-binding protein-associated factor and hGCN5 acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-INHIBITOR P21(WAF1/CIP1); TRANSCRIPTION FACTOR CREB; LONG-TERM FACILITATION; VIRUS TYPE-1 TAX; SYMPATHETIC NEURONS; PC12 CELLS; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS	The transcriptional coactivators, p300/CREB-binding protein-associated factor (PCAF) and hGCN5, are recruited to chromatin-remodeling complexes on enhancers of various gene promoters in response to growth factor stimulation. However, the molecular mechanisms by which surface receptor signals modulate the assembly of nuclear transcription complexes are not fully understood. Here we report that nerve growth factor receptor signaling induces nuclear translocation of PCAF and hGCN5 dependent upon the phosphorylation of Ser and Thr residues within their histone acetyltransferase domains, which requires activation of PI3K, Rsk2(pp90), and MSK-1. Neurotrophin stimulation induces p53(K320) acetylation by PCAF and transcriptionally activates p53-responsive enhancer elements within the p21(WAF/CIP1) promoter associated with G(1)/S arrest during neuronal differentiation. Most importantly, these findings represent the first evidence for signal-dependent nuclear translocation of PCAF and hGCN5 acetyltransferases and allude to a novel mechanism for ligand/receptor modulation of nuclear chromatin-remodeling complexes in neurons.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; NCI, Lab Receptor Biol & Gene Express, Fluorescence Imaging Facil, Ctr Canc Res ,NIH, Bethesda, MD 20892 USA	Southern Methodist University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harrod, R (corresponding author), So Methodist Univ, Dept Biol Sci, Mol Virol Lab, 334-DLS,6501 Airline Dr, Dallas, TX 75275 USA.	rharrod@mail.smu.edu		Mauldin, Kasuen/0000-0001-9220-8033; Karpova, Tatiana/0000-0001-6025-2128	NATIONAL CANCER INSTITUTE [ZICBC010571, Z01BC010571] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Billon N, 1996, ONCOGENE, V13, P2047; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Li XC, 2000, P NATL ACAD SCI USA, V97, P8584, DOI 10.1073/pnas.140222497; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Liu L, 1999, MOL CELL BIOL, V19, P1202; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nagano T, 2003, MOL CELL NEUROSCI, V24, P340, DOI 10.1016/S1044-7431(03)00172-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Parker D, 1996, MOL CELL BIOL, V16, P694; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Pierchala BA, 2004, J BIOL CHEM, V279, P27986, DOI 10.1074/jbc.M312237200; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SUNGHOE C, 1999, P NATL ACAD SCI USA, V96, P4095; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vaghefi H, 2004, J BIOL CHEM, V279, P15604, DOI 10.1074/jbc.M311500200; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang B, 2002, NAT NEUROSCI, V5, P539, DOI 10.1038/nn853; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	61	35	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55667	55674		10.1074/jbc.M408174200	http://dx.doi.org/10.1074/jbc.M408174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496412	hybrid			2022-12-25	WOS:000225960800086
J	Rancour, DM; Park, S; Knight, SD; Bednarek, SY				Rancour, DM; Park, S; Knight, SD; Bednarek, SY			Plant UBX domain-containing protein 1, PUX1, regulates the oligomeric structure and activity of Arabidopsis CDC48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; MULTIPLE SEQUENCE ALIGNMENT; P97 AAA ATPASE; CELL-CYCLE; MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; ADAPTER PROTEIN; UBIQUITIN	p97/CDC48 is a highly abundant hexameric AAA-ATPase that functions as a molecular chaperone in numerous diverse cellular activities. We have identified an Arabidopsis UBX domain-containing protein, PUX1, which functions to regulate the oligomeric structure of the Arabidopsis homolog of p97/CDC48, AtCDC48, as well as mammalian p97. PUX1 is a soluble protein that co-fractionates with non-hexameric AtCDC48 and physically interacts with AtCDC48 in vivo. Binding of PUX1 to AtCDC48 is mediated through the UBX-containing C-terminal domain. However, disassembly of the chaperone is dependent upon the N-terminal domain of PUX1. These findings provide evidence that the assembly and disassembly of the hexameric p97/CDC48 complex is a dynamic process. This new unexpected level of regulation for p97/CDC48 was demonstrated to be critical in vivo as pux1 loss-of-function mutants display accelerated growth relative to wild-type plants. These results suggest a role for AtCDC48 and PUX1 in regulating plant growth.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bednarek, SY (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	bednarek@biochem.wisc.edu		Rancour, David/0000-0002-3624-5750				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BarPeled M, 1997, PLANT PHYSIOL, V114, P315, DOI 10.1104/pp.114.1.315; Beemster GTS, 1998, PLANT PHYSIOL, V116, P1515, DOI 10.1104/pp.116.4.1515; Beemster GTS, 2003, TRENDS PLANT SCI, V8, P154, DOI 10.1016/S1360-1385(03)00046-3; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chook YM, 2002, BIOCHEMISTRY-US, V41, P6955, DOI 10.1021/bi012122p; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Decottignies A, 2004, YEAST, V21, P127, DOI 10.1002/yea.1071; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; EGERTON M, 1994, J BIOL CHEM, V269, P11435; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Kang BH, 2001, PLANT PHYSIOL, V126, P47, DOI 10.1104/pp.126.1.47; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Partridge JJ, 2003, MOL BIOL CELL, V14, P4221, DOI 10.1091/mbc.E03-02-0111; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Roggy JL, 1999, MOL BIOCHEM PARASIT, V98, P1, DOI 10.1016/S0166-6851(98)00114-5; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Rowlands MG, 2004, ANAL BIOCHEM, V327, P176, DOI 10.1016/j.ab.2003.10.038; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Sugita S, 2000, BIOCHEMISTRY-US, V39, P2940, DOI 10.1021/bi9920984; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchiyama K, 2003, J CELL BIOL, V161, P1067, DOI 10.1083/jcb.200303048; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yamada T, 2000, FEBS LETT, V466, P287, DOI 10.1016/S0014-5793(99)01673-7; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yuan XM, 2004, J BIOMOL NMR, V28, P309, DOI 10.1023/B:JNMR.0000013689.02494.07; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	76	79	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54264	54274		10.1074/jbc.M405498200	http://dx.doi.org/10.1074/jbc.M405498200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498773	hybrid			2022-12-25	WOS:000225793600047
J	Izumikawa, T; Kitagawa, H; Mizuguchi, S; Nomura, KH; Nomura, K; Tamura, J; Gengyo-Ando, K; Mitani, S; Sugahara, K				Izumikawa, T; Kitagawa, H; Mizuguchi, S; Nomura, KH; Nomura, K; Tamura, J; Gengyo-Ando, K; Mitani, S; Sugahara, K			Nematode chondroitin polymerizing factor showing cell-/organ-specific expression is indispensable for chondroitin synthesis and embryonic cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; HEPARAN-SULFATE; N-ACETYLGALACTOSAMINYLTRANSFERASE; TUMOR SUPPRESSORS; GENETIC INTERFERENCE; BIOSYNTHESIS; ELONGATION; INITIATION	Chondroitin polymerization was first demonstrated in vitro when human chondroitin synthase (ChSy) was coexpressed with human chondroitin polymerizing factor (ChPF), which is homologous to ChSy but has little glycosyltransferase activity. To analyze the biological function of chondroitin, the Caenorhabditis elegans ortholog of human ChSy (sqv-5) was recently cloned, and the expression of its product was depleted by RNA-mediated interference (RNAi) and deletion mutagenesis. Blocking of chondroitin synthesis resulted in defects of cytokinesis in early embryogenesis, and eventually, cell division stopped. Here, we cloned the ortholog of human ChPF in C. elegans, PAR2.4. Despite little glycosyltransferase activity of the gene product, chondroitin polymerization was demonstrated as in the case of mammals when PAR2.4 was coexpressed with cChSy in vitro. The worm phenotypes including the reversion of cytokinesis, observed after the depletion of PAR2.4 by RNAi, were very similar to the cChSy (sqv-5)-RNAi phenotypes. Thus, PAR2.4 in addition to cChSy is indispensable for the biosynthesis of chondroitin in C. elegans, and the two cooperate to synthesize chondroitin in vivo. The expression of the PAR2.4 protein was observed in seam cells, which can act as neural stem cells in early embryonic lineages. The expression was also detected in vulva and distal tip cells of the growing gonad arms from L3 through to the young adult stage. These findings are consistent with the notion that chondroitin is involved in the organogenesis of the vulva and maturation of the gonad and also indicative of an involvement in distal tip cell migration and neural development.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyushu Univ, Grad Sch, Fac Sci, Dept Biol Sci, Fukuoka 8128581, Japan; JST, CREST, Kawaguchi, Saitama 3320012, Japan; Tottori Univ, Fac Reg Sci, Dept Reg Environm, Tottori 6808551, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan	Kobe Pharmaceutical University; Kyushu University; Japan Science & Technology Agency (JST); Tottori University; Tokyo Women's Medical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020; Gengyo-Ando, Keiko/B-2753-2012; Gengyo-Ando, Keiko/AAC-4504-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; 				Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Koh K, 2001, DEVELOPMENT, V128, P2867; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Tamura J, 1999, J CARBOHYD CHEM, V18, P1, DOI 10.1080/07328309908543974; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	34	48	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53755	53761		10.1074/jbc.M409615200	http://dx.doi.org/10.1074/jbc.M409615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485872	hybrid			2022-12-25	WOS:000225680600113
J	Komori, K; Hidaka, M; Horiuchi, T; Fujikane, R; Shinagawa, H; Ishino, Y				Komori, K; Hidaka, M; Horiuchi, T; Fujikane, R; Shinagawa, H; Ishino, Y			Cooperation of the N-terminal helicase and C-terminal endonuclease activities of archaeal Hef protein in processing stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION RESOLVASE; DNA-REPLICATION; PYROCOCCUS-FURIOSUS; BRANCH MIGRATION; RECQ HELICASES; REPAIR; MUS81-EME1; RESOLUTION; GENOME; DOMAIN	Blockage of replication fork progression often occurs during DNA replication, and repairing and restarting stalled replication forks are essential events in all organisms for the maintenance of genome integrity. The repair system employs processing enzymes to restore the stalled fork. In Archaea Hef is a well conserved protein that specifically cleaves nicked, flapped, and fork-structured DNAs. This enzyme contains two distinct domains that are similar to the DEAH helicase family and XPF nuclease superfamily proteins. Analyses of truncated mutant proteins consisting of each domain revealed that the C-terminal nuclease domain independently recognized and incised fork-structured DNA. The N-terminal helicase domain also specifically unwound fork-structured DNA and Holliday junction DNA in the presence of ATP. Moreover, the endonuclease activity of the whole Hef protein was clearly stimulated by ATP hydrolysis catalyzed by the N-terminal domain. These enzymatic properties suggest that Hef efficiently resolves stalled replication forks by two steps, which are branch point transfer to the 5'-end of the nascent lagging strand by the N-terminal helicase followed by template strand incision for leading strand synthesis by the C-terminal endonuclease.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Higashi Ku, Fukuoka 8128581, Japan; Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Microbiol, Osaka 5650871, Japan	Kyushu University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University	Ishino, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	ishino@agr.kyushu-u.ac.jp		Fujikane, Ryosuke/0000-0002-6621-3848; Ishino, Yoshizumi/0000-0001-9419-0826				Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Briggs GS, 2004, PHILOS T R SOC B, V359, P49, DOI 10.1098/rstb.2003.1364; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Ciccia A, 2003, J BIOL CHEM, V278, P25172, DOI 10.1074/jbc.M302882200; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; DiRuggiero J, 1998, NEW DEVELOPMENTS IN MARINE BIOTECHNOLOGY, P193; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Gaillard PHL, 2003, MOL CELL, V12, P747, DOI 10.1016/S1097-2765(03)00342-3; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403; Hollingsworth NM, 2004, GENE DEV, V18, P117, DOI 10.1101/gad.1165904; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Jansen JG, 2003, DNA REPAIR, V2, P1075, DOI 10.1016/S1568-7864(03)00119-8; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Komori K, 2002, GENES GENET SYST, V77, P227, DOI 10.1266/ggs.77.227; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Komori K, 2000, J BIOL CHEM, V275, P40385, DOI 10.1074/jbc.M006294200; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lehmann AR, 2003, CELL CYCLE, V2, P300, DOI 10.4161/cc.2.4.407; Maniantis T., 1989, MOL CLONING LAB MANU, P382; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nishino T, 2003, STRUCTURE, V11, P445, DOI 10.1016/S0969-2126(03)00046-7; Nishino T, 2001, STRUCTURE, V9, P197, DOI 10.1016/S0969-2126(01)00576-7; Ogrunc M, 2003, J BIOL CHEM, V278, P21715, DOI 10.1074/jbc.M302484200; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; PRAKASH L, 1977, GENETICS, V86, P33; Roberts JA, 2003, MOL MICROBIOL, V48, P361, DOI 10.1046/j.1365-2958.2003.03444.x; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scheller J, 2000, GENETICS, V155, P1069; Sgouros J, 1999, TRENDS BIOCHEM SCI, V24, P95, DOI 10.1016/S0968-0004(99)01355-9; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Whitby MC, 2003, J BIOL CHEM, V278, P6928, DOI 10.1074/jbc.M210006200; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Xiao W, 1998, MOL GEN GENET, V257, P614, DOI 10.1007/s004380050689; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9	63	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53175	53185		10.1074/jbc.M409243200	http://dx.doi.org/10.1074/jbc.M409243200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485882	hybrid			2022-12-25	WOS:000225680600047
J	Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H				Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H			Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models	ONCOGENE			English	Article						Aurora-A; mitosis; mammary gland; p53; Cre-loxP	SPINDLE ASSEMBLY CHECKPOINT; CENTROSOME AMPLIFICATION; TETRAPLOIDY CHECKPOINT; CHROMOSOME SEGREGATION; PROTEIN-KINASE; BREAST-CANCER; APOPTOSIS; CELLS; GENE; P53	Aurora-A, a serine/threonine mitotic kinase, was reported to be overexpressed in various human cancers, and its overexpression induces aneuploidy, centrosome amplification and tumorigenic transformation in cultured human and rodent cells. However, the underlying mechanisms and pathological settings by which Aurora-A promotes tumorigenesis are largely unknown. Here, we created a transgenic mouse model to investigate the involvement of Aurora-A overexpression in the development of mammary glands and tumorigenesis using a Cre-loxP system. The conditional expression of Aurora-A resulted in significantly increased binucleated cell formation and apoptosis in the mammary epithelium. The surviving mammary epithelial cells composed hyperplastic areas after a short latency. Induction of Aurora-A overexpression in mouse embryonic fibroblasts prepared from the transgenic mice also led to aberrant mitosis and binucleated cell formation followed by apoptosis. The levels of p53 protein were remarkably increased in these Aurora-A-overexpressing cells, and the apoptosis was significantly suppressed by deletion of p53. Given that no malignant tumor formation was found in the Aurora-A-overexpressing mouse model after a long latency, additional factors, such as p53 inactivation, are required for the tumorigenesis of Aurora-A-overexpressing mammary epithelium. Our findings indicated that this mouse model is a useful system to study the physiological roles of Aurora-A and the genetic pathways of Aurora-A-induced carcinogenesis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Saitama Med Sch, Dept Pathol, Omiya, Japan; Kumamoto Univ, Inst Resource Dev & Anal, Ctr Anim Resources & Dev, Div Transgen Technol, Kumamoto, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Saitama Medical University; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Arima, Yoshimi/J-8057-2013; Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045; Arima, Yoshimi/0000-0002-2384-1406				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; FRANCISCO L, 1994, CELL MOL BIOL RES, V40, P207; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hogan B, 1994, MANIPULATING MOUSE E; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li DH, 2003, CLIN CANCER RES, V9, P991; Lund LR, 1996, DEVELOPMENT, V122, P181; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tanaka T, 1999, CANCER RES, V59, P2041; TSUKADA T, 1993, ONCOGENE, V8, P3313; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	122	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8720	8730		10.1038/sj.onc.1208153	http://dx.doi.org/10.1038/sj.onc.1208153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480417				2022-12-25	WOS:000225165100002
J	Scragg, JL; Fearon, IM; Boyle, JP; Ball, SG; Varadi, G; Peers, C				Scragg, JL; Fearon, IM; Boyle, JP; Ball, SG; Varadi, G; Peers, C			Alzheimer's amyloid peptides mediate hypoxic up-regulation of L-type Ca2+ channels	FASEB JOURNAL			English	Article						chronic hypoxia; Alzheimer's disease; ion channel	PRESYNAPTIC CALCIUM CHANNELS; EATON MYASTHENIC SYNDROME; PRECURSOR PROTEIN; BETA-PEPTIDES; CAROTID-BODY; CELLULAR MECHANISMS; CELLS; CHEMORECEPTORS; INVOLVEMENT; SECRETASE	We examined the effects of chronic hypoxia on recombinant human L-type Ca2+ channel alpha(1C) subunits stably expressed in HEK 293 cells, using whole-cell patch-clamp recordings. Current density was dramatically increased following 24 h exposure to chronic hypoxia (CH), and membrane channel protein levels were enhanced. CH also increased the levels of Alzheimer's amyloid beta peptides (AbetaPs), determined immunocytochemically. Pharmacological prevention of AbetaP production (via exposure to inhibitors of secretase enzymes that are required to cleave AbetaP from its precursor protein) prevented hypoxic augmentation of currents, as did inhibition of vesicular trafficking with bafilomycin A1. The enhancing effect of AbetaPs or CH were abolished following incubation with the monoclonal 3D6 antibody, raised against the extracellular N' terminus of AbetaP. Immunolocalization and immunoprecipitation studies provided compelling evidence that AbetaPs physically associated with the a1C subunit, and this association was promoted by hypoxia. These data suggest an important role for AbetaPs in mediating the increase in Ca2+ channel activity following CH and show that AbetaPs act post-transcriptionally to promote a1C subunit insertion into (and/or retention within) the plasma membrane. Such an action will likely contribute to the Ca2+ dyshomeostasis of Alzheimer's disease and may contribute to the mechanisms underlying the known increased incidence of this neurodegenerative disease following hypoxic	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Leeds; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; McMaster University	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk		Peers, Chris/0000-0002-8354-346X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL 22619] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Fearon IM, 2000, CIRC RES, V87, P537, DOI 10.1161/01.RES.87.7.537; Fearon IM, 1997, J PHYSIOL-LONDON, V500, P551, DOI 10.1113/jphysiol.1997.sp022041; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; Green KN, 2002, J NEUROCHEM, V81, P1043, DOI 10.1046/j.1471-4159.2002.00907.x; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Johnson D, 1997, EDN, V42, P94; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; LANG B, 1987, J PHYSIOL-LONDON, V390, P257, DOI 10.1113/jphysiol.1987.sp016698; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; Masters CL, 1998, BRIT MED J, V316, P446, DOI 10.1136/bmj.316.7129.446; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Moroney J T, 1997, Ann N Y Acad Sci, V826, P433, DOI 10.1111/j.1749-6632.1997.tb48498.x; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; PEERS C, 1993, NEUROSCI LETT, V153, P45, DOI 10.1016/0304-3940(93)90073-T; Peers C, 2001, RESP RES, V2, P145, DOI 10.1186/rr51; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; STEA A, 1995, J NEUROSCI, V15, P2192, DOI 10.1523/JNEUROSCI.15-03-02192.1995; Taylor SC, 1999, J BIOL CHEM, V274, P31217, DOI 10.1074/jbc.274.44.31217; Ueda K, 1997, J NEUROCHEM, V68, P265; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016	42	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					150	+		10.1096/fj.04-2659fje	http://dx.doi.org/10.1096/fj.04-2659fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15494446				2022-12-25	WOS:000224849900015
J	Szeto, HH; Schiller, PW; Zhao, KS; Luo, GX				Szeto, HH; Schiller, PW; Zhao, KS; Luo, GX			Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides	FASEB JOURNAL			English	Article						membrane transduction; mitochondria; permeability transition; cytoplasm; confocal microscopy	BASIC DOMAIN; PLASMA-MEMBRANE; CYTOCHROME-C; PEPTIDES; TAT; HIV-1; INTERNALIZATION; MECHANISM; DELIVERY; ANALOGS	Fluorescent labels are commonly used to investigate the mechanisms of cellular uptake and intracellular distribution of cell-penetrating peptides. However, labels such as fluorescein and rhodamine are relatively large and very lipophilic and may significantly alter physicochemical properties of small peptides. To minimize the impact of the fluorescent probe on a tetrapeptide, we substituted one of the amino acids (Lys(4)) in a tetrapeptide ([Dmt(1)]DALDA, Dmt- D-Arg-Phe-Lys-NH2 where Dmt = 2', 6'-dimethyltyrosine) with two different fluorescent amino acids (beta-dansyl-L-alpha,beta-diaminopropionic acid (dnsDap(4)) or beta-anthraniloyl-L-alpha,beta-diaminopropionic acid (atnDap(4))). Initial studies with confocal laser scanning microscopy (CLSM) showed very different localization patterns for the two fluorescent analogs, with [Dmt(1), atnDap(4)] DALDA showing mitochondrial localization and [Dmt(1), dnsDap(4)] DALDA showing diffuse cytoplasmic localization. Studies with isolated mouse liver mitochondria suggested that [Dmt(1), dnsDap(4)] DALDA targeted the mitochondrial matrix resulting in mitochondrial depolarization, opening of the permeability transition pore, mitochondrial swelling, and rapid release of the peptide into the cytoplasm. In contrast, [Dmt(1), atnDap(4)] DALDA was retained in the inner mitochondrial membrane and did not induce mitochondrial swelling. Furthermore, [Dmt(1), atnDap(4)] DALDA protected mitochondria against Ca2+-induced swelling. Importantly, the unlabeled parent peptide [Dmt(1)] DALDA behaved like [Dmt(1), atnDap(4)] DALDA and was mitoprotective. These findings suggest that experimental results obtained with fluorescent labels must be interpreted with caution, and the use of multiple fluorophores, together with confirmation using the original or radiolabeled molecule, is recommended.	Cornell Univ, Joan & Sanford I Weill Med coll, Dept Pharmacol, New York, NY 10021 USA; Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada	Cornell University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Szeto, HH (corresponding author), Cornell Univ, Joan & Sanford I Weill Med coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	hhszeto@med.cornell.edu			NIDA NIH HHS [DA08924] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008924] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENJOUAD A, 1993, FEBS LETT, V319, P119, DOI 10.1016/0014-5793(93)80049-Z; Berezowska I, 2003, PEPTIDES, V24, P1195, DOI 10.1016/j.peptides.2003.07.004; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P469, DOI 10.1006/bbrc.2001.4790; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; VARDANIS A, 1977, J BIOL CHEM, V252, P807; Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Zhao GM, 2003, J PHARMACOL EXP THER, V307, P947, DOI 10.1124/jpet.103.054775; Zhao KS, 2003, J PHARMACOL EXP THER, V304, P425, DOI 10.1124/jpet.102.040147	22	70	72	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					118	+		10.1096/fj.04-1982fje	http://dx.doi.org/10.1096/fj.04-1982fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15489247				2022-12-25	WOS:000224849900017
J	Kawakatsu, T; Ogita, H; Fukuhara, T; Fukuyama, T; Minami, Y; Shimizu, K; Takai, Y				Kawakatsu, T; Ogita, H; Fukuhara, T; Fukuyama, T; Minami, Y; Shimizu, K; Takai, Y			Vav2 as a Rac-GDP/GTP exchange factor responsible for the nectin-induced, c-Src- and Cdc42-mediated activation of Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; SMALL G-PROTEIN; ADHERENS JUNCTIONS; TYROSINE PHOSPHORYLATION; CADHERIN SUPERFAMILY; TRANS-INTERACTIONS; KINASE ACTIVATION; FAMILY PROTEINS; HOMOLOGY DOMAIN; CDC42	Nectins are Ca2+ -independent immunoglobulin-like cell-cell adhesion molecules that form homo. and hetero-trans-dimers (trans-interactions). Nectins first form cell-cell contact and then recruit cadherins to the nectin-based cell-cell contact sites to form adherens junctions cooperatively with cadherins. In addition, the trans-interactions of nectins induce the activation of Cdc42 and Rac small G proteins, which enhances the formation of adherens junctions by forming filopodia and lamellipodia, respectively. The trans-interactions of nectins first recruit and activate c-Src at the nectinbased cell-cell contact sites. c-Src then phosphorylates and activates FRG, a Cdc42-GDP/GTP exchange factor (GEF) for Cdc42. The activation of both c-Src and Cdc42 by FRG is necessary for the activation of Rac, but the Rac-GEF responsible for this activation of Rac remains unknown. We showed here that the nectin-induced activation of Rac was inhibited by a dominant negative mutant of Vav2, a Rac-GEF. Nectins recruited and tyrosine-phosphorylated Vav2 through c-Src at the nectinbased cell-cell contact sites, whereas Cdc42 was not necessary for the nectin-induced recruitment of Vav2 or the nectin-induced, c-Src-mediated tyrosine phosphorylation of Vav2. Cdc42 activated through c-Src then enhanced the GEF activity of tyrosine-phosphorylated Vav2 on Rac1. These results indicate that Vav2 is a GEF responsible for the nectin-induced, c-Src-, and Cdc42-mediated activation of Rac.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ogita, Hisakazu/AAE-4416-2020	Ogita, Hisakazu/0000-0001-6750-1668				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; FUKUYAMA T, 2004, J BIOL CHEM; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takeichi M, 2000, PHILOS T ROY SOC B, V355, P885, DOI 10.1098/rstb.2000.0624; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takenawa T, 2001, J CELL SCI, V114, P1801; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Yagi T, 2000, GENE DEV, V14, P1169; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YONEMURA S, 1995, J CELL SCI, V108, P127	53	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4940	4947		10.1074/jbc.M408710200	http://dx.doi.org/10.1074/jbc.M408710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15485841	hybrid			2022-12-25	WOS:000227096600115
J	Church, C; Goehring, B; Forsha, D; Wazny, P; Poyton, RO				Church, C; Goehring, B; Forsha, D; Wazny, P; Poyton, RO			A role for Pet100p in the assembly of yeast cytochrome c oxidase - Interaction with a subassembly that accumulates in a pet100 mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; NEUROSPORA-CRASSA; MOLECULAR CHAPERONES; PROTEIN-SYNTHESIS; 2.8 ANGSTROM; HUMAN-CELLS; MITOCHONDRIAL; GENE; SUBUNIT	The biogenesis of multimeric protein complexes of the inner mitochondrial membrane in yeast requires a number of nuclear-coded ancillary proteins. One of these, Pet100p, is required for cytochrome c oxidase. Previous studies have shown that Pet100p is not required for the synthesis, processing, or targeting of cytochrome c oxidase subunits to the mitochondrion nor for heme A biosynthesis. Here, we report that Pet100p does not affect the localization of cytochrome c oxidase subunit polypeptides to the inner mitochondrial membrane but instead functions after they have arrived at the inner membrane. We have also localized Pet100p to the inner mitochondrial membrane in wild type cells, where it is present in a subassembly ( Complex A) with cytochrome c oxidase subunits VII, VIIa, and VIII. Pet100p does not interact with the same subunits after they have been assembled into the holoenzyme. In addition, we have identified two subassemblies that are present in pet100 null mutant cells: one subassembly (Complex A') is composed of subunits VII, VIIa, and VIII but not Pet100p, and another subassembly ( Complex B) is composed of subunits Va and VI. Because pet100 null mutant cells lack assembled cytochrome c oxidase but accumulate Complexes A' and B it appears likely that these subassemblies of cytochrome c oxidase subunits are intermediates along an assembly pathway for holocytochrome c oxidase and that Pet100p functions in this pathway to facilitate the interaction(s) between Complex A' and other cytochrome c oxidase subassemblies and subunits.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Poyton, RO (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	Poyton@spot.Colorado.EDU		Forsha, Daniel/0000-0003-1999-6509	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barros MH, 2004, J BIOL CHEM, V279, P31943, DOI 10.1074/jbc.M405014200; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BLACKSCHAEFER CL, 1991, BIOCHEM J, V274, P199, DOI 10.1042/bj2740199; Burke PV, 1998, J EXP BIOL, V201, P1163; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; Carlson CG, 2003, J BIOL CHEM, V278, P3770, DOI 10.1074/jbc.M209893200; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Church C, 1998, J EXP BIOL, V201, P1729; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; DUHL DMJ, 1991, THESIS U COLORADO BO; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Forsha D, 2001, BIOCHEM SOC T, V29, P436, DOI 10.1042/BST0290436; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GLICK B, 1991, ANNU REV GENET, V25, P21; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Herrmann JM, 2004, J BIOL CHEM, V279, P2507, DOI 10.1074/jbc.M310468200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PON L, 1991, MOL CELLULAR BIOL YE, P333; POWER SD, 1984, J BIOL CHEM, V259, P6564; Poyton R O, 1996, Methods Enzymol, V264, P36, DOI 10.1016/S0076-6879(96)64006-3; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; POYTON RO, 1975, J BIOL CHEM, V250, P762; POYTON RO, 1975, P NATL ACAD SCI USA, V72, P172, DOI 10.1073/pnas.72.1.172; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; POYTON RO, 1996, ADV MOL CEL, V17, P247; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SCHWAB AJ, 1972, EUR J BIOCHEM, V30, P511, DOI 10.1111/j.1432-1033.1972.tb02122.x; SEBALD W, 1972, EUR J BIOCHEM, V30, P413, DOI 10.1111/j.1432-1033.1972.tb02112.x; SEBALD W, 1973, EUR J BIOCHEM, V38, P311, DOI 10.1111/j.1432-1033.1973.tb03064.x; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VELOURS J, 1977, ARCH BIOCHEM BIOPHYS, V182, P295, DOI 10.1016/0003-9861(77)90310-1; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; YASUHARA T, 1994, J BIOCHEM-TOKYO, V115, P1166, DOI 10.1093/oxfordjournals.jbchem.a124474	65	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1854	1863		10.1074/jbc.M410726200	http://dx.doi.org/10.1074/jbc.M410726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15507444	hybrid			2022-12-25	WOS:000226341700019
J	Cardinale, A; Filesi, I; Vetrugno, V; Pocchiari, M; Sy, MS; Biocca, S				Cardinale, A; Filesi, I; Vetrugno, V; Pocchiari, M; Sy, MS; Biocca, S			Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FV FRAGMENTS; INTRACELLULAR IMMUNIZATION; BIOCHEMICAL-PROPERTIES; RETROGRADE TRANSPORT; EXPRESSION; ANTIBODIES; CELLS; DIFFERENTIATION; REPLICATION; DEGRADATION	The conversion of the normal cellular prion protein (PrPC) into the abnormal scrapie isoform (PrPSc) is a key feature of prion diseases. The pathogenic mechanisms and the subcellular sites of the conversion are complex and not completely understood. In particular, little is known on the role of the early compartment of the secretory pathway in the processing of PrPC and in the pathogenesis of prion diseases. In order to interfere with the intracellular traffic of endogenous PrPC we have generated two anti-prion single chain antibody fragments (scFv) directed against different epitopes, each fragment tagged either with a secretory leader or with the ER retention signal KDEL. The stable expression of these constructs in PC12 cells allowed us to study their specific effects on the synthesis, maturation, and processing of endogenous PrPC and on PrPSc formation. We found that ER-targeted anti-prion scFvs retain PrPC in the ER and inhibit its translocation to the cell surface. Retention in the ER strongly affects the maturation and glycosylation state of PrPC, with the appearance of a new aberrant endo-H sensitive glycosylated species. Interestingly, ER-trapped PrPC acquires detergent insolubility and proteinase K resistance. Furthermore, we show that ER-targeted anti-prion antibodies prevent PrPSc accumulation in nerve growth factor-differentiated PC12 cells, providing a new tool to study the molecular pathology of prion diseases.	Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44120 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44120 USA	University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); Case Western Reserve University; Case Western Reserve University	Biocca, S (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	biocca@med.uniroma2.it	Pocchiari, Maurizio/J-8443-2018; Biocca, Silvia/AAH-7310-2021	Pocchiari, Maurizio/0000-0002-7269-2486; Biocca, Silvia/0000-0001-5838-4674; vetrugno, vito antonio/0000-0001-7126-1011				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Cardinale A, 2004, METHODS, V34, P171, DOI 10.1016/j.ymeth.2004.04.006; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; CATTANEO A, 1997, INTRACELLULAR ANTIBO; Caughey B, 2003, BRIT MED BULL, V66, P109, DOI 10.1093/bmb/66.1.109; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Chiesa R, 2000, J NEUROCHEM, V75, P72, DOI 10.1046/j.1471-4159.2000.0750072.x; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; CREBBER A, 1997, J IMMUNOL METHODS, V201, P35; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Figini M, 2003, GENE THER, V10, P1018, DOI 10.1038/sj.gt.3301962; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; GOLDFARB LG, 1995, ANNU REV MED, V46, P57; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu YP, 2003, J NEUROCHEM, V84, P10, DOI 10.1046/j.1471-4159.2003.01255.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harris B, 2003, CLIO MED, V71, P85; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kang SC, 2003, J PATHOL, V199, P534, DOI 10.1002/path.1294; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Roovers RC, 1998, BRIT J CANCER, V78, P1407, DOI 10.1038/bjc.1998.700; RUBENSTEIN R, 1984, J GEN VIROL, V65, P2191, DOI 10.1099/0022-1317-65-12-2191; RUBENSTEIN R, 1990, J GEN VIROL, V71, P825, DOI 10.1099/0022-1317-71-4-825; Sblattero D, 2000, NAT BIOTECHNOL, V18, P75, DOI 10.1038/71958; Schachter H, 2001, CELL MOL LIFE SCI, V58, P1085, DOI 10.1007/PL00000923; Sigurdsson EM, 2003, NEUROSCI LETT, V336, P185, DOI 10.1016/S0304-3940(02)01192-8; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Weissmann C, 2001, PHILOS T R SOC B, V356, P177, DOI 10.1098/rstb.2000.0763; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	58	62	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					685	694		10.1074/jbc.M407360200	http://dx.doi.org/10.1074/jbc.M407360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513919	hybrid			2022-12-25	WOS:000226025100081
J	Mathews, WR; Wang, FD; Eide, DJ; Van Doren, M				Mathews, WR; Wang, FD; Eide, DJ; Van Doren, M			Drosophila fear of intimacy encodes a Zrt/IRT-like protein (ZIP) family zinc transporter functionally related to mammalian ZIP proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SEGMENTS; ARABIDOPSIS-THALIANA; STRUCTURE PREDICTION; TOPOLOGY PREDICTION; MEMBRANE-PROTEINS; BREAST-CANCER; GENE ENCODES; IDENTIFICATION; CADHERIN; HYDROPHOBICITY	Zinc is essential for many cellular processes, and its concentration in the cell must be tightly controlled. The Zrt/IRT-like protein ( ZIP) family of zinc transporters have recently been identified as the main regulators of zinc influx into the cytoplasm ( 1); however, little is known about their in vivo roles. Previously, we have shown that fear of intimacy (foi) encodes a putative member of the ZIP family that is essential for development in Drosophila ( 2). Here we demonstrate that FOI can act as an ion transporter in both yeast and mammalian cell assays and is specific for zinc. We also provide insight into the mechanism of action of the ZIP family through membrane topology and structure-function analyses of FOI. Our work demonstrates that Drosophila FOI is closely related to mammalian ZIP proteins at the functional level and that Drosophila represents an ideal system for understanding the in vivo roles of this family. In addition, this work indicates that the control of zinc by ZIP transporters may play a critical role in regulating developmental processes.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	Johns Hopkins University; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Van Doren, M (corresponding author), Johns Hopkins Univ, Dept Biol, 302 Mudd Hall,3400 N Charles St, Baltimore, MD 21218 USA.	vandoren@jhu.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NIGMS NIH HHS [GM63023, GM56285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285, R01GM063023] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baggett JJ, 2003, GENETICS, V165, P1661; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Begum NA, 2002, GENOMICS, V80, P630, DOI 10.1006/geno.2002.7000; Chidgey M, 2001, J CELL BIOL, V155, P821, DOI 10.1083/jcb.200105009; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Hambidge M, 2000, J NUTR, V130, p1344S, DOI 10.1093/jn/130.5.1344S; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Jenkins AB, 2003, DEVELOPMENT, V130, P4417, DOI 10.1242/dev.00639; JURETIC D, 1993, BIOPOLYMERS, V33, P255, DOI 10.1002/bip.360330208; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Kury Sebastien, 2003, Hum Mutat, V22, P337, DOI 10.1002/humu.9178; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; MANNING DL, 1994, EUR J CANCER, V30A, P675, DOI 10.1016/0959-8049(94)90543-6; MINET M, 1992, PLANT J, V2, P417; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Persson B, 1996, PROTEIN SCI, V5, P363; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Tomiya N, 2003, ACCOUNTS CHEM RES, V36, P613, DOI 10.1021/ar020202v; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Van Doren M, 2003, DEVELOPMENT, V130, P2355, DOI 10.1242/dev.00454; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, HUM MOL GENET, V13, P563, DOI 10.1093/hmg/ddh049; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	50	47	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					787	795		10.1074/jbc.M411308200	http://dx.doi.org/10.1074/jbc.M411308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509557	hybrid			2022-12-25	WOS:000226025100092
J	Ruan, BF; Bovee, ML; Sacher, M; Stathopoulos, C; Poralla, K; Francklyn, CS; Soll, D				Ruan, BF; Bovee, ML; Sacher, M; Stathopoulos, C; Poralla, K; Francklyn, CS; Soll, D			A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; ANTIBIOTIC BORRELIDIN; BIOSYNTHETIC-ENZYMES; IN-VITRO; ZINC ION; PROTEIN; ACID; RESISTANCE; MUTATIONS; DESIGN	Borrelidin, a compound with anti-microbial and anti-angiogenic properties, is a known inhibitor of bacterial and eukaryal threonyl-tRNA synthetase (ThrRS). The inhibition mechanism of borrelidin is not well understood. Archaea contain archaeal and bacterial genre ThrRS enzymes that can be distinguished by their sequence. We explored species-specific borrelidin inhibition of ThrRSs. The activity of ThrRS from Sulfolobus solfataricus and Halobacterium sp. NRC-1 was inhibited by borrelidin, whereas ThrRS enzymes from Methanocaldococcus jannaschii and Archaeoglobus fulgidus were not. In Escherichia coli ThrRS, borrelidin binding induced a conformational change, and threonine was not activated as shown by ATP-PPi exchange and a transient kinetic assay measuring intrinsic tryptophan fluorescence changes. These assays further showed that borrelidin is a noncompetitive tight binding inhibitor of E. coli ThrRS with respect to threonine and ATP. Genetic selection of borrelidin-resistant mutants showed that borrelidin binds to a hydrophobic region (Thr-307, His-309, Cys-334, Pro-335, Leu-489, Leu-493) proximal to the zinc ion at the active site of the E. coli ThrRS. Mutating residue Leu-489 --> Trp reduced the space of the hydrophobic cluster and resulted in a 1500-fold increase of the K-i value from 4 nM to 6 muM. An alignment of ThrRS sequences showed that this cluster is conserved in most organisms except for some Archaea ( e. g. M. jannaschii, A. fulgidus) and some pathogens ( e. g. Helicobacter pylori). This study illustrates how one class of natural product inhibitors affects aminoacyl-tRNA synthetase function, providing potentially useful information for structure-based inhibitor design.	Univ Vermont, Dept Biochem, Burlington, VT 05405 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Tubingen, Inst Mikrobiol, D-72076 Tubingen, Germany	University of Vermont; Yale University; Yale University; Eberhard Karls University of Tubingen	Francklyn, CS (corresponding author), Univ Vermont, Dept Biochem, Hlth Sci Complex, Burlington, VT 05405 USA.	franck@emba.uvm.edu; soll@trna.chem.yale.edu		Stathopoulos, Constantinos/0000-0002-5699-4118	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022854, R01GM054899] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054899, R01 GM022854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Bovee ML, 2003, BIOCHEMISTRY-US, V42, P15102, DOI 10.1021/bi0355701; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Copeland R.A., 2000, ENZYMES PRACTICAL IN, P305; Cura V, 2000, EUR J BIOCHEM, V267, P379, DOI 10.1046/j.1432-1327.2000.01011.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Eastwood EL, 2003, BIOORG MED CHEM LETT, V13, P2235, DOI 10.1016/S0960-894X(03)00406-2; FREIST W, 1995, BIOL CHEM H-S, V376, P213; FROHLER J, 1980, J BACTERIOL, V143, P1135; Hanessian S, 2003, J AM CHEM SOC, V125, P13784, DOI 10.1021/ja030139k; HUTTER R, 1966, BIOCHEM Z, V344, P190; Ibba M, 2001, EMBO REP, V2, P382; Kawamura T, 2003, J ANTIBIOT, V56, P709, DOI 10.7164/antibiotics.56.709; Kitabatake M, 2002, J BIOL CHEM, V277, P23882, DOI 10.1074/jbc.M202639200; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; LOFTFIELD RB, 1973, METABOLIC INHIBITORS, P107; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; MONREAL J, 1970, BIOCHIM BIOPHYS ACTA, V199, P280, DOI 10.1016/0005-2787(70)90717-3; NASS G, 1969, BIOCHEM BIOPH RES CO, V34, P84, DOI 10.1016/0006-291X(69)90532-4; Olano C, 2004, CHEM BIOL, V11, P87, DOI 10.1016/j.chembiol.2003.12.018; Otoguro K, 2003, J ANTIBIOT, V56, P727, DOI 10.7164/antibiotics.56.727; PAETZ W, 1973, EUR J BIOCHEM, V35, P331, DOI 10.1111/j.1432-1033.1973.tb02843.x; PORALLA K, 1968, ARCH MIKROBIOL, V61, P143, DOI 10.1007/BF00412150; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Tsuchiya E, 2001, J ANTIBIOT, V54, P84, DOI 10.7164/antibiotics.54.84; Vong BG, 2003, ORG LETT, V5, P1617, DOI 10.1021/ol034243i; Walter F, 2002, EMBO J, V21, P760, DOI 10.1093/emboj/21.4.760; Williams J W, 1979, Methods Enzymol, V63, P437; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; YANAGISAWA T, 1994, J BIOL CHEM, V269, P24304	35	49	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					571	577		10.1074/jbc.M411039200	http://dx.doi.org/10.1074/jbc.M411039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507440	hybrid			2022-12-25	WOS:000226025100068
J	Xu, L; Peng, HB; Wu, DY; Hu, KP; Goldring, MB; Olsen, BR; Li, YF				Xu, L; Peng, HB; Wu, DY; Hu, KP; Goldring, MB; Olsen, BR; Li, YF			Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with Osteoarthritis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; MATRIX-METALLOPROTEINASE; GENE-EXPRESSION; CARTILAGE; CLONING; FAMILY; MOUSE; CHONDROCYTES; ADAMTS; P38	Human genetic studies indicate that mutations in type IX and XI collagens result in early-onset osteoarthritis (OA) with a wide spectrum of osteochondrodysplasia. However, a convincing causal chain of events underlying the role of these collagen mutations in the pathogenesis of OA has not been elucidated. Here we show that the expression of a cell surface collagen receptor, discoidin domain receptor 2 (DDR2), is increased in chondrocytes of the articular cartilage of knee joints in mice that develop OA as a result of a heterozygous mutation in type XI collagen. At the same time point, 6 months, we also found increased expression and activity of matrix metalloproteinase 13 (MMP-13) in the mutant mouse knee cartilage. The expression of both DDR2 and MMP-13 was increased in chondrocytes cultured on plates coated with native type II collagen but not on gelatin, and overexpression of DDR2, but not of a truncated form, was found to induce the expression of MMP-13 when chondrocytes were cultured on type II collagen but not on plastic. The DDR2-induced expression of MMP-13 appears to be specific, since we did not observe induction of MMP-1, MMP-3, MMP-8, ADAMTS-4, ADAMTS-5, and IL-1 transcripts in human chondrocytes or Mmp-3, Mmp-8, Adamts-4, Adamts-5, and Il-1 in mouse chondrocytes. Our data suggest that the defect in the cartilage matrix of mice that are heterozygous for a type XI collagen mutation (cho/+) permits activation and up-regulation of DDR2 in chondrocytes. This could be due to increased exposure of chondrocytes to type II collagen as a result of the decreased amount of type XI collagen in the mutant cartilage. The specific induction of MMP-13 by DDR2 in response to its cartilage-specific ligand, type II collagen, may contribute to cartilage damage in hereditary OA.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA; Harvard Univ, Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; New England Baptist Hospital; Harvard University; Harvard School of Dental Medicine	Li, YF (corresponding author), 188 Longwood Ave, Boston, MA 02115 USA.	yefu_li@hms.harvard.edu			NIAMS NIH HHS [R01-AR36819, P01-AR050245, R01-AR45378] Funding Source: Medline; NIA NIH HHS [R01-AG22021] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036819, P01AR050245, R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALVES F, 1995, ONCOGENE, V10, P609; APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; Diab M, 1993, Orthop Rev, V22, P165; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; DUANCE V C, 1991, Biochemical Society Transactions, V19, p376S; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; JIMENEZ SA, 1994, ANN RHEUM DIS, V53, P789, DOI 10.1136/ard.53.12.789; KARN T, 1993, ONCOGENE, V8, P3433; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LAI C, 1994, ONCOGENE, V9, P2567; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Loughlin J, 2002, RHEUM DIS CLIN N AM, V28, P95, DOI 10.1016/S0889-857X(03)00071-1; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; PEYRON JG, 1992, OSTEOARTHRITIS DIAGN, P15; Reginato AM, 2002, ARTHRITIS RES, V4, P337, DOI 10.1186/ar595; Ricke WA, 2002, BIOL REPROD, V66, P1083, DOI 10.1095/biolreprod66.4.1083; SCOTT JC, 1999, OSTEOARTHRITIS CLIN, P20; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Simonet WS, 2002, MOL GENET METAB, V77, P31; Spector Tim D, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS39; Spranger J, 1998, PEDIATR RADIOL, V28, P745, DOI 10.1007/s002470050459; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tetlow LC, 2001, ARTHRITIS RHEUM-US, V44, P585, DOI 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Vikkula M, 1996, ANN MED, V28, P301, DOI 10.3109/07853899608999084; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Wang JC, 2002, J AUTOIMMUN, V19, P161, DOI 10.1006/jaut.2002.0606; WEISS C, 1973, FED PROC, V32, P1459; Xu L, 2003, ARTHRITIS RHEUM, V48, P2509, DOI 10.1002/art.11233; Xu L, 2001, MATRIX BIOL, V20, P147, DOI 10.1016/S0945-053X(00)00138-4	40	142	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					548	555		10.1074/jbc.M411036200	http://dx.doi.org/10.1074/jbc.M411036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509586	hybrid			2022-12-25	WOS:000226025100065
J	Grote, K; Bavendiek, U; Grothusen, C; Flach, I; Hilfiker-Kleiner, D; Drexler, H; Schieffer, B				Grote, K; Bavendiek, U; Grothusen, C; Flach, I; Hilfiker-Kleiner, D; Drexler, H; Schieffer, B			Stretch-inducible expression of the angiogenic factor CCN1 in vascular smooth muscle cells is mediated by Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; MULTIPLE SIGNALING PATHWAYS; MESSENGER-RNA EXPRESSION; HUMAN ENDOTHELIAL-CELLS; GROWTH-FACTOR; MECHANICAL STRETCH; ANGIOTENSIN-II; CYR61; INDUCTION; STRAIN	CCN1 is an angiogenic factor that promotes cell adhesion, proliferation, and differentiation. CCN1-deficient mice suffer embryonic death because of vascular defects, demonstrating that CCN1 is required for vessel development. Because mechanical stretch may act as a trigger for vessel development, we investigated the impact of mechanical stretch on the regulatory mechanism of CCN1 expression. Mechanical stretch rapidly enhances CCN1 expression and release in vascular smooth muscle cells (VSMC) in vitro and CCN1 expression in murine aortic segments in vivo. Transfection experiments of VSMC with deletion constructs of the CCN1 promoter revealed the regulatory region responsible for the stretch-induced CCN1 expression in the similar to200-bp promoter region upstream of the TATA-box containing potential binding sites for early growth response-1 (Egr1), nuclear factor of activated T-cells and cAMP response element binding protein. Decoy oligonucleotides to Egr-1, but not to nuclear factor of activated T-cells or cAMP response element binding protein, abolished the stretch-induced transcription of CCN1. In addition, mutagenesis of the Egr-1 binding site within the CCN1 promoter completely blunted the stretch-induced activation of the promoter. Furthermore, mechanical stretch induced the expression and DNA-binding activity of Egr-1 in VSMC as demonstrated by Western blot and electromobility shift assay. Moreover, a pressure over-load-dependent de novo synthesis of Egr-1 was observed after aortic banding. These findings indicate that mechanical stretch leads to enhanced expression of CCN1 via the mechanosensitive transcription factor Egr-1, suggesting a central role for mechanical stretch in the regulation of CCN1-dependent pro-angiogenic potency.	Hannover Med Sch, Abt Kardiol & Angiol, Dept Cardiol & Angiol, D-30625 Hannover, Germany	Hannover Medical School	Grote, K (corresponding author), Hannover Med Sch, Abt Kardiol & Angiol, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	grote.karsten@mh-hannover.de		Grote, Karsten/0000-0001-7914-3159				Akuzawa N, 2000, ARTERIOSCL THROM VAS, V20, P377, DOI 10.1161/01.ATV.20.2.377; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bavendiek U, 2002, J BIOL CHEM, V277, P25032, DOI 10.1074/jbc.M204003200; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; Brading AF, 1997, SCAND J UROL NEPHROL, V31, P51; Chaqour B, 2002, AM J PHYSIOL-ENDOC M, V283, pE765, DOI 10.1152/ajpendo.00131.2002; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Dzau V J, 1993, Curr Opin Nephrol Hypertens, V2, P27, DOI 10.1097/00041552-199301000-00004; Fuchs M, 2003, FASEB J, V17, P2118, DOI 10.1096/fj.03-0331fje; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Morawietz H, 1999, CIRC RES, V84, P678, DOI 10.1161/01.RES.84.6.678; Naftilan A J, 1994, Curr Opin Nephrol Hypertens, V3, P218, DOI 10.1097/00041552-199403000-00014; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Schunkert H, 1995, J CLIN INVEST, V96, P2768, DOI 10.1172/JCI118346; Smith JD, 2001, ENDOTHELIUM-J ENDOTH, V8, P41, DOI 10.3109/10623320109063156; Stula M, 2000, MOL CELL BIOCHEM, V210, P101, DOI 10.1023/A:1007126218740; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Tamura I, 2001, AM J PHYSIOL-CELL PH, V281, pC1524, DOI 10.1152/ajpcell.2001.281.5.C1524; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu KJ, 2000, INT J MOL MED, V6, P433; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X; Yamaguchi S, 2002, LAB INVEST, V82, P949, DOI 10.1097/01.LAB.0000020408.77307.E9	33	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55675	55681		10.1074/jbc.M406532200	http://dx.doi.org/10.1074/jbc.M406532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492009	hybrid			2022-12-25	WOS:000225960800087
J	Ran, QT; Liang, HY; Gu, MJ; Qi, WB; Walter, CA; Roberts, LJ; Herman, B; Richardson, A; Van Remmen, H				Ran, QT; Liang, HY; Gu, MJ; Qi, WB; Walter, CA; Roberts, LJ; Herman, B; Richardson, A; Van Remmen, H			Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; LIPID-PEROXIDATION; OXIDANT STRESS; CYTOCHROME-C; DAMAGE; CELLS; INJURY; GENE; DIQUAT; PHGPX	Glutathione peroxidase 4 (Gpx4) is uniquely involved in the detoxification of oxidative damage to membrane lipids. Our previous studies showed that Gpx4 is essential for mouse survival and that Gpx4 deficiency makes cells vulnerable to oxidative injury. In the present study, we generated two lines of transgenic mice overexpressing Gpx4 (Tg(GPX4) mice) using a genomic clone containing the human GPX4 gene. Both lines of Tg(GPX4) mice, Tg5 and Tg6, had elevated levels of Gpx4 (mRNA and protein) in all tissues investigated, and overexpression of Gpx4 did not cause alterations in activities of glutathione peroxidase 1, catalase, Cu/Zn superoxide dismutase, and manganese superoxide dismutase. The human GPX4 transgene rescued the lethal phenotype of null mutation of the mouse Gpx4 gene, indicating that the transgene can replace the essential role of mouse Gpx4 in mouse development. Cell death induced by t-butylhydroperoxide and diquat was significantly less in murine embryonic fibroblasts from Tg(GPX4) mice compared with wild type mice. Liver damage and lipid peroxidation induced by diquat were reduced significantly in Tg(GPX4) mice. In addition, diquat-induced apoptosis was decreased in Tg(GPX4) mice, as evidenced by attenuated caspase-3 activation and reduced cytochrome c release from mitochondria. These data demonstrate that Gpx4 plays a role in vivo in the mechanism of apoptosis induced by oxidative stress that most likely occurs through oxidative damage to mitochondrial phospholipids such as cardiolipin.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, San Antonio Canc Inst, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Vanderbilt University; Vanderbilt University	Van Remmen, H (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, GRECC 182, 7400 Merton Mintor Blvd, San Antonio, TX 78284 USA.	vanremmen@uthscsa.edu	Liang, Hanyu/A-1066-2010		NIA NIH HHS [P01 AG 19316, K01 AG 22014, 1P30 AG 13319] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013319, K01AG022014, P01AG019316] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANTUNES F, 1995, FREE RADICAL BIO MED, V19, P669, DOI 10.1016/0891-5849(95)00040-5; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; AWAD JA, 1994, J PHARMACOL EXP THER, V270, P858; Barriere G, 2004, ANTICANCER RES, V24, P1387; Brigelius-Flohe R, 2000, ATHEROSCLEROSIS, V152, P307, DOI 10.1016/S0021-9150(99)00486-4; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chen CJ, 2000, PROSTAG LEUKOTR ESS, V62, P261, DOI 10.1103/PhysRevD.62.094026; Chen XL, 2003, MECH AGEING DEV, V124, P219, DOI 10.1016/S0047-6374(02)00161-6; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Esworthy RS, 2000, AM J PHYSIOL-GASTR L, V279, pG426, DOI 10.1152/ajpgi.2000.279.2.G426; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Fu YX, 1999, FREE RADICAL BIO MED, V27, P605, DOI 10.1016/S0891-5849(99)00104-5; Girotti AW, 1998, J LIPID RES, V39, P1529; Guo ZM, 1998, MUTAT RES-DNA REPAIR, V409, P37, DOI 10.1016/S0921-8777(98)00041-X; Guo ZM, 2001, MECH AGEING DEV, V122, P1771, DOI 10.1016/S0047-6374(01)00298-6; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hurst R, 2001, FREE RADICAL BIO MED, V31, P1051, DOI 10.1016/S0891-5849(01)00685-2; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; Jones GM, 2000, J TOXICOL-CLIN TOXIC, V38, P123, DOI 10.1081/CLT-100100926; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Mylonas C, 1999, IN VIVO, V13, P295; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Ran QT, 2003, FREE RADICAL BIO MED, V35, P1101, DOI 10.1016/S0891-5849(03)00466-0; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; ROHN TT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P67, DOI 10.1016/0005-2736(93)90277-7; Sakamoto H, 2002, J BIOL CHEM, V277, P50431, DOI 10.1074/jbc.M204190200; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; SMITH CV, 1985, J PHARMACOL EXP THER, V235, P172; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; van Kuijk F J, 1985, J Free Radic Biol Med, V1, P421, DOI 10.1016/0748-5514(85)90156-4; Wang HP, 2001, FREE RADICAL BIO MED, V30, P825, DOI 10.1016/S0891-5849(01)00469-5; Yagi K, 1996, BIOCHEM BIOPH RES CO, V219, P486, DOI 10.1006/bbrc.1996.0260; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x	45	184	190	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55137	55146		10.1074/jbc.M410387200	http://dx.doi.org/10.1074/jbc.M410387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496407	hybrid			2022-12-25	WOS:000225960800020
J	Xiao, KH; Shenoy, SK; Nobles, K; Lefkowitz, RJ				Xiao, KH; Shenoy, SK; Nobles, K; Lefkowitz, RJ			Activation-dependent conformational changes in beta-arrestin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CARBOXYL-TERMINAL REGION; CRYSTAL-STRUCTURE; BETA-ARRESTINS; LIMITED PROTEOLYSIS; VISUAL ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATED RHODOPSIN; CLATHRIN ADAPTER; BINDING	beta-Arrestins are multifunctional adaptor proteins, which mediate desensitization, endocytosis, and alternate signaling pathways of seven membrane-spanning receptors (7MSRs). Crystal structures of the basal inactive state of visual arrestin (arrestin 1) and beta-arrestin 1 (arrestin 2) have been resolved. However, little is known about the conformational changes that occur in beta-arrestins upon binding to the activated phosphorylated receptor. Here we characterize the conformational changes in beta-arrestin 2 (arrestin 3) by comparing the limited tryptic proteolysis patterns and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) profiles of beta-arrestin 2 in the presence of a phosphopeptide (V2R-pp) derived from the C terminus of the vasopressin type II receptor (V2R) or the corresponding nonphosphopeptide (V2R-np). V2R-pp binds to beta-arrestin 2 specifically, whereas V2R-np does not. Activation of beta-arrestin 2 upon V2R-pp binding involves the release of its C terminus, as indicated by exposure of a previously inaccessible cleavage site, one of the polar core residues Arg(394), and rearrangement of its N terminus, as indicated by the shielding of a previously accessible cleavage site, residue Arg(8). Interestingly, binding of the polyanion heparin also leads to release of the C terminus of beta-arrestin 2; however, heparin and V2R-pp have different binding site(s) and/or induce different conformational changes in beta-arrestin 2. Release of the C terminus from the rest of beta-arrestin 2 has functional consequences in that it increases the accessibility of a clathrin binding site (previously demonstrated to lie between residues 371 and 379) thereby enhancing clathrin binding to beta-arrestin 2 by 10-fold. Thus, the V2R-pp can activate beta-arrestin 2 in vitro, most likely mimicking the effects of an activated phosphorylated 7MSR. These results provide the first direct evidence of conformational changes associated with the transition of beta-arrestin 2 from its basal inactive conformation to its biologically active conformation and establish a system in which receptor-beta-arrestin interactions can be modeled in vitro.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021; Xiao, Kunhong/AAG-4275-2020	Shenoy, Sudha/0000-0002-2565-4663; Xiao, Kunhong/0000-0002-1069-1226	NHLBI NIH HHS [HL 70631, R01 HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R01HL070631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Huang SG, 2003, ARCH BIOCHEM BIOPHYS, V420, P40, DOI 10.1016/j.abb.2003.07.005; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li ZY, 2000, BBA-PROTEIN STRUCT M, V1481, P37, DOI 10.1016/S0167-4838(00)00121-7; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Varne A, 2002, FEBS LETT, V516, P129, DOI 10.1016/S0014-5793(02)02519-X; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200	32	109	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55744	55753		10.1074/jbc.M409785200	http://dx.doi.org/10.1074/jbc.M409785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15501822	hybrid			2022-12-25	WOS:000225960800096
J	Arniges, M; Vazquez, E; Fernandez-Fernandez, JM; Valverde, MA				Arniges, M; Vazquez, E; Fernandez-Fernandez, JM; Valverde, MA			Swelling-activated Ca2+ entry via TRPV4 channel is defective in cystic fibrosis airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; ARACHIDONIC-ACID RELEASE; HEAT-EVOKED ACTIVATION; PRIMARY CULTURES; CATION CHANNEL; PHORBOL ESTER; CL-CURRENTS; VR-OAC; CELLS; CFTR	The vertebrate transient receptor potential cationic channel TRPV4 has been proposed as an osmo- and mechanosensor channel. Studies using knock-out animal models have further emphasized the relevance of the TRPV4 channel in the maintenance of the internal osmotic equilibrium and mechanosensation. However, at the cellular level, there is still one important question to answer: does the TRPV4 channel generate the Ca2+ signal in those cells undergoing a Ca2+-dependent regulatory volume decrease (RVD) response? RVD in human airway epithelia requires the generation of a Ca2+ signal to activate Ca2+-dependent K+ channels. The RVD response is lost in airway epithelia affected with cystic fibrosis (CF), a disease caused by mutations in the cystic fibrosis transmembrane conductance regulator channel. We have previously shown that the defective RVD in CF epithelia is linked to the lack of swelling-dependent activation of Ca2+-dependent K+ channels. In the present study, we show the expression of TRPV4 in normal human airway epithelia, where it functions as the Ca2+ entry pathway that triggers the RVD response after hypotonic stress, as demonstrated by TRPV4 antisense experiments. However, cell swelling failed to trigger Ca2+ entry via TRPV4 channels in CF airway epithelia, although the channel's response to a specific synthetic activator, 4alpha-phorbol 12,13-didecanoate, was maintained. Furthermore, RVD was recovered in CF airway epithelia treated with 4alpha-phorbol 12,13-didecanoate. Together, these results suggest that defective RVD in CF airway epithelia might be caused by the absence of a TRPV4-mediated Ca2+ signal and the subsequent activation of Ca2+-dependent K+ channels.	Univ Pompeu Fabra, Lab Fisiol Mol, Unitat Senyalitzacio Cellular, Barcelona 08003, Spain	Pompeu Fabra University	Valverde, MA (corresponding author), Univ Pompeu Fabra, Lab Fisiol Mol, Unitat Senyalitzacio Cellular, C Dr Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@upf.edu	Fernández-Fernández, José Manuel M/M-8157-2015	Fernández-Fernández, José Manuel M/0000-0003-2330-8449; Valverde, Miguel A./0000-0002-6961-3361; Vazquez, Esther/0000-0003-1052-0424				Barriere H, 2003, AM J PHYSIOL-RENAL, V284, pF796, DOI 10.1152/ajprenal.00237.2002; Basavappa S, 1998, J NEUROPHYSIOL, V79, P1441, DOI 10.1152/jn.1998.79.3.1441; Belfodil R, 2003, AM J PHYSIOL-RENAL, V284, pF812, DOI 10.1152/ajprenal.00238.2002; Berguerand M, 1997, AM J RESP CELL MOL, V17, P481, DOI 10.1165/ajrcmb.17.4.2734; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BUSCH AE, 1992, BIOCHEM BIOPH RES CO, V184, P804, DOI 10.1016/0006-291X(92)90661-4; CARLSTEDTDUKE J, 1986, P NATL ACAD SCI USA, V83, P9202, DOI 10.1073/pnas.83.23.9202; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 1998, J GEN PHYSIOL, V111, P623, DOI 10.1085/jgp.111.5.623; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; FELIPE A, 1993, AM J PHYSIOL, V265, pC1230, DOI 10.1152/ajpcell.1993.265.5.C1230; Fernandez-Fernandez JM, 2002, AM J PHYSIOL-CELL PH, V283, pC1705, DOI 10.1152/ajpcell.00245.2002; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; GRAHAM A, 1992, J PHYSIOL-LONDON, V453, P475, DOI 10.1113/jphysiol.1992.sp019240; Guler AD, 2002, J NEUROSCI, V22, P6408; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; Lock H, 2000, J BIOL CHEM, V275, P34849, DOI 10.1074/jbc.C000633200; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Niemeyer MI, 2001, J BIOL CHEM, V276, P43166, DOI 10.1074/jbc.M107192200; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Porcelli AM, 1999, CELL MOL LIFE SCI, V56, P167, DOI 10.1007/s000180050015; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1985, J BIOL CHEM, V260, P1596; Sardini A, 2003, BBA-BIOMEMBRANES, V1618, P153, DOI 10.1016/j.bbamem.2003.10.008; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; VALVERDE MA, 1995, P NATL ACAD SCI USA, V92, P9038, DOI 10.1073/pnas.92.20.9038; Valverde MA, 2000, CELL PHYSIOL BIOCHEM, V10, P321, DOI 10.1159/000016365; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	48	128	141	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54062	54068		10.1074/jbc.M409708200	http://dx.doi.org/10.1074/jbc.M409708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489228	hybrid			2022-12-25	WOS:000225793600023
J	Morton, HC; Pleass, RJ; Woof, JM; Brandtzaeg, P				Morton, HC; Pleass, RJ; Woof, JM; Brandtzaeg, P			Characterization of the ligand binding site of the bovine IgA Fc receptor (bFc alpha R)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; MOLECULAR-BASIS; IDENTIFICATION; RESIDUES; CD89; INSIGHTS; 19Q13.4; COMPLEX; CLUSTER; CLONING	Recently, we identified a bovine IgA Fc receptor (bFcalphaR), which shows high homology to the human myeloid FcalphaR, CD89. IgA binding has previously been shown to depend on several specific residues located in the B-C and F-G loops of the membrane-distal extracellular domain 1 of CD89. To compare the ligand binding properties of these two FcalphaRs, we have mapped the IgA binding site of bFcalphaR. We show that, in common with CD89, Tyr-35 in the B-C loop is essential for IgA binding. However, in contrast to earlier observations on CD89, mutation of residues in the F-G loop did not significantly inhibit IgA binding.	Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Dundee, Sch Med, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland	University of Oslo; National Hospital Norway; University of Dundee	Morton, HC (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.	h.c.morton@medisin.uio.no	Pleass, Richard/N-7831-2019; Pleass, Richard J/L-4148-2015; Morton, H. Craig/H-8600-2012	Pleass, Richard/0000-0001-7438-8296; Pleass, Richard J/0000-0001-7438-8296; Morton, H. Craig/0000-0002-9440-5759	Medical Research Council [G0300145] Funding Source: Medline; MRC [G0300145] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Claypool SM, 2002, J BIOL CHEM, V277, P28038, DOI 10.1074/jbc.M202367200; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Ding Y, 2003, J BIOL CHEM, V278, P27966, DOI 10.1074/jbc.C300223200; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Klungland H, 1997, MAMM GENOME, V8, P300, DOI 10.1007/s003359900425; KREMER EJ, 1992, HUM GENET, V89, P107, DOI 10.1007/BF00207054; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; McQueen KL, 2002, EUR J IMMUNOL, V32, P810, DOI 10.1002/1521-4141(200203)32:3<810::AID-IMMU810>3.0.CO;2-P; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Morton HC, 2004, IMMUNOLOGY, V111, P204, DOI 10.1111/j.0019-2805.2003.01808.x; Morton HC, 2001, J BIOL CHEM, V276, P47794, DOI 10.1074/jbc.M104066200; Morton HC, 1999, J EXP MED, V189, P1715; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Storset AK, 2003, EUR J IMMUNOL, V33, P980, DOI 10.1002/eji.200323710; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781; Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; ZHANG GP, 1995, J IMMUNOL, V155, P1534	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54018	54022		10.1074/jbc.M407807200	http://dx.doi.org/10.1074/jbc.M407807200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485844	hybrid, Green Published			2022-12-25	WOS:000225793600017
J	Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH				Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH			Role of the BLT2, a leukotriene B-4 receptor, in Ras transformation	ONCOGENE			English	Article						BLT2; cancer; leukotriene B-4; Ras transformation	CELL LUNG-CANCER; COLLAGEN-INDUCED ARTHRITIS; TERNARY COMPLEX-FORMATION; SIGNAL-REGULATED KINASE; SERUM RESPONSE ELEMENT; CYCLOOXYGENASE-2 COX-2; TRANSCRIPTION FACTOR; MEDIATES CHEMOTAXIS; PHOSPHOLIPASE A(2); GENE-EXPRESSION	Oncogenic Ras is known to drive both the Rac and Raf-MAP-kinase pathways, which act in concert to cause cell transformation. Unlike the Raf-MAP-kinase cascade, however, the downstream elements of Rac pathway are not fully understood. Previously, we showed that cytosolic phospholipase A(2) (cPLA(2)) and subsequent metabolism of arachidonic acid act downstream of Rac to mediate the transformation signaling induced by Ha-Ras(V12). In the present study, we observed that leukotriene B-4 (LTB4) and its synthetic enzymes as well as BLT2, the low-affinity LTB4 receptor, are all elevated in Ha-Ras(V12)-transformed cells. In addition, the malignant phenotypes of Ras-transformed cells were markedly inhibited by BLT2 blockade, as was their tumorigenicity in vivo. Finally, in situ hybridization analysis revealed that expression of BLT2 is significantly upregulated in a variety of human cancers. Taken together, our results suggest that an LTB4-BLT2-linked cascade plays a crucial mediatory role in the cell transformation induced by oncogenic Ha-Ras(V12), possibly acting downstream of Rac-cPLA(2).	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Abou-Issa HM, 2001, ANTICANCER RES, V21, P3425; Bae SH, 2001, CLIN CANCER RES, V7, P1410; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bauer AK, 2000, CARCINOGENESIS, V21, P543, DOI 10.1093/carcin/21.4.543; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COROMINAS M, 1991, ONCOGENE, V6, P645; Dang CT, 2002, ONCOLOGY-NY, V16, P30; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Fournier DB, 2000, J CELL BIOCHEM, P97; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDMAN DW, 1991, J IMMUNOL, V146, P2671; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Gunning WT, 2002, CANCER RES, V62, P4199; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Izumi T, 2002, J BIOCHEM, V132, P1; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; KOCH K, 1994, J MED CHEM, V37, P3197, DOI 10.1021/jm00046a001; Kreimer-Erlacher H, 2001, PHOTOCHEM PHOTOBIOL, V74, P323, DOI 10.1562/0031-8655(2001)074<0323:HMFAHR>2.0.CO;2; KUJUBU DA, 1991, J BIOL CHEM, V274, P24372; KUMAR CC, 1992, CANCER RES, V52, P6877; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVERS SJ, 1996, SIGNAL TRANSDUCTION; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Patti R, 2002, CANCER LETT, V180, P13, DOI 10.1016/S0304-3835(02)00003-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; Shureiqi I, 2001, CANCER RES, V61, P6307; Tong WG, 2002, CLIN CANCER RES, V8, P3232; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200	55	44	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9259	9268		10.1038/sj.onc.1208151	http://dx.doi.org/10.1038/sj.onc.1208151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489890				2022-12-25	WOS:000225638000011
J	Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL				Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL			Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells	ONCOGENE			English	Article						cyclin A1; AML; subcellular localization; CDK1; RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; PML-RAR-ALPHA; FUSION PROTEINS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; HUMAN CANCER	An important role of the cell cycle regulatory protein cyclin A1 in the development of acute myeloid leukemia (AML) was previously demonstrated in a transgenic mouse model. We have now turned our attention to study specific aspects of the activity and subcellular distribution of cyclin A1 using bone marrow samples from normal donors and patients with AML, as well as leukemic cell lines. We show that the localization of cyclin A1 in normal hematopoietic cells is nuclear, whereas in leukemic cells from AML patients and cell lines, it is predominantly cytoplasmic. In leukemic cell lines treated with all-trans retinoic acid (ATRA), cyclin A1 localized to the nucleus. Further, there was a direct interaction between cyclin A1 and cyclin-dependent kinase 1, as well as a major ATRA receptor, RARalpha, in ATRA-treated cells but not in untreated leukemic cells. Our results indicate that the altered intracellular distribution of cyclin A1 in leukemic cells correlates with the status of the leukemic phenotype.	Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; BMC, Div Mol Med & Gene Therapy, S-22184 Lund, Sweden; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Obstet & Gynecol, New York, NY 10032 USA	Lund University; Skane University Hospital; Columbia University; Columbia University; Columbia University	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678	NATIONAL CANCER INSTITUTE [T32CA009363, R21CA095362] Funding Source: NIH RePORTER; NCI NIH HHS [CA09363, CA95362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, BLOOD, V96, P475; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Dao MA, 1999, LEUKEMIA, V13, P1473, DOI 10.1038/sj.leu.2401537; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Furukawa Y, 1997, Hum Cell, V10, P159; Furukawa Y, 1998, Hum Cell, V11, P81; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARIDOR G, 1993, J CELL SCI, V106, P535; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Palmqvist R, 2000, AM J PATHOL, V157, P1947, DOI 10.1016/S0002-9440(10)64833-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Singh SP, 1998, CANCER RES, V58, P1730; Stein GS, 2000, J CELL SCI, V113, P2527; Sweeney C, 1996, DEVELOPMENT, V122, P53; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yaroslavskiy B, 2001, J CELL BIOCHEM, V83, P380, DOI 10.1002/jcb.1243; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	40	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9082	9089		10.1038/sj.onc.1208090	http://dx.doi.org/10.1038/sj.onc.1208090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489899	Green Published			2022-12-25	WOS:000225492800009
J	Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS				Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS			Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1	ONCOGENE			English	Article						tumor progression; redox signaling; transcription coactivator; cell cycle	DOMAIN-BINDING PROTEIN-1; NF-KAPPA-B; COP9 SIGNALOSOME; TRANSCRIPTION FACTORS; INHIBITOR P27(KIP1); DIRECT ASSOCIATION; OXIDATIVE STRESS; REDOX REGULATION; CELL-CYCLE; EXPRESSION	Thioredoxin (Trx) is a cellular redox enzyme that plays multiple roles in regulating cell growth and apoptosis. Jun activation domain-binding protein 1 (Jab1) was originally identified as a coactivator of activator protein 1 (AP-1) transcription and was also shown to promote degradation of the cyclin-dependent kinase inhibitor, p27Kip1. Recently, Jab1 expression was associated with the progression and poor prognosis of pituitary, epithelial ovarian, and breast cancers, suggesting that it plays a role in oncogenesis. Here, we report that Trx specifically interacts with and modulates the function of Jab1. Fluorescence resonance energy transfer and co-immunoprecipitation studies revealed that Trx and Jab1 colocalize and directly interact with each other. Further, Trx negatively regulates two important Jab1-controlled signaling pathways, activation of AP-1 transcription and degradation of p27Kip1, probably through a direct interaction between Trx and C-terminal of Jab1. The negative effect of Trx on AP-1 activity is Jab1-dependent, as it disappears when Jab1 levels are suppressed by an antisense approach. In addition, Trx competes with p27Kip1 for Jab1 binding. Taken together, our results suggest that Trx may regulate cell cycle and growth through a novel modulation of Jab1-mediated proliferation signals, further indicating that Trx may have the ability to control tumor progression.	Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea; PaiChai Univ, Div Life Sci, Taejon 302735, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pai Chai University; Chonnam National University	Kwon, KS (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, 52 Oun Dong, Taejon 305333, South Korea.	kwonks@kribb.re.kr		Chae, Suhn-Kee/0000-0003-2164-1053				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen XX, 2003, J BIOL CHEM, V278, P49022, DOI 10.1074/jbc.M304057200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ito Y, 2003, ANTICANCER RES, V23, P4121; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lu CR, 2002, FASEB J, V16, P90, DOI 10.1096/fj.01-0506fje; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yodoi J, 2001, BIOFACTORS, V15, P107, DOI 10.1002/biof.5520150212	40	58	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8868	8875		10.1038/sj.onc.1208116	http://dx.doi.org/10.1038/sj.onc.1208116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480426				2022-12-25	WOS:000225354600002
J	Glaser, T; Perez-Bouza, A; Klein, K; Brustle, O				Glaser, T; Perez-Bouza, A; Klein, K; Brustle, O			Generation of purified oligodendrocyte progenitors from embryonic stem cells	FASEB JOURNAL			English	Article						lineage selection; myelination; neural repair	CENTRAL-NERVOUS-SYSTEM; IN-VITRO DIFFERENTIATION; MYELIN-DEFICIENT RAT; HUMAN SCHWANN-CELLS; NEURAL PRECURSORS; SPINAL-CORD; NUCLEOTIDE 3'-PHOSPHODIESTERASE; MULTIPLE-SCLEROSIS; ADHESION MOLECULE; LINEAGE CELLS	Demyelination is a key component in the pathogenesis of many neurological disorders. Transplantation of myelinating cells may offer a therapeutic approach to restore neurological function in these diseases. Recent findings suggest that pluripotent embryonic stem (ES) cells can serve as an unlimited donor source for neural transplantation. The clinical application of ES cells for myelin repair will depend critically on the ability to enrich oligodendroglial progenitors in high purity. Combining controlled differentiation in the presence of growth factors and genetic lineage selection, we devised a cell culture protocol yielding highly purified oligodendrocyte progenitors. Murine ES cell clones stably transfected with a construct encoding the beta-galactosidase-neomycine phosphotransferase fusion protein (betageo) under control of the 2'3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter were differentiated into bipotential glial precursors. Subsequent induction of a CNP-positive stage and selection in neomycine resulted in a homogenous cell population with a pre-oligodendrocyte phenotype. The selected cells continued to proliferate in the presence of FGF-2 and PDGF and, upon growth factor withdrawal, differentiated into mature galactocerebroside (GalC)-positive oligodendrocytes. Transplantation studies in myelin-deficient (md) rats indicate that ES cell-derived oligodendrocyte progenitors generated with this method may serve as an attractive donor source for myelin repair.	Univ Bonn, Med Ctr, Inst Resconstruct Neurobiol, D-53105 Bonn, Germany; Hertie Fdn, D-53105 Bonn, Germany	University of Bonn	Brustle, O (corresponding author), Univ Bonn, Med Ctr, Inst Resconstruct Neurobiol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	brustle@uni-bonn.de						ABNEY ER, 1983, DEV BIOL, V100, P166, DOI 10.1016/0012-1606(83)90207-5; Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Almazan G, 2001, MICROSC RES TECHNIQ, V52, P753, DOI 10.1002/jemt.1060; Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; BARONVANEVERCOOREN A, 1992, DEV NEUROSCI-BASEL, V14, P73, DOI 10.1159/000111650; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Ben-Hur T, 1998, J NEUROSCI, V18, P5777, DOI 10.1523/jneurosci.18-15-05777.1998; Billon N, 2002, J CELL SCI, V115, P3657, DOI 10.1242/jcs.00049; Blakemore WF, 2000, CELL TRANSPLANT, V9, P289, DOI 10.1177/096368970000900214; BLAKEMORE WF, 1985, J NEUROL SCI, V70, P207, DOI 10.1016/0022-510X(85)90088-7; BLAKEMORE WF, 1977, NATURE, V266, P68, DOI 10.1038/266068a0; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; DAMJANOV I, 1993, INT J DEV BIOL, V37, P39; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1999, J NEUROBIOL, V40, P271, DOI 10.1002/(SICI)1097-4695(19990905)40:3<271::AID-NEU1>3.0.CO;2-C; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Franklin RJM, 1996, EXP NEUROL, V137, P263, DOI 10.1006/exnr.1996.0025; Franklin RJM, 2002, BRAIN RES BULL, V57, P827, DOI 10.1016/S0361-9230(01)00765-1; GALLO V, 1995, J NEUROSCI, V15, P394; Gravel M, 1998, J NEUROSCI RES, V53, P393; Grinspan J, 2002, J NEUROPATH EXP NEUR, V61, P297, DOI 10.1093/jnen/61.4.297; GRINSPAN JB, 1995, J NEUROSCI RES, V41, P540, DOI 10.1002/jnr.490410414; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HARDY R, 1991, DEVELOPMENT, V111, P1061; Honmou O, 1996, J NEUROSCI, V16, P3199; JESSEN KR, 1990, DEVELOPMENT, V109, P91; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KOEPPEN AH, 1988, J NEUROL SCI, V84, P315, DOI 10.1016/0022-510X(88)90135-9; KURIYAMA T, 1990, 6TH P INT CRYOC C, V2, P3; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Nagasawa K, 2001, CURR DRUG METAB, V2, P355, DOI 10.2174/1389200013338243; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; Rodriguez-Pena A, 1999, J NEUROBIOL, V40, P497, DOI 10.1002/(SICI)1097-4695(19990915)40:4<497::AID-NEU7>3.0.CO;2-#; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Shields SA, 2000, J NEUROSCI RES, V60, P571, DOI 10.1002/(SICI)1097-4547(20000601)60:5<571::AID-JNR1>3.0.CO;2-Q; Stangel M, 2002, PROG NEUROBIOL, V68, P361, DOI 10.1016/S0301-0082(02)00105-3; Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; Tucker KL, 1997, NUCLEIC ACIDS RES, V25, P3745, DOI 10.1093/nar/25.18.3745; VANDENBERG LH, 1995, ANN NEUROL, V38, P674, DOI 10.1002/ana.410380419; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; Zhang SC, 1998, J NEUROCYTOL, V27, P475, DOI 10.1023/A:1006953023845; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	75	62	66	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					112	+		10.1096/fj.04-1931fje	http://dx.doi.org/10.1096/fj.04-1931fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486057				2022-12-25	WOS:000224849900021
J	Yin, L				Yin, L			Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY PROTEIN 1-ALPHA; MULTIPLE-MYELOMA; BONE DESTRUCTION; NOTCH; FRINGE; ACTIVATION; MODEL; GLYCOSYLTRANSFERASE; MICROENVIRONMENT; PROTEOGLYCANS	There is a symbiotic relationship between continued growth and proliferation of myeloma cells and the bone destructive process. It has been shown in animal models that blocking bone destruction can result in decreased myeloma tumor burden. Osteoclasts are bone destroying cells found in the bone marrow, and their significance in myeloma is supported by recent findings that osteoclasts alone can support sustained survival and proliferation of purified primary myeloma cells in ex vivo co-cultures. However, molecular mechanisms associated with interactions between myeloma cells and osteoclasts remain unclear. Here, we show that when myeloma plasma cells are co-cultured with osteoclasts, chondroitin synthase 1 (CHSY1) is the most significantly altered soluble, secreted protein present in the conditioned medium. RNA interference experiments with CHSY1 small interfering RNA ( siRNA) reduced the amount of CHSY1 in the co-culture conditioned medium, and this was associated with a 6.25-fold increase in apoptotic myeloma cells over control co-cultures. CHSY1 contains a Fringe domain, and Fringe is well known for its regulation of Notch signaling via its DDD motif. And interestingly, Fringe domain in CHSY1 has this DDD motif. Shortly after co-culture with osteoclasts, we found that the Notch2 receptor was activated in myeloma cells but Notch1 was not. Activation of Notch2 was down-regulated by CHSY1 siRNA treatment. Modulating Notch signaling by CHSY1 via its DDD motif provides new insight into mechanisms of the interactions between myeloma cells and their bone marrow microenvironment. Targeting this interaction could shed light on treatment of myeloma, which is currently incurable.	Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Yin, L (corresponding author), 1 Canton Rd,Mailbox 035, Quincy, MA 02171 USA.	larryyin888@yahoo.com						Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593; Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116; Choi SJ, 2000, BLOOD, V96, P671; Dhodapkar MV, 1998, BRIT J HAEMATOL, V103, P530, DOI 10.1046/j.1365-2141.1998.00976.x; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Grigorieva I, 1998, EXP HEMATOL, V26, P597; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; HARDIN J, 1994, BLOOD, V84, P3063; Hussein MA, 2002, CURR OPIN ONCOL, V14, P31, DOI 10.1097/00001622-200201000-00006; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Koch U, 2003, SEMIN IMMUNOL, V15, P99, DOI 10.1016/S1044-5323(03)00006-X; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood-2003-06-1992; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Mustonen T, 2002, DEV BIOL, V248, P281, DOI 10.1006/dbio.2002.0734; Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood-2002-12-3905; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365-2141.2002.03257.x; Yaccoby S, 1999, BLOOD, V94, P3576, DOI 10.1182/blood.V94.10.3576.422k01_3576_3582; Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008-5472.CAN-03-1131; Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15666	15672		10.1074/jbc.M409877200	http://dx.doi.org/10.1074/jbc.M409877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15485809	hybrid			2022-12-25	WOS:000228444800027
J	Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP				Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP			Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; erythropoietin; Lyn; STAT5; GATA-1; EKLF	TRANSCRIPTION FACTOR; DNA-BINDING; ERYTHROID-DIFFERENTIATION; TYROSINE PHOSPHORYLATION; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; STAT5A(-/-)5B(-/-) MICE; RECEPTOR; PROLIFERATION; ACTIVATION	In vitro studies have implicated the Lyn tyrosine kinase in erythropoietin signaling. In this study, we show that J2E erythroid cells lacking Lyn have impaired signaling and reduced levels of transcription factors STAT5a, EKLF and GATA-1. Since mice lacking STAT5, EKLF or GATA-1 have red cell abnormalities, this study also examined the erythroid compartment of Lyn(-/-) mice. Significantly, STAT5, EKLF and GATA-1 levels were appreciably lower in Lyn(-/-) erythroblasts, and the phenotype of Lyn(-/-) animals was remarkably similar to GATA-1(low) animals. Although young adult Lyn-deficient mice had normal hematocrits, older mice developed anemia. Grossly enlarged erythroblasts and florid erythrophagocytosis were detected in the bone marrow of mice lacking Lyn. Markedly elevated erythroid progenitors and precursor levels were observed in the spleens, but not bone marrow, of Lyn(-/-) animals indicating that extramedullary erythropoiesis was occurring. These data indicate that Lyn(-/-) mice display extramedullary stress erythropoiesis to compensate for intrinsic and extrinsic erythroid defects.	Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, PathCtr, Nedlands, WA, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134				Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; BUSFIELD SJ, 1992, BLOOD, V80, P412; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Chin H, 1998, BLOOD, V91, P3734; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Harashima A, 2002, BLOOD, V100, P4440, DOI 10.1182/blood-2002-03-0864; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1987, J IMMUNOL, V139, P3091; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V28, P175; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Vannucchi AM, 2001, BLOOD, V97, P3040, DOI 10.1182/blood.V97.10.3040; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Whyatt D, 2000, NATURE, V406, P519, DOI 10.1038/35020086; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457	64	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					336	343		10.1038/sj.onc.1208199	http://dx.doi.org/10.1038/sj.onc.1208199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516974				2022-12-25	WOS:000226279700005
J	Altarejos, JY; Taniguchi, M; Clanachan, AS; Lopaschuk, GD				Altarejos, JY; Taniguchi, M; Clanachan, AS; Lopaschuk, GD			Myocardial ischemia differentially regulates LKB1 and an alternate 5 '-AMP-activated protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; WORKING RAT HEARTS; SKELETAL-MUSCLE; GLUCOSE-METABOLISM; YEAST SNF1; UPSTREAM KINASES; GAMMA-SUBUNITS; MALONYL-COA; AMP	During myocardial ischemia, activation of 5'-AMP-activated protein kinase (AMPK) leads to the stimulation of glycolysis and fatty acid oxidation. Together these metabolic changes contribute to cardiac dysfunction. Although AMPK signaling in the ischemic heart is well characterized, the relative contribution of phosphorylation by AMPK kinase (AMPKK), and positive allosterism by the ratios of AMP: ATP and creatine (Cr):phosphocreatine (PCr), in stimulating AMPK during ischemia are unknown. In hearts subjected to severe ischemia, the ratios of AMP: ATP and Cr: PCr were significantly elevated as compared with aerobic hearts. Severe ischemia stimulated AMPK signaling, as demonstrated by an increase in both AMPK activity and acetylCoA carboxylase phosphorylation. Although AMPK phosphorylation was increased by severe ischemia, the protein abundance and activity of the recently identified AMPKK, LKB1, were similar between aerobic and severely ischemic hearts. However, in contrast to LKB1, the activity of AMPKK was stimulated in severely ischemic hearts. To further delineate the relative roles of positive allosterism and AMPKK in the regulation of AMPK during ischemia, hearts were subjected to mild ischemia. Although mild ischemia did not alter the ratios of AMP: ATP and Cr: PCr, mild ischemia increased AMPK activity and increased AMPK phosphorylation. Mild ischemia also stimulated the activity of AMPKK. In summary, we demonstrate that myocardial ischemia stimulates AMPK via an AMPKK other than LKB1. Additionally, we show that changes in high energy phosphates are not essential for the activation of AMPK by ischemia. Our data emphasize the critical role AMPKK plays in mediating AMPK signaling during myocardial ischemia.	Univ Alberta, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta	Lopaschuk, GD (corresponding author), Univ Alberta, Cardiovasc Res Grp, 423 Heritage Med Res Bldg, Edmonton, AB T6G 2S2, Canada.	gary.lopaschuk@ualberta.ca						ALLY A, 1992, J CHROMATOGR-BIOMED, V575, P19, DOI 10.1016/0378-4347(92)80499-G; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZP, 2003, DIABETES, V52, P2205, DOI 10.2337/diabetes.52.9.2205; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Depre C, 1999, CIRCULATION, V99, P578, DOI 10.1161/01.CIR.99.4.578; Durante PE, 2002, AM J PHYSIOL-ENDOC M, V283, pE178, DOI 10.1152/ajpendo.00404.2001; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; FINEGAN BA, 1992, AM J PHYSIOL, V262, pH1501; Fraser H, 1999, BRIT J PHARMACOL, V128, P197, DOI 10.1038/sj.bjp.0702765; Frosig C, 2004, AM J PHYSIOL-ENDOC M, V286, pE411, DOI 10.1152/ajpendo.00317.2003; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Itani SI, 2003, DIABETES, V52, P1635, DOI 10.2337/diabetes.52.7.1635; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lavanchy N, 1996, MOL CELL BIOCHEM, V161, P273, DOI 10.1007/BF00240059; LIEDTKE AJ, 1975, AM J PHYSIOL, V228, P655, DOI 10.1152/ajplegacy.1975.228.2.655; Liu B, 1996, CIRC RES, V79, P940, DOI 10.1161/01.RES.79.5.940; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lopaschuk GD, 1997, AM J CARDIOL, V80, pA11, DOI 10.1016/S0002-9149(97)00453-0; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McNulty PH, 1996, J CLIN INVEST, V98, P62, DOI 10.1172/JCI118778; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Neely J R, 1975, Recent Adv Stud Cardiac Struct Metab, V8, P301; NEELY JR, 1973, AM J PHYSIOL, V225, P651; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; SADDIK M, 1991, J BIOL CHEM, V266, P8162; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; Taylor EB, 2004, AM J PHYSIOL-ENDOC M, V287, pE1082, DOI 10.1152/ajpendo.00179.2004; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Xing YQ, 2003, J BIOL CHEM, V278, P28372, DOI 10.1074/jbc.M303521200	49	85	88	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					183	190		10.1074/jbc.M411810200	http://dx.doi.org/10.1074/jbc.M411810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507450	hybrid			2022-12-25	WOS:000226025100023
J	Soboleva, TA; Jans, DA; Johnson-Saliba, M; Baker, RT				Soboleva, TA; Jans, DA; Johnson-Saliba, M; Baker, RT			Nuclear-cytoplasmic shuttling of the oncogenic mouse UNP/USP4 deubiquitylating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-SPECIFIC PROTEASE; FUNCTIONAL-CHARACTERIZATION; LOCALIZATION SEQUENCE; UNP; EXPORT; EXPRESSION; ENCODES; BINDING; IMPORT; CELLS	The oncogenic deubiquitylating enzyme (DUB) Unp/Usp4, which binds to the retinoblastoma family of tumor suppressor proteins, was originally described as a nuclear protein. However, more recent studies have shown it to be cytoplasmic. In addition, analysis of its subcellular localization has been complicated by the existence of the paralog Usp15. In this study, we resolved this controversy by investigating the localization of exogenously expressed Usp4 ( using red fluorescent protein-Usp4) and of endogenous Usp4 (using highly specific antibodies that can distinguish Usp4 from Usp15). We found that by inhibiting nuclear export with leptomycin B, both exogenous and endogenous Usp4 accumulate in the nucleus. Further, using a Rev-green fluorescent protein-based export assay, we confirmed the existence of a nuclear export signal ((VEVYLLELKL142)-V-133) in Usp4. In addition, a functional nuclear import signal ((766)QPQKKKK(772)) was also identified, which was specifically recognized by importin alpha/beta. Finally, we show that the equilibrium of Usp4 subcellular localization varies between different cell types. Usp4 is thus the first DUB reported to have nucleocytoplasmic shuttling properties. The implications of this shuttling for its function as a DUB are discussed.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Nucl Signalling Lab, Canberra, ACT 0200, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Australian National University; John Curtin School of Medical Research; Monash University	Baker, RT (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Nucl Signalling Lab, Canberra, ACT 0200, Australia.	Rohan.Baker@anu.edu.au	; Soboleva, Tatiana A/O-3110-2018	Jans, David/0000-0001-5115-4745; Soboleva, Tatiana A/0000-0003-0391-8530				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Angelats C, 2003, MAMM GENOME, V14, P31, DOI 10.1007/s00335-002-3035-0; Baker RT, 2000, MOL B INT U, V12, P236; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Blanchette P, 2001, ONCOGENE, V20, P5533, DOI 10.1038/sj.onc.1204823; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gilchrist CA, 2000, BBA-PROTEIN STRUCT M, V1481, P297, DOI 10.1016/S0167-4838(00)00134-5; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jiang H, 2000, ONCOGENE, V19, P3878, DOI 10.1038/sj.onc.1203722; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NISHI K, 1994, J BIOL CHEM, V269, P6320; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Park KC, 2000, BIOCHEM J, V349, P443, DOI 10.1042/0264-6021:3490443; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soboleva TA, 2004, CURR PROTEIN PEPT SC, V5, P191, DOI 10.2174/1389203043379765; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Zhu YA, 1997, J BIOL CHEM, V272, P51	46	37	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					745	752		10.1074/jbc.M401394200	http://dx.doi.org/10.1074/jbc.M401394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494318	hybrid			2022-12-25	WOS:000226025100088
J	Eminel, S; Klettner, A; Roemer, L; Herdegen, T; Waetzig, V				Eminel, S; Klettner, A; Roemer, L; Herdegen, T; Waetzig, V			JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; AMYLOID PRECURSOR PROTEIN; BAX-DEPENDENT APOPTOSIS; RESPIRATORY COMPLEX I; FAS LIGAND INDUCTION; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; PARKINSONS-DISEASE	6-Hydroxydopamine (6-OHDA) causes death of dopaminergic neurons by mitochondrial dysfunction with JNKs as central mediators. Here we provide novel insights into specific actions of JNK isoforms in 6-OHDA-induced death of PC12 cells. Twenty five muM 6-OHDA enhanced total JNK activity in the cytoplasm, nucleus, and at the mitochondria. Inhibition of JNKs by 2 muM SP600125 or transfection with dominant-negative JNK2 (dnJNK2) rescued more than 60% of the otherwise dying PC12 cells after 24 h, whereas transfection with dnJNK1 had no protective effects. In contrast to constitutively present JNK1, JNK2 amounts increased in the nucleus and at the mitochondria after 6-OHDA stimulation. JNK inhibition by SP600125 or transfection of dnJNK2 reduced the pool of active JNKs in the nucleus, the release of cytochrome c, as well as the cleavage of caspase-3 and its substrate poly(ADP-ribose) polymerase-1. Transfection with dnJNK1, however, had no effects on the translocation of JNKs to the mitochondria or the release of cytochrome c. Our data provide novel functional insights into the pathological role of individual JNK isoforms, the signalosome at the mitochondria, and the mode of JNK-induced release of cytochrome c.	Schleswig Holstein Univ Med Ctr, Inst Pharmacol, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Herdegen, T (corresponding author), Schleswig Holstein Univ Med Ctr, Inst Pharmacol, Campus Kiel,Hosp Str 4, D-24105 Kiel, Germany.	herdegen.office@pharmakologie.uni-kiel.de	herdegen, thomas/E-5135-2010; Klettner, Alexa Karina/M-8344-2018					Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BRECHT S, 2005, IN PRESS EUR J NEURO; BRICHESE L, 2004, IN PRESS CELL CYCLE; Butterfield L, 1999, BIOCHEM J, V338, P681, DOI 10.1042/0264-6021:3380681; Cash AD, 2002, NEUROSCIENTIST, V8, P489, DOI 10.1177/107385802236968; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cohen G, 2000, ANN NY ACAD SCI, V899, P112; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; DAVIDSON RN, 1986, BRIT J DIS CHEST, V80, P335, DOI 10.1016/0007-0971(86)90087-2; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Eckert G P, 2003, J Nutr Health Aging, V7, P18; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Glinka Y, 1997, J NEURAL TRANSM-SUPP, P55; Glinka Y, 1996, J NEUROCHEM, V66, P2004; Glinka Y, 1998, EUR J PHARMACOL, V351, P121, DOI 10.1016/S0014-2999(98)00279-9; GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3; Han BS, 2003, NEUROSCI LETT, V341, P99, DOI 10.1016/S0304-3940(03)00173-3; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Holmberg C, 2002, J BIOL CHEM, V277, P31918, DOI 10.1074/jbc.M200719200; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Klettner A, 2003, BRIT J PHARMACOL, V138, P1004, DOI 10.1038/sj.bjp.0705132; KUMAR R, 1995, J NEUROCHEM, V64, P1703; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Marques CA, 2003, J BIOL CHEM, V278, P28294, DOI 10.1074/jbc.M212265200; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Molton SA, 2003, ONCOGENE, V22, P4690, DOI 10.1038/sj.onc.1206692; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055; Nishi K, 1997, BRAIN RES, V771, P133, DOI 10.1016/S0006-8993(97)00862-7; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Storch A, 2000, J NEURAL TRANSM, V107, P281, DOI 10.1007/s007020050023; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vasilevskaya I, 2003, DRUG RESIST UPDATE, V6, P147, DOI 10.1016/S1368-7646(03)00043-8; von Coelln R, 2001, J NEUROCHEM, V77, P263, DOI 10.1046/j.1471-4159.2001.t01-1-00236.x; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wiltshire C, 2002, BIOCHEM J, V367, P577, DOI 10.1042/BJ20020553; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xu RH, 2001, BRAIN RES, V899, P10, DOI 10.1016/S0006-8993(01)02122-9; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zablocka B, 2003, MOL BRAIN RES, V110, P245, DOI 10.1016/S0169-328X(02)00653-8	81	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55385	55392		10.1074/jbc.M405858200	http://dx.doi.org/10.1074/jbc.M405858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504737	hybrid			2022-12-25	WOS:000225960800052
J	Pathak, SK; Bhattacharyya, A; Pathak, S; Basak, C; Mandal, D; Kundu, M; Basu, J				Pathak, SK; Bhattacharyya, A; Pathak, S; Basak, C; Mandal, D; Kundu, M; Basu, J			Toll-like receptor 2 and mitogen- and stress-activated kinase 1 are effectors of mycobacterium avium-induced cyclooxygenase-2 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-FACTOR; GENE-EXPRESSION; SYNTHASE-2 GENE; PHORBOL ESTER; C/EBP-DELTA; MAP KINASE; LIPOPOLYSACCHARIDE	Understanding how pathogenic mycobacteria subvert the protective immune response is crucial to the development of strategies aimed at controlling mycobacterial infections. Prostaglandin E-2 exerts an immunosuppressive function in the context of mycobacterial infection. Because cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin biosynthesis, there is a need to delineate the mechanisms through which pathogenic mycobacteria regulate COX-2 expression in macrophages. Our studies demonstrate that the NF-kappaB and CRE elements of the COX-2 promoter are critical to Mycobacterium avium-induced COX-2 gene expression. M. avium-triggered signaling originates at the Toll-like receptor 2 (TLR2). Ras associates with TLR2 and activates the mitogen-activated protein kinase ( MAPK) extracellular signal-regulated kinase (ERK), whereas tumor necrosis factor receptor-associated factor 6 (TRAF6)/transforming growth factor beta-activated kinase 1 (TAK1)-dependent signaling activates p38 MAPK. Both ERK and p38 MAPK activation converge to regulate the activation of mitogen- and stress-activated kinase 1 (MSK1). MSK1 mediates the phosphorylation of the transcription factor CREB accounting for its stimulatory effect on CRE-dependent gene expression. M. avium-triggered cytoplasmic NF-kappaB activation following IkappaB phosphorylation is necessary but not sufficient for COX-2 promoter-driven gene expression. MSK1 activation is also essential for M. avium-triggered NF-kappaB-dependent gene expression, presumably mediating nucleosomal modifications. These studies demonstrate that the nuclear kinase MSK1 is necessary in regulating the pathogen-driven expression of a gene by controlling two transcription factors. The attenuation of MSK1 may therefore have potential benefit in restricting survival of pathogenic mycobacteria in macrophages.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Kundu, M (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	manikuntala@vsnl.net; joyoti@vsnl.com	mandal, debabrata/AAF-6690-2019; PATHAK, SHRESH/I-6938-2012	PATHAK, SHRESH/0000-0001-5275-1816; Bhattacharyya, Asima/0000-0001-7292-6644				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Basu J, 2004, CURR SCI INDIA, V86, P103; Bhattacharyya A, 2002, FEMS IMMUNOL MED MIC, V34, P73, DOI 10.1111/j.1574-695X.2002.tb00605.x; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen G, 1999, LIFE SCI, V64, P1231, DOI 10.1016/S0024-3205(99)00055-7; CHEN JD, 1997, MOL PHARM, V59, P493; CHOUAIB S, 1985, J IMMUNOL, V135, P1172; DAVIE JR, 2003, SCI STKE; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giri DK, 1998, J IMMUNOL, V161, P4834; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; HASLER F, 1983, J IMMUNOL, V131, P768; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moreno JM, 2002, IMMUNOLOGY, V106, P257, DOI 10.1046/j.1365-2567.2002.01403.x; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; RIDGWAY D, 1991, J CLIN IMMUNOL, V11, P357, DOI 10.1007/BF00918801; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tse HM, 2002, J IMMUNOL, V168, P825, DOI 10.4049/jimmunol.168.2.825; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	41	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55127	55136		10.1074/jbc.M409885200	http://dx.doi.org/10.1074/jbc.M409885200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496409	hybrid			2022-12-25	WOS:000225960800019
J	Ridsdale, R; Tseu, I; Roth-Kleiner, M; Wang, JX; Post, M				Ridsdale, R; Tseu, I; Roth-Kleiner, M; Wang, JX; Post, M			Increased phosphatidylcholine production but disrupted glycogen metabolism in fetal type II cells of mice that overexpress CTP : Phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; LUNG SURFACTANT; SP-B; PULMONARY SURFACTANT; GENE-EXPRESSION; MOUSE LUNG; IDENTIFICATION; PROTEIN; PHOSPHORYLATION; DOMAIN	CTP:phosphocholine cytidylyltransferase (CCT) is a rate-determining enzyme in the de novo synthesis of phosphatidylcholine (PtdCho). Alveolar type II cells synthesize large quantities of disaturated PtdCho, the surface-active agent of pulmonary surfactant, particularly at late gestation when the lung prepares itself for postnatal air breathing. To clarify the role of CCTalpha in lung surfactant maturation, we overexpressed CCTalpha(1-367) using the surfactant protein-C promoter. Lungs of transgenic mice were analyzed at day 18 of gestation (term=19 days). Overexpression of CCTalpha(1-367) increased the synthesis and content of PtdCho in fetal type II cells isolated from the transgenic mice. Also, PtdCho content of fetal lung fluid was increased. No changes in surfactant protein content were detected. Interestingly, fetal type II cells of transgenic mice contained more glycogen than control cells. Incorporation studies with [U-C-14] glucose demonstrated that overexpression of CCTalpha(1-367) in fetal type II cells increased glycogen synthesis without affecting glycogen breakdown. To determine which domain contributes to this glycogen phenotype, two additional transgenes were created overexpressing either CCTalpha(1-239) or CCTalpha(239-367). Glycogen synthesis and content were increased in fetal type II cells expressing CCTalpha(239-367) but not CCTalpha(1-239). We conclude that overexpression of CCTalpha increases surfactant PtdCho synthesis without affecting surfactant protein levels but that it disrupts glycogen metabolism in differentiating type II cells via its regulatory domain.	Univ Toronto, Hosp Sick Children, Res Inst, Canadian Inst Hlth Res Grp Lung Dev,Div Lung Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Post, M (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst, Canadian Inst Hlth Res Grp Lung Dev,Div Lung Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	martin.post@sickkids.ca						Bernhard W, 2001, AM J RESP CELL MOL, V25, P725, DOI 10.1165/ajrcmb.25.6.4616; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; BREHIER A, 1981, EXP LUNG RES, V2, P273, DOI 10.3109/01902148109052323; Buettner R, 2004, AM J PHYSIOL-ENDOC M, V286, pE828, DOI 10.1152/ajpendo.00453.2003; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CARLSON KS, 1987, PEDIATR RES, V22, P79, DOI 10.1203/00006450-198707000-00018; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; FARRELL PM, 1986, BIOCHIM BIOPHYS ACTA, V878, P159, DOI 10.1016/0005-2760(86)90142-6; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; Helmink BA, 2003, BIOCHEMISTRY-US, V42, P5043, DOI 10.1021/bi027431+; Hogan B, 1994, MANIPULATING MOUSE E; HOGAN M, 1994, AM J PHYSIOL, V267, pL25, DOI 10.1152/ajplung.1994.267.1.L25; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Ikegami M, 2000, J APPL PHYSIOL, V89, P644, DOI 10.1152/jappl.2000.89.2.644; Ikegami M, 1997, AM J PHYSIOL-LUNG C, V272, pL479, DOI 10.1152/ajplung.1997.272.3.L479; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; Koc H, 2002, ANAL CHEM, V74, P4734, DOI 10.1021/ac025624x; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Li JL, 2002, AM J RESP CELL MOL, V26, P709, DOI 10.1165/ajrcmb.26.6.4720; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Melton KR, 2003, AM J PHYSIOL-LUNG C, V285, pL543, DOI 10.1152/ajplung.00011.2003; POST M, 1980, BIOCHIM BIOPHYS ACTA, V618, P308, DOI 10.1016/0005-2760(80)90037-5; Post M, 1992, PULMONARY SURFACTANT, P379; Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3; Ridsdale R, 2004, AM J PHYSIOL-LUNG C, V287, pL743, DOI 10.1152/ajplung.00146.2004; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; RINAUDO MT, 1981, INT J BIOCHEM, V13, P511; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; SEIFTER S, 1950, ARCH BIOCHEM, V25, P191; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; ZIMMERMANN LJ, 1993, AM J PHYSIOL, V264, pL575, DOI 10.1152/ajplung.1993.264.6.L575	49	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55946	55957		10.1074/jbc.M407670200	http://dx.doi.org/10.1074/jbc.M407670200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498769	hybrid			2022-12-25	WOS:000225960800118
J	Shimaya, A; Kovacina, KS; Roth, RA				Shimaya, A; Kovacina, KS; Roth, RA			On the mechanism for neomycin reversal of wortmannin inhibition of insulin stimulation of glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; 3T3-L1 ADIPOCYTES; AKT; RECEPTOR; PHOSPHORYLATION; TRANSLOCATION; RESISTANCE; SUBSTRATE; TRANSPORT; BINDING	Although a number of studies and approaches have indicated that activation of the Ser/Thr kinase called Akt/protein kinase B is critical for the insulin-stimulated increase of glucose uptake in adipocytes, other studies have indicated that this enzyme may play an ancillary role. For example, a recent study indicated that neomycin would allow insulin-stimulated Glut4 translocation and glucose transport in the presence of the phosphatidylinositol (PI) 3-kinase inhibitor, wortmannin, a known inhibitor of Akt activation (James, D. J., Salaun, C., Brandie, F. M., Connell, J. M. C., and Chamberlain, L. H. ( 2004) J. Biol. Chem. 279, 20567 20570). To better understand this observation, we examined a number of downstream targets of Akt. As previously reported, treatment of 3T3-L1 adipocytes with neomycin prevented the wortmannin inhibition of insulin-stimulated glucose transport. However, in the presence of neomycin, wortmannin did not inhibit the insulin-stimulated phosphorylation of several downstream targets of Akt including a proline-rich Akt substrate of 40 kDa, ribosomal protein S6, and glycogen synthase kinase-3. In addition, neomycin did not prevent the ability of a structurally unrelated PI 3-kinase inhibitor, LY294002, to inhibit the insulin-stimulated activation of glucose uptake. Moreover, neomycin reversed the inhibitory effect of wortmannin but not LY294002 on insulin stimulation of Akt kinase activity. Finally, neomycin was found to inactivate in vitro the PI 3-kinase inhibitory actions of wortmannin but not LY294002. These results indicate that the effects of neomycin in adipocytes are not mediated via its ability to sequester phosphatidylinositol 4,5-bisphosphate but are instead caused by the ability of neomycin to inactivate wortmannin.	Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR, Rm 3145B,269 Campus Dr, Stanford, CA 94305 USA.	rroth@stanford.edu			NIDDK NIH HHS [DK 34976] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; GUIRAMAND J, 1990, TOXICOL LETT, V51, P331, DOI 10.1016/0378-4274(90)90076-X; James DJ, 2004, J BIOL CHEM, V279, P20567, DOI 10.1074/jbc.C400096200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KOHN AD, 1995, EMBO J, V4288, P4295; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHACHT J, 1979, ARCH OTO-RHINO-LARYN, V224, P129, DOI 10.1007/BF00455236; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437	24	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55277	55282		10.1074/jbc.M411540200	http://dx.doi.org/10.1074/jbc.M411540200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504741	hybrid			2022-12-25	WOS:000225960800038
J	Wang, L; Mao, XC; Ju, DH; Xie, YM				Wang, L; Mao, XC; Ju, DH; Xie, YM			Rpn4 is a physiological substrate of the Ubr2 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END RULE PATHWAY; SACCHAROMYCES-CEREVISIAE; 26S PROTEASOME; MULTIUBIQUITIN CHAIN; REGULATORY PARTICLE; FEEDBACK-CIRCUIT; RING-H2 FINGER; CELL-DIVISION; DEGRADATION; PROTEIN	The homeostatic abundance of the proteasome in Saccharomyces cerevisiae is controlled by a feedback circuit in which transcriptional activator Rpn4 up-regulates the proteasome genes and is destroyed by the assembled, active proteasome. Remarkably, the degradation of Rpn4 can be mediated by two independent pathways. One pathway is independent of ubiquitin, whereas the other involves ubiquitination on internal lysines. In the present study, we investigated the mechanism underlying the ubiquitin-dependent degradation of Rpn4. We demonstrated, through in vivo and in vitro assays, that Rpn4 is a physiological substrate of the Ubr2 ubiquitin ligase, which was originally identified as a sequence homolog of Ubr1, the E3 component of the N-end rule pathway. The ubiquitin-conjugating enzyme Rad6, which directly interacts with Ubr2, is also required for the ubiquitin-dependent degradation of Rpn4. Furthermore, we showed that deletion of UBR2 exhibited a strong synthetic growth defect with a mutation in the Rpt1 proteasome subunit when Rpn4 was overexpressed. This study not only identified the ubiquitination apparatus for Rpn4 but also unveiled the first physiological substrate of Ubr2. The biological significance of Ubr2-mediated degradation of Rpn4 is also discussed.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; E China Normal Univ, Shanghai Inst Brain Funct Genom, Shanghai 200062, Peoples R China	Barbara Ann Karmanos Cancer Institute; Wayne State University; East China Normal University	Xie, YM (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.	xiey@karmanos.org			NIEHS NIH HHS [ES 06639] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ju DH, 2004, BIOCHEM BIOPH RES CO, V321, P51, DOI 10.1016/j.bbrc.2004.06.105; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; SIKORSKI RS, 1989, GENETICS, V122, P19; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	69	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55218	55223		10.1074/jbc.M410085200	http://dx.doi.org/10.1074/jbc.M410085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504724	hybrid			2022-12-25	WOS:000225960800030
J	Yamauchi, K; Nishimura, Y; Shigematsu, S; Takeuchi, Y; Nakamura, J; Aizawa, T; Hashizume, K				Yamauchi, K; Nishimura, Y; Shigematsu, S; Takeuchi, Y; Nakamura, J; Aizawa, T; Hashizume, K			Vascular endothelial cell growth factor attenuates actions of transforming growth factor-beta in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS IN-VITRO; SIGNAL-TRANSDUCTION; ACTIVATION; FAMILY; SMAD3; PHOSPHORYLATION; COMPLICATIONS; PROMOTER; MEDIATOR; RECEPTOR	Because vascular endothelial cell growth factor (VEGF) and transforming growth factor-alpha (TGF-beta) are both involved in cellular growth and differentiation, we examined whether VEGF modifies TGF-beta signaling cascade in human umbilical cord vein endothelial cells (HUVEC). Production of plasminogen activator inhibitor-1 (PAI-1), which is under the specific control of TGF-beta, was strongly enhanced (3.5-fold) by TGF-beta treatment. Remarkably, physiological concentration of VEGF (30 nM) profoundly (by 60%) attenuated the TGF-beta stimulation of PAI-1 production without an effect on the basal PAI-1 production. In HUVECs transiently transfected with an expression construct containing a PAI-1 promoter fused to luciferase reporter gene, TGF-beta-stimulation of transcription of PAI-1 was clearly (by 60%) inhibited by VEGF. TGF-beta phosphorylation of Smad2/3, an obligatory step of intracellular TGF-beta signaling, was also suppressed by VEGF. VEGF attenuation of TGF-beta action was also demonstrated in two other endothelial cell lines. In conclusion, VEGF attenuates TGF-beta action in the human endothelial cell, specifically at the level of transcription of PAI-1 gene and Smad2/3 phosphorylation.	Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, Matsumoto, Nagano 3908621, Japan	Shinshu University	Yamauchi, K (corresponding author), Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	keishi@hsp.md.shinshu-u.ac.jp						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Chiarelli F, 2000, HORM RES, V53, P53, DOI 10.1159/000023515; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Gambaro G, 1998, CRIT REV CL LAB SCI, V35, P117, DOI 10.1080/10408369891234174; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; KLASSEN KJ, 1993, CORONARY ARTERY DIS, V4, P713, DOI 10.1097/00019501-199308000-00007; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; MIKHAIL N, 1993, J CARDIOVASC PHARM, V22, pS64; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Pfeiffer A, 1997, DIABETES, V46, pS26, DOI 10.2337/diab.46.2.S26; PFEIFFER A, 1995, EXP CLIN ENDOCR DIAB, V103, P7, DOI 10.1055/s-0029-1211323; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zochodne DW, 1996, SEMIN NEUROL, V16, P153, DOI 10.1055/s-2008-1040971	29	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55104	55108		10.1074/jbc.M407423200	http://dx.doi.org/10.1074/jbc.M407423200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494412	hybrid			2022-12-25	WOS:000225960800016
J	Yang, YZ; Cao, JS; Shi, YG				Yang, YZ; Cao, JS; Shi, YG			Identification and characterization of a gene encoding human LPGAT1, an endoplasmic reticulum-associated lysophosphatidylglycerol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BARTH-SYNDROME; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; ANTIPHOSPHOLIPID SYNDROME; CARDIOLIPIN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; SPECIES PATTERN; LUNG SURFACTANT; II CELLS; MUTANT	Phosphatidylglycerol (PG) is an important membrane polyglycerolphospholipid required for the activity of a variety of enzymes and is a precursor for synthesis of cardiolipin and bis(monoacylglycerol) phosphate. PG is subjected to remodeling subsequent to its de novo biosynthesis to incorporate appropriate acyl content for its biological functions and to prevent the harmful effect of lysophosphatidylglycerol (LPG) accumulation. The enzymes involved in the remodeling process have not yet been identified. We report here the identification and characterization of a human gene encoding an acyl-CoA: lysophosphatidylglycerol acyltransferase (LPGAT1). Expression of the LPGAT1 cDNA in Sf9 insect and COS-7 cells led to a significant increase in LPG acyltransferase activity. In contrast, no significant acyltransferase activities were detected against glycerol 3-phosphate or a variety of lysophospholipids, including lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine. The recombinant human LPGAT1 enzyme recognized various acyl-CoAs and LPGs as substrates but demonstrated clear preference to long chain saturated fatty acyl-CoAs and oleoyl-CoA as acyl donors, which is consistent with the lipid composition of endogenous PGs identified from different tissues. Kinetic analyses of LPGAT1 expressed in COS-7 cells showed that oleoyl-LPG was preferred over palmitoyl-LPG as an acyl receptor, whereas oleoyl-CoA was preferred over lauroyl-CoA as an acyl donor. Consistent with its proposed microsomal origin, LPGAT1 was localized to the endoplasmic reticulum by subcellular fractionation and immunohistochemical analyses. Northern blot analysis indicated that the human LPGAT1 was widely distributed, suggesting a dynamic functional role of the enzyme in different tissues.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DC 0545, Indianapolis, IN 46285 USA.	shi_yuguang@lilly.com						AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V218, P57, DOI 10.1016/0005-2760(70)90092-5; AMIDON B, 1995, BIOCHEMISTRY-US, V34, P5554, DOI 10.1021/bi00016a029; Berger A, 1993, Adv Food Nutr Res, V37, P259, DOI 10.1016/S1043-4526(08)60118-7; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Cheng P, 1996, BBA-LIPID LIPID MET, V1302, P61, DOI 10.1016/0005-2760(96)00012-4; Choy PC, 1997, BBA-LIPID LIPID MET, V1348, P124, DOI 10.1016/S0005-2760(97)00114-8; CHOY PC, 1992, METHOD ENZYMOL, V209, P80; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; FUNKHOUSER JD, 1981, BIOCHIM BIOPHYS ACTA, V666, P1, DOI 10.1016/0005-2760(81)90084-9; GREENFIELD D, 2001, NETW MAG, V16, P18; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; HALLMAN M, 1976, AM J OBSTET GYNECOL, V125, P613, DOI 10.1016/0002-9378(76)90782-1; HATCH GM, 1995, BIOCHEM J, V306, P759, DOI 10.1042/bj3060759; Heravi J, 1999, BBA-MOL CELL BIOL L, V1437, P277, DOI 10.1016/S1388-1981(99)00021-9; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Ma BJ, 1999, J LIPID RES, V40, P1837; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; MAN RYK, 1983, LIFE SCI, V32, P1325, DOI 10.1016/0024-3205(83)90806-8; MASON RJ, 1980, J BIOL CHEM, V255, P5101; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; OKANO G, 1979, LIPIDS, V14, P541, DOI 10.1007/BF02533529; Rand JH, 2003, ANNU REV MED, V54, P409, DOI 10.1146/annurev.med.54.101601.152412; ROONEY SA, 1975, J LIPID RES, V16, P418; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SANDERS RL, 1975, BIOCHEMISTRY-US, V14, P835, DOI 10.1021/bi00675a030; SANFORD GL, 1983, BIOCHEM BIOPH RES CO, V116, P23, DOI 10.1016/0006-291X(83)90375-3; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; Taylor WA, 2003, J BIOL CHEM, V278, P12716, DOI 10.1074/jbc.M210329200; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; THORNBURG T, 1991, J BIOL CHEM, V266, P6834; Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174; VANCURA A, 1994, J BIOL CHEM, V269, P27209; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; WITTELS B, 1973, J BIOL CHEM, V248, P2906; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	52	73	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55866	55874		10.1074/jbc.M406710200	http://dx.doi.org/10.1074/jbc.M406710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485873	hybrid			2022-12-25	WOS:000225960800110
J	Zou, XL; Seemann, JR; Neuman, D; Shen, QXJ				Zou, XL; Seemann, JR; Neuman, D; Shen, QXJ			A WRKY gene from creosote bush encodes an activator of the abscisic acid signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING PROTEINS; BZIP TRANSCRIPTION FACTORS; LEUCINE-ZIPPER PROTEINS; ABA-RESPONSE COMPLEXES; CONSERVED B3 DOMAIN; PHOSPHOLIPASE-D; BARLEY ALEURONE; PHOSPHATASE 2C; SPECIFICATION ELEMENTS; NEGATIVE REGULATOR	The creosote bush (Larrea tridentata) is a xerophytic evergreen C3 shrub thriving in vast arid areas of North America. As the first step toward understanding the molecular mechanisms controlling the drought tolerance of this desert plant, we have isolated a dozen genes encoding transcription factors, including LtWRKY21 that encodes a protein of 314 amino acid residues. Transient expression studies with the GFP-LtWRKY21 fusion construct indicate that the LtWRKY21 protein is localized in the nucleus and is able to activate the promoter of an abscisic acid (ABA)-inducible gene, HVA22, in a dosage-dependent manner. The transactivating activity of LtWRKY21 relies on the C-terminal sequence containing the WRKY domain and a N-terminal motif that is essential for the repression activity of some regulators in ethylene signaling. LtWRKY21 interacts synergistically with ABA and transcriptional activators VP1 and ABI5 to control the expression of the HVA22 promoter. Co-expression of VP1, ABI5, and LtWRKY21 leads to a much higher expression of the HVA22 promoter than does the ABA treatment alone. In contrast, the LtWRKY21-mediated transactivation is inhibited by two known negative regulators of ABA signaling: 1-butanol, an inhibitor of phospholipase D, and abi1-1, a dominant negative mutant protein phosphatase. Interestingly, abi1-1 does not block the synergistic effect of LtWRKY21, VP1, and ABI5 co-expression, indicating that LtWRKY21, VP1, and ABI5 may form a complex that functions downstream of ABI1 to control ABA-regulated expression of genes.	Univ Nevada, Dept Biol Sci, Las Vegas, NV 89154 USA; Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; University of Rhode Island	Shen, QXJ (corresponding author), Univ Nevada, Dept Biol Sci, M-S 4004,4505 Maryland Pkwy, Las Vegas, NV 89154 USA.	jeffery.shen@ccmail.nevada.edu		Seemann, Jeffrey/0000-0002-5160-175X	NCRR NIH HHS [P20 RR 16464] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abe H, 2003, PLANT CELL, V15, P63, DOI 10.1105/tpc.006130; Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; ADDICOTT FT, 1983, ABSCISIC ACID, P1; Albinsky D, 1999, PLANT J, V17, P73, DOI 10.1046/j.1365-313X.1999.00354.x; Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Bailey PC, 1999, THEOR APPL GENET, V98, P281, DOI 10.1007/s001220051069; Bobb AJ, 1997, NUCLEIC ACIDS RES, V25, P641, DOI 10.1093/nar/25.3.641; BOBB AJ, 1995, PLANT J, V8, P331, DOI 10.1046/j.1365-313X.1995.08030331.x; BRUCE WB, 1989, P NATL ACAD SCI USA, V86, P9692, DOI 10.1073/pnas.86.24.9692; Carson CB, 1997, PLANT J, V12, P1231, DOI 10.1046/j.1365-313x.1997.12061231.x; Casaretto J, 2003, PLANT CELL, V15, P271, DOI 10.1105/tpc.007096; Chandler JW, 1997, MOL GEN GENET, V256, P539, DOI 10.1007/s004380050599; Chen CH, 2000, PLANT MOL BIOL, V42, P387, DOI 10.1023/A:1006399311615; Chern MS, 1996, PLANT CELL, V8, P305, DOI 10.1105/tpc.8.2.305; Choi HI, 2000, J BIOL CHEM, V275, P1723, DOI 10.1074/jbc.275.3.1723; Cormack RS, 2002, BBA-GENE STRUCT EXPR, V1576, P92, DOI 10.1016/S0167-4781(02)00298-1; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Dellagi A, 2000, MOL PLANT MICROBE IN, V13, P1092, DOI 10.1094/MPMI.2000.13.10.1092; Du LQ, 2000, PLANT J, V24, P837, DOI 10.1046/j.1365-313x.2000.00923.x; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Ezcurra I, 2000, PLANT J, V24, P57, DOI 10.1046/j.1365-313x.2000.00857.x; Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; Freire MA, 1995, PLANT MOL BIOL, V29, P797, DOI 10.1007/BF00041169; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; Gampala SSL, 2002, J BIOL CHEM, V277, P1689, DOI 10.1074/jbc.M109980200; Gampala SSL, 2001, J BIOL CHEM, V276, P9855, DOI 10.1074/jbc.M009168200; Ghassemian M, 2000, PLANT CELL, V12, P1117, DOI 10.1105/tpc.12.7.1117; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Hallouin M, 2002, PLANT PHYSIOL, V130, P265, DOI 10.1104/pp.004168; Hao DY, 1998, J BIOL CHEM, V273, P26857, DOI 10.1074/jbc.273.41.26857; Hara K, 2000, MOL GEN GENET, V263, P30, DOI 10.1007/PL00008673; HATTORI T, 1994, PLANT MOL BIOL, V24, P805, DOI 10.1007/BF00029862; Himmelbach A, 2003, CURR OPIN PLANT BIOL, V6, P470, DOI 10.1016/S1369-5266(03)00090-6; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; Hinderhofer K, 2001, PLANTA, V213, P469, DOI 10.1007/s004250000512; Hiratsu K, 2002, FEBS LETT, V514, P351, DOI 10.1016/S0014-5793(02)02435-3; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; HOECKER U, 1995, GENE DEV, V9, P2459, DOI 10.1101/gad.9.20.2459; Hollung K, 1997, PLANT MOL BIOL, V35, P561, DOI 10.1023/A:1005815017718; Huang T, 2002, PLANT MOL BIOL, V48, P339, DOI 10.1023/A:1014062714786; Hugouvieux V, 2001, CELL, V106, P477, DOI 10.1016/S0092-8674(01)00460-3; ISHIGURO S, 1994, MOL GEN GENET, V244, P563, DOI 10.1007/BF00282746; Ishitani M, 1998, PLANT CELL, V10, P1151, DOI 10.1105/tpc.10.7.1151; Johannesson H, 2003, PLANT MOL BIOL, V51, P719, DOI 10.1023/A:1022567625228; Jones HD, 1997, PLANT J, V12, P911, DOI 10.1046/j.1365-313X.1997.12040911.x; Jones HD, 2000, PLANT J, V21, P133, DOI 10.1046/j.1365-313x.2000.00662.x; Kang JY, 2002, PLANT CELL, V14, P343, DOI 10.1105/tpc.010362; Kim CY, 2000, MOL PLANT MICROBE IN, V13, P470, DOI 10.1094/MPMI.2000.13.4.470; Kim SY, 1998, J PLANT PHYSIOL, V152, P607, DOI 10.1016/S0176-1617(98)80019-9; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; KNIGHT CD, 1995, PLANT CELL, V7, P499, DOI 10.1105/tpc.7.5.499; Kuhn JM, 2003, CURR OPIN PLANT BIOL, V6, P463, DOI 10.1016/S1369-5266(03)00084-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurup S, 2000, PLANT J, V21, P143, DOI 10.1046/j.1365-313x.2000.00663.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Lopez-Molina L, 2000, PLANT CELL PHYSIOL, V41, P541, DOI 10.1093/pcp/41.5.541; Lu C, 2002, P NATL ACAD SCI USA, V99, P15812, DOI 10.1073/pnas.242607499; Lu C, 2000, PLANT CELL, V12, P2351, DOI 10.1105/tpc.12.12.2351; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCCARTY DR, 1995, ANNU REV PLANT PHYS, V46, P71, DOI 10.1146/annurev.pp.46.060195.000443; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Nagpal P, 2000, PLANT PHYSIOL, V123, P563, DOI 10.1104/pp.123.2.563; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; Niu XP, 2002, PLANT CELL, V14, P2565, DOI 10.1105/tpc.003400; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Ritchie S, 1998, P NATL ACAD SCI USA, V95, P2697, DOI 10.1073/pnas.95.5.2697; Robatzek S, 2002, GENE DEV, V16, P1139, DOI 10.1101/gad.222702; Robatzek S, 2001, PLANT J, V28, P123, DOI 10.1046/j.1365-313X.2001.01131.x; Rock CD, 2000, NEW PHYTOL, V148, P357, DOI 10.1046/j.1469-8137.2000.00769.x; Rohde A, 1998, J EXP BOT, V49, P1059, DOI 10.1093/jexbot/49.323.1059; Rushton PJ, 1995, PLANT MOL BIOL, V29, P691, DOI 10.1007/BF00041160; Sanchez JP, 2001, PLANT CELL, V13, P1143, DOI 10.1105/tpc.13.5.1143; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; Seki M, 2002, PLANT J, V31, P279, DOI 10.1046/j.1365-313X.2002.01359.x; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; SHEN QX, 1993, J BIOL CHEM, V268, P23652; Shen QX, 1996, PLANT CELL, V8, P1107, DOI 10.1105/tpc.8.7.1107; SHEN QX, 1995, PLANT CELL, V7, P295, DOI 10.1105/tpc.7.3.295; Shen QX, 2001, PLANT MOL BIOL, V47, P437, DOI 10.1023/A:1011667312754; Shen QXJ, 2004, PLANT MOL BIOL, V54, P111, DOI 10.1023/B:PLAN.0000028773.94595.e8; Shiota H, 1998, PLANT CELL PHYSIOL, V39, P1184, DOI 10.1093/oxfordjournals.pcp.a029319; Steber CM, 2001, PLANT PHYSIOL, V125, P763, DOI 10.1104/pp.125.2.763; Sun CX, 2003, PLANT CELL, V15, P2076, DOI 10.1105/tpc.014597; Suzuki M, 2003, PLANT PHYSIOL, V132, P1664, DOI 10.1104/pp.103.022475; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; Tiwari SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/tpc.017384; Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; Xiong LM, 2001, GENE DEV, V15, P1971, DOI 10.1101/gad.891901; Xu YH, 2004, PLANT PHYSIOL, V135, P507, DOI 10.1104/pp.104.038612; Yu DQ, 2001, PLANT CELL, V13, P1527, DOI 10.1105/tpc.13.7.1527; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255; Zhang ZL, 2004, PLANT PHYSIOL, V134, P1500, DOI 10.1104/pp.103.034967	105	83	111	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55770	55779		10.1074/jbc.M408536200	http://dx.doi.org/10.1074/jbc.M408536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504732	hybrid, Green Published			2022-12-25	WOS:000225960800099
J	Culina, S; Lauvau, G; Gubler, B; van Endert, PM				Culina, S; Lauvau, G; Gubler, B; van Endert, PM			Calreticulin promotes folding of functional human leukocyte antigen class I molecules in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CYTOTOXIC T-LYMPHOCYTES; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; QUALITY-CONTROL; HEAVY-CHAINS; LOADING COMPLEX; CELL-LINE; CALNEXIN	The assembly of MHC class I molecules with beta(2)-microglobulin and peptides is assisted by the housekeeping chaperones calnexin, calreticulin, and Erp57 and the dedicated accessory protein, tapasin. Tapasin and calreticulin are essential for efficient MHC class I assembly, but their precise action during class I assembly remains to be elucidated. Previous in vitro studies have demonstrated that the lectin calreticulin interacts with monoglucosylated MHC class I heavy chains, whatever their state of assembly with light chains and peptide, and inhibits their aggregation above physiological temperature. We used a soluble single chain HLA-A2/beta(2)-microglobulin molecule, A2SC, to study the effect of calreticulin on the peptide binding capacity of HLA class I molecules. Calreticulin inhibited the formation of A2SC aggregates both when co-expressed in insect cells and during incubations at elevated temperature. Calreticulin dramatically enhanced acquisition of peptide binding capacity when added to denatured A2SC molecules during refolding at 4degreesC. However, it had no effect on the rapid loss of A2SC peptide binding capacity at physiological temperature. We conclude that calreticulin promotes the folding of HLA class I molecules to a state in which, at low temperature, they spontaneously acquire peptide binding capacity. However, it does not induce or maintain a peptide-receptive state of the class I-binding site, which is likely to be promoted by one or several other components of the class I loading complexes. By being amenable to complementation with additional proteins, the described system should be useful for identification of these components.	Univ Paris 05, INSERM, U580, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	van Endert, PM (corresponding author), Univ Paris 05, INSERM, U580, 161 Rue Sevres, F-75015 Paris, France.	vanendert@necker.fr	van Endert, Peter/R-4606-2017; Gubler, Brigitte/D-9479-2018	van Endert, Peter/0000-0003-3782-0750; Culina, Slobodan/0000-0001-6461-6953				AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; Harris MR, 1998, J IMMUNOL, V160, P5404; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; Lee L, 1996, HUM IMMUNOL, V49, P28, DOI 10.1016/0198-8859(96)00056-0; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Lone YC, 1998, J IMMUNOTHER, V21, P283, DOI 10.1097/00002371-199807000-00006; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SCOTT JE, 1995, J IMMUNOL, V155, P143; SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1; Solheim JC, 1997, J IMMUNOL, V158, P2236; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Toshitani K, 1996, P NATL ACAD SCI USA, V93, P236, DOI 10.1073/pnas.93.1.236; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wearsch PA, 2004, J BIOL CHEM, V279, P25112, DOI 10.1074/jbc.M401721200; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8	41	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54210	54215		10.1074/jbc.M410841200	http://dx.doi.org/10.1074/jbc.M410841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494401	hybrid			2022-12-25	WOS:000225793600040
J	Daikoku, T; Kudoh, A; Fujita, M; Sugaya, Y; Isomura, H; Tsurumi, T				Daikoku, T; Kudoh, A; Fujita, M; Sugaya, Y; Isomura, H; Tsurumi, T			In vivo dynamics of EBNA1-oriP interaction during latent and lytic replication of Epstein-Barr virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN-1 COLOCALIZES; DEPENDENT KINASE-ACTIVITY; ORIGIN-BINDING-PROTEIN; BAMHI-F-PROMOTER; DNA-REPLICATION; STABLE REPLICATION; MAMMALIAN-CELLS; ORIP; EBNA-1; PLASMIDS	The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is required for maintenance of the viral genome DNA during the latent phase of EBV replication but continues to be synthesized after the induction of viral productive replication. An EBV genome-wide chromatin immunoprecipitation assay revealed that EBNA1 constantly binds to oriP of the EBV genome during not only latent but also lytic infection. Although the total levels of EBNA1 proved constant throughout the latter, the levels of the oriP-bound form were increased as lytic infection proceeded. EBV productive DNA replication occurs at discrete sites in nuclei, called replication compartments, where viral replication proteins are clustered. Confocal laser microscopic analyses revealed that whereas EBNA1 was distributed broadly in nuclei as fine punctate dots during the latent phase of infection, the protein became redistributed to the viral replication compartments and localized as distinct spots within and/or nearby the compartments after the induction of lytic replication. Taking these findings into consideration, oriP regions of the EBV genome might be organized by EBNA1 into replication domains that may set up scaffolding for lytic replication and transcription.	Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Natl Canc Ctr, Div Virol, Tokyo 1040045, Japan	Aichi Cancer Center; National Cancer Center - Japan	Tsurumi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp		Fujita, Masatoshi/0000-0001-6617-2452				ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GROGAN EA, 1983, P NATL ACAD SCI-BIOL, V80, P7650, DOI 10.1073/pnas.80.24.7650; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; Ito S, 2003, ARCH VIROL, V148, P1633, DOI 10.1007/s00705-003-0122-9; Ito S, 2003, J VIROL, V77, P3824, DOI 10.1128/JVI.77.6.3824-3831.2003; Ito S, 2002, J GEN VIROL, V83, P2377, DOI 10.1099/0022-1317-83-10-2377; JANKELEVICH S, 1992, EMBO J, V11, P1165, DOI 10.1002/j.1460-2075.1992.tb05157.x; JIANG WQ, 1991, J CELL SCI, V99, P497; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; Kudoh A, 2004, J VIROL, V78, P104, DOI 10.1128/JVI.78.1.104-115.2004; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; Marechal V, 1999, J VIROL, V73, P4385, DOI 10.1128/JVI.73.5.4385-4392.1999; Mattia E, 1999, VIROLOGY, V262, P9, DOI 10.1006/viro.1999.9854; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; NILLER HH, 1995, J BIOL CHEM, V270, P12864, DOI 10.1074/jbc.270.21.12864; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; Pfuller R, 1996, J VIROL, V70, P3423; PLATT THK, 1993, J VIROL, V67, P1739, DOI 10.1128/JVI.67.3.1739-1745.1993; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Ritzi M, 2003, J CELL SCI, V116, P3971, DOI 10.1242/jcs.00708; SCHAEFER BC, 1995, J VIROL, V69, P5039, DOI 10.1128/JVI.69.8.5039-5047.1995; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Sears J, 2003, J VIROL, V77, P11767, DOI 10.1128/JVI.77.21.11767-11780.2003; Shirakata M, 1998, J BIOCHEM-TOKYO, V123, P175; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; SUNG NS, 1994, MOL CELL BIOL, V14, P7144, DOI 10.1128/MCB.14.11.7144; Tsurumi T, 2001, CURR TOP MICROBIOL, V258, P65; WEN LT, 1990, VIROLOGY, V178, P293, DOI 10.1016/0042-6822(90)90407-I; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; Zetterberg H, 1999, J GEN VIROL, V80, P457, DOI 10.1099/0022-1317-80-2-457	49	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54817	54825		10.1074/jbc.M405911200	http://dx.doi.org/10.1074/jbc.M405911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498777	hybrid			2022-12-25	WOS:000225793600110
J	Harrell, JM; Murphy, PJM; Morishima, Y; Chen, HF; Mansfield, JF; Galigniana, MD; Pratt, WB				Harrell, JM; Murphy, PJM; Morishima, Y; Chen, HF; Mansfield, JF; Galigniana, MD; Pratt, WB			Evidence for glucocorticoid receptor transport on microtubules by dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; CYTOPLASMIC DYNEIN; IN-VIVO; HSP90-BINDING IMMUNOPHILINS; HSP90; BINDING; ASSOCIATION; MECHANISM; COMPLEX; FKBP52	Rapid, ligand-dependent movement of glucocorticoid receptors (GR) from cytoplasm to the nucleus is hsp90-dependent, and much of the movement system has been defined. GR.hsp90 heterocomplexes isolated from cells contain one of several hsp90-binding immunophilins that link the complex to cytoplasmic dynein, a molecular motor that processes along microtubular tracks to the nucleus. The immunophilins link to dynein indirectly via the dynamitin component of the dynein-associated dynactin complex (Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004) J. Biol. Chem. 279, 22483-22489). Although it is known that rapid, hsp90-dependent GR movement requires intact microtubules, it has not been shown that the movement is dynein-dependent. Here, we show that overexpression of dynamitin, which blocks movement by dissociating the dynein motor from its cargo, inhibits ligand-dependent movement of the GR to the nucleus. We show that native GR.hsp90.immnunophilin complexes contain dynamitin as well as dynein and that GR heterocomplexes isolated from cytosol containing paclitaxel and GTP to stabilize microtubules also contain tubulin. The complete movement system, including the dynein motor complex and tubulin, can be assembled under cell-free conditions by incubating GR immune pellets with paclitaxel/GTP-stabilized cytosol prepared from GR(-) L cells. This is the first evidence that the movement of a steroid receptor is dynein-dependent, and it is the first isolation of a steroid receptor bound to the entire system that determines its retrograde movement.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Engn, Univ Michigan N Campus Electron Microbeam Anal La, Ann Arbor, MI 48109 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol,Programa Regulac Hormonal & Metab, Consejo Nacl Invest Cient & Techn Argentina, Buenos Aires, DF, Argentina	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Harrell, JM (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3, Ann Arbor, MI 48109 USA.	harrellj@umich.edu	Chen, Haifeng/H-8438-2014	GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, P60DK020572, R37DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [P60DK-20572, DK31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; BARSONY J, 1992, J BIOL CHEM, V267, P24457; Betley TA, 2001, LANGMUIR, V17, P2768, DOI 10.1021/la001297h; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 2004, MOL BRAIN RES, V123, P27, DOI 10.1016/j.molbrainres.2003.12.015; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P10879, DOI 10.1021/bi00159a031; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Yang J, 1996, MOL ENDOCRINOL, V10, P3, DOI 10.1210/me.10.1.3; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0	34	93	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54647	54654		10.1074/jbc.M406863200	http://dx.doi.org/10.1074/jbc.M406863200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485845	Green Published, hybrid			2022-12-25	WOS:000225793600091
J	Jiang, HB; Jiang, Q; Feng, J				Jiang, HB; Jiang, Q; Feng, J			Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; INDUCED APOPTOSIS; DISEASE; DEGRADATION; AGGRESOMES; STRESS; GLYCOSYLATION; INHIBITION; MUTATIONS; BINDING	Mutations of parkin, a protein-ubiquitin E3 ligase, are linked to Parkinson's disease (PD). Although a variety of parkin substrates have been identified, none of these is selectively expressed in dopaminergic neurons, whose degeneration plays a critical role in PD. Here we show that parkin significantly increased dopamine uptake in the human dopaminergic neuroblastoma cell line SH-SY5Y. This effect was accompanied by increased V-max of dopamine uptake and unchanged K-m. Consistent with this, increased binding sites for dopamine transporter (DAT) ligand were observed in SH-SY5Y cells overexpressing parkin. The results were confirmed when parkin was transfected in HEK293 cells stably expressing DAT. In these cells, parkin enhanced the ubiquitination and degradation of DAT, increased its cell surface expression, and augmented dopamine uptake. The effects of parkin were significantly abrogated by its PD-causing mutations. Because the cell surface expression of functional DAT requires its oligomerization, misfolded DAT, induced either by the protein glycosylation inhibitor tunicamycin or by its C-terminal truncation, significantly attenuated cell surface expression of native DAT and reduced dopamine uptake. Expression of parkin, but not its T240R mutant, significantly alleviated these detrimental effects of misfolded DAT. Thus, our studies suggest that parkin increases dopamine uptake by enhancing the ubiquitination and degradation of misfolded DAT, so as to prevent it from interfering with the oligomerization and cell surface expression of native DAT. This function of parkin would enhance the precision of dopaminergic transmission, increase the efficiency of dopamine utilization, and reduce dopamine toxicity on neighboring cells.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu			AHRQ HHS [HS41722] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; Feng Jian, 2003, Current Neuropharmacology, V1, P301, DOI 10.2174/1570159033477053; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hersch SM, 1997, J COMP NEUROL, V388, P211; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; JENNER P, 1996, NEUROLOGY S3, V47, P161; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Muqit MMK, 2004, HUM MOL GENET, V13, P117, DOI 10.1093/hmg/ddh012; PATEL A, 1993, J NEUROCHEM, V61, P496; Ren Y, 2003, J NEUROSCI, V23, P3316; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	35	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54380	54386		10.1074/jbc.M409282200	http://dx.doi.org/10.1074/jbc.M409282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492001	hybrid			2022-12-25	WOS:000225793600060
J	Ouhammouch, M; Werner, F; Weinzierl, ROJ; Geiduschek, EP				Ouhammouch, M; Werner, F; Weinzierl, ROJ; Geiduschek, EP			A fully recombinant system for activator-dependent archaeal transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TFIIE-ALPHA; INITIATION; SUBUNIT; DOMAIN; RECOGNITION; PROTEIN	The core components of the archaeal transcription apparatus closely resemble those of eukaryotic RNA polymerase II, while the DNA-binding transcriptional regulators are predominantly of bacterial type. Here we report the construction of an entirely recombinant system for positively regulated archaeal transcription. By omitting individual subunits, or sets of subunits, from the in vitro assembly of the 12-subunit RNA polymerase from the hyperthermophile Methanocaldococcus jannaschii, we describe a functional dissection of this RNA polymerase II-like enzyme, and its interactions with the general transcription factor TFE, as well as with the transcriptional activator Ptr2.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	University of California System; University of California San Diego; University of California System; University of California San Diego; Imperial College London	Ouhammouch, M (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	mouham@biomail.ucsd.edu		Werner, Finn/0000-0002-3930-3821				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Ouhammouch M, 2004, CURR OPIN GENET DEV, V14, P133, DOI 10.1016/j.gde.2004.01.002; Ouhammouch M, 2003, P NATL ACAD SCI USA, V100, P5097, DOI 10.1073/pnas.0837150100; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9	19	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51719	51721		10.1074/jbc.C400446200	http://dx.doi.org/10.1074/jbc.C400446200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15485836	hybrid			2022-12-25	WOS:000225493400002
J	Waetzig, GH; Rosenstiel, P; Arlt, A; Till, A; Brautigam, K; Schafer, H; Rose-John, S; Seegert, D; Schreiber, S				Waetzig, GH; Rosenstiel, P; Arlt, A; Till, A; Brautigam, K; Schafer, H; Rose-John, S; Seegert, D; Schreiber, S			Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta 1	FASEB JOURNAL			English	Article						anti-inflammatory agents; autoimmune diseases; inflammation; mitogen-activated protein kinases; signal transduction	INFLAMMATORY-BOWEL-DISEASE; ACTIVATED PROTEIN-KINASE; PROPRIA T-LYMPHOCYTES; GROWTH-FACTOR-BETA; FACTOR-ALPHA; CROHNS-DISEASE; TGF-BETA; IN-VITRO; MONOCYTIC CELLS; FAS LIGAND	The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in inflammatory disorders. Transmembrane TNF-alpha and its two receptors are cleaved by the proteinase TNF-alpha converting enzyme (TACE), resulting in appreciable serum levels of soluble TNF-alpha and soluble TNF-alpha receptors (sTNFR1 and -2). The only known functions of sTNFR1 are to antagonize and buffer circulating TNF-alpha. Here, we present evidence that sTNFR1 exerts immunoregulatory functions by induction of apoptosis in monocytes through reverse signaling via transmembrane TNF-alpha. sTNFR1-induced apoptosis is independent of death receptor pathways but depends on autocrine transforming growth factor (TGF)-beta1 signaling through the mitogen-activated protein kinase p38alpha. This novel mechanism has implications for understanding the physiological role of sTNFR1 and for TNF-alpha-blocking therapies of autoimmune diseases.	Schleswig Holstein Univ Med Ctr, Inst Clin Mol Biol, D-24105 Kiel, Germany; Schleswig Holstein Univ Med Ctr, Lab Mol Gastroenterol & Hepatol, Dept Med 1, D-24105 Kiel, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Conaris Res Inst AG, D-24118 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel	Schreiber, S (corresponding author), Schleswig Holstein Univ Med Ctr, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Braeutigam, Karen/F-3518-2014; Arlt, Alexander/G-7308-2019; Till, Andreas/AAO-6375-2021; Seegert, Dirk/B-8826-2011; Schäfer, Heiner/C-1055-2011; Rosenstiel, Philip/A-5137-2009; Waetzig, Georg/AAV-7486-2021; Rose-John, Stefan/A-7998-2010; Till, Andreas/E-9661-2013	Arlt, Alexander/0000-0002-6160-1059; Rosenstiel, Philip/0000-0002-9692-8828; Rose-John, Stefan/0000-0002-7519-3279; Till, Andreas/0000-0002-0139-9143				ALLANLA, 2003, NAT CELL BIOL, V5, P647; ANDUS T, 1992, HEPATOLOGY, V16, P749, DOI 10.1002/hep.1840160322; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; BOMBARA C, 1992, J CELL PHYSIOL, V153, P30, DOI 10.1002/jcp.1041530106; CORTI A, 1995, J INTERF CYTOK RES, V15, P143, DOI 10.1089/jir.1995.15.143; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duan RS, 2002, J AUTOIMMUN, V19, P169, DOI 10.1006/jaut.2002.0618; Eissner G, 2000, J IMMUNOL, V164, P6193, DOI 10.4049/jimmunol.164.12.6193; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fernandez-Real JM, 2003, J CLIN ENDOCR METAB, V88, P2714, DOI 10.1210/jc.2002-021583; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; HADZISELIMOVIC F, 1995, GUT, V37, P260, DOI 10.1136/gut.37.2.260; Haeffner A, 1997, J IMMUNOL, V158, P1310; Harashima S, 2001, J IMMUNOL, V166, P130, DOI 10.4049/jimmunol.166.1.130; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUMBERT M, 1994, AM J RESP CRIT CARE, V149, P1681, DOI 10.1164/ajrccm.149.6.8004330; Ina K, 1999, J IMMUNOL, V163, P1081; KELLEY JL, 1987, EXP MOL PATHOL, V46, P266, DOI 10.1016/0014-4800(87)90049-9; Kirchner S, 2004, J LEUKOCYTE BIOL, V75, P324, DOI 10.1189/jlb.0703343; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; Krause Stefan W., 1996, Immunobiology, V196, P522; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lugering A, 2001, GASTROENTEROLOGY, V121, P1145, DOI 10.1053/gast.2001.28702; Mitoma H, 2004, GASTROENTEROLOGY, V126, P934, DOI 10.1053/j.gastro.2004.01.036; Moon YS, 2004, METABOLISM, V53, P863, DOI 10.1016/j.metabol.2004.02.007; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, J IMMUNOL, V164, P4672, DOI 10.4049/jimmunol.164.9.4672; Noguchi M, 1998, GUT, V43, P203, DOI 10.1136/gut.43.2.203; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Pelaia G, 2003, AM J RESP CELL MOL, V29, P12, DOI 10.1165/rcmb.2002-0074OC; POCSIK E, 1995, J INFLAMM, V45, P152; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Randow F, 1997, J IMMUNOL, V158, P2911; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spengler U, 1996, CYTOKINE, V8, P864, DOI 10.1006/cyto.1996.0115; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; STEINSHAMN S, 1995, BRIT J HAEMATOL, V89, P719; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Suzuki I, 2000, J IMMUNOL, V165, P5537, DOI 10.4049/jimmunol.165.10.5537; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; ten Hove T, 2002, GUT, V50, P206, DOI 10.1136/gut.50.2.206; Trinchard-Lugan I, 2001, EUR CYTOKINE NETW, V12, P391; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Waetzig GH, 2003, GASTROENTEROLOGY, V125, P633, DOI 10.1016/S0016-5085(03)00979-X; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wiley SR, 1996, J IMMUNOL, V157, P3635	62	80	81	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					91	+		10.1096/fj.04-2073fje	http://dx.doi.org/10.1096/fj.04-2073fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15514103				2022-12-25	WOS:000224849900004
J	Vondruskova, E; van den Burg, J; Zikova, A; Ernst, NL; Stuart, K; Benne, R; Lukes, J				Vondruskova, E; van den Burg, J; Zikova, A; Ernst, NL; Stuart, K; Benne, R; Lukes, J			RNA interference analyses suggest a transcript-specific regulatory role for mitochondrial RNA-binding proteins MRP1 and MRP2 in RNA editing and other RNA processing in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREEDITED MESSENGER-RNA; GUIDE RNA; U-DELETION; IN-VITRO; BAND IV; COMPLEX; GENE; GBP21; LEISHMANIA; INSERTION	Mitochondrial RNA-binding proteins MRP1 and MRP2 occur in a heteromeric complex that appears to play a role in U-insertion/deletion editing in trypanosomes. Reduction in the levels of MRP1 (gBP21) and/or MRP2 (gBP25) mRNA by RNA interference in procyclic Trypanosoma brucei resulted in severe growth inhibition. It also resulted in the loss of both proteins, even when only one of the MRP mRNAs was reduced, indicating a mutual dependence for stability. Elimination of the MRPs gave rise to substantially reduced levels of edited CyB and RPS12 mRNAs but little or no reduction of the level of edited Cox2, Cox3, and A6 mRNAs as measured by poisoned primer extension analyses. In contrast, edited NADH-dehydrogenase (ND) subunit 7 mRNA was increased 5-fold in MRP1+2 double knockdown cells. Furthermore, MRP elimination resulted in reduced levels of Cox1, ND4, and ND5 mRNAs, which are never edited, whereas mitoribosomal 12 S rRNA levels were not affected. These data indicate that MRP1 and MRP2 are not essential for RNA editing per se but, rather, play a regulatory role in the editing of specific transcripts and other RNA processing activities.	Acad Sci Czech Republ, Inst Parasitol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol, Ceske Budejovice 37005, Czech Republic; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Washington, Seattle Biomed Res Inst, Seattle, WA 98195 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; University of Amsterdam; Academic Medical Center Amsterdam; Center for Infectious Disease Research; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lukes, J (corresponding author), Acad Sci Czech Republ, Inst Parasitol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	jula@paru.cas.cz	Lukes, Julius/H-6760-2012; Zikova, Alena/G-7855-2014	Lukes, Julius/0000-0002-0578-6618; Zikova, Alena/0000-0002-8686-0225	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014102, R01AI014102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TE, 1998, MOL CELL BIOL, V18, P6014, DOI 10.1128/MCB.18.10.6014; Aphasizhev R, 2003, P NATL ACAD SCI USA, V100, P10617, DOI 10.1073/pnas.1833120100; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; Blom D, 2001, NUCLEIC ACIDS RES, V29, P2950, DOI 10.1093/nar/29.14.2950; Cruz-Reyes J, 2001, MOL CELL BIOL, V21, P884, DOI 10.1128/MCB.21.3.884-892.2001; Domingo GJ, 2003, EUKARYOT CELL, V2, P569, DOI 10.1128/EC.2.3.569-577.2003; Drozdz M, 2002, EMBO J, V21, P1791, DOI 10.1093/emboj/21.7.1791; Estevez AM, 1999, MOL BIOCHEM PARASIT, V100, P5, DOI 10.1016/S0166-6851(99)00024-9; Gao GH, 2003, J BIOL CHEM, V278, P27570, DOI 10.1074/jbc.M303317200; Grams J, 2000, EMBO J, V19, P5525, DOI 10.1093/emboj/19.20.5525; Hayman ML, 1999, J BIOL CHEM, V274, P12067, DOI 10.1074/jbc.274.17.12067; Huang CE, 2002, MOL CELL BIOL, V22, P3194, DOI 10.1128/MCB.22.9.3194-3203.2002; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Igo RP, 2000, MOL CELL BIOL, V20, P8447, DOI 10.1128/MCB.20.22.8447-8457.2000; Igo RP, 2002, EUKARYOT CELL, V1, P112, DOI 10.1128/EC.1.1.112-118.2002; KIM KS, 1994, J BIOL CHEM, V269, P1206; Koller J, 1997, J BIOL CHEM, V272, P3749, DOI 10.1074/jbc.272.6.3749; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; Lambert L, 1999, NUCLEIC ACIDS RES, V27, P1429, DOI 10.1093/nar/27.6.1429; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; Madison-Antenucci S, 1998, EMBO J, V17, P6368, DOI 10.1093/emboj/17.21.6368; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Madison-Antenucci S, 2001, MOL CELL, V7, P879, DOI 10.1016/S1097-2765(01)00231-3; Muller UF, 2002, NUCLEIC ACIDS RES, V30, P447, DOI 10.1093/nar/30.2.447; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; O'Hearn SF, 2003, MOL CELL BIOL, V23, P7909, DOI 10.1128/MCB.23.21.7909-7919.2003; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; Panigrahi AK, 2001, MOL CELL BIOL, V21, P380, DOI 10.1128/MCB.21.2.380-389.2001; PARKER HL, 1995, MOL BIOCHEM PARASIT, V69, P269, DOI 10.1016/0166-6851(94)00208-5; Pelletier M, 2000, NUCLEIC ACIDS RES, V28, P1266, DOI 10.1093/nar/28.5.1266; Pelletier M, 2003, RNA, V9, P457, DOI 10.1261/rna.2160803; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, J BIOL CHEM, V267, P1123; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Sbicego S, 2003, EUKARYOT CELL, V2, P560, DOI 10.1128/EC.2.3.560-568.2003; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; SIMPSON L, 2003, RNA NY, V9, P41; Stuart K, 2002, MOL MICROBIOL, V45, P591, DOI 10.1046/j.1365-2958.2002.03028.x; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825; Wang BB, 2003, EUKARYOT CELL, V2, P578, DOI 10.1128/EC.2.3.578-587.2003; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200	49	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2429	2438		10.1074/jbc.M405933200	http://dx.doi.org/10.1074/jbc.M405933200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15504736	hybrid			2022-12-25	WOS:000226449100008
J	Liu, J; Gluzman, IY; Drew, ME; Goldberg, DE				Liu, J; Gluzman, IY; Drew, ME; Goldberg, DE			The role of Plasmodium falciparum food vacuole plasmepsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC PROTEASES; POTENT INHIBITORS; MALARIA PARASITES; SITE; SPECIFICITY; EXPRESSION	Plasmepsins (PMs) are thought to have an important function in hemoglobin degradation in the malarial parasite Plasmodium falciparum and have generated interest as antimalarial drug targets. Four paralogous plasmepsins reside in the food vacuole of P. falciparum. Targeted gene disruption by double crossover homologous recombination has been employed to study food vacuole plasmepsin function in cultured parasites. Parasite clones with deletions in each of the individual PM I, PM II, and HAP genes as well as clones with a double PM IV/PM I disruption have been generated. All of these clones lack the corresponding PMs, are viable, and appear morphologically normal. PM II and PM IV/I disruptions have longer doubling times than the 3D7 parental line in rich RPMI medium. This appears to be because of a decreased level of productive progeny rather than an increased cell cycle time. In amino acid-limited medium, all four knockouts exhibit slower growth than the parental strain. Compared with 3D7, knock-out clone sensitivity to aspartic and cysteine protease inhibitors is changed minimally. These results suggest substantial functional redundancy and have important implications for the design of antimalarial drugs. The slow growth phenotype may explain why P. falciparum has maintained four plasmepsin genes with overlapping functions.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu	Drew, Mark/E-2993-2011; Liu, Jun/G-4889-2011	Liu, Jun/0000-0002-3347-5139	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreeva N, 2004, PROTEINS, V55, P705, DOI 10.1002/prot.20078; Banerjee R, 2003, MOL BIOCHEM PARASIT, V129, P157, DOI 10.1016/S0166-6851(03)00119-1; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Banerjee Ritu, 2001, P43; Barkan D, 2000, INT J PARASITOL, V30, P649, DOI 10.1016/S0020-7519(00)00035-7; Boss C, 2003, CURR MED CHEM, V10, P883, DOI 10.2174/0929867033457674; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Forslund AH, 2000, AM J PHYSIOL-ENDOC M, V278, pE857, DOI 10.1152/ajpendo.2000.278.5.E857; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i; Klemba M, 2004, J CELL BIOL, V164, P47, DOI 10.1083/jcb200307147; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010; Martins TM, 2003, ACTA TROP, V89, P1, DOI 10.1016/S0001-706X(03)00199-2; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; Papp B, 2004, NATURE, V429, P661, DOI 10.1038/nature02636; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Siripurkpong P, 2002, J BIOL CHEM, V277, P41009, DOI 10.1074/jbc.M204852200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Westling J, 1999, PROTEIN SCI, V8, P2001, DOI 10.1110/ps.8.10.2001; *WHO, 2004, 94 WHO	34	217	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1432	1437		10.1074/jbc.M409740200	http://dx.doi.org/10.1074/jbc.M409740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15513918	hybrid			2022-12-25	WOS:000226195200071
J	Chang, S; Pikaard, CS				Chang, S; Pikaard, CS			Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; GENE-EXPRESSION; TRICHOSTATIN-A; FACULTATIVE HETEROCHROMATIN; H3 METHYLTRANSFERASE; NUCLEOLAR DOMINANCE; CHROMATIN-STRUCTURE; X-CHROMOSOME; INACTIVE-X; ACETYLATION	Blocking histone deacetylation with trichostatin A (TSA) or blocking cytosine methylation using 5-aza-2'-deoxycytosine (aza-dC) can derepress silenced genes in multicellular eukaryotes, including animals and plants. We questioned whether DNA methylation and histone deacetylation overlap in the regulation of endogenous plant genes by monitoring changes in expression of similar to7800 Arabidopsis thaliana genes following treatment with aza-dC, TSA, or both chemicals together. RNA levels for similar to4% of the genes were reproducibly changed 3-fold or more by at least one treatment. Distinct subsets of genes are up-regulated or down-regulated in response to aza-dC, TSA, or simultaneous treatment with both chemicals, with little overlap among subsets. Surprisingly, the microarray data indicate that TSA and aza-dC are often antagonistic rather than synergistic in their effects. Analysis of green fluorescent protein transgenic plants confirmed this finding, showing that TSA can block the up-regulation of silenced green fluorescent protein transgenes in response to aza-dC or a ddm1 ( decrease in DNA methylation 1) mutation. Our results indicate that global inhibition of DNA methylation or histone deacetylation has complex, nonredundant effects for the majority of responsive genes and suggest that activation of some genes requires one or more TSA-sensitive deacetylation events in addition to cytosine demethylation.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pikaard, CS (corresponding author), Washington Univ, Dept Biol, 1 Brookings Dr, St Louis, MO 63130 USA.	pikaard@biology.wustl.edu	Pikaard, Craig S/K-8772-2012	Pikaard, Craig S/0000-0001-8204-7459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060380] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM60380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amedeo P, 2000, NATURE, V405, P203, DOI 10.1038/35012108; Astrand C, 2004, EUR J BIOCHEM, V271, P1153, DOI 10.1111/j.1432-1033.2004.04019.x; Avramova ZV, 2002, PLANT PHYSIOL, V129, P40, DOI 10.1104/pp.010981; Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Chadwick BP, 2003, SEMIN CELL DEV BIOL, V14, P359, DOI 10.1016/j.semcdb.2003.09.016; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Chow JC, 2003, CELL MOL LIFE SCI, V60, P2586, DOI 10.1007/s00018-003-3121-9; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeRubertis F, 1996, NATURE, V384, P589; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Eissenberg JC, 2003, PROG NUCLEIC ACID RE, V74, P275, DOI 10.1016/S0079-6603(03)01016-X; Feng Q, 2001, GENE DEV, V15, P827; Finkelstein D, 2002, PLANT MOL BIOL, V48, P119, DOI 10.1023/A:1013765922672; GARTLER SM, 1994, DEV GENET, V15, P504, DOI 10.1002/dvg.1020150609; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kankel MW, 2003, GENETICS, V163, P1109; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Lindemann RK, 2004, CELL CYCLE, V3, P779; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Probst AV, 2003, PLANT J, V33, P743, DOI 10.1046/j.1365-313X.2003.01667.x; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113; Scheid OM, 2002, P NATL ACAD SCI USA, V99, P13659, DOI 10.1073/pnas.202380499; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Shaker S, 2003, LEUKEMIA RES, V27, P437, DOI 10.1016/S0145-2126(02)00222-9; Shi HD, 2003, CANCER RES, V63, P2164; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tariq M, 2002, EMBO REP, V3, P951, DOI 10.1093/embo-reports/kvf195; TURNER BM, 1991, J CELL SCI, V99, P13; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VAN LC, 1996, GENE EXPRESSION, V5, P245; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200; Wolffe AP, 1998, J EXP ZOOL, V282, P239, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;239::AID-JEZ25&gt;3.0.CO;2-N; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	63	91	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					796	804		10.1074/jbc.M409053200	http://dx.doi.org/10.1074/jbc.M409053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516340	hybrid			2022-12-25	WOS:000226025100093
J	Chen, S; Chen, LL; Tan, JZ; Chen, J; Du, L; Sun, T; Shen, JH; Chen, KX; Jiang, HL; Shen, X				Chen, S; Chen, LL; Tan, JZ; Chen, J; Du, L; Sun, T; Shen, JH; Chen, KX; Jiang, HL; Shen, X			Severe acute respiratory syndrome coronavirus 3C-like proteinase n terminus is indispensable for proteolytic activity but not for enzyme dimerization - Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARS-CORONAVIRUS; FLUOROGENIC SUBSTRATE; RNA-POLYMERASE; MAIN PROTEASE; PURIFICATION; REVEALS; PEPTIDE; DESIGN; BIOSYNTHESIS; SPECIFICITY	Severe acute respiratory syndrome (SARS) coronavirus is a novel human coronavirus and is responsible for SARS infection. SARS coronavirus 3C-like proteinase (SARS 3CL(pro)) plays key roles in viral replication and transcription and is an attractive target for anti-SARS drug discovery. In this report, we quantitatively characterized the dimerization features of the full-length and N-terminal residues 1-7 deleted SARS 3CL(pro)s by using glutaraldehyde cross-linking SDS-PAGE, size-exclusion chromatography, and isothermal titration calorimeter techniques. Glutaraldehyde cross-linking SDS-PAGE and size-exclusion chromatography results show that, similar to the full-length SARS 3CL(pro), the N-terminal deleted SARS 3CL(pro) still remains a dimer/monomer mixture within a wide range of protein concentrations. Isothermal titration calorimeter determinations indicate that the equilibrium dissociation constant (K-d) of the N-terminal deleted proteinase dimer (262 muM) is very similar to that of the full-length proteinase dimer (227 muM). Enzymatic activity assay using the fluorescence resonance energy transfer method reveals that N-terminal deletion results in almost complete loss of enzymatic activity for SARS 3CL(pro). Molecular dynamics and docking simulations demonstrate the N-terminal deleted proteinase dimer adopts a state different from that of the full-length proteinase dimer, which increases the angle between the two protomers and reduces the binding pocket that is not beneficial to the substrate binding. This conclusion is verified by the surface plasmon resonance biosensor determination, indicating that the model substrate cannot bind to the N-terminal deleted proteinase. These results suggest the N terminus is not indispensable for the proteinase dimerization but may fix the dimer at the active state and is therefore vital to enzymatic activity.	Chinese Acad Sci, Shanghai Inst Mat Med, Grad Sch,Shanghai Inst Biol Sci, Drug Discovery & Design Ctr,State Key Lab Drug Re, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS	Jiang, HL (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Grad Sch,Shanghai Inst Biol Sci, Drug Discovery & Design Ctr,State Key Lab Drug Re, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.	hljiang@mail.shcnc.ac.cn; xshen@mail.shcnc.ac.cn	Sun, Tao/B-8884-2014; Chen, Ling-Ling/AAY-3547-2021; Du, Li/L-2353-2015	Sun, Tao/0000-0002-4204-0372				Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P3819, DOI 10.1021/bi0116700; Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; Chen S, 2005, ACTA PHARMACOL SIN, V26, P99, DOI 10.1111/j.1745-7254.2005.00010.x; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; FOUCHIER RA, 2003, NATURE, P423; GARCIAECHEVERRIA C, 1992, FEBS LETT, V297, P100, DOI 10.1016/0014-5793(92)80336-F; HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q; KATHRYN VH, 2002, J CLIN INVEST, V111, P1605; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; Lovatt A, 1996, EUR BIOPHYS J BIOPHY, V24, P354; McPhail D, 1997, J CHEM SOC FARADAY T, V93, P2283, DOI 10.1039/a701327b; Mittoo S, 2003, ANAL BIOCHEM, V319, P234, DOI 10.1016/S0003-2697(03)00324-5; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Spiga O, 2002, FEBS LETT, V511, P33, DOI 10.1016/S0014-5793(01)03274-4; Sun HF, 2003, PROTEIN EXPRES PURIF, V32, P302, DOI 10.1016/j.pep.2003.08.016; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; Van Gunsteren WF, 1987, GROMOS 87 MANUAL; Xiong B, 2003, ACTA PHARMACOL SIN, V24, P497; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	34	80	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					164	173		10.1074/jbc.M408211200	http://dx.doi.org/10.1074/jbc.M408211200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507456	Green Published, hybrid			2022-12-25	WOS:000226025100021
J	Parent, M; Yung, TMC; Rancourt, A; Ho, ELY; Vispe, S; Suzuki-Matsuda, F; Uehara, A; Wada, T; Handa, H; Satoh, MS				Parent, M; Yung, TMC; Rancourt, A; Ho, ELY; Vispe, S; Suzuki-Matsuda, F; Uehara, A; Wada, T; Handa, H; Satoh, MS			Poly(ADP-ribose) polymerase-1 is a negative regulator of HIV-1 transcription through competitive binding to TAR RNA with Tat center dot Positive transcription elongation factor b (p-TEFb) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NF-KAPPA-B; DNA TOPOISOMERASES; GENE-EXPRESSION; PROTEIN-KINASE; II ELONGATION; CYCLIN T1; IN-VITRO; ACTIVATION; DSIF	Human immunodeficiency virus, type 1 (HIV-1) transcription is regulated by a virus-encoded protein, Tat, which forms a complex with a host cellular factor, positive transcription elongation factor b (P-TEFb). When this complex binds to TAR RNA synthesized from the HIV-1 long terminal repeat promoter element, transcription is trans-activated. In this study we showed that, in host cells, HIV-1 transcription is negatively regulated by competition of poly(ADP-ribose) polymerase-1 (PARP-1) with Tat.P-TEFb for binding to TAR RNA. PARP-1, which has a high affinity for TAR RNA (K-D = 1.35 x 10(-10) (M)), binds to the loop region of TAR RNA and displaces Tat or Tat.P-TEFb from the RNA. In vitro transcription assays showed that this displacement leads to suppression of Tat-mediated trans-activation of transcription. Furthermore in vivo expression of luciferase or destabilized enhanced green fluorescent protein genes under the control of the HIV-1 long terminal repeat promoter was suppressed by PARP-1. Thus, these results suggest that PARP-1 acts as a negative regulator of HIV-1 transcription through competitive binding with Tat or the Tat.P-TEFb complex to TAR RNA.	Univ Laval, Med Ctr, Div Hlth & Environm Res, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Anat & Physiol, Ste Foy, PQ G1V 4G2, Canada; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Laval University; Laval University; Tokyo Institute of Technology	Satoh, MS (corresponding author), Univ Laval, Med Ctr, Div Hlth & Environm Res, 2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gwack Y, 2003, MOL CELL BIOL, V23, P8282, DOI 10.1128/MCB.23.22.8282-8294.2003; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; Siva AC, 2002, J VIROL, V76, P11904, DOI 10.1128/JVI.76.23.11904-11910.2002; TERWILLIGER E, 1988, J ACQ IMMUN DEF SYND, V1, P317; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200; Yung TMC, 2004, J BIOL CHEM, V279, P11992, DOI 10.1074/jbc.M312459200; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	49	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					448	457		10.1074/jbc.M408435200	http://dx.doi.org/10.1074/jbc.M408435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498776	hybrid			2022-12-25	WOS:000226025100054
J	Robinson, KN; Manto, K; Buchsbaum, RJ; MacDonald, JIS; Meakin, SO				Robinson, KN; Manto, K; Buchsbaum, RJ; MacDonald, JIS; Meakin, SO			Neurotrophin-dependent tyrosine phosphorylation of Ras guanine-releasing factor 1 and associated neurite outgrowth is dependent on the HIKE domain of TrkA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE ACTIVITY; ACTIVATION LOOP TYROSINES; KINASE ACTIVATION; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; DIFFERENT ROLES; BINDING DOMAIN; PH DOMAINS; GROWTH; RECEPTORS	Ras guanine-releasing factor 1 (RasGrf1), a guanine nucleotide exchange factor for members of the Ras and Rho family of GTPases, is highly expressed in the brain. It is regulated by two separate mechanisms, calcium regulation through interaction with its calcium/calmodulin-binding IQ domain and serine and tyrosine phosphorylation. RasGrf1 is activated downstream of G-protein-coupled receptors and the non-receptor tyrosine kinases, Src and Ack1. Previously, we demonstrated a novel interaction between the intracellular domain of the nerve growth factor-regulated TrkA receptor tyrosine kinase and an N-terminal fragment of RasGrf1. We now show that RasGrf1 is phosphorylated and interacts with TrkA, -B, and -C in co-transfection studies. This interaction and phosphorylation of RasGrf1 is dependent on the HIKE domain of TrkA ( a region shown to interact with pleckstrin homology domains) but not on any of the phosphotyrosine residues that act as docking sites for intracellular signaling molecules such as Shc and FRS-2. The PH1 domain alone of RasGrf1 is sufficient for phosphorylation by the TrkA receptor. A potential role for Trk activation of RasGrf1 is suggested through transfection studies in PC12 cells in which RasGrf1 significantly increases neurite outgrowth at low doses of neurotrophin stimulation. Notably, this neurite outgrowth is dependent on an intact HIKE domain, as nnr5-S10 cells expressing a TrkA HIKE domain mutant do not exhibit potentiated neurite outgrowth in the presence of RasGrf1. These studies identify RasGrf1 as a novel target of neurotrophin activation and suggest an additional pathway whereby neurotrophin-stimulated neurite outgrowth may be regulated.	John P Robarts Res Inst, Lab Neural Signaling, London, ON N6A 5K8, Canada; Tufts Univ, New England Med Ctr, Div Hematol Oncol, Mol Oncol Res Inst, Boston, MA 02111 USA; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Tufts Medical Center; Tufts University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Lab Neural Signaling, 100 Perth Dr, London, ON N6A 5K8, Canada.	smeakin@robarts.ca	Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1998, BIOESSAYS, V20, P691, DOI 10.1002/(SICI)1521-1878(199809)20:9<691::AID-BIES1>3.3.CO;2-H; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Jiang H, 1999, J BIOL CHEM, V274, P26209, DOI 10.1074/jbc.274.37.26209; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lamoureux P, 1997, J CELL SCI, V110, P635; LEVESQUE JP, 1991, BIOTECHNIQUES, V11, P313; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lu PJ, 1997, J BIOL CHEM, V272, P466; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martinez A, 1998, J NEUROSCI, V18, P7336; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Matynia A, 2002, ANNU REV GENET, V36, P687, DOI 10.1146/annurev.genet.36.062802.091007; Mazzucchelli C, 2000, CELL MOL LIFE SCI, V57, P604, DOI 10.1007/PL00000722; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 2000, REC RES DEV NEUROCH, V3, P75; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SHOU CC, 1995, ONCOGENE, V10, P1887; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tian XJ, 2004, EMBO J, V23, P1567, DOI 10.1038/sj.emboj.7600151; Wang JK, 1997, ONCOGENE, V14, P1767, DOI 10.1038/sj.onc.1201021; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Yang HB, 2003, J BIOL CHEM, V278, P13278, DOI 10.1074/jbc.M209805200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zippel R, 1997, MOL BRAIN RES, V48, P140	70	38	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					225	235		10.1074/jbc.M410454200	http://dx.doi.org/10.1074/jbc.M410454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513915	hybrid			2022-12-25	WOS:000226025100028
J	Blume, A; Benie, AJ; Stolz, F; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T				Blume, A; Benie, AJ; Stolz, F; Schmidt, RR; Reutter, W; Hinderlich, S; Peters, T			Characterization of ligand binding to the bifunctional key enzyme in the sialic acid biosynthesis by NMR - I. Investigation of the UDP-GlcNAc 2-epimerase functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE 2-EPIMERASE; TRANSFER DIFFERENCE NMR; 1ST 2 STEPS; RAT-LIVER; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; ESCHERICHIA-COLI; D-GLUCOSAMINE; PURIFICATION; RECOGNITION; EXPRESSION	The bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase is the key enzyme for the biosynthesis of sialic acids. As terminal components of glycoconjugates, sialic acids are associated with a variety of pathological processes such as inflammation and cancer. For the first time, this study reveals characteristics of the interaction of the epimerase site of the enzyme with its natural substrate, UDP-N-acetylglucosamine (UDP-GlcNAc) and derivatives thereof at atomic resolution. Saturation transfer difference NMR experiments were crucial in obtaining ligand binding epitopes and to rank ligands according to their binding affinities. Employing a fragment based approach, it was possible to assign the major component of substrate recognition to the UDP moiety. In particular, the binding epitopes of the uridine moieties of UMP, UDP, UDP-GalNAc, and UDP-GlcNAc are rather similar, suggesting that the binding mode of the UDP moiety is the same in all cases. In contrast, the hexopyranose units of UDP-GlcNAc and UDP-GalNAc display small differences reflecting the inability of the enzyme to process UDP-GalNAc. Surprisingly, saturation transfer difference NMR titrations show that UDP has the largest binding affinity to the epimerase site and that at least one phosphate group is required for binding. Consequently, this study provides important new data for rational drug design.	Charite Univ Med Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; Univ Lubeck, Inst Chem, D-23538 Lubeck, Germany; Univ Konstanz, Fachbereich Chem, Fach M 725, D-78457 Constance, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lubeck; University of Konstanz	Hinderlich, S (corresponding author), Charite Univ Med Berlin, Inst Biochem & Mol Biol, Campus Benjamin Franklin,Arnimallee 22, D-14195 Berlin, Germany.	stephan.hinderlich@charite.de; thomas.peters@chemie.uni-luebeck.de	Peters, Thomas/AAE-1509-2022; Peters, Thomas/GQB-3622-2022	Peters, Thomas/0000-0002-7570-8260; Benie, Andrew/0000-0001-8274-0456				Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e; Benie AJ, 2004, J BIOL CHEM, V279, P55722, DOI 10.1074/jbc.M410239200; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; Biet T, 2001, ANGEW CHEM INT EDIT, V40, P4189, DOI 10.1002/1521-3773(20011119)40:22<4189::AID-ANIE4189>3.0.CO;2-A; Blume A, 2004, PROTEIN EXPRES PURIF, V35, P387, DOI 10.1016/j.pep.2004.02.013; Blume A, 2002, FEBS LETT, V521, P127, DOI 10.1016/S0014-5793(02)02856-9; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Chen H, 2002, GLYCOBIOLOGY, V12, P65, DOI 10.1093/glycob/12.2.65; Chou WK, 2003, J AM CHEM SOC, V125, P2455, DOI 10.1021/ja021309g; CORFIELD AP, 1982, OCCURRENCE SIALIC AC, P5; DENNIS JW, 1985, CANCER RES, V45, P6034; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; Jayalakshmi V, 2004, J AM CHEM SOC, V126, P8610, DOI 10.1021/ja048703u; Jayalakshmi V, 2002, J MAGN RESON, V155, P106, DOI 10.1006/jmre.2001.2499; KAMERLING JP, 1979, BIOCHIM BIOPHYS ACTA, V583, P403, DOI 10.1016/0304-4165(79)90465-3; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KEPPLER DOR, 1970, EUR J BIOCHEM, V17, P246, DOI 10.1111/j.1432-1033.1970.tb01160.x; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meinecke R, 2001, J MED CHEM, V44, P3059, DOI 10.1021/jm0109154; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PRAVDIC N, 1975, CARBOHYD RES, V45, P302, DOI 10.1016/S0008-6215(00)85889-9; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V268, P590, DOI 10.1016/0005-2744(72)90356-7; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Stolz F, 2004, J ORG CHEM, V69, P665, DOI 10.1021/jo0353029; Stolz F, 2004, EUR J ORG CHEM, V2004, P3304, DOI 10.1002/ejoc.200400197; Suzuki Y, 2000, J VIROL, V74, P11825, DOI 10.1128/JVI.74.24.11825-11831.2000; Vann WF, 2004, J BACTERIOL, V186, P706, DOI 10.1128/JB.186.3.706-712.2004; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Vogtherr M, 2000, J AM CHEM SOC, V122, P6093, DOI 10.1021/ja0001916; WATSON DR, 1966, J BIOL CHEM, V241, P5627	43	19	19	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55715	55721		10.1074/jbc.M410238200	http://dx.doi.org/10.1074/jbc.M410238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498764	hybrid			2022-12-25	WOS:000225960800092
J	Panchenko, MV; Zhou, MI; Cohen, HT				Panchenko, MV; Zhou, MI; Cohen, HT			von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHD-FINGER; ZINC-FINGER; PROTEIN; CHROMATIN; DOMAIN; GENE; CBP; IDENTIFICATION; ACETYLATION; COMPLEX	Jade-1 was identified as a protein partner of the von Hippel-Lindau tumor suppressor pVHL. The interaction of Jade-1 and pVHL correlates with renal cancer risk. We have investigated the molecular function of Jade-1. Jade-1 has two zinc finger motifs called plant homeodomains (PHD). A line of evidence suggests that the PHD finger functions in chromatin remodeling and protein-protein interactions. We determined the cellular localization of Jade-1 and examined whether Jade-1 might have transcriptional and histone acetyltransferase (HAT) functions. Biochemical cell fractionation studies as well as confocal images of cells immunostained with a specific Jade-1 antibody revealed that endogenous Jade-1 is localized predominantly in the cell nucleus. Tethering of Gal4-Jade-1 fusion protein to Gal4-responsive promoters in co-transfection experiments activated transcription 5-6-fold, indicating that Jade-1 is a possible transcriptional activator. It was remarkable that overexpression of Jade-1 in cultured cells specifically increased levels of endogenous acetylated histone H4, but not histone H3, strongly suggesting that Jade-1 associates with HAT activity specific for histone H4. Deletion of the two PHD fingers completely abolished Jade-1 transcriptional and HAT activities, indicating that these domains are indispensable for Jade-1 nuclear functions. In addition, we demonstrated that TIP60, a known HAT with histone H4/H2A specificity, physically associates with Jade-1 and is able to augment Jade-1 HAT function in live cells, strongly suggesting that TIP60 might mediate Jade-1 HAT activity. Thus, Jade-1 is a novel candidate transcriptional co-activator associated with HAT activity and may play a key role in the pathogenesis of renal cancer and von Hippel-Lindau disease.	Boston Univ, Med Ctr, Evans Biomed Res Ctr,Sch Med, Dept Med,Sect Nephrol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Hematol Oncol Sect, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA 02118 USA	Boston University; Boston University; Boston Medical Center	Cohen, HT (corresponding author), Boston Univ, Med Ctr, Evans Biomed Res Ctr,Sch Med, Dept Med,Sect Nephrol, X-535,650 Albany St, Boston, MA 02118 USA.	htcohen@bu.edu		Panchenko, Maria/0000-0001-6247-6598; Cohen, Herbert/0000-0003-1900-8718	NATIONAL CANCER INSTITUTE [R01CA079830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007053, R01DK067569] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079830, R012 CA 79830] Funding Source: Medline; NIDDK NIH HHS [R01 DK 67569, T32 DK 07053-30, R01 DK067569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DiCamillo SJ, 2002, J BIOL CHEM, V277, P18938, DOI 10.1074/jbc.M200243200; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kalkhoven E, 2003, HUM MOL GENET, V12, P441, DOI 10.1093/hmg/ddg039; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwan AHY, 2003, STRUCTURE, V11, P803, DOI 10.1016/S0969-2126(03)00122-9; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Ramsey C, 2002, HUM MOL GENET, V11, P3299, DOI 10.1093/hmg/11.26.3299; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Sharpe BK, 2002, STRUCTURE, V10, P639, DOI 10.1016/S0969-2126(02)00757-8; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Szelci J, 2000, J STEROID BIOCHEM, V72, P89, DOI 10.1016/S0960-0760(00)00025-X; Trappe R, 2002, BIOCHEM BIOPH RES CO, V293, P816, DOI 10.1016/S0006-291X(02)00277-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Tzouanacou E, 2003, MOL CELL BIOL, V23, P8553, DOI 10.1128/MCB.23.23.8553-8562.2003; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhou MI, 2004, CANCER RES, V64, P1278, DOI 10.1158/0008-5472.CAN-03-0884; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	40	36	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56032	56041		10.1074/jbc.M410487200	http://dx.doi.org/10.1074/jbc.M410487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502158	hybrid			2022-12-25	WOS:000225960800127
J	Saugstad, JA; Roberts, JA; Dong, J; Zeitouni, S; Evans, RJ				Saugstad, JA; Roberts, JA; Dong, J; Zeitouni, S; Evans, RJ			Analysis of the membrane topology of the acid-sensing ion channel 2a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTION; RECEPTOR; PROTONS; ISCHEMIA; PROTEINS; CURRENTS; ASIC2	Acid-sensing ion channels, or ASICs, are members of the amiloride-sensitive cationic channel superfamily that are predicted to have intracellular amino and carboxyl termini and two transmembrane domains connected by a large extracellular loop. This prediction comes from biochemical studies of the mammalian epithelial sodium channels where glycosylation mutants identified the extracellular regions of the channel and a combination of antibody sensitivity and protease action substantiated the intracellular nature of the amino and carboxyl termini. However, although there are highly conserved regions within the different cation channel family members, membrane topology prediction programs provide several alternative structures for the ASICs. Thus, we used glycosylation studies to define the actual membrane topology of the ASIC2a subtype. We deleted the five predicted endogenous asparagine-linked glycosylation sites (Asn-Xaa-(Ser/Thr)) at Asn-22, Asn-365, Asn-392, Asn-478, and Asn-487 to map the extracellular topology. We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders. Finally, we used cell permeabilization studies to confirm the intracellular amino termini of ASIC2a. The data show that Asn-365 and Asn-392 are extracellular and that the introduction of asparagine-linked glycosylation sites at His-72, Ala-81, Tyr-414, and Tyr-423 leads to an increase in molecular mass consistent with an extracellular apposition. In addition, heterologous expression of ASIC2a requires membrane permeabilization for antibody staining. These data confirm the membrane topology prediction that the ASIC2a subtype consists of intracellular amino and carboxyl termini and two transmembrane domains connected by a large extracellular loop.	Legacy Res, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA; Legacy Res, Discoveries Sight, Portland, OR 97232 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Saugstad, JA (corresponding author), Legacy Res, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	JSaugstad@DowNeurobiology.org	Roberts, Jon/A-6771-2012		NATIONAL EYE INSTITUTE [R03EY015267] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY015267, R03 EY015267-01] Funding Source: Medline; NINDS NIH HHS [R42 NS065515] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Hong K, 2000, J NEUROSCI, V20, P2575; Ikeda M, 2003, NUCLEIC ACIDS RES, V31, P406, DOI 10.1093/nar/gkg020; Ikeda Masami, 2002, In Silico Biology, V2, P19; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Roza C, 2004, J PHYSIOL-LONDON, V558, P659, DOI 10.1113/jphysiol.2004.066001; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Ugawa S, 2003, J NEUROSCI, V23, P3616; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026	29	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55514	55519		10.1074/jbc.M411849200	http://dx.doi.org/10.1074/jbc.M411849200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504740	Green Accepted, hybrid			2022-12-25	WOS:000225960800067
J	Baetz, A; Frey, M; Heeg, K; Dalpke, AH				Baetz, A; Frey, M; Heeg, K; Dalpke, AH			Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT INHIBITOR-1 (SSI-1)/SUPPRESSOR; ADAPTER MOLECULE; INTERFERON-BETA; IFN-GAMMA; GENE-EXPRESSION; MACROPHAGES; LIPOPOLYSACCHARIDE; INDUCTION; ACTIVATION; PATHWAY	Suppressor of cytokine signaling ( SOCS) proteins constitute a class of negative regulators for Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways. These intracellular proteins are induced by cytokine signaling, but they can also be induced by stimulation of Toll-like receptors (TLR). It has even been suggested that SOCS proteins are important negative regulators of TLR signaling. Here we have elucidated the nature of the regulatory role of SOCS in TLR signaling. Induction of SOCS-3 and cytokine-inducible Src homology 2-containing protein (CIS) by TLR stimulation was strictly dependent on MyD88 but showed differing needs in case of SOCS-1. However, induction of SOCS proteins by TLR ligands was independent of type I interferon. In macrophages overexpressing SOCS, we were not able to observe an inhibitory effect of SOCS-1, SOCS-2, SOCS-3, or CIS on prototypical TLR target genes such as tumor necrosis factor-alpha. However, we found that TLR-2, TLR-3, TLR-4, and TLR-9 stimulation induced interferon-beta (IFN-beta), which is able to exert auto- and paracrine signaling, leading to the activation of secondary genes like IP-10. SOCS- 1 and, to a lesser extent, SOCS- 3 and CIS were able to inhibit this indirect signaling pathway following TLR stimulation, whereas neither MAP kinase nor NFkappaB signaling were affected. However, STAT-1 tyrosine phosphorylation following TLR triggering was severely impaired by SOCS- 1 overexpression. Thus, our data suggest that SOCS proteins induced by TLR stimulation limit the extent of TLR signaling by inhibiting type I IFN signaling but not the main NFkappaB pathway.	Univ Marburg, Inst Med Microbiol & Hyg, D-35037 Marburg, Germany; Heidelberg Univ, Dept Hyg & Med Microbiol, D-69120 Heidelberg, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg	Dalpke, AH (corresponding author), Univ Marburg, Inst Med Microbiol & Hyg, D-35037 Marburg, Germany.	dalpke@mailer.uni-marburg.de						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Crespo A, 2002, EUR J IMMUNOL, V32, P710, DOI 10.1002/1521-4141(200203)32:3<710::AID-IMMU710>3.0.CO;2-T; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dalpke AH, 2003, EUR J IMMUNOL, V33, P1776, DOI 10.1002/eji.200323621; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; De Sepulveda P, 1999, EMBO J, V18, P904; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Hattori Y, 1996, BIOCHEM MOL BIOL INT, V40, P889; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Park SH, 2003, DNA CELL BIOL, V22, P131, DOI 10.1089/104454903321515931; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Stoiber D, 1999, J IMMUNOL, V163, P2640; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	47	225	244	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54708	54715		10.1074/jbc.M410992200	http://dx.doi.org/10.1074/jbc.M410992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491991	hybrid			2022-12-25	WOS:000225793600098
J	Rotmann, A; Stand, D; Martine, U; Closs, EI				Rotmann, A; Stand, D; Martine, U; Closs, EI			Protein kinase C activation promotes the internalization of the human cationic amino acid transporter hCAT-1 - A new regulatory mechanism for hCAT-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; HUMAN DOPAMINE TRANSPORTER; L-ARGININE TRANSPORT; MURINE RETROVIRUSES; ENDOTHELIAL-CELLS; EXPRESSION; GENE; TRAFFICKING; MACROPHAGES; MEMBRANE	The human cationic amino acid transporter hCAT-1 is almost ubiquitously expressed and probably the most important entity for supplying cells with extracellular arginine, lysine, and ornithine. We have previously shown that hCAT-1-mediated transport is decreased after protein kinase C (PKC) activation by phorbol 12-myristate 13-acetate (PMA) (Graf, P., Forstermann, U., and Closs, E. I. ( 2001) Br. J. Pharmacol. 132, 1193-1200). In the present study, we examined the mechanism of this down-regulation. In both Xenopus laevis oocytes and U373MG glioblastoma cells, PMA treatment promoted the internalization of hCAT-1 ( fused to the enhanced green fluorescence protein (EGFP)) as visualized by fluorescence microscopy. Biotinylation of cell surface proteins and subsequent Western blot analyses confirmed that the cell surface expression of hCAT-1.EGFP was significantly reduced upon PMA treatment. Pretreatment with the PKC inhibitor bisindolylmaleimide I prevented the reduction by PMA of both hCAT-1.EGFP-induced arginine transport and the internalization of the transporter. Similar results were obtained with hCAT-1 expressed endogenously in DLD-1 colon carcinoma cells. Inhibition of protein synthesis did not augment the PMA effect. In addition, the PMA effect was reverted in washout experiments without changing the hCAT-1 protein expression, suggesting that the PMA effect is reversible in these cells. PKC did not phosphorylate hCAT-1 directly as evidenced by in vivo phosphorylation experiments and mutational analysis, indicating an indirect action of PKC on hCAT-1.	Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Closs, EI (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.	Closs@mail.uni-mainz.de	Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Bauman AL, 2000, J NEUROSCI, V20, P7571; Closs EI, 2004, J NUTR, V134, p2752S, DOI 10.1093/jn/134.10.2752S; Closs EI, 2002, CURR OPIN NEPHROL HY, V11, P99, DOI 10.1097/00041552-200201000-00015; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Graf P, 2001, BRIT J PHARMACOL, V132, P1193, DOI 10.1038/sj.bjp.0703921; Grusovin J, 2003, FRONT BIOSCI-LANDMRK, V8, pD620, DOI 10.2741/1052; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Krotova KY, 2003, AM J PHYSIOL-LUNG C, V284, pL1037, DOI 10.1152/ajplung.00308.2002; Lee KH, 2004, NEUROCHEM RES, V29, P1405, DOI 10.1023/B:NERE.0000026404.08779.43; Lee SY, 1999, J VIROL, V73, P5994, DOI 10.1128/JVI.73.7.5994-6005.1999; Lopez-Corcuera B, 2001, BIOCHEM SOC T, V29, P742, DOI 10.1042/0300-5127:0290742; Manner CK, 2003, J NEUROCHEM, V85, P476, DOI 10.1046/j.1471-4159.2003.01695.x; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; PAN M, 1995, ANN SURG, V221, P590, DOI 10.1097/00000658-199505000-00017; Pan M, 2002, J GASTROINTEST SURG, V6, P876, DOI 10.1016/S1091-255X(02)00052-5; PAN M, 1995, BIOCHIM BIOPHYS ACTA, V4, P27; Pastor CM, 1995, AM J PHYSIOL-GASTR L, V269, pG861, DOI 10.1152/ajpgi.1995.269.6.G861; Perkins CP, 1997, GENE DEV, V11, P914, DOI 10.1101/gad.11.7.914; Peters KW, 2001, PFLUG ARCH EUR J PHY, V443, pS65, DOI 10.1007/s004240100647; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Racke K, 1998, J PHYSIOL-LONDON, V511, P813, DOI 10.1111/j.1469-7793.1998.813bg.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Simon A, 2003, CIRC RES, V93, P813, DOI 10.1161/01.RES.0000097761.19223.0D; Vekony N, 2001, BIOCHEMISTRY-US, V40, P12387, DOI 10.1021/bi011345c; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	35	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54185	54192		10.1074/jbc.M409556200	http://dx.doi.org/10.1074/jbc.M409556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491978	hybrid			2022-12-25	WOS:000225793600037
J	Zhang, J; Hellwig, P; Osborne, JP; Gennis, RB				Zhang, J; Hellwig, P; Osborne, JP; Gennis, RB			Arginine 391 in subunit I of the cytochrome bd quinol oxidase from Escherichia coli stabilizes the reduced form of the hemes and is essential for quinol oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; AEROBIC RESPIRATORY-CHAIN; UBIQUINOL OXIDASE; ELECTRON-TRANSFER; D COMPLEX; SPECTROSCOPIC EVIDENCE; CONFORMATIONAL-CHANGES; B(558) COMPONENT; AXIAL LIGANDS; SITE	The cytochrome bd quinol oxidase is one of two respiratory oxidases in Escherichia coli. It oxidizes dihydroubiquinol or dihydromenaquinol while reducing dioxygen to water. The bd-type oxidases have only been found in prokaryotes and have been implicated in the survival of some bacteria, including pathogens, under conditions of low aeration. With a high affinity for dioxygen, cytochrome bd not only couples respiration to the generation of a proton motive force but also scavenges O-2. In the current work, the role of a highly conserved arginine residue is explored by site-directed mutagenesis. Four mutations were made: R391A, R391K, R391M, and R391Q. All of the mutations except R391K result in enzyme lacking ubiquinol oxidase activity. Oxidase activity using the artificial reductant N,N,N',N'-tetramethyl-p-phenylenediamine in place of ubiquinol was, however, unimpaired by the mutations, indicating that the catalytic center where O-2 is reduced is intact. UV-visible spectra of each of the mutant oxidases show no perturbations to any of the three heme components (heme b(558), heme b(595), and heme d). However, spectroelectrochemical titrations of the R391A mutant reveal that the midpoint potentials of all of the heme components are substantially lower compared with the wild type enzyme. Since Arg(391) is close to Met(393), one of the axial ligands to heme b(558), it is to be expected that the R391A mutation might destabilize the reduced form of heme b(558). The fact that the midpoint potentials of heme d and heme b(595) are also significantly lowered in the R391A mutant is consistent with these hemes being physically close together on the periplasmic side of the membrane.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Frankfurt, Inst Biophys, D-65690 Frankfurt, Germany	University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews St, Urbana, IL 61801 USA.	r-gennis@uiuc.edu		hellwig, petra/0000-0001-6294-5163				Baughn AD, 2004, NATURE, V427, P441, DOI 10.1038/nature02285; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; Endley S, 2001, J BACTERIOL, V183, P2454, DOI 10.1128/JB.183.8.2454-2462.2001; FANG H, 1989, J BIOL CHEM, V264, P8026; Hastings SF, 1998, EUR J BIOCHEM, V255, P317, DOI 10.1046/j.1432-1327.1998.2550317.x; Hellwig P, 1998, BBA-BIOENERGETICS, V1409, P107, DOI 10.1016/S0005-2728(98)00151-0; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; HILL S, 1990, J BACTERIOL, V172, P2071, DOI 10.1128/jb.172.4.2071-2078.1990; Hirota S, 1995, BIOSPECTROSCOPY, V1, P305, DOI 10.1002/bspy.350010502; Junemann S, 1997, BIOCHEMISTRY-US, V36, P9323, DOI 10.1021/bi970055m; JUNEMANN S, 1994, FEBS LETT, V345, P198, DOI 10.1016/0014-5793(94)00372-6; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; Juty NS, 1997, MICROBIOL-SGM, V143, P2673, DOI 10.1099/00221287-143-8-2673; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; Lemos RS, 2001, FEBS LETT, V496, P40, DOI 10.1016/S0014-5793(01)02399-7; LORENCE RM, 1984, BIOCHIM BIOPHYS ACTA, V790, P148, DOI 10.1016/0167-4838(84)90218-8; LORENCE RM, 1988, J BIOL CHEM, V11, P5271; MILLER MJ, 1985, J BIOL CHEM, V260, P4003; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Osborne JP, 1999, BBA-BIOENERGETICS, V1410, P32, DOI 10.1016/S0005-2728(98)00171-6; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; Sun J, 1996, BIOCHEMISTRY-US, V35, P2403, DOI 10.1021/bi9518252; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Way SS, 1999, J BACTERIOL, V181, P1229, DOI 10.1128/JB.181.4.1229-1237.1999; Zhang J, 2004, FEBS LETT, V561, P58, DOI 10.1016/S0014-5793(04)00125-5; Zhang J, 2001, BIOCHEMISTRY-US, V40, P8548, DOI 10.1021/bi010469m; Zhang J, 2002, BIOCHEMISTRY-US, V41, P4612, DOI 10.1021/bi011784b	33	17	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53980	53987		10.1074/jbc.M408626200	http://dx.doi.org/10.1074/jbc.M408626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475358	hybrid			2022-12-25	WOS:000225793600012
J	Sdek, P; Ying, HQ; Zheng, HW; Margulis, A; Tang, XR; Tian, K; Xiao, ZXJ				Sdek, P; Ying, HQ; Zheng, HW; Margulis, A; Tang, XR; Tian, K; Xiao, ZXJ			The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ONCOPROTEIN MDM2; TUMOR-SUPPRESSOR; GENE-PRODUCT; RING FINGER; UBIQUITIN LIGASE; BINDING DOMAIN; P53; PROTEIN; RB	Retinoblastoma (Rb) protein is a paradigm of tumor suppressors. Inactivation of Rb plays a critical role in the development of human malignancies. MDM2, an oncogene frequently found amplified and overexpressed in a variety of human tumors and cancers, directly interacts and inhibits the p53 tumor suppressor protein. In addition, MDM2 has been shown to stimulate E2F transactivation activity and promote S-phase entry independent of p53, yet the mechanism of which is still not fully understood. In this study, we demonstrate that MDM2 specifically binds to Rb C-pocket and that the central acidic domain of MDM2 is essential for Rb interaction. In addition, we show that overexpression of MDM2 reduces Rb-E2F complexes in vivo. Moreover, the ectopic expression of the wild type MDM2, but not mutant MDM2 defective in Rb interaction, stimulates E2F transactivation activity and inhibits Rb growth suppression function. Taken together, these results suggest that MDM2-mediated inhibition of Rb likely contributes to MDM2 oncogenic activity.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu	Ying, Haoqiang/AAK-4325-2020; Sdek, Patima/A-5340-2010	Tang, Xiaoren/0000-0002-2402-3659; Zheng, Hongwu/0000-0002-5823-4913	NCI NIH HHS [R01CA79804] Funding Source: Medline; NIGMS NIH HHS [R01GM70017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu L, 2003, FEBS LETT, V544, P218, DOI 10.1016/S0014-5793(03)00502-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumura T, 1996, ONCOLOGY, V53, P308; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; WATANABE T, 1994, BLOOD, V84, P3158; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	41	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53317	53322		10.1074/jbc.M406062200	http://dx.doi.org/10.1074/jbc.M406062200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485814	hybrid			2022-12-25	WOS:000225680600063
J	Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F				Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F			Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; urothelial cell carcinoma; IGF-II; tumour suppressor gene; DNA array		The b isoform of fibroblast growth factor receptor 2, FGFR2b/FGFR2-IIIb/Ksam-IIC1/KGFR, a tyrosine kinase receptor, is expressed in a wide variety of epithelia and is downregulated in several human carcinomas including prostate, salivary and urothelial cell carcinomas. FGFR2b has been shown to inhibit growth in tumour cell lines derived from these carcinomas. Here, we investigated the molecular mechanisms underlying the inhibition of human urothelial carcinoma cell growth following FGFR2b expression. Using a nylon DNA array, we analysed the gene expression pro. le of the T24 bladder tumour cell line, transfected or not with a construct encoding FGFR2b. The expression of FGFR2b in T24 cells decreased insulin-like growth factor (IGF)-II mRNA levels. This decrease was correlated with a decrease in IGF-II secretion and may have been responsible for the observed inhibition of cell growth because the addition of exogenous IGF-II restored growth rates to normal levels. Using SU5402, an inhibitor of FGFR tyrosine kinase activity, and a kinase dead mutant of the receptor, FGFR2b Y659F/Y660F, we also demonstrated that the growth inhibition and decrease in IGF-II secretion induced by FGFR2b did not require tyrosine kinase activity. Finally, we demonstrated the involvement of the distal carboxy-terminal domain of the receptor in decreasing IGF-II expression and inhibiting T24 cell growth, as Ksam-IIC3, a variant of FGFR2b carrying a short carboxy-terminus, neither downregulated IGF-II nor inhibited cell proliferation. Our data suggest that FGFR2b inhibits the growth of bladder carcinoma cells by reducing IGF-II levels via its carboxy-terminal domain, independent of its tyrosine kinase activity.	Inst Curie, Sect Rech, CNRS, UMR144, F-75248 Paris, France; AstraZeneca, Canc & Infect Res Area, Macclesfield SK10 4TG, Cheshire, England; Hop Paul Brousse, F-94807 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; AstraZeneca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Radvanyi, F (corresponding author), Inst Curie, Sect Rech, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris, France.	francois.radvanyi@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020; BROET, PHILIPPE/0000-0001-9122-2810				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO;2-Y; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Broet P, 2002, J COMPUT BIOL, V9, P671, DOI 10.1089/106652702760277381; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; FENG S, 1997, CANCER RES, V23, P5369; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Freeman KW, 2003, CANCER RES, V63, P6237; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Naimi B, 2002, PROSTATE, V52, P245, DOI 10.1002/pros.10104; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sakaguchi K, 1999, ONCOGENE, V18, P5497, DOI 10.1038/sj.onc.1202947; Volm M, 1997, EUR J CANCER, V33, P691, DOI 10.1016/S0959-8049(96)00411-X; WARE LB, 2002, AM J PHYSIOL-LUNG C, V5, P924; WILKIE AOM, 1995, CURR BIOL, V5, P500; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	46	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9201	9211		10.1038/sj.onc.1208150	http://dx.doi.org/10.1038/sj.onc.1208150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516981				2022-12-25	WOS:000225638000005
J	Zzaman, S; Reddy, JM; Bastia, D				Zzaman, S; Reddy, JM; Bastia, D			The DnaK-DnaJ-GrpE chaperone system activates inert wild type pi initiator protein of R6K into a form active in replication initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PLASMID R6K; MOLECULAR CHAPERONE; IN-VITRO; SPECIFICITY COMPONENT; NUCLEOTIDE-SEQUENCE; NEGATIVE CONTROL; BINDING-SITES; ORIGIN-GAMMA	The plasmid R6K is an interesting model system for investigating initiation of DNA replication, not only near the primary binding sites of the initiator protein pi but also at a distance, caused by pi-mediated DNA looping. An important milestone in the mechanistic analysis of this replicon was the development of a reconstituted replication system consisting of 22 different highly purified proteins (Abhyankar, M. A., Zzaman, S., and Bastia, D. ( 2003) J. Biol. Chem. 278, 45476 - 45484). Although the in vitro reconstituted system promotes ori gamma-specific initiation of replication by a mutant form of the initiator called pi*, the wild type (WT) pi is functionally inert in this system. Here we show that the chaperone DnaK along with its co-chaperone DnaJ and the nucleotide exchange factor GrpE were needed to activate WTpi and caused it to initiate replication in vitro at the correct origin. We show further that the reaction was relatively chaperone-specific and that other chaperones, such as ClpB and ClpX, were incapable of activating WTpi. The molecular mechanism of activation appeared to be a chaperone-catalyzed facilitation of dimeric inert WT pi into iteron-bound monomers. Protein-protein interaction analysis by enzyme-linked immunosorbent assay revealed that, in the absence of ATP, DnaJ directly interacted with pi but its binary interactions with DnaK and GrpE and with ClpB and ClpX were at background levels, suggesting that pi is recruited by protein-protein interaction with DnaJ and then fed into the DnaK chaperone machine to promote initiator activation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@musc.edu						Abhyankar MM, 2004, J BIOL CHEM, V279, P6711, DOI 10.1074/jbc.M312052200; Abhyankar MM, 2003, J BIOL CHEM, V278, P45476, DOI 10.1074/jbc.M308516200; ALFANO C, 1989, J BIOL CHEM, V264, P10709; BASTIA D, 1981, GENE, V14, P81, DOI 10.1016/0378-1119(81)90150-5; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chattoraj D K, 1995, Genet Eng (N Y), V17, P81; Chattoraj DK, 1996, GENES CELLS, V1, P189, DOI 10.1046/j.1365-2443.1996.d01-235.x; Chattoraj DK, 1997, PROG NUCLEIC ACID RE, V57, P145, DOI 10.1016/S0079-6603(08)60280-9; CROSA JH, 1978, J MOL BIOL, V124, P443, DOI 10.1016/0022-2836(78)90181-X; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; Dibbens JA, 1997, MOL MICROBIOL, V26, P185, DOI 10.1046/j.1365-2958.1997.5691920.x; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; HUPP TR, 1993, J BIOL CHEM, V268, P13143; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KAWASAKI Y, 1992, J BIOL CHEM, V267, P11520; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KELLEY WL, 1992, NEW BIOL, V4, P569; KELLEY WL, 1992, P NATL ACAD SCI USA, V89, P5078, DOI 10.1073/pnas.89.11.5078; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Konieczny I, 1999, GENET ENG P, V21, P95; LOVETT MA, 1975, P NATL ACAD SCI USA, V72, P2905, DOI 10.1073/pnas.72.8.2905; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; PARK SK, 1993, J BIOL CHEM, V268, P20170; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SHON M, 1982, J BIOL CHEM, V257, P13823; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; Zylicz M, 2001, IUBMB LIFE, V51, P283; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; Zzaman S, 2004, J BIOL CHEM, V279, P17404, DOI 10.1074/jbc.M400021200	64	19	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50886	50894		10.1074/jbc.M407531200	http://dx.doi.org/10.1074/jbc.M407531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485812	hybrid			2022-12-25	WOS:000225355800031
J	Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M				Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M			The erythropoietin-receptor pathway modulates survival of cancer cells	ONCOGENE			English	Article						cancer; Epo; EpoR; NF-kappa B; radiation response	NF-KAPPA-B; QUALITY-OF-LIFE; EPOETIN-ALPHA; DOUBLE-BLIND; TUMOR-CELLS; ANEMIA; RADIOSENSITIVITY; CHEMOTHERAPY; RADIOTHERAPY; SENSITIVITY	Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-kappaB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-kappaB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-kappaB did not require degradation of IkappaBalpha and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.	Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, D-79106 Freiburg, Germany; Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Radiat Oncol, Gliwice, Poland	University of Freiburg; Maria Sklodowska-Curie National Research Institute of Oncology	Pajonk, F (corresponding author), Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, Robert Koch Str 3, D-79106 Freiburg, Germany.	pajonk@uni-freiburg.de	Pajonk, Frank/E-4247-2010	Suwinski, Rafal/0000-0002-3895-7938				Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Batra S, 2003, LAB INVEST, V83, P1477, DOI 10.1097/01.LAB.0000090156.94795.48; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Damen JE, 1996, EXP HEMATOL, V24, P1455; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dunst J, 2003, INT J RADIAT ONCOL, V56, P778, DOI 10.1016/S0360-3016(03)00123-8; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Frommhold H, 1998, STRAHLENTHER ONKOL, V174, P31; Gabrilove JL, 2001, J CLIN ONCOL, V19, P2875, DOI 10.1200/JCO.2001.19.11.2875; Harrison LB, 2002, ONCOLOGY-BASEL, V63, P11, DOI 10.1159/000067147; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HIRST DG, 1984, INT J RADIAT BIOL, V46, P345, DOI 10.1080/09553008414551521; HIRST DG, 1987, INT J RADIAT BIOL, V51, P597, DOI 10.1080/09553008414552131; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JOINER B, 1993, BRIT J CANCER, V68, P720, DOI 10.1038/bjc.1993.417; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; POSKITT TR, 1987, CANCER INVEST, V5, P231, DOI 10.3109/07357908709011739; Ribatti D, 2003, HISTOPATHOLOGY, V42, P246, DOI 10.1046/j.1365-2559.2003.01581.x; SANTUCCI MA, 1994, STEM CELLS, V12, P506, DOI 10.1002/stem.5530120506; Suwinski R, 1999, RADIOTHER ONCOL, V50, P57, DOI 10.1016/S0167-8140(99)00014-6; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214	29	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8987	8991		10.1038/sj.onc.1208140	http://dx.doi.org/10.1038/sj.onc.1208140			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480420				2022-12-25	WOS:000225354600014
J	Wojciechowska, M; Bacolla, A; Larson, JE; Wells, RD				Wojciechowska, M; Bacolla, A; Larson, JE; Wells, RD			The myotonic dystrophy type 1 triplet repeat sequence induces gross deletions and qInversions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAK; ORIENTATION-DEPENDENT MANNER; TRANSCRIPTION-COUPLED REPAIR; REPLICATION IN-VIVO; B DNA CONFORMATIONS; ESCHERICHIA-COLI; HUMAN-DISEASE; STICKY DNA	The capacity of (CTG . CAG)(n) and (GAA . TTC)(n) repeat tracts in plasmids to induce mutations in DNA flanking regions was evaluated in Escherichia coli. Long repeats of these sequences are involved in the etiology of myotonic dystrophy type 1 and Friedreich's ataxia, respectively. Long (CTG . CAG)(n) (where n = 98 and 175) caused the deletion of most, or all, of the repeats and the flanking GFP gene. Deletions of 0.6 - 1.8 kbp were found as well as inversions. Shorter repeat tracts ( where n = 0 or 17) were essentially inert, as observed for the (GAA . TTC)(176)-containing plasmid. The orientation of the triplet repeat sequence (TRS) relative to the unidirectional origin of replication had a pronounced effect, signaling the participation of replication and/or repair systems. Also, when the TRS was transcribed, the level of deletions was greatly elevated. Under certain conditions, 30 - 50% of the products contained gross deletions. DNA sequence analyses of the breakpoint junctions in 47 deletions revealed the presence of 1-8-bp direct or inverted homologies in all cases. Also, the presence of non-B folded conformations (i.e. slipped structures, cruciforms, or triplexes) at or near the breakpoints was predicted in all cases. This genetic behavior, which was previously unrecognized for a TRS, may provide the basis for a new type of instability of the myotonic dystrophy protein kinase (DMPK) gene in patients with a full mutation.	Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	wojciechowska, marzena/H-4900-2014; Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Beletskii A, 2000, J MOL BIOL, V300, P1057, DOI 10.1006/jmbi.2000.3944; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Epstein HF, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P147; Feschenko VV, 2003, P NATL ACAD SCI USA, V100, P1134, DOI 10.1073/pnas.0233122100; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GACY AM, 1995, CELL, V81, P533; Gellibolian R, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P561; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hartenstine MJ, 2002, J BIOL CHEM, V277, P41379, DOI 10.1074/jbc.M207013200; Hebert ML, 2004, J MOL BIOL, V336, P655, DOI 10.1016/j.jmb.2003.12.038; HO C, 1993, J BACTERIOL, V175, P5411, DOI 10.1128/JB.175.17.5411-5419.1993; Iyer RR, 2000, J BIOL CHEM, V275, P2174, DOI 10.1074/jbc.275.3.2174; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Krasilnikova MM, 1998, EMBO J, V17, P5095, DOI 10.1093/emboj/17.17.5095; Lahiri M, 2004, MOL CELL, V15, P287, DOI 10.1016/j.molcel.2004.06.034; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Liu L, 2002, MOL CELL BIOL, V22, P3852, DOI 10.1128/MCB.22.11.3852-3863.2002; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; Rangarajan S, 1997, P NATL ACAD SCI USA, V94, P946, DOI 10.1073/pnas.94.3.946; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schumacher S, 2001, J MOL BIOL, V307, P39, DOI 10.1006/jmbi.2000.4489; SELBY CP, 1993, J BACTERIOL, V175, P7509, DOI 10.1128/JB.175.23.7509-7514.1993; Siianova E Iu, 2001, Mol Biol (Mosk), V35, P208; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden RR, 1998, ADV GENOM B, V5, P1; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Trigueros S, 2001, J BIOL CHEM, V276, P2243, DOI 10.1074/jbc.M008930200; Vasquez KM, 1999, NUCLEIC ACIDS RES, V27, P1176, DOI 10.1093/nar/27.4.1176; Vetcher AA, 2004, J BIOL CHEM, V279, P6434, DOI 10.1074/jbc.M309595200; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vilette D, 1996, MOL GEN GENET, V252, P398, DOI 10.1007/BF02173004; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; ZHONG N, 1995, AM J HUM GENET, V57, P351	76	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					941	952		10.1074/jbc.M410427200	http://dx.doi.org/10.1074/jbc.M410427200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15489504	hybrid			2022-12-25	WOS:000226195200013
J	Schultz, JR; Petz, LN; Nardulli, AM				Schultz, JR; Petz, LN; Nardulli, AM			Cell- and ligand-specific regulation of promoters containing activator protein-1 and sp1 sites by estrogen receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; BREAST-CANCER CELLS; MESSENGER-RIBONUCLEIC-ACID; BONE-MINERAL DENSITY; ELEMENT HALF-SITE; RESPONSE ELEMENT; POSTMENOPAUSAL WOMEN; GENE-EXPRESSION; ER-ALPHA; TRANSCRIPTIONAL ACTIVATION	Estrogen plays a critical role in development and maintenance of female reproductive and mammary tissues, but is also involved in maintenance of cardiovascular, skeletal, and neural function. Although it is widely accepted that the estrogen-occupied receptor mediates its effects by interacting with estrogen response elements (EREs) residing in target genes, a number of estrogen-responsive genes contain no identifiable ERE. To understand how estrogen-responsive genes lacking EREs but containing activator protein 1 (AP-1) and Sp1 sites respond to hormone treatment, we have identified four discrete regions of the human progesterone receptor gene that contain AP-1 or Sp1 sites and examined their abilities to modulate transcription in the presence of 17beta-estradiol, ICI 182,780, tamoxifen, raloxifene, genistein, or daidzein. Transient cotransfection assays demonstrated that ERalpha was a more potent activator of transcription than ERbeta in bone, uterine, and mammary cells. The Sp1-containing promoters were substantially more potent transcriptional enhancers than the AP-1-containing promoters, but a 1.5-kb region of the human progesterone receptor gene containing both AP-1 and Sp1 sites was the most hormone-responsive promoter tested. The ability of ligands to modulate transcription of AP-1- or Sp1-containing promoters was dependent on cell context, but the expression of AP-1 or Sp1 proteins was not necessarily related to transcriptional response. Taken together, these studies have helped to delineate the roles of ER alpha and ERbeta in modulating transcription of genes containing AP-1 and Sp1 sites and define the effects of widely used, pharmacologic agents in target cells with distinct cellular environments.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Nardulli, AM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	anardull@life.uiuc.edu	Schroeder, Jennifer R/G-3679-2014	Schroeder, Jennifer R/0000-0002-1975-721X	NICHD NIH HHS [5T32 HD07028] Funding Source: Medline; NIDDK NIH HHS [R01 DK061463, DK 61463, R01 DK061463-03, R01 DK053884, DK 53884, R01 DK053884-07] Funding Source: Medline; NIEHS NIH HHS [ES07326] Funding Source: Medline; NIGMS NIH HHS [T32 GM07283] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053884, R01DK061463, R56DK053884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Couse JF, 2001, REPROD FERT DEVELOP, V13, P211, DOI 10.1071/RD00128; Couse JF, 2000, J STEROID BIOCHEM, V74, P287, DOI 10.1016/S0960-0760(00)00105-9; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DUBIK D, 1992, ONCOGENE, V7, P1587; Fritz WA, 1998, CARCINOGENESIS, V19, P2151, DOI 10.1093/carcin/19.12.2151; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOTTARDIS MM, 1988, CANCER RES, V48, P812; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hess RA, 1997, J ANDROL, V18, P602; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132; JORDAN VC, 1979, J STEROID BIOCHEM, V11, P285, DOI 10.1016/0022-4731(79)90310-8; Ju YH, 2002, CANCER RES, V62, P2474; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kuiper GGJM, 1997, FEBS LETT, V410, P87, DOI 10.1016/S0014-5793(97)00413-4; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Merz-Demlow BE, 2000, AM J CLIN NUTR, V71, P1462; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; OSBORNE CK, 1995, J NATL CANCER I, V87, P746, DOI 10.1093/jnci/87.10.746; Osborne MP, 1999, ANN NY ACAD SCI, V889, P146, DOI 10.1111/j.1749-6632.1999.tb08732.x; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Petz LN, 2004, MOL ENDOCRINOL, V18, P521, DOI 10.1210/me.2003-0105; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; RISHI AK, 1995, CANCER RES, V55, P4999; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Subbiah MTR, 1998, P SOC EXP BIOL MED, V217, P23; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; ToranAllerand CD, 1996, DEV NEUROSCI-BASEL, V18, P36, DOI 10.1159/000111393; Tremblay A, 1998, ENDOCRINOLOGY, V139, P111, DOI 10.1210/en.139.1.111; TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219	58	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					347	354		10.1074/jbc.M407879200	http://dx.doi.org/10.1074/jbc.M407879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509581	hybrid			2022-12-25	WOS:000226025100042
J	Jin, TG; Kurakin, A; Benhaga, N; Abe, K; Mohseni, M; Sandra, F; Song, K; Kay, BK; Khosravi-Far, R				Jin, TG; Kurakin, A; Benhaga, N; Abe, K; Mohseni, M; Sandra, F; Song, K; Kay, BK; Khosravi-Far, R			Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FLICE-INHIBITORY PROTEINS; PROGRAMMED CELL-DEATH; LIGAND TRAIL; MOLECULAR-CLONING; INDUCED APOPTOSIS; TNF-FAMILY; FADD; CASPASE-8; ACTIVATION	Here we show a novel mechanism by which FLICE-like inhibitory protein (c-FLIP) regulates apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand ( TRAIL) and one of its receptors, DR5. c-FLIP is a critical regulator of the TNF family of cytokine receptor signaling. c-FLIP has been postulated to prevent formation of the competent death-inducing signaling complex ( DISC) in a ligand-dependent manner, through its interaction with FADD and/or caspase-8. In order to identify regulators of TRAIL function, we used the intracellular death domain ( DD) of DR5 as a target to screen a phage-displayed combinatorial peptide library. The DD of DR5 selected from the library a peptide that showed sequence similarity to a stretch of amino acids in the C terminus of c-FLIPL. The phage-displayed peptide selectively interacted with the DD of DR5 in in vitro binding assays. Similarly, full-length c-FLIP (c-FLIPL) and the C-terminal p12 domain of c-FLIP interacted with DR5 both in in vitro pull-down assays and in mammalian cells. This interaction was independent of TRAIL. To the contrary, TRAIL treatment released c-FLIPL from DR5, permitting the recruitment of FADD to the active DR5 signaling complex. By employing FADD-deficient Jurkat cells, we demonstrate that DR5 and c-FLIPL interact in a FADD-independent manner. Moreover, we show that a cellular membrane permeable version of the peptide corresponding to the DR5 binding domain of c-FLIP induces apoptosis in mammalian cells. Taken together, these findings indicate that c-FLIPL interacts with the DD of DR5, thus preventing death signaling by DR5 prior to the formation of an active DISC. Because TRAIL and DR5 are ubiquitously expressed, the interaction of c-FLIPL and DR5 indicates a mechanism by which tumor selective apoptosis can be achieved through protecting normal cells from undergoing death receptor-induced apoptosis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Buck Inst Age Res, Novato, CA 94945 USA; Argonne Natl Lab, Argonne, IL 60439 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Buck Institute for Research on Aging; United States Department of Energy (DOE); Argonne National Laboratory	Khosravi-Far, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 99 Brookline Ave,RN 270F, Boston, MA 02215 USA.	rkhosrav@bidmc.harvard.edu	Sandra, Ferry/AAN-9713-2020; Sandra, Ferry/M-9414-2015; Khosravi-Far, Roya/C-3789-2008	Sandra, Ferry/0000-0002-5852-1074; Sandra, Ferry/0000-0002-5852-1074; 	NATIONAL CANCER INSTITUTE [R55CA087675] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080192] Funding Source: NIH RePORTER; NCI NIH HHS [1R55 CA 87675, R55 CA087675-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL080192-07, HL 080192, R01 HL080192] Funding Source: Medline; PHS HHS [T32 H 07893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe K, 2000, ANN NY ACAD SCI, V926, P52; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; ESPOSTI MD, 1999, J LEUKOCYTE BIOL, V65, P535; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Futaki S, 2003, CURR PROTEIN PEPT SC, V4, P87, DOI 10.2174/1389203033487261; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guo F, 2002, CANCER BIOL THER, V1, P528, DOI 10.4161/cbt.1.5.170; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kay BK, 2000, FEBS LETT, V480, P55, DOI 10.1016/S0014-5793(00)01778-6; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kurakin A, 1998, J PEPT RES, V52, P331; Leverkus M, 2000, CANCER RES, V60, P553; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Meier P, 2003, NAT CELL BIOL, V5, P1035, DOI 10.1038/ncb1203-1035; Micheau O, 2003, EXPERT OPIN THER TAR, V7, P559, DOI 10.1517/eott.7.4.559.22500; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 2004, CURR CANCER DRUG TAR, V4, P97, DOI 10.2174/1568009043481597; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takada H, 2003, MOL CELL BIOL, V23, P4026, DOI 10.1128/MCB.23.11.4026-4033.2003; Takenobu T, 2002, MOL CANCER THER, V1, P1043; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang XL, 2002, CANCER BIOL THER, V1, P407, DOI 10.4161/cbt.1.4.16; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	72	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55594	55601		10.1074/jbc.M401056200	http://dx.doi.org/10.1074/jbc.M401056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485835	Green Accepted, hybrid			2022-12-25	WOS:000225960800077
J	Kong, WY; Longaker, MT; Lorenz, HP				Kong, WY; Longaker, MT; Lorenz, HP			Cyclophilin C-associated protein is a mediator for fibronectin fragment-induced matrix metalloproteinase-13 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; COLLAGENASE-3 MMP-13; MAC-2-BINDING PROTEIN; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; I COLLAGEN; KINASE-C; ACTIVATION; BINDING; GLYCOPROTEIN	The function of cyclophilin C-associated protein (CyCAP) on expression of extracellular matrix and matrix metalloproteinases ( MMPs) was studied in CyC-AP-null mice. Fibronectin showed increased expression of the 53- and 29-kDa fragments in skin and wounds from CyC-AP-null mice. Type I collagen had an initial degraded pattern in the skin of CyC-AP-null mice, which did not occur in wild-type mice. MMP-3, MMP-13, MMP-14, and tumor necrosis factor-alpha (TNFalpha) had a higher expression in CyC-AP-null skin. During wound healing, MMP-13 and TNFalpha were stimulated to an even higher level, suggesting they are regulated by multiple factors. To understand the regulatory mechanisms of the up-regulated MMPs, the direct effects of TNFalpha, IL-1beta, 45-kDa fibronectin fragment (FN-45), and the 70-kDa fibronectin fragments (FN-70) on the expression of MMPs were studied. MMP-13 expression increased significantly in both CyC-AP-null and wild-type dermal fibroblasts after treatment with IL-1beta or with TNFalpha. However, MMP-13 expression did not increase in CyC-AP-null fibroblasts but did increase only in wild-type fibroblasts after FN-45 and FN-70 treatment. MMP-3 activation was induced by FN-45 and did not show a difference between CyC-AP-null and wild-type fibroblasts, suggesting different regulatory pathways for FN-45 on MMP-13 and MMP-3 expression. Our data are the first to demonstrate that deletion of CyC-AP can abolish fibronectin fragment-induced MMP-13 expression through an unknown mechanism. CyC-AP is an important factor for the regulation of MMP-13 expression.	Stanford Univ, Sch Med, Pediat Surg Res Lab, Stanford, CA 94305 USA	Stanford University	Lorenz, HP (corresponding author), Stanford Univ, Sch Med, Pediat Surg Res Lab, 257 Campus Dr, Stanford, CA 94305 USA.	plorenz@stanford.edu			NIDCR NIH HHS [DE 00463-03] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALON R, 1994, J IMMUNOL, V152, P1304; CHICHEPORTICHE Y, 1994, J BIOL CHEM, V269, P5512; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; GARCIAPARDO A, 1992, BIOCHEM BIOPH RES CO, V186, P135, DOI 10.1016/S0006-291X(05)80785-5; HAYASHI M, 1981, J BIOL CHEM, V256, P1292; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Inohara H, 1996, CANCER RES, V56, P4530; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; Moilanen M, 2003, BIOCHEMISTRY-US, V42, P5414, DOI 10.1021/bi020582s; Moore BA, 2000, BBA-MOL BASIS DIS, V1502, P307, DOI 10.1016/S0925-4439(00)00056-9; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1989, FEBS LETT, V249, P353, DOI 10.1016/0014-5793(89)80657-X; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Penc SF, 1998, J LEUKOCYTE BIOL, V64, P351, DOI 10.1002/jlb.64.3.351; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Romberger DJ, 1997, INT J BIOCHEM CELL B, V29, P939, DOI 10.1016/S1357-2725(96)00172-0; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Shum JKS, 2002, J BIOL CHEM, V277, P42830, DOI 10.1074/jbc.M205094200; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; Siwik DA, 2000, CIRC RES, V86, P1259, DOI 10.1161/01.RES.86.12.1259; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Trahey M, 1999, P NATL ACAD SCI USA, V96, P3006, DOI 10.1073/pnas.96.6.3006; Yasuda T, 2003, LAB INVEST, V83, P153, DOI 10.1097/01.LAB.0000056999.08437.B2; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620	35	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55334	55340		10.1074/jbc.M410804200	http://dx.doi.org/10.1074/jbc.M410804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507443	hybrid			2022-12-25	WOS:000225960800045
J	Lusetti, SL; Drees, JC; Stohl, EA; Seifert, HS; Cox, MM				Lusetti, SL; Drees, JC; Stohl, EA; Seifert, HS; Cox, MM			The DinI and RecX proteins are competing modulators of RecA function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; FILAMENTS; COMPLEXES; EXCHANGE; REPAIR; SSDNA; GENE; RECOMBINATION	The DinI and RecX proteins of Escherichia coli both modulate the function of RecA protein, but have very different effects. DinI protein stabilizes RecA filaments, preventing disassembly but permitting assembly. RecX protein blocks RecA filament extension, which can lead to net filament disassembly. We demonstrate that both proteins can interact with the RecA filament, and propose that each can replace the other. The DinI/RecX displacement reactions are slow, requiring multiple minutes even when a large excess of the challenging protein is present. The effects of RecX protein on RecA filaments are manifest at lower modulator concentrations than the effects of DinI protein. Together, the DinI and RecX proteins constitute a new regulatory network. The two proteins compete directly as mainly positive (DinI) and negative (RecX) modulators of RecA function.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Feinberg School of Medicine	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 44239, R01 AI044239] Funding Source: Medline; NIGMS NIH HHS [R01 GM 52725] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; DREES JC, 2004, J BIOL CHEM; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Pages V, 2003, DNA REPAIR, V2, P273, DOI 10.1016/S1568-7864(02)00217-3; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, J MOL BIOL, V333, P345, DOI 10.1016/j.jmb.2003.08.053; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; WEISEMANN JM, 1985, J BACTERIOL, V163, P748, DOI 10.1128/JB.163.2.748-755.1985; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256	33	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55073	55079		10.1074/jbc.M410371200	http://dx.doi.org/10.1074/jbc.M410371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489505	hybrid			2022-12-25	WOS:000225960800012
J	Paulhe, F; Imhof, BA; Wehrle-Haller, B				Paulhe, F; Imhof, BA; Wehrle-Haller, B			A specific endoplasmic reticulum export signal drives transport of stem cell factor (Kitl) to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-GOLGI TRANSPORT; COPII-DEPENDENT TRANSPORT; EARLY SECRETORY PATHWAY; VIRUS G-PROTEIN; GROWTH-FACTOR; PROTGF-ALPHA; C-KIT; MELANOCYTE PRECURSORS; MEMBRANE-PROTEINS; SELECTIVE EXPORT	Stem cell factor, also known as Kit ligand (Kitl), belongs to the family of dimeric transmembrane growth factors. Efficient cell surface presentation of Kitl is essential for the migration, proliferation, and survival of melanocytes, germ cells, hemopoietic stem cells, and mastocytes. Here we demonstrate that intracellular transport of Kitl to the cell surface is driven by a motif in the cytoplasmic tail that acts independently of the previously described basolateral sorting signal. Transport of Kitl to the cell surface is controlled at the level of the endoplasmic reticulum ( ER) and requires a C-terminal valine residue positioned at a distance of 19-36 amino acids from the border between the transmembrane and cytoplasmic domains. Deletion or substitution of the valine with other hydrophobic amino acids results in ER accumulation and reduced cell surface transport of Kitl at physiological expression levels. When these mutant proteins are overexpressed in the ER, they are transported by bulk flow to the cell surface albeit at lower efficiency. A fusion construct between Kitl and the green fluorescent protein-labeled extracellular domain of a temperature-sensitive mutant of vesicular stomatitis virus G protein revealed the valine-dependent recruitment into coat protein complex II-coated ER exit sites and vesicular ER to Golgi transport in living cells. Thus the C-terminal valine defines a specific ER export signal in Kitl. It is responsible for the capture of Kitl at coat protein complex II-coated ER exit sites, leading to subsequent cell surface transport under physiological conditions.	Ctr Med Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland	University of Geneva	Wehrle-Haller, B (corresponding author), Ctr Med Univ Geneva, Dept Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Bernhard.Wehrle-Haller@medecine.unige.ch						Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Chalfie M, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, pVII; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; NOURRY C, 2003, SCI STKE; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Powers J, 2002, MOL BIOL CELL, V13, P880, DOI 10.1091/mbc.01-10-0499; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stephens DJ, 2000, J CELL SCI, V113, P2177; Tajima Y, 1998, J EXP MED, V187, P1451, DOI 10.1084/jem.187.9.1451; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; Urena JM, 1999, J CELL SCI, V112, P773; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Wehrle-Haller B, 1999, DEV BIOL, V210, P71, DOI 10.1006/dbio.1999.9260; Wehrle-Haller B, 2003, PIGM CELL RES, V16, P287, DOI 10.1034/j.1600-0749.2003.00055.x; Wehrle-Haller B, 2001, J BIOL CHEM, V276, P12667, DOI 10.1074/jbc.M008357200; WehrleHaller B, 1996, DEV BIOL, V177, P463, DOI 10.1006/dbio.1996.0178; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	61	20	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55545	55555		10.1074/jbc.M407813200	http://dx.doi.org/10.1074/jbc.M407813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475566	hybrid			2022-12-25	WOS:000225960800071
J	Tran, POT; Parker, SM; LeRoy, E; Franklin, CC; Kavanagh, TJ; Zhang, T; Zhou, HR; Vliet, P; Oseid, E; Harmon, JS; Robertson, RP				Tran, POT; Parker, SM; LeRoy, E; Franklin, CC; Kavanagh, TJ; Zhang, T; Zhou, HR; Vliet, P; Oseid, E; Harmon, JS; Robertson, RP			Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE SYNTHESIS; DIABETES-MELLITUS; GLUCOSE TOXICITY; GENE-EXPRESSION; BETA-CELLS; SYNTHETASE; INTERLEUKIN-1-BETA; INHIBITION; DEFENSE; ENZYMES	The catalytic subunit of glutamylcysteine ligase (GCLC) primarily regulates de novo synthesis of glutathione (GSH) in mammalian cells and is central to the antioxidant capacity of the cell. However, GCLC expression in pancreatic islets has not been previously examined. We designed experiments to ascertain whether GCLC is normally expressed in islets and whether it is up-regulated by interleukin-1beta (IL-1beta). GCLC expression levels were intermediate compared with other metabolic tissues (kidney, liver, muscle, fat, and lung). IL-1beta up-regulated GCLC expression (10 ng/ml IL-1beta, 3.76+/-0.86; 100 ng/ml IL-1beta, 4.22+/-0.68-fold control) via the p38 form of mitogen-activated protein kinase and NFkappaB and also increased reactive oxygen species levels (10 ng/ml IL-1beta, 5.41+/-1.8-fold control). This was accompanied by an increase in intraislet GSH/GSSG ratio (control, 7.1+/-0.1; 10 ng/ml IL-1beta, 8.0+/-0.5; 100 ng/ml IL-1beta, 8.2+/-0.5-fold control; p<0.05). To determine whether overexpression of GCLC increases the antioxidant capacity of the islet and prevents the adverse effects of IL-1 beta on glucose-induced insulin secretion, islets were infected with an adenovirus encoding GCLC. IL-1 beta significantly decreased glucose-stimulated insulin secretion (control, 123.8 +/- 17.7; IL-1 beta, 40.2 +/- 3.9 microunits/ml insulin/islet). GCLC overexpression increased intraislet GSH levels and partially prevented the decrease in glucose-stimulated insulin secretion caused by IL-1 beta. These data provide the first report of GCLC expression in the islet and demonstrate that adenoviral overexpression of GCLC increases intracellular GSH levels and protects the beta cell from the adverse effects of IL-1 beta.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, NIEHS, Ctr Ecogenet & Environm Hlth, NIH,Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Robertson, RP (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	rpr@pnri.org	Roberston, R Paul/AAX-5613-2021		NCI NIH HHS [CA90473] Funding Source: Medline; NIDDK NIH HHS [R01 DK38325] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038325] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Catherwood MA, 2002, KIDNEY INT, V61, P599, DOI 10.1046/j.1523-1755.2002.00168.x; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Lu SC, 1999, INVEST OPHTH VIS SCI, V40, P1776; MAEDLER K, J CLIN INVESTIG, V110, pHI851; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURAKAMI K, 1989, METABOLISM, V38, P753, DOI 10.1016/0026-0495(89)90061-9; REED DJ, CURRENT PROTOCOLS TO; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; Sharma A, 2000, METABOLISM, V49, P160, DOI 10.1016/S0026-0495(00)91117-X; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; YOSHIDA K, 1995, DIABETOLOGIA, V38, P201, DOI 10.1007/s001250050271	21	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53988	53993		10.1074/jbc.M404809200	http://dx.doi.org/10.1074/jbc.M404809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485876	hybrid			2022-12-25	WOS:000225793600013
J	Kuai, J; Wooters, J; Hall, JP; Rao, VR; Nickbarg, E; Chatterjee-Kishore, M; Qiu, YC; Lin, LL				Kuai, J; Wooters, J; Hall, JP; Rao, VR; Nickbarg, E; Chatterjee-Kishore, M; Qiu, YC; Lin, LL			NAK is recruited to the TNFR1 complex in a TNF alpha-dependent manner and mediates the production of RANTES - Identification of endogenous TNFR-interacting proteins by a proteomic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; LYMPHOTOXIN BETA-RECEPTOR; SEVERE LIVER DEGENERATION; DEATH DOMAIN; INTRACELLULAR DOMAIN; EMBRYONIC LETHALITY; SIGNAL-TRANSDUCTION; DEFICIENT MICE; KINASE IKK	Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine with pleiotropic immunological and biological activities. TNFalpha signaling is triggered by the engagement of soluble TNFalpha to two types of cell surface receptors, TNFR1 and TNFR2. This recruits cytosolic proteins to the intracellular domains of the receptors and initiates signaling to downstream effectors. In this study, we used a proteomic approach to identify these cytosolic proteins from affinity-purified, endogenous TNFalpha.TNFR complexes in human myelomonocytic U937 cells. Seven proteins were identified, including TRADD, TRAP2, and TRAF2, which are three proteins known to be recruited to TNFalpha receptors. NAK, RasGAP3, TRCP1, and TRCP2 were also identified. We further showed that NAK is recruited to TNFR1 in a temporally regulated and TNFalpha-dependent manner and that it mediates the TNFalpha-induced production of the chemokine RANTES ( regulated on activation normal T cell expressed and secreted). These data demonstrate that NAK is a component of the TNFalpha.TNFR1 signaling complex and confirm the physiological role of NAK in the TNFalpha-mediated response.	Wyeth Res, Inflammat Signaling, Dept Inflammat, Cambridge, MA 02140 USA; Wyeth Res, Dept Prot Chem & Proteom, Cambridge, MA 02140 USA; Wyeth Res, Dept Genom, Cambridge, MA 02140 USA	Pfizer; Pfizer; Pfizer	Lin, LL (corresponding author), Wyeth Res, Inflammat Signaling, Dept Inflammat, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	llin@wyeth.com						Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dunbar JD, 1997, J IMMUNOL, V158, P4252; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hornung F, 2000, J IMMUNOL, V164, P6180, DOI 10.4049/jimmunol.164.12.6180; Houthaeve T, 1997, J PROTEIN CHEM, V16, P343, DOI 10.1023/A:1026372302560; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rudolph D, 2000, GENE DEV, V14, P854; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331	34	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53266	53271		10.1074/jbc.M411037200	http://dx.doi.org/10.1074/jbc.M411037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485837	hybrid			2022-12-25	WOS:000225680600057
J	Pirih, FQ; Tang, A; Ozkurt, IC; Nervina, JM; Tetradis, S				Pirih, FQ; Tang, A; Ozkurt, IC; Nervina, JM; Tetradis, S			Nuclear orphan receptor Nurr1 directly transactivates the osteocalcin gene in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER GENE; INDUCED BONE-RESORPTION; PROTEIN-KINASE-A; PARATHYROID-HORMONE; TYROSINE KINASE; MICE LACKING; NGFI-B; RET PROTOONCOGENE; DEFICIENT MICE; EXPRESSION	Nurr1, an NGFI-B nuclear orphan receptor, which transactivates promoters through an NGFI-B response element (NBRE), is strongly induced by parathyroid hormone through the cAMP-protein kinase A signaling pathway in osteoblasts. Here, we demonstrate that multiple agents activating diverse signaling pathways in osteoblasts induce Nurr1. The strongest Nurr1 inducers were activators of cAMP-protein kinase A-coupled signaling, followed by protein kinase C- and calcium-coupled signaling activators. Receptor tyrosine kinase activators had minimal effect, whereas serine/threonine kinase activators had no effect on basal Nurr1 mRNA levels. Computer analysis of osteoblastic promoters indicated two potential NBREs in the rat osteocalcin (Ocn) promoter. Intriguingly, the proximal site maps to the cAMP-responsive cis-element. We tested whether Nurr1 induces Ocn expression through the NBRE-like site. Recombinant and endogenous Nurr1 protein from primary mouse osteoblasts bound to a consensus NBRE in EMSAs. Nurr1 induced a consensus 3xNBRE-luciferase reporter construct in mouse osteoblasts. Recombinant and endogenous Nurr1 protein bound to the proximal NBRE-like site in the Ocn promoter in EMSAs. Endogenous Nurr1 protein bound to this site as a monomer, because neither retinoid X receptor alpha nor retinoid X receptor beta antibody supershifted the protein-DNA complex. Ocn promoter-luciferase constructs lacking or containing a mutated proximal NBRE-like site had markedly blunted responses to Nurr1 overexpression. Finally, adenovirally expressed Nurr1 protein bound to the proximal NBRE-like site in chromatin immunoprecipitation assays and induced Ocn mRNA in primary rat osteoblasts. We conclude that Ocn is a Nurr1 target gene, which positions Nurr1 in the core of transcriptional factors regulating osteoblastic gene expression.	Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Sect Orthodont, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Tetradis, S (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Rm 53-068 CHS, Los Angeles, CA 90095 USA.	sotirist@dent.ucla.edu			NIDCR NIH HHS [R01-DE13316, T32 DE007296] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013316, T32DE007296] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Bassett MH, 2004, MOL ENDOCRINOL, V18, P279, DOI 10.1210/me.2003-0005; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756-3282(99)00232-X; Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; Brosenitsch TA, 2001, J NEUROSCI, V21, P2571, DOI 10.1523/JNEUROSCI.21-08-02571.2001; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200; Iida-Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; Jiang D, 2004, J BIOL CHEM, V279, P5329, DOI 10.1074/jbc.M311547200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Lee HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; NODA M, 1988, J BIOL CHEM, V263, P18574; Ozkurt IC, 2003, J BIOL CHEM, V278, P26803, DOI 10.1074/jbc.M212652200; Park JI, 2003, MOL CELL ENDOCRINOL, V202, P25, DOI 10.1016/S0303-7207(03)00057-1; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 2002, J BIOL CHEM, V277, P35088, DOI 10.1074/jbc.M205816200; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; Wallen-Mackenzie A, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	53	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53167	53174		10.1074/jbc.M405677200	http://dx.doi.org/10.1074/jbc.M405677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485875	hybrid			2022-12-25	WOS:000225680600046
J	Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM				Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM			Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft	ONCOGENE			English	Article						prostate cancer; androgen-independence; molecular expression analysis; LuCaP 23.1 xenograft	HUMAN-PROSTATE-CANCER; EPIDERMAL-GROWTH-FACTOR; CELL-LINES; RECEPTOR GENE; PLASMINOGEN-ACTIVATOR; FACTOR-ALPHA; TUMOR-MODEL; IN-VIVO; EXPRESSION; CASTRATION	After therapeutic hormone deprivation, most prostate cancer (PrCa) cells develop androgen-independent (AI) growth. PrCa is highly heterogeneous and multifocal, suggesting that several molecular processes or pathways may be contributing to AI. The human LuCaP 23.1 xenograft model retains clinical hallmarks of PrCa, including heterogeneous growth, PSA production, androgen-responsiveness and progression to AI. In this work, we studied the effect of androgen depletion (castration) on the growth of LuCaP 23.1 xenografts. A total of 100 nude mice were implanted and analysed for their growth profiles before and after castration. By 11 and 15 weeks, tumours were harvested and assessed for molecular marker expression specific for PrCa. Prior to castration we found 37 fast growing (FG) tumours (948.9 +/- 76.9 mm(3)) and 63 slow growing (SG) tumours (229.6 +/- 18.4 mm(3)), a previously undescribed result for this PrCa model. Quantitative RT-PCR showed that in comparison to SGs, FGs contained high HER1, uPA and thymidilate synthetase (TS) expression with low levels of 5alpha-reductase 2 mRNA. All FG tumours progressed rapidly to AI growth 5 weeks after castration (FG-P). In SG castrated tumours, 66% of tumours (SG-P) showed retarded progression (by 12 weeks) to AI, whereas 34% responded to castration (SG-R). Molecular analysis permitted us to define distinct molecular profiles integrating different pathways associated with AI progression. FG-P, and a subgroup of SG-P tumours, presented significantly high levels of peptidylglycine alpha-amidating monooxygenase (PAM), HER1, HER2, TS, and uPA mRNA, all of which correlated with AR expression. The second subgroup of SG-P tumours showed overexpression of the antiapoptotic gene Bcl-2. A third subgroup of SG-P tumours showed significant expression of hypoxia-related gene (adrenomedullin) after castration. This work permitted to define distinct molecular profiles related to different AI growth in the LuCaP 23.1 xenograft.	Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France; CHU Timone, APHM, Marseille, France; Hop Salvator, APHM, Serv Urol, Marseille, France; Jack Bell Res Ctr, Prostate Ctr, Vancouver, BC, Canada	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of British Columbia	Rocchi, P (corresponding author), Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France.	procchi@vanhosp.bc.ca	Rocchi, Palma/P-5455-2014; Muracciole, Xavier/P-5640-2016	Rocchi, Palma/0000-0002-4383-4684; Karsenty, Gilles/0000-0002-9047-3332; Ouafik, L'Houcine/0000-0002-4848-1232				Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Bladou F, 1996, INT J CANCER, V67, P785, DOI 10.1002/(SICI)1097-0215(19960917)67:6<785::AID-IJC6>3.0.CO;2-N; Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dahiya R, 1996, UROLOGY, V48, P963, DOI 10.1016/S0090-4295(96)00376-7; Delos S, 1998, INT J CANCER, V75, P840; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Ellis WJ, 1996, CLIN CANCER RES, V2, P1039; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GAYLIS FD, 1989, J UROLOGY, V142, P193, DOI 10.1016/S0022-5347(17)38709-8; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Helenius MA, 2001, CANCER RES, V61, P5340; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; Huss WJ, 2001, CANCER RES, V61, P2736; JANIK P, 1975, CANCER RES, V35, P3698; Jenster G, 1999, SEMIN ONCOL, V26, P407; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; Koivisto P, 1997, CANCER RES, V57, P314; LANDSTROM M, 1994, CANCER RES, V54, P4281; Liu AY, 1996, INT J CANCER, V65, P85, DOI 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.3.CO;2-E; LYON PB, 1995, PROSTATE, V27, P179, DOI 10.1002/pros.2990270402; McGowen R, 2000, CANCER RES, V60, P4771; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; Miyake H, 1999, CANCER RES, V59, P4030; Negri-Cesi P, 1999, PROSTATE, V41, P224, DOI 10.1002/(SICI)1097-0045(19991201)41:4<224::AID-PROS2>3.0.CO;2-Q; Nelson JB, 2000, CANCER INVEST, V18, P87, DOI 10.3109/07357900009023066; Nelson JB, 2000, BJU INT, V85, P45, DOI 10.1046/j.1464-410X.2000.00063.x; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Rocchi P, 2001, CANCER RES, V61, P1196; Ross RK, 1998, CANCER RES, V58, P4497; Scher HI, 1995, CLIN CANCER RES, V1, P545; Scher HI, 2000, J NATL CANCER I, V92, P1866, DOI 10.1093/jnci/92.23.1866; Solit DB, 2002, CLIN CANCER RES, V8, P986; TURKERI LN, 1994, PROSTATE, V25, P199, DOI 10.1002/pros.2990250405; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wen Y, 2000, CANCER RES, V60, P6841; Xing RHM, 1999, ENDOCRINOLOGY, V140, P4056, DOI 10.1210/en.140.9.4056; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhang LQ, 2003, CANCER RES, V63, P4552; Zudaire E, 2003, REGUL PEPTIDES, V112, P175, DOI 10.1016/S0167-0115(03)00037-5	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9111	9119		10.1038/sj.onc.1208154	http://dx.doi.org/10.1038/sj.onc.1208154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489889				2022-12-25	WOS:000225492800012
J	Legler, DF; Doucey, MA; Schneider, P; Chapatte, L; Bender, FC; Bron, C				Legler, DF; Doucey, MA; Schneider, P; Chapatte, L; Bender, FC; Bron, C			Differential insertion of GPI-anchored GFPs into lipid rafts of live cells	FASEB JOURNAL			English	Article						glycosylphosphatidyl-inositol; green fluorescent protein	TARGETING PROTEINS; MEMBRANE-PROTEINS; DOMAINS; SURFACE; PHOSPHATIDYLINOSITOL; THY-1; PURIFICATION; MICRODOMAINS; RECRUITMENT; ENDOCYTOSIS	Partitioning of proteins in cholesterol and sphingolipid enriched plasma membrane microdomains, called lipid rafts, is critical for many signal transduction and protein sorting events. Although raft partitioning of many signaling molecules remains to be determined, glycosylphosphatidyl-inositol (GPI)-anchored proteins possess high affinity for lipid rafts and are currently exploited as markers to investigate fundamental mechanisms in protein sorting and signal transduction events. In this study, we demonstrate that two recombinant GPI-anchored green fluorescent proteins (GFP-GPIs) that differ in their GPI signal sequence confer distinct localization in plasma membrane microdomains. GFP fused to the GPI signal of the decay accelerating factor GFP-GPI(DAF) partitioned exclusively in lipid rafts, whereas GFP fused to the GPI signal of TRAIL-R3, GFP-GPI(TRAIL-R3), associated only minimally with microdomains. In addition, we investigated the unique ability of purified GFP-GPIs to insert into membrane microdomains of primary lymphocytes. This cell surface painting allows rapid, stable, and functional association of the GPI-anchored proteins with the target cell plasma membrane. The distinct membrane localization of the two GFP-GPIs was observed irrespective of whether the GPI-anchored molecules were painted or transfected. Furthermore, we show that painted GFP-GPI(DAF) was totally dependent on the GPI anchor and that the membrane insertion was increased by the addition of raft-associated lipids such as cholesterol, sphingomyelin, and dipalmitoyl-phosphatidylethanolamine. Thus, this study provides evidence that different GPI signal sequences lead to distinct membrane microdomain localization and that painted GFP-GPI(DAF) serves as an excellent fluorescent marker for lipid rafts in live cells.	Univ Konstanz, Dept Biol, Div Immunol, D-78457 Constance, Germany; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Konstanz; University of Lausanne	Legler, DF (corresponding author), Univ Konstanz, Dept Biol, Div Immunol, Univ Str 10,Room P1105, D-78457 Constance, Germany.	Daniel.Legler@uni-konstanz.de		Schneider, Pascal/0000-0003-0677-9409; Legler, Daniel F./0000-0001-8610-4764				Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cebecauer M, 1998, BIOCHEM BIOPH RES CO, V243, P706, DOI 10.1006/bbrc.1998.8149; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chen R, 2002, J CELL BIOCHEM, V84, P68, DOI 10.1002/jcb.1267; De Angelis DA, 1998, P NATL ACAD SCI USA, V95, P12312, DOI 10.1073/pnas.95.21.12312; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Horejsi V, 2002, TRENDS IMMUNOL, V23, P562, DOI 10.1016/S1471-4906(02)02330-X; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Legler DF, 2004, EUR J IMMUNOL, V34, P1608, DOI 10.1002/eji.200424938; Legler DF, 2001, FASEB J, V15, P1601, DOI 10.1096/fj.00-0841fje; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LUESCHER B, 1985, J IMMUNOL, V134, P1084; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McHugh RS, 1999, CANCER RES, V59, P2433; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Milhiet PE, 2002, EMBO REP, V3, P485, DOI 10.1093/embo-reports/kvf096; MOLLBY R, 1973, BIOCHIM BIOPHYS ACTA, V321, P569, DOI 10.1016/0005-2744(73)90200-3; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; NAGARAJAN S, 1995, J IMMUNOL METHODS, V184, P241, DOI 10.1016/0022-1759(95)00095-R; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sedwick CA, 2002, SCI STKE, V122, P2; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WALTER EI, 1992, J BIOL CHEM, V267, P1245; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	51	96	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					73	+		10.1096/fj.03-1338fje	http://dx.doi.org/10.1096/fj.03-1338fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15516372	Green Published			2022-12-25	WOS:000224849900002
J	Rubin, BB; Downey, GP; Koh, A; Degousee, N; Ghomashchi, F; Nallan, L; Stefanski, E; Harkin, DW; Sun, CX; Smart, BP; Lindsay, TF; Cherepanov, V; Vachon, E; Kelvin, D; Sadilek, M; Brown, GE; Yaffe, MB; Plumb, J; Grinstein, S; Glogauer, M; Gelbe, MH				Rubin, BB; Downey, GP; Koh, A; Degousee, N; Ghomashchi, F; Nallan, L; Stefanski, E; Harkin, DW; Sun, CX; Smart, BP; Lindsay, TF; Cherepanov, V; Vachon, E; Kelvin, D; Sadilek, M; Brown, GE; Yaffe, MB; Plumb, J; Grinstein, S; Glogauer, M; Gelbe, MH			Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection - Cpla2-alpha does not regulate neutrophil NADPH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; GRAM-NEGATIVE BACTERIAL; GROUP-X; RESPIRATORY BURST; DEFICIENT MICE; PIVOTAL ROLE; LUNG INJURY; GROUP-V; A(2); PHAGOCYTOSIS	The role of a cytosolic phospholipase A(2)-alpha( cPLA(2)-alpha) in neutrophil arachidonic acid release, platelet-activating factor ( PAF) biosynthesis, NADPH oxidase activation, and bacterial killing in vitro, and the innate immune response to bacterial infection in vivo was examined. cPLA(2)-alpha activity was blocked with the specific cPLA(2)-alpha inhibitor, Pyrrolidine-1 ( human cells), or by cPLA(2)-alpha gene disruption ( mice). cPLA(2)-alpha inhibition or gene disruption led to complete suppression of neutrophil arachidonate release and PAF biosynthesis but had no effect on neutrophil NADPH oxidase activation, FcgammaII/III or CD11b surface expression, primary or secondary granule secretion, or phagocytosis of Escherichia coli in vitro. In contrast, cPLA(2)-alpha inhibition or gene disruption diminished neutrophil-mediated E. coli killing in vitro, which was partially rescued by exogenous arachidonic acid or PAF but not leukotriene B-4. Following intratracheal inoculation with live E. coli in vivo, pulmonary PAF biosynthesis, inflammatory cell infiltration, and clearance of E. coli were attenuated in cPLA(2)-alpha(-I-) mice compared with wild type littermates. These studies identify a novel role for cPLA(2)-alpha in the regulation of neutrophil-mediated bacterial killing and the innate immune response to bacterial infection.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Toronto, Hlth Network, Div Vasc Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 2C4, Canada; Univ Toronto, Hlth Network, Dept Med, Div Resp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hlth Network, Toride Kyodo Gen Hosp, Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Div Expt Therapeut, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Toronto Gen Res Inst,Hlth Network, Dept Immunol, Toronto, ON M5G 2C4, Canada; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Dent, Toronto, ON M5S 3E2, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gelbe, MH (corresponding author), Univ Washington, Dept Chem, Campus Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Glogauer, Michael/D-2504-2011	gelb, michael/0000-0001-7000-5219; Downey, Gregory P/0000-0003-3253-5862; Harkin, Denis/0000-0002-4701-8350; Glogauer, Michael/0000-0002-6248-5977	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050040-10, HL50040, R01 HL036235-21, HL36236, R01 HL036235, R01 HL050040] Funding Source: Medline; NIGMS NIH HHS [R01 GM059281, GM59281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen LAH, 2002, CURR BIOL, V12, P1762, DOI 10.1016/S0960-9822(02)01216-2; Bailie MB, 1996, J IMMUNOL, V157, P5221; Baker PRS, 2002, BBA-MOL CELL RES, V1592, P175, DOI 10.1016/S0167-4889(02)00314-2; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Baughman RP, 1999, RESPIRATION, V66, P95, DOI 10.1159/000029349; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Blackwood RA, 1996, J LEUKOCYTE BIOL, V59, P663, DOI 10.1002/jlb.59.5.663; BLIGH EG, 1959, CAN J MED SCI, V37, P911, DOI DOI 10.1139/O59-099; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Daniels I, 1998, CLIN DIAGN LAB IMMUN, V5, P683, DOI 10.1128/CDLI.5.5.683-689.1998; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; ELY EW, 1995, BBA-LIPID LIPID MET, V1258, P135; Fonteh AN, 2002, EUR J BIOCHEM, V269, P3760, DOI 10.1046/j.1432-1033.2002.03070.x; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gao XP, 2002, J IMMUNOL, V168, P3974, DOI 10.4049/jimmunol.168.8.3974; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; Lee WL, 2003, MICROBES INFECT, V5, P1299, DOI 10.1016/j.micinf.2003.09.014; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lie WJ, 2003, CLIN EXP ALLERGY, V33, P1125, DOI 10.1046/j.1365-2222.2003.01726.x; Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998; Marshall J, 2000, J IMMUNOL, V164, P2084, DOI 10.4049/jimmunol.164.4.2084; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015; Morgan E, 2004, CLIN IMMUNOL, V110, P252, DOI 10.1016/j.clim.2003.11.017; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Sajjan U, 2001, INFECT IMMUN, V69, P5138, DOI 10.1128/IAI.69.8.5138-5150.2001; SAKATA A, 1987, J IMMUNOL, V138, P4353; Shmelzer Z, 2003, J CELL BIOL, V162, P683, DOI 10.1083/jcb.200211056; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; Souza DG, 2003, BRIT J PHARMACOL, V139, P733, DOI 10.1038/sj.bjp.0705296; Stroncek DF, 1998, TRANSFUSION, V38, P663, DOI 10.1046/j.1537-2995.1998.38798346635.x; TAVARES DL, 1998, EUR J PHARMACOL, V358, P69; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; Yaffe MB, 1999, SURGERY, V126, P248, DOI 10.1016/S0039-6060(99)70162-5; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	59	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					7519	7529		10.1074/jbc.M407438200	http://dx.doi.org/10.1074/jbc.M407438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15475363	hybrid, Green Accepted			2022-12-25	WOS:000227395700014
J	Takaishi, M; Makino, T; Morohashi, M; Huh, N				Takaishi, M; Makino, T; Morohashi, M; Huh, N			Identification of human hornerin and its expression in regenerating and psoriatic skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL ENVELOPES; KERATIN INTERMEDIATE-FILAMENTS; BARRIER FUNCTION; STRATUM-CORNEUM; SUBCELLULAR-DISTRIBUTION; ICHTHYOSIS-VULGARIS; INHERITED DISORDERS; EPIDERMAL FILAGGRIN; LINKED CONSTITUENT; IN-VIVO	We previously isolated a new member of the fused-type S100 protein family (hornerin) from the mouse (Makino, T., Takaishi, M., Morohashi, M., and Huh, N.-h. (2001) J. BioL Chem. 276,47445-47452). Mouse hornerin shares structural features, expression profiles, and intracellular localization with profilaggrin, indicating possible involvement of hornerin in cornification. In this study, we identified and partially characterized a human ortholog of mouse hornerin. The human hornerin gene was mapped between trichohyalin and filaggrin on chromosome 1q21.3, the region being completely syntenic with the counterpart of the mouse. The deduced amino acid sequence of 2850 residues shows typical structural features of "fused-type" S100 protein family members. Mature transcripts and protein from human hornerin were not detected in normal stratified epithelium, including the trunk epidermis, tongue, and esophagus. After screening of various normal and pathological human tissues, we found that human hornerin was expressed in psoriatic skin. Hornerin protein was present in the keratinizing region, although at a lower level and in fewer cells compared with filaggrin. Mature transcripts and protein from hornerin were also detected in regenerating human skin after wounding. Hornerin mRNA was induced 5 days after wounding. The mRNA level remained almost constant until 15 days and declined at 30 days after wounding. Hornerin protein was detected in the proximal epidermis (but not in the distal epidermis) at 15 days after wounding. These results indicate that hornerin has a function similar to but distinct from that of filaggrin in cornification.	Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, Okayama 7008558, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Dermatol, Toyama 9300194, Japan	Okayama University; University of Toyama	Huh, N (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, 2-5-1 Shikatachou, Okayama 7008558, Japan.	namu@md.okayama-u.ac.jp						Ammirati CT, 1998, DERMATOL CLIN, V16, P497, DOI 10.1016/S0733-8635(05)70248-5; Baden H P, 1994, J Dermatol Sci, V7 Suppl, pS20, DOI 10.1016/0923-1811(94)90031-0; DALE BA, 1977, BIOCHIM BIOPHYS ACTA, V491, P193, DOI 10.1016/0005-2795(77)90055-1; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; FIETZ MJ, 1990, J CELL BIOL, V110, P427, DOI 10.1083/jcb.110.2.427; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Iizuka H, 1996, BRIT J DERMATOL, V135, P433, DOI 10.1111/j.1365-2133.1996.tb01509.x; Ishida-Yamamoto A, 1998, J DERMATOL SCI, V18, P139, DOI 10.1016/S0923-1811(98)00041-3; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KORGE B, 1990, J INVEST DERMATOL, V95, P450, DOI 10.1111/1523-1747.ep12555613; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; LEE SC, 1993, J BIOL CHEM, V268, P12164; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; LONSDALEECCLES JD, 1984, BIOCHEMISTRY-US, V23, P1239, DOI 10.1021/bi00301a034; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Madison KC, 2003, J INVEST DERMATOL, V121, P231, DOI 10.1046/j.1523-1747.2003.12359.x; Makino T, 2003, J HISTOCHEM CYTOCHEM, V51, P485, DOI 10.1177/002215540305100410; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; MING ME, 1994, J INVEST DERMATOL, V103, P780, DOI 10.1111/1523-1747.ep12413024; Nakane H, 2002, J INVEST DERMATOL, V119, P50, DOI 10.1046/j.1523-1747.2002.01803.x; NIRUNSUKSIRI W, 1995, J BIOL CHEM, V270, P871, DOI 10.1074/jbc.270.2.871; OGUIN WM, 1991, ANN NY ACAD SCI, V642, P51; Penabad CP, 1998, BRIT J DERMATOL, V139, P958; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Schmuth M, 2004, J INVEST DERMATOL, V122, P909, DOI 10.1111/j.0022-202X.2004.22431.x; SCOTT IR, 1981, BIOCHEM J, V194, P829, DOI 10.1042/bj1940829; Simon M, 1996, BIOCHEM J, V317, P173, DOI 10.1042/bj3170173; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STEVEN AC, 1994, J CELL SCI, V107, P693; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; TAKAHASHI M, 1992, FEBS LETT, V308, P79, DOI 10.1016/0014-5793(92)81055-Q; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; Yoneda Kozo, 1992, Journal of Dermatology (Tokyo), V19, P761	47	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4696	4703		10.1074/jbc.M409026200	http://dx.doi.org/10.1074/jbc.M409026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15507446	hybrid			2022-12-25	WOS:000227096600085
J	Terwel, D; Lasrado, R; Snauwaert, J; Vandeweert, E; Van Haesendonck, C; Borghgraef, P; Van Leuven, F				Terwel, D; Lasrado, R; Snauwaert, J; Vandeweert, E; Van Haesendonck, C; Borghgraef, P; Van Leuven, F			Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; LONG-TERM POTENTIATION; GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; TAU-PROTEINS; AXONAL-TRANSPORT; PHOSPHORYLATION; TANGLES; EPITOPE; BRAIN	Protein tau-3R/4R isoform ratio and phosphorylation regulates binding to microtubules and, when disturbed by aging or mutations, results in diverse tauopathies and in neurodegeneration. The underlying mechanisms were studied here in three transgenic mouse strains with identical genetic background, all expressing the tau4R/2N isoform driven specifically in neurons by the thy1 gene promoter. Two strains, expressing human tau-4R/2N or mutant tau-4R/2N-P301L at similar, moderate levels, developed very different phenotypes. Tau4R/2N mice became motor-impaired already around age 6-8 weeks, accompanied by axonopathy (dilatations, spheroids), but no tau aggregates, and surviving normally. In contrast, tau-P301L mice developed neurofibrillary tangles from age 6 months, without axonal dilatations and, despite only minor motor problems, all succumbing before the age of 13 months. The third strain, obtained by tau knock-out/knock-in (tau-KOKI), expressed normal levels of wild-type human tau-4R/2N replacing all mouse tau isoforms. Tau-KOKI mice survived normally with minor motor problems late in life and without any obvious pathology. Biochemically, a fraction of neuronal tau in aging tau-P301L mice was hyper-phosphorylated concomitant with conformational changes and aggregation, but overall, tau-4R/2N was actually more phosphorylated than tau-P301L. Significantly, tau with changed conformation and with hyper-phosphorylation co-localized in the same neurons in aging tau-P301L mice. Taken together, we conclude that excessive binding of tau-4R/2N as opposed to reduced binding of tau-P301L to microtubules is responsible for the development of axonopathy and tauopathy, respectively, in tau-4R/2N and tau-P301L mice and that the conformational change of tauP301L is a major determinant in triggering the tauopathy.	Katholieke Univ Leuven, Dept Human Genet, Expt Genet Grp, LEGT,EGG, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Solid State Phys & Magnetism, B-3001 Louvain, Belgium	KU Leuven; KU Leuven	Van Leuven, F (corresponding author), Katholieke Univ Leuven, Dept Human Genet, Expt Genet Grp, LEGT,EGG, Campus Gasthuisberg O&N 06, B-3000 Louvain, Belgium.	fredvl@med.kuleuven.ac.be						Allen B, 2002, J NEUROSCI, V22, P9340; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Andorfer CA, 2000, DEV NEUROSCI-BASEL, V22, P303, DOI 10.1159/000017454; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BOEDERT M, 1996, ANN NY REV SCI, V777, P121; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; CailletBoudin ML, 1996, NEUROREPORT, V8, P307, DOI 10.1097/00001756-199612200-00061; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; Dewachter I, 2002, J NEUROSCI, V22, P3445; Fitzjohn SM, 2001, J NEUROSCI, V21, P4691, DOI 10.1523/JNEUROSCI.21-13-04691.2001; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P1; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P15009, DOI 10.1021/bi035722s; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Gotz J, 2004, MOL PSYCHIATR, V9, P664, DOI 10.1038/sj.mp.4001508; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Gureviciene I, 2004, NEUROBIOL DIS, V15, P188, DOI 10.1016/j.nbd.2003.11.011; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Heutink P, 2000, HUM MOL GENET, V9, P979, DOI 10.1093/hmg/9.6.979; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 2001, TRENDS MOL MED, V7, P467, DOI 10.1016/S1471-4914(01)02123-2; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kunzi V, 2002, J NEUROSCI, V22, P7471; LARCHER JC, 1992, DEV BIOL, V154, P195, DOI 10.1016/0012-1606(92)90059-P; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lin WL, 2003, AM J PATHOL, V162, P213, DOI 10.1016/S0002-9440(10)63812-6; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; MERCKEN M, 1992, J NEUROCHEM, V58, P548, DOI 10.1111/j.1471-4159.1992.tb09754.x; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; Moreno-Herrero F, 2004, BIOPHYS J, V86, P517, DOI 10.1016/S0006-3495(04)74130-2; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; RIEDERER BM, 1994, BRAIN RES BULL, V33, P155, DOI 10.1016/0361-9230(94)90245-3; Ris L, 2003, J BIOL CHEM, V278, P44393, DOI 10.1074/jbc.M300971200; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Styren SC, 2000, J HISTOCHEM CYTOCHEM, V48, P1223, DOI 10.1177/002215540004800906; Terwel D, 2002, NEUROMOL MED, V2, P151, DOI 10.1385/NMM:2:2:151; Togo T, 2002, J NEUROPATH EXP NEUR, V61, P547, DOI 10.1093/jnen/61.6.547; Tolnay M, 1998, NEUROPATH APPL NEURO, V24, P53, DOI 10.1046/j.1365-2990.1998.00090.x; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; van Leuven F, 2000, PROG NEUROBIOL, V61, P305, DOI 10.1016/S0301-0082(99)00055-6; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	59	193	214	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3963	3973		10.1074/jbc.M409876200	http://dx.doi.org/10.1074/jbc.M409876200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15509565	hybrid			2022-12-25	WOS:000226983900099
J	Bowen, WS; Van Dyke, N; Murgola, EJ; Lodmell, JS; Hill, WE				Bowen, WS; Van Dyke, N; Murgola, EJ; Lodmell, JS; Hill, WE			Interaction of thiostrepton and elongation factor-G with the ribosomal protein L11-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; FACTOR EF-G; 23S RNA; TRANSLATION TERMINATION; CONFORMATIONAL-CHANGE; GTPASE CENTER; 70S RIBOSOME; BINDING; SUBUNIT; COMPLEX	Ribosomal protein L11 and the L11 binding region of ribosomal RNA constitute an important domain involved in active functions of the ribosome during translation. We studied the effects of L11 knock-out and truncation mutations on the structure of the rRNA in this region and on its interactions with a translation elongation factor and the antibiotic thiostrepton. The results indicated that the structure of the L11-binding rRNA becomes conformationally flexible when ribosomes lack the entire L11 protein, but not when the C-terminal domain is present on ribosomes. Probing wild type and mutant ribosomes in the presence of the antibiotic thiostrepton and elongation factor-G (EF-G) rigorously localized the binding cleft of thiostrepton and suggested a role for the rRNA in the L11-binding domain in modulating factor binding. Our results also provide evidence that the structure of the rRNA stabilized by the C-terminal domain of L11 is necessary to stabilize EF-G binding in the post-translocation state, and thiostrepton may modulate this structure in a manner that interferes with the ribosome-EF-G interaction. The implications for recent models of thiostrepton activity and factor interactions are discussed.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Montana System; University of Montana; University of Texas System; UTMD Anderson Cancer Center	Hill, WE (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	bi_weh@selway.umt.edu			NIGMS NIH HHS [GM21499, GM35717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035717, R01GM021499] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; Arkov AL, 2000, BIOCHIMIE, V82, P671, DOI 10.1016/S0300-9084(00)01162-7; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Batey RT, 1996, J MOL BIOL, V261, P550, DOI 10.1006/jmbi.1996.0482; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BODLEY JW, 1970, J BIOL CHEM, V245, P5656; Bowen WS, 2001, METHODS, V25, P344, DOI 10.1006/meth.2001.1246; BROT N, 1974, P NATL ACAD SCI USA, V71, P89, DOI 10.1073/pnas.71.1.89; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-15; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; CUNDLIFFE E, 1979, J MOL BIOL, V132, P235, DOI 10.1016/0022-2836(79)90393-0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DIJK J, 1979, NUCLEIC ACIDS RES, V6, P2717, DOI 10.1093/nar/6.8.2717; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; ECKSTEIN F, 1971, BIOCHEM BIOPH RES CO, V45, P1151, DOI 10.1016/0006-291X(71)90139-2; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Gale EF, 1981, MOL BASIS ANTIBIOTIC, P402; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HIGHLAND JH, 1975, J BIOL CHEM, V250, P1141; JUCKER FM, 1995, RNA, V1, P219; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; Lentzen G, 2003, CHEM BIOL, V10, P769, DOI 10.1016/S1074-5521(03)00173-X; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Muth GW, 1999, NUCLEIC ACIDS RES, V27, P1906, DOI 10.1093/nar/27.8.1906; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STERN S, 1988, METHOD ENZYMOL, V164, P481; STOFFLER G, 1980, J BIOL CHEM, V255, P517; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TAM MF, 1981, J BIOL CHEM, V256, P6430; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; Van Dyke N, 2003, J MOL BIOL, V330, P9, DOI 10.1016/S0022-2836(03)00537-0; Van Dyke N, 2002, J MOL BIOL, V319, P329, DOI 10.1016/S0022-2836(02)00304-2; Wilson KS, 2004, J MOL BIOL, V337, P15, DOI 10.1016/j.jmb.2004.01.013; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	49	34	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2934	2943		10.1074/jbc.M407008200	http://dx.doi.org/10.1074/jbc.M407008200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15492007	hybrid			2022-12-25	WOS:000226449100069
J	Le, XF; Lammayot, A; Gold, D; Lu, YL; Mao, WQ; Chang, T; Patel, A; Mills, GB; Bast, RC				Le, XF; Lammayot, A; Gold, D; Lu, YL; Mao, WQ; Chang, T; Patel, A; Mills, GB; Bast, RC			Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MONOCLONAL-ANTIBODY; RECEPTOR; TRASTUZUMAB; KINASE; ERBB2; HERCEPTIN; OVEREXPRESSION; SENSITIZATION; MECHANISM	The molecular mechanisms by which the anti-HER2 antibodies trastuzumab and its murine equivalent 4D5 inhibit tumor growth and potentiate chemotherapy are not fully understood. Inhibition of signaling through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway may be particularly important. Treatment of breast cancer cells that overexpress HER2 with trastuzumab inhibited HER2-HER3 association, decreased PDK1 activity, reduced Thr-308 and Ser-473 phosphorylation of AKT, and reduced AKT enzymatic activity. To place the role of PI3K-AKT in perspective, gene expression was studied by using Affymetrix microarrays and real time reverse transcription-PCR. Sixteen genes were consistently down-regulated 2.0-4.9-fold in two antibody-treated breast cancer cell lines. Fourteen of the 16 genes were involved in three major functional areas as follows: 7 in cell cycle regulation, particularly of the G(2)-M; 5 in DNA repair/replication; and 2 in modifying chromatin structure. Of the 16 antibody-regulated genes, 64% had roles in cell growth/maintenance and 52% contributed to the cell cycle. Direct inhibition of PI3K with an inhibitor markedly reduced expression of 14 genes that were also affected by the antibody. Constitutive activation of AKT1 blocked the effect of the anti-HER2 antibody on cell cycle arrest and on eight differentially expressed genes. The antibody enhanced docetaxel-induced growth inhibition but did not increase the fraction of apoptotic cells induced with docetaxel alone. In contrast, the antibody plus docetaxel markedly down-regulated two genes, HEC and DEEPEST, required for passage through G(2)-M. Thus, anti-HER2 antibody preferentially affects genes contributing to cell cycle progression and cell growth/maintenance, in part through the PI3K-AKT signaling. Transcriptional regulation by anti-HER2 antibody through PI3K-AKT pathway may potentiate the growth inhibitory activity of docetaxel by affecting cell cycle progression.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER; NCI NIH HHS [CA39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2003, BREAST CANCER RES, V5, P96, DOI 10.1186/bcr574; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; Baselga J, 1998, CANCER RES, V58, P2825; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Jarvinen TAH, 1999, GENE CHROMOSOME CANC, V26, P142; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kono K, 2002, CANCER RES, V62, P5813; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CLIN CANCER RES, V6, P260; Le XF, 2000, CANCER RES, V60, P3522; Lee S, 2002, CANCER RES, V62, P5703; Liang K, 2003, MOL CANCER THER, V2, P1113; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Pietras RJ, 1999, CANCER RES, V59, P1347; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; SAMANTA A, 1995, P NATL ACAD SCI USA, V92, P6582, DOI 10.1073/pnas.92.14.6582; Scott GK, 2002, MOL CANCER THER, V1, P385; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yakes FM, 2002, CANCER RES, V62, P4132	40	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2092	2104		10.1074/jbc.M403080200	http://dx.doi.org/10.1074/jbc.M403080200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15504738	hybrid			2022-12-25	WOS:000226341700044
J	Norton, AW; Hosier, S; Terew, JM; Li, N; Dhingra, A; Vardi, N; Baehr, W; Cote, RH				Norton, AW; Hosier, S; Terew, JM; Li, N; Dhingra, A; Vardi, N; Baehr, W; Cote, RH			Evaluation of the 17-kDa prenyl-binding protein as a regulatory protein for phototransduction in retinal photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; PIGMENTOSA GTPASE REGULATOR; INHIBITORY GAMMA-SUBUNIT; CGMP-PHOSPHODIESTERASE; DELTA-SUBUNIT; PDE-DELTA; MONOCLONAL-ANTIBODIES; C-ELEGANS; TRANSDUCIN	The mammalian rod photoreceptor phosphodiesterase (PDE6) holoenzyme is isolated in both a membrane-associated and a soluble form. Membrane binding is a consequence of prenylation of PDE6 catalytic subunits, whereas soluble PDE6 is purified with a 17-kDa prenyl-binding protein (PDEdelta) tightly bound. This protein, here termed PrBP/delta, has been hypothesized to reduce activation of PDE6 by transducin, thereby desensitizing the photoresponse. To test the potential role of PrBP/delta in regulating phototransduction, we examined the abundance, localization, and potential binding partners of PrBP/delta in retina and in purified rod outer segment (ROS) suspensions whose physiological and biochemical properties are well characterized. The amphibian homologue of PrBP/delta was cloned and sequenced and found to have 82% amino acid sequence identity with mammalian PrBP/delta. In contrast to bovine ROS, all of the PDE6 in purified frog ROS is membrane-associated. However, addition of recombinant frog PrBP/delta can solubilize PDE6 and prevent its activation by transducin. PrBP/delta also binds other prenylated photoreceptor proteins in vitro, including opsin kinase (GRK1/GRK7) and rab8. Quantitative immunoblot analysis of the PrBP/delta content of purified ROS reveals insufficient amounts of PrBP/delta (<0.1 PrBP/delta per PDE6) to serve as a subunit of PDE6 in either mammalian or amphibian photoreceptors. The immunolocalization of PrBP/delta in frog and bovine retina shows greatest PrBP/delta immunolabeling outside the photoreceptor cell layer. Within photoreceptors, only the inner segments of frog double cones are strongly labeled, whereas bovine photoreceptors reveal more PrBP/delta labeling near the junction of the inner and outer segments (connecting cilium) of photoreceptors. Together, these results rule out PrBP/delta as a PDE6 subunit and implicate PrBP/delta in the transport and membrane targeting of prenylated proteins (including PDE6) from their site of synthesis in the inner segment to their final destination in the outer segment of rods and cones.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Univ Utah, Ctr Hlth, Moran Eye Ctr, Salt Lake City, UT 84132 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA	University System Of New Hampshire; University of New Hampshire; Utah System of Higher Education; University of Utah; University of Pennsylvania	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA.	Rick.Cote@unh.edu	Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NATIONAL EYE INSTITUTE [R01EY011105, R01EY008123, R01EY005798] Funding Source: NIH RePORTER; NEI NIH HHS [EY11105, EY05798, EY08123, R01 EY008123, R01 EY011105, R01 EY005798] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; CLERC A, 1992, J BIOL CHEM, V267, P6620; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Cote RH, 2000, METHOD ENZYMOL, V315, P646; COTE RH, 2003, HDB CELL SIGNALING, P453; DERETIC D, 1995, J CELL SCI, V108, P215; FLORIO SK, 1996, J BIOL CHEM, V271, P1; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; Grayson C, 2002, HUM MOL GENET, V11, P3065, DOI 10.1093/hmg/11.24.3065; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Higashide T, 1996, J BIOL CHEM, V271, P1797, DOI 10.1074/jbc.271.3.1797; Higashide T, 1998, INVEST OPHTH VIS SCI, V39, P690; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hong DH, 2000, P NATL ACAD SCI USA, V97, P3649, DOI 10.1073/pnas.060037497; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; HURWITZ RL, 1984, ADV CYCLIC NUCL PROT, V17, P239; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; Johnson MA, 1998, VISUAL NEUROSCI, V15, P743, DOI 10.1017/S0952523898154135; Kobayashi A, 2003, FEBS LETT, V534, P26, DOI 10.1016/S0014-5793(02)03766-3; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, FEBS LETT, V440, P454, DOI 10.1016/S0014-5793(98)01501-4; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004; Liu Q, 2002, INVEST OPHTH VIS SCI, V43, P22; Lorenz B, 1998, EUR J HUM GENET, V6, P283, DOI 10.1038/sj.ejhg.5200215; Maduro MF, 2000, J NEUROGENET, V13, P191, DOI 10.3109/01677060009084494; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; PENTIA DC, 2005, IN PRESS METHODS MOL; PITTLER SJ, 1992, FEBS LETT, V313, P103, DOI 10.1016/0014-5793(92)81422-I; ROHLICH P, 1989, J COMP NEUROL, V290, P105, DOI 10.1002/cne.902900107; Rohlich P, 2000, MICROSC RES TECHNIQ, V50, P327; ROHLICH P, 1993, CURR EYE RES, V12, P935, DOI 10.3109/02713689309020400; SCHNETKAMP PPM, 1982, METHOD ENZYMOL, V81, P110; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; STAVENGA DG, 2002, MOL MECH VISUAL TRAN; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; Wang WQ, 1999, GENE, V236, P325, DOI 10.1016/S0378-1119(99)00246-2; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zhang HB, 2004, J BIOL CHEM, V279, P407, DOI 10.1074/jbc.M306559200; Zhang HB, 2003, INVEST OPHTH VIS SCI, V44, P2858, DOI 10.1167/iovs.03-0072; Zhang HB, 2003, MOL VIS, V9, P231; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	57	50	51	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1248	1256		10.1074/jbc.M410475200	http://dx.doi.org/10.1074/jbc.M410475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15504722	hybrid, Green Accepted			2022-12-25	WOS:000226195200049
J	Sawada, S; Suzuki, H; Ichimaida, F; Yamaguchi, M; Iwashita, T; Fukui, Y; Hemmi, H; Nishino, T; Nakayama, T				Sawada, S; Suzuki, H; Ichimaida, F; Yamaguchi, M; Iwashita, T; Fukui, Y; Hemmi, H; Nishino, T; Nakayama, T			UDP-glucuronic acid : anthocyanin glucuronosyltransferase from red daisy (Bellis perennis) flowers - Enzymology and phylogenetics of a novel glucuronosyltransferase involved in flower pigment biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT GLYCOSYLTRANSFERASES; MOLECULAR-CLONING; EXPRESSION; GENE; PURIFICATION; FAMILY; GLYCOPROTEINS; TRANSFERASES; MERISTEM; SYNTHASE	In contrast to the wealth of biochemical and genetic information on vertebrate glucuronosyltransferases (UGATs), only limited information is available on the role and phylogenetics of plant UGATs. Here we report on the purification, characterization, and cDNA cloning of a novel UGAT involved in the biosynthesis of flower pigments in the red daisy (Bellis perennis). The purified enzyme, BpUGAT, was a soluble monomeric enzyme with a molecular mass of 54 kDa and catalyzed the regiospecific transfer of a glucuronosyl unit from UDPglucuronate to the 2"-hydroxyl group of the 3-glucosyl moiety of cyanidin 3-O-6"-O-malonylglucoside with a k(cat) value of 34 s(-1) at pH 7.0 and 30 degreesC. BpUGAT was highly specific for cyanidin 3-O-glucosides (e.g. K-m for cyanidin 3-O-6"-O-malonylglucoside, 19 muM) and UDP-glucuronate (K-m, 476 muM). The BpUGAT cDNA was isolated on the basis of the amino acid sequence of the purified enzyme. Quantitative PCR analysis showed that transcripts of BpUGAT could be specifically detected in red petals, consistent with the temporal and spatial distributions of enzyme activity in the plant and also consistent with the role of the enzyme in pigment biosynthesis. A sequence analysis revealed that BpUGAT is related to the glycosyltransferase 1 (GT1) family of the glycosyltransferase superfamily ( according to the Carbohydrate-Active Enzymes (CAZy) data base). Among GT1 family members that encompass vertebrate UGATs and plant secondary product glycosyltransferases, the highest sequence similarity was found with flavonoid rhamnosyltransferases of plants (28 - 40% identity). Although the biological role ( pigment biosynthesis) and enzymatic properties of BpUGAT are significantly different from those of vertebrate UGATs, both of these UGATs share a similarity in that the products produced by these enzymes are more water-soluble, thus facilitating their accumulation in vacuoles (in BpUGAT) or their excretion from cells in vertebrate UGATs), corroborating the proposed general significance of GT1 family members in the metabolism of small lipophilic molecules.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Minami Kyushu Univ, Fac Hort, Miyazaki 8840003, Japan; Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Suntory Res Ctr, Shimamoto, Osaka 6188503, Japan	Tohoku University; Suntory Holdings Ltd; Suntory Holdings Ltd	Nakayama, T (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	nakayama@seika.che.tohoku.ac.jp	Suzuki, Hirokazu/AAG-2285-2020; Hemmi, Hisashi/I-6868-2014	Suzuki, Hirokazu/0000-0002-9507-6467; Hemmi, Hisashi/0000-0002-9538-809X				BANSAL SK, 1980, ANAL BIOCH, V109; BARPELED M, 1991, J BIOL CHEM, V266, P20953; BAYER EA, 1987, ANAL BIOCHEM, V161, P123, DOI 10.1016/0003-2697(87)90661-0; Bock KW, 2003, BIOCHEM PHARMACOL, V66, P691, DOI 10.1016/S0006-2952(03)00296-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIERLEY CH, 1993, BIOESSAYS, V15, P749, DOI 10.1002/bies.950151108; Brouillard R., 1994, FLAVONOIDS ADV RES 1, P565; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; Hefner T, 2002, BIOORGAN MED CHEM, V10, P1731, DOI 10.1016/S0968-0896(02)00029-9; Iwai H, 2002, P NATL ACAD SCI USA, V99, P16319, DOI 10.1073/pnas.252530499; Jones P, 2001, PLANTA, V213, P164, DOI 10.1007/s004250000492; Keegstra K, 2001, CURR OPIN PLANT BIOL, V4, P219, DOI 10.1016/S1369-5266(00)00164-3; KONDO M, 1991, ELECTROPHORESIS, V12, P685, DOI 10.1002/elps.1150120918; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Kurosawa Y, 2002, PLANTA, V215, P620, DOI 10.1007/s00425-002-0781-x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2004, EMBO J, V23, P2915, DOI 10.1038/sj.emboj.7600295; Nagashima S, 2000, PHYTOCHEMISTRY, V53, P533, DOI 10.1016/S0031-9422(99)00593-2; Nakayama T, 2000, SCIENCE, V290, P1163, DOI 10.1126/science.290.5494.1163; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; SAITO N, 1988, PHYTOCHEMISTRY, V27, P2963, DOI 10.1016/0031-9422(88)80697-6; SCHULZ M, 1988, PHYTOCHEMISTRY, V27, P1261, DOI 10.1016/0031-9422(88)80175-4; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Shimoda Y, 1999, J BIOL CHEM, V274, P17115, DOI 10.1074/jbc.274.24.17115; Strack D., 1994, FLAVONOIDS ADV RES 1, P1; Suzuki H, 2001, J BIOL CHEM, V276, P49013, DOI 10.1074/jbc.M108444200; TOKI K, 1991, PHYTOCHEMISTRY, V30, P3769, DOI 10.1016/0031-9422(91)80107-C; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Woo HH, 1999, PLANT CELL, V11, P2303, DOI 10.1105/tpc.11.12.2303; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405	34	80	119	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					899	906		10.1074/jbc.M410537200	http://dx.doi.org/10.1074/jbc.M410537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509561	hybrid			2022-12-25	WOS:000226195200008
J	Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH				Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH			Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12	ONCOGENE			English	Article						Ras; NIH3T3; RNAi; siRNA; microarray; osteopontin	DOWNSTREAM-REGULATED GENE-2; FAMILY SMALL GTPASES; CELL-MIGRATION; RAS; EXPRESSION; BINDING; CD44; IDENTIFICATION; PROTEIN; RAC1	Activated forms of Ras family members are prevalent in many cancers where Ras mutants transduce signals essential for transformation, angiogenesis, invasion and metastasis. As a cancer progression model, we used NIH3T3 cells to explore the mechanism of Ras-induced tumorigenesis. Ras family mutants H-RasV12 and Rit79L strongly induced foci formation, while Rho family mutants RhoA-QL, Rac1-QL and Cdc42-QL were less effective. A comparison of downstream transcriptional targets of Ras and Rho family members using a 26 383 element cDNA microarray revealed that the osteopontin (OPN) gene exhibited the best correlation between magnitude of gene expression change and level of foci formation (r=0.96, P<0.001). In association with H-RasV12- and Rit79L-mediated transformation, foci secreted OPN protein and upregulated the OPN receptor CD44, suggesting the novel initiation of an aberrant OPN-CD44-Rac autocrine pathway. In support of this were the following observations. First, RGD-deficient OPN protein-binding activity was present in H-RasV12- transformed cells but not in control cells, and binding activity was inhibited by the CD44 blocking antibody. Second, foci formation, cell invasion and Rac activity were induced by H-RasV12 and inhibited by the CD44 blocking antibody. Third, foci formation by H-RasV12 was substantially reduced by a short interfering RNA ( siRNA) specifically targeting OPN expression for knockdown. Fourth, H-RasV12- mediated transformation was not blocked by the GRGDS peptide, suggesting that OPN effects were not mediated by the integrins. Lastly, OPN knockdown affected the downstream expression of 160 '2nd tier' genes, and at least a subset of these genes appears to be involved in transformation. Indeed, four genes were selected for knockdown, each resulting in a disruption of foci formation and/or invasion. These results underscore the role of aberrant autocrine signaling and transcriptional networking during tumorigenesis.	Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); George Washington University	Gutkind, JS (corresponding author), Inst Genom Res, Dept Funct Genom, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	sg39v@nih.gov; nhlee@tigr.org	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bachelder RE, 2003, CANCER RES, V63, P5230; Berken A, 2003, ONCOGENE, V22, P8524, DOI 10.1038/sj.onc.1207195; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Bug G, 2002, J LEUKOCYTE BIOL, V72, P837; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Crowe DL, 2004, ANTICANCER RES, V24, P593; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Feng F, 2000, BREAST CANCER RES TR, V63, P71, DOI 10.1023/A:1006466516192; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Katagiri YU, 1996, J CELL BIOCHEM, V62, P123, DOI 10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O; Katagiri YU, 1999, CANCER RES, V59, P219; Mahabeleshwar GH, 2004, J BIOL CHEM, V279, P9733, DOI 10.1074/jbc.M311400200; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Oates AJ, 1997, INVAS METAST, V17, P1; Oates AJ, 1996, ONCOGENE, V13, P97; Ownby SE, 2002, LIPIDS, V37, P185, DOI 10.1007/s11745-002-0879-1; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Qu XH, 2002, J BIOL CHEM, V277, P35574, DOI 10.1074/jbc.M206451200; Rozsnyay Z, 1999, IMMUNOL LETT, V68, P101, DOI 10.1016/S0165-2478(99)00037-1; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sehgal A, 1999, ANTICANCER RES, V19, P4947; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Singh R. P., 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P75, DOI 10.1615/JEnvPathToxOncol.v22.i2.10; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Wu Y, 2000, BRIT J CANCER, V83, P156; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					489	501		10.1038/sj.onc.1208209	http://dx.doi.org/10.1038/sj.onc.1208209			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516973				2022-12-25	WOS:000226279700019
J	Yang, L; Liu, GX; Zakharov, SI; Morrow, JP; Rybin, VO; Steinberg, SF; Marx, SO				Yang, L; Liu, GX; Zakharov, SI; Morrow, JP; Rybin, VO; Steinberg, SF; Marx, SO			Ser(1928) is a common site for Ca(v)1.2 phosphorylation by protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; CALCIUM-CHANNELS; CA2+ CHANNEL; ALPHA(1C) SUBUNIT; ALPHA-1 SUBUNIT; ANGIOTENSIN-II; N-TERMINUS; RECEPTOR; RAT; MODULATION	Voltage-dependent Ca2+ channel (Ca(v)1.2, L-type Ca2+ channel) function is highly regulated by hormones and neurotransmitters in large part through the activation of kinases and phosphatases. Regulation of Ca(v)1.2 by protein kinase C (PKC) is of significant physiologic importance, mediating, in part, the cardiac response to hormonal regulation. Although PKC has been reported to mediate activation and/or inhibition of Ca(v)1.2 function, the molecular mechanisms mediating the response have not been definitively elucidated. We show that PKC forms a macromolecular complex with the alpha(1c) subunit of Ca(v)1.2 through direct interaction with the C terminus. This interaction leads to phosphorylation of the channel in response to activators of PKC. We identify Ser(1928) as the residue that is phosphorylated by PKC in vitro and in vivo. Ser(1928) has been identified previously as the site mediating, in part, the protein kinase A up-regulation of channel activity. Thus, the protein kinase A and PKC signaling pathways converge on the Ca(v)1.2 complex at Ser(1928) to increase channel activity. Our results identify two mechanisms leading to regulation of Ca(v)1.2 activity by PKC: pre-association of the channel with PKC isoforms and phosphorylation of specific sites within the alpha(1c) subunit.	Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Marx, SO (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, 630 W 168 St,P&S 9-401, New York, NY 10032 USA.	sm460@columbia.edu		Morrow, John/0000-0002-9264-5273	NHLBI NIH HHS [HL77860, R01 HL68093, R01 HL74161] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074161, R01HL077860, R01HL068093] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello EA, 2001, AM J PHYSIOL-HEART C, V280, pH1528, DOI 10.1152/ajpheart.2001.280.4.H1528; BATTAINI F, 1995, NEUROBIOL AGING, V16, P137, DOI 10.1016/0197-4580(94)00154-5; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; BOURINET E, 1992, PFLUG ARCH EUR J PHY, V421, P247, DOI 10.1007/BF00374834; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; Brandon NJ, 2002, J NEUROSCI, V22, P6353; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Correia SS, 2003, J BIOL CHEM, V278, P6307, DOI 10.1074/jbc.M205587200; Davare MA, 2003, P NATL ACAD SCI USA, V100, P16018, DOI 10.1073/pnas.2236970100; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; duBell WH, 2004, J PHYSIOL-LONDON, V556, P79, DOI 10.1113/jphysiol.2003.059329; Dubell WH, 2002, AM J PHYSIOL-HEART C, V282, pH38, DOI 10.1152/ajpheart.00536.2001; Erdbrugger W, 1997, BRIT J PHARMACOL, V120, P177, DOI 10.1038/sj.bjp.0700877; FABIATO A, 1979, ANNU REV PHYSIOL, V41, P473, DOI 10.1146/annurev.ph.41.030179.002353; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kamp TJ, 2002, CIRC RES, V91, P451, DOI 10.1161/01.RES.0000035346.21625.4A; Kelso E, 1996, EUR J PHARMACOL, V308, P351, DOI 10.1016/0014-2999(96)00366-4; Kurata S, 1999, PHARMACOLOGY, V59, P21, DOI 10.1159/000028302; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Malhotra A, 2001, MOL CELL BIOCHEM, V225, P97, DOI 10.1023/A:1012261903611; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pi YQ, 1997, CIRC RES, V81, P92, DOI 10.1161/01.RES.81.1.92; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Robu VG, 2003, J BIOL CHEM, V278, P48154, DOI 10.1074/jbc.M304396200; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Schreur KD, 1996, AM J PHYSIOL-CELL PH, V270, pC655, DOI 10.1152/ajpcell.1996.270.2.C655; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; WEBSTER RJ, 1994, J MOL CELL CARDIOL, V26, P1273, DOI 10.1006/jmcc.1994.1147; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; Woo SH, 1999, PFLUG ARCH EUR J PHY, V437, P335, DOI 10.1007/s004240050787; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	58	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					207	214		10.1074/jbc.M410509200	http://dx.doi.org/10.1074/jbc.M410509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509562	hybrid			2022-12-25	WOS:000226025100026
J	Hryciw, DH; Ekberg, J; Lee, A; Lensink, IL; Kumar, S; Guggino, WB; Cook, DI; Pollock, CA; Poronnik, P				Hryciw, DH; Ekberg, J; Lee, A; Lensink, IL; Kumar, S; Guggino, WB; Cook, DI; Pollock, CA; Poronnik, P			Nedd4-2 functionally interacts with ClC-5 - Involvement in constitutive albumin endocytosis in proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; UBIQUITIN LIGASE NEDD4-2; CHLORIDE CHANNEL; DENTS-DISEASE; IMPAIRS ENDOCYTOSIS; RENAL-FAILURE; PROTEIN; RECEPTOR; SERUM; DEGRADATION	Constitutive albumin uptake by the proximal tubule is achieved by a receptor-mediated process in which the Cl- channel, ClC-5, plays an obligate role. Here we investigated the functional interaction between ClC-5 and ubiquitin ligases Nedd4 and Nedd4-2 and their role in albumin uptake in opossum kidney proximal tubule (OK) cells. In vivo immunoprecipitation using an anti-HECT antibody demonstrated that ClC-5 bound to ubiquitin ligases, whereas glutathione S-transferase pull-downs confirmed that the C terminus of ClC-5 bound both Nedd4 and Nedd4-2. Nedd4-2 alone was able to alter ClC-5 currents in Xenopus oocytes by decreasing cell surface expression of ClC-5. In OK cells, a physiological concentration of albumin (10 mug/ml) rapidly increased cell surface expression of ClC-5, which was also accompanied by the ubiquitination of ClC-5. Albumin uptake was reduced by inhibiting either the lysosome or proteasome. Total levels of Nedd4-2 and proteasome activity also increased rapidly in response to albumin. Overexpression of ligase defective Nedd4-2 or knockdown of endogenous Nedd4-2 with small interfering RNA resulted in significant decreases in albumin uptake. In contrast, pathophysiological concentrations of albumin (100 and 1000 mug/ml) reduced the levels of ClC-5 and Nedd4-2 and the activity of the proteasome to the levels seen in the absence of albumin. These data demonstrate that normal constitutive uptake of albumin by the proximal tubule requires Nedd4-2, which may act via ubiquitination to shunt ClC-5 into the endocytic pathway.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ Sydney, Royal N Shore Hosp, Kolling Inst, Sydney, NSW 2065, Australia	University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia; Johns Hopkins University; University of Sydney; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Poronnik, P (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	p.poronnik@uq.edu.au	Kumar, Sharad/AAX-7787-2020; Hryciw, Deanne/P-2642-2019; Ekberg, Jenny/AAV-2006-2020	Kumar, Sharad/0000-0001-7126-9814; Hryciw, Deanne/0000-0003-1697-8890; Poronnik, Philip/0000-0002-6246-528X; Ekberg, Jenny/0000-0001-5151-4966	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Drumm K, 2003, CELL PHYSIOL BIOCHEM, V13, P199, DOI 10.1159/000072422; Flores SY, 2003, PFLUG ARCH EUR J PHY, V446, P334, DOI 10.1007/s00424-003-1027-x; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Gekle M, 1997, AM J PHYSIOL-RENAL, V272, pF668, DOI 10.1152/ajprenal.1997.272.5.F668; Gekle M, 2001, J PHYSIOL-LONDON, V531, P619, DOI 10.1111/j.1469-7793.2001.0619h.x; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Hegde AN, 2004, PROG NEUROBIOL, V73, P311, DOI 10.1016/j.pneurobio.2004.05.005; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hryciw DH, 2003, J BIOL CHEM, V278, P40169, DOI 10.1074/jbc.M307890200; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kirkpatrick DS, 2003, TOXICOL APPL PHARM, V186, P101, DOI 10.1016/S0041-008X(02)00019-4; Klisic J, 2003, J AM SOC NEPHROL, V14, P3008, DOI 10.1097/01.ASN.0000098700.70804.D3; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee EM, 2003, AM J PHYSIOL-RENAL, V285, pF748, DOI 10.1152/ajprenal.00442.2002; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lou XJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134918; Maack T, 2000, KIDNEY PHYSL PATHOPH, P3005; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Marshansky V, 2002, CURR OPIN NEPHROL HY, V11, P527, DOI 10.1097/00041552-200209000-00009; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Moulin P, 2003, KIDNEY INT, V63, P1285, DOI 10.1046/j.1523-1755.2003.00851.x; Norden AGW, 2001, KIDNEY INT, V60, P1885, DOI 10.1046/j.1523-1755.2001.00016.x; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Portero-Otin M, 1999, DIABETES, V48, P2215, DOI 10.2337/diabetes.48.11.2215; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Russo LM, 2002, AM J KIDNEY DIS, V39, P899, DOI 10.1053/ajkd.2002.32764; Schwake M, 2001, J BIOL CHEM, V276, P12049, DOI 10.1074/jbc.M010642200; Shankland SJ, 2000, AM J PHYSIOL-RENAL, V278, pF515, DOI 10.1152/ajprenal.2000.278.4.F515; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Wang SS, 2000, HUM MOL GENET, V9, P2937, DOI 10.1093/hmg/9.20.2937; WRONG OM, 1994, Q J MED, V87, P473; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	60	77	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54996	55007		10.1074/jbc.M411491200	http://dx.doi.org/10.1074/jbc.M411491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489223	hybrid			2022-12-25	WOS:000225960800004
J	Lacour, S; Leroy, O; Kolb, A; Landini, P				Lacour, S; Leroy, O; Kolb, A; Landini, P			Substitutions in region 2.4 of sigma(70) allow recognition of the sigma(S)-dependent aidB promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; GENERAL STRESS-RESPONSE; ESCHERICHIA-COLI; BACTERIAL TRANSCRIPTION; INTRACELLULAR LEVELS; SUBUNIT SYNTHESIS; SEQUENCE; COMPETITION; E-SIGMA(S); HOLOENZYME	The strict dependence of transcription from the aidB promoter (PaidB) on the Esigma(S) form of RNA polymerase is because of the presence of a C nucleotide as the first residue of the - 10 promoter sequence ( - 12C), which does not allow an open complex formation by Esigma(70). In this report, sigma(70) mutants carrying either the Q437H or the T440I single amino acid substitutions, which allow -12C recognition by sigma(70), were tested for their ability to carry out transcription from PaidB. The Gln-437 and Thr-440 residues are located in region 2.4 of sigma(70) and correspond to Gln-152 and Glu-155 in sigma(S). Interestingly, the Q437H mutant of sigma(70), but not T440I, was able to promote an open complex formation and to initiate transcription at PaidB. In contrast to T440I, a T440E mutant was proficient in carrying out transcription from PaidB. No sigma(70) mutant displayed significantly increased interaction with a PaidB mutant in which the -12C was substituted by a T (PaidB((C12T))), which is also efficiently recognized by wild type sigma(70). The effect of the T440E mutation suggests that the corresponding Glu-155 residue in sigma(S) might be involved in -12C recognition. However, substitution to alanine of the Glu-155 residue, as well as of Gln-152, in the sigma(S) protein did not significantly affect Esigma(S) interaction with PaidB. Our results reiterate the importance of the -12C residue for sigma(S)-specific promoter recognition and strongly suggest that interaction with the -10 sequence and open complex formation are carried out by different determinants in the two sigma factors.	Swiss Fed Inst Environm Technol, CH-8600 Dubendorf, Switzerland; Inst Pasteur, Unite Regulat Transcript, Dept Microbiol Fondamentale & Med, CNRS,URA 1773, F-75724 Paris 15, France; Univ Milan, Dept Mol Biosci & Biotechnol, I-20100 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Milan	Landini, P (corresponding author), Univ Milan, Dept Mol Biosci & Biotechnol, Via Celoria 26, I-20133 Milan, Italy.	paolo.landini@unimi.it	Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Lacour, Stephan/0000-0002-6066-4189				Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Checroun C, 2004, NUCLEIC ACIDS RES, V32, P45, DOI 10.1093/nar/gkh155; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, CELL MOL BIOL RES, V39, P311; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; Lacour S, 2003, J BIOL CHEM, V278, P37160, DOI 10.1074/jbc.M305281200; Lacour S, 2002, BIOCHEM BIOPH RES CO, V292, P922, DOI 10.1006/bbrc.2002.6744; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; Lee SJ, 2004, MOL CELL, V14, P153, DOI 10.1016/S1097-2765(04)00202-3; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Rhodius VA, 2000, J MOL BIOL, V299, P311, DOI 10.1006/jmbi.2000.3737; Sanderson A, 2003, FEBS LETT, V544, P199, DOI 10.1016/S0014-5793(03)00500-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; Wise A, 1996, J BACTERIOL, V178, P2785, DOI 10.1128/jb.178.10.2785-2793.1996	39	3	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55255	55261		10.1074/jbc.M410855200	http://dx.doi.org/10.1074/jbc.M410855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507429	Green Published, hybrid			2022-12-25	WOS:000225960800035
J	Reiley, W; Zhang, MY; Sun, SC				Reiley, W; Zhang, MY; Sun, SC			Negative regulation of JNK signaling by the tumor suppressor CYLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; JUN NH2-TERMINAL KINASE; NECROSIS-FACTOR; TERMINAL KINASE; UBIQUITIN LIGASE; CELL-DEATH; ACTIVATION; APOPTOSIS; EXPRESSION; INDUCTION	CYLD is a tumor suppressor that is mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple tumors of the skin appendages. Recent studies suggest that transfected CYLD has deubiquitinating enzyme activity and inhibits the activation of transcription factor NF-kappaB. However, the role of endogenous CYLD in regulating cell signaling remains poorly defined. Here we report a critical role for CYLD in negatively regulating the c-Jun NH2-terminal kinase (JNK). CYLD knockdown by RNA interference results in hyperactivation of JNK by diverse immune stimuli, including tumor necrosis factor-alpha, interleukin-1, lipopolysaccharide, and an agonistic anti-CD40 antibody. The JNK-inhibitory function of CYLD appears to be specific for immune receptors because the CYLD knockdown has no significant effect on stress-induced JNK activation. Consistently, CYLD negatively regulates the activation of MKK7, an upstream kinase known to mediate JNK activation by immune stimuli. We further demonstrate that CYLD also negatively regulates IkappaB kinase, although this function of CYLD is seen in a receptor-dependent manner. These findings identify the JNK signaling pathway as a major downstream target of CYLD and suggest a receptor-dependent role of CYLD in regulating the IkappaB kinase pathway.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922, T32CA060395] Funding Source: NIH RePORTER; NCI NIH HHS [CA 094922, 5T32 CA 60395-09] Funding Source: Medline; NIAID NIH HHS [AI 45045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brooke HG, 1892, BRIT J DERMATOL, V4, P269; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HIMENO T, 1990, CANCER RES, V50, P4941; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jensen LE, 2003, FEBS LETT, V553, P190, DOI 10.1016/S0014-5793(03)00998-0; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Liu ZG, 2003, MOL CELL, V12, P795, DOI 10.1016/S1097-2765(03)00399-X; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spiegler E., 1899, ARCH DERMATOL SYPHIL, V50, P163; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsuiki H, 2003, CANCER RES, V63, P250; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xu X, 1996, ONCOGENE, V13, P135; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	56	125	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55161	55167		10.1074/jbc.M411049200	http://dx.doi.org/10.1074/jbc.M411049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496400	hybrid			2022-12-25	WOS:000225960800023
J	Kimball, SR; Siegfried, BA; Jefferson, LS				Kimball, SR; Siegfried, BA; Jefferson, LS			Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-METABOLISM; TRANSLATION INITIATION; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE; TUBEROUS-SCLEROSIS; S6 KINASE; HELICASE ACTIVITY; CELLULAR-ENERGY; PHOSPHORYLATION; MTOR	The opposing actions of glucagon and insulin on glucose metabolism within the liver are essential mechanisms for maintaining plasma glucose concentrations within narrow limits. Less well studied are the counter-regulatory actions of glucagon on protein metabolism. In the present study, the effect of glucagon on amino acid-induced signaling through the mammalian target of rapamycin ( mTOR), an important controller of the mRNA binding step in translation initiation, was examined using the perfused rat liver as an experimental model. The results show that amino acids enhance signaling through mTOR resulting in phosphorylation of eukaryotic initiation factor 4E-binding protein (4E-BP)1, the 70-kDa ribosomal protein (rp)S6 kinase, S6K1, and rpS6. In contrast, glucagon repressed both basal and amino acid-induced signaling through mTOR, as assessed by changes in the phosphorylation of 4E-BP1 and S6K1. The repression was associated with the activation of protein kinase A and enhanced phosphorylation of LKB1 and the AMP-activated protein kinase (AMPK). Surprisingly, the phosphorylation of two S6K1 substrates, rpS6 and eukaryotic initiation factor 4B, was not repressed but instead was increased by glucagon treatment, regardless of the amino acid concentration. The latter finding could be explained by the glucagon-induced phosphorylation of the ERK1 and the 90-kDa rpS6 kinase p90(rsk). Thus, glucagon represses phosphorylation of 4E-BP1 and S6K1 through the activation of a protein kinase A-LKB-AMPK-mTOR signaling pathway, while simultaneously enhancing phosphorylation of other downstream effectors of mTOR through the activation of the extracellular signal-regulated protein kinase 1-p90(rsk) signaling pathway. Amino acids also enhance AMPK phosphorylation, although to a lesser extent than glucagon and amino acids combined.	Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	skimball@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13499] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthony JC, 2000, J NUTR, V130, P2413; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Charlton MR, 1996, J CLIN INVEST, V98, P90, DOI 10.1172/JCI118782; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; COUET C, 1990, AM J PHYSIOL, V258, pE78, DOI 10.1152/ajpendo.1990.258.1.E78; Dalle S, 2004, J BIOL CHEM, V279, P20345, DOI 10.1074/jbc.M312483200; Dixon M, 1999, HEPATOLOGY, V29, P1418, DOI 10.1002/hep.510290516; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Exton J H, 1975, Methods Enzymol, V39, P25; FELDHOFF RC, 1977, J BIOL CHEM, V252, P3611; FLAKOLL PJ, 1994, METABOLISM, V43, P1509, DOI 10.1016/0026-0495(94)90009-4; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JEFFERIES HBJ, 1996, COLD SPRING HARBOR M, V30, P389; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; Kimball SR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1080, DOI 10.1152/ajpendo.2000.279.5.E1080; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Kwiatkowski DJ, 2003, CANCER BIOL THER, V2, P471, DOI 10.4161/cbt.2.5.446; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; NAIR KS, 1995, J CLIN INVEST, V95, P2926, DOI 10.1172/JCI118000; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sampson JR, 2003, BIOCHEM SOC T, V31, P592, DOI 10.1042/BST0310592; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; TOLMAN EL, 1973, J BIOL CHEM, V248, P4552; WOODSIDE KH, 1974, J BIOL CHEM, V249, P5458; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Yoshizawa F, 1998, AM J PHYSIOL-ENDOC M, V275, pE814, DOI 10.1152/ajpendo.1998.275.5.E814	53	107	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54103	54109		10.1074/jbc.M410755200	http://dx.doi.org/10.1074/jbc.M410755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494402	hybrid			2022-12-25	WOS:000225793600028
J	Kojma, Y; Hirata, K; Ishida, T; Shimokawa, Y; Inoue, N; Kawashima, S; Quertermous, T; Yokoyama, M				Kojma, Y; Hirata, K; Ishida, T; Shimokawa, Y; Inoue, N; Kawashima, S; Quertermous, T; Yokoyama, M			Endothelial lipase modulates monocyte adhesion to the vessel wall - A potential role in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELL-DERIVED LIPASE; SERUM-LIPOPROTEINS; ENHANCES BINDING; HEPARAN-SULFATE; MESSENGER-RNA; ATHEROSCLEROSIS; GENE; EXPRESSION; ENDOTOXIN	Endothelial lipase (EL), a new member of the lipoprotein lipase gene family, plays a central role in high density lipoprotein metabolism. Previous studies indicated that EL is expressed in endothelial cells, macrophages, and smooth muscle cells in atherosclerotic lesions in human coronary arteries. However, the functional role of EL in the local vessel wall remains obscure. In this study, we evaluated the ability of EL to modulate monocyte adhesion to the endothelial cell surface. EL mRNA and protein levels were markedly increased in tissues of the mouse model of inflammation induced by lipopolysaccharide injection. Adhesion assays in vitro revealed that overexpression of EL in COS7 or Pro5 cells enhanced monocyte bindings to the EL-expression cells. Heparin or heparinase treatment inhibited EL-mediated increases of monocyte adhesion in a dose-dependent manner. Moreover, ex vivo adhesion assays revealed that the number of adherent monocytes on aortic strips was significantly increased in EL transgenic mice and decreased in EL knock-out mice as compared with wildtype mice. These results suggest that EL on the endothelial cell surface can promote monocyte adhesion to the vascular endothelium through the interaction with heparan sulfate proteoglycans. Thus, the up-regulation of EL by inflammatory stimuli may be involved in the progression of inflammation.	Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Stanford Univ, Donald W Reynolds Cardiovasc Clin Res Ctr, Div Cardiovasc Med, Sch Med, Stanford, CA 94305 USA	Kobe University; Stanford University	Hirata, K (corresponding author), Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	hiratak@med.kobe-u.ac.jp		Quertermous, Thomas/0000-0002-7645-9067				AVIRAM M, 1988, J BIOL CHEM, V263, P15416; Azumi H, 2003, CARDIOVASC RES, V58, P647, DOI 10.1016/S0008-6363(03)00287-6; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; DICHEK HL, 1993, J LIPID RES, V34, P1393; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; Feingold KR, 1999, ATHEROSCLEROSIS, V142, P379, DOI 10.1016/S0021-9150(98)00265-2; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HILL MR, 1995, INFECT IMMUN, V63, P858, DOI 10.1128/IAI.63.3.858-864.1995; Hirata K, 2000, BIOCHEM BIOPH RES CO, V272, P90, DOI 10.1006/bbrc.2000.2747; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Ishida T, 2004, J BIOL CHEM, V279, P45085, DOI 10.1074/jbc.M406360200; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Ishida T, 2004, GENOMICS, V83, P24, DOI 10.1016/S0888-7543(03)00181-2; Ishida T, 1999, CARDIOVASC RES, V41, P267, DOI 10.1016/S0008-6363(98)00162-X; JACKSON RL, 1983, ENZYMES, V16, P141; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2003, CIRC RES, V92, P644, DOI 10.1161/01.RES.0000064502.47539.6D; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Mamputu JC, 1997, J LIPID RES, V38, P1722; McCoy MG, 2002, J LIPID RES, V43, P921; NAVAB M, 1994, CORONARY ARTERY DIS, V5, P198, DOI 10.1097/00019501-199403000-00003; Obunike JC, 1997, ARTERIOSCL THROM VAS, V17, P1414, DOI 10.1161/01.ATV.17.7.1414; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSNER S, 1978, ATHEROSCLEROSIS, V31, P93, DOI 10.1016/0021-9150(78)90041-2; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Rutledge JC, 1997, CIRC RES, V80, P819; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Santamarina-Fojo S, 2000, INT J TISSUE REACT, V22, P39; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; Wang GP, 2002, ARTERIOSCL THROM VAS, V22, P1777, DOI 10.1161/01.ATV.0000035404.18281.37; WEI YZ, 1995, STEM CELLS, V13, P541, DOI 10.1002/stem.5530130512; Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931; Yu KCW, 2004, J LIPID RES, V45, P1614, DOI 10.1194/jlr.M400069-JLR200; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	42	40	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54032	54038		10.1074/jbc.M411112200	http://dx.doi.org/10.1074/jbc.M411112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485805	hybrid			2022-12-25	WOS:000225793600019
J	Wang, B; Liu, K; Lin, FT; Lin, WC				Wang, B; Liu, K; Lin, FT; Lin, WC			A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; PHOSPHORYLATION; P53; DEGRADATION; ASSOCIATION; STABILITY; ACCUMULATION; SPECIFICITY	Genotoxic stress triggers apoptosis through multiple signaling pathways. Recent studies have demonstrated a specific induction of E2F1 accumulation and a role for E2F1 in apoptosis upon DNA damage. Induction of E2F1 is mediated by phosphorylation events that are dependent on DNA damage-responsive protein kinases, such as ATM. How ATM phosphorylation leads to E2F1 stabilization is unknown. We now show that 14-3-3tau, a phosphoserine-binding protein, mediates E2F1 stabilization. 14-3-3tau interacts with ATM-phosphorylated E2F1 during DNA damage and inhibits E2F1 ubiquitination. Depletion of 14-3-3tau or E2F1, but not E2F2 or E2F3, blocks adriamycin-induced apoptosis. 14-3-3tau is also required for expression and induction of E2F1 apoptotic targets, such as p73, Apaf-1, and caspases, during DNA damage. Together, these data demonstrate a novel function for 14-3-3tau in the regulation of E2F1 protein stability and apoptosis during DNA damage.	Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lin, WC (corresponding author), 520A Wallace Tumor Inst, 1530 3rd Ave S, Birmingham, AL 35294 USA.	wclin@uab.edu			NCI NIH HHS [CA100848, CA100857, R01 CA100848, R01 CA100857] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100848, R01CA100857] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Martelli F, 1999, P NATL ACAD SCI USA, V96, P2858, DOI 10.1073/pnas.96.6.2858; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Meng RD, 1999, INT J ONCOL, V14, P5; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohta T, 2001, CANCER RES, V61, P1347; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003	42	76	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54140	54152		10.1074/jbc.M410493200	http://dx.doi.org/10.1074/jbc.M410493200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494392	Green Accepted, hybrid			2022-12-25	WOS:000225793600033
J	Avkin, S; Goldsmith, M; Velasco-Miguel, S; Geacintov, N; Friedberg, EC; Livneh, Z				Avkin, S; Goldsmith, M; Velasco-Miguel, S; Geacintov, N; Friedberg, EC; Livneh, Z			Quantitative analysis of translesion DNA synthesis across a benzo[a] pyrene-guanine adduct in mammalian cells - The role of DNA polymerase kappa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM VARIANT; BENZO<A>PYRENE DIOL EPOXIDE; PRONE LESION BYPASS; ESCHERICHIA-COLI; SEQUENCE CONTEXT; ERROR-FREE; HUMAN HOMOLOG; Y-FAMILY; IN-VITRO; POL-V	Replication across unrepaired DNA lesions in mammalian cells is effected primarily by specialized, low fidelity DNA polymerases. We studied translesion DNA synthesis (TLS) across a benzo[ a] pyrene-guanine (BP-G) adduct, a major mutagenic DNA lesion generated by tobacco smoke. This was done using a quantitative assay that measures TLS indirectly, by measuring the recovery of gapped plasmids transfected into cultured mammalian cells. Analysis of PolK(+/+) mouse embryo fibroblasts (MEFs) showed that TLS across the BP-G adduct occurred with an efficiency of 48 +/- 4%, which is an order of magnitude higher than in Escherichia coli. In PolK(-/-) MEFs, bypass was 16 +/- 1%, suggesting that at least two-thirds of the BP-G adducts in MEFs were bypassed exclusively by polymerase kappa (polkappa). In contrast, poleta was not required for bypass across BP-G in a human XP-V cell line. Analysis of misinsertion specificity across BP-G revealed that bypass was more error-prone in MEFs lacking polkappa. Expression of polkappa from a plasmid introduced into PolK(-/-) MEFs restored both the extent and fidelity of bypass across BP-G. Polkappa was not required for bypass of a synthetic abasic site. In vitro analysis demonstrated efficient bypass across BP-G by both polkappa and poleta, suggesting that the biological role of polkappa in TLS across BP-G is due to regulation of TLS and not due to an exclusive ability to bypass this lesion. These results indicate that BP-G is bypassed in mammalian cells with relatively high efficiency and that polkappa bypasses BP-G in vivo with higher efficiency and higher accuracy than other DNA polymerases.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA; NYU, Dept Chem, New York, NY 10003 USA	Weizmann Institute of Science; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	zvi.livneh@weizmann.ac.il			NATIONAL CANCER INSTITUTE [R01CA099194] Funding Source: NIH RePORTER; NCI NIH HHS [CA099194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Arghavani MB, 1998, BIOCHEMISTRY-US, V37, P8575, DOI 10.1021/bi980237w; Avkin S, 2002, P NATL ACAD SCI USA, V99, P3764, DOI 10.1073/pnas.062038699; Avkin S, 2002, MUTAT RES-FUND MOL M, V510, P81, DOI 10.1016/S0027-5107(02)00254-3; Berdichevsky A, 2002, MOL CELL, V10, P917, DOI 10.1016/S1097-2765(02)00679-2; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Cleaver JE, 1999, CANCER RES, V59, P1102; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Goodwin BK, 2000, J AGR RESOUR ECON, V25, P195; Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; MAO B, 1995, CARCINOGENESIS, V16, P357, DOI 10.1093/carcin/16.2.357; Maor-Shoshani A, 2003, P NATL ACAD SCI USA, V100, P14760, DOI 10.1073/pnas.2433503100; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Schenten D, 2002, EUR J IMMUNOL, V32, P3152, DOI 10.1002/1521-4141(200211)32:11<3152::AID-IMMU3152>3.0.CO;2-2; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Shukla R, 1997, BIOCHEMISTRY-US, V36, P10256, DOI 10.1021/bi970541+; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Washington MT, 2001, P NATL ACAD SCI USA, V98, P8355, DOI 10.1073/pnas.121007298; YANG JL, 1987, MOL CELL BIOL, V7, P1267, DOI 10.1128/MCB.7.3.1267; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1	55	149	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53298	53305		10.1074/jbc.M409155200	http://dx.doi.org/10.1074/jbc.M409155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475561	hybrid			2022-12-25	WOS:000225680600061
J	Ma, BY; Nussinov, R				Ma, BY; Nussinov, R			Release factors eRF1 and RF2 - A universal mechanism controls the large conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME RECYCLING FACTOR; TRANSFER-RNA HYDROLYSIS; POLYPEPTIDE RELEASE; CRYSTAL-STRUCTURE; TRANSLATION TERMINATION; HISTIDINE PROTONATION; STRUCTURALLY DISTINCT; ANGSTROM RESOLUTION; STOP CODONS; FACTOR RRF	Class I release factors 1 and 2 (RF1 and RF2) terminate protein synthesis by recognizing stop codons on the mRNA via their conserved amino acid motifs (NIKS in eRF1 and SPF in RF2) and by the conserved tripeptide (GGQ) interactions with the ribosomal peptidyltransferase center. Crystal structures of eRF1 and RF2 do not fit their ribosomal binding pocket (similar to73 Angstrom). Cryoelectron microscopy indicates large conformational changes in the ribosome-bound RF2. Here, we investigate the conformational dynamics of the eRF1 and RF2 using molecular dynamics simulation, structural alignment, and electrostatic analysis of domain interactions. We show that relaxed eRF1 has a shape remarkably similar to the ribosome-bound RF2 observed by cryoelectron microscopy. The similarity between the two release factors is as good as between elongation factor G and elongation factor Tuguanosine-5'(beta,gamma-imido)triphosphate-tRNA. Further, the conformational transitions and dynamics of eRF1 and RF2 between the free and ribosome-bound states are most likely controlled by protonation of conserved histidines. For eRF1, the distance between the NIKS and GGQ motifs shrinks from 97.5 Angstromin the crystal to 70-80 Angstrom. For RF2, the separation between SPF and GGQ elongates from 32 Angstrom in the crystal to 50 Angstrom. Coulombic interaction strongly favors the open conformation of eRF1; however, solvation and histidine protonation modulate the domain interactions, making the closed conformation of eRF1 more accessible. Thus, RF1 and RF2 function like molecular machines, most likely fueled by histidine protonation. The unified conformational control and the shapes of eRF1 and RF2 support the proposition that the termination of protein synthesis involves similar mechanisms across species.	NCI, Basic Res Program, SAIC Frederick Inc, Lab Expt & Computat Biol,NIH, Frederick, MD 21702 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine	Ma, BY (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Lab Expt & Computat Biol,NIH, Frederick, MD 21702 USA.	mab@ncifcrf.gov; ruthn@ncifcrf.gov	Ma, Buyong/F-9491-2011	Ma, Buyong/0000-0002-7383-719X; Nussinov, Ruth/0000-0002-8115-6415	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ankerst M, 1999, Proc Int Conf Intell Syst Mol Biol, P34; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Brodersen DE, 2003, NAT STRUCT BIOL, V10, P78, DOI 10.1038/nsb0203-78; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carneiro FA, 2003, J BIOL CHEM, V278, P13789, DOI 10.1074/jbc.M210615200; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; Inagaki Y, 2002, NUCLEIC ACIDS RES, V30, P532, DOI 10.1093/nar/30.2.532; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Kjeldgaard M, 2003, MOL CELL, V11, P8, DOI 10.1016/S1097-2765(03)00015-7; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Kong CG, 2004, MOL CELL, V14, P233, DOI 10.1016/S1097-2765(04)00206-0; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Lee MS, 2003, J COMPUT CHEM, V24, P1348, DOI 10.1002/jcc.10272; Lundback T, 2000, BIOCHEMISTRY-US, V39, P8909, DOI 10.1021/bi000231i; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Park C, 2001, BIOCHEMISTRY-US, V40, P4949, DOI 10.1021/bi0100182; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Pichon C, 2001, ADV DRUG DELIVER REV, V53, P75, DOI 10.1016/S0169-409X(01)00221-6; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Uno M, 2002, P NATL ACAD SCI USA, V99, P1819, DOI 10.1073/pnas.032457599; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; Wolfson AD, 2001, COLD SPRING HARB SYM, V66, P185, DOI 10.1101/sqb.2001.66.185; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	35	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53875	53885		10.1074/jbc.M407412200	http://dx.doi.org/10.1074/jbc.M407412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475364	hybrid			2022-12-25	WOS:000225680600126
J	Patnaik, D; Chin, HG; Esteve, PO; Benner, J; Jacobsen, SE; Pradhan, S				Patnaik, D; Chin, HG; Esteve, PO; Benner, J; Jacobsen, SE; Pradhan, S			Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; LYSINE-9 METHYLATION; CATALYTIC MECHANISM; CPG METHYLATION; SUPPRESSOR GENE; STEADY-STATE; HETEROCHROMATIN; CHROMATIN; PROTEIN; ARABIDOPSIS	Lysine-specific murine histone H3 methyltransferase, G9a, was expressed and purified in a baculovirus expression system. The primary structure of the recombinant enzyme is identical to the native enzyme. Enzymatic activity was favorable at alkaline conditions (> pH 8) and low salt concentration and virtually unchanged between 25 and 42 degreesC. Purified G9a was used for substrate specificity and steady-state kinetic analysis with peptides representing un- or dimethylated lysine 9 histone H3 tails with native lysine 4 or with lysine 4 changed to alanine (K4AK9). In vitro methylation of the H3 tail peptide resulted in trimethylation of Lys-9 and the reaction is processive. The turnover number (k(cat)) for methylation was 88 and 32 h(-1) on the wild type and K4AK9 histone H3 tail, respectively. The Michaelis constants for wild type and K4AK9 (K-m(pep)) were 0.9 and 1.0 muM and for S-adenosyl-L-methionine (K-m(AdoMet)) were 1.8 and 0.6 muM, respectively. Comparable kinetic constants were obtained for recombinant histone H3. The conversion of K4AK9 di- to trimethyl-lysine was 7-fold slower than methyl group addition to unmethylated peptide. Preincubation studies showed that G9a-AdoMet and G9a-peptide complexes are catalytically active. Initial velocity data with peptide and S-adenosyl-L-methionine (AdoMet) and product inhibition studies with S-adenosyl-L-homocysteine were performed to assess the kinetic mechanism of the reaction. Double reciprocal plots and preincubation studies revealed S- adenosyl- L-homocysteine as a competitive inhibitor to AdoMet and mixed inhibitor to peptide. Trimethylated peptides acted as a competitive inhibitor to substrate peptide and mixed inhibitor to AdoMet suggesting a random mechanism in a Bi Bi reaction for recombinant G9a where either substrate can bind first to the enzyme, and either product can release first.	New England Biolabs Inc, Beverly, MA 01915 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Pradhan, S (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	pradhan@neb.com	Patnaik, Debasis/K-8779-2019; Patnaik, Debasis/A-9752-2016	Patnaik, Debasis/0000-0002-9829-3352; Patnaik, Debasis/0000-0002-9829-3352	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM060398, R01GM060398] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60398] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; BORUN TW, 1972, J BIOL CHEM, V247, P4288; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CRANKSHAW MW, 1993, PROTEIN SEQUENCE ANA, P1; Eskeland R, 2004, BIOCHEMISTRY-US, V43, P3740, DOI 10.1021/bi035964s; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Malygin EG, 2003, J BIOL CHEM, V278, P15713, DOI 10.1074/jbc.M213213200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; SEGAL IH, 1975, ENZYME KINETICS BEHA; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	38	115	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53248	53258		10.1074/jbc.M409604200	http://dx.doi.org/10.1074/jbc.M409604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485804	hybrid			2022-12-25	WOS:000225680600055
J	Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP				Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP			ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)	ONCOGENE			English	Article						mitogen-activated protein kinase (MAPK); Ras; natural killer cells	NATURAL-KILLER-CELLS; GERANYLGERANYLTRANSFERASE-I; CHROMOSOMAL-ABNORMALITIES; PERIPHERAL-BLOOD; RECEPTOR; KINASE; PROTEIN; EXPRESSION; APOPTOSIS; LEUKEMIA	Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3(-), CD16(+) or CD56(+) lymphocytes. The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation. There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy. We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease). Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells. Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas. Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL. These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.	James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Penn State Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Epling-Burnett, PK (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,Res Bldg 2,Room 115, Tampa, FL 33612 USA.	burnetpk@moffitt.usf.edu			NCI NIH HHS [R01 CA098472, CA83146, CA94872, CA90633, CA83947] Funding Source: Medline; NIAID NIH HHS [AI052613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083146, K24CA083947, R01CA090633, R01CA098472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI052613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Epling-Burnette PK, 2004, BLOOD, V103, P3431, DOI 10.1182/blood-2003-02-0400; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Husain Z, 2002, IMMUNOLOGY, V106, P373, DOI 10.1046/j.1365-2567.2002.01444.x; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Lamy T, 1998, BLOOD, V92, P4771, DOI 10.1182/blood.V92.12.4771.424k32_4771_4777; LANIER LL, 1986, J EXP MED, V163, P209, DOI 10.1084/jem.163.1.209; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lima M, 2002, BLOOD CELL MOL DIS, V28, P181, DOI 10.1006/bcmd.2002.0506; Loughran TP, 1997, BLOOD, V90, P1977, DOI 10.1182/blood.V90.5.1977; LOUGHRAN TP, 1994, LEUKEMIA RES, V18, P423, DOI 10.1016/0145-2126(94)90078-7; LOUGHRAN TP, 1985, ANN INTERN MED, V102, P169, DOI 10.7326/0003-4819-102-2-169; LOUGHRAN TP, 1993, BLOOD, V82, P1; MCVICAR DW, 2001, SCI STKE, pRE1, DOI DOI 10.1126/STKE.2001.75.RE1; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MONTAGNA D, 1992, BIOL NEONATE, V62, P385; OHNO T, 1988, CANCER-AM CANCER SOC, V62, P1918, DOI 10.1002/1097-0142(19881101)62:9<1918::AID-CNCR2820620909>3.0.CO;2-8; ORTALDO JR, 1995, J EXP MED, V181, P339, DOI 10.1084/jem.181.1.339; Perzova RN, 2000, BRIT J HAEMATOL, V109, P64, DOI 10.1046/j.1365-2141.2000.01972.x; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEMENZATO G, 1987, CANCER-AM CANCER SOC, V60, P2971, DOI 10.1002/1097-0142(19871215)60:12<2971::AID-CNCR2820601220>3.0.CO;2-O; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Sun JZ, 1999, CANCER RES, V59, P4919; Takahashi A, 2001, J IMMUNOL, V166, P6771, DOI 10.4049/jimmunol.166.11.6771; TANIWAKI M, 1990, AM J HEMATOL, V33, P32, DOI 10.1002/ajh.2830330107; TEFFERI A, 1994, BLOOD, V84, P2721; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; Zingoni A, 2000, EUR J IMMUNOL, V30, P644, DOI 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H	41	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9220	9229		10.1038/sj.onc.1208122	http://dx.doi.org/10.1038/sj.onc.1208122			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516985	Bronze			2022-12-25	WOS:000225638000007
J	Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA				Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA			Mlh1 mediates tissue-specific regulation of mitotic recombination	ONCOGENE			English	Article						Mlh1; mismatch repair; mitotic recombination; point mutation; mouse model	DNA MISMATCH REPAIR; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; MUTATOR PHENOTYPE; APC MUTATIONS; MOUSE GENOME; MICE; CELLS; DEFICIENT; HETEROZYGOSITY	Mitotic recombination (MR) between chromosome homologs in somatic cells is a major pathway to the loss of heterozygosity (LOH), which may cause cancer if tumor suppressor genes are involved. MR can be suppressed by DNA sequence heterology (homeology) in hybrid mice from matings between species or between subspecies. We now report that MR is relatively suppressed in F1 hybrids between inbred strains C57BL/6 and 129S2. The frequency of MR in fibroblasts is lower in F1 hybrid mice than in either of the two parental strains. However, MR in T cells is not affected by strain background. Thus, relatively small genetic differences are capable of restricting MR in a tissue-specific manner. Using Mlh1-deficient mice, we tested the role of mismatch repair in MR in two isogenic cell types. In fibroblasts of C57BL/6 x 129S2 F1 mice, the suppression of MR is alleviated in the absence of MLH1. In contrast, MR is not affected by Mlh1 status in T cells. The frequency of point mutations at the reporter gene loci Aprt and Hprt, on the other hand, is significantly increased in both T cells and fibroblasts of Mlh1(-/-) mice. Thus, different cell types respond differently to MLH1 deficiency, and the contribution of MR to tumorigenesis may be tissue-dependent in the absence of mismatch repair.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University System of Ohio; University of Cincinnati	Shao, CS (corresponding author), Rutgers State Univ, Dept Genet, 604 Allison Rd, Piscataway, NJ 08854 USA.	shao@biology.rutgers.edu; jay@biology.rutgers.edu	Kucherlapati, Raju/ABC-8807-2021; Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIEHS NIH HHS [R01ES011633] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011633] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cervantes RB, 2002, P NATL ACAD SCI USA, V99, P3586, DOI 10.1073/pnas.062527199; Datta A, 1996, MOL CELL BIOL, V16, P1085; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hall MC, 2003, NUCLEIC ACIDS RES, V31, P2025, DOI 10.1093/nar/gkg324; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; LOEB LA, 1991, CANCER RES, V51, P3075; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2002, ONCOGENE, V21, P2840, DOI 10.1038/sj.onc.1205358; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Shin CY, 2002, DNA REPAIR, V1, P995, DOI 10.1016/S1568-7864(02)00149-0; Shin CY, 2002, ONCOGENE, V21, P1768, DOI 10.1038/sj.onc.1205241; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wijnhoven SWP, 2003, CARCINOGENESIS, V24, P139, DOI 10.1093/carcin/24.1.139; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9017	9024		10.1038/sj.onc.1208148	http://dx.doi.org/10.1038/sj.onc.1208148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480418				2022-12-25	WOS:000225492800002
J	Ott, MC; Scott, JR; Bihari, A; Badhwar, A; Otterbein, LE; Gray, DK; Harris, KA; Potter, RF				Ott, MC; Scott, JR; Bihari, A; Badhwar, A; Otterbein, LE; Gray, DK; Harris, KA; Potter, RF			Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion	FASEB JOURNAL			English	Article						heme oxygenase; microcirculation; leukocyte adhesion	REMOTE HEPATIC-INJURY; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; HEME OXYGENASE-1; LEUKOCYTE RECRUITMENT; ISCHEMIA-REPERFUSION; PARENCHYMAL INJURY; SINUSOIDAL TONE; ORGAN FAILURE; SMOOTH-MUSCLE	The induction of heme oxygenase (HO), the rate limiting enzyme in the conversion of heme into carbon monoxide (CO) and biliverdin, limits liver injury following remote trauma such as hind limb ischemia/reperfusion (I/R). Using intravital video microscopy, we tested the hypothesis that inhaled CO (250 ppm) would mimic HO-derived liver protection. Hind limb I/R significantly decreased sinusoidal diameter and volumetric flow, increased leukocyte accumulation within sinusoids, increased leukocyte rolling and adhesion within postsinusoidal venules, and significantly increased hepatocyte injury compared with naive animals. Inhalation of CO alone did not alter any microcirculatory or inflammatory parameters. Inhalation of CO following I/R restored volumetric flow, decreased stationary leukocytes within sinusoids, decreased leukocyte rolling and adhesion within postsinusoidal venules, and significantly reduced hepatocellular injury following hind limb I/R. HO inhibition did not alter microcirculatory parameters in naive mice, but did increase inflammation, as well as increase hepatocyte injury following hind limb I/R. Inhalation of CO during HO inhibition significantly reduced such microcirculatory deficits, hepatic inflammation, and injury in response to hind limb I/R. In conclusion, these results suggest that HO-derived hepatic protection is mediated by CO, and inhalation of low concentrations of CO may represent a novel therapeutic approach to prevent remote organ injury during systemic inflammatory response syndrome, or SIRS.	Victoria Res Labs, Ctr Crit Illness Res, Lawson Hlth Res Inst, London, ON N6A 4G5, Canada; Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; London Hlth Sci Ctr, Dept Gen Surg, London, ON, Canada	Western University (University of Western Ontario); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; London Health Sciences Centre	Potter, RF (corresponding author), Victoria Res Labs, Ctr Crit Illness Res, Lawson Hlth Res Inst, 6th Floor,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	rpotter@uwo.ca		Ott, Michael/0000-0002-0816-7089				Alberti C, 2003, AM J RESP CRIT CARE, V168, P77, DOI 10.1164/rccm.200208-785OC; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brock RW, 1999, AM J PHYSIOL-GASTR L, V277, pG55, DOI 10.1152/ajpgi.1999.277.1.G55; Brock RW, 2001, AM J PHYSIOL-GASTR L, V280, pG279, DOI 10.1152/ajpgi.2001.280.2.G279; Brock RW, 1999, HEPATOLOGY, V30, P137, DOI 10.1002/hep.510300132; Brun-Buisson C, 2000, INTENS CARE MED, V26, pS64, DOI 10.1007/s001340051121; Fondevila C, 2003, TRANSPLANT P, V35, P1798, DOI 10.1016/S0041-1345(03)00720-6; Fox-Robichaud A, 2000, HEPATOLOGY, V31, P1123, DOI 10.1053/he.2000.6961; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Harbrecht BG, 2002, J TRAUMA, V53, P517, DOI 10.1097/00005373-200209000-00020; Harbrecht BG, 2001, AM SURGEON, V67, P122; Iwasashi H, 2003, SURG TODAY, V33, P30, DOI 10.1007/s005950300005; JAESCHKE H, 2003, SHOCK, V18, P152; Kato Y, 2003, HEPATOLOGY, V38, P364, DOI 10.1053/jhep.2003.50300; Katori M, 2002, TRANSPL IMMUNOL, V9, P227, DOI 10.1016/S0966-3274(02)00043-6; Lalor PF, 2002, J IMMUNOL, V169, P983, DOI 10.4049/jimmunol.169.2.983; Lawlor DK, 1999, J VASC SURG, V30, P533, DOI 10.1016/S0741-5214(99)70081-9; McCarter SD, 2003, GENE THER, V10, P1629, DOI 10.1038/sj.gt.3302063; Menezes J, 1999, AM J PHYSIOL-GASTR L, V277, pG144, DOI 10.1152/ajpgi.1999.277.1.G144; Moore BA, 2003, GASTROENTEROLOGY, V124, P377, DOI 10.1053/gast.2003.50060; Morisaki H, 2002, ANESTHESIOLOGY, V97, P701, DOI 10.1097/00000542-200209000-00025; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Nie RG, 2002, J HEPATOL, V36, P624, DOI 10.1016/S0168-8278(02)00025-9; Ohlmann A, 2003, EXP BIOL MED, V228, P584, DOI 10.1177/15353702-0322805-51; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 1999, CHEST, V116, p61S, DOI 10.1378/chest.116.suppl_1.61S-a; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; Rensing H, 2002, HEPATOLOGY, V36, P1453, DOI 10.1053/jhep.2002.36934; Rensing H, 1999, CRIT CARE MED, V27, P2766, DOI 10.1097/00003246-199912000-00027; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Sass G, 2001, J CLIN INVEST, V107, P439, DOI 10.1172/JCI10613; Scott JR, 2002, AM J PHYSIOL-GASTR L, V283, pG561, DOI 10.1152/ajpgi.00462.2001; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Tanaka Jin, 2003, Leg Med (Tokyo), V5, P146, DOI 10.1016/S1344-6223(03)00076-2; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; Vachharajani TJ, 2000, AM J PHYSIOL-HEART C, V278, pH1613, DOI 10.1152/ajpheart.2000.278.5.H1613; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Wunder C, 2002, J PHYSIOL-LONDON, V540, P1013, DOI 10.1113/physiol.2001.015446; Xiang L, 2003, INFLAMM RES, V52, P353, DOI 10.1007/s00011-003-1184-6; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003; Zuckerbraun BS, 2003, HEPATOLOGY, V37, P742, DOI 10.1053/jhep.2003.50139	50	48	56	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					106	+		10.1096/fj.04-2514fje	http://dx.doi.org/10.1096/fj.04-2514fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15514102				2022-12-25	WOS:000224849900003
J	Komissarov, AA; Andreasen, PA; Bodker, JS; Declerck, PJ; Anagli, JY; Shore, JD				Komissarov, AA; Andreasen, PA; Bodker, JS; Declerck, PJ; Anagli, JY; Shore, JD			Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEASE COMPLEX; CENTER LOOP INSERTION; TUMOR-GROWTH; MECHANISM; THROMBIN; BINDING; TYPE-1; NEUTRALIZATION; PURIFICATION; SUBSTRATE	The serpin plasminogen activator inhibitor-1 (PAI-1) is a potential therapeutic target in cardiovascular and cancerous diseases. PAI-1 circulates in blood as a complex with vitronectin. A PAI-1 variant (N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-3-diazole (NBD) P9 PAI-1) with a fluorescent tag at the reactive center loop (RCL) was used to study the effects of vitronectin and monoclonal antibodies (mAbs) directed against alpha-helix F (Mab-2 and MA-55F4C12) on the reactions of PAI-1 with tissue-type and urokinase-type plasminogen activators. Both mAbs delay the RCL insertion and induce an increase in the stoichiometry of inhibition (SI) to 1.4-9.5. Binding of vitronectin to NBD P9 PAI-1 does not affect SI but results in a 2.0-6.5-fold decrease in the limiting rate constant (k(lim)) of RCL insertion for urokinase-type plasminogen activator at pH 6.2-8.0 and for tissue-type plasminogen activator at pH 6.2. Binding of vitronectin to the complexes of NBD P9 PAI-1 with mAbs results in a decrease in klim and in a 1.5-22-fold increase in SI. Thus, vitronectin and mAbs demonstrated additivity in the effects on the reaction with target proteinases. The same step in the reaction mechanism remains limiting for the rate of RCL insertion in the absence and presence of Vn and mAbs. We hypothesize that vitronectin, bound to alpha-helix F on the side opposite to the epitopes of the mAbs, potentiates the mAb-induced delay in RCL insertion and the associated substrate behavior by selectively decreasing the rate constant for the inhibitory branch of PAI-1 reaction (k(i)). These results demonstrate that mAbs represent a valid approach for inactivation of vitronectin-bound PAI-1 in vivo.	Henry Ford Hlth Syst, Div Biochem Res, Dept Pathol, Detroit, MI 48202 USA; Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, DK-8000 Aarhus, Denmark; Catholic Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital; Aarhus University; Universite Catholique Louvain	Komissarov, AA (corresponding author), Henry Ford Hlth Sci Ctr, Div Biochem Res, Dept Pathol, 1 Ford Pl,5D, Detroit, MI 48202 USA.	akomiss1@hfhs.org	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NHLBI NIH HHS [HL 54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Coombs GS, 1998, J BIOL CHEM, V273, P4323, DOI 10.1074/jbc.273.8.4323; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Gils A, 2004, THROMB HAEMOSTASIS, V91, P425, DOI 10.1160/TH03-12-0764; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ibarra CA, 2004, J BIOL CHEM, V279, P3643, DOI 10.1074/jbc.M310601200; Jensen JK, 2004, FEBS LETT, V556, P175, DOI 10.1016/S0014-5793(03)01405-4; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Komissarov AA, 2004, J BIOL CHEM, V279, P23007, DOI 10.1074/jbc.M401383200; Komissarov AA, 2002, J BIOL CHEM, V277, P43858, DOI 10.1074/jbc.M204110200; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Renatus M, 1997, J BIOL CHEM, V272, P21713, DOI 10.1074/jbc.272.35.21713; Rezaie AR, 2001, J BIOL CHEM, V276, P15567, DOI 10.1074/jbc.C100123200; Schousboe SL, 2000, THROMB HAEMOSTASIS, V83, P742, DOI 10.1055/s-0037-1613903; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; Urano T, 2000, SEMIN THROMB HEMOST, V26, P39, DOI 10.1055/s-2000-9801; vanMeijer M, 1997, BLOOD, V90, P1874, DOI 10.1182/blood.V90.5.1874; vanMeijer M, 1997, THROMB HAEMOSTASIS, V77, P516; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; Wind T, 2002, BIOL CHEM, V383, P21, DOI 10.1515/BC.2002.003; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	43	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1482	1489		10.1074/jbc.M408608200	http://dx.doi.org/10.1074/jbc.M408608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516335	hybrid			2022-12-25	WOS:000226195200077
J	Mangoni, ML; Saugar, JM; Dellisanti, M; Barra, D; Simmaco, M; Rivas, L				Mangoni, ML; Saugar, JM; Dellisanti, M; Barra, D; Simmaco, M; Rivas, L			Temporins, small antimicrobial peptides with leishmanicidal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI PROMASTIGOTES; MEMBRANE PERMEABILIZATION; ANTIBACTERIAL PROTEINS; MECHANISM; SKIN; MELITTIN; BINDING; MICROORGANISMS; PURIFICATION; CHEMOTHERAPY	Leishmaniasis encompasses a wide range of infections caused by the human parasitic protozoan species belonging to the Leishmania genus. It appears frequently as an opportunistic disease, especially in virus-infected immunodepressed people. Similarly to other pathogens, parasites became resistant to most of the first-line drugs. Therefore, there is an urgent need to develop antiparasitic agents with new modes of action. Gene-encoded antimicrobial peptides are promising candidates, but so far only a few of them have shown antiprotozoa activities. Here we found that temporins A and B, 13-amino acid antimicrobial peptides secreted from the skin of the European red frog Rana temporaria, display anti-Leishmania activity at micromolar concentrations, with no cytolytic activity against human erythrocytes. To the best of our knowledge, temporins represent the shortest natural peptides having the highest leishmanicidal activity and the lowest number of positively charged amino acids ( a single lysine/arginine) and maintain biological function in serum. Their lethal mechanism involves plasma membrane permeation based on the following data. (i) They induce a rapid collapse of the plasma membrane potential. (ii) They induce the influx of the vital dye SYTOXTM Green. (iii) They reduce intracellular ATP levels. (iv) They severely damage the membrane of the parasite, as shown by transmission electron microscopy. Besides giving us basic important information, the unique properties of temporins, as well as their membranolytic effect, which should make it difficult for the pathogen to develop resistance, suggest them as potential candidates for the future design of antiparasitic drugs with a new mode of action.	Azienda Osped S Andrea, Dipartimento Sci Biochim A Rossi Fanelli, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Fondazione Cenci Bolognetti; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Mangoni, ML (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	marialuisa.mangoni@uniroma1.it	Simmaco, Maurizio/AAC-2870-2019; Rivas, Luis/O-8657-2017; Barra, Donatella/D-1236-2011; Saugar, Jose M./C-7047-2008	Simmaco, Maurizio/0000-0003-4164-1472; Rivas, Luis/0000-0002-2958-3233; Saugar, Jose M./0000-0001-8950-5766; Mangoni, Maria Luisa/0000-0002-5991-5868				BAKER MA, 1993, CANCER RES, V53, P3052; Bera A, 2003, MOL BIOCHEM PARASIT, V127, P23, DOI 10.1016/S0166-6851(02)00300-6; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Croft SL, 2002, CURR PHARM DESIGN, V8, P319, DOI 10.2174/1381612023396258; De Lucca AJ, 2000, EXPERT OPIN INV DRUG, V9, P273, DOI 10.1517/13543784.9.2.273; De Lucca AJ, 1998, MED MYCOL, V36, P291, DOI 10.1080/02681219880000461; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; DIAZACHIRICA P, 1996, PEPTIDES CHEM STRUCT, P183; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Guerrero E, 2004, ANTIMICROB AGENTS CH, V48, P2980, DOI 10.1128/AAC.48.8.2980-2986.2004; Halverson T, 2000, PEPTIDES, V21, P469, DOI 10.1016/S0196-9781(00)00178-9; Handman E, 2000, ADV PARASIT, V44, P1; HANKS JH, 1958, P SOC EXP BIOL MED, V98, P188, DOI 10.3181/00379727-98-23985; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Kim JB, 2000, REGUL PEPTIDES, V90, P53, DOI 10.1016/S0167-0115(00)00107-5; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; Luque-Ortega JR, 2003, BIOCHEM J, V375, P221, DOI 10.1042/BJ20030544; Luque-Ortega JR, 2001, ANTIMICROB AGENTS CH, V45, P1121, DOI 10.1128/AAC.45.4.1121-1125.2001; Mangoni ML, 2000, EUR J BIOCHEM, V267, P1447, DOI 10.1046/j.1432-1327.2000.01143.x; Mbongo N, 1998, ANTIMICROB AGENTS CH, V42, P352; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; Mor A, 2000, DRUG DEVELOP RES, V50, P440, DOI 10.1002/1098-2299(200007/08)50:3/4<440::AID-DDR27>3.3.CO;2-W; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Oh H, 2000, ANTIMICROB AGENTS CH, V44, P68, DOI 10.1128/AAC.44.1.68-72.2000; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; PAN AA, 1984, J PARASITOL, V70, P834, DOI 10.2307/3281780; Papo N, 2003, BIOCHEMISTRY-US, V42, P9346, DOI 10.1021/bi027212o; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806; Rinaldi AC, 2001, J PEPT RES, V58, P213, DOI 10.1034/j.1399-3011.2001.00896.x; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; Thevissen K, 1999, APPL ENVIRON MICROB, V65, P5451; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; VanHellemond JJ, 1997, PARASITOLOGY, V114, P351, DOI 10.1017/S0031182096008591; Vizioli J, 2002, TRENDS PARASITOL, V18, P475, DOI 10.1016/S1471-4922(02)02428-5; Vouldoukis I, 1996, FEBS LETT, V380, P237, DOI 10.1016/0014-5793(96)00050-6; Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731; Wade D, 2000, FEBS LETT, V479, P6, DOI 10.1016/S0014-5793(00)01754-3; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e	60	165	168	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					984	990		10.1074/jbc.M410795200	http://dx.doi.org/10.1074/jbc.M410795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15513914	Green Published, hybrid			2022-12-25	WOS:000226195200017
J	Robichon, C; Vidal-Ingigliardi, D; Pugsley, AP				Robichon, C; Vidal-Ingigliardi, D; Pugsley, AP			Depletion of apolipoprotein N-acyltransferase causes mislocalization of outer membrane lipoproteins in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDASE; SORTING SIGNALS; CLONING VECTORS; LOCALIZATION; PROTEIN; TRANSPORTER; SEQUENCE; ACID; SECRETION; TOPOLOGY	Lipoproteins in Gram-negative Enterobacteriaceae carry three fatty acids on the N-terminal cysteine residue, two as a diacylglyceride and one through an N-linkage following signal peptide cleavage. Most lipoproteins are anchored in the outer membrane, facing the periplasm, but some lipoproteins remain in the plasma membrane, depending on the amino acid at position +2, immediately after the fatty-acylated cysteine. In vitro, the last step in lipoprotein maturation, N-acylation of apolipoproteins by the plasma membrane apolipoprotein N-acyltransferase (Lnt), is necessary for efficient recognition of outer membrane lipoproteins by the Lol system, which transports them from the plasma to the outer membrane (Fukuda, A., Matsuyama, S.-I., Hara, T., Nakayama, J., Nagasawa, H., and Tokuda, H. (2002) J. Biol. Chem. 277, 43512 - 43518). To study the role of Lnt in vivo, we constructed a conditional lnt mutant of Escherichia coli. The apo-form of peptidoglycan-anchored major lipoprotein (Lpp) and two other outer membrane lipoproteins accumulated in the plasma membrane when lnt expression was reduced. We also found that Lnt is an essential protein in E. coli and that the lethality is partially because of the retention of apoLpp in the plasma membrane. Topology mapping of Lnt with beta-galactosidase and alkaline phosphatase fusions indicated the presence of six membrane- spanning segments. The lnt gene in a mutant of Salmonella enterica displaying thermosensitive Lnt activity (Gupta, S. D., Gan, K., Schmid, M. B., and Wu, H. C. ( 1993) J. Biol. Chem. 268, 16551 - 16556) was found to carry a mutation causing a single glutamate to lysine substitution at a highly conserved position in the last predicted periplasmic loop of the protein.	Inst Pasteur, Mol Genet Unit, CNRS, URA2172, F-75724 Paris 5, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pugsley, AP (corresponding author), Inst Pasteur, Mol Genet Unit, CNRS, URA2172, 25 Rue Dr Roux, F-75724 Paris 5, France.	max@pasteur.fr						Babu MM, 2002, BIOINFORMATICS, V18, P641, DOI 10.1093/bioinformatics/18.4.641; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; Clavel T, 1998, MOL MICROBIOL, V29, P359, DOI 10.1046/j.1365-2958.1998.00945.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; GENNITY JM, 1992, J BACTERIOL, V174, P2095, DOI 10.1128/JB.174.7.2095-2101.1992; GUPTA SD, 1993, J BIOL CHEM, V268, P16551; GUPTA SD, 1991, FEMS MICROBIOL LETT, V78, P37; GUPTA SD, 1995, J BACTERIOL, V177, P4207, DOI 10.1128/jb.177.15.4207-4215.1995; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HAYASHI S, 1985, J BIOL CHEM, V260, P5753; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; Hu LA, 1998, BIOCHEM J, V336, P69, DOI 10.1042/bj3360069; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; ICHIHARA S, 1981, J BIOL CHEM, V256, P3125; ICHIKAWA JK, 1994, J BACTERIOL, V176, P1630, DOI 10.1128/jb.176.6.1630-1638.1994; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIN JJC, 1978, P NATL ACAD SCI USA, V75, P4891, DOI 10.1073/pnas.75.10.4891; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MORENO F, 1980, NATURE, V286, P356, DOI 10.1038/286356a0; Narita S, 2003, MOL MICROBIOL, V49, P167, DOI 10.1046/j.1365-2958.2003.03569.x; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; PUGSLEY AP, 1991, J BIOL CHEM, V266, P13640; RICHET E, 1994, EMBO J, V13, P4558, DOI 10.1002/j.1460-2075.1994.tb06777.x; Robichon C, 2003, MOL MICROBIOL, V49, P1145, DOI 10.1046/j.1365-2958.2003.03654.x; ROGERS SD, 1991, J BACTERIOL, V173, P6742, DOI 10.1128/jb.173.21.6742-6748.1991; SARSERO JP, 1995, J BACTERIOL, V177, P297, DOI 10.1128/jb.177.2.297-306.1995; SAUVONNET N, 1995, J BACTERIOL, V177, P5238, DOI 10.1128/jb.177.18.5238-5246.1995; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Shu W, 2000, J MOL BIOL, V299, P1101, DOI 10.1006/jmbi.2000.3776; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; Suzuki M, 2002, J BACTERIOL, V184, P5418, DOI 10.1128/JB.184.19.5418-5425.2002; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Tiwari RP, 1996, MICROBIOL-SGM, V142, P601, DOI 10.1099/13500872-142-3-601; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; VONHEIJNE G, 1980, BIOCHEM BIOPH RES CO, V93, P82, DOI 10.1016/S0006-291X(80)80248-8; Wu HC, 1996, ESCHERICHIA COLI SAL, V1, P1005; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YAMAGUCHI K, 1988, J BACTERIOL, V170, P3747, DOI 10.1128/jb.170.8.3747-3749.1988	52	84	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					974	983		10.1074/jbc.M411059200	http://dx.doi.org/10.1074/jbc.M411059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15513925	hybrid			2022-12-25	WOS:000226195200016
J	Jogl, G; Hsiao, YS; Tong, L				Jogl, G; Hsiao, YS; Tong, L			Crystal structure of mouse carnitine octanoyltransferase and molecular determinants of substrate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ANOMALOUS DIFFRACTION; LIVER PEROXISOMES; ACETYLTRANSFERASE; PALMITOYLTRANSFERASE; SYSTEM; ACYLTRANSFERASES; MITOCHONDRIA; SPECIFICITY; TRANSPORT	Carnitine acyltransferases have crucial functions in fatty acid metabolism. Members of this enzyme family show distinctive substrate preferences for short-, medium- or long-chain fatty acids. The molecular mechanism for this substrate selectivity is not clear as so far only the structure of carnitine acetyltransferase has been determined. To further our understanding of these important enzymes, we report here the crystal structures at up to 2.0-resolution of mouse carnitine octanoyltransferase alone and in complex with the substrate octanoylcarnitine. The structures reveal significant differences in the acyl group binding pocket between carnitine octanoyltransferase and carnitine acetyltransferase. Amino acid substitutions and structural changes produce a larger hydrophobic pocket that binds the octanoyl group in an extended conformation. Mutation of a single residue (Gly-553) in this pocket can change the substrate preference between short- and medium- chain acyl groups. The side chains of Cys-323 and Met-335 at the bottom of this pocket assume dual conformations in the substrate complex, and mutagenesis studies suggest that the Met-335 residue is important for catalysis.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; Tong, Liang/0000-0002-0563-6468	NIDDK NIH HHS [DK67238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai YY, 2004, EMBO J, V23, P2047, DOI 10.1038/sj.emboj.7600221; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Cordente AG, 2004, J BIOL CHEM, V279, P33899, DOI 10.1074/jbc.M402685200; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; DeLano W, 2002, PYMOL 0 99; FARRELL SO, 1983, ARCH BIOCHEM BIOPHYS, V222, P123, DOI 10.1016/0003-9861(83)90509-X; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Giannessi F, 2001, J MED CHEM, V44, P2383, DOI 10.1021/jm010889+; Govindasamy L, 2004, J STRUCT BIOL, V146, P416, DOI 10.1016/j.jsb.2004.01.011; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hsiao YS, 2004, J BIOL CHEM, V279, P31584, DOI 10.1074/jbc.M403484200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramsay RR, 1999, AM J MED SCI, V318, P28, DOI 10.1097/00000441-199907000-00005; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1987, BIOCHEM J, V244, P271, DOI 10.1042/bj2440271; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Sigauke E, 2003, LAB INVEST, V83, P1543, DOI 10.1097/01.LAB.0000098428.51765.83; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Wagman AS, 2001, CURR PHARM DESIGN, V7, P417, DOI 10.2174/1381612013397915; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	36	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					738	744		10.1074/jbc.M409894200	http://dx.doi.org/10.1074/jbc.M409894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492013	hybrid			2022-12-25	WOS:000226025100087
J	Ko, K; Taylor, D; Argenton, P; Innes, J; Pedram, B; Seibert, F; Granell, A; Ko, Z				Ko, K; Taylor, D; Argenton, P; Innes, J; Pedram, B; Seibert, F; Granell, A; Ko, Z			Evidence that the plastid translocon Tic40 components possess modulating capabilities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT APPARATUS; ENVELOPE MEMBRANE; CHLOROPLAST; RECEPTOR; PRECURSOR; TOC159; ACCUMULATION; EXPRESSION; ATTOC159; HOMOLOGS	The transport of proteins into the plastid is a process that faces changing cellular needs such as the situation found in different plant organs or developing tissues. The plastid translocon must therefore be responsive to the changing cell environment to deliver efficiently different arrays of structurally diverse proteins. Although the Tic40-related envelope proteins appear to be translocon components designed to address the varying needs of protein translocation, details of their involvement remain elusive. This study was thus designed to combine plant-based experiments and yeast mitochondrion-based approaches for unveiling clues related to how the Tic40 components may behave during the protein translocation process. The main findings related to how Tic40 proteins may work are: 1) natural fluctuations are apparent in developing tissues, in different organs of the same plant, and in different species; 2) transgenic Arabidopsis seedlings can tolerate functionally a wide range of variations in Tic40 levels, from partial suppression to excessive production; 3) the Tic40 proteins themselves exhibit configurational changes in their association with yeast mitochondria in response to different carbon sources; 4) the presence of Tic40 proteins in yeast mitochondria influences regulatory aspects of the mitochondrial translocon; and 5) the Tic40 proteins associate with mitochondrial translocon components involved in regulatory-like events. The combined data provide evidence that Tic40 proteins possess modulating capabilities.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Univ Politecn Valencia, Consejo Super Invest Cient, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain	Queens University - Canada; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Ko, Z (corresponding author), Queens Univ, Dept Biol, Biosci Complex, Kingston, ON K7L 3N6, Canada.	kok@biology.queensu.ca	Granell, Antonio/G-3664-2010					Aronsson H, 2002, FEBS LETT, V529, P215, DOI 10.1016/S0014-5793(02)03342-2; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Chou ML, 2003, EMBO J, V22, P2970, DOI 10.1093/emboj/cdg281; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DAUM G, 1982, J BIOL CHEM, V257, P3028; Fitzpatrick LM, 2001, PLANT J, V27, P59, DOI 10.1046/j.0960-7412.2001.01061.x; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gordon B, 2002, ARCH BIOCHEM BIOPHYS, V404, P147, DOI 10.1016/S0003-9861(02)00281-3; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Heins L, 2002, EMBO J, V21, P2616, DOI 10.1093/emboj/21.11.2616; Hiltbrunner A, 2004, PLANT MOL BIOL, V54, P427, DOI 10.1023/B:PLAN.0000036374.92546.51; Hiltbrunner A, 2001, BIOCHEM CELL BIOL, V79, P629, DOI 10.1139/bcb-79-5-629; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Ivanova Y, 2004, MOL BIOL CELL, V15, P3379, DOI 10.1091/mbc.E03-12-0923; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Jarvis P, 2001, BBA-MOL CELL RES, V1541, P64, DOI 10.1016/S0167-4889(01)00147-1; JASCUR T, 1991, METHOD CELL BIOL, V34, P359; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; KLEE HJ, 1985, BIO-TECHNOL, V3, P637, DOI 10.1038/nbt0785-637; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Ko K, 2004, FUNCT PLANT BIOL, V31, P285, DOI 10.1071/FP03195; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; Kubis S, 2004, PLANT CELL, V16, P2059, DOI 10.1105/tpc.104.023309; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Melo PM, 2003, PLANT PHYSIOL, V132, P390, DOI 10.1104/pp.102.016675; Pang P, 1997, J BIOL CHEM, V272, P25623, DOI 10.1074/jbc.272.41.25623; PLAXTON WC, 1989, EUR J BIOCHEM, V181, P443, DOI 10.1111/j.1432-1033.1989.tb14745.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Smith MD, 2004, J CELL BIOL, V165, P323, DOI 10.1083/jcb.200311074; Soll J, 2002, CURR OPIN PLANT BIOL, V5, P529, DOI 10.1016/S1369-5266(02)00296-0; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; Sun CW, 2001, PLANT CELL, V13, P2053, DOI 10.1105/tpc.13.9.2053; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; Vojta A, 2004, J BIOL CHEM, V279, P21401, DOI 10.1074/jbc.M401968200; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; WU CB, 1994, J BIOL CHEM, V269, P32264; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; Yu TS, 2001, PLANT PHYSIOL, V127, P90, DOI 10.1104/pp.127.1.90	43	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					215	224		10.1074/jbc.M410088200	http://dx.doi.org/10.1074/jbc.M410088200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513916	hybrid			2022-12-25	WOS:000226025100027
J	Oh, KJ; Barbuto, S; Meyer, N; Kim, RS; Collier, RJ; Korsmeyer, SJ				Oh, KJ; Barbuto, S; Meyer, N; Kim, RS; Collier, RJ; Korsmeyer, SJ			Conformational changes in BID, a pro-apoptotic BCL-2 family member, upon membrane binding - A site-directed spin labeling study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TOXIN-T DOMAIN; OUTER MITOCHONDRIAL-MEMBRANE; DIPHTHERIA-TOXIN; CRYSTAL-STRUCTURE; CELL-DEATH; BACILLUS-THURINGIENSIS; OLIGOMERIZES BAK; DELTA-ENDOTOXIN; CONTACT SITES	The BCL-2 family proteins constitute a critical control point in apoptosis. BCL-2 family proteins display structural homology to channel-forming bacterial toxins, such as colicins, transmembrane domain of diphtheria toxin, and the N-terminal domain of delta-endotoxin. By analogy, it has been hypothesized the BCL-2 family proteins would unfold and insert into the lipid bilayer upon membrane association. We applied the site-directed spin labeling method of electron paramagnetic resonance spectroscopy to the pro-apoptotic member BID. Here we show that helices 6-8 maintain an alpha-helical conformation in membranes with a lipid composition resembling mitochondrial outer membrane contact sites. However, unlike colicins and the transmembrane domain of diphtheria toxin, these helices of BID are bound to the lipid bilayer without adopting a transmembrane orientation. Our study presents a more detailed model for the reorganization of the structure of tBID on membranes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med,Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Korsmeyer, SJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med,Dana Farber Canc Inst, Boston, MA 02115 USA.	Stanley_korsmeyer@dfci.harvard.edu		OH, KYOUNG JOON/0000-0002-4729-9674	NATIONAL CANCER INSTITUTE [P01CA068484] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA68484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Esposti MD, 2002, CELL DEATH DIFFER, V9, P234, DOI 10.1038/sj.cdd.4400997; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; Franzin CM, 2004, MAGN RESON CHEM, V42, P172, DOI 10.1002/mrc.1322; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gong XM, 2004, J BIOL CHEM, V279, P28954, DOI 10.1074/jbc.M403490200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Hochman A, 1998, J NEUROCHEM, V71, P741; Hu X, 2003, APOPTOSIS, V8, P277, DOI 10.1023/A:1023676906857; Huang QL, 2003, J MOL BIOL, V332, P1123, DOI 10.1016/j.jmb.2003.08.007; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Hubbell WL, 1994, MEMBRANE PROTEIN STR, P244; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kachel K, 1998, J BIOL CHEM, V273, P22950, DOI 10.1074/jbc.273.36.22950; Kienker PK, 1997, J MEMBRANE BIOL, V157, P27, DOI 10.1007/s002329900213; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Oh KJ, 1999, BIOCHEMISTRY-US, V38, P10336, DOI 10.1021/bi990520a; Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; Oh KJ, 2000, METH MOL B, V145, P147; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	78	73	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					753	767		10.1074/jbc.M405428200	http://dx.doi.org/10.1074/jbc.M405428200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501827	hybrid			2022-12-25	WOS:000226025100089
J	Helmlinger, D; Bonnet, J; Mandel, JL; Trottier, Y; Devys, D				Helmlinger, D; Bonnet, J; Mandel, JL; Trottier, Y; Devys, D			Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; INHIBITS HUNTINGTIN AGGREGATION; TRUNCATED ANDROGEN RECEPTOR; BULBAR MUSCULAR-ATROPHY; HEAT-SHOCK PROTEINS; POLYGLUTAMINE DISEASE; MOLECULAR CHAPERONES; MOUSE MODEL; MEDIATED NEURODEGENERATION; CELLULAR TOXICITY	Nine neurodegenerative diseases, including spinocerebellar ataxia type 7 (SCA7), are caused by the expansion of polyglutamine stretches in the respective disease-causing proteins. A hallmark of these diseases is the aggregation of expanded polyglutamine-containing proteins in nuclear inclusions that also accumulate molecular chaperones and components of the ubiquitin-proteasome system. Manipulation of HSP70 and HSP40 chaperone levels has been shown to suppress aggregates in cellular models, prevent neuronal death in Drosophila, and improve to some extent neurological symptoms in mouse models. An important issue in mammals is the relative expression levels of toxic and putative rescuing proteins. Furthermore, overexpression of both HSP70 and its co-factor HSP40/HDJ2 has never been investigated in mice. We decided to address this question in a SCA7 transgenic mouse model that progressively develops retinopathy, similar to SCA7 patients. To co-express HSP70 and HDJ2 with the polyglutamine protein, in the same cell type, at comparable levels and with the same time course, we generated transgenic mice that express the heat shock proteins specifically in rod photoreceptors. While co-expression of HSP70 with its co-factor HDJ2 efficiently suppressed mutant ataxin-7 aggregation in transfected cells, they did not prevent either neuronal toxicity or aggregate formation in SCA7 mice. Furthermore, nuclear inclusions in SCA7 mice were composed of a cleaved mutant ataxin-7 fragment, whereas they contained the full-length protein in transfected cells. We propose that differences in the aggregation process might account for the different effects of chaperone overexpression in cellular and animal models of polyglutamine diseases.	Coll France, CNRS,INSERM ULP, Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Devys, D (corresponding author), Coll France, CNRS,INSERM ULP, Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol, BP 10142, F-67404 Illkirch Graffenstaden, France.	devys@igbmc.u-strasbg.fr	Helmlinger, Dom/T-4419-2019; Trottier, Yvon/H-8852-2016; Mandel, Jean Louis/Q-2668-2016	Trottier, Yvon/0000-0001-7230-4810; Mandel, Jean Louis/0000-0002-0535-6589; Helmlinger, Dom/0000-0003-1501-0423; Devys, Didier/0000-0001-9655-3512				Adachi H, 2003, J NEUROSCI, V23, P2203; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Ghosh S, 2004, HUM MOL GENET, V13, P2011, DOI 10.1093/hmg/ddh214; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Helmlinger D, 2004, J NEUROSCI, V24, P1881, DOI 10.1523/JNEUROSCI.4407-03.2004; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Mauger C, 1999, MOL BRAIN RES, V74, P35, DOI 10.1016/S0169-328X(99)00256-9; Michalik A, 2004, EUR J HUM GENET, V12, P2, DOI 10.1038/sj.ejhg.5201108; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Mitsui K, 2002, J NEUROSCI, V22, P9267; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Opal P, 2002, TRENDS MOL MED, V8, P232, DOI 10.1016/S1471-4914(02)02310-9; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Takahashi J, 2002, BRAIN, V125, P1534, DOI 10.1093/brain/awf154; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2000, HUM MOL GENET, V9, P2491, DOI 10.1093/hmg/9.17.2491; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55969	55977		10.1074/jbc.M409062200	http://dx.doi.org/10.1074/jbc.M409062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494410	hybrid, Green Published			2022-12-25	WOS:000225960800120
J	Llamas, A; Mendel, RR; Schwarz, N				Llamas, A; Mendel, RR; Schwarz, N			Synthesis of adenylated molybdopterin - An essential step for molybdenum insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MOEA; CRYSTAL-STRUCTURE; COFACTOR BIOSYNTHESIS; PROTEIN; SYNTHASE; DEHYDROGENASE; MECHANISM; MOLYBDATE; BINDING; IDENTIFICATION	The molybdenum cofactor (Moco) is part of the active site of all molybdenum (Mo)-dependent enzymes, except nitrogenase. Moco consists of molybdopterin (MPT), a phosphorylated pyranopterin with an ene-dithiolate coordinating Mo and it is synthesized by an evolutionary old multistep pathway. The plant protein Cnx1 from Arabidopsis thaliana catalyzes with its two domains ( E and G) the terminal step of Moco biosynthesis, the insertion of Mo into MPT. Recently, the high-resolution MPT-bound structure of the Cnx1 G domain (Cnx1G) has been determined (Kuper, J., Llamas, A., Hecht, H. J., Mendel, R. R., and Schwarz, G. ( 2004) Nature 430, 803 - 806). Besides defining the MPT-binding site a novel and unexpected modification of MPT has been identified, adenylated MPT. Here we demonstrate that it is Cnx1G that catalyzes the adenylation of MPT. In vitro synthesized MPT was quantitatively transferred from Escherichia coli MPT synthase to Cnx1G. The subsequent adenylation reaction by Cnx1G was Mg2+- and ATP-dependent. Whereas Mn2+ could partially replace Mg2+, ATP was the only nucleotide accepted by Cnx1G. Consequently the formation of pyrophosphate was demonstrated, which was dependent on the ability of Cnx1G to bind MPT. Pyrophosphate, either formed in the reaction or added externally, inhibited the Cnx1G-catalyzed MPT adenylation reaction. Catalytically inactive Cnx1G mutant variants showed impaired MPT adenylation confirming that MPT-AMP is the reaction product of Cnx1G. Therefore Cnx1G is a MPT adenylyltransferase catalyzing the activation of MPT, a universal reaction in the Moco synthetic pathway because Cnx1G is able to reconstitute also bacterial and mammalian Moco biosynthesis.	Tech Univ Braunschweig, Dept Plant Biol, D-3806 Braunschweig, Germany	Braunschweig University of Technology	Schwarz, N (corresponding author), Tech Univ Braunschweig, Dept Plant Biol, Spielmannstr 7, D-3806 Braunschweig, Germany.	g.schwarz@tu-bs.de	Llamas, Angel/B-7104-2015; Schwarz, Guenter/ABE-9643-2021; Llamas, Angel/L-1638-2014	Llamas, Angel/0000-0001-6042-9472; Schwarz, Guenter/0000-0002-2118-9338; Llamas, Angel/0000-0001-6042-9472				An JH, 1999, BIOCHEM J, V344, P159, DOI 10.1042/0264-6021:3440159; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Fresquet V, 2004, BIOORG CHEM, V32, P63, DOI 10.1016/j.bioorg.2003.10.002; Guse A, 2003, J BIOL CHEM, V278, P25302, DOI 10.1074/jbc.M302639200; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; JOHNSON JL, 1980, P NATL ACAD SCI-BIOL, V77, P3715, DOI 10.1073/pnas.77.6.3715; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Kuper J, 2003, ARCH BIOCHEM BIOPHYS, V411, P36, DOI 10.1016/S0003-9861(02)00714-2; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Schwarz G, 2004, HUM MOL GENET, V13, P1249, DOI 10.1093/hmg/ddh136; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Schwarz G, 2000, PLANT CELL, V12, P2455, DOI 10.1105/tpc.12.12.2455; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Stiefel EI, 1996, SCIENCE, V272, P1599, DOI 10.1126/science.272.5268.1599; Witte CP, 1998, FEBS LETT, V431, P205, DOI 10.1016/S0014-5793(98)00756-X; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	31	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55241	55246		10.1074/jbc.M409862200	http://dx.doi.org/10.1074/jbc.M409862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504727	hybrid			2022-12-25	WOS:000225960800033
J	Zang, MX; Li, Y; Wang, H; Wang, JB; Jia, HT				Zang, MX; Li, Y; Wang, H; Wang, JB; Jia, HT			Cooperative interaction between the basic helix-loop-helix transcription factor dHAND and myocyte enhancer factor 2C regulates myocardial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; MEF2; PROTEIN; PROMOTER; BINDING; ROLES; HAND2; TBX5; MYOD	Cardiac-restricted transcription factors dHAND and myocyte enhancer factor 2C are expressed in the developing heart and activate several cardiac promoters. However, their regulatory mechanisms are still to be understood. To elucidate their exact regulatory functions, we have developed an RNA interference strategy to specifically inhibit dHAND and myocyte enhancer factor 2C protein production in H9c2 cells, which are derived from rat embryonic heart. Expression of endogenous cardiac genes atrial natriuretic peptide and alpha-myosin heavy chain was down-regulated in H9c2 cells lacking both dHAND and myocyte enhancer factor 2C, indicating that these factors are required for the maintenance of the cardiac genetic program. Consistent with these, expression of atrial natriuretic peptide and alpha-myosin heavy chain was up-regulated in H9c2 cells, which overexpressed dHAND and myocyte enhancer factor 2C. In addition, dHAND and myocyte enhancer factor 2C interact to synergistically activate atrial natriuretic peptide and alpha-myosin heavy chain transcription. Furthermore, chromatin immunoprecipitation analysis in H9c2 cells treated with phenylephrine showed that dHAND and myocyte enhancer factor 2C protein complex bind to the A/T sequence on atrial natriuretic peptide promoter. Taken together, these results not only suggest that the complex cis-trans interaction of dHAND, myocyte enhancer factor 2C, and the target gene may fine-tune gene expression in cardiac myocytes but also provide a molecular paradigm to elucidate the mechanisms of action of dHAND and myocyte enhancer factor 2C in the developing heart.	Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Nutr & Food Hyg,Lab Dev Mol Biol, Beijing 100083, Peoples R China; Clin Res Inst Montreal, Lab Cardiac Growth & Differentiat, Montreal, PQ H2W 1R7, Canada; Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Peking University	Li, Y (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Nutr & Food Hyg,Lab Dev Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	liyong@bjmu.edu.cn		Wang, Hao/0000-0003-1537-661X				Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Finn SG, 2001, BIOCHEM J, V358, P489, DOI 10.1042/0264-6021:3580489; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MCDONOUGH PM, 1993, AM J PHYSIOL, V264, pH625, DOI 10.1152/ajpheart.1993.264.2.H625; Miano JM, 2002, J MOL CELL CARDIOL, V34, P1287, DOI 10.1006/jmcc.2002.2101; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; Thomas T, 1998, DEVELOPMENT, V125, P3005; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Zang MX, 2004, J CELL BIOCHEM, V93, P1255, DOI 10.1002/jcb.20225	25	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54258	54263		10.1074/jbc.M408502200	http://dx.doi.org/10.1074/jbc.M408502200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485823	hybrid			2022-12-25	WOS:000225793600046
J	Fabbretti, E; Sokolova, E; Masten, L; D'Arco, M; Fabbro, A; Nistri, A; Giniatullin, R				Fabbretti, E; Sokolova, E; Masten, L; D'Arco, M; Fabbro, A; Nistri, A; Giniatullin, R			Identification of negative residues in the P2X(3) ATP receptor ectodomain as structural determinants for desensitization and the Ca2+-sensing modulatory sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PHYSIOLOGY; DRG NEURONS; DEPENDENCE; RECOVERY; CALCIUM; DOMAIN; MOTIF	On nociceptive neurons, one important mechanism to generate pain signals is the activation of P2X(3) receptors, which are membrane proteins gated by extracellular ATP. In the presence of the agonist, P2X(3) receptors rapidly desensitize and then recover slowly. One unique property of P2X(3) receptors is the recovery acceleration by extracellular Ca2+ that can play the role of the gain-setter of receptor function only when P2X(3) receptors are desensitized. To study negatively charged sites potentially responsible for this action of Ca2+, we mutated 15 non-conserved aspartate or glutamate residues in the P2X3 receptor ectodomain with alanine and expressed such mutated receptors in human embryonic kidney cells studied with patch clamping. Unlike most mutants, D266A (P2X(3) receptor numbering) desensitized very slowly, indicating that this residue is important for generating desensitization. Recovery appeared structurally distinct from desensitization because E111A and D266A had a much faster recovery and D220A and D289A had a much slower one despite their standard desensitization. Furthermore, E161A, E187A, or E270A mutants showed lessened sensitivity to the action of extracellular Ca2+, suggesting that these determinants were important for the effect of this cation on desensitization recovery. This study is the first report identifying several negative residues in the P2X(3) receptor ectodomain differentially contributing to the general process of receptor desensitization. At least one residue was important to enable the development of rapid desensitization, whereas others controlled recovery from it or the facilitating action of Ca2+. Thus, these findings outline diverse potential molecular targets to modulate P2X(3) receptor function in relation to its functional state.	SISSA, Neurobiol Sector, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA)	Nistri, A (corresponding author), SISSA, Neurobiol Sector, Via Beirut 4, I-34014 Trieste, Italy.	nistri@sissa.it	Giniatullin, Rashid/Y-9687-2018	Giniatullin, Rashid/0000-0002-1580-6280	Telethon [GGP04037] Funding Source: Medline	Telethon(Fondazione Telethon)		Borst JGG, 1999, J PHYSIOL-LONDON, V521, P123, DOI 10.1111/j.1469-7793.1999.00123.x; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Cook SP, 1998, J NEUROSCI, V18, P9238; Ding SH, 2000, J PHYSIOL-LONDON, V522, P199, DOI 10.1111/j.1469-7793.2000.t01-1-00199.x; Egan TM, 2004, CURR TOP MED CHEM, V4, P821, DOI 10.2174/1568026043451005; Fischer W, 2003, J NEUROCHEM, V85, P779, DOI 10.1046/j.1471-4159.2003.01716.x; Giniatullin R, 2003, NEUROPHARMACOLOGY, V44, P132, DOI 10.1016/S0028-3908(02)00338-6; Haines WR, 1999, MOL PHARMACOL, V56, P720; He ML, 2003, J BIOL CHEM, V278, P10182, DOI 10.1074/jbc.M209094200; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 2002, J BIOL CHEM, V277, P46891, DOI 10.1074/jbc.M205274200; Li ZY, 2004, J NEUROSCI, V24, P7378, DOI 10.1523/JNEUROSCI.1423-04.2004; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North R Alan, 2003, Curr Opin Investig Drugs, V4, P833; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Rettinger J, 2004, J BIOL CHEM, V279, P6426, DOI 10.1074/jbc.M306987200; Sokolova E, 2004, BRIT J PHARMACOL, V141, P1048, DOI 10.1038/sj.bjp.0705701; Virginio C, 1998, J PHYSIOL-LONDON, V510, P27, DOI 10.1111/j.1469-7793.1998.027bz.x; Vulchanova L, 1998, EUR J NEUROSCI, V10, P3470, DOI 10.1046/j.1460-9568.1998.00355.x; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Xiong KM, 2004, NEUROSCI LETT, V365, P195, DOI 10.1016/j.neulet.2004.04.078; Zemkova H, 2004, J NEUROSCI, V24, P6968, DOI 10.1523/JNEUROSCI.1471-04.2004	26	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53109	53115		10.1074/jbc.M409772200	http://dx.doi.org/10.1074/jbc.M409772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475563	hybrid			2022-12-25	WOS:000225680600039
J	Morton, DB				Morton, DB			Atypical soluble guanylyl cyclases in Drosophila can function as molecular oxygen sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SUBUNIT; HEME; MECHANISMS	Conventional soluble guanylyl cyclases are heterodimeric enzymes that synthesize cGMP and are activated by nitric oxide. Recently, a separate class of soluble guanylyl cyclases has been identified that are only slightly activated by or are insensitive to nitric oxide. These atypical guanylyl cyclases include the vertebrate beta2 subunit and examples from the invertebrates Manduca sexta, Caenorhabditis elegans, and Drosophila melanogaster. A member of this family, GCY-35 in C. elegans, was recently shown to be required for a behavioral response to low oxygen levels and may be directly regulated by oxygen (Gray, J. M., Karow, D. S., Lu, H., Chang, A. J., Chang, J. S., Ellis, R. E., Marletta, M. A., and Bargmann, C. I. ( 2004) Nature 430, 317 - 322). Drosophila contains three genes that code for atypical soluble guanylyl cyclases: Gyc-88E, Gyc-89Da, and Gyc-89Db. COS-7 cells co-transfected with Gyc-88E and Gyc-89Da or Gyc-89Db accumulate low levels of cGMP under normal atmospheric oxygen concentrations and are potently activated under anoxic conditions. The increase in activity is graded over oxygen concentrations of 0 - 21%, can be detected within 1 min of exposure to anoxic conditions and is blocked by the soluble guanylyl cyclase inhibitor, 1H-[1,2,4] oxadiazolo[ 4,3-a] quinoxaline-1-one (ODQ). Gyc-88E and Gyc-89Db are co-expressed in a subset of sensory neurons where they would be ideally situated to act as oxygen sensors. This is the first demonstration of a soluble guanylyl cyclase that is activated in response to changing oxygen concentrations.	Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA	Oregon Health & Science University	Morton, DB (corresponding author), Oregon Hlth & Sci Univ, Dept Integrat Biosci, SD,611 SW Campus Dr, Portland, OR 97239 USA.	mortonda@ohsu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029740, R29NS029740] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29740] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; Kingan TG, 1997, J EXP BIOL, V200, P3245; Koglin M, 2001, J BIOL CHEM, V276, P30737, DOI 10.1074/jbc.M102549200; Langlais KK, 2004, J EXP BIOL, V207, P2323, DOI 10.1242/jeb.01025; Lawson DM, 2003, BIOCHEM SOC T, V31, P553, DOI 10.1042/BST0310553; Lucas KA, 2000, PHARMACOL REV, V52, P375; Morton DB, 2004, MOL NEUROBIOL, V29, P97, DOI 10.1385/MN:29:2:097; Peers C, 2001, RESP RES, V2, P145, DOI 10.1186/rr51; Prabhakar NR, 2000, RESP PHYSIOL, V122, P209, DOI 10.1016/S0034-5687(00)00160-2; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; SHAH S, 1995, J BIOL CHEM, V270, P15368, DOI 10.1074/jbc.270.25.15368; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296	15	48	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50651	50653		10.1074/jbc.C400461200	http://dx.doi.org/10.1074/jbc.C400461200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15485853	hybrid			2022-12-25	WOS:000225355800004
J	Chalitchagorn, K; Shuangshoti, S; Hourpai, N; Kongruttanachok, N; Tangkijvanich, P; Thong-ngam, D; Voravud, N; Sriuranpong, V; Mutirangura, A				Chalitchagorn, K; Shuangshoti, S; Hourpai, N; Kongruttanachok, N; Tangkijvanich, P; Thong-ngam, D; Voravud, N; Sriuranpong, V; Mutirangura, A			Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis	ONCOGENE			English	Article						LINE-1 methylation; global hypomethylation; COBRA PCR; microdissection; cellular differentiation; multistep carcinogenesis	DNA METHYLATION; L1 RETROTRANSPOSONS; COLORECTAL-CANCER; CPG ISLANDS; HYPOMETHYLATION; CARCINOMAS; SEQUENCES; ASSAY; SERUM	Genome-wide losses of DNA methylation have been regarded as a common epigenetic event in malignancies and may play crucial roles in carcinogenesis. Limited information is available on the global methylation status in normal tissues and other cancer types beyond colonic carcinoma. Here we applied the combined bisulfite restriction analysis PCR to evaluate the methylation status of LINE-1 repetitive sequences in genomic DNA derived from microdissected samples from several human normal and neoplastic tissues. We found that methylation of LINE-1 in leukocytes was independent of age and gender. In contrast, normal tissues from different organs showed tissue-specific levels of methylated LINE-1. Globally, most carcinomas including breast, colon, lung, head and neck, bladder, esophagus, liver, prostate, and stomach, revealed a greater percentage of hypomethylation than their normal tissue counterparts. Furthermore, DNA derived from sera of patients with carcinoma displayed more LINE-1 hypomethylation than those of noncarcinoma individuals. Finally, in a colonic carcinogenesis model, we detected significantly greater hypomethylation in carcinoma than those of dysplastic polyp and histological normal colonic epithelium. Thus, the methylation status is a unique feature of a specific tissue type and the global hypomethylation is a common epigenetic process in cancer, which may progressively evolve during multistage carcinogenesis.	Chulalongkorn Univ, Fac Med, Dept Anat, Genet Unit, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Grad Sch, Interdept Program Biomed Sci, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Biochem, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Physiol, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Med, Med Oncol Unit, Bangkok 10330, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Mutirangura, A (corresponding author), Chulalongkorn Univ, Fac Med, Dept Anat, Genet Unit, Bangkok 10330, Thailand.	mapiwat@chula.ac.th	Werawatganon, Duangporn/X-2507-2019; Mutirangura, Apiwat/C-8197-2009	Werawatganon, Duangporn/0000-0001-8847-9690; 				Anker P, 2000, MEDICINA-BUENOS AIRE, V60, P699; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jurgens B, 1996, CANCER RES, V56, P5698; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lyon Mary F., 1994, European Journal of Human Genetics, V2, P255; Mutirangura A, 1999, INT J CANCER, V83, P210, DOI 10.1002/(SICI)1097-0215(19991008)83:2<210::AID-IJC11>3.3.CO;2-P; Mutirangura A, 1998, CLIN CANCER RES, V4, P665; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Santourlidis S, 1999, PROSTATE, V39, P166; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yang AS, 2003, SCIENCE, V302	23	331	349	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8841	8846		10.1038/sj.onc.1208137	http://dx.doi.org/10.1038/sj.onc.1208137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480421				2022-12-25	WOS:000225165100014
J	Aavik, E; Mahapatra, A; Boldrick, J; Chen, X; Barry, C; DuToit, D; Sarwal, M; Hayry, P				Aavik, E; Mahapatra, A; Boldrick, J; Chen, X; Barry, C; DuToit, D; Sarwal, M; Hayry, P			Correlation between gene expression and morphological alterations in baboon carotid after balloon dilatation injury	FASEB JOURNAL			English	Article						balloon angioplasty; carotid arteries; genes	SMOOTH-MUSCLE-CELLS; CDNA ARRAY ANALYSIS; ABDOMINAL AORTIC-ANEURYSMS; RENAL-ALLOGRAFT REJECTION; DNA MICROARRAY; UP-REGULATION; ATHEROSCLEROSIS; PROLIFERATION; ANGIOPLASTY; APOPTOSIS	Treatment for fibroproliferative restenosis after angioplasty and endovascular surgery is an unmet medical need. Rational therapy and drug design still lack the very basic knowledge about the underlying biological processes leading to pathological changes in the vessel wall. We have developed a primate model for vascular response to denudation-overstretch injury of baboon carotid artery. With this model, we have investigated the time course of vascular expression of 41,000 human cDNA clones and correlated these changes with carotid histology and function. Analysis revealed 20,788 differentially regulated cDNA clones. After high stringency data selection, the most prominently regulated 1629 cDNA clones representing 1510 genes of known function were clustered. Genes corresponding to functional and anatomical alterations in the injured carotid wall were further aligned into functional groups according to Gene Ontology classification. The observed expression patterns faithfully reflected the functional and anatomical alterations observed in the vascular wall in response to injury. The analysis presents a tentative model for genomic response to balloon catheter injury and a road map to identify time-related genomic alterations in human vascular specimens.	Univ Helsinki, Transplantat Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum, Rat Drug Design Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat Transplantat, Stanford, CA 94305 USA; Univ Stellenbosch, Dept Surg, Cape Town, South Africa	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Stanford University; Stanford University; Stellenbosch University	Hayry, P (corresponding author), Univ Helsinki, Transplantat Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	pekka.hayry@helsinki.fi						Aavik E, 2002, FASEB J, V16, P724, DOI 10.1096/fj.01-0272fje; Absi TS, 2003, J THORAC CARDIOV SUR, V126, P344, DOI 10.1016/S0022-5223(02)73576-9; Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Archacki SR, 2003, PHYSIOL GENOMICS, V15, P65, DOI 10.1152/physiolgenomics.00181.2002; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Chua MS, 2003, PEDIATR NEPHROL, V18, P319, DOI 10.1007/s00467-003-1083-7; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Du Toit D, 2001, ANN MED, V33, P63, DOI 10.3109/07853890109002061; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Faber BCG, 2001, CIRC RES, V89, P547, DOI 10.1161/hh1801.096340; Geary RL, 2002, ARTERIOSCL THROM VAS, V22, P2010, DOI 10.1161/01.ATV.0000038147.93527.35; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grimm PC, 2001, NEW ENGL J MED, V345, P93, DOI 10.1056/NEJM200107123450203; Higgins JPT, 2004, MOL BIOL CELL, V15, P649, DOI 10.1091/mbc.E03-06-0432; Hilker M, 2003, EUR J CARDIO-THORAC, V23, P620, DOI 10.1016/S1010-7940(03)00017-4; Hiltunen MO, 2002, ATHEROSCLEROSIS, V165, P23, DOI 10.1016/S0021-9150(02)00187-9; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Martinet W, 2002, ARTERIOSCL THROM VAS, V22, P2023, DOI 10.1161/01.ATV.0000041843.44312.12; Muller BT, 2002, EUR J VASC ENDOVASC, V24, P356, DOI 10.1053/ejvs.2002.1731; Murray JI, 2004, MOL BIOL CELL, V15, P2361, DOI 10.1091/mbc.E03-11-0799; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Napoli C, 2003, HEART, V89, P597, DOI 10.1136/heart.89.6.597; Neuville P, 2000, ARTERIOSCL THROM VAS, V20, P1882, DOI 10.1161/01.ATV.20.8.1882; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; Perlman H, 1997, CIRCULATION, V95, P981; Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Thyberg J, 1997, J HISTOCHEM CYTOCHEM, V45, P837, DOI 10.1177/002215549704500608; Tung WS, 2001, J VASC SURG, V34, P143, DOI 10.1067/mva.2001.113310; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wilcox JN, 2001, ANN NY ACAD SCI, V947, P68; Zohlnhofer D, 2001, CIRCULATION, V103, P1396, DOI 10.1161/01.CIR.103.10.1396	35	12	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					130	+		10.1096/fj.04-2225fje	http://dx.doi.org/10.1096/fj.04-2225fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15496494				2022-12-25	WOS:000224849900013
J	Arastu-Kapur, S; Arendt, CS; Purnat, T; Carter, NS; Ullman, B				Arastu-Kapur, S; Arendt, CS; Purnat, T; Carter, NS; Ullman, B			Second-site suppression of a nonfunctional mutation within the Leishmania donovani inosine-guanosine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; LACTOSE PERMEASE; ESCHERICHIA-COLI; PROTEIN; HENT1; NITROBENZYLTHIOINOSINE; SENSITIVITY; GENE; IDENTIFICATION; TOPOLOGY	LdNT2 is a member of the equilibrative nucleoside transporter family, which possesses several conserved residues located mainly within transmembrane domains. One of these residues, Asp(389) within LdNT2, was shown previously to be critical for transporter function without affecting ligand affinity or plasma membrane targeting. To further delineate the role of Asp(389) in LdNT2 function, second-site suppressors of the ldnt2-D389N null mutation were selected in yeast deficient in purine nucleoside transport and incapable of purine biosynthesis. A library of random mutants within the ldnt2-D389N background was screened in yeast for restoration of growth on inosine. Twelve different clones were obtained, each containing secondary mutations enabling inosine transport. One mutation, N175I, occurred in four clones and conferred augmented inosine transport capability compared with LdNT2 in yeast. N175I was subsequently introduced into an ldnt2-D389N construct tagged with green fluorescent protein and transfected into a Deltaldnt1/Deltaldnt2 Leishmania donovani knockout. GFP-N175I/D389N significantly suppressed the D389N phenotype and targeted properly to the plasma membrane and flagellum. Most interestingly, N175I increased the inosine K-m by 10-fold within the D389N background relative to wild type GFP-LdNT2. Additional substitutions introduced at Asn(175) established that only large, nonpolar amino acids suppressed the D389N phenotype, indicating that suppression by Asn(175) has a specific size and charge requirement. Because multiple suppressor mutations alleviate the constraint imparted by the D389N mutation, these data suggest that Asp(389) is a conformationally sensitive residue. To impart spatial information to the clustering of second-site mutations, a three-dimensional model was constructed based upon members of the major facilitator superfamily using threading analysis. The model indicates that Asn(175) and Asp(389) lie in close proximity and that the second-site suppressor mutations cluster to one region of the transporter.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	ullmanb@ohsu.edu		PURNAT, Tina/0000-0002-0257-6631	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R01AI044138] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23682, R01 AI44138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Cain SM, 2000, J MEMBRANE BIOL, V176, P159, DOI 10.1007/s002320001085; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; CARTER NS, 2003, MOL MED PARASITOLOGY, P197; Colon Migdalisel, 2004, Methods Mol Biol, V241, P175; DREW ME, 1995, MOL CELL BIOL, V15, P5508; Endres CJ, 2004, BIOCHEM J, V380, P131, DOI 10.1042/BJ20031880; Green AL, 2003, BIOCHEMISTRY-US, V42, P11226, DOI 10.1021/bi034810+; Guthrie C, 1991, GUIDE YEAST GENETICS; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Orengo CA, 1999, PROTEINS, P149; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SenGupta DJ, 2004, BIOCHEM PHARMACOL, V67, P453, DOI 10.1016/j.bcp.2003.09.018; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; SIKORSKI RS, 1989, GENETICS, V122, P19; Stewart C, 1998, J BIOL CHEM, V273, P28078, DOI 10.1074/jbc.273.43.28078; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Valdes R, 2004, BIOCHEMISTRY-US, V43, P6793, DOI 10.1021/bi049873m; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; YANG BC, 1992, CURR GENET, V21, P83; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387	37	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2213	2219		10.1074/jbc.M408224200	http://dx.doi.org/10.1074/jbc.M408224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15501825	hybrid			2022-12-25	WOS:000226341700057
J	Vila-Perello, M; Sanchez-Vallet, A; Garcia-Olmedo, F; Molina, A; Andreu, D				Vila-Perello, M; Sanchez-Vallet, A; Garcia-Olmedo, F; Molina, A; Andreu, D			Structural dissection of a highly knotted peptide reveals minimal motif with antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PROTEIN; RESISTANCE; THIONIN; MODE; SUSCEPTIBILITY; PUROTHIONIN; MECHANISMS; ANALOGS; DESIGN	The increasing occurrence of bacterial resistance to antibiotics is driving a renewed interest on antimicrobial peptides, in the hope that understanding the structural features responsible for their activity will provide leads into new anti-infective drug candidates. Most chemical studies in this field have focused on linear peptides of various eukaryotic origins, rather than on structures with complex folding patterns found also in nature. We have undertaken the structural dissection of a highly knotted, cysteine-rich plant thionin, with the aim of defining a minimal, synthetically accessible, structure that preserves the bioactive properties of the parent peptide. Using efficient strategies for directed disulfide bond formation, we have prepared a substantially simplified (45% size reduction) version with undiminished antimicrobial activity against a representative panel of pathogens. Analysis by circular dichroism shows that the downsized peptide preserves the central double alpha-helix of the parent form as an essential bioactive motif. Membrane permeability and surface plasmon resonance studies confirm that the mechanism of action remains unchanged.	Pompeu Fabra Univ, Dept Expt & Hlth Sci, E-08003 Barcelona, Spain; Univ Politecn Madrid, ETSIA, Dept Biotechnol, Biochem Lab, E-28040 Madrid, Spain	Pompeu Fabra University; Universidad Politecnica de Madrid	Andreu, D (corresponding author), Pompeu Fabra Univ, Dept Expt & Hlth Sci, Dr Aiguader 80, E-08003 Barcelona, Spain.	david.andreu@upf.edu	Molina, Antonio/G-9789-2015; Sánchez-vallet, Andrea/B-6128-2019; Andreu, David/I-4359-2014	Molina, Antonio/0000-0003-3137-7938; Sánchez-vallet, Andrea/0000-0002-3668-9503; Andreu, David/0000-0002-6317-6666				Andreu D, 1994, Methods Mol Biol, V35, P91; ANDREU D, 1983, P NATL ACAD SCI-BIOL, V80, P6475, DOI 10.1073/pnas.80.21.6475; Andreu D, 2000, SOLID-PHASE SYNTHESIS, P365; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Annis I, 1997, METHOD ENZYMOL, V289, P198; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; Berrocal-Lobo M, 2002, PLANT PHYSIOL, V128, P951, DOI 10.1104/pp.010685; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; CARMONA MJ, 1993, PLANT J, V3, P457, DOI 10.1046/j.1365-313X.1993.t01-24-00999.x; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; DECALEYA RF, 1972, APPL MICROBIOL, V23, P998, DOI 10.1128/AEM.23.5.998-1000.1972; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRACKI WS, 1992, TOXICON, V30, P1427, DOI 10.1016/0041-0101(92)90518-A; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Garcia-Olmedo F., 1992, Genes involved in plant defense., P283; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hackeng TM, 1998, BIOPOLYMERS, V46, P53, DOI 10.1002/(SICI)1097-0282(199808)46:2<53::AID-BIP1>3.0.CO;2-W; Hughes P, 2000, J BIOL CHEM, V275, P823, DOI 10.1074/jbc.275.2.823; LEE FS, 1993, J COMPUT CHEM, V14, P161, DOI 10.1002/jcc.540140205; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Mangoni ML, 2003, BIOCHEMISTRY-US, V42, P14023, DOI 10.1021/bi034521l; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; Mozsolits H, 2002, BIOPOLYMERS, V66, P3, DOI 10.1002/bip.10200; Osusky M, 2000, NAT BIOTECHNOL, V18, P1162, DOI 10.1038/81145; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; Romestand B, 2003, EUR J BIOCHEM, V270, P2805, DOI 10.1046/j.1432-1033.2003.03657.x; Roth BL, 1997, APPL ENVIRON MICROB, V63, P2421, DOI 10.1128/AEM.63.6.2421-2431.1997; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sitaram N, 2002, ANTIMICROB AGENTS CH, V46, P2279, DOI 10.1128/AAC.46.7.2279-2283.2002; Vila-Perello M, 2003, FEBS LETT, V536, P215, DOI 10.1016/S0014-5793(03)00053-X; WADA K, 1982, J BIOCHEM-TOKYO, V91, P257, DOI 10.1093/oxfordjournals.jbchem.a133683; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yount NY, 2004, P NATL ACAD SCI USA, V101, P7363, DOI 10.1073/pnas.0401567101; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	32	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1661	1668		10.1074/jbc.M410577200	http://dx.doi.org/10.1074/jbc.M410577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15494403	hybrid, Green Accepted			2022-12-25	WOS:000226195200097
J	Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D				Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D			Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line	ONCOGENE			English	Article						Myc; serum; target genes; B-cells	GENE-EXPRESSION; GENOMIC TARGETS; GROWTH-FACTOR; LYMPHOCYTES; PROTEIN; FIBROBLASTS; CHROMATIN; CYCLE	Proliferation of higher eukaryotic cells is triggered by the proto-oncogene c-myc (myc), which is induced downstream of a large number of growth factor receptors. Myc, a basic helix-loop-helix leucine zipper transcription factor, transmits growth signals by up- and downregulation of target genes. The importance of Myc in growth control is well established. However, the number of growth control genes requiring Myc as an essential factor for regulation after mitogenic stimulation of cells is not yet clear. Here, we have studied the transcriptional programme of a human B-cell line, P493-6, in response to Myc and serum. P493-6 cells do not express the endogenous myc, nor is it induced by serum stimulation. Proliferation of the cells is dependent upon both the expression of a tetracycline-regulated myc gene and serum stimulation. Using DNA microarrays, expression pro. ling was performed following stimulation of cells with serum, with Myc, or with both. We observed serum regulation of > 1000 genes. A number of these genes were synergistically or antagonistically regulated by Myc. Moreover, we identified > 300 Myc-regulated genes that were almost unresponsive to serum. Gene ontology analysis revealed that a high proportion of Myc target genes are involved in ribosome biogenesis and tRNA metabolism. The data support our current notion that Myc is essential for the regulation of a large number of growth-related genes in B cells, and cannot be replaced by other serum-induced factors.	GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Max von Pettenkofer Inst, D-80336 Munich, Germany; Roche Diagnost GmbH, Roche Pharma Res Penzberg, Dept TR ON, D-82372 Penzberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Roche Holding	Eick, D (corresponding author), GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, Marchioninistr 25, D-81377 Munich, Germany.	eick@gsf.de	Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Newton JS, 1996, BIOCHEM SOC T, V24, pS7, DOI 10.1042/bst024007s; NORVELL A, 1995, J IMMUNOL, V154, P4404; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	25	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					520	524		10.1038/sj.onc.1208198	http://dx.doi.org/10.1038/sj.onc.1208198			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516975				2022-12-25	WOS:000226279700022
J	Chavas, LMG; Tringali, C; Fusi, P; Venerando, B; Tettamanti, G; Kato, R; Monti, E; Wakatsuki, S				Chavas, LMG; Tringali, C; Fusi, P; Venerando, B; Tettamanti, G; Kato, R; Monti, E; Wakatsuki, S			Crystal structure of the human cytosolic sialidase Neu2 - Evidence for the dynamic nature of substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; NEURAMINIDASE INHIBITORS; PROGRAM; GENE; DIFFERENTIATION; OVEREXPRESSION; EXPRESSION; INFLUENZA; CLONING; VIRUS	Gangliosides play key roles in cell differentiation, cell-cell interactions, and transmembrane signaling. Sialidases hydrolyze sialic acids to produce asialo compounds, which is the first step of degradation processes of glycoproteins and gangliosides. Sialidase involvement has been implicated in some lysosomal storage disorders such as sialidosis and galactosialidosis. Neu2 is a recently identified human cytosolic sialidase. Here we report the first high resolution x-ray structures of mammalian sialidase, human Neu2, in its apo form and in complex with an inhibitor, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid ( DANA). The structure shows the canonical six-blade beta-propeller observed in viral and bacterial sialidases with its active site in a shallow crevice. In the complex structure, the inhibitor lies in the catalytic crevice surrounded by ten amino acids. In particular, the arginine triad, conserved among sialidases, aids in the proper positioning of the carboxylate group of DANA within the active site region. The tyrosine residue, Tyr(334), conserved among mammalian and bacterial sialidases as well as in viral neuraminidases, facilitates the enzymatic reaction by stabilizing a putative carbonium ion in the transition state. The loops containing Glu(111) and the catalytic aspartate Asp(46) are disordered in the apo form but upon binding of DANA become ordered to adopt two short alpha-helices to cover the inhibitor, illustrating the dynamic nature of substrate recognition. The N-acetyl and glycerol moieties of DANA are recognized by Neu2 residues not shared by bacterial sialidases and viral neuraminidases, which can be regarded as a key structural difference for potential drug design against bacteria, influenza, and other viruses.	High Energy Accelerator Res Org, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; Grad Univ Adv Studies, Kanagawa 2400193, Japan; Univ Milan, Dept Med Chem Biochem & Biotechnol, Lab Interdisciplinare Tecnol Avanzate, I-20090 Milan, Italy; Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy	High Energy Accelerator Research Organization (KEK); Graduate University for Advanced Studies - Japan; University of Milan; University of Milano-Bicocca; University of Brescia	Wakatsuki, S (corresponding author), High Energy Accelerator Res Org, Inst Mat Struct Sci, Photon Factory, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan.	soichi.wakatsuki@kek.jp	Chavas, Leonard M.G./AAZ-2286-2020; Tringali, Cristina Alessandra/Q-7259-2017	Tringali, Cristina Alessandra/0000-0002-0632-6197; Kato, Ryuichi/0000-0003-2087-2896; Fusi, Paola/0000-0002-2746-1742; MONTI, Eugenio/0000-0002-4742-7445; Wakatsuki, Soichi/0000-0001-5896-7968				Akita H, 1997, HISTOCHEM CELL BIOL, V107, P495, DOI 10.1007/s004180050137; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1993, STRUCTURE, V1, P19, DOI 10.1016/0969-2126(93)90005-2; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Chan K F, 1991, Glycobiology, V1, P193, DOI 10.1093/glycob/1.2.193; Colman PM, 2002, VACCINE, V20, pS55, DOI 10.1016/S0264-410X(02)00132-9; Copley RR, 2001, PROTEIN SCI, V10, P285, DOI 10.1110/ps.31901; DeLano W, 2002, PYMOL 0 99; Fanzani A, 2003, FEBS LETT, V547, P183, DOI 10.1016/S0014-5793(03)00709-9; GILLARD BK, 1993, GLYCOBIOLOGY, V3, P57, DOI 10.1093/glycob/3.1.57; GRAMER MJ, 1995, BIO-TECHNOL, V13, P692, DOI 10.1038/nbt0795-692; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; McKimm-Breschkin JL, 2003, ANGEW CHEM INT EDIT, V42, P3118, DOI 10.1002/anie.200250402; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Muthing J, 2001, CARBOHYD RES, V330, P347, DOI 10.1016/S0008-6215(00)00295-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SWEELEY CC, 1993, ADV LIPID RES, V26, P235; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WARNER TG, 1993, GLYCOBIOLOGY, V3, P455, DOI 10.1093/glycob/3.5.455	35	130	137	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					469	475		10.1074/jbc.M411506200	http://dx.doi.org/10.1074/jbc.M411506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501818	hybrid			2022-12-25	WOS:000226025100056
J	Lee, M; Hadi, M; Hallden, G; Aponte, GW				Lee, M; Hadi, M; Hallden, G; Aponte, GW			Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACID-BINDING PROTEIN; C-JUN; PANCREATIC-POLYPEPTIDE; GENE-EXPRESSION; RHO GTPASES; FOOD-INTAKE; DIFFERENTIAL REGULATION; INSULIN-SECRETION; PRIMARY CULTURE	Peptide YY (PYY) and neuropeptide Y (NPY) are regulatory peptides synthesized in the intestine and brain, respectively, that modify physiological functions affecting nutrient assimilation and feeding behavior. Because PYY and NPY also alter the expression of intestine-specific differentiation marker proteins and the tetraspanin CD63, which is involved in cell adhesion, we investigated whether intestinal cell differentiation could be linked to mucosal cell adhesion and migration through these peptides. PYY and NPY significantly decreased cell adhesion and increased cell migration in a dose-dependent manner prior to cell confluency in our model system, non-tumorigenic small intestinal hBRIE 380i cells. Both peptides reduced CD63 expression and CD63-dependent cell adhesion. CD63 overexpression increased and antisense CD63 cDNA decreased intestinal cell adhesion. In parallel, both PYY and NPY increased expression of matrix metalloproteinase-3 (MMP-3) to a level sufficient to induce cell migration by activating the Rho GTPase Cdc42. The effects of both peptides on cell migration were blocked in cells constitutively over-expressing dominant-negative Cdc42. PYY and NPY also significantly induced the expression of the differentiation marker villin, which could be eliminated by an MMP inhibitor at a concentration that inhibits cell migration. Increased MMP-3 activity, which enhanced cell migration, also induced villin mRNA levels. Therefore, these data indicate that the alteration of adhesion and migration by PYY and NPY occurs in part by synchronous modulation of three proteins that are involved in extracellular matrix-basolateral membrane interactions, CD63, MMP-3 and Cdc42, and that PYY/NPY regulation of expression of mucosal proteins such as villin is linked to the process of cell migration and adhesion.	Univ Calif Berkeley, Dept Nutr Sci & Technol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Aponte, GW (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Technol, 119 Morgan Hall, Berkeley, CA 94720 USA.	gwa@nature.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058592] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58592] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN GG, 1972, AM J ANAT, V133, P391, DOI 10.1002/aja.1001330403; APONTE GW, 1988, AM J PHYSIOL, V254, pG829, DOI 10.1152/ajpgi.1988.254.6.G829; APONTE GW, 1989, FASEB J, V3, P1949, DOI 10.1096/fasebj.3.8.2721855; APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baksheev L, 2000, TRENDS ENDOCRIN MET, V11, P401, DOI 10.1016/S1043-2760(00)00307-6; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Batterham RL, 2003, ANN NY ACAD SCI, V994, P162, DOI 10.1111/j.1749-6632.2003.tb03176.x; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berglund MM, 2003, EXP BIOL MED, V228, P217, DOI 10.1177/153537020322800301; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Calviello G, 1999, LIPIDS, V34, P599, DOI 10.1007/s11745-999-0404-6; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chaudhary M, 2000, DIGESTION, V61, P223, DOI 10.1159/000007762; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; CLARKE RM, 1975, J ANAT, V120, P321; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEYEBENES EG, 1995, NEUROSCI LETT, V190, P77, DOI 10.1016/0304-3940(95)11505-Q; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Dou YL, 2001, MED ENG PHYS, V23, P557, DOI 10.1016/S1350-4533(01)00091-1; Drucker DJ, 2002, GUT, V50, P428, DOI 10.1136/gut.50.3.428; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Ekblad E, 2002, PEPTIDES, V23, P251, DOI 10.1016/S0196-9781(01)00601-5; Eto B, 1997, PEPTIDES, V18, P1249, DOI 10.1016/S0196-9781(97)00185-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GIBBS J, 1973, J COMP PHYSIOL PSYCH, V84, P488, DOI 10.1037/h0034870; Guo XG, 2003, J BIOL CHEM, V278, P13207, DOI 10.1074/jbc.M208896200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hallden G, 1999, J BIOL CHEM, V274, P27914, DOI 10.1074/jbc.274.39.27914; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; Hallden G, 1997, J BIOL CHEM, V272, P12591, DOI 10.1074/jbc.272.19.12591; Hansel DE, 2001, J NEUROSCI RES, V66, P1, DOI 10.1002/jnr.1191; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; HEATH JP, 1993, SYM SOC EXP BIOL, V47, P35; Helmrath M A, 1998, J Gastrointest Surg, V2, P44, DOI 10.1016/S1091-255X(98)80102-9; Hernandes L, 2003, BIOCELL, V27, P347; Jang HI, 2003, EXP MOL MED, V35, P317, DOI 10.1038/emm.2003.43; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KAUR P, 1986, CELL TISSUE KINET, V19, P611, DOI 10.1111/j.1365-2184.1986.tb00762.x; Keire DA, 2002, PEPTIDES, V23, P305, DOI 10.1016/S0196-9781(01)00602-7; KOTLER DP, 1982, AM J CLIN NUTR, V36, P457, DOI 10.1093/ajcn/36.3.457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larhammar D, 1996, REGUL PEPTIDES, V65, P165, DOI 10.1016/0167-0115(96)00110-3; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liddle RA, 2000, J GASTROENTEROL, V35, P181, DOI 10.1007/s005350050328; Liu M, 2003, EXP BIOL MED, V228, P1181, DOI 10.1177/153537020322801013; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; LopezValpuesta FJ, 1996, P ROY SOC B-BIOL SCI, V263, P881, DOI 10.1098/rspb.1996.0130; Malmstrom RE, 2001, LIFE SCI, V69, P1999, DOI 10.1016/S0024-3205(01)01286-3; Mannon PJ, 2000, BIOCHEM J, V350, P655, DOI 10.1042/0264-6021:3500655; Michel MC, 1998, PHARMACOL REV, V50, P143; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Naveilhan P, 2001, J NEUROCHEM, V78, P1201, DOI 10.1046/j.1471-4159.2001.00534.x; Nobes CD, 2000, METHOD ENZYMOL, V325, P441; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; Orskov C, 1996, SCAND J GASTROENTERO, V31, P665, DOI 10.3109/00365529609009147; PALKOVITS M, 1992, CIBA F SYMP, V168, P3; Ray RM, 2003, J BIOL CHEM, V278, P13039, DOI 10.1074/jbc.M208741200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rubin DC, 1996, AM J PHYSIOL-GASTR L, V270, pG143, DOI 10.1152/ajpgi.1996.270.1.G143; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Smith M, 1997, MELANOMA RES, V7, pS163; Sonoyama K, 2000, P SOC EXP BIOL MED, V223, P270, DOI 10.1046/j.1525-1373.2000.22338.x; Swartz-Basile DA, 2003, AM J PHYSIOL-GASTR L, V285, pG424, DOI 10.1152/ajpgi.00524.2002; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; Trivedi P, 2001, J VIROL, V75, P4929, DOI 10.1128/JVI.75.10.4929-4935.2001; VAN AL, 1997, GENE DEV, V11, P2295; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Voisin T, 2000, J PHARMACOL EXP THER, V292, P638; Walsh John H., 1994, P1; WILLIAMSON RCN, 1982, SCAND J GASTROENTERO, V17, P21; Woessner JF, 1998, BIOL EXTRAC, P1; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, P724; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	91	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					125	136		10.1074/jbc.M408858200	http://dx.doi.org/10.1074/jbc.M408858200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504731	hybrid			2022-12-25	WOS:000226025100017
J	Zheng, L; Settle, M; Brubaker, G; Schmitt, D; Hazen, SL; Smith, JD; Kinter, M				Zheng, L; Settle, M; Brubaker, G; Schmitt, D; Hazen, SL; Smith, JD; Kinter, M			Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC INTIMA; HUMAN NEUTROPHILS EMPLOY; ACUTE CORONARY SYNDROMES; CARDIOVASCULAR-DISEASE; LIPID-PEROXIDATION; PROTEIN NITRATION; MASS-SPECTROMETRY; DEFICIENT MICE; VIVO	We recently reported that apolipoprotein A-I (apoA-I), the major protein component of high density lipoprotein, is a selective target for myeloperoxidase (MPO)catalyzed nitration and chlorination in both and serum of subjects with cardiovascular disease. We further showed that the extent of both apoA-I nitration and chlorination correlated with functional impairment in reverse cholesterol transport activity of the isolated lipoprotein. Herein we used tandem mass spectrometry to map the sites of MPO-mediated apoA-I nitration and chlorination in vitro and in vivo and to relate the degree of site-specific modifications to loss of apoA-I lipid binding and cholesterol efflux functions. Of the seven tyrosine residues in apoA-I, Tyr-192, Tyr-166, Tyr-236, and Tyr-29 were nitrated and chlorinated in MPO-mediated reactions. Site-specific liquid chromatography-mass spectrometry quantitative analyses demonstrated that the favored modification site following exposure to MPO-generated oxidants is Tyr-192. MPO-dependent nitration and chlorination both proceed with Tyr-166 as a secondary site and with Tyr-236 and Tyr-29 modified only minimally. Parallel functional studies demonstrated dose-dependent losses of ABCA1-dependent cholesterol acceptor and lipid binding activities with apoA-I modification by MPO. Finally tandem mass spectrometry analyses showed that apoA-I in human atherosclerotic tissue is nitrated at the MPO-preferred sites, Tyr-192 and Tyr-166. The present studies suggest that site-specific modifications of apoA-I by MPO are associated with impaired lipid binding and ABCA1-dependent cholesterol acceptor functions, providing a molecular mechanism that likely contributes to the clinical link between MPO levels and cardiovascular disease risk.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Kinter, M (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kinterm@ccf.org	Hazen, Stanley L/ABD-5845-2021; Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X; Kinter, Michael/0000-0001-7409-8918	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016794, M01RR018390, S10RR015794] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066082, P01HL076491, R01HL070621, R01HL077692] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15794, RR16794, RR018390] Funding Source: Medline; NHLBI NIH HHS [HL70621, HL66082, P01 HL076491, HL077692] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bergt C, 1999, FEBS LETT, V452, P295, DOI 10.1016/S0014-5793(99)00677-8; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2001, EUR J BIOCHEM, V268, P3523, DOI 10.1046/j.1432-1327.2001.02253.x; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Heinecke JW, 2003, AM J CARDIOL, V91, p12A; Ji YB, 2003, MOL PHARMACOL, V63, P136, DOI 10.1124/mol.63.1.136; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Koeck T, 2004, MOL CELL PROTEOMICS, V3, P548, DOI 10.1074/mcp.M300141-MCP200; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; Macdonald DL, 2003, ARTERIOSCL THROM VAS, V23, P1583, DOI 10.1161/01.ATV.0000085840.67498.00; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; Navab M, 2002, CURR OPIN LIPIDOL, V13, P363, DOI 10.1097/00041433-200208000-00003; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Orton KJP, 1927, J CHEM SOC, P986, DOI 10.1039/jr9270000986; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruse CI, 2002, ANAL CHEM, V74, P1658, DOI 10.1021/ac0157122; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Vadseth C, 2004, J BIOL CHEM, V279, P8820, DOI 10.1074/jbc.M306101200; Vita JA, 2004, CIRCULATION, V110, P1134, DOI 10.1161/01.CIR.0000140262.20831.8F; Wang WQ, 1998, J BIOL CHEM, V273, P17391, DOI 10.1074/jbc.273.28.17391; Willard BB, 2003, ANAL CHEM, V75, P2370, DOI 10.1021/ac034033j; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	53	174	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					38	47		10.1074/jbc.M407019200	http://dx.doi.org/10.1074/jbc.M407019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498770	hybrid			2022-12-25	WOS:000226025100006
J	Spence, E; Bailey, S; Nenninger, A; Moller, SG; Robinson, C				Spence, E; Bailey, S; Nenninger, A; Moller, SG; Robinson, C			A homolog of Albino3/OxaI is essential for thylakoid biogenesis in the cyanobacterium Synechocystis sp PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; MEMBRANE-PROTEIN INSERTION; HETEROTROPHIC GROWTH; PATHWAYS; MITOCHONDRIAL; CHLOROPLASTS; TRANSPORT; IMPORT; BACTERIAL; SEQUENCE	YidC/OxaI play essential roles in the insertion of a wide range of membrane proteins in Eschericha coli and mitochondria, respectively. In contrast, the chloroplast thylakoid homolog Albino3 (Alb3) facilitates the insertion of only a specialized subset of proteins, and the vast majority insert into thylakoids by a pathway that is so far unique to chloroplasts. In this study, we have analyzed the role of Alb3 in the cyanobacterium Synechocystis sp. PCC6803, which contains internal thylakoids that are similar in some respects to those of chloroplasts. The single alb3 gene (slr1471) was disrupted by the introduction of an antibiotic cassette, and photoautotrophic growth resulted in the generation of a merodiploid species (but not full segregation), indicating an essential role for Alb3 in maintaining the photosynthetic apparatus. Thylakoid organization is lost under these conditions, and the levels of photosynthetic pigments fall to similar to40% of wild-type levels. Photosynthetic electron transport and oxygen evolution are reduced by a similar extent. Growth on glucose relieves the selective pressure to maintain photosynthetic competence, and under these conditions, the cells become completely bleached, again indicating that Alb3 is essential for thylakoid biogenesis. Full segregation could not be achieved under any growth regime, strongly suggesting that the slr1471 open reading frame is essential for cell viability.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Leicester, Fac Med & Biol Sci, Dept Biol, Leicester LE1 7RT, Leics, England	University of Warwick; University of Leicester	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk		Moller, Simon/0000-0002-0460-3592				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Bellafiore S, 2002, PLANT CELL, V14, P2303, DOI 10.1105/tpc.003442; Campbell D, 1998, MICROBIOL MOL BIOL R, V62, P667, DOI 10.1128/MMBR.62.3.667-683.1998; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DOUCE R, 1996, ADV PHOTOSYNTH, V4, P69; Fulgosi H, 2002, P NATL ACAD SCI USA, V99, P11501, DOI 10.1073/pnas.172032599; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Robinson C, 2001, TRAFFIC, V2, P245, DOI 10.1034/j.1600-0854.2001.1r010.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	33	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55792	55800		10.1074/jbc.M411041200	http://dx.doi.org/10.1074/jbc.M411041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498761	hybrid			2022-12-25	WOS:000225960800101
J	Clark, AB; Kunkel, TA				Clark, AB; Kunkel, TA			Cadmium inhibits the functions of eukaryotic MutS complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; ATPASE DOMAINS; PROTEIN MUTS; CANCER; REPLICATION; MECHANISMS; AFFINITY; DEFECTS; SUBUNIT	Exposure of yeast cells to low concentrations of cadmium results in elevated mutation rates due to loss of mismatch repair (MMR), and cadmium inhibits MMR activity in extracts of human cells (1). Here we show that cadmium inhibits both Msh2-Msh6- and Msh2-Msh3-dependent human MMR activity in vitro. This inhibition, which occurs at a step or steps preceding repair DNA synthesis, is observed for repair directed by either a 3' or a 5' nick. In an attempt to identify the protein target(s) of cadmium inhibition, we show that cadmium inhibition of MMR is not reversed by addition of zinc to the repair reaction, suggesting that the target is not a zinc metalloprotein. We then show that cadmium inhibits ATP hydrolysis by yeast Msh2-Msh6 but has no effect on ATPase hydrolysis by yeast Mlh1-Pms1. Steady state kinetic analysis with wild type Msh2-Msh6, and with heterodimers containing subunit-specific Glu to Ala replacements inferred to inactivate the ATPase activity of either Msh2 or Msh6, suggest that cadmium inhibits ATP hydrolysis by Msh6 but not Msh2. Cadmium also reduces DNA binding by Msh2-Msh6 and more so for mismatched than matched duplexes. These data indicate that eukaryotic Msh2-Msh3 and Msh2-Msh6 complexes are targets for inhibition of MMR by cadmium, a human lung carcinogen that is ubiquitous in the environment.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065089, ZIAES065089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; *DHHS NIEHS NAT TO, 2000, 9 DHHSNIEHS NAT TOX; Drotschmann K, 2002, DNA REPAIR, V1, P743, DOI 10.1016/S1568-7864(02)00081-2; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172; Jiricny J, 2003, CURR OPIN GENET DEV, V13, P61, DOI 10.1016/S0959-437X(03)00004-2; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lamers MH, 2004, J BIOL CHEM, V279, P43879, DOI 10.1074/jbc.M406380200; Lamers MH, 2003, EMBO J, V22, P746, DOI 10.1093/emboj/cdg064; Li GM, 2003, FRONT BIOSCI-LANDMRK, V8, pD997, DOI 10.2741/1121; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Lutzen A, 2004, BIOCHEM BIOPH RES CO, V321, P21, DOI 10.1016/j.bbrc.2004.06.102; MARCOVECCHIO JE, 1993, ENVIRON MONIT ASSESS, V25, P119, DOI 10.1007/BF00549133; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; McMurray CT, 2003, NAT GENET, V34, P239, DOI 10.1038/ng0703-239; Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; Schofield MJ, 2003, ANNU REV MICROBIOL, V57, P579, DOI 10.1146/annurev.micro.57.030502.090847; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; THOMAS DC, 1995, METHODS COMPANION ME, V7; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Yang W, 2000, COLD SPRING HARB SYM, V65, P225, DOI 10.1101/sqb.2000.65.225	39	42	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53903	53906		10.1074/jbc.C400495200	http://dx.doi.org/10.1074/jbc.C400495200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15513922	hybrid			2022-12-25	WOS:000225793600002
J	Kathiriya, IS; King, IN; Murakami, M; Nakagawa, M; Astle, JM; Gardner, KA; Gerard, RD; Olson, EN; Srivastava, D; Nakagawa, O				Kathiriya, IS; King, IN; Murakami, M; Nakagawa, M; Astle, JM; Gardner, KA; Gerard, RD; Olson, EN; Srivastava, D; Nakagawa, O			Hairy-related transcription factors inhibit GATA-dependent cardiac gene expression through a signal-responsive mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DEFECTS; HEAVY-CHAIN GENE; PROTEIN-KINASE; IN-VIVO; VENTRAL MORPHOGENESIS; TRANSGENIC MICE; TUBE FORMATION; HYPERTROPHY; ENHANCER; PATHWAY	Combinatorial actions of transcription factors in multiprotein complexes dictate gene expression profiles in cardiac development and disease. The Hairy-related transcription factor (HRT) family of basic helix-loop-helix proteins is composed of transcriptional repressors highly expressed in the cardiovascular system. However, it has remained unclear whether HRT proteins modulate gene expression driven by cardiac transcriptional activators. Here, we have shown that HRT proteins inhibit cardiac gene transcription by interfering with GATA transcription factors that are implicated in cardiac development and hypertrophy. HRT proteins inhibited GATA-dependent transcriptional activation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter. Adenovirus-mediated expression of Hrt2 suppressed mRNA expression of ANF and other cardiac-specific genes in cultured cardiomyocytes. Among various signaling molecules implicated in cardiomyocyte growth, constitutively active Akt1/protein kinase Balpha relieved Hrt2-mediated inhibition of GATA-dependent transcription. HRT proteins physically interacted with GATA proteins, and the basic domain of HRT was critical for physical association as well as transcriptional inhibition. These results suggest that HRT proteins may regulate specific sets of cardiac genes by modulating the function of GATA proteins and other cardiac transcriptional activators in a signal-dependent manner.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nakagawa, O (corresponding author), 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Osamu.Nakagawa@UTSouthwestern.edu			NHLBI NIH HHS [L40 HL078465, L40 HL078465-02] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akazawa H, 2003, CIRC RES, V92, P1079, DOI 10.1161/01.RES.0000072977.86706.23; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Hasegawa K, 1997, CIRCULATION, V96, P3943; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lien CL, 1999, DEVELOPMENT, V126, P75; McFadden DG, 2000, DEVELOPMENT, V127, P5331; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tremblay JJ, 2003, J BIOL CHEM, V278, P22128, DOI 10.1074/jbc.M213149200; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	60	55	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54937	54943		10.1074/jbc.M409879200	http://dx.doi.org/10.1074/jbc.M409879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485867	hybrid			2022-12-25	WOS:000225793600123
J	Jaburek, M; Miyamoto, S; Di Mascio, P; Garlid, KD; Jezek, P				Jaburek, M; Miyamoto, S; Di Mascio, P; Garlid, KD; Jezek, P			Hydroperoxy fatty acid cycling mediated by mitochondrial uncoupling protein UCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; RESPIRATORY-CHAIN; PROTON TRANSPORT; OXIDATIVE STRESS; FREE-RADICALS; MECHANISM; SUPEROXIDE; GENERATION; ACTIVATION; LIVER	Functional activation of mitochondrial uncoupling protein-2 (UCP2) is proposed to decrease reactive oxygen species production. Skulachev and Goglia (Skulachev, V. P., and Goglia, F. (2003) FASEB J. 17, 1585-1591) hypothesized that hydroperoxy fatty acid anions are translocated by UCPs but cannot flip-flop across the membrane. We found that the second aspect is otherwise; the addition of synthesized linoleic acid hydroperoxides (LAOOH, a mix of four isomers) caused a fast flip-flop-dependent acidification of liposomes, comparable with the linoleic acid (LA)-dependent acidification. Using Escherichia coli-expressed UCP2 reconstituted into liposomes we found that LAOOH induced purine nucleotide-sensitive H+ uniport in UCP2-proteoliposomes with higher affinity than LA (K-m values 97 muM for LAOOH and 275 muM for LA). In UCP2-proteoliposomes LAOOH also induced purine nucleotide-sensitive K+ influx balanced by anionic charge transfer, indicating that LAOOH was also transported as an anion with higher affinity than linoleate anion, the Km values being 90 and 350 muM, respectively. These data suggest that hydroperoxy fatty acids are transported via UCP2 by a fatty acid cycling mechanism. This may alternatively explain the observed activation of UCP2 by the externally generated superoxide. The ability of LAOOH to induce UCP2-mediated H+ uniport points to the essential role of superoxide reaction products, such as hydroperoxyl radical, hydroxyl radical, or peroxynitrite, initiating lipoperoxidation, the released products of which support the UCP2-mediated uncoupling and promote the feedback down-regulation of mitochondrial reactive oxygen species production.	Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport Biophys, CR-14220 Prague, Czech Republic; Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05513970 Sao Paulo, Brazil; Portland State Univ, Dept Biol, Portland, OR 97207 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Universidade de Sao Paulo; Portland State University	Jezek, P (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept 75, Videnska 1083, CR-14220 Prague 4, Czech Republic.	jezek@biomed.cas.cz	Miyamoto, Sayuri/A-2144-2008; Di Mascio, Paolo/D-1264-2014; Jaburek, Martin/B-9652-2012; Jezek, Petr/B-9264-2012; Jabůrek, Martin/H-1114-2019	Miyamoto, Sayuri/0000-0002-5714-8984; Di Mascio, Paolo/0000-0003-4125-8350; Jezek, Petr/0000-0002-2720-9395; Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235	FIC NIH HHS [TW01487] Funding Source: Medline; NIDDK NIH HHS [DK 56273] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056273] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKENS J, 1991, J BIOL CHEM, V266, P15091; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bernardi P, 2002, VITAM HORM, V65, P97, DOI 10.1016/S0083-6729(02)65061-7; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; Deiana M, 2001, TOXICOL LETT, V123, P125, DOI 10.1016/S0378-4274(01)00372-1; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duval C, 2002, BIOCHEM CELL BIOL, V80, P757, DOI 10.1139/O02-158; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P1, DOI 10.1016/S0005-2728(03)00109-9; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Girotti AW, 1998, J LIPID RES, V39, P1529; GNAIGER E, 2003, HYPOXIA LIFECYCLE, P1; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Guidarelli A, 2002, BIOCHEM J, V366, P307, DOI 10.1042/BJ20020284; HALLIWELL B, 2002, FREE RADICAL BIO MED, P936; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Lima ES, 2002, BIOCHEMISTRY-US, V41, P10717, DOI 10.1021/bi025504j; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; Madesh M, 1997, ARCH BIOCHEM BIOPHYS, V346, P187, DOI 10.1006/abbi.1997.0288; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MELOV S, 2002, ANN NY ACAD SCI, V959, P219; Miyamoto S, 2003, LIPIDS, V38, P641, DOI 10.1007/s11745-003-1109-6; Miyamoto S, 2003, J AM CHEM SOC, V125, P6172, DOI 10.1021/ja029115o; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Spiteller G, 2002, ANN NY ACAD SCI, V959, P30, DOI 10.1111/j.1749-6632.2002.tb02080.x; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Urbankova E, 2003, J BIOL CHEM, V278, P32497, DOI 10.1074/jbc.M303721200; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	58	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53097	53102		10.1074/jbc.M405339200	http://dx.doi.org/10.1074/jbc.M405339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475368	hybrid			2022-12-25	WOS:000225680600037
J	Kaido, T; Yebra, M; Cirulli, V; Montgomery, AM				Kaido, T; Yebra, M; Cirulli, V; Montgomery, AM			Regulation of human beta-cell adhesion, motility, and insulin secretion by collagen IV and its receptor alpha(1)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; ALPHA(2)BETA(1) INTEGRINS; RAT; EXPRESSION; ISLETS; PANCREAS; ADULT; MIGRATION; PORCINE	Collagens have been shown to influence the survival and function of cultured beta-cells; however, the utilization and function of individual collagen receptors in beta-cells is largely unknown. The integrin superfamily contains up to five collagen receptors, but we have determined that alpha(1)beta(1) is the primary receptor utilized by both fetal and adult beta-cells. Cultured beta-cells adhered to and migrated on collagen type IV (Col-IV), and these responses were mediated almost exclusively by alpha(1)beta(1). The migration of cultured beta-cells to Col-IV significantly exceeded that to other matrix components suggesting that this substrate is of unique importance for beta-cell motility. The interaction of alpha(1)beta(1) with Col-IV also resulted in significant insulin secretion at basal glucose concentrations. A subset of beta-cells in developing islets was confirmed to express alpha(1)beta(1), and this expression co-localized with Col-IV in the basal membranes of juxtaposed endothelial cells. Our findings indicate that alpha(1)beta(1) and Col-IV contribute to beta-cell functions known to be important for islet morphogenesis and glucose homeostasis.	Univ Calif San Diego, Whittier Inst Diabet, Islet Res Lab, Dept Pediat, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Montgomery, AM (corresponding author), Univ Calif San Diego, Whittier Inst Diabet, Islet Res Lab, Dept Pediat, 9894 Genesee Ave, La Jolla, CA 92037 USA.	ammontgo@ucsd.edu						Barg S, 2003, PHARMACOL TOXICOL, V92, P3, DOI 10.1034/j.1600-0773.2003.920102.x; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; Beattie GM, 1997, J CLIN ENDOCR METAB, V82, P1852, DOI 10.1210/jc.82.6.1852; Bernard-Kargar C, 2001, DIABETES, V50, pS125, DOI 10.2337/diabetes.50.2007.S125; BONNERWEIR S, 1988, DIABETES, V37, P616, DOI 10.2337/diabetes.37.5.616; Bosco D, 2001, DIABETES, V50, P1039, DOI 10.2337/diabetes.50.5.1039; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Bosman FT, 2003, J PATHOL, V200, P423, DOI 10.1002/path.1437; Chao S H, 1992, Cell Transplant, V1, P51; Cirulli V, 2000, J CELL BIOL, V150, P1445, DOI 10.1083/jcb.150.6.1445; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Edamura K, 2003, CELL TRANSPLANT, V12, P439, DOI 10.3727/000000003108746867; Gogal RM, 2000, CYTOMETRY, V39, P310, DOI 10.1002/(SICI)1097-0320(20000401)39:4<310::AID-CYTO10>3.0.CO;2-V; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; Kadono G, 2004, PANCREAS, V29, P61, DOI 10.1097/00006676-200407000-00057; Kaido T, 2004, J BIOL CHEM, V279, P17731, DOI 10.1074/jbc.M308425200; Kantengwa S, 1997, EXP CELL RES, V237, P394, DOI 10.1006/excr.1997.3803; KerrConte J, 1996, DIABETES, V45, P1108, DOI 10.2337/diabetes.45.8.1108; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; LIKE AA, 1978, LAB INVEST, V38, P470; LUCASCLERC C, 1993, MOL CELL ENDOCRINOL, V94, P9, DOI 10.1016/0303-7207(93)90046-M; Mercurio AM, 2002, AM J PATHOL, V161, P3, DOI 10.1016/S0002-9440(10)64149-1; METRAKOS P, 1994, TRANSPLANT P, V26, P3349; Moulin V, 2002, BRIT J DERMATOL, V147, P886, DOI 10.1046/j.1365-2133.2002.04975.x; Nagata N, 2002, J BIOMAT SCI-POLYM E, V13, P579, DOI 10.1163/15685620260178418; Nagata N, 2001, CELL TRANSPLANT, V10, P447; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Rooprai HK, 1999, NEUROSCI LETT, V263, P214, DOI 10.1016/S0304-3940(99)00125-1; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; VANDEIJNEN JHM, 1994, CELL TISSUE RES, V277, P115, DOI 10.1007/BF00303087; Vogel WF, 2001, EUR J DERMATOL, V11, P506; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wang RN, 1999, J HISTOCHEM CYTOCHEM, V47, P499, DOI 10.1177/002215549904700408; WEINEL RJ, 1992, INT J CANCER, V52, P827, DOI 10.1002/ijc.2910520526; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; White SA, 1999, J MOL MED-JMM, V77, P79, DOI 10.1007/s001090050306; Yuan S, 1995, TRANSPLANT P, V27, P3364; Yuan SY, 1996, DIFFERENTIATION, V61, P67, DOI 10.1046/j.1432-0436.1996.6110067.x	51	145	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53762	53769		10.1074/jbc.M411202200	http://dx.doi.org/10.1074/jbc.M411202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485856	hybrid			2022-12-25	WOS:000225680600114
J	Liu, AMF; Wong, YH				Liu, AMF; Wong, YH			G(16)-mediated activation of nuclear factor kappa B by the adenosine A(1) receptor involves c-Src, protein kinase C, and ERK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; FMET-LEU-PHE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; COUPLED RECEPTORS; ALPHA; G-ALPHA(16); EXPRESSION; NECROSIS; PATHWAYS	The G(i)-linked adenosine A1 receptor has been shown to mediate anti-inflammatory actions, possibly via modulation of the transcription factor nuclear factor-kappaB (NFkappaB). Here we demonstrate that an adenosine A1 agonist, N-6-cyclohexyladenosine (CHA), activated IKKalpha/beta phosphorylation through PTX-insensitive G proteins in human lymphoblastoma Reh cells. To delineate the mechanism of action, different PTX-insensitive G proteins were expressed in human embryonic kidney 293 cells. Only Galpha(16) supported the CHA-induced IKK phosphorylation and NFkappaB-driven luciferase activity in time-dependent, dose-dependent, and PTX-insensitive manners. Gbetagamma subunits also modulated IKK/NFkappaB, as indicated by the stimulatory actions of G(beta1gamma2) and the abrogation of CHA-induced response by transducin. The participation of phospholipase Cbeta, protein kinase C, and calmodulin-dependent kinase II in CHA-induced IKK/NFkappaB activation were demonstrated by employing specific inhibitors and dominant-negative mutants. Inhibition of c-Src and numerous intermediates along the extracellular signal-regulated (ERK) kinase cascade including Ras, Raf-1 kinase, and MEK1/2 abolished the CHA-induced IKK/NFkappaB activation. Although c-Jun N-terminal kinase and p38 MAPK were also activated by CHA, they were not required for the IKK/NFkappaB regulation. Similar results were obtained using Reh cells. These data suggest that the G(16)-mediated activation of IKK/NFkappaB by CHA required a complex signaling network composed of multiple intermediates.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	boyung@ust.hk		Wong, Yung Hou/0000-0002-0123-7697				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chan JSC, 2000, MOL PHARMACOL, V57, P700, DOI 10.1124/mol.57.4.700; Crespo Piero, 2004, Methods Mol Biol, V250, P203; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; Druey KM, 2003, EXPERT OPIN THER TAR, V7, P475, DOI 10.1517/14728222.7.4.475; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fredholm BB, 2003, DRUG NEWS PERSPECT, V16, P283, DOI 10.1358/dnp.2003.16.5.829316; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hill KJ, 2003, BRIT J PHARMACOL, V139, P721, DOI 10.1038/sj.bjp.0705294; Ho MKC, 2002, NEUROSIGNALS, V11, P115, DOI 10.1159/000058548; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Lee HT, 2004, J AM SOC NEPHROL, V15, P102, DOI 10.1097/01.ASN.0000102474.68613.AE; Lee HT, 2002, AM J PHYSIOL-RENAL, V282, pF844, DOI 10.1152/ajprenal.00195.2001; Lee JWM, 1998, J NEUROCHEM, V70, P2203; Liu AMF, 2003, J BIOMOL SCREEN, V8, P39, DOI 10.1177/1087057102239665; Liu J, 2002, J BIOL CHEM, V277, P20927, DOI 10.1074/jbc.M110712200; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; Marty C, 2003, MOL CELL BIOL, V23, P3847, DOI 10.1128/MCB.23.11.3847-3858.2003; Mody SM, 2000, MOL PHARMACOL, V57, P13; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang Y, 2003, J AM SOC NEPHROL, V14, P28, DOI 10.1097/01.ASN.0000043180.18456.47; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang M, 2003, MOL PHARMACOL, V64, P447, DOI 10.1124/mol.64.2.447; Yang M, 2001, J IMMUNOL, V166, P6885, DOI 10.4049/jimmunol.166.11.6885; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhen XC, 2001, MOL PHARMACOL, V60, P857	49	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53196	53204		10.1074/jbc.M410196200	http://dx.doi.org/10.1074/jbc.M410196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485865	Green Published, hybrid			2022-12-25	WOS:000225680600049
J	Yan, XL; Forbes, BE; McNeil, KA; Baxter, RC; Firth, SM				Yan, XL; Forbes, BE; McNeil, KA; Baxter, RC; Firth, SM			Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEIN; CELL-SURFACE BINDING; ACID-LABILE SUBUNIT; FACTOR-I; AMINO-ACIDS; STRUCTURAL DETERMINANTS; HIGH-AFFINITY; FRAGMENTS; DOMAIN; SUBSTITUTIONS	Insulin-like growth factor-binding protein-3 (IGFBP-3), the major IGFBP in the circulation, sequesters IGF in a stable ternary complex with the acid-labile subunit. The high affinity IGF-binding site is proposed to reside within an N-terminal hydrophobic domain in IGFBP-3, but C-terminal residues have also been implicated in the homologous protein IGFBP-5. We have mutated in various combinations Leu(77), Leu(80), and Leu(81) in the N terminus and Gly(217) and Gln(223) in the C terminus of IGFBP-3. All mutants retained immunoreactivity toward a polyclonal IGFBP-3 antibody, whereas IGF ligand blotting showed that all of the mutants had reduced binding to IGFs. Both solution IGF binding assays and BIAcore analysis indicated that mutations to the N-terminal region caused greater reduction in IGF binding activity than C-terminal mutations. The combined N- and C-terminal mutants showed undetectable binding to IGF-I but retained <10% IGF-II binding activity. Reduced ternary complex formation was seen only in mutants that had considerably reduced IGF-I binding, consistent with previous studies indicating that the binary IGF.IGFBP-3 complex is required for acid-labile subunit binding. Decreased IGF binding was also reflected in the inability of the mutants to inhibit IGF-I signaling in IGF receptor overexpressing cells. However, when present in excess, IGFBP-3 analogs defined as non-IGF-binding by biochemical assays could still inhibit IGF signaling. This suggests that residual binding activity of IGFBP-3 mutants may still be sufficient to inhibit IGF biological activity and questions the use of such analogs to study IGF-independent effects of IGFBP-3.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Adelaide	Firth, SM (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	sfirth@med.usyd.edu.au	Baxter, Robert C/F-3927-2012; Forbes, Briony/R-1838-2019	Baxter, Robert C/0000-0001-5061-2142; Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FIELDER PJ, 1994, GROWTH REGULAT, V4, P164; Firth SM, 1999, PROTEIN EXPRES PURIF, V16, P202, DOI 10.1006/prep.1999.1075; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; GARGOSKY SE, 1991, J ENDOCRINOL, V131, P491, DOI 10.1677/joe.0.1310491; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Hwa V, 1999, ACTA PAEDIATR, V88, P37, DOI 10.1111/j.1651-2227.1999.tb14349.x; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1994, CURR OPIN ENDOCRINOL, V1, P16; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, BIOPHYS J, V75, P583, DOI 10.1016/S0006-3495(98)77549-6; OH YM, 1993, J BIOL CHEM, V268, P14964; Payet LD, 2003, ENDOCRINOLOGY, V144, P2797, DOI 10.1210/en.2003-0102; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; Standker L, 2003, BIOCHEM BIOPH RES CO, V304, P708, DOI 10.1016/S0006-291X(03)00658-2; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; Twigg SM, 1998, J BIOL CHEM, V273, P28791, DOI 10.1074/jbc.273.44.28791; WALSH G, 1995, BIO-TECHNOL, V13, P1167, DOI 10.1038/nbt1195-1167; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	48	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53232	53240		10.1074/jbc.M409345200	http://dx.doi.org/10.1074/jbc.M409345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485880	hybrid			2022-12-25	WOS:000225680600053
J	Cazorla, O; Szilagyi, S; Le Guennec, JY; Vassort, G; Lacampagne, A				Cazorla, O; Szilagyi, S; Le Guennec, JY; Vassort, G; Lacampagne, A			Transmural stretch-dependent regulation of contractile properties in rat heart and its alteration after myocardial infarction	FASEB JOURNAL			English	Article						Ca2+ sensitization; Frank-Starling law; ventricular myocytes; myosin light chain 2; heart failure	LIGHT-CHAIN PHOSPHORYLATION; FRANK-STARLING MECHANISM; MYOFILAMENT CA2+ SENSITIVITY; SKINNED CARDIAC-MUSCLE; FAILING HUMAN HEART; PROTEIN-KINASE-C; VENTRICULAR MYOCYTES; CALCIUM SENSITIVITY; LENGTH DEPENDENCE; MYOSIN-FILAMENTS	The "stretch-sensitization" response is essential to the regulation of heart contractility. An increase in diastolic volume improves systolic contraction. The cellular mechanisms of this modulation, the Frank-Starling law, are still uncertain. Moreover, their alterations in heart failure remains controversial. Here, using left ventricular skinned rat myocytes, we show a nonuniform stretch-sensitization of myofilament activation across the ventricular wall. Stretch-dependent Ca2+ sensitization of myofilaments increases from sub-epicardium to sub-endocardium and is correlated with an increase in passive tension. This passive tension-dependent component of myofibrillar activation is not associated with expression of titin isoforms, changes in troponin I level, and phosphorylation status. Instead, we observe that stretch induces phosphorylation of ventricular myosin light chain 2 isoform (VLC2b) in sub-endocardium specifically. Thus, VLC2b phosphorylation could act as a stretch-dependent modulator of activation tuned within normal heart. Moreover, in postmyocardial infarcted rat, the gradient of stretch-dependent Ca2+ sensitization disappears associated with a lack of VLC2b phosphorylation in sub-endocardium. In conclusion, nonuniformity is a major characteristic of the normal adult left ventricle (LV). The heterogeneous myocardial deformation pattern might be caused not only by the morphological heterogeneity of the tissue in the LV wall, but also by the nonuniform contractile properties of the myocytes across the wall. The loss of a contractile transmural gradient after myocardial infarction should contribute to the impaired LV function.	CHU Arnaud de Villeneuve, INSERM, U637, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Vassort, G (corresponding author), CHU Arnaud de Villeneuve, INSERM, U637, F-34295 Montpellier, France.	vassort@montp.inserm.fr	LE GUENNEC, Jean-Yves/P-1067-2016; cazorla, olivier/D-8376-2016; Lacampagne, Alain/S-3719-2016	cazorla, olivier/0000-0003-0775-203X; Lacampagne, Alain/0000-0003-0264-1787				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; Anand IS, 1997, CIRCULATION, V96, P3974, DOI 10.1161/01.cir.96.11.3974; Bogaert J, 2001, AM J PHYSIOL-HEART C, V280, pH610; Cazorla O, 1999, J MOL CELL CARDIOL, V31, P1215, DOI 10.1006/jmcc.1999.0954; Cazorla O, 2003, BRIT J PHARMACOL, V139, P99, DOI 10.1038/sj.bjp.0705221; Cazorla O, 1997, J MOL CELL CARDIOL, V29, P1629, DOI 10.1006/jmcc.1997.0402; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Cazorla O, 2000, J MOL CELL CARDIOL, V32, P735, DOI 10.1006/jmcc.2000.1115; CLEMENT O, 1992, BIOCHEM J, V285, P311, DOI 10.1042/bj2850311; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7; Fuchs F, 1996, J MOL CELL CARDIOL, V28, P1375, DOI 10.1006/jmcc.1996.0129; Fukuda N, 2003, J PHYSIOL-LONDON, V553, P147, DOI 10.1113/jphysiol.2003.049759; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Granzier HL, 2004, CIRC RES, V94, P284, DOI 10.1161/01.RES.0000117769.88862.F8; HATHAWAY DR, 1985, AM J PHYSIOL, V249, pC345; Helmes M, 1996, CIRC RES, V79, P619, DOI 10.1161/01.RES.79.3.619; Holubarsch C, 1996, CIRCULATION, V94, P683, DOI 10.1161/01.CIR.94.4.683; Konhilas JP, 2003, J PHYSIOL-LONDON, V547, P951, DOI 10.1113/jphysiol.2002.038117; Konhilas JP, 2002, CIRC RES, V90, P59, DOI 10.1161/hh0102.102269; KONHILAS JP, 2003, J PHYSL         0124; KOPP SJ, 1979, J BIOL CHEM, V254, P2007; Lakatta E. G, 1992, HEART CARDIOVASCULAR, P1325; LIU XL, 1995, J MOL CELL CARDIOL, V27, P2613, DOI 10.1006/jmcc.1995.0048; MARGOSSIAN SS, 1992, CIRCULATION, V85, P1720, DOI 10.1161/01.CIR.85.5.1720; Metzger JM, 1999, CIRC RES, V84, P1310, DOI 10.1161/01.RES.84.11.1310; MORANO I, 1988, J MOL CELL CARDIOL, V20, P875, DOI 10.1016/S0022-2828(88)80142-1; Moss RL, 2002, CIRC RES, V90, P11, DOI 10.1161/res.90.1.11; Neagoe C, 2002, CIRCULATION, V106, P1333, DOI 10.1161/01.CIR.0000029803.93022.93; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; RODRIGUEZ EK, 1993, AM J PHYSIOL, V264, pH1048, DOI 10.1152/ajpheart.1993.264.4.H1048; SCHWINGER RHG, 1994, CIRC RES, V74, P959, DOI 10.1161/01.RES.74.5.959; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Toursel T, 2002, J APPL PHYSIOL, V92, P1465, DOI 10.1152/japplphysiol.00621.2001; van der Velden J, 2003, CARDIOVASC RES, V57, P505, DOI 10.1016/S0008-6363(02)00662-4; van der Velden J, 2003, CARDIOVASC RES, V57, P37, DOI 10.1016/S0008-6363(02)00606-5; van der Velden J, 2002, BASIC RES CARDIOL S1, V97, P1118, DOI DOI 10.1007/S003950200040; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; Wannenburg T, 1997, AM J PHYSIOL-HEART C, V273, pH2428, DOI 10.1152/ajpheart.1997.273.5.H2428	43	66	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					88	+		10.1096/fj.04-2066fje	http://dx.doi.org/10.1096/fj.04-2066fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498894	Green Submitted			2022-12-25	WOS:000224849900012
J	Umeda, N; Suzuki, T; Yukawa, M; Ohya, Y; Shindo, H; Watanabe, K; Suzuki, T				Umeda, N; Suzuki, T; Yukawa, M; Ohya, Y; Shindo, H; Watanabe, K; Suzuki, T			Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of the wobble base in mitochondrial tRNAs - Implications for the molecular pathogenesis of human mitochondrial diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SEROVAR TYPHIMURIUM; MODIFICATION DEFECT; RIBONUCLEIC-ACID; MODIFIED URIDINE; GENE; MUTATION; ISCS	Human mitochondrial (mt) tRNA(Lys) has a taurine-containing modified uridine, 5-taurinomethyl-2-thiouridine (taum(5)s(2)U), at its anticodon wobble position. We previously found that the mt tRNA(Lys), carrying the A8344G mutation from cells of patients with myoclonus epilepsy associated with ragged-red fibers (MERRF), lacks the taum(5)s(2)U modification. Here we describe the identification and characterization of a tRNA-modifying enzyme MTU1 (mitochondrial tRNA-specific 2-thiouridylase 1) that is responsible for the 2-thiolation of the wobble position in human and yeast mt tRNAs. Disruption of the yeast MTU1 gene eliminated the 2-thio modification of mt tRNAs and impaired mitochondrial protein synthesis, which led to reduced respiratory activity. Furthermore, when MTO1 or MSS1, which are responsible for the C5 substituent of the modified uridine, was disrupted along with MTU1, a much more severe reduction in mitochondrial activity was observed. Thus, the C5 and 2-thio modifications act synergistically in promoting efficient cognate codon decoding. Partial inactivation of MTU1 in HeLa cells by small interference RNA also reduced their oxygen consumption and resulted in mitochondria with defective membrane potentials, which are similar phenotypic features observed in MERRF.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan	University of Tokyo; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	ts@chembio.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731				AGRIS PF, 1973, BIOCHEMISTRY-US, V12, P4331, DOI 10.1021/bi00746a005; Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185; Antonicka H, 1999, BIOCHEM J, V342, P537, DOI 10.1042/0264-6021:3420537; Apffel A, 1997, ANAL CHEM, V69, P1320, DOI 10.1021/ac960916h; Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; BJORK GR, 1995, BIOSYNTHESIS FUNCTIO, P165; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945; Curran J. F., 1998, MODIFICATION EDITING, P493; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; GUTHRIE C, 1991, GUIDE YEAST GENETICS, P149; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; HOLLEY RW, 1963, BIOCHEM BIOPH RES CO, V10, P186, DOI 10.1016/0006-291X(63)90048-2; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Kalhor HR, 2003, MOL CELL BIOL, V23, P9283, DOI 10.1128/MCB.23.24.9283-9292.2003; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; KATOH T, 2003, NUCL ACIDS RES S, V3, P249; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Kurata S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng145; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X; Li XM, 2002, MOL CELL BIOL, V22, P7701, DOI 10.1128/MCB.22.21.7701-7711.2002; LUSTIG F, 1993, P NATL ACAD SCI USA, V90, P3343, DOI 10.1073/pnas.90.8.3343; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakayashiki T, 1998, J BACTERIOL, V180, P2931, DOI 10.1128/JB.180.11.2931-2935.1998; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SIKORSKI RS, 1989, GENETICS, V122, P19; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; SUZUKI T, 2005, IN PRESS TRENDS CURR, pCH1; Takai K, 2003, NUCLEIC ACIDS RES, V31, P6383, DOI 10.1093/nar/gkg839; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yan QF, 2004, BBA-GENE STRUCT EXPR, V1676, P119, DOI 10.1016/j.bbaexp.2003.11.010; Yarian C, 2000, BIOCHEMISTRY-US, V39, P13390, DOI 10.1021/bi001302g; Yarian C, 2002, J BIOL CHEM, V277, P16391, DOI 10.1074/jbc.M200253200; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905; YOKOYAMA S, 1979, NUCLEIC ACIDS RES, V6, P2611, DOI 10.1093/nar/6.7.2611; Yokoyama S, 1995, MODIFIED NUCLEOSIDES, P207; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599	63	167	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1613	1624		10.1074/jbc.M409306200	http://dx.doi.org/10.1074/jbc.M409306200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509579	Green Published, hybrid			2022-12-25	WOS:000226195200092
J	Heeren, J; Grewal, T; Laatsch, A; Becker, N; Rinninger, F; Rye, KA; Beisiegel, U				Heeren, J; Grewal, T; Laatsch, A; Becker, N; Rinninger, F; Rye, KA; Beisiegel, U			Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; MONOCYTE-DERIVED MACROPHAGES; LIPID EFFLUX; IN-VIVO; CELLULAR CHOLESTEROL; ALZHEIMERS-DISEASE; MOUSE HEPATOCYTES; E POLYMORPHISM	After internalization of triglyceride-rich lipoproteins (TRL) in hepatoma cells, TRL particles are immediately disintegrated in the early endosomal compartment. This involves the targeting of lipids and apoprotein B along the degradative pathway and the recycling of TRL-derived apoE through recycling endosomes. Re-secretion of apoE is accompanied by the concomitant association of apoE and cellular cholesterol with high-density lipoproteins (HDL). Since epidemiological data showed that apoE3 and apoE4 have differential effects on HDL metabolism, we investigated whether the intracellular processing of TRL-derived apoE4 differs from apoE3-TRL. In this study, we demonstrated by radioactive and immunofluorescence uptake experiments that cell-surface binding and internalization of TRL-derived apoE4 are increased compared with apoE3 in hepatoma cells. Pulse-chase experiments revealed that HDL-induced recycling, but not disintegration and degradation, of apoE4-enriched TRL is strongly reduced in these cells. Furthermore, impaired HDL-induced apoE4 recycling is associated with reduced cholesterol efflux. Studies performed in Tangier fibroblasts showed that apoE recycling does not depend on ATP-binding cassette transporter A1 activity. These studies provide initial evidence that impaired recycling of apoE4 could interfere with intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile observed in apoE4 homozygotes.	Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Mol Cell Biol 2, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ New S Wales, Ctr Immunol, St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Heart Res Inst, Camperdown, NSW 2050, Australia	University of Hamburg; University of Hamburg; St Vincents Hospital Sydney; University of New South Wales Sydney; University of Sydney; Heart Research Institute	Heeren, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol Mol Cell Biol 2, Martinistr 52, D-20246 Hamburg, Germany.	heeren@uke.uni-hamburg.de		Becker, Nils/0000-0002-4732-0138; Grewal, Thomas/0000-0002-7937-8887				BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bohnet K, 1996, J LIPID RES, V37, P1316; Costet P, 2000, J BIOL CHEM, V275, P28240; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Farkas MH, 2004, J LIPID RES, V45, P1546, DOI 10.1194/jlr.M400104-JLR200; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; Hopkins PCR, 2002, J LIPID RES, V43, P1881, DOI 10.1194/jlr.M200172-JLR200; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Laatsch A, 2004, EUR J CELL BIOL, V83, P113, DOI 10.1078/0171-9335-00364; Lin CY, 1999, J LIPID RES, V40, P1618; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Malloy SI, 2004, ARTERIOSCL THROM VAS, V24, P91, DOI 10.1161/01.ATV.0000094963.07902.FB; Mamotte CDS, 1999, AM J PHYSIOL-ENDOC M, V276, pE553, DOI 10.1152/ajpendo.1999.276.3.E553; Mann WA, 1999, ATHEROSCLEROSIS, V145, P61, DOI 10.1016/S0021-9150(99)00015-5; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	55	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55483	55492		10.1074/jbc.M409324200	http://dx.doi.org/10.1074/jbc.M409324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485881	hybrid			2022-12-25	WOS:000225960800063
J	Hertel, J; Struthers, H; Horj, CB; Hruz, PW				Hertel, J; Struthers, H; Horj, CB; Hruz, PW			A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER ISOFORM GLUT4; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; DIFFERENTIATION; HYPERLIPIDEMIA; INFECTION; MEMBRANE; BINDING; EPITOPE; CELLS	Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible noncompetitive inhibitors of GLUT4 with binding affinities in the low micromolar range and are known to contribute to alterations in glucose homeostasis during treatment of HIV infection. As aspartyl protease inhibitors, these compounds all possess a core peptidomimetic structure together with flanking hydrophobic moieties. To determine the molecular basis for GLUT4 inhibition, a family of related oligopeptides containing structural elements found in PIs was screened for their ability to inhibit 2-deoxyglucose transport in primary rat adipocytes. The peptide oxybenzylcarbonyl-His-Phe-Phe-O-ethyl ester (zHFFe) was identified as a potent inhibitor of zero-trans glucose flux with a K-i of 26 muM. Similar to PIs, transport inhibition by this peptide was acute, noncompetitive, and reversible. Within a Xenopus oocyte expression system, zHFFe acutely and reversibly inhibited GLUT4-mediated glucose uptake, whereas GLUT1 activity was unaffected at concentrations as high as 1 mM. The related photoactivatable peptide zHFF-p-benzoylphenylalanine-[I-125] Tyr-O-ethyl ester selectively labeled GLUT4 in rat adipocytes and indinavir effectively protected against photolabeling. Furthermore, GLUT4 bound to a peptide affinity column containing the zHFF sequence and was eluted by indinavir. These data establish a structural basis for PI effects on GLUT4 activity and support the direct binding of PIs to the transport protein as the mechanism for acute inhibition of insulin-stimulated glucose uptake.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hruz, PW (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	hruz_p@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	NIAID NIH HHS [AI 48747, K08 AI049747] Funding Source: Medline; NIDDK NIH HHS [DK 064572, R01 DK064572] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048747, K08AI049747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064572] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1986, BIOCHEMISTRY-US, V25, P3944, DOI 10.1021/bi00361a031; Cammalleri C, 2003, J LIPID RES, V44, P103, DOI 10.1194/jlr.M200245-JLR200; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; INOUYE K, 1966, BIOCHEMISTRY-US, V5, P2473, DOI 10.1021/bi00871a044; KELLER K, 1989, J BIOL CHEM, V264, P18884; Koster JC, 2003, DIABETES, V52, P1695, DOI 10.2337/diabetes.52.7.1695; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; MURPHY R, 2003, P 10 C RETR OPP INF; NOOR M, 2000, ANTIVIR THER S, V5, P8; Noordam JC, 2002, J CHEMOMETR, V16, P1, DOI 10.1002/cem.656; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Schutt M, 2000, DIABETOLOGIA, V43, P1145, DOI 10.1007/s001250051505; Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; Wang S, 2002, ANTIVIR THER, V7, pL6; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Woerle IJ, 2003, DIABETES, V52, P918, DOI 10.2337/diabetes.52.4.918; Xu AM, 2004, ENDOCRINOLOGY, V145, P487, DOI 10.1210/en.2003-1140	23	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55147	55152		10.1074/jbc.M410826200	http://dx.doi.org/10.1074/jbc.M410826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496402	Green Accepted, hybrid			2022-12-25	WOS:000225960800021
J	Monjas, A; Alcover, A; Alarcon, B				Monjas, A; Alcover, A; Alarcon, B			Engaged and bystander T cell receptors are down-modulated by different endocytotic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ANTIGEN RECEPTOR; MULTIVALENT STRUCTURE; INTRACELLULAR FATE; MEMBRANE RAFTS; ACTIVATION; TCR; INTERNALIZATION; COMPLEXES; SUPERANTIGEN	T cell antigen receptor (TCR) engagement by stimulatory antibodies or its major histocompatibility complex-antigen ligand results in its down-modulation from the cell surface, a phenomenon that is thought to play a role in T cell desensitization. However, TCR engagement results in the down-modulation not only of the engaged receptors but also of non-engaged bystander TCRs. We have investigated the mechanisms that mediate the down-modulation of engaged and bystander receptors and show that co-modulation of the bystander TCRs requires protein-tyrosine kinase activity and is mediated by clathrin-coated pits. In contrast, the down-modulation of engaged TCRs is independent of protein-tyrosine kinases and clathrin pits, suggesting that this process is mediated by an alternate mechanism. Indeed, down-modulation of engaged TCRs appears to depend upon lipid rafts, because cholesterol depletion with methyl-beta-cyclodextrin completely blocks this process. Thus, two independent pathways of internalization are involved in TCR down-modulation and act differentially on directly engaged and bystander receptors. Finally, we propose that although both mechanisms coexist, the predominance of one or the other mechanisms will depend on the dose of ligand.	Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Inst Pasteur, Unite Biol Interact Cellulaires, CNRS, URA 2582, F-75724 Paris 15, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Alarcon, B (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain.	balarcon@cbm.uam.es	Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070; Alcover, Andres/0000-0002-9507-3450				Abad JL, 2002, J GENE MED, V4, P27, DOI 10.1002/jgm.242; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Benmerah A, 1999, J CELL SCI, V112, P1303; Bonefeld CM, 2003, J IMMUNOL, V171, P3003, DOI 10.4049/jimmunol.171.6.3003; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Crotzer VL, 2004, J EXP MED, V199, P981, DOI 10.1084/jem.20031105; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; Dietrich J, 2002, J IMMUNOL, V168, P5434, DOI 10.4049/jimmunol.168.11.5434; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Haks MC, 2001, J IMMUNOL, V166, P2576, DOI 10.4049/jimmunol.166.4.2576; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jose ES, 1997, VIROLOGY, V239, P303, DOI 10.1006/viro.1997.8872; Jose ES, 1998, EUR J IMMUNOL, V28, P12; Jose ES, 2000, IMMUNITY, V12, P161, DOI 10.1016/S1074-7613(00)80169-7; JOSE ES, 1999, J BIOL CHEM, V274, P33740; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Legendre V, 1999, INT IMMUNOL, V11, P1731, DOI 10.1093/intimm/11.11.1731; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; LUTON F, 1994, J IMMUNOL, V153, P63; Martin S, 1998, EUR J IMMUNOL, V28, P2991, DOI 10.1002/(SICI)1521-4141(199810)28:10<2991::AID-IMMU2991>3.3.CO;2-2; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NIEDERGANG F, 1995, J BIOL CHEM, V270, P12839, DOI 10.1074/jbc.270.21.12839; Niedergang F, 1998, J IMMUNOL, V161, P6054; Niedergang F, 1997, J IMMUNOL, V159, P1703; Niedergang F, 1997, RES IMMUNOL, V148, P231, DOI 10.1016/S0923-2494(97)80865-6; Salio M, 1997, EUR J IMMUNOL, V27, P1769, DOI 10.1002/eji.1830270726; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Stotz SH, 1999, J EXP MED, V189, P253, DOI 10.1084/jem.189.2.253; Torres PS, 2003, J IMMUNOL, V170, P5947, DOI 10.4049/jimmunol.170.12.5947; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0	43	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55376	55384		10.1074/jbc.M409342200	http://dx.doi.org/10.1074/jbc.M409342200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15516342	hybrid			2022-12-25	WOS:000225960800051
J	Emonard, H; Bellon, G; Troeberg, L; Berton, A; Robinet, A; Henriet, P; Marbaix, E; Kirkegaard, K; Patthy, L; Eeckhout, Y; Nagase, H; Hornebeck, W; Courtoy, PJ				Emonard, H; Bellon, G; Troeberg, L; Berton, A; Robinet, A; Henriet, P; Marbaix, E; Kirkegaard, K; Patthy, L; Eeckhout, Y; Nagase, H; Hornebeck, W; Courtoy, PJ			Low density lipoprotein receptor-related protein mediates endocytic clearance of Pro-MMP-2 center dot TIMP-2 complex through a thrombospondin-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE MT1-MMP; ENDOMETRIAL STROMAL CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; TISSUE INHIBITOR; IV COLLAGENASE; GELATINASE-A; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; TYROSINE PHOSPHORYLATION; CELLULAR INTERNALIZATION	The low density lipoprotein receptor-related protein (LRP) mediates the endocytic clearance of various proteinases and proteinase . inhibitor complexes, including thrombospondin (TSP)-dependent endocytosis of matrix metalloproteinase (MMP)-2 ( or gelatinase A), a key effector of extracellular matrix remodeling and cancer progression. However, the zymogen of MMP-2 (pro-MMP-2) mostly occurs in tissues as a complex with the tissue inhibitor of MMPs (TIMP-2). Here we show that clearance of the pro-MMP-2 . TIMP-2 complex is also mediated by LRP, because addition of receptor-associated protein ( RAP), a natural LRP ligand antagonist, inhibited endocytosis and lysosomal degradation of I-125-pro-MMP-2 . TIMP-2. Both TIMP-2 and the pro-MMP-2 collagen-binding domain independently competed for endocytosis of I-125-pro-MMP-2 . TIMP-2 complex. Surface plasmon resonance studies indicated that pro-MMP-2, TIMP-2, and pro-MMP-2 . TIMP- 2 directly interact with LRP in the absence of TSP. LRP-mediated endocytic clearance of I-125-pro-MMP-2 was inhibited by anti-TSP antibodies and accelerated upon complexing with TSP-1, but these treatments had no effect on I-125-pro-MMP-2 . TIMP- 2 uptake. This implies that mechanisms of clearance by LRP of pro-MMP-2 and pro-MMP-2 . TIMP- 2 complex are different. Interestingly, RAP did not inhibit binding of I-125-pro-MMP-2 . TIMP- 2 to the cell surface. We conclude that clearance of pro-MMP-2 . TIMP- 2 complex is a TSP-independent two-step process, involving (i) initial binding to the cell membrane in a RAP-insensitive manner and (ii) subsequent LRP-dependent (RAP-sensitive) internalization and degradation.	Fac Med, IFR Biomol 53, CNRS, UMR 6198, F-51100 Reims, France; Christian de Duve Inst Cellular Pathol, Cell Biol Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England; Univ Aarhus, Inst Med Biochem, Aarhus, Denmark; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Universite Catholique Louvain; Imperial College London; University of Oxford; Aarhus University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Courtoy, PJ (corresponding author), UCL ICP 7541, CELL Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.	courtoy@cell.ucl.ac.be	Emonard, Hervé/AAD-5432-2019; Patthy, Laszlo/Q-6058-2019; Emonard, Herve/R-9718-2019; Patthy, Laszlo/A-2353-2013	/0000-0003-0939-4651; Kirkegaard, Kirstine/0000-0001-8267-9042; Henriet, Patrick/0000-0003-4602-8888				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Berton A, 2001, J BIOL CHEM, V276, P20458, DOI 10.1074/jbc.M011664200; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; CASSLEN B, 1995, J CLIN ENDOCR METAB, V80, P2776, DOI 10.1210/jc.80.9.2776; Casslen B, 1998, MOL HUM REPROD, V4, P585, DOI 10.1093/molehr/4.6.585; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; deVries TJ, 1996, CANCER RES, V56, P1432; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Foca C, 2000, MOL HUM REPROD, V6, P921, DOI 10.1093/molehr/6.10.921; Fridman R, 2003, CURR TOP DEV BIOL, V54, P75, DOI 10.1016/S0070-2153(03)54005-4; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh T, 1998, CANCER RES, V58, P1048; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; KANCHA RK, 1994, ONCOL RES, V6, P365; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LIMET JN, 1985, EUR J BIOCHEM, V146, P539, DOI 10.1111/j.1432-1033.1985.tb08685.x; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Nagase H, 1997, BIOL CHEM, V378, P151; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Tyteca D, 2002, EXP CELL RES, V281, P86, DOI 10.1006/excr.2002.5613; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	69	86	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54944	54951		10.1074/jbc.M406792200	http://dx.doi.org/10.1074/jbc.M406792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489233	hybrid			2022-12-25	WOS:000225793600124
J	Rametti, A; Esclaire, F; Yardin, C; Terro, F				Rametti, A; Esclaire, F; Yardin, C; Terro, F			Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICAL FILAMENT-TAU; CEREBELLAR GRANULE CELLS; ICE-LIKE PROTEASES; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MICROTUBULE-BINDING; SERUM DEPRIVATION; PC12 CELLS; PROTEIN; DEPHOSPHORYLATION	Neurofibrillary tangles (NFTs) are classic lesions of Alzheimer's disease. NFTs are bundles of abnormally phosphorylated tau, the paired helical filaments. The initiating mechanisms of NFTs and their role in neuronal loss are still unknown. Accumulating evidence supports a role for the activation of proteolytic enzymes, caspases, in neuronal death observed in brains of patients with Alzheimer's disease. Alterations in tau phosphorylation and tau cleavage by caspases have been previously reported in neuronal apoptosis. However, the links between the alterations in tau phosphorylation and its proteolytic cleavage have not yet been documented. Here, we show that, during staurosporine-induced neuronal apoptosis, tau first undergoes transient hyperphosphorylation, which is followed by dephosphorylation and cleavage. This cleavage generated a 10-kDa fragment in addition to the 17- and 50-kDa tau fragments previously reported. Prior tau dephosphorylation by a glycogen synthase kinase-3beta inhibitor, lithium, enhanced tau cleavage and sensitized neurons to staurosporine-induced apoptosis. Caspase inhibition prevented tau cleavage without reversing changes in tau phosphorylation linked to apoptosis. Furthermore, the microtubule depolymerizing agent, colchicine, induced tau dephosphorylation and caspase-independent tau cleavage and degradation. Both phenomena were blocked by inhibiting protein phosphatase 2A (PP2A) by okadaic acid. These experiments indicate that tau dephosphorylation precedes and is required for its cleavage and degradation. We propose that the absence of cleavage and degradation of hyperphosphorylated tau ( due to PP2A inhibition) may lead to its accumulation in degenerating neurons. This mechanism may contribute to the aggregation of hyperphosphorylated tau into paired helical filaments in Alzheimer's disease where reduced PP2A activity has been reported.	Fac Med Limoges, Dept Histol & Cell Biol, EA 3842, F-87025 Limoges, France		Terro, F (corresponding author), Fac Med Limoges, Dept Histol & Cell Biol, EA 3842, 2 Rue Dr Marcland, F-87025 Limoges, France.	faraj.terro@unilim.fr	TERRO, FARAJ/O-8423-2016	TERRO, FARAJ/0000-0002-3655-3964				Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003; BAUM L, 1995, MOL BRAIN RES, V34, P1, DOI 10.1016/0169-328X(95)00111-5; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BUEESCHERRER V, 1995, AM J PATHOL, V146, P924; Canu N, 1998, J NEUROSCI, V18, P7061; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; Davis PK, 1999, J BIOL CHEM, V274, P35686, DOI 10.1074/jbc.274.50.35686; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hall Garth F., 1999, J Alzheimers Dis, V1, P379; JAMESON L, 1980, BIOCHEMISTRY-US, V19, P2472, DOI 10.1021/bi00552a027; JENKINS SM, 2000, BIOCHEM J, V275, P263; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lesort M, 1997, MOL BRAIN RES, V45, P127, DOI 10.1016/S0169-328X(96)00284-7; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; McCarthy MJ, 1997, J CELL SCI, V110, P2165; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Mills JC, 1998, J CELL SCI, V111, P625; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sergeant N, 1997, J NEUROCHEM, V69, P834; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Terro F, 2000, NEUROSCI LETT, V278, P149, DOI 10.1016/S0304-3940(99)00911-8; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; YEN SH, 1995, NEUROBIOL AGING, V16, P381, DOI 10.1016/0197-4580(95)00022-7; Zhang JW, 2000, J NEUROCHEM, V75, P2346, DOI 10.1046/j.1471-4159.2000.0752346.x	38	51	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54518	54528		10.1074/jbc.M408186200	http://dx.doi.org/10.1074/jbc.M408186200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475565	hybrid			2022-12-25	WOS:000225793600076
J	Fang, J; Chen, TP; Chadwick, B; Li, E; Zhang, Y				Fang, J; Chen, TP; Chadwick, B; Li, E; Zhang, Y			Ring1b-mediated H2A ubiquitination associates with inactive X chromosomes and is involved in initiation of X inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-27 METHYLATION; HISTONE H3; TRANSCRIPTIONAL ACTIVATION; FEMALE MAMMALS; STEM-CELLS; XIST GENE; MOUSE; COMPLEXES; PROTEIN; RAD6	Histone modifications are thought to serve as epigenetic markers that mediate dynamic changes in chromatin structure and regulation of gene expression. As a model system for understanding epigenetic silencing, X chromosome inactivation has been previously linked to a number of histone modifications including methylation and hypoacetylation. In this study, we provide evidence that supports H2A ubiquitination as a novel epigenetic marker for the inactive X chromosome (Xi) and links H2A ubiquitination to initiation of X inactivation. We found that the H2A-K119 ubiquitin E3 ligase Ring1b, a Polycomb group protein, is enriched on Xi in female trophoblast stem (TS) cells as well as differentiating embryonic stem (ES) cells. Consistent with Ring1b mediating H2A ubiquitination, ubiquitinated H2A (ubH2A) is also enriched on the Xi of both TS and ES cells. We demonstrate that the enrichment of Ring1b and ubH2A on Xi is transient during TS and ES cell differentiation, suggesting that the Ring1b and ubH2A are involved in the initiation of both imprinted and random X inactivation. Furthermore, we showed that the association of Ring1b and ubH2A with Xi is mitotically stable in nondifferentiated TS cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Duke Univ, Med Ctr, Inst Genome Sci & Policy, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Novartis; Duke University	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	yi_zhang@med.unc.edu		Chadwick, Brian/0000-0001-5272-8384; Zhang, Yi/0000-0002-2789-0811; Fang, Jia/0000-0001-8583-1652	NIGMS NIH HHS [GM63076, GM68804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cohen DE, 2002, CURR OPIN GENET DEV, V12, P219, DOI 10.1016/S0959-437X(02)00289-7; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Uy GD, 2002, DEVELOPMENT, V129, P3913; VASSILEV AP, 1995, J CELL SCI, V108, P1205; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; ZHANG Y, 2004, IN PRESS COLD SPRING, V49	44	202	232	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52812	52815		10.1074/jbc.C400493200	http://dx.doi.org/10.1074/jbc.C400493200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15509584	hybrid, Green Published			2022-12-25	WOS:000225680600003
J	Henderson, NS; So, SSK; Martin, C; Kulkarni, R; Thanassi, DG				Henderson, NS; So, SSK; Martin, C; Kulkarni, R; Thanassi, DG			Topology of the outer membrane usher PapC determined by site-directed fluorescence labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; CELL-SURFACE LOCALIZATION; GENERAL SECRETORY PATHWAY; DRIVES FIBER FORMATION; X-RAY-STRUCTURE; PILUS BIOGENESIS; OXALOBACTER-FORMIGENES; SUBUNIT COMPLEXES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	In contrast to typical membrane proteins that span the lipid bilayer via transmembrane alpha-helices, bacterial outer membrane proteins adopt a beta-barrel architecture composed of antiparallel transmembrane beta-strands. The topology of outer membrane proteins is difficult to predict accurately using computer algorithms, and topology mapping protocols commonly used for alpha-helical membrane proteins do not work for beta-barrel proteins. We present here the topology of the PapC usher, an outer membrane protein required for assembly and secretion of P pili by the chaperone/usher pathway in uropathogenic Escherichia coli. An initial attempt to map PapC topology by insertion of protease cleavage sites was largely unsuccessful due to lack of cleavage at most sites and the requirement to disrupt the outer membrane to identify periplasmic sites. We therefore adapted a site-directed fluorescence labeling technique to permit topology mapping of outer membrane proteins using small molecule probes in intact bacteria. Using this method, we demonstrated that PapC has the potential to encode up to 32 transmembrane beta-strands. Based on experimental evidence, we propose that the usher consists of an N-terminal beta-barrel domain comprised of 26 beta-strands and that a distinct C-terminal domain is not inserted into the membrane but is located instead within the lumen of the N-terminal beta-barrel similar to the plug domains encoded by the outer membrane iron-siderophore uptake proteins.	SUNY Stony Brook, Ctr Infect Dis 242, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Thanassi, DG (corresponding author), SUNY Stony Brook, Ctr Infect Dis 242, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	David.Thanassi@stonybrook.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagos PG, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-29; BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BOCK K, 1985, J BIOL CHEM, V260, P8545; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Guedin S, 2000, J BIOL CHEM, V275, P30202, DOI 10.1074/jbc.M005515200; Harms Nellie, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P319; KLEMM P, 1990, MOL GEN GENET, V220, P334; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; Newton SMC, 1996, J BACTERIOL, V178, P3447, DOI 10.1128/jb.178.12.3447-3456.1996; Ng TW, 2004, J BACTERIOL, V186, P5321, DOI 10.1128/JB.186.16.5321-5331.2004; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nishlyama M, 2003, J MOL BIOL, V330, P513, DOI 10.1016/S0022-2836(03)00591-6; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Saulino ET, 1998, EMBO J, V17, P2177, DOI 10.1093/emboj/17.8.2177; SCHIFFERLI DM, 1994, J BACTERIOL, V176, P1099, DOI 10.1128/JB.176.4.1099-1110.1994; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Seal RP, 1998, METHOD ENZYMOL, V296, P318; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Tamm LK, 2001, J BIOL CHEM, V276, P32399, DOI 10.1074/jbc.R100021200; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Thanassi DG, 2002, J BACTERIOL, V184, P6260, DOI 10.1128/JB.184.22.6260-6269.2002; VALENT QA, 1995, MOL MICROBIOL, V16, P1243, DOI 10.1111/j.1365-2958.1995.tb02346.x; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	49	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53747	53754		10.1074/jbc.M409192200	http://dx.doi.org/10.1074/jbc.M409192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485883	hybrid			2022-12-25	WOS:000225680600112
J	Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB				Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB			Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappa B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation	ONCOGENE			English	Article						NSAID; NF-kappa B; I kappa B alpha; COX-2; cyclin D1; proliferation	NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RANDOMIZED-TRIAL; PHORBOL ESTER; IN-VITRO; ASPIRIN; KINASE	Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been shown to suppress transcription factor NF-kappaB, which controls the expression of genes such as cyclooxygenase (COX)-2 and cyclin D1, leading to inhibition of proliferation of tumor cells. There is no systematic study as to how these drugs differ in their ability to suppress NF-kappaB activation and NF-kappaB-regulated gene expression or cell proliferation. In the present study, we investigated the effect of almost a dozen different commonly used NSAIDs on tumor necrosis factor (TNF)-induced NF-kappaB activation and NF-kappaB-regulated gene products, and on cell proliferation. Dexamethasone, an anti-inflammatory steroid, was included for comparison with NSAIDs. As indicated by DNA binding, none of the drugs alone activated NF-kappaB. All compounds inhibited TNF-induced NF-kappaB activation, but with highly variable efficacy. The 50% inhibitory concentration required was 5.67, 3.49, 3.03, 1.25, 0.94, 0.60, 0.38, 0.084, 0.043, 0.027, 0.024, and 0.010 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. All drugs inhibited IkappaBalpha kinase and suppressed IkappaBalpha degradation and NF-kappaB-regulated reporter gene expression. They also suppressed NF-kappaB-regulated COX-2 and cyclin D1 protein expression in a dose-dependent manner. All compounds inhibited the proliferation of tumor cells, with 50% inhibitory concentrations of 6.09, 1.12, 0.65, 0.49, 1.01, 0.19, 0.36, 0.012, 0.016, 0.047, 0.013, and 0.008 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. Overall these results indicate that aspirin and ibuprofen are least potent, while resveratrol, curcumin, celecoxib, and tamoxifen are the most potent anti-inflammatory and antiproliferative agents of those we studied.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Botting JH, 1999, DRUG TODAY, V35, P225, DOI 10.1358/dot.1999.35.4-5.552199; Bryant CE, 2003, AM J VET RES, V64, P211, DOI 10.2460/ajvr.2003.64.211; Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Arriba AF, 1999, MOL PHARMACOL, V55, P753; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giercksky KE, 2001, BEST PRACT RES CL GA, V15, P821, DOI 10.1053/bega.2001.0237; Goel A, 2003, CLIN CANCER RES, V9, P383; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; Hinz M, 1999, MOL CELL BIOL, V19, P2690; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jack DB, 1997, LANCET, V350, P437, DOI 10.1016/S0140-6736(97)07087-6; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kisley LR, 2002, CARCINOGENESIS, V23, P1653, DOI 10.1093/carcin/23.10.1653; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Moysich KB, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-31; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; O'Neill EA, 1998, NATURE, V396, P15, DOI 10.1038/23810; ROTH GJ, 1994, BLOOD, V83, P885; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Scheuren N, 1998, BRIT J PHARMACOL, V123, P645, DOI 10.1038/sj.bjp.0701652; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams CS, 2000, CANCER RES, V60, P6045; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	47	245	257	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9247	9258		10.1038/sj.onc.1208169	http://dx.doi.org/10.1038/sj.onc.1208169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489888				2022-12-25	WOS:000225638000010
J	Wu, YY; Chang, YC; Hsu, TL; Hsieh, SL; Lai, MZ				Wu, YY; Chang, YC; Hsu, TL; Hsieh, SL; Lai, MZ			Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR SUPERFAMILY; LIGAND-INDUCED APOPTOSIS; DEATH RECEPTORS; CANCER-CELLS; CYTOCHROME-C; FAS LIGAND; IN-VIVO; T-CELL; MEDIATED APOPTOSIS; LEUKEMIA-CELLS	Decoy receptor 3 (DcR3)/TR6/M68 is a soluble receptor that binds to the Fas ligand LIGHT and TL1A. Elevated levels of DcR3 expression have been found in many tumors. We report an unexpected effect of DcR3 by sensitizing Jurkat and U937 cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cell death triggered by anti-Fas and tumor necrosis factor was unaffected by DcR3. DcR3 by itself did not stimulate apoptosis. The ability to augment TRAIL-initiated cell death was not observed with soluble lymphotoxin beta receptor or soluble death receptor 3, indicating that binding to LIGHT or TL1A alone is insufficient to trigger TRAIL sensitivity. Incubation with DcR3 did not increase the surface expression of TRAIL receptor, and the level of Fas-associated death domain protein and cellular FLICE-like inhibitory protein was not altered. Instead, in the presence of DcR3, TRAIL engagement resulted in an increased activation of caspase-8, an elevated cleavage of Bid, and enhanced release of Smac and cytochrome c from mitochondria to cytosol compared with TRAIL alone. This led to increased activation of caspase-9 and caspase-3. The unusual ability of DcR3 to promote TRAIL-triggered death may be used to potentiate TRAIL efficacy during treatment tumors overexpressing DcR3.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11529, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Taiwan Univ, Inst Immunol, Taipei 11529, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Hsu, Tsui-Ling/H-6704-2015; Hsu, Tsui-Ling/AAE-8821-2019; Lai, Ming-Zong/AAA-4408-2021; Hsieh, Shie-Liang Edmond/ABA-9184-2021	Hsu, Tsui-Ling/0000-0002-2912-3261; Lai, Ming-Zong/0000-0002-3237-4803				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chang YC, 2004, J LEUKOCYTE BIOL, V75, P486, DOI 10.1189/jlb.0903448; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hsu MJ, 2004, EXP CELL RES, V292, P241, DOI 10.1016/j.yexcr.2003.09.019; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hsu TL, 2002, J IMMUNOL, V168, P4846, DOI 10.4049/jimmunol.168.10.4846; Keane MM, 1999, CANCER RES, V59, P734; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ohshima K, 2000, CANCER LETT, V160, P89, DOI 10.1016/S0304-3835(00)00567-X; Otsuki T, 2000, CLIN EXP IMMUNOL, V119, P323; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Roth W, 2001, CANCER RES, V61, P2759; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shi GX, 2003, J IMMUNOL, V171, P3407, DOI 10.4049/jimmunol.171.7.3407; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Takahama Yasushi, 2002, Gastric Cancer, V5, P61, DOI 10.1007/s101200200011; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wan XC, 2003, J CELL BIOCHEM, V89, P603, DOI 10.1002/jcb.10523; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang CR, 2004, CANCER RES, V64, P1122, DOI 10.1158/0008-5472.CAN-03-0609; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427	51	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44211	44218		10.1074/jbc.408842200	http://dx.doi.org/10.1074/jbc.408842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15475369	Bronze			2022-12-25	WOS:000224383100100
J	Hinault, C; Mothe-Satney, I; Gautier, N; Lawrence, JC; Van Obberghen, E				Hinault, C; Mothe-Satney, I; Gautier, N; Lawrence, JC; Van Obberghen, E			Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice	FASEB JOURNAL			English	Article						glucose metabolism; phosphorylation; signaling; insulin-resistance	PROTEIN-KINASE B; P70 S6 KINASE; MESSENGER-RNA TRANSLATION; MAMMALIAN TARGET; SKELETAL-MUSCLE; PHAS-I; GROWTH-FACTOR; RAPAMYCIN; PHOSPHORYLATION; CELLS	Amino acids are nutrients responsible for mammalian target of rapamycin ( mTOR) regulation in mammalian cells. The mTOR protein is mainly known for its role in regulating cell growth, notably via protein synthesis. In addition to amino acids, mTOR is regulated by insulin via a phosphatidylinositol 3-kinase ( PI 3-kinase)-dependent pathway. mTOR mediates crosstalk between amino acids and insulin signaling. We show that in freshly isolated rat adipocytes, insulin stimulates the phosphorylation of mTOR on serine 2448, a protein kinase B (PKB) consensus phosphorylation site. This site is also phosphorylated by amino acids, which in contrast to insulin do not activate PKB. Moreover, insulin and amino acids have an additive effect on mTOR phosphorylation, indicating that they act via two independent pathways. Importantly, amino acids, notably leucine, permit insulin to stimulate PKB when PI 3-kinase is inhibited. They also rescue glucose transport and the mTOR pathway. Further, leucine alone can improve insulin activation of PKB in db/db mice. Our results define the importance of amino acids in insulin signaling and reveal leucine as a key amino acid in disease situations associated with insulin-resistance in adipocytes.	Fac Med, Inst Federatif Rech, INSERM, U145, F-06107 Nice 02, France; Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA USA; Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Virginia; University of Virginia	Mothe-Satney, I (corresponding author), Fac Med, Inst Federatif Rech, INSERM, U145, Ave Valombrose, F-06107 Nice 02, France.	satney@unice.fr	MOTHE-SATNEY, ISABELLE/Q-6377-2016; hinault, charlotte/P-6003-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; hinault, charlotte/0000-0002-3588-039X				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anthony JC, 2000, J NUTR, V130, P2413; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; KODAMA H, 1994, DIABETOLOGIA, V37, P739, DOI 10.1007/s001250050173; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Lynch CJ, 2001, J NUTR, V131, p861S, DOI 10.1093/jn/131.3.861S; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RODBELL M, 1964, J BIOL CHEM, V239, P375; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	42	70	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1894	+		10.1096/fj.03-1409fje	http://dx.doi.org/10.1096/fj.03-1409fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15479767				2022-12-25	WOS:000224849900022
J	Katsuki, M; Chuang, VTG; Nishi, K; Kawahara, K; Nakayama, H; Yamaotsu, N; Hirono, S; Otagiri, M				Katsuki, M; Chuang, VTG; Nishi, K; Kawahara, K; Nakayama, H; Yamaotsu, N; Hirono, S; Otagiri, M			Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha 1-acid glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN ALPHA(1)-ACID GLYCOPROTEIN; ITERATIVE PARTIAL EQUALIZATION; HUMAN EPIDERMOID CARCINOMA; CELL-CYCLE ARREST; PHASE-I TRIAL; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; LOCAL-ANESTHETICS; SCORING FUNCTION	7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor anticancer drug currently undergoing a phase II clinical trial. The low distribution volumes and systemic clearance of UCN-01 in human patients have been found to be caused in part by its extraordinarily high affinity binding to human alpha1-acid glycoprotein (hAGP). In the present study, we photolabeled hAGP with [H-3]UCN-01 without further chemical modification. The photolabeling specificity of [H-3]UCN-01 was confirmed by findings in which other hAGP binding ligands inhibited formation of covalent bonds between hAGP and [H-3]UCN-01. The amino acid sequence of the photolabeled peptide was concluded to be SDVVYTDXK, corresponding to residues Ser-153 to Lys-161 of hAGP. No PTH derivatives were detected at the 8th cycle, which corresponded to the 160th Trp residue. This strongly implies that Trp-160 was photolabeled by [H-3]UCN-01. Three recombinant hAGP mutants (W25A, W122A, and W160A) and wild-type recombinant hAGP were photolabeled by [H-3]UCN-01. Only mutant W160A showed a marked decrease in the extent of photoincorporation. These results strongly suggest that Trp-160 plays a prominent role in the high affinity binding of [H-3]UCN-01 to hAGP. A docking model of UCN-01 and hAGP around Trp-160 provided further details of the binding site topology.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Biopharmaceut, Kumamoto 8620973, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol Cell Funct, Kumamoto 8620973, Japan; Univ Kebangsaan Malaysia, Fac Allied Hlth Sci, Dept Pharm, Kuala Lumpur 50300, Malaysia; Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Kumamoto University; Kumamoto University; Universiti Kebangsaan Malaysia; Kitasato University	Otagiri, M (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	otagirim@gpo.kumamoto-u.ac.jp	Chuang, Victor/A-3644-2011; Yamaotsu, Noriyuki/AAW-2545-2020; Chuang, Victor/A-3644-2011	Chuang, Victor/0000-0002-2141-630X; Yamaotsu, Noriyuki/0000-0002-4302-1085; Chuang, Victor/0000-0003-4543-2256				Abe S, 2000, JPN J CANCER RES, V91, P1192, DOI 10.1111/j.1349-7006.2000.tb00904.x; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1997, CANCER RES, V57, P1495; Bailey DN, 2004, THER DRUG MONIT, V26, P40, DOI 10.1097/00007691-200402000-00009; Braman J, 1996, Methods Mol Biol, V57, P31; Bruno R, 2003, CLIN CANCER RES, V9, P1077; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; CHERESH DA, 1984, IMMUNOLOGY, V51, P541; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037; DAVIS MT, 1992, PROTEIN SCI, V1, P935, DOI 10.1002/pro.5560010712; DENTE L, 1987, EMBO J, V6, P2289, DOI 10.1002/j.1460-2075.1987.tb02503.x; Duche JC, 2000, CLIN BIOCHEM, V33, P197, DOI 10.1016/S0009-9120(00)00048-5; Eder JP, 2004, INVEST NEW DRUG, V22, P139, DOI 10.1023/B:DRUG.0000011790.31292.ef; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; FAN C, 1995, ONCOLOGY, V52, P498; FRIEDMAN ML, 1985, BIOCHEM J, V232, P863, DOI 10.1042/bj2320863; Fuse E, 1998, CANCER RES, V58, P3248; Fuse E, 1999, CANCER RES, V59, P1054; Gambacorti-Passerini C, 2003, CLIN CANCER RES, V9, P625; GASTEIGER J, 1981, ORG MAGN RESONANCE, V15, P353, DOI 10.1002/mrc.1270150408; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Hatanaka Yasumaru, 2002, Current Topics in Medicinal Chemistry, V2, P271, DOI 10.2174/1568026023394182; HAUGHEY DB, 1985, J PHARM PHARMACOL, V37, P285, DOI 10.1111/j.2042-7158.1985.tb05066.x; Hedaya MA, 2001, ANTICANCER RES, V21, P4005; Hochepied T, 2003, CYTOKINE GROWTH F R, V14, P25, DOI 10.1016/S1359-6101(02)00054-0; Israili ZH, 2001, DRUG METAB REV, V33, P161, DOI 10.1081/DMR-100104402; Johnson LN, 2002, PHARMACOL THERAPEUT, V93, P113, DOI 10.1016/S0163-7258(02)00181-X; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KATIRA A, 1993, CLIN EXP IMMUNOL, V92, P347; Katsuki M, 2004, PHARM RES-DORDR, V21, P1648, DOI 10.1023/B:PHAM.0000041461.93787.6b; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Kopecky V, 2003, BIOCHEM BIOPH RES CO, V300, P41, DOI 10.1016/S0006-291X(02)02765-1; KREMER JMH, 1988, PHARMACOL REV, V40, P1; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Kurata N, 2000, BIOL PHARM BULL, V23, P893; KUTE T, 1976, BIOCHIM BIOPHYS ACTA, V420, P195, DOI 10.1016/0005-2795(76)90358-5; MACKIEWICZ A, 1995, GLYCOCONJUGATE J, V12, P241, DOI 10.1007/BF00731326; MARSILI M, 1980, CROAT CHEM ACTA, V53, P601; Mazoit JX, 2004, CLIN PHARMACOKINET, V43, P17, DOI 10.2165/00003088-200443010-00002; MIYOSHI T, 1992, BIOCHEM PHARMACOL, V43, P2161, DOI 10.1016/0006-2952(92)90175-I; Monnerat C, 2004, ANN ONCOL, V15, P316, DOI 10.1093/annonc/mdh052; MORITA K, 1995, THER DRUG MONIT, V17, P107, DOI 10.1097/00007691-199504000-00001; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; Nakai D, 2004, J PHARM SCI-US, V93, P847, DOI 10.1002/jps.20012; Nishi K, 2004, DRUG METAB DISPOS, V32, P1069, DOI 10.1124/dmd.104.000513; Penuelas S, 2003, EUR J BIOCHEM, V270, P4809, DOI 10.1046/j.1432-1033.2003.03874.x; Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485; PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; ROUTLEDGE PA, 1986, BRIT J CLIN PHARMACO, V22, P499, DOI 10.1111/j.1365-2125.1986.tb02927.x; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Sausville EA, 1998, CANCER CHEMOTH PHARM, V42, pS54, DOI 10.1007/s002800051080; SCHMID K, 1977, BIOCHIM BIOPHYS ACTA, V492, P291, DOI 10.1016/0005-2795(77)90080-0; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2002, HEMATOL ONCOL CLIN N, V16, P1229, DOI 10.1016/S0889-8588(02)00049-7; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Taheri S, 2003, J PHARMACOL EXP THER, V304, P71, DOI 10.1124/jpet.102.042028; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tenzer A., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P35, DOI 10.2174/1568011033353533; URIEN S, 1995, BIOCHEM J, V306, P545, DOI 10.1042/bj3060545; VANDIJK W, 1995, ADV EXP MED BIOL, V376, P223; Veering BT, 2002, ANESTHESIOLOGY, V96, P1062, DOI 10.1097/00000542-200205000-00006; Yu Q, 2002, CANCER RES, V62, P5743; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171; Zsila F, 2004, BIOORGAN MED CHEM, V12, P3239, DOI 10.1016/j.bmc.2004.03.074	74	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1384	1391		10.1074/jbc.M411076200	http://dx.doi.org/10.1074/jbc.M411076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509559	hybrid			2022-12-25	WOS:000226195200065
J	Wada, S; Tanabe, K; Yamazaki, A; Niimi, M; Uehara, Y; Niimi, K; Lamping, E; Cannon, RD; Monk, BC				Wada, S; Tanabe, K; Yamazaki, A; Niimi, M; Uehara, Y; Niimi, K; Lamping, E; Cannon, RD; Monk, BC			Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE; YEAST; GENE; EPIDEMIOLOGY; KINASES	Fungal ATP-binding cassette transporter regulation was investigated using Candida glabrata Cdr1p and Pdh1p expressed in Saccharomyces cerevisiae. Rephosphorylation of Pdh1p and Cdr1p was protein kinase A inhibitor-sensitive but responded differentially to Tpk isoforms, stressors, and glucose concentration. Cdr1p Ser(307), which borders the nucleotide binding domain 1 ABC signature motif, and Ser(484), near the membrane, were dephosphorylated on glucose depletion and independently rephosphorylated during glucose exposure or under stress. The S484A enzyme retained half the wild type ATPase activity without affecting azole resistance, but the S307A enzyme was unstable to plasma membrane isolation. Studies of pump function suggested conformational interaction between Ser(484) and Ser(307). An S307A/S484A double mutant, which failed to efflux the Cdr1p substrate rhodamine 6G, had a fluconazole susceptibility 4-fold greater than the Cdr1p expressing strain, twice that of the S307A mutant, but 64-fold less than the control null strain. Stable intragenic suppressors indicative of homodimer nucleotide binding domain 1-nucleotide binding domain 1 interactions partially restored rhodamine 6G pumping and increased fluconazole and rhodamine 6G resistance in the S307A/S484A mutant. Nucleotide binding domain 1 of Cdr1p is a sensor of important physiological stimuli.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Otago, Dept Oral Sci, Dunedin, New Zealand	National Institute of Infectious Diseases (NIID); University of Otago	Niimi, M (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	niimi@nih.go.jp	Lamping, Erwin/C-5104-2009	Cannon, Richard/0000-0002-5398-2066; Monk, Brian/0000-0003-2264-3480; Lamping, Erwin/0000-0002-4942-4782				Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Izumikawa K, 2003, YEAST, V20, P249, DOI 10.1002/yea.962; Jha S, 2003, BIOCHEM BIOPH RES CO, V310, P869, DOI 10.1016/j.bbrc.2003.09.094; Kolling R, 2002, FEBS LETT, V531, P548, DOI 10.1016/S0014-5793(02)03621-9; Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3; Miyazaki H, 1998, ANTIMICROB AGENTS CH, V42, P1695, DOI 10.1128/AAC.42.7.1695; Nanduri J, 2001, MOL BIOL CELL, V12, P1835, DOI 10.1091/mbc.12.6.1835; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; Sanglard D, 1999, ANTIMICROB AGENTS CH, V43, P2753, DOI 10.1128/AAC.43.11.2753; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Taglicht D, 1998, METHOD ENZYMOL, V292, P130; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; Wada S, 2002, J BIOL CHEM, V277, P46809, DOI 10.1074/jbc.M207817200	27	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					94	103		10.1074/jbc.M408252200	http://dx.doi.org/10.1074/jbc.M408252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498768				2022-12-25	WOS:000226025100013
J	Ge, L; Shenoy, SK; Lefkowitz, RJ; DeFea, K				Ge, L; Shenoy, SK; Lefkowitz, RJ; DeFea, K			Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; ALPHA-1-ANTITRYPSIN DEFICIENCY; REPLACEMENT THERAPY; FACTOR VIIA; RECEPTOR 2; PSEUDOPODIA; CHEMOTAXIS; INVASION; SCAFFOLD; DESENSITIZATION	Protease-activated receptor-2 (PAR-2) is activated by trypsin-like serine proteases and can promote cell migration through an ERK1/2-dependent pathway, involving formation of a scaffolding complex at the leading edge of the cell. Previous studies also showed that expression of a dominant negative fragment of beta-arrestin-1 reduces PAR-2-stimulated internalization, ERK1/2 activation, and cell migration; however, this reagent may block association of many proteins, including beta-arrestin-2 with clathrin-coated pits. Here we investigate the role of PAR-2 in the constitutive migration of a metastatic breast cancer cell line, MDA MB-231, and use small interfering RNA to determine the contribution of each beta-arrestin to this process. We demonstrate that a trypsin-like protease secreted from MDA MB-231 cells can promote cell migration through autocrine activation of PAR-2 and this correlates with constitutive localization of PAR-2, beta-arrestin-2, and activated ERK1/2 to pseudopodia. Addition of MEK-1 inhibitors, trypsin inhibitors, a scrambled PAR-2 peptide, and silencing of beta-arrestins with small interfering RNA also reduce base-line migration of MDA MB-231 cells. In contrast, a less metastatic PAR-2 expressing breast cancer cell line does not exhibit constitutive migration, pseudopodia formation, or trypsin secretion; in these cells PAR-2 is more uniformly distributed around the cell periphery. These data demonstrate a requirement for both beta-arrestins in PAR-2-mediated motility and suggest that autocrine activation of PAR-2 by secreted proteases may contribute to the migration of metastatic tumor cells through beta-arrestin-dependent ERK1/2 activation.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Biochem & Mol Biol Program, Riverside, CA 92521 USA; Univ Calif Riverside, Cellular Mol & Dev Biol Program, Riverside, CA 92521 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	DeFea, K (corresponding author), Univ Calif Riverside, Div Biomed Sci, B605 Stat Rd, Riverside, CA 92521 USA.	katie.defea@ucr.edu	Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663; DeFea, Kathryn/0000-0001-6056-907X	NHLBI NIH HHS [R01 HL 016037] Funding Source: Medline; NIGMS NIH HHS [R01 GM066151-02, R01 GM 066151, R01 GM066151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Al-Ani B, 2002, J PHARMACOL EXP THER, V300, P702, DOI 10.1124/jpet.300.2.702; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; COURTNEY M, 1985, NATURE, V313, P149, DOI 10.1038/313149a0; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ducroc R, 2002, LIFE SCI, V70, P1359, DOI 10.1016/S0024-3205(01)01519-3; Eden E, 2003, CHEST, V123, P765, DOI 10.1378/chest.123.3.765; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; GADEK JE, 1981, J CLIN INVEST, V68, P1158, DOI 10.1172/JCI110360; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Greenberg DL, 2003, BIOCHEMISTRY-US, V42, P702, DOI 10.1021/bi027100x; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Kamath L, 2001, CANCER RES, V61, P5933; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McGuire JJ, 2004, J PHARMACOL EXP THER, V309, P1124, DOI 10.1124/jpet.103.064584; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; ZHANG RD, 1991, INVAS METAST, V11, P204	32	140	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55419	55424		10.1074/jbc.M410312200	http://dx.doi.org/10.1074/jbc.M410312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489220	hybrid			2022-12-25	WOS:000225960800056
J	Ganesan, LP; Wei, G; Pengal, RA; Moldovan, L; Moldovan, N; Ostrowski, MC; Tridandapani, S				Ganesan, LP; Wei, G; Pengal, RA; Moldovan, L; Moldovan, N; Ostrowski, MC; Tridandapani, S			The serine/threonine kinase Akt promotes Fc gamma receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTEGRIN-LINKED KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; S6 KINASE; CELLULAR-SURVIVAL; HUMAN MONOCYTES; PKB; PHOSPHORYLATION; IDENTIFICATION	Fcgamma receptor (FcgammaR) clustering by immune complexes activates multiple signaling pathways leading to phagocytosis. We and others have previously reported that Akt is phosphorylated in response to FcgammaR clustering. However, the functional consequence of Akt activation by FcgammaR is not known. Using Raw 264.7 macrophage cells transfected to overexpress either constitutively active myristoylated (Myr)-Akt or a dominant-negative CAAX-Akt and bone marrow macrophages (BMMs) from wild-type and transgenic mice expressing macrophage-specific Myr-Akt, we analyzed the function of Akt in phagocytosis. We report that overexpression of Myr-Akt resulted in significant increase in phagocytic efficiency, whereas CAAX-Akt down-regulated phagocytosis in Raw 264.7 cells. Likewise BMMs expressing Myr-Akt displayed enhanced phagocytic ability. Analyzing the downstream effectors of Akt, we demonstrate that p70S6 kinase is constitutively phosphorylated in Myr-Akt-expressing BMMs. p70S6 kinase is reported to influence actin cytoskeleton and cell migration, suggesting that Akt may influence phagocytosis through the activation of p70S6 kinase. Consistent with this, overexpression of either wild-type or constitutively active but not a kinase-inactive p70S6 kinase in Raw 264.7 cells significantly enhanced phagocytosis. Likewise suppression of p70S6 kinase with rapamycin down-regulated phagocytic efficiency conferred by the expression of constitutively active Akt. These findings demonstrate a novel role for Akt in phagocytosis through the activation of p70S6 kinase.	Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tridandapani, S (corresponding author), Ohio State Univ, Dept Internal Med, Div Pulm & Crit Care Med, 473 W 12th Ave, Columbus, OH 43210 USA.	tridandapani.2@osu.edu	Tridandapani, Susheela/E-4209-2011; Ostrowski, Michael/H-3108-2011	Moldovan, Leni/0000-0003-1967-2408; Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [P01 CA095426, P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095426, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Johanson SO, 1999, EXP CELL RES, V248, P223, DOI 10.1006/excr.1999.4405; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Ozes ON, 1999, NATURE, V401, P82; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pricop L, 2001, J IMMUNOL, V166, P531, DOI 10.4049/jimmunol.166.1.531; Ptak W, 1998, SCAND J IMMUNOL, V47, P136; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Strzelecka-Kiliszek A, 2002, J IMMUNOL, V169, P6787, DOI 10.4049/jimmunol.169.12.6787; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tridandapani S, 2003, J IMMUNOL, V170, P4572, DOI 10.4049/jimmunol.170.9.4572; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150	47	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54416	54425		10.1074/jbc.M408188200	http://dx.doi.org/10.1074/jbc.M408188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485887	hybrid			2022-12-25	WOS:000225793600064
J	Kunjilwar, K; Strang, C; DeRubeis, D; Pfaffinger, PJ				Kunjilwar, K; Strang, C; DeRubeis, D; Pfaffinger, PJ			KChIP3 rescues the functional expression of Shal channel tetramerization mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED-STATE INACTIVATION; POTASSIUM CHANNELS; K+ CHANNEL; TERMINAL DOMAINS; KV4 CHANNELS; T1 DOMAIN; I-TO; MODULATION; PROTEIN; BINDING	KChIP proteins regulate Shal, Kv4.x, channel expression by binding to a conserved sequence at the N terminus of the subunit. The binding of KChIP facilitates a redistribution of Kv4 protein to the cell surface, producing a large increase in current along with significant changes in channel gating kinetics. Recently we have shown that mutants of Kv4.2 lacking the ability to bind an intersubunit Zn2+ between their T1 domains fail to form functional channels because they are unable to assemble to tetramers and remain trapped in the endoplasmic reticulum. Here we find that KChIPs are capable of rescuing the function of Zn2+ site mutants by driving the mutant subunits to assemble to tetramers. Thus, in addition to known trafficking effects, KChIPs play a direct role in subunit assembly by binding to monomeric subunits within the endoplasmic reticulum and promoting tetrameric channel assembly. Zn2+-less Kv4.2 channels expressed with KChIP3 demonstrate several distinct kinetic changes in channel gating, including a reduced time to peak and faster entry into the inactivated state as well as extending the time to recover from inactivation by 3-4 fold.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Pfaffinger, PJ (corresponding author), Baylor Coll Med, Div Neurosci, 1 Baylor Plaza, Houston, TX 77030 USA.	paulp@bcm.tmc.edu			NICHD NIH HHS [HD24064] Funding Source: Medline; NINDS NIH HHS [P01NS37444, R01NS31583] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031583, P01NS037444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Beck EJ, 2001, BIOPHYS J, V81, P867, DOI 10.1016/S0006-3495(01)75747-5; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Gebauer M, 2004, BIOPHYS J, V86, P210, DOI 10.1016/S0006-3495(04)74097-7; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Jahng AW, 2002, J BIOL CHEM, V277, P47885, DOI 10.1074/jbc.M208416200; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lilliehook C, 2003, J NEUROSCI, V23, P9097; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nanao MH, 2003, P NATL ACAD SCI USA, V100, P8670, DOI 10.1073/pnas.1432840100; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; SHEN NV, 1993, NEURON, V11, P67; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Strang C, 2003, J BIOL CHEM, V278, P31361, DOI 10.1074/jbc.M304268200; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5	27	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54542	54551		10.1074/jbc.M409721200	http://dx.doi.org/10.1074/jbc.M409721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485870	hybrid			2022-12-25	WOS:000225793600079
J	Fliegauf, M; Stock, M; Berg, T; Lubbert, M				Fliegauf, M; Stock, M; Berg, T; Lubbert, M			Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO	ONCOGENE			English	Article						chromosomal translocation (8;21); acute myeloid leukemia; transcription factor; gene regulation; representational difference analysis	ACUTE MYELOID-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CORE-BINDING-FACTOR; T-CELL-RECEPTOR; PROTEIN-PROTEIN INTERACTIONS; STIMULATING FACTOR-RECEPTOR; T(8/21) FUSION PROTEIN; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; DNA-BINDING	The chromosomal translocation t(8;21) fuses the AML1 (RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8 in human acute myeloid leukemias (AMLs), resulting in expression of the chimeric transcription factor AML1/ETO. AML1/ETO-mediated dysregulation of target genes critical for hematopoietic differentiation and proliferation is thought to contribute to the leukemic phenotype. Several mechanisms, including recruitment of histone deacetylases (HDACs) to AML1 target genes, may be responsible for altered gene expression. We used an ecdysone-inducible expression system in the human monoblastic U-937 cell line to isolate genes that were differentially expressed upon induction of AML1/ETO expression. By representational difference analysis (cDNA-RDA), we identified 26 genes whose expression levels were significantly modulated following AML1/ETO induction for 48 h. None of these genes has previously been described as a target of AML1, ETO or AML1/ETO. One gene downregulated by AML1/ETO in vitro, Williams Beuren syndrome critical region 5 (WBSCR5), was expressed in primary t(8;21)-negative AML blasts but not in primary t(8;21)-positive AML blasts, strongly implying a role of this gene in the phenotype of t(8;21)-positive AML. Four upregulated and four downregulated genes were further studied with all-trans-retinoic acid (ATRA), an inducer of differentiation of U-937 cells, and Trichostatin A (TSA), an HDAC inhibitor. Three out of eight genes including WBSCR5 were regulated during ATRA-induced monocytic differentiation of U-937 cells, however, none of them antagonistically, upon both ATRA treatment and AML1/ETO induction. AML1/ETO-associated dysregulation of gene expression was not mediated by a TSA-sensitive mechanism. The identified genes provide a useful model to study the mechanism by which the AML1/ETO fusion protein exerts its function in transcriptional dysregulation in AML. The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study.	Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Depb Biol 3, D-79104 Freiburg, Germany; Univ Freiburg, Depb Biol 1, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	luebbert@mm11.ukl.uni-freiburg.de	Stock, Michael/B-9829-2009; Berg, Tobias/AAT-5094-2021	Berg, Tobias/0000-0003-2668-0449; Stock, Michael/0000-0002-3322-0961				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burger JA, 2000, BLOOD, V96, P2655; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Doyle JL, 2000, CYTOGENET CELL GENET, V90, P285, DOI 10.1159/000056790; ERICKSON P, 1992, BLOOD, V80, P1825; FLIEGAUF M, 2003, HEMAT BLOOD, V41, P28; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Frank R, 1995, ONCOGENE, V11, P2667; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRIMM T, 1980, Z KARDIOL, V69, P168; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Koonpaew S, 2004, J BIOL CHEM, V279, P11229, DOI 10.1074/jbc.M311394200; Kozu T, 1996, J CANCER RES CLIN, V122, P254, DOI 10.1007/BF01209655; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; RICCIO ML, 1993, DNA SEQUENCE, V4, P129, DOI 10.3109/10425179309020152; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TKACZYK C, 2004, BLOOD; Uchida H, 1997, J IMMUNOL, V158, P2251; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	71	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9070	9081		10.1038/sj.onc.1208042	http://dx.doi.org/10.1038/sj.onc.1208042			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489901				2022-12-25	WOS:000225492800008
J	Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H				Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H			Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; patched; p53; microarrays; mouse	ALVEOLAR RHABDOMYOSARCOMA; MYOGENIC DIFFERENTIATION; P53 MUTATIONS; MOUSE MODEL; STEM-CELLS; MICE; EXPRESSION; SARCOMAS; TUMORS; MUSCLE	Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarco-magenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclin-dependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation- and expression-specific therapy.	Univ Gottingen, Inst Human Genet, Gottingen, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Pathol, Neuherberg, Germany; Univ Gottingen, Dept Pathol, D-3400 Gottingen, Germany	University of Gottingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Hahn, H (corresponding author), Univ Gottingen, Inst Human Genet, Heinrich Duker Weg 12, Gottingen, Germany.	hhahn@gwdg.de	Rosemann, Michael/AAX-8082-2020; Rosemann, Michael/O-2449-2015	Rosemann, Michael/0000-0002-5855-065X; Rosemann, Michael/0000-0002-5855-065X; Calzada, Julia/0000-0003-0816-9305; Kappler, Roland/0000-0002-8581-2803				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Amthor H, 2002, DEV BIOL, V243, P115, DOI 10.1006/dbio.2001.0555; Armand AS, 2003, DEV DYNAM, V227, P256, DOI 10.1002/dvdy.10306; Astolfi A, 2001, GENE, V274, P139, DOI 10.1016/S0378-1119(01)00619-9; Boman F, 1997, PEDIATR PATHOL LAB M, V17, P233, DOI 10.1080/107710497174886; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; Coindre JM, 2003, HISTOPATHOLOGY, V43, P1, DOI 10.1046/j.1365-2559.2003.01639.x; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; Doyle DD, 2003, BIOCHEM BIOPH RES CO, V304, P22, DOI 10.1016/S0006-291X(03)00528-X; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; Kappler R, 2004, INT J ONCOL, V25, P113; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Moretti A, 2002, EUR J CANCER, V38, P2290, DOI 10.1016/S0959-8049(02)00454-9; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Ragazzini P, 2004, HISTOL HISTOPATHOL, V19, P401, DOI 10.14670/HH-19.401; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; STRATTON MR, 1990, ONCOGENE, V5, P1297; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wada MR, 2002, DEVELOPMENT, V129, P2987; Wetmore C, 2001, CANCER RES, V61, P513; WEXLER LH, 1997, RHABDOMYOSARCOMA UND; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	46	29	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8785	8795		10.1038/sj.onc.1208133	http://dx.doi.org/10.1038/sj.onc.1208133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480423				2022-12-25	WOS:000225165100008
J	Beardsley, A; Fang, K; Mertz, H; Castranova, V; Friend, S; Liu, J				Beardsley, A; Fang, K; Mertz, H; Castranova, V; Friend, S; Liu, J			Loss of caveolin-1 polarity impedes endothelial cell polarization and directional movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE DOMAINS; SMOOTH-MUSCLE-CELLS; IN-VIVO; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; MIGRATING CELLS; PROTEIN-KINASE; PHOSPHORYLATION; GROWTH; RECEPTOR	The ability of a cell to move requires the asymmetrical organization of cellular activities. To investigate polarized cellular activity in moving endothelial cells, human endothelial cells were incubated in a Dunn chamber to allow migration toward vascular endothelial growth factor. Immunofluorescent staining with a specific antibody against caveolin-1 revealed that caveolin-1 was concentrated at the rear of moving cells. Similarly, monolayer scraping to induce random cell walk resulted in relocation of caveolin-1 to the cell rear. These results suggest that posterior polarization of caveolin-1 is a common feature both for chemotaxis and chemokinesis. Dual immunofluorescent labeling showed that, during cell spreading, caveolin-1 was compacted in the cell center and excluded from nascent focal contacts along the circular lamellipodium, as revealed by integrin beta(1) and FAK staining. When cells were migrating, integrin beta(1) and FAK appeared at polarized lamellipodia, whereas caveolin-1 was found at the posterior of moving cells. Notably, wherever caveolin-1 was polarized, there was a conspicuous absence of lamellipod protrusion. Transmission electron microscopy showed that caveolae, similar to their marker caveolin-1, were located at the cell center during cell spreading or at the cell rear during cell migration. In contrast to its unphosphorylated form, tyrosine-phosphorylated caveolin-1, upon fibronectin stimulation, was associated with the focal complex molecule phosphopaxillin along the lamellipodia of moving cells. Thus, unphosphorylated and phosphorylated caveolin-1 were located at opposite poles during cell migration. Importantly, loss; of caveolin-1 polarity by targeted down-regulation of the protein prevented cell polarization and directional movement. Our present results suggest a potential role of caveolin polarity in lamellipod extension and cell migration.	W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; W Virginia Univ, Hlth Sci Ctr, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Hlth Sci Ctr, Dept Obstet & Gynecol, Morgantown, WV 26506 USA; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA	West Virginia University; West Virginia University; West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Liu, J (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, POB 9229, Morgantown, WV 26506 USA.	junliu@hsc.wvu.edu						ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Griffoni C, 2000, BIOCHEM BIOPH RES CO, V276, P756, DOI 10.1006/bbrc.2000.3484; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Isshiki M, 2002, J CELL SCI, V115, P475; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Manes S, 2000, IUBMB LIFE, V49, P89; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; ZICHA D, 1991, J CELL SCI, V99, P769; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	42	112	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3541	3547		10.1074/jbc.M409040200	http://dx.doi.org/10.1074/jbc.M409040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15504729	hybrid, Green Submitted			2022-12-25	WOS:000226983900051
J	Ost, TWB; Daff, S				Ost, TWB; Daff, S			Thermodynamic and kinetic analysis of the nitrosyl, carbonyl, and dioxy heme complexes of neuronal nitric-oxide synthase - The roles of substrate and tetrahydrobiopterin in oxygen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-OMEGA-HYDROXYARGININE; ELECTRON-TRANSFER; SINGLE-TURNOVER; LOW-TEMPERATURE; REDUCTASE DOMAIN; L-ARGININE; MECHANISM; PTERIN; CALMODULIN; BINDING	Mammalian NO synthases catalyze the monooxygenation of L-arginine (L-Arg) to N-hydroxyarginine (NOHA) and the subsequent monooxygenation of this to NO and citrulline. Both steps proceed via formation of an oxyferrous heme complex and may ultimately lead to a ferrous NO complex, from which NO must be released. Electrochemical reduction of NO-bound neuronal nitric-oxide synthase ( nNOS) oxygenase domain was used to form the ferrous heme NO complex, which was found to be stable only in the presence of low NO concentrations, due to catalytic degradation of NO at the nNOS heme site. The reduction potential for the heme-NO complex was approximately - 140 mV, which shifted to 0 mV in the presence of either L-Arg or NOHA. This indicates that the complex is stabilized by 14 kJ mol(-1) in the presence of substrate, consistent with a strong H-bonding interaction between NO and the guanidino group. Neither substrate influenced the reduction potential of the ferrous heme CO complex, however. Both L-Arg and NOHA appear to interact with bound NO in a similar way, indicating that both bind as guanidinium ions. The dissociation constant for NO bound to ferrous heme in the presence of L-Arg was determined electrochemically to be 0.17 nM, and the rate of dissociation was estimated to be 10(-4) s(-1), which is much slower than the rate of catalysis. Stopped-flow kinetic analysis of oxyferrous formation and decay showed that both L-Arg and NOHA also stabilize the ferrous heme dioxy complex, resulting in a 100-fold decrease in its rate of decay. Electron transfer from the active-site cofactor tetrahydrobiopterin (H4B) has been proposed to trigger the monoxygenation process. Consistent with this, substitution by the analogue/ inhibitor 4-amino-H4B stabilized the oxyferrous complex by a further two orders of magnitude. H4B is required, therefore, to break down both the oxyferrous and ferrous nitrosyl complexes of nNOS during catalysis. The energetics of these processes necessitates an electron donor/acceptor operating within a specific reduction potential range, defining the role of H4B.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh	Daff, S (corresponding author), Univ Edinburgh, Sch Chem, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Simon.Daff@ed.ac.uk						AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bartberger MD, 2002, P NATL ACAD SCI USA, V99, P10958, DOI 10.1073/pnas.162095599; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 2004, J BIOL CHEM, V279, P32243, DOI 10.1074/jbc.M404044200; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Garnaud PE, 2004, BIOCHEMISTRY-US, V43, P11035, DOI 10.1021/bi049312v; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Marchal S, 2003, BIOPHYS J, V85, P3303, DOI 10.1016/S0006-3495(03)74749-3; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Mayer B., 2000, HDB EXPT PHARM, V143; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Meunier B, 2000, STRUCT BOND, V97, P1; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Miles CS, 2000, BBA-PROTEIN STRUCT M, V1543, P383, DOI 10.1016/S0167-4838(00)00236-3; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; WEI CC, 2003, CHEM REV, V104, P1969	53	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					965	973		10.1074/jbc.M411191200	http://dx.doi.org/10.1074/jbc.M411191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15507439	hybrid			2022-12-25	WOS:000226195200015
J	Vilkaitis, G; Suetake, I; Klimasauskas, S; Tajima, S				Vilkaitis, G; Suetake, I; Klimasauskas, S; Tajima, S			Processive methylation of hemimethylated CpG sites by mouse Dnmt1 DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS-MEDIATED EXPRESSION; DE-NOVO METHYLATION; MURINE DNA; CYTOSINE-5 METHYLTRANSFERASES; IMMUNODEFICIENCY SYNDROME; CELLS; GENE; PATTERNS; PURIFICATION; SEQUENCES	DNA methyltransferase Dnmt1 ensures clonal transmission of lineage-specific DNA methylation patterns in a mammalian genome during replication. Dnmt1 is targeted to replication foci, interacts with PCNA, and favors methylating the hemimethylated form of CpG sites. To understand the underlying mechanism of its maintenance function, we purified recombinant forms of full-length Dnmt1, a truncated form of Dnmt1-(291-1620)lacking the binding sites for PCNA and DNA and examined their processivity using a series of long unmethylated and hemimethylated DNA substrates. Direct analysis of methylation patterns using bisulfite-sequencing and hairpin-PCR techniques demonstrated that full-length Dnmt1 methylates hemimethylated DNA with high processivity and a fidelity of over 95%, but unmethylated DNA with much less processivity. The truncated form of Dnmt1 showed identical properties to full-length Dnmt1 indicating that the N-terminal 290-amino acid residue region of Dnmt1 is not required for preferential activity toward hemimethylated sites or for processivity of the enzyme. Remarkably, our analyses also revealed that Dnmt1 methylates hemimethylated CpG sites on one strand of double-stranded DNA during a single processive run. Our findings suggest that these inherent enzymatic properties of Dnmt1 play an essential role in the faithful and efficient maintenance of methylation patterns in the mammalian genome.	Inst Biotechnol, LT-02241 Vilnius, Lithuania; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Vilnius University; Osaka University	Klimasauskas, S (corresponding author), Inst Biotechnol, Graiciuno 8, LT-02241 Vilnius, Lithuania.	klimasau@ibt.lt	Suetake, Isao/D-4326-2009; Vilkaitis, Giedrius/AAI-9157-2021; Klimasauskas, Saulius/M-3053-2016; Suetake, Isao/G-3144-2013	Suetake, Isao/0000-0002-1246-8474; Klimasauskas, Saulius/0000-0002-1395-2030; Vilkaitis, Giedrius/0000-0003-2427-3997				Araujo FD, 2001, J BIOL CHEM, V276, P6930, DOI 10.1074/jbc.M009037200; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brank AS, 2002, PROTEIN EXPRES PURIF, V25, P31, DOI 10.1006/prep.2001.1606; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark J, 2003, ANAL BIOCHEM, V321, P50, DOI 10.1016/S0003-2697(03)00402-0; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Laird CD, 2004, P NATL ACAD SCI USA, V101, P204, DOI 10.1073/pnas.2536758100; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; MATSUO K, 1994, NUCLEIC ACIDS RES, V22, P5354, DOI 10.1093/nar/22.24.5354; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2003, BIOCHEMISTRY-US, V42, P5321, DOI 10.1021/bi034160+; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; RENBAUM P, 1992, FEBS LETT, V313, P243, DOI 10.1016/0014-5793(92)81201-V; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; TAKAGI H, 1995, EUR J BIOCHEM, V231, P282, DOI 10.1111/j.1432-1033.1995.tb20698.x; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Ushijima T, 2003, GENOME RES, V13, P868, DOI 10.1101/gr.969603; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vilkaitis G, 1999, ANAL BIOCHEM, V271, P116, DOI 10.1006/abio.1999.4116; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	40	138	146	4	98	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					64	72		10.1074/jbc.M411126200	http://dx.doi.org/10.1074/jbc.M411126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509558	hybrid			2022-12-25	WOS:000226025100009
J	Buss, H; Dorrie, A; Schmitz, ML; Hoffmann, E; Resch, K; Kracht, M				Buss, H; Dorrie, A; Schmitz, ML; Hoffmann, E; Resch, K; Kracht, M			Constitutive and interleukin-1-inducible phosphorylation of p65 NF-kappa B at serine 536 is mediated by multiple protein kinases including I kappa B kinase (IKK)-alpha, IKK beta, IKK epsilon, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LIVER DEGENERATION; RELA/P65 SUBUNIT; MICE LACKING; ZETA-PKC; ACTIVATION; P53; DEGRADATION; DISRUPTION; INDUCTION	Phosphorylation of NF-kappaB p65(RelA) serine 536 is physiologically induced in response to a variety of proinflammatory stimuli, but the responsible pathways have not been conclusively unraveled, and the function of this phosphorylation is largely elusive. In contrast to previous studies, we found no evidence for a role of c-Jun N-terminal kinase, p38 kinase, extracellular signal-regulated kinase, or phosphatidylinositol 3-kinase in interleukin-1- or tumor necrosis factor-induced Ser-536 phosphorylation, as revealed by pharmacological inhibitors. We were not able to suppress Ser-536 phosphorylation by either RNA interference directed at IkappaB kinase (IKK)-alpha/beta (the best characterized Ser-536 kinases so far) or the IKKbeta inhibitor SC-514 or dominant negative mutants of either IKK. A green fluorescent protein p65 fusion protein was phosphorylated at Ser-536 in the absence of IKK activation, suggesting the existence of IKKalpha/beta-independent Ser-536 kinases. Chromatographic fractionation of cell extracts allowed the identification of two distinct enzymatic activities phosphorylating Ser-536. Peak 1 represents an unknown kinase, whereas peak 2 contained IKKalpha, IKKbeta, IKKepsilon, and TBK1. Overexpressed IKKepsilon and TBK1 phosphorylate Ser-536 in vivo and in vitro. Reconstitution of mutant p65 proteins in p65-deficient fibroblasts that either mimicked phosphorylation (S536D) or preserved a predicted hydrogen bond between Ser-536 and Asp-533 (S536N) revealed that phosphorylation of Ser-536 favors interleukin-8 transcription mediated by TATA-binding protein-associated factor II31, a component of TFIID. In the absence of phosphorylation, the hydrogen bond favors binding of the corepressor amino-terminal enhancer of split to the p65 terminal transactivation domain. Collectively, our results provide evidence for at least five kinases that converge on Ser-536 of p65 and a novel function for this phosphorylation site in the recruitment of components of the basal transcriptional machinery to the interleukin-8 promoter.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	Hannover Medical School; University of Bern	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Jabbur JR, 2002, ONCOGENE, V21, P7100, DOI 10.1038/sj.onc.1205856; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; KRACHT M, 1994, BIOCHEM J, V302, P897, DOI 10.1042/bj3020897; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	56	296	305	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55633	55643		10.1074/jbc.M409825200	http://dx.doi.org/10.1074/jbc.M409825200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489227	hybrid			2022-12-25	WOS:000225960800082
J	Rosales, JL; Ernst, JD; Hallows, J; Lee, KY				Rosales, JL; Ernst, JD; Hallows, J; Lee, KY			GTP-dependent secretion from neutrophils is regulated by Cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-5 CDK5; BOVINE BRAIN; PROTEIN; PHOSPHORYLATION; EXOCYTOSIS; MEMBRANE; P35; ACTIVATION; EXPRESSION; RECEPTOR	We have previously shown evidence for the existence of a calcium-independent, GTP-regulated mechanism of secretion from neutrophils, but this secretory mechanism remains to be fully elucidated. Cyclin-dependent kinase 5 (Cdk5), the various substrates of which include Munc18 and synapsin 1, has been implicated in neuronal secretion. Although the Cdk5 activator, p35, and Cdk5p35 activity are primarily associated with neurons, we report here that p35 also exists in neutrophils and that an active Cdk5-p35 complex is present in these cells. Cdk5-p35 activity in human neutrophils is mostly localized in secretory granules, which show an increase in Cdk5-p35 level and activity upon GTP stimulation. The potent Cdk5 inhibitor, roscovitine, completely blocks GTP-stimulated granule Cdk5 activity, which accompanies lactoferrin secretion from neutrophil-specific granules. Roscovitine also inhibits GTP-induced lactoferrin secretion and surface localization of the secretion markers, CD63 and CD66b, to a certain extent. Furthermore, neutrophils from wild-type mice treated with roscovitine and neutrophils from p35(-/-) mice exhibit comparable surface expression levels of both CD63 and CD66b upon GTP stimulation. Although our data suggest that other molecules control GTP-induced secretion from neutrophils, it is clear that Cdk5-p35 is required to elicit the maximum GTP-induced secretory response. Our observation that multiple proteins in neutrophil granules serve as specific substrates of Cdk5 further supports the premise that the kinase is a key component of the GTP-regulated secretory apparatus in neutrophils.	Univ Calgary, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	University of Calgary; University of Washington; University of Washington Seattle; New York University	Rosales, JL (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada.	rosales@ucalgary.ca		Ernst, Joel/0000-0001-9951-6207; Rosales, Jesusa/0000-0002-2543-3801				Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCKCROFT S, 1989, FEBS LETT, V245, P25, DOI 10.1016/0014-5793(89)80184-X; DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885; Downey GP, 1998, J IMMUNOL, V160, P434; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gao CY, 1997, DEV GENET, V20, P267; Hallows JL, 2003, J NEUROSCI, V23, P10633; Kaldi K, 2002, J LEUKOCYTE BIOL, V71, P695; KUIJPERS TW, 1991, BLOOD, V78, P1105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lard LR, 1999, J LEUKOCYTE BIOL, V66, P411, DOI 10.1002/jlb.66.3.411; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Meshki J, 2004, AM J PHYSIOL-CELL PH, V286, pC264, DOI 10.1152/ajpcell.00287.2003; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; Qi RZ, 2004, FEBS LETT, V561, P177, DOI 10.1016/S0014-5793(04)00174-7; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Rosales JL, 1997, J IMMUNOL, V159, P6195; Rosales JL, 2000, J CELL BIOCHEM, V80, P37; Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Smith D, 2003, NEUROSIGNALS, V12, P239, DOI 10.1159/000074626; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tapper H, 1997, J IMMUNOL, V159, P409; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Xin XN, 2004, J CELL SCI, V117, P4739, DOI 10.1242/jcs.01333	33	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53932	53936		10.1074/jbc.M408467200	http://dx.doi.org/10.1074/jbc.M408467200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492003	hybrid			2022-12-25	WOS:000225793600006
J	Toleman, C; Paterson, AJ; Whisenhunt, TR; Kudlow, JE				Toleman, C; Paterson, AJ; Whisenhunt, TR; Kudlow, JE			Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; BETA-D-GLUCOSAMINIDASE; TRANSCRIPTIONAL REPRESSION; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; CYTOSOLIC PROTEINS; GLYCOSYLATION; NUCLEAR; ACETYLGLUCOSAMINIDASE; STREPTOZOTOCIN	Histones and transcription factors are regulated by a number of post-translational modifications that in turn regulate the transcriptional activity of genes. These modifications occur in large, multisubunit complexes. We have reported previously that mSin3A can recruit O-GlcNAc transferase (OGT) along with histone deacetylase into such a corepressor complex. This physical association allows OGT to act cooperatively with histone deacetylation in gene repression by catalyzing the O-GlcNAc modification on specific transcription factors to inhibit their activity. For rapid, reversible gene regulation, the enzymes responsible for the converse reactions must be present. Here, we report that O-GlcNAcase, which is responsible for the removal of O-GlcNAc additions on nuclear and cytosolic proteins, possesses intrinsic histone acetyltransferase (HAT) activity in vitro. Free as well as reconstituted nucleosomal histones are substrates of this bifunctional enzyme. This protein, now termed NCOAT (nuclear cytoplasmic O-GlcNAcase and acetyltransferase) has a typical HAT domain that has both active and inactive states. This finding demonstrates that NCOAT may be regulated to reduce the state of glycosylation of transcriptional activators while increasing the acetylation of histones to allow for the concerted activation of eukaryotic gene transcription.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	kudlow@uab.edu						Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; AUSUBEL J, 1990, CURRENT PROTOCOLS MO, V1; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Comtesse N, 2001, BIOCHEM BIOPH RES CO, V283, P634, DOI 10.1006/bbrc.2001.4815; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TURK J, 1993, BIOCHEM BIOPH RES CO, V197, P1458, DOI 10.1006/bbrc.1993.2641; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; WOLFFE A, 1992, CHROMATIN STRUCTURE; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	49	163	187	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53665	53673		10.1074/jbc.M410406200	http://dx.doi.org/10.1074/jbc.M410406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485860	hybrid			2022-12-25	WOS:000225680600103
J	Mason, DX; Jackson, TJ; Lin, AW				Mason, DX; Jackson, TJ; Lin, AW			Molecular signature of oncogenic ras-induced senescence	ONCOGENE			English	Article						Ras oncogene; G(1) tetraploidy; senescence biomarker; HDAC; topoisomerase; quiescence	DNA TOPOISOMERASE-II; HISTONE DEACETYLASE; HUMAN FIBROBLASTS; GENE-EXPRESSION; GROWTH ARREST; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN-CELLS; CANCER; P53	Senescence irreversibly arrests the proliferation of cells that have sustained significant cellular stress. Replicative senescence, due to the shortening and dysfunction of telomeres, appears to provide a barrier to the immortalization of cells and development of cancer. In normal human fibroblasts, senescence induced by oncogenic H-ras displays a nearly identical cellular phenotype to that of replicative senescence, suggesting the activation of a common senescence mechanism. In this study, we investigated the gene expression profile of oncogenic H-ras-induced senescent human diploid fibroblasts. We found altered gene expression of various cell cycle regulators in both oncogenic H-ras-induced senescent cells and replicative senescent cells. Similar to replicative senescent cells, H-ras-induced senescent cells exhibited specific downregulation of genes involved in G(2)/M checkpoint control and contained tetraploid cells that were arrested in a G(1) state. This observation suggests that the inactivation of G(2)/M checkpoints may be involved in senescence and may play a role in the generation of senescent G(1) tetraploid cells. Lastly, we have identified two genes, topoisomerase IIalpha and HDAC9, whose expression was specifically altered under several conditions associated with senescence, suggesting that these two molecules may be novel biomarkers for senescent human fibroblasts.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Lin, AW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	Athena.lin@roswellpark.org			NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Benanti JA, 2004, CELL CYCLE, V3, P715; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAMPISI J, 1992, ANN NY ACAD SCI, V663, P195, DOI 10.1111/j.1749-6632.1992.tb38663.x; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Castro ME, 2004, J CELL BIOCHEM, V92, P514, DOI 10.1002/jcb.20079; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Greider C W, 2000, Harvey Lect, V96, P33; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kramer DL, 2001, CANCER RES, V61, P7754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen Annette K, 2003, Prog Cell Cycle Res, V5, P295; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEEBADDA WKC, 2004, IN PRESS; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	62	87	91	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9238	9246		10.1038/sj.onc.1208172	http://dx.doi.org/10.1038/sj.onc.1208172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489886				2022-12-25	WOS:000225638000009
J	Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR				Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR			PPAR delta status and Apc-mediated tumourigenesis in the mouse intestine	ONCOGENE			English	Article						PPARdelta; tumourigenesis; Apc; intestine; PPARbeta	ACTIVATED RECEPTOR-DELTA; COLORECTAL-CANCER CELLS; GENE-EXPRESSION; BETA-CATENIN; TARGETED DISRUPTION; ADENOMA; GROWTH; BRAIN; MICE	Based on recent reports that peroxisome proliferator-activated receptor delta (PPARdelta) activation promotes tumourigenesis, we have investigated the role of this protein in Apc-mediated intestinal tumourigenesis. We demonstrate that the inactivation of Apc in the adult small intestine, while causing the expected nuclear accumulation of beta-catenin, does not cause the expected increase in PPARdelta mRNA or protein but conversely, the levels of PPARdelta mRNA and protein are lowered. Furthermore, we find that Apc(Min)PPARdelta-null mice exhibit an increased predisposition to intestinal tumourigenesis. Our data suggest that PPARdelta is not directly regulated by beta-catenin, and that inhibition of PPARdelta activity is unlikely to be an appropriate strategy for the chemoprevention or chemotherapy of intestinal malignancies.	Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Leicester, Dept Canc Studies, Leicester LE2 7LX, Leics, England; Cambridge Inst Med Res, Canc Res UK Dept Oncol, Cambridge CB2 2XY, England; Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol, Fenske Lab 226, University Pk, PA 16802 USA	Cardiff University; University of Leicester; Cancer Research UK; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Clarke, AR (corresponding author), Univ Wales Coll Cardiff, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.	clarkear@cf.ac.uk	Hayes, Anthony/F-2658-2012; Peters, Jeffrey/D-8847-2011; Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Peters, Jeffrey/0000-0003-2782-2998				Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Notterman DA, 2001, CANCER RES, V61, P3124; Orner GA, 2003, CARCINOGENESIS, V24, P263, DOI 10.1093/carcin/24.2.263; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Rosenberger TA, 2002, LIPIDS, V37, P495, DOI 10.1007/s11745-002-0923-1; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	20	100	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8992	8996		10.1038/sj.onc.1208143	http://dx.doi.org/10.1038/sj.onc.1208143			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480419				2022-12-25	WOS:000225354600015
J	Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY				Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY			Rho/rhotekin-mediated NF-kappa B activation confers resistance to apoptosis	ONCOGENE			English	Article						Rho GTPases; rhotekin; nuclear factor-kappa B; antiapoptosis; gastric cancer	RHO EFFECTOR RHOTEKIN; ACTIN STRESS FIBERS; LUNG-CANCER CELLS; BREAST-CANCER; PROTEIN-KINASE; CYCLIN D1; EXPRESSION; GTPASES; GENE; BINDING	Rhotekin ( RTKN), the gene coding for the Rho effector, RTKN, was shown to be overexpressed in human gastric cancer ( GC). In this study, we further showed that RTKN is expressed at a low level in normal cells and is overexpressed in many cancer-derived cell lines. The function of RTKN as an effector protein in Rho GTPase-mediated pathways regulating apoptosis was investigated. By transfection and expression of RTKN in cells that expressed endogenous RTKN at a low basal level, we showed that RTKN overexpression conferred cell resistance to apoptosis induced by serum deprivation or treatment with sodium butyrate, and the increased resistance correlated to the level of RTKN. Conversely, reducing RTKN expression by small interfering RNAs greatly sensitized cells to apoptosis. The RTKN-mediated antiapoptotic effect was blocked by the nuclear factor-kappaB (NF-kappaB) inhibitors, curcumin or parthenolide, but not by the phosphatidylinositol 3'-OH-kinase inhibitor, LY294002, or the MAP kinase inhibitor, PD98059. Reporter gene assays and electrophoretic mobility shift assay confirmed that RTKN overexpression led to constitutive activation of NF-kappaB through the phosphorylation of IkappaB by IKKbeta. By using the RTKN truncation mutants, we showed that RTKN mediated Rho activity eliciting signaling pathway to activate NF-kappaB, with a concomitant induction of expression of the NF-kappaB antiapoptotic genes, cIAP-2, BCl-xL, A1, and A20. Consistent with these data, RTKN-expressing cells showed increased chemoresistance to 5-fluorouracil and paclitaxol, and the resistance was greatly attenuated by NF-kappaB inhibitor. In conclusion, overactivated Rho/RTKN/NF-kappaB signaling pathway through overexpression of RTKN may play a key role in gastric tumorigenesis by conferring cells resistance to apoptosis, and this signaling pathway may serve as an important target for novel therapeutic approaches to the treatment of human GC.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2 Acad Rd, Taipei 11529, Taiwan.	bmchen@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018					Arlt A, 2002, CANCER RES, V62, P910; Asin S, 1999, J VIROL, V73, P3893, DOI 10.1128/JVI.73.5.3893-3903.1999; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHEN JY, 1993, ONCOGENE, V8, P2159; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gildea JJ, 2002, CANCER RES, V62, P6418; IKEDA H, 2003, AM J PHYSL GASTROINT; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053/gast.2001.25544; Kaneko K, 2002, PANCREAS, V24, P251, DOI 10.1097/00006676-200204000-00007; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim JY, 2000, BIOCHEM BIOPH RES CO, V273, P140, DOI 10.1006/bbrc.2000.2909; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lai JM, 2001, BIOCHEM J, V359, P227, DOI 10.1042/0264-6021:3590227; Liu CA, 2004, J BIOMED SCI, V11, P661, DOI 10.1159/000079679; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sanlioglu S, 2001, CANCER GENE THER, V8, P897, DOI 10.1038/sj.cgt.7700394; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tu H, 1999, MOL CELL BIOL, V19, P602; van Golen KL, 2000, CANCER RES, V60, P5832; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zhou J, 2003, WORLD J GASTROENTERO, V9, P9, DOI 10.3748/wjg.v9.i1.9	56	64	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8731	8742		10.1038/sj.onc.1208106	http://dx.doi.org/10.1038/sj.onc.1208106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480428				2022-12-25	WOS:000225165100003
J	Wreden, CC; Wlizla, M; Reimer, RJ				Wreden, CC; Wlizla, M; Reimer, RJ			Varied mechanisms underlie the free sialic acid storage disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; SALLA-DISEASE; ENDOPLASMIC-RETICULUM; PHOSPHATE TRANSPORTER; LYSOSOMAL MEMBRANE; SYNAPTIC VESICLES; XENOPUS OOCYTES; DOWN-REGULATION; BATTEN-DISEASE; GENE	Salla disease and infantile sialic acid storage disorder are autosomal recessive neurodegenerative diseases characterized by loss of a lysosomal sialic acid transport activity and the resultant accumulation of free sialic acid in lysosomes. Genetic analysis of these diseases has identified several unique mutations in a single gene encoding a protein designated sialin (Verheijen, F. W., Verbeek, E., Aula, N., Beerens, C. E., Havelaar, A. C., Joosse, M., Peltonen, L., Aula, P., Galjaard, H., van der Spek, P. J., and Mancini, G. M. (1999) Nat. Genet. 23, 462-465; Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J. E., Aula, P., and Peltonen, L. ( 2000) Am. J. Hum. Genet. 67, 832-840). From the biochemical phenotype of the diseases and the predicted polytopic structure of the protein, it has been suggested that sialin functions as a lysosomal sialic acid transporter. Here we directly demonstrate that this activity is mediated by sialin and that the recombinant protein has functional characteristics similar to the native lysosomal sialic acid transport system. Furthermore, we describe the effect of disease-causing mutations on the protein. We find that the majority of the mutations are associated with a complete loss of activity, while the mutations associated with the milder forms of the disease lead to reduced, but residual, function. Thus, there is a direct correlation between sialin function and the disease state. In addition, we find with one mutation that the protein is retained in the endoplasmic reticulum, indicating that altered trafficking of sialin is also associated with disease. This analysis of the molecular mechanism of sialic acid storage disorders is a further step in identifying therapeutic approaches to these diseases.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University	Reimer, RJ (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	rjreimer@stanford.edu		Wlizla, Marcin/0000-0001-7328-0734	NINDS NIH HHS [NS045634-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS045634] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aula N, 2000, AM J HUM GENET, V67, P832, DOI 10.1086/303077; Aula N, 2002, MOL GENET METAB, V77, P99, DOI 10.1016/S1096-7192(02)00124-5; AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BLOM HJ, 1990, BIOCHEM J, V268, P621, DOI 10.1042/bj2680621; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Broer S, 1998, J MEMBRANE BIOL, V164, P71, DOI 10.1007/s002329900394; Busch AE, 1996, P NATL ACAD SCI USA, V93, P5347, DOI 10.1073/pnas.93.11.5347; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen XZ, 2000, BIOCHEM BIOPH RES CO, V272, P726, DOI 10.1006/bbrc.2000.2851; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; Havelaar AC, 1999, FEBS LETT, V446, P65, DOI 10.1016/S0014-5793(99)00187-8; HIRSCHBERG CB, 1976, BIOCHEMISTRY-US, V15, P3591, DOI 10.1021/bi00661a029; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1991, J CLIN INVEST, V87, P1329, DOI 10.1172/JCI115136; Mancini GMS, 2000, J INHERIT METAB DIS, V23, P278, DOI 10.1023/A:1005640214408; MOSER HW, 1992, CURR OPIN NEUROL NEU, V5, P355; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Reimer RJ, 2004, PFLUG ARCH EUR J PHY, V447, P629, DOI 10.1007/s00424-003-1087-y; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; RENLUND M, 1983, NEUROLOGY, V33, P57, DOI 10.1212/WNL.33.1.57; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schiffmann R, 2002, DRUGS, V62, P733, DOI 10.2165/00003495-200262050-00002; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; TIETZE F, 1989, J BIOL CHEM, V264, P15316; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; Varho TT, 2002, PEDIATR NEUROL, V26, P267, DOI 10.1016/S0887-8994(01)00406-4; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; VIRTANEN I, 1980, PEDIATR RES, V14, P1199, DOI 10.1203/00006450-198011000-00010; von Essen M, 2002, J IMMUNOL, V168, P4519, DOI 10.4049/jimmunol.168.9.4519; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003	45	53	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1408	1416		10.1074/jbc.M411295200	http://dx.doi.org/10.1074/jbc.M411295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516337	hybrid			2022-12-25	WOS:000226195200068
J	Futami, T; Miyagishi, M; Taira, K				Futami, T; Miyagishi, M; Taira, K			Identification of a network involved in thapsigargin-induced apoptosis using a library of small interfering RNA expression vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; GENE-EXPRESSION; HAIRPIN RNAS; SEQUENCE; NEURONS	We describe here the construction of a library of small interfering RNA expression vectors targeted to a few hundred apoptosis-related genes and the application of this library to an investigation of thapsigargin (TG)-induced apoptosis. Thapsigargin triggers endoplasmic reticulum stress, with subsequent apoptosis, but the molecular mechanisms underlying this process are incompletely understood. Using our library, we identified three anti-apoptotic genes, namely, NOXA, E2F1, and MAPK1, in addition to already characterized genes in the apoptotic pathway. In contrast to proposals by others, our data revealed (i) that TG-induced apoptosis is associated with Apaf1 in a caspase-3- and caspase-9-independent manner; (ii) that the E2F1-PUMA pathway might be involved; and (iii) that the ERK pathway, via MAP3K8 (mitogen-activated protein kinase kinase 8), is required for the induction by TG of apoptosis. Our study demonstrates clearly that unexpected and novel genes can be identified effectively by our method, and it provides evidence for the efficacy and utility of the comprehensive analysis of signaling networks and pathways using a library of small interfering RNA expression vectors.	Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Taira, K (corresponding author), Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Tokyo 1138656, Japan.	taira@chembio.t.u-tokyo.ac.jp	Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futami T, 2003, ANTISENSE NUCLEIC A, V13, P9, DOI 10.1089/108729003764097304; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; MIYAGISHI M, 2005, IN PRESS RNA INTERFE; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	32	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					826	831		10.1074/jbc.M409948200	http://dx.doi.org/10.1074/jbc.M409948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485892	hybrid			2022-12-25	WOS:000226025100096
J	Benzeno, S; Diehl, JA				Benzeno, S; Diehl, JA			C-terminal sequences direct cyclin D1-CRM1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; CELLULAR-TRANSFORMATION; DEPENDENT KINASE; CDK INHIBITORS; D1; PHOSPHORYLATION; G(1); P27(KIP1); LOCALIZATION; PROTEIN	GSK-3beta-dependent phosphorylation of cyclin D1 at a conserved C-terminal residue, Thr-286, promotes CRM1-dependent cyclin D1 nuclear export. Herein, we have identified a short stretch of residues adjacent to Thr-286 that mediates CRM1 association and thus cyclin D1 nuclear export. We found that disruption of this hydrophobic patch, stretching from amino acids 290 to 295 within cyclin D1, results in constitutively nuclear cyclin D1-CDK4 complexes with an increased propensity to potentiate transformation of murine fibroblasts. Our data support a model wherein deregulation of cyclin D1 nuclear export might contribute to human neoplastic growth.	Univ Penn, Leonard & madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [CA 93237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lu FM, 2003, CANCER RES, V63, P7056; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	30	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56061	56066		10.1074/jbc.M411910200	http://dx.doi.org/10.1074/jbc.M411910200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15513923	hybrid			2022-12-25	WOS:000225960800130
J	Nijhout, HF; Reed, MC; Budu, P; Ulrich, CM				Nijhout, HF; Reed, MC; Budu, P; Ulrich, CM			A mathematical model of the folate cycle - New insights into folate homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; SERINE HYDROXYMETHYLTRANSFERASE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; FOLIC-ACID; METHYLENETETRAHYDROFOLATE REDUCTASE; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; POLYGLUTAMATE SPECIFICITY; BINDING-PROTEINS; RAT-LIVER	A mathematical model is developed for the folate cycle based on standard biochemical kinetics. We use the model to provide new insights into several different mechanisms of folate homeostasis. The model reproduces the known pool sizes of folate substrates and the fluxes through each of the loops of the folate cycle and has the qualitative behavior observed in a variety of experimental studies. Vitamin B-12 deficiency, modeled as a reduction in the V-max of the methionine synthase reaction, results in a secondary folate deficiency via the accumulation of folate as 5-methyltetrahydrofolate (the "methyl trap"). One form of homeostasis is revealed by the fact that a 100-fold up-regulation of thymidylate synthase and dihydrofolate reductase (known to occur at the G(1)/S transition) dramatically increases pyrimidine production without affecting the other reactions of the folate cycle. The model also predicts that an almost total inhibition of dihydrofolate reductase is required to significantly inhibit the thymidylate synthase reaction, consistent with experimental and clinical studies on the effects of methotrexate. Sensitivity to variation in enzymatic parameters tends to be local in the cycle and inversely proportional to the number of reactions that interconvert two folate substrates. Another form of homeostasis is a consequence of the nonenzymatic binding of folate substrates to folate enzymes. Without folate binding, the velocities of the reactions decrease approximately linearly as total folate is decreased. In the presence of folate binding and allosteric inhibition, the velocities show a remarkable constancy as total folate is decreased.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Duke Univ, Dept Math, Durham, NC 27708 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA	Duke University; Duke University; Fred Hutchinson Cancer Center	Nijhout, HF (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	hfn@duke.edu			NATIONAL CANCER INSTITUTE [R01CA105437, R01CA059045] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59045, CA 105437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BAGGO JE, 2000, AM J CLIN NUTR, V74, P701; Bailey L. B., 1995, FOLATE HLTH DIS, P123; Bailey L. B., 1995, FOLATE HLTH DIS; BARAM J, 1988, J BIOL CHEM, V263, P7105; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Blakley R L, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P23; BRODIE JD, 1971, BIOCHEMISTRY-US, V10, P3079; CAPERELLI CA, 1985, BIOCHEMISTRY-US, V24, P1316, DOI 10.1021/bi00327a008; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; Carmel R., 2001, HOMOCYSTEINE HLTH DI; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Chen J, 2003, CANCER EPIDEM BIOMAR, V12, P958; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; CIESLA J, 1995, BBA-PROTEIN STRUCT M, V1249, P127, DOI 10.1016/0167-4838(95)00032-P; Cleland W. W, 1970, ENZYMES, V2, P1; CONWAY JG, 1983, J BIOL CHEM, V258, P3825; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; COOK RJ, 1986, METHOD ENZYMOL, V122, P255; Cook RJ, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P113; Cook RJ, 2000, AM J CLIN NUTR, V72, P1419; DAUBNER SC, 1982, J BIOL CHEM, V257, P140; De Bree A, 2002, PHARMACOL REV, V54, P599, DOI 10.1124/pr.54.4.599; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; Fukushima M, 2003, INT J MOL MED, V12, P839; Giovannucci E, 2002, J NUTR, V132, p2350S, DOI 10.1093/jn/132.8.2350S; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; Gregory J F 3rd, 1996, Adv Food Nutr Res, V40, P81, DOI 10.1016/S1043-4526(08)60021-2; Gregory JF, 2002, ANNU REV NUTR, V22, P199, DOI 10.1146/annurev.nutr.22.120701.083554; Gregory JF, 2001, AM J CLIN NUTR, V74, P702; Gregory JF, 2000, AM J CLIN NUTR, V72, P1535; Haldane JBS, 1930, ENZYMES; HERBERT V, 1962, J CLIN INVEST, V41, P1263, DOI 10.1172/JCI104589; *I MED, 1998, DIET REF INT THAM RI, P203; Jackman A L, 1999, ANTIFOLATE DRUGS CAN; JACKSON RC, 1980, INT J BIOMED COMPUT, V11, P197, DOI 10.1016/0020-7101(80)90045-8; JACKSON RC, 1983, BIOCHEM PHARMACOL, V32, P3783, DOI 10.1016/0006-2952(83)90150-8; JACKSON RC, 1995, TOXICOLOGY, V102, P197, DOI 10.1016/0300-483X(95)03048-K; JACKSON RC, 1979, PHARMACOL THERAPEUT, V4, P245, DOI 10.1016/0163-7258(79)90138-4; Jackson RC, 1999, CANC DRUG DISC DEV, P1; JACKSON RC, 1973, ARCH BIOCHEM BIOPHYS, V158, P827, DOI 10.1016/0003-9861(73)90579-1; Kim DW, 1997, ANAL BIOCHEM, V253, P201, DOI 10.1006/abio.1997.2388; Kim DW, 1996, BIOCHEMISTRY-US, V35, P15772, DOI 10.1021/bi9619684; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MASUDA T, 1987, J BIOCHEM, V101, P643, DOI 10.1093/jb/101.3.643; MATTHEWS RG, 1986, METHOD ENZYMOL, V122, P372; MATTHEWS RG, 1982, BIOCHEMISTRY-US, V21, P1230, DOI 10.1021/bi00535a019; MATTHEWS RG, 1982, ADV ENZYME REGUL, V20, P123, DOI 10.1016/0065-2571(82)90012-7; MATTHEWS RG, 1982, BIOCHEMISTRY-US, V19, P2040; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Morris MS, 2003, LANCET NEUROL, V2, P425, DOI 10.1016/S1474-4422(03)00438-1; MORRISON PF, 1989, J BIOL CHEM, V264, P10552; Obama K, 2002, INT J ONCOL, V21, P309; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Reed MC, 2004, J THEOR BIOL, V226, P33, DOI 10.1016/j.jtbi.2003.08.001; Refsum H, 2001, BRIT J NUTR, V85, pS109, DOI 10.1079/BJN2000302; Robien K, 2003, AM J EPIDEMIOL, V157, P571, DOI 10.1093/aje/kwg024; ROSS J, 1984, BIOCHEMISTRY-US, V23, P1796, DOI 10.1021/bi00303a033; ROWE PB, 1973, BIOCHEMISTRY-US, V12, P1962, DOI 10.1021/bi00734a020; Ryan BM, 2001, J LAB CLIN MED, V138, P164, DOI 10.1067/mlc.2001.117161; SANTI DV, 1972, P NATL ACAD SCI USA, V69, P1855, DOI 10.1073/pnas.69.7.1855; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; Schirch V, 1997, METHOD ENZYMOL, V281, P146; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHULZ AR, 1994, ENZYME KINETICS DIS, P38; SEGEL IH, 1975, ENZYME KINETICS, P275; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SHANE B, 1985, ANNU REV NUTR, V5, P115, DOI 10.1146/annurev.nu.05.070185.000555; Shane B., 1995, FOLATE HLTH DIS, V2, P1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPEARS CP, 1982, CANCER RES, V42, P450; Stites TE, 1997, AM J CLIN NUTR, V65, P53, DOI 10.1093/ajcn/65.1.53; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; STRONG WB, 1990, J BIOL CHEM, V265, P12149; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; VORONTSOV I N, 1980, Biokhimiya, V45, P83; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wagner C, 1996, J NUTR, V126, pS1228, DOI 10.1093/jn/126.suppl_4.1228S; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WAGNER C, 1995, ARCH BIOCHEM BIOPHYS, V316, P141, DOI 10.1006/abbi.1995.1021; Wagner C, 1995, FOLATE HLTH DIS, P23; WHITE JC, 1981, J BIOL CHEM, V256, P5722; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; ZAMIEROWSKI M, 1974, BIOCHEM BIOPH RES CO, V60, P81, DOI 10.1016/0006-291X(74)90175-2; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	90	138	148	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55008	55016		10.1074/jbc.M410818200	http://dx.doi.org/10.1074/jbc.M410818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496403	hybrid			2022-12-25	WOS:000225960800005
J	Carland, JE; Moorhouse, AJ; Barry, PH; Johnston, GAR; Chebib, M				Carland, JE; Moorhouse, AJ; Barry, PH; Johnston, GAR; Chebib, M			Charged residues at the 2 ' position of human GABA(c) rho 1 receptors invert ion selectivity and influence open state probability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; M2 DOMAIN; CHANNEL CONDUCTANCE; XENOPUS-OOCYTES; AMINO-ACID; SUBUNIT; MUTATIONS; CLONING; PICROTOXIN; AGONIST	The ability of members of the nicotinicoid superfamily of ligand-gated ion channels to selectively conduct anions or cations is critical to their function within the central nervous system. Recent work has demonstrated that residues at the intracellular end of the second transmembrane domain, between the -3' and 2' positions, form the ion selectivity filter of these receptors. In this study, the proline residue at the 2' position (Pro-2') at the intracellular end of the second transmembrane domain of the gamma-aminobutyric acid type C rho1 subunit was mutated to glutamate (rho1P2'E) and arginine (rho1P2'R). Dilution potential experiments indicated that the charge selectivity of the rho1P2'E receptor channels had been inverted, with the channels now becoming predominantly cation selective, indicating the ability of negatively charged residues at this 2' position to control charge selectivity. The mutation was also seen to have significantly decreased agonist potency and intrinsic efficacy. In contrast, the rho1P2'R receptor channels were anion-selective but were now found to be constitutively open with high holding currents (inhibited by low gamma-aminobutyric acid doses and the competitive antagonist, 1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid alone) and increased agonist activity. Hill coefficients of both mutants were decreased, but competitive antagonist studies indicated that their binding sites were not significantly affected.	Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Univ New S Wales, Dept Physiol & Pharmacol, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney	Chebib, M (corresponding author), Univ Sydney, Fac Pharm, A15, Sydney, NSW 2006, Australia.	maryc@pharm.usyd.edu.au	Moorhouse, Andrew J/B-8526-2011; Johnston, Graham AR/B-9827-2009; Johnston, Graham/AAJ-9569-2021	Moorhouse, Andrew J/0000-0001-7957-2498; Johnston, Graham/0000-0001-8872-4078; Carland, Jane/0000-0002-1456-876X				Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Carland JE, 2004, NEUROPHARMACOLOGY, V46, P770, DOI 10.1016/j.neuropharm.2003.11.027; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Chebib M, 1998, EUR J PHARMACOL, V357, P227, DOI 10.1016/S0014-2999(98)00552-4; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DANI JA, 1986, BIOPHYS J, V49, P607, DOI 10.1016/S0006-3495(86)83688-8; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; Duke RK, 2000, J NEUROCHEM, V75, P2602, DOI 10.1046/j.1471-4159.2000.0752602.x; ENZ R, 1995, NEUROREPORT, V6, P1569, DOI 10.1097/00001756-199507310-00026; Filippova N, 2004, J BIOL CHEM, V279, P20906, DOI 10.1074/jbc.M401012200; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HANRAHAN JR, 2001, J CHEM SOC P1, V19, P2389; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 2002, J GEN PHYSIOL, V119, P411, DOI 10.1085/jgp.20028553; Ogurusu T, 1996, BBA-GENE STRUCT EXPR, V1305, P15, DOI 10.1016/0167-4781(95)00205-7; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; ROBINSON RA, 1965, ACTIVITY COEFFICIENT; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; WOLF AV, 1980, CRC HDB CHEM PHYSICS, pD261; WOTRIN VE, 2003, J PHYSL, P527; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P109; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756	47	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54153	54160		10.1074/jbc.M410625200	http://dx.doi.org/10.1074/jbc.M410625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485818	hybrid			2022-12-25	WOS:000225793600034
J	Chang, Q; Gyftogianni, E; van de Graaf, SFJ; Hoefs, S; Weidema, FA; Bindels, RJM; Hoenderop, JGJ				Chang, Q; Gyftogianni, E; van de Graaf, SFJ; Hoefs, S; Weidema, FA; Bindels, RJM; Hoenderop, JGJ			Molecular determinants in TRPV5 channel assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CALCIUM-CHANNEL; D-3-1-ALPHA-HYDROXYLASE KNOCKOUT MICE; NEPHROGENIC DIABETES-INSIPIDUS; SHAKER POTASSIUM CHANNEL; CA2+ CHANNEL; CONFORMATIONAL-CHANGES; FUNCTIONAL EXPRESSION; GENE STRUCTURE; DIETARY CA2+; K+ CHANNELS	The epithelial Ca2+ channels TRPV5 and TRPV6 mediate the Ca2+ influx in 1,25-dihydroxyvitamin D-3-responsive epithelia and are therefore essential in the maintenance of the body Ca2+ balance. These Ca2+ channels assemble in (hetero) tetrameric channel complexes with different functional characteristics regarding Ca2+-dependent inactivation, ion selectivity, and pharmacological block. Glutathione S-transferase pull-downs and co-immunoprecipitations demonstrated an essential role of the intracellular N- and C-tails in TRPV5 channel assembly by physical interactions between N-N tails, C-C tails, and N-C-tails. Patch clamp analysis in human embryonic kidney (HEK293) cells and Ca-45(2+) uptake experiments in Xenopus laevis oocytes co-expressing TRPV5 wild-type and truncated proteins indicated that TRPV5DeltaN (deleted N-tail) and TRPV5DeltaC (deleted C-tail) decreased channel activity of wild-type TRPV5 in a dominant-negative manner, whereas TRPV5DeltaNDeltaC (deleted N-tail/C-tail) did not affect TRPV5 activity. Oocytes co-expressing wild-type TRPV5 and TRPV5DeltaN or TRPV5DeltaC showed virtually no wild-type TRPV5 expression on the plasma membrane, whereas co-expression of wild-type TRPV5 and TRPV5DeltaNDeltaC displayed normal channel surface expression. This indicates that TRPV5 trafficking toward the plasma membrane was disturbed by assembly with TRPV5DeltaN or TRPV5DeltaC but not with TRPV5DeltaNDeltaC. TRPV5 channel assembly signals were refined between amino acid positions 64-77 and 596-601 in the N- tail and C-tail, respectively. Pull-down assays and co-immunoprecipitations demonstrated that N- or C-tail mutants lacking these critical assembly domains were unable to interact with tails of TRPV5. In conclusion, two domains in the N- tail (residues 64-77) and C-tail (residues 596-601) of TRPV5 are important for channel subunit assembly, subsequent trafficking of the TRPV5 channel complex to the plasma membrane, and channel activity.	Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Hoenderop, JGJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.Hoenderop@ncmls.ru.nl	Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013	Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; van de Graaf, Stan/0000-0003-4238-4359				Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Hoenderop JGJ, 2004, KIDNEY INT, V65, P531, DOI 10.1111/j.1523-1755.2004.00402.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Mulders SM, 1997, AM J PHYSIOL-RENAL, V273, pF451, DOI 10.1152/ajprenal.1997.273.3.F451; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; van Abel M, 2003, AM J PHYSIOL-GASTR L, V285, pG78, DOI 10.1152/ajpgi.00036.2003; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121	40	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54304	54311		10.1074/jbc.M406222200	http://dx.doi.org/10.1074/jbc.M406222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489237	Green Published, hybrid			2022-12-25	WOS:000225793600051
J	Omara-Opyene, AL; Moura, PA; Sulsona, CR; Bonilla, JA; Yowell, CA; Fujioka, H; Fidock, DA; Dame, JB				Omara-Opyene, AL; Moura, PA; Sulsona, CR; Bonilla, JA; Yowell, CA; Fujioka, H; Fidock, DA; Dame, JB			Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROFOLATE-REDUCTASE; HUMAN MALARIA PARASITES; CYSTEINE PROTEASE; HEMOGLOBIN DEGRADATION; ASPARTIC PROTEINASE; FOOD VACUOLE; II INHIBITORS; INFECTING MAN; CATHEPSIN-D; IDENTIFICATION	The digestive vacuole plasmepsins PfPM1, PfPM2, PfPM4, and PfHAP (a histoaspartic proteinase) are 4 aspartic proteinases among 10 encoded in the Plasmodium falciparum malarial genome. These have been hypothesized to initiate and contribute significantly to hemoglobin degradation, a catabolic function essential to the survival of this intraerythrocytic parasite. Because of their perceived significance, these plasmepsins have been proposed as potential targets for antimalarial drug development. To test their essentiality, knockout constructs were prepared for each corresponding gene such that homologous recombination would result in two partial, nonfunctional gene copies. Disruption of each gene was achieved, as confirmed by PCR, Southern, and Northern blot analyses. Western and two-dimensional gel analyses revealed the absence of mature or even truncated plasmepsins corresponding to the disrupted gene. Reduced growth rates were observed with PfPM1 and PfPM4 knockouts, indicating that although these plasmepsins are not essential, they are important for parasite development. Abnormal mitochondrial morphology also appeared to accompany loss of PfPM2, and an abundant accumulation of electron-dense vesicles in the digestive vacuole was observed upon disruption of PfPM4; however, those phenotypes only manifested in about a third of the disrupted cells. The ability to compensate for loss of individual plasmepsin function may be explained by close similarity in the structure and active site of these four vacuolar enzymes. Our data imply that drug discovery efforts focused on vacuolar plasmepsins must incorporate measures to develop compounds that can inhibit two or more of this enzyme family.	Univ Florida, Dept Pathobiol, Gainesville, FL 32611 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University	Dame, JB (corresponding author), Univ Florida, Dept Pathobiol, Gainesville, FL 32611 USA.	damej@mail.vetmed.ufl.edu		Dame, John B./0000-0002-5772-5454; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [AI39211] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039211] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 2003, J MOL BIOL, V329, P505, DOI 10.1016/S0022-2836(03)00444-3; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Berry C, 1999, FEBS LETT, V447, P149, DOI 10.1016/S0014-5793(99)00276-8; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P3203, DOI 10.1016/S0960-894X(98)00554-X; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GAMBOADE DN, 1996, BLOOD, V87, P4448; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Goodyer ID, 1997, EXP PARASITOL, V86, P158, DOI 10.1006/expr.1997.4156; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lew VL, 2004, BLOOD CELL MOL DIS, V32, P353, DOI 10.1016/j.bcmd.2004.01.006; Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z; Nezami A, 2002, BIOCHEMISTRY-US, V41, P2273, DOI 10.1021/bi0117549; Noteberg D, 2003, J MED CHEM, V46, P734, DOI 10.1021/jm020951i; OConnell KL, 1997, ELECTROPHORESIS, V18, P349, DOI 10.1002/elps.1150180309; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; Omara-Opyene AL, 1997, MOL BIOCHEM PARASIT, V90, P247, DOI 10.1016/S0166-6851(97)00158-8; Oscarsson K, 2003, BIOORGAN MED CHEM, V11, P1235, DOI 10.1016/S0968-0896(02)00643-0; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033; Rosenthal PJ, 1998, EMERG INFECT DIS, V4, P49, DOI 10.3201/eid0401.980107; Sabnis YA, 2003, PROTEIN SCI, V12, P501, DOI 10.1110/ps.0228103; Saliba KJ, 1998, BIOCHEM PHARMACOL, V56, P313, DOI 10.1016/S0006-2952(98)00140-3; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Silva AM, 1998, ADV EXP MED BIOL, V436, P363; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Wyatt DM, 2002, FEBS LETT, V513, P159, DOI 10.1016/S0014-5793(02)02241-X	59	101	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54088	54096		10.1074/jbc.M409605200	http://dx.doi.org/10.1074/jbc.M409605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491999	hybrid			2022-12-25	WOS:000225793600026
J	Tisdale, EJ; Kelly, C; Artalejo, CR				Tisdale, EJ; Kelly, C; Artalejo, CR			Glyceraldehyde-3-phosphate dehydrogenase interacts with Rab2 and plays an essential role in endoplasmic reticulum to Golgi transport exclusive of its glycolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; VESICULAR TRANSPORT; VESICLE FORMATION; PROTEIN; NEUROLEUKIN; MEMBRANE; CELLS; COMPLEX; BINDING; RECRUITMENT	Rab2 requires atypical protein kinase C iota/lambda (aPKCiota/lambda) to promote vesicle formation from (v) under bar esicular (t) under bar ubular (c) under bar lusters (VTCs). The Rab2-generated vesicles are enriched in recycling proteins suggesting that the carriers are retrograde-directed and retrieve transport machinery back to the endoplasmic reticulum. These vesicles also contained the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We have previously established that GAPDH is required for membrane transport between the endoplasmic reticulum and the Golgi complex. Moreover, GAPDH is phosphorylated by aPKCiota/lambda and binds to the aPKCiota/lambda regulatory domain. In this study, we employed a combination of in vivo and in vitro assays and determined that GAPDH also interacts with Rab2. The site of GAPDH interaction was mapped to Rab2 residues 20-50. In addition to its glycolytic function, GAPDH has multiple intracellular roles. However, the function of GAPDH in the early secretory pathway is unknown. One possibility is that GAPDH ultimately provides energy in the form of ATP. To determine whether GAPDH catalytic activity was critical for transport in the early secretory pathway, a conservative substitution was made at Cys-149 located at the active site, and the mutant was biochemically characterized in a battery of assays. Although GAPDH (C149G) has no catalytic activity, Rab2 recruited the mutant protein to membranes in a quantitative binding assay. GAPDH ( C149G) is phosphorylated by aPKCiota/lambda and binds directly to Rab2 when evaluated in an overlay binding assay. Importantly, VSV-G transport between the ER and Golgi complex is restored when an in vitro trafficking assay is performed with GAPDH-depleted cytosol and GAPDH (C149G). These data suggest that GAPDH imparts a unique function necessary for membrane trafficking from VTCs that does not require GAPDH glycolytic activity.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave,6374 Scott Hall, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH047181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58921, R01 DK058921] Funding Source: Medline; NIMH NIH HHS [MH47181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; GURNEY ME, 1986, SCIENCE, V234, P566, DOI 10.1126/science.3764429; Harrison J., 1976, P1; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Steck T L, 1974, Methods Enzymol, V31, P172; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 2003, J BIOL CHEM, V278, P52524, DOI 10.1074/jbc.M309343200; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; VINALS AEL, 1987, BIOCHEM BIOPH RES CO, V143, P403, DOI 10.1016/0006-291X(87)90680-2; WATANABE K, 1996, CANCER RES, V56, P2954; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yun M, 2000, BIOCHEMISTRY-US, V39, P10702, DOI 10.1021/bi9927080; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	36	80	88	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54046	54052		10.1074/jbc.M409472200	http://dx.doi.org/10.1074/jbc.M409472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485821	hybrid			2022-12-25	WOS:000225793600021
J	Vuong, C; Kocianova, S; Voyich, JM; Yao, YF; Fischer, ER; DeLeo, FR; Otto, M				Vuong, C; Kocianova, S; Voyich, JM; Yao, YF; Fischer, ER; DeLeo, FR; Otto, M			A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSACCHARIDE INTERCELLULAR ADHESIN; STAPHYLOCOCCUS-EPIDERMIDIS; INFECTION; LOCUS; MODEL; PATHOGENESIS; AUTOLYSIN; MUTANTS; AUREUS; SYSTEM	Biofilms play an important role in many chronic bacterial infections. Production of an extracellular mixture of sugar polymers called exopolysaccharide is characteristic and critical for biofilm formation. However, there is limited information about the mechanisms involved in the biosynthesis and modification of exopolysaccharide components and how these processes influence bacterial pathogenesis. Staphylococcus epidermidis is an important human pathogen that frequently causes persistent infections by biofilm formation on indwelling medical devices. It produces a poly-N-acetylglucosamine molecule that emerges as an exopolysaccharide component of many bacterial pathogens. Using a novel method based on size exclusion chromatography-mass spectrometry, we demonstrate that the surface-attached protein IcaB is responsible for deacetylation of the poly-N-acetylglucosamine molecule. Most likely due to the loss of its cationic character, non-deacetylated poly - acetylglucosamine in an isogenic icaB mutant strain was devoid of the ability to attach to the bacterial cell surface. Importantly, deacetylation of the polymer was essential for key virulence mechanisms of S. epidermidis, namely biofilm formation, colonization, and resistance to neutrophil phagocytosis and human antibacterial peptides. Furthermore, persistence of the icaB mutant strain was significantly impaired in a murine model of device-related infection. This is the first study to describe a mechanism of exopolysaccharide modification that is indispensable for the development of biofilm-associated human disease. Notably, this general virulence mechanism is likely similar for other pathogenic bacteria and constitutes an excellent target for therapeutic maneuvers aimed at combating biofilm-associated infection.	NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; NIAID, Microscopy Core Facil, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Otto, M (corresponding author), NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	motto@niaid.nih.gov		Otto, Michael/0000-0002-2222-4115; DeLeo, Frank/0000-0003-3150-2516; Vuong, Cuong/0000-0001-6125-3245	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000904, ZIAAI000904] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allignet J, 2001, INFECT IMMUN, V69, P712, DOI 10.1128/IAI.69.2.712-718.2001; Bruckner R, 1997, FEMS MICROBIOL LETT, V151, P1; Cramton SE, 1999, INFECT IMMUN, V67, P5427, DOI 10.1128/IAI.67.10.5427-5433.1999; Darby C, 2002, NATURE, V417, P243, DOI 10.1038/417243a; Deery MJ, 2001, RAPID COMMUN MASS SP, V15, P2273, DOI 10.1002/rcm.458.abs; Fassel TA, 1999, METHOD ENZYMOL, V310, P194; Gerke C, 1998, J BIOL CHEM, V273, P18586, DOI 10.1074/jbc.273.29.18586; Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Hinnebusch BJ, 1996, SCIENCE, V273, P367, DOI 10.1126/science.273.5273.367; Kadurugamuwa JL, 2003, INFECT IMMUN, V71, P882, DOI 10.1128/IAI.71.2.882-890.2003; MACK D, 1994, INFECT IMMUN, V62, P3244, DOI 10.1128/IAI.62.8.3244-3253.1994; Mack D, 1996, J BACTERIOL, V178, P175, DOI 10.1128/jb.178.1.175-183.1996; Maira-Litran T, 2002, INFECT IMMUN, V70, P4433, DOI 10.1128/IAI.70.8.4433-4440.2002; Rupp ME, 2001, J INFECT DIS, V183, P1038, DOI 10.1086/319279; Rupp ME, 1999, INFECT IMMUN, V67, P2627, DOI 10.1128/IAI.67.5.2627-2632.1999; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Sutherland IW, 2001, MICROBIOL-UK, V147, P3, DOI 10.1099/00221287-147-1-3; Voyich JM, 2003, P NATL ACAD SCI USA, V100, P1996, DOI 10.1073/pnas.0337370100; Vuong C, 2004, CELL MICROBIOL, V6, P269, DOI 10.1046/j.1462-5822.2004.00367.x; Vuong C, 2000, INFECT IMMUN, V68, P1048, DOI 10.1128/IAI.68.3.1048-1053.2000; Vuong C, 2002, MICROBES INFECT, V4, P481, DOI 10.1016/S1286-4579(02)01563-0; Vuong C, 2000, J INFECT DIS, V182, P1688, DOI 10.1086/317606; Vuong C, 2004, J INFECT DIS, V190, P1498, DOI 10.1086/424487; Wang X, 2004, J BACTERIOL, V186, P2724, DOI 10.1128/JB.186.9.2724-2734.2004; Watnick P, 2000, J BACTERIOL, V182, P2675, DOI 10.1128/JB.182.10.2675-2679.2000; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x	28	381	409	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54881	54886		10.1074/jbc.M411374200	http://dx.doi.org/10.1074/jbc.M411374200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15501828	hybrid			2022-12-25	WOS:000225793600117
J	Akama, H; Kanemaki, M; Yoshimura, M; Tsukihara, T; Kashiwagi, T; Yoneyama, H; Narita, S; Nakagawa, A; Nakae, T				Akama, H; Kanemaki, M; Yoshimura, M; Tsukihara, T; Kashiwagi, T; Yoneyama, H; Narita, S; Nakagawa, A; Nakae, T			Crystal structure of the drug discharge outer membrane protein, OprM, of Pseudomonas aeruginosa - Dual modes of membrane anchoring and occluded cavity end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX SYSTEM; MEXA-MEXB-OPRM; ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; FUSION PROTEIN; PUMP; MUTATIONS; COMPONENT; TRANSPORTER; INVOLVEMENT	The OprM lipoprotein of Pseudomonas aeruginosa is a member of the MexAB-OprM xenobiotic-antibiotic transporter subunits that is assumed to serve as the drug discharge duct across the outer membrane. The channel structure must differ from that of the porin-type open pore because the protein facilitates the exit of antibiotics but not the entry. For better understanding of the structure-function linkage of this important pump subunit, we studied the x-ray crystallographic structure of OprM at the 2.56-Angstrom resolution. The overall structure exhibited trimeric assembly of the OprM monomer that consisted mainly of two domains: the membrane-anchoring beta-barrel and the cavity-forming alpha-barrel. OprM anchors the outer membrane by two modes of membrane insertions. One is via the covalently attached NH2-terminal fatty acids and the other is the beta-barrel structure consensus on the outer membrane-spanning proteins. The beta-barrel had a pore opening with a diameter of about 6-8 Angstrom, which is not large enough to accommodate the exit of any antibiotics. The periplasmic alpha-barrel was about 100 Angstrom long formed mainly by a bundle of alpha-helices that formed a solvent-filled cavity of about 25,000 Angstrom(3). The proximal end of the cavity was tightly sealed, thereby not permitting the entry of any molecule. The result of this structure was that the resting state of OprM had a small outer membrane pore and a tightly closed periplasmic end, which sounds plausible because the protein should not allow free access of antibiotics. However, these observations raised another unsolved problem about the mechanism of opening of the OprM cavity ends. The crystal structure offers possible mechanisms of pore opening and pump assembly.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan	Osaka University; Tokai University	Nakagawa, A (corresponding author), Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan.	atsushi@protein.osaka-u.ac.jp; nakae@is.icc.u-tokai.ac.jp	Nakagawa, Atsushi/M-5731-2019; Nakagawa, Atsushi/D-4329-2009	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861; Yoshimura, Masato/0000-0002-7466-2192; Narita, Shin-ichiro/0000-0001-9425-2943				Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; Andersen C, 2002, P NATL ACAD SCI USA, V99, P11103, DOI 10.1073/pnas.162039399; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Elkins CA, 2003, J BACTERIOL, V185, P5349, DOI 10.1128/JB.185.18.5349-5356.2003; Gerken H, 2004, MOL MICROBIOL, V54, P620, DOI 10.1111/j.1365-2958.2004.04301.x; Higgins MK, 2004, P NATL ACAD SCI USA, V101, P9994, DOI 10.1073/pnas.0400375101; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LEI Y, 1991, BIOCHEM BIOPH RES CO, V178, P1043, DOI 10.1016/0006-291X(91)90997-L; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Mokhonov VV, 2004, BIOCHEM BIOPH RES CO, V322, P483, DOI 10.1016/j.bbrc.2004.07.140; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; NAKAE T, 1995, MICROBIOL IMMUNOL, V39, P221, DOI 10.1111/j.1348-0421.1995.tb02193.x; Nakajima A, 2000, J BIOL CHEM, V275, P30064, DOI 10.1074/jbc.M005742200; Nehme D, 2004, J BACTERIOL, V186, P2973, DOI 10.1128/JB.186.10.2973-2983.2004; NIKAIDO H, 1996, SCIENCE, V264, P221; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; Saito K, 1999, FEMS MICROBIOL LETT, V179, P67, DOI 10.1016/S0378-1097(99)00394-8; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Wong KKY, 2001, J BACTERIOL, V183, P367, DOI 10.1128/JB.183.1.367-374.2001; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Yoshihara E, 2002, EUR J BIOCHEM, V269, P4738, DOI 10.1046/j.1432-1033.2002.03134.x	28	172	182	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52816	52819		10.1074/jbc.C400445200	http://dx.doi.org/10.1074/jbc.C400445200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15507433	Green Published, hybrid			2022-12-25	WOS:000225680600004
J	Hogan, A; Yakubchyk, Y; Chabot, J; Obagi, C; Daher, E; Maekawa, K; Gee, SH				Hogan, A; Yakubchyk, Y; Chabot, J; Obagi, C; Daher, E; Maekawa, K; Gee, SH			The phosphoinositol 3,4-bisphosphate-binding protein TAPP1 interacts with syntrophins and regulates actin cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; DIACYLGLYCEROL KINASE-ZETA; PDZ DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; ANTIGEN RECEPTOR; SODIUM-CHANNELS; ADAPTER PROTEIN; SKELETAL-MUSCLE; BINDING DOMAIN	Syntrophins are scaffold proteins of the dystrophin glycoprotein complex (DGC), which target ion channels, receptors, and signaling proteins to specialized subcellular domains. A yeast two-hybrid screen of a human brain cDNA library with the PSD-95, Discs-large, ZO-1 (PDZ) domain of gamma1-syntrophin yielded overlapping clones encoding the C terminus of TAPP1, a pleckstrin homology (PH) domain-containing adapter protein that interacts specifically with phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-2). In biochemical assays, the C terminus of TAPP1 bound specifically to the PDZ domains of gamma1-, alpha1-, and beta2-syntrophin and was required for syntrophin binding and for the correct subcellular localization of TAPP1. TAPP1 is recruited to the plasma membrane of cells stimulated with platelet-derived growth factor ( PDGF), a motogen that produces PI(3,4)P-2. Cell migration in response to PDGF stimulation is characterized by a rapid reorganization of the actin cytoskeleton, which gives rise to plasma membrane specializations including peripheral and dorsal circular ruffles. Both TAPP1 and syntrophins were localized to PDGF-induced circular membrane ruffles in NIH-3T3 cells. Ectopic expression of TAPP1 potently blocked PDGF-induced formation of dorsal circular ruffles, but did not affect peripheral ruffling. Interestingly, coexpression of alpha1- or gamma1-syntrophin with TAPP1 prevented the blockade of circular ruffling. In addition to syntrophins, several other proteins of the DGC were enriched in circular ruffles. Collectively, our results suggest syntrophins regulate the localization of TAPP1, which may be important for remodeling the actin cytoskeleton in response to growth factor stimulation.	Univ Ottawa, Ctr Neuromuscular Dis, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Shionogi Inst Med Sci, Osaka 5660022, Japan	University of Ottawa; Shionogi & Company Limited	Gee, SH (corresponding author), Univ Ottawa, Ctr Neuromuscular Dis, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	stevegee@uottawa.ca						Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Gee SH, 1998, J NEUROSCI, V18, P128; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Janmey PA, 2004, NAT REV MOL CELL BIO, V5, P658, DOI 10.1038/nrm1434; Kimber WA, 2003, BIOCHEM J, V376, P525, DOI 10.1042/BJ20031154; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; Marshall AJ, 2002, MOL CELL BIOL, V22, P5479, DOI 10.1128/MCB.22.15.5479-5491.2002; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohrschneider LR, 2000, GENE DEV, V14, P505; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Watt SA, 2004, BIOCHEM J, V377, P653, DOI 10.1042/BJ20031397; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517	45	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53717	53724		10.1074/jbc.M410654200	http://dx.doi.org/10.1074/jbc.M410654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485858	hybrid			2022-12-25	WOS:000225680600109
J	Jiang, F; Bao, JY; Li, PF; Nicosia, SV; Bai, WL				Jiang, F; Bao, JY; Li, PF; Nicosia, SV; Bai, WL			Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D-3 through the down-regulation of telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; CATALYTIC SUBUNIT; VITAMIN-D; C-MYC; PROSTATE-CANCER; EXPRESSION; INHIBITION; GROWTH; RECEPTOR; ACID	The maintenance of telomere length is required for continued cell proliferation, and similar to85-90% of human cancers, including ovarian epithelial cancers (OCa), show high activity of telomerase. In the present study we report that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)VD3) induces OCa cell apoptosis by down-regulating telomerase. Quantitative reverse transcription-PCR analysis shows that 1,25(OH)(2)VD3 decreases the level of human telomerase reverse transcriptase ( hTERT) mRNA, the catalytic subunit of telomerase. The decrease is not due to transcriptional repression through the putative vitamin D response element present in the 5' regulatory region of hTERT gene. Instead, 1,25(OH)(2)VD3 decreases the stability of the hTERT mRNA. Stable expression of hTERT in OCa cells decreases their response to 1,25(OH)(2)VD3-induced growth suppression. Although the cell cycle progression of these clones stably expressing hTERT is inhibited by 1,25(OH)(2)VD3 to a similar degree as that of the parental cells, these clones are more resistant to apoptosis induced by 1,25(OH)(2)VD3. In contrast to parental cells, which lose proliferation potential after the 1,25(OH)(2)VD3 treatment, hTERT-expressing clones resume rapid growth after withdrawal of 1,25(OH)(2)VD3. Overall, the study suggests that the down-regulation of telomerase activity by 1,25(OH)(2)VD3 and the resulting cell death are important components of the response of OCa cells to 1,25(OH)(2)VD3-induced growth suppression.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Program Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Braunstein I, 2001, CANCER RES, V61, P5529; Cech TR, 2004, CELL, V116, P273, DOI 10.1016/S0092-8674(04)00038-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Feldman D, 1995, Adv Exp Med Biol, V375, P53; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Ikeda N, 2003, MOL CANCER THER, V2, P739; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kyo S, 1999, INT J CANCER, V80, P804; Kyo S, 1999, CANCER RES, V59, P5917; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Saretzki G, 2003, CANCER LETT, V194, P209, DOI 10.1016/S0304-3835(02)00708-5; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; Takahashi T, 1997, LEUKEMIA LYMPHOMA, V27, P25, DOI 10.3109/10428199709068268; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Villa R, 2000, INT J ONCOL, V16, P995; WELSH J, 1994, BIOCHEM CELL BIOL, V72, P537, DOI 10.1139/o94-072; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	33	117	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53213	53221		10.1074/jbc.M410395200	http://dx.doi.org/10.1074/jbc.M410395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485861	hybrid			2022-12-25	WOS:000225680600051
J	Koutsodontis, G; Kardassis, D				Koutsodontis, G; Kardassis, D			Inhibition of p53-mediated transcriptional responses by mithramycin A	ONCOGENE			English	Article						p53; mithramycin A; 5-fluorouracil; genotoxic stress; p21(Cip1); PUMA; Sp1	COLORECTAL-CANCER CELLS; DEPENDENT KINASES; PAGETS-DISEASE; CDK INHIBITORS; FAMILY-MEMBERS; SMAD PROTEINS; IN-VIVO; P53; PROMOTER; SP1	In the present work, we show that mithramycin A, a drug that is currently used for the treatment of patients with Paget's disease of the bone as well as with several forms of cancer, is a strong activator of the tumor suppressor p53 protein in human hepatoma cells. The time course of p53 activation by mithramycin A was similar to the known chemotherapeutic compound 5-fluorouracil (5-FU). Both 5-FU and mithramycin A induced site-specific phosphorylation of p53 at serine 15. However, in contrast to 5-FU, mithramycin A failed to activate p53 target genes including the cell cycle inhibitor p21(Cip1) gene as well as the proapoptotic genes PUMA (p53-upregulated mediator of apotosis) and BAK (bcl2-homologous antagonist/killer) and blocked the induction of the above genes by 5-FU. Using transactivation assays in Sp1-deficient cells, we showed that mithramycin A inhibited the transcriptional activation of the p21(Cip1) and PUMA promoters by Sp1 and p53. Using chromatin immunoprecipitation assays and a novel protein-protein interaction assay based on biotinylation in vivo, we established that 5-FU enhanced the formation of p53-Sp1 complexes in solution and the subsequent recruitment of both factors to the p21(Cip1) promoter. Mithramycin A also enhanced the recruitment of p53 to the distal p21(Cip1) promoter but totally blocked the recruitment of Sp1 to the proximal p21(Cip1) promoter. Our findings suggest that inhibition of Sp1 binding to the promoters of several p53 target genes, such as the p21(Cip1) gene as well as certain proapoptotic genes, by mithramycin A, prevents the transcriptional induction of these genes by p53 and propose a mechanism that could account for some of the tumor suppressing and antiapoptotic effects of mithramycin A.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	kardasis@imbb.forth.gr						AICH P, 1995, BIOCHEMISTRY-US, V34, P1376, DOI 10.1021/bi00004a032; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELIAS EG, 1972, J BONE JOINT SURG AM, VA 54, P1730, DOI 10.2106/00004623-197254080-00013; Gartel AL, 2002, MOL CANCER THER, V1, P639; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HALL TJ, 1993, BIOCHEM BIOPH RES CO, V195, P1245, DOI 10.1006/bbrc.1993.2178; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jayasuriya H, 2002, J NAT PROD, V65, P1091, DOI 10.1021/np010642f; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Majee S, 1999, BIOCHEM PHARMACOL, V57, P981, DOI 10.1016/S0006-2952(98)00374-8; Majee S, 1999, EUR J BIOCHEM, V260, P619, DOI 10.1046/j.1432-1327.1999.00159.x; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z; RYAN WG, 1970, J AMER MED ASSOC, V213, P1153, DOI 10.1001/jama.213.7.1153; Schavinsky-Khrapunsky Y, 2003, ONCOGENE, V22, P5315, DOI 10.1038/sj.onc.1206782; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005	47	62	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9190	9200		10.1038/sj.onc.1208141	http://dx.doi.org/10.1038/sj.onc.1208141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489892				2022-12-25	WOS:000225638000004
J	Smits, SL; Gerwig, GJ; van Vliet, ALW; Lissenberg, A; Briza, P; Kamerling, JP; Vlasak, R; de Groot, RJ				Smits, SL; Gerwig, GJ; van Vliet, ALW; Lissenberg, A; Briza, P; Kamerling, JP; Vlasak, R; de Groot, RJ			Nidovirus sialate-O-acetylesterases - Evolution and substrate specificity of coronaviral and toroviral receptor-destroying enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATITIS-VIRUS; INFLUENZA-C VIRUS; ACID-CONTAINING RECEPTORS; HEMAGGLUTININ-ESTERASE; BOVINE CORONAVIRUS; SIALIC ACIDS; GENOME ORGANIZATION; RNA RECOMBINATION; AMINOPEPTIDASE-N; GLYCOPROTEIN	Many viruses achieve reversible attachment to sialic acid (Sia) by encoding envelope glycoproteins with receptor-binding and receptor-destroying activities. Toroviruses and group 2 coronaviruses bind to O-acetylated Sias, presumably via their spike proteins (S), whereas other glycoproteins, the hemagglutinin-esterases (HE), destroy Sia receptors by de-O-acetylation. Here, we present a comprehensive study of these enzymes. Sialate-9-O-acetylesterases specific for 5-N-acetyl-9-O-acetylneuraminic acid, described for bovine and human coronaviruses, also occur in equine coronaviruses and in porcine toroviruses. Bovine toroviruses, however, express novel sialate-9-O-acetylesterases, which prefer the di-O-acetylated substrate 5-N-acetyl-7(8),9-di-O-acetylneuraminic acid. Whereas most rodent coronaviruses express sialate-4-O-acetylesterases, the HE of murine coronavirus DVIM cleaves 9-O-acetylated Sias. Under the premise that HE specificity reflects receptor usage, we propose that two types of Sias serve as initial attachment factors for coronaviruses in mice. There are striking parallels between orthomyxo- and nidovirus biology. Reminiscent of antigenic shifts in orthomyxoviruses, rodent coronaviruses exchanged S and HE sequences through recombination to extents not appreciated before. As for orthomyxovirus reassortants, the fitness of nidovirus recombinant offspring probably depends both on antigenic properties and on compatibility of receptor-binding and receptor-destroying activities.	Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3584 CL Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Bioorgan Chem, Sect Glycosci & Biocatalysis, NL-3584 CH Utrecht, Netherlands; Salzburg Univ, Dept Biol Mol, A-5020 Salzburg, Austria; Salzburg Univ, Dept Cell Biol, A-5020 Salzburg, Austria	Utrecht University; Utrecht University; Salzburg University; Salzburg University	de Groot, RJ (corresponding author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3584 CL Utrecht, Netherlands.	R.Groot@vet.uu.nl	Briza, Peter/D-7309-2012; Smits, Saskia/A-2953-2014	Briza, Peter/0000-0002-4941-6782; 				Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Brian DA, 1995, CORONAVIRIDAE, P165; Cavanagh D, 1997, ARCH VIROL, V142, P629; Cavanagh D, 1995, CORONAVIRIDAE, P73; Comeron JM, 1999, BIOINFORMATICS, V15, P763, DOI 10.1093/bioinformatics/15.9.763; Comeron JM, 1995, J MOL EVOL, V41, P1152, DOI 10.1007/BF00173196; Cornelissen LAHM, 1997, J VIROL, V71, P5277, DOI 10.1128/JVI.71.7.5277-5286.1997; de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104; DEGROOT RJ, 1989, VIROLOGY, V171, P493, DOI 10.1016/0042-6822(89)90619-3; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DEREGT D, 1989, J GEN VIROL, V70, P993, DOI 10.1099/0022-1317-70-4-993; Falk K, 2004, J VIROL, V78, P3063, DOI 10.1128/JVI.78.6.3063-3071.2004; GAGNETEN S, 1995, J VIROL, V69, P889, DOI 10.1128/JVI.69.2.889-895.1995; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; Hellebo A, 2004, J VIROL, V78, P3055, DOI 10.1128/JVI.78.6.3055-3062.2004; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; Kamerling JP, 1989, CLIN BIOCH PRINCIPLE, V1, P176; Klausegger A, 1999, J VIROL, V73, P3737, DOI 10.1128/JVI.73.5.3737-3743.1999; KOOPMANS M, 1990, AM J VET RES, V51, P1443; Kroneman A, 1998, J VIROL, V72, P3507, DOI 10.1128/JVI.72.5.3507-3511.1998; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; Mijnes JDF, 1996, J VIROL, V70, P5466, DOI 10.1128/JVI.70.8.5466-5475.1996; Morimoto N, 2001, ANAL CHEM, V73, P5422, DOI 10.1021/ac0104328; Morrison TG, 2001, TRENDS MICROBIOL, V9, P103, DOI 10.1016/S0966-842X(01)01959-X; Popova R, 2002, VIROLOGY, V294, P222, DOI 10.1006/viro.2001.1307; Regl G, 1999, J VIROL, V73, P4721, DOI 10.1128/JVI.73.6.4721-4727.1999; REUTER G, 1983, EUR J BIOCHEM, V134, P139, DOI 10.1111/j.1432-1033.1983.tb07542.x; Rosenthal PB, 1998, NATURE, V396, P92, DOI 10.1038/23974; Schauer R, 2004, ZOOLOGY, V107, P49, DOI 10.1016/j.zool.2003.10.002; Schauer R, 1997, N COMP BIOC B, V29, P243; SCHULTZE B, 1992, VIROLOGY, V189, P792, DOI 10.1016/0042-6822(92)90608-R; Schultze B, 1996, J VIROL, V70, P5634, DOI 10.1128/JVI.70.8.5634-5637.1996; SCHULTZE B, 1990, VIRUS RES, V16, P185, DOI 10.1016/0168-1702(90)90022-4; SCHULTZE B, 1991, J VIROL, V65, P6232, DOI 10.1128/JVI.65.11.6232-6237.1991; Schwegmann-Wessels C, 2002, J VIROL, V76, P6037, DOI 10.1128/JVI.76.12.6037-6043.2002; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Smits SL, 2003, J VIROL, V77, P9567, DOI 10.1128/JVI.77.17.9567-9577.2003; SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H; Strasser P, 2004, GLYCOCONJUGATE J, V20, P551; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; Wagner R, 2002, REV MED VIROL, V12, P159, DOI 10.1002/rmv.352; WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533; Wurzer WJ, 2002, J GEN VIROL, V83, P395, DOI 10.1099/0022-1317-83-2-395; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; YOKOMORI K, 1991, VIROLOGY, V183, P647, DOI 10.1016/0042-6822(91)90994-M; YOO DW, 1992, J GEN VIROL, V73, P2591, DOI 10.1099/0022-1317-73-10-2591; ZANONI R, 1986, J GEN VIROL, V67, P2485, DOI 10.1099/0022-1317-67-11-2485	59	67	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	2005	280	8					6933	6941		10.1074/jbc.M409683200	http://dx.doi.org/10.1074/jbc.M409683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902DT	15507445	hybrid, Green Published			2022-12-25	WOS:000227332700083
J	Galvez, BG; Genis, L; Matias-Roman, S; Oblander, SA; Tryggvason, K; Apte, SS; Arroyo, AG				Galvez, BG; Genis, L; Matias-Roman, S; Oblander, SA; Tryggvason, K; Apte, SS; Arroyo, AG			Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/CCL2 and Interleukin-8/CXCL8 in endothelial cells during angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; EXPRESSION; RECEPTORS; MT1-MMP; INTERNALIZATION; ACTIVATION; MIGRATION; INVASION; OLIGOMERIZATION; CYTOKINES	We have investigated the putative role and regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in angiogenesis induced by inflammatory factors of the chemokine family. The absence of MT1-MMP from null mice or derived mouse lung endothelial cells or the blockade of its activity with inhibitory antibodies resulted in the specific decrease of in vivo and in vitro angiogenesis induced by CCL2 but not CXCL12. Similarly, CCL2- and CXCL8-induced tube formation by human endothelial cells (ECs) was highly dependent on MT1-MMP activity. CCL2 and CXCL8 significantly increased MT1-MMP surface expression, clustering, activity, and function in human ECs. Investigation of the signaling pathways involved in chemokine-induced MT1-MMP activity in ECs revealed that CCL2 and CXCL8 induced cortical actin polymerization and sustained activation of phosphatidylinositol 3-kinase (PI3K) and the small GTPase Rac. Inhibition of PI3K or actin polymerization impaired CCL2- induced MT1-MMP activity. Finally, dimerization of MT1-MMP was found to be enhanced by CCL2 in ECs in a PI3K- and actin polymerization-dependent manner. In summary, we identify MT1-MMP as a molecular target preferentially involved in angiogenesis mediated by CCL2 and CXCL8, but not CXCL12, and suggest that MT1-MMP dimerization might be an important mechanism of its regulation during angiogenesis.	Ctr Nacl Invest Cardiovasc, Dept Invest Basica, Tres Cantos 28760, Spain; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Karolinska Inst, Dept Matrix Biol & Biochem, S-17177 Stockholm, Sweden	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Cleveland Clinic Foundation; Karolinska Institutet	Arroyo, AG (corresponding author), Ctr Nacl Invest Cardiovasc, Dept Invest Basica, Ronda Poniente 5, Tres Cantos 28760, Spain.	agarroyo@cnic.es	Arroyo, Alicia G./L-2796-2014; Gálvez, Beatriz G./H-1644-2015; Arroyo, Alicia G/M-2507-2018	Arroyo, Alicia G./0000-0002-1536-3846; Gálvez, Beatriz G./0000-0002-8082-9323; Arroyo, Alicia G/0000-0002-1536-3846; Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR47074] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047074] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Dzenko KA, 2001, J NEUROSCI, V21, P9214, DOI 10.1523/JNEUROSCI.21-23-09214.2001; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Garcia-Lopez MA, 2001, LAB INVEST, V81, P409, DOI 10.1038/labinvest.3780248; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Haque NS, 2004, BLOOD, V103, P1296, DOI 10.1182/blood-2002-05-1480; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Lane WJ, 2000, BLOOD, V96, P4152; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schootemeijer A, 1997, THROMB HAEMOSTASIS, V77, P143; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sgadari C, 1997, BLOOD, V89, P2635, DOI 10.1182/blood.V89.8.2635; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; SWAISGOOD M, 1989, EXP CELL RES, V180, P515, DOI 10.1016/0014-4827(89)90078-5; Szekanecz Z, 2003, SEMIN IMMUNOL, V15, P15, DOI 10.1016/S1044-5323(02)00124-0; Szekanecz Z, 2001, CURR OPIN RHEUMATOL, V13, P202, DOI 10.1097/00002281-200105000-00009; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; Vicente-Manzanares M, 2002, J IMMUNOL, V168, P400, DOI 10.4049/jimmunol.168.1.400; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Werle M, 2002, CARDIOVASC RES, V56, P284, DOI 10.1016/S0008-6363(02)00600-4; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	42	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1292	1298		10.1074/jbc.M408673200	http://dx.doi.org/10.1074/jbc.M408673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516694	hybrid			2022-12-25	WOS:000226195200054
J	Solovjov, DA; Pluskota, E; Plow, EF				Solovjov, DA; Pluskota, E; Plow, EF			Distinct roles for the alpha and beta subunits in the functions of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; I-DOMAIN; A-DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; EXTRACELLULAR SEGMENT; RECOGNITION SITE; GAMMA-CHAIN; MAC-1; ADHESION	Integrin alpha(M)beta(2) (Mac-1, CD11b/CD18) is a noncovalently linked heterodimer of alpha(M) and beta(2) subunits on the surface of leukocytes, where it plays a pivotal role in the adhesion and migration of these cells. Using HEK293 cells expressing alpha(M)beta(2) or the individual constituent chains on their surface, we analyzed the contributions of the alpha(M) or beta(2) subunits to functional responses mediated by the integrin. In cells expressing only alpha(M) or beta(2), the individual subunits were not associated with the endogenous integrins of the cells, and other partners for the subunits were not detected by surface labeling and immunoprecipitation under a variety of conditions. The alpha(M) cells mediated adhesion and spreading on a series of alpha(M)beta(2) ligands (fibrinogen, Factor X, iC3b, ICAM-1 (intercellular adhesion molecule-1), and denatured ovalbumin) but could not support cell migration to any of these. The spreading of the alpha(M) cells suggested an unanticipated linkage of this subunit to the cytoskeleton. The beta(2) cells supported migration and attachment but not spreading on a subset of the alpha(M)beta(2) ligands. The heterodimeric receptor and its individual subunits were purified from the cells by affinity chromatography and recapitulated the ligand binding properties of the corresponding cell lines. These data indicate that each subunit of alpha(M)beta(2) contributes distinct properties to alpha(M)beta(2) and that, in most but not all cases, the response of the integrin is a composite of the functions of its individual subunits.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Plow, EF (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB-50,9500 Euclid Ave, Cleveland, OH 44195 USA.	plowe@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1986, J CLIN INVEST, V78, P968, DOI 10.1172/JCI112687; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dabrosin C, 2002, AM J PATHOL, V161, P909, DOI 10.1016/S0002-9440(10)64251-4; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Ding ZM, 1999, J IMMUNOL, V163, P5029; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Drbal K, 2001, IMMUNOBIOLOGY, V203, P687, DOI 10.1016/S0171-2985(01)80017-6; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Forsyth CB, 2001, J EXP MED, V193, P1123, DOI 10.1084/jem.193.10.1123; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Leitinger B, 1999, BIOCHEM SOC T, V27, P826, DOI 10.1042/bst0270826; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liu SC, 2000, J CELL SCI, V113, P3563; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILLER LJ, 1987, J IMMUNOL, V138, P2381; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Pluskota E, 2001, BLOOD, V98, p700A; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; Seow KT, 2002, BIOCHEM PHARMACOL, V64, P805, DOI 10.1016/S0006-2952(02)01142-5; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Ustinov VA, 2002, J BIOL CHEM, V277, P18769, DOI 10.1074/jbc.M110242200; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yalamanchili P, 2000, J BIOL CHEM, V275, P21877, DOI 10.1074/jbc.M908868199; Yan SR, 1997, J IMMUNOL, V158, P1902; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	64	200	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1336	1345		10.1074/jbc.M406968200	http://dx.doi.org/10.1074/jbc.M406968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15485828	hybrid			2022-12-25	WOS:000226195200059
J	Kardos, J; Yamamoto, K; Hasegawa, K; Naiki, H; Goto, Y				Kardos, J; Yamamoto, K; Hasegawa, K; Naiki, H; Goto, Y			Direct measurement of the thermodynamic parameters of amyloid formation by isothermal titration calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; FIBRIL FORMATION; IN-VITRO; PROTEIN AGGREGATION; SELF-ASSOCIATION; HEAT-CAPACITY; BETA(2)-MICROGLOBULIN; BINDING; VARIANTS; STATE	Amyloid fibril deposition is associated with over 20 degenerative diseases, including Alzheimer's, Parkinson's, and prion diseases. Although research over the last few years has revealed the morphology and structural features of the amyloid form, knowledge about the thermodynamics of amyloid formation is limited. Here, we report for the first time a direct thermodynamic study of amyloid formation using isothermal titration calorimetry. beta(2)-Microglobulin, a protein responsible for dialysis-related amyloidosis, was used for extending amyloid fibrils in a seed-controlled reaction in the cell of the calorimeter. We investigated the enthalpy and heat capacity changes of the reaction, where the monomeric, acid-denatured molecules adopt an ordered, cross-beta-sheet structure in the rigid amyloid fibrils. Despite the dramatic difference in morphology, beta(2)-microglobulin exhibited a similar heat capacity change upon amyloid formation to that of the folding to the native globular state, whereas the enthalpy change of the reaction proved to be markedly lower. In comparison with the native state, the results outline the important structural features of the amyloid fibrils: a similar extent of surface burial even with the supramolecular architecture of amyloid fibrils, a lower level of internal packing, and the possible presence of unfavorable side chain contributions.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Eotvos Lorand Univ, Dept Biochem, H-1117 Budapest, Hungary; Univ Fukui, Fac Med Sci, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); Eotvos Lorand University; University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Kardos, József/J-1035-2017; Naiki, Hironobu/G-5599-2014	Kardos, József/0000-0002-2135-2932; 				Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P879, DOI 10.1110/ps.42401; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Ferrao-Gonzales AD, 2003, J MOL BIOL, V328, P963, DOI 10.1016/S0022-2836(03)00368-1; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Freire E, 1995, Methods Mol Biol, V40, P191; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kinoshita M, 2004, CHEM PHYS LETT, V387, P54, DOI 10.1016/j.cplett.2004.01.112; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Litvinovich SV, 1998, J MOL BIOL, V280, P245, DOI 10.1006/jmbi.1998.1863; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Martsev SP, 2002, BIOCHEMISTRY-US, V41, P3389, DOI 10.1021/bi015894u; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Schuler B, 1999, J BIOL CHEM, V274, P18589, DOI 10.1074/jbc.274.26.18589; Shnyrov VL, 2000, BIOPHYS CHEM, V88, P61, DOI 10.1016/S0301-4622(00)00199-X; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Souillac PO, 2002, J BIOL CHEM, V277, P12657, DOI 10.1074/jbc.M109230200; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v	45	104	105	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55308	55314		10.1074/jbc.M409677200	http://dx.doi.org/10.1074/jbc.M409677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494406	Green Published, hybrid			2022-12-25	WOS:000225960800042
J	Doucette, PA; Whitson, LJ; Cao, XH; Schirf, V; Demeler, B; Valentine, JS; Hansen, JC; Hart, PJ				Doucette, PA; Whitson, LJ; Cao, XH; Schirf, V; Demeler, B; Valentine, JS; Hansen, JC; Hart, PJ			Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant - Insights into the molecular basis for dimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN-SUPEROXIDE DISMUTASE; SUBUNIT STRUCTURE; ESCHERICHIA-COLI; WILD-TYPE; ANALYTICAL ULTRACENTRIFUGATION; ELECTROSTATIC RECOGNITION; QUATERNARY STRUCTURE; WHEAT-GERM; MUTANT	The dissociation of apo- and metal-bound human copper-zinc superoxide dismutase (SOD1) dimers induced by the chaotrope guanidine hydrochloride (GdnHCl) or the reductant Tris(2-carboxyethyl) phosphine ( TCEP) has been analyzed using analytical ultracentrifugation. Global fitting of sedimentation equilibrium data under native solution conditions ( without GdnHCl or TCEP) demonstrate that both the apo- and metal-bound forms of SOD1 are stable dimers. Sedimentation velocity experiments show that apo- SOD1 dimers dissociate cooperatively over the range 0.5-1.0 M GdnHCl. In contrast, metal-bound SOD1 dimers possess a more compact shape and dissociate at significantly higher GdnHCl concentrations (2.0-3.0 M). Reduction of the intrasubunit disulfide bond within each SOD1 subunit by 5-10 mM TCEP promotes dissociation of apo- SOD1 dimers, whereas the metal-bound enzyme remains a stable dimer under these conditions. The Cys-57 --> Ser mutant of SOD1, a protein incapable of forming the intrasubunit disulfide bond, sediments as a monomer in the absence of metal ions and as a dimer when metals are bound. Taken together, these data indicate that the stability imparted to the human SOD1 dimer by metal binding and the formation of the intrasubunit disulfide bond are mediated by independent molecular mechanisms. By combining the sedimentation data with previous crystallographic results, a molecular explanation is provided for the existence of different SOD1 macromolecular shapes and multiple SOD1 dimeric species with different stabilities.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; Colorado State University	Valentine, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jsv@chem.ucla.edu; pjhart@biochem.uthscsa.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Demeler, Borries/0000-0002-2414-9518	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [R01 NS039112, NS39112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERNETHY JL, 1974, J BIOL CHEM, V249, P7339; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1995, EUR J BIOCHEM, V234, P855, DOI 10.1111/j.1432-1033.1995.855_a.x; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; BANNISTER JV, 1978, BIOCHEM BIOPH RES CO, V81, P469, DOI 10.1016/0006-291X(78)91557-7; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; BEAUCHAMP CO, 1973, BIOCHIM BIOPHYS ACTA, V317, P50, DOI 10.1016/0005-2795(73)90198-0; BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CARRICO RJ, 1970, J BIOL CHEM, V245, P723; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Cole J L, 1999, J Biomol Tech, V10, P163; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; DEMELER B, 2004, ULTRASCAND SOFTWARE; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Djinovic Carugo K, 1996, Acta Crystallogr D Biol Crystallogr, V52, P176, DOI 10.1107/S0907444995007608; Doucette P, 2004, THESIS U CALIFORNIA; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FEE JA, 1973, J BIOL CHEM, V248, P4229; Ferraroni M, 1999, J MOL BIOL, V288, P413, DOI 10.1006/jmbi.1999.2681; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1972, J BIOL CHEM, V247, P6960; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GOSCIN SA, 1972, ARCH BIOCHEM BIOPHYS, V153, P778, DOI 10.1016/0003-9861(72)90398-0; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HART PJ, 2004, INPRESS MED INORGANI; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; INOUYE K, 1994, J BIOCHEM-TOKYO, V115, P507, DOI 10.1093/oxfordjournals.jbchem.a124367; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P5055, DOI 10.1021/bi00590a005; MARMOCCHI F, 1974, FEBS LETT, V44, P337, DOI 10.1016/0014-5793(74)81172-5; MARMOCCHI F, 1978, FEBS LETT, V94, P109, DOI 10.1016/0014-5793(78)80917-X; MARMOCCHI F, 1975, PHYSIOL CHEM PHYS M, V7, P465; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; Paciaroni A, 1999, EUR BIOPHYS J BIOPHY, V28, P447, DOI 10.1007/s002490050227; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; RIGO A, 1978, BIOCHEMISTRY-US, V17, P534, DOI 10.1021/bi00596a025; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Russell TR, 2004, BIOCHEMISTRY-US, V43, P1580, DOI 10.1021/bi035578a; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; SILVA N, 1993, BIOPHYS CHEM, V48, P171, DOI 10.1016/0301-4622(93)85008-6; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Valentine J. S., 1981, METAL IONS BIOL, P291; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515	76	136	139	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54558	54566		10.1074/jbc.M409744200	http://dx.doi.org/10.1074/jbc.M409744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485869	hybrid			2022-12-25	WOS:000225793600081
J	Grass, I; Thiel, S; Honing, S; Haucke, V				Grass, I; Thiel, S; Honing, S; Haucke, V			Recognition of a basic AP-2 binding motif within the C2B domain of synaptotagmin is dependent on multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; ENDOCYTOSIS; RECEPTOR; SITE; AP2; MECHANISM; INTERACTS; MUTANTS; PROTEIN; CLUSTER	Synaptotagmin is a multifunctional membrane protein that may regulate exo-endocytic cycling of synaptic vesicles at the presynaptic plasmalemma. Its C2B domain has been postulated to interact with a variety of effector molecules including acidic phospholipids, phosphoinositides, SNAREs ( soluble N-ethylmaleimide- sensitive factor attachment protein receptors), calcium channels, and the clathrin adaptor complex AP-2. Here we report that a basic motif within the C2B domain is required and sufficient for binding to AP-2 via its mu2 subunit and that this interaction is dependent on multimerization of the AP-2 binding site. Moreover, we show that upon fusion to a plasma membrane reporter protein this sequence is sufficient to target the chimeric molecule for internalization. We hypothesize that basic motifs within multimeric membrane proteins may represent a novel type of clathrin/AP-2-dependent endocytosis signal.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Univ Gottingen, Dept Biochem 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Free University of Berlin; University of Gottingen	Haucke, V (corresponding author), Free Univ Berlin, Inst Chem Biochem, Takustr 6, D-14195 Berlin, Germany.	vhaucke@chemie.fu-berlin.de		Haucke, Volker/0000-0003-3119-6993				Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Fache MP, 2004, J CELL BIOL, V166, P571, DOI 10.1083/jcb.200312155; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Jarousse N, 2003, TRAFFIC, V4, P468, DOI 10.1034/j.1600-0854.2003.00101.x; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Poskanzer KE, 2003, NATURE, V426, P559, DOI 10.1038/nature02184; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Walther K, 2004, P NATL ACAD SCI USA, V101, P964, DOI 10.1073/pnas.0307862100; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	37	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54872	54880		10.1074/jbc.M409995200	http://dx.doi.org/10.1074/jbc.M409995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491995	hybrid			2022-12-25	WOS:000225793600116
J	Meng, GY; Zhao, YT; Nag, A; Zeng, MS; Dimri, G; Gao, GS; Wazer, DE; Kumar, R; Band, H; Band, V				Meng, GY; Zhao, YT; Nag, A; Zeng, MS; Dimri, G; Gao, GS; Wazer, DE; Kumar, R; Band, H; Band, V			Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; NUCLEAR HORMONE-RECEPTORS; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; PROTEIN COACTIVATOR; E6 ONCOPROTEIN; COMPLEXES; ALPHA; DOMAIN	We have recently identified the hADA3 protein, the human homologue of yeast transcriptional coactivator yADA3, as a novel HPV16 E6 target. Using ectopic expression approaches, we further demonstrated that hADA3 directly binds to the 9-cis retinoic acid receptors alpha and beta, and functions as a coactivator for retinoid receptor-mediated transcriptional activation. Here, we examined the role of endogenous hADA3 as a coactivator for estrogen receptor ( ER), an important member of the nuclear hormone receptor superfamily. We show that ADA3 directly interacts with ERalpha and ERbeta. Using the chromatin immunoprecipitation assay, we also show that hADA3 is a component of the activator complexes bound to the native ER response element within the promoter of the estrogen-responsive gene pS2. Furthermore, using an ER response element-luciferase reporter, we show that overexpression of ADA3 enhances the ERalpha- and ERbeta-mediated sequence-specific transactivation. Reverse transcription-PCR analysis showed an ADA3-mediated increase in estrogen-induced expression of the endogenous pS2 gene. More importantly, using RNA interference against hADA3, we demonstrate that inhibition of endogenous hADA3 inhibited ER-mediated transactivation and the estrogen-induced increase in the expression of pS2, cathepsin D, and progesterone receptor, three widely known ER-responsive genes. The HPV E6 protein, by targeting hADA3 for degradation, inhibited the ERalpha-mediated transactivation and the protein expression of ER target genes. Thus, our results demonstrate that ADA3 directly binds to human estrogen receptor and enhances the transcription of ER-responsive genes, suggesting a broader role of mammalian hADA3 as a coactivator of nuclear hormone receptors and the potential role of these pathways in HPV oncogenesis.	Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Mol Oncol, Evanston, IL 60201 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Tufts Medical Center; Tufts University; University of Texas System; UTMD Anderson Cancer Center	Band, V (corresponding author), Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Dept Med,Div Canc Biol, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu		zeng, musheng/0000-0003-3509-5591	NATIONAL CANCER INSTITUTE [R01CA096986, R01CA096844, R01CA095221, R01CA099163, R01CA087986, R01CA081076, R01CA076118, R01CA094143, R01CA099900] Funding Source: NIH RePORTER; NCI NIH HHS [CA76118, CA99163, CA94143, R01 CA095221-01A1, R01 CA095221-03, R01 CA096986-01A1, R01 CA096986-02, R01 CA096986-05, R01 CA095221-05, CA81076, R01 CA096986-04, CA96844, R01 CA096986-03, CA99900, R01 CA095221-02, CA87986, R01 CA095221-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; An WJ, 2003, J BIOL CHEM, V278, P1504, DOI 10.1074/jbc.M209355200; AUBORN KJ, 1991, INT J CANCER, V49, P867, DOI 10.1002/ijc.2910490611; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Band Vimla, 2003, Methods Mol Biol, V223, P237; Barnes CJ, 2004, CELL MOL LIFE SCI, V61, P281, DOI 10.1007/s00018-003-3222-5; Benecke A, 2002, NUCLEIC ACIDS RES, V30, P2508, DOI 10.1093/nar/30.11.2508; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Campos SM, 2003, ONCOLOGY-BASEL, V64, P289, DOI 10.1159/000070284; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; de Villiers EM, 2003, INT J CANCER, V103, P705, DOI 10.1002/ijc.10868; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dimri GP, 2002, CANCER RES, V62, P4736; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Edwards DP, 2000, J MAMMARY GLAND BIOL, V5, P307, DOI 10.1023/A:1009503029176; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Jaber BM, 2004, J MOL ENDOCRINOL, V32, P307, DOI 10.1677/jme.0.0320307; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MITRANIROSENBAUM S, 1989, J GEN VIROL, V70, P2227, DOI 10.1099/0022-1317-70-8-2227; Moodley J, 2004, CURR OPIN OBSTET GYN, V16, P27, DOI 10.1097/00001703-200402000-00006; Newfield L, 1998, P SOC EXP BIOL MED, V217, P322; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; SPYRATOS F, 1994, BRIT J CANCER, V69, P394, DOI 10.1038/bjc.1994.73; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wang WM, 2003, BIOCHEM BIOPH RES CO, V303, P932, DOI 10.1016/S0006-291X(03)00444-3; Yuan LWC, 2002, ONCOGENE, V21, P2253, DOI 10.1038/sj.onc.1205283; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	46	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54230	54240		10.1074/jbc.M404482200	http://dx.doi.org/10.1074/jbc.M404482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496419	hybrid			2022-12-25	WOS:000225793600043
J	Ray, A; Kumar, D; Ray, P; Ray, BK				Ray, A; Kumar, D; Ray, P; Ray, BK			Transcriptional activity of serum amyloid A-activating factor-1 is regulated by distinct functional modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NUCLEAR-LOCALIZATION SIGNALS; ADENOVIRUS E1A PROTEIN; DNA-BINDING DOMAINS; ALZ-50 CLONE 1; GENE-EXPRESSION; CRYSTAL-STRUCTURE; KINASE-A; SP1; PROMOTER	Serum amyloid A-activating transcription factor-1 (SAF-1) plays a major role in regulating transcription of several inflammation-responsive genes, including SAA and matrix metalloproteinase-1, that are implicated in the pathogenesis of reactive secondary amyloidosis, atherosclerosis, and arthritis. SAF-1 is a 477-amino acid protein with six zinc fingers. Its activation during inflammatory condition by a phosphorylation event that leads to an altered structure suggested possible structural modification of this protein as a leading cause of higher activity. However, no information is available regarding structural features that might regulate its activity. Here, we have characterized its functional domains, delineating activation and repression modules, DNA binding, and nuclear localization activities. Using GAL4AD chimeras and a DNA-binding assay with proteins prepared from various deletion constructs, the core DNA-binding domain of SAF-1 is mapped between amino acids 282 and 361, which contain second, third, and fourth zinc fingers. Results from several deletion and point mutants using green fluorescent protein reporter show that SAF-1 contains two independent nuclear localization signals; one is composed of a stretch of basic amino acids, and the other is a bipartite signal located within the core DNA-binding domain. SAF-1 contains several negative and positively functioning transactivation modules clustered at the two ends of this protein. Removal of any one of the terminal negative modules renders the SAF-1 protein functionally very active. These findings suggest that the terminal repression modules act in conjunction to regulate the functional activity of this protein.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.	rayb@missouri.edu			NIDDK NIH HHS [DK49205] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EKKER SC, 1991, EMBO J, V10, P179; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Jordan-Sciutto KL, 1999, J BIOL CHEM, V274, P35262, DOI 10.1074/jbc.274.49.35262; Jordan-Sciutto KL, 2000, BIOCHEMISTRY-US, V39, P3206, DOI 10.1021/bi992211q; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2003, ARTHRITIS RHEUM, V48, P134, DOI 10.1002/art.10706; Ray A, 2003, J BIOL CHEM, V278, P22586, DOI 10.1074/jbc.M300705200; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; Ray BK, 2001, J IMMUNOL, V167, P2343, DOI 10.4049/jimmunol.167.4.2343; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Ugai H, 2001, BIOCHEM BIOPH RES CO, V286, P1087, DOI 10.1006/bbrc.2001.5469; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646	42	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54637	54646		10.1074/jbc.M411830200	http://dx.doi.org/10.1074/jbc.M411830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15498774	hybrid			2022-12-25	WOS:000225793600090
J	Han, GS; Gable, K; Yan, LY; Natarajan, M; Krishnamurthy, J; Gupta, SD; Borovitskaya, A; Harmon, JM; Dunn, TM				Han, GS; Gable, K; Yan, LY; Natarajan, M; Krishnamurthy, J; Gupta, SD; Borovitskaya, A; Harmon, JM; Dunn, TM			The topology of the Lcb1p subunit of yeast serine palmitoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY SENSORY NEUROPATHY; MEMBRANE-PROTEIN STRUCTURE; PREDICTION; MUTATIONS; ENZYME; LOCALIZATION; COMPONENT; MUTANTS; SPTLC1	The structural organization and topology of the Lcb1p subunit of yeast and mammalian serine palmitoyltransferases (SPT) were investigated. In the yeast protein, three membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions. The first domain of the yeast protein, located between residues 50 and 84, was not required for the stability, membrane association, interaction with Lcb2p, or enzymatic activity. Deletion of the comparable domain of the mammalian protein SPTLC1 also had little effect on its function, demonstrating that this region is not required for membrane localization or heterodimerization with SPTLC2. The second and third membrane-spanning domains of yeast Lcb1p, located between residues 342 and 371 and residues 425 and 457, respectively, create a luminal loop of similar to60 residues. In contrast to the first membrane-spanning domain, the second and third membrane-spanning domains were both required for Lcb1p stability. In addition, mutations in the luminal loop destabilized the SPT heterodimer indicating that this region of the protein is important for SPT structure and function. Mutations in the extreme carboxyl-terminal region of Lcb1p also disrupted heterodimer formation. Taken together, these data suggest that in contrast to other members of the alpha-oxoamine synthases that are soluble homodimers, the Lcb1p and Lcb2p subunits of the SPT heterodimer may interact in the cytosol, as well as within the membrane and/or the lumen of the endoplasmic reticulum.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	tdunn@usuhs.mil		Natarajan, Mukil/0000-0001-8908-7306; Harmon, Jeffrey/0000-0001-7833-931X	NINDS NIH HHS [NS47717] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047717] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Dunn TM, 2000, METHOD ENZYMOL, V312, P317; El Bawab S, 2002, J LIPID RES, V43, P141; Gable K, 2002, J BIOL CHEM, V277, P10194, DOI 10.1074/jbc.M107873200; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Sherman F., 1986, METHODS YEAST GENETI; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Uhlinger DJ, 2001, THROMB HAEMOSTASIS, V86, P1320; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200	30	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53707	53716		10.1074/jbc.M410014200	http://dx.doi.org/10.1074/jbc.M410014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485854	hybrid			2022-12-25	WOS:000225680600108
J	Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP				Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP			Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint	ONCOGENE			English	Article						asbestos; reactive oxygen species; mesothelial cells; p21(Cip1/Waf1); G1 checkpoint	PLEURAL MESOTHELIAL CELLS; INDUCED TRANSFORMATION; CROSS-LINKING; P53; EXPRESSION; MECHANISMS; DISEASE; ANTHRACYCLINES; ACTIVATION; APOPTOSIS	Exposure to asbestos fibers increases the risk of development of mesotheliomas and lung carcinomas, but not fibrosarcomas. We present data suggesting that resistance of fibroblasts to asbestos-induced carcinogenesis is likely to be connected with their lower ability to generate reactive oxygen species (ROS) in response to asbestos exposure and stricter control of proliferation of cells bearing asbestos/ROS-induced injuries. In fact, chrysotile (Mg6Si4O10(OH)(8)) asbestos exposure (5-10 mug/cm(2)) increased intracellular ROS and 8-oxo-guanine contents in rat pleural mesothelial cells, but not in lung fibroblasts. Simultaneously, moderate dosages of chrysotile and other agents increasing ROS levels ( hydrogen peroxide, H2O2 and ethyl-methanesulfonate, EMS) inhibited cell cycle progression, in particular G1-to-S transition, in fibroblasts, but not in mesothelial cells. The arrested fibroblasts underwent cell death, while the majority of chrysotile-treated mesothelial cells survived. The differences in cell cycle response to asbestos/ROS-induced injuries correlated with distinct activity of p53-p21(Cip1/Waf1) pathway in the two cell types. Chrysotile, H2O2 and EMS caused p53 upregulation in both cell types, but mesothelial cells, unlike fibroblasts, showed no accumulation of p21(Cip1/Waf1). Of note, treatment with doxorubicin caused similar p53-dependent p21(Cip1/Waf1) upregulation and cell cycle arrest in both cell types. This suggests differential response of fibroblasts and mesothelial cells specifically to asbestos/ROS exposure rather than to all DNA-damaging insults.	Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Univ Oslo, Moscow Ctr Med Studies, Moscow, Russia	N.N. Blokhin Russian Cancer Research Center; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kopnin, BP (corresponding author), Blokhin Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 115478, Russia.	bkopnin@yahoo.com	Kopnin, Pavel/R-8213-2019; Kravchenko, Irina V/K-5414-2015; Kopnin, Boris/R-8240-2019	Kopnin, Pavel/0000-0002-2078-4274; Kravchenko, Irina V/0000-0002-1715-1281; Kopnin, Boris/0000-0003-3100-2212				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BARRETT JC, 1994, ENVIRON HEALTH PERSP, V102, P19, DOI 10.2307/3432053; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; BRODY AR, 1993, ENVIRON HEALTH PERSP, V100, P21, DOI 10.2307/3431517; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fei PW, 2002, CANCER RES, V62, P7316; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; JAURAND MC, 1981, IN VITRO CELL DEV B, V17, P98; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kravchenko IV, 1998, TERATOGEN CARCIN MUT, V18, P141, DOI 10.1002/(SICI)1520-6866(1998)18:3<141::AID-TCM5>3.3.CO;2-E; Kravchenko IV, 2001, TERATOGEN CARCIN MUT, V21, P315, DOI 10.1002/tcm.1019; Levresse V, 1997, AM J RESP CELL MOL, V17, P660, DOI 10.1165/ajrcmb.17.6.2854; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Luce RA, 2001, METHOD ENZYMOL, V340, P396; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Muhle H, 2000, INT ARCH OCC ENV HEA, V73, pS53, DOI 10.1007/PL00014627; Neuberger M, 2003, INT ARCH OCC ENV HEA, V76, P161, DOI 10.1007/s00420-002-0397-2; Pass HI, 1996, J CELL BIOCHEM, P142; Prives C, 1999, J PATHOL, V187, P112; PYLEV L, 2002, GIG SANIT, V3, P61; Richardson DS, 1997, BLOOD REV, V11, P201, DOI 10.1016/S0268-960X(97)90020-5; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Torday JS, 2001, PEDIATR RES, V49, P843, DOI 10.1203/00006450-200106000-00021; Vasilieva LA, 1998, CANCER LETT, V134, P209, DOI 10.1016/S0304-3835(98)00255-9	34	26	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8834	8840		10.1038/sj.onc.1208108	http://dx.doi.org/10.1038/sj.onc.1208108			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480427				2022-12-25	WOS:000225165100013
J	Bernatchez, S; Szymanski, CM; Ishiyama, N; Li, JJ; Jarrell, HC; Lau, PC; Berghuis, AM; Young, NM; Wakarchuk, WW				Bernatchez, S; Szymanski, CM; Ishiyama, N; Li, JJ; Jarrell, HC; Lau, PC; Berghuis, AM; Young, NM; Wakarchuk, WW			Single bifunctional UDP-GlcNAc/Glc 4-epimerase supports the synthesis of three cell surface glycoconjugates in Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; N-ACETYLGLUCOSAMINE 4-EPIMERASE; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; GALACTOSE 4-EPIMERASE; GALE GENE; HAEMOPHILUS-INFLUENZAE; NEISSERIA-MENINGITIDIS; STRUCTURAL-ANALYSIS; C4 EPIMERASE	The major cell-surface carbohydrates (lipooligosaccharide, capsule, and glycoprotein N-linked heptasaccharide) of Campylobacter jejuni NCTC 11168 contain Gal and/or GalNAc residues. GalE is the sole annotated UDP-glucose 4-epimerase in this bacterium. The presence of GalNAc residues in these carbohydrates suggested that GalE might be a UDP-GlcNAc 4-epimerase. GalE was shown to epimerize UDP-Glc and UDP-GlcNAc in coupled assays with C. jejuni glycosyltransferases and in sugar nucleotide epimerization equilibria studies. Thus, GalE possesses UDP-GlcNAc 4-epimerase activity and was renamed Gne. The K-m(app) values of a purified MalE-Gne fusion protein for UDP-GlcNAc and UDP-GalNAc are 1087 and 1070 gm, whereas those for UDP-Glc and UDP-Gal are 780 and 784 mum. The k(cat) and k(cat)/K-m(app) values were three to four times higher for UDP-GalNAc and UDP-Gal than for UDP-GlcNAc and UDP-Glc. The comparison of the kinetic parameters of MalE-Gne to those of other characterized bacterial UDP-GlcNAc 4-epimerases indicated that Gne is a bifunctional UDP-GlcNAc/Glc 4-epimerase. The UDP sugar-binding site of Gne was modeled by using the structure of the UDP-GlcNAc 4-epimerase WbpP from Pseudomonas aeruginosa. Small differences were noted, and these may explain the bifunctional character of the C. jejuni Gne. In a gne mutant of C jejuni, the lipooligosaccharide was shown by capillary electrophoresis-mass spectrometry to be truncated by at least five sugars. Furthermore, both the glycoprotein N-linked heptasaccharide and capsule were no longer detectable by high resolution magic angle spinning NMR. These data indicate that Gne is the enzyme providing Gal and GalNAc residues with the synthesis of all three cell-surface carbohydrates in C. jejuni NCTC 11168.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 1A4, Canada	National Research Council Canada; McGill University; McGill University	Wakarchuk, WW (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	warren.wakarchuk@nrc-enrc.gc.ca	Wakarchuk, Warren/Q-9514-2017; Berghuis, Albert M/A-6495-2008; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Berghuis, Albert/0000-0002-2663-025X				AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Antoine T, 2003, CHEMBIOCHEM, V4, P406, DOI 10.1002/cbic.200200540; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; Bengoechea JA, 2002, J BACTERIOL, V184, P4277, DOI 10.1128/JB.184.15.4277-4287.2002; Berger E, 2001, BIOCHEMISTRY-US, V40, P6699, DOI 10.1021/bi0104571; Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809; BUTTIN G, 1963, J MOL BIOL, V7, P164, DOI 10.1016/S0022-2836(63)80044-3; Carrillo CD, 2004, J BIOL CHEM, V279, P20327, DOI 10.1074/jbc.M401134200; Chen X, 2000, Curr Opin Drug Discov Devel, V3, P756; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; ESTRELA AI, 1991, J GEN MICROBIOL, V137, P943, DOI 10.1099/00221287-137-4-943; Fang JW, 1999, J ORG CHEM, V64, P4089, DOI 10.1021/jo990159y; Fang JW, 2000, CARBOHYD RES, V329, P873, DOI 10.1016/S0008-6215(00)00245-7; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fry BN, 2000, INFECT IMMUN, V68, P2594, DOI 10.1128/IAI.68.5.2594-2601.2000; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 2002, J BIOL CHEM, V277, P327, DOI 10.1074/jbc.M108452200; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2002, INFECT IMMUN, V70, P787, DOI 10.1128/IAI.70.2.787-793.2002; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hokke CH, 1996, GLYCOCONJUGATE J, V13, P687, DOI 10.1007/BF00731458; Ishiyama N, 2004, J BIOL CHEM, V279, P22635, DOI 10.1074/jbc.M401642200; Jennings MP, 1998, MOL MICROBIOL, V29, P975, DOI 10.1046/j.1365-2958.1998.00962.x; JENNINGS MP, 1993, MOL MICROBIOL, V10, P361, DOI 10.1111/j.1365-2958.1993.tb01962.x; Kanipes MI, 2004, INFECT IMMUN, V72, P2452, DOI 10.1128/IAI.72.4.2452-2455.2004; Kleiger G, 2002, J MOL BIOL, V323, P69, DOI 10.1016/S0022-2836(02)00885-9; Kowal P, 2002, BIOCHEMISTRY-US, V41, P15410, DOI 10.1021/bi026384i; Kwon DH, 1998, CURR MICROBIOL, V37, P144, DOI 10.1007/s002849900354; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LEMAIRE HG, 1986, NUCLEIC ACIDS RES, V14, P7705, DOI 10.1093/nar/14.19.7705; Linton D, 2000, MOL MICROBIOL, V37, P501, DOI 10.1046/j.1365-2958.2000.02020.x; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Liu ZY, 2003, APPL ENVIRON MICROB, V69, P2110, DOI 10.1128/AEM.69.4.2110-2115.2003; MASKELL DJ, 1992, J INFECT DIS, V165, pS90, DOI 10.1093/infdis/165-Supplement_1-S90; MASKELL DJ, 1992, MOL MICROBIOL, V6, P3051, DOI 10.1111/j.1365-2958.1992.tb01763.x; MASOUD H, 1995, J BACTERIOL, V177, P6718, DOI 10.1128/jb.177.23.6718-6726.1995; MASOUD H, 1994, BIOCHEMISTRY-US, V33, P10568, DOI 10.1021/bi00201a002; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; PERRY MB, 1986, BIOCHEM CELL BIOL, V64, P21, DOI 10.1139/o86-004; Pierson DE, 1996, J BACTERIOL, V178, P5916, DOI 10.1128/jb.178.20.5916-5924.1996; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; ROBERTSON BD, 1993, MOL MICROBIOL, V8, P891, DOI 10.1111/j.1365-2958.1993.tb01635.x; Sadovskaya I, 1998, EUR J BIOCHEM, V255, P673, DOI 10.1046/j.1432-1327.1998.2550673.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schulz JM, 2004, J BIOL CHEM, V279, P32796, DOI 10.1074/jbc.M405005200; Shao J, 2003, CHEM COMMUN, P1422, DOI 10.1039/b300831b; Shao J, 2002, APPL ENVIRON MICROB, V68, P5634, DOI 10.1128/AEM.68.11.5634-5640.2002; Shepherd JG, 2000, INFECT IMMUN, V68, P6056, DOI 10.1128/IAI.68.10.6056-6061.2000; Soldo B, 2003, GENE, V319, P65, DOI 10.1016/S0378-1119(03)00793-5; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Virji M, 1997, GENE, V192, P141, DOI 10.1016/S0378-1119(97)00082-6; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x; Vorgias C E, 1991, Protein Expr Purif, V2, P330, DOI 10.1016/1046-5928(91)90091-V; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wang L, 2002, J BACTERIOL, V184, P2620, DOI 10.1128/JB.184.10.2620-2625.2002; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200; Zhang JB, 2001, CURR ORG CHEM, V5, P1169, DOI 10.2174/1385272013374671; Zhang LJ, 1996, MICROBIOL-UK, V142, P277, DOI 10.1099/13500872-142-2-277	77	95	106	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4792	4802		10.1074/jbc.M407767200	http://dx.doi.org/10.1074/jbc.M407767200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15509570	hybrid			2022-12-25	WOS:000227096600097
J	Hosfield, DJ; Wu, YQ; Skene, RJ; Hilgers, M; Jennings, A; Snell, GP; Aertgeerts, K				Hosfield, DJ; Wu, YQ; Skene, RJ; Hilgers, M; Jennings, A; Snell, GP; Aertgeerts, K			Conformational flexibility in crystal structures of human 11 beta-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASES/REDUCTASES; HEPATIC INSULIN SENSITIVITY; ENDOPLASMIC-RETICULUM; ADIPOSE-TISSUE; FUNCTIONAL ASSIGNMENTS; ESCHERICHIA-COLI; ELECTRON-DENSITY; VISCERAL OBESITY; MICE; REDUCTASE	Human 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1) is an ER-localized membrane protein that catalyzes the interconversion of cortisone and cortisol. In adipose tissue, excessive cortisol production through 11beta-HSD1 activity has been implicated in the pathogenesis of type II diabetes and obesity. We report here biophysical, kinetic, mutagenesis, and structural data on two ternary complexes of 11beta-HSD1. The combined results reveal flexible active site interactions relevant to glucocorticoid recognition and demonstrate how four 11beta-HSD1 C termini converge to form an as yet uncharacterized tetramerization motif. A C-terminal Pro-Cys motif is localized at the center of the tetramer and forms reversible enzyme disulfides that alter enzyme activity. Conformational flexibility at the tetramerization interface is coupled to structural changes at the enzyme active site suggesting how the central Pro-Cys motif may regulate enzyme activity. Together, the crystallographic and biophysical data provide a structural framework for understanding 11beta-HSD1 activities and will ultimately facilitate the development of specific inhibitors.	Syrrx Inc, Dept Struct Chem, San Diego, CA 92121 USA		Hosfield, DJ (corresponding author), Syrrx Inc, Dept Struct Chem, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.	david.hosfield@syrrx.com		Skene, Robert/0000-0002-1482-6546				AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alfaidy N, 2001, J CLIN ENDOCR METAB, V86, P5585, DOI 10.1210/jc.86.11.5585; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BUSH KT, 1994, BIOCHEM J, V303, P705, DOI 10.1042/bj3030705; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Engeli S, 2004, OBES RES, V12, P9, DOI 10.1038/oby.2004.3; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; HALGREN TA, 1992, J AM CHEM SOC, V114, P7827, DOI 10.1021/ja00046a032; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Jamieson PM, 2000, J ENDOCRINOL, V165, P685, DOI 10.1677/joe.0.1650685; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; LEMONICK MD, 2004, TIME, V163, P57; Maser E, 2002, BIOCHEMISTRY-US, V41, P2459, DOI 10.1021/bi015803t; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Morton NM, 2004, DIABETES, V53, P931, DOI 10.2337/diabetes.53.4.931; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Nardai G, 2003, BIOFACTORS, V17, P259, DOI 10.1002/biof.5520170125; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Persson B, 2003, CHEM-BIOL INTERACT, V143, P271, DOI 10.1016/S0009-2797(02)00223-5; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SANDEEP TC, 2004, P NATL ACAD SCI US; Sawicki MW, 1999, P NATL ACAD SCI USA, V96, P840, DOI 10.1073/pnas.96.3.840; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Seckl JR, 2004, RECENT PROG HORM RES, V59, P359, DOI 10.1210/rp.59.1.359; Shi TS, 2004, J AM CHEM SOC, V126, P790, DOI 10.1021/ja030311k; Stewart PM, 1999, VITAM HORM, V57, P249; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Wake DJ, 2004, MOL CELL ENDOCRINOL, V215, P45, DOI 10.1016/j.mce.2003.11.015; Walker BR, 2004, OBES RES, V12, P1, DOI 10.1038/oby.2004.1; Walker EA, 2003, TRENDS ENDOCRIN MET, V14, P334, DOI 10.1016/S1043-2760(03)00134-6; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; YANG K, 1992, ENDOCRINOLOGY, V131, P2120, DOI 10.1210/en.131.5.2120; Yau JLW, 2001, P NATL ACAD SCI USA, V98, P4716, DOI 10.1073/pnas.071562698; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	51	96	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2005	280	6					4639	4648		10.1074/jbc.M411104200	http://dx.doi.org/10.1074/jbc.M411104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	898SN	15513927	hybrid			2022-12-25	WOS:000227096600079
J	Qin, L; Tamasi, J; Raggatt, L; Lit, X; Feyen, JHM; Lee, DC; DiCicco-Bloom, E; Partridge, NC				Qin, L; Tamasi, J; Raggatt, L; Lit, X; Feyen, JHM; Lee, DC; DiCicco-Bloom, E; Partridge, NC			Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELLS; EGF RECEPTOR; MICE LACKING; GENE-EXPRESSION; PROTEIN; DIFFERENTIATION; INTERMITTENT; INCREASES; FAMILY; RATS	Parathyroid hormone (PTH) is the Major mediator of calcium homeostasis and bone remodeling and is now known to be an effective drug for osteoporosis treatment. Yet the mechanisms responsible for its functions in bone are largely unknown. Here we report that the expression of amphiregulin (AR), a member of the epidermal growth factor (EGF) family, is rapidly and highly up-regulated by PTH in several osteohlastic cell lines and bone tissues. Other osteotropic hormones (1alpha,25dihydroxyvitamin D-3 and prostaglandin E-2) also strongly stimulate AR expression. We found all EGF-like ligands and their receptors are expressed in osteoblasts, but AR is the only member that is highly regulated by PTH. Functional studies demonstrated that although AR is a potent growth factor for preosteoblasts, it completely inhibits further differentiation. AR also strongly and quickly stimulated Akt and ERK phosphorylation and c-fos and c-jun expression in an EGF receptor-dependent manner. Moreover, AR null mice displayed significantly less tibial trabecular bone than wild-type mice. Taken together, we have identified a novel growth factor that is PTH-regulated and appears to have an important role in bone metabolism.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Pennington, NJ 08534 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Ctr Comprehens Canc, Chapel Hill, NC 27599 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Raggatt, Liza-Jane/S-4530-2016; Raggatt, Liza-Jane/A-5297-2011; Qin, Ling/B-3147-2012	Raggatt, Liza-Jane/0000-0002-7920-6225; Partridge, Nicola/0000-0002-5406-4814	NCI NIH HHS [CA43793] Funding Source: Medline; NIDDK NIH HHS [DK48109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akutsu N, 2001, BIOCHEM BIOPH RES CO, V281, P1051, DOI 10.1006/bbrc.2001.4466; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANTOSZ ME, 1987, J BONE MINER RES, V2, P385; BERNIER SM, 1992, J CELL PHYSIOL, V152, P317, DOI 10.1002/jcp.1041520213; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; DRAKE MT, 1994, ENDOCRINOLOGY, V134, P1733, DOI 10.1210/en.134.4.1733; GRONTHOS S, 1995, BLOOD, V85, P929, DOI 10.1182/blood.V85.4.929.bloodjournal854929; GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221-8747(84)90026-2; HATA RI, 1984, ENDOCRINOLOGY, V115, P867, DOI 10.1210/endo-115-3-867; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KUMEGAWA M, 1983, CALCIFIED TISSUE INT, V35, P542, DOI 10.1007/BF02405091; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1985, CALCIFIED TISSUE INT, V37, P519, DOI 10.1007/BF02557835; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; Satomura K, 1998, J CELL PHYSIOL, V177, P426, DOI 10.1002/(SICI)1097-4652(199812)177:3<426::AID-JCP6>3.0.CO;2-F; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Troyer KL, 2001, GASTROENTEROLOGY, V121, P68, DOI 10.1053/gast.2001.25478; Yarden Y, 2001, EUR J CANCER, V37, pS3	40	67	73	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3974	3981		10.1074/jbc.M409807200	http://dx.doi.org/10.1074/jbc.M409807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15509566	hybrid, Green Published			2022-12-25	WOS:000226983900100
J	Gregory, CA; Perry, AS; Reyes, E; Conley, A; Gunn, WG; Prockop, DJ				Gregory, CA; Perry, AS; Reyes, E; Conley, A; Gunn, WG; Prockop, DJ			Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELLS; HEMATOPOIETIC STEM; WNT; OSTEOBLAST; EXPRESSION; DIFFERENTIATION; MINERALIZATION; COMMUNICATION; CULTURE; ASSAY	It is established that human mesenchymal stem cells (hMSCs) from bone marrow are a source of osteoblast progenitors in vivo and under appropriate conditions, differentiate into osteoblasts ex vivo. Because hMSCs are recovered by iliac crest aspirate and enriched by virtue of their adherence to tissue culture plastic, the cells provide a convenient ex vivo model for the study of osteogenic tissue repair in an experimentally accessible system. Recent advances in the field of skeletal development and osteogenesis have demonstrated that signaling through the canonical wingless (Wnt) pathway is critical for the differentiation of progenitor cell lines into osteoblasts. Inhibition of such signals can predispose MSCs to cell cycle entry and inhibit osteogenesis. Here, we report that synthetic peptides derived from the second cysteine-rich domain of the canonical Wnt inhibitor Dickkopf-1 (Dkk-1) have utility in controlling the growth and recovery of hMSCs from bone marrow stroma. Three peptides corresponding to residues 217 269 in Dkk-1 were each found to enhance the proliferation of hMSCs in culture over 2 days. The most active peptide exhibited agonistic characteristics in that it ablated the proliferation lag observed when cultures of hMSCs receive fresh medium. It also reduced the expression of endogenous Dkk-1 ( Gregory, C. A., Singh, H., and Prockop, D. J. ( 2003) J. Biol. Chem. 278, 28067 28078). When the cytosolic level of beta-catenin was elevated by addition of LiCl to cultures of hMSCs, the peptide also accelerated degradation of beta-catenin on withdrawal of lithium. A second peptide, corresponding to residues 184 - 204 had preferential and high affinity for hMSCs in the log phase of proliferation. Peptide overlay assays on hMSC lysates confirmed that the peptide bound to a 184-kDa protein corresponding to the molecular mass of LRP6. Cells recovered by this peptide had enhanced osteogenic potential but less chondrogenic potential compared with controls. Because Wnt antagonists increase the number of non-committed hMSCs in culture, they may be of use in increasing the rate of osseous wound healing in vivo by increasing the level of systemically migrating hMSCs. Therefore, such molecules could contribute to the development of a novel family of pharmaceutical agents for the improvement of the healing process in humans.	Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70130 USA	Tulane University	Prockop, DJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70130 USA.	dprocko@tulane.edu	Gunn, William/B-6134-2008	Gregory, Carl/0000-0001-6444-5541; Gunn, William/0000-0002-3555-2054	NIAMS NIH HHS [AR47796, AR48323] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048323, R21AR047796] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; BENNETT JH, 1991, J CELL SCI, V99, P131; Bilbe G, 1996, BONE, V19, P437, DOI 10.1016/S8756-3282(96)00254-2; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Houghton A, 1998, BONE, V22, P7, DOI 10.1016/S8756-3282(97)00229-9; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huynh MH, 1999, DEV GROWTH DIFFER, V41, P407; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Oviedo-Orta E, 2000, IMMUNOLOGY, V99, P578, DOI 10.1046/j.1365-2567.2000.00991.x; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; PIERSMA AH, 1985, EXP HEMATOL, V13, P237; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566	35	78	91	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2309	2323		10.1074/jbc.M406275200	http://dx.doi.org/10.1074/jbc.M406275200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15504735	hybrid			2022-12-25	WOS:000226341700068
J	Jessop, CE; Bulleid, NJ				Jessop, CE; Bulleid, NJ			Glutathione directly reduces an oxidoreductase in the endoplasmic reticulum of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BOND FORMATION; ESCHERICHIA-COLI; REDOX STATE; RAT-LIVER; PATHWAY; TISSUES; PDI; THIOREDOXIN; METABOLISM	The formation of disulfide bonds is an essential step in the folding of many glycoproteins and secretory proteins. Non-native disulfide bonds are often formed between incorrect cysteine residues, and thus the cell has dedicated a family of oxidoreductases that are thought to isomerize non-native bonds. For an oxidoreductase to be capable of performing isomerization or reduction reactions, it must be maintained in a reduced state. Here we show that most of the oxidoreductases are predominantly reduced in vivo. Following oxidative stress the oxidoreductases are quickly reduced, demonstrating that a robust reductive pathway is in place in mammalian cells. Using ERp57 as a model we show that the reductive pathway is cytosol-dependent and that the component responsible for the reduction of the oxidoreductases is the low molecular mass thiol glutathione. In addition, ERp57 is not reduced following oxidative stress when inhibitors of glutathione synthesis or glutathione reduction are added to cells. Glutathione directly reduces ERp57 at physiological concentrations in vitro, and biotinylated glutathione forms a mixed disulfide with ERp57 in microsomes. Our results demonstrate that glutathione plays a direct role in the isomerization of disulfide bonds by maintaining the mammalian oxidoreductases in a reduced state.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	neil.bulleid@man.ac.uk		Bulleid, Neil/0000-0002-9839-5279				Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakravarthi S, 2004, J BIOL CHEM, V279, P39872, DOI 10.1074/jbc.M406912200; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KELLEY JJ, 1967, CANCER RES, V27, P137; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; Stipanuk MH, 2004, ANNU REV NUTR, V24, P539, DOI 10.1146/annurev.nutr.24.012003.132418; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Uppal A, 2003, BIOTECHNOL APPL BIOC, V37, P45, DOI 10.1042/BA20020052; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng J, 2001, J BIOL CHEM, V276, P15747, DOI 10.1074/jbc.M011444200	42	130	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55341	55347		10.1074/jbc.M411409200	http://dx.doi.org/10.1074/jbc.M411409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507438	hybrid			2022-12-25	WOS:000225960800046
J	Li, DX; Hirsila, M; Koivunen, P; Brenner, MC; Xu, L; Yang, C; Kivirikko, KI; Myllyharju, J				Li, DX; Hirsila, M; Koivunen, P; Brenner, MC; Xu, L; Yang, C; Kivirikko, KI; Myllyharju, J			Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1 alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases - Substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN; PROTEIN; ALPHA; HYDROXYPROLINE; RECOGNITION; DESTRUCTION; SUBUNIT; REVEALS; COMPLEX; ENZYMES	Three human prolyl 4-hydroxylases (P4Hs) regulate the hypoxia-inducible transcription factors (HIFs) by hydroxylating a Leu-Xaa-Xaa-Leu-Ala-Pro motif. We report here that the two leucines in the Leu-Glu-Met-Leu-Ala-Pro core motif of a 20-residue peptide corresponding to the sequence around Pro(564) in HIF-1alpha can be replaced by many residues with no or only a modest decrease in its substrate properties or in some cases even a slight increase. The glutamate and methionine could be substituted by almost any residue, eight amino acids in the former position and four in the latter being even better for HIF-P4H-3 than the wild-type residues. Alanine was by far the strictest requirement, because no residue could fully substitute for it in the case of HIF-P4H-1, and only serine or isoleucine, valine, and serine did this in the cases of HIF-P4Hs 2 and 3. Peptides with more than one substitution, having the core sequences Trp-Glu-Met-Val-Ala-Pro, Tyr-Glu-Met-Ile-Ala-Pro, Ile-Glu-Met-Ile-Ala-Pro, Trp-Glu-Met-Val-Ser-Pro, and Trp-Glu-Ala-Val-Ser-Pro were in most cases equally as good or almost as good substrates as the wild-type peptide. The acidic residues present in the 20-residue peptide also played a distinct role, but alanine substitution for any six of them, and in some combinations even three of them, had no negative effects. Substitution of the proline by 3,4-dehydroproline or L-azetidine-2-carboxylic acid, but not any other residue, led to a high rate of uncoupled 2-oxoglutarate decarboxylation with no hydroxylation. The data obtained for the three HIF-P4Hs in various experiments were in most cases similar, but in some cases HIF-P4H-3 showed distinctly different properties.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; DEJONG L, 1984, BIOCHIM BIOPHYS ACTA, V787, P105; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Wu M, 2000, BIOORG MED CHEM LETT, V10, P1511, DOI 10.1016/S0960-894X(00)00224-9; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	32	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55051	55059		10.1074/jbc.M410287200	http://dx.doi.org/10.1074/jbc.M410287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485863	hybrid			2022-12-25	WOS:000225960800010
J	Liu, J; Ernst, SA; Gladycheva, SE; Lee, YYF; Lentz, SI; Ho, CS; Li, QW; Stuenkel, EL				Liu, J; Ernst, SA; Gladycheva, SE; Lee, YYF; Lentz, SI; Ho, CS; Li, QW; Stuenkel, EL			Fluorescence resonance energy transfer reports properties of syntaxin1A interaction with Munc18-1 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; SYNAPTIC VESICLE DOCKING; PROTEIN-PROTEIN INTERACTIONS; N-TERMINAL DOMAIN; NEUROTRANSMITTER RELEASE; CALCIUM-CHANNELS; 3-DIMENSIONAL STRUCTURE; TRANSMITTER RELEASE; MEMBRANE-FUSION; RAT-BRAIN	Syntaxin1A, a neural-specific N-ethylmaleimide-sensitive factor attachment protein receptor protein essential to neurotransmitter release, in isolation forms a closed conformation with an N-terminal alpha-helix bundle folded upon the SNARE motif (H3 domain), thereby limiting interaction of the H3 domain with cognate SNAREs. Munc18-1, a neural-specific member of the Sec1/Munc18 protein family, binds to syntaxin1A, stabilizing this closed conformation. We used fluorescence resonance energy transfer (FRET) to characterize the Munc18-1/syntaxin1A interaction in intact cells. Enhanced cyan fluorescent protein-Munc18-1 and a citrine variant of enhanced yellow fluorescent protein-syntaxin1A, or mutants of these proteins, were expressed as donor and acceptor pairs in human embryonic kidney HEK293-S3 and adrenal chromaffin cells. Apparent FRET efficiency was measured using two independent approaches with complementary results that unambiguously verified FRET and provided a spatial map of FRET efficiency. In addition, enhanced cyan fluorescent protein-Munc18-1 and a citrine variant of enhanced yellow fluorescent protein-syntaxin1A colocalized with a Golgi marker and exhibited FRET at early expression times, whereas a strong plasma membrane colocalization, with similar FRET values, was apparent at later times. Trafficking of syntaxin1A to the plasma membrane was dependent on the presence of Munc18-1. Both syntaxin1A(L165A/E166A), a constitutively open conformation mutant, and syntaxin1A(I233A), an H3 domain point mutant, demonstrated apparent FRET efficiency that was reduced similar to70% from control. In contrast, the H3 domain mutant syntaxin1A(I209A) had no effect. By using phosphomimetic mutants of Munc18-1, we also established that Ser-313, a Munc18-1 protein kinase C phosphorylation site, and Thr-574, a cyclin-dependent kinase 5 phosphorylation site, regulate Munc18-1/syntaxin1A interaction in HEK293-S3 and chromaffin cells. We conclude that FRET imaging in living cells may allow correlated regulation of Munc18-1/syntaxin1A interactions to Ca2+-regulated secretory events.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Michigan Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Stuenkel, EL (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 7807 Med Sci II Bldg, Ann Arbor, MI 48109 USA.	esterm@umich.edu		Stuenkel, Edward/0000-0001-8225-5725; Lentz, Stephen/0000-0003-1686-7998	NINDS NIH HHS [NS 39914] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039914] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Betz A, 1997, J BIOL CHEM, V272, P2520; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Degtiar VE, 2000, J NEUROSCI, V20, P4355, DOI 10.1523/JNEUROSCI.20-12-04355.2000; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fisher RJ, 1999, PFLUG ARCH EUR J PHY, V437, P754, DOI 10.1007/s004240050842; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Gladycheva SE, 2004, J PHYSIOL-LONDON, V558, P857, DOI 10.1113/jphysiol.2004.067249; Graham ME, 2004, J BIOL CHEM, V279, P32751, DOI 10.1074/jbc.M400827200; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Marsal J, 1997, P NATL ACAD SCI USA, V94, P14871, DOI 10.1073/pnas.94.26.14871; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Phillips GN, 1997, CURR OPIN STRUC BIOL, V7, P821, DOI 10.1016/S0959-440X(97)80153-4; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Rowe J, 2001, J CELL SCI, V114, P3323; Rowe J, 1999, J CELL SCI, V112, P1865; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SNYDER B, 1982, BIOPHYS J, V40, P137, DOI 10.1016/S0006-3495(82)84468-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Stanley EF, 2003, EUR J NEUROSCI, V18, P2403, DOI 10.1046/j.1460-9568.2003.02948.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200; Toonen RFG, 2003, BIOCHEM SOC T, V31, P848, DOI 10.1042/BST0310848; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Wu MN, 2001, EUR J CELL BIOL, V80, P196, DOI 10.1078/0171-9335-00143; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	71	41	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55924	55936		10.1074/jbc.M410024200	http://dx.doi.org/10.1074/jbc.M410024200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489225	hybrid			2022-12-25	WOS:000225960800116
J	Madsen, EM; Lindegaard, MLS; Andersen, CB; Damm, P; Nielsen, LB				Madsen, EM; Lindegaard, MLS; Andersen, CB; Damm, P; Nielsen, LB			Human placenta secretes apolipoprotein B-100-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; TOCOPHEROL TRANSFER PROTEIN; GENE-EXPRESSION; VITAMIN-E; YOLK-SAC; DENSITY LIPOPROTEINS; EMBRYONIC LETHALITY; VERY-LOW; RAT; ACCUMULATION	Supply of lipids from the mother is essential for fetal growth and development. In mice, disruption of yolk sac cell secretion of apolipoprotein (apo) B-containing lipoproteins results in embryonic lethality. In humans, the yolk sac is vestigial. Nutritional functions are instead established very early during pregnancy in the placenta. To examine whether the human placenta produces lipoproteins, we examined apoB and microsomal triglyceride transfer protein (MTP) mRNA expression in placental biopsies. ApoB and MTP are mandatory for assembly and secretion of apoB-containing lipoproteins. Both genes were expressed in placenta and microsomal extracts from human placenta contained triglyceride transfer activity, indicating expression of bioactive MTP. To detect lipoprotein secretion, biopsies from term placentas were placed in medium with [S-35] methionine and [S-35] cysteine for 3 - 24 h. Upon sucrose gradient ultracentrifugation of the labeled medium, fractions were analyzed by apoB-immunoprecipitation. S-35-labeled apoB-100 was recovered in d similar to 1.02-1.04 g/ml particles (i.e. similar to the density of plasma low density lipoproteins). Electron microscopy of negatively stained lipoproteins secreted from placental tissue showed spherical particles with a diameter of 47 +/- 10 nm. These results demonstrate that human placenta expresses both apoB and MTP and consequently synthesize and secrete apoB-100-containing lipoproteins. Placental lipoprotein formation constitutes a novel pathway of lipid transfer from the mother to the developing fetus.	Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Clin Obstet, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem KB3011, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk		Damm, Peter/0000-0002-2067-5246				Acuff RV, 1998, AM J CLIN NUTR, V67, P459, DOI 10.1093/ajcn/67.3.459; Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; BOREN J, 1994, J BIOL CHEM, V269, P25879; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; CHENG DW, 1957, ANAT REC, V129, P167, DOI 10.1002/ar.1091290204; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Christoffersen C, 2003, ENDOCRINOLOGY, V144, P3483, DOI 10.1210/en.2003-0242; Christoffersen C, 2002, HYPERTENSION, V40, P54, DOI 10.1161/01.HYP.0000021780.21830.DD; CLARKE JTR, 1981, CAN J BIOCHEM CELL B, V59, P412, DOI 10.1139/o81-057; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; ELLSWORTH JL, 1986, J LIPID RES, V27, P858; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Gabsi S, 2001, EUR J NEUROL, V8, P477, DOI 10.1046/j.1468-1331.2001.00273.x; HAMILTON RL, 1980, J LIPID RES, V21, P981; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; Havel RJ, 2001, METABOLIC MOL BASES, P2705; Herrera E, 2000, DIABETES-METAB RES, V16, P202, DOI 10.1002/1520-7560(200005/06)16:3<202::AID-DMRR116>3.3.CO;2-R; HERRERA E, 1998, FETAL NEONATAL PHYSL, P447; HOPKINS B, 1986, J EMBRYOL EXP MORPH, V97, P177; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kane J, 2001, METAB MOL BASES INHE, P2717; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KING DW, 1967, J NUTR, V91, P159, DOI 10.1093/jn/91.2.159; LINTON MF, 1993, J LIPID RES, V34, P521; MALLOV S, 1965, P SOC EXP BIOL MED, V119, P301; Maunsbach A, 1999, BIOMEDICAL ELECT MIC; Muller-Schmehl K, 2004, FREE RADICAL RES, V38, P413, DOI 10.1080/10715760310001659611; Nielsen LB, 2002, J BIOL CHEM, V277, P27014, DOI 10.1074/jbc.M203458200; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; Nielsen LB, 1999, J MOL CELL CARDIOL, V31, P695, DOI 10.1006/jmcc.1998.0918; Oram JF, 2001, J BIOL CHEM, V276, P39898, DOI 10.1074/jbc.M106984200; PARKER CR, 1983, EARLY HUM DEV, V8, P289, DOI 10.1016/0378-3782(83)90011-7; PLONNE D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P174, DOI 10.1016/0005-2760(92)90275-Z; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; SADLER TW, 1995, LANGMANS MED EMBRYOL, P82; SCHNEIDER H, 1984, AM J OBSTET GYNECOL, V148, P836, DOI 10.1016/0002-9378(84)90591-X; Staun-Ram Elsebeth, 2004, Reprod Biol Endocrinol, V2, P59, DOI 10.1186/1477-7827-2-59; Terasawa Y, 1999, J LIPID RES, V40, P1967; TRANUMJENSEN J, 1988, METHOD ENZYMOL, V165, P357; Urner JA, 1931, ANAT REC, V50, P175, DOI 10.1002/ar.1090500205; Van Aerde JE., 1998, FETAL NEONATAL PHYSI, P458; Walzem RL, 1999, J NUTR, V129, p467S, DOI 10.1093/jn/129.2.467S; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3	48	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55271	55276		10.1074/jbc.M411404200	http://dx.doi.org/10.1074/jbc.M411404200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504742	hybrid			2022-12-25	WOS:000225960800037
J	Nakata, S; Matsumura, I; Tanaka, H; Ezoe, S; Satoh, Y; Ishikawa, J; Era, T; Kanakura, Y				Nakata, S; Matsumura, I; Tanaka, H; Ezoe, S; Satoh, Y; Ishikawa, J; Era, T; Kanakura, Y			NF-kappa B family proteins participate in multiple steps of hematopoiesis through elimination of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE-DEPENDENT GROWTH; TRANSCRIPTION FACTORS; MICE LACKING; SPLENIC MICROARCHITECTURE; TARGETED DISRUPTION; IMMUNE-RESPONSES; EXHIBIT DEFECTS; CELL LINE; EXPRESSION; APOPTOSIS	examine the roles for NF-kappaB family proteins in hematopoiesis, we first expressed dominant negative Rel/NF-kappaB (IkappaBSR) in a factor-dependent cell line, Ba/F3. Although IkappaBSR neither affected thrombopoietindependent nor gp130-mediated growth, it suppressed interleukin-3- and erythropoietin-dependent growth at low concentrations. In addition, IkappaBSR enhanced factor-deprived apoptosis through the accumulation of reactive oxygen species (ROS). When expressed in normal hematopoietic stem/progenitor cells, IkappaBSR induced apoptosis even in the presence of appropriate cytokines by accumulating ROS. We also expressed IkappaBSR in an inducible fashion at various stages of hematopoiesis using the OP9 system, in which hematopoietic cells are induced to develop from embryonic stem cells. When IkappaBSR was expressed at the stage of Flk-1(+) cells (putative hemangioblasts), IkappaBSR inhibited the development of primitive hematopoietic progenitor cells by inducing apoptosis through the ROS accumulation. Furthermore, when IkappaBSR was expressed after the development of hematopoietic progenitor cells, it inhibited their terminal differentiation toward erythrocytes, megakaryocytes, and granulocytes by inducing apoptosis through the ROS accumulation. These results indicate that NF-kappaB is required for preventing apoptosis at multiple steps of hematopoiesis by eliminating ROS.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; RIKEN Ctr Dev Biol, Stem Cell Biol Grp, Tyuo Ku, Kobe, Hyogo 6500047, Japan	Osaka University; RIKEN	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp						Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kataoka Y, 2003, J BIOL CHEM, V278, P44178, DOI 10.1074/jbc.M304884200; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; MATSUMURA I, 1995, BLOOD, V86, P703, DOI 10.1182/blood.V86.2.703.bloodjournal862703; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	43	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55578	55586		10.1074/jbc.M408238200	http://dx.doi.org/10.1074/jbc.M408238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485843	hybrid			2022-12-25	WOS:000225960800075
J	Orcutt, SJ; Krishnaswamy, S				Orcutt, SJ; Krishnaswamy, S			Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XA; MACROMOLECULAR SUBSTRATE; FACTOR-VA; CATALYZED ACTIVATION; BOVINE TRYPSINOGEN; REACTION-MECHANISM; CRYSTAL-STRUCTURE; EXOSITE BINDING; COMPLEX; MEIZOTHROMBIN	Thrombin formation results from cleavage of prothrombin following Arg(271) and Arg(320). Both bonds are accessible for cleavage, yet the sequential action of prothrombinase on Arg(320) followed by Arg(271) is implied by the intermediate observed during prothrombin activation. We have studied the individual cleavage reactions catalyzed by prothrombinase by using a series of recombinant derivatives: wild type prothrombin (IIWT) contained both cleavage sites; IIQ271 contained a single cleavable site at Arg(320); IIQ320 and IIA320 contained a single cleavable site at Arg(271); and IIQQ was resistant to cleavage. Cleavage at Arg(320) in IIQ271 could account for the initial cleavage reaction leading to the consumption of either plasma prothrombin or IIWT, whereas cleavage at Arg(271) in either IIQ320 or IIA320 was found to be similar to30-fold slower. Equivalent kinetic constants were obtained for three of the four possible half-reactions. Slow cleavage at Arg(271) in intact prothrombin resulted from an similar to 30-fold reduction in V-max. Thus, the observed pathway of bond cleavage by prothrombinase can be explained by the kinetic constants for the four possible individual cleavage reactions. IIQ320 was a competitive inhibitor of IIQ271 cleavage, and IIQQ was a competitive inhibitor for each reaction with K-i approximate to K-m. The data are inconsistent with previous proposals and suggest a model in which substrates for each of the four possible half-reactions bind in a mutually exclusive manner and with equal affinity to prothrombinase in a cleavage site-independent way. Despite equivalent exosite binding interactions between all four possible substrates and the enzyme, we propose that ordered bond cleavage results from the constraints associated with the binding of substrates in one of two conformations to a single form of prothrombinase.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310A Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Krishnaswamy, Sriram/Z-4380-2019		NHLBI NIH HHS [HL-74124, HL-62523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062523, P01HL074124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington P. R., 1992, DATA REDUCTION ERROR, P141; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Boskovic DS, 2004, J BIOL CHEM, V279, P20786, DOI 10.1074/jbc.M400469200; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; ESMON CT, 1974, J BIOL CHEM, V249, P7782; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Moore J.W., 1981, KINETICS MECH, V3rd, P284; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; ROSING J, 1986, J BIOL CHEM, V261, P4224; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TANS G, 1991, J BIOL CHEM, V266, P21864; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Weinreb GE, 2003, J BIOL CHEM, V278, P5679, DOI 10.1074/jbc.M208423200; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026	49	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54927	54936		10.1074/jbc.M410866200	http://dx.doi.org/10.1074/jbc.M410866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494418	hybrid			2022-12-25	WOS:000225793600122
J	Yang, JC; Wong, RK; Wang, XJ; Moibi, J; Hessner, MJ; Greene, S; Wu, JM; Sukumvanich, S; Wolf, BA; Gao, ZY				Yang, JC; Wong, RK; Wang, XJ; Moibi, J; Hessner, MJ; Greene, S; Wu, JM; Sukumvanich, S; Wolf, BA; Gao, ZY			Leucine culture reveals that ATP synthase functions as a fuel sensor in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; HUMAN SKELETAL-MUSCLE; UNCOUPLING PROTEIN-2; ADENINE-NUCLEOTIDES; SIGNALING PATHWAY; RAT ISLETS; B-CELLS; GLUCOSE; GLUCOKINASE; RELEASE	Our goal was to investigate whether leucine culture affects beta-cell glucose sensing. One-day culture of rat islets with 10 mM leucine had no effect on glucose-induced insulin secretion. One-week leucine culture decreased the threshold for glucose-induced insulin secretion and increased maximal insulin secretion at 30 mM glucose. Glucose-induced cytosolic free Ca2+ was increased at 1 week but not at 1 day of leucine culture. Without glucose, ATP content was not different with or without leucine culture for 1 week. With 20 mM glucose, ATP content was higher by 1.5-fold in islets cultured for 1 week with leucine than those without leucine. Microarray experiments indicated that culture of RINm5F cells with leucine increased expression of ATP synthase beta subunit 3.2-fold, which was confirmed by real time reverse transcription-PCR analysis (3.0-+/-0.4-fold) in rat islets at 1 week but not after 1 day with leucine culture. Down-regulation of ATP synthase beta subunit by siRNA decreased INS1 cell ATP content and insulin secretion with 20 mM glucose. Overexpression of ATP synthase beta subunit in INS1 cell increased insulin secretion in the presence of 5 and 20 mM glucose. In conclusion, one-week leucine culture of rat islets up-regulated ATP synthase and increased ATP content, which resulted in elevated [Ca2+] levels and more insulin exocytosis by glucose. Depletion of ATP synthase beta subunit with siRNA produced opposite effects. These data reveal the fuel-sensing role of mitochondrial ATP synthase in the control of ATP production from glucose and the control of glucose-induced insulin secretion.	Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Medical College of Wisconsin	Gao, ZY (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, 803 Abramson,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	gao@email.chop.edu						Anello M, 2001, AM J PHYSIOL-ENDOC M, V281, pE1082, DOI 10.1152/ajpendo.2001.281.5.E1082; Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Brownlee M, 2003, J CLIN INVEST, V112, P1788, DOI 10.1172/JCI200320501; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Deng SP, 2004, DIABETES, V53, P624, DOI 10.2337/diabetes.53.3.624; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fitzhugh DJ, 2000, J IMMUNOL, V165, P6677, DOI 10.4049/jimmunol.165.12.6677; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; Hojlund K, 2003, J BIOL CHEM, V278, P10436, DOI 10.1074/jbc.M212881200; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Kutlu B, 2003, DIABETES, V52, P348, DOI 10.2337/diabetes.52.2.348; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lee SH, 2003, J HISTOCHEM CYTOCHEM, V51, P1005, DOI 10.1177/002215540305100804; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Lin X, 2003, J VIROL, V77, P8227, DOI 10.1128/JVI.77.15.8227-8236.2003; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Massa O, 2001, DIABETOLOGIA, V44, P898; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Weinhaus AJ, 2003, J CLIN ENDOCR METAB, V88, P2753, DOI 10.1210/jc.2002-021542; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zhang DD, 2001, MT RES DEV, V21, P61, DOI 10.1659/0276-4741(2001)021[0061:TCFLOT]2.0.CO;2	41	28	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53915	53923		10.1074/jbc.M405309200	http://dx.doi.org/10.1074/jbc.M405309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489222	hybrid			2022-12-25	WOS:000225793600004
J	Jun, Y; Fratti, RA; Wickner, W				Jun, Y; Fratti, RA; Wickner, W			Diacylglycerol and its formation by phospholipase C regulate Rab- and SNARE-dependent yeast vacuole fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; ETHER LIPID ANALOGS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; SELECTIVE-INHIBITION; VESICLE FUSION; GTPASE YPT7P; ALPHA-SNAP; PROTEIN; DOCKING	Although diacylglycerol (DAG) can trigger liposome fusion, biological membrane fusion requires Rab and SNARE proteins. We have investigated whether DAG and phosphoinositide-specific phospholipase C (PLC) have a role in the Rab- and SNARE-dependent homotypic vacuole fusion in Saccharomyces cerevisiae. Vacuole fusion was blocked when DAG was sequestered by a recombinant C1b domain. DAG underwent ATP-dependent turnover during vacuole fusion, but was replenished by the hydrolysis of phosphatidylinositol 4,5-bisphosphate to DAG by PLC. The PLC inhibitors 3-nitrocoumarin and U73122 blocked vacuole fusion in vitro, whereas their inactive homologues did not. Plc1p is the only known PLC in yeast. Yeast cells lacking the PLC1 gene have many small vacuoles, indicating defects in protein trafficking to the vacuole or vacuole fusion, and purified Plc1p stimulates vacuole fusion. Docking-dependent Ca2+ efflux is absent in plc1Delta vacuoles and was restored only upon the addition of both Plc1p and the Vam7p SNARE. However, vacuoles purified from plc1Delta strains still retain PLC activity and significant 3-nitrocoumarin- and U73122-sensitive fusion, suggesting that there is another PLC in S. cerevisiae with an important role in vacuole fusion.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu	Jun, Youngsoo/Q-3624-2018	Jun, Youngsoo/0000-0002-2387-032X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023377, R01GM023377] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23377] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ANGUS WW, 1975, J BIOL CHEM, V250, P22; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; BELDE PJM, 1993, FEBS LETT, V323, P113, DOI 10.1016/0014-5793(93)81460-H; BERGGREN MI, 1993, CANCER RES, V53, P4297; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kahana JA, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P139; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; MIZUNOKAMIYA M, 1995, J BIOCHEM-TOKYO, V118, P693, DOI 10.1093/oxfordjournals.jbchem.a124967; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; POWIS G, 1992, CANCER RES, V52, P2835; SANCHEZMIGALLON MP, 1995, BIOPHYS J, V68, P558, DOI 10.1016/S0006-3495(95)80217-1; SANCHEZMIGALLON MP, 1994, ARCH BIOCHEM BIOPHYS, V314, P205, DOI 10.1006/abbi.1994.1431; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; SIKORSKI RS, 1989, GENETICS, V122, P19; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Taylor GS, 2001, ANAL BIOCHEM, V295, P122, DOI 10.1006/abio.2001.5179; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Tisi R, 2001, CELL BIOCHEM FUNCT, V19, P229, DOI 10.1002/cbf.918; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; Villar AV, 2000, BIOCHEMISTRY-US, V39, P14012, DOI 10.1021/bi992515c; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Ward PD, 2002, J BIOL CHEM, V277, P35760, DOI 10.1074/jbc.M203134200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644	61	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53186	53195		10.1074/jbc.M411363200	http://dx.doi.org/10.1074/jbc.M411363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485855	hybrid			2022-12-25	WOS:000225680600048
J	Lee, JH; Cook, JR; Yang, ZH; Mirochnitchenko, O; Gunderson, SI; Felix, AM; Herth, N; Hoffmann, R; Pestka, S				Lee, JH; Cook, JR; Yang, ZH; Mirochnitchenko, O; Gunderson, SI; Felix, AM; Herth, N; Hoffmann, R; Pestka, S			PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM PROTEINS; ASYMMETRIC DIMETHYLARGININE; SUBSTRATE-SPECIFICITY; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; METHYLATION; RESIDUES; COMPLEX; TRANSCRIPTION; HOMOLOG	The cDNA for PRMT7, a recently discovered human protein-arginine methyltransferase, (PRMT), was cloned and expressed in Escherichia coli and mammalian cells. Immunopurified PRMT7 actively methylated histones, myelin basic protein, a fragment of human fibrillarin (GAR) and spliceosomal protein SmB. Amino acid analysis showed that the modifications produced were predominantly monomethylarginine and symmetric dimethylarginine (SDMA). Examination of PRMT7 expressed in E. coli demonstrated that peptides corresponding to sequences contained in histone H4, myelin basic protein, and SmD3 were methylated. Furthermore, analysis of the methylated proteins showed that symmetric dimethylarginine and relatively small amounts of monomethylarginine and asymmetric dimethylarginine were produced. SDMA was also formed when a GRG tripeptide was methylated by PRMT7, indicating that a GRG motif is by itself sufficient for symmetric dimethylation to occur. Symmetric dimethylation is reduced dramatically compared with monomethylation as the concentration of the substrate is increased. The data demonstrate that PRMT7 (like PRMT5) is a Type II methyltransferase capable of producing SDMA modifications in proteins.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ 08854 USA; Ramapo Coll, Mahwah, NJ 07430 USA; Univ Leipzig, Fac Chem & Mineral, Ctr Biotechnol & Biochem, D-04103 Leipzig, Germany; PBL Biomed Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Ramapo College New Jersey (RCNJ); Leipzig University	Pestka, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 675 Hoes Ln,Rm 727, Piscataway, NJ 08854 USA.	pestka@waksman.rutgers.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059465, T32AI007403, R01AI043369, R01AI036450] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43369, R01 AI36450, R01 AI059465, 2 T32-AI07403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chie L, 2003, ANN CLIN LAB SCI, V33, P200; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Fleck C, 2003, CLIN CHIM ACTA, V336, P1, DOI 10.1016/S0009-8981(03)00338-3; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gros L, 2003, CANCER RES, V63, P164; Hebert MD, 2002, DEV CELL, V3, P329, DOI 10.1016/S1534-5807(02)00222-8; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Miranda TB, 2004, BIOCHEM BIOPH RES CO, V323, P382, DOI 10.1016/j.bbrc.2004.08.107; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PAQUET A, 1976, CAN J CHEM, V54, P733, DOI 10.1139/v76-106; PESTKA S, 1972, J BIOL CHEM, V247, P4669; Pipkorn R, 2002, J PEPT RES, V59, P105, DOI 10.1034/j.1399-3011.2002.01958.x; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Rajagopalan S, 2003, ARTHRITIS RHEUM-US, V48, P1992, DOI 10.1002/art.11060; Rattazzi M, 2003, J NEPHROL, V16, P11; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIGLER GF, 1983, BIOPOLYMERS, V22, P2157, DOI 10.1002/bip.360221002; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; STOCK A, 1987, J BIOL CHEM, V262, P8011; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Valkonen VP, 2001, LANCET, V358, P2127, DOI 10.1016/S0140-6736(01)07184-7; Yoo JH, 2001, ATHEROSCLEROSIS, V158, P425, DOI 10.1016/S0021-9150(01)00444-0	41	162	164	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2005	280	5					3656	3664		10.1074/jbc.M405295200	http://dx.doi.org/10.1074/jbc.M405295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	897DJ	15494416	hybrid			2022-12-25	WOS:000226983900065
J	Kodali, S; Galgoci, A; Young, K; Painter, R; Silver, LL; Herath, KB; Singh, SB; Cully, D; Barrett, JF; Schmatz, D; Wang, J				Kodali, S; Galgoci, A; Young, K; Painter, R; Silver, LL; Herath, KB; Singh, SB; Cully, D; Barrett, JF; Schmatz, D; Wang, J			Determination of selectivity and efficacy of fatty acid synthesis inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; SYNTHASE-III FABH; ESCHERICHIA-COLI; THIOLACTOMYCIN RESISTANCE; PSEUDOMONAS-AERUGINOSA; SMALL-MOLECULE; CERULENIN; GENE; IDENTIFICATION; BIOSYNTHESIS	Type II fatty acid synthesis (FASII) is essential to bacterial cell viability and is a promising target for the development of novel antibiotics. In the past decade, a few inhibitors have been identified for this pathway, but none of them lend themselves to drug development. To find better inhibitors that are potential drug candidates, we developed a high throughput assay that identifies inhibitors simultaneously against multiple targets within the FASII pathway of most bacterial pathogens. We demonstrated that the inverse t(1/2) value of the FASII enzyme-catalyzed reaction gives a measure of FASII activity. The K-m values of octanoyl-CoA and lauroyl-CoA were determined to be 1.1 +/- 0.3 and 10 +/- 2.7 muM in Staphylococcus aureus and Bacillus subtilis, respectively. The effects of free metals and reducing agents on enzyme activity showed an inhibition hierarchy of Zn2+ > Ca2+ > Mn2+ > Mg2+; no inhibition was found with beta-mercaptoethanol or dithiothreitol. We used this assay to screen the natural product libraries and isolated an inhibitor, bischloroanthrabenzoxocinone (BABX) with a new structure. BABX showed IC50 values of 11.4 and 35.3 mug/ml in the S. aureus and Escherichia coli FASII assays, respectively, and good antibacterial activities against S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2 to 0.4 mug/ml. Furthermore, the effectiveness, selectivity, and the in vitro and in vivo correlations of BABX as well as other fatty acid inhibitors were elucidated, which will aid in future drug discovery.	Merck & Co Inc, Merck Res Labs, Dept Human & Anim Infect Dis, Rahway, NJ 07065 USA	Merck & Company	Wang, J (corresponding author), Merck & Co Inc, Merck Res Labs, Dept Human & Anim Infect Dis, POB 2000,R80Y-205, Rahway, NJ 07065 USA.	jun_wang2@merck.com	Silver, Lynn L/A-7789-2009	Silver, Lynn L/0000-0002-8416-0487				ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Chuanchuen R, 2001, ANTIMICROB AGENTS CH, V45, P428, DOI 10.1128/AAC.45.2.428-432.2001; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; Daines RA, 2003, J MED CHEM, V46, P5, DOI 10.1021/jm025571b; DOLAK LA, 1986, J ANTIBIOT, V39, P26, DOI 10.7164/antibiotics.39.26; FALL RR, 1972, J BIOL CHEM, V247, P8005; He X, 2002, ANTIMICROB AGENTS CH, V46, P1310, DOI 10.1128/AAC.46.5.1310-1318.2002; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Jackowski S, 2002, ANTIMICROB AGENTS CH, V46, P1246, DOI 10.1128/AAC.46.5.1246-1252.2002; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; LYNEN F, 1962, METHOD ENZYMOL, V5, P443, DOI 10.1016/S0076-6879(62)05256-8; Markham PN, 2001, CURR OPIN MICROBIOL, V4, P509, DOI 10.1016/S1369-5274(00)00243-5; MATSUMAE A, 1964, J ANTIBIOT, V17, P1; Miller JH, 1972, EXPT MOL GENETICS, P201; MOHAN S, 1994, J BIOL CHEM, V269, P32896; NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401; OMURA S, 1983, J ANTIBIOT, V36, P109, DOI 10.7164/antibiotics.36.109; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Perrin D.D, 1974, BUFFERS PH METAL ION, P48; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROCK CO, 1979, J BIOL CHEM, V254, P7116; Ross EM, 1999, CRC METH SIG TRANS, P123; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; Schweizer HP, 1998, ANTIMICROB AGENTS CH, V42, P394; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; SINGER M, 1989, MICROBIOL REV, V53, P1; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	46	96	99	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1669	1677		10.1074/jbc.M406848200	http://dx.doi.org/10.1074/jbc.M406848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516341	hybrid			2022-12-25	WOS:000226195200098
J	Copeland, NA; Kleanthous, C				Copeland, NA; Kleanthous, C			The role of an activating peptide in protease-mediated suicide of Escherichia coli K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE GENE-EXPRESSION; MAJOR HEAD PROTEIN; BACTERIOPHAGE-LAMBDA; SEQUENCE-ANALYSIS; GOL SITE; EF-TU; TRANSLATION; COLI; LIT; T4-BACTERIOPHAGE	Activation of latent proteinases ensures that the timing of proteolysis is regulated precisely, a process that generally involves proteolytic excision of a pro-region or a tightly bound inhibitor. Here we define the activation mechanism for Lit, a dormant suicide proteinase in Escherichia coli K-12. Previous work has shown that Gol, a short sequence within the major capsid protein gp23, activates Lit during the latter stages of T4 phage infection. This results in cell death and exclusion of the phage from the culture. The Lit site specifically cleaves the host translation factor EF-Tu ( elongation factor Tu) after it has formed a weak complex with Gol, which can be supplied as a 29-residue peptide. Gol is absolutely required for Lit activation. but its role in proteolysis is unknown. Using a purified three-component system and kinetic analysis, we demonstrate that under physiological conditions Lit hydrolyzes its substrate very slowly (k(cat) of similar to 1 s(-1)). Given the abundance of EF-Tu in the cell, this finding is consistent with a cell-killing mechanism in which a few cleaved EF-Tu proteins are able block translating ribosomes from functioning. We also demonstrate that less than half of the 29 Gol residues are needed for Lit activation and that the role of the peptide is not to provide catalytic groups but to influence catalysis indirectly through stabilization of the ternary Lit.Gol.EF-Tu complex. Hence, phage-elicited suicide of E. coli K-12 by Lit is a variant form of "cofactor-induced activation," a mechanism of protease activation that has only been documented previously in pathogen subversion of mammalian hemostasis cascades.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Kleanthous, C (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.	ck11@york.ac.uk		Copeland, Nikki/0000-0002-6204-4717				Amitsur M, 2003, MOL MICROBIOL, V50, P129, DOI 10.1046/j.1365-2958.2003.03691.x; BERGSLAND KJ, 1990, J MOL BIOL, V213, P477, DOI 10.1016/S0022-2836(05)80209-8; Bingham R, 2000, J BIOL CHEM, V275, P23219, DOI 10.1074/jbc.M002546200; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; Boyd EF, 2002, TRENDS MICROBIOL, V10, P521, DOI 10.1016/S0966-842X(02)02459-9; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; CHAMPNESS WC, 1982, J MOL BIOL, V155, P395, DOI 10.1016/0022-2836(82)90478-8; CHAMPNESS WC, 1984, J VIROL, V50, P555, DOI 10.1128/JVI.50.2.555-562.1984; Cimarelli A, 1999, J VIROL, V73, P5388, DOI 10.1128/JVI.73.7.5388-5401.1999; COOLEY W, 1979, J BACTERIOL, V140, P83, DOI 10.1128/JB.140.1.83-91.1979; Copeland NA, 2004, BIOCHEMISTRY-US, V43, P7948, DOI 10.1021/bi0495026; Desplats C, 2003, RES MICROBIOL, V154, P259, DOI 10.1016/S0923-2508(03)00069-X; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Gamage SD, 2003, INFECT IMMUN, V71, P3107, DOI 10.1128/IAI.71.6.3107-3115.2003; Georgiou T, 1998, P NATL ACAD SCI USA, V95, P2891, DOI 10.1073/pnas.95.6.2891; Gottesman S, 1998, P NATL ACAD SCI USA, V95, P2731, DOI 10.1073/pnas.95.6.2731; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; HILL CW, 1989, J BACTERIOL, V171, P4083, DOI 10.1128/jb.171.7.4083-4084.1989; Hotokezaka Y, 2002, J BIOL CHEM, V277, P18545, DOI 10.1074/jbc.M201022200; KAO C, 1988, J BACTERIOL, V170, P2056, DOI 10.1128/jb.170.5.2056-2062.1988; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Kawaguchi Y, 1997, J VIROL, V71, P1019, DOI 10.1128/JVI.71.2.1019-1024.1997; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Malki A, 2002, BIOCHEM BIOPH RES CO, V296, P749, DOI 10.1016/S0006-291X(02)00935-X; MOONEY DT, 1987, J VIROL, V61, P2828, DOI 10.1128/JVI.61.9.2828-2834.1987; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Murase K, 2003, CHEM BIOL, V10, P161, DOI 10.1016/S1074-5521(03)00025-5; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; PARMA DH, 1992, GENE DEV, V6, P497, DOI 10.1101/gad.6.3.497; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; Slavcev RA, 2003, MOL GENET GENOMICS, V269, P40, DOI 10.1007/s00438-002-0787-x; Slavcev RA, 2002, J BACTERIOL, V184, P857, DOI 10.1128/JB.184.3.857-858.2002; Snyder L, 2003, J MOL BIOL, V334, P349, DOI 10.1016/j.jmb.2003.09.063; SNYDER L, 1995, MOL MICROBIOL, V15, P415, DOI 10.1111/j.1365-2958.1995.tb02255.x; Snyder L, 1994, MOL BIOL BACTERIOP T, P391; Teichmann SA, 2002, J MOL BIOL, V324, P399, DOI 10.1016/S0022-2836(02)01144-0; TERTART F, 2001, J BACTERIOL, V183, P358; Waldor MK, 1998, TRENDS MICROBIOL, V6, P295, DOI 10.1016/S0966-842X(98)01320-1; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; YU YTN, 1994, P NATL ACAD SCI USA, V91, P802, DOI 10.1073/pnas.91.2.802	43	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					112	117		10.1074/jbc.M411280200	http://dx.doi.org/10.1074/jbc.M411280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501819	hybrid			2022-12-25	WOS:000226025100015
J	Tanikawa, J; Nomura, T; Macmillan, EM; Shinagawa, T; Jin, WZ; Kokura, K; Baba, D; Shirakawa, M; Gonda, TJ; Ishii, S				Tanikawa, J; Nomura, T; Macmillan, EM; Shinagawa, T; Jin, WZ; Kokura, K; Baba, D; Shirakawa, M; Gonda, TJ; Ishii, S			p53 suppresses c-Myb-induced trans-activation and transformation by recruiting the corepressor mSin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; V-MYB; NEGATIVE REGULATION; FUNCTIONAL DOMAIN; TUMOR SUPPRESSION; EXPRESSION; GENE; APOPTOSIS	p53 is known to repress transcription of a number of genes, but the mechanism of p53 recruitment to these target genes is unknown. The c-myb proto-oncogene product (c-Myb) positively regulates proliferation of immature hematopoietic cells, whereas p53 blocks cell cycle progression. Here, we demonstrate that p53 inhibits c-Myb-induced transcription and transformation by directly binding to c-Myb. The ability of c-Myb to maintain the undifferentiated state of M1 cells was also suppressed by p53. p53 did not affect the ability of c-Myb to bind to DNA but formed a ternary complex with the corepressor mSin3A and c-Myb. Thus, p53 antagonizes c-Myb by recruiting mSin3A to down-regulate specific Myb target genes.	RIKEN Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia; Yokohama City Univ, Grad Sch Integrated Sci, Kanagawa 2300045, Japan	RIKEN; Hanson Institute; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; Yokohama City University	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.jp	Gonda, Thomas J/A-3620-2012; Shinagawa, Tsutomu/CAA-9979-2022; Ishii, Shunsuke/A-5271-2016; Jin, Wanzhu/B-5699-2012	Shinagawa, Tsutomu/0000-0001-5671-1512; Ishii, Shunsuke/0000-0002-6530-2478; Jin, Wanzhu/0000-0002-5860-2958				An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HU YL, 1991, ONCOGENE, V6, P1549; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nomura T, 2004, J BIOL CHEM, V279, P16715, DOI 10.1074/jbc.M313069200; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; TSUKADA T, 1993, ONCOGENE, V8, P3313; Uchimura Y, 2004, FEBS LETT, V564, P85, DOI 10.1016/S0014-5793(04)00321-7; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55393	55400		10.1074/jbc.M411658200	http://dx.doi.org/10.1074/jbc.M411658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509555	hybrid			2022-12-25	WOS:000225960800053
J	Cho, JH; Johnson, GVW				Cho, JH; Johnson, GVW			Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; GRANULOVACUOLAR DEGENERATION; NEUROFIBRILLARY TANGLES; MICROTUBULE-BINDING; TRANSGENIC MICE; PROTEIN-TAU; PC12 CELLS; PHOSPHORYLATION; ACTIVATION; APOPTOSIS	Tau is a substrate of caspases, and caspase-cleaved tau has been detected in Alzheimer's disease brain but not in control brain. Furthermore, in vitro studies have revealed that caspase-cleaved tau is more fibrillogenic than full-length tau. Considering these previous findings, the purpose of this study was to determine how the caspase cleavage of tau affected tau function and aggregation in a cell model system. The effects of glycogen synthase kinase 3beta (GSK3beta), a well established tau kinase, on these processes also were examined. Tau or tau that had been truncated at Asp-421 to mimic caspase cleavage (Tau-D421) was transfected into cells with or without GSK3beta, and phosphorylation, microtubule binding, and tau aggregation were examined. Tau-D421 was not as efficiently phosphorylated by GSK3beta as full-length tau. Tau-D421 efficiently bound microtubules, and in contrast to the full-length tau, co-expression with GSK3beta did not result in a reduction in the ability of Tau-D421 to bind microtubules. In the absence of GSK3beta, neither Tau-D421 nor full-length tau formed Sarkosyl-insoluble inclusions. However, in the presence of GSK3beta, Tau-D421, but not full-length tau, was present in the Sarkosyl-insoluble fraction and formed thioflavin-S-positive inclusions in the cell. Nonetheless, co-expression of GSK3beta and Tau-D421 did not result in an enhancement of cell death. These data suggest that a combination of phosphorylation events and caspase activation contribute to the tau oligomerization process in Alzheimer's disease, with GSK3beta-mediated tau phosphorylation preceding caspase cleavage.	Univ Alabama, Sch Med, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Sch Med, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Davis PK, 1999, J BIOL CHEM, V274, P35686, DOI 10.1074/jbc.274.50.35686; Davis PK, 1997, J NEUROCHEM, V68, P2338; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Hardy J, 2003, J MOL NEUROSCI, V20, P203, DOI 10.1385/JMN:20:2:203; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Johnson G V, 1999, J Alzheimers Dis, V1, P329; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Rossiter JP, 2000, NEUROPATH APPL NEURO, V26, P342, DOI 10.1046/j.1365-2990.2000.00252.x; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; VALLET PG, 1992, ACTA NEUROPATHOL, V83, P170, DOI 10.1007/BF00308476	47	89	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54716	54723		10.1074/jbc.M403364200	http://dx.doi.org/10.1074/jbc.M403364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494420	hybrid			2022-12-25	WOS:000225793600099
J	Hu, YL; Fay, AW; Dos Santos, PC; Naderi, F; Ribbe, MW				Hu, YL; Fay, AW; Dos Santos, PC; Naderi, F; Ribbe, MW			Characterization of Azotobacter vinelandii nifZ deletion strains - Indication of stepwise MoFe protein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM-COFACTOR; FEMO-COFACTOR; NITROGEN-FIXATION; P-CLUSTERS; BIOSYNTHESIS; COMPLEX; EPR; PURIFICATION; MECHANISM; INSERTION	The nifZ gene product (NifZ) of Azotobacter vinelandii has been implicated in MoFe protein maturation. However, its exact function in this process remains largely unknown. Here, we report a detailed biochemical/biophysical characterization of His-tagged MoFe proteins purified from A. vinelandii nifZ and nifZ/nifB deletion strains DJ1182 and YM6A (DeltanifZ and DeltanifZDeltanifB MoFe proteins, respectively). Our data from EPR, metal, activity, and stability analyses indicate that one alphabeta subunit pair of the DeltanifZ MoFe protein contains a P cluster ([8Fe-7S]) and an iron-molybdenum cofactor (FeMoco) ([Mo-7Fe-9S-X-homocitrate]), whereas the other contains a presumed P cluster precursor, possibly comprising a pair of [4Fe-4S]-like clusters, and a vacant FeMoco site. Likewise, the DeltanifZDeltanifB MoFe protein has the same composition as the DeltanifZ MoFe protein except for the absence of FeMoco, an effect caused by the deletion of the nifB gene. These results suggest that the MoFe protein is likely assembled stepwise, i.e. one alphabeta subunit pair of the tetrameric MoFe protein is assembled prior to the other, and that NifZ might act as a chaperone in the assembly of the second alphabeta subunit pair by facilitating a conformational rearrangement that is required for the formation of the P cluster through the condensation of two [4Fe-4S]-like clusters. The possibility of NifZ exercising its effect through the Fe protein was ruled out because the Fe proteins from nifZ and nifZ/nifB deletion strains are not defective in their normal functions. However, the detailed mechanism of how NifZ carries out its exact function in MoFe protein maturation awaits further investigation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of California System; University of California Irvine; Virginia Polytechnic Institute & State University	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 2236 McGaugh Hall, Irvine, CA 92697 USA.	mribbe@uci.edu	Naderi, Fereshteh/AAN-9952-2021	Dos Santos, Patricia/0000-0002-3364-0931	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-67626] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; Campbell M., 2004, J BIOL CHEM, V279, P28276; Chen KS, 2002, J BIOL CHEM, V277, P5603, DOI 10.1074/jbc.M108916200; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Eady RR, 2003, COORDIN CHEM REV, V237, P23, DOI 10.1016/S0010-8545(02)00248-5; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Frazzon J, 2002, MET IONS BIOL SYST, V39, P163; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; Grossmann JG, 2001, J BIOL CHEM, V276, P6582, DOI 10.1074/jbc.M005350200; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; Huang JF, 1999, ACTA BOT SIN, V41, P1217; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; Jung YS, 2000, J BIOL CHEM, V275, P36974, DOI 10.1074/jbc.M004947200; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; LUDDEN PW, 1993, ACS SYM SER, V535, P196; LUDDEN PW, 1998, BIOL NITROGEN FIXATI, P33; MORNINGSTAR JE, 1987, J AM CHEM SOC, V109, P6854, DOI 10.1021/ja00256a051; MUCHMORE SW, 1996, MECH METALLOCLUSTER, V11, P111; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; Ribbe MW, 2002, J BIOL CHEM, V277, P23469, DOI 10.1074/jbc.M202061200; Ribbe MW, 2001, P NATL ACAD SCI USA, V98, P5521, DOI 10.1073/pnas.101119498; Ribbe MW, 2000, J BIOL CHEM, V275, P17631, DOI 10.1074/jbc.275.23.17631; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Rubio L. M., 2002, Nitrogen fixation at the millennium, P101, DOI 10.1016/B978-044450965-9/50004-5; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; TAL S, 1991, J BIOL CHEM, V266, P10654; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; Wang DY, 1999, ACTA BOT SIN, V41, P71; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685	58	44	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54963	54971		10.1074/jbc.M408983200	http://dx.doi.org/10.1074/jbc.M408983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485884	hybrid			2022-12-25	WOS:000225793600126
J	Pacifico, F; Mauro, C; Barone, C; Crescenzi, E; Mellone, S; Monaco, M; Chiappetta, G; Terrazzano, G; Liguoro, D; Vito, P; Consiglio, E; Formisano, S; Leonardi, A				Pacifico, F; Mauro, C; Barone, C; Crescenzi, E; Mellone, S; Monaco, M; Chiappetta, G; Terrazzano, G; Liguoro, D; Vito, P; Consiglio, E; Formisano, S; Leonardi, A			Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL CARCINOMA; CYTOCHROME-C; ACTIVATION; EXPRESSION; JNK; FAMILY; TARGET; ALPHA	Thyroid cancer includes three types of carcinomas classified as differentiated thyroid carcinomas (DTC), medullary thyroid carcinomas, and undifferentiated carcinomas (UTC). DTC and medullary thyroid carcinomas generally have a good prognosis, but UTC are usually fatal. Consequently, there is a need for new effective therapeutic modalities to improve the survival of UTC patients. Here we show that NF-kappaB is activated in human thyroid neoplasms, particularly in undifferentiated carcinomas. Thyroid cell lines, reproducing in vitro the different thyroid neoplasias, also show basal NF-kappaB activity and resistance to drug-induced apoptosis, which correlates with the level of NF-kappaB activation. Activation of NF-kappaB in the DTC cell line NPA renders these cells resistant to drug-induced apoptosis. Stable expression of a super-repressor form of IkappaBalpha (IkappaBalphaM) in the UTC cell line FRO results in enhanced sensitivity to drug-induced apoptosis, to the loss of the ability of these cells to form colonies in soft agar, and to induce tumor growth in nude mice. In addition, we show that FRO cells display a very low JNK activity that is restored in FRO-IkappaBalphaM clones. Moreover, inhibition of JNK activity renders FRO-IkappaBalphaM clones resistant to apoptosis induced by chemotherapeutic agents. Our results indicate that NF-kappaB plays a pivotal role in thyroid carcinogenesis, being required for tumor growth and for resistance to drug-induced apoptosis, the latter function very likely through the inhibition of JNK activity. Furthermore, the strong constitutive NF-kappaB activity in human anaplastic thyroid carcinomas, besides representing a novel diagnostic tool, makes NF-kappaB a target for the development of novel therapeutic strategies.	Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Ist Nazl Tumori Fdn G Pascale, I-80131 Naples, Italy; Univ Sannio, Fac Sci, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione Pascale; University of Sannio	Leonardi, A (corresponding author), Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	leonardi@unina.it	Mauro, Claudio/AAN-1848-2021; leonardi, antonio/A-2887-2009; Pacifico, Francesco/AAX-3958-2020; vito, pasquale/ABF-5505-2020	Mauro, Claudio/0000-0002-3736-0099; leonardi, antonio/0000-0001-8636-9623; Pacifico, Francesco/0000-0001-9563-3596; vito, pasquale/0000-0002-5721-7716; CRESCENZI, ELVIRA/0000-0002-9258-8053; TERRAZZANO, Giuseppe/0000-0003-3556-6891				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALL DW, 1996, THYROID, P1166; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duffey DC, 1999, CANCER RES, V59, P3468; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FIGGE J, 1999, THYROID CANC COMPREH, P515; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Hwang JH, 2003, J CLIN ENDOCR METAB, V88, P408, DOI 10.1210/jc.2002-021381; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Ludwig L, 2001, CANCER RES, V61, P4526; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; McIver B, 2001, SURGERY, V130, P1028, DOI 10.1067/msy.2001.118266; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TENNVALL J, 1994, CANCER-AM CANCER SOC, V74, P1348, DOI 10.1002/1097-0142(19940815)74:4<1348::AID-CNCR2820740427>3.0.CO;2-D; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	47	93	103	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54610	54619		10.1074/jbc.M403492200	http://dx.doi.org/10.1074/jbc.M403492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475567	Green Published, hybrid			2022-12-25	WOS:000225793600087
J	Proudfoot, M; Kuznetsova, E; Brown, G; Rao, NN; Kitagawa, M; Mori, H; Savchenko, A; Yakunin, AF				Proudfoot, M; Kuznetsova, E; Brown, G; Rao, NN; Kitagawa, M; Mori, H; Savchenko, A; Yakunin, AF			General enzymatic screens identify three new nucleotidases in Escherichia coli - Biochemical characterization of SurE, YfbR, and YjjG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC 5'-NUCLEOTIDASE I; K-M 5'-NUCLEOTIDASE; ACID-PHOSPHATASE; CRYSTAL-STRUCTURE; CYTOPLASMIC 5'-NUCLEOTIDASE; PHOSPHOSERINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; SOLUBLE 5'-NUCLEOTIDASE; FUNCTIONAL-ANALYSIS; KINETIC-PROPERTIES	To find proteins with nucleotidase activity in Escherichia coli, purified unknown proteins were screened for the presence of phosphatase activity using the general phosphatase substrate p-nitrophenyl phosphate. Proteins exhibiting catalytic activity were then assayed for nucleotidase activity against various nucleotides. These screens identified the presence of nucleotidase activity in three uncharacterized E. coli proteins, SurE, YfbR, and YjjG, that belong to different enzyme superfamilies: SurE-like family, HD domain family ( YfbR), and haloacid dehalogenase (HAD)-like superfamily ( YjjG). The phosphatase activity of these proteins had a neutral pH optimum (pH 7.0-8.0) and was strictly dependent on the presence of divalent metal cations (SurE: Mn2+ > Co2+ > Ni2+ > Mg2+; YfbR: Co2+ > Mn2+ > Cu2+; YjjG: Mg2+ > Mn2+ > Co2+). Further biochemical characterization of SurE revealed that it has a broad substrate specificity and can dephosphorylate various ribo- and deoxyribonucleoside 5'-monophosphates and ribonucleoside 3'-monophosphates with highest affinity to 3'-AMP. SurE also hydrolyzed polyphosphate (exopolyphosphatase activity) with the preference for short-chain-length substrates (P20-25). YfbR was strictly specific to deoxyribonucleoside 5'-monophosphates, whereas YjjG showed narrow specificity to 5'-dTMP, 5'-dUMP, and 5'-UMP. The three enzymes also exhibited different sensitivities to inhibition by various nucleoside di- and triphosphates: YfbR was equally sensitive to both di- and triphosphates, SurE was inhibited only by triphosphates, and YjjG was insensitive to these effectors. The differences in their sensitivities to nucleotides and their varied substrate specificities suggest that these enzymes play unique functions in the intracellular nucleotide metabolism in E. coli.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Takara Bio Inc, Dragon Genom Ctr, Yokaichi, Mie 5121211, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	University of Toronto; Stanford University; Takara Bio Inc.; Nara Institute of Science & Technology	Yakunin, AF (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	a.iakounine@utoronto.ca	Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1993, J BIOL CHEM, V268, P633; Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; AN G, 1979, J BACTERIOL, V137, P1100, DOI 10.1128/JB.137.3.1100-1110.1979; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; EVANS WH, 1973, BIOCHEM J, V133, P189, DOI 10.1042/bj1330189; Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; GLASER L, 1967, J BIOL CHEM, V242, P1944; GUREVITZ M, 1982, EUR J BIOCHEM, V124, P553; HEINEMEYER EA, 1977, FEBS LETT, V84, P357, DOI 10.1016/0014-5793(77)80724-2; Hogg T, 2004, CELL, V117, P57, DOI 10.1016/S0092-8674(04)00260-0; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; KAMINSKA BJ, 1986, J BIOL CHEM, V261, P449; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; Kim YC, 2004, J BIOL CHEM, V279, P517, DOI 10.1074/jbc.M306054200; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KOHN J, 1963, J BACTERIOL, V86, P713, DOI 10.1128/JB.86.4.713-716.1963; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KOSHLAND DE, 1984, TRENDS BIOCHEM SCI, V9, P155, DOI 10.1016/0968-0004(84)90125-7; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lee JY, 2001, NAT STRUCT BIOL, V8, P789, DOI 10.1038/nsb0901-789; MADRIDMARINA V, 1986, J BIOL CHEM, V261, P444; Mechold U, 1996, J BACTERIOL, V178, P1401, DOI 10.1128/jb.178.5.1401-1411.1996; Mura C, 2003, J MOL BIOL, V326, P1559, DOI 10.1016/S0022-2836(03)00056-1; NEU HC, 1967, J BIOL CHEM, V242, P3896; NEWSHOLME EA, 1984, TRENDS BIOCHEM SCI, V9, P277, DOI 10.1016/0968-0004(84)90165-8; Niedzwiecka J, 1996, BIOCHEM BIOPH RES CO, V221, P471, DOI 10.1006/bbrc.1996.0619; NISHIKAWA S, 1986, BIOCHEM BIOPH RES CO, V138, P789, DOI 10.1016/S0006-291X(86)80566-6; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHANDLEY SF, 1995, FASEB J, V9, pA1299; OKAZAKI R, 1964, J BIOL CHEM, V239, P269; Orford MR, 1996, J NEUROCHEM, V67, P795; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rees DC, 2003, BRIT J HAEMATOL, V120, P375, DOI 10.1046/j.1365-2141.2003.03980.x; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reilly TJ, 2004, PROTEIN EXPRES PURIF, V33, P48, DOI 10.1016/j.pep.2003.08.020; Riehle MM, 2001, P NATL ACAD SCI USA, V98, P525, DOI 10.1073/pnas.021448998; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; Sala-Newby GB, 2001, BBA-GENE STRUCT EXPR, V1521, P12, DOI 10.1016/S0167-4781(01)00278-0; Sala-Newby GB, 2000, J BIOL CHEM, V275, P11666, DOI 10.1074/jbc.275.16.11666; SCHRADER WP, 1978, J BACTERIOL, V133, P576, DOI 10.1128/JB.133.2.576-583.1978; SETO D, 1988, J BIOL CHEM, V263, P1494; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; TRETON BY, 1992, CURR GENET, V22, P345, DOI 10.1007/BF00352435; Valentin-Hansen P, 1978, Methods Enzymol, V51, P308; Visick JE, 1998, FEMS MICROBIOL LETT, V167, P19, DOI 10.1111/j.1574-6968.1998.tb13202.x; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; Wu J, 2003, J BIOL CHEM, V278, P18117, DOI 10.1074/jbc.M301983200; WURST H, 1994, J BIOL CHEM, V269, P10996; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200; Yakunin AF, 2004, J BIOL CHEM, V279, P36819, DOI 10.1074/jbc.M405120200; Zhang GF, 2004, BIOCHEMISTRY-US, V43, P4990, DOI 10.1021/bi036309n; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	70	77	83	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54687	54694		10.1074/jbc.M411023200	http://dx.doi.org/10.1074/jbc.M411023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489502	hybrid			2022-12-25	WOS:000225793600095
J	Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A				Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A			ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; ST18; chromosome 8q11	DNA METHYLATION; ZINC-FINGER; REGION; HETEROZYGOSITY; CARCINOGENESIS; IDENTIFICATION; INVOLVEMENT; PARAMETERS; MUTATIONS	We have identified a gene, ST18 ( suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type ( configuration Cys-X-5-Cys-X-12-His-X-4-Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany; Signature Diagnost AG, D-10719 Berlin, Germany; Atugen AG, D-13125 Berlin, Germany; Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany; Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Robert Rossle Hosp, Clin Surg & Surg Oncol, D-13122 Berlin, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Jandrig, B (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany.	jandrig@mdc-berlin.de	Siebert, Reiner/A-8049-2010					Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Astrom AK, 2000, INT J ONCOL, V16, P1107; Bardet V, 2002, GENE CHROMOSOME CANC, V33, P178, DOI 10.1002/gcc.10014; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bottger V, 1999, J MOL RECOGNIT, V12, P191; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Dahiya R, 1998, INT J ONCOL, V12, P811; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osborne RJ, 2000, CANCER RES, V60, P3706; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Zhang Y, 1999, CYTOGENET CELL GENET, V87, P115, DOI 10.1159/000015375	26	64	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2004	23	57					9295	9302		10.1038/sj.onc.1208131	http://dx.doi.org/10.1038/sj.onc.1208131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489893				2022-12-25	WOS:000225638000015
J	Chappell, KJ; Nall, TA; Stoermer, MJ; Fang, NX; Tyndall, JDA; Fairlie, DP; Young, PR				Chappell, KJ; Nall, TA; Stoermer, MJ; Fang, NX; Tyndall, JDA; Fairlie, DP; Young, PR			Site-directed mutagenesis and kinetic studies of the West Nile virus NS3 protease identify key enzyme-substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; RETRACTED ARTICLE. SEE; CRYSTAL-STRUCTURE; SERINE-PROTEASE; CLEAVAGE SITE; HOMOLOGY MODEL; DRUG DESIGN; DENGUE; PROTEINASE; FLAVIVIRUS	The flavivirus West Nile virus (WNV) has spread rapidly throughout the world in recent years causing fever, meningitis, encephalitis, and fatalities. Because the viral protease NS2B/NS3 is essential for replication, it is attracting attention as a potential therapeutic target, although there are currently no antiviral inhibitors for any flavivirus. This paper focuses on elucidating interactions between a hexapeptide substrate (Ae-KPGLKR-p-nitroanilide) and residues at S1 and S2 in the active site of WNV protease by comparing the catalytic activities of selected mutant recombinant proteases in vitro. Homology modeling enabled the predictions of key mutations in VWNV NS3 protease at S1 (V115A/F, D129A/ E/N, S135A, Y150A/F, S160A, and S163A) and S2 (N152A) that might influence substrate recognition and catalytic efficiency. Key conclusions are that the substrate P1 Arg strongly interacts with S1 residues Asp-129, Tyr-150, and Ser-163 and, to a lesser extent, Ser-160, and P2 Lys makes an essential interaction with Asn-152 at S2. The inferred substrate-enzyme interactions provide a basis for rational protease inhibitor design and optimization. High sequence conservation within flavivirus proteases means that this study may also be relevant to design of protease inhibitors for other flavivirus proteases.	Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Otago, Sch Pharm, Dunedin 9015, New Zealand	University of Queensland; University of Queensland; University of Otago	Young, PR (corresponding author), Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia.	p.young@uq.edu.au	Fairlie, David P/F-8865-2014; Young, Paul R/A-6176-2010; Stoermer, Martin J/E-2317-2012; tyndall, joel/C-2803-2008	Fairlie, David P/0000-0002-7856-8566; Young, Paul R/0000-0002-2040-5190; Stoermer, Martin J/0000-0003-3445-2104; tyndall, joel/0000-0003-0783-1635				Abbenante G, 2000, LETT PEPT SCI, V7, P347, DOI 10.1023/A:1013016323676; Amberg SM, 1999, J VIROL, V73, P8083, DOI 10.1128/JVI.73.10.8083-8094.1999; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Buckley A, 2003, J GEN VIROL, V84, P2807, DOI 10.1099/vir.0.19341-0; *CBBG, XWINNMR VERS 2 6; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; Gussio R, 1996, J MED CHEM, V39, P1645, DOI 10.1021/jm9508088; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hicks RP, 2003, BIOPOLYMERS, V68, P459, DOI 10.1002/bip.10325; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; LIN C, 1993, VIROLOGY, V192, P596, DOI 10.1006/viro.1993.1076; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P6218, DOI 10.1073/pnas.90.13.6218; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; Tesh RB, 2002, EMERG INFECT DIS, V8, P1392, DOI 10.3201/eid0812.020229; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valle RPC, 1998, J VIROL, V72, P624, DOI 10.1128/JVI.72.1.624-632.1998; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; Wuthrich K, 1986, NMR PROTEINS NUCL AC	39	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2896	2903		10.1074/jbc.M409931200	http://dx.doi.org/10.1074/jbc.M409931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15494419	hybrid			2022-12-25	WOS:000226449100065
J	Papanikolopoulou, K; Schoehn, G; Forge, V; Forsyth, VT; Riekel, C; Hernandez, JF; Ruigrok, RWH; Mitraki, A				Papanikolopoulou, K; Schoehn, G; Forge, V; Forsyth, VT; Riekel, C; Hernandez, JF; Ruigrok, RWH; Mitraki, A			Amyloid fibril formation from sequences of a natural beta-structured fibrous protein, the adenovirus fiber	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SYNCHROTRON X-RAY; ELECTRON-MICROSCOPY; IN-VITRO; MOLECULAR-ORGANIZATION; CRYSTAL-STRUCTURE; CASPASE CLEAVAGE; FULL-LENGTH; TAU; PEPTIDE	Amyloid fibrils are fibrous beta-structures that derive from abnormal folding and assembly of peptides and proteins. Despite a wealth of structural studies on amyloids, the nature of the amyloid structure remains elusive; possible connections to natural, beta-structured fibrous motifs have been suggested. In this work we focus on understanding amyloid structure and formation from sequences of a natural, beta-structured fibrous protein. We show that short peptides (25 to 6 amino acids) corresponding to repetitive sequences from the adenovirus fiber shaft have an intrinsic capacity to form amyloid fibrils as judged by electron microscopy, Congo Red binding, infrared spectroscopy, and x-ray fiber diffraction. In the presence of the globular C-terminal domain of the protein that acts as a trimerization motif, the shaft sequences adopt a triple-stranded, beta-fibrous motif. We discuss the possible structure and arrangement of these sequences within the amyloid fibril, as compared with the one adopted within the native structure. A 6-amino acid peptide, corresponding to the last beta-strand of the shaft, was found to be sufficient to form amyloid fibrils. Structural analysis of these amyloid fibrils suggests that perpendicular stacking of beta-strand repeat units is an underlying common feature of amyloid formation.	UJF, CEA, Inst Biol Struct, CNRS,UMR 5075, F-38027 Grenoble, France; European Mol Biol Lab, F-38042 Grenoble, France; CEA Grenoble, Dept Reponse & Dynam, Unite Mixte Rech 5090, Lab Biophys Mol & Cellulaire, F-38054 Grenoble 9, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble, France; Univ Keele, Sch Chem & Phys, Lennard Jones Labs, Keele ST5 5BG, Staffs, England; European Synchrotron Radiat Facil, F-38042 Grenoble, France; Univ Grenoble 1, EA 2939, Lab Virol Mol & Struct, Grenoble 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; European Molecular Biology Laboratory (EMBL); CEA; Institut Laue-Langevin (ILL); Keele University; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Mitraki, A (corresponding author), Univ Crete, Dept Mat Sci & Technol, POB 2208, Iraklion 71003, Crete, Greece.	mitraki@materials.uoc.gr	Forsyth, V. Trevor/A-9129-2010; MITRAKI, Anna/A-6034-2014	Forsyth, V. Trevor/0000-0003-0380-3477; MITRAKI, Anna/0000-0001-5072-1939; Schoehn, Guy/0000-0002-1459-3201				Abraha A, 2000, J CELL SCI, V113, P3737; BAUER HH, 1995, J STRUCT BIOL, V115, P1, DOI 10.1006/jsbi.1995.1024; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Chroboczek J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P163; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; Giannetti AM, 2000, PROTEIN SCI, V9, P2427, DOI 10.1110/ps.9.12.2427; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; Hammersley A. P., 1998, ESRF98HA01T; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Inouye H, 2002, BIOPHYS J, V83, P1716, DOI 10.1016/S0006-3495(02)73939-8; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Jimenez JL, 2002, P NATL ACAD SCI USA, V99, P9196, DOI 10.1073/pnas.142459399; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Lashuel HA, 2000, J AM CHEM SOC, V122, P5262, DOI 10.1021/ja9937831; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; Luckey M, 2000, FEBS LETT, V468, P23, DOI 10.1016/S0014-5793(00)01184-4; Mitraki A, 2002, J STRUCT BIOL, V137, P236, DOI 10.1006/jsbi.2002.4447; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; NOVELLI A, 1991, VIROLOGY, V185, P365, DOI 10.1016/0042-6822(91)90784-9; Papanikolopoulou K, 2004, J MOL BIOL, V342, P219, DOI 10.1016/j.jmb.2004.07.008; Papanikolopoulou K, 2004, J BIOL CHEM, V279, P8991, DOI 10.1074/jbc.M311791200; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; RIEKEL C, 2002, FIBRE DIFFRACTION RE, V10, P11; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Serpell LC, 1999, METHOD ENZYMOL, V309, P526; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Shotton MW, 1998, J APPL CRYSTALLOGR, V31, P758, DOI 10.1107/S0021889898005287; Sikorski P, 2003, STRUCTURE, V11, P915, DOI 10.1016/S0969-2126(03)00149-7; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Squire J. M., 2003, FIBRE DIFFR REV, V11, P7; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; van Raaij MJ, 2001, J MOL BIOL, V314, P1137, DOI 10.1006/jmbi.2000.5204; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Wigley WC, 2002, NAT STRUCT BIOL, V9, P381, DOI 10.1038/nsb784; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	62	55	58	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2481	2490		10.1074/jbc.M406282200	http://dx.doi.org/10.1074/jbc.M406282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15513921	hybrid			2022-12-25	WOS:000226449100014
J	Giagtzoglou, N; Koumbanakis, A; Fullard, J; Zarifi, I; Delidakis, C				Giagtzoglou, N; Koumbanakis, A; Fullard, J; Zarifi, I; Delidakis, C			Role of the ScC terminus in transcriptional activation and E(spl) repressor recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; PRECURSOR SELECTION; ORGAN DEVELOPMENT; DROSOPHILA; HAIRY; ENHANCER; GENES; SPLIT; DIFFERENTIATION; SPECIFICATION	Neurogenesis in all animals is triggered by the activity of a group of basic helix-loop-helix transcription factors, the proneural proteins, whose expression endows ectodermal regions with neural potential. The eventual commitment to a neural precursor fate involves the interplay of these proneural transcriptional activators with a number of other transcription factors that fine tune transcriptional responses at target genes. Most prominent among the factors antagonizing proneural protein activity are the HES basic helix-loop-helix proteins. We have previously shown (1) that two HES proteins of Drosophila, E(spl)mgamma and E(spl)m7, interact with the proneural protein Sc and thereby get recruited onto Sc target genes to repress transcription. Using in vivo and in vitro assays we have now discovered an important dual role for the Sc C-terminal domain. On one hand it acts as a transcription activation domain, and on the other it is used to recruit E(spl) proteins. In vivo, the Sc C-terminal domain is required for E(spl) recruitment in an enhancer context-dependent fashion, suggesting that in some enhancers alternative interaction surfaces can be used to recruit E(spl) proteins.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Greece	Foundation for Research & Technology - Hellas (FORTH); University of Crete	Delidakis, C (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Vasilika Vouton, GR-71110 Iraklion, Greece.	delidaki@imbb.forth.gr		Delidakis, Christos/0000-0003-3912-701X				Alifragis P, 1997, P NATL ACAD SCI USA, V94, P13099, DOI 10.1073/pnas.94.24.13099; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bray S, 1998, SEMIN CELL DEV BIOL, V9, P591, DOI 10.1006/scdb.1998.0262; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Culi J, 1998, GENE DEV, V12, P2036, DOI 10.1101/gad.12.13.2036; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; ERICKSON JW, 1993, GENE DEV, V7, P1688, DOI 10.1101/gad.7.9.1688; Fashena SJ, 2000, METHOD ENZYMOL, V328, P14, DOI 10.1016/S0076-6879(00)28387-0; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Giagtzoglou N, 2003, DEVELOPMENT, V130, P259, DOI 10.1242/dev.00206; Hassan BA, 2000, GENE DEV, V14, P1852; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Jafar-Nejad H, 2003, GENE DEV, V17, P2966, DOI 10.1101/gad.1122403; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Jimenez G, 1997, MOL CELL BIOL, V17, P4355, DOI 10.1128/MCB.17.8.4355; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Quan XJ, 2004, DEVELOPMENT, V131, P1679, DOI 10.1242/dev.01055; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6	29	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1299	1305		10.1074/jbc.M408949200	http://dx.doi.org/10.1074/jbc.M408949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15507447	hybrid			2022-12-25	WOS:000226195200055
J	Pan, GJ; Pei, DQ				Pan, GJ; Pei, DQ			The stem cell pluripotency factor NANOG activates transcription with two unusually potent subdomains at its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT TRANSACTIVATION DOMAINS; SUSTAINING FACTOR; SELF-RENEWAL; ES CELLS; EXPRESSION; IDENTIFICATION; OCT-4; CLONING; MOUSE	Embryonic stem cells are pluripotent progenitors for virtually all cell types in our body and thus possess unlimited therapeutic potentials for regenerative medicine. NANOG, an NK-2 type homeodomain gene, has been proposed to play a key role in maintaining stem cell pluripotency presumably by regulating the expression of genes critical to stem cell renewal and differentiation. Here, we provide the evidence that NANOG behaves as a transcription activator with two unusually strong activation domains embedded in its C terminus. First, we identified these two transactivators by employing the Gal4-DNA binding domain fusion and reporter system and named them WR and CD2. Whereas CD2 contains no obvious structural motif, the WR or Trp repeat contains 10 pentapeptide repeats starting with a Trp in each unit. Substitution of Trp with Ala in each repeat completely abolished its activity, whereas mutations at the conserved Ser, Gln, and Asn had relatively minor or no effect on WR activity. We then validated the activities of WR and CD2 in NANOG by constructing a reporter plasmid bearing five NANOG binding sites. Deletion of both WR and CD2 from NANOG completely eliminated its transactivation function. Paradoxically, whereas the removal of CD2 reduced NANOG activity by similar to30-70%, the removal of WR not only did not diminish but actually enhanced its activity by similar to50-100% depending on the cell lines analyzed. These data suggest that either WR or CD2 is sufficient for NANOG to function as a transactivator.	Tsinghua Univ, Inst Biomed, Dept Biol Sci & Biotechnol,Inst Pharmacol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Tsinghua University; University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Tsinghua Univ, Inst Biomed, Dept Biol Sci & Biotechnol,Inst Pharmacol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	duanqing@aol.com	zhou, xingru/G-4442-2012	Pan, Guangjin/0000-0002-2378-7198				Audet J, 2004, EXPERT OPIN BIOL TH, V4, P631, DOI 10.1517/eobt.4.5.631.31058; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Constantinescu S, 2003, J CELL MOL MED, V7, P103, DOI 10.1111/j.1582-4934.2003.tb00209.x; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hart AH, 2004, DEV DYNAM, V230, P187, DOI 10.1002/dvdy.20034; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pan GJ, 2003, CELL RES, V13, P499, DOI 10.1038/sj.cr.7290193; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271	18	59	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1401	1407		10.1074/jbc.M407847200	http://dx.doi.org/10.1074/jbc.M407847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15502159	hybrid			2022-12-25	WOS:000226195200067
J	Fishman, A; Tao, Y; Rui, LY; Wood, TK				Fishman, A; Tao, Y; Rui, LY; Wood, TK			Controlling the regiospecific oxidation of aromatics via active site engineering of toluene para-monooxygenase of Ralstonia pickettii PKO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE METHANE MONOOXYGENASE; PSEUDOMONAS-STUTZERI OX1; METHYLOSINUS-TRICHOSPORIUM OB3B; METHYLOCOCCUS-CAPSULATUS BATH; ENHANCED 1-NAPHTHOL SYNTHESIS; BURKHOLDERIA-CEPACIA G4; O-XYLENE MONOOXYGENASE; DIRECTED EVOLUTION; TRICHLOROETHYLENE DEGRADATION; CHLOROFORM DEGRADATION	A primary goal of protein engineering is to control catalytic activity. Here we show that through mutagenesis of three active site residues, the catalytic activity of a multicomponent monooxygenase is altered so that it hydroxylates all three positions of toluene as well as both positions of naphthalene. Hence, for the first time, an enzyme has been engineered so that its regiospecific oxidation of a substrate can be controlled. Through the A107G mutation in the alpha-subunit of toluene para-monooxygenase, a variant was formed that hydroxylated toluene primarily at the ortho-position while converting naphthalene to 1-naphthol. Conversely, the A107T variant produced >98% p-cresol and p-nitrophenol from toluene and nitrobenzene, respectively, as well as produced 2-naphthol from naphthalene. The mutation I100S/G103S produced a toluene para-monooxygenase variant that formed 75% m-cresol from toluene and 100% m-nitrophenol from nitrobenzene; thus, for the first time a true meta-hydroxylating toluene monooxygenase was created.	Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut; University of Connecticut	Wood, TK (corresponding author), Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.	twood@engr.uconn.edu	Wood, Thomas/GWZ-2481-2022; Fishman, Ayelet/A-6293-2018	Wood, Thomas/0000-0001-8962-8571; Fishman, Ayelet/0000-0002-1644-9377; Wood, Thomas/0000-0002-6258-529X				Bertoni G, 1998, APPL ENVIRON MICROB, V64, P3626; Branden C, 1999, INTRO PROTEIN STRUCT, P14; Brazeau BJ, 2003, BIOCHEMISTRY-US, V42, P5618, DOI 10.1021/bi027429i; Burton SG, 2003, TRENDS BIOTECHNOL, V21, P543, DOI 10.1016/j.tibtech.2003.10.006; Bylina EJ, 2000, ASM NEWS, V66, P211; BYRNE AM, 1995, GENE, V154, P65, DOI 10.1016/0378-1119(94)00844-I; Byrne AM, 1996, J BACTERIOL, V178, P6327, DOI 10.1128/jb.178.21.6327-6337.1996; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; Dolfing Jan, 1993, Biodegradation, V4, P261, DOI 10.1007/BF00695974; EATON RW, 1995, J BACTERIOL, V177, P6983, DOI 10.1128/jb.177.23.6983-6988.1995; Fishman A, 2004, BIOTECHNOL BIOENG, V87, P779, DOI 10.1002/bit.20185; Fishman A, 2004, J BACTERIOL, V186, P3117, DOI 10.1128/JB.186.10.3117-3123.2004; FISHMAN A, 2004, IN PRESS BIOCATAL BI; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAIGLER BE, 1991, APPL ENVIRON MICROB, V57, P3156, DOI 10.1128/AEM.57.11.3156-3162.1991; HOWEGRANT M, 1991, KIRKOTHMER ENCY CHEM, V16, P994; Jahng D, 1996, BIOTECHNOL BIOENG, V51, P349, DOI 10.1002/(SICI)1097-0290(19960805)51:3&lt;349::AID-BIT10&gt;3.0.CO;2-H; JAHNG DJ, 1994, APPL ENVIRON MICROB, V60, P2473, DOI 10.1128/AEM.60.7.2473-2482.1994; Kahng HY, 2000, J BACTERIOL, V182, P1232, DOI 10.1128/JB.182.5.1232-1242.2000; Kirk O, 2002, CURR OPIN BIOTECH, V13, P345, DOI 10.1016/S0958-1669(02)00328-2; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; Leahy JG, 1996, APPL ENVIRON MICROB, V62, P825, DOI 10.1128/AEM.62.3.825-833.1996; Li Z, 2002, CURR OPIN CHEM BIOL, V6, P136, DOI 10.1016/S1367-5931(02)00296-X; Liebeton K, 2000, CHEM BIOL, V7, P709, DOI 10.1016/S1074-5521(00)00015-6; Luu PP, 1995, APPL MICROBIOL BIOT, V44, P259, DOI 10.1007/BF00164512; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; MCMURRY J, 2004, ORGANIC CHEM, P528; Mitchell KH, 2003, P NATL ACAD SCI USA, V100, P3784, DOI 10.1073/pnas.0636619100; Mitchell KH, 2002, BIOCHEMISTRY-US, V41, P3176, DOI 10.1021/bi012036p; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; OLSEN RH, 1994, J BACTERIOL, V176, P3749, DOI 10.1128/JB.176.12.3749-3756.1994; Park J, 2002, APPL ENVIRON MICROB, V68, P5231, DOI 10.1128/AEM.68.11.5231-5240.2002; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Perry R. H, 1973, CHEM ENG HDB; Pikus JD, 2000, BIOCHEMISTRY-US, V39, P791, DOI 10.1021/bi992187g; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; Reetz MT, 1997, ANGEW CHEM INT EDIT, V36, P2830, DOI 10.1002/anie.199728301; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Rui LY, 2005, APPL MICROBIOL BIOT, V66, P422, DOI 10.1007/s00253-004-1698-z; Rui LY, 2004, APPL ENVIRON MICROB, V70, P3246, DOI 10.1128/AEM.70.6.3246-3252.2004; Sakamoto T, 2001, APPL ENVIRON MICROB, V67, P3882, DOI 10.1128/AEM.67.9.3882-3887.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sazinsky MH, 2004, J BIOL CHEM, V279, P30600, DOI 10.1074/jbc.M400710200; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shim H, 2001, APPL MICROBIOL BIOT, V56, P265, DOI 10.1007/s002530100650; Smith CA, 2003, APPL ENVIRON MICROB, V69, P7385, DOI 10.1128/AEM.69.12.7385-7394.2003; Straathof AJJ, 2002, CURR OPIN BIOTECH, V13, P548, DOI 10.1016/S0958-1669(02)00360-9; Tao Y, 2004, APPL ENVIRON MICROB, V70, P3814, DOI 10.1128/AEM.70.7.3814-3820.2004; Tao Y, 2004, J BACTERIOL, V186, P4705, DOI 10.1128/JB.186.14.4705-4713.2004; van Beilen JB, 2003, TRENDS BIOTECHNOL, V21, P170, DOI 10.1016/S0167-7799(03)00032-5; Vardar G, 2004, APPL ENVIRON MICROB, V70, P3253, DOI 10.1128/AEM.70.6.3253-3262.2004; Vardar G, 2005, J BIOTECHNOL, V115, P145, DOI 10.1016/j.jbiotec.2004.08.008; Zhou NY, 1998, FEBS LETT, V430, P181, DOI 10.1016/S0014-5793(98)00653-X	58	56	63	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					506	514		10.1074/jbc.M410320200	http://dx.doi.org/10.1074/jbc.M410320200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498762	hybrid			2022-12-25	WOS:000226025100060
J	Johnson, CP; Fujimoto, I; Rutishauser, U; Leckband, DE				Johnson, CP; Fujimoto, I; Rutishauser, U; Leckband, DE			Direct evidence that neural cell adhesion molecule (NCAM) polysialylation increases intermembrane repulsion and abrogates adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; GLYCOPROTEINS; BINDING; FORCES	Molecular force measurements quantified the impact of polysialylation on the adhesive properties both of membrane-bound neural cell adhesion molecule (NCAM) and of other proteins on the same membrane. These results show quantitatively that NCAM polysialylation increases the range and magnitude of intermembrane repulsion. The repulsion is sufficient to overwhelm both homophilic NCAM and cadherin attraction at physiological ionic strength, and it abrogates the protein-mediated intermembrane adhesion. The steric repulsion is ionic strength dependent and decreases substantially at high monovalent salt concentrations with a concomitant increase in the intermembrane attraction. The magnitude of the repulsion also depends on the amount of polysialic acid (PSA) on the membranes, and the PSA-dependent attenuation of cadherin adhesion increases with increasing PSA-NCAM:cadherin ratios. These findings agree qualitatively with independent reports based on cell adhesion studies and reveal the likely molecular mechanism by which NCAM polysialylation regulates cell adhesion and intermembrane space.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Memorial Sloan Kettering Cancer Center	Leckband, DE (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.	leckband@uiuc.edu		Fujimoto, Ichiro/0000-0001-7088-6407; Johnson, Colin/0000-0002-6783-2835	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063536] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM63536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Chen Y, 1999, METHODS, V19, P234, DOI 10.1006/meth.1999.0854; Derjaguin B, 1934, KOLLOID Z, V69, P155, DOI 10.1007/BF01433225; FINNE J, 1985, J BIOL CHEM, V260, P1265; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; ISRAELACHVILI JN, 1992, SURF SCI REP, V14, P109, DOI 10.1016/0167-5729(92)90015-4; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Leckband D, 2000, ANNU REV BIOPH BIOM, V29, P1, DOI 10.1146/annurev.biophys.29.1.1; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; Muller JD, 2003, METHOD ENZYMOL, V361, P69; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; PINCUS P, 1991, MACROMOLECULES, V24, P2912, DOI 10.1021/ma00010a043; Prosser RA, 2003, J NEUROSCI, V23, P652, DOI 10.1523/JNEUROSCI.23-02-00652.2003; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sanchez SA, 2001, BIOCHEMISTRY-US, V40, P6903, DOI 10.1021/bi001599i; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Tanaka F, 2000, CANCER RES, V60, P3072; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YANG PF, 1994, J BIOL CHEM, V269, P23039; Yeung C, 1997, LANGMUIR, V13, P6746, DOI 10.1021/la970830z; Yeung C, 1999, LANGMUIR, V15, P6829, DOI 10.1021/la990019j; Zhu B, 2003, BIOPHYS J, V84, P4033, DOI 10.1016/S0006-3495(03)75129-7	29	178	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					137	145		10.1074/jbc.M410216200	http://dx.doi.org/10.1074/jbc.M410216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504723	hybrid			2022-12-25	WOS:000226025100018
J	Schneider, A; Araujo, GW; Trajkovic, K; Herrmann, MM; Merkler, D; Mandelkow, EM; Weissert, R; Simons, M				Schneider, A; Araujo, GW; Trajkovic, K; Herrmann, MM; Merkler, D; Mandelkow, EM; Weissert, R; Simons, M			Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; MULTIPLE-SCLEROSIS; AXONAL DAMAGE; ACTIVATOR P35; PHOSPHORYLATION; CDK5; BRAIN; KINASE; P25	Axonal damage is a major morphological correlate and cause of permanent neurological deficits in patients with multiple sclerosis (MS), a multifocal, inflammatory and demyelinating disease of the central nervous system. Hyperphosphorylation and pathological aggregation of microtubule-associated protein tau is a common feature of many neurodegenerative diseases with axonal degeneration including Alzheimer's disease. We have therefore analyzed tau phosphorylation, solubility and distribution in the brainstem of rats with experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Tau was hyperphosphorylated at several sites also phosphorylated in Alzheimer's disease and became partially detergent-insoluble in EAE brains. Morphological examination demonstrated accumulation of amorphous deposits of abnormally phosphorylated tau in the cell body and axons of neurons within demyelinating plaques. Hyperphosphorylation of tau was accompanied by up-regulation of p25, an activator of cyclin-dependent kinase 5. Phosphorylation of tau, activation of cdk5, and axonal pathology were significantly reduced when diseased rats were treated with prednisolone, a standard therapy of acute relapses in MS. Hyperphosphorylation of tau was not observed in a genetic or nutritional model of axonal degeneration or demyelination, suggesting that inflammation as detected in the brains of rats with EAE is the specific trigger of tau pathology. In summary, our data provide evidence that axonal damage in EAE and possibly MS is linked to tau pathology.	Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol, D-72076 Tubingen, Germany; Univ Gottingen, Ctr Biochem & Mol Cell Biol, D-37075 Gottingen, Germany; Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; Univ Gottingen, Dept Neuropathol, D-37099 Gottingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Gottingen; Max Planck Society; University of Gottingen	Weissert, R (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	robert.weissert@uni-tuebingen.de; msimons@gwdg.de	Weissert, Robert/AAA-4791-2019; Trajkovic, Katarina/AAJ-4219-2021; Weissert, Robert/B-2585-2009; Schneider, Anja/F-5293-2010; Merkler, Doron/N-9157-2016	Trajkovic, Katarina/0000-0002-2716-1491; Weissert, Robert/0000-0002-1295-1271; Simons, Mikael/0000-0001-5329-192X; Schneider, Anja/0000-0001-9540-8700; Merkler, Doron/0000-0002-0247-2007				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Friedhoff P, 2000, BBA-MOL BASIS DIS, V1502, P122, DOI 10.1016/S0925-4439(00)00038-7; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hamdane M, 2003, J BIOL CHEM, V278, P34026, DOI 10.1074/jbc.M302872200; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kins S, 2001, J BIOL CHEM, V276, P38193; Kornek B, 1999, BRAIN PATHOL, V9, P651; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shields DC, 1999, J NEUROSCI RES, V55, P533, DOI 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8; Shin T, 2003, J NEUROIMMUNOL, V140, P118, DOI 10.1016/S0165-5728(03)00174-7; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382	51	47	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55833	55839		10.1074/jbc.M409954200	http://dx.doi.org/10.1074/jbc.M409954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494405	hybrid			2022-12-25	WOS:000225960800106
J	Tan, W; Kim, S; Boyer, TG				Tan, W; Kim, S; Boyer, TG			Tetrameric oligomerization mediates transcriptional repression by the BRCA1-dependent Kruppel-associated box-zinc finger protein ZBRK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; KRAB; CELLS; SUBFAMILY; DOMAINS; FAMILY; BRCA1; KS1	The Kruppel-associated box (KRAB)-zinc finger protein ZBRK1 has been implicated in the transcriptional regulation of DNA damage-response genes that function in cell growth control and survival. Recently, we described a novel BRCA1-dependent C-terminal transcriptional repression domain (CTRD) within ZBRK1, the mode of repression of which is functionally distinguishable from that of the N-terminal KRAB repression domain within ZBRK1. The identification of BRCA1 binding-competent but repression-defective CTRD mutants further revealed that BRCA1 binding is necessary, but not sufficient, for ZBRK1 CTRD function. During an unbiased search for possible co-regulators of the CTRD, we identified ZBRK1 itself, suggesting that ZBRK1 can oligomerize through its CTRD. Herein we explore the physical and functional requirements for ZBRK1 oligomerization in ZBRK1-directed transcriptional repression. Protein interaction analyses confirmed that ZBRK1 can homo-oligomerize both in vitro and in vivo and further mapped the ZBRK1 oligomerization domain to the CTRD C terminus. Biochemical analyses, including protein cross-linking and gel filtration chromatography, revealed that ZBRK1 homo-oligomers exist as tetramers in solution. Functionally, ZBRK1 oligomerization facilitates ZBRK1-directed transcriptional repression through ZBRK1 response elements; requirements for oligomerization-dependent repression include the ZBRK1 CTRD and KRAB repression domains but not the DNA binding activity of ZBRK1. These observations suggest that higher order oligomers of ZBRK1 may assemble on target ZBRK1 response elements through both protein-DNA and CTRD-dependent protein-protein interactions. These findings thus reveal an unanticipated dual function for ZBRK1 in both DNA binding-dependent and -independent modes of transcriptional repression and further establish the CTRD as a novel protein interaction surface responsible for directing homotypic and heterotypic interactions necessary for ZBRK1-directed transcriptional repression.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Boyer, TG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	boyer@uthscsa.edu			NATIONAL CANCER INSTITUTE [R01CA098301] Funding Source: NIH RePORTER; NCI NIH HHS [CA 098301-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; Krebs CJ, 2003, GENE DEV, V17, P2664, DOI 10.1101/gad.1135703; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Ran QT, 2001, EXP CELL RES, V263, P156, DOI 10.1006/excr.2000.5068; Schumacher C, 2000, J BIOL CHEM, V275, P17173, DOI 10.1074/jbc.M000119200; Shannon M, 2003, GENOME RES, V13, P1097, DOI 10.1101/gr.963903; Shannon M, 1996, GENOMICS, V33, P112, DOI 10.1006/geno.1996.0166; Shannon M, 1998, DNA SEQUENCE, V8, P303, DOI 10.3109/10425179809034075; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	26	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55153	55160		10.1074/jbc.M410926200	http://dx.doi.org/10.1074/jbc.M410926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496401	hybrid			2022-12-25	WOS:000225960800022
J	Turnbull, CI; Looi, K; Mangum, JE; Meyer, M; Sayer, RJ; Hubbard, MJ				Turnbull, CI; Looi, K; Mangum, JE; Meyer, M; Sayer, RJ; Hubbard, MJ			Calbindin independence of calcium transport in developing teeth contradicts the calcium ferry dogma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTAL ENAMEL CELLS; VITAMIN-D-RECEPTOR; ENDOPLASMIC-RETICULUM; RENAL CALBINDIN-D28K; PURKINJE-CELLS; KNOCKOUT MICE; CA2+; PROTEIN; ABSORPTION; EXPRESSION	Cytosolic calcium-binding proteins termed calbindins are widely regarded as a key component of the machinery used to transport calcium safely across cells. Acting as mobile buffers, calbindins are thought to ferry calcium in bulk and simultaneously protect against its potentially cytotoxic effects. Here, we contradict this dogma by showing that teeth and bones were produced normally in null mutant mice lacking calbindin(28kDa). Structural analysis of dental enamel, the development of which depends critically on active calcium transport, showed that mineralization was unaffected in calbindin(28kDa)-null mutants. An unchanged rate of calcium transport was verified by measurements of Ca-45 incorporation into developing teeth in vivo. In enamel-forming cells, the absence of calbindin(28kDa) was not compensated by other cytosolic calcium-binding proteins as detectable by Ca-45 overlay, two-dimensional gel, and equilibrium binding analyses. Despite a 33% decrease in cytosolic buffer capacity, cytotoxicity was not evident in either the null mutant enamel or its formative cells. This is the first definitive evidence that calbindins are not required for active calcium transport, either as ferries or as facilitative buffers. Moreover, in challenging the broader notion of a cytosolic route for calcium, the findings support an alternative paradigm involving passage via calcium-tolerant organelles.	Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Sch Dent Sci, Parkville, Vic 3052, Australia; Univ Otago, Dept Biochem, Dunedin 9001, New Zealand; Univ Otago, Dept Physiol, Dunedin 9001, New Zealand; Univ Munich, Inst Physiol, D-80336 Munich, Germany	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Otago; University of Otago; University of Munich	Hubbard, MJ (corresponding author), Royal Childrens Hosp, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia.	mike.hubbard@unimelb.edu.au	Hubbard, Mike (Michael) J/AAE-6573-2022	Hubbard, Mike (Michael) J/0000-0002-5432-9421				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Barski JJ, 2003, J NEUROSCI, V23, P3469; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; BERDAL A, 1993, DEV BIOL, V155, P172, DOI 10.1006/dbio.1993.1016; Berdal A, 1996, J BONE MINER RES, V11, P768; Bronner F, 2003, J CELL BIOCHEM, V88, P387, DOI 10.1002/jcb.10330; Christakos S, 2004, J STEROID BIOCHEM, V89-90, P401, DOI 10.1016/j.jsbmb.2004.03.007; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; Franklin IK, 2001, BIOCHEM J, V358, P217, DOI 10.1042/0264-6021:3580217; HEMMINGSEN C, 1995, CALCIFIED TISSUE INT, V56, P372, DOI 10.1007/BF00301605; Hemmingsen C, 1997, KIDNEY BLOOD PRESS R, V20, P247, DOI 10.1159/000174153; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; HUBBARD MJ, 1982, J DENT RES, V61, P14, DOI 10.1177/00220345820610010201; Hubbard MJ, 1998, CONNECT TISSUE RES, V38, P17, DOI 10.3109/03008209809017013; Hubbard MJ, 1996, EUR J BIOCHEM, V239, P611, DOI 10.1111/j.1432-1033.1996.0611u.x; Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x; HUBBARD MJ, 1995, EUR J BIOCHEM, V230, P68, DOI 10.1111/j.1432-1033.1995.0068i.x; Hubbard MJ, 2000, CRIT REV ORAL BIOL M, V11, P437, DOI 10.1177/10454411000110040401; Larsson Dennis, 2002, Journal of Biomedicine & Biotechnology, V2, P117, DOI 10.1155/S1110724302205045; Lee CT, 2002, KIDNEY INT, V62, P2055, DOI 10.1046/j.1523-1755.2002.00670.x; LIMEBACK H, 1992, J DENT RES, V71, P346, DOI 10.1177/00220345920710020101; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nijenhuis T, 2004, J AM SOC NEPHROL, V15, P549, DOI 10.1097/01.ASN.0000113318.56023.B6; Nijenhuis T, 2003, KIDNEY INT, V64, P555, DOI 10.1046/j.1523-1755.2003.00128.x; Peng JB, 2003, NEWS PHYSIOL SCI, V18, P158, DOI 10.1152/nips.01440.2003; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; Sayer RJ, 2000, CELL TISSUE RES, V302, P171, DOI 10.1007/s004410000285; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413; Song YR, 2003, J NUTR, V133, P374, DOI 10.1093/jn/133.2.374; Sooy K, 2000, CURR OPIN NEPHROL HY, V9, P341, DOI 10.1097/00041552-200007000-00004; Sooy K, 1999, J BIOL CHEM, V274, P34343, DOI 10.1074/jbc.274.48.34343; Takano Y, 1995, Connect Tissue Res, V33, P127, DOI 10.3109/03008209509016992; TIMMERMANS JAH, 1995, J NUTR, V125, pS1981, DOI 10.1093/jn/125.suppl_7.1981S; WASSERMAN RH, 1995, J NUTR, V125, pS1971, DOI 10.1093/jn/125.suppl_7.1971S; WOOD JD, 2004, J ASS RES OTOLARYNGO	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55850	55854		10.1074/jbc.M409299200	http://dx.doi.org/10.1074/jbc.M409299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494408	hybrid			2022-12-25	WOS:000225960800108
J	Colley, WC; van der Merwe, M; Vance, JR; Burgin, AB; Bjornsti, MA				Colley, WC; van der Merwe, M; Vance, JR; Burgin, AB; Bjornsti, MA			Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN; YEAST; MECHANISMS; COVALENT; CELLS; RESISTANCE; SENSITIVITY; COMPLEXES; MUTANTS; REPAIR	Eukaryotic DNA topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA and constitutes the cellular target of camptothecin (CPT). Mutation of conserved residues in close proximity to the active site tyrosine (Tyr(727) of yeast Top1p) alters the DNA cleavage religation equilibrium, inducing drug-independent cell lethality. Previous studies indicates that yeast Top1T722Ap and Top1N726Hp cytotoxicity results from elevated levels of covalent enzyme-DNA intermediates. Here we show that Top1T722Ap acts as a CPT mimetic by exhibiting reduced rates of DNA religation, whereas increased Top1N726Hp.DNA complexes result from elevated DNA binding and cleavage. We also report that the combination of the T722A and N726H mutations in a single protein potentiates the cytotoxic action of the enzyme beyond that induced by co-expression of the single mutants. Moreover, the addition of CPT to cells expressing the double top1T722A/N726H mutant did not enhance cell lethality. Thus, independent alterations in DNA cleavage and religation contribute to the lethal phenotype. The formation of distinct cytotoxic lesions was also evidenced by the different responses induced by low levels of these self-poisoning enzymes in isogenic strains defective for the Rad9 DNA damage checkpoint, processive DNA replication, or ubiquitin-mediated proteolysis. Substitution of Asn(726) with Phe or Tyr also produces self-poisoning enzymes, implicating stacking interactions in the increased kinetics of DNA cleavage by Top1N726Hp and Top1N726Fp. In contrast, replacing the amide side chain of Asn(726) with Gln renders Top1N726Qp resistant to CPT, suggesting that the orientation of the amide within the active site is critical for effective CPT binding.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; deCODE Genet Inc, Biostruct Grp, Bainbridge Isl, WA 98110 USA	St Jude Children's Research Hospital	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38105 USA.	mary-ann.bjornsti@stjude.org			NCI NIH HHS [CA21765, CA58755] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA058755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Bjornsti MA, 2002, CANCER CELL, V2, P267, DOI 10.1016/S1535-6108(02)00160-5; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2000, ANN NY ACAD SCI, V922, P56; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; KAISER C, 1994, METHODS YEAST GENETI, P133; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Simon JA, 2000, CANCER RES, V60, P328; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Zhang H, 2003, MUTAT RES-FUND MOL M, V527, P37, DOI 10.1016/S0027-5107(03)00074-5	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54069	54078		10.1074/jbc.M409764200	http://dx.doi.org/10.1074/jbc.M409764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489506	hybrid			2022-12-25	WOS:000225793600024
J	Gingras, S; Parganas, E; de Pauw, A; Ihle, JN; Murray, PJ				Gingras, S; Parganas, E; de Pauw, A; Ihle, JN; Murray, PJ			Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNALING-1; GENE-EXPRESSION; IFN-GAMMA; NEGATIVE REGULATION; IN-VIVO; SUPPRESSOR; MACROPHAGES; MICE; LIPOPOLYSACCHARIDE; INHIBITION	Suppressor of cytokine signaling 1 (SOCS1) is an obligate negative regulator of cytokine signaling and most importantly in vivo, signaling via the interferon-gamma (IFN-gamma) receptor. SOCS1, via its Src homology 2 domain, binds to phosphotyrosine residues in its targets, reducing the amplitude of signaling from cytokine receptors. SOCS1 is also implicated in blocking Toll-like receptor (TLR) signaling in macrophages activated by TLR agonists such as lipopolysaccharide (LPS), thus regulating multiple steps in the activation of innate immune responses. To rigorously test this, we isolated macrophages from Socs1-/- mice on multiple genetic backgrounds. We found no evidence that SOCS1 blocked TLR-activated pathways, endotoxin tolerance, or nitric oxide production. However, Socs1-/-; IFN-gamma-/- mice were extremely susceptible to LPS challenge, confirming previous findings. Because LPS induces IFN-beta production from macrophages, we tested whether SOCS1 regulates IFN-alpha/beta receptor signaling. We find that SOCS1 is required to inhibit IFN-alpha/beta receptor signaling in vitro. Furthermore, the absence of a single allele encoding TYK2, a JAK ( Janus kinase) family member essential IFN-alpha/beta receptor signaling, rescued Socs1-/- mice from early lethality, even in the presence of IFN-gamma. We conclude that previous reports linking SOCS1 to TLR signaling are most likely due to effects on IFN-alpha/beta receptor signaling.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital	Murray, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.murray@stjude.org	Murray, Peter J/K-4725-2018	Murray, Peter J/0000-0001-6329-9802	NIAID NIH HHS [AI53478-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI053478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chong MMW, 2003, IMMUNITY, V18, P475, DOI 10.1016/S1074-7613(03)00078-5; Cornish AL, 2003, J BIOL CHEM, V278, P22755, DOI 10.1074/jbc.M303021200; Cornish AL, 2003, J IMMUNOL, V170, P878, DOI 10.4049/jimmunol.170.2.878; Crespo A, 2000, BIOCHEM J, V349, P99, DOI 10.1042/0264-6021:3490099; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Kamezaki K, 2004, INT IMMUNOL, V16, P1173, DOI 10.1093/intimm/dxh118; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Lang R, 2002, J IMMUNOL, V168, P3402, DOI 10.4049/jimmunol.168.7.3402; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Shimoda K, 2002, BLOOD, V99, P2094, DOI 10.1182/blood.V99.6.2094; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774	29	108	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54702	54707		10.1074/jbc.M411043200	http://dx.doi.org/10.1074/jbc.M411043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15491990	hybrid			2022-12-25	WOS:000225793600097
J	Li, Z; David, G; Hung, KW; DePinho, RA; Fu, AKY; Ip, NY				Li, Z; David, G; Hung, KW; DePinho, RA; Fu, AKY; Ip, NY			Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; HISTONE DEACETYLASE ACTIVITY; COREPRESSOR COMPLEX; NEURONAL MIGRATION; INTEGRAL COMPONENT; GENE-TRANSCRIPTION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; PROTEIN-KINASE; BOVINE BRAIN	Cyclin-dependent kinase 5 (Cdk5), a serine/threonine kinase that displays kinase activity predominantly in neurons, is activated by two non-cyclin activators, p35 or p39. Here, we report a physical and functional interaction between the Cdk5/p35 complex and mouse Sds3 (mSds3), an essential component of mSin3-histone deacetylase ( HDAC) co-repressor complex. mSds3 binds to p35 both in vitro and in vivo, enabling active Cdk5 to phosphorylate mSds3 at serine 228. A mSds3 S228A mutant retained mSin3 binding activity, but its dimerization was not greatly enhanced by p35 when compared with wild type. Notably, p35 overexpression augmented mSds3-mediated transcriptional repression in vitro. Interestingly, mutational studies revealed that the ability of exogenous mSds3 to rescue cell growth and viability in mSds3 null cells correlates with its ability to be phosphorylated by Cdk5. The identification of mSds3 as a substrate of the Cdk5/p35 complex reveals a new regulatory mechanism in controlling the mSin3-HDAC transcriptional repressor activity and provides a new potential therapeutic means to inhibit specific HDAC activities in disease.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China; Dana Farber Canc Inst, Dept Med Oncol Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK		DePinho, Ronald/0000-0002-5625-577X; Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Fu, Kit Yu/0000-0003-4085-6201; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Cheng K, 2003, NEUROSIGNALS, V12, P180, DOI 10.1159/000074619; Cheng K, 2002, J BIOL CHEM, V277, P31988, DOI 10.1074/jbc.M201161200; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fu AKY, 1999, MOL CELL NEUROSCI, V14, P241, DOI 10.1006/mcne.1999.0784; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Fu WY, 2002, NEUROREPORT, V13, P243, DOI 10.1097/00001756-200202110-00014; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; Lin H, 2004, J BIOL CHEM, V279, P29302, DOI 10.1074/jbc.M403664200; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Mattson MP, 2003, AGEING RES REV, V2, P329, DOI 10.1016/S1568-1637(03)00013-8; Morabito MA, 2004, J NEUROSCI, V24, P865, DOI 10.1523/JNEUROSCI.4582-03.2004; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi RZ, 2004, FEBS LETT, V561, P177, DOI 10.1016/S0014-5793(04)00174-7; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xie ZG, 2004, CELL CYCLE, V3, P108; Zhang JW, 2002, J NEUROCHEM, V81, P307, DOI 10.1046/j.1471-4159.2002.00824.x; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	40	28	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54438	54444		10.1074/jbc.M411002200	http://dx.doi.org/10.1074/jbc.M411002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489224	hybrid, Green Published			2022-12-25	WOS:000225793600066
J	Rodolfo, C; Mormone, E; Matarrese, P; Ciccosanti, F; Farrace, MG; Garofano, E; Piredda, L; Fimia, GM; Malorni, W; Piacentini, M				Rodolfo, C; Mormone, E; Matarrese, P; Ciccosanti, F; Farrace, MG; Garofano, E; Piredda, L; Fimia, GM; Malorni, W; Piacentini, M			Tissue transglutaminase is a multifunctional BH3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN NEUROBLASTOMA-CELLS; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; GTP-BINDING PROTEIN; RETINOIC ACID; ANTENNAPEDIA HOMEODOMAIN; PERMEABILITY TRANSITION; MITOCHONDRIAL-MEMBRANE; BH3 DOMAIN	Tissue transglutaminase (TG2) protein accumulates to high levels in cells during early stages of apoptosis both in vivo and in vitro. The analysis of the TG2 primary sequence showed the presence of an eight amino acid domain, sharing 70% identity with the Bcl-2 family BH3 domain. Cell-permeable peptides, mimicking the domain sequence, were able to induce Bax conformational change and translocation to mitochondria, mitochondrial depolarization, release of cytochrome c, and cell death. Moreover, we found that the TG2-BH3 peptides as well as TG2 itself were able to interact with the pro-apoptotic Bcl-2 family member Bax, but not with anti-apoptotic members Bcl-2 and Bcl-XL. Mutants in the TG2-BH3 domain failed to sensitize cells toward apoptosis. In TG2-overexpressing cells about half of the protein is localized on the outer mitochondrial membrane where, upon cell death induction, it cross-links many protein substrates including Bax. TG2 is the first member of a new subgroup of multifunctional BH3-only proteins showing a large mass size (80 kDa) and enzymatic activity.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Dept Drug Res & Evaluat, Sect Cell Aging & Degenerat, I-00161 Rome, Italy; IRCCS Lazzaro Spallanzani, INMI, Cell Biol Lab, I-00149 Rome, Italy; IRCCS Lazzaro Spallanzani, INMI, EM, I-00149 Rome, Italy	University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); IRCCS Lazzaro Spallanzani; IRCCS Lazzaro Spallanzani	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	mauro.piacentini@uniroma2.it	Rodolfo, Carlo/H-8953-2019; Ciccosanti, Fabiola/B-5284-2017; Mormone, Elisabetta/AAB-1736-2021; Matarrese, Paola/A-4369-2014; Piacentini, Mauro/I-2411-2016; Malorni, Walter/G-5874-2016; Fimia, Gian Maria/K-3232-2016	Rodolfo, Carlo/0000-0001-7087-545X; Ciccosanti, Fabiola/0000-0003-0481-6878; Piacentini, Mauro/0000-0003-2919-1296; Fimia, Gian Maria/0000-0003-4438-3325; malorni, walter/0000-0002-1223-7000				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Bernassola F, 1999, ANN NY ACAD SCI, V887, P83, DOI 10.1111/j.1749-6632.1999.tb07924.x; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Ikura K, 1998, ARCH BIOCHEM BIOPHYS, V356, P280, DOI 10.1006/abbi.1998.0775; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nardacci R, 2003, CELL DEATH DIFFER, V10, pS79, DOI 10.1038/sj.cdd.4401112; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Piacentini M, 1999, IMMUNOL TODAY, V20, P130, DOI 10.1016/S0167-5699(98)01416-9; Piacentini M, 1994, Prog Clin Biol Res, V385, P123; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Szegezdi E, 2000, CELL DEATH DIFFER, V7, P1225, DOI 10.1038/sj.cdd.4400751; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2001, METHOD CELL BIOL, V65, P147, DOI 10.1016/S0091-679X(01)65009-X	51	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54783	54792		10.1074/jbc.M410938200	http://dx.doi.org/10.1074/jbc.M410938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485857	hybrid, Green Published			2022-12-25	WOS:000225793600106
J	Srisodsai, A; Kurotani, R; Chiba, Y; Sheikh, F; Young, HA; Donnelly, RP; Kimura, S				Srisodsai, A; Kurotani, R; Chiba, Y; Sheikh, F; Young, HA; Donnelly, RP; Kimura, S			Interleukin-10 induces uteroglobin-related protein (UGRP) 1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; FACTOR-I; CYTOKINE PRODUCTION; HOMEOBOX GENE; DNA-BINDING; B GENE; A GENE; IL-10; PROMOTER; RECEPTOR	UGRP1 is a downstream target gene for homeodomain transcription factor T/EBP/NKX2.1, which is predominantly expressed in lung epithelial cells, and may play an anti-inflammatory role in lung inflammation. To understand the role of UGRP1 in inflammation, its expression was investigated in relation to cytokine signaling. In vivo experiments using mouse embryonic lung organ culture and intranasal administration of interleukin (IL) 10 revealed that constitutive expression of Ugrp1 mRNA is enhanced by IL-10. Increase of protein levels was also demonstrated by immunohistochemistry using embryonic lungs. This IL-10 induction of Ugrp1 gene expression occurs at the transcriptional level when examined using mouse embryonic lung primary cultures. In human lung NCI-H441 cells that in contrast to mouse lung cells, do not exhibit constitutive expression of the gene, expression of the UGRP1 gene was induced in a rapid and stable fashion. Two T/EBP, but not STAT3, binding sites located in the human UGRP1 gene promoter are responsible for IL-10 induction of the UGRP1 gene as judged by transfection, gel shift, and chromatin immunoprecipitation analyses. The IL-10 receptor chains, IL-10R1 and IL-10R2, are expressed in H441 cells, however, STAT3 was only weakly activated upon IL-10 treatment. In contrast, STAT3 was strongly activated when the cells were treated with other cytokines such as IL-22 and interferon-beta but UGRP1 expression was not increased. Together these results demonstrate that IL-10 induces UGRP1 gene expression in lung epithelial cells through a T/EBP/NKX2.1-dependent pathway. The results further suggest that UGRP1 might be a target for IL-10 anti-inflammatory activities in the lung.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; US FDA, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; NCI, Expt Immunol Lab, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kimura, S (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 3112B,9000 Rockville Pike, Bethesda, MD 20892 USA.	shioko@helix.nih.gov	Donnelly, Raymond P./AFT-8600-2022; Young, Howard/A-6350-2008	Donnelly, Raymond P./0000-0002-0695-5276; Young, Howard/0000-0002-3118-5111	NATIONAL CANCER INSTITUTE [Z01BC010449, ZIABC010449] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; Bin LH, 2003, J IMMUNOL, V171, P924, DOI 10.4049/jimmunol.171.2.924; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; Denning TL, 2000, INT IMMUNOL, V12, P133, DOI 10.1093/intimm/12.2.133; Donnelly RP, 2004, J LEUKOCYTE BIOL, V76, P314, DOI 10.1189/jlb.0204117; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KIKKAWA F, 1990, MOL CELL BIOL, V10, P6216, DOI 10.1128/MCB.10.12.6216; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Liu Y, 1997, J IMMUNOL, V158, P604; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Niimi T, 2002, CYTOGENET GENOME RES, V97, P120, DOI 10.1159/000064067; Niimi T, 2002, AM J HUM GENET, V70, P718, DOI 10.1086/339272; Niimi T, 2001, MOL ENDOCRINOL, V15, P2021, DOI 10.1210/me.15.11.2021; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Rolfe FG, 1997, AM J RESP CELL MOL, V17, P243, DOI 10.1165/ajrcmb.17.2.2819; Ruan SB, 2002, INFECT IMMUN, V70, P6107, DOI 10.1128/IAI.70.11.6107-6113.2002; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; Wang M, 2003, BRIT J CANCER, V88, P1605, DOI 10.1038/sj.bjc.6600855; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yuan BB, 2000, DEV DYNAM, V217, P180, DOI 10.1002/(SICI)1097-0177(200002)217:2<180::AID-DVDY5>3.0.CO;2-3; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	46	21	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54358	54368		10.1074/jbc.M405331200	http://dx.doi.org/10.1074/jbc.M405331200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485815	hybrid			2022-12-25	WOS:000225793600058
J	Zhou, SX; Schmelz, A; Seufferlein, T; Li, YP; Zhao, JS; Bachem, MG				Zhou, SX; Schmelz, A; Seufferlein, T; Li, YP; Zhao, JS; Bachem, MG			Molecular mechanisms of low intensity pulsed ultrasound in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIN STRESS FIBERS; BINDING PROTEIN RHO; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; THERAPEUTIC ULTRASOUND; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; ADHESION; REQUIRES	Soluble factors such as polypeptide growth factors, mitogenic lipids, inflammatory cytokines, and hormones are known regulators of cell proliferation. However, the effect of mechanical stimuli on cell proliferation is less well understood. Here we examined the effect of low intensity pulsed ultrasound ( US), which is used to promote wound healing, on the proliferation of primary human foreskin fibroblasts and the underlying signaling mechanisms. We show that a single 6-11-min US stimulation increases bromodeoxyuridine incorporation. In addition, an increase in the total cell number is observed after sequential US stimulation. US induced stress fiber and focal adhesion formation via activation of Rho. We further observed that US selectively induced activation of extracellular signal-regulated kinase (ERK) 1/2. Inhibition of Rho-associated coiled-coil-containing protein kinase ( ROCK) prevented US-induced ERK1/2 activation, demonstrating that the Rho/ROCK pathway is an upstream regulator of ERK activation in response to US. Consequently, activation of ROCK and MEK-1 was required for US-induced DNA synthesis. Finally, an integrin beta(1) blocking antibody as well as a RGD peptide prevented US-induced DNA synthesis. In addition, US slightly increased phosphorylation of Src at Tyr(416), and Src activity was found to be required for ERK1/2 activation in response to US. In conclusion, our data demonstrate for the first time that US promotes cell proliferation via activation of integrin receptors and a Rho/ROCK/Src/ERK signaling pathway.	Univ Ulm, Dept Clin Chem, D-89081 Ulm, Germany; Univ Ulm, Dept Traumatol, D-89070 Ulm, Germany; Med Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; SE Univ, Sch Publ Hlth, Nanjing 210009, Peoples R China	Ulm University; Ulm University; Ulm University; Southeast University - China	Bachem, MG (corresponding author), Univ Klin Ulm, Zent Einrichtung Klin Chem, Robert Koch Str 8, D-89081 Ulm, Germany.	max.bachem@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018					Aplin AE, 1998, PHARMACOL REV, V50, P197; Armulik A, 2004, MOL BIOL CELL, V15, P2558, DOI 10.1091/mbc.E03-09-0700; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014-5793(03)01157-8; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLARK RAF, 1985, J AM ACAD DERMATOL, V13, P701, DOI 10.1016/S0190-9622(85)70213-7; CORREAMEYER E, 2002, AM J PHYSIOL, V82, pL883; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HASHIMOTO D, 2001, ALLERGOL INT, V50, P63; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ingber DE, 2003, P NATL ACAD SCI USA, V100, P1472, DOI 10.1073/pnas.0530201100; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Leung KS, 2004, CLIN ORTHOP RELAT R, P253; Luttenberger T, 2000, LAB INVEST, V80, P47, DOI 10.1038/labinvest.3780007; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360; Numaguchi K, 1999, CIRC RES, V85, P5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Parvizi J, 1999, J ORTHOPAED RES, V17, P488, DOI 10.1002/jor.1100170405; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reher P, 1998, EUR J CANCER, V34, P1962, DOI 10.1016/S0959-8049(98)00238-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278; Zhang ZJ, 2003, ULTRASOUND MED BIOL, V29, P1645, DOI 10.1016/j.ultrasmedbio.2003.08.011; Zhao ZY, 2003, DEV DYNAM, V226, P24, DOI 10.1002/dvdy.10212	46	172	191	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54463	54469		10.1074/jbc.M404786200	http://dx.doi.org/10.1074/jbc.M404786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485877	Green Published, hybrid			2022-12-25	WOS:000225793600069
J	Malone, MH; Wang, ZQ; Distelhorst, CW				Malone, MH; Wang, ZQ; Distelhorst, CW			The glucocorticoid-induced gene tdag8 encodes a pro-apoptotic G protein-coupled receptor whose activation promotes glucocorticoid-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED THYMOCYTE APOPTOSIS; ABC-TRANSPORTER TAP; CELL-DEATH; LYMPHOMA-CELLS; MOLECULAR-MECHANISMS; IN-VITRO; RESISTANCE; EXPRESSION; BIM; BAX	The apoptotic action of glucocorticoids on lymphocytes makes them effective therapeutics for many lymphoid malignancies. Although it is clear that glucocorticoid-induced apoptosis requires transcription, the gene products that induce apoptosis remain unknown. Using gene expression profiles of lymphoma cell lines and primary thymocytes treated with the synthetic glucocorticoid dexamethasone, we discovered that induction of tdag8 (T-cell death-associated gene 8) was a common event in each model system investigated. Activation of TDAG8 by its agonist psychosine markedly enhanced dexamethasone-induced apoptosis in a TDAG8-dependent manner. Expression of a TDAG8-GFP fusion protein was sufficient to induce apoptosis, and repression of endogenous TDAG8 using RNA interference partially inhibited dexamethasone-induced apoptosis. Together, these data suggest that TDAG8 is a regulator of glucocorticoid-induced apoptosis and that agonists of TDAG8 may be promising agents to improve the efficacy of glucocorticoids for the treatment of leukemia and lymphoma.	Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Dept Med, WRB 3-133,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@po.cwru.edu			NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA042755] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, T32 CA059366-10, R01 CA042755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos CL, 1998, CYTOKINE, V10, P662, DOI 10.1006/cyto.1998.0351; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; Briehl MM, 1997, ONCOL RES, V9, P281; Cancedda C, 2002, ANN NY ACAD SCI, V966, P49, DOI 10.1111/j.1749-6632.2002.tb04201.x; COHEN JJ, 1984, J IMMUNOL, V132, P38; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; DOUGHERTY TF, 1943, P SOC EXP BIOL MED, V53; FLOMERFELT FA, 1993, J CELL PHYSIOL, V154, P573, DOI 10.1002/jcp.1041540316; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; HEILMAN RR, 1944, ENDOCRINOLOGY, V34, P416; Hillmann AG, 2000, CANCER RES, V60, P2056; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Izquierdo MA, 1996, BRIT J CANCER, V74, P1961, DOI 10.1038/bjc.1996.660; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Lage H, 2001, FEBS LETT, V503, P179, DOI 10.1016/S0014-5793(01)02722-3; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MIGLIORATI G, 1992, PHARMACOL RES, V25, P15, DOI 10.1016/1043-6618(92)90518-G; MIGLIORATI G, 1993, BLOOD, V81, P1352; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P619; PANAYIOTIDIS P, 1994, BRIT J HAEMATOL, V86, P169, DOI 10.1111/j.1365-2141.1994.tb03269.x; PEARSON OH, 1949, CANCER, V2, P943, DOI 10.1002/1097-0142(194911)2:6<943::AID-CNCR2820020602>3.0.CO;2-P; Raggers RJ, 1999, J CELL SCI, V112, P415; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; ROBERTSON AMG, 1978, J PATHOL, V126, P181, DOI 10.1002/path.1711260307; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; SIBLEY CH, 1974, CELL, V2, P221, DOI 10.1016/0092-8674(74)90014-2; Tome ME, 2001, CANCER RES, V61, P2766; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield PD, 2001, J LIPID RES, V42, P2092; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; YAMAMOTO KR, 1974, P NATL ACAD SCI USA, V71, P3901, DOI 10.1073/pnas.71.10.3901; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	58	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52850	52859		10.1074/jbc.M408040200	http://dx.doi.org/10.1074/jbc.M408040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485889	hybrid			2022-12-25	WOS:000225680600009
J	Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC				Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC			p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; p38 MAPK inhibitor; SCIO-469; PS-341; Hsp27	MARROW STROMAL CELLS; PROTEASOME INHIBITOR; DRUG-RESISTANCE; MITOCHONDRIAL PROTEIN; MOLECULAR-MECHANISMS; BIOLOGIC SEQUELAE; SIGNALING PATHWAY; KINASE PATHWAY; APOPTOSIS; GROWTH	Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma ( MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confers PS-341 resistance, and that inhibition of Hsp27 overcomes PS-341 resistance. Since Hsp27 is a downstream target of p38 mitogen-activated protein kinase (MAPK)/MAPK-mitogen-activated protein kinase-2 (MAPKAPK2), we hypothesized that inhibition of p38 MAPK activity could augment PS-341 cytotoxicity by downregulating Hsp27. Although p38 MAPK inhibitor SCIO-469 (Scios Inc, CA, USA) alone did not induce significant growth inhibition, it blocked baseline and PS-341-triggered phosphorylation of p38 MAPK as well as upregulation of Hsp27, associated with enhanced cytotoxicity in MM.1S cells. Importantly, SCIO-469 enhanced phosphorylation of c-Jun NH2-terminal kinase (JNK) and augmented cleavage of caspase-8 and poly(ADP)-ribose polymerase. Moreover, SCIO-469 downregulated PS-341-induced increases in G2/M-phase cells, associated with downregulation of p21(Cip1) expression. Importantly, SCIO-469 treatment augmented cytotoxicity of PS-341 even against PS-341-resistant cell lines and patient MM cells. These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Scios Inc, Fremont, CA 94555 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Scios	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020; Hamasaki, Makoto/AAO-2229-2020; Munshi, Nikhil/ABE-2338-2021	Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947, IP50 CA10070-01] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, CANCER RES, V63, P6174; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Christians U, 2002, CLIN PHARMACOKINET, V41, P813, DOI 10.2165/00003088-200241110-00003; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Guay J, 1997, J CELL SCI, V110, P357; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kisselv AF, 2001, CHEM BIOL, V21, P1; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LeBlanc R, 2002, CANCER RES, V62, P4996; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ogata A, 1997, J IMMUNOL, V159, P2212; Orlowski RZ, 2003, BLOOD, V102, p449A; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwarzenbach H, 2002, MED ONCOL, V19, P87, DOI 10.1385/MO:19:2:87; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sun JZ, 2001, CANCER RES, V61, P1280; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	48	102	119	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8766	8776		10.1038/sj.onc.1208118	http://dx.doi.org/10.1038/sj.onc.1208118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480425	Bronze			2022-12-25	WOS:000225165100006
J	Suchting, S; Heal, P; Tahtis, K; Stewart, LM; Bicknell, R				Suchting, S; Heal, P; Tahtis, K; Stewart, LM; Bicknell, R			Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration	FASEB JOURNAL			English	Article						slits; roundabouts; anti-angiogenesis	TUMOR ANGIOGENESIS; SLIT PROTEINS; NEURONAL MIGRATION; VERTEBRATE SLIT; GUIDANCE; GROWTH; ROUNDABOUT; LIGAND; MORPHOGENESIS; EXPRESSION	Roundabout receptors are molecular guidance molecules that function by interaction with Slit proteins to regulate axon guidance, neuronal migration, and leukocyte chemotaxis. We recently isolated a novel roundabout gene, called Robo4, which is restricted in expression to the endothelium, notably in areas of angiogenesis. The aim of this study was to use the soluble extracellular domain of Robo4 as a probe of function in angiogenesis and endothelial biology. Thus, the soluble extracellular domain of the receptor (Robo4Fc) showed diverse in vivo and in vitro activities including 1) inhibition of angiogenesis in vivo in the rodent subcutaneous sponge model, 2) inhibition of tube formation in the rat aortic ring assay, 3) inhibition of VEGF- and bFGF-stimulated endothelial cell migration, and 4) inhibition of endothelial proliferation. To assess whether Robo4Fc was inhibiting Slit-mediated effects, we determined whether Robo4 and Slit interact. Recombinant Slits-1, -2, and -3 were shown by immunoprecipitation and BiaCore analysis to bind to Robo1 but not Robo4. Further study of the role of Robo4 in angiogenesis appears justified.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Angiogenesis Lab,Canc Res UK, Oxford OX3 9DS, England; St Bartholomews Hosp, Appl Dev Lab, London EC1A 7BE, England	Cancer Research UK; University of Oxford; University of London; Queen Mary University London	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Angiogenesis Lab,Canc Res UK, Oxford OX3 9DS, England.	roy.bicknell@cancer.org.uk	Stewart, Lauren/HHC-2911-2022	Bicknell, Roy/0000-0002-0941-8919				Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hirata T, 2001, J NEUROSCI, V21, P2373, DOI 10.1523/JNEUROSCI.21-07-02373.2001; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; JIRAGE D, 2004, KEYST S ANG NOV BAS; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kramer SG, 2001, SCIENCE, V292, P737, DOI 10.1126/science.1058766; Krebs LT, 2000, GENE DEV, V14, P1343; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Little MH, 2001, AM J PHYSIOL-CELL PH, V281, pC486, DOI 10.1152/ajpcell.2001.281.2.C486; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ogawa T, 2002, CANCER GENE THER, V9, P633, DOI 10.1038/sj.cgt.7700478; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Patel K, 2001, DEVELOPMENT, V128, P5031; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Shutter JR, 2000, GENE DEV, V14, P1313; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stewart LM, 1999, CANCER IMMUNOL IMMUN, V47, P299, DOI 10.1007/s002620050534; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Williams C, 2000, CURR OPIN BIOTECH, V11, P42, DOI 10.1016/S0958-1669(99)00053-1; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371	43	137	152	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					121	+		10.1096/fj.04-1991fje	http://dx.doi.org/10.1096/fj.04-1991fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486058				2022-12-25	WOS:000224849900019
J	Kurisu, G; Nishiyama, D; Kusunoki, M; Fujikawa, S; Katoh, M; Hanke, GT; Hase, T; Teshima, K				Kurisu, G; Nishiyama, D; Kusunoki, M; Fujikawa, S; Katoh, M; Hanke, GT; Hase, T; Teshima, K			A structural basis of Equisetum arvense ferredoxin isoform II producing an alternative electron transfer with ferredoxin-NADP(+) reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNDLE-SHEATH-CELLS; 2FE-2S FERREDOXIN; DIFFERENTIAL EXPRESSION; BINDING-SITES; CRYSTALLOGRAPHY; ISOPROTEINS; RESOLUTION; PROTEIN; CLONING; CDNA	We have determined the crystal structure, at 1.2-Angstrom resolution, of Equisetum arvense ferredoxin isoform II (FdII), which lacks residues equivalent to Arg(39) and Glu(28) highly conserved among other ferredoxins (Fds). In other Fds these residues form an intramolecular salt bridge crucial for stabilization of the [2Fe-2S] cluster, which is disrupted upon complex formation with Fd-NADP(+) oxidoreductase (FNR) to form two intermolecular salt bridges. The overall structure of FdII resembles the known backbone structures of E. arvense isoform I (FdI) and other plant-type Fds. Dramatically, in the FdII structure a unique, alternative salt bridge is formed between Arg(22) and Glu(58). This results in a different relative orientation of the alpha-helix formed by Leu(23) - Glu(29) and eliminates the possibility of forming three of the five intermolecular salt bridges identified on formation of a complex between maize FdI and maize FNR. Mutation of FdII, informed by structural differences with FdI, showed that the alternative salt bridge and the absence of an otherwise conserved Tyr residue are important for the alternative stabilization of the FdII [2Fe-2S] cluster. We also investigated FdI and FdII electron transfer to FNR on chloroplast thylakoid membranes. The K-m and V-max values of FdII are similar to those of FdI, contrary to previous measurements of the reverse reaction, from FNR to Fd. The affinity between reduced FdI and oxidized FNR is much greater than that between oxidized FdI and reduced FNR, whereas this is not the case with FdII. The pH dependence of electron transfer by FdI, FdII, and an FdII mutant with FdI features was measured and further indicated that the binding mode to FNR differs between FdI and FdII. Based on this evidence, we hypothesize that binding modes with other Fd-dependent reductases may also vary between FdI and FdII. The structural differences between FdI and FdII therefore result in functional differences that may influence partitioning of electrons into different redox metabolic pathways.	Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan; Osaka Univ, Inst Prot Res, Res Ctr Struct & Funct Proteom, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Hiroshima University; Osaka University; Osaka University	Teshima, K (corresponding author), Hiroshima Univ, Fac Integrated Arts & Sci, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.	teshi@hiroshima-u.ac.jp	Hase, Toshiharu/H-9271-2013; KURISU, GENJI/AAD-7109-2022; KURISU, GENJI/ABA-5960-2020	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807; Hanke, Guy/0000-0002-6167-926X				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bes MT, 1999, STRUCT FOLD DES, V7, P1201, DOI 10.1016/S0969-2126(00)80054-4; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; Blankenship RE, 2001, NAT STRUCT BIOL, V8, P94, DOI 10.1038/84191; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L., 2002, PYMOL MOL GRAPHICS S, DOI DOI 10.1007/S10822-016-9944-X; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; Hanke GT, 2004, PLANT PHYSIOL, V134, P255, DOI 10.1104/pp.103.032755; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; HASE T, 1991, PLANT PHYSIOL, V96, P77, DOI 10.1104/pp.96.1.77; HASE T, 1977, J BIOCHEM-TOKYO, V82, P277, DOI 10.1093/oxfordjournals.jbchem.a131680; IKEMIZU S, 1994, ACTA CRYSTALLOGR D, V50, P167, DOI 10.1107/S0907444993009588; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMATA Y, 1989, PLANT PHYSIOL, V89, P1193, DOI 10.1104/pp.89.4.1193; Kimata-Ariga Y, 2000, EMBO J, V19, P5041, DOI 10.1038/sj.emboj.7593319; KNAFF DB, 1996, PHOTOSYNTHESIS LIGHT, P333; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; MATSUBARA H, 1968, J BIOL CHEM, V243, P1732; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Matsumura T, 1997, PLANT PHYSIOL, V114, P653, DOI 10.1104/pp.114.2.653; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; Muramoto T, 2002, PLANT PHYSIOL, V130, P1958, DOI 10.1104/pp.008128; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Schultz DJ, 2000, PLANT PHYSIOL, V124, P681, DOI 10.1104/pp.124.2.681; SHERIDAN RP, 1981, J BIOL CHEM, V256, P5052; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; Teshima K, 2003, FEBS LETT, V546, P189, DOI 10.1016/S0014-5793(03)00559-3; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684	33	14	14	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2275	2281		10.1074/jbc.M408904200	http://dx.doi.org/10.1074/jbc.M408904200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15513928	hybrid			2022-12-25	WOS:000226341700064
J	Park, YJ; Chodaparambil, JV; Bao, YH; McBryant, SJ; Luger, K				Park, YJ; Chodaparambil, JV; Bao, YH; McBryant, SJ; Luger, K			Nucleosome assembly protein 1 exchanges histone H2A-H2B dimers and assists nucleosome sliding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; RNA-POLYMERASE-II; RECOMBINANT HISTONES; STRUCTURAL FEATURES; CORE HISTONES; H2A/H2B DIMER; IN-VITRO; CHROMATIN; DNA; NUCLEOPLASMIN	Eukaryotic chromatin is highly dynamic and turns over rapidly even in the absence of DNA replication. Here we show that the acidic histone chaperone nucleosome assembly protein 1 (NAP-1) from yeast reversibly removes and replaces histone protein dimer H2A-H2B or histone variant dimers from assembled nucleosomes, resulting in active histone exchange. Transient removal of H2A-H2B dimers facilitates nucleosome sliding along the DNA to a thermodynamically favorable position. Histone exchange as well as nucleosome sliding is independent of ATP and relies on the presence of the C-terminal acidic domain of yeast NAP-1, even though this region is not required for histone binding and chromatin assembly. Our results suggest a novel role for NAP-1 ( and perhaps other acidic histone chaperones) in mediating chromatin fluidity by incorporating histone variants and assisting nucleosome sliding. NAP-1 may function either untargeted ( if acting alone) or may be targeted to specific regions within the genome through interactions with additional factors.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Luger, K (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 316 MRB, Ft Collins, CO 80523 USA.	kluger@lamar.colostate.edu	Park, Young-Jun/AAF-6249-2021; Chodaparambil, Jayanth V/F-3229-2015	Park, Young-Jun/0000-0003-2901-6949; SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331; Chodaparambil, Jayanth/0000-0002-4217-8355	NIGMS NIH HHS [GM67777, GM551909, R01 GM067777, R01 GM061909] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061909, R01GM067777] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Bruno M, 2004, METHOD ENZYMOL, V375, P211; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Fyodorov DV, 2003, METHOD ENZYMOL, V371, P499; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Korber P, 2004, CELL, V117, P5, DOI 10.1016/S0092-8674(04)00296-X; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Langst G, 2001, J CELL SCI, V114, P2561; Lankenau S, 2003, GENETICS, V163, P611; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; McBryant SJ, 2004, BIOCHEMISTRY-US, V43, P10592, DOI 10.1021/bi035881b; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Muthurajan UM, 2003, BIOPOLYMERS, V68, P547, DOI 10.1002/bip.10317; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Rehtanz M, 2004, MOL CELL BIOL, V24, P2153, DOI 10.1128/MCB.24.5.2153-2168.2004; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rhoades AR, 2004, MOL CELL BIOL, V24, P3907, DOI 10.1128/MCB.24.9.3907-3917.2004; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178	54	148	150	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1817	1825		10.1074/jbc.M411347200	http://dx.doi.org/10.1074/jbc.M411347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15516689	hybrid			2022-12-25	WOS:000226341700015
J	Brittingham, R; Colombo, M; Ito, H; Steplewski, A; Birk, DE; Uitto, J; Fertala, A				Brittingham, R; Colombo, M; Ito, H; Steplewski, A; Birk, DE; Uitto, J; Fertala, A			Single amino acid substitutions in procollagen VII affect early stages of assembly of anchoring fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; COLLAGEN TRIPLE-HELIX; PEMPHIGOID ANTIGEN; ANTIPARALLEL DIMER; MOLECULAR-GENETICS; BINDING-SITES; NC-2 DOMAIN; PROTEIN; CLONING; HEMIDESMOSOMES	Procollagen VII is a homotrimer of 350-kDa pro-alpha1(VII) chains, each consisting of a central collagenous domain flanked by the noncollagenous N-terminal NC1 domain and the C-terminal NC2 domain. After secretion from cells, procollagen VII molecules form anti-parallel dimers with a C-terminal 60-nm overlap. Characteristic alignment of procollagen VII monomers forming a dimer depends on site-specific binding between the NC2 domain and the triple-helical region adjacent to Cys-2634 of the interacting procollagen VII molecules. Formation of the intermolecular disulfide bonds between Cys-2634 and either Cys-2802 or Cys-2804 is promoted by the cleavage of the NC2 domain by procollagen C-proteinase. By employing recombinant procollagen VII variants harboring G2575R, R2622Q, or G2623C substitutions previously disclosed in patients with dystrophic epidermolysis bullosa, we studied how these amino acid substitutions affect intermolecular interactions. Binding assays utilizing an optical biosensor demonstrated that the G2575R substitution increased affinity between mutant molecules. In contrast, homotypic binding between the R2622Q or G2623C molecules was not detected. In addition, kinetics of heterotypic binding of all analyzed mutants to wild type collagen VII were different from those for binding between wild type molecules. Moreover, solid-state binding assays demonstrated that R2622Q and G2623C substitutions prevent formation of stable assemblies of procollagen C-proteinase-processed mutants. These results indicate that single amino acid substitutions in procollagen VII alter its self-assembly and provide a basis for understanding the pathomechanisms leading from mutations in the COL7A1 gene to fragility of the dermal-epidermal junction seen in patients with dystrophic forms of epidermolysis bullosa.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Fertala, A (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Bluemle Life Sci Bldg,Rm 424,233 S 10th St, Philadelphia, PA 19107 USA.	andrzej.fertala@jefferson.edu	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; Cabral WA, 2002, J BIOL CHEM, V277, P4215, DOI 10.1074/jbc.M109048200; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Chen M, 2002, J BIOL CHEM, V277, P2118, DOI 10.1074/jbc.M108779200; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; Chen M, 2000, J BIOL CHEM, V275, P24429, DOI 10.1074/jbc.M003440200; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; CHRISTIANO AM, 1995, HUM MOL GENET, V4, P1579; Colombo M, 2003, BIOCHEMISTRY-US, V42, P11434, DOI 10.1021/bi034925d; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; FERTALA A, 1994, J BIOL CHEM, V269, P11584; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fertala A, 2001, BIOCHEMISTRY-US, V40, P14422, DOI 10.1021/bi0109109; Garland PB, 1996, Q REV BIOPHYS, V29, P91, DOI 10.1017/S0033583500005758; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LI KH, 1993, J BIOL CHEM, V268, P8825; Liu CG, 1996, P NATL ACAD SCI USA, V93, P4278, DOI 10.1073/pnas.93.9.4278; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; Pulkkinen L, 2002, J AM ACAD DERMATOL, V47, P91, DOI 10.1067/mjd.2002.120601; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; RYHANEN L, 1983, ARCH BIOCHEM BIOPHYS, V223, P562, DOI 10.1016/0003-9861(83)90621-5; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; Steplewski A, 2004, J MOL BIOL, V338, P989, DOI 10.1016/j.jmb.2004.03.037; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TANAKA T, 1991, J BIOL CHEM, V266, P12555; Uitto J, 2001, ARCH DERMATOL, V137, P1458; VIJAYAKUMAR M, 1989, PHYS REV A, V40, P6834, DOI 10.1103/PhysRevA.40.6834; Wiche G, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P475; WICHE G, 1989, CRIT REV BIOCHEM MOL, V24, P41, DOI 10.3109/10409238909082551	44	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					191	198		10.1074/jbc.M406210200	http://dx.doi.org/10.1074/jbc.M406210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509587	hybrid			2022-12-25	WOS:000226025100024
J	Martindale, JJ; Wall, JA; Martinez-Longoria, DM; Aryal, P; Rockman, HA; Guo, YR; Bolli, R; Glembotski, CC				Martindale, JJ; Wall, JA; Martinez-Longoria, DM; Aryal, P; Rockman, HA; Guo, YR; Bolli, R; Glembotski, CC			Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; NF-KAPPA-B; P38-ALPHA MAP KINASE; P38 MAPK; CARDIAC-HYPERTROPHY; REPERFUSION INJURY; CELL-SURVIVAL; LATE-PHASE; APOPTOSIS; EXPRESSION	The mitogen-activated protein kinases ( MAPK) have been the subject of many studies to identify signaling pathways that promote cell survival or death. In cultured cardiac myocytes, p38 MAPK promotes cell survival or death depending on whether it is activated by mitogen-activated protein kinase kinase 6 (MKK6) or MKK3, respectively. The objectives of the current study were to examine the effects of MKK6-mediated p38 activation in the heart in vivo. Accordingly, we generated transgenic (TG) mice that overexpress wild type MKK6 in a cardiac-restricted manner. Although p38 was about 17-fold more active in TG than non-transgenic (NTG) mouse hearts, TG mouse hearts were morphologically and functionally similar to those of NTG littermates. However, upon transient ischemia followed by reperfusion, the MKK6 TG mouse hearts exhibited significantly better functional recovery and less injury than NTG mouse hearts. Because MKK6 increases levels of the protective small heat shock protein, alphaB-crystallin (alphaBC), in cultured cardiac myocytes, we examined alphaBC levels in the mouse hearts. The level of alphaBC was 2-fold higher in MKK6 TG than NTG mouse hearts. Moreover, ischemia followed by reperfusion induced a 6.4-fold increase in alphaBC levels in the mitochondrial fractions of TG mouse hearts but no increase in alphaBC levels in any of the other fractions analyzed. These alterations in alphaBC expression and localization suggest possible mechanisms of cardio-protection in MKK6 TG mouse hearts.	San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Duke Univ, Med Ctr, Dept Med & Genet, Durham, NC 27710 USA; Univ Louisville, Inst Mol Cardiol, Louisville, KY 40292 USA	California State University System; San Diego State University; California State University System; San Diego State University; Duke University; University of Louisville	Glembotski, CC (corresponding author), San Diego State Univ, SDSU Heart Inst, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu	Guo, Yiru/L-2618-2015	Guo, Yiru/0000-0002-0614-9899	NHLBI NIH HHS [HL-68088, R01 HL055757, R01 HL063975, HL-75573, P01 HL046345, R01 HL070897, HL-55757, R01 HL068088, HL-70897, HL-63975, R37 HL055757, R01 HL075573, HL-46345] Funding Source: Medline; NINDS NIH HHS [R01 NS025037, NS/HL-25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055757, R01HL068088, R01HL070897, R01HL055757, R01HL075573, R01HL063975, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 2000, CIRC RES, V86, P607, DOI 10.1161/01.RES.86.6.607; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Esposito G, 2000, AM J PHYSIOL-HEART C, V279, pH3101, DOI 10.1152/ajpheart.2000.279.6.H3101; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Guo YR, 1998, AM J PHYSIOL-HEART C, V275, pH1375; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jones W Keith, 2003, Cardiovasc Toxicol, V3, P229, DOI 10.1385/CT:3:3:229; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kajstura J, 1996, LAB INVEST, V74, P86; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Li SP, 2003, CANCER RES, V63, P3473; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Marais E, 2001, J MOL CELL CARDIOL, V33, P769, DOI 10.1006/jmcc.2001.1347; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mocanu MM, 2000, BASIC RES CARDIOL, V95, P472, DOI 10.1007/s003950070023; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Morrison LE, 2003, CIRC RES, V92, P203, DOI 10.1161/01.RES.0000052989.83995.A5; Nakagawa M, 2001, EXP CELL RES, V271, P161, DOI 10.1006/excr.2001.5362; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Otsu K, 2003, BIOCHEM BIOPH RES CO, V302, P56, DOI 10.1016/S0006-291X(03)00096-2; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901, DOI 10.1152/ajpheart.2000.279.3.H901; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	51	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					669	676		10.1074/jbc.M406690200	http://dx.doi.org/10.1074/jbc.M406690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15492008	hybrid, Green Accepted			2022-12-25	WOS:000226025100079
J	Miller, AJ; Levy, C; Davis, IJ; Razin, E; Fisher, DE				Miller, AJ; Levy, C; Davis, IJ; Razin, E; Fisher, DE			Sumoylation of MITF and its related family members TFE3 and TFEB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; SUMO E3 LIGASE; ANDROGEN RECEPTOR; GENE; ACTIVATION; EXPRESSION; MELANOCYTES; REPRESSION; PROTEINS; MELANOMA	MITF and its related family members TFE3 and TFEB heterodimerize with each other, recognize the same DNA sequences, and are subject to many of the same post-translational modifications. We show that lysine residues within conserved small ubiquitin-like modifier ( SUMO) consensus sites in these family members are subject to SUMO modification. Mutation of these sites significantly affects the transcriptional activity of MITF but does not alter dimerization, DNA binding, stability, or nuclear localization. Mutagenesis reducing the number of MITF binding sites in the promoter of TRPM1 from three to one eliminated the difference in transcriptional activity between the MITF mutants. Among other MITF target gene promoter constructs, differences in transcriptional activity between wild type and nonsumoylatable MITF were only seen in promoters with multiple MITF binding sites. These data support a synergy control model in which the functional consequences of MITF sumoylation depend on promoter context. Sumoylation, thus, provides a possible mechanism for altering the effects of MITF by affecting the target genes that it activates.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med,Childrens Hosp, Dept Pediat Hematol Oncol,Melanoma Program Med On, Dana Farber Canc Inst, Boston, MA 02115 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Hebrew University of Jerusalem	Fisher, DE (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	David_Fisher@dfci.harvard.edu		Davis, Ian/0000-0002-1552-0960	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369, R01AR045662] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45662, AR43369] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Buschmann T, 2001, J BIOL CHEM, V276, P40389, DOI 10.1074/jbc.M103786200; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Goding CR, 2000, GENE DEV, V14, P1712; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Huber WE, 2003, J BIOL CHEM, V278, P45224, DOI 10.1074/jbc.M309036200; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; Levy C, 2003, MOL CELL BIOL, V23, P9073, DOI 10.1128/MCB.23.24.9073-9080.2003; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; SILVERS WK, 1979, COAT COLORS MICE MOD, P268; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	63	110	119	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					146	155		10.1074/jbc.M411757200	http://dx.doi.org/10.1074/jbc.M411757200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507434	hybrid			2022-12-25	WOS:000226025100019
J	van Bueren, AL; Morland, C; Gilbert, HJ; Boraston, AB				van Bueren, AL; Morland, C; Gilbert, HJ; Boraston, AB			Family 6 carbohydrate binding modules recognize the non-reducing end of beta-1,3-linked glucans by presenting a unique ligand binding surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE RECOGNITION; CELL-SEPARATION; ACTIVE ENZYMES; XYLANASE 10A; CELLULOSE; REVEALS; COMPLEX; PROTEIN; IDENTIFICATION; COEFFICIENTS	Enzymes that hydrolyze insoluble complex polysaccharide structures contain non-catalytic carbohydrate binding modules (CBMS) that play a pivotal role in the action of these enzymes against recalcitrant substrates. Family 6 CBMs (CBM6s) are distinct from other CBM families in that these protein modules contain multiple distinct ligand binding sites, a feature that makes CBM6s particularly appropriate receptors for the beta-1,3-glucan laminarin, which displays an extended U-shaped conformation. To investigate the mechanism by which family 6 CBMs recognize laminarin, we report the biochemical and structural properties of a CBM6 ( designated BhCBM6) that is located in an enzyme, which is shown, in this work, to display beta-1,3-glucanase activity. BhCBM6 binds beta-1,3-glucooligosaccharides with affinities of similar to1 x 10(5) M-1. The x-ray crystal structure of this CBM in complex with laminarihexaose reveals similarity with the structures of other CBM6s but a unique binding mode. The binding cleft in this protein is sealed at one end, which prevents binding of linear polysaccharides such as cellulose, and the orientation of the sugar at this site prevents glycone extension of the ligand and thus conferring specificity for the non-reducing ends of glycans. The high affinity for extended beta-1,3-glucooligosaccharides is conferred by interactions with the surface of the protein located between the two binding sites common to CBM6s and thus reveals a third ligand binding site in family 6 CBMs. This study therefore demonstrates how the multiple binding clefts and highly unusual protein surface of family 6 CBMs confers the extensive range of specificities displayed by this protein family. This is in sharp contrast to other families of CBMs where variation in specificity between different members reflects differences in the topology of a single binding site.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Newcastle Univ, Sch Biomed Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Victoria; Newcastle University - UK	Boraston, AB (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055 STN CSC, Victoria, BC V8W 3P6, Canada.	boraston@uvic.ca		Boraston, Alisdair/0000-0001-6417-0592				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baladron V, 2002, EUKARYOT CELL, V1, P774, DOI 10.1128/EC.1.5.774-786.2002; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, BIOCHEM J, V361, P35, DOI 10.1042/0264-6021:3610035; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 1999, ROY SOC CH, P202; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Davies GJ, 2002, BIOCHEM SOC T, V30, P291, DOI 10.1042/BST0300291; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; Fliegmann J, 2004, J BIOL CHEM, V279, P1132, DOI 10.1074/jbc.M308552200; Frecer V, 2000, BIOMACROMOLECULES, V1, P91, DOI 10.1021/bm990002f; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Martin-Cuadrado AB, 2003, J CELL SCI, V116, P1689, DOI 10.1242/jcs.00377; McCartney L, 2004, ANAL BIOCHEM, V326, P49, DOI 10.1016/j.ab.2003.11.011; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Read SM, 1996, CARBOHYD RES, V281, P187, DOI 10.1016/0008-6215(95)00350-9; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; van Bueren AL, 2004, J MOL BIOL, V340, P869, DOI 10.1016/j.jbm.2004.05.038; Zverlov VV, 2001, MICROBIOL-SGM, V147, P621, DOI 10.1099/00221287-147-3-621	38	79	81	3	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					530	537		10.1074/jbc.M410113200	http://dx.doi.org/10.1074/jbc.M410113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15501830	hybrid			2022-12-25	WOS:000226025100063
J	Bayly, R; Chuen, L; Currie, RA; Hyndman, BD; Casselman, R; Blobel, GA; LeBrun, DP				Bayly, R; Chuen, L; Currie, RA; Hyndman, BD; Casselman, R; Blobel, GA; LeBrun, DP			E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; LOOP-HELIX PROTEINS; TRANSCRIPTION-FACTOR-BINDING; TRANSACTIVATION DOMAIN; ONCOPROTEIN E2A-PBX1; HOMEODOMAIN PROTEIN; ACTIVATION DOMAIN; PBX1 HOMEODOMAIN; MAMMALIAN-CELLS; E2A GENE	The E2A gene encodes DNA-binding transcription factors, called E12 and E47, involved in cell specification and maturation. E2A is also involved in a chromosomal translocation that leads to the expression of an oncogenic transcription factor called E2A-PBX1 in cases of acute leukemia. In the work described here, we elucidate the interaction between E2A-PBX1 and transcriptional co-activators. We confirm that the E2A portion can interact with CBP and PCAF and map required elements on E2A and CBP. On CBP, the interaction involves the KIX domain, a well characterized domain that mediates interactions with several other oncogenic transcription factors. On E2A, the interaction with CBP requires conserved alpha-helical domains that reside within activation domains 1 and 2 (AD1 and AD2, respectively). Using purified, recombinant proteins, we show that the E2A-CBP interaction is direct. Notwithstanding the previously demonstrated ability of AD1 and AD2 to function independently, some of our findings suggest functional cooperativity between these two domains. Finally, we show that the CBP/p300-interactive helical domains of E2A are important in the induction of proliferation in cultured primary bone marrow cells retrovirally transduced with E2A-PBX1. Our findings suggest that some aspects of E2A-PBX1 oncogenesis involve a direct interaction with the KIX domain of CBP/p300.	Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; Childrens Hosp, Div Hematol, Philadelphia, PA 19104 USA	McMaster University; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	LeBrun, DP (corresponding author), Queens Univ, Richardson Lab, Dept Pathol & Lab Med, Kingston, ON K7L 3N6, Canada.	lebrun@cliff.path.queensu.ca	Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ARONHEIM A, 1993, NUCLEIC ACIDS RES, V21, P1601, DOI 10.1093/nar/21.7.1601; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bayly R, 2000, MOL CELL BIOL, V20, P5789, DOI 10.1128/MCB.20.16.5789-5796.2000; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Campbell KM, 2002, BIOCHEMISTRY-US, V41, P13956, DOI 10.1021/bi026222m; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frangioni JV, 2000, NAT BIOTECHNOL, V18, P1080, DOI 10.1038/80280; Goodman RH, 2000, GENE DEV, V14, P1553; Goto NK, 2002, J BIOL CHEM, V277, P43168, DOI 10.1074/jbc.M207660200; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LeBrun DP, 2003, FRONT BIOSCI, V8, pS206, DOI 10.2741/1030; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Massari ME, 1996, MOL CELL BIOL, V16, P121; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Parker D, 1999, MOL CELL BIOL, V19, P5601; Parker D, 1996, MOL CELL BIOL, V16, P694; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Rutherford MN, 2001, LEUKEMIA, V15, P362, DOI 10.1038/sj.leu.2402059; Rutherford MN, 1998, AM J PATHOL, V153, P165, DOI 10.1016/S0002-9440(10)65557-5; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	43	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55362	55371		10.1074/jbc.M408654200	http://dx.doi.org/10.1074/jbc.M408654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507449	hybrid			2022-12-25	WOS:000225960800049
J	Chavakis, T; Keiper, T; Matz-Westphal, R; Hersemeyer, K; Sachs, UJ; Nawroth, PP; Preissner, KT; Santoso, S				Chavakis, T; Keiper, T; Matz-Westphal, R; Hersemeyer, K; Sachs, UJ; Nawroth, PP; Preissner, KT; Santoso, S			The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; UROKINASE RECEPTOR; PECAM-1; COUNTERRECEPTOR; INTERACTS; LIGAND; JAMS; GLYCOPROTEIN; ENDOTHELIUM; MONOCYTES	The third member of the family of junctional adhesion molecules (JAMs), JAM-3, also called JAM-C, was recently shown to be a novel counter-receptor on platelets for the leukocyte beta(2)-integrin Mac-1 (alphaMbeta(2), CD11b/CD18). Here, new functional aspects of the role of endothelial cell JAM-C were investigated. Endothelial cells express JAM-C, which is predominantly localized within junctions at interendothelial contacts, since it codistributes with a tight junction component, zonula occludens-1. Whereas JAM-C does not participate in neutrophil adhesion to endothelial cells, it mediates neutrophil transmigration in a Mac-1-dependent manner. In particular, inhibition of JAM-C significantly reduced neutrophil transendothelial migration, and the combination of JAM-C and platelet/endothelial cell adhesion molecule-1 blockade almost completely abolished neutrophil transendothelial migration in vitro. In vivo, inhibition of JAM-C with soluble mouse JAM-C resulted in a 50% reduction of neutrophil emigration in the mouse model of acute thioglycollate-induced peritonitis. Thus, JAM-C participates in neutrophil transmigration and thereby provides a novel molecular target for antagonizing interactions between vascular cells that promote inflammatory vascular pathologies.	Heidelberg Univ, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, D-35392 Giessen, Germany	Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Justus Liebig University Giessen	Chavakis, T (corresponding author), Heidelberg Univ, Dept Internal Med 1, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	triantafyllos.chavakis@med.uni-heidelberg.de	Chavakis, Triantafyllos/ABE-8845-2020; Sachs, Ulrich/GSI-7824-2022	MATZ, Rachel/0000-0001-5832-7063	NATIONAL CANCER INSTITUTE [ZIABC010663, Z01BC010663] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ager Ann, 1994, Trends in Cell Biology, V4, P326, DOI 10.1016/0962-8924(94)90234-8; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kroll H, 2000, BLOOD, V96, P1409, DOI 10.1182/blood.V96.4.1409.h8001409_1409_1414; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Liu Y, 2000, J CELL SCI, V113, P2363; Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rohnelt RK, 1997, INT IMMUNOL, V9, P435, DOI 10.1093/intimm/9.3.435; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Santoso S, 1999, BLOOD, V94, P4103, DOI 10.1182/blood.V94.12.4103.424k27_4103_4111; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	40	153	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55602	55608		10.1074/jbc.M404676200	http://dx.doi.org/10.1074/jbc.M404676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485832	hybrid			2022-12-25	WOS:000225960800078
J	Chen, Y; Jin, R; Dong, HY; Feng, YM				Chen, Y; Jin, R; Dong, HY; Feng, YM			In vitro refolding/infolding pathways of amphioxus insulin-like peptide - Implications for folding behavior of insulin family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; DISULFIDE-FORMING PATHWAY; HUMAN PROINSULIN; B-CHAIN/DOMAIN; KINETIC TRAP; C-PEPTIDE; IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1; EVOLUTION; DESIGN	Amphioxus insulin-like peptide (AILP) belongs to the insulin superfamily and is proposed as the common ancestor of insulin and insulin-like growth factor 1. Herein, the studies on oxidative refolding and reductive unfolding of AILP are reported. During the refolding process, four major intermediates, P1, P2, P3, and P4, were captured, which were almost identical to those intermediates, U1, U2, U3, and U4, captured during the AILP unfolding process. P4 ( U4) has the native disulfide A20-B19; P1 ( U1), P2 ( U2), and P3 ( U3) have two disulfide bonds, which include A20-B19. Based on the analysis of the time course distribution and properties of the intermediates, we proposed that fully reduced AILP refolded through 1SS, 2SS, and 3SS intermediate stages to the native form; native AILP unfolded through 2SS and 1SS intermediate stages to the full reduced form. A schematic flow chart of major oxidative refolding and reductive unfolding pathways of AILP was proposed. Implication for the folding behavior of insulin family proteins was discussed. There may be seen three common folding features in the insulin superfamily: 1) A20-B19 disulfide is most important and formed during the initial stage of folding process; 2) the second disulfide is nonspecifically formed, which then rearranged to native disulfide; 3) in vitro refolding and unfolding pathways may share some common folding intermediates but flow in opposite directions. Furthermore, although swap AILP is a thermodynamically stable final product, a refolding study of swap AILP demonstrated that it is also a productive intermediate of native AILP during refolding.	Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Key Lab Proteom, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Feng, YM (corresponding author), Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Key Lab Proteom, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengym@sunm.shcnc.ac.cn						ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Chen Y, 2004, BIOCHEMISTRY-US, V43, P9225, DOI 10.1021/bi049710y; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10603, DOI 10.1021/bi020223x; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; Jia XY, 2003, PROTEIN SCI, V12, P2412, DOI 10.1110/ps.0389303; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; Kuhlman B, 2004, CURR OPIN STRUC BIOL, V14, P89, DOI 10.1016/j.sbi.2004.01.002; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Min CY, 2004, EUR J BIOCHEM, V271, P1737, DOI 10.1111/j.1432-1033.2004.04079.x; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; Qiao ZS, 2003, J BIOL CHEM, V278, P17800, DOI 10.1074/jbc.M300906200; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; Rosenfeld RD, 1997, ARCH BIOCHEM BIOPHYS, V342, P298, DOI 10.1006/abbi.1997.9996; Scheraga HA, 2001, METHOD ENZYMOL, V341, P189, DOI 10.1016/S0076-6879(01)41153-0; Shen L, 2001, ACTA BIOCH BIOPH SIN, V33, P629; Vajdos FF, 2001, BIOCHEMISTRY-US, V40, P11022, DOI 10.1021/bi0109111; Wang S, 2003, BIOCHEMISTRY-US, V42, P9687, DOI 10.1021/bi0346289; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598	40	8	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55224	55233		10.1074/jbc.M409030200	http://dx.doi.org/10.1074/jbc.M409030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15501824	hybrid			2022-12-25	WOS:000225960800031
J	Honda, Y; Kitaoka, M				Honda, Y; Kitaoka, M			A family 8 glycoside hydrolase from bacillus halodurans C-125 (BH2105) is a reducing end xylose-releasing exo-oligoxylanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.8 ANGSTROM RESOLUTION; AMINO-ACID-SEQUENCE; ACTIVE-SITE; CELLOBIOSE PHOSPHORYLASE; CELLVIBRIO-GILVUS; ESCHERICHIA-COLI; D-GLUCOSE; LOW PH; XYLANASE; SUBSTRATE	The gene encoding family 8 glycoside hydrolases from Bacillus halodurans C-125 (BH2105), an alkalophilic bacterium with a known genomic sequence, was expressed in Escherichia coli. The protein was expressed with the intact N-terminal sequence, suggesting that it did not possess a signal peptide and that it was an intracellular enzyme. The recombinant enzyme showed no hydrolytic activity on xylan, whereas it had been annotated as xylanase Y. It hydrolyzed xylooligosaccharide whose degree of polymerization is greater than or equal to 3 in an exosplitting manner with anomeric inversion, releasing the xylose unit at the reducing end. Judging from its substrate specificity and reaction mechanism, we named the enzyme reducing end xylose-releasing exo-oligoxylanase (Rex). Rex was found to utilize only the beta-anomer of the substrate to form beta-xylose and alpha-xylooligosaccharide. The optimum pH of the enzymatic reaction (6.2-7.3) was found in the neutral range, a range beneficial for intracellular enzymes. The genomic sequence suggests that B. halodurans secretes two endoxylanases and possesses two alpha-arabinofuranosidases, one alpha-glucuronidase, and three beta-xylosidases intracellularly in addition to Rex. The extracellular enzymes supposedly hydrolyze xylan into arabino/glucurono-xylooligosaccharides that are then transported into the cells. Rex may play a role as a key enzyme in intracellular xylan metabolism in B. halodurans by cleaving xylooligosaccharides that were produced by the action of other intracellular enzymes from the arabino/glucurono-xylooligosaccharides.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Kitaoka, M (corresponding author), Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	mkitaoka@nfri.affrc.go.jp	Kitaoka, Motomitsu/R-1536-2019	Kitaoka, Motomitsu/0000-0002-0083-1838				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Canals A, 2003, ACTA CRYSTALLOGR D, V59, P1447, DOI 10.1107/S0907444903012629; Collins T, 2002, J BIOL CHEM, V277, P35133, DOI 10.1074/jbc.M204517200; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; Dupont C, 1998, BIOCHEM J, V330, P41, DOI 10.1042/bj3300041; FLETCHER HG, 1963, METHODS CARBOHYDR CH, P197; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Fushinobu S, 1998, PROTEIN ENG, V11, P1121, DOI 10.1093/protein/11.12.1121; Gruber K, 1998, BIOCHEMISTRY-US, V37, P13475, DOI 10.1021/bi980864l; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Hakulinen N, 2003, EUR J BIOCHEM, V270, P1399, DOI 10.1046/j.1432-1033.2003.03496.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONDA H, 1985, J BACTERIOL, V161, P784, DOI 10.1128/JB.161.2.784-785.1985; Honda Y, 2002, J BIOSCI BIOENG, V93, P313, DOI 10.1016/S1389-1723(02)80034-2; Horikoshi K, 1999, MICROBIOL MOL BIOL R, V63, P735, DOI 10.1128/MMBR.63.4.735-750.1999; KITAOKA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1987, DOI 10.1271/bbb.57.1987; KITAOKA M, 1993, CARBOHYD RES, V247, P355, DOI 10.1016/0008-6215(93)84271-7; Koga D, 1998, BIOSCI BIOTECH BIOCH, V62, P1643, DOI 10.1271/bbb.62.1643; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 2002, BIOCHEM BIOPH RES CO, V295, P818, DOI 10.1016/S0006-291X(02)00748-9; McCarthy AA, 2000, ACTA CRYSTALLOGR D, V56, P1367, DOI 10.1107/S0907444900009896; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; Nidetzky B, 2000, BIOCHEM J, V351, P649, DOI 10.1042/0264-6021:3510649; Nishimoto M, 2002, J BIOSCI BIOENG, V93, P428, DOI 10.1263/jbb.93.428; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; REITHEL FJ, 1945, J AM CHEM SOC, V67, P1056, DOI 10.1021/ja01223a006; SAHA BC, 1997, FUELS CHEM BIOMASS, V666, P47; SAHA BC, 1999, UTILIZING NATURES AD, V723, P167; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Shintate K, 2003, CARBOHYD RES, V338, P1981, DOI 10.1016/S0008-6215(03)00314-8; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TAPIO S, 1991, J BIOL CHEM, V266, P19450; TSUMURAYA Y, 1990, ARCH BIOCHEM BIOPHYS, V281, P58, DOI 10.1016/0003-9861(90)90412-R; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; WAFFENSCHMIDT S, 1987, ANAL BIOCHEM, V165, P337, DOI 10.1016/0003-2697(87)90278-8; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Wouters J, 2001, ACTA CRYSTALLOGR D, V57, P1813, DOI 10.1107/S0907444901015153	44	76	78	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55097	55103		10.1074/jbc.M409832200	http://dx.doi.org/10.1074/jbc.M409832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491996	hybrid			2022-12-25	WOS:000225960800015
J	Maheswaran, M; Urbanke, C; Forchhammer, K				Maheswaran, M; Urbanke, C; Forchhammer, K			Complex formation and catalytic activation by the P-II signaling protein of N-acetyl-L-glutamate kinase from Synechococcus elongatus strain PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIFA REGULATORY SYSTEM; GLNB GENE-PRODUCT; TRANSDUCTION PROTEIN; ARGININE-BIOSYNTHESIS; PLASTID CARBON; PII; NITROGEN; PHOSPHORYLATION; ACETYLGLUTAMATE; CYANOBACTERIA	The signal transduction protein P-II from the cyanobacterium Synechococcus elongatus strain PCC 7942 forms a complex with the key enzyme of arginine biosynthesis, N-acetyl-L-glutamate kinase (NAGK). Here we report the effect of complex formation on the catalytic properties of NAGK. Although pH and ion dependence are not affected, the catalytic efficiency of NAGK is strongly enhanced by binding of P-II, with K-m decreasing by a factor of 10 and V-max increasing 4-fold. In addition, arginine feedback inhibition of NAGK is strongly decreased in the presence of P-II, resulting in a tight control of NAGK activity under physiological conditions by P-II. Analysis of the NAGK-P-II complex suggests that one P-II trimer binds to one NAGK hexamer with a K-d of similar to3 nM. Complex formation is strongly affected by ATP and ADP. ADP is a strong inhibitor of complex formation, whereas ATP inhibits complex formation only in the absence of divalent cations or in the presence of Mg2+ ions, together with increased 2-oxoglutarate concentrations. Ca2+ is able to antagonize the negative effect of ATP and 2-oxoglutarate. ADP and ATP exert their adverse effect on NAGK-P-II complex formation through binding to the P-II protein.	Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany; Hannover Med Sch, Zent Einrichtung Biophys Biochem Verfahren, D-30623 Hannover, Germany	Justus Liebig University Giessen; Hannover Medical School	Forchhammer, K (corresponding author), Univ Giessen, Inst Mikrobiol & Mol Biol, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.	Karl.Forchhammer@mikro.bio.uni-giessen.de		MANI, MAHESWARAN/0000-0001-8056-8787				Abadjieva A, 2001, J BIOL CHEM, V276, P42869, DOI 10.1074/jbc.M103732200; Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Burillo S, 2004, J BACTERIOL, V186, P3346, DOI 10.1128/JB.186.11.3346-3354.2004; Caldovic L, 2003, BIOCHEM J, V372, P279, DOI 10.1042/BJ20030002; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954; Fernandez-Murga ML, 2004, J BACTERIOL, V186, P6142, DOI 10.1128/JB.186.18.6142-6149.2004; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; Forchhammer K, 2004, PHYSIOL PLANTARUM, V120, P51, DOI 10.1111/j.0031-9317.2004.0218.x; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P5812, DOI 10.1128/jb.177.20.5812-5817.1995; Forchhammer K., 1999, PHOTOTROPHYC PROKARY, P549; HAAS D, 1975, EUR J BIOCHEM, V52, P365, DOI 10.1111/j.1432-1033.1975.tb04004.x; HALLENBECK PC, 1992, BIOCHIM BIOPHYS ACTA, V1118, P161, DOI 10.1016/0167-4838(92)90145-4; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Irmler A, 2001, P NATL ACAD SCI USA, V98, P12978, DOI 10.1073/pnas.231254998; Irmler A, 1997, MOL MICROBIOL, V26, P81, DOI 10.1046/j.1365-2958.1997.5521918.x; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; KINDLER B, 1997, THESIS U HANNOVER; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee HM, 2000, EUR J BIOCHEM, V267, P591, DOI 10.1046/j.1432-1327.2000.01043.x; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Moorhead GBG, 2003, PLANT PHYSIOL, V133, P492, DOI 10.1104/pp.103.025627; Najafi SMA, 1997, J BACTERIOL, V179, P5628, DOI 10.1128/jb.179.17.5628-5631.1997; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palinska KA, 2002, MICROBIOL-SGM, V148, P2405, DOI 10.1099/00221287-148-8-2405; Pawlowski A, 2003, J BACTERIOL, V185, P5240, DOI 10.1128/JB.185.17.5240-5247.2003; Paz-Yepes J, 2003, FEBS LETT, V543, P42, DOI 10.1016/S0014-5793(03)00384-3; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Pioszak AA, 2003, BIOCHEMISTRY-US, V42, P8885, DOI 10.1021/bi030065p; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; Ruppert U, 2002, MOL MICROBIOL, V44, P855, DOI 10.1046/j.1365-2958.2002.02927.x; Smith CS, 2004, BBA-PROTEINS PROTEOM, V1699, P145, DOI 10.1016/j.bbapap.2004.02.009; SON HS, 1987, J BIOL CHEM, V262, P8690; Torrecilla I, 2004, MICROBIOL-SGM, V150, P3731, DOI 10.1099/mic.0.27403-0; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Xu YB, 2003, ACTA CRYSTALLOGR D, V59, P2183, DOI 10.1107/S0907444903019589	47	83	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55202	55210		10.1074/jbc.M410971200	http://dx.doi.org/10.1074/jbc.M410971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502156	hybrid			2022-12-25	WOS:000225960800028
J	Nishiuchi, T; Shinshi, H; Suzuki, K				Nishiuchi, T; Shinshi, H; Suzuki, K			Rapid and transient activation of transcription of the ERF3 gene by wounding in tobacco leaves - Possible involvement of NtWRKYs and autorepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; ETHYLENE-RESPONSIVE ELEMENT; INDUCED EXPRESSION; ARABIDOPSIS; PATHOGEN; PROMOTER; STRESS; ATF3; HOMEOSTASIS; REVEALS	This study investigated the regulatory mechanism of rapid and transient induction of a transcriptional repressor ERF3 gene by wounding in tobacco ( Nicotiana tabacum) leaves. Deletion and mutation analysis of the promoter region have suggested that the proximal W boxes (TGAC(C/T)) and a GCC box, respectively, may be involved in the positive and negative regulation of wound-induced expression of the ERF3 gene. Electrophoretic mobility shift assays indicated that wounding enhanced the specific binding activity of nuclear factors to the W boxes. NtWRKY1, -2, and -4, which are tobacco group I WRKYs, interacted specifically with the W boxes and activated transcription via the W boxes. On the other hand, deletion of the GCC box from NsERF3 promoter-GUS reporter gene caused a delay in down-regulation of transcription after wound induction. In addition, ERF3 repressed transcription via the NsERF3 promoter activated by NtWRKYs. These results suggest the possible involvement of NtWRKYs and autorepression in the rapid and transient expression of the ERF3 gene by wounding.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Gene Regulat Grp, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Suzuki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Gene Regulat Grp, Cent 6, Tsukuba, Ibaraki 3058566, Japan.	kaoru-suzuki@aist.go.jp	Nishiuchi, Takumi/F-1708-2013; Suzuki, Kaoru/H-7676-2016	Suzuki, Kaoru/0000-0002-4467-7617; Nishiuchi, Takumi/0000-0001-9429-5396				Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Chen CH, 2000, PLANT MOL BIOL, V42, P387, DOI 10.1023/A:1006399311615; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; GREEN S, 1989, AM BOOK REV, V11, P1; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hara K, 2000, MOL GEN GENET, V263, P30, DOI 10.1007/PL00008673; Johnson CS, 2002, PLANT CELL, V14, P1359, DOI 10.1105/tpc.001404; KAWAOKA A, 1994, PLANT J, V6, P87, DOI 10.1046/j.1365-313X.1994.6010087.x; Kitajima S, 2000, PLANT CELL PHYSIOL, V41, P817, DOI 10.1093/pcp/41.6.817; Nishiuchi T, 1995, PLANT MOL BIOL, V29, P599, DOI 10.1007/BF00020987; Nishiuchi T, 1999, PLANT PHYSIOL, V121, P1239, DOI 10.1104/pp.121.4.1239; Nishiuchi T, 2002, PLANT MOL BIOL, V49, P473, DOI 10.1023/A:1015553232309; Ohme-Takagi M, 2000, PLANT CELL PHYSIOL, V41, P1187, DOI 10.1093/pcp/pcd057; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Ohta M, 2000, PLANT J, V22, P29, DOI 10.1046/j.1365-313x.2000.00709.x; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Robatzek S, 2002, GENE DEV, V16, P1139, DOI 10.1101/gad.222702; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; Rushton PJ, 2002, PLANT CELL, V14, P749, DOI 10.1105/tpc.010412; Stankovic B, 2000, PLANTA, V212, P60, DOI 10.1007/s004250000362; Sugimoto K, 2003, PLANT J, V36, P550, DOI 10.1046/j.1365-313X.2003.01899.x; Sun CX, 2003, PLANT CELL, V15, P2076, DOI 10.1105/tpc.014597; Suzuki K, 1998, PLANT J, V15, P657, DOI 10.1046/j.1365-313x.1998.00243.x; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Yamamoto S, 1999, PLANT J, V20, P571, DOI 10.1046/j.1365-313X.1999.00634.x; YAMAMOTO S, BIOCH BIOPHYS ACTA, V1679, P279; Yang PZ, 1999, PLANT J, V18, P141, DOI 10.1046/j.1365-313X.1999.00437.x; Yoda H, 2002, MOL GENET GENOMICS, V267, P154, DOI 10.1007/s00438-002-0651-z	33	121	146	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55355	55361		10.1074/jbc.M409674200	http://dx.doi.org/10.1074/jbc.M409674200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509567	hybrid			2022-12-25	WOS:000225960800048
J	Peter, JC; Wallukat, G; Tugler, J; Maurice, D; Roegel, JC; Briand, JP; Hoebeke, J				Peter, JC; Wallukat, G; Tugler, J; Maurice, D; Roegel, JC; Briand, JP; Hoebeke, J			Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTORS; INVERSE AGONIST; CHAGAS-DISEASE; PROTEIN-L; BINDING; AUTOANTIBODIES; ANTAGONIST; EPITOPES; SURFACE	Antibodies directed against the second extracellular loop of G protein-coupled receptors are known to have functional activities. From a partial agonist monoclonal antibody directed against the M2 muscarinic receptor, we constructed and produced a single chain variable fragment with high affinity for its target epitope. The fragment is able to recognize its receptor on Chinese hamster ovary cells transfected with the M2 muscarinic acetylcholine receptor to block the effect of carbachol on this receptor and to exert an inverse agonist activity on the basal activity of the receptor. The antibody fragment is also able to increase the basal rhythm of cultured neonatal rat cardiomyocytes and to inhibit in a non-competitive manner the negative chronotropic effect of carbachol. This antibody fragment is able to exert its inverse agonist activity in vivo on mouse heart activity. The immunological strategy presented here could be useful to develop specific allosteric inverse agonist reagents for G protein-coupled receptors.	Inst Biol Mol & Cellulaire, Lab Therapeut Chem & Immunol, CNRS, UPR 9021, F-67084 Strasbourg, France; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Sch Med, Inst Pharmacol, Forenap Therapeut Discovery, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; CHU Strasbourg; Universite de Franche-Comte	Hoebeke, J (corresponding author), Inst Biol Mol & Cellulaire, Lab Therapeut Chem & Immunol, CNRS, UPR 9021, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	j.hoebeke@ibmc.u-strasbg.fr	Maurice, Donald/AAE-9332-2019					AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; Aubrey N, 2001, BIOL CHEM, V382, P1621, DOI 10.1515/BC.2001.197; Bes C, 2001, FEBS LETT, V508, P67, DOI 10.1016/S0014-5793(01)03036-8; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; Borda ES, 1996, INT J CARDIOL, V54, P149, DOI 10.1016/0167-5273(96)02592-2; Brodde OE, 1998, J CLIN INVEST, V101, P471, DOI 10.1172/JCI1113; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Daeffler L, 1999, BRIT J PHARMACOL, V126, P1246, DOI 10.1038/sj.bjp.0702407; Daeffler L, 2000, FUND CLIN PHARMACOL, V14, P73, DOI 10.1111/j.1472-8206.2000.tb00395.x; Eftekhari P, 2001, EUR J IMMUNOL, V31, P573, DOI 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9; Elies R, 1996, J IMMUNOL, V157, P4203; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Graille M, 2001, STRUCTURE, V9, P679, DOI 10.1016/S0969-2126(01)00630-X; HALLE W, 1970, AM J CARDIOL, V25, P292, DOI 10.1016/S0002-9149(70)80006-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P397, DOI 10.1016/S0022-2828(08)80036-3; WALLUKAT G, 1987, BIOMED BIOCHIM ACTA, V46, P634	32	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55697	55706		10.1074/jbc.M407213200	http://dx.doi.org/10.1074/jbc.M407213200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15485827	hybrid			2022-12-25	WOS:000225960800090
J	Rausell, C; Pardo-Lopez, L; Sanchez, J; Munoz-Garay, C; Morera, C; Soberon, M; Bravo, A				Rausell, C; Pardo-Lopez, L; Sanchez, J; Munoz-Garay, C; Morera, C; Soberon, M; Bravo, A			Unfolding events in the water-soluble monomeric Cry1Ab toxin during transition to oligomeric pre-pore and membrane-inserted pore channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECTICIDAL CRYSTAL PROTEINS; STAPHYLOCOCCAL ALPHA-TOXIN; BRUSH-BORDER MEMBRANE; BACILLUS-THURINGIENSIS; DELTA-ENDOTOXIN; MANDUCA-SEXTA; AMINOPEPTIDASE-N; FORMING TOXIN; BINDING; DOMAIN	The insecticidal crystal (Cry) proteins produced by Bacillus thuringiensis undergo several conformational changes from crystal inclusion protoxins to membrane-inserted channels in the midgut epithelial cells of the target insect. Here we analyzed the stability of the different forms of Cry1Ab toxin, monomeric toxin, pre-pore complex, and membrane-inserted channel, after urea and thermal denaturation by monitoring intrinsic tryptophan fluorescence of the protein and 1-anilinonaphthalene-8-sulfonic acid binding to partially unfolded proteins. Our results showed that flexibility of the monomeric toxin was dramatically enhanced upon oligomerization and was even further increased by insertion of the pre-pore into the membrane as shown by the lower concentration of chaotropic agents needed to achieve unfolding of the oligomeric species. The flexibility of the toxin structures is further increased by alkaline pH. We found that the monomer-monomer interaction in the pre-pore is highly stable because urea promotes oligomer denaturation without disassembly. Partial unfolding and limited proteolysis studies demonstrated that domains II and III were less stable and unfold first, followed by unfolding of the most stable domain I, and also that domain I is involved in monomer-monomer interaction. The thermal-induced unfolding and analysis of energy transfer from Trp residues to bound 1-anilinonaphthalene-8-sulfonic acid dye showed that in the membrane-inserted pore domains II and III are particularly sensitive to heat denaturation, in contrast to domain I, suggesting that only domain I may be inserted into the membrane. Finally, the insertion into the membrane of the oligomeric pre-pore structure was not affected by pH. However, a looser conformation of the membrane-inserted domain I induced by neutral or alkaline pH correlates with active channel formation. Our studies suggest for the first time that a more flexible conformation of Cry toxin could be necessary for membrane insertion, and this flexible structure is induced by toxin oligomerization. Finally the alkaline pH found in the midgut lumen of lepidopteran insects could increase the flexibility of membrane-inserted domain I necessary for pore formation.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico	Bravo, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	bravo@ibt.unam.mx	de la Parra, Maria Alejandra Bravo/R-6740-2017; Rausell, Carolina/ABG-9554-2020	Rausell, Carolina/0000-0002-5849-9102; Bravo, Alejandra/0000-0002-7573-7475; Munoz-Garay, Carlos/0000-0002-7218-4027; Pardo Lopez, Liliana/0000-0002-8927-1733				ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Barry JK, 1999, BIOCHEMISTRY-US, V38, P6520, DOI 10.1021/bi9900727; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Cabiaux V, 1997, INT J BIOL MACROMOL, V21, P285, DOI 10.1016/S0141-8130(97)00078-0; Cabiaux V, 1997, BIOCHEMISTRY-US, V36, P15224, DOI 10.1021/bi971216p; CONVENTS D, 1990, J BIOL CHEM, V265, P1369; CONVENTS D, 1991, EUR J BIOCHEM, V195, P631, DOI 10.1111/j.1432-1033.1991.tb15747.x; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; Fang Y, 1997, BIOCHEMISTRY-US, V36, P9518, DOI 10.1021/bi970600j; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Guidry JJ, 2000, PROTEIN SCI, V9, P2109, DOI 10.1110/ps.9.11.2109; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFTE H, 1988, APPL ENVIRON MICROB, V54, P2010; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; Lesieur C, 1999, J BIOL CHEM, V274, P36722, DOI 10.1074/jbc.274.51.36722; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Lorence A, 1997, FEBS LETT, V414, P303, DOI 10.1016/S0014-5793(97)01014-4; Loseva OI, 2001, BIOCHEMISTRY-US, V40, P14143, DOI 10.1021/bi010171w; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; MUGA A, 1993, J BIOL CHEM, V268, P1553; ORT P, 1995, J PROTEIN CHEM, V14, P241, DOI 10.1007/BF01886765; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Sirangelo I, 2002, PHOTOCHEM PHOTOBIOL, V76, P381, DOI 10.1562/0031-8655(2002)076<0381:ROTAFE>2.0.CO;2; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Vecsey-Semjen B, 1999, BIOCHEMISTRY-US, V38, P4296, DOI 10.1021/bi982472k; VecseySemjen B, 1996, J BIOL CHEM, V271, P8655, DOI 10.1074/jbc.271.15.8655; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WEBER G, 1966, BIOCHEMISTRY-US, V5, P1900, DOI 10.1021/bi00870a017; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	42	42	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55168	55175		10.1074/jbc.M406279200	http://dx.doi.org/10.1074/jbc.M406279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498772	hybrid			2022-12-25	WOS:000225960800024
J	So, S; Adachi, N; Lieber, MR; Koyama, H				So, S; Adachi, N; Lieber, MR; Koyama, H			Genetic interactions between BLM and DNA ligase IV in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; BLOOMS-SYNDROME HELICASE; END-JOINING PATHWAYS; EMBRYONIC STEM-CELLS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; RECQ HELICASES; ERROR-PRONE	BLM has been implicated in DNA double-strand break (DSB) repair, but its precise role remains obscure. To explore this, we generated BLM-/- and BLM(-/-)LIG4(-/-) cells from the human pre-B cell line Nalm-6. BLM-/- cells exhibited retarded growth, increased mutation rates, and hypersensitivity to agents that block replication fork progression. Interestingly, these phenotypes were significantly suppressed by deletion of LIG4, suggesting that nonhomologous end-joining (NHEJ) is unfavorable for integrity and survival of cells lacking BLM. We propose that the absence of BLM leads to accumulation of replication-associated, one-ended DSBs, which are deleterious to cells and lead to genomic instability when repaired by NHEJ. In addition, the NHEJ pathway per se was marginally affected by BLM deficiency, as evidenced by x-ray sensitivity and I-SceI-based DSB repair assays. More intriguingly, however, these experiments revealed the presence of an alternative, DNA ligase IV-independent end-joining pathway, which was significantly affected by the loss of BLM. Collectively, our results provide the first evidence for genetic interactions between BLM and NHEJ in human cells.	Yokohama City Univ, Grad Sch Integrated Sci, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Microbiol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol, Los Angeles, CA 90089 USA	Yokohama City University; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Koyama, H (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Kihara Inst Biol Res, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	koyama@yokohama-cu.ac.jp		Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Adachi N, 2004, BIOCHEM BIOPH RES CO, V318, P856, DOI 10.1016/j.bbrc.2004.04.099; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Helleday T, 1998, CARCINOGENESIS, V19, P973, DOI 10.1093/carcin/19.6.973; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Karathanasis E, 2002, GENETICS, V161, P1015; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kobayashi M, 2001, CANCER LETT, V166, P71, DOI 10.1016/S0304-3835(01)00447-5; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Langland G, 2002, CANCER RES, V62, P2766; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luria SE, 1943, GENETICS, V28, P491; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Min BS, 2004, P NATL ACAD SCI USA, V101, P8906, DOI 10.1073/pnas.0403000101; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Onclercq-Delic R, 2003, NUCLEIC ACIDS RES, V31, P6272, DOI 10.1093/nar/gkg834; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; Sado K, 2001, J BIOL CHEM, V276, P9742, DOI 10.1074/jbc.M010530200; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tachibana A, 1996, MOL CARCINOGEN, V17, P41, DOI 10.1002/(SICI)1098-2744(199609)17:1<41::AID-MC6>3.3.CO;2-Z; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Traverso G, 2003, CANCER RES, V63, P8578; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	56	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55433	55442		10.1074/jbc.M409827200	http://dx.doi.org/10.1074/jbc.M409827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509577	hybrid			2022-12-25	WOS:000225960800058
J	Yu, G; Luo, HY; Wu, YL; Wu, JP				Yu, G; Luo, HY; Wu, YL; Wu, JP			EphrinB1 is essential in T-cell-T-cell co-operation during T-cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; EPH FAMILY RECEPTORS; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; TRANSGENIC MICE; CYCLOSPORINE-A; CROSS-LINKING; B LIGANDS; EXPRESSION; RAPAMYCIN	kinases are the largest family of receptor tyrosine kinases, and their ligands are ephrins (EFNs), which are also cell surface molecules. We have very limited knowledge about the expression and function of these kinases and their ligands in the immune system. In this study we investigated the effect of EFNB1 on mouse T-cells. EFNB1 and the Eph kinases it interacts with (collectively called EFNB1 receptors (EFNB1R)) were expressed on T-cells, B cells, and monocytes/macrophages. Some T-cells were double positive for EFNB1 and EFBB1R. Solid phase EFNB1 in the presence of suboptimal TCR ligation augmented T-cell responses in terms interferon-gamma secretion, proliferation, and cytotoxic T lymphocyte activity but not interleukin-2 production. After T-cell receptor (TCR) ligation, EFNB1R congregated to TCR caps, and then both of them translocated to raft caps. This provides a morphological basis for EFNB1R to enhance TCR signaling. Further downstream of the signaling pathway, EFNB1R stimulation led to increased LAT (linker for activation of T-cells) phosphorylation and p44/42 and p38 MAPK activation. Similar to CD28 costimulation, EFNB1R costimulation was insensitive to cyclosporin A inhibition. On the other hand, unlike the former, EFNB1R costimulation failed to activate Akt, which is essential in triggering interleukin-2 production. Our study suggests that EFNB1 is pivotal in T-cell-T-cell costimulation and in reducing T-cell response threshold to antigen stimulation.	Univ Montreal, CHUM, Notre Dame Hosp, Res Ctr,Lab Immunol, Montreal, PQ H2L 4M1, Canada; Univ Montreal, CHUM, Notre Dame Hosp, Serv Nephrol, Montreal, PQ H2L 4M1, Canada; Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Surg, Hangzhou 310016, Peoples R China	Universite de Montreal; Universite de Montreal; Zhejiang University	Wu, JP (corresponding author), Univ Montreal, CHUM, Notre Dame Hosp, Res Ctr,Lab Immunol, Pavil DeSeve,Rm Y-5616,1560 Sherbrooke St, Montreal, PQ H2L 4M1, Canada.	jianping.wu@umontreal.ca						Almawi WY, 1999, EUR J PHARMACOL, V381, P51, DOI 10.1016/S0014-2999(99)00558-0; ANDRES AC, 1994, ONCOGENE, V9, P1461; Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; Chang TT, 1999, J EXP MED, V190, P733, DOI 10.1084/jem.190.5.733; Chen HF, 1996, J IMMUNOL, V157, P4297; CIOSSEK T, 1995, ONCOGENE, V11, P2085; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Ghosh P, 2002, BLOOD, V99, P4517, DOI 10.1182/blood-2001-11-0062; Gurniak CB, 1996, ONCOGENE, V13, P777; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUET S, 1989, J IMMUNOL, V143, P798; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; Lickliter JD, 1996, P NATL ACAD SCI USA, V93, P145, DOI 10.1073/pnas.93.1.145; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; LUO HY, 1992, TRANSPLANTATION, V53, P1071, DOI 10.1097/00007890-199205000-00019; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Mann F, 2002, NEURON, V35, P461, DOI 10.1016/S0896-6273(02)00786-9; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Munoz JJ, 2002, J IMMUNOL, V169, P177, DOI 10.4049/jimmunol.169.1.177; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; Salojin KV, 1999, J IMMUNOL, V163, P844; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Shi GX, 2002, BLOOD, V100, P3279, DOI 10.1182/blood-2002-05-1404; Shimoyama M, 2002, BIOCHEM BIOPH RES CO, V298, P87, DOI 10.1016/S0006-291X(02)02399-9; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Tai XG, 1996, J EXP MED, V184, P753, DOI 10.1084/jem.184.2.753; Tang XX, 1999, CLIN CANCER RES, V5, P455; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Yu G, 2003, J IMMUNOL, V171, P106, DOI 10.4049/jimmunol.171.1.106; Yu G, 2003, J BIOL CHEM, V278, P47209, DOI 10.1074/jbc.M306659200; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163-7258(97)00112-5	51	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55531	55539		10.1074/jbc.M410814200	http://dx.doi.org/10.1074/jbc.M410814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502157	hybrid			2022-12-25	WOS:000225960800069
J	Gline, SE; Cambier, S; Govaerts, C; Nishimura, SL				Gline, SE; Cambier, S; Govaerts, C; Nishimura, SL			A 50-angstrom separation of the integrin alpha(v)beta(3) extracellular domain C termini reveals an intermediate activation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; LIGAND-BINDING; HIGH-AFFINITY; ALPHA-V-BETA-3; RECEPTOR; COMPLEX; ALPHA-IIB-BETA-3	The integrin alpha(v)beta(3) has been shown to exist in low and high affinity conformations. Activation to the high affinity state is thought to depend on the "switchblade-like" opening, from a low affinity bent conformation with a closed headpiece to an extended form of the integrin with an open headpiece. Activation has been shown to depend on separation of the cytoplasmic domains. How cytoplasmic domain separation is related to separation of the transmembrane domains is unknown, and the distance of separation of the transmembrane domains required for activation has not been defined. A constrained secreted form of alpha(v)beta(3) was engineered that introduced a 50-Angstrom separation of the integrin C-terminal tails of the extracellular domains of the alpha(v) and beta(3) subunits. Receptor binding and recognition by ligand-induced binding state (LIBS) monoclonal antibodies demonstrated that the mutant receptor was locked into a low affinity state that was likely in a partially extended conformation but with a closed headpiece. In the presence of RGD peptide, the constrained receptor was able to fully extend, as determined by full exposure of LIBS epitopes. In the presence of the appropriate LIBS antibody, high affinity ligand binding of the constrained receptor was achieved. The results support the existence of transient intermediate activation states of secreted alpha(v)beta(3). Furthermore, these results with the secreted alpha(v)beta(3) receptor support a model for the full-length membrane-bound form of alpha(v)beta(3), whereby a 50-Angstrom lateral separation of the integrin alpha(v) and beta(3) transmembrane domains would be sufficient to enforce the switchblade-like opening to the extended conformation but insufficient for full receptor activation.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco	Nishimura, SL (corresponding author), San Francisco Gen Hosp, Dept Pathol, Bldg 3,Rm 207,1001 Potrero Ave, San Francisco, CA 94110 USA.	cdog@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL070622, R01HL063993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044155] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70622, HL63993] Funding Source: Medline; NINDS NIH HHS [NS-44155] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; NEWMAN PJ, 1987, BLOOD, V69, P668; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	23	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54567	54572		10.1074/jbc.M406582200	http://dx.doi.org/10.1074/jbc.M406582200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475365	hybrid			2022-12-25	WOS:000225793600082
J	Mandal, AK; Yang, Y; Kertesz, TM; Arguello, JM				Mandal, AK; Yang, Y; Kertesz, TM; Arguello, JM			Identification of the transmembrane metal binding site in Cu+-transporting P-IB-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; WILSONS-DISEASE PROTEIN; HIGH-AFFINITY TRANSPORT; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; CALCIUM-PUMP; ARCHAEOGLOBUS-FULGIDUS; CATION-BINDING; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL CONSEQUENCES	P-IB-type ATPases have an essential role maintaining copper homeostasis. Metal transport by these membrane proteins requires the presence of a transmembrane metal occlusion/binding site. Previous studies showed that Cys residues in the H6 transmembrane segment are required for metal transport. In this study, the participation in metal binding of conserved residues located in transmembrane segments H7 and H8 was tested using CopA, a model Cu+-ATPase from Archaeoglobus fulgidus. Four invariant amino acids in the central portion of H7 (Tyr(682) and Asn(683)) and H8 (Met(711) and Ser(715)) were identified as required for Cu+ binding. Replacement of these residues abolished enzyme activity. These proteins did not undergo Cu+-dependent phosphorylation by ATP but were phosphorylated by P-i in the absence of Cu+. Moreover, the presence of Cu+ could not prevent the enzyme phosphorylation by P-i. Other conserved residues in the H7-H8 region were not required for metal binding. Mutation of two invariant Pro residues had little effect on enzyme function. Replacement of residues located close to the cytoplasmic end of H7-H8 led to inactive enzymes. However, these were able to interact with Cu+ and undergo phosphorylation. This suggests that the integrity of this region is necessary for conformational transitions but not for ligand binding. These data support the presence of a unique transmembrane Cu+ binding/translocation site constituted by Tyr-Asn in H7, Met and Ser in H8, and two Cys in H6 of Cu+-ATPases. The likely Cu+ coordination during transport appears distinct from that observed in Cu+ chaperone proteins or catalytic/redox metal binding sites.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA	Worcester Polytechnic Institute	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, 100 Inst Rd, Worcester, MA 01609 USA.	arguello@wpi.edu	Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Eitinger T, 1997, J BIOL CHEM, V272, P17139, DOI 10.1074/jbc.272.27.17139; Eren E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/pp.104.046292; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Fulkerson JF, 1998, J BIOL CHEM, V273, P235, DOI 10.1074/jbc.273.1.235; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; Hsi G, 2004, HUM GENET, V114, P165, DOI 10.1007/s00439-003-1045-y; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Loudianos G, 1999, J MED GENET, V36, P833; Lowe J, 2004, J BIOL CHEM, V279, P25986, DOI 10.1074/jbc.M308736200; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; LUTSENKO S, 1995, P NATL ACAD SCI USA, V87, P4566; Mana-Capelli S, 2003, J BIOL CHEM, V278, P40534, DOI 10.1074/jbc.M306907200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mikhailova L, 2002, BIOCHEMISTRY-US, V41, P8195, DOI 10.1021/bi025721k; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; POST RL, 1972, J BIOL CHEM, V247, P6530; Ralle M, 1999, J INORG BIOCHEM, V74, P271; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; Tsivkovskii R, 2003, J BIOL CHEM, V278, P13302, DOI 10.1074/jbc.M300034200; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008	61	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54802	54807		10.1074/jbc.M410854200	http://dx.doi.org/10.1074/jbc.M410854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494391	hybrid			2022-12-25	WOS:000225793600108
J	Mosley, AL; Ozcan, S				Mosley, AL; Ozcan, S			The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-EXPRESSION; TRANSCRIPTION FACTOR PDX-1; MUSCLE DIFFERENTIATION; CELL FUNCTION; PHOSPHORYLATION; PROMOTER; COACTIVATOR; CBP/P300; COMPLEX; BINDING	We have previously demonstrated that high concentrations of glucose stimulate insulin gene expression by causing hyperacetylation of histone H4 at the insulin gene promoter. Furthermore, we have shown that the glucose-mediated hyperacetylation of histone H4 depends on the recruitment of the histone acetyltransferase p300 by the beta cell-specific transcription factor Pdx-1. In this study, we demonstrate that the histone deacetylases Hdac-1 and Hdac-2 are rapidly recruited to the insulin promoter in the mouse insulinoma cell line MIN6 when cells are switched from high to low glucose media. Moreover, we demonstrate that the beta cell-specific homeodomain protein Pdx-1 interacts with histone deacetylases Hdac-1 and Hdac-2 at low levels of glucose. In vitro studies indicate that the interaction between Pdx-1 and Hdac-1 or Hdac-2 is direct and requires the C terminus of Pdx-1. Treatment of MIN6 cells with okadaic acid, which inhibits the activity of protein phosphatases, abolishes the interaction of Pdx-1 with Hdac-1 and Hdac-2 on low levels of glucose, suggesting the requirement of a dephosphorylation event for this interaction to occur. These data indicate that insulin gene expression is decreased on low levels of glucose by recruitment of Hdac-1 and Hdac-2 to the insulin promoter by the transcription factor Pdx-1.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, MN608, Lexington, KY 40536 USA.	sozcan@uky.edu						Asahara H, 1999, MOL CELL BIOL, V19, P8219; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Edlund H, 2001, DIABETOLOGIA, V44, P1071, DOI 10.1007/s001250100623; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; Goodman RH, 2000, GENE DEV, V14, P1553; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heltweg B, 2002, ANAL BIOCHEM, V302, P175, DOI 10.1006/abio.2001.5542; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leibowitz G, 2001, DIABETES, V50, pS138, DOI 10.2337/diabetes.50.2007.S138; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Melloul D, 2004, ANN NY ACAD SCI, V1014, P28, DOI 10.1196/annals.1294.003; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Mosley Amber L, 2003, Methods Mol Med, V83, P73; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	48	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54241	54247		10.1074/jbc.M410379200	http://dx.doi.org/10.1074/jbc.M410379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496408	hybrid			2022-12-25	WOS:000225793600044
J	Sorgen, PL; Duffy, HS; Sahoo, P; Coombs, W; Delmar, M; Spray, DC				Sorgen, PL; Duffy, HS; Sahoo, P; Coombs, W; Delmar, M; Spray, DC			Structural changes in the carboxyl terminus of the gap junction protein connexin43 indicates signaling between binding domains for c-Src and zonula occludens-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; V-SRC; CARDIAC MYOCYTES; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; NULL MUTATION; PH REGULATION; CHANNELS; COMMUNICATION	Regulation of cell-cell communication by the gap junction protein connexin43 can be modulated by a variety of connexin-associating proteins. In particular, c-Src can disrupt the connexin43 (Cx43)-zonula occludens-1 (ZO-1) interaction, leading to down-regulation of gap junction intercellular communication. The binding sites for ZO-1 and c-Src correspond to widely separated Cx43 domains (similar to100 residues apart); however, little is known about the structural modifications that may allow information to be transferred over this distance. Here, we have characterized the structure of the connexin43 carboxyl-terminal domain (Cx43CT) to assess its ability to interact with domains from ZO-1 and c-Src. NMR data indicate that the Cx43CT exists primarily as an elongated random coil, with two regions of alpha-helical structure. NMR titration experiments determined that the ZO-1 PDZ-2 domain affected the last 19 Cx43CT residues, a region larger than that reported to be required for Cx43CT-ZO-1 binding. The c-Src SH3 domain affected Cx43CT residues Lys-264-Lys-287, Ser-306-Glu-316, His-331-Phe-337, Leu-356-Val-359, and Ala-367-Ser-372. Only region Lys-264-Lys-287 contains the residues previously reported to act as an SH3 binding domain. The specificity of these interactions was verified by peptide competition experiments. Finally, we demonstrated that the SH3 domain could partially displace the Cx43CT-PDZ-2 complex. These studies represent the first structural characterization of a connexin domain when integrated in a multimolecular complex. Furthermore, we demonstrate that the structural characteristics of a disordered Cx43CT are advantageous for signaling between different binding partners that may be important in describing the mechanism of channel closure or internalization in response to pathophysiological stimuli.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	University of Nebraska System; University of Nebraska Medical Center; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sorgen, PL (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	psorgen@unmc.edu		Delmar, Mario/0000-0002-2085-5589; Spray, David/0000-0001-8368-5073	NHLBI NIH HHS [HL39707] Funding Source: Medline; NIGMS NIH HHS [GM57691] Funding Source: Medline; NIMH NIH HHS [MH65495] Funding Source: Medline; NINDS NIH HHS [NS41282] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL039707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; ATKINSON MM, 1995, J CELL SCI, V108, P3079; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Brizuela BJ, 2001, DEV BIOL, V230, P217, DOI 10.1006/dbio.2000.0116; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukauskas FF, 2002, J GEN PHYSIOL, V119, P171, DOI 10.1085/jgp.119.2.171; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dermietzel R, 2000, BRAIN RES REV, V32, P45, DOI 10.1016/S0165-0173(99)00067-3; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; DUNHAM B, 1992, CIRC RES, V70, P1233, DOI 10.1161/01.RES.70.6.1233; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; Fujimoto K, 1997, J CELL SCI, V110, P311; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Giepmans BNG, 2004, CARDIOVASC RES, V62, P233, DOI 10.1016/j.cardiores.2003.12.009; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; Herve JC, 2004, BBA-BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022; Homma N, 1998, CIRC RES, V83, P27, DOI 10.1161/01.RES.83.1.27; Iacobas DA, 2004, NEUROCHEM INT, V45, P243, DOI 10.1016/j.neuint.2003.12.008; Iacobas DA, 2003, PHYSIOL GENOMICS, V15, P177, DOI 10.1152/physiolgenomics.00062.2003; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; Liao Y, 2001, P NATL ACAD SCI USA, V98, P9989, DOI 10.1073/pnas.171305298; Lin R, 2001, CELL COMMUN ADHES, V8, P265, DOI 10.3109/15419060109080735; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Morley GE, 1999, J CARDIOVASC ELECTR, V10, P1361, DOI 10.1111/j.1540-8167.1999.tb00192.x; MUNSTER PN, 1993, PFLUG ARCH EUR J PHY, V423, P181, DOI 10.1007/BF00374392; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Saez JC, 1997, J MOL CELL CARDIOL, V29, P2131, DOI 10.1006/jmcc.1997.0447; Scemes E, 2000, J NEUROSCI, V20, P1435; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 2004, CARDIOVASC RES, V62, P228, DOI 10.1016/j.cardiores.2003.11.013; Solan JL, 2003, J CELL SCI, V116, P2203, DOI 10.1242/jcs.00428; Sorgen PL, 2004, BIOPHYS J, V87, P574, DOI 10.1529/biophysj.103.039230; Sorgen PL, 2002, J BIOMOL NMR, V23, P245, DOI 10.1023/A:1019892719979; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SPRAY DC, 1991, BRAIN RES, V568, P1, DOI 10.1016/0006-8993(91)91373-9; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; VUISTER GW, 1993, J MAGN RESON, V96, P432; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	79	150	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54695	54701		10.1074/jbc.M409552200	http://dx.doi.org/10.1074/jbc.M409552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15492000	hybrid			2022-12-25	WOS:000225793600096
J	Vives, RR; Crublet, E; Andrieu, JP; Gagnon, J; Rousselle, P; Lortat-Jacob, H				Vives, RR; Crublet, E; Andrieu, JP; Gagnon, J; Rousselle, P; Lortat-Jacob, H			A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE OLIGOSACCHARIDES; LAMININ ALPHA-1 CHAIN; PSEUDORABIES VIRUS; BINDING DOMAIN; GLYCOSAMINOGLYCAN BINDING; RECEPTOR-BINDING; RANTES; SITE; CHEMOKINES	The binding of proteins to glycosaminoglycans (GAGs) is the prerequisite for a large number of cellular processes and regulatory events and is associated to many pathologies. However, progress in the understanding of these mechanisms has been hampered by the lack of simple and comprehensive analytical tools for the identification of the structural attributes involved in protein/saccharide interaction. Characterization of GAG binding motifs on proteins has so far relied on site-directed mutagenesis studies, protein sequence mapping using synthetic peptides, molecular modeling, or structural analysis. Here, we report the development of a novel approach for identifying protein residues involved in the binding to heparin, the archetypal member of the GAG family. This method, which uses native proteins, is based on the formation of cross-linked complexes of the protein of interest with heparin beads, the proteolytic digestion of these complexes, and the subsequent identification of the heparin binding containing peptides by N terminus sequencing. Analysis of the CC chemokine regulated on activation, normal T-cell expressed, and secreted (RANTES), the envelope glycoprotein gC from pseudorabies virus and the laminin-5 alpha3LG4/5 domain validated the techniques and provided novel information on the heparin binding motifs present within these proteins. Our results highlighted this method as a fast and valuable alternative to existing approaches. Application of this technique should greatly contribute to facilitate the structural study of protein/GAG interactions and the understanding of their biological functions.	UJF, CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 01, France; Univ Grenoble 1, Fac Med, CNRS, FRE 2685, F-38706 La Tronche, France; Univ Grenoble 1, Fac Pharm, CNRS, FRE 2685, F-38706 La Tronche, France; IFR 128 BioSci Lyon Gerland, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Vives, RR (corresponding author), UJF, CEA, CNRS, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble 01, France.	vives@ibs.fr	Rousselle, Patricia/J-5290-2019; Rousselle, Patricia/CAF-3915-2022; Gagnon, Jean/C-3136-2008; Vives, Romain/I-9372-2012	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562; Gagnon, Jean/0000-0002-0177-824X; 				Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Baker SE, 1996, J CELL SCI, V109, P2509; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P637, DOI 10.1016/j.sbi.2003.09.002; Flynn SJ, 1996, J VIROL, V70, P1355, DOI 10.1128/JVI.70.3.1355-1364.1996; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Karger A, 1996, J VIROL, V70, P2138, DOI 10.1128/JVI.70.4.2138-2145.1996; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LIANG XP, 1993, VIROLOGY, V194, P233, DOI 10.1006/viro.1993.1254; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; Nishiyama T, 2000, J DERMATOL SCI, V24, pS51, DOI 10.1016/S0923-1811(00)00142-0; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Suzuki N, 2003, BIOCHEMISTRY-US, V42, P12625, DOI 10.1021/bi030014s; Trybala E, 1998, J BIOL CHEM, V273, P5047, DOI 10.1074/jbc.273.9.5047; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Yamashita H, 2004, J MOL BIOL, V335, P1145, DOI 10.1016/j.jmb.2003.11.047; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003	46	39	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54327	54333		10.1074/jbc.M409760200	http://dx.doi.org/10.1074/jbc.M409760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485868				2022-12-25	WOS:000225793600054
J	Walker, KD; Klettke, K; Akiyama, T; Croteau, R				Walker, KD; Klettke, K; Akiyama, T; Croteau, R			Cloning, heterologous expression, and characterization of a phenylalanine aminomutase involved in Taxol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE AMMONIA-LYASE; 4-METHYLIDENEIMIDAZOLE-5-ONE-CONTAINING TYROSINE AMINOMUTASE; ANTIBIOTIC C-1027 BIOSYNTHESIS; STREPTOMYCES-GRISEUS; PHENYLPROPANOID METABOLISM; LEUCINE 2,3-AMINOMUTASE; CLOSTRIDIUM-STICKLANDII; RADICAL MECHANISMS; STRUCTURAL GENE; BETA-TYROSINE	Biosynthesis of the N-benzoyl phenylisoserinoyl side chain of the anticancer drug Taxol starts with the conversion of 2S-alpha-phenylalanine to 3R-beta-phenylalanine by phenylalanine aminomutase (PAM). A gene cloning approach was based on the assumption that PAM would resemble the well known plant enzyme phenylalanine ammonia lyase. A phenylalanine ammonia lyase-like sequence acquired from a Taxus cuspidata cDNA library was expressed functionally in Escherichia coli and confirmed as the target aminomutase that is virtually identical to the recombinant enzyme and clone from Taxus chinensis, acquired recently by a reverse genetics approach (Bristol-Myers Squibb (August 14, 2003) U.S. Patent WO 03/066871 A2). The full-length cDNA has an open reading frame of 2094 base pairs and encodes a protein of 698 residues with a calculated molecular mass of 76,530 Da. The recombinant mutase has a pH optimum of 8.5, a k(cat) value of 0.015 s(-1), and a K-m of 45+/-8 muM for 2S-alpha-phenylalanine. The stereochemical mechanism of PAM involves the removal and interchange of the pro-3S hydrogen and the amino group, which rebonds at C-3 with retention of configuration. The recombinant enzyme appears to catalyze both the forward and reverse reactions with specificity for both 2S-alpha-phenylalanine and 3S- or 3R-beta-phenylalanine substrates, respectively, whereas the related phenylpropanoids 2S-aminocyclohexanepropanoic acid, 2R-alpha-phenylalanine, and 2S-alpha-tyrosine are not converted to their beta-isomers by the mutase.	Michigan State Univ, Dept Chem & Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Michigan State University; Michigan State University; Washington State University	Walker, KD (corresponding author), Michigan State Univ, Dept Chem, 320 Chem, E Lansing, MI 48824 USA.	walke284@msu.edu		Walker, Kevin/0000-0001-5208-6692	NCI NIH HHS [CA-55254] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055254, R37CA055254] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERHART DJ, 1983, J AM CHEM SOC, V105, P5461, DOI 10.1021/ja00354a046; APPERT C, 1994, EUR J BIOCHEM, V225, P491, DOI 10.1111/j.1432-1033.1994.00491.x; Campbell MM, 1996, PLANT PHYSIOL, V110, P3, DOI 10.1104/pp.110.1.3; Chen HP, 2001, J BIOL CHEM, V276, P44744, DOI 10.1074/jbc.M108365200; Christenson SD, 2003, BIOCHEMISTRY-US, V42, P12708, DOI 10.1021/bi035223r; Christenson SD, 2003, J AM CHEM SOC, V125, P6062, DOI 10.1021/ja034609m; COMMERCON A, 1992, TETRAHEDRON LETT, V33, P5185, DOI 10.1016/S0040-4039(00)79128-3; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; FREER I, 1981, J CHEM SOC CHEM COMM, P80, DOI 10.1039/c39810000080; Frey P. A., 1999, Chemistry and biochemistry of B12., P835; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; GEORG GI, 1994, EXPERT OPIN THER PAT, V4, P109; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; He LF, 2000, BIOCHEMISTRY-US, V39, P3972, DOI 10.1021/bi992518p; Hefner J, 1998, ARCH BIOCHEM BIOPHYS, V360, P62, DOI 10.1006/abbi.1998.0926; HOCKING MB, 1969, CAN J CHEMISTRY, V47, P4567, DOI 10.1139/v69-757; Holton RA., 1995, TAXOL SCI APPL, P97, DOI DOI 10.1002/CHIN.199552275; Jennewein S, 2004, P NATL ACAD SCI USA, V101, P9149, DOI 10.1073/pnas.0403009101; JORDAN PM, 1994, CURR OPIN STRUC BIOL, V4, P902, DOI 10.1016/0959-440X(94)90273-9; Ketchum REB, 2003, PHYTOCHEMISTRY, V62, P901, DOI 10.1016/S0031-9422(02)00711-2; KURYLOBOROWSKA Z, 1972, BIOCHIM BIOPHYS ACTA, V264, P1, DOI 10.1016/0304-4165(72)90110-9; Kyndt JA, 2002, FEBS LETT, V512, P240, DOI 10.1016/S0014-5793(02)02272-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER M, 1995, ANGEW CHEM INT EDIT, V34, P1464, DOI 10.1002/anie.199514641; MORLEY CGD, 1970, BIOCHEMISTRY-US, V9, P4890, DOI 10.1021/bi00827a010; PARNESS J, 1982, BIOCHEM BIOPH RES CO, V105, P1082, DOI 10.1016/0006-291X(82)91080-4; PARRY RJ, 1980, J AM CHEM SOC, V102, P836, DOI 10.1021/ja00522a065; POSTON JM, 1988, METHOD ENZYMOL, V166, P130; POSTON JM, 1980, J BIOL CHEM, V255, P67; POSTON JM, 1978, PHYTOCHEMISTRY, V17, P401, DOI 10.1016/S0031-9422(00)89324-3; PRABHAKARAN PC, 1988, J AM CHEM SOC, V110, P5785, DOI 10.1021/ja00225a033; RETEY J, 1978, HELV CHIM ACTA, V61, P2989, DOI 10.1002/hlca.19780610824; Rother R, 2001, EUR J BIOCHEM, V268, P6011; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P8433, DOI 10.1073/pnas.92.18.8433; Schwede TF, 1999, BIOCHEMISTRY-US, V38, P5355, DOI 10.1021/bi982929q; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STEELE CL, 2003, Patent No. 2003633941; Walker K, 2002, P NATL ACAD SCI USA, V99, P12715, DOI 10.1073/pnas.192463699; Walker K, 2002, P NATL ACAD SCI USA, V99, P9166, DOI 10.1073/pnas.082115799; WALKER K, 1997, THESIS U WASHINGTON; Walker KD, 1998, J AM CHEM SOC, V120, P5333, DOI 10.1021/ja980457x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU PC, 1992, GENE, V115, P19, DOI 10.1016/0378-1119(92)90535-W; WU PC, 1995, J BACTERIOL, V177, P854, DOI 10.1128/jb.177.3.854-857.1995; WU PC, 1992, J BACTERIOL, V174, P1647, DOI 10.1128/jb.174.5.1647-1655.1992; Zeng G, 1998, BIOTECHNIQUES, V25, P788	46	100	119	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53947	53954		10.1074/jbc.M411215200	http://dx.doi.org/10.1074/jbc.M411215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15494399	hybrid			2022-12-25	WOS:000225793600008
J	Zamboni, DS; Campos, MA; Torrecilhas, ACT; Kiss, K; Samuel, JE; Golenbock, DT; Lauw, FN; Roy, CR; Almeida, IC; Gazzinelli, RT				Zamboni, DS; Campos, MA; Torrecilhas, ACT; Kiss, K; Samuel, JE; Golenbock, DT; Lauw, FN; Roy, CR; Almeida, IC; Gazzinelli, RT			Stimulation of Toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; TUMOR-NECROSIS-FACTOR; PHASE-II; Q-FEVER; LIPID-A; CELL ACTIVATION; HUMAN MONOCYTES; IN-VITRO; LIPOPOLYSACCHARIDE; LIPOPROTEINS	Innate and adaptive immune responses are initiated upon recognition of microbial molecules by Toll-like receptors (TLRs). We have investigated the importance of these receptors in the induction of pro-inflammatory cytokines and macrophage resistance to infection with Coxiella burnetii, an obligate intracellular bacterium and the etiological agent of Q fever. By using a Chinese hamster ovary/CD14 cell line expressing either functional TLR2 or TLR4, we determined that C. burnetii phase II activates TLR2 but not TLR4. Macrophages deficient for TLR2, but not TLR4, produced less tumor necrosis factor-alpha and interleukin-12 upon C. burnetii infection. Furthermore, it was found that TLR2 activation interfered with C. burnetii intracellular replication, as macrophages from TLR2-deficient mice were highly permissive for C. burnetii growth compared with macrophages from wild type mice or TLR4-deficient mice. Although LPS modifications distinguish virulent C. burnetii phase I bacteria from avirulent phase II organisms, electrospray ionization-mass spectrometry analysis showed that the lipid A moieties isolated from these two phase variants are identical. Purified lipid A derived from either phase I or phase II LPS failed to activate TLR2 and TLR4. Indeed, the lipid A molecules were able to interfere with TLR4 signaling in response to purified Escherichia coli LPS. These studies indicate that TLR2 is an important host determinant that mediates recognition of C. burnetii and a response that limits growth of this intracellular pathogen.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Oswaldo Cruz Fdn, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil; Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508000 Sao Paulo, Brazil; Texas A&M Univ Syst, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Texas A&M University System; Texas A&M University College Station; University of Massachusetts System; University of Massachusetts Worcester; Universidade Federal de Minas Gerais	Zamboni, DS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, Rm 354,295 Congress Ave, New Haven, CT 06536 USA.	dario.zamboni@yale.edu	Almeida, Igor C./AAF-9409-2019; Torrecilhas, Ana Claudia/AFR-7084-2022; Campos, Marco Antonio/AAU-6229-2021; Zamboni, Dario S/D-3024-2012; /W-6163-2019; Campos, Marco A/C-4000-2013	Almeida, Igor C./0000-0002-2443-8213; Torrecilhas, Ana Claudia/0000-0001-5724-2199; Campos, Marco Antonio/0000-0003-4683-0176; Zamboni, Dario S/0000-0002-7856-7512; Campos, Marco A/0000-0003-4683-0176; Roy, Craig/0000-0003-4490-440X; Gazzinelli, Ricardo/0000-0003-2427-7699	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037744, R01AI049309, R21AI037744, R29AI037744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37744, AI49309, AI448191] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; AMANO KI, 1984, J BACTERIOL, V160, P994, DOI 10.1128/JB.160.3.994-1002.1984; Baca Oswald G., 1994, Trends in Microbiology, V2, P476, DOI 10.1016/0966-842X(94)90651-3; Beron W, 2002, INFECT IMMUN, V70, P5816, DOI 10.1128/IAI.70.10.5816-5821.2002; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; CHAN S, 1994, ANAL BIOCHEM, V218, P63, DOI 10.1006/abio.1994.1141; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; Dellacasagrande J, 2000, INFECT IMMUN, V68, P5673, DOI 10.1128/IAI.68.10.5673-5678.2000; Dellacasagrande J, 1999, J IMMUNOL, V162, P2259; Delude RL, 1998, J IMMUNOL, V161, P3001; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Girard R, 2003, J CELL SCI, V116, P293, DOI 10.1242/jcs.00212; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heinzen RA, 1999, TRENDS MICROBIOL, V7, P149, DOI 10.1016/S0966-842X(99)01475-4; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Honstettre A, 2004, J IMMUNOL, V172, P3695, DOI 10.4049/jimmunol.172.6.3695; Honstettre AL, 2003, J INFECT DIS, V187, P956, DOI 10.1086/368129; Hoover TA, 2002, INFECT IMMUN, V70, P6726, DOI 10.1128/IAI.70.12.6726-2733.2002; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Marrie TJ, 2004, CURR OPIN INFECT DIS, V17, P137, DOI 10.1097/00001432-200404000-00012; MAURIN M, 1992, INFECT IMMUN, V60, P5013, DOI 10.1128/IAI.60.12.5013-5016.1992; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; Muroi M, 2003, INFECT IMMUN, V71, P3221, DOI 10.1128/IAI.71.6.3221-3226.2003; Norlander L, 2000, MICROBES INFECT, V2, P417, DOI 10.1016/S1286-4579(00)00325-7; Ogawa T, 2002, INT IMMUNOL, V14, P1325, DOI 10.1093/intimm/dxf097; Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAMUEL JE, 1985, INFECT IMMUN, V49, P775, DOI 10.1128/IAI.49.3.775-779.1985; SCHRAMEK S, 1982, INFECT IMMUN, V38, P53, DOI 10.1128/IAI.38.1.53-57.1982; Seshadri R, 2003, P NATL ACAD SCI USA, V100, P5455, DOI 10.1073/pnas.0931379100; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Toman R, 2003, ACTA VIROL, V47, P129; Tomasik P, 2004, C F P F C S, V5, P1; Tujulin E, 1999, VET IMMUNOL IMMUNOP, V68, P159, DOI 10.1016/S0165-2427(99)00023-9; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLIAMS JC, 1991, BIOL COXIELLA BURNET, P175; WILLIAMS JC, 1991, BIOL COXIELLA BURNET, P21; WOLLENWEBER HW, 1985, ARCH MICROBIOL, V142, P6, DOI 10.1007/BF00409228; Zamboni DS, 2004, INFECT IMMUN, V72, P2395, DOI 10.1128/IAI.72.4.2395-2399.2004; Zamboni DS, 2004, INFECT IMMUN, V72, P2075, DOI 10.1128/IAI.72.4.2075-2080.2004; Zamboni DS, 2002, MICROBES INFECT, V4, P591, DOI 10.1016/S1286-4579(02)01577-0; Zamboni DS, 2001, J MICROBIOL METH, V43, P223, DOI 10.1016/S0167-7012(00)00223-2; Zamboni DS, 2003, INFECT IMMUN, V71, P1225, DOI 10.1128/IAI.71.3.1225-1233.2003; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	56	74	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54405	54415		10.1074/jbc.M410340200	http://dx.doi.org/10.1074/jbc.M410340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485838	hybrid			2022-12-25	WOS:000225793600063
J	Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM				Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM			Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines	ONCOGENE			English	Article						telomeres; aberrations; genome; immortalization; human	SURFACE EPITHELIAL-CELLS; MOLECULAR CYTOGENETIC CHARACTERIZATION; G-STRAND OVERHANG; TO-END FUSIONS; MAMMALIAN TELOMERES; HUMAN FIBROBLASTS; LENGTH; CANCER; SENESCENCE; CARCINOMA	Chromosomal aberrations are common in cancers. However, the search for chromosomal aberrations leading to development of specific solid tumors has been severely hindered because the majority of solid tumors have complex chromosomal aberrations that differ within the same tumor types. A similar phenomenon exists in immortalized cell tines. The underlying mechanisms driving these diverse aberrations are largely unknown. Telomeres play crucial roles in protecting the integrity of eucaryotic chromosomes and maintaining genomic stability of human cells. Telomere lengths on individual chromosomes in normal human somatic cells are heterogeneous and undergo progressive shortening with aging process. In this study, for the first time, a molecular cytogenetic method using sequential telomere quantitative fluorescence in situ hybridization and spectral karyotyping on the same human metaphases was applied successfully to examine the dynamic profiles of individual telomere shortening and their relationship to chromosome aberrations in multiple human cell lines undergoing immortalization. Human ovarian surface epithelial cells and esophageal epithetial cells were immortalized by the expression of HPV16 E6 and E7, which drive cells to proliferate by inactivating p53 and Rb genes. In these cell lines, we consistently detected large-scale differences in telomere signal intensities not only among nonhomologous chromosome arms but also between some homologous chromosome arms. The cell lines derived from different donors had different profiles of critically short telomeres (lacking telomere signals). Strikingly, the different profiles of chromosomal structural aberrations in multiple immortalized cell lines were highly significantly associated with the distinct distributions of critically short telomeres in whole-genome. Since cellular immortalization is one of the hallmarks of cancer, our findings suggest that distinct profiles of critically short telomeres in different human individuals might play an essential role in determining the complex and individual-specific chromosomal structural aberrations in human solid tumors.	Univ Hong Kong, Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Hong Kong, Fac Med, Dept Pediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China; Henan Med Univ, Ctr Med Expt, Canc Res Lab, Zhengzhou, Henan Province, Peoples R China	University of Hong Kong; University of Hong Kong; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Hong Kong; Zhengzhou University	Cheung, ALM (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hkucc.hku.hk	Deng, Wen/M-5208-2019; Deng, Wen/C-4154-2009; Tsao, George/C-4422-2009; /A-3639-2009; /C-4230-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; /0000-0003-3217-1456; MAK, P H S/0000-0002-8474-3578; Guan, Xin-Yuan/0000-0002-4485-6017				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; BENN PA, 1976, AM J HUM GENET, V28, P465; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DELANGE T, 1995, TELOMERES, P265; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Drexler HG, 1999, LEUKEMIA, V13, P1601, DOI 10.1038/sj.leu.2401510; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Graakjaer J, 2004, AGING CELL, V3, P97, DOI 10.1111/j.1474-9728.2004.00093.x; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; KARGER S, 1995, INT SYSTEM HUMAN CYT; Karlseder J, 2003, CANCER LETT, V194, P189, DOI 10.1016/S0304-3835(02)00706-1; Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003; Keys B, 2004, AGING CELL, V3, P103, DOI 10.1111/j.1474-9728.2004.00094.x; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Masters J, 2002, INT J CANCER, V99, P154, DOI 10.1002/ijc.10315; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; van Bokhoven A, 2003, PROSTATE, V57, P226, DOI 10.1002/pros.10291; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	52	56	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9090	9101		10.1038/sj.onc.1208119	http://dx.doi.org/10.1038/sj.onc.1208119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489894				2022-12-25	WOS:000225492800010
J	Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D				Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D			Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes	ONCOGENE			English	Article						apoptosis; lymphoma; mitoxantrone	TOPOISOMERASE-II; LYMPHOPROLIFERATIVE DISORDERS; AGGRESSIVE VARIANTS; FOLLICULAR LYMPHOMA; MISSENSE MUTATIONS; CYCLE ARREST; IN-VITRO; P53; FLUDARABINE; EXPRESSION	Mantle cell lymphoma (MCL) is a mature B-cell proliferation characterized by the presence of translocation t(11;14)(q13;q32), an aggressive clinical course, and poor response to chemotherapy. The majority of drugs currently used in the treatment of lymphoproliferative disorders induce cell death by triggering apoptosis, but few data concerning drug-induced apoptosis in MCL have been reported. We have analysed the mechanisms of drug-induced cell death in four cell lines with the t(11; 14) and in primary cells from 10 patients with MCL. Mitoxantrone, a topoisomerase II inhibitor, induced a strong cytotoxic effect in three cell lines (JVM-2, REC-1, and Granta 519), and in primary MCL cells. This cytotoxic effect due to apoptosis induction was observed despite the presence of either p53 or ATM abnormalities. However, no cytotoxic effect was detected after incubation with DNA-damaging agents in the NCEB-1 cell line, carrying p53 and ATM alterations, despite the presence of functional mitochondrial machinery. These results support that mitoxantrone can be effective in the treatment of MCL but that this activity requires the integrity of functional DNA-damage response genes.	Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Hematopathol Unit,Dept Pathol, E-08036 Barcelona, Spain; Hosp del Mar, Dept Pathol, Lab Cytogenet & Mol Biol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Colomer, D (corresponding author), Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain.	dcolomer@clinic.ub.es	COLOMER, DOLORS/ABG-6894-2020; Solé, Francesc/K-8373-2012; Campo, Elias/AAC-5593-2019; MARCE, Silvia/J-6651-2017; sole, francesc/A-2430-2011; Bosch, Francesc/AAE-7052-2019	Solé, Francesc/0000-0002-3251-2161; Campo, Elias/0000-0001-9850-9793; MARCE, Silvia/0000-0001-9128-6822; Bosch, Francesc/0000-0001-9241-2886; Ana, Ferrer/0000-0002-3381-9472; Espinet, Blanca/0000-0002-4294-8145; COLOMER, DOLORS/0000-0001-7486-8484				Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; Bailly JD, 1997, LEUKEMIA, V11, P1523, DOI 10.1038/sj.leu.2400762; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Bellosillo B, 1998, BRIT J HAEMATOL, V100, P142, DOI 10.1046/j.1365-2141.1998.00520.x; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; Bertoni F, 2004, BRIT J HAEMATOL, V124, P130, DOI 10.1046/j.1365-2141.2003.04761.x; Bogner C, 2003, BRIT J HAEMATOL, V122, P260, DOI 10.1046/j.1365-2141.2003.04438.x; Bosch F, 2002, BRIT J HAEMATOL, V119, P976, DOI 10.1046/j.1365-2141.2002.03959.x; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; BOSCH F, 1994, BLOOD, V84, P2726; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Campo E, 2003, HUM PATHOL, V34, P330, DOI 10.1053/hupa.2003.97; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEISABELLA P, 1991, LIFE SCI, V48, P2195, DOI 10.1016/0024-3205(91)90333-7; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240; Flinn IW, 2000, BLOOD, V96, P71, DOI 10.1182/blood.V96.1.71.013k21_71_75; Hernandez L, 1996, BLOOD, V87, P3351, DOI 10.1182/blood.V87.8.3351.bloodjournal8783351; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; M'kacher R, 2003, ONCOGENE, V22, P7905, DOI 10.1038/sj.onc.1206826; Martinez N, 2003, CANCER RES, V63, P8226; Molina-Arcas M, 2003, BLOOD, V101, P2328, DOI 10.1182/blood-2002-07-2236; Muller-Hermelink, 2001, PATHOLOGY GENETICS T, P168; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reiman T, 2002, LEUKEMIA, V16, P1886, DOI 10.1038/sj.leu.2402579; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Schlegelberger B, 1999, BLOOD, V94, P3114; Schrader C, 2004, LEUKEMIA, V18, P1200, DOI 10.1038/sj.leu.2403387; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SolalCeligny P, 1996, J CLIN ONCOL, V14, P514, DOI 10.1200/JCO.1996.14.2.514; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901	46	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8941	8949		10.1038/sj.onc.1208084	http://dx.doi.org/10.1038/sj.onc.1208084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480431				2022-12-25	WOS:000225354600009
J	Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS				Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS			Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion	ONCOGENE			English	Article						cAMP-dependent protein kinase; cancer; gene therapy; DNA microarray; confocal microscopy	RI-ALPHA SUBUNIT; RII(BETA) REGULATORY SUBUNIT; CANCER CELL-GROWTH; CYCLIC-AMP; CATALYTIC SUBUNIT; RESPONSE ELEMENT; GENE-EXPRESSION; BREAST-CANCER; AUTOPHOSPHORYLATION SITE; PROSTATE-CANCER	The cAMP-dependent protein kinase types I (PKA-I) and II (PKA-II), composed of identical catalytic ( C) subunits but distinct regulatory ( R) subunits (RI versus RII), are expressed in a balance of cell growth and differentiation. Distortion of this balance may underlie tumorigenesis and tumor growth. Here, we used PC3M prostate carcinoma cells as a model to overexpress wild type and mutant R and C subunit genes and examined the effects of differential expression of these genes on tumor growth. Only the RIIbeta and mutant RIalpha-P (a functional mimic of RIIbeta) transfectants exhibited growth inhibition in vitro, reverted phenotype, and apoptosis, and inhibited in vivo tumor growth. DNA microarrays demonstrated that RIIbeta and RIalpha-P overexpression upregulated a cluster of differentiation genes, while downregulating transformation and proliferation signatures. Overexpression of RIalpha and Calpha, which upregulated PKA-I, elicited the expression signatures opposite that elicited by RIIbeta overexpression. Total colocalization of Calpha and RIIbeta seen by confocal microscopy in the RIIbeta cell nucleus supports the opposed genomic regulation demonstrated between Calpha and RIIbeta cells. Differential expression of PKA R subunits may therefore serve as a tumor-target-based gene therapy for PC3M prostate and other cancers.	NCI, Cellular Biochem Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Basic Res Lab, NIH, 9000 Rockville Pike,Bldg 10,Room 5B05, Bethesda, MD 20892 USA.	yc12b@nih.gov		Becker, Kevin/0000-0002-6794-6656; Neary, Catherine/0000-0003-0562-7913; /0000-0002-6224-6685	NCI NIH HHS [N02-BC76512/C2700212] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ALPER O, 1999, ONCOGENE, V218, P55; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADBURY AW, 1994, BRIT J CANCER, V69, P738, DOI 10.1038/bjc.1994.139; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; Cho YS, 2002, P NATL ACAD SCI USA, V99, P15626, DOI 10.1073/pnas.242617799; Cho YS, 2002, CLIN CANCER RES, V8, P607; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cho-Chung Yoon S., 1999, Frontiers in Bioscience, V4, pd898, DOI 10.2741/Cho-Chung; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Cvijic ME, 2000, CLIN CANCER RES, V6, P2309; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Lee GR, 1999, MOL CELL BIOCHEM, V195, P77, DOI 10.1023/A:1006934113439; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; Neary CL, 2001, ONCOGENE, V20, P8019, DOI 10.1038/sj.onc.1204992; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; Nesterova M, 2000, ANTISENSE NUCLEIC A, V10, P423, DOI 10.1089/oli.1.2000.10.423; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Srivastava RK, 1999, MOL CELL BIOCHEM, V195, P25, DOI 10.1023/A:1006990231186; Srivastava RK, 1998, P NATL ACAD SCI USA, V95, P6687, DOI 10.1073/pnas.95.12.6687; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; TORTORA G, 1990, J BIOL CHEM, V265, P18067; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	44	49	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8847	8856		10.1038/sj.onc.1208165	http://dx.doi.org/10.1038/sj.onc.1208165			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480415				2022-12-25	WOS:000225165100015
J	Heurgue-Hamard, V; Champ, S; Mora, L; Merkoulova-Rainon, T; Kisselev, LL; Buckingham, RH				Heurgue-Hamard, V; Champ, S; Mora, L; Merkoulova-Rainon, T; Kisselev, LL; Buckingham, RH			The glutamine residue of the conserved GGQ motif in Saccharomyces cerevisiae release factor eRF1 is methylated by the product of the YDR140w gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION TERMINATION FACTORS; STOP CODON RECOGNITION; ESCHERICHIA-COLI; STRUCTURALLY DISTINCT; CRYSTAL-STRUCTURE; FACTOR RF3; IN-VIVO; PROTEIN; RIBOSOME; IDENTIFICATION	Polypeptide release factors from eubacteria and eukaryotes, although similar in function, belong to different protein families. They share one sequence motif, a GGQ tripeptide that is vital to release factor (RF) activity in both kingdoms. In bacteria, the Gln residue of the motif in RF1 and RF2 is modified to N-5-methyl-Gln by the S-adenoSyl L-methionine-dependent methyltransferase PrmC and the absence of Gln methylation decreases the release activity of Escherichia coli RF2 in vitro severalfold. We show here that the same modification is made to the GGQ motif of Saccharomyces cerevisiae release factor eRF1, the first time that N5-methyl-Gln has been found outside the bacterial kingdom. The product of the YDR140w gene is required for the methylation of eRF1 in vivo and for optimal yeast cell growth. YDR140w protein has significant homology to PrmC but lacks the N-terminal domain thought to be involved in the recognition of the bacterial release factors. Overproduced in S. cerevisiae, YDR140w can methylate eRF1 from yeast or man in vitro using S-adenoSyl L-methionine as methyl donor provided that eRF3 and GTP are also present, suggesting that the natural substrate of the methyltransferase YDR140w is the ternary complex eRF1.eRF3-GTP.	Inst Biol Physicochim, CNRS, UPR9073, F-75005 Paris, France; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 119991, Russia	Centre National de la Recherche Scientifique (CNRS); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Buckingham, RH (corresponding author), Inst Biol Physicochim, CNRS, UPR9073, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	richard.buckingham@ibpc.fr		Buckingham, Richard/0000-0002-8567-4500; HEURGUE-HAMARD, VALERIE/0000-0003-1576-7231				Adams A, 1997, METHODS YEAST GENETI; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova L, 2002, RNA, V8, P129, DOI 10.1017/S1355838202013262; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Garbom S, 2004, INFECT IMMUN, V72, P1333, DOI 10.1128/IAI.72.3.1333-1340.2004; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Heurgue-Hamard V, 2002, EMBO J, V21, P769, DOI 10.1093/emboj/21.4.769; Hosoda N, 2003, J BIOL CHEM, V278, P38287, DOI 10.1074/jbc.C300300200; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Kisselev LL, 2000, MOL BIOL+, V34, P363, DOI 10.1007/BF02759667; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Klaholz BP, 2004, NATURE, V427, P862, DOI 10.1038/nature02332; Kong CG, 2004, MOL CELL, V14, P233, DOI 10.1016/S1097-2765(04)00206-0; Kononenko A V, 2004, Mol Biol (Mosk), V38, P303; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHOEST J, 1977, MOL GEN GENET, V154, P175, DOI 10.1007/BF00330833; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; Mora L, 2003, MOL MICROBIOL, V50, P1467, DOI 10.1046/j.1365-2958.2003.03799.x; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Nakahigashi K, 2002, P NATL ACAD SCI USA, V99, P1473, DOI 10.1073/pnas.032488499; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schubert HL, 2003, BIOCHEMISTRY-US, V42, P5592, DOI 10.1021/bi034026p; Seit-Nebi A, 2001, NUCLEIC ACIDS RES, V29, P3982, DOI 10.1093/nar/29.19.3982; Shin DH, 2004, J MOL BIOL, V341, P227, DOI 10.1016/j.jmb.2004.05.055; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	34	71	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2005	280	4					2439	2445		10.1074/jbc.M407252200	http://dx.doi.org/10.1074/jbc.M407252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	889NG	15509572	hybrid			2022-12-25	WOS:000226449100009
J	Kubota, K; Nishii, W; Kojima, M; Takahashi, K				Kubota, K; Nishii, W; Kojima, M; Takahashi, K			Specific inhibition and stabilization of aspergilloglutamic peptidase by the propeptide - Identification of critical sequences and residues in the propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID PROTEINASE-A; SLOW-BINDING INHIBITION; ASPERGILLUS-NIGER; CATHEPSIN-B; MOLECULAR-STRUCTURE; CATALYTIC-ACTIVITY; POTENCY; ZYMOGEN; PEPSIN; ENZYME	Aspergilloglutamic peptidase ( formerly called aspergillopepsin II) is an acid endopeptidase produced by Aspergillus niger var. macrosporus, with a novel catalytic dyad of a glutamic acid and a glutamine residue, thus belonging to a novel peptidase family G1. The mature enzyme is generated from its precursor by removal of the putative 41-residue propeptide and an 11-residue intervening peptide through autocatalytic activation. In the present study, the propeptide (Ala(1)-Asn(41)) and a series of its truncated peptides were chemically synthesized, and their effects on the enzyme activity and thermal stability were examined to identify the sequences and residues in the propeptide most critical to the inhibition and thermal stabilization. The synthetic propeptide was shown to be a potent competitive inhibitor of the enzyme ( K-i = 27 nM at pH 4.0). Various shorter propeptide fragments derived from the central region of the propeptide had significant inhibitory effect, whereas their Ala scan-substituted peptides, especially R19A and H20A, showed only weak inhibition. Substitution of the Pro(23)-Pro(24) sequence near His(20) with an Ala-Ala sequence changed the peptide Lys(18) - Tyr(25) to a substrate with His(20) as the P1 residue. Furthermore, the propeptide was shown to be able to significantly protect the enzyme from thermal denaturation (DeltaT(m) = similar to 19 degreesC at pH 5.6). The protective potencies of the propeptide as well as truncated propeptides and their Ala scan-substituted peptides are parallel with their inhibitory potencies. These results indicate that the central part, and especially Arg(19) and His(20) therein, of the propeptide is most critical to the inhibition and thermal stabilization and that His(20) interacts with the enzyme at or near the S1 site in a nonproductive fashion.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Mol Biochem, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Takahashi, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Mol Biochem, 1432-1 Horinouchi, Tokyo 1920392, Japan.	kenjitak@ls.toyaku.ac.jp						Basak A, 2003, BIOCHEM J, V373, P231, DOI 10.1042/BJ20030120; BECKER D, 1992, PROTEIN-STRUCT FUNCT, V12, P339; Billington CJ, 2000, BIOCHEM BIOPH RES CO, V276, P924, DOI 10.1006/bbrc.2000.3553; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DONOHUE MJ, 1996, J BIOL CHEM, V271, P26477; DUNN BM, 1978, J BIOL CHEM, V253, P7269; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Fujinaga M, 2004, P NATL ACAD SCI USA, V101, P3364, DOI 10.1073/pnas.0400246101; Fukada H, 1995, THERMOCHIM ACTA, V267, P373, DOI 10.1016/0040-6031(95)02494-8; GOU YL, 2000, FEBS LETT, V469, P203; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; Hu ZX, 1996, J BIOL CHEM, V271, P3375; Huang XP, 2000, J BIOL CHEM, V275, P26607, DOI 10.1074/jbc.M910243199; INOUE H, 1991, J BIOL CHEM, V266, P19484; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; Khan AR, 1998, PROTEIN SCI, V7, P815; KOELSCH G, 1994, FEBS LETT, V343, P6, DOI 10.1016/0014-5793(94)80596-2; Komatsu S, 1998, ADV EXP MED BIOL, V436, P345; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; ODA K, 2004, HDB PROTEOLYTIC ENZY, V1, P217; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; Sasaki H, 2004, P JPN ACAD B-PHYS, V80, P435, DOI 10.2183/pjab.80.435; Serkina AV, 1999, FEBS LETT, V456, P215, DOI 10.1016/S0014-5793(99)00791-7; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAKAHASHI K, 1991, J BIOL CHEM, V266, P19480; Takahashi K, 1998, ADV EXP MED BIOL, V436, P275; TAKAHASHI K, 1995, METHOD ENZYMOL, V248, P146; Takahashi K, 1997, BIOSCI BIOTECH BIOCH, V61, P381, DOI 10.1271/bbb.61.381; TAKAHASHI K, 2004, HDB PROTEOLYTIC ENZY, V1, P221; Tang B, 2002, BIOCHEM BIOPH RES CO, V296, P78, DOI 10.1016/S0006-291X(02)00838-0; TAYLOR M, 1995, PROTEIN ENG, V15, P59; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; Yabuki Y, 2004, FEBS LETT, V569, P161, DOI 10.1016/j.febslet.2004.05.041; Yu YL, 1998, FEBS LETT, V429, P9, DOI 10.1016/S0014-5793(98)00548-1	43	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					999	1006		10.1074/jbc.M410852200	http://dx.doi.org/10.1074/jbc.M410852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516690	hybrid			2022-12-25	WOS:000226195200019
J	Ueda, T; Brenner, S; Malech, HL; Langemeijer, SM; Perl, S; Kirby, M; Phang, OA; Krouse, AE; Donahue, RE; Kang, EM; Tisdale, JF				Ueda, T; Brenner, S; Malech, HL; Langemeijer, SM; Perl, S; Kirby, M; Phang, OA; Krouse, AE; Donahue, RE; Kang, EM; Tisdale, JF			Cloning and functional analysis of the rhesus macaque ABCG2 gene - Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW-CELLS; MULTIDRUG-RESISTANCE TRANSPORTER; EX-VIVO; P-GLYCOPROTEIN; EFFLUX PUMP; EXPANSION; TRANSDUCTION; TRANSPLANTATION; OVEREXPRESSION; HOECHST-33342	Hematopoietic cells can be highly enriched for repopulating ability based upon the efflux of the fluorescent Hoechst 33342 dye by sorting for SP ( side population) cells, a phenotype attributed to expression of ABCG2, a member of the ABC transporter superfamily. Intriguingly, murine studies suggest that forced ABCG2 expression prevents hematopoietic differentiation. We cloned the full-length rhesus ABCG2 and introduced it into a retroviral vector. ABCG2-transduced human peripheral blood progenitor cells (PBPCs) acquired the SP phenotype but showed significantly reduced growth compared with control. Two rhesus macaques received autologous PBPCs split for transduction with the ABCG2 or control vectors. Marking levels were similar between fractions with no discrepancy between bone marrow and peripheral blood marking. Analysis for the SP phenotype among bone marrow and mature blood populations confirmed ABCG2 expression at levels predicted by vector copy number long term, demonstrating no block to differentiation in the large animal. In vitro studies showed selective protection against mitoxantrone among ABCG2-transduced rhesus PBPCs. Our results confirm the existence of rhesus ABCG2, establish its importance in conferring the SP phenotype, suggest no detrimental effect of its overexpression upon differentiation in vivo, and imply a potential role for its overexpression as an in vivo selection strategy for gene therapy applications.	NIDDK, Mol & Clin Hematol Branch, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA; NHLBI, Res Court, NIH, Bethesda, MD 20892 USA; Univ Klinikum Carl Gustav Carus, Klin Kinder & Jugend Med, D-01307 Dresden, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Technische Universitat Dresden; Carl Gustav Carus University Hospital	Tisdale, JF (corresponding author), NIDDK, Mol & Clin Hematol Branch, NIH, Bldg 10,Rm 9N116,9000 Rockville Pike, Bethesda, MD 20892 USA.		Brenner, Sebastian/D-7456-2013	Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000644, ZIAAI000644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK027011, Z01DK027012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abkowitz JL, 2002, BLOOD, V100, P2665, DOI 10.1182/blood-2002-03-0822; Abonour R, 2000, NAT MED, V6, P652, DOI 10.1038/76225; Brenner S, 2003, BLOOD, V102, P2789, DOI 10.1182/blood-2002-05-1482; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hanazono Y, 1999, BLOOD, V94, P2263, DOI 10.1182/blood.V94.7.2263.419k36_2263_2270; Hulspas R, 2000, CYTOMETRY, V40, P245, DOI 10.1002/1097-0320(20000701)40:3<245::AID-CYTO10>3.3.CO;2-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kang EM, 2002, BLOOD, V99, P698, DOI 10.1182/blood.V99.2.698; Kang EM, 2001, MOL THER, V3, P911, DOI 10.1006/mthe.2001.0337; Kiem HP, 2004, MOL THER, V9, P389, DOI 10.1016/j.ymthe.2003.12.006; Kim HJ, 2000, BLOOD, V96, P1; Kim M, 2002, CLIN CANCER RES, V8, P22; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; Licht T, 1997, STEM CELLS, V15, P104, DOI 10.1002/stem.150104; Litman T, 2000, J CELL SCI, V113, P2011; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NIENHUIS AW, 1987, J CLIN INVEST, V80, P573, DOI 10.1172/JCI113106; Rabindran SK, 1998, CANCER RES, V58, P5850; Rabindran SK, 2000, CANCER RES, V60, P47; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Sellers SE, 2001, BLOOD, V97, P1888, DOI 10.1182/blood.V97.6.1888; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Tsai EJ, 2002, BLOOD, V100, P72, DOI 10.1182/blood.V100.1.72; Ujhelly O, 2003, HUM GENE THER, V14, P403, DOI 10.1089/104303403321209005; van Herwaarden AE, 2003, CANCER RES, V63, P6447; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	42	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					991	998		10.1074/jbc.M409796200	http://dx.doi.org/10.1074/jbc.M409796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516692	hybrid			2022-12-25	WOS:000226195200018
J	Ahuja, U; Thony-Meyer, L				Ahuja, U; Thony-Meyer, L			CcmD is involved in complex formation between CcmC and the heme chaperone CcmE during cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PATHWAY; BIOGENESIS; PROTEINS; RANGE	CcmD is a small membrane protein involved in heme delivery to the heme chaperone CcmE during cytochrome c maturation. Here we show that it physically interacts with CcmE and CcmC, another essential component of the heme delivery system. We demonstrate the formation of a ternary complex consisting of CcmCDE. A deletion analysis of individual domains revealed that the central hydrophobic domain is essential for its function. Moreover, the C-terminal, cytoplasmic domain seems to require a net positive charge to be functional. Our topology analysis indicates that CcmD is an integral interfacial membrane protein with its N and C termini extruding into the cytoplasmic side of the membrane. Interactions of CcmD with either ferrochelatase, the last heme biosynthetic enzyme, or directly with heme were not detectable. We postulate a function for CcmD in protein-protein interaction or membrane protein assembly required for the heme delivery process.	ETH, Inst Mikrobiol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thony-Meyer, L (corresponding author), ETH, Inst Mikrobiol, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	lthoeny@micro.biol.ethz.ch	Ahuja, Umesh/ABC-2954-2020					Ahuja U, 2003, J BIOL CHEM, V278, P52061, DOI 10.1074/jbc.M310077200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1	25	33	36	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					236	243		10.1074/jbc.M410912200	http://dx.doi.org/10.1074/jbc.M410912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15513913	hybrid			2022-12-25	WOS:000226025100029
J	Endo, Y; Wolf, V; Muraiso, K; Kamijo, K; Soon, L; Uren, A; Barshishat-Kupper, M; Rubin, JS				Endo, Y; Wolf, V; Muraiso, K; Kamijo, K; Soon, L; Uren, A; Barshishat-Kupper, M; Rubin, JS			Wnt-3a-dependent cell motility involves RhoA activation and is specifically regulated by dishevelled-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERGENT EXTENSION MOVEMENTS; NONCANONICAL WNT PATHWAY; BETA-CATENIN; SIGNALING PATHWAY; TUMOR-FORMATION; POLARITY; PROTEINS; GASTRULATION; WINGLESS; ACTIN	Wnts stimulate cell migration, although the mechanisms responsible for this effect are not fully understood. To investigate the pathways that mediate Wnt-dependent cell motility, we treated Chinese hamster ovary cells with Wnt-3a-conditioned medium and monitored changes in cell shape and movement. Wnt-3a induced cell spreading, formation of protrusive structures, reorganization of stress fibers and migration. Although Wnt-3a stabilized beta-catenin, two inhibitors of the beta-catenin/canonical pathway, Dickkopf-1 and a dominant-negative T cell factor construct, did not reduce motility. The small GTPase RhoA also was activated by Wnt-3a. In contrast to beta-catenin signaling, inhibition of Rho kinase partially blocked motility. Because Dishevelled (Dvl) proteins are effectors of both canonical and noncanonical Wnt signaling, we used immunofluorescent analysis and small interference RNA technology to evaluate the role of Dvl in cell motility. Specific knock-down of Dvl-2 expression markedly reduced Wnt-3a-dependent changes in cell shape and movement, suggesting that this Dvl isoform had a predominant role in mediating Wnt-3a-dependent motility in Chinese hamster ovary cells.	NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	Rubin, JS (corresponding author), NCI, LCMB, CCR, NIH, Bldg 37,Rm 2042,37 Convent Dr,MSC 4256, Bethesda, MD 20892 USA.	rubinj@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010251, ZIABC010251] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Copp AJ, 2003, TRENDS NEUROSCI, V26, P453, DOI 10.1016/S0166-2236(03)00212-1; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Polakis P, 2000, GENE DEV, V14, P1837; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Shibamoto S, 1998, GENES CELLS, V3, P659; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Spellman PT, 2002, GENOME BIOL, V3; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Tada M, 2000, DEVELOPMENT, V127, P2227; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wallingford JB, 2001, DEVELOPMENT, V128, P2581; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wittmann T, 2001, J CELL SCI, V114, P3795; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Yang YS, 1996, GENE, V180, P121, DOI 10.1016/S0378-1119(96)00430-1	52	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					777	786		10.1074/jbc.M406391200	http://dx.doi.org/10.1074/jbc.M406391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509575	hybrid			2022-12-25	WOS:000226025100091
J	Hammel, M; Fierobe, HP; Czjzek, M; Finet, S; Receveur-Brechot, V				Hammel, M; Fierobe, HP; Czjzek, M; Finet, S; Receveur-Brechot, V			Structural insights into the mechanism of formation of cellulosomes probed by small angle X-ray scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COHESIN-DOCKERIN INTERACTION; PROCESSIVE ENDOCELLULASE CELF; CLOSTRIDIUM-CELLULOLYTICUM; CRYSTAL-STRUCTURE; BIOLOGICAL MACROMOLECULES; ANGSTROM RESOLUTION; BINDING DOMAIN; THERMOCELLUM; PROTEIN; PURIFICATION	Exploring the mechanism by which the multiprotein complexes of cellulolytic organisms, the cellulosomes, attain their exceptional synergy is a challenge for biologists. We have studied the solution structures of the Clostridium cellulolyticum cellulosomal enzyme Cel48F in the free and complexed states with cohesins from Clostridium thermocellum and Clostridium cellulolyticum by small angle x-ray scattering in order to investigate the conformational events likely to occur upon complexation. The solution structure of the free cellulase indicates that the dockerin module is folded, whereas the linker connecting the catalytic module to the dockerin is extended and flexible. Remarkably, the docking of the different cohesins onto Cel48F leads to a pleating of the linker. The global structure determined here allowed modeling of the atomic structure of the C. cellulolyticum dockerin-cohesin interface, highlighting the local differences between both organisms responsible for the species specificity.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, UPR Bioenerget & Ingn Prot 9036, F-13402 Marseille 20, France; Austrian Acad Sci, Inst Biophys & Xray Struct Res, A-8042 Graz, Austria; European Synchrotron Radiat Facil, F-38043 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Austrian Academy of Sciences; European Synchrotron Radiation Facility (ESRF)	Receveur-Brechot, V (corresponding author), CNRS, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	receveur@afmb.cnrs-mrs.fr	FIEROBE, Henri-Pierre/P-4372-2019	Hammel, Michal/0000-0002-5610-9289; Receveur-Brechot, Veronique/0000-0002-7464-6192				Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; Bergmann A, 2000, J APPL CRYSTALLOGR, V33, P1212, DOI 10.1107/S0021889800008372; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; CHEN HM, 1995, PROTEIN ENG, V8, P575, DOI 10.1093/protein/8.6.575; Delarue M, 2004, P NATL ACAD SCI USA, V101, P6957, DOI 10.1073/pnas.0400301101; FIEROBE HP, 1993, EUR J BIOCHEM, V217, P557, DOI 10.1111/j.1432-1033.1993.tb18277.x; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2002, J BIOL CHEM, V277, P49621, DOI 10.1074/jbc.M207672200; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; Gal L, 1997, APPL ENVIRON MICROB, V63, P903, DOI 10.1128/AEM.63.3.903-909.1997; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; Glatter von O., 1982, SMALL ANGLE XRAY SCA, P167; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammel M, 2002, J MOL BIOL, V321, P85, DOI 10.1016/S0022-2836(02)00621-6; Handelsman T, 2004, FEBS LETT, V572, P195, DOI 10.1016/j.febslet.2004.07.040; Jindou S, 2004, J BIOL CHEM, V279, P9867, DOI 10.1074/jbc.M308673200; Kakiuchi M, 1998, J BACTERIOL, V180, P4303, DOI 10.1128/JB.180.16.4303-4308.1998; Koch MHJ, 2003, Q REV BIOPHYS, V36, P147, DOI 10.1017/S0033583503003871; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lamed R, 2001, APPL BIOCHEM BIOTECH, V90, P67, DOI 10.1385/ABAB:90:1:67; Lytle BL, 2001, J MOL BIOL, V307, P745, DOI 10.1006/jmbi.2001.4522; Maamar H, 2004, MOL MICROBIOL, V51, P589, DOI 10.1046/j.1365-2958.2003.03859.x; Marquez JA, 2003, EMBO J, V22, P4616, DOI 10.1093/emboj/cdg448; Mechaly A, 2001, J BIOL CHEM, V276, P9883, DOI 10.1074/jbc.M009237200; Millet IS, 2002, ADV PROTEIN CHEM, V62, P241; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Parsiegla G, 1998, EMBO J, V17, P5551, DOI 10.1093/emboj/17.19.5551; Perret S, 2004, J BACTERIOL, V186, P6544, DOI 10.1128/JB.186.19.6544-6552.2004; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; ReverbelLeroy C, 1997, J BACTERIOL, V179, P46, DOI 10.1128/jb.179.1.46-52.1997; Shimon LJW, 2000, ACTA CRYSTALLOGR D, V56, P1560, DOI 10.1107/S0907444900012889; Shimon LJW, 1997, STRUCTURE, V5, P381, DOI 10.1016/S0969-2126(97)00195-0; Spinelli S, 2000, J MOL BIOL, V304, P189, DOI 10.1006/jmbi.2000.4191; Suhre K, 2004, NUCLEIC ACIDS RES, V32, pW610, DOI 10.1093/nar/gkh368; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Tama F, 2001, PROTEIN ENG, V14, P1, DOI 10.1093/protein/14.1.1; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wilson DN, 2003, ANGEW CHEM INT EDIT, V42, P3464, DOI 10.1002/anie.200200544; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	52	44	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55985	55994		10.1074/jbc.M408979200	http://dx.doi.org/10.1074/jbc.M408979200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502162	hybrid			2022-12-25	WOS:000225960800122
J	Kumita, H; Matsuura, K; Hino, T; Takahashi, S; Hori, H; Fukumori, Y; Morishima, I; Shiro, Y				Kumita, H; Matsuura, K; Hino, T; Takahashi, S; Hori, H; Fukumori, Y; Morishima, I; Shiro, Y			NO reduction by nitric-oxide reductase from denitrifying bacterium Pseudomonas aeruginosa - Characterization of reaction intermediates that appear in the single turnover cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS FUSARIUM-OXYSPORUM; CYTOCHROME-C-OXIDASE; NONHEME IRON ENZYMES; HEME-COPPER OXIDASES; ACTIVE-SITE; PARACOCCUS-DENITRIFICANS; RESONANCE RAMAN; ELECTRONIC-STRUCTURE; ESCHERICHIA-COLI; THEORETICAL DESCRIPTION	Nitric-oxide reductase (NOR) of a denitrifying bacterium catalyzes NO reduction to N2O at the binuclear catalytic center consisting of high spin heme b(3) and non-heme Fe-B. The structures of the reaction intermediates in the single turnover of the NO reduction by NOR from Pseudomonas aeruginosa were investigated using optical absorption and EPR spectroscopies combined with an originally designed freeze-quench device. In the EPR spectrum of the sample, in which the fully reduced NOR was mixed with an NO solution and quenched at 0.5 ms after the mixing, two characteristic signals for the ferrous Fe-B - NO and the penta-coordinated ferrous heme b(3) - NO species were observed. The CO inhibition of its formation indicated that two NO molecules were simultaneously distributed into the two irons of the same binuclear center of the enzyme in this state. The time- and temperature-dependent EPR spectral changes indicated that the species that appeared at 0.5 ms is a transient reaction intermediate prior to the N2O formation, in good agreement with the so-called "trans" mechanism. It was also found that the final state of the enzyme in the single turnover cycle is the fully oxidized state, in which the mu-oxo-bridged ligand is absent between the two irons of its binuclear center, unlike the resting form of NOR as isolated. On the basis of these present findings, we propose a newly developed mechanism for the NO reduction reaction conducted by NOR.	RIKEN Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158501, Japan; Osaka Univ, Grad Sch Engn Sci, Div Bioengn, Osaka 5608531, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Dept Life Sci, Kanazawa, Ishikawa 9201192, Japan	RIKEN; Kyoto University; Osaka University; Kanazawa University	Shiro, Y (corresponding author), RIKEN Harima Inst SPring 8, 1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.	yshiro@riken.jp	Fukumori, Yoshihiro/J-2483-2014; Matsuura, Koji/AAU-9111-2021; Shiro, Yoshitsugu Y/J-3757-2014; MATSUURA, Koji/B-2419-2011	Shiro, Yoshitsugu Y/0000-0003-0695-8327; 				Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; BROWN CA, 1995, J AM CHEM SOC, V117, P715, DOI 10.1021/ja00107a015; Butland G, 2001, J BACTERIOL, V183, P189, DOI 10.1128/JB.183.1.189-199.2001; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; CHIOU YM, 1995, INORG CHEM, V34, P3270, DOI 10.1021/ic00116a020; Clay MD, 2003, P NATL ACAD SCI USA, V100, P3796, DOI 10.1073/pnas.0636858100; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Field SJ, 2002, J BIOL CHEM, V277, P20146, DOI 10.1074/jbc.M112202200; GALPIN JR, 1978, BIOCHIM BIOPHYS ACTA, V536, P356, DOI 10.1016/0005-2795(78)90494-4; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; Gronberg KLC, 2004, J BIOL CHEM, V279, P17120, DOI 10.1074/jbc.M400824200; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Hendriks J, 2000, BBA-BIOENERGETICS, V1459, P266, DOI 10.1016/S0005-2728(00)00161-4; Hendriks JHM, 2001, BIOCHEMISTRY-US, V40, P13361, DOI 10.1021/bi011428t; Hendriks JHM, 2002, BIOCHEMISTRY-US, V41, P2331, DOI 10.1021/bi0121050; HENRY Y, 1973, J MOL BIOL, V73, P469, DOI 10.1016/0022-2836(73)90094-6; Jackson TA, 2003, J AM CHEM SOC, V125, P8348, DOI 10.1021/ja029523s; KON H, 1968, J BIOL CHEM, V243, P4350; Koutny M, 1999, BIOCHEM BIOPH RES CO, V262, P562, DOI 10.1006/bbrc.1999.1245; MacNeil JH, 1997, J AM CHEM SOC, V119, P1668, DOI 10.1021/ja963588b; Matsuura K, 2004, BIOCHEMISTRY-US, V43, P2288, DOI 10.1021/bi0355490; Moenne-Loccoz P, 2000, J AM CHEM SOC, V122, P9344, DOI 10.1021/ja0016295; Moenne-Loccoz P, 1998, J AM CHEM SOC, V120, P5147, DOI 10.1021/ja973671e; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NELSON MJ, 1987, J BIOL CHEM, V262, P12137; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; Okamoto N, 1998, BIOCHEMISTRY-US, V37, P8839, DOI 10.1021/bi980469v; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Oubrie A, 2002, BIOCHEMISTRY-US, V41, P10858, DOI 10.1021/bi026140y; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; Pinakoulaki E, 2002, J BIOL CHEM, V277, P23407, DOI 10.1074/jbc.M201913200; Pinakoulaki E, 2003, BIOCHEMISTRY-US, V42, P14856, DOI 10.1021/bi035289m; Sakurai N, 1997, BIOCHEMISTRY-US, V36, P13809, DOI 10.1021/bi971070u; Sakurai N, 1998, BIOCHEM BIOPH RES CO, V243, P400, DOI 10.1006/bbrc.1998.8106; Sakurai T, 1998, BIOCHEM BIOPH RES CO, V251, P248, DOI 10.1006/bbrc.1998.9451; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Shimizu H, 2000, J BIOL CHEM, V275, P4816, DOI 10.1074/jbc.275.7.4816; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1991, J BIOL CHEM, V266, P11078; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Takaya N, 1999, ARCH BIOCHEM BIOPHYS, V372, P340, DOI 10.1006/abbi.1999.1499; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; Trogler WC, 1999, COORDIN CHEM REV, V187, P303, DOI 10.1016/S0010-8545(98)00254-9; Tsuruta S, 1998, FEMS MICROBIOL LETT, V168, P105, DOI 10.1016/S0378-1097(98)00427-3; TURK T, 1992, BIOCHEM BIOPH RES CO, V183, P938; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; Wasser IM, 2004, INORG CHEM, V43, P651, DOI 10.1021/ic0348143; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; Watmough NJ, 1998, J BIOENERG BIOMEMBR, V30, P55, DOI 10.1023/A:1020507511285; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; YE RW, 1994, APPL ENVIRON MICROB, V60, P1053, DOI 10.1128/AEM.60.4.1053-1058.1994; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YOSHIMURA T, 1991, B CHEM SOC JPN, V64, P2819, DOI 10.1246/bcsj.64.2819; ZHANG Y, 1992, J AM CHEM SOC, V114, P9189, DOI 10.1021/ja00049a062	61	90	91	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55247	55254		10.1074/jbc.M409996200	http://dx.doi.org/10.1074/jbc.M409996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504726	hybrid			2022-12-25	WOS:000225960800034
J	Morelli, L; Llovera, E; Mathov, I; Lue, LF; Frangione, B; Ghiso, J; Castano, EM				Morelli, L; Llovera, E; Mathov, I; Lue, LF; Frangione, B; Ghiso, J; Castano, EM			Insulin-degrading enzyme in brain microvessels - Proteolysis of amyloid beta vasculotropic variants and reduced activity in cerebral amyloid angiopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; A-BETA; TRANSGENIC MICE; EXTRACELLULAR LEVELS; APOLIPOPROTEIN-E; CATHEPSIN-D; DUTCH-TYPE; PROTEIN; DEGRADATION; EXPRESSION	The accumulation of amyloid beta (Abeta) in the walls of small vessels in the cerebral cortex is associated with diseases characterized by dementia or stroke. These include Alzheimer's disease, Down syndrome, and sporadic and hereditary cerebral amyloid angiopathies (CAAs) related to mutations within the Abeta sequence. A higher tendency of Abeta to aggregate, a defective clearance to the systemic circulation, and insufficient proteolytic removal have been proposed as mechanisms that lead to Abeta accumulation in the brain. By using immunoprecipitation and mass spectrometry, we show that insulin-degrading enzyme (IDE) from isolated human brain microvessels was capable of degrading I-125-insulin and cleaved Abeta-(1-40) wild type and the genetic variants Abeta A21G (Flemish), Abeta E22Q (Dutch), and Abeta E22K (Italian) at the predicted sites. In microvessels from Alzheimer's disease cases with CAA, IDE protein levels showed a 44% increase as determined by sandwich enzyme-linked immunosorbent assay and Western blot. However, the activity of IDE upon radiolabeled insulin was significantly reduced in CAA as compared with age-matched controls. These results support the notion that a defect in Abeta proteolysis by IDE contributes to the accumulation of this peptide in the cortical microvasculature. Moreover they raise the possibility that IDE inhibition or inactivation is a pathogenic mechanism that may open novel strategies for the treatment of cerebrovascular Abeta amyloidoses.	Consejo Nacl Invest Cient & Tecn, Catedra Quim Biol Patol, Dept Quim Biol,Fac Farm & Bioquim, IQUIFIB, Buenos Aires, DF, Argentina; Sun Hlth Res Inst, Sun City, AZ 85351 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Banner Research; Banner Health; Banner Sun Health Research Institute; New York University; New York University	Castano, EM (corresponding author), Consejo Nacl Invest Cient & Tecn, Catedra Quim Biol Patol, Dept Quim Biol,Fac Farm & Bioquim, IQUIFIB, Junin 956,C1113AAD, Buenos Aires, DF, Argentina.	edcast@ffyb.uba.ar			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG005891, R01AG008721, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05891, AG 10491, AG 08721] Funding Source: Medline; NINDS NIH HHS [NS 38777] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bernstein HG, 1999, NEUROSCI LETT, V263, P161, DOI 10.1016/S0304-3940(99)00135-4; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Carpentier M, 2002, J NEUROPATH EXP NEUR, V61, P849, DOI 10.1093/jnen/61.10.849; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Chalmers K, 2003, NEUROPATH APPL NEURO, V29, P231, DOI 10.1046/j.1365-2990.2003.00457.x; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Davis J, 2003, J BIOL CHEM, V278, P19054, DOI 10.1074/jbc.M301398200; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Deb S, 1996, J NEUROCHEM, V66, P1641; Deng A, 2001, AM J PATHOL, V159, P1061, DOI 10.1016/S0002-9440(10)61781-6; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DUCKWORTH WC, 1981, ENDOCRINOLOGY, V108, P1142, DOI 10.1210/endo-108-4-1142; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jung SS, 2003, J NEUROCHEM, V85, P1208, DOI 10.1046/j.1471-4159.2003.01745.x; KALARIA RN, 1993, AM J PATHOL, V143, P886; KAMINO K, 1992, AM J HUM GENET, V51, P998; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Kuo YM, 2000, MOL MED, V6, P430, DOI 10.1007/BF03401785; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; LEMERE CA, 1995, AM J PATHOL, V146, P848; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lue LF, 1996, J NEUROPATH EXP NEUR, V55, P1083, DOI 10.1097/00005072-199655100-00008; Marr RA, 2003, J NEUROSCI, V23, P1992; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MCKENZIE RA, 1984, ARCH BIOCHEM BIOPHYS, V229, P604, DOI 10.1016/0003-9861(84)90193-0; Melchor JP, 2003, J NEUROSCI, V23, P8867; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Morelli L, 2002, NEUROCHEM RES, V27, P1387, DOI 10.1023/A:1021679817756; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; OGAWA W, 1992, J BIOL CHEM, V267, P1310; PARDRIDGE WM, 1987, J NEUROCHEM, V49, P1394, DOI 10.1111/j.1471-4159.1987.tb01005.x; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; Preston SD, 2003, NEUROPATH APPL NEURO, V29, P106, DOI 10.1046/j.1365-2990.2003.00424.x; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Roher AE, 2003, MOL MED, V9, P112, DOI 10.1007/BF03402043; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Thal DR, 2002, J NEUROPATH EXP NEUR, V61, P282, DOI 10.1093/jnen/61.3.282; Tucker HM, 2000, J NEUROSCI, V20, P3937; Van Dorpe J, 2000, AM J PATHOL, V157, P1283, DOI 10.1016/S0002-9440(10)64644-5; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; YONG WH, 1992, ARCH NEUROL-CHICAGO, V49, P51, DOI 10.1001/archneur.1992.00530250055016	66	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					56004	56013		10.1074/jbc.M407283200	http://dx.doi.org/10.1074/jbc.M407283200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489232	hybrid			2022-12-25	WOS:000225960800124
J	Regaya, I; Beeton, C; Ferrat, G; Andreotti, N; Darbon, H; De Waard, M; Sabatier, JM				Regaya, I; Beeton, C; Ferrat, G; Andreotti, N; Darbon, H; De Waard, M; Sabatier, JM			Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; DISULFIDE BRIDGE; CHEMICAL-SYNTHESIS; LEIUROTOXIN-I; HIGH-AFFINITY; MAUROTOXIN; MAURUS; SPECTROSCOPY; INHIBITOR; PEPTIDES	Maurotoxin (MTX) and HsTx1 are two scorpion toxins belonging to the alpha-KTx6 structural family. These 34-residue toxins, cross-linked by four disulfide bridges, share 59% sequence identity and fold along the classical alpha/beta scaffold. Despite these structural similarities, they fully differ in their pharmacological profiles. MTX is highly active on small (SK) and intermediate (IK) conductance Ca2+-activated (K+) channels and on voltage-gated Kv1.2 channel, whereas HsTx1 potently blocks voltage-gated Kv1.1 and Kv1.3 channels only. Here, we designed and chemically produced MTX-HsTx1, a chimera of both toxins that contains the N-terminal helical region of MTX (sequence 1-16) and the C-terminal beta-sheet region of HsTx1 (sequence 17-34). The three-dimensional structure of the peptide in solution was solved by H-1 NMR. MTX-HsTx1 displays the activity of MTX on SK channel, whereas it exhibits the pharmacological profile of HsTx1 on Kv1.1, Kv1.2, Kv1.3, and IK channels. These data demonstrate that the helical region of MTX exerts a key role in SK channel recognition, whereas the beta-sheet region of HsTx1 is crucial for activity on all other channel types tested.	CNRS Format Rech Expt 2738, Biochim Lab, F-13916 Marseille 20, France; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; CNRS, Unite Propre Rech 9039, F-13402 Marseille, France; CEA, INSERM,U607, Inst Federatif Rech 27, Dept Rech Dynam Cellulaire Canaux Calc Fonct & Pa, F-38054 Grenoble 09, France; Lab Cellpep SA, F-13015 Marseille, France	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Irvine; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sabatier, JM (corresponding author), CNRS Format Rech Expt 2738, Biochim Lab, Blvd Pierre Dramard, F-13916 Marseille 20, France.	sabatier.jm@jean-roche.univ-mrs.fr	De Waard, Michel/G-7406-2014; Regaya, Imed/L-7899-2018	De Waard, Michel/0000-0002-2782-9615; Beeton, Christine/0000-0002-2500-5874; Regaya, Imed/0000-0001-8671-5186; SABATIER, Jean-Marc/0000-0002-9040-5647				Avdonin V, 2000, BIOPHYS J, V79, P776, DOI 10.1016/S0006-3495(00)76335-1; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Blanc E, 1997, PROTEINS, V29, P321, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;321::AID-PROT6&gt;3.0.CO;2-D; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier E, 2000, J PEPT RES, V55, P419, DOI 10.1034/j.1399-3011.2000.00715.x; Castle NA, 2003, MOL PHARMACOL, V63, P409, DOI 10.1124/mol.63.2.409; Darbon H, 1999, PERSPECT DRUG DISCOV, V16, P41; Fajloun Z, 2000, J BIOL CHEM, V275, P39394, DOI 10.1074/jbc.M006810200; Fajloun Z, 2000, J BIOL CHEM, V275, P13605, DOI 10.1074/jbc.275.18.13605; GRAY EG, 1962, J ANAT, V96, P79; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lebrun B, 1997, BIOCHEM J, V328, P321, DOI 10.1042/bj3280321; M'Barek S, 2003, J BIOL CHEM, V278, P31095, DOI 10.1074/jbc.M304271200; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Olamendi-Portugal T, 1998, TOXICON, V36, P759, DOI 10.1016/S0041-0101(97)00163-3; OlamendiPortugal T, 1996, BIOCHEM J, V315, P977, DOI 10.1042/bj3150977; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Savarin P, 1999, PROTEIN SCI, V8, P2672; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; [No title captured]	35	48	51	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55690	55696		10.1074/jbc.M410055200	http://dx.doi.org/10.1074/jbc.M410055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498765	hybrid			2022-12-25	WOS:000225960800089
J	Rubi, B; del Arco, A; Bartley, C; Satrustegui, J; Maechler, P				Rubi, B; del Arco, A; Bartley, C; Satrustegui, J; Maechler, P			The malate-aspartate NADH shuttle member Aralar1 determines glucose metabolic fate, mitochondrial activity, and insulin secretion in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE DEHYDROGENASE; PYRIDINE NUCLEOTIDES; PANCREATIC-ISLETS; RAT-LIVER; EXOCYTOSIS; GLUTAMATE; MODEL; GLYCOLYSIS; OXIDATION; PYRUVATE	The NADH shuttle system, which transports reducing equivalents from the cytosol to the mitochondria, is essential for the coupling of glucose metabolism to insulin secretion in pancreatic beta cells. Aralar1 and citrin are two isoforms of the mitochondrial aspartate/glutamate carrier, one key constituent of the malate-aspartate NADH shuttle. Here, the effects of Aralar1 overexpression in INS-1E beta cells and isolated rat islets were investigated for the first time. We prepared a recombinant adenovirus encoding for human Aralar1 (AdCA-Aralar1), tagged with the small FLAG epitope. Transduction of INS-1E cells and isolated rat islets with AdCA-Aralar1 increased aralar1 protein levels and immunostaining revealed mitochondrial localization. Compared with control INS-1E cells, overexpression of Aralar1 potentiated metabolism secretion coupling stimulated by 15 mM glucose. In particular, there was an increase of NAD(P)H generation, of mitochondrial membrane hyperpolarization, ATP levels, glucose oxidation, and insulin secretion (+45%, p < 0.01). Remarkably, this was accompanied by reduced lactate production. Rat islets overexpressing Aralar1 secreted more insulin at 16.7 mM glucose (+65%, p < 0.05) compared with controls. These results show that aspartate-glutamate carrier capacity limits glucose-stimulated insulin secretion and that Aralar1 overexpression enhances mitochondrial metabolism.	Univ Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain; Fac Ciencias Medio Ambiente, Toledo 45071, Spain	University of Geneva; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Maechler, P (corresponding author), Univ Med Ctr, Dept Cell Physiol & Metab, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Pierre.Maechler@medecine.unige.ch	del Arco, Araceli/R-5653-2019; Satrustegui, Jorgina/R-6732-2019	Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; Maechler, Pierre/0000-0002-2005-1433; del Arco, Araceli/0000-0002-6839-542X				Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERRY MN, 1994, EUR J BIOCHEM, V225, P557, DOI 10.1111/j.1432-1033.1994.00557.x; Brennan L, 2002, DIABETES, V51, P1714, DOI 10.2337/diabetes.51.6.1714; Broca C, 2003, FEBS LETT, V545, P167, DOI 10.1016/S0014-5793(03)00526-X; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; Collins CL, 1998, BIOTECHNIQUES, V24, P803, DOI 10.2144/98245st04; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE262, DOI 10.1152/ajpendo.00542.2002; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Everse J, 1975, Methods Enzymol, V41, P41; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Ishihara H, 1996, DIABETES, V45, P1238, DOI 10.2337/diabetes.45.9.1238; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; MacDonald MJ, 2002, METABOLISM, V51, P318, DOI 10.1053/meta.2002.29960; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; MACDONALD MJ, 2000, SCIENCE, V287, P931; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 2002, CELL MOL LIFE SCI, V59, P1803, DOI 10.1007/PL00012507; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200; Novelli M, 2001, MOL CELL ENDOCRINOL, V175, P57, DOI 10.1016/S0303-7207(01)00400-2; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Song DK, 2000, METABOLISM, V49, P92, DOI 10.1016/S0026-0495(00)90838-2; SUGANO T, 1990, J BIOL CHEM, V265, P21549; Tan C, 2002, DIABETES, V51, P2989, DOI 10.2337/diabetes.51.10.2989; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; WATKINS D, 1971, ENDOCRINOLOGY, V88, P1380, DOI 10.1210/endo-88-6-1380; WATKINS D, 1968, SCIENCE, V162, P283, DOI 10.1126/science.162.3850.283; WATKINS DT, 1972, ENDOCRINOLOGY, V90, P272, DOI 10.1210/endo-90-1-272; WATKINS DT, 1977, ENDOCRINOLOGY, V100, P1461, DOI 10.1210/endo-100-5-1461; Yu W, 2000, DIABETES, V49, P945, DOI 10.2337/diabetes.49.6.945; ZAMMIT VA, 1976, BIOCHEM J, V154, P677, DOI 10.1042/bj1540677	52	89	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55659	55666		10.1074/jbc.M409303200	http://dx.doi.org/10.1074/jbc.M409303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494407	hybrid			2022-12-25	WOS:000225960800085
J	Tomlinson, MG; Heath, VL; Turck, CW; Watson, SP; Weiss, A				Tomlinson, MG; Heath, VL; Turck, CW; Watson, SP; Weiss, A			SHIP family inositol phosphatases interact with and negatively regulate the tec tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; ADAPTER PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LIPID PHOSPHATASE; SELF-ASSOCIATION; BINDING PROTEIN; SH3 DOMAIN; T-CELLS	The Tec family of protein-tyrosine kinases (PTKs), that includes Tec, Itk, Btk, Bmx, and Txk, plays an essential role in phospholipase Cgamma (PLCgamma) activation following antigen receptor stimulation. This function requires activation of phosphatidylinositol 3-kinase (PI 3-kinase), which promotes Tec membrane localization through phosphatidylinositol 3,4,5-trisphosphate (PtdIns 3,4,5-P-3) generation. The mechanism of negative regulation of Tec family PTKs is poorly understood. In this study, we show that the inositol 5' phosphatases SHIP1 and SHIP2 interact preferentially with Tec, compared with other Tec family members. Four lines of evidence suggest that SHIP phosphatases are negative regulators of Tec. First, SHIP1 and SHIP2 are potent inhibitors of Tec activity. Second, inactivation of the Tec SH3 domain, which is necessary and sufficient for SHIP binding, generates a hyperactive form of Tec. Third, SHIP1 inhibits Tec membrane localization. Finally, constitutively targeting Tec to the membrane relieves SHIP1-mediated inhibition. These data suggest that SHIP phosphatases can interact with and functionally inactivate Tec by de-phosphorylation of local PtdIns 3,4,5-P-3 and inhibition of Tec membrane localization.	Univ Birmingham, Inst Biomed Res, Div Med Sci, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Birmingham; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tomlinson, MG (corresponding author), Univ Birmingham, Inst Biomed Res, Div Med Sci, Ctr Cardiovasc Sci, Wolfson Dr, Birmingham B15 2TT, W Midlands, England.	m.g.tomlinson@bham.ac.uk	Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Tomlinson, Michael/0000-0002-1189-0091	NCI NIH HHS [CA 72531] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aoki N, 2004, J BIOL CHEM, V279, P10765, DOI 10.1074/jbc.M310401200; Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Damen JE, 2001, BLOOD, V97, P1343, DOI 10.1182/blood.V97.5.1343; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Garcon F, 2004, EUR J IMMUNOL, V34, P1972, DOI 10.1002/eji.200324777; Garcon F, 2004, J IMMUNOL, V173, P770, DOI 10.4049/jimmunol.173.2.770; Gerard A, 2004, ONCOGENE, V23, P1594, DOI 10.1038/sj.onc.1207283; Heath VL, 2004, EUKARYOT CELL, V3, P695, DOI 10.1128/EC.3.3.695-704.2004; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; James P, 1996, GENETICS, V144, P1425; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Labno CM, 2003, CURR BIOL, V13, P1619, DOI 10.1016/j.cub.2003.08.005; Laederach A, 2003, J MOL BIOL, V329, P1011, DOI 10.1016/S0022-2836(03)00531-X; Laederach A, 2002, PROTEIN SCI, V11, P36, DOI 10.1110/ps.ps.26702; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu WM, 2001, NAT IMMUNOL, V2, P939, DOI 10.1038/ni1001-939; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; March ME, 2002, SEMIN IMMUNOL, V14, P37, DOI 10.1006/smim.2001.0340; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Nore BF, 2003, BBA-PROTEINS PROTEOM, V1645, P123, DOI 10.1016/S1570-9639(02)00524-1; Okada H, 1998, J IMMUNOL, V161, P5129; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Pursglove SE, 2002, J BIOL CHEM, V277, P755, DOI 10.1074/jbc.M108318200; Reth M, 2004, NAT REV IMMUNOL, V4, P269, DOI 10.1038/nri1335; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; SWEENEY MJ, 2002, BIOMOLEC TECHN, V13, P43; Takesono A, 2002, J CELL SCI, V115, P3039; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; ZARRINPAR A, 2003, SCI STKE	63	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55089	55096		10.1074/jbc.M408141200	http://dx.doi.org/10.1074/jbc.M408141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15492005	hybrid			2022-12-25	WOS:000225960800014
J	Kawamura, K; Takano, K; Suetsugu, S; Kurisu, S; Yamazaki, D; Miki, H; Takenawa, T; Endo, T				Kawamura, K; Takano, K; Suetsugu, S; Kurisu, S; Yamazaki, D; Miki, H; Takenawa, T; Endo, T			N-WASP and WAVE2 acting downstream of phosphatidylinositol 3-kinase are required for myogenic cell migration induced by hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SKELETAL-MUSCLE; ARP2/3 COMPLEX; DEPOLYMERIZING PROTEIN; EPITHELIAL-CELLS; HOMOLOGY DOMAINS; SATELLITE CELLS; NEURAL CREST; STEM-CELLS; ACTIVATION	During skeletal muscle regeneration caused by injury, muscle satellite cells proliferate and migrate toward the site of muscle injury. This migration is mainly induced by hepatocyte growth factor (HGF) secreted by intact myofibers and also released from injured muscle. However, the intracellular machinery for the satellite cell migration has not been elucidated. To examine the mechanisms of satellite cell migration, we utilized satellite cell-derived mouse C2C12 skeletal muscle cells. HGF induced reorganization of actin cytoskeleton to form lamellipodia in C2C12 myoblasts. HGF treatment facilitated both nondirectional migration of the myoblasts in phagokinetic track assay and directional chemotactic migration toward HGF in a three-dimensional migration chamber assay. Endogenous N-WASP and WAVE2 were concentrated in the lamellipodia at the leading edge of the migrating cells. Moreover, exogenous expression of wild-type N-WASP or WAVE2 promoted lamellipodial formation and migration. By contrast, expression of the dominant-negative mutant of N-WASP or WAVE2 and knockdown of N-WASP or WAVE2 expression by the RNA interference prevented the HGF-induced lamellipodial formation and migration. When the cells were treated with LY294002, an inhibitor of phosphatidylinositol 3-kinase, the HGF-induced lamellipodial formation and migration were abrogated. These results imply that both N-WASP and WAVE2, which are activated downstream of phosphatidylinositol 3-kinase, are required for the migration through the lamellipodial formation of C2C12 cells induced by HGF.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Inst Med Sci, Div Canc Genom, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	Chiba University; Chiba University; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.	t.endo@faculty.chiba-u.jp	Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Kurisu, Shusaku/AAB-1799-2022; Suetsugu, Shiro/B-3300-2010	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Kurisu, Shusaku/0000-0002-4876-4419				Abe T, 2003, J CELL SCI, V116, P155, DOI 10.1242/jcs.00208; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Birchmeier C, 2000, CURR OPIN CELL BIOL, V12, P725, DOI 10.1016/S0955-0674(00)00159-9; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; BISCHOFF R, 1994, MYOGENESIS, V2, P97; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dahl JP, 2003, J NEUROSCI, V23, P3343; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Gammill LS, 2003, NAT REV NEUROSCI, V4, P795, DOI 10.1038/nrn1219; Grounds MD, 2002, J HISTOCHEM CYTOCHEM, V50, P589, DOI 10.1177/002215540205000501; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lorenz M, 2004, CURR BIOL, V14, P697, DOI 10.1016/j.cub.2004.04.008; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miller KJ, 2000, AM J PHYSIOL-CELL PH, V278, pC174, DOI 10.1152/ajpcell.2000.278.1.C174; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Sheehan SM, 2000, MUSCLE NERVE, V23, P239, DOI 10.1002/(SICI)1097-4598(200002)23:2<239::AID-MUS15>3.0.CO;2-U; Sheehan SM, 1999, J CELL PHYSIOL, V181, P499, DOI 10.1002/(SICI)1097-4652(199912)181:3<499::AID-JCP14>3.0.CO;2-1; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Takenawa T, 2001, J CELL SCI, V114, P1801; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Villena J, 2004, J CELL PHYSIOL, V198, P169, DOI 10.1002/jcp.10422; Ward ME, 2004, P NATL ACAD SCI USA, V101, P970, DOI 10.1073/pnas.0306258101; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yamaguchi H, 2002, CANCER RES, V62, P2503; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	68	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54862	54871		10.1074/jbc.M408057200	http://dx.doi.org/10.1074/jbc.M408057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15496413	hybrid			2022-12-25	WOS:000225793600115
J	Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y				Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y			Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer	ONCOGENE			English	Article						CLUAP1; clusterin; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; COLORECTAL CARCINOGENESIS; CELL-DEATH; CLUSTERIN; CARCINOMAS; PROTEIN; INVOLVEMENT; ADENOMAS; COMPLEX; GAINS	To disclose mechanisms of colorectal carcinogenesis and identify novel diagnostic markers and drug targets for treatment of these tumors, we previously analysed the expression profiles of 11 colorectal cancers using a genome-wide cDNA microarray containing 23 040 genes. Among the genes commonly transactivated in the cancers, we identified a novel human gene, which we termed CLUAP1 (clusterin-associated protein 1). It encodes a nuclear protein of 413 amino acids containing a coiled-coil domain. To investigate its function, we searched for CLUAP1-interacting proteins using yeast two-hybrid system and identified nuclear Clusterin. Expression of CLUAP1 was gradually increased in the late S to G2/ M phases of cell cycle and it returned to the basal level in the G0/G1 phases. Suppression of this gene by short interfering RNAs resulted in growth retardation in the transfected cells. These data provide better understanding of colorectal carcinogenesis, and inactivation of CLUAP1 may conceivably serve in the future as a novel therapeutic intervention for treatment of colon cancer.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp		Takahashi, Meiko/0000-0002-8344-5472				Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Debure L, 2003, J CELL SCI, V116, P3109, DOI 10.1242/jcs.00619; He QJ, 2003, CANCER GENET CYTOGEN, V144, P112, DOI 10.1016/S0165-4608(02)00959-7; Hough CD, 2001, CANCER RES, V61, P3869; Kitahara O, 2001, CANCER RES, V61, P3544; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; Nakao K, 1998, SURG TODAY, V28, P567, DOI 10.1007/s005950050185; Okabe H, 2003, CANCER RES, V63, P3043; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Shimokawa T, 2003, CANCER RES, V63, P6116; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wellmann A, 2000, BLOOD, V96, P398; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	20	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9289	9294		10.1038/sj.onc.1208100	http://dx.doi.org/10.1038/sj.onc.1208100			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15480429				2022-12-25	WOS:000225638000014
J	Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E				Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E			Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells	ONCOGENE			English	Article						apoptosis; death receptors; lipid rafts; resveratrol	INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CANCER-CELLS; LIPID RAFTS; ACTIVATION; CASPASE-8; SENSITIZATION; COMPOUND; PATHWAY	The natural phytoalexin resveratrol (3,5,4'-trihydroxystilbene) exhibits both chemopreventive and antitumor activities through a variety of mechanisms. We have shown previously that resveratrol-induced apoptosis of a human colon cancer cell line involved the redistribution of CD95 (Fas/Apo-1) into lipid rafts. Here, we show that, in colon cancer cells that resist to resveratrol-induced apoptosis, the polyphenol also induces a redistribution of death receptors into lipid rafts. This effect sensitizes these tumor cells to death receptor-mediated apoptosis. In resveratrol-treated cells, tumor necrosis factor (TNF), anti-CD95 antibodies and TNF-related apoptosis-inducing ligand (TRAIL) activate a caspase-dependent death pathway that escapes Bcl-2-mediated inhibition. Resveratrol does not enhance the number of death receptors at the surface of tumor cells but induces their redistribution into lipid rafts and facilitates the caspase cascade activation in response to death receptor stimulation. The cholesterol sequestering agent nystatin prevents resveratrol-induced death receptor redistribution and cell sensitization to death receptor stimulation. Thus, whatever its ability to induce apoptosis in a tumor cell, resveratrol induces redistribution of death receptors into lipid rafts. This redistribution sensitizes the cells to death receptor stimulation. Such a sensitizing effect may be of therapeutic interest if TRAIL agonists are introduced in clinics.	INSERM, U517, IFR100, Fac Med, F-21000 Dijon, France; Univ Burgundy, Mol & Cellular Biol Lab, GDR CNRS 2583, IFR92, F-21000 Dijon, France; CHU Bocage, INSERM, U498, IFR100, F-21034 Dijon, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Solary, E (corresponding author), INSERM, U517, IFR100, Fac Med, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr	Delmas, Dominique/AAD-9749-2019; micheau, olivier/C-3574-2011; REBE, Cédric/AAD-4316-2019	Delmas, Dominique/0000-0003-3576-0248; micheau, olivier/0000-0001-8499-7984; REBE, Cédric/0000-0001-8831-145X; Solary, Eric/0000-0002-8629-1341; Delmas, Dominique/0000-0002-8911-8499				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Clement MV, 1998, BLOOD, V92, P996; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorrie J, 2001, CANCER RES, V61, P4731; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Keane MM, 1999, CANCER RES, V59, P734; Kubota T, 2003, ANTICANCER RES, V23, P4039; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Lacour S, 2001, CANCER RES, V61, P1645; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sun ZJ, 2002, WORLD J GASTROENTERO, V8, P79, DOI 10.3748/wjg.v8.i1.79; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zoberi I, 2002, CANCER LETT, V175, P165, DOI 10.1016/S0304-3835(01)00719-4	41	166	168	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8979	8986		10.1038/sj.onc.1208086	http://dx.doi.org/10.1038/sj.onc.1208086			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480430				2022-12-25	WOS:000225354600013
J	Golan-Mashiach, M; Dazard, JE; Gerecht-Nir, S; Amariglio, N; Fisher, T; Jacob-Hirsch, J; Bielorai, B; Osenberg, S; Barad, O; Getz, G; Toren, A; Rechavi, G; Itskovitz-Eldor, J; Domany, E; Givol, D				Golan-Mashiach, M; Dazard, JE; Gerecht-Nir, S; Amariglio, N; Fisher, T; Jacob-Hirsch, J; Bielorai, B; Osenberg, S; Barad, O; Getz, G; Toren, A; Rechavi, G; Itskovitz-Eldor, J; Domany, E; Givol, D			Design principle of gene expression used by human stem cells: implication for pluripotency	FASEB JOURNAL			English	Article						differentiation; self-renewal; microarray; clustering	HEMATOPOIETIC STEM; MOLECULAR SIGNATURE; ES CELLS; DIFFERENTIATION; MOUSE; MAINTENANCE; LINES; P63; MORPHOGENESIS; KERATINOCYTES	Human embryonic stem cells (ESC) are undifferentiated and are endowed with the capacities of self-renewal and pluripotential differentiation. Adult stem cells renew their own tissue, but whether they can transdifferentiate to other tissues is still controversial. To understand the genetic program that underlies the pluripotency of stem cells, we compared the transcription profile of ESC with that of progenitor/stem cells of human hematopoietic and keratinocytic origins, along with their mature cells to be viewed as snapshots along tissue differentiation. ESC gene profiles show higher complexity with significantly more highly expressed genes than adult cells. We hypothesize that ESC use a strategy of expressing genes that represent various differentiation pathways and selection of only a few for continuous expression upon differentiation to a particular target. Such a strategy may be necessary for the pluripotency of ESC. The progenitors of either hematopoietic or keratinocytic cells also follow the same design principle. Using advanced clustering, we show that many of the ESC expressed genes are turned off in the progenitors/stem cells followed by a further down-regulation in adult tissues. Concomitantly, genes specific to the target tissue are up-regulated toward mature cells of skin or blood.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Case Western Reserve Univ, Dept Epidemiol & Biostat, Sch Med, Cleveland, OH 44106 USA; Tel Aviv Univ, Dept Pediat Hematol Oncol, Chaim Sheba Med Ctr, IL-52621 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-52621 Tel Aviv, Israel; Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, Dept Obstet & Gynecol, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, Biotechnol Interdisciplinary Unit, Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Case Western Reserve University; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	david.givol@weizmann.ac.il	DOMANY, EYTAN/K-1560-2012					Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Handgretinger R, 2003, ANN NY ACAD SCI, V996, P141, DOI 10.1111/j.1749-6632.2003.tb03242.x; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sokal R. R., 2012, BIOMETRY; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; Vanhoutteghem A, 2004, P NATL ACAD SCI USA, V101, P3468, DOI 10.1073/pnas.0400268101; Xu CH, 1999, DEVELOPMENT, V126, P483; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; YANAI I, 2004, BIOINFORMATICS  0930, DOI DOI 10.1093/BIOINFORMATICS/BTI042; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	50	59	61	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					147	149		10.1096/fj.04-2417fje	http://dx.doi.org/10.1096/fj.04-2417fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498892	Green Submitted			2022-12-25	WOS:000224849900010
J	Suganami, T; Mukoyama, M; Mori, K; Yokoi, H; Koshikawa, M; Sawai, K; Hidaka, S; Ebihara, K; Tanaka, T; Sugawara, A; Kawachi, H; Vinson, C; Ogawa, Y; Nakao, K				Suganami, T; Mukoyama, M; Mori, K; Yokoi, H; Koshikawa, M; Sawai, K; Hidaka, S; Ebihara, K; Tanaka, T; Sugawara, A; Kawachi, H; Vinson, C; Ogawa, Y; Nakao, K			Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy	FASEB JOURNAL			English	Article						lipoatrophic diabetes; TGF-beta 1; podocytes; proteinuria; transgenic mice	MICE OVEREXPRESSING LEPTIN; MATRIX GENE-EXPRESSION; GROWTH-FACTOR-BETA; TGF-BETA; PANCREAS TRANSPLANTATION; EXTRACELLULAR-MATRIX; INSULIN SENSITIVITY; GLUCOSE-METABOLISM; HYPERTENSIVE-RATS; TRANSGENIC MICE	Diabetic nephropathy is the leading cause of end-stage renal disease, for which effective therapy to prevent the progression at advanced stages remains to be established. There is also a long debate whether diabetic glomerular injury is reversible or not. Lipoatrophic diabetes, a syndrome caused by paucity of adipose tissue, is characterized by severe insulin resistance, dyslipidemia, and fatty liver. Here, we show that a genetic model of lipoatrophic diabetes (A-ZIP/F-1 mice) manifests a typical renal injury observed in human diabetic nephropathy that is associated with glomerular hypertrophy, diffuse and pronounced mesangial widening, accumulation of extracellular matrix proteins, podocyte damage, and overt proteinuria. By crossing A-ZIP/F-1 mice with transgenic mice overexpressing an adipocyte-derived hormone leptin, we also reveal that leptin completely prevents the development of hyperglycemia and nephropathy in A-ZIP/F-1 mice. Furthermore, continuous leptin administration to A-ZIP/F-1 mice by minipump beginning at 40 weeks of age significantly alleviates the glomerular injury and proteinuria. These findings demonstrate the therapeutic usefulness of leptin at least for a certain type of diabetic nephropathy. The model presented here will serve as a novel tool to analyze the molecular mechanism underlying not only the progression but also the regression of diabetic nephropathy.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Niigata Univ, Dept Cell Biol, Inst Nephrol, Grad Sch Med & Dent Sci, Niigata, Japan	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Niigata University	Mukoyama, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	muko@kuhp.kyoto-u.ac.jp	SUGANAMI, Takayoshi/A-9475-2016; Mori, Kiyoshi/N-1267-2014; Yokoi, Hideki/AAV-9038-2021; Yokoi, Hideki/R-1289-2016	Mori, Kiyoshi/0000-0002-7285-8351; Yokoi, Hideki/0000-0001-8343-9737; Yokoi, Hideki/0000-0001-8343-9737; Ogawa, Yoshihiro/0000-0002-0834-2836	NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUNA GM, 1983, LANCET, V2, P1274; Aizawa-Abe M, 2000, J CLIN INVEST, V105, P1243, DOI 10.1172/JCI8341; Andreelli F, 2000, J CLIN ENDOCR METAB, V85, P715, DOI 10.1210/jc.85.2.715; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chen S, 2003, BIOCHEM BIOPH RES CO, V300, P16, DOI 10.1016/S0006-291X(02)02708-0; Doublier S, 2003, DIABETES, V52, P1023, DOI 10.2337/diabetes.52.4.1023; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; GOLDSTEIN BJ, 1994, SYNDROME EXTREME INS; Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995; Kawachi H, 2000, KIDNEY INT, V57, P1949, DOI 10.1046/j.1523-1755.2000.00044.x; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Koop K, 2003, J AM SOC NEPHROL, V14, P2063, DOI 10.1097/01.ASN.0000078803.53165.C9; Kopp JB, 1996, LAB INVEST, V74, P991; Masuzaki H, 1999, DIABETES, V48, P1615, DOI 10.2337/diabetes.48.8.1615; Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447; Miyanaga F, 2003, DIABETOLOGIA, V46, P1329, DOI 10.1007/s00125-003-1193-6; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; ORLOFF MJ, 1986, DIABETES, V35, P347, DOI 10.2337/diabetes.35.3.347; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; Sawai K, 2003, J AM SOC NEPHROL, V14, P1154, DOI 10.1097/01.ASN.0000060576.61218.3D; Saxena NK, 2003, J CELL BIOCHEM, V89, P311, DOI 10.1002/jcb.10494; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Suganami T, 2003, HYPERTENSION, V42, P1183, DOI 10.1161/01.HYP.0000101689.64849.97; Suganami T, 2001, J HYPERTENS, V19, P1095, DOI 10.1097/00004872-200106000-00015; Suganami T, 2001, J AM SOC NEPHROL, V12, P2652, DOI 10.1681/ASN.V12122652; WAJCHENBERG BL, 1983, ACTA DIABETOL LAT, V20, P1, DOI 10.1007/BF02629124; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Wolf G, 1999, KIDNEY INT, V56, P860, DOI 10.1046/j.1523-1755.1999.00626.x; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yaoita E, 2002, AM J PATHOL, V161, P1597, DOI 10.1016/S0002-9440(10)64438-0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	39	46	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					127	+		10.1096/fj.04-2183fje	http://dx.doi.org/10.1096/fj.04-2183fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15496495				2022-12-25	WOS:000224849900014
J	Akerman, SE; Muller, S				Akerman, SE; Muller, S			Peroxiredoxin-linked detoxification of hydroperoxides in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; THIOREDOXIN REDUCTASE; GLUTATHIONE-REDUCTASE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT SYSTEMS; 1-CYS PEROXIREDOXIN; PEROXIDASE-ACTIVITY; HYDROGEN-PEROXIDE; THIOL PEROXIDASE; REDOX REGULATION	The apicomplexan parasite Toxoplasma gondii is highly susceptible to oxidative stress caused by tertbutyl-hydroperoxide, juglone, and phenazine methylsulfate with IC50 in the nanomolar range. Using dichlorofluorescein diacetate, a detector of endogenous oxidative stress, it was shown that juglone and phenazine methylsulfate are potentially toxic to the parasites without affecting the host cells. These results demonstrate that T. gondii is vulnerable to oxidative challenge that results from disruption of its redox balance and so this could be an effective approach to therapeutic intervention. This study has characterized redox active and antioxidant peroxidases belonging to the class of 1-Cys and 2-Cys peroxiredoxins that play crucial roles in maintaining redox balance. The tachyzoite stages of T. gondii express thioredoxin (TgTrx), 1-Cys peroxiredoxin (TgTrx-Px2), and a 2-Cys peroxiredoxin (TgTrx-Px1) and immunofluorescent studies revealed that all three proteins are located in the cytosol of the parasite confirming previous studies on TgTrx-Px1 (Kwok, L. Y., Schluter, D., Clayton, C., and Soldati, D. ( 2004) Mol. Microbiol. 51, 47-61). TgTrx-Px1 showed K-m values for H2O2 and tert-butyl hydroperoxide in the nanomolar range, emphasizing the great affinity of the protein for theses substrates. Moreover, the catalytic efficiency of TgTrx-Px1 for these substrates at 10(6)-10(7) M-1 s(-1) is unusually high, which qualifies the enzyme as an extremely potent antioxidant. Kinetic analyses revealed that TgTrx-Px1 is inhibited by tert-butyl hydroperoxide, and apparent inhibition constants were determined to be between 33 and 35.6 muM depending on the concentration of the non-inhibitory substrate thioredoxin. TgTrx-Px2 protected glutamine synthetase from inactivation by Fe3+/DTT, showing that it is an active peroxiredoxin.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Glasgow; University of Dundee	Muller, S (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	s.muller@bio.gla.ac.uk						Akerman SE, 2003, MOL BIOCHEM PARASIT, V130, P75, DOI 10.1016/S0166-6851(03)00161-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brydges SD, 2003, J CELL SCI, V116, P4675, DOI 10.1242/jcs.00750; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bunik VI, 2003, EUR J BIOCHEM, V270, P1036, DOI 10.1046/j.1432-1033.2003.03470.x; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CORNISHBOWDEN A, 2004, FUNDAMENTALS ENZYME, P137; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Denkers EY, 2003, CELL MICROBIOL, V5, P75, DOI 10.1046/j.1462-5822.2003.00258.x; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Ding M, 2000, J CELL SCI, V113, P2409; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Gilberger TW, 2000, MOL BIOCHEM PARASIT, V107, P169, DOI 10.1016/S0166-6851(00)00188-2; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gratepanche S, 2002, MOL BIOCHEM PARASIT, V120, P237, DOI 10.1016/S0166-6851(02)00004-X; HEBBEL RP, 1990, BLOOD, V76, P1015; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Jakubowski W, 2000, CELL BIOL INT, V24, P757, DOI 10.1006/cbir.2000.0556; Kaasch AJ, 2000, J BIOL CHEM, V275, P1112, DOI 10.1074/jbc.275.2.1112; Kampkotter A, 2003, J MOL BIOL, V325, P25, DOI 10.1016/S0022-2836(02)01174-9; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; Krnajski Z, 2002, J BIOL CHEM, V277, P25970, DOI 10.1074/jbc.M203539200; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Kwok LY, 2004, MOL MICROBIOL, V51, P47, DOI 10.1046/j.1365-2958.2003.03823.x; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; LESCOVAC V, 2003, COMPREHENSIVE ENZYME, P191; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; Muller S, 2004, MOL MICROBIOL, V53, P1291, DOI 10.1111/j.1365-2958.2004.04257.x; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Odberg-Ferragut C, 2000, MOL BIOCHEM PARASIT, V106, P121, DOI 10.1016/S0166-6851(99)00211-X; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	50	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					564	570		10.1074/jbc.M406367200	http://dx.doi.org/10.1074/jbc.M406367200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507457	hybrid			2022-12-25	WOS:000226025100067
J	Berrou, L; Dodier, Y; Raybaud, A; Tousignant, A; Dafi, O; Pelletier, JN; Parent, L				Berrou, L; Dodier, Y; Raybaud, A; Tousignant, A; Dafi, O; Pelletier, JN; Parent, L			The C-terminal residues in the alpha-interacting domain (AID) helix anchor Ca-V beta subunit interaction and modulation of Ca(V)2.3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CALCIUM-CHANNELS; VOLTAGE-DEPENDENT INACTIVATION; I-II LINKER; FUNCTIONAL EXPRESSION; CLONING; COMPLEX; BINDING; SITE; ASSOCIATION; INHIBITION	The alpha-interacting domain (AID) in the I-II linker of high voltage-activated (HVA) Ca2+ channel alpha1 subunits binds with high affinity to Ca(v)beta auxiliary subunits. The recently solved crystal structures of the AID-Ca(v)beta complex in Ca(v)1.1/1.2 have revealed that this interaction occurs through a set of six mostly invariant residues Glu/Asp(6), Leu(7), Gly(9), Tyr(10), Trp(13), and Ile(14) ( where the superscript refers to the position of the residue starting with the QQ signature doublet) distributed among three alpha-helical turns in the proximal section of the I-II linker. We show herein that alanine mutations of N-terminal AID residues Gln(1), Gln(2), Ile(3), Glu(4), Glu(6), Leu(7), and Gly(9) in Ca(v)2.3 did not abolish [S-35]Ca(v)beta1b or [S-35]Ca(v)beta3 subunit overlay binding to fusion proteins nor did they prevent the typical modulation of whole cell currents by Ca(v)beta3. Mutations of the invariant Tyr(10) with either hydrophobic (Ala), aromatic (Phe), or positively charged (Arg, Lys) residues yielded Ca(v)beta3-responsive whole cell currents, whereas mutations with negatively charged residues (Asp, Glu) disrupted Ca(v)beta3 binding and modulation. In contrast, modulation and binding by Ca(v)beta3 was significantly weakened in I14A (neutral and hydrophobic) and I14S (neutral and polar) mutants and eradicated in negatively charged I14D and I14E or positively charged I14R and I14K mutants. Ca(v)beta3-induced modulation was only preserved with the conserved I14L mutation. Molecular replacement analyses carried out using a three-dimensional homology model of the AID helix from Ca(v)2.3 suggests that a high degree of hydrophobicity and a restrained binding pocket could account for the strict structural specificity of the interaction site found at position Ile14. Altogether these results indicate that the C-terminal residues Trp13 (1) and Ile(14) anchor Ca(v)beta subunit functional modulation of HVA Ca2+ channels.	Univ Montreal, Dept Physiol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Etud Prot Membranaires, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Phys, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Chim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Parent, L (corresponding author), Univ Montreal, Dept Physiol, POB 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	lucie.parent@umontreal.ca						Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bell DC, 2001, J NEUROPHYSIOL, V85, P816, DOI 10.1152/jn.2001.85.2.816; Bernatchez G, 2001, J MEMBRANE BIOL, V184, P143, DOI 10.1007/s00232-001-0083-4; Bernatchez G, 2001, BBA-BIOMEMBRANES, V1514, P217, DOI 10.1016/S0005-2736(01)00373-X; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Chica RA, 2004, PROTEIN SCI, V13, P979, DOI 10.1110/ps.03433304; Dafi O, 2004, BIOPHYS J, V87, P3181, DOI 10.1529/biophysj.104.045559; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Doucet N, 2004, J BIOL CHEM, V279, P46295, DOI 10.1074/jbc.M407606200; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Kangas E, 1998, J CHEM PHYS, V109, P7522, DOI 10.1063/1.477375; Neuhuber B, 1998, J BIOL CHEM, V273, P9110, DOI 10.1074/jbc.273.15.9110; Neuhuber B, 1998, P NATL ACAD SCI USA, V95, P5015, DOI 10.1073/pnas.95.9.5015; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Parent L, 1997, J MEMBRANE BIOL, V160, P127, DOI 10.1007/s002329900302; PARENT L, 1995, FEBS LETT, V360, P144, DOI 10.1016/0014-5793(95)00090-V; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Sheinerman FB, 2002, J MOL BIOL, V318, P161, DOI 10.1016/S0022-2836(02)00030-X; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088	44	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					494	505		10.1074/jbc.M410859200	http://dx.doi.org/10.1074/jbc.M410859200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507442	hybrid			2022-12-25	WOS:000226025100059
J	Buck, TM; Skach, WR				Buck, TM; Skach, WR			Differential stability of biogenesis intermediates reveals a common pathway for aquaporin-1 topological maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NEPHROGENIC DIABETES-INSIPIDUS; ALKALINE-PHOSPHATASE FUSIONS; NA,K-ATPASE ALPHA-SUBUNIT; ENDOPLASMIC-RETICULUM; WATER CHANNELS; MEMBRANE-PROTEINS; TRANSLOCATION CHANNEL; TERMINAL 3RD; ER MEMBRANE	Topological studies of multi-spanning membrane proteins commonly use sequentially truncated proteins fused to a C-terminal translocation reporter to deduce transmembrane (TM) segment orientation and key biogenesis events. Because these truncated proteins represent an incomplete stage of synthesis, they transiently populate intermediate folding states that may or may not reflect topology of the mature protein. For example, in Xenopus oocytes, the aquaporin-1 (AQP1) water channel is cotranslationally directed into a four membrane-spanning intermediate, which matures into the six membrane-spanning topology at a late stage of synthesis (Skach, W. R., Shi, L. B., Calayag, M. C., Frigeri, A., Lingappa, V. R., and Verkman, A. S. ( 1994) J. Cell Biol. 125, 803-815 and Lu, Y., Turnbull, I. R., Bragin, A., Carveth, K., Verkman, A. S., and Skach, W. R. ( 2000) Mol. Biol. Cell 11, 2973-2985). The hallmark of this process is that TM3 initially acquires an Nexo/Ccyto ( Type I) topology and must rotate 180 to acquire its mature orientation. In contrast, recent studies in HEK-293 cells have suggested that TM3 acquires its mature topology cotranslationally without the need for reorientation (Dohke, Y., and Turner, R. J. ( 2002) J. Biol. Chem. 277, 15215 15219). Here we re-examine AQP1 biogenesis and show that irrespective of the reporter or fusion site used, oocytes and mammalian cells yielded similar topologic results. AQP1 intermediates containing the first three TM segments generated two distinct cohorts of polypeptides in which TM3 spanned the ER membrane in either an Ncyto/Cexo ( mature) or Nexo/Ccyto ( immature) topology. Pulse-chase analyses revealed that the immature form was predominant immediately after synthesis but that it was rapidly degraded via the proteasome-mediated endoplasmic reticulum associated degradation (ERAD) pathway with a half-life of less than 25 min in HEK cells. As a result, the mature topology predominated at later time points. We conclude that (i) differential stability of biogenesis intermediates is an important factor for in vivo topological analysis of truncated chimeric proteins and (ii) cotranslational events of AQP1 biogenesis reflect a common AQP1 folding pathway in diverse expression systems.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA	Oregon Health & Science University	Skach, WR (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	skachw@ohsu.edu		Buck, Teresa/0000-0002-9013-9756	NIDDK NIH HHS [DK51818] Funding Source: Medline; NIGMS NIH HHS [GM53457] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BUCK TM, 2004, AM J PHYSIOL, V287, pC1291; Carveth K, 2002, J BIOL CHEM, V277, P39507, DOI 10.1074/jbc.M205759200; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Dohke Y, 2004, J BIOL CHEM, V279, P12242, DOI 10.1074/jbc.M312456200; Dohke Y, 2002, J BIOL CHEM, V277, P15215, DOI 10.1074/jbc.C100646200; Eichler J, 2004, TRENDS BIOCHEM SCI, V29, P221, DOI 10.1016/j.tibs.2004.03.001; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Foster W, 2000, J BIOL CHEM, V275, P34157, DOI 10.1074/jbc.M000165200; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Fujiyoshi Y, 2002, CURR OPIN STRUC BIOL, V12, P509, DOI 10.1016/S0959-440X(02)00355-X; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SADLISH H, 2004, IN PRESS J MEMBR BIO; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SKACH WR, 1995, BIOPHYSICAL, V68, pA334; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; Toriano R, 1998, J MEMBRANE BIOL, V161, P141, DOI 10.1007/s002329900321; Turner RJ, 2003, J MEMBRANE BIOL, V192, P149, DOI 10.1007/s00232-002-1071-z; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618	61	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					261	269		10.1074/jbc.M409920200	http://dx.doi.org/10.1074/jbc.M409920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516332	hybrid			2022-12-25	WOS:000226025100032
J	Piboonpocanun, S; Chiba, H; Mitsuzawa, H; Martin, W; Murphy, RC; Harbeck, RJ; Voelker, DR				Piboonpocanun, S; Chiba, H; Mitsuzawa, H; Martin, W; Murphy, RC; Harbeck, RJ; Voelker, DR			Surfactant protein A binds Mycoplasma pneumoniae with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY HOST-DEFENSE; ALVEOLAR MACROPHAGES; PHOSPHOLIPID SECRETION; MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; CANDIDA-ALBICANS; DEFICIENT MICE; IN-VITRO; II CELLS; COLLECTINS	Surfactant Protein A (SP-A) is an abundant, multifunctional lectin that resides within the bronchoalveolar compartment of the lung and plays an important role in the innate immunity of the organ. Mycoplasma pneumoniae is a human pathogen that resides in the same compartment as SP-A, and we examined the interaction between the two. Preparations of human and rat SP-A recognized the mycoplasma with high affinity in the presence of Ca2+, exhibiting apparent K-d values in the nanomolar range. Membranes prepared from the microbe also bound human and rat SP-A with similar characteristics and affinity to the intact cells. The ligand for SP-A was insensitive to proteolysis. Lipid extracts prepared from the mycoplasma, bound SP-A with high affinity when examined by ligand blot analysis. These lipid extracts were also potent competitive inhibitors (IC50=0.2 nM) of human SP-A binding to mycoplasma membranes. The major lipid ligands for the protein identified by mass spectrometry are a group of disaturated phosphatidylglycerols. The addition of SP-A to cultures of M. pneumoniae markedly attenuated the growth of the organism assessed by colony formation, metabolic activity, and DNA replication. The bacteriostatic effects of SP-A were reversed by dipalmitoylphosphatidylglycerol. These findings demonstrate that human SP-A can play a direct role in antibody-independent immunity to M. pneumoniae by interacting with lipid ligands expressed on the surface of the organism and implicate SP-A in the immediate host response to the bacteria.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org	Murphy, Robert/AAO-5349-2020; Piboonpocanun, Surapon/M-7823-2019	Murphy, Robert/0000-0002-9430-6515; , surapon/0000-0003-4374-8003	NHLBI NIH HHS [P01 HL073907, HL45286, P01-HL073907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073907, R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GIL JC, 1993, ANN ALLERGY, V70, P23; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hickman-Davis JM, 2004, AM J RESP CELL MOL, V30, P319, DOI 10.1165/rcmb.2003-0246OC; HickmanDavis JM, 1997, INFECT IMMUN, V65, P2278, DOI 10.1128/IAI.65.6.2278-2282.1997; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Rosseau S, 1999, J IMMUNOL, V163, P4495; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Sano H, 1999, J IMMUNOL, V163, P387; STAMME C, 2000, AM J RESP CRIT CARE, V161, pA515; Tully X, 1995, MOL DIAGNOSTIC PROCE, P33; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889	32	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					9	17		10.1074/jbc.M411570200	http://dx.doi.org/10.1074/jbc.M411570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15498759	hybrid			2022-12-25	WOS:000226025100003
J	Jing, H; Yen, JH; Ganea, D				Jing, H; Yen, JH; Ganea, D			A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; TRANSCRIPTION FACTOR; DENDRITIC CELLS; PROSTANOID RECEPTORS; PHOSPHORYLATION; EPAC; RAP1	In response to pathogen-associated molecular patterns, dendritic cells initiate an innate immune response characterized by expression and release of proinflammatory cytokines and chemokines. The extent of the inflammatory response is limited by various endogenous factors, including lipid mediators such as prostaglandin E-2 (PGE(2)). We described previously the inhibitory effect of PGE(2) on the expression and release of the inflammatory chemokines CCL3 and CCL4 from activated dendritic cells. In this study we describe a novel PGE2 signaling pathway that proceeds through EP-2-->cAMP-->EPAC-->phosphatidylinositol 3-kinase-->protein kinase B-->GSK-3 and results in increased DNA binding of the CCAAT displacement protein (CDP), a potent mammalian transcriptional repressor. The direct link between CDP and CCL3/4 transcription was established in knock-down experiments using CDP small interference RNA.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu		Yen, Jui-Hung Jimmy/0000-0002-7325-9756	NIAID NIH HHS [AI 47325, AI 52306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI147325, R56AI047325, R01AI047325, R01AI052306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amsterdam A, 2002, BIOCHEM PHARMACOL, V64, P843, DOI 10.1016/S0006-2952(02)01147-4; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Delgado M, 2004, PHARMACOL REV, V56, P249, DOI 10.1124/pr.56.2.7; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujita H, 2004, J INVEST DERMATOL, V122, P1331, DOI 10.1111/j.0022-202X.2004.22534.x; Granucci F, 2004, INT ARCH ALLERGY IMM, V134, P179, DOI 10.1159/000078764; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Jing H, 2003, J LEUKOCYTE BIOL, V74, P868, DOI 10.1189/jlb.0303116; Jozefowski S, 2003, INT IMMUNOPHARMACOL, V3, P865, DOI 10.1016/S1567-5769(03)00072-9; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kalinski P, 1997, ADV EXP MED BIOL, V417, P363; Kalinski P, 2001, BLOOD, V97, P3466, DOI 10.1182/blood.V97.11.3466; KATAMURA K, 1995, J IMMUNOL, V155, P4604; MARTIN CA, 1991, CELL IMMUNOL, V135, P245, DOI 10.1016/0008-8749(91)90269-H; Matsumoto M, 1998, INT IMMUNOL, V10, P1825, DOI 10.1093/intimm/10.12.1825; Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Nirodi C, 2001, J BIOL CHEM, V276, P26122, DOI 10.1074/jbc.M102872200; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; Okada N, 2001, CANCER RES, V61, P7913; PROFFITT J, 1995, GENE, V152, P173, DOI 10.1016/0378-1119(94)00701-S; RITTER LM, 1995, MOL CELL BIOL, V15, P3110; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Shen ZH, 1997, J IMMUNOL, V158, P2723; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Steinman RM, 2003, PATHOL BIOL, V51, P59, DOI 10.1016/S0369-8114(03)00096-8; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; VANLIESHOUT TW, 2004, IN PRESS ANN RHEUM D; Vassiliou E, 2003, CELL IMMUNOL, V223, P120, DOI 10.1016/S0008-8749(03)00158-8	38	70	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55176	55186		10.1074/jbc.M409816200	http://dx.doi.org/10.1074/jbc.M409816200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15498767	hybrid			2022-12-25	WOS:000225960800025
J	Katragadda, M; Morikis, D; Lambris, JD				Katragadda, M; Morikis, D; Lambris, JD			Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; CATALYTIC MECHANISM; COMPLEMENT INHIBITOR; MONOCLONAL-ANTIBODY; WATER-MOLECULES; HEAT-CAPACITY; BINDING-SITE; PROTEIN; PEPTIDE; CYCLOPHILIN	Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. Although the activity of compstatin has been improved severalfold using combinatorial and rational design approaches, the molecular basis for its interaction with C3 is not yet fully understood. In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compstatin with C3 using four different compstatin analogs. Our studies indicate that the C3-compstatin interaction is an enthalpy-driven process. Substitution of the valine and histidine residues at positions 4 and 9 with tryptophan and alanine, respectively, resulted in the increase of enthalpy of the interaction, thereby increasing the binding affinity for C3. The data also suggest that the interaction is mediated by water molecules. These interfacial water molecules could be the source for unfavorable entropy and large negative heat capacity changes observed in the interaction. Although part of the negative heat capacity changes could be accounted for by the water molecules, the rest might be resulting from the conformational changes in C3 and/or compstatin up on binding. Finally, we propose based on the pK(a) values determined from the protonation studies that histidine on compstatin participates in protonation changes and contributes to the specificity of the interaction between compstatin and C3. These protonation changes vary significantly between the binding of different compstatin analogs to C3.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA; Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA	University of Pennsylvania; University of California System; University of California Riverside	Lambris, JD (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA.	lambris@mail.med.upenn.edu	Morikis, Dimitrios/L-8527-2013; Lambris, John/Q-5633-2018	Morikis, Dimitrios/0000-0003-0083-4665; Lambris, John/0000-0002-9370-5776	NIGMS NIH HHS [GM 069736, GM 62134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062134, R24GM069736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHOVCHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P7323, DOI 10.1073/pnas.78.12.7323; Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w; DECRISTOFARO R, 1995, BIOCHEM J, V310, P49, DOI 10.1042/bj3100049; Doyle ML, 1998, METHOD ENZYMOL, V295, P88; Fanghanel J, 2003, BIOPHYS CHEM, V100, P351, DOI 10.1016/S0301-4622(02)00292-2; FINUCANE MD, 1992, BIOCHEM J, V286, P889, DOI 10.1042/bj2860889; Gallo P, 1998, J BIOCHEM-TOKYO, V124, P880, DOI 10.1093/oxfordjournals.jbchem.a022202; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; Gribenko AV, 2002, PROTEIN SCI, V11, P1367, DOI 10.1110/ps.0202202; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; Hernaiz MJ, 2002, EUR J BIOCHEM, V269, P2860, DOI 10.1046/j.1432-1033.2002.02964.x; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; Jacobson T, 2004, ARCH BIOCHEM BIOPHYS, V422, P125, DOI 10.1016/j.abb.2003.12.016; Klepeis JL, 2003, J AM CHEM SOC, V125, P8422, DOI 10.1021/ja034846p; KORNBLATT JA, 1993, BIOPHYS J, V65, P1059, DOI 10.1016/S0006-3495(93)81168-8; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Makrides SC, 1998, PHARMACOL REV, V50, P59; Mallik B, 2003, PROTEINS, V53, P130, DOI 10.1002/prot.10491; Matulis D, 2001, BIOPHYS CHEM, V93, P53, DOI 10.1016/S0301-4622(01)00208-3; McNemar C, 1997, BIOCHEMISTRY-US, V36, P10006, DOI 10.1021/bi9704360; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311; Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200; Morikis D, 2001, PROTEIN SCI, V10, P2379, DOI 10.1110/ps.17301; Morton CJ, 1996, PROTEIN SCI, V5, P2115, DOI 10.1002/pro.5560051018; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ortiz-Salmeron E, 2003, J BIOL CHEM, V278, P46938, DOI 10.1074/jbc.M305043200; Ottiger M, 1997, J MOL BIOL, V272, P64, DOI 10.1006/jmbi.1997.1220; Patskovsky YV, 1999, BIOCHEMISTRY-US, V38, P1193, DOI 10.1021/bi982164m; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Sundberg EJ, 2000, BIOCHEMISTRY-US, V39, P15375, DOI 10.1021/bi000704l; Swaminathan CP, 1999, J BIOL CHEM, V274, P31272, DOI 10.1074/jbc.274.44.31272; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; YU LP, 1994, BBA-PROTEIN STRUCT M, V1209, P24, DOI 10.1016/0167-4838(94)90132-5	49	21	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					54987	54995		10.1074/jbc.M409963200	http://dx.doi.org/10.1074/jbc.M409963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489226	hybrid			2022-12-25	WOS:000225960800003
J	Yamanaka, M; Shegogue, D; Pei, HP; Bu, SZ; Bielawska, A; Bielawski, J; Pettus, B; Hannun, YA; Obeid, L; Trojanowska, M				Yamanaka, M; Shegogue, D; Pei, HP; Bu, SZ; Bielawska, A; Bielawski, J; Pettus, B; Hannun, YA; Obeid, L; Trojanowska, M			Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMAL FIBROBLASTS; GENE-EXPRESSION; TISSUE INHIBITOR; KINASE-ACTIVITY; ONCOSTATIN-M; PROTEIN; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; INTERACTS; METALLOPROTEINASE-1	Transforming growth factor-beta(TGF-beta) signaling plays a pivotal role in extracellular matrix deposition by stimulating collagen production and other extracellular matrix proteins and by inhibiting matrix degradation. The present study was undertaken to define the role of sphingosine kinase (SphK) in TGF-beta signaling. TGF-beta markedly up-regulated SphK1 mRNA and protein amounts and caused a prolonged increase in SphK activity in dermal fibroblasts. Concomitantly, TGF-beta reduced sphingosine-1-phosphate phosphatase activity. Consistent with the changes in enzyme activity, corresponding changes in sphingolipid levels were observed such that sphingosine 1-phosphate (S1P) was increased (similar to2-fold), whereas sphingosine and ceramide were reduced after 24 h of TGF-beta treatment. Given the relatively early induction of SphK gene expression in response to TGF-beta, we examined whether SphK1 may be involved in the regulation of TGF-beta-inducible genes that exhibit compatible kinetics, e.g. tissue inhibitor of metalloproteinase-1 (TIMP-1). We demonstrate that decreasing SphK1 expression by small interfering RNA (siRNA) blocked TGF-beta-mediated up-regulation of TIMP-1 protein suggesting that up-regulation of SphK1 contributes to the induction of TIMP-1 in response to TGF-beta. The role of SphK1 as a positive regulator of TIMP-1 gene expression was further corroborated by using ectopically expressed SphK1 in the absence of TGF-beta. Adenovirally expressed SphK1 led to a 2-fold increase of endogenous S1P and to increased TIMP-1 mRNA and protein production. In addition, ectopic SphK1 and TGF-beta cooperated in TIMP-1 up-regulation. Mechanistically, experiments utilizing TIMP-1 promoter constructs demonstrated that the action of SphK1 on the TIMP-1 promoter is through the AP1-response element, consistent with the SphK1-mediated up-regulation of phospho-c-Jun levels, a key component of AP1. Together, these experiments demonstrate that SphK/S1P are important components of the TGF-beta signaling pathway involved in up-regulation of the TIMP-1 gene.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Ste 912, Charleston, SC 29425 USA.	trojanme@musc.edu		Trojanowska, Maria/0000-0001-9550-7178; obeid, lina/0000-0002-0734-0847	NIAMS NIH HHS [P60 AR049459] Funding Source: Medline; NIA NIH HHS [AG16538] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR049459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R44AG016538, R43AG016538] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; French KJ, 2003, CANCER RES, V63, P5962; Fujita T, 2004, BIOCHEM J, V382, P717, DOI 10.1042/BJ20040141; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Levy MT, 2000, J HEPATOL, V32, P218, DOI 10.1016/S0168-8278(00)80066-5; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2000, METHOD ENZYMOL, V311, P215; ONEILL L, 1991, CARDIOSCIENCE, V2, P1; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Sohara N, 2002, J HEPATOL, V36, P191, DOI 10.1016/S0168-8278(01)00265-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003-0119; SULLARDS MC, 2001, SCI STKE; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074/jbc.M312091200; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	45	112	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53994	54001		10.1074/jbc.M410144200	http://dx.doi.org/10.1074/jbc.M410144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485866	hybrid			2022-12-25	WOS:000225793600014
J	Satake, H; Ogasawara, M; Kawada, T; Masuda, K; Aoyama, M; Minakata, H; Chiba, T; Metoki, H; Satou, Y; Satoh, N				Satake, H; Ogasawara, M; Kawada, T; Masuda, K; Aoyama, M; Minakata, H; Chiba, T; Metoki, H; Satou, Y; Satoh, N			Tachykinin and tachykinin receptor of an ascidian, Ciona intestinalis - Evolutionary origin of the vertebrate tachykinin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P-LIKE; GENE-EXPRESSION; NEUROKININ-A; K RECEPTOR; PROTOCHORDATE; ORGANIZATION; PEPTIDE; BRAIN; MOUSE; IMMUNOREACTIVITY	Tachykinins (TKs) are the most prevalent vertebrate brain/gut peptides. In this study, we originally identified authentic TKs and their receptor from a protochordate, Ciona intestinalis. The Ciona TK (Ci-TK) precursor, like mammalian gamma-preprotachykinin A (gamma-PPTA), encodes two TKs, Ci-TK-I and -II, including the -FXGLM-NH2 vertebrate TK consensus. Mass spectrometry of the neural extract revealed the production of both Ci-TKs. Ci-TK-I contains several Substance P (SP)-typical amino acids, whereas a Thr is exceptionally located at position 4 from the C terminus of Ci-TK-II. The Ci-TK gene encodes both Ci-TKs in the same exon, indicating no alternative generation of Ci-TKs, unlike the PPTA gene. These results suggested that the alternative splicing of the PPTA gene was established during evolution of vertebrates. The only Ci-TK receptor, Ci-TK-R, was equivalently activated by Ci-TK-I, SP, and neurokinin A at physiological concentrations, whereas Ci-TK-II showed 100-fold less potent activity, indicating that the ligand selectivity of Ci-TK-R is distinct from those of vertebrate TK receptors. Ci-TK-I, like SP, also elicited the typical contraction on the guinea pig ileum. The Ci-TK gene was expressed in neurons of the brain ganglion, small cells in the intestine, and the zone 7 in the endostyle, which corresponds to the vertebrate thyroid gland. Furthermore, the Ci-TK-R mRNA was distributed in these three tissues plus the gonad. These results showed that Ci-TKs play major roles in sexual behavior and feeding in protochordates as brain/gut peptides and endocrine/paracrine molecules. Taken together, our data revealed the biochemical and structural origins of vertebrate TKs and their receptors.	Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Kyoto Univ, Grad Sch Sci, Dept Zool, Sakyo Ku, Kyoto, Japan	Suntory Holdings Ltd; Chiba University; Kyoto University	Satake, H (corresponding author), Suntory Inst Bioorgan Res, Wakayamadai 1-1-1, Shimamoto, Osaka 6188503, Japan.	satake@sunbor.or.jp	Metoki, Hirohito/B-3376-2009; Satou, Yutaka/AAJ-2194-2021; Satou, Yutaka/K-7131-2012; Satoh, Nori/C-4123-2009	Metoki, Hirohito/0000-0002-1894-3328; Satou, Yutaka/0000-0001-5193-0708; Satou, Yutaka/0000-0001-5193-0708; Satoh, Nori/0000-0002-4480-3572				Adams BA, 2003, ENDOCRINOLOGY, V144, P1907, DOI 10.1210/en.2002-0216; BOLLNER T, 1992, J COMP NEUROL, V325, P572, DOI 10.1002/cne.903250409; Burighel P, 1997, MICROSCOPICAL ANATOM, V15, P221; CHIWAKATA C, 1991, ENDOCRINOLOGY, V128, P2441, DOI 10.1210/endo-128-5-2441; Corbo JC, 2001, CELL, V106, P535, DOI 10.1016/S0092-8674(01)00481-0; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Di Fiore MM, 2000, P NATL ACAD SCI USA, V97, P2343, DOI 10.1073/pnas.040549097; Evangelista S, 2001, CURR PHARM DESIGN, V7, P19, DOI 10.2174/1381612013398446; FRISTCH HAR, 1982, CELL TISSUE RES, V223, P369; GRUNDITZ T, 1987, ENDOCRINOLOGY, V121, P575, DOI 10.1210/endo-121-2-575; HOLLAND PW, 1994, DEV S, V43, P125; JOHNSEN AH, 1990, J BIOL CHEM, V265, P3054; JONASSEN JA, 1987, ENDOCRINOLOGY, V121, P1555, DOI 10.1210/endo-121-4-1555; Kanda A, 2003, PEPTIDES, V24, P35, DOI 10.1016/S0196-9781(02)00274-7; Kawada T, 1999, BIOCHEM BIOPH RES CO, V263, P848, DOI 10.1006/bbrc.1999.1465; Kawada T, 2002, EUR J BIOCHEM, V269, P4238, DOI 10.1046/j.1432-1033.2002.03106.x; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KOZAWA H, 1991, BIOCHEM BIOPH RES CO, V177, P588, DOI 10.1016/0006-291X(91)92024-E; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Kurtz MM, 2002, GENE, V296, P205, DOI 10.1016/S0378-1119(02)00861-2; LEMBECK F, 1985, PEPTIDES, V6, P231, DOI 10.1016/0196-9781(85)90379-1; Lin XW, 1997, PEPTIDES, V18, P817, DOI 10.1016/S0196-9781(97)00013-2; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Moss C, 1998, TISSUE CELL, V30, P517, DOI 10.1016/S0040-8166(98)80031-1; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; Ogasawara M, 1999, J EXP ZOOL, V285, P158, DOI 10.1002/(SICI)1097-010X(19990815)285:2<158::AID-JEZ8>3.0.CO;2-0; Ogasawara M, 1998, BIOL BULL-US, V195, P60, DOI 10.2307/1542776; Ogasawara M, 2002, DEV GENES EVOL, V212, P173, DOI 10.1007/s00427-002-0230-7; ONEIL GS, 1987, GEN COMP ENDOCR, V66, P314, DOI 10.1016/0016-6480(87)90240-1; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Page NM, 2003, P NATL ACAD SCI USA, V100, P6245, DOI 10.1073/pnas.0931458100; Patak E, 2003, BRIT J PHARMACOL, V139, P523, DOI 10.1038/sj.bjp.0705279; Pennefather JN, 2004, LIFE SCI, V74, P1445, DOI 10.1016/j.lfs.2003.09.039; Pintado CO, 2003, BIOL REPROD, V69, P940, DOI 10.1095/biolreprod.103.017111; ROTH KA, 1990, J CLIN ENDOCR METAB, V71, P1089, DOI 10.1210/jcem-71-5-1089; Sasakura Y, 2003, P NATL ACAD SCI USA, V100, P7726, DOI 10.1073/pnas.1230736100; Satake H, 2003, ZOOL SCI, V20, P533, DOI 10.2108/zsj.20.533; Satake H, 1999, J BIOL CHEM, V274, P5605, DOI 10.1074/jbc.274.9.5605; Satoh N, 2003, TRENDS GENET, V19, P376, DOI 10.1016/S0168-9525(03)00144-6; Satou Y, 2001, GENESIS, V30, P103, DOI 10.1002/gene.1040; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; Takeuchi H, 2003, INSECT MOL BIOL, V12, P291, DOI 10.1046/j.1365-2583.2003.00414.x; TORRENS Y, 1989, J NEUROCHEM, V52, P1913, DOI 10.1111/j.1471-4159.1989.tb07276.x; WANG YX, 1992, BIOCHEM J, V287, P827, DOI 10.1042/bj2870827; WAUGH D, 1994, PEPTIDES, V15, P155, DOI 10.1016/0196-9781(94)90185-6; Zhang Y, 2000, NAT IMMUNOL, V1, P392, DOI 10.1038/80826	51	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53798	53805		10.1074/jbc.M408161200	http://dx.doi.org/10.1074/jbc.M408161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485888	hybrid			2022-12-25	WOS:000225680600118
J	Schmeck, B; Zahlten, J; Moog, K; van Laak, V; Huber, S; Hocke, AC; Opitz, B; Hoffmann, E; Kracht, M; Zerrahn, J; Hammerschmidt, S; Rosseau, S; Suttorp, N; Hippenstiel, S				Schmeck, B; Zahlten, J; Moog, K; van Laak, V; Huber, S; Hocke, AC; Opitz, B; Hoffmann, E; Kracht, M; Zerrahn, J; Hammerschmidt, S; Rosseau, S; Suttorp, N; Hippenstiel, S			Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMMUNITY-ACQUIRED PNEUMONIA; RHO-PROTEIN-INHIBITION; P65 SUBUNIT; C-JUN; KINASE; ACTIVATION; EXPRESSION; CELLS; TRANSFORMATION	Streptococcus pneumoniae is the major cause of community-acquired pneumonia and one of the most common causes of death by infectious disease in industrialized countries. Little is known concerning the mechanisms of target cell activation in this disease. The present study shows that NF-kappaB and p38 MAPK signaling pathways contribute to chemokine synthesis by lung epithelial cells in response to pneumococci. In infected lungs of mice pneumococci stimulate expression of the interleukin (IL)-8 homolog keratinocyte-derived chemokine and granulocyte-macrophage colony-stimulating factor, as well as activate p38 MAPK. Human bronchial epithelium was chosen as a cellular model, because it establishes the first barrier against pathogens, and little is known about its function in innate immunity. Pneumococci infection induces expression of IL-8 and granulocyte-macrophage colony-stimulating factor as well as activation of p38 MAPK in human bronchial epithelial cells (BEAS-2B). Inhibition of p38 MAPK activity by SB202190 and SB203580 blocks pneumococci-induced cytokine release. In mouse lungs in vivo as well as in cultured cells, pneumococci activate NF-kappaB in an IkappaB kinase-dependent manner. Inhibition of p38 MAPK by chemical inhibitors or by RNA interference targeting p38alpha reduces pneumococci-induced NF-kappaB-dependent gene transcription. Blockade of p38 activity did not affect inducible nuclear translocation and recruitment of NF-kappaB/RelA to the IL-8 promotor but did reduce the level of phosphorylated RelA ( serine 536) at IL-8 promotor and inhibited pneumococci-mediated recruitment of RNA polymerase II to IL-8 promotor. Thus, p38 MAPK contributes to pneumococci-induced chemokine transcription by modulating p65 NF-kappaB-mediated transactivation.	Univ Med Berlin, Charite, Dept Internal Med Infect Dis, D-13353 Berlin, Germany; Hannover Med Sch, Inst Pharmacol, D-30623 Hannover, Germany; Max Planck Inst Infect Biol, D-10117 Berlin, Germany; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; Max Planck Society; University of Wurzburg	Hippenstiel, S (corresponding author), Univ Med Berlin, Charite, Dept Internal Med Infect Dis, Augustenburger Pl 1, D-13353 Berlin, Germany.	stefan.hippenstiel@charite.de	Rosseau, Simone/AAO-1201-2020; Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681; Suttorp, Norbert/0000-0002-3958-1151; Hippenstiel, Stefan/0000-0002-5146-1064; Opitz, Bastian/0000-0003-1276-836X; Kracht, Michael/0000-0002-8501-043X; Hoffmann-Lucke, Elke/0000-0002-2437-0140				Austrian R, 1999, J INFECT DIS, V179, pS338, DOI 10.1086/513841; Benton KA, 1997, MICROB PATHOGENESIS, V23, P201, DOI 10.1006/mpat.1997.0150; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Finch R, 2001, CLIN MICROBIOL INFEC, V7, P30, DOI 10.1046/j.1469-0691.2001.00052.x; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hale KK, 1999, J IMMUNOL, V162, P4246; Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399; Hippenstiel S, 2002, BIOCHEM PHARMACOL, V64, P971, DOI 10.1016/S0006-2952(02)01162-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Koedel U, 2003, J IMMUNOL, V170, P438, DOI 10.4049/jimmunol.170.1.438; Krull M, 1999, J IMMUNOL, V162, P4834; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; REDDEL RR, 1988, CANCER RES, V48, P1904; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schmeck B, 2003, INFLAMMATION, V27, P89, DOI 10.1023/A:1023278600596; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; TIRABY JG, 1973, P NATL ACAD SCI USA, V70, P3541, DOI 10.1073/pnas.70.12.3541; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang EJ, 2001, INFECT IMMUN, V69, P5294, DOI 10.1128/IAI.69.9.5294-5304.2001; Zhou LM, 2003, AM J RESP CELL MOL, V28, P762, DOI 10.1165/rcmb.2002-0261OC; Zysk G, 2001, INFECT IMMUN, V69, P845, DOI 10.1128/IAI.69.2.845-852.2001	36	103	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53241	53247		10.1074/jbc.M313702200	http://dx.doi.org/10.1074/jbc.M313702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15485852	hybrid			2022-12-25	WOS:000225680600054
J	Shi, SL; Noda, M; Kitayama, H				Shi, SL; Noda, M; Kitayama, H			Rap1 mutants with increased affinity for the guanine-nucleotide exchange factor C3G	ONCOGENE			English	Article						Rap1; C3G; dominant inhibitory mutant; random mutagenesis	SIGNAL-TRANSDUCTION; MAP KINASE; RAS; PROTEIN; ACTIVATION; GENE; GTPASE; CRK; ASSOCIATION; ADHESION	The mutant of Ras protein with serine to asparagine mutation at residue 17 (Ras-17N) is known to interfere with the signaling function of the wild-type Ras protein by sequestering its guanine-nucleotide exchange factors ( GEFs). The similar mutant of another Ras family protein Rap1 (Rap1-17N) fails to effectively interfere with the interaction between the wild-type Rap1 and one of its GEFs, C3G, in vitro. In the present study, we have attempted to isolate Rap1 mutants with increased affinity for C3G using random mutagenesis and yeast two-hybrid screening. Based on the pattern of mutations found among these mutants, we could design a potent C3G-binder, named Rap1-AGE, harboring mutations in three sites (17A, 29G, and 117E). The association of Rap1-AGE with C3G in the cells was confirmed by co-immunoprecipitation experiments. The ability of Rap1-AGE to inhibit C3G-mediated Rap1-activation and cell spreading was also demonstrated. On the other hand, Rap1 activation mediated by two other GEFs, Epac and smgGDS, was not inhibited by Rap1-AGE. These results suggest that Rap1-AGE acts as a dominant interfering factor against C3G and serves as a useful tool in analyzing the roles of C3G-Rap1 signaling pathway in various biological processes.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Kitayama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	hkitayam@virus.kyoto-u.ac.jp						BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN SY, 1994, ONCOGENE, V9, P2691; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Imamura Y, 2004, NEUROSCIENCE, V127, P973, DOI 10.1016/j.neuroscience.2004.05.051; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	48	5	5	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8711	8719		10.1038/sj.onc.1208132	http://dx.doi.org/10.1038/sj.onc.1208132			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480424	Green Submitted			2022-12-25	WOS:000225165100001
J	Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA				Niethammer, AG; Wodrich, H; Loeffler, M; Lode, HN; Emmerich, K; Abdollahi, A; Krempien, R; Debus, J; Huber, PE; Reisfeld, RA			Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy	FASEB JOURNAL			English	Article						vaccine; T cells; cancer; immunology	ORAL DNA VACCINE; PROTECTIVE IMMUNITY; P-GLYCOPROTEIN; MYELOMA CELLS; TUMOR; CANCER; EXPRESSION; PROGRESS; THERAPY; GROWTH	Acquired multidrug resistance (MDR) remains a major challenge in the treatment of cancer with chemotherapeutic drugs. It can be mediated by the up-regulated expression of different proteins within the tumor cell membrane. Here, we used murine multidrug resistance-1 (MDR-1) as a target-antigen for the immunotherapy of cancer. We successfully demonstrated that peripheral T cell tolerance can be broken by oral administration of a DNA vaccine encoding MDR-1 and carried by attenuated Salmonella typhimurium to secondary lymphoid organs. Thus, mice, immunized orally three times at 2-wk intervals and challenged 2 wk thereafter with either MDR-1 expressing CT-26 colon carcinoma cells or MDR-1 expressing Lewis lung carcinoma cells, revealed a significant increase in life span. This was evident, when compared with animals either vaccinated with the empty control vector or challenged with the parental cell lines lacking overexpression of MDR-1. The immune response induced was antigen-specific and CD8(+) T cell-mediated. The presence of the target antigen led to up-regulation of activation markers on CD8(+) T cells and resulted in a strong cytotoxic T cell response as well as lysis of tumor target cells in vitro. We furthermore established the vaccine to be an effective treatment for established multi-drug-resistant tumor metastases, resulting in a significantly increased life span of experimental animals. Absence of CD8(+) T cells due to in vivo depletion led to abrogation of effectiveness. Taken together, our results demonstrate that T cell tolerance against the MDR-1 self-antigen can be broken. It is anticipated that the combination of such an approach with chemotherapy could lead to more effective treatments of cancer.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Heidelberg Med Sch, Dept Radiat Oncol, D-69120 Heidelberg, Germany; Charite Childrens Hosp, Dept Pediat Oncol, Berlin, Germany; Schering AG, D-13342 Berlin, Germany	Scripps Research Institute; Scripps Research Institute; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG	Reisfeld, RA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Reisfeld@scripps.edu	Wodrich, Harald/P-1777-2019	Wodrich, Harald/0000-0002-4764-1708; Lode, Holger/0000-0002-1201-208X	NATIONAL CANCER INSTITUTE [R01CA083856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83856] Funding Source: Medline; PHS HHS [T32-A107244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Azuma E, 1997, EUR J HAEMATOL, V59, P14; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341; FERRY DR, 1994, BRIT MED J, V308, P148, DOI 10.1136/bmj.308.6922.148; Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Henness S, 2002, INT J RADIAT ONCOL, V54, P895, DOI 10.1016/S0360-3016(02)03037-7; Itoh K, 1991, In Vivo, V5, P647; Jager E, 2000, ONKOLOGIE, V23, P410, DOI 10.1159/000027202; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Legrand O, 2001, BLOOD, V97, P502, DOI 10.1182/blood.V97.2.502; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; Mackensen A, 2000, INT J CANCER, V86, P385, DOI 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T; Marchand M, 1999, INT J CANCER, V80, P219, DOI 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S; MUUL LM, 1987, J IMMUNOL, V138, P989; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Niethammer AG, 2001, VACCINE, V20, P421, DOI 10.1016/S0264-410X(01)00362-0; Niethammer AG, 2001, CANCER RES, V61, P6178; Reisfeld RA, 2004, INT ARCH ALLERGY IMM, V133, P295, DOI 10.1159/000077009; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 2001, J INTERN MED, V250, P462, DOI 10.1046/j.1365-2796.2001.00911.x; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Shtil AA, 1999, BLOOD, V93, P1831, DOI 10.1182/blood.V93.6.1831.406k38_1831_1837; Shtil AA, 2000, LEUKEMIA LYMPHOMA, V38, P59, DOI 10.3109/10428190009060319; Xiang R, 2001, CLIN CANCER RES, V7, p856S; Yamada A, 2001, CANCER RES, V61, P6459	29	18	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					158	+		10.1096/fj.04-2355fje	http://dx.doi.org/10.1096/fj.04-2355fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15498893				2022-12-25	WOS:000224849900011
J	Sanderson, MP; Erickson, SN; Gough, PJ; Garton, KJ; Wille, PT; Raines, EW; Dunbar, AJ; Dempsey, PJ				Sanderson, MP; Erickson, SN; Gough, PJ; Garton, KJ; Wille, PT; Raines, EW; Dunbar, AJ; Dempsey, PJ			ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ALPHA-CONVERTING-ENZYME; SMOOTH-MUSCLE-CELLS; METALLOPROTEASE-DISINTEGRIN MDC9; CANINE KIDNEY-CELLS; FACTOR RECEPTOR; TGF-ALPHA; EGF RECEPTOR; MICE LACKING; HB-EGF	Betacellulin belongs to the family of epidermal growth factor-like growth factors that are expressed as transmembrane precursors and undergo proteolytic ectodomain shedding to release a soluble mature growth factor. In this study, we investigated the ectodomain shedding of the betacellulin precursor (pro-BTC) in conditionally immortalized wild-type (WT) and ADAM-deficient cell lines. Sequential ectodomain cleavage of the predominant cell-surface 40-kDa form of pro-BTC generated a major (26-28 kDa) and two minor ( 20 and 15 kDa) soluble forms and a cellular remnant lacking the ectodomain (12 kDa). Pro-BTC shedding was activated by calcium ionophore (A23187) and by the metalloprotease activator p-aminophenylmercuric acetate ( APMA), but not by phorbol esters. Culturing cells in calcium-free medium or with the protein kinase Cdelta inhibitor rottlerin, but not with broad-based protein kinase C inhibitors, blocked A23187-activated pro-BTC shedding. These same treatments were without effect for constitutive and APMA-induced cleavage events. All pro-BTC shedding was blocked by treatment with a broad-spectrum metalloprotease inhibitor (GM6001). In addition, constitutive and activated pro-BTC shedding was differentially blocked by TIMP-1 or TIMP-3, but was insensitive to treatment with TIMP-2. Pro-BTC shedding was functional in cells from ADAM17- and ADAM9-deficient mice and in cells overexpressing WT or catalytically inactive ADAM17. In contrast, overexpression of WT ADAM10 enhanced constitutive and activated shedding of pro-BTC, whereas overexpression of catalytically inactive ADAM10 reduced shedding. These results demonstrate, for the first time, activated pro-BTC shedding in response to extracellular calcium influx and APMA and provide evidence that ADAM10 mediates constitutive and activated pro-BTC shedding.	GroPep Ltd, Thebarton, SA 5031, Australia; Pacific NW Res Inst, Seattle, WA 98122 USA; Flinders Univ S Australia, Sch Biol Sci, Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5001, Australia; Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Flinders University South Australia; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Dempsey, PJ (corresponding author), GroPep Ltd, 28 Dalgleish St, Thebarton, SA 5031, Australia.	pdempsey@pnri.org	Sanderson, Michael/I-1674-2017	Sanderson, Michael/0000-0001-5362-486X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067267, P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059778, R01DK063363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL67267] Funding Source: Medline; NIDDK NIH HHS [DK59778, DK63363] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Brown CL, 2001, J BIOL CHEM, V276, P29538, DOI 10.1074/jbc.M102114200; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Bursi R, 2002, J MED CHEM, V45, P781, DOI 10.1021/jm0110385; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dello Sbarba P, 2002, BIOL CHEM, V383, P69; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Dunbar AJ, 2000, INT J BIOCHEM CELL B, V32, P805, DOI 10.1016/S1357-2725(00)00028-5; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hahn D, 2003, J BIOL CHEM, V278, P42829, DOI 10.1074/jbc.M211169200; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Ishiyama N, 1998, DIABETOLOGIA, V41, P623, DOI 10.1007/s001250050959; Itoh T, 2001, J BIOL CHEM, V276, P40698, DOI 10.1074/jbc.M106603200; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; Li L, 2004, DIABETES, V53, P608, DOI 10.2337/diabetes.53.3.608; Li L, 2003, AM J PHYSIOL-ENDOC M, V285, pE577, DOI 10.1152/ajpendo.00120.2003; Li L, 2001, ENDOCRINOLOGY, V142, P5379, DOI 10.1210/en.142.12.5379; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mifune M, 2004, AM J PHYSIOL-CELL PH, V287, pC807, DOI 10.1152/ajpcell.00436.2003; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nanba D, 2004, CYTOKINE GROWTH F R, V15, P13, DOI 10.1016/j.cytogfr.2003.10.002; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Riese DJ, 1996, ONCOGENE, V12, P345; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Shin HS, 2003, CIRC RES, V93, P302, DOI 10.1161/01.RES.0000086803.64109.9E; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Tamura R, 2001, ATHEROSCLEROSIS, V155, P413, DOI 10.1016/S0021-9150(00)00576-1; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	84	85	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					1826	1837		10.1074/jbc.M408804200	http://dx.doi.org/10.1074/jbc.M408804200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15507448	hybrid			2022-12-25	WOS:000226341700016
J	Atrih, A; Richardson, JM; Prescott, AR; Ferguson, MAJ				Atrih, A; Richardson, JM; Prescott, AR; Ferguson, MAJ			Trypanosoma brucei glycoproteins contain novel giant poly-N-acetyllactosamine carbohydrate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; FLAGELLAR ADHESION ZONE; MEDIATED ENDOCYTOSIS; AFRICAN TRYPANOSOMES; POCKET; PROTEINS; PARASITES; GLYCANS	The flagellar pocket of the bloodstream form of the African sleeping sickness parasite Trypanosoma brucei contains material that binds the beta-D-galactose-specific lectin ricin (Brickman, M. J., and Balber, A. E. ( 1990) J. Protozool. 37, 219 - 224). Glycoproteins were solubilized from bloodstream form T. brucei cells in 8 M urea and 3% SDS and purified by ricin affinity chromatography. Essentially all binding of ricin to these glycoproteins was abrogated by treatment with peptide N-glycosidase, showing that the ricin ligands are attached to glycoproteins via N-glycosidic linkages to asparagine residues. Glycans released by peptide N-glycosidase were resolved by Bio-Gel P-4 gel filtration into two fractions: a low molecular mass mannose-rich fraction and a high molecular mass galactose and N-acetylglucosamine-rich fraction. The latter fraction was further separated by high pH anion exchange chromatography and analyzed by gas chromatography mass spectrometry, one- and two-dimensional NMR, electrospray mass spectrometry, and methylation linkage analysis. The high molecular mass ricin-binding N-glycans are based on a conventional Manalpha1-3( Manalpha1-6) Manbeta1-4GlcNAc beta1-4GlcNAc core structure and contain poly-N-acetyllactosamine chains. A significant proportion of these structures are extremely large and of unusual structure. They contain an average of 54 N-acetyllactosamine (Galbeta1-4GlcNAc) repeats per glycan, linked mostly by - 4GlcNAcbeta1-6Galbeta1- interrepeat linkages, with an average of one - 4Glc-NAcbeta1- 3(-4GlcNAcbeta1 -6) Galbeta1- branch point in every six repeats. These structures, which also bind tomato lectin, are twice the size reported for the largest mammalian poly-N- acetyllactosamine N-linked glycans and also differ in their preponderance of - 4GlcNAcbeta1 - 6Galbeta1- over - 4GlcNacbeta1-3Galbeta1-interrepeat linkages. Molecular modeling suggests that - 4GlcNAcbeta1 - 6Galbeta1- interrepeat linkages produce relatively compact structures that may give these giant N- linked glycans unique physicochemical properties. Fluorescence microscopy using fluorescein isothiocyanate-ricin indicates that ricin ligands are located mainly in the flagellar pocket and in the endosomal/lysosomal system of the trypanosome.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JR, Midlothian, Scotland	University of Dundee; University of Edinburgh	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.	M.a.j.ferguson@dundee.ac.uk	Richardson, Julia/D-1808-2013; Ferguson, Michael A. J./F-7829-2010; Prescott, Alan/Y-5956-2018	Richardson, Julia/0000-0002-1547-3009; Ferguson, Michael A. J./0000-0003-1321-8714; Prescott, Alan/0000-0002-0747-7317				Alexander DL, 2002, J CELL SCI, V115, P3253; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; Geuskens M, 2000, MOL BIOCHEM PARASIT, V108, P269, DOI 10.1016/S0166-6851(00)00228-0; Geyer A, 2001, EUR J BIOCHEM, V268, P4044, DOI 10.1046/j.1432-1327.2001.02321.x; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Jeffries TR, 2001, J CELL SCI, V114, P2617; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Lauder RM, 2001, BIOCHEM J, V358, P523, DOI 10.1042/0264-6021:3580523; LEE MGS, 1994, J BIOL CHEM, V269, P8408; LEE N, 1990, J BIOL CHEM, V265, P20476; Liu JY, 2000, J BIOL CHEM, V275, P12032, DOI 10.1074/jbc.275.16.12032; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Morgan GW, 2001, J CELL SCI, V114, P2605; Nolan DP, 1997, J BIOL CHEM, V272, P29212, DOI 10.1074/jbc.272.46.29212; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	36	63	64	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					865	871		10.1074/jbc.M411061200	http://dx.doi.org/10.1074/jbc.M411061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509560	Green Published, hybrid			2022-12-25	WOS:000226195200004
J	Guo, YJ; Rebecchi, M; Scarlata, S				Guo, YJ; Rebecchi, M; Scarlata, S			Phospholipase C beta(2) binds to and inhibits phospholipase C delta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; HETEROTRIMERIC G-PROTEINS; C ISOZYMES; BETA-GAMMA; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TRANSGLUTAMINASE-II; BILAYER-MEMBRANES; COUPLED RECEPTORS; CALCIUM-RELEASE; SIGNAL MEDIATOR	Phospholipase Cbeta (PLCbeta) isoforms, which are under the control of Galpha(q) and Gbetagamma subunits, generate Ca2+ signals induced by a broad array of extracellular agonists, whereas PLCdelta isoforms depend on a rise in cytosolic Ca2+ for their activation. Here we find that PLCbeta(2) binds strongly to PLCdelta(1) and inhibits its catalytic activity in vitro and in living cells. In vitro, this PLC complex can be disrupted by increasing concentrations of free Gbetagamma subunits. Such competition has consequences for signaling, because in HEK293 cells PLCbeta(2) suppresses elevated basal [Ca2+] and inositol phosphates levels and the sustained agonist-induced elevation of Ca2+ levels caused by PLCdelta(1). Also, expression of both PLCs results in a synergistic release of [Ca2+] upon stimulation in A10 cells. These results support a model in which PLCbeta(2) suppresses the basal catalytic activity of PLCdelta(1), which is relieved by binding of Gbetagamma subunits to PLCbeta(2) allowing for amplified calcium signals.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	Suzanne.Scarlata@sunysb.edu			NIGMS NIH HHS [GM53132, GM60376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060376, R01GM053132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Baek KJ, 1996, BIOCHEM J, V315, P739; BANNO Y, 1994, J BIOL CHEM, V269, P15846; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CHO YS, 1993, FEBS LETT, V334, P257, DOI 10.1016/0014-5793(93)80689-R; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAS T, 1993, J BIOL CHEM, V268, P27398; Di Salvo J, 1998, FEBS LETT, V422, P85, DOI 10.1016/S0014-5793(97)01606-2; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P52; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GERFEN CR, 1988, P NATL ACAD SCI USA, V85, P3208, DOI 10.1073/pnas.85.9.3208; Ghosh I, 2000, J AM CHEM SOC, V122, P5658, DOI 10.1021/ja994421w; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo YJ, 2003, J BIOL CHEM, V278, P29995, DOI 10.1074/jbc.M301438200; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; HOU CF, 1994, J BIOL CHEM, V269, P10357; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lee SB, 1996, BLOOD, V88, P1684; MIZUGUCHI M, 1991, BRAIN RES, V548, P35, DOI 10.1016/0006-8993(91)91103-8; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; RUNNELS LW, 1997, THESIS STATE U NEW Y; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; YAMADA M, 1991, DEV BRAIN RES, V59, P7, DOI 10.1016/0165-3806(91)90023-C; YAMADA M, 1993, BRAIN RES, V606, P335, DOI 10.1016/0006-8993(93)91004-C	52	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1438	1447		10.1074/jbc.M407593200	http://dx.doi.org/10.1074/jbc.M407593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509571	hybrid			2022-12-25	WOS:000226195200072
J	Williams, ME; Burton, B; Urrutia, A; Shcherbatko, A; Chavez-Noriega, LE; Cohen, CJ; Aiyar, J				Williams, ME; Burton, B; Urrutia, A; Shcherbatko, A; Chavez-Noriega, LE; Cohen, CJ; Aiyar, J			Ric-3 promotes functional expression of the nicotinic acetylcholine receptor alpha 7 subunit in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; PHARMACOLOGICAL PROPERTIES; BUNGAROTOXIN RECEPTORS; XENOPUS-OOCYTES; PROTEIN; CALCIUM; BINDING; BRAIN; LINE; GENE	Expression of functional, recombinant alpha7 nicotinic acetylcholine receptors in several mammalian cell types, including HEK293 cells, has been problematic. We have isolated the recently described human ric-3 cDNA and co-expressed it in Xenopus oocytes and HEK293 cells with the human nicotinic acetylcholine receptor alpha7 subunit. In addition to confirming the previously reported effect on alpha7 receptor expression in Xenopus oocytes we demonstrate that ric-3 promotes the formation of functional alpha7 receptors in mammalian cells, as determined by whole cell patch clamp recording and surface alpha-bungarotoxin binding. Upon application of 1 mM nicotine, currents were undetectable in HEK293 cells expressing only the alpha7 subunit. In contrast, co-expression of alpha7 and ric-3 cDNAs resulted in currents that averaged 42 pA/pF with kinetics similar to those observed in cells expressing endogenous alpha7 receptors. Immunoprecipitation studies demonstrate that alpha7 and ric-3 proteins co-associate. Additionally, cell surface labeling with biotin revealed the presence of alpha7 protein on the plasma membrane of cells lacking ric-3, but surface alpha-bungarotoxin staining was only observed in cells co-expressing ric-3. Thus, ric-3 appears to be necessary for proper folding and/or assembly of alpha7 receptors in HEK293 cells.	Merck Res Labs, San Diego, CA 92121 USA	Merck & Company	Chavez-Noriega, LE (corresponding author), Merck Res Labs, BMB-8-120,33 Ave Louis Pasteur, Boston, MA 02115 USA.	laura_chaveznoriega@merck.com						Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Berg DK, 2002, J NEUROBIOL, V53, P512, DOI 10.1002/neu.10116; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Bourin M, 2003, CURR MED RES OPIN, V19, P169, DOI 10.1185/030079903125001631; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; Conroy WG, 2003, NEURON, V38, P759, DOI 10.1016/S0896-6273(03)00324-6; Cooper ST, 1997, J NEUROCHEM, V68, P2140; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DELTORO ED, 1994, J COMP NEUROL, V349, P325, DOI 10.1002/cne.903490302; Dineley KT, 2000, J BIOL CHEM, V275, P13974, DOI 10.1074/jbc.275.18.13974; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Elliott KJ, 1996, J MOL NEUROSCI, V7, P217, DOI 10.1007/BF02736842; GOPALAKRISHNAN M, 1995, EUR J PHARM-MOLEC PH, V290, P237, DOI 10.1016/0922-4106(95)00083-6; Graham AJ, 2002, CNS NEUROL DISORD-DR, V1, P387, DOI 10.2174/1568007023339283; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Hans M, 1999, J NEUROSCI, V19, P1610; Hope AG, 1996, BRIT J PHARMACOL, V118, P1237, DOI 10.1111/j.1476-5381.1996.tb15529.x; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Lin L, 2002, J BIOL CHEM, V277, P41872, DOI 10.1074/jbc.M206857200; Lindstrom J, 1996, Ion Channels, V4, P377; Lukas RJ, 1999, PHARMACOL REV, V51, P397; Martin LF, 2004, PSYCHOPHARMACOLOGY, V174, P54, DOI 10.1007/s00213-003-1750-1; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Peng JH, 1999, BRAIN RES, V825, P172, DOI 10.1016/S0006-8993(99)01066-5; PENG X, 1994, MOL PHARMACOL, V45, P546; Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3; PUCHACZ E, 1994, FEBS LETT, V354, P155, DOI 10.1016/0014-5793(94)01108-7; Quik M, 1996, J NEUROCHEM, V67, P145; Rakhilin S, 1999, J CELL BIOL, V146, P203; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; Schroeder KM, 2003, J NEUROCHEM, V85, P581, DOI 10.1046/j.1471-4159.2003.01658.x; SEGUELA P, 1993, J NEUROSCI, V13, P596; Zhao LK, 2003, J PHARMACOL EXP THER, V305, P1132, DOI 10.1124/jpet.103.048777	41	123	129	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1257	1263		10.1074/jbc.M410039200	http://dx.doi.org/10.1074/jbc.M410039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15504725	hybrid			2022-12-25	WOS:000226195200050
J	Krug, A; Wendisch, VF; Bott, M				Krug, A; Wendisch, VF; Bott, M			Identification of AcnR, a TetR-type repressor of the aconitase gene acn in Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS ACONITASE; ESCHERICHIA-COLI ACONITASES; DNA MICROARRAY ANALYSES; POSTTRANSCRIPTIONAL REGULATION; BINDING PROTEIN; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; ACETATE METABOLISM; MOLECULAR ANALYSIS; RESPIRATORY-CHAIN	In Corynebacterium glutamicum, the activity of aconitase is 2.5-4-fold higher on propionate, citrate, or acetate than on glucose. Here we show that this variation is caused by transcriptional regulation. In search for putative regulators, a gene (acnR) encoding a TetR-type transcriptional regulator was found to be encoded immediately downstream of the aconitase gene (acn) in C. glutamicum. Deletion of the acnR gene led to a 5-fold increased acn-mRNA level and a 5-fold increased aconitase activity, suggesting that AcnR functions as repressor of acn expression. DNA microarray analyses indicated that acn is the primary target gene of AcnR in the C. glutamicum genome. Purified AcnR was shown to be a homodimer, which binds to the acn promoter in the region from -11 to -28 relative to the transcription start. It thus presumably acts by interfering with the binding of RNA polymerase. The acn-acnR organization is conserved in all corynebacteria and mycobacteria with known genome sequence and a putative AcnR consensus binding motif (CAGNACnnncGTACTG) was identified in the corresponding acn upstream regions. Mutations within this motif inhibited AcnR binding. Because the activities of citrate synthase and isocitrate dehydrogenase were previously reported not to be increased during growth on acetate, our data indicate that aconitase is a major control point of tricarboxylic acid cycle activity in C. glutamicum, and they identify AcnR as the first transcriptional regulator of a tricarboxylic acid cycle gene in the Corynebacterianeae.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bott, M (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	m.bott@fz-juelich.de	Wendisch, Volker F./M-5940-2016; Bott, Michael/E-8004-2011	Wendisch, Volker F./0000-0003-3473-0012; Bott, Michael/0000-0002-4701-8254				Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bott M, 2003, J BIOTECHNOL, V104, P129, DOI 10.1016/S0168-1656(03)00144-5; Brock M, 2002, EUR J BIOCHEM, V269, P6184, DOI 10.1046/j.1432-1033.2002.03336.x; Claes WA, 2002, J BACTERIOL, V184, P2728, DOI 10.1128/JB.184.10.2728-2739.2002; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cunningham L, 1997, MICROBIOL-UK, V143, P3795, DOI 10.1099/00221287-143-12-3795; Eggeling L, 1999, APPL MICROBIOL BIOT, V52, P146, DOI 10.1007/s002530051501; EIKMANNS BJ, 1995, J BACTERIOL, V177, P774, DOI 10.1128/jb.177.3.774-782.1995; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engels S, 2004, MOL MICROBIOL, V52, P285, DOI 10.1111/j.1365-2958.2003.03979.x; Engohang-Ndong J, 2004, MOL MICROBIOL, V51, P175, DOI 10.1046/j.1365-2958.2003.03809.x; Gerstmeir R, 2004, J BACTERIOL, V186, P2798, DOI 10.1128/JB.186.9.2798-2809.2004; Gerstmeir R, 2003, J BIOTECHNOL, V104, P99, DOI 10.1016/S0168-1656(03)00167-6; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Hermann T, 2003, J BIOTECHNOL, V104, P155, DOI 10.1016/S0168-1656(03)00149-4; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Ishige T, 2003, J BACTERIOL, V185, P4519, DOI 10.1128/JB.185.15.4519-4529.2003; Jourlin-Castelli C, 2000, J MOL BIOL, V295, P865, DOI 10.1006/jmbi.1999.3420; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kim HJ, 2003, J BACTERIOL, V185, P1672, DOI 10.1128/JB.185.5.1672-1680.2003; Kim SI, 2003, J MOL BIOL, V334, P609, DOI 10.1016/j.jmb.2003.09.078; Kimura Eiichiro, 2003, Adv Biochem Eng Biotechnol, V79, P37; Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI [10.2323/jgam.3.193, DOI 10.2323/JGAM.3.193]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange C, 2003, APPL ENVIRON MICROB, V69, P2521, DOI 10.1128/AEM.69.5.2521-2532.2003; MENKEL E, 1989, APPL ENVIRON MICROB, V55, P684, DOI 10.1128/AEM.55.3.684-688.1989; Moker N, 2004, MOL MICROBIOL, V54, P420, DOI 10.1111/j.1365-2958.2004.04249.x; Molenaar D, 2000, J BACTERIOL, V182, P6884, DOI 10.1128/JB.182.24.6884-6891.2000; Molenaar D, 1998, EUR J BIOCHEM, V254, P395, DOI 10.1046/j.1432-1327.1998.2540395.x; Niebisch A, 2001, ARCH MICROBIOL, V175, P282, DOI 10.1007/s002030100262; Pfefferle Walter, 2003, Adv Biochem Eng Biotechnol, V79, P59; Polen T, 2003, APPL ENVIRON MICROB, V69, P1759, DOI 10.1128/AEM.69.3.1759-1774.2003; PRODROMOU C, 1991, J GEN MICROBIOL, V137, P2505, DOI 10.1099/00221287-137-11-2505; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Skerra A, 2000, METHOD ENZYMOL, V326, P271; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tang Y, 1999, MICROBIOL-SGM, V145, P3069, DOI 10.1099/00221287-145-11-3069; Tang Y, 2004, MOL MICROBIOL, V51, P1817, DOI 10.1111/j.1365-2958.2003.03954.x; Tang Y, 2002, MICROBIOL-SGM, V148, P1027, DOI 10.1099/00221287-148-4-1027; Textor S, 1997, ARCH MICROBIOL, V168, P428, DOI 10.1007/s002030050518; Usuda Y, 1996, MICROBIOL-UK, V142, P3347, DOI 10.1099/13500872-142-12-3347; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; Wendisch VF, 2003, J BIOTECHNOL, V104, P273, DOI 10.1016/S0168-1656(03)00147-0; Wendisch VF, 2001, ANAL BIOCHEM, V290, P205, DOI 10.1006/abio.2000.4982; Wendisch VF, 2000, J BACTERIOL, V182, P3088, DOI 10.1128/JB.182.11.3088-3096.2000; Wong DK, 1999, INFECT IMMUN, V67, P327, DOI 10.1128/IAI.67.1.327-336.1999	63	57	68	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					585	595		10.1074/jbc.M408271200	http://dx.doi.org/10.1074/jbc.M408271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15494411	Green Published, hybrid			2022-12-25	WOS:000226025100070
J	Mironov, SL; Ivannikov, MV; Johansson, M				Mironov, SL; Ivannikov, MV; Johansson, M			[Ca2+](i) signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules - From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; BRAIN MITOCHONDRIA; CELL-DEATH; CALCIUM; BINDING; TUBULIN; PROPAGATION; MEMBRANES; TAXOL; CONDUCTANCE	The positioning and dynamics of organelles depend on membrane-cytoskeleton interactions. Mitochondria relocate along microtubules (MT), but it is not clear whether MT have direct effects on mitochondrial function. Using two-photon microscopy and the mitochondrial fluorescent dyes rhodamine 123 and Rhod-2, we showed that Taxol and nocodazole, which correspondingly stabilize and disrupt MT, decreased potential and Ca2+ in the mitochondria of brain stem pre-Botzinger complex neurons. Without changing basal cytoplasmic Ca2+ ([Ca2+](i)), Taxol promoted the generation of [Ca2+](i) spikes in dendrites. These spikes were abolished after blockade of Ca2+ influx and after depletion of internal Ca2+ stores, indicating the involvement of Ca2+-induced Ca2+ release. Nocodazole decreased mitochondrial potential and [Ca2+] m and produced a long lasting increase in [Ca2+](i). MT-acting drugs depolarized single immobilized mitochondria and released previously stored Ca2+. All of these effects were inhibited by pretreatment with blockers of mitochondrial permeability transition pore (mPTP), cyclosporin A, and 2-aminoethoxydiphenyl borate. Induction of mPTP by Taxol and nocodazole was confirmed by using a calcein/Co2+ imaging technique. Electron and optical microscopy revealed tubulin bound to mitochondria. Mitochondria, MT, and endoplasmic reticulum ( ER) showed strong co-localization, the degree of which decreased after MT were disrupted. We propose that changes in the structure of MT by Taxol and nocodazole promote the induction of mPTP. Subsequent Ca2+ efflux stimulates the Ca2+ release from the ER that drives spontaneous [Ca2+](i) transients. Thus, close positioning of mitochondria to the ER as determined by MT can be essential for the local [Ca](i) signaling in neurons.	Univ Gottingen, Dept Neuro & Sensory Physiol, Inst Physiol, D-37073 Gottingen, Germany	University of Gottingen	Mironov, SL (corresponding author), Univ Gottingen, Dept Neuro & Sensory Physiol, Inst Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	slm@ukps.gwdg.de						Andre N, 2002, FEBS LETT, V532, P256, DOI 10.1016/S0014-5793(02)03691-8; Antman K, 2001, NEW ENGL J MED, V344, P762, DOI 10.1056/NEJM200103083441010; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BERNIERVALENTIN F, 1983, J CELL BIOL, V97, P209, DOI 10.1083/jcb.97.1.209; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buck KB, 2002, J NEUROSCI, V22, P9358; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Crompton M, 2003, CURR MED CHEM, V10, P1473, DOI 10.2174/0929867033457197; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Fogarty KE, 2000, J BIOL CHEM, V275, P22487, DOI 10.1074/jbc.M909402199; Frambach I, 2004, J COMP NEUROL, V475, P303, DOI 10.1002/cne.20165; Fuller KM, 2003, CURR OPIN BIOTECH, V14, P35, DOI 10.1016/S0958-1669(02)00008-3; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Levy M, 2003, J BIOL CHEM, V278, P17727, DOI 10.1074/jbc.M212878200; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Loewenstein Y, 2003, NAT NEUROSCI, V6, P961, DOI 10.1038/nn1109; MARTZ D, 1984, CELL MOTIL CYTOSKEL, V4, P89, DOI 10.1002/cm.970040203; MIRONOV SL, 1995, NEUROPHARMACOLOGY, V34, P1123, DOI 10.1016/0028-3908(95)00080-P; MIRONOV SL, 1990, J THEOR BIOL, V146, P87, DOI 10.1016/S0022-5193(05)80045-1; MIRONOV SL, 1991, NEUROSCI LETT, V123, P200, DOI 10.1016/0304-3940(91)90930-R; Mironov SL, 1996, BRAIN RES, V714, P27, DOI 10.1016/0006-8993(95)01456-X; Mironov SL, 1998, J PHYSIOL-LONDON, V512, P75, DOI 10.1111/j.1469-7793.1998.075bf.x; Mironov SL, 2001, J PHYSIOL-LONDON, V533, P227, DOI 10.1111/j.1469-7793.2001.0227b.x; Muller M, 2003, J PHYS D APPL PHYS, V36, P1747, DOI 10.1088/0022-3727/36/14/314; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; POSTMA TJ, 1995, ANN ONCOL, V6, P489, DOI 10.1093/oxfordjournals.annonc.a059220; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Richter DW, 2001, TRENDS NEUROSCI, V24, P464, DOI 10.1016/S0166-2236(00)01867-1; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Ross JL, 2003, BIOPHYS J, V84, P3959, DOI 10.1016/S0006-3495(03)75123-6; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schneckenburger H, 2004, PHOTOCH PHOTOBIO SCI, V3, P127, DOI 10.1039/b306129a; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; TERASAKI M, 1994, CELL MOTIL CYTOSKEL, V29, P291, DOI 10.1002/cm.970290402; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Vergun O, 2003, BIOPHYS J, V85, P3358, DOI 10.1016/S0006-3495(03)74755-9; Ward MW, 2000, J NEUROSCI, V20, P7208	54	121	124	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					715	721		10.1074/jbc.M409819200	http://dx.doi.org/10.1074/jbc.M409819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516333	hybrid			2022-12-25	WOS:000226025100084
J	Qing, GL; Qu, ZX; Xiao, GT				Qing, GL; Qu, ZX; Xiao, GT			Regulation of NF-kappa B2 p100 processing by its cis-acting domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IKK-ALPHA; MEDIATED ACTIVATION; KINASE; PROTEINS; BETA; GENE; GENERATION; EXPRESSION; SIGNAL	Processing of NF-kappaB2 precursor protein p100 to generate p52 is tightly regulated. However, this proteolytic event could be actively induced by the NF-kappaB-inducing kinase and the human T-cell leukemia virus-encoded oncoprotein Tax or be constitutively turned on due to the loss of the C-terminal portion of p100. Whereas NF-kappaB-inducing kinase-mediated p100 processing requires beta-transducin repeat-containing protein, constitutive processing of p100 is independent of this protein. On the other hand, Tax-induced processing of p100 appears to be both beta-transducin repeat-containing protein-dependent and -independent. We show here that, besides the C-terminal sequences, multiple functional regions, including the two alpha-helices, dimerization domain, nuclear localization sequence, and glycine-rich region, located in the N terminus of p100, also play important roles in both constitutive and inducible processing, suggesting a common mechanism for p100 processing. We further demonstrate that with the help of the C-terminal death domain and IkappaB kinase alpha-targeting serines, the C-terminal ankyrin-repeat domain of p100 strongly interacts with its N-terminal dimerization domain and nuclear localization sequence, thereby bringing the C- and N-terminal sequences together to form a three-dimensional domain. This presumptive domain is not only responsible for suppression of constitutive processing but also required for inducible processing of p100. Taken together, these studies highlight the mechanism by which the different sequences within p100 work in concert to regulate its processing and shed light on the mechanisms of how p100 processing is tightly and delicately controlled.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Lab, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Xiao, GT (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Lab, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu						Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LANOIX J, 1994, ONCOGENE, V9, P841; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Lin L, 1996, MOL CELL BIOL, V16, P2248; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; ZHANG JD, 1994, ONCOGENE, V9, P1931	47	42	43	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					18	27		10.1074/jbc.M406619200	http://dx.doi.org/10.1074/jbc.M406619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15485830	hybrid			2022-12-25	WOS:000226025100004
J	Rosenzweig, JA; Weltman, G; Plano, GV; Schesser, K				Rosenzweig, JA; Weltman, G; Plano, GV; Schesser, K			Modulation of Yersinia type three secretion system by the S1 domain of polynucleotide phosphorylase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VIRULENCE GENES; LOW-TEMPERATURE; QUALITY-CONTROL; PROTEIN; PESTIS; PSEUDOTUBERCULOSIS; TRANSLOCATION; EXPRESSION; MEMBRANE	Both low temperatures and encounters with host phagocytes are two stresses that have been relatively well studied in many species of bacteria. Previous work has shown that the exoribonuclease polynucleotide phosphorylase (PNPase) is required for Yersiniae to grow at low temperatures. Here, we show that PNPase also enhances the ability of Yersinia pseudotuberculosis and Yersinia pestis to withstand the killing activities of murine macrophages. PNPase is required for the optimal functioning of the Yersinia type three secretion system (TTSS), an organelle that injects effector proteins directly into host cells. Unexpectedly, the effect of PNPase on the TTSS is independent of its ribonuclease activity and instead requires its S1 RNA binding domain. In contrast, catalytically inactive enzyme does not enhance the low temperature growth effect of PNPase. Surprisingly, wild-type-like TTSS functioning was restored to the pnp mutant strain by expressing just the similar to70 amino acid S1 domains from either PNPase, RNase R, RNase II, or RpsA. Our findings suggest that PNPase plays multifaceted roles in enhancing Yersinia survival in response to stressful conditions.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Schesser, K (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.	kschesser@med.miami.edu			NIAID NIH HHS [AI50552, R01 AI53459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050552, R01AI053459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bartram D, 2001, INT J TESTING, V1, P33, DOI DOI 10.1207/S15327574IJT0101_3; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Clements MO, 2002, P NATL ACAD SCI USA, V99, P8784, DOI 10.1073/pnas.132047099; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Day JB, 1998, MOL MICROBIOL, V30, P777, DOI 10.1046/j.1365-2958.1998.01110.x; Day JB, 2003, MOL MICROBIOL, V47, P807, DOI 10.1046/j.1365-2958.2003.03343.x; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Garcia-Mena J, 1999, MOL MICROBIOL, V33, P235, DOI 10.1046/j.1365-2958.1999.01451.x; Goverde RLJ, 1998, MOL MICROBIOL, V28, P555, DOI 10.1046/j.1365-2958.1998.00816.x; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jarrige AC, 2002, J MOL BIOL, V321, P397, DOI 10.1016/S0022-2836(02)00645-9; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; LINDLER LE, 1990, INFECT IMMUN, V58, P2569, DOI 10.1128/IAI.58.8.2569-2577.1990; Luttinger A, 1996, MOL MICROBIOL, V19, P343, DOI 10.1046/j.1365-2958.1996.380907.x; Mills SD, 1998, EUR J CELL BIOL, V77, P35, DOI 10.1016/S0171-9335(98)80100-3; Neuhaus K, 2000, J BACTERIOL, V182, P3285, DOI 10.1128/JB.182.11.3285-3288.2000; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PLANO GV, 1993, J BACTERIOL, V175, P3536, DOI 10.1128/jb.175.11.3536-3545.1993; Polissi A, 2003, RES MICROBIOL, V154, P573, DOI 10.1016/S0923-2508(03)00167-0; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; SODEINDE OA, 1988, INFECT IMMUN, V56, P2749, DOI 10.1128/IAI.56.10.2749-2752.1988; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; Williams AW, 1998, J BACTERIOL, V180, P350, DOI 10.1128/JB.180.2.350-358.1998; Xia B, 2001, MOL MICROBIOL, V40, P179, DOI 10.1046/j.1365-2958.2001.02372.x; Yamanaka K, 2001, J BACTERIOL, V183, P2808, DOI 10.1128/JB.183.9.2808-2816.2001	34	60	60	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					156	163		10.1074/jbc.M405662200	http://dx.doi.org/10.1074/jbc.M405662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15509583	hybrid			2022-12-25	WOS:000226025100020
J	Al-Ayyoubi, M; Gettins, PGW; Volz, K				Al-Ayyoubi, M; Gettins, PGW; Volz, K			Crystal structure of human maspin, a serpin with antitumor properties - Reactive center loop of maspin is exposed but constrained	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; INHIBITORY CONFORMATION; TUMOR-GROWTH; EXPRESSION; CELLS; ANGIOGENESIS; PROTEINS; SITE; COLLAGEN; PEDF	Maspin, a member of the serpin superfamily, has tumor suppressing activity against breast and prostate cancer. Maspin inhibits tumor growth by blocking cell invasion, and its reactive center loop (RCL) is thought to mediate this activity. To understand this function on the molecular level, we have solved the three-dimensional structure of Maspin to 3.1 Angstrom resolution. The molecular structure shows the characteristic features of the serpin fold, but the RCL of Maspin is unique in length, composition, and placement. Although the RCL of Maspin is accessible and cleavable by some proteinases, it functions in the uncleaved, constrained conformation observed here. These structural results will contribute to our understanding of the mechanism by which Maspin suppresses tumors.	Univ Illinois, Dept Microbiol & Immunol, 835 S Wolcott Ave, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Volz, K (corresponding author), Univ Illinois, Dept Microbiol & Immunol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	kvolz@uic.edu			NHLBI NIH HHS [HL 64013, HL 49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R37HL049234, R01HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Hendrix MJC, 2000, NAT MED, V6, P374, DOI 10.1038/74624; Hojo T, 2001, CANCER LETT, V171, P103, DOI 10.1016/S0304-3835(01)00569-9; HOPKINS PCR, 1994, SCIENCE, V265, P1893; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; Maass N, 2001, J PATHOL, V195, P321; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; *MOL SIM INC, 1997, QUANTA BAS OP; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2001, CANCER RES, V61, P6945; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Yasui N, 2003, BIOCHEMISTRY-US, V42, P3160, DOI 10.1021/bi0206558; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	41	42	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55540	55544		10.1074/jbc.M409957200	http://dx.doi.org/10.1074/jbc.M409957200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15501821	hybrid			2022-12-25	WOS:000225960800070
J	Clayburgh, DR; Rosen, S; Witkowski, ED; Wang, FJ; Blair, S; Dudek, S; Garcia, JGN; Alverdy, JC; Turner, JR				Clayburgh, DR; Rosen, S; Witkowski, ED; Wang, FJ; Blair, S; Dudek, S; Garcia, JGN; Alverdy, JC; Turner, JR			A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSIOLOGICAL REGULATION; CELL-LINE; PHOSPHORYLATION; RHO; EXPRESSION; BARRIER; CACO-2; ORGANIZATION; ACTIVATION; PROTEINS	Activation of Na+-nutrient cotransport leads to increased tight junction permeability in intestinal absorptive (villus) enterocytes. This regulation requires myosin II regulatory light chain (MLC) phosphorylation mediated by MLC kinase (MLCK). We examined the spatio-temporal segregation of MLCK isoform function and expression along the crypt-villus axis and found that long MLCK, which is expressed as two alternatively spliced isoforms, accounts for 97 +/- 4% of MLC kinase activity in interphase intestinal epithelial cells. Expression of the MLCK1 isoform is limited to well differentiated enterocytes, both in vitro and in vivo, and this expression correlates closely with development of Na+-nutrient cotransport-dependent tight junction regulation. Consistent with this role, MLCK1 is localized to the perijunctional actomyosin ring. Furthermore, specific knockdown of MLCK1 using siRNA reduced tight junction permeability in monolayers with active Na+-glucose cotransport, confirming a functional role for MLCK1. These results demonstrate unique physiologically relevant patterns of expression and subcellular localization for long MLCK isoforms and show that MLCK1 is the isoform responsible for tight junction regulation in absorptive enterocytes.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Third Mil Med Univ, SW Hosp, Inst Burn Res, Chongquig 400038, Peoples R China; Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	University of Chicago; University of Chicago; Army Medical University; Johns Hopkins University	Turner, JR (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	Wang, Fengjun/A-4114-2009	Clayburgh, Daniel/0000-0002-3296-4926	NCI NIH HHS [P30 CA014599, P30 CA 14599] Funding Source: Medline; NIDDK NIH HHS [P30 DK 42086, R01 DK061931, R01 DK 61931, P30 DK042086, R01 DK068271] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061931, P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, CELL, V30, P349, DOI 10.1016/0092-8674(82)90232-X; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Birukov KG, 1998, J CELL BIOCHEM, V70, P402, DOI 10.1002/(SICI)1097-4644(19980901)70:3<402::AID-JCB13>3.0.CO;2-M; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Fihn BM, 2000, GASTROENTEROLOGY, V119, P1029, DOI 10.1053/gast.2000.18148; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Huang QB, 2003, SHOCK, V20, P363, DOI 10.1097/01.shk.0000079425.0000.db; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; JUMARIE C, 1991, J CELL PHYSIOL, V149, P24, DOI 10.1002/jcp.1041490105; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Komatsu S, 2004, J CELL BIOL, V165, P243, DOI 10.1083/jcb.200309056; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Llor X, 1999, CLIN CANCER RES, V5, P1767; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; MARCIAL MA, 1984, J MEMBRANE BIOL, V80, P59, DOI 10.1007/BF01868690; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; PAPPENHEIMER JR, 1987, J MEMBRANE BIOL, V100, P123, DOI 10.1007/BF02209145; PETERSON MD, 1992, J CELL SCI, V102, P581; PINTO M, 1983, BIOL CELL, V47, P323; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; Turner JR, 2000, ADV DRUG DELIVER REV, V41, P265, DOI 10.1016/S0169-409X(00)00046-6; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 1999, AM J PHYSIOL-CELL PH, V277, pC554, DOI 10.1152/ajpcell.1999.277.3.C554; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Yuhan R, 1997, GASTROENTEROLOGY, V113, P1873, DOI 10.1016/S0016-5085(97)70006-4; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	34	120	124	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55506	55513		10.1074/jbc.M408822200	http://dx.doi.org/10.1074/jbc.M408822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15507455	Green Accepted, hybrid			2022-12-25	WOS:000225960800066
J	Deka, RK; Neil, L; Hagman, KE; Machius, M; Tomchick, DR; Brautigam, CA; Norgard, MV				Deka, RK; Neil, L; Hagman, KE; Machius, M; Tomchick, DR; Brautigam, CA; Norgard, MV			Structural evidence that the 32-kilodalton lipoprotein (Tp32) of Treponema pallidum is an L-methionine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; BORRELIA-BURGDORFERI LIPOPROTEINS; ESCHERICHIA-COLI; OUTER-MEMBRANE; PERIPLASMIC LYSINE; ABC TRANSPORTERS; ARGININE; ENCODES; SYSTEM; LIGAND	A structure-to-function approach was undertaken to gain insights into the potential function of the 32-kDa membrane lipoprotein (Tp32) of Treponema pallidum, the syphilis bacterium. The crystal structure of rTp32 (determined at a resolution of 1.85 Angstrom) shows that the organization of rTp32 is similar to other periplasmic ligand-binding proteins (PLBPs), in that it consists of two alpha/beta domains, linked by two crossovers, with a binding pocket between them. In the pocket, a molecule of L-methionine was detected in the electron density map. Residues from both domains interact with the ligand. One of the crossover regions is comprised of a 3(10)-helix, a feature not typical in other ligand-binding proteins. Sequence comparison shows strong similarity to other hypothetical methionine-binding proteins. Together, the data support the notion that rTp32 is a component of a periplasmic methionine uptake transporter system in T. pallidum.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.norgard@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Brautigam, Chad/0000-0001-6563-1338	NIAID NIH HHS [AI 56305] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER PS, 1994, INFECT IMMUN, V62, P1381, DOI 10.1128/IAI.62.4.1381-1391.1994; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Deka RK, 2004, J BACTERIOL, V186, P2303, DOI 10.1128/JB.186.8.2303-2308.2004; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gal J, 2002, J BACTERIOL, V184, P4930, DOI 10.1128/JB.184.17.4930-4932.2002; Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hullo MF, 2004, RES MICROBIOL, V155, P80, DOI 10.1016/j.resmic.2003.11.008; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merlin C, 2002, J BACTERIOL, V184, P5513, DOI 10.1128/JB.184.19.5513-5517.2002; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 1998, METHOD ENZYMOL, V292, P3; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P26323; Oliver DB, 1996, ESCHERICHIA COLI SAL, P88; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4; Rodionov DA, 2004, NUCLEIC ACIDS RES, V32, P3340, DOI 10.1093/nar/gkh659; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P2213, DOI 10.1107/S0907444902016384; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; Zhang ZG, 2003, ARCH MICROBIOL, V180, P88, DOI 10.1007/s00203-003-0561-4	45	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55644	55650		10.1074/jbc.M409263200	http://dx.doi.org/10.1074/jbc.M409263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489229	hybrid			2022-12-25	WOS:000225960800083
J	Korkhov, VM; Farhan, H; Freissmuth, M; Sitte, HH				Korkhov, VM; Farhan, H; Freissmuth, M; Sitte, HH			Oligomerization of the gamma-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HUMAN SEROTONIN TRANSPORTER; RAT GABA TRANSPORTER-1; PLASMA-MEMBRANE; LEUCINE-ZIPPER; NEUROTRANSMITTER TRANSPORTERS; CROSS-LINKING; COILED-COIL; PROTEIN; ASSOCIATION	The available evidence indicates that members of the neurotransmitter: sodium symporter family form constitutive oligomers. Their second transmembrane helix (TM2) contains a leucine heptad repeat proposed to be involved in oligomerization. In artificial transmembrane segments, interhelical interactions are stabilized by polar residues. We searched for these hydrogen bond donors in TM2 by mutating the five polar residues in TM2 of the gamma-aminobutyric acid transporter- 1 (GAT1). We tested the ability of the resulting mutants to oligomerize by fluorescence microscopy, Foerster resonance energy transfer, and beta-lactamase fragment complementation. Of all generated mutants, only Y86A-(but not Y86F-), E101A-, E101Q-, and E101D-GAT1 were judged by these criteria to be deficient in oligomerization and were retained intracellularly. The observations are consistent with a model where the leucine heptad repeat in TM2 drives a homophilic association that is stabilized by Tyr(86) and Glu(101); Tyr(86) participates in hydrophobic stacking. Glu(101) is in the a-position of the leucine heptad repeat (where positions 1-7 are denoted a-g, and each leucine is in the central d- position). Thus, Glu(101) is in the position predicted for the hydrogen bond donor (i.e. sandwiched between Leu(97) and Leu(104), which are one helical turn above and below Glu(101)). These key residues, namely Tyr(86) and Glu(101), are conserved in related transporters from archaeae to humans; they are therefore likely to support oligomeric assembly in transporter orthologs and possibly other proteins with multiple transmembrane segments.	Vienna Med Univ, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Vienna Med Univ, Inst Pharmacol, Waehringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Sitte, Harald/O-7025-2019; Farhan, Hesso/C-7997-2012; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Farhan, Hesso/0000-0002-0889-8463; Sitte, Harald/0000-0002-1339-7444; Korkhov, Volodymyr/0000-0002-0962-9433; Freissmuth, Michael/0000-0001-9398-1765				Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Aggeli A, 1998, BIOCHEMISTRY-US, V37, P8121, DOI 10.1021/bi972112h; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Chelli R, 2002, J AM CHEM SOC, V124, P6133, DOI 10.1021/ja0121639; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Farhan H, 2004, J BIOL CHEM, V279, P28553, DOI 10.1074/jbc.M307325200; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Hahn MK, 2003, J NEUROSCI, V23, P4470; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	35	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55728	55736		10.1074/jbc.M409449200	http://dx.doi.org/10.1074/jbc.M409449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15496410	hybrid			2022-12-25	WOS:000225960800094
J	Lemonnier, M; Buckingham, ME				Lemonnier, M; Buckingham, ME			Characterization of a cardiac-specific enhancer, which directs alpha-cardiac actin gene transcription in the mouse adult heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BINDING-FACTOR; IN-VITRO; CARG BOXES; EXPRESSION; MEF2; UPSTREAM; PROMOTER; ELEMENTS; ACTIVATION	Expression of the mouse alpha-cardiac actin gene in skeletal and cardiac muscle is regulated by enhancers lying 5' to the proximal promoter. Here we report the characterization of a cardiac-specific enhancer located within -2.354/-1.36 kbp of the gene, which is active in cardiocytes but not in C2 skeletal muscle cells. In vivo it directs reporter gene expression to the adult heart, where the proximal promoter alone is inactive. An 85-bp region within the enhancer is highly conserved between human and mouse and contains a central AT-rich site, which is essential for enhancer activity. This site binds myocyte enhancer factor (MEF)2 factors, principally MEF2D and MEF2A in cardiocyte nuclear extracts. These results are discussed in the context of MEF2 activity and of the regulation of the alpha-cardiac actin locus.	Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buckingham, ME (corresponding author), Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	margab@pasteur.fr						AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GARNER I, 1986, EMBO J, V5, P2559, DOI 10.1002/j.1460-2075.1986.tb04535.x; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Hadchouel J, 2003, DEVELOPMENT, V130, P3415, DOI 10.1242/dev.00552; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Kelly RG, 2003, J CELL SCI, V116, P5005, DOI 10.1242/jcs.00824; Kelly RG, 1999, TRENDS CARDIOVAS MED, V9, P3, DOI 10.1016/S1050-1738(98)00034-6; Kolodziejczyk SM, 1999, CURR BIOL, V9, P1203, DOI 10.1016/S0960-9822(00)80027-5; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LI ZL, 1993, NEUROMUSCULAR DISORD, V3, P423, DOI 10.1016/0960-8966(93)90089-3; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MANIATIS T, 1989, MOL CLONING, P52; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTINEZ HM, 1983, NUCLEIC ACIDS RES, V11, P4629, DOI 10.1093/nar/11.13.4629; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Molinari S, 2004, MOL CELL BIOL, V24, P2944, DOI 10.1128/MCB.24.7.2944-2957.2004; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Razeghi P, 2002, CIRCULATION, V106, P407, DOI 10.1161/01.CIR.0000026392.80723.DC; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	51	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55651	55658		10.1074/jbc.M411082200	http://dx.doi.org/10.1074/jbc.M411082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15491989	hybrid			2022-12-25	WOS:000225960800084
J	Levin, DS; Vijayakumar, S; Liu, XP; Bermudez, VP; Hurwitz, J; Tomkinson, AE				Levin, DS; Vijayakumar, S; Liu, XP; Bermudez, VP; Hurwitz, J; Tomkinson, AE			A conserved interaction between the replicative clamp loader and DNA ligase in eukaryotes - Implications for Okazaki fragment joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; FACTOR-C; IN-VITRO; COMPLEX; REPAIR; PROTEINS; IDENTIFICATION; POLYMERASES; RECONSTITUTION; ASSOCIATION	The recruitment of DNA ligase I to replication foci and the efficient joining of Okazaki fragments is dependent on the interaction between DNA ligase I and proliferating cell nuclear antigen (PCNA). Although the PCNA sliding clamp tethers DNA ligase I to nicked duplex DNA circles, the interaction does not enhance DNA joining. This suggests that other factors may be involved in the joining of Okazaki fragments. In this study, we describe an association between replication factor C (RFC), the clamp loader, and DNA ligase I in human cell extracts. Subsequently, we demonstrate that there is a direct physical interaction between these proteins that involves both the N- and C-terminal domains of DNA ligase I, the N terminus of the large RFC subunit p140, and the p36 and p38 subunits of RFC. Although RFC inhibited DNA joining by DNA ligase I, the addition of PCNA alleviated inhibition by RFC. Notably, the effect of PCNA on ligation was dependent on the PCNA-binding site of DNA ligase I. Together, these results provide a molecular explanation for the key in vivo role of the DNA ligase I/PCNA interaction and suggest that the joining of Okazaki fragments is coordinated by pairwise interactions among RFC, PCNA, and DNA ligase I.	Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Maryland, Sch Med, Mol & Cellular Biol Grad Program, Baltimore, MD 21201 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center; University System of Maryland; University of Maryland Baltimore	Tomkinson, AE (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland.edu			NIGMS NIH HHS [GM 57479, GM 38559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057479] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P10237, DOI 10.1073/pnas.1434308100; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEE SH, 1991, J BIOL CHEM, V266, P594; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Miyata T, 2004, NAT STRUCT MOL BIOL, V11, P632, DOI 10.1038/nsmb788; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; RON D, 1992, BIOTECHNIQUES, V13, P866; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	33	38	39	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55196	55201		10.1074/jbc.M409250200	http://dx.doi.org/10.1074/jbc.M409250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15502161	hybrid			2022-12-25	WOS:000225960800027
J	Liu, JG; Guan, XQ; Tamura, T; Ozato, K; Ma, XJ				Liu, JG; Guan, XQ; Tamura, T; Ozato, K; Ma, XJ			Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; NF-KAPPA-B; PROINFLAMMATORY CYTOKINE; IL-12 PRODUCTION; DENDRITIC CELLS; P40 EXPRESSION; C-REL; IRF-1; PROMOTER; MACROPHAGES	Interferon regulatory factor-1 (IRF-1) and interferon consensus sequence-binding protein (ICSBP or IRF-8) are two members of the IRF family of transcription factors that play critical roles in interferon signaling in a wide range of host responses to infection and malignancy. Interleukin-12 (IL-12) is a key factor in the induction of innate resistance and generation of T helper type 1 cells and cytotoxic T lymphocytes. In this work, we find that ICSBP-deficient macrophages are highly defective in the production of IL-12. The defect is also observed at the level of IL-12 p40 and p35 mRNA expression. Transcriptional analyses revealed that ICSBP is a potent activator of the IL-12 p35 gene. It acts through a site localized to -226 to -219, named ICSBP-response element (ICSBP-RE), in the human IL-12 p35 promoter through physical association with IRF-1 both in vitro and in vivo. Co-expression of ICSBP and IRF-1 synergistically stimulates the IL-12 p35 promoter activity. Mutations at the ICSBP-RE results in the loss of protein binding as well as transcriptional activation by ICSBP alone or together with IRF-1. This study provides novel mechanistic information on how signals initiated during innate and adaptive immune responses synergize to yield greater IL-12 production and sustained cellular immunity.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Ma, XJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	xim2002@med.cornell.edu			NATIONAL CANCER INSTITUTE [K01CA079772] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045899] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79772] Funding Source: Medline; NIAID NIH HHS [AI 045899] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babik JM, 1999, J IMMUNOL, V162, P4069; Carra G, 2000, J IMMUNOL, V164, P4752, DOI 10.4049/jimmunol.164.9.4752; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Edwards AD, 2002, J IMMUNOL, V169, P3652, DOI 10.4049/jimmunol.169.7.3652; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Grumont R, 2001, J EXP MED, V194, P1021, DOI 10.1084/jem.194.8.1021; Hayes MP, 1998, BLOOD, V91, P4645, DOI 10.1182/blood.V91.12.4645.412k36_4645_4651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JG, 2003, J EXP MED, V198, P1265, DOI 10.1084/jem.20030026; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Murphy FJ, 2000, J IMMUNOL, V164, P839, DOI 10.4049/jimmunol.164.2.839; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seki E, 2002, J IMMUNOL, V169, P3863, DOI 10.4049/jimmunol.169.7.3863; Snijders A, 1996, J IMMUNOL, V156, P1207; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271	31	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55609	55617		10.1074/jbc.M406565200	http://dx.doi.org/10.1074/jbc.M406565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15489234	hybrid			2022-12-25	WOS:000225960800079
J	Makagiansar, IT; Williams, S; Dahlin-Huppe, K; Fukushi, J; Mustelin, T; Stallcup, WB				Makagiansar, IT; Williams, S; Dahlin-Huppe, K; Fukushi, J; Mustelin, T; Stallcup, WB			Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SPANNING PROTEOGLYCAN; CYTOPLASMIC DOMAIN; PROGENITOR CELLS; MELANOMA-CELLS; PHORBOL ESTER; HUMAN GENOME; RECEPTOR; INTEGRIN; ENGAGEMENT	Protein kinase C ( PKC)-alpha phosphorylation of recombinant NG2 cytoplasmic domain and phorbol ester-induced PKC-dependent phosphorylation of full-length NG2 expressed in U251 cells are both blocked by mutation of Thr(2256), identifying this residue as a primary phosphorylation site. In untreated U251/NG2 cells, NG2 is present along with ezrin and alpha(3)beta(1) integrin in apical cell surface protrusions. Phorbol ester treatment causes redistribution of all three components to lamellipodia, accompanied by increased cell motility. U251 cells expressing NG2 with a valine substitution at position 2256 are resistant to phorbol ester treatment: NG2 remains in membrane protrusions and cell motility is unchanged. In contrast, NG2 with a glutamic acid substitution at position 2256 redistributes to lamellipodia even without phorbol ester treatment, rendering transfected U251 cells spontaneously motile. PKC-alpha-mediated NG2 phosphorylation at Thr(2256) is therefore a key step for initiating cell polarization and motility.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Makagiansar, IT (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	irwanm@burnham.org		Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [R01 CA 96949, R01 CA 95287] Funding Source: Medline; NIAID NIH HHS [R01 AI 55741, R01 AI 48032, R01 AI 35603, R01 AI 53585] Funding Source: Medline; NICHD NIH HHS [P01 HD 25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA096949, R01CA095287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048032, R01AI035603, R01AI055741, R01AI053585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Chekenya M, 2002, FASEB J, V16, P586, DOI 10.1096/fj.01-0632fje; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; GARRIGUES HJ, 1986, J CELL BIOL, V103, P1699, DOI 10.1083/jcb.103.5.1699; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; Grako KA, 1999, J CELL SCI, V112, P905; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; IIDA J, 1995, CANCER RES, V55, P2177; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; LUO K, 1990, ONCOGENE, V5, P921; Majumdar M, 2003, CELL SIGNAL, V15, P79, DOI 10.1016/S0898-6568(02)00045-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; PONTEN J, 1978, MED BIOL, V56, P184; Schneider S, 2001, J NEUROSCI, V21, P920, DOI 10.1523/JNEUROSCI.21-03-00920.2001; Stallcup WB, 2002, J NEUROCYTOL, V31, P423, DOI 10.1023/A:1025731428581; Stallcup WB, 2001, J CELL SCI, V114, P2315; Stegmuller J, 2003, J BIOL CHEM, V278, P3590, DOI 10.1074/jbc.M210010200; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Thorp KM, 1996, IMMUNOLOGY, V87, P434, DOI 10.1046/j.1365-2567.1996.486567.x; Tillet E, 2002, J CELL BIOCHEM, V86, P726, DOI 10.1002/jcb.10268; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	54	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55262	55270		10.1074/jbc.M411045200	http://dx.doi.org/10.1074/jbc.M411045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15504744	hybrid			2022-12-25	WOS:000225960800036
J	Zhou, BR; Yi, L; Fen, D; Zheng, Z; Jie, C				Zhou, BR; Yi, L; Fen, D; Zheng, Z; Jie, C			Mixed macromolecular crowding accelerates the oxidative refolding of reduced, denatured lysozyme - Implications for protein folding in intracellular environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; MUSCLE CREATINE-KINASE; ESCHERICHIA-COLI; HEN LYSOZYME; MASS-SPECTROMETRY; AGGREGATION; CYTOPLASM; KINETICS; VOLUME; GROEL	The oxidative refolding of reduced, denatured hen egg white lysozyme in the presence of a mixed macromolecular crowding agent containing both bovine serum albumin (BSA) and polysaccharide has been studied from a physiological point of view. When the total concentration of the mixed crowding agent is 100 g/liter, in which the weight ratio of BSA to dextran 70 is 1:9, the refolding yield of lysozyme after refolding for 4 h under this condition increases 24% compared with that in the presence of BSA and 16% compared with dextran 70. A remarkable increase in the refolding yield of lysozyme by a mixed crowding agent containing BSA and Ficoll 70 is also observed. Further folding kinetics analyses show that these two mixed crowding agents accelerate the oxidative refolding of lysozyme remarkably, compared with single crowding agents. These results suggest that the stabilization effects of mixed macromolecular crowding agents are stronger than those of single polysaccharide crowding agents such as dextran 70 and Ficoll 70, whereas the excluded volume effects of mixed macromolecular crowding agents are weaker than those of single protein crowding agents such as BSA. Both the refolding yield and the rate of the oxidative refolding of lysozyme in these two mixed crowded solutions with suitable weight ratios are higher than those in single crowded solutions, indicating that mixed macromolecular crowding agents are more favorable to lysozyme folding and can be used to simulate the intracellular environments more accurately than single crowding agents do.	Wuhan Univ, Coll Life Sci, Natl Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University	Yi, L (corresponding author), Wuhan Univ, Coll Life Sci, Natl Key Lab Virol, Wuhan 430072, Peoples R China.	liangyi@whu.edu.cn	Liang, Yi/V-1396-2017; Zhou, Bing-Rui/D-4766-2009; Zhou, Zheng/AAK-2669-2021	Liang, Yi/0000-0002-7349-8300; Zhou, Zheng/0000-0002-3124-6041; Zhou, Bing-Rui/0000-0002-5375-7977				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; Elcock AH, 2003, P NATL ACAD SCI USA, V100, P2340, DOI 10.1073/pnas.0535055100; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Flaugh SL, 2001, BIOMACROMOLECULES, V2, P538, DOI 10.1021/bm015502z; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; Galan A, 2001, J BIOL CHEM, V276, P957, DOI 10.1074/jbc.M006861200; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; Hall D, 2003, BBA-PROTEINS PROTEOM, V1649, P127, DOI 10.1016/S1570-9639(03)00167-5; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Huang BX, 2004, J AM SOC MASS SPECTR, V15, P1237, DOI 10.1016/j.jasms.2004.05.004; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; Kuznetsova IM, 2002, BIOCHEMISTRY-US, V41, P13127, DOI 10.1021/bi026412x; Li J, 2001, J BIOL CHEM, V276, P34396, DOI 10.1074/jbc.M103392200; Liang Y, 2003, J BIOL CHEM, V278, P30098, DOI 10.1074/jbc.M304050200; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Minton AP, 2000, BIOPHYS J, V78, P101, DOI 10.1016/S0006-3495(00)76576-3; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; MINTON AP, 1992, P NATL ACAD SCI USA, V89, P10504, DOI 10.1073/pnas.89.21.10504; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Ren GP, 2003, J PROTEIN CHEM, V22, P431, DOI 10.1023/B:JOPC.0000005458.08802.11; Rival Y, 2004, ATHEROSCLEROSIS SUPP, V5, P27; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Roux P, 1997, J BIOL CHEM, V272, P24843, DOI 10.1074/jbc.272.40.24843; Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Tokuriki N, 2004, PROTEIN SCI, V13, P125, DOI 10.1110/ps.03288104; van den Berg B, 2000, EMBO J, V19, P3870, DOI 10.1093/emboj/19.15.3870; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; Wenner JR, 1999, BIOPHYS J, V77, P3234, DOI 10.1016/S0006-3495(99)77154-7; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	48	87	93	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55109	55116		10.1074/jbc.M409086200	http://dx.doi.org/10.1074/jbc.M409086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15494409	hybrid			2022-12-25	WOS:000225960800017
J	Lee, BY; Thulin, CD; Willardson, BM				Lee, BY; Thulin, CD; Willardson, BM			Site-specific phosphorylation of phosducin in intact retina - Dynamics of phosphorylation and effects on G protein beta gamma dimer binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DRIVEN TRANSLOCATION; ROD PHOTORECEPTOR CELLS; MICE LACKING; TRANSDUCIN; COMPLEX; SUBUNIT; MECHANISM; PHOSPHODIESTERASE; DEPHOSPHORYLATION; ADAPTATION	Phosducin (Pdc) is a G protein betagamma dimer (Gbetagamma) binding protein, highly expressed in retinal photoreceptor and pineal cells, yet whose physiological role remains elusive. Light controls the phosphorylation of Pdc in a cAMP and Ca2+-dependent manner, and phosphorylation in turn regulates the binding of Pdc to G(t)betagamma or 14-3-3 proteins in vitro. To directly examine the phosphorylation of Pdc in intact retina, we prepared antibodies specific to the three principal phosphorylation sites (Ser-54, Ser-73, and Ser-106) and measured the kinetics of phosphorylation/dephosphorylation during light/dark adaptation and the subsequent effects on G(t)betagamma binding. Ser-54 phosphorylation increased slowly (t(1/2)similar to90 min) during dark adaptation to similar to70% phosphorylated and decreased rapidly (t(1/2)similar to2 min) during light adaptation to less than 20% phosphorylated. Ser-73 phosphorylation increased much faster during dark adaptation (t(1/2)similar to3 min) to similar to50% phosphorylated and decreased more slowly during light adaptation (t(1/2)similar to9 min) to less than 20% phosphorylated. The Ca2+ chelator BAPTA-AM blocked Ser-54 phosphorylation during dark adaptation but had no effect on Ser-73 phosphorylation. In contrast, Ser-106 was not phosphorylated in either the light or dark. Importantly, Gbetagamma binding to Pdc was enhanced by Ca2+ chelation and the binding kinetics closely paralleled those of Ser-54 dephosphorylation, indicating that Ser-54 phosphorylation controls G(t)betagamma binding in vivo. These results suggest a pivotal role of Ser-54 and Ser-73 phosphorylation in determining the interactions of Pdc with its binding partners, G(t)betagamma and 14-3-3 protein, which may regulate the light-dependent translocation of the photoreceptor G protein.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	barry_willardson@byu.edu		Willardson, Barry/0000-0002-8503-2268	NATIONAL EYE INSTITUTE [R01EY012287] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; Brown BM, 2002, BIOCHEMISTRY-US, V41, P13526, DOI 10.1021/bi0204490; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COHEN AI, 1990, VISUAL NEUROSCI, V4, P43, DOI 10.1017/S0952523800002753; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; Granovsky AE, 2001, BIOCHEMISTRY-US, V40, P13209, DOI 10.1021/bi011127j; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Margulis A, 2002, MOL VIS, V8, P477; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; Nir I, 2002, J NEUROSCI, V22, P2063, DOI 10.1523/JNEUROSCI.22-06-02063.2002; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; REIG JA, 1990, J BIOL CHEM, V265, P5816; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thulin CD, 1999, MOL VIS, V5, pU13; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54008	54017		10.1074/jbc.M405669200	http://dx.doi.org/10.1074/jbc.M405669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485848	hybrid			2022-12-25	WOS:000225793600016
J	Sell, DR; Monnier, VM				Sell, DR; Monnier, VM			Conversion of arginine into ornithine by advanced glycation in senescent human collagen and lens crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-ASPARTIC ACID; END-PRODUCTS; CROSS-LINKS; DIABETIC COMPLICATIONS; MAILLARD REACTION; SKIN COLLAGEN; PROTEIN; METHYLGLYOXAL; GLYCOXIDATION; PENTOSIDINE	Long lived proteins undergo age-related postsynthetic modifications that destabilize them by altering their conformation, charge, and helicity, thereby enhancing their resistance toward proteolysis and propensity to aggregate. The unexpected finding of substantial amounts of ornithine, the nonprotein amino acid, and decarbamidation product of arginine in acid hydrolysates of lens crystallins and skin collagen led us to investigate its source and mechanism of formation. In order to exclude ornithine formation as an artifact of acid hydrolysis, proteins were reductively alkylated with formaldehyde to convert ornithine to dimethyl-ornithine. The proteins were assayed for carboxymethyl-ornithine and glycated ornithine ("furornithine") by liquid chromatography coupled to electrospray ionization mass spectrometry. Ornithine in acid hydrolysates of human lens and skin proteins increased from 1 to 15 nmol/mg protein from ages 10 to 90 years, whereas dimethyl-ornithine increased from 0.5 to 15 and from 0 to 5 nmol/mg protein, respectively. Carboxymethyl-ornithine and furornithine increased with age in lens and skin from similar to0 to 60 and 0 to 180 pmol/mg protein, respectively. In collagen, ornithine was elevated above levels of nondiabetic controls only when both diabetes and end stage renal disease were present. The age-related increase of these modifications provides evidence for substantial in vivo formation of ornithine in aging human tissue proteins. The mechanism of ornithine formation is not known, but data suggest that arginine-derived advanced glycation end products might serve as precursors for the in vivo conversion of ornithine from arginine.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sell, DR (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	drs7@cwru.edu	Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018629] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007099, EY07099, R01 EY007099-17, R01 EY007099-18] Funding Source: Medline; NIA NIH HHS [AG18629] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AAKESSON I, 1971, EUR J CLIN INVEST, V1, P281, DOI 10.1111/eci.1971.1.4.281; Ahmed N, 2002, BIOCHEM J, V364, P1; Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573; Bailey AJ, 2001, MECH AGEING DEV, V122, P735, DOI 10.1016/S0047-6374(01)00225-1; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x; Biemel KM, 2001, NAHRUNG, V45, P210, DOI 10.1002/1521-3803(20010601)45:3&lt;210::AID-FOOD210&gt;3.0.CO;2-L; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Boonyakiat Y, 2001, J VIROL, V75, P10000, DOI 10.1128/JVI.75.20.10000-10004.2001; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; BUONO RD, 1991, DIFFERENTIATION, V46, P97; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; Chaimbault P, 1999, J CHROMATOGR A, V855, P191, DOI 10.1016/S0021-9673(99)00685-8; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; Liu BF, 2004, INVEST OPHTH VIS SCI, V45, P1983, DOI 10.1167/iovs.03-0995; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014; MOORE S, 1954, J BIOL CHEM, V211, P907; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Nelson D.L., 2004, PRINCIPLES BIOCH, V4th; Paul RG, 1998, BIOCHEM J, V330, P1241, DOI 10.1042/bj3301241; PIRIE A., 1965, INVEST OPHTHALMOL, V4, P629; RAMACHANDRULA A, 1992, J CELL SCI, V101, P859; SELL DR, 1993, DIABETOLOGIA, V36, P936, DOI 10.1007/BF02374476; Sell DR, 2003, J GERONTOL A-BIOL, V58, P508; Sell DR, 2000, FASEB J, V14, P145, DOI 10.1096/fasebj.14.1.145; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; SLETTEN K, 1971, NATURE-NEW BIOL, V231, P118, DOI 10.1038/newbio231118a0; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; THORNALLEY PJ, 2005, IN PRESS P 8 INT S M; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Vlassara H, 2004, REV ENDOCR METAB DIS, V5, P181, DOI 10.1023/B:REMD.0000032406.84813.f6; Vlassara H, 2003, MT SINAI J MED, V70, P232; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; Wilker SC, 2001, ANAL BIOCHEM, V290, P353, DOI 10.1006/abio.2001.4992; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yu H, 2003, J HISTOCHEM CYTOCHEM, V51, P1151, DOI 10.1177/002215540305100905	44	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54173	54184		10.1074/jbc.M408946200	http://dx.doi.org/10.1074/jbc.M408946200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15489230	hybrid			2022-12-25	WOS:000225793600036
J	Zhang, YH; Biggs, JR; Kraft, AS				Zhang, YH; Biggs, JR; Kraft, AS			Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CORE-BINDING-FACTOR; BLOCKS GRANULOCYTIC DIFFERENTIATION; IMMATURE MYELOID CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SYNERGISTICALLY ACTIVATE; GROWTH-INHIBITION; LEUKEMIC-CELLS; RUNT-DOMAIN; IN-VITRO	We find that phorbol ester (PE) treatment of K562 cells greatly stimulates promoters (T cell receptor beta, myeloperoxidase, macrophage colony-stimulating factor receptor, and granulocyte macrophage colony-stimulating factor receptor) containing AML1 transcription factor binding sites. This stimulation of AML1c transcriptional activity is mediated by direct phosphorylation of the AML1c molecule on multiple phosphorylation sites. Eleven AML1c (S/T)P sites in the transcriptional activating domain are phosphorylated at a basal level in untreated K562 cells; treatment of the K562 cells with PE results in increased phosphorylation at five of these sites (serines 276, 293, 303, 462, and threonine 300). Mutation of these five sites to alanine inhibits PE-induced transcriptional activity; mutation of the sites to an acidic amino acid, aspartic acid, stimulates constitutive activity. Single mutations in four amino acids or double mutations (serines 276 and 293 or threonine 300 and serine 303) have little effect on AML1c transcriptional activity. Inhibitor assays suggest that the ERK family of protein kinases is activated by PEs to phosphorylate the (S/T)P sites within the AML1c molecule and markedly enhance the transcriptional activity of AML1c.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina	Kraft, AS (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	Kraft@musc.edu			NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggs JR, 1998, CELL GROWTH DIFFER, V9, P667; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gonzalez R, 1999, MELANOMA RES, V9, P599, DOI 10.1097/00008390-199912000-00010; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; MURAKAMI K, 1993, ONCOGENE, V8, P1559; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Smithgall TE, 1998, PHARMACOL REV, V50, P1; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tonks A, 2003, BLOOD, V101, P624, DOI 10.1182/blood-2002-06-1732; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WOTTON D, 1993, LEUKEMIA, V7, pS55; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	40	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53116	53125		10.1074/jbc.M405502200	http://dx.doi.org/10.1074/jbc.M405502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475366	hybrid			2022-12-25	WOS:000225680600040
J	Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN				Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN			The interaction of p53 with replication protein A mediates suppression of homologous recombination	ONCOGENE			English	Article						p53; RPA; homologous recombination; replication	WILD-TYPE P53; STRAND BREAK REPAIR; DNA-BINDING DOMAIN; HUMAN RAD51; MUTANT P53; CELL-CYCLE; 3'-TO-5' EXONUCLEASE; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; RPA	The tumor suppressor protein p53 is emerging as a central regulator of homologous recombination (HR) processes and DNA replication. P53 may downregulate HR through multiple mechanisms including the reported associations with the Rad51 and Rad54 recombinases, and the BLM and WRN helicases. Here, we investigated whether the interaction of p53 with human replication protein A (RPA) is necessary for the regulation of HR. By employing a plasmid-based HR assay in p53-null H1299 lung carcinoma cells, we, studied the HR-suppressing properties of a panel of p53 mutants, which varied in their ability to interact with RPA. Both wild-type p53 and a transactivation-deficient p53 mutant (L22Q/W23S) suppressed HR and prevented RPA binding to ssDNA in vitro and in vivo. Conversely, p53 mutations that specifically disrupt the RPA-binding domain, while not compromising p53 transactivation function (D48H/D49H and W53S/F54S), did not affect HR. Suppression of HR was also not seen with missense mutations in the p53 core domain (His175 and His273), which retained the ability to interact with RPA, suggesting that the disruption of additional binding interactions of p53, for example, with Rad51 or recombination intermediates, also impacts on HR. We hypothesize that sequestration of RPA by p53 at the sites of recombination is one means by which p53 can inhibit HR processes. Our data support and extend the previously formulated 'dual model' of p53's role as guardian of the genome.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA; New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA	Harvard University; Massachusetts General Hospital; New York Medical College	Powell, SN (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA.	snpowell@partners.org			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Alberts B, 2003, NATURE, V421, P431, DOI 10.1038/nature01407; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Linke SP, 2003, CANCER RES, V63, P2596; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; Wiese C, 2001, CANCER RES, V61, P1129; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Willers Henning, 2002, Journal of Biomedicine & Biotechnology, V2, P86, DOI 10.1155/S1110724302204027; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhou JM, 2003, NUCLEIC ACIDS RES, V31, P3881, DOI 10.1093/nar/gkg468; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	73	72	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9025	9033		10.1038/sj.onc.1207982	http://dx.doi.org/10.1038/sj.onc.1207982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489903				2022-12-25	WOS:000225492800003
J	Kriem, B; Sponne, I; Fifre, A; Malaplate-Armand, C; Lozac'h-Pillot, K; Koziel, V; Yen-Potin, FT; Bihain, B; Oster, T; Olivier, JL; Pillot, T				Kriem, B; Sponne, I; Fifre, A; Malaplate-Armand, C; Lozac'h-Pillot, K; Koziel, V; Yen-Potin, FT; Bihain, B; Oster, T; Olivier, JL; Pillot, T			Cytosolic phospholipase A(2) mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide	FASEB JOURNAL			English	Article						Alzheimer's disease; arachidonic acid	CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; A-BETA; A(2) CPLA(2); CELL-DEATH; MEMBRANE; ACTIVATION; IMMUNOREACTIVITY; TRANSLOCATION; A-BETA(1-42)	Recent data have revealed that soluble oligomeric forms of amyloid peptide (Abeta) may be the proximate effectors of the neuronal injury and death occurring in Alzheimer's disease (AD). However, the molecular mechanisms associated with the neuronal cell death induced by the nonfibrillar Abeta remain to be elucidated. In this study, we investigated the role of the cytosolic Ca2+-dependent phospholipase A(2) (cPLA(2)), and its associated metabolic pathway, i.e., the arachidonic acid (AA) cascade, in the apoptotic cell death induced by soluble oligomers of Abeta. The treatment of rat cortical neurons with low concentrations of soluble Abeta (1-40) or Abeta (1-42) peptide resulted in an early calcium-dependent release of AA associated with a transient relocalization of cPLA(2). Both cPLA(2) antisense oligonucleotides and a selective inhibitor of cPLA2 activity abolished the release of AA from neurons and also protected cells against apoptosis induced by Abeta. Furthermore, inhibitors of the PKC, p38, and MEK/ERK pathways that are involved in cPLA(2) phosphorylation and activation reduced Abeta-induced cell death. Finally, we demonstrate that inhibitors of cyclooxygenase-2 reduced the Abeta-induced cell death by 55%. Our studies suggest a novel neuronal response of soluble oligomers of Abeta, which occurs through a cPLA(2) signaling cascade and an AA-dependent death pathway. This may prove to be crucial in AD processes and could provide important targets for drug development.	Univ Nancy 1, Fac Med, INSERM, EMI 0014, F-54505 Vandoeuvre Les Nancy, France; Lab Med & Therapeut Mol, F-54505 Vandoeuvre Les Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Pillot, T (corresponding author), Univ Nancy 1, Fac Med, INSERM, EMI 0014, 9 Ave Foret Haye, F-54505 Vandoeuvre Les Nancy, France.	Thierry.Pillot@medecine.uhp-nancy.fr	Yen, Frances T/G-9175-2014; Olivier, Jean luc/AAQ-2721-2021	Yen, Frances T/0000-0001-8740-4304; 				Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Arai K, 2001, EUR J NEUROSCI, V13, P2319, DOI 10.1046/j.0953-816x.2001.01623.x; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Drouet B, 2000, CELL MOL LIFE SCI, V57, P705, DOI 10.1007/s000180050035; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Estus S, 1997, J NEUROSCI, V17, P7736; Evans JH, 2004, MOL BIOL CELL, V15, P371, DOI 10.1091/mbc.e03-05-0338; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Farooqui AA, 1990, DEMENTIA, V1, P208, DOI DOI 10.1159/000107144; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Klapisz E, 1999, EUR J BIOCHEM, V265, P957, DOI 10.1046/j.1432-1327.1999.00797.x; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kramer RM, 1996, J LIPID MEDIAT CELL, V14, P3, DOI 10.1016/0929-7855(96)01501-5; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MCCLURE RJ, 1994, ANN NY ACAD SCI, V747, P110; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pettegrew JW, 2001, NEUROCHEM RES, V26, P771, DOI 10.1023/A:1011603916962; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sponne I, 2003, J BIOL CHEM, V278, P3437, DOI 10.1074/jbc.M206745200; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Stephenson DT, 1996, NEUROBIOL DIS, V3, P51, DOI 10.1006/nbdi.1996.0005; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; VIAL D, 1995, J NEUROCHEM, V64, P2765; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	43	113	114	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					85	+		10.1096/fj.04-1807fje	http://dx.doi.org/10.1096/fj.04-1807fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15486059				2022-12-25	WOS:000224849900020
J	Balashova, N; Chang, FJ; Lamothe, M; Sun, Q; Beuve, A				Balashova, N; Chang, FJ; Lamothe, M; Sun, Q; Beuve, A			Characterization of a novel type of endogenous activator of soluble guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; HEAT-SHOCK-PROTEIN; NITRIC-OXIDE RECEPTOR; YC-1 ACTIVATION; CHAPERONE; BINDING; PURIFICATION; KINETICS; SYNTHASE; ADENYLYL	Nitric oxide (NO) remains the only firmly established endogenous modulator of soluble guanylyl cyclase (sGC) activity, but physiological, structural, and biochemical evidence now suggests that in vivo regulation of sGC involves direct interaction with other factors. We searched for such endogenous modulators in human umbilical vein endothelial cells and COS-7 cells. The cytosolic fraction of both cell types stimulated the activity of semipurified sGC severalfold in the absence or presence of a saturating concentration of NO. The cytosolic factor was sensitive to proteinase K and destroyed by boiling, suggesting that it contains a protein component. Size exclusion chromatography revealed peaks of activity between 40 and 70 kDa. The sGC-activating effect was further purified by ion exchange chromatography. In the presence of the benzylindazole YC-1 or NO, the partially purified factor synergistically activated sGC, suggesting that this factor had a mode of activation different from that of YC-1 or NO. Four candidate activators were identified from the final purification step by matrix-assisted laser desorption ionization mass spectrometry analysis. Using an sGC affinity matrix, one of them, the molecular chaperone Hsp70, was shown to directly interact with sGC. This interaction was further confirmed by co-immunoprecipitation in lung tissues and by co-localization in smooth muscle cells. sGC and Hsp70 co-localized at the plasma membrane, supporting the idea that sGC can be translocated to the membrane. Hsp70 co-purifies with the sGC-activating effect, and immunodepletion of Hsp70 from COS-7 cytosol coincided with a marked attenuation of the sGC- activating effect, yet the effect was not rescued by the addition of pure Hsp70. Thus, Hsp70 is a novel sGC- interacting protein that is responsible for the sGC- activating effect, probably in association with other factors or after covalent modification.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Beuve, A (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	annie.beuve@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067640] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM067640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Bellamy TC, 2002, MOL CELL BIOCHEM, V230, P165, DOI 10.1023/A:1014204426331; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Condorelli P, 2001, BIOPHYS J, V80, P2110, DOI 10.1016/S0006-3495(01)76184-X; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1998, MOL PHARMACOL, V53, P123, DOI 10.1124/mol.53.1.123; GARBERS DL, 1979, J BIOL CHEM, V254, P240; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Hanafy KA, 2004, J BIOL CHEM, V279, P46946, DOI 10.1074/jbc.M404134200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kim HJ, 2002, J BIOL CHEM, V277, P23193, DOI 10.1074/jbc.M201007200; KIM TD, 1994, J BIOL CHEM, V269, P15540; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Koesling D, 1999, METHODS, V19, P485, DOI 10.1006/meth.1999.0891; Kumar R, 2001, J BIOL CHEM, V276, P11371, DOI 10.1074/jbc.M010480200; Lamothe M, 2004, BIOCHEMISTRY-US, V43, P3039, DOI 10.1021/bi0360051; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; Meurer S, 2004, J BIOL CHEM, V279, P49346, DOI 10.1074/jbc.M410565200; Musch MW, 1999, GASTROENTEROLOGY, V117, P115, DOI 10.1016/S0016-5085(99)70557-3; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Schmidt K, 2001, MOL PHARMACOL, V59, P220, DOI 10.1124/mol.59.2.220; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tzima E, 2000, EUR J BIOCHEM, V267, P4720, DOI 10.1046/j.1432-1327.2000.01525.x; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	46	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2005	280	3					2186	2196		10.1074/jbc.M411545200	http://dx.doi.org/10.1074/jbc.M411545200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	887YP	15509556	hybrid			2022-12-25	WOS:000226341700054
J	Feinberg, H; Guo, Y; Mitchell, DA; Drickamer, K; Weis, WI				Feinberg, H; Guo, Y; Mitchell, DA; Drickamer, K; Weis, WI			Extended neck regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CARBOHYDRATE-RECOGNITION; SELECTIVE RECOGNITION; STRUCTURAL BASIS; BINDING; PROTEINS; NONINTEGRIN; DISTINCT; DOMAINS	The human cell surface receptors DC-SIGN ( dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin) and DC-SIGNR (DC-SIGN-related) bind to oligosaccharide ligands found on human tissues as well as on pathogens including viruses, bacteria, and parasites. The extracellular portion of each receptor contains a membrane-distal carbohydrate-recognition domain (CRD) and forms tetramers stabilized by an extended neck region consisting of 23 amino acid repeats. Cross-linking analysis of full-length receptors expressed in fibroblasts confirms the tetrameric state of the intact receptors. Hydrodynamic studies on truncated receptors demonstrate that the portion of the neck of each protein adjacent to the CRD is sufficient to mediate the formation of dimers, whereas regions near the N terminus are needed to stabilize the tetramers. Some of the intervening repeats are missing from polymorphic forms of DC-SIGNR. Two different crystal forms of truncated DC-SIGNR comprising two neck repeats and the CRD reveal that the CRDs are flexibly linked to the neck, which contains alpha-helical segments interspersed with non-helical regions. Differential scanning calorimetry measurements indicate that the neck and CRDs are independently folded domains. Based on the crystal structures and hydrodynamic data, models for the full extracellular domains of the receptors have been generated. The observed flexibility of the CRDs in the tetramer, combined with previous data on the specificity of these receptors, suggests an important role for oligomerization in the recognition of endogenous glycans, in particular those present on the surfaces of enveloped viruses recognized by these proteins.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Stanford University; Stanford University; University of Oxford	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011; Mitchell, Daniel A/A-6580-2009; Guo, Yuan/B-1319-2018	Weis, William I/0000-0002-5583-6150; Mitchell, Daniel A/0000-0003-0936-6212; Guo, Yuan/0000-0003-4607-7356; Drickamer, Kurt/0000-0001-5026-5996	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Crocker PR, 1997, GLYCOCONJUGATE J, V14, P601, DOI 10.1023/A:1018588526788; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Soilleux EJ, 2003, CLIN SCI, V104, P437, DOI 10.1042/CS20020092; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; Su SV, 2004, J BIOL CHEM, V279, P19122, DOI 10.1074/jbc.M400184200; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	29	147	158	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1327	1335		10.1074/jbc.M409925200	http://dx.doi.org/10.1074/jbc.M409925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15509576	hybrid			2022-12-25	WOS:000226195200058
J	Kim, KJ; Chung, JW; Kim, KS				Kim, KJ; Chung, JW; Kim, KS			67-kDa laminin receptor promotes internalization of cytotoxic necrotizing factor 1-expressing Escherichia coli K1 into human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; BACTERIAL-MENINGITIS; INVASION; PROTEIN; TRANSLOCATION; CONTRIBUTES; ACTIVATION; EXPRESSION; PRECURSOR	Escherichia coli K1 is the most common Gram-negative organism causing meningitis, and its invasion of human brain microvascular endothelial cells (HBMEC) is a prerequisite for penetration into the central nervous system. We have reported previously that cytotoxic necrotizing factor 1 (CNF1) contributes to E. coli K1 invasion of HBMEC and interacts with 37-kDa laminin receptor precursor (37LRP) of HBMEC, which is a precursor of 67-kDa laminin receptor (67LR). In the present study, we examined the role of 67LR in the CNF1-expressing E. coli K1 invasion of HBMEC. Immunofluorescence microscopy and ligand overlay assays showed that 67LR is present on the HBMEC membrane and interacts with CNF1 protein as well as the CDPGYIGSR laminin peptide. 67LR was up-regulated and clustered at the sites of E. coli K1 on HBMEC in a CNF1-dependent manner. Pretreatment of CNF1 + E. coli K1 with recombinant 37-kDa laminin receptor precursor reduced the invasion rate to the level of Deltacnf1 mutant, and the invasion rate of CNF1 + E. coli K1 was enhanced in 67LR-overexpressing HBMEC, indicating 67LR is involved in the CNF1 + E. coli K1 invasion of HBMEC. Coimmunoprecipitation analysis showed that, upon incubation with CNF1 + E. coli K1 but not with Deltacnf1 mutant, focal adhesion kinase and paxillin were recruited and associated with 67LR. When immobilized onto polystyrene beads, CNF1 was sufficient to induce internalization of coupled beads into HBMEC through interaction with 67LR. Taken together, this is the first demonstration that E. coli K1 invasion of HBMEC occurs through the ligand-receptor (CNF1-67LR) interaction, and 67LR promotes CNF1-expressing E. coli K1 internalization of HBMEC.	Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, Baltimore, MD 21287 USA	Johns Hopkins University	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.	kwangkim@jhmi.edu			NIAID NIH HHS [AI 47225] Funding Source: Medline; NINDS NIH HHS [NS 26310] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310, R56NS026310] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boquet P, 2001, TOXICON, V39, P1673, DOI 10.1016/S0041-0101(01)00154-4; Chung JW, 2003, J BIOL CHEM, V278, P16857, DOI 10.1074/jbc.M301028200; CODY RL, 1986, EXP CELL RES, V165, P107, DOI 10.1016/0014-4827(86)90536-7; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; Dawson KG, 1999, PEDIATR INFECT DIS J, V18, P816, DOI 10.1097/00006454-199902000-00015; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Fabbri A, 2002, INT J MED MICROBIOL, V291, P551; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gingras D, 2000, BIOCHEM J, V348, P273, DOI 10.1042/0264-6021:3480273; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Kim KJ, 2003, CELL MICROBIOL, V5, P245, DOI 10.1046/j.1462-5822.2003.t01-1-00271.x; Kim KS, 2003, NAT REV NEUROSCI, V4, P376, DOI 10.1038/nrn1103; Kim KS, 2001, INFECT IMMUN, V69, P5217, DOI 10.1128/IAI.69.9.5217-5222.2001; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; ROMANOV VI, 1995, BIOCHEM BIOPH RES CO, V208, P637, DOI 10.1006/bbrc.1995.1386; Scott WN, 2000, BBA-PROTEIN STRUCT M, V1481, P25, DOI 10.1016/S0167-4838(00)00120-5; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; YANNARIELLOBROWN J, 1988, J CELL BIOL, V106, P1773, DOI 10.1083/jcb.106.5.1773	29	104	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					1360	1368		10.1074/jbc.M410176200	http://dx.doi.org/10.1074/jbc.M410176200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15516338	hybrid			2022-12-25	WOS:000226195200062
J	Anrather, J; Racchumi, G; Iadecola, C				Anrather, J; Racchumi, G; Iadecola, C			cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CASEIN KINASE-II; P65 SUBUNIT; ENDOTHELIAL-CELLS; INDEPENDENT MECHANISM; ACTIVATION; GENE; EXPRESSION; BINDING; ALPHA	Phosphorylation of nuclear factor-kappaB (NF-kappaB) subunits emerges as a mechanism by which transcriptional activity of nuclear NF-kappaB complexes is regulated in an inhibitor kappaB-independent fashion. As the main transactivator, the p65 subunit of NF-kappaB has an outstanding position in the hierarchy of NF-kappaB proteins. p65 is a multiply phosphorylated protein with phosphorylation sites in the C-terminal transactivation domain and the N-terminal Rel homology domain (RHD). In this study, we describe two previously non-reported phospho-acceptor sites within the p65 RHD. We show that differential phosphorylation of serine residues within the RHD modulates transcriptional activity in a cis-acting element and promoter-specific context, thus leading to a phosphorylation state-dependent gene expression profile. RelA(-/-) mouse embryonic fibroblasts reconstituted with wild-type p65 or p65 phosphorylation-deficient mutants showed a distinctive expression profile of synthetic kappaB-dependent reporters as well as endogenous genes. Hypophosphorylated p65 did not display cis-acting element-specific changes in DNA binding or dimerization behavior. This study shows for the first time that site-specific phosphorylation can target a transcription factor to a particular subset of genes.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY 10021 USA	Cornell University	Anrather, J (corresponding author), 411 E 69th St,Rm KB410, New York, NY 10021 USA.	joa2006@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059476] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59476] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Brostjan C, 1997, J IMMUNOL, V158, P3836; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; KAWAI M, 1995, J IMMUNOL, V154, P2333; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	43	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					244	252		10.1074/jbc.M409344200	http://dx.doi.org/10.1074/jbc.M409344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15516339	hybrid			2022-12-25	WOS:000226025100030
J	Ge, WW; Wen, WY; Strong, W; Leystra-Lantz, C; Strong, MJ				Ge, WW; Wen, WY; Strong, W; Leystra-Lantz, C; Strong, MJ			Mutant copper-zinc superoxide dismutase binds to and destabilizes human low molecular weight neurofilament mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; 3' UNTRANSLATED REGION; MOTOR-NEURON DISEASE; MYOTONIC-DYSTROPHY; 3'-UNTRANSLATED REGION; SELECTIVE LOSS; SPINAL-CORD; MOUSE MODEL; CTG REPEAT; NF-L	The mechanism by which mutated copper-zinc superoxide dismutase (SOD1) causes familial amyotrophic lateral sclerosis is believed to involve an adverse gain of function, independent of the physiological antioxidant enzymatic properties of SOD1. In this study, we have observed that mutant SOD1 (G41S, G85A, and G93A) but not the wild type significantly reduced the stability of the low molecular weight neurofilament mRNA in a dosage-dependent manner. We have also demonstrated that mutant SOD1 but not the wild type bound directly to the neurofilament mRNA 3'-untranslated region and that the binding was necessary to induce mRNA destabilization. These observations provide an explanation for a novel gain of function in which mutant SOD1 expression in motor neurons alters an intermediate filament protein expression.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Strong, MJ (corresponding author), Rm 7OF10,UC-LHSC,339 Windermere Rd, London, ON N6A 5A5, Canada.	mstrong@uwo.ca	Strong, Michael/AAU-5699-2020; Strong, Michael J/H-9689-2012	Strong, Michael/0000-0003-1988-6262; 				Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Canete-Soler R, 1998, J BIOL CHEM, V273, P12655, DOI 10.1074/jbc.273.20.12655; Canete-Soler R, 1998, J BIOL CHEM, V273, P12650, DOI 10.1074/jbc.273.20.12650; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Ge WW, 2003, J BIOL CHEM, V278, P26558, DOI 10.1074/jbc.M302886200; Ge WW, 2002, J BIOL CHEM, V277, P42701, DOI 10.1074/jbc.M206635200; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; JANSEN G, 1996, NAT GENET, V13, pB316; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Lin H, 2004, J NEUROSCI, V24, P2716, DOI 10.1523/JNEUROSCI.5689-03.2004; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Menzies FM, 2002, J NEUROCHEM, V82, P1118, DOI 10.1046/j.1471-4159.2002.01045.x; Nabors LLB, 2003, CANCER RES, V63, P4181; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Ranum LPW, 2004, AM J HUM GENET, V74, P793, DOI 10.1086/383590; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Robertson J, 2003, J CELL BIOL, V160, P939, DOI 10.1083/jcb.200205027; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Strong MJ, 2003, PHARMACOL THERAPEUT, V98, P379, DOI 10.1016/S0163-7258(03)00040-8; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Wong NKY, 2000, J NEUROPATH EXP NEUR, V59, P972, DOI 10.1093/jnen/59.11.972; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200	42	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					118	124		10.1074/jbc.M405065200	http://dx.doi.org/10.1074/jbc.M405065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507437	hybrid			2022-12-25	WOS:000226025100016
J	Kim, JS; Coon, SL; Blackshaw, S; Cepko, CL; Moller, M; Mukda, S; Zhao, WQ; Charlton, CG; Klein, DC				Kim, JS; Coon, SL; Blackshaw, S; Cepko, CL; Moller, M; Mukda, S; Zhao, WQ; Charlton, CG; Klein, DC			Methionine adenosyltransferase: Adrenergic-cAMP mechanism regulates a daily rhythm in pineal expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE SYNTHETASE; MELATONIN SYNTHESIS; SK-N-BE(2)C CELLS; GLAND; RAT; GENE; TRANSCRIPTION; BIOSYNTHESIS; HYDROXYLASE	(S)-Adenosylmethionine (SAM) is a critical element of melatonin synthesis as the methyl donor in the last step of the pathway, the O-methylation of N-acetyl 5-hydroxytryptamine by hydroxyindole-O-methyltransferase. The activity of the enzyme that synthesizes SAM, methionine adenosyltransferase (MAT), increases 2.5-fold at night in the pineal gland. In this study, we found that pineal MAT2A mRNA and the protein it encodes, MAT II, also increase at night, suggesting that the increase in MAT activity is caused by an increase in MAT II gene products. The night levels of MAT2A mRNA in the pineal gland were severalfold higher than in other neural and non-neural tissues examined, consistent with the requirement for SAM in melatonin synthesis. Related studies indicate that the nocturnal increase in MAT2A mRNA is caused by activation of a well described neural pathway that mediates photoneural-circadian regulation of the pineal gland. MAT2A mRNA and MAT II protein were increased in organ culture by treatment with norepinephrine ( NE), the sympathetic neurotransmitter that stimulates the pineal gland at night. NE is known to markedly elevate pineal cAMP, and here it was found that cAMP agonists elevate MAT2A mRNA levels by increasing MAT2A mRNA synthesis and that drugs that block cAMP activation of cAMP dependent protein kinase block effects of NE. Therefore, the NE-cAMP dependent increase in pineal MAT activity seems to reflect an increase in MAT II protein, which occurs in response to cAMP-->protein kinase-dependent increased MAT2A expression. The existence of this MAT regulatory system underscores the importance that MAT plays in melatonin biogenesis. These studies also point to the possibility that SAM production in other tissues might be regulated through cAMP.	NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Copenhagen, Panum Inst, Inst Med Anat, DK-2200 Copenhagen N, Denmark; Mahidol Univ, Neurobehav Biol Ctr, Inst Sci & Technol Res & Dev, Nakhon Pathom 73170, Thailand; Meharry Med Coll, Nashville, TN 37208 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School; University of Copenhagen; Mahidol University; Meharry Medical College	Klein, DC (corresponding author), NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bldg 49,Rm 6A82, Bethesda, MD 20892 USA.	klein@helix.nih.gov		Klein, David/0000-0002-1792-5806	NEI NIH HHS [EY08064] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000095, Z01HD000095] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008064] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALER R, 1995, J BIOL CHEM, V270, P27319, DOI 10.1074/jbc.270.45.27319; Blackshaw S, 1997, J NEUROSCI, V17, P8074; Bottiglieri T, 2002, AM J CLIN NUTR, V76, p1151S, DOI 10.1093/ajcn/76.5.1151S; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Ganguly S, 2002, CELL TISSUE RES, V309, P127, DOI 10.1007/s00441-002-0579-y; Goldstein A, 1964, BIOSTATISTICS INTRO; GUCHHAIT RB, 1978, J NEUROCHEM, V31, P921, DOI 10.1111/j.1471-4159.1978.tb00128.x; GUCHHAIT RB, 1981, J NEUROCHEM, V36, P2092, DOI 10.1111/j.1471-4159.1981.tb10840.x; GUCHHAIT RB, 1976, J NEUROCHEM, V26, P187; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Hiroki T, 1997, EUR J BIOCHEM, V250, P653, DOI 10.1111/j.1432-1033.1997.00653.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Humphries A, 2002, J NEUROENDOCRINOL, V14, P101, DOI 10.1046/j.0007-1331.2001.00738.x; Kim JS, 1996, MOL BRAIN RES, V39, P177, DOI 10.1016/0169-328X(96)00023-X; Kim JS, 1997, MOL BRAIN RES, V51, P154, DOI 10.1016/S0169-328X(97)00227-1; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LOSADA MEO, 1989, EUR J PHARMACOL, V163, P353; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mischoulon D, 2002, AM J CLIN NUTR, V76, p1158S, DOI 10.1093/ajcn/76.5.1158S; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; Moller M, 1997, CELL TISSUE RES, V288, P279, DOI 10.1007/s004410050813; MUDD SH, 1962, J BIOL CHEM, V237, P1372; PARFITT A, 1976, NEUROPHARMACOLOGY, V15, P353, DOI 10.1016/0028-3908(76)90083-6; PARFITT AG, 1976, ENDOCRINOLOGY, V99, P840, DOI 10.1210/endo-99-3-840; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; SITARAM BR, 1995, J NEUROCHEM, V65, P1887; Smith M, 2001, MOL CELL BIOL, V21, P3704, DOI 10.1128/MCB.21.11.3704-3713.2001; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; Swanson DJ, 1998, J BIOL CHEM, V273, P24065, DOI 10.1074/jbc.273.37.24065; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Zeng ZH, 2001, BIOCHEM J, V353, P163, DOI 10.1042/bj3530163; Zhao WQ, 2001, EXP NEUROL, V171, P127, DOI 10.1006/exnr.2001.7726	35	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					677	684		10.1074/jbc.M408438200	http://dx.doi.org/10.1074/jbc.M408438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15504733	hybrid			2022-12-25	WOS:000226025100080
J	Mukhopadhyay, S; Langsetmo, K; Stafford, WF; Henry, GD; Baleja, JD; Sarkar, S				Mukhopadhyay, S; Langsetmo, K; Stafford, WF; Henry, GD; Baleja, JD; Sarkar, S			Identification of a region of fast skeletal troponin T required for stabilization of the coiled-coil formation with troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE THIN FILAMENT; COMPARATIVE SEQUENCE-ANALYSIS; REGULATORY SYSTEM; CROSS-LINKING; CONTRACTION; BINDING; DOMAIN; TROPOMYOSIN; STABILITY; ISOFORMS	We have previously identified evolutionarily conserved heptad hydrophobic repeat (HR) domains in all isoprotein members of troponin T (TnT) and troponin I (TnI), two subunits of the Ca2+-regulatory troponin complex. Our suggestion that the HR domains are involved in the formation of a coiled-coil heterodimer of TnT and TnI has been recently confirmed by the crystal structure of the core domain of the human cardiac troponin complex. Here we studied a series of recombinant deletion mutants of the fast skeletal TnT to determine the minimal sequence required for stable coiled-coil formation with the HR domain of the fast skeletal TnI. Using circular dichroism spectroscopy, we measured the alpha helical content of the coiled-coil formed by the various TnT peptides with TnI HR domain. Sedimentation equilibrium experiments confirmed that the individual peptides of TnT were monomeric but formed heterodimers when mixed with HR domain of TnI. Isothermal titration calorimetry was then used to directly measure the affinity of the TnT peptides for the TnI HR domain. Surprisingly we found that the HR regions alone of the fast skeletal TnT and TnI, as defined earlier, were insufficient to form a coiled-coil. Furthermore we showed that an additional 14 amino acid residues N-terminal to the conserved HR region ( TnT residues 165-178) are essential for the stable coiled-coil formation. We discuss the implication of our finding in the fast skeletal troponin isoform in the light of the crystal structure of the cardiac isoform.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Univ Calcutta, Univ Coll Sci, Dept Biochem, Kolkata 700019, W Bengal, India; Boston Biomed Res Inst, Watertown, MA 02472 USA	Tufts University; Tufts University; Tufts University; University of Calcutta; Boston Biomedical Research Institute	Sarkar, S (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, M&V 519,136 Harrison Ave, Boston, MA 02111 USA.	satyapriya.sarkar@tufts.edu	Stafford, Walter/ABC-6553-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067985] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL39374] Funding Source: Medline; NICHD NIH HHS [P01-HD 23681] Funding Source: Medline; NIGMS NIH HHS [GM 067985] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blumenschein TMA, 2001, J BIOL CHEM, V276, P36606, DOI 10.1074/jbc.M105130200; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Dutta K, 2001, PROTEIN SCI, V10, P2531, DOI 10.1110/ps.ps.28801; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Jha PK, 1996, BIOCHEMISTRY-US, V35, P16573, DOI 10.1021/bi9622433; Jha PK, 1998, BIOCHEMISTRY-US, V37, P12253, DOI 10.1021/bi980025z; John DM, 2000, PROTEIN SCI, V9, P1416, DOI 10.1110/ps.9.7.1416; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Meier M, 2002, J STRUCT BIOL, V137, P65, DOI 10.1006/jsbi.2002.4467; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; PEARLSTONE JR, 1980, CAN J BIOCHEM, V56, P659; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Stefancsik R, 2003, COMP FUNCT GENOM, V4, P609, DOI 10.1002/cfg.343; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Vu C, 2001, PROTEIN SCI, V10, P631, DOI 10.1110/ps.41101; WU QL, 1993, DNA SEQUENCE, V4, P113, DOI 10.3109/10425179309020150; WU QL, 1994, DNA CELL BIOL, V13, P217, DOI 10.1089/dna.1994.13.217; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	36	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2005	280	1					538	547		10.1074/jbc.M409537200	http://dx.doi.org/10.1074/jbc.M409537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	883PG	15507453	hybrid			2022-12-25	WOS:000226025100064
J	Schneider, U; Blechschmidt, K; Schwemmle, M; Staeheli, P				Schneider, U; Blechschmidt, K; Schwemmle, M; Staeheli, P			Overlap of interaction domains indicates a central role of the P protein in assembly and regulation of the Borna disease virus polymerase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; STRAND RNA VIRUS; RESPIRATORY SYNCYTIAL VIRUS; INFECTED-CELLS; GENOME REPLICATION; PHOSPHOPROTEIN P; X-PROTEIN; IN-VITRO; TRANSCRIPTION; SYSTEM	The active polymerase complex of Borna disease virus is composed of the viral proteins N, P, and L. The viral X ( negative regulatory factor) protein acts as a regulator of polymerase activity. Interactions of P with N and X were previously studied, but interactions with L were poorly defined. Using a mammalian two-hybrid system, we observed that L specifically interacts with P but not with N, X, or itself. Mapping of the L-binding domain in the P molecule revealed that it overlaps with two adjacent domains required for multimerization and interaction with N. Competition experiments showed that the interaction between L and P was inefficient when N was present, indicating that L may preferentially interact with free P in infected cells. Interestingly, a multimerization-defective P mutant maintained the ability to interact with L, N, and X but failed to support reporter gene expression from an artificial Borna disease virus minigenome. Furthermore, dominant negative effects on minigenome activity were only observed when P mutants with an intact multimerization domain were used, suggesting that P multimers, rather than monomers, exhibit biological activity. P mutants lacking functional interaction domains for L or N still formed complexes with these viral proteins when wild-type P was available as a bridging molecule, indicating that P multimers have the potential to act as scaffolds on which the RNA polymerase complex is assembled.	Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany	University of Freiburg	Schneider, U (corresponding author), Univ Freiburg, Dept Virol, Hermann Herder Str 11, D-79104 Freiburg, Germany.	urs.schneider@uniklinik-freiburg.de; peter.staeheli@uniklinik-freiburg.de						Atreya PL, 1998, J VIROL, V72, P1452, DOI 10.1128/JVI.72.2.1452-1461.1998; Berg M, 1998, J GEN VIROL, V79, P2957, DOI 10.1099/0022-1317-79-12-2957; Billich C, 2002, BIOL PSYCHIAT, V51, P979, DOI 10.1016/S0006-3223(02)01387-2; BRIESE T, 1994, P NATL ACAD SCI USA, V91, P4362, DOI 10.1073/pnas.91.10.4362; BRIESE T, 1992, P NATL ACAD SCI USA, V89, P11486, DOI 10.1073/pnas.89.23.11486; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Cadd T, 1996, J VIROL, V70, P5067, DOI 10.1128/JVI.70.8.5067-5074.1996; Choudhary SK, 2002, VIROLOGY, V302, P373, DOI 10.1006/viro.2002.1668; Collins PL, 1996, P NATL ACAD SCI USA, V93, P81, DOI 10.1073/pnas.93.1.81; CUBITT B, 1994, J VIROL, V68, P1371, DOI 10.1128/JVI.68.3.1371-1381.1994; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; Curran J, 1998, J VIROL, V72, P4274, DOI 10.1128/JVI.72.5.4274-4280.1998; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; De BP, 2000, J VIROL, V74, P5886, DOI 10.1128/JVI.74.13.5886-5895.2000; de la Torre JC, 2002, J INFECT DIS, V186, pS241, DOI 10.1086/344936; GAO Y, 1995, J VIROL, V69, P7718, DOI 10.1128/JVI.69.12.7718-7723.1995; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HORIKAMI SM, 1995, VIROLOGY, V211, P577, DOI 10.1006/viro.1995.1440; Kobayashi T, 2003, J VIROL, V77, P8099, DOI 10.1128/JVI.77.14.8099-8107.2003; Lee KJ, 2000, J VIROL, V74, P3470, DOI 10.1128/JVI.74.8.3470-3477.2000; MURPHY MF, 1974, CELL, V3, P77, DOI 10.1016/0092-8674(74)90043-9; Pattnaik AK, 1997, J VIROL, V71, P8167, DOI 10.1128/JVI.71.11.8167-8175.1997; PATTNAIK AK, 1992, CELL, V69, P1011, DOI 10.1016/0092-8674(92)90619-N; Perez M, 2003, J GEN VIROL, V84, P3099, DOI 10.1099/vir.0.19467-0; Poenisch M, 2004, J GEN VIROL, V85, P1895, DOI 10.1099/vir.0.80002-0; SCHNEEMANN A, 1994, J VIROL, V68, P6514, DOI 10.1128/JVI.68.10.6514-6522.1994; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; SCHNEIDER PA, 1994, J VIROL, V68, P5007, DOI 10.1128/JVI.68.8.5007-5012.1994; Schneider U, 2003, J VIROL, V77, P11781, DOI 10.1128/JVI.77.21.11781-11789.2003; Schwemmle M, 1998, J BIOL CHEM, V273, P9007, DOI 10.1074/jbc.273.15.9007; Staeheli P, 2000, J GEN VIROL, V81, P2123, DOI 10.1099/0022-1317-81-9-2123; TAKACS AM, 1993, P NATL ACAD SCI USA, V90, P10375, DOI 10.1073/pnas.90.21.10375; Tarbouriech N, 2000, NAT STRUCT BIOL, V7, P777; Tober C, 1998, J VIROL, V72, P8124, DOI 10.1128/JVI.72.10.8124-8132.1998; Walker MP, 2000, J VIROL, V74, P4425, DOI 10.1128/JVI.74.9.4425-4428.2000; Watanabe K, 1996, J VIROL, V70, P241, DOI 10.1128/JVI.70.1.241-247.1996; Weber F, 2001, VIROLOGY, V281, P67, DOI 10.1006/viro.2000.0774; Wolff T, 2000, J GEN VIROL, V81, P939, DOI 10.1099/0022-1317-81-4-939	40	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55290	55296		10.1074/jbc.M408913200	http://dx.doi.org/10.1074/jbc.M408913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15509569	hybrid			2022-12-25	WOS:000225960800040
J	Chami, M; Prandini, A; Campanella, M; Pinton, P; Szabadkai, G; Reed, JC; Rizzuto, R				Chami, M; Prandini, A; Campanella, M; Pinton, P; Szabadkai, G; Reed, JC; Rizzuto, R			Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; CELL-DEATH; APOPTOSIS; CALCIUM; MITOCHONDRIA; PROTEIN; HOMEOSTASIS; RECEPTOR	Recent work has shown that Bcl-2 and other antiapoptotic proteins partially deplete the endoplasmic reticulum (ER) Ca2+ store and that this alteration of Ca2+ signaling reduces cellular sensitivity to apoptotic stimuli. We expressed in HeLa cells Bcl-2, Bax, and Bcl-2/Bax chimeras in which the putative pore-forming domains of the two proteins (alpha5-alpha6) were mutually swapped, comparing the effects on Ca2+ signaling of the two proteins and relating them to defined molecular domains. The results showed that only Bcl-2 reduces ER Ca2+ levels and that this effect does not depend on the alpha5-alpha6 helices of this oncoprotein. Soon after its expression, Bax increased ER Ca2+ loading, with ensuing potentiation of mitochondrial Ca2+ responses. Then the cells progressed into an apoptotic phenotype (which included drastic reductions of cytosolic and mitochondrial Ca2+ responses and alterations of organelle morphology). These results provide a coherent scenario that highlights a primary role of Ca2+ signals in deciphering apoptotic stimuli.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	University of Ferrara; University of Ferrara; Sanford Burnham Prebys Medical Discovery Institute	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via L Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	Rizzuto, Rosario/B-6312-2008; Pinton, Paolo/J-8025-2012; Chami, Mounia/S-6471-2019; Campanella, Michelangelo/K-8172-2016	Pinton, Paolo/0000-0001-7108-6508; Chami, Mounia/0000-0003-1498-7187; Szabadkai, Gyorgy/0000-0002-3006-3577; Rizzuto, Rosario/0000-0001-7044-5097; Campanella, Michelangelo/0000-0002-6948-4184	Telethon [GTF02013] Funding Source: Medline	Telethon(Fondazione Telethon)		Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Chami M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, TRENDS CELL BIOL, V8, P288, DOI 10.1016/S0962-8924(98)01301-4; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208	35	91	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54581	54589		10.1074/jbc.M409663200	http://dx.doi.org/10.1074/jbc.M409663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485871	hybrid			2022-12-25	WOS:000225793600084
J	Han, B; Bai, XH; Lodyga, M; Xu, J; Yang, BB; Keshavjee, S; Post, M; Liu, MY				Han, B; Bai, XH; Lodyga, M; Xu, J; Yang, BB; Keshavjee, S; Post, M; Liu, MY			Conversion of mechanical force into biochemical signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENT INTEGRITY; FAMILY TYROSINE KINASES; MECHANOSENSORY TRANSDUCTION; C-SRC; CAENORHABDITIS-ELEGANS; MOLECULAR-BASIS; SHEAR-STRESS; STRETCH; CELLS; MECHANOTRANSDUCTION	Physical forces play important roles in regulating cell proliferation, differentiation, and death by activating intracellular signal transduction pathways. How cells sense mechanical stimulation, however, is largely unknown. Most studies focus on cellular membrane proteins such as ion channels, integrins, and receptors for growth factors as mechanosensory units. Here we show that mechanical stretch-induced c-Src protein tyrosine kinase activation is mediated through the actin filament-associated protein ( AFAP). Distributed along the actin filaments, AFAP can directly active c-Src through binding to its Src homology 3 and/or 2 domains. Mutations at these specific binding sites on AFAP blocked mechanical stretch-induced c-Src activation. Therefore, mechanical force can be transmitted along the cytoskeleton, and interaction between cytoskeletal associated proteins and enzymes related to signal transduction may convert physical forces into biochemical reactions. Cytoskeleton deformation-induced protein-protein interaction via specific binding sites may represent a novel intracellular mechanism for cells to sense mechanical stimulation.	Univ Hlth Network, Toronto Gen Res Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Liu, MY (corresponding author), Univ Toronto, Toronto Gen Hosp, Rm MBRC5R422,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	mingyao.liu@utoronto.ca		Liu, Mingyao/0000-0002-9188-8417; Keshavjee, Shaf/0000-0003-4547-8094				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Chalfie M, 1997, BIOL BULL, V192, P125, DOI 10.2307/1542584; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Epstein ND, 2003, CELL, V112, P147, DOI 10.1016/S0092-8674(03)00037-0; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Langille BL, 2001, MICROCIRCULATION, V8, P195, DOI 10.1038/sj.mn.7800085; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Sai XR, 1999, J CELL SCI, V112, P1365; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; TURNER CH, 1995, AM J PHYSIOL, V269, P438; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	42	117	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54793	54801		10.1074/jbc.M406880200	http://dx.doi.org/10.1074/jbc.M406880200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485829	hybrid			2022-12-25	WOS:000225793600107
J	Pan, F; Egile, C; Lipkin, T; Li, R				Pan, F; Egile, C; Lipkin, T; Li, R			ARPC1/Arc40 mediates the interaction of the actin-related protein 2 and 3 complex with Wiskott-Aldrich syndrome protein family activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ARP2/3 COMPLEX; INDIVIDUAL SUBUNITS; N-WASP; POLYMERIZATION; FILAMENTS; MOTILITY; PURIFICATION; CYTOSKELETON; NUCLEATION; HOMOLOGY	The actin-related protein 2 and 3 (Arp2/3) complex is a seven-subunit protein complex that nucleates actin filaments at the cell cortex. Despite extensive cross-linking, crystallography, genetic and biochemical studies, the contribution of each subunit to the activity of the complex remains largely unclear. In this study we characterized the function of the 40-kDa subunit, ARPC1/Arc40, of the yeast Arp2/3 complex. We showed that this subunit is indeed a stable component of the Arp2/3 complex, but its highly unusual electrophoretic mobility eluded detection in previous studies. Recombinant Arc40 bound the VCA domain of Wiskott-Aldrich syndrome protein family activators at a K-d of 0.45 muM, close to that of the full complex with VCA (0.30 muM), and this interaction was dependent on the conserved tryptophan at the COOH terminus of VCA. Using a newly constructed Deltaarc40 yeast strain, we showed that loss of Arc40 severely reduced the binding affinity of the Arp2/3 complex with VCA as well as the nucleation activity of the complex, suggesting that Arc40 contains an important contact site of the Arp2/3 complex with VCA. The Deltaarc40 cells exhibited reduced growth rate, loss of actin patches, and accumulation of cables like actin aggregates, phenotypes typical of other subunit nulls, suggesting that Arc40 functions exclusively within the Arp2/3 complex.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Li, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Bldg C2-417,240 Longwood Ave, Boston, MA 02115 USA.	rli@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066311, R01GM057063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM057063, GM66311] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Beltzner CC, 2004, J MOL BIOL, V336, P551, DOI 10.1016/j.jmb.2003.12.017; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hufner K, 2001, J BIOL CHEM, V276, P35761, DOI 10.1074/jbc.M106520200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lechler T, 2001, J CELL BIOL, V155, P261, DOI 10.1083/jcb.200104094; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sherman F., 1974, METHODS YEAST GENETI; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	34	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54629	54636		10.1074/jbc.M402357200	http://dx.doi.org/10.1074/jbc.M402357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15485833	hybrid			2022-12-25	WOS:000225793600089
J	van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R				van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R			The Phox2B homeobox gene is mutated in sporadic neuroblastomas	ONCOGENE			English	Article						Phox2B; mutations; neuroblastoma; TrkA	N-MYC; ALLELIC LOSS; EXPRESSION; MUTATIONS; REARRANGEMENTS; AMPLIFICATION; DNA	Neuroblastomas are embryonal tumours of the sympathoadrenal lineage with a clinical course ranging from spontaneous regression to fatal progression. The Phox2B homeobox transcription factor functions in the differentiation of the sympatho-adrenal lineage. Targets of Phox2B are, for example, genes of the ( nor) adrenalin synthesis route, like Dopamine Beta Hydroxylase (DBH). Congenital Central Hypoventilation Syndrome was recently found to result from Phox2B mutations and two such patients in addition developed neuroblastoma. A germline mutation in Phox2B was identified in a family with hereditary neuroblastoma. Here, we report the first analysis of Phox2B in a series of 237 sporadic neuroblastomas and 22 cell lines. Six frameshift mutations were found in exons 2 and 3; including one in cell line SK-N-SH. Two patients showed de novo constitutional mutations. One of them was diagnosed with Haddad syndrome. All analysed cases expressed the mutated and wild-type Phox2B alleles. Ectopic expression of TrkA, the Nerve Growth Factor receptor, strongly downregulated Phox2B and DBH expression in cell line SH-SY5Y. However, TrkA and Phox2B showed a positive correlation in a panel of 66 neuroblastoma tumours. Although Phox2B mutations are infrequent ( 2.3%), they implicate a role for the Phox2B pathway in oncogenesis.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Childrens Hosp Essen, Dept Oncol Hematol & Endocrinol, D-45122 Essen, Germany; Univ Amsterdam, Acad Med Ctr, Dept Neurogenet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	r.versteeg@amc.uva.nl	Schramm, Alexander/G-5688-2010; Eggert, Angelika/AAE-6907-2022; Versteeg, Rogier/AAQ-1765-2020; Baas, Frank/F-9574-2010	Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Baas, Frank/0000-0003-3912-5428; Versteeg, Rogier/0000-0001-7172-0388				Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bonfield JK, 1998, NUCLEIC ACIDS RES, V26, P3404, DOI 10.1093/nar/26.14.3404; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Caron H, 1996, HUM GENET, V97, P834; Easton J, 1998, CANCER RES, V58, P2624; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Huber K, 2002, ANN NY ACAD SCI, V971, P554, DOI 10.1111/j.1749-6632.2002.tb04526.x; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; Lavoie H, 2003, HUM MOL GENET, V12, P2967, DOI 10.1093/hmg/ddg329; LIMPT VA, 2003, INT J CANCER, V105, P61; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sasaki A, 2003, HUM GENET, V114, P22, DOI 10.1007/s00439-003-1036-z; SCHULTE JH, 2004, IN PRESS ONCOGENE; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Spieker N, 2001, GENOMICS, V71, P214, DOI 10.1006/geno.2000.6408; Stanke M, 2004, MOL CELL NEUROSCI, V25, P374, DOI 10.1016/j.mcn.2003.10.021; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813	34	94	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9280	9288		10.1038/sj.onc.1208157	http://dx.doi.org/10.1038/sj.onc.1208157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516980				2022-12-25	WOS:000225638000013
J	Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R				Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R			Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2)	FASEB JOURNAL			English	Article						airway epithelium; trypsin; tryptase	CYSTIC-FIBROSIS MOUSE; CL-SECRETION; INFLAMMATION; INHIBITION; MODULATION; EXPRESSION; EPITHELIUM; CHANNELS	Protease-activated receptors (PARs) are widely distributed in human airways. They couple to G-proteins and are activated after proteolytic cleavage of the N terminus of the receptor. Evidence is growing that PAR subtype 2 plays a pivotal role in inflammatory airway diseases, such as allergic asthma or bronchitis. However, nothing is known about the effects of PAR-2 on electrolyte transport in the native airways. PAR-2 is expressed in airway epithelial cells, where they are activated by mast cell tryptase, neutrophil proteinase 3, or trypsin. Recent studies produced conflicting results about the functional consequence of PAR-2 stimulation. Here we report that stimulation of PAR-2 receptors in mouse and human airways leads to a change in electrolyte transport and a shift from absorption to secretion. Although PAR-2 appears to be expressed on both sides of the epithelium, only basolateral stimulation results in inhibition of amiloride sensitive Na+ conductance and stimulation of both luminal Cl- channels and basolateral K+ channels. The present data indicate that these changes occur through activation of phospholipase C and increase in intracellular Ca2+, which activates basolateral SK4 K+ channels and luminal Ca2+-dependent Cl- channels. In addition, the present data suggest a PAR-2 mediated release of prostaglandin E2, which may contribute to the secretory response. In conclusion, these results provide further evidence for a role of PAR-2 in inflammatory airway disease: stimulation of these receptors may cause accumulation of airway surface liquid, which, however, may help to flush noxious stimuli away from the affected airways.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Heidelberg Univ, Kinderklin 3, Mukoviszidose Zentrum, Heidelberg, Germany	University of Regensburg; University of Queensland; Ruprecht Karls University Heidelberg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Markovich, Daniel/F-7884-2012; Mall, Marcus A./AAA-1498-2022; Schreiber, Robert/Q-7550-2019	Mall, Marcus A./0000-0002-4057-2199; Kunzelmann, Karl/0000-0002-4583-7037				Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Cicala C, 2001, BRIT J PHARMACOL, V132, P1229, DOI 10.1038/sj.bjp.0703934; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KAWABATA A, 2004, IN PRESS J PHARM EXP; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC; Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060; MALL M, 2002, AM J PHYSIOL, V282, P200; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Oceandy D, 2003, J MEMBRANE BIOL, V192, P159, DOI 10.1007/s00232-002-1072-y; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Risse PA, 2004, LIFE SCI, V75, P991, DOI 10.1016/j.lfs.2004.02.008; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Vergnolle N, 2004, BRIT J PHARMACOL, V141, P1264, DOI 10.1038/sj.bjp.0705750; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	38	89	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					969	+		10.1096/fj.04-2469fje	http://dx.doi.org/10.1096/fj.04-2469fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809358				2022-12-25	WOS:000228865300031
